,pmid,sentence_id,sentences,section_name,index,starts,ends,limitation_annotation,categories,category_spans,category_annotation,coarse_grained_categories
917,PMC2277384,28930,Training in dual diagnosis interventions (the COMO Study): Randomised controlled trial,Title,[175136],[31464],[86],[False],[0],[0],[False],['0']
918,PMC2277384,28931,Background,Abstract,[175142],[87],[98],[False],[0],[0],[False],['0']
919,PMC2277384,28932,"Despite the high prevalence of co-morbid substance use among mental health service users (dual diagnosis), very few mental health workers in the UK have had training and/or clinical experience to equip them to deliver targeted interventions to this client group.",Abstract,[175148],[99],[361],[False],[0],[0],[False],['0']
920,PMC2277384,28933,Method,Abstract,[175154],[362],[368],[False],[0],[0],[False],['0']
921,PMC2277384,28934,"In a randomised controlled trial of training for dual diagnosis interventions, 79 case managers from 12 community mental health teams in South London were randomly allocated to either receive training and follow-up supervision (experimental group) or no training and supervision (control group).",Abstract,[175160],[369],[664],[False],[0],[0],[False],['0']
922,PMC2277384,28935,"Baseline measures of attitude, self-efficacy and knowledge were collected prior to randomisation, and were repeated at 18 months post-training.",Abstract,[175166],[665],[808],[False],[0],[0],[False],['0']
923,PMC2277384,28936,An intention to treat analysis of follow-up data (adjusted for baseline score for that outcome and team) was performed.,Abstract,[175172],[809],[928],[False],[0],[0],[False],['0']
924,PMC2277384,28937,Results,Abstract,[175178],[929],[936],[False],[0],[0],[False],['0']
925,PMC2277384,28938,"At 18 months post-training, the AAPPQ (The Alcohol and Alcohol Problems Perception Questionnaire) total score was did not differ significantly between the two groups (adjusted difference 7.43 [95% CI -0.86 to 15.71], p = 0.08).",Abstract,[175184],[937],[1164],[False],[0],[0],[False],['0']
926,PMC2277384,28939,"There were significant differences in favour of the experimental group on 2 of the 6 subscales of the AAPPQ: 'adequacy of knowledge and skills in working with alcohol"" (adjusted difference 3.598 [95% CI 1.03 to 6.16], p = 0.007) and ""self-esteem in working with alcohol"" (adjusted difference 3.00 [95% CI 0.46 to 5.54], p = 0.021).",Abstract,[175190],[1165],[1496],[False],[0],[0],[False],['0']
927,PMC2277384,28940,"In addition there were significant improvements for the experimental group on ""Knowledge About Dual Diagnosis"" (adjusted difference 2.00 [95% CI 0.80 to 3.22], p = 0.002) and ""Self-Efficacy Scale"" (adjusted difference 13.55 [95% CI 8.00 to 26.86], p = 0.001).",Abstract,[175196],[1497],[1756],[False],[0],[0],[False],['0']
928,PMC2277384,28941,"The effect of membership of teams was added to the analysis of covariance and this changed the results for only one variable: ""self-esteem working with drinkers"" was no longer significant.",Abstract,[175202],[1757],[1945],[False],[0],[0],[False],['0']
929,PMC2277384,28942,Conclusion,Abstract,[175208],[1946],[1956],[False],[0],[0],[False],['0']
930,PMC2277384,28943,A brief training course in dual diagnosis interventions had a significant effect on secondary measures of knowledge and self-efficacy that was detectable at 18 months post-training.,Abstract,[175214],[1957],[2138],[False],[0],[0],[False],['0']
931,PMC2277384,28944,Improvements in attitudes towards working with drinkers and drug users in mental health settings failed to reach statistical significance.,Abstract,[175220],[2139],[2277],[False],[0],[0],[False],['0']
932,PMC2277384,28945,"Future research should explore the effects of dose of dual diagnosis training, and the successful integration of skills gained into routine care.",Abstract,[175226],[2278],[2423],[False],[0],[0],[False],['0']
933,PMC2277384,28946,Trial Registration:,Abstract,[175232],[2424],[2443],[False],[0],[0],[False],['0']
934,PMC2277384,28947,ISRCTN98891022 14th March 2007,Abstract,[175238],[2444],[2474],[False],[0],[0],[False],['0']
935,PMC2277384,28948,Background,Background,[175244],[2475],[2486],[False],[0],[0],[False],['0']
936,PMC2277384,28949,Developing better services for people with co-morbid mental health and substance use problems has become a national priority in the UK [1].,Background,[175250],[2487],[2626],[False],[0],[0],[False],['0']
937,PMC2277384,28950,"In 2002, the Department of Health published the Good Practice Guidelines for working with dual diagnosis patients [2].",Background,[175256],[2627],[2745],[False],[0],[0],[False],['0']
938,PMC2277384,28951,"The guidance acknowledges that co-morbid substance use problems are common within mental health service users and therefore it is ""usual rather than exceptional"" (p.19) to encounter this clinical problem.",Background,[175262],[2746],[2950],[False],[0],[0],[False],['0']
939,PMC2277384,28952,Prevalence studies [3-5] have indicated that around a third of people with psychosis have co morbid substance use problems.,Background,[175268],[2951],[3074],[False],[0],[0],[False],['0']
940,PMC2277384,28953,There is an emerging evidence base that an integrated approach that combines mental health and substance use approaches (such as cognitive behavioural therapy and motivational interviewing) can be beneficial for people with serious mental health and substance use problems [6-9].,Background,[175274],[3075],[3354],[False],[0],[0],[False],['0']
941,PMC2277384,28954,Therefore it was proposed that mental health services should take a primary role in delivering effective integrated interventions for people with serious mental illness and substance use problems [2].,Background,[175280],[3355],[3555],[False],[0],[0],[False],['0']
942,PMC2277384,28955,"This is known as ""mainstreaming"".",Background,[175286],[3556],[3589],[False],[0],[0],[False],['0']
943,PMC2277384,28956,However there is concern as to whether the current mental health workforce is capable of providing such care.,Background,[175292],[3590],[3699],[False],[0],[0],[False],['0']
944,PMC2277384,28957,A number of surveys of mental health staff reveal a deficit in clinical experience and training in substance use problems [10-12].,Background,[175298],[3700],[3830],[False],[0],[0],[False],['0']
945,PMC2277384,28958,One possible solution to this discrepancy between the needs of the service users and the capabilities of the workforce is to develop and deliver specific training programmes that would aim to improve the care that people with dual diagnosis receive.,Background,[175304],[3831],[4080],[False],[0],[0],[False],['0']
946,PMC2277384,28959,"There is some evidence to suggest that training may be an effective strategy for disseminating psychosocial interventions into the general mental health workforce [13] and Gray et al [14,15] demonstrated in a randomised controlled trial that a 10 day training course in medication management for community psychiatric nurses resulted in increased skill acquisition and improved psychopathology for the service users who received the intervention.",Background,[175310],[4081],[4527],[False],[0],[0],[False],['0']
947,PMC2277384,28960,"Medication management is a combination of motivational interviewing, psycho-education, problem-solving and cognitive behavioural techniques and is designed for people with serious mental illness.",Background,[175316],[4528],[4723],[False],[0],[0],[False],['0']
948,PMC2277384,28961,To date the only published study of dual diagnosis training is the COMPASS project in Birmingham.,Background,[175322],[4724],[4821],[False],[0],[0],[False],['0']
949,PMC2277384,28962,"Using a quasi-experimental design, Graham and colleagues evaluated the impact of a 6 half day course of dual diagnosis which was delivered to assertive outreach teams using a whole team training approach [16].",Background,[175328],[4822],[5031],[False],[0],[0],[False],['0']
950,PMC2277384,28963,"They trained 5 teams in total; 3 teams initially and then the last 2, 18 months later.",Background,[175334],[5032],[5118],[False],[0],[0],[False],['0']
951,PMC2277384,28964,"In addition to the training, there was a manual and a specialist dual diagnosis worker was attached to the team to provide advice, supervision and support in the implementation of the approach.",Background,[175340],[5119],[5312],[False],[0],[0],[False],['0']
952,PMC2277384,28965,Overall there was a significant improvement in knowledge and confidence in dual diagnosis interventions from pre training to 18 months after training for all five teams.,Background,[175346],[5313],[5482],[False],[0],[0],[False],['0']
953,PMC2277384,28966,"However, there was no significant difference when the teams that had received the training were compared to those who had not had the training.",Background,[175352],[5483],[5626],[False],[0],[0],[False],['0']
954,PMC2277384,28967,Graham and colleagues [16] recommend that further research should be conducted into the effects of training on both case managers and service users.,Background,[175358],[5627],[5775],[False],[0],[0],[False],['0']
955,PMC2277384,28968,The aim of the COMO (co-morbidity) dual diagnosis study is to asses the impact of training in integrated dual diagnosis interventions on case managers working in community mental health teams.,Background,[175364],[5776],[5968],[False],[0],[0],[False],['0']
956,PMC2277384,28969,A 5 day training course was designed specifically for this study.,Background,[175370],[5969],[6034],[False],[0],[0],[False],['0']
957,PMC2277384,28970,"A separate paper [17] reports the design, methodology, and main service user outcomes.",Background,[175376],[6035],[6121],[False],[0],[0],[False],['0']
958,PMC2277384,28971,This paper will focus on the training aspect of the study and the impact of this upon case managers.,Background,[175382],[6122],[6222],[False],[0],[0],[False],['0']
959,PMC2277384,28972,"The main hypotheses tested were that case managers who received the training would have significant improvements in (i) attitudes, (ii) knowledge, and (iii) confidence (self-efficacy) in working with people with dual diagnosis problems in a community mental health setting (when compared to those without training).",Background,[175388],[6223],[6538],[False],[0],[0],[False],['0']
960,PMC2277384,28973,Method,Method,[175394],[6539],[6546],[False],[0],[0],[False],['0']
961,PMC2277384,28974,"In terms of the case managers, the study was a randomised controlled trial that compared training against no training.",Method,[175400],[6547],[6665],[False],[0],[0],[False],['0']
962,PMC2277384,28975,"This took place in the South London and Maudsley NHS Trust (now Foundation Trust), located in inner London, and was open to all community mental health teams in the organisation.",Method,[175406],[6666],[6844],[False],[0],[0],[False],['0']
963,PMC2277384,28976,"Ethical approval was granted by the Institute of Psychiatry Ethics Committee (now joint South London and Maudsley and Institute of Psychiatry NHS Research Ethics Committee) and was obtained on 17th September, 1999 (reference 075/99).",Method,[175412],[6845],[7078],[False],[0],[0],[False],['0']
964,PMC2277384,28977,Case managers within the recruited teams were randomly allocated to either training or no training.,Method,[175418],[7079],[7178],[False],[0],[0],[False],['0']
965,PMC2277384,28978,Informed consent was obtained from the case managers to participate in the trial.,Method,[175424],[7179],[7260],[False],[0],[0],[False],['0']
966,PMC2277384,28979,"They were informed that all aspects of the trial were voluntary, and they could withdraw at any time.",Method,[175430],[7261],[7362],[False],[0],[0],[False],['0']
967,PMC2277384,28980,Case managers who were randomised to the control group were offered the training once the follow-up data had been collected at 18 months post-training.,Method,[175436],[7363],[7514],[False],[0],[0],[False],['0']
968,PMC2277384,28981,"To be eligible for inclusion, participants were expected to be working with their caseloads continuously throughout the 18 month research period.",Method,[175442],[7515],[7660],[False],[0],[0],[False],['0']
969,PMC2277384,28982,The sample size was calculated for the broader study on the basis of three service user outcomes using p = 0.05 and 80% power.,Method,[175448],[7661],[7787],[False],[0],[0],[False],['0']
970,PMC2277384,28983,The largest sample size of the three was adopted (220 patients).,Method,[175454],[7788],[7852],[False],[0],[0],[False],['0']
971,PMC2277384,28984,"In terms of case managers, we assumed that 20% of the community mental health case-loads would be people with co-morbid psychosis and substance misuse.",Method,[175460],[7853],[8004],[False],[0],[0],[False],['0']
972,PMC2277384,28985,"Therefore from an average case-load of 20 we would expect to identify 4 service users per case manager, so that if we aimed for a service user sample of 220, we would need to recruit 55 case managers.",Method,[175466],[8005],[8205],[False],[0],[0],[False],['0']
973,PMC2277384,28986,The number of case managers actually recruited was 79 which was large enough to detect a standardised effect of 0.65 on the Knowledge about Dual Diagnosis (KADD) questionnaire.,Method,[175472],[8206],[8382],[False],[0],[0],[False],['0']
974,PMC2277384,28987,Baseline data were collected from participating staff within those teams prior to knowledge of whether they had been randomly allocated to the training group.,Method,[175478],[8383],[8541],[False],[0],[0],[False],['0']
975,PMC2277384,28988,"In order to minimise bias, the research assistants were blind to randomisation, and the randomisation itself was performed by an independent statistician to maintain concealment.",Method,[175484],[8542],[8720],[False],[0],[0],[False],['0']
976,PMC2277384,28989,Primary Outcome Measure,Method|Primary Outcome Measure,[175490],[8721],[8744],[False],[0],[0],[False],['0']
977,PMC2277384,28990,There are to date no valid and reliable measures of attitudes specifically for working with people with co-morbid mental health and substance use.,Method|Primary Outcome Measure,[175496],[8745],[8891],[False],[0],[0],[False],['0']
978,PMC2277384,28991,The Alcohol and Alcohol Problems Perception Questionnaire (AAPPQ) [18] was chosen as it has demonstrated reliability and validity in measuring attitudes towards working with alcohol drinkers by generic workers (including mental health workers).,Method|Primary Outcome Measure,[175502],[8892],[9136],[False],[0],[0],[False],['0']
979,PMC2277384,28992,It consists of a series of statements about aspects of working with drinkers.,Method|Primary Outcome Measure,[175508],[9137],[9214],[False],[0],[0],[False],['0']
980,PMC2277384,28993,Each statement is rated on a 7 point scale from strongly disagree to strongly agree.,Method|Primary Outcome Measure,[175514],[9215],[9299],[False],[0],[0],[False],['0']
981,PMC2277384,28994,"In this study, the AAPPQ items were repeated, replacing ""drinkers"" with ""drug users"" to obtain a measure of attitudes towards drug users.",Method|Primary Outcome Measure,[175520],[9300],[9437],[False],[0],[0],[False],['0']
982,PMC2277384,28995,"There are 6 subscales to the AAPPQ: the agents willingness to work with drinkers/drug users (motivation); their self-reported adequacy in knowledge and skills in working with drinkers/drug users, their self-esteem in working with drinkers/drug users, the extent to which they have the right to work with drinkers/drug users (role legitimacy); expectations of job satisfaction in working with drinkers/drug users; and role support in working with drinkers/drug users.",Method|Primary Outcome Measure,[175526],[9438],[9904],[False],[0],[0],[False],['0']
983,PMC2277384,28996,"Cartwright and colleagues [18] reported that there was good test re-test reliability, and Cronbach alpha coefficients for the scales ranged between 0.7 and 0.9.",Method|Primary Outcome Measure,[175532],[9905],[10065],[False],[0],[0],[False],['0']
984,PMC2277384,28997,It has been used in previous studies as a measure of attitudes of mental health workers towards working with drinkers.,Method|Primary Outcome Measure,[175538],[10066],[10184],[False],[0],[0],[False],['0']
985,PMC2277384,28998,Lightfoot and Orford [19] used the AAPPQ with community mental health nurses and social workers.,Method|Primary Outcome Measure,[175544],[10185],[10281],[False],[0],[0],[False],['0']
986,PMC2277384,28999,They reported an overall Cronbach alpha of 0.83 with the range for the subscales of between 0.7 and 0.9.,Method|Primary Outcome Measure,[175550],[10282],[10386],[False],[0],[0],[False],['0']
987,PMC2277384,29000,"In this study, good internal consistency was demonstrated; the items for the overall AAPPQ scale had a Cronbach alpha coefficient of 0.9, and the subscales ranged from 0.7– 0.9.",Method|Primary Outcome Measure,[175556],[10387],[10564],[False],[0],[0],[False],['0']
988,PMC2277384,29001,Secondary Outcome Measures,Method|Secondary Outcome Measures,[175562],[10565],[10591],[False],[0],[0],[False],['0']
989,PMC2277384,29002,"Basic information about professional background, grade, length of time in profession, previous study relevant to dual diagnosis, and previous clinical experience in substance use field was collected from each participant.",Method|Secondary Outcome Measures,[175568],[10592],[10813],[False],[0],[0],[False],['0']
990,PMC2277384,29003,The secondary outcomes were measured by scales designed specifically for the study and are therefore intended for exploratory data analyses to generate hypotheses.,Method|Secondary Outcome Measures,[175574],[10814],[10977],[False],[0],[0],[False],['0']
991,PMC2277384,29004,The Self-Efficacy Scale (SES) Dual Diagnosis Attitudes (DDA) and the Knowledge about Dual Diagnosis Questionnaires (KADD) were developed for the study as a literature search revealed that dual diagnosis specific measures of knowledge and confidence did not exist at that time.,Method|Secondary Outcome Measures,[175580],[10978],[11254],[False],[0],[0],[False],['0']
992,PMC2277384,29005,These measures were devised by an expert group with experience in working with and training mental health workers in dual diagnosis interventions.,Method|Secondary Outcome Measures,[175586],[11255],[11401],[False],[0],[0],[False],['0']
993,PMC2277384,29006,"The group agreed that the final versions of the SES, the DDA, and the KADD had face and content validity.",Method|Secondary Outcome Measures,[175592],[11402],[11507],[False],[0],[0],[False],['0']
994,PMC2277384,29007,The measures were administered to 3 dual diagnosis experts (independent of the study) and they all scored highly on the scales.,Method|Secondary Outcome Measures,[175598],[11508],[11635],[False],[0],[0],[False],['0']
995,PMC2277384,29008,The SES consisted of a list of key skills which related to working with someone with mental health and substance use problems.,Method|Secondary Outcome Measures,[175604],[11636],[11762],[False],[0],[0],[False],['0']
996,PMC2277384,29009,"This included assessment, health education, and interventions such as motivational interviewing techniques.",Method|Secondary Outcome Measures,[175610],[11763],[11870],[False],[0],[0],[False],['0']
997,PMC2277384,29010,"Each item was rated from 0% which indicated no confidence at all in being able to perform the specific skill, to 100% (totally confident in ones ability).",Method|Secondary Outcome Measures,[175616],[11871],[12025],[False],[0],[0],[False],['0']
998,PMC2277384,29011,"It had a good internal consistency with a Cronbach alpha coefficient of 0.97, and a range of inter-item correlations from 0.537–1.000.",Method|Secondary Outcome Measures,[175622],[12026],[12160],[False],[0],[0],[False],['0']
999,PMC2277384,29012,Due to the high internal consistency of this scale future work should assess whether the scale could be refined by using a smaller subset of items.,Method|Secondary Outcome Measures,[175628],[12161],[12308],[False],[0],[0],[False],['0']
1000,PMC2277384,29013,The DDA consisted of a series of statements about dual diagnosis and each item was rated on a four point scale of 1 disagree strongly to 4 agree strongly.,Method|Secondary Outcome Measures,[175634],[12309],[12463],[False],[0],[0],[False],['0']
1001,PMC2277384,29014,There was no neutral option in order to polarise the views.,Method|Secondary Outcome Measures,[175640],[12464],[12523],[False],[0],[0],[False],['0']
1002,PMC2277384,29015,It had a low internal consistency with a Cronbach alpha coefficient of 0.58.,Method|Secondary Outcome Measures,[175646],[12524],[12600],[False],[0],[0],[False],['0']
1003,PMC2277384,29016,The KADD was a 20 item multiple choice questionnaire based on the content of the dual diagnosis training.,Method|Secondary Outcome Measures,[175652],[12601],[12706],[False],[0],[0],[False],['0']
1004,PMC2277384,29017,Trainees were asked to choose the correct response from a choice of 4.,Method|Secondary Outcome Measures,[175658],[12707],[12777],[False],[0],[0],[False],['0']
1005,PMC2277384,29018,The KADD also had a good internal consistency (Cronbach alpha of 0.70).,Method|Secondary Outcome Measures,[175664],[12778],[12849],[False],[0],[0],[False],['0']
1006,PMC2277384,29019,"In addition to the previously mentioned scales, job satisfaction and burn-out were measured by using the Minnesota Job Satisfaction Scale (MSS) [20], and the Maslach Burn-Out Inventory (MBI) [21].",Method|Secondary Outcome Measures,[175670],[12850],[13046],[False],[0],[0],[False],['0']
1007,PMC2277384,29020,Burn-out and job dissatisfaction were measured as it has been suggested that trainees are less likely to implement training if they are feeling burnt-out and unhappy in their work.,Method|Secondary Outcome Measures,[175676],[13047],[13227],[False],[0],[0],[False],['0']
1008,PMC2277384,29021,"The MSS is a valid and reliable tool that consists of 20 items, and it assesses aspects of work that are a source of satisfaction or dissatisfaction.",Method|Secondary Outcome Measures,[175682],[13228],[13377],[False],[0],[0],[False],['0']
1009,PMC2277384,29022,Each item is assessed on a 5 point scale ranging from 1 (very dissatisfied) to 5 (very satisfied).,Method|Secondary Outcome Measures,[175688],[13378],[13476],[False],[0],[0],[False],['0']
1010,PMC2277384,29023,"A score of 60 indicates a neutral level of job satisfaction, and a score over 80 indicates job satisfaction.",Method|Secondary Outcome Measures,[175694],[13477],[13585],[False],[0],[0],[False],['0']
1011,PMC2277384,29024,The MBI is a valid and reliable tool designed to assess burn-out in people whose occupations involve the delivery of care.,Method|Secondary Outcome Measures,[175700],[13586],[13708],[False],[0],[0],[False],['0']
1012,PMC2277384,29025,"It consists of 22 items and respondents are asked to rate how often they experience a range of positive and negative work-related feelings, using a scale ranging from 0 (never experienced job related feelings) to 7 (experiencing job related feelings on a daily basis).",Method|Secondary Outcome Measures,[175706],[13709],[13977],[False],[0],[0],[False],['0']
1013,PMC2277384,29026,"Three sub scores are derived from the responses: depersonalisation (feeling emotionally detached and callous), emotional exhaustion (feeling emotionally drained and fatigued), and lack of personal accomplishment (feeling that no matter what they do nothing makes a difference; feeling de-skilled).",Method|Secondary Outcome Measures,[175712],[13978],[14275],[False],[0],[0],[False],['0']
1014,PMC2277384,29027,Maslach and Jackson [21] calculated the range of scores for burn-out for different professionals.,Method|Secondary Outcome Measures,[175718],[14276],[14373],[False],[0],[0],[False],['0']
1015,PMC2277384,29028,"For mental health workers, high burn-out is indicted by a score of 8 or more on depersonalisation; 21 or more for emotional exhaustion and 28 or less for personal accomplishment.",Method|Secondary Outcome Measures,[175724],[14374],[14552],[False],[0],[0],[False],['0']
1016,PMC2277384,29029,Average burn-out for the subscales falls within the following ranges: depersonalisation 5–7; emotional exhaustion 14–20; and personal accomplishment 33–29.,Method|Secondary Outcome Measures,[175730],[14553],[14708],[False],[0],[0],[False],['0']
1017,PMC2277384,29030,The Training Intervention,Method|The Training Intervention,[175736],[14709],[14734],[False],[0],[0],[False],['0']
1018,PMC2277384,29031,"The training package was designed to increase mental health case managers' skills and competencies to detect, assess, and intervene with co-morbid substance use problems.",Method|The Training Intervention,[175742],[14735],[14905],[False],[0],[0],[False],['0']
1019,PMC2277384,29032,"The expectation was that case managers would integrate the key skills from the training into their practice, so that they could begin to address substance use.",Method|The Training Intervention,[175748],[14906],[15065],[False],[0],[0],[False],['0']
1020,PMC2277384,29033,"In addition to individual work, the training also addressed issues of referral to other agencies (such as specialist substance use services) or joint working with other professionals if the case was complex.",Method|The Training Intervention,[175754],[15066],[15273],[False],[0],[0],[False],['0']
1021,PMC2277384,29034,"The training course was too brief to produce ""experts"" in dual diagnosis interventions; the aim (within the limits of time and resources) was to help case managers be more effective in working with co-morbid substance use issues.",Method|The Training Intervention,[175760],[15274],[15503],[False],[0],[0],[False],['0']
1022,PMC2277384,29035,"The training was based on the Institute of Psychiatry, Kings College London, 12 day accredited dual diagnosis module (which was the first accredited clinical skills course in dual diagnosis interventions in the UK), and comprised of 5 days of classroom based training, delivered one day per week, and an 80 page treatment manual.",Method|The Training Intervention,[175766],[15504],[15833],[False],[0],[0],[False],['0']
1023,PMC2277384,29036,"The training utilised a range of methods including didactic presentations, small group discussion and exercises, clinical case discussions, reflection on practice, and role-play.",Method|The Training Intervention,[175772],[15834],[16012],[False],[0],[0],[False],['0']
1024,PMC2277384,29037,"The teaching methods were designed to link theory to the case managers' previous experience, knowledge and clinical experience.",Method|The Training Intervention,[175778],[16013],[16140],[False],[0],[0],[False],['0']
1025,PMC2277384,29038,"After the training had ended, the trainees were offered monthly one hour supervision sessions for the length of the 18 month period post training.",Method|The Training Intervention,[175784],[16141],[16287],[False],[0],[0],[False],['0']
1026,PMC2277384,29039,"The content of the training included the Integrated Treatment Approach [22] which included comprehensive assessment, step-wise working (using Osher and Kofoed's Four Stage Model) [23], taking a flexible and long term view of working with dual diagnosis, Motivational Interviewing techniques (such assessing readiness to change and working with ambivalence) [24], and cognitive behavioural techniques for psychosis including assessment of problem areas and relapse prevention [25].",Method|The Training Intervention,[175790],[16288],[16768],[False],[0],[0],[False],['0']
1027,PMC2277384,29040,"For consistency, the training and supervision were provided by the person who developed the training package (EH).",Method|The Training Intervention,[175796],[16769],[16883],[False],[0],[0],[False],['0']
1028,PMC2277384,29041,"The skill components of the training were demonstrated by video clips, and also described in detail within the manual.",Method|The Training Intervention,[175802],[16884],[17002],[False],[0],[0],[False],['0']
1029,PMC2277384,29042,"Trainees practiced the skills within the training, and were required to try out the skills in clinical practice and discuss progress within the classroom and in follow-up supervision.",Method|The Training Intervention,[175808],[17003],[17186],[False],[0],[0],[False],['0']
1030,PMC2277384,29043,Statistical Analysis,Method|Statistical Analysis,[175814],[17187],[17207],[False],[0],[0],[False],['0']
1031,PMC2277384,29044,"The strength of evidence for any differences between the two groups was assessed using analysis of covariance with baseline scores as covariate, and post treatment scores as dependent variable.",Method|Statistical Analysis,[175820],[17208],[17401],[False],[0],[0],[False],['0']
1032,PMC2277384,29045,"Data were input to databases using SPSS and analysed using SPSS 14 [26] and analysis was performed on all participants who had been originally randomised to receive training or waiting list control, and who had follow-up data.",Method|Statistical Analysis,[175826],[17402],[17628],[False],[0],[0],[False],['0']
1033,PMC2277384,29046,Outcomes were analysed irrespective of whether or not the case manager had participated in or completed the training (intention to treat).,Method|Statistical Analysis,[175832],[17629],[17767],[False],[0],[0],[False],['0']
1034,PMC2277384,29047,Statistical significance was evaluated at p = 0.05 level.,Method|Statistical Analysis,[175838],[17768],[17825],[False],[0],[0],[False],['0']
1035,PMC2277384,29048,No adjustment was made for multiple testing as the secondary outcomes were exploratory in nature.,Method|Statistical Analysis,[175844],[17826],[17923],[False],[0],[0],[False],['0']
1036,PMC2277384,29049,"In order to address whether membership of different teams affected the results, the analysis of covariance was repeated with ""team"" as an additional fixed factor, and the results were compared with the first analysis.",Method|Statistical Analysis,[175850],[17924],[18141],[False],[0],[0],[False],['0']
1037,PMC2277384,29050,"In addition, analyses were repeated including any baseline variables that appeared to characterise loss to follow up.",Method|Statistical Analysis,[175856],[18142],[18259],[False],[0],[0],[False],['0']
1038,PMC2277384,29051,Results,Results,[175862],[18260],[18268],[False],[0],[0],[False],['0']
1039,PMC2277384,29052,Sample,Results|Sample,[175868],[18269],[18275],[False],[0],[0],[False],['0']
1040,PMC2277384,29053,The demographic profile is typical of community mental health teams in London [27].,Results|Sample,[175874],[18276],[18359],[False],[0],[0],[False],['0']
1041,PMC2277384,29054,"At baseline, the intervention and control groups were comparable on demographic characteristics (Table 1).",Results|Sample,[175880],[18360],[18466],[False],[0],[0],[False],['0']
1042,PMC2277384,29055,"In terms of previous relevant training and clinical experience, 18% of the intervention group and 15% of the control group had attended any study days relevant to working with dual diagnosis, and 22% of the intervention group and 25% of the control group had never worked in a substance misuse treatment service.",Results|Sample,[175886],[18467],[18779],[False],[0],[0],[False],['0']
1043,PMC2277384,29056,"In terms of the training, 83% (N = 33) of the 40 case-managers randomised to training participated in it.",Results|Sample,[175892],[18780],[18885],[False],[0],[0],[False],['0']
1044,PMC2277384,29057,(See Figure 1 for staff CONSORT diagram [28]).,Results|Sample,[175898],[18886],[18932],[False],[0],[0],[False],['0']
1045,PMC2277384,29058,"Those who could not attend the training (N = 6) for reasons of illness and annual leave had an individual session with the trainer to go over the course content, attended the follow-on supervision and received the training manual.",Results|Sample,[175904],[18933],[19163],[False],[0],[0],[False],['0']
1046,PMC2277384,29059,"Of those who did attend the training, 81% attended at least 4.5 days out of 5 days.",Results|Sample,[175910],[19164],[19247],[False],[0],[0],[False],['0']
1047,PMC2277384,29060,"With reasonably good levels of exposure to the training in the intervention group, all those who entered the trial were included in the analysis (intention to treat).",Results|Sample,[175916],[19248],[19414],[False],[0],[0],[False],['0']
1048,PMC2277384,29061,"At 18 months post-training, follow-up data were obtained on 80% (63 of 79) of the case managers who completed baseline measures (control = 27; intervention = 36).",Results|Sample,[175922],[19415],[19577],[False],[0],[0],[False],['0']
1049,PMC2277384,29062,"Participants evaluated the course on the last day, and rated the training highly on clinical relevance, content, and presentation; however this may be slightly biased as the people who attended on day 5 may have viewed the course more favourably than those didn't attend.",Results|Sample,[175928],[19578],[19849],[False],[0],[0],[False],['0']
1050,PMC2277384,29063,Primary outcome: Attitudes,Results|Sample,[175934],[19850],[19876],[False],[0],[0],[False],['0']
1051,PMC2277384,29064,"At follow-up, after adjusting for baseline differences using analysis of covariance, the overall attitude score at follow-up between intervention and control groups was not significantly different at p = 0.05 although there was a trend toward significance (intervention mean 116.56 s.d.",Results|Sample,[175940],[19877],[20163],[False],[0],[0],[False],['0']
1052,PMC2277384,29065,21.02 vs. control mean 131.15 s.d.,Results|Sample,[175946],[20164],[20198],[False],[0],[0],[False],['0']
1053,PMC2277384,29066,"16.15, p = 0.078).",Results|Sample,[175952],[20199],[20217],[False],[0],[0],[False],['0']
1054,PMC2277384,29067,"There were, however, significant differences on 2 of the subscales of the AAPPQ: ""adequacy of knowledge and skills in working with drinkers"" (intervention 31.71, s.d.",Results|Sample,[175958],[20218],[20384],[False],[0],[0],[False],['0']
1055,PMC2277384,29068,"4.44 vs. control mean 26.29, s.d.6.88, p < 0.05) and ""self esteem in working with drinkers"" (intervention mean 29.56, s.d.5.16 vs. control mean 25.64, s.d.",Results|Sample,[175964],[20385],[20540],[False],[0],[0],[False],['0']
1056,PMC2277384,29069,"4.74, p = 0.021).",Results|Sample,[175970],[20541],[20558],[False],[0],[0],[False],['0']
1057,PMC2277384,29070,(Table 2).,Results|Sample,[175976],[20559],[20569],[False],[0],[0],[False],['0']
1058,PMC2277384,29071,"When repeating the ANCOVAs adding ""team"" as a fixed factor, significance changed for only one sub-scale.",Results|Sample,[175982],[20570],[20674],[False],[0],[0],[False],['0']
1059,PMC2277384,29072,"The adjusted mean for sub-scale ""self-esteem in working with drinkers"" was still higher for the intervention group, but felt short of significance (mean difference -2.67 95% [CI -5.67 to 0.33] p = 0.079).",Results|Sample,[175988],[20675],[20879],[False],[0],[0],[False],['0']
1060,PMC2277384,29073,"Secondary outcomes: Knowledge, Self-efficacy and Dual Diagnosis Attitudes",Results|Sample,[175994],[20880],[20953],[False],[0],[0],[False],['0']
1061,PMC2277384,29074,"At follow-up, the secondary outcomes; scores for self efficacy (intervention mean 69.49, s.d.",Results|Sample,[176000],[20954],[21047],[False],[0],[0],[False],['0']
1062,PMC2277384,29075,"12.55 vs. control mean 52.08 s.d.21.172, p < 0.001) and knowledge (intervention mean 12.97, s.d.2.83, control mean 10.55, s.d.",Results|Sample,[176006],[21048],[21174],[False],[0],[0],[False],['0']
1063,PMC2277384,29076,"3.92, p < 0.001), were significantly higher in the intervention group after adjusting for baseline differences using analysis of covariance (table 3).",Results|Sample,[176012],[21175],[21325],[False],[0],[0],[False],['0']
1064,PMC2277384,29077,There was no difference in the means for the Dual Diagnosis Attitudes Questionnaire at follow-up.,Results|Sample,[176018],[21326],[21423],[False],[0],[0],[False],['0']
1065,PMC2277384,29078,"Again the ANCOVAs were repeated with ""team"" as a fixed factor.",Results|Sample,[176024],[21424],[21486],[False],[0],[0],[False],['0']
1066,PMC2277384,29079,The inclusion of team in the analysis did not affect the results (i.e.,Results|Sample,[176030],[21487],[21557],[False],[0],[0],[False],['0']
1067,PMC2277384,29080,whether there was a significant difference or not) for the secondary measures.,Results|Sample,[176036],[21558],[21636],[False],[0],[0],[False],['0']
1068,PMC2277384,29081,Burn-Out and Job Satisfaction,Results|Burn-Out and Job Satisfaction,[176042],[21637],[21666],[False],[0],[0],[False],['0']
1069,PMC2277384,29082,The scores for the Maslach Burn-out Inventory revealed study participants were experiencing average levels of burn-out on emotional exhaustion and depersonalisation and high levels of burn-out related to personal accomplishment.,Results|Burn-Out and Job Satisfaction,[176048],[21667],[21895],[False],[0],[0],[False],['0']
1070,PMC2277384,29083,The Minnesota Satisfaction Survey scores demonstrated that the case managers were not particularly satisfied in their work.,Results|Burn-Out and Job Satisfaction,[176054],[21896],[22019],[False],[0],[0],[False],['0']
1071,PMC2277384,29084,There were no differences in scores on the subscales of the Maslach Burnout Inventory and Minnesota satisfaction scales between the two groups at follow-up.,Results|Burn-Out and Job Satisfaction,[176060],[22020],[22176],[False],[0],[0],[False],['0']
1072,PMC2277384,29085,Participants lost to follow-up,Results|Participants lost to follow-up,[176066],[22177],[22207],[False],[0],[0],[False],['0']
1073,PMC2277384,29086,A higher proportion of those who did not complete follow-up questionnaires were in the control group; 32% of those who completed baseline measures did not complete the follow-up questionnaires compared with only 10% of the intervention group.,Results|Participants lost to follow-up,[176072],[22208],[22450],[False],[0],[0],[False],['0']
1074,PMC2277384,29087,Data was not available on whether the non-completers simply refused to complete the questionnaires or whether they had left the service and could not be traced.,Results|Participants lost to follow-up,[176078],[22451],[22611],[False],[0],[0],[False],['0']
1075,PMC2277384,29088,Non-completers were not significantly different from completers in terms of sociodemographic characteristics and baseline means for primary and secondary measures.,Results|Participants lost to follow-up,[176084],[22612],[22775],[False],[0],[0],[False],['0']
1076,PMC2277384,29089,However there were a difference in depersonalisation scores between completers and non-completers in the control group.,Results|Participants lost to follow-up,[176090],[22776],[22895],[False],[0],[0],[False],['0']
1077,PMC2277384,29090,"This difference fell short of significance (p = 0.065), but the analysis of covariance for the primary and secondary outcomes were repeated using depersonalisation as an added covariate in order to control for any bias that this might have introduced into the main analysis.",Results|Participants lost to follow-up,[176096],[22896],[23170],[False],[0],[0],[False],['0']
1078,PMC2277384,29091,"This did not, however, affect the conclusions.",Results|Participants lost to follow-up,[176102],[23171],[23217],[False],[0],[0],[False],['0']
1079,PMC2277384,29092,Discussion,Discussion,[176108],[23218],[23229],[False],[0],[0],[False],['0']
1080,PMC2277384,29093,"The aim of this paper is to evaluate the effectiveness of a (relatively brief) training programme on case manager attitudes, confidence and knowledge related to working with dual diagnosis.",Discussion,[176114],[23230],[23419],[False],[0],[0],[False],['0']
1081,PMC2277384,29094,"The results have demonstrated that the training intervention has positive effects on some of the case manager outcomes when compared to the control group, and that these effects are detectable at 18 months post training.",Discussion,[176120],[23420],[23640],[False],[0],[0],[False],['0']
1082,PMC2277384,29095,"The impact of the training was mostly concentrated on self-reported confidence in skills, knowledge and an AAPPQ attitude subscale related to adequacy of knowledge and skills with working with drinkers.",Discussion,[176126],[23641],[23843],[False],[0],[0],[False],['0']
1083,PMC2277384,29096,"However the training did not appear to have an impact on the other AAPPQ attitudes subscales such as role legitimacy, motivation to work with alcohol and drug users, expectation of job satisfaction and role support.",Discussion,[176132],[23844],[24059],[False],[0],[0],[False],['0']
1084,PMC2277384,29097,This meant that overall there was no significant difference in AAPPQ total score.,Discussion,[176138],[24060],[24141],[False],[0],[0],[False],['0']
1085,PMC2277384,29098,There was also no difference between the two groups on mean scores for the dual diagnosis attitude scale.,Discussion,[176144],[24142],[24247],[False],[0],[0],[False],['0']
1086,PMC2277384,29099,The sample was showing signs of burn-out and was not particularly satisfied with their jobs.,Discussion,[176150],[24248],[24340],[False],[0],[0],[False],['0']
1087,PMC2277384,29100,This may have affected their willingness to implement an intervention that advocates getting more involved with a complex and challenging service user group.,Discussion,[176156],[24341],[24498],[False],[0],[0],[False],['0']
1088,PMC2277384,29101,"Team membership reduced the significance of the subscale ""self-esteem about working with drinkers"" but not any of the other results.",Discussion,[176162],[24499],[24631],[False],[0],[0],[False],['0']
1089,PMC2277384,29102,This suggests that there was no major moderating effect of being a member of a particular team on outcomes.,Discussion,[176168],[24632],[24739],[False],[0],[0],[False],['0']
1090,PMC2277384,29103,"These findings suggest that the training should be revisited to look at how to increase people's sense of motivation, sense of a right to work with these problems, how to increase perception of job satisfaction, and also look at how supported they are in their roles working with people with dual diagnosis.",Discussion,[176174],[24740],[25047],[False],[0],[0],[False],['0']
1091,PMC2277384,29104,"These aspects together will increase workers therapeutic commitment, which Cartwright and colleagues [18] believes is essential for engagement with treatment.",Discussion,[176180],[25048],[25206],[False],[0],[0],[False],['0']
1092,PMC2277384,29105,The positive and significant changes in the secondary measures of self-confidence and knowledge are limited in their interpretation.,Discussion,[176186],[25207],[25339],[False],[0],[0],[False],['0']
1093,PMC2277384,29106,They were both specifically designed for the study and their psychometric properties are yet to be established.,Discussion,[176192],[25340],[25451],[False],[0],[0],[False],['0']
1094,PMC2277384,29107,"In addition they are both self-report questionnaires, and there were no independent verification of skills at baseline or follow-up.",Discussion,[176198],[25452],[25584],[False],[0],[0],[False],['0']
1095,PMC2277384,29108,Therefore it is difficult to conclude that these positive changes in self-efficacy translated into actual practice change.,Discussion,[176204],[25585],[25707],[False],[0],[0],[False],['0']
1096,PMC2277384,29109,"It would have been useful to measure the level of competency of the case managers' pre and post training, and assess whether they were able to incorporate what they had learnt into their routine practice.",Discussion,[176210],[25708],[25912],[False],[0],[0],[False],['0']
1097,PMC2277384,29110,Limitations of the study,Discussion|Limitations of the study,[176216],[25913],[25937],[False],[0],[0],[False],['0']
1098,PMC2277384,29111,Follow-up measures were only obtained at 18 months post-training.,Discussion|Limitations of the study,[176222],[25938],[26003],[True],['MissingData'],['Follow-up measures were only obtained at 18 months post-training'],[True],['MissingData']
1099,PMC2277384,29112,This means that any initial gains as a result of the training will not have been recorded and may have eroded over time.,Discussion|Limitations of the study,[176234],[26004],[26124],[False],[0],[0],[False],['0']
1100,PMC2277384,29113,"Therefore it is recommended that future training research incorporates regular follow-up points (immediately after training, then 6 monthly intervals) so that acquisition and erosion can be monitored more accurately.",Discussion|Limitations of the study,[176240],[26125],[26341],[False],[0],[0],[False],['0']
1101,PMC2277384,29114,"Apart from the AAPPQ attitudes questionnaire, the Maslach Burnout Inventory and the Minnesota Satisfaction Survey, the other measures (Knowledge, Self-Efficacy and Dual Diagnosis Attitudes) were devised specifically for the trial.",Discussion|Limitations of the study,[176247],[26342],[26572],[True],['ValidityOfMeasurement'],['were devised specifically for the trial'],[True],['OutcomeMeasures']
1102,PMC2277384,29115,Further exploration of the psychometric properties of these measures is essential.,Discussion|Limitations of the study,[176258],[26573],[26655],[False],[0],[0],[False],['0']
1103,PMC2277384,29116,In terms of multiple testing there is a danger that some of the tests may yield significant results by chance alone.,Discussion|Limitations of the study,[176266],[26656],[26772],[True],['MultipleTesting'],['multiple testing'],[True],['StatisticalAnalysis']
1104,PMC2277384,29117,"However, as the secondary outcomes were exploratory in nature, and not definitive conclusions.",Discussion|Limitations of the study,[176276],[26773],[26867],[False],[0],[0],[False],['0']
1105,PMC2277384,29118,"Therefore significant results were areas for informing further research only, and no adjustment were made for multiple tests.",Discussion|Limitations of the study,[176282],[26868],[26993],[False],[0],[0],[False],['0']
1106,PMC2277384,29119,"The training ""intervention"" comprised of three elements; the five training days, an 80 page treatment manual, and monthly supervision.",Discussion|Limitations of the study,[176288],[26994],[27128],[False],[0],[0],[False],['0']
1107,PMC2277384,29120,"It is unclear whether all these elements were essential for the staff changes, or whether particular aspects more powerful than others.",Discussion|Limitations of the study,[176297],[27129],[27264],[True],['CompositeIntervention'],['It is unclear whether all these elements were essential'],[True],['Intervention']
1108,PMC2277384,29121,"Future training research should assess the effects of the various aspects of the training intervention on outcomes, as well as dose of training.",Discussion|Limitations of the study,[176306],[27265],[27409],[False],[0],[0],[False],['0']
1109,PMC2277384,29122,"The medication management training [14,15] showed a positive effect on both participants and service users and was twice as long as the dual diagnosis training.",Discussion|Limitations of the study,[176312],[27410],[27570],[False],[0],[0],[False],['0']
1110,PMC2277384,29123,A further limitation was that there was no data on attendance at the supervision sessions; therefore no exploration of the impact of supervision can be made.,Discussion|Limitations of the study,[176322],[27571],[27728],[True],['MissingData'],['there was no data on attendance at the supervision sessions'],[True],['MissingData']
1111,PMC2277384,29124,"Future research should ensure that there is an accurate record of supervision for each participant, and that this can be used to compare the outcomes of those who had a high level of supervision and those who had a low level of supervision.",Discussion|Limitations of the study,[176330],[27729],[27969],[False],[0],[0],[False],['0']
1112,PMC2277384,29125,"To reduce the effects of contamination, the intervention group were asked not to discuss the content of the training with the team members that had not received the training (control group).",Discussion|Limitations of the study,[176336],[27970],[28160],[False],[0],[0],[False],['0']
1113,PMC2277384,29126,"However, it is possible that they may have shared their manuals and discussed elements of the training during clinical discussions at team meetings.",Discussion|Limitations of the study,[176347],[28161],[28309],[True],['Patient'],['they may have shared their manuals and discussed elements of the training during clinical discussions at team meetings'],[True],['Blinding']
1114,PMC2277384,29127,The only way to minimise contamination would have been to randomly allocate whole teams to training intervention or control conditions.,Discussion|Limitations of the study,[176354],[28310],[28445],[False],[0],[0],[False],['0']
1115,PMC2277384,29128,"The difficulty with this design is ensuring that enough teams are recruited as clusters and that the teams are similar enough (in terms of catchment area demographics, team skill-mix, remit, models of care etc) to make comparisons meaningful.",Discussion|Limitations of the study,[176360],[28446],[28688],[False],[0],[0],[False],['0']
1116,PMC2277384,29129,"However, whole team training has been shown to produce positive outcomes, and could make implementation of a psychosocial intervention more effective [29].",Discussion|Limitations of the study,[176366],[28689],[28844],[False],[0],[0],[False],['0']
1117,PMC2277384,29130,Future research should evaluate the impact of whole team dual diagnosis training.,Discussion|Limitations of the study,[176372],[28845],[28926],[False],[0],[0],[False],['0']
1118,PMC2277384,29131,Conclusion,Conclusion,[176378],[28927],[28938],[False],[0],[0],[False],['0']
1119,PMC2277384,29132,The COMO project had the ambitious remit of training mental health staff to use a dual diagnosis treatment approach using a relatively brief training intervention.,Conclusion,[176384],[28939],[29102],[False],[0],[0],[False],['0']
1120,PMC2277384,29133,"The results demonstrate that a relatively brief training can have some limited effect on how people perceive their skills, and on improving knowledge.",Conclusion,[176390],[29103],[29253],[False],[0],[0],[False],['0']
1121,PMC2277384,29134,The training made less impact on overall attitude change.,Conclusion,[176396],[29254],[29311],[False],[0],[0],[False],['0']
1122,PMC2277384,29135,"This finding has major implications for the current policy of ""mainstreaming"" care for dual diagnosis.",Conclusion,[176402],[29312],[29414],[False],[0],[0],[False],['0']
1123,PMC2277384,29136,"It is unlikely that brief training courses such as this (without other service developments such as specialist dual diagnosis workers providing intensive support and supervision, and multi-agency strategies), will be sufficient to meet the needs of this client group.",Conclusion,[176408],[29415],[29682],[False],[0],[0],[False],['0']
1124,PMC2277384,29137,"Further research is needed to look at how trainees change their practice and skills following training, and to what extent they are able to implement the approach with the service users on their caseload.",Conclusion,[176414],[29683],[29887],[False],[0],[0],[False],['0']
1125,PMC2277384,29138,"In addition further work should explore the effectiveness of of training in differing mental health services, not just community mental health teams.",Conclusion,[176420],[29888],[30037],[False],[0],[0],[False],['0']
1126,PMC2277384,29139,"Given the high prevalence of people with substance misuse problems in assertive outreach crisis intervention, acute psychiatric inpatient units, early intervention in psychosis, and forensic mental health services, it may make sense to focus dual diagnosis training in these services where the interventions advocated (such as flexibility, focus on engagement, comprehensive care and longitudinal view) may be more convergent with their current practices.",Conclusion,[176426],[30038],[30493],[False],[0],[0],[False],['0']
1127,PMC2277384,29140,"In addition, there needs to be evaluations of other service models for people with co-morbid substance use and mental health problems such as specialist workers based in community teams, and dedicated dual diagnosis services.",Conclusion,[176432],[30494],[30719],[False],[0],[0],[False],['0']
1128,PMC2277384,29141,Competing interests,Competing interests,[176438],[30720],[30740],[False],[0],[0],[False],['0']
1129,PMC2277384,29142,The author(s) declare that they have no competing interests.,Competing interests,[176444],[30741],[30801],[False],[0],[0],[False],['0']
1130,PMC2277384,29143,Authors' contributions,Authors' contributions,[176450],[30802],[30825],[False],[0],[0],[False],['0']
1131,PMC2277384,29144,EH is the main author of the paper.,Authors' contributions,[176456],[30826],[30861],[False],[0],[0],[False],['0']
1132,PMC2277384,29145,"She designed and delivered the training package, was involved in the development of the case manager outcome measures, and was on the trial steering group.",Authors' contributions,[176462],[30862],[31017],[False],[0],[0],[False],['0']
1133,PMC2277384,29146,"SW was part of the trial steering group, and was involved in the development of the case manager outcome measures, and in editing the paper.",Authors' contributions,[176468],[31018],[31158],[False],[0],[0],[False],['0']
1134,PMC2277384,29147,"KG was on the trial steering group, and was involved in the development of the training package and the case manager outcome measures.",Authors' contributions,[176474],[31159],[31293],[False],[0],[0],[False],['0']
1135,PMC2277384,29148,SJ was the principle investigator of the trial and has edited and revised this paper.,Authors' contributions,[176480],[31294],[31379],[False],[0],[0],[False],['0']
1136,PMC2277384,29149,"GT was one of the principle investigators of the trial, and has edited and revised this paper.",Authors' contributions,[176486],[31380],[31474],[False],[0],[0],[False],['0']
1137,PMC2277384,29150,"EF and JM were on the trial steering group, and were involved in the development of the training, the case manager outcome measures.",Authors' contributions,[176492],[31475],[31607],[False],[0],[0],[False],['0']
1138,PMC2277384,29151,"NS was a research worker for the trial, and was involved in the collection and management of the data.",Authors' contributions,[176498],[31608],[31710],[False],[0],[0],[False],['0']
1139,PMC2277384,29152,Pre-publication history,Pre-publication history,[176504],[31711],[31735],[False],[0],[0],[False],['0']
1140,PMC2277384,29153,The pre-publication history for this paper can be accessed here:,Pre-publication history,[176510],[31736],[31800],[False],[0],[0],[False],['0']
1141,PMC2277384,29154,Acknowledgements,Acknowledgements,[176516],[31801],[31819],[False],[0],[0],[False],['0']
1142,PMC2277384,29155,I would like to acknowledge the following people who contributed to this trial.,Acknowledgements,[176522],[31820],[31899],[False],[0],[0],[False],['0']
1143,PMC2277384,29156,Firstly Dr Helen Miles and Dr Sarah Afuwape who were research workers involved in recruiting the community mental health teams and collecting the baseline and follow-up data.,Acknowledgements,[176528],[31900],[32074],[False],[0],[0],[False],['0']
1144,PMC2277384,29157,I would like to acknowledge Dr Morven Leese and Dr Ian Smith for their design and statistical input.,Acknowledgements,[176534],[32075],[32175],[False],[0],[0],[False],['0']
1145,PMC2277384,29158,I would also like to acknowledge Dr John Balacz and Dr Jed Boardman for their input into the development of the trial.,Acknowledgements,[176540],[32176],[32294],[False],[0],[0],[False],['0']
1146,PMC2277384,29159,I would also like to acknowledge the contributions of the community mental health teams in the South London and Maudsley trust for their cooperation and involvement in the training and data collection.,Acknowledgements,[176546],[32295],[32496],[False],[0],[0],[False],['0']
1147,PMC2291568,13010,"Effects of Deworming on Malnourished Preschool Children in India: An Open-Labelled, Cluster-Randomized Trial",Title,[79371],[28682],[108],[False],[0],[0],[False],['0']
1148,PMC2291568,13011,Background,Abstract,[79375],[109],[120],[False],[0],[0],[False],['0']
1149,PMC2291568,13012,More than a third of the world's children are infected with intestinal nematodes.,Abstract,[79379],[121],[202],[False],[0],[0],[False],['0']
1150,PMC2291568,13013,"Current control approaches emphasise treatment of school age children, and there is a lack of information on the effects of deworming preschool children.",Abstract,[79383],[203],[356],[False],[0],[0],[False],['0']
1151,PMC2291568,13014,Methodology,Methodology,[79387],[357],[369],[False],[0],[0],[False],['0']
1152,PMC2291568,13015,"We studied the effects on the heights and weights of 3,935 children, initially 1 to 5 years of age, of five rounds of anthelmintic treatment (400 mg albendazole) administered every 6 months over 2 years.",Methodology,[79391],[370],[573],[False],[0],[0],[False],['0']
1153,PMC2291568,13016,"The children lived in 50 areas, each defined by precise government boundaries as urban slums, in Lucknow, North India.",Methodology,[79395],[574],[692],[False],[0],[0],[False],['0']
1154,PMC2291568,13017,"All children were offered vitamin A every 6 months, and children in 25 randomly assigned slum areas also received 6-monthly albendazole.",Methodology,[79399],[693],[829],[False],[0],[0],[False],['0']
1155,PMC2291568,13018,"Treatments were delivered by the State Integrated Child Development Scheme (ICDS), and height and weight were monitored at baseline and every 6 months for 24 months (trial registration number NCT00396500).",Methodology,[79403],[830],[1035],[False],[0],[0],[False],['0']
1156,PMC2291568,13019,"p Value calculations are based only on the 50 area-specific mean values, as randomization was by area.",Methodology,[79407],[1036],[1138],[False],[0],[0],[False],['0']
1157,PMC2291568,13020,Findings,Findings,[79411],[1139],[1148],[False],[0],[0],[False],['0']
1158,PMC2291568,13021,The ICDS infrastructure proved able to deliver the interventions.,Findings,[79415],[1149],[1214],[False],[0],[0],[False],['0']
1159,PMC2291568,13022,"95% (3,712/3,912) of those alive at the end of the study had received all five interventions and had been measured during all four follow-up surveys, and 99% (3,855/3,912) were measured at the last of these surveys.",Findings,[79419],[1215],[1430],[False],[0],[0],[False],['0']
1160,PMC2291568,13023,"At this final follow up, the albendazole-treated arm exhibited a similar height gain but a 35 (SE 5) % greater weight gain, equivalent to an extra 1 (SE 0.15) kg over 2 years (99% CI 0.6–1.4 kg, p = 10−11).",Findings,[79423],[1431],[1637],[False],[0],[0],[False],['0']
1161,PMC2291568,13024,Conclusions,Conclusions,[79427],[1638],[1650],[False],[0],[0],[False],['0']
1162,PMC2291568,13025,"In such urban slums in the 1990s, five 6-monthly rounds of single dose anthelmintic treatment of malnourished, poor children initially aged 1–5 years results in substantial weight gain.",Conclusions,[79431],[1651],[1836],[False],[0],[0],[False],['0']
1163,PMC2291568,13026,"The ICDS system could provide a sustainable, inexpensive approach to the delivery of anthelmintics or micronutrient supplements to such populations.",Conclusions,[79435],[1837],[1985],[False],[0],[0],[False],['0']
1164,PMC2291568,13027,"As, however, we do not know the control parasite burden, these results are difficult to generalize.",Conclusions,[79442],[1986],[2085],[True],['RelevantOutcomeExcluded'],['we do not know the control parasite burden'],[True],['OutcomeMeasures']
1165,PMC2291568,13028,Trial Registration,Trial Registration,[79447],[2086],[2105],[False],[0],[0],[False],['0']
1166,PMC2291568,13029,ClinicalTrials.gov NCT00396500,Trial Registration,[79451],[2106],[2136],[False],[0],[0],[False],['0']
1167,PMC2291568,13030,Introduction,Introduction,[79455],[2137],[2154],[False],[0],[0],[False],['0']
1168,PMC2291568,13031,Intestinal nematodes are amongst the most common agents of chronic infection in low income countries [1].,Introduction,[79459],[2155],[2260],[False],[0],[0],[False],['0']
1169,PMC2291568,13032,"In India, it has been reported that about half the population is infected with round worm (Ascaris lumbricoides), whipworm (Trichuris trichiura) and/or hookworm (Necator americanus, Ancylostoma duodenale) [2].",Introduction,[79463],[2261],[2470],[False],[0],[0],[False],['0']
1170,PMC2291568,13033,These infections could have significant effects on the development of children [3].,Introduction,[79467],[2471],[2554],[False],[0],[0],[False],['0']
1171,PMC2291568,13034,"Any effects on physical development would typically be subtle and chronic, manifesting as longstanding anaemia [4]–[6], reduced physical fitness [7], and somewhat constrained growth [8].",Introduction,[79471],[2555],[2741],[False],[0],[0],[False],['0']
1172,PMC2291568,13035,"There might also be subtle, but important developmental effects on cognition and educational achievement [9]–[11].",Introduction,[79475],[2742],[2856],[False],[0],[0],[False],['0']
1173,PMC2291568,13036,"Recognition of these potential consequences of infection has led to increasing emphasis on community-based anthelmintic treatment to reduce worm burdens in children irrespective of direct evidence of infection, particularly children of school age [1],[3],[12],[13].",Introduction,[79479],[2857],[3122],[False],[0],[0],[False],['0']
1174,PMC2291568,13037,The current focus on schoolchildren reflects three factors: the evidence of an effect on weight and cognition in this age group; the accessibility of school children to treatment delivered through the education infrastructure; and the epidemiological observation that school children tend to harbour the largest worm burdens [12].,Introduction,[79483],[3123],[3453],[False],[0],[0],[False],['0']
1175,PMC2291568,13038,"Few studies have examined the impact of infection on younger children, partly because the burden of worms and, it has been assumed, disease is light at this early age, and perhaps because of the practical difficulty in reaching the pre-school population.",Introduction,[79487],[3454],[3708],[False],[0],[0],[False],['0']
1176,PMC2291568,13039,"Two recent studies from Africa, however, suggest different conclusions.",Introduction,[79491],[3709],[3780],[False],[0],[0],[False],['0']
1177,PMC2291568,13040,"A study of deworming children during home visits in rural Zanzibar indicated that the youngest children, who are most at risk of growth retardation, showed the greatest increase in growth rate after treatment with anthelmintics [4], while a study of deworming pre-school children during “health days” in Uganda increased growth rate and was cost-effective [14].",Introduction,[79495],[3781],[4142],[False],[0],[0],[False],['0']
1178,PMC2291568,13041,The situation in North India suggested that deworming of children younger than school age might be beneficial and practical.,Introduction,[79499],[4143],[4267],[False],[0],[0],[False],['0']
1179,PMC2291568,13042,In Uttar Pradesh (U.P.),Introduction,[79503],[4268],[4291],[False],[0],[0],[False],['0']
1180,PMC2291568,13043,"in North India, high levels of worm infection and malnutrition have been observed in pre-school children [15] and our observations indicate that more than a third of pre-school children around Lucknow are infected, predominantly with Ascaris lumbricoides.",Introduction,[79507],[4292],[4547],[False],[0],[0],[False],['0']
1181,PMC2291568,13044,A study of supplementary nutrition suggested some benefit from deworming such children [16].,Introduction,[79511],[4548],[4640],[False],[0],[0],[False],['0']
1182,PMC2291568,13045,"Furthermore, the State Integrated Child Development Scheme (ICDS) provides a health care infrastructure that aims to reach all children up to 5 or 6 years of age, and thus provides a potentially cost effective mechanism for delivering anthelmintics to these children [17].",Introduction,[79515],[4641],[4913],[False],[0],[0],[False],['0']
1183,PMC2291568,13046,"This was a cluster-randomized trial, since for a study on this scale randomization by area was the only feasible strategy.",Introduction,[79519],[4914],[5036],[False],[0],[0],[False],['0']
1184,PMC2291568,13047,The study was conducted using the existing community and health infrastructures to allow the possibility that the interventions could be institutionalised and scaled up with minimum additional inputs.,Introduction,[79523],[5037],[5237],[False],[0],[0],[False],['0']
1185,PMC2291568,13048,Methods,Methods,[79527],[5238],[5246],[False],[0],[0],[False],['0']
1186,PMC2291568,13049,"We conducted an open-labelled, cluster-randomized trial within the ICDS infrastructure in urban Lucknow UP with the hypotheses that the ICDS could deliver anthelmintics regularly to pre-school children in the urban slums of Lucknow, and that if they did then this would result in a growth benefit (trial registration number NCT00396500).",Methods,[79531],[5247],[5584],[False],[0],[0],[False],['0']
1187,PMC2291568,13050,We obtained approval from the institutional human ethics committee in Lucknow.,Methods,[79535],[5585],[5663],[False],[0],[0],[False],['0']
1188,PMC2291568,13051,The primary objective was to assess the impact of 6 monthly deworming on weight and height gain over 2 years in children initially aged 1 to 5 years of age.,Methods,[79539],[5664],[5820],[False],[0],[0],[False],['0']
1189,PMC2291568,13052,The protocol for this trial and supporting CONSORT checklist are available as Supporting Information; see Protocol S1 and Checklist S1.,Methods,[79543],[5821],[5956],[False],[0],[0],[False],['0']
1190,PMC2291568,13053,"There are 203 designated urban slum areas in urban Lucknow, each of which has about 100 pre-school children and is served by a pre-school centre, known as an anganwadi ( = courtyard) center.",Methods,[79547],[5957],[6147],[False],[0],[0],[False],['0']
1191,PMC2291568,13054,"An ICDS worker in each area uses the anganwadi center to provide general care to children under 5, including administration of 100,000 units of vitamin A syrup every 6 months.",Methods,[79551],[6148],[6323],[False],[0],[0],[False],['0']
1192,PMC2291568,13055,A geographically convenient group of fifty of these slum areas was chosen for the study.,Methods,[79555],[6324],[6412],[False],[0],[0],[False],['0']
1193,PMC2291568,13056,"All these areas continued their vitamin A supplementation and other usual care during the study period, and 25 were randomly allocated to offer in addition, 400 mg of albendazole (Zentel, SmithKline Beecham) as 10 ml suspension at the same time as the six-monthly vitamin A.",Methods,[79559],[6413],[6687],[False],[0],[0],[False],['0']
1194,PMC2291568,13057,"The ICDS workers were provided training regarding: (a) indications of the interventions, precautions during the storage and administration of the interventions, and adverse effects; (b) strategies for community mobilization; (c) record keeping; and (d) procedures for weight and height measurement.",Methods,[79563],[6688],[6986],[False],[0],[0],[False],['0']
1195,PMC2291568,13058,Interventions were administered orally in the anganwadi centers by the visiting research team working in collaboration with the local anganwadi center staff.,Methods,[79567],[6987],[7144],[False],[0],[0],[False],['0']
1196,PMC2291568,13059,"All resident children between 1 and 5 years of age were recruited to the study, and all parents of eligible children provided written consent.",Methods,[79571],[7145],[7287],[False],[0],[0],[False],['0']
1197,PMC2291568,13060,"None of the parents refused participation, because when, after much discussion, those in such communities chose to cooperate they all became willing to do so for the common good.",Methods,[79575],[7288],[7466],[False],[0],[0],[False],['0']
1198,PMC2291568,13061,"A research team was trained to measure height to the nearest 0.1 cm, using a stadiometer, and weight to the nearest 0.1 kg, using electronic weighing scales which were calibrated daily.",Methods,[79579],[7467],[7652],[False],[0],[0],[False],['0']
1199,PMC2291568,13062,"Anthropometry of each child was done at baseline, and then at 6-month intervals for 24 months.",Methods,[79583],[7653],[7747],[False],[0],[0],[False],['0']
1200,PMC2291568,13063,Adverse events were not assessed in this trial.,Methods,[79587],[7748],[7795],[False],[0],[0],[False],['0']
1201,PMC2291568,13064,Sample size,Sample size,[79591],[7796],[7808],[False],[0],[0],[False],['0']
1202,PMC2291568,13065,"It was expected from cross-sectional surveys that the 2-year weight gain in this poorly nourished population would be only about 3 kg, perhaps with standard deviation (SD) about 1 or 1.5 kg.",Sample size,[79595],[7809],[7999],[False],[0],[0],[False],['0']
1203,PMC2291568,13066,Exact sample size calculations were not possible because it was not known what fraction f of this variance was due to real differences between different slums.,Sample size,[79599],[8000],[8159],[False],[0],[0],[False],['0']
1204,PMC2291568,13067,"If 25 albendazole and 25 control slum areas are compared, with about 100 children per slum area, then unless f is very small, the standard error of the treatment effect (SE) is approximately   (formally,  ; f is sometimes called the intra-cluster correlation coefficient, or ICC).",Sample size,[79603],[8160],[8440],[False],[0],[0],[False],['0']
1205,PMC2291568,13068,"If, for example, f = 1/4 then SE would be about 0.2 kg, so the study would have a reasonable chance of detecting a 2-year weight gain of 0.5 kg.",Sample size,[79607],[8441],[8585],[False],[0],[0],[False],['0']
1206,PMC2291568,13069,"ICCs for future reference were estimated as the fractional reduction on comparing the residual mean squares after regression on initial age, sex and cluster membership with those after regression only on initial age, sex and treatment allocation.",Sample size,[79611],[8586],[8832],[False],[0],[0],[False],['0']
1207,PMC2291568,13070,"Random allocation was done by SA, listing the anganwadi centers of each slum area serially in alphabetical order, numbering them from 1 to 50, and then generating a single random number by computer that allocated either all odd or all even numbers to a specific intervention type.",Sample size,[79615],[8833],[9113],[False],[0],[0],[False],['0']
1208,PMC2291568,13071,Analysis,Analysis,[79619],[9114],[9123],[False],[0],[0],[False],['0']
1209,PMC2291568,13072,"EPI 6.1 statistical software was used to calculate the weight-for-age, height-for-age and weight-for-height z-scores, which compare the study children to the nutritional standards of the World Health Organization.",Analysis,[79623],[9124],[9337],[False],[0],[0],[False],['0']
1210,PMC2291568,13073,"The z-score measures show, in standard deviations, how far a particular measurement departs from these standards.",Analysis,[79627],[9338],[9451],[False],[0],[0],[False],['0']
1211,PMC2291568,13074,"The baseline prevalences of undernutrition (weight-for-age z-score ≤−2), stunting (height-for-age z-score ≤−2) and wasting (weight-for-height z-score ≤−2 ) were calculated for all the enrolled children.",Analysis,[79631],[9452],[9654],[False],[0],[0],[False],['0']
1212,PMC2291568,13075,"Because randomization was by area, we first assessed the area-specific results, one per area.",Analysis,[79635],[9655],[9748],[False],[0],[0],[False],['0']
1213,PMC2291568,13076,"We then compared these 50 numbers with each other (25 versus 25), and our means and standard errors reflect the variation between these 50 values.",Analysis,[79639],[9749],[9895],[False],[0],[0],[False],['0']
1214,PMC2291568,13077,"For example, height and weight gain in one year and at two years were compared in 25 “usual care” versus 25 “usual care plus albendazole” areas.",Analysis,[79643],[9896],[10040],[False],[0],[0],[False],['0']
1215,PMC2291568,13078,Reported here are the mean weight and height gains with their standard errors.,Analysis,[79647],[10041],[10119],[False],[0],[0],[False],['0']
1216,PMC2291568,13079,"Weight and height gains were also calculated separately for children who were underweight, stunted and wasted at enrolment in both groups.",Analysis,[79651],[10120],[10258],[False],[0],[0],[False],['0']
1217,PMC2291568,13080,"Although in such analyses area-specific results are affected by regression to the mean, the comparison of 25 versus 25 areas remains unbiased.",Analysis,[79655],[10259],[10401],[False],[0],[0],[False],['0']
1218,PMC2291568,13081,All p-values refer to two-sided significance tests.,Analysis,[79659],[10402],[10453],[False],[0],[0],[False],['0']
1219,PMC2291568,13082,Results,Results,[79663],[10454],[10462],[False],[0],[0],[False],['0']
1220,PMC2291568,13083,"A total of 3935 children, aged 1 to 5 years at entry, 1967 from 25 anganwadi centers allocated “usual care” and 1968 from 25 anganwadi centers allocated “usual care plus albendazole” were enrolled in the study from April to August, 1994 and followed up until December, 1996 (Figure 1).",Results,[79667],[10463],[10748],[False],[0],[0],[False],['0']
1221,PMC2291568,13084,"Relative to WHO reference standards, the point prevalence at baseline of underweight was 49% (1924 children), stunting 63% (2471), and wasting 18% (699).",Results,[79671],[10749],[10902],[False],[0],[0],[False],['0']
1222,PMC2291568,13085,"The children were all from families with incomes below the national poverty level, and 51% were girls.",Results,[79675],[10903],[11005],[False],[0],[0],[False],['0']
1223,PMC2291568,13086,"The children were treated and surveyed 5 times (at 0, 6, 12, 18 and 24 months) and anthropometric data were collected on all 5 occasions from 95% (3712/3912) of the surviving children in each arm of the study.",Results,[79679],[11006],[11215],[False],[0],[0],[False],['0']
1224,PMC2291568,13087,"At 24 months, 99% (3855/3912) of the surviving children were measured.",Results,[79683],[11216],[11286],[False],[0],[0],[False],['0']
1225,PMC2291568,13088,"There were 23 deaths in 2 years, of which 13 were in the usual care arm and 10 were in the arm receiving usual care plus albendazole.",Results,[79687],[11287],[11420],[False],[0],[0],[False],['0']
1226,PMC2291568,13089,"At the 1 year follow up there was no significant difference in height gain (7.5 [SE 0.3] cm vs. 7.6 [SE 0.2] cm), but the usual care plus albendazole arm had gained significantly more weight (1.57 [SE 0.06] kg vs. 1.93 [SE 0.08] kg, difference 0.36 [SE 0.10] kg, p = 0.0007).",Results,[79691],[11421],[11696],[False],[0],[0],[False],['0']
1227,PMC2291568,13090,"At 2 years the albendazole group showed slightly greater height gain (13.4 cm vs. 14.1 cm, difference 0.7 [SE 0.4] cm, p = 0.11) but this difference was still not significant.",Results,[79695],[11697],[11872],[False],[0],[0],[False],['0']
1228,PMC2291568,13091,"The usual care plus albendazole arm continued, however, to show a highly significant difference in weight gain (2.8 [SE 0.1] kg vs. 3.8 [SE 0.1] kg, difference 1.0 [SE 0.15] kg, p = 10−11), with the dewormed children exhibiting a 35 (SE 5) % higher weight gain.",Results,[79699],[11873],[12134],[False],[0],[0],[False],['0']
1229,PMC2291568,13092,This is equivalent to an additional 1.0 (SE 0.15) kg over 2 years (99% CI: 0.6–1.4 kg).,Results,[79703],[12135],[12222],[False],[0],[0],[False],['0']
1230,PMC2291568,13093,For the 2-year gains in height and weight the intra-cluster correlation coefficients were not zero (0.11 for height gain [95% CI 0.07–0.15]; 0.17 for weight gain [95% CI 0.11–0.23]: see Methods).,Results,[79707],[12223],[12418],[False],[0],[0],[False],['0']
1231,PMC2291568,13094,"The SE calculations allow for this, however, as they are based only on the 50 area-specific mean gains.",Results,[79711],[12419],[12522],[False],[0],[0],[False],['0']
1232,PMC2291568,13095,"The mean heights in the two arms at each visit are shown in Figure 2, with all mean values and standard errors calculated only from the 50 (25 vs 25) area-specific mean results.",Results,[79715],[12523],[12700],[False],[0],[0],[False],['0']
1233,PMC2291568,13096,"The usual care plus albendazole arm children were, by chance, slightly taller at entry (1.2 [SE 0.6] cm, p = 0.06), and this difference in mean height persisted throughout the study.",Results,[79719],[12701],[12883],[False],[0],[0],[False],['0']
1234,PMC2291568,13097,Figure 3 shows the corresponding results for weight.,Results,[79723],[12884],[12936],[False],[0],[0],[False],['0']
1235,PMC2291568,13098,"The usual care plus albendazole arm children had, by chance, slightly lower mean weight at entry (0.3 [SE 0.2] kg, p = 0.19), but as the study progressed this was reversed by the significantly greater weight gain.",Results,[79727],[12937],[13150],[False],[0],[0],[False],['0']
1236,PMC2291568,13099,The non-significant differences in height and weight at baseline pointed in opposite directions before any treatment had been given.,Results,[79731],[13151],[13283],[False],[0],[0],[False],['0']
1237,PMC2291568,13100,"If, as a data-dependent response to these unexpectedly opposite differences, we were to compare baseline weight-for-height, the difference would be significant (p = 0.0013).",Results,[79735],[13284],[13457],[False],[0],[0],[False],['0']
1238,PMC2291568,13101,"We regard this, however, after much investigation of the original records, as merely an oddity of the randomization rather than a failure of it, and its effects are appropriately allowed for in the main analysis by our emphasis on mean changes from baseline over the 2-year study period.",Results,[79739],[13458],[13745],[False],[0],[0],[False],['0']
1239,PMC2291568,13102,We compared the scale of the age-specific weight gain in the usual care arm with the differences in weight between age classes at baseline (Table 1).,Results,[79743],[13746],[13895],[False],[0],[0],[False],['0']
1240,PMC2291568,13103,The observed weight gain in the study was similar to the differences in weight between year classes at the beginning of the study.,Results,[79747],[13896],[14026],[False],[0],[0],[False],['0']
1241,PMC2291568,13104,"The growth rate, by both measures, declines with age, as expected.",Results,[79751],[14027],[14093],[False],[0],[0],[False],['0']
1242,PMC2291568,13105,"When these data are compared with the weight gains in the usual care plus albendazole arm, there was a significant increase in weight with treatment for all age classes.",Results,[79755],[14094],[14263],[False],[0],[0],[False],['0']
1243,PMC2291568,13106,This indicates some growth benefit even in the younger children who are likely to harbour lower worm burdens.,Results,[79759],[14264],[14373],[False],[0],[0],[False],['0']
1244,PMC2291568,13107," Table 2 shows that for all children, irrespective of treatment group, the weight gain at 2 years was greater for those children who were malnourished initially.",Results,[79763],[14374],[14535],[False],[0],[0],[False],['0']
1245,PMC2291568,13108,"This effect was significant for underweight and wasting, but not for stunting.",Results,[79767],[14536],[14614],[False],[0],[0],[False],['0']
1246,PMC2291568,13109,"It is, however, difficult to correct this observation for the effects of measurement error.",Results,[79771],[14615],[14706],[False],[0],[0],[False],['0']
1247,PMC2291568,13110,One way of doing so is to note that the 2-year weight gain is also significantly correlated with the weight at the mid-year.,Results,[79775],[14707],[14831],[False],[0],[0],[False],['0']
1248,PMC2291568,13111,"For all nutritional categories, the weight gain was significantly greater for those children who received albendazole in addition to usual care.",Results,[79779],[14832],[14976],[False],[0],[0],[False],['0']
1249,PMC2291568,13112,"In the under-nourished categories, the greatest gain in weight was for wasted children and the least for stunted children.",Results,[79783],[14977],[15099],[False],[0],[0],[False],['0']
1250,PMC2291568,13113,Discussion,Discussion,[79787],[15100],[15111],[False],[0],[0],[False],['0']
1251,PMC2291568,13114,"These results suggest that, at the time of the study (mid 1990s), 6 monthly deworming as a part of an ICDS program in these urban slums in north India was associated with substantial weight gain in malnourished pre-school children.",Discussion,[79791],[15112],[15343],[False],[0],[0],[False],['0']
1252,PMC2291568,13115,"The mechanism for this gain was not assessed by the present study design as we have no measure of faecal worm egg counts, but it may reflect a direct effect of deworming on nutrition.",Discussion,"[79795, 79796]","[15344, 15344]","[15527, 15527]","[True, True]","['RelevantOutcomeExcluded', 'RelevantOutcomeExcluded']","['The mechanism for this gain was not assessed', 'we have no measure of faecal worm egg counts']","[True, True]",['OutcomeMeasures']
1253,PMC2291568,13116,"The effect may also be indirect since a negative association between ascariasis and vitamin A absorption has been described [18], but a study in an area of low infection prevalence showed a benefit of vitamin A supplementation that was not further enhanced by deworming [19].",Discussion,[79803],[15528],[15803],[False],[0],[0],[False],['0']
1254,PMC2291568,13117,A moderate increase in weight but not height appears to be a consistent phenomenon in deworming trials of worm-affected populations.,Discussion,[79807],[15804],[15936],[False],[0],[0],[False],['0']
1255,PMC2291568,13118,"Of five published randomized trials of anthelmintic treatment that showed significantly increased growth in preschool children [4],[14],[20], all reported benefits in ponderal growth, and only one an increase in linear growth.",Discussion,[79811],[15937],[16163],[False],[0],[0],[False],['0']
1256,PMC2291568,13119,"The lack of a significant height gain may reflect an initial increase in tissue mass rather than linear growth for such disadvantaged children; in the children in Lucknow the height gain was greatest for those stunted initially, and least for those wasted (data not shown).",Discussion,[79815],[16164],[16437],[False],[0],[0],[False],['0']
1257,PMC2291568,13120,"The results of the present study are also of similar scale to previous trials where the annual gain is typically in the range 5% to 10% above the control group [4],[14],[20].",Discussion,[79819],[16438],[16612],[False],[0],[0],[False],['0']
1258,PMC2291568,13121,"The gain observed in the present study was equivalent to an additional 1.0 (SE 0.15) kg over 2 years, and even the lower 99% confidence limit of 0.6 kg represents an additional gain of 0.3 kg per year.",Discussion,[79823],[16613],[16814],[False],[0],[0],[False],['0']
1259,PMC2291568,13122,"Since the size of the populations living in urban slums is increasing world wide, these findings could be of growing relevance to middle and low income countries [21].",Discussion,[79827],[16815],[16982],[False],[0],[0],[False],['0']
1260,PMC2291568,13123,In pre-school children there is a direct correlation between weight and relative risk of death.,Discussion,[79831],[16983],[17078],[False],[0],[0],[False],['0']
1261,PMC2291568,13124,"In 8 prospective studies of children 6 to 59 months of age, set in Asia and Africa, the mean relative risk of death from common childhood diseases is 8.4 (SE 2.1) with severe, 4.6 (SE 0.9) with moderate and 2.5 (SE 0.3) for mild malnutrition (where severe malnutrition is weight-for-age z-score <−3, moderate is between −3 and −2 and mild is between −2 and −1) [22] .",Discussion,[79835],[17079],[17446],[False],[0],[0],[False],['0']
1262,PMC2291568,13125,"However, 80% of deaths in children under five years of age occur in those that are only mildly malnourished [22] .",Discussion,[79839],[17447],[17561],[False],[0],[0],[False],['0']
1263,PMC2291568,13126,In India in particular a high proportion of mortality in children aged 1–5 years old may be attributed to the potentiating effects of malnutrition on infectious disease [22].,Discussion,[79843],[17562],[17736],[False],[0],[0],[False],['0']
1264,PMC2291568,13127,"In the present study the scale of weight gain that can be achieved in poor urban settings in India might be sufficient to contribute to reduced mortality, although a very large study would be needed to demonstrate this directly.",Discussion,[79849],[17737],[17965],[True],['UnderpoweredStudy'],['a very large study would be needed'],[True],['UnderpoweredStudy']
1265,PMC2291568,13128,"This study suggests that deworming tablets which costs less than US$ 0.10 per annum, and can be delivered through the existing ICDS infrastructure, could contribute to improved child growth and, perhaps, survival in urban north India.",Discussion,[79855],[17966],[18200],[False],[0],[0],[False],['0']
1266,PMC2291568,13129,"The authors have declared that no competing interests exist.This study was funded by the Clinical Trial Service Unit (CTSU), University of Oxford, United Kingdom, and co-funded by the International Clinical Epidemiology Network Inc., Philadelphia, United States of America.",,[79859],[18201],[18476],[False],[0],[0],[False],['0']
1267,PMC2291568,13130,Albendazole was donated by SmithKline Beecham (now GlaxoSmithKline).,,[79863],[18477],[18545],[False],[0],[0],[False],['0']
1651,PMC2744862,27667,Radial extracorporeal shockwave treatment compared with supervised exercises in patients with subacromial pain syndrome: single blind randomised study,Title,[165948],[38908],[150],[False],[0],[0],[False],['0']
1652,PMC2744862,27668,Objective To compare the effectiveness of radial extracorporeal shockwave treatment with that of supervised exercises in patients with shoulder pain.,Abstract,[165951],[151],[301],[False],[0],[0],[False],['0']
1653,PMC2744862,27669,Design Single blind randomised study.,Abstract,[165954],[302],[339],[False],[0],[0],[False],['0']
1654,PMC2744862,27670,"Setting Outpatient clinic of physical medicine and rehabilitation department in Oslo, Norway.",Abstract,[165957],[340],[433],[False],[0],[0],[False],['0']
1655,PMC2744862,27671,Participants 104 patients with subacromial shoulder pain lasting at least three months.,Abstract,[165960],[434],[521],[False],[0],[0],[False],['0']
1656,PMC2744862,27672,Interventions Radial extracorporeal shockwave treatment: one session weekly for four to six weeks.,Abstract,[165963],[522],[621],[False],[0],[0],[False],['0']
1657,PMC2744862,27673,Supervised exercises: two 45 minute sessions weekly for up to 12 weeks.,Abstract,[165966],[622],[693],[False],[0],[0],[False],['0']
1658,PMC2744862,27674,Primary outcome measure Shoulder pain and disability index.,Abstract,[165969],[694],[753],[False],[0],[0],[False],['0']
1659,PMC2744862,27675,"Results A treatment effect in favour of supervised exercises at 6, 12, and 18 weeks was found.",Abstract,[165972],[754],[848],[False],[0],[0],[False],['0']
1660,PMC2744862,27676,The adjusted treatment effect was −8.4 (95% confidence interval −16.5 to −0.6) points.,Abstract,[165975],[849],[935],[False],[0],[0],[False],['0']
1661,PMC2744862,27677,A significantly higher proportion of patients in the group treated with supervised exercises improved—odds ratio 3.2 (1.3 to 7.8).,Abstract,[165978],[936],[1066],[False],[0],[0],[False],['0']
1662,PMC2744862,27678,More patients in the shockwave treatment group had additional treatment between 12 and 18 weeks—odds ratio 5.5 (1.3 to 26.4).,Abstract,[165981],[1067],[1192],[False],[0],[0],[False],['0']
1663,PMC2744862,27679,Conclusion Supervised exercises were more effective than radial extracorporeal shockwave treatment for short term improvement in patients with subacromial shoulder pain.,Abstract,[165984],[1193],[1362],[False],[0],[0],[False],['0']
1664,PMC2744862,27680,Trial registration Clinical trials NCT00653081.,Abstract,[165987],[1363],[1411],[False],[0],[0],[False],['0']
1665,PMC2744862,27681,Introduction,Introduction,[165990],[1412],[1425],[False],[0],[0],[False],['0']
1666,PMC2744862,27682,"The shoulder is the fourth most common site of musculoskeletal pain reported by patients to general practitioners and physiotherapists.1 Rotator cuff disease, impingement syndrome, and rotator cuff tendinosis are terms used synonymously with subacromial shoulder pain.",Introduction,[165993],[1426],[1694],[False],[0],[0],[False],['0']
1667,PMC2744862,27683,"The exact source and mechanism of the pain is unknown.2 Histopathology studies show mainly degenerative changes in the rotator cuff tendons, but other factors also contribute to the pain and dysfunction.1 3",Introduction,[165996],[1695],[1901],[False],[0],[0],[False],['0']
1668,PMC2744862,27684,"Patients with subacromial shoulder pain are often treated with physiotherapy, non-steroidal anti-inflammatory drugs, and corticosteroid injections.",Introduction,[165999],[1902],[2049],[False],[0],[0],[False],['0']
1669,PMC2744862,27685,"Physiotherapy includes a variety of modalities such as electrotherapy, radial extracorporeal shockwave treatment, ultrasound treatment, laser treatment, manual therapy, supervised exercises, sling exercise treatment, and acupuncture.4 5 6 7 Some evidence exists for the effectiveness of corticosteroid injections, non-steroidal anti-inflammatory drugs, and exercises for chronic shoulder pain.8 9 10 A recent systematic review concluded that surgery and exercises are equally effective for rotator cuff disease.11 In studies of musculoskeletal pain, women report pain that is more severe, more frequent, and of a longer duration than do men.12 13 Stratification by sex or adjustment for sex is therefore recommended in the analysis of data from trials.",Introduction,[166002],[2050],[2802],[False],[0],[0],[False],['0']
1670,PMC2744862,27686,"In a systematic review, Harniman et al found moderate evidence that low energy radial extracorporeal shockwave treatment was not effective for non-calcifying rotator cuff tendinosis.6 Additional studies including patients with calcifying or non-calcifying tendinosis reported no treatment effect compared with sham or control.14 15 Despite these findings, shockwave treatment is increasingly used for subacromial shoulder pain.",Introduction,[166005],[2803],[3230],[False],[0],[0],[False],['0']
1671,PMC2744862,27687,"To our knowledge, radial extracorporeal shockwave treatment has not been compared with exercises in a clinical trial including patients with shoulder pain.",Introduction,[166008],[3231],[3386],[False],[0],[0],[False],['0']
1672,PMC2744862,27688,The purpose of this study was to compare the short term effect of radial extracorporeal shockwave treatment and supervised exercises in patients with subacromial shoulder pain.,Introduction,[166011],[3387],[3563],[False],[0],[0],[False],['0']
1673,PMC2744862,27689,Methods,Methods,[166014],[3564],[3572],[False],[0],[0],[False],['0']
1674,PMC2744862,27690,Participants,Methods|Participants,[166017],[3573],[3585],[False],[0],[0],[False],['0']
1675,PMC2744862,27691,The study was designed as a randomised single blind clinical study.,Methods|Participants,[166020],[3586],[3653],[False],[0],[0],[False],['0']
1676,PMC2744862,27692,"Participants were recruited by physicians at the outpatient clinic of the Physical Medicine and Rehabilitation Department at Ullevaal University Hospital, Oslo, Norway, between July 2006 and August 2007.",Methods|Participants,[166023],[3654],[3857],[False],[0],[0],[False],['0']
1677,PMC2744862,27693,Women and men aged between 18 and 70 years with subacromial shoulder pain lasting at least three months were eligible for inclusion.,Methods|Participants,[166026],[3858],[3990],[False],[0],[0],[False],['0']
1678,PMC2744862,27694,"The following diagnostic criteria were used: dysfunction or pain on abduction, normal passive glenohumeral range of motion, pain on two of three isometric tests (abduction at 0° or 30°, external or internal rotation), and a positive Kennedy-Hawkins sign.1 16 17 Park et al recommend these combined clinical tests for a clinical diagnosis of subacromial impingement syndrome (or rotator cuff tendinosis) with a post-test probability of 95%.17 Patients with rotator cuff rupture were included if they fulfilled the above criteria.",Methods|Participants,[166029],[3991],[4519],[False],[0],[0],[False],['0']
1679,PMC2744862,27695,"Exclusion criteria were bilateral shoulder pain, previous surgery on the affected shoulder, instability, clinical signs of a cervical syndrome, rheumatoid arthritis, clinical and radiological signs of glenohumeral or acromioclavicular arthritis, inability to understand Norwegian, serious psychiatric disorder, use of anticoagulant drugs (except low dose aspirin), pregnancy, previous experience of one of the study interventions, or unwillingness to accept either of the interventions in this study.",Methods|Participants,[166032],[4520],[5020],[False],[0],[0],[False],['0']
1680,PMC2744862,27696,Randomisation,Methods|Randomisation,[166035],[5021],[5034],[False],[0],[0],[False],['0']
1681,PMC2744862,27697,"The patients were referred to the investigator (KE, a physiotherapist), received oral and written information about the two treatments, and gave their informed consent before the baseline evaluation.",Methods|Randomisation,[166038],[5035],[5234],[False],[0],[0],[False],['0']
1682,PMC2744862,27698,A statistician not involved in data collection or analysis randomly allocated patients to treatment groups in blocks of four to six.,Methods|Randomisation,[166041],[5235],[5367],[False],[0],[0],[False],['0']
1683,PMC2744862,27699,Randomisation was stratified by sex.,Methods|Randomisation,[166044],[5368],[5404],[False],[0],[0],[False],['0']
1684,PMC2744862,27700,A person not involved in the treatments opened the sealed envelopes and assigned appointments according to treatment group.,Methods|Randomisation,[166047],[5405],[5528],[False],[0],[0],[False],['0']
1685,PMC2744862,27701,Outcomes,Methods|Outcomes,[166050],[5529],[5537],[False],[0],[0],[False],['0']
1686,PMC2744862,27702,"The participants completed a comprehensive questionnaire including questions on demographics, education, duration of pain, sick leave, emotional distress, and the outcome measures.",Methods|Outcomes,[166053],[5538],[5718],[False],[0],[0],[False],['0']
1687,PMC2744862,27703,"The main outcome measure was the shoulder pain and disability index (SPADI), a self report questionnaire for patients with shoulder pain.",Methods|Outcomes,[166056],[5719],[5856],[False],[0],[0],[False],['0']
1688,PMC2744862,27704,"The questionnaire consists of 13 questions divided into two domains: pain (five items) and disability (eight items).18 Answers are scored on visual analogue scales from 0 cm (best) to 11 cm (worst) and in accordance with the original scoring system.18 The total score ranges from 0 to 100 points, with a higher score indicating worse shoulder pain and disability.18 A version adapted to Norwegian language and culture, translated and back translated by independent philologists, was used in this study.19 20",Methods|Outcomes,[166059],[5857],[6364],[False],[0],[0],[False],['0']
1689,PMC2744862,27705,"Intensity of pain during rest and activity in the previous week was measured on a nine point Lickert-type scale, on which 1 indicates no pain and 9 indicates severe pain.21 Participants were asked two questions about specific function of the shoulder: “Can you carry a shopping bag (5 kg)?” and “Can you take down something from a wall cupboard?” These questions were scored on a scale from 1 (easy) to 7 (impossible).21 Active range of motion was measured bilaterally with an accuracy of 5°.21 22 The patients decided when the pain condition confined the movement.",Methods|Outcomes,[166062],[6365],[6930],[False],[0],[0],[False],['0']
1690,PMC2744862,27706,Participants reported work status according to a validated questionnaire.23 A status of retired was recorded separately.,Methods|Outcomes,[166065],[6931],[7051],[False],[0],[0],[False],['0']
1691,PMC2744862,27707,"They also recorded use of drug treatment, including both daily and weekly treatments for pain, sleep problems, and depression.",Methods|Outcomes,[166068],[7052],[7178],[False],[0],[0],[False],['0']
1692,PMC2744862,27708,Follow-up,Methods|Follow-up,[166071],[7179],[7188],[False],[0],[0],[False],['0']
1693,PMC2744862,27709,"At six weeks the patients completed a postal questionnaire, including the outcome measures, at home.",Methods|Follow-up,[166074],[7189],[7289],[False],[0],[0],[False],['0']
1694,PMC2744862,27710,The 12 week and 18 week follow-ups were done at the hospital.,Methods|Follow-up,[166077],[7290],[7351],[False],[0],[0],[False],['0']
1695,PMC2744862,27711,A blinded physiotherapist made the baseline and follow-up measurements.,Methods|Follow-up,[166080],[7352],[7423],[False],[0],[0],[False],['0']
1696,PMC2744862,27712,The patients were instructed not to discuss their treatment with the blinded physiotherapist.,Methods|Follow-up,[166083],[7424],[7517],[False],[0],[0],[False],['0']
1697,PMC2744862,27713,Interventions,Methods|Interventions,[166086],[7518],[7531],[False],[0],[0],[False],['0']
1698,PMC2744862,27714,Both treatments were given at the Department of Physical Medicine and Rehabilitation.,Methods|Interventions,[166089],[7532],[7617],[False],[0],[0],[False],['0']
1699,PMC2744862,27715,"The supervised exercise regimen, developed at Ullevaal University Hospital by Bøhmer in the 1980s,5 was provided by two physiotherapists experienced in its performance.",Methods|Interventions,[166092],[7618],[7786],[False],[0],[0],[False],['0']
1700,PMC2744862,27716,Patients attended two 45 minute sessions weekly for a maximum of 12 weeks.,Methods|Interventions,[166095],[7787],[7861],[False],[0],[0],[False],['0']
1701,PMC2744862,27717,"The first session included gathering medical history and bilateral inspection of alignment, including the scapula and the glenohumeral joint.",Methods|Interventions,[166098],[7862],[8003],[False],[0],[0],[False],['0']
1702,PMC2744862,27718,"Movement pattern, the immediate co-contraction, and timing of the scapula and the arm were observed during elevation to obtain a functional diagnosis for individual guidance of treatment.5 24 The principal focus was on relearning of normal movement patterns, which could then be transferred to daily activities.5 The initial aim was to unload the stress on the rotator cuff and subacromial structures.5 During this phase, a mirror for awareness of posture, manual techniques for loosening tense muscles, an elastic rubber band, and a sling fixed to the ceiling were used.5 24 The patients received immediate feedback and correction (supervision) by the physiotherapist.",Methods|Interventions,[166101],[8004],[8673],[False],[0],[0],[False],['0']
1703,PMC2744862,27719,"Once dysfunctional neuromuscular patterns were normalised, endurance exercises were performed with gradually increasing resistance.",Methods|Interventions,[166104],[8674],[8805],[False],[0],[0],[False],['0']
1704,PMC2744862,27720,"Principles of closed and open kinetic chain and plyometric exercises were incorporated in the next phase of training.5 24 Patients had an adjusted programme at home, which consisted of correction of alignment during daily living and simple low loaded exercises with a thin elastic cord to provide assistance and resistance to the movement.",Methods|Interventions,[166107],[8806],[9145],[False],[0],[0],[False],['0']
1705,PMC2744862,27721,Simple advice was given.,Methods|Interventions,[166110],[9146],[9170],[False],[0],[0],[False],['0']
1706,PMC2744862,27722,"Radial extracorporeal shockwave treatment (Swiss Dolor Clast, EMS) was provided by a physiotherapist experienced in its use.",Methods|Interventions,[166113],[9171],[9295],[False],[0],[0],[False],['0']
1707,PMC2744862,27723,The treatment was administered once a week for four to six weeks; three to five tender points were treated each time.,Methods|Interventions,[166116],[9296],[9413],[False],[0],[0],[False],['0']
1708,PMC2744862,27724,"Points were identified through a patient oriented biofeedback process (insertion of supraspinatus tendon, dorsolaterally below the acromion, and a maximum of three trigger points in the rotator cuff muscles).25 The frequency applied was 12-8 Hertz with from 2000 pulses per session, with a pressure between 2.5 and 4.0 Bar, depending on what the patient tolerated without local anaesthetic.",Methods|Interventions,[166119],[9414],[9804],[False],[0],[0],[False],['0']
1709,PMC2744862,27725,Radial extracorporeal shockwave treatment uses low to medium energy shockwaves generated when a projectile is accelerated by compressed air and hits an applicator.7 These impulses are delivered into the tissue and spread as spherical “radial” waves (rather than being focused).,Methods|Interventions,[166122],[9805],[10082],[False],[0],[0],[False],['0']
1710,PMC2744862,27726,Patients were informed that the suggested mechanism for pain relief was hyperstimulation analgesia and increased neovascularisation that improves regeneration of tissue.6 25 Patients were advised to avoid activities that elicited pain.,Methods|Interventions,[166125],[10083],[10318],[False],[0],[0],[False],['0']
1711,PMC2744862,27727,All the patients were asked not to have any additional treatment except analgesics (including anti-inflammatory drugs) for their shoulder pain for the time between the start of treatment and the 18 week follow-up.,Methods|Interventions,[166128],[10319],[10532],[False],[0],[0],[False],['0']
1712,PMC2744862,27728,Sample size,Methods|Sample size,[166131],[10533],[10544],[False],[0],[0],[False],['0']
1713,PMC2744862,27729,"The study was designed to detect a difference of 10 points in the shoulder pain and disability index score between groups with α value set at 0.05 (type I error) and β at 0.2 (type II error).26 After a pilot study, and in accordance with a previous study, the standard deviation was estimated to 20.26 The sample size was calculated as 48 in each group for a univariate analysis of covariance.27 This is a linear model using baseline measures of the primary outcome as a covariate.",Methods|Sample size,[166134],[10545],[11026],[False],[0],[0],[False],['0']
1714,PMC2744862,27730,The ρ was set to 0.5.27 The study has three post-treatment registrations.,Methods|Sample size,[166137],[11027],[11100],[False],[0],[0],[False],['0']
1715,PMC2744862,27731,Statistical analyses,Methods|Statistical analyses,[166140],[11101],[11121],[False],[0],[0],[False],['0']
1716,PMC2744862,27732,"The main outcome variable (shoulder pain and disability index score) is considered to be a continuous variable.26 To evaluate the treatment effect (the mean difference between the groups at six, 12, and 18 weeks), we used the mixed model analysis (repeated measurements).28 This model includes the interaction between treatment and elapsed time, baseline values are adjusted, and we assume that data are missing at random.28 The distribution of future values for a participant who drops out at time t and one who remains in at time t is expected to be the same if they have the same covariates and the same history of outcome until time t.28 Model assumptions were checked by residual plots.",Methods|Statistical analyses,[166143],[11122],[11813],[False],[0],[0],[False],['0']
1717,PMC2744862,27733,We estimated the smallest detectable real difference between two measurements on the same person to be 19.6 points on the shoulder pain and disability index and used this as a cut-off point.19 We calculated the number needed to treat (NNT) according to the method of Guyatt et al.29,Methods|Statistical analyses,[166146],[11814],[12096],[False],[0],[0],[False],['0']
1718,PMC2744862,27734,We checked the secondary outcome measures for normal distribution and found that parametric statistics were appropriate.30 We used logistic regression with adjustment for baseline values to compare work status and drug treatment.,Methods|Statistical analyses,[166149],[12097],[12326],[False],[0],[0],[False],['0']
1719,PMC2744862,27735,"We analysed data according to the intention to treat principle, in which the study groups are compared in terms of the treatment to which they were randomly allocated.",Methods|Statistical analyses,[166152],[12327],[12494],[False],[0],[0],[False],['0']
1720,PMC2744862,27736,Results,Results,[166155],[12495],[12503],[False],[0],[0],[False],['0']
1721,PMC2744862,27737,"A total of 141 patients were eligible for inclusion, and 104 were randomised for study intervention (fig 1).",Results,[166158],[12504],[12612],[False],[0],[0],[False],['0']
1722,PMC2744862,27738,"The groups were similar at baseline with regard to age, education, dominant arm affected, duration of pain, sick leave, shoulder pain and disability index score, and secondary outcome variables (tables 1, 2 and 3).",Results,[166161],[12613],[12827],[False],[0],[0],[False],['0']
1723,PMC2744862,27739,Seventeen (33%) patients in the radial extracorporeal shockwave group and 12 (23%) in the supervised exercise group were on sick leave because of shoulder pain.,Results,[166164],[12828],[12988],[False],[0],[0],[False],['0']
1724,PMC2744862,27740,Five patients in the radial extracorporeal shockwave group and two in the supervised exercise group claimed for disability pension.,Results,[166167],[12989],[13120],[False],[0],[0],[False],['0']
1725,PMC2744862,27741,Patients treated with radial extracorporeal shockwaves (n=52) received a median of five (interquartile range 4-6) treatments.,Results,[166170],[13121],[13246],[False],[0],[0],[False],['0']
1726,PMC2744862,27742,"One patient had only one treatment, and one patient had two treatments.",Results,[166173],[13247],[13318],[False],[0],[0],[False],['0']
1727,PMC2744862,27743,Patients in the supervised exercise group (n=51) received a median of 14 (11-16) treatments.,Results,[166176],[13319],[13411],[False],[0],[0],[False],['0']
1728,PMC2744862,27744,"One patient did not receive supervised exercises because of depression, and another had only four sessions because of an increase in pain and a suspected adhesive capsulitis.",Results,[166179],[13412],[13586],[False],[0],[0],[False],['0']
1729,PMC2744862,27745,One patient crossed over to the supervised exercise group after one treatment with radial extracorporeal shockwaves (fig 1).,Results,[166182],[13587],[13711],[False],[0],[0],[False],['0']
1730,PMC2744862,27746,Fourteen patients did not return the questionnaire at six weeks.,Results,[166185],[13712],[13776],[False],[0],[0],[False],['0']
1731,PMC2744862,27747,"Two patients randomised to supervised exercises did not attend follow-up at 12 and 18 weeks, and two patients in the radial extracorporeal shockwave group did not attend the 18 week follow-up (fig 1).",Results,[166188],[13777],[13977],[False],[0],[0],[False],['0']
1732,PMC2744862,27748,"Thirteen patients in the radial extracorporeal shockwave group and three patients in the supervised exercise group received additional treatment (cortisone injections, chiropractic treatment, physical therapy/supervised exercises) between 12 and 18 weeks (odds ratio 5.5, 95% confidence interval 1.3 to 26.4; P=0.014).",Results,[166191],[13978],[14296],[False],[0],[0],[False],['0']
1733,PMC2744862,27749,Primary outcome,Results|Primary outcome,[166194],[14297],[14312],[False],[0],[0],[False],['0']
1734,PMC2744862,27750,"The treatment effect was in favour of supervised exercises at six, 12, and 18 weeks.",Results|Primary outcome,[166197],[14313],[14397],[False],[0],[0],[False],['0']
1735,PMC2744862,27751,"At 18 weeks the treatment effect was −8.4 (95% confidence interval −16.5 to −0.6; P=0.047) points (table 2, fig 2).",Results|Primary outcome,[166200],[14398],[14513],[False],[0],[0],[False],['0']
1736,PMC2744862,27752,The treatment effect was consistent when adjusted for sex (P=0.049).,Results|Primary outcome,[166203],[14514],[14582],[False],[0],[0],[False],['0']
1737,PMC2744862,27753,"Thirty two out of 50 (64%) patients treated with supervised exercises and 18/50 (36%) patients treated with radial extracorporeal shockwaves achieved a reduction in shoulder pain and disability index score exceeding the smallest detectable difference of 19.6 points (odds ratio 3.2, 1.3 to 7.8; P=0.009).",Results|Primary outcome,[166206],[14583],[14887],[False],[0],[0],[False],['0']
1738,PMC2744862,27754,Two (4%) patients in the group of supervised exercises and three (6%) in the radial extracorporeal shockwave group deteriorated after treatment.,Results|Primary outcome,[166209],[14888],[15032],[False],[0],[0],[False],['0']
1739,PMC2744862,27755,The number needed to treat was 3.2 (95% confidence interval 2.1 to 7.1).,Results|Primary outcome,[166212],[15033],[15105],[False],[0],[0],[False],['0']
1740,PMC2744862,27756,Secondary outcomes,Results|Secondary outcomes,[166215],[15106],[15124],[False],[0],[0],[False],['0']
1741,PMC2744862,27757,"At 18 weeks, results for pain, function, and active range of motion were not statistically significant (table 2).",Results|Secondary outcomes,[166218],[15125],[15238],[False],[0],[0],[False],['0']
1742,PMC2744862,27758,More patients in the supervised exercise group returned to work (P=0.016) (table 3).,Results|Secondary outcomes,[166221],[15239],[15323],[False],[0],[0],[False],['0']
1743,PMC2744862,27759,Six patients in the supervised exercise group and one in the radial extracorporeal shockwave group used less drug treatment (table 3).,Results|Secondary outcomes,[166224],[15324],[15458],[False],[0],[0],[False],['0']
1744,PMC2744862,27760,Adverse events,Results|Adverse events,[166227],[15459],[15473],[False],[0],[0],[False],['0']
1745,PMC2744862,27761,One patient in the supervised exercise group reported a considerable increase in pain and stiffness consistent with adhesive capsulitis and had only four treatments.,Results|Adverse events,[166230],[15474],[15639],[False],[0],[0],[False],['0']
1746,PMC2744862,27762,"In the group treated with radial extracorporeal shockwaves, one patient dropped out after one treatment and one after two treatments because of the aggravation of pain; one of them crossed over to the supervised exercise group (table 4).",Results|Adverse events,[166233],[15640],[15877],[False],[0],[0],[False],['0']
1747,PMC2744862,27763,Discussion,Discussion,[166236],[15878],[15889],[False],[0],[0],[False],['0']
1748,PMC2744862,27764,"We found a small but statistically significant difference in favour of supervised exercises over radial extracorporeal shockwave treatment for the primary outcome (shoulder pain and disability index) at six, 12, and 18 weeks in patients with subacromial shoulder pain.",Discussion,[166239],[15890],[16158],[False],[0],[0],[False],['0']
1749,PMC2744862,27765,The difference was consistent after adjustment for education and duration of pain.,Discussion,[166242],[16159],[16241],[False],[0],[0],[False],['0']
1750,PMC2744862,27766,"In addition, more patients from the radial extracorporeal shockwave group (13 v 3) had additional treatment after 12 weeks, suggesting that they were less satisfied.",Discussion,[166245],[16242],[16407],[False],[0],[0],[False],['0']
1751,PMC2744862,27767,"The results for the differences in secondary outcomes were in favour of exercises, but differences were not significant except for change in work status after 18 weeks, which may indicate that supervised exercise is a more comprehensive rehabilitation intervention.",Discussion,[166248],[16408],[16673],[False],[0],[0],[False],['0']
1752,PMC2744862,27768,Strengths and limitations,Discussion|Strengths and limitations,[166251],[16674],[16699],[False],[0],[0],[False],['0']
1753,PMC2744862,27769,"The advantages of this study are the randomised design, stratification by sex, treatments provided by physiotherapists experienced in the use of the methods, high compliance, blinded observer, large number of patients attending follow-up, and intention to treat analysis.",Discussion|Strengths and limitations,[166254],[16700],[16971],[False],[0],[0],[False],['0']
1754,PMC2744862,27770,At least three possible limitations must be taken into account when interpreting the results.,Discussion|Strengths and limitations,[166257],[16972],[17065],[False],[0],[0],[False],['0']
1755,PMC2744862,27771,"Firstly, we did not include a placebo group and cannot exclude the possibility that the observed results reflect a placebo effect or the natural course of the condition.",Discussion|Strengths and limitations,[166260],[17066],[17235],[True],['NoPlaceboGroup'],['we did not include a placebo group'],[True],['Control']
1756,PMC2744862,27772,"A previous trial reported that a supervised exercise regimen was superior to placebo, so we found it difficult to justify the inclusion of a placebo group.21 On the other hand, two trials found no difference between sham and extracorporeal shockwave treatment.7 14 We did not include a placebo radial extracorporeal shockwave group and cannot substantiate the placebo effect in our study.",Discussion|Strengths and limitations,[166266],[17236],[17624],[False],[0],[0],[False],['0']
1757,PMC2744862,27773,"Secondly, local anaesthetics were not injected into the subacromial space to improve diagnostic accuracy.",Discussion|Strengths and limitations,[166271],[17625],[17730],[True],['NonstandardTreatmentCharacteristics'],['local anaesthetics were not injected into the subacromial space'],[True],['Intervention']
1758,PMC2744862,27774,"On the other hand, rotator cuff disease or subacromial shoulder pain is a clinical diagnosis and we used the recommended combination of clinical tests to improve patient selection.17 Thirdly, the study may be underpowered for detecting differences in the secondary outcome variables.",Discussion|Strengths and limitations,[166276],[17731],[18014],[True],['UnderpoweredStudy'],['the study may be underpowered'],[True],['UnderpoweredStudy']
1759,PMC2744862,27775,We used a univariate analysis of covariance to calculate the sample size with regard to the primary outcome.27,Discussion|Strengths and limitations,[166281],[18015],[18125],[False],[0],[0],[False],['0']
1760,PMC2744862,27776,Comparison with existing literature,Discussion|Comparison with existing literature,[166284],[18126],[18161],[False],[0],[0],[False],['0']
1761,PMC2744862,27777,Our results are in agreement with results from previous trials recommending exercise therapy9 10 11 31 and do not strengthen the evidence for extracorporeal shockwave treatment.6 7 14 15 32 The difference in shoulder pain and disability index score of 8.4 points at the 18 week follow-up was somewhat smaller than the difference (10 points) the study was designed to detect.,Discussion|Comparison with existing literature,[166287],[18162],[18536],[False],[0],[0],[False],['0']
1762,PMC2744862,27778,"For interpreting the effectiveness of the treatment, we must consider not only statistical significance but also whether the improvement (or deterioration) is relevant for the patients or clinicians.33 By using the smallest detectable real difference for an individual patient of 19.6 points as a cut-off point, we found that a larger proportion of patients in the supervised exercise group than in the radial extracorporeal shockwave treatment group improved.19 This suggests that more patients receiving supervised exercises had clinically relevant improvement.19 34 The number needed to treat to benefit from supervised exercises was three, which is considered clinically important.29 However, the estimate of number needed to treat has to be interpreted with caution because of possible differences in the study population recruited from a university hospital and the population in primary care to which we wish to extrapolate.",Discussion|Comparison with existing literature,[166290],[18537],[19468],[False],[0],[0],[False],['0']
1763,PMC2744862,27779,"The shoulder pain and disability index is a combined score reported to be one of the most responsive shoulder specific questionnaires available and more responsive than single subjective evaluations of pain and function or objective measures of range of motion.19 The observed improvements were largest at six weeks, suggesting that a reduction of mechanical subacromial stress and normalisation of movement patterns had occurred within a relatively short treatment period.",Discussion|Comparison with existing literature,[166293],[19469],[19942],[False],[0],[0],[False],['0']
1764,PMC2744862,27780,"The content of the supervised exercise intervention was slightly different from the study of Brox et al.21 Fewer patients used a sling for home exercises in our study; all supervision was finished within 12 weeks; and separate lessons on functional anatomy, pain management, and ergonomics were not included.",Discussion|Comparison with existing literature,[166296],[19943],[20251],[False],[0],[0],[False],['0']
1765,PMC2744862,27781,Follow-up in Brox et al’s study was at three and six months and two years.,Discussion|Comparison with existing literature,[166299],[20252],[20326],[False],[0],[0],[False],['0']
1766,PMC2744862,27782,Conclusions,Discussion|Conclusions,[166302],[20327],[20338],[False],[0],[0],[False],['0']
1767,PMC2744862,27783,"After 18 weeks, supervised exercises were better than radial extracorporeal shockwave treatment in terms of the primary outcome variable—the shoulder pain and disability index—and one secondary outcome variable—work status.",Discussion|Conclusions,[166305],[20339],[20562],[False],[0],[0],[False],['0']
1768,PMC2744862,27784,"We found no significant differences for the other secondary outcome variables of pain, function, active range of motion, and use of drug treatment.",Discussion|Conclusions,[166308],[20563],[20710],[False],[0],[0],[False],['0']
1769,PMC2744862,27785,"More patients in the supervised exercise group improved, probably owing to a treatment effect.",Discussion|Conclusions,[166311],[20711],[20805],[False],[0],[0],[False],['0']
2314,PMC2893119,22509,Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study,Title,[133355],[50069],[140],[False],[0],[0],[False],['0']
2315,PMC2893119,22510,Aim,Abstract,[133357],[141],[145],[False],[0],[0],[False],['0']
2316,PMC2893119,22511,Studies of beta blockade in patients with type 2 diabetes have shown inferiority of metoprolol treatment compared to carvedilol on indices of insulin resistance.,Abstract,[133359],[146],[307],[False],[0],[0],[False],['0']
2317,PMC2893119,22512,The aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type 2 diabetes.,Abstract,[133361],[308],[489],[False],[0],[0],[False],['0']
2318,PMC2893119,22513,Method,Abstract,[133363],[490],[496],[False],[0],[0],[False],['0']
2319,PMC2893119,22514,24 patients with type 2 diabetes were randomized to receive either 200 mg metoprolol succinate or 50 mg carvedilol daily.,Abstract,[133365],[497],[618],[False],[0],[0],[False],['0']
2320,PMC2893119,22515,Endothelium-dependent vasodilation was assessed by using venous occlusion plethysmography with increasing doses of intra-arterial infusions of the agonist serotonin.,Abstract,[133367],[619],[784],[False],[0],[0],[False],['0']
2321,PMC2893119,22516,Insulin-stimulated endothelial function was assessed after co-infusion of insulin for sixty minutes.,Abstract,[133369],[785],[885],[False],[0],[0],[False],['0']
2322,PMC2893119,22517,Vaso-reactivity studies were done before and after the two-month treatment period.,Abstract,[133371],[886],[968],[False],[0],[0],[False],['0']
2323,PMC2893119,22518,Results,Abstract,[133373],[969],[976],[False],[0],[0],[False],['0']
2324,PMC2893119,22519,"Insulin-stimulated endothelial function was deteriorated after treatment with metoprolol, the percentage change in forearm blood-flow was 60.19% ± 17.89 (at the highest serotonin dosages) before treatment and -33.80% ± 23.38 after treatment (p = 0.007).",Abstract,[133375],[977],[1230],[False],[0],[0],[False],['0']
2325,PMC2893119,22520,Treatment with carvedilol did not change insulin-stimulated endothelial function.,Abstract,[133377],[1231],[1312],[False],[0],[0],[False],['0']
2326,PMC2893119,22521,Endothelium-dependent vasodilation without insulin was not changed in either of the two treatment groups.,Abstract,[133379],[1313],[1418],[False],[0],[0],[False],['0']
2327,PMC2893119,22522,Conclusion,Abstract,[133381],[1419],[1429],[False],[0],[0],[False],['0']
2328,PMC2893119,22523,This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes.,Abstract,[133383],[1430],[1608],[False],[0],[0],[False],['0']
2329,PMC2893119,22524,Trial registration,Abstract,[133385],[1609],[1627],[False],[0],[0],[False],['0']
2330,PMC2893119,22525,Current Controlled Trials NCT00497003,Abstract,[133387],[1628],[1665],[False],[0],[0],[False],['0']
2331,PMC2893119,22526,Introduction,Introduction|Introduction,[133389],[1666],[1679],[False],[0],[0],[False],['0']
2332,PMC2893119,22527,Type 2 diabetes is associated with a high risk of cardiovascular complications [1].,Introduction|Introduction,[133391],[1680],[1763],[False],[0],[0],[False],['0']
2333,PMC2893119,22528,"Beta-blockers are generally considered to worsen metabolic control in patients with diabetes, but the GEMINI (The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives) study demonstrated improved metabolic control in patients with type 2 diabetes and hypertension treated with carvedilol as compared with metoprolol [2].",Introduction|Introduction,[133393],[1764],[2120],[False],[0],[0],[False],['0']
2334,PMC2893119,22529,"Further, in the presence of heart failure, carvedilol was shown to be associated with improved survival (The Carvedilol or Metoprolol European Trial [COMET]) and with fewer cases of new onset diabetes compared to metoprolol tartrate [3,4].",Introduction|Introduction,[133395],[2121],[2360],[False],[0],[0],[False],['0']
2335,PMC2893119,22530,These results lead us to hypothesize that carvedilol and metoprolol might have different vascular effects related to insulin sensitivity.,Introduction|Introduction,[133397],[2361],[2498],[False],[0],[0],[False],['0']
2336,PMC2893119,22531,"Endothelial dysfunction is thought to be one of the earliest changes in the pathogenesis of atherosclerosis [5], and is associated with an increased risk of cardiovascular disease [6].",Introduction|Introduction,[133399],[2499],[2683],[False],[0],[0],[False],['0']
2337,PMC2893119,22532,"Diabetes and insulin resistance are associated with endothelial dysfunction [7] as well as reduced insulin sensitivity of the endothelium - reduced insulin-stimulated endothelial function [8,9].",Introduction|Introduction,[133401],[2684],[2878],[False],[0],[0],[False],['0']
2338,PMC2893119,22533,"Further, improved regulation of glucose control with insulin in patients with type 2 diabetes is known to be associated with fewer vascular complications [UKPDS - (UK Prospective Diabetes Study)] [1] and we and others have shown it to result in improved endothelial insulin sensitivity [8,9] and improved endothelial function [10].",Introduction|Introduction,[133403],[2879],[3210],[False],[0],[0],[False],['0']
2339,PMC2893119,22534,"In this study, we hypothesized that the beneficial effects of carvedilol compared to metoprolol could be related to an improvement of endothelial function and/or endothelial insulin resistance in patients with type 2 diabetes.",Introduction|Introduction,[133405],[3211],[3437],[False],[0],[0],[False],['0']
2340,PMC2893119,22535,Methods,Methods,[133407],[3438],[3446],[False],[0],[0],[False],['0']
2341,PMC2893119,22536,Study group,Methods|Study group,[133409],[3447],[3458],[False],[0],[0],[False],['0']
2342,PMC2893119,22537,A total of 19 patients with type 2 diabetes and 10 lean healthy controls were included and completed the study.,Methods|Study group,[133411],[3459],[3570],[False],[0],[0],[False],['0']
2343,PMC2893119,22538,Measurements of endothelial function as well as insulin stimulated endothelial function were performed in all individuals.,Methods|Study group,[133413],[3571],[3693],[False],[0],[0],[False],['0']
2344,PMC2893119,22539,"All patients with type 2 diabetes met the diagnostic criteria for type 2 diabetes, as defined by the American Diabetes Association (ADA) [11].",Methods|Study group,[133415],[3694],[3836],[False],[0],[0],[False],['0']
2345,PMC2893119,22540,None of the patients were treated with insulin.,Methods|Study group,[133417],[3837],[3884],[False],[0],[0],[False],['0']
2346,PMC2893119,22541,"Patients with a history of atherosclerosis or heart disease of any cause were excluded, as were patients with known diabetic retinopathy, nephropathy or neuropathy.",Methods|Study group,[133419],[3885],[4049],[False],[0],[0],[False],['0']
2347,PMC2893119,22542,"Additional exclusion criteria were known intolerance to beta-blocker treatment, bradycardia, hypotension and untreated hypertension.",Methods|Study group,[133421],[4050],[4182],[False],[0],[0],[False],['0']
2348,PMC2893119,22543,Patients with severe asthma or patients who received treatment with beta-agonists were also excluded from the study.,Methods|Study group,[133423],[4183],[4299],[False],[0],[0],[False],['0']
2349,PMC2893119,22544,None of the persons in the control group received any kind of medication and had no history of cardiovascular disease.,Methods|Study group,[133425],[4300],[4418],[False],[0],[0],[False],['0']
2350,PMC2893119,22545,"Diabetes, hypertension and smoking were also exclusion criteria in the healthy control group.",Methods|Study group,[133427],[4419],[4512],[False],[0],[0],[False],['0']
2351,PMC2893119,22546,"Patients were recruited by advertisement in a local newspaper, and all patients gave written informed consent before entering the study.",Methods|Study group,[133429],[4513],[4649],[False],[0],[0],[False],['0']
2352,PMC2893119,22547,"The study was approved by the ethics committee of the city of Copenhagen (ref KF 02-071/03), as well as the Danish Medicines Agency (ref 2612-2423).",Methods|Study group,[133431],[4650],[4798],[False],[0],[0],[False],['0']
2353,PMC2893119,22548,Design,Methods|Design,[133433],[4799],[4805],[False],[0],[0],[False],['0']
2354,PMC2893119,22549,"Patients with type 2 diabetes were randomized to receive treatment with metoprolol succinate (N = 10; SeloZok, AstraZeneca, Cheshire, England) or carvedilol (N = 9; Dimitone, Roche, Basel, Switzerland).",Methods|Design,[133435],[4806],[5008],[False],[0],[0],[False],['0']
2355,PMC2893119,22550,The target dose was 200 mg once daily for metoprolol and 25 mg twice daily for carvedilol in order to secure equipotent doses of the two beta-blockers.,Methods|Design,[133437],[5009],[5160],[False],[0],[0],[False],['0']
2356,PMC2893119,22551,The study was designed as an open parallel group study.,Methods|Design,[133439],[5161],[5216],[False],[0],[0],[False],['0']
2357,PMC2893119,22552,"Before and after the two-month treatment period, endothelial function and insulin-stimulated endothelial function were measured.",Methods|Design,[133441],[5217],[5345],[False],[0],[0],[False],['0']
2358,PMC2893119,22553,Venous occlusion plethysmography,Methods|Venous occlusion plethysmography,[133443],[5346],[5378],[False],[0],[0],[False],['0']
2359,PMC2893119,22554,Forearm blood-flow was measured by using venous occlusion plethysmography as described previously [8].,Methods|Venous occlusion plethysmography,[133445],[5379],[5481],[False],[0],[0],[False],['0']
2360,PMC2893119,22555,All measurements were done blinded to the treatment protocol.,Methods|Venous occlusion plethysmography,[133447],[5482],[5543],[False],[0],[0],[False],['0']
2361,PMC2893119,22556,The patients did not take their usual medication in the morning on the day of examination.,Methods|Venous occlusion plethysmography,[133449],[5544],[5634],[False],[0],[0],[False],['0']
2362,PMC2893119,22557,All examinations were done after an overnight fast and abstinence from smoking.,Methods|Venous occlusion plethysmography,[133451],[5635],[5714],[False],[0],[0],[False],['0']
2363,PMC2893119,22558,"The patients lay supine in a quiet room, with the temperature kept constant.",Methods|Venous occlusion plethysmography,[133453],[5715],[5791],[False],[0],[0],[False],['0']
2364,PMC2893119,22559,Both forearms were placed at a horizontal level with the right atrium while measurements were done.,Methods|Venous occlusion plethysmography,[133455],[5792],[5891],[False],[0],[0],[False],['0']
2365,PMC2893119,22560,"An arterial cannula with an external diameter of 1 mm was inserted into the brachial artery, preferentially in the non-dominant arm.",Methods|Venous occlusion plethysmography,[133457],[5892],[6024],[False],[0],[0],[False],['0']
2366,PMC2893119,22561,The arterial cannula was used for intra-arterial infusions and blood pressure measurement.,Methods|Venous occlusion plethysmography,[133459],[6025],[6115],[False],[0],[0],[False],['0']
2367,PMC2893119,22562,"To assess endothelium-dependent vasodilation, forearm blood-flow was measured during infusion of increasing doses of serotonin (7, 21, 70 ng/min) [Serotonin (Clinalfa, Läufelfingen, Switzerland)].",Methods|Venous occlusion plethysmography,[133461],[6116],[6312],[False],[0],[0],[False],['0']
2368,PMC2893119,22563,"For each dose, serotonin was infused for 4 minutes, before blood-flow measurements were done, to obtain a steady state.",Methods|Venous occlusion plethysmography,[133463],[6313],[6432],[False],[0],[0],[False],['0']
2369,PMC2893119,22564,"Measurements of forearm blood-flow were done simultaneously in both the infused and the non-infused arm, and presented as the ratio between the two arms.",Methods|Venous occlusion plethysmography,[133465],[6433],[6586],[False],[0],[0],[False],['0']
2370,PMC2893119,22565,"Endothelium-independent vasodilation in the forearm was examined by exchanging serotonin infusion with increasing doses of sodium nitroprusside [Nitropress (Abbott Laboratories, North Chicago, IL)].",Methods|Venous occlusion plethysmography,[133467],[6587],[6785],[False],[0],[0],[False],['0']
2371,PMC2893119,22566,"The doses of sodium nitroprusside (0.5, 1 and 1.5 μg/min) were chosen according to previous studies, to ensure matching blood-flow to the flows obtained by studies of serotonin in healthy people [12,13].",Methods|Venous occlusion plethysmography,[133469],[6786],[6989],[False],[0],[0],[False],['0']
2372,PMC2893119,22567,Insulin-stimulated endothelial function was assessed by an intra-arterial co-infusion of serotonin and insulin.,Methods|Venous occlusion plethysmography,[133471],[6990],[7101],[False],[0],[0],[False],['0']
2373,PMC2893119,22568,"Insulin [Actrapid (Novo Nordisk Scandinavia, Malmö, Sweden) in a 1% human albumin solution (vehicle)] was infused at a rate of 0.05 mU/kg body weight/min for 60 minutes and followed by co-infusion of serotonin to achieve a dose-response study as described above.",Methods|Venous occlusion plethysmography,[133473],[7102],[7364],[False],[0],[0],[False],['0']
2374,PMC2893119,22569,"To determine the NO-dependent fraction of insulin-stimulated serotonin response, an intra-arterial co-infusion of L-NMMA [L-NMMA (Clinalfa)] was infused for 10 min, with a dose of 3.3 mg/min, followed by a dose-response study with serotonin.",Methods|Venous occlusion plethysmography,[133475],[7365],[7606],[False],[0],[0],[False],['0']
2375,PMC2893119,22570,"To allow wash-out between measurements, all infusions were stopped for at least 30 minutes while saline was infused at a rate of 60 ml/h to maintain the cannula patent.",Methods|Venous occlusion plethysmography,[133477],[7607],[7775],[False],[0],[0],[False],['0']
2376,PMC2893119,22571,All blood-flow measurements are presented as a relative blood-flow given as the actual flow (ml/min) of the infused arm as a proportion to the non-infused arm.,Methods|Venous occlusion plethysmography,[133479],[7776],[7935],[False],[0],[0],[False],['0']
2377,PMC2893119,22572,"This has been done to correct for the systemic changes in flow during the day and changes in between the two days of examinations, irrespective of the infusions of substances.",Methods|Venous occlusion plethysmography,[133481],[7936],[8111],[False],[0],[0],[False],['0']
2378,PMC2893119,22573,Statistics,Statistics,[133483],[8112],[8123],[False],[0],[0],[False],['0']
2379,PMC2893119,22574,This study is a small size study with the purpose of finding differences between both serotonin stimulated endothelial function as well as insulin stimulated endothelial function in groups.,Statistics,[133485],[8124],[8313],[False],[0],[0],[False],['0']
2380,PMC2893119,22575,Endothelial function is presented as a mean of flow.,Statistics,[133487],[8314],[8366],[False],[0],[0],[False],['0']
2381,PMC2893119,22576,Means of flow were compared with a paired t-test at baseline before treatment and again after treatment with either of the two beta blockers.,Statistics,[133489],[8367],[8508],[False],[0],[0],[False],['0']
2382,PMC2893119,22577,Dose-response curves were compared by combined analysis of variance and covariance (mixed model analysis).,Statistics,[133491],[8509],[8615],[False],[0],[0],[False],['0']
2383,PMC2893119,22578,Experimental subject and the interaction between experimental subject and dose of serotonin were entered as random variables whereas study group (metoprolol or carvedilol) dose of serotonin were entered as fixed terms.,Statistics,[133493],[8616],[8834],[False],[0],[0],[False],['0']
2384,PMC2893119,22579,Calculations were performed with the SAS (Statistical Analysis Systems) version 9.1,Statistics,[133495],[8835],[8918],[False],[0],[0],[False],['0']
2385,PMC2893119,22580,Results,Results,[133497],[8919],[8927],[False],[0],[0],[False],['0']
2386,PMC2893119,22581,Characteristics of the two treatment groups as well as the healthy control group are shown in Table 1.,Results,[133499],[8928],[9030],[False],[0],[0],[False],['0']
2387,PMC2893119,22582,No significant differences were seen between the two diabetes groups at baseline.,Results,[133501],[9031],[9112],[False],[0],[0],[False],['0']
2388,PMC2893119,22583,"Compared to the healthy control group, the type 2 diabetic patients had a higher BMI and higher fasting glucose as well as glycosylated hemoglobin, as expected.",Results,[133503],[9113],[9273],[False],[0],[0],[False],['0']
2389,PMC2893119,22584,"There were no significant differences in total cholesterol between the groups, but the type 2 diabetes group tended to have higher triglycerides- and well as LDL-levels.",Results,[133505],[9274],[9443],[False],[0],[0],[False],['0']
2390,PMC2893119,22585,The actual p-values for the changes between the groups are presented in Table 1.,Results,[133507],[9444],[9524],[False],[0],[0],[False],['0']
2391,PMC2893119,22586,"In the group of patients treated with carvedilol or metoprolol, 3 patients were smokers whereas there were no smokers in the control group.",Results,[133509],[9525],[9664],[False],[0],[0],[False],['0']
2392,PMC2893119,22587,The patients in the control group were slightly younger than the patients in the two groups with type 2 diabetes.,Results,[133511],[9665],[9778],[False],[0],[0],[False],['0']
2393,PMC2893119,22588,Twenty four patients were randomized in the study.,Results,[133513],[9779],[9829],[False],[0],[0],[False],['0']
2394,PMC2893119,22589,"Of those, five patients were withdrawn from the study: One because of technical difficulties in reading the results of the study and two because of difficulties with the arterial cannula.",Results,[133515],[9830],[10017],[False],[0],[0],[False],['0']
2395,PMC2893119,22590,Two patients were withdrawn from the study due to adverse reactions during the treatment period: One patient who developed a severe cutaneous allergic reaction during treatment with carvedilol and one patient who had a minor stroke during treatment period with metoprolol.,Results,[133517],[10018],[10290],[False],[0],[0],[False],['0']
2396,PMC2893119,22591,Two additional patients with adverse reactions during the treatment were not withdrawn from the study and results of their vaso-reactivity studies were included.,Results,[133519],[10291],[10452],[False],[0],[0],[False],['0']
2397,PMC2893119,22592,"Of these, one patient developed diarrhea during treatment with carvedilol and one patient in the metoprolol group had a mild episode of depression.",Results,[133521],[10453],[10600],[False],[0],[0],[False],['0']
2398,PMC2893119,22593,"Ten patients with type 2 diabetes received treatment with metoprolol succinate, mean daily dose of 175 mg, and 9 patients received treatment with carvedilol, mean daily dose of 44 mg for a period of 2 months.",Results,[133523],[10601],[10809],[False],[0],[0],[False],['0']
2399,PMC2893119,22594,Doses of metoprolol succinate and carvedilol were equivalent in this study which corresponds with a dose of 88% of target dose for both drugs.,Results,[133525],[10810],[10952],[False],[0],[0],[False],['0']
2400,PMC2893119,22595,Changes in baseline characteristics after treatment with either carvedilol or metoprolol are presented in Table 2 and 3 respectively.,Results,[133527],[10953],[11086],[False],[0],[0],[False],['0']
2401,PMC2893119,22596,"After treatment with metoprolol, there was a significant mean increase in body weight of 1.8 kg (1.8% change) (p = 0.02), whereas a non-significant mean increase in body weight of 0.6 kg (0.6% change) was seen in the carvedilol group (p = 0.43).",Results,[133529],[11087],[11332],[False],[0],[0],[False],['0']
2402,PMC2893119,22597,"Fasting blood glucose, fasting insulin and glycosylated hemoglobin remained unchanged at the end of the treatment with any of the two beta-blockers (Table 2 and 3).",Results,[133531],[11333],[11497],[False],[0],[0],[False],['0']
2403,PMC2893119,22598,Systolic blood pressure did not change with metoprolol while carvedilol treatment tended to lower systolic blood pressure although this change was non-significant (142.4 ± 5.09 mmHg before treatment versus 136.9 ± 5.80 mmHg after treatment) (-3.7% change) (p = 0.38).,Results,[133533],[11498],[11765],[False],[0],[0],[False],['0']
2404,PMC2893119,22599,"Diastolic blood pressure decreased after treatment with a beta-blocker to a similar level in both treatment groups; from 71.4 ± 2.59 mmHg to 61.3 ± 3.13 mmHg (-14.1% change) in the carvedilol group (p < 0.05) and 70.5 ± 4.67 mmHg to 64.0 ± 3.84 mmHg (-9.2% change) in the metoprolol group (p < 0.05), while resting heart rate decreased only significantly in the carvedilol group from 67.1 ± 2.16 to 60.7 ± 1.74 (-9.5% change) (p < 0.05).",Results,[133535],[11766],[12203],[False],[0],[0],[False],['0']
2405,PMC2893119,22600,Endothelial function,Results|Endothelial function,[133537],[12204],[12224],[False],[0],[0],[False],['0']
2406,PMC2893119,22601,The patients with type 2 diabetes had a significant lower response to serotonin than the healthy control group (Fig.,Results|Endothelial function,[133539],[12225],[12341],[False],[0],[0],[False],['0']
2407,PMC2893119,22602,1).,Results|Endothelial function,[133541],[12342],[12345],[False],[0],[0],[False],['0']
2408,PMC2893119,22603,Relative flow (±SEM) at baseline at the three dose levels of serotonin infusion were 1.17 ± 0.08; 1.26 ± 0.11; 1.62 ± 0.16 and 1.84 ± 0.20 in the group of patients with type 2 diabetes compared to 1.12 ± 0.12; 1.15 ± 0.11; 1.71 ± 0.15 and 2.69 ± 0.23 in the healthy control group (p = 0.002).,Results|Endothelial function,[133543],[12346],[12638],[False],[0],[0],[False],['0']
2409,PMC2893119,22604,"Also, the insulin-stimulated serotonin response was significantly lower in patients with type 2 diabetes (Fig.",Results|Endothelial function,[133545],[12639],[12749],[False],[0],[0],[False],['0']
2410,PMC2893119,22605,2): The percentage increase in blood-flow after co-infusion of insulin compared to serotonin alone was 45.96 ± 11.56%; 67.40 ± 18.11% and 84.57 ± 25.73% in the healthy control group and 26.48 ± 7.74%; 26.40 ± 11.52% and 19.75 ± 13.87% (p = 0.02) in the group of patients with type 2 diabetes.,Results|Endothelial function,[133547],[12750],[13042],[False],[0],[0],[False],['0']
2411,PMC2893119,22606,Treatment with carvedilol or metoprolol did not change endothelium-dependent vasodilation.,Results|Endothelial function,[133549],[13043],[13133],[False],[0],[0],[False],['0']
2412,PMC2893119,22607,"Before treatment the relative blood-flow was 1.25 ± 0.14; 1.24 ± 0.08; 1.64 ± 0.16 and 1.96 ± 0.14 in the carvedilol group at serotonin doses of 0, 7, 21 and 70 ng/minute respectively.",Results|Endothelial function,[133551],[13134],[13318],[False],[0],[0],[False],['0']
2413,PMC2893119,22608,"After two months treatment with carvedilol, the relative blood-flow was 1.32 ± 0.14; 1.26 ± 0.18; 1.67 ± 0.15 and 2.35 ± 0.29 (P = 0.22) (Fig.",Results|Endothelial function,[133553],[13319],[13461],[False],[0],[0],[False],['0']
2414,PMC2893119,22609,3).,Results|Endothelial function,[133555],[13462],[13465],[False],[0],[0],[False],['0']
2415,PMC2893119,22610,In the metoprolol group relative blood-flow was 1.10 ± 0.08; 1.28 ± 0.21; 1.60 ± 0.26 and 1.73 ± 0.20 before treatment and 1.03 ± 0.05; 1.12 ± 0.09; 1.62 ± 0.17 and 2.13 ± 0.17 after two months treatment (p = 0.30) (Fig.,Results|Endothelial function,[133557],[13466],[13686],[False],[0],[0],[False],['0']
2416,PMC2893119,22611,4).,Results|Endothelial function,[133559],[13687],[13690],[False],[0],[0],[False],['0']
2417,PMC2893119,22612,After two months treatment with carvedilol the percentage increase in blood-flow after co-infusion with insulin was unchanged whereas treatment with metoprolol deteriorated the insulin-stimulated response significantly (Fig.,Results|Endothelial function,[133561],[13691],[13915],[False],[0],[0],[False],['0']
2418,PMC2893119,22613,5).,Results|Endothelial function,[133563],[13916],[13919],[False],[0],[0],[False],['0']
2419,PMC2893119,22614,The percentage change after co-infusion of insulin in the group of patients treated with metoprolol was 29.77% ± 29.83; 31.44% ± 31.01 and 60.19% ± 17.89 before treatment and 41.46% ± 20.09; -9.45% ± 14.64 and -33.80% ± 23.38 after treatment (p = 0.007) at the three dose levels of serotonin respectively.,Results|Endothelial function,[133565],[13920],[14225],[False],[0],[0],[False],['0']
2420,PMC2893119,22615,"Endothelium independent vasodilation, assessed after infusions of sodium nitroprusside, was unchanged after treatment with either of the two beta blockers (Fig 6 and 7).",Results|Endothelial function,[133567],[14226],[14395],[False],[0],[0],[False],['0']
2421,PMC2893119,22616,L-NMMA co-infusion abolished the increase in blood-flow during serotonin and insulin co-infusion in both the carvedilol and metoprolol group at baseline and was not changed by either treatment with carvedilol or metoprolol.,Results|Endothelial function,[133569],[14396],[14619],[False],[0],[0],[False],['0']
2422,PMC2893119,22617,Discussion,Discussion,[133571],[14620],[14631],[False],[0],[0],[False],['0']
2423,PMC2893119,22618,"The main result of this study is that insulin-stimulated endothelial function remained preserved during treatment with carvedilol and blunted during treatment with metoprolol, whereas endothelium-dependent and endothelium-independent vasodilation was unchanged in both groups.",Discussion,[133573],[14632],[14908],[False],[0],[0],[False],['0']
2424,PMC2893119,22619,"The lack of effect of carvedilol in endothelial function in the absence of stimulation with insulin, is somehow in contrast with a recent study where carvedilol has shown to improve endothelial function assessed by measures on albuminuria and measures on brachial reactivity by ultrasound, compared with metoprolol [14].",Discussion,[133575],[14909],[15229],[False],[0],[0],[False],['0']
2425,PMC2893119,22620,"It cannot be ruled out that we could have demonstrated an improvement of the serotonin-stimulated flow in a larger population but intra-arterial co-infusion of insulin and serotonin provides a unique possibility to assess specifically insulin sensitivity of the endothelium [15], whereby it further supports that an improved vascular nitric oxide reactivity is the main mechanism that accounts for the beneficial effects of carvedilol.",Discussion,[133577],[15230],[15665],[False],[0],[0],[False],['0']
2426,PMC2893119,22621,"This is additionally supported by the observation in our study that co-infusion of serotonin, insulin and L-NMMA totally abolished vasodilation both before and after treatment with either of the two beta blockers.",Discussion,[133579],[15666],[15879],[False],[0],[0],[False],['0']
2427,PMC2893119,22622,These findings could not be explained by changes in either blood pressure or metabolic glucose control.,Discussion,[133581],[15880],[15983],[False],[0],[0],[False],['0']
2428,PMC2893119,22623,"Furthermore, it is possible that a lower CRP measured at baseline in the carvedilol group accounts for the lack of potential to improve serotonin response (Table 1).",Discussion,[133583],[15984],[16149],[False],[0],[0],[False],['0']
2429,PMC2893119,22624,"Nevertheless, this difference at baseline rather strengthens our study, since in spite of a ""healthier"" condition of the carvedilol group it was possible to improve the insulin-stimulated serotonin response.",Discussion,[133585],[16150],[16357],[False],[0],[0],[False],['0']
2430,PMC2893119,22625,Insulin resistance is an independent risk factor of developing cardiovascular disease [16].,Discussion,[133587],[16358],[16449],[False],[0],[0],[False],['0']
2431,PMC2893119,22626,Diabetes is a condition with insulin resistance including vascular insulin resistance [8].,Discussion,[133589],[16450],[16540],[False],[0],[0],[False],['0']
2432,PMC2893119,22627,This was also found in our study.,Discussion,[133591],[16541],[16574],[False],[0],[0],[False],['0']
2433,PMC2893119,22628,"By improving metabolic glucose control in patients with type 2 diabetes, vascular insulin resistance also improves [8].",Discussion,[133593],[16575],[16694],[False],[0],[0],[False],['0']
2434,PMC2893119,22629,Insulin stimulated vasodilation has been found to be NO dependent [17].,Discussion,[133595],[16695],[16766],[False],[0],[0],[False],['0']
2435,PMC2893119,22630,A blunted insulin stimulated vasodilation itself leads to vasoconstriction and is thereby proatherogenic.,Discussion,[133597],[16767],[16872],[False],[0],[0],[False],['0']
2436,PMC2893119,22631,"Co-morbidity with hypertension, ischemic heart disease or heart failure is common in patients with type 2 diabetes.",Discussion,[133599],[16873],[16988],[False],[0],[0],[False],['0']
2437,PMC2893119,22632,Treatment with beta adrenergic blockers is therefore often necessary to reduce their total risk of cardiovascular disease.,Discussion,[133601],[16989],[17111],[False],[0],[0],[False],['0']
2438,PMC2893119,22633,"As insulin resistance serves as a key role between diabetes and cardiovascular disease, it is of importance that beta blocker treatment does not aggravate insulin resistance.",Discussion,[133603],[17112],[17286],[False],[0],[0],[False],['0']
2439,PMC2893119,22634,Vascular insulin resistance deteriorates glucose supply and thereby utilization in peripheral tissue.,Discussion,[133605],[17287],[17388],[False],[0],[0],[False],['0']
2440,PMC2893119,22635,Vascular insulin resistance may therefore be an important factor when treating patients with type 2 diabetes or metabolic syndrome.,Discussion,[133607],[17389],[17520],[False],[0],[0],[False],['0']
2441,PMC2893119,22636,"The importance of the findings in this study for the prognosis of patients is unknown, but the result could inspire to further studies of the importance of vascular insulin sensitivity given the favorable effects of carvedilol compared to metoprolol observed in the COMET study (The Carvedilol or Metoprolol European Trial) [3,4].",Discussion,[133609],[17521],[17851],[False],[0],[0],[False],['0']
2442,PMC2893119,22637,Carvedilol has been found superior to metoprolol in the control of glucose metabolism in patients with type 2 diabetes and hypertension [2].,Discussion,[133611],[17852],[17992],[False],[0],[0],[False],['0']
2443,PMC2893119,22638,"Also studies show that carvedilol does not deteriorate insulin resistance, as it was found in a direct comparison with metoprolol [18].",Discussion,[133613],[17993],[18128],[False],[0],[0],[False],['0']
2444,PMC2893119,22639,"In the study by Jacob et al, insulin sensitivity was measured by use of the euglycemic hyperinsulinaemic clamp method and the study included patients with hypertension, but not diabetes.",Discussion,[133615],[18129],[18315],[False],[0],[0],[False],['0']
2445,PMC2893119,22640,"Compared to atenolol, a selective beta-1 adrenergic receptor blocker, carvedilol has also shown a more favorable effect on systemic glucose metabolism [19], whereas atenolol and metoprolol both decreased insulin sensitivity to a similar level, when compared directly with an euglycemic hyperinsulinaemic clamp [20].",Discussion,[133617],[18316],[18631],[False],[0],[0],[False],['0']
2446,PMC2893119,22641,"These studies all show a systemic change in insulin resistance, whereas our study shows that the two beta-blockers, metoprolol and carvedilol, have a differential effect on vascular insulin sensitivity, with an advantage in favor of carvedilol.",Discussion,[133619],[18632],[18876],[False],[0],[0],[False],['0']
2447,PMC2893119,22642,In the group of patients treated with metoprolol we found an increase in body weight of 1.8 kg (p = 0.02) after 2 months of treatment.,Discussion,[133621],[18877],[19011],[False],[0],[0],[False],['0']
2448,PMC2893119,22643,"In contrast to this, no significant weight gain was found in the group of patients treated with carvedilol.",Discussion,[133623],[19012],[19119],[False],[0],[0],[False],['0']
2449,PMC2893119,22644,This is in accordance with the weight gain seen after treatment with beta-blockers in large clinical trials [21].,Discussion,[133625],[19120],[19233],[False],[0],[0],[False],['0']
2450,PMC2893119,22645,"In the GEMINI trial, a significant weight gain of 1.2 kg was found in the metoprolol arm compared to a non-significant weight gain in the carvedilol arm [2]; whether this can explain the general metabolic disadvantages seen with metoprolol in large clinical trials is uncertain.",Discussion,[133627],[19234],[19512],[False],[0],[0],[False],['0']
2451,PMC2893119,22646,Whether the weight gain in the metoprolol group seen in our study is associated with deterioration of insulin-stimulated endothelial function is also not known.,Discussion,[133629],[19513],[19673],[False],[0],[0],[False],['0']
2452,PMC2893119,22647,An inverse association between weight and adiponectin level has been found [22] and low plasma-adiponectin levels are considered to be a predictor of cardiovascular disease in patients with type 2 diabetes [23].,Discussion,[133631],[19674],[19885],[False],[0],[0],[False],['0']
2453,PMC2893119,22648,"In a recent study, metoprolol was found to decrease adiponectin level in hypertensive patients [24].",Discussion,[133633],[19886],[19986],[False],[0],[0],[False],['0']
2454,PMC2893119,22649,"Adiponectin could play a role in the relationship between vascular insulin resistance and treatment with metoprolol found in our study, and the weight-gain seen could also be an important factor.",Discussion,[133635],[19987],[20182],[False],[0],[0],[False],['0']
2455,PMC2893119,22650,"The beta-1 adrenergic receptor blocker atenolol causes enhancement of endothelium-dependent vasodilation during short time infusion and during 3 months treatment [25,26].",Discussion,[133637],[20183],[20353],[False],[0],[0],[False],['0']
2456,PMC2893119,22651,"In contrast, the non-selective beta-blocker propranolol causes attenuation of endothelial function during direct intra-arterial infusion and causes coronary artery vasoconstriction [25,27,28].",Discussion,[133639],[20354],[20546],[False],[0],[0],[False],['0']
2457,PMC2893119,22652,Four months treatment with carvedilol in patients with coronary artery disease improved endothelial function whereas no change was seen after short term treatment of 2 hours [29].,Discussion,[133641],[20547],[20726],[False],[0],[0],[False],['0']
2458,PMC2893119,22653,The long term effect on endothelial reactivity therefore seems to be dependent on the properties of the beta-blockers.,Discussion,[133643],[20727],[20845],[False],[0],[0],[False],['0']
2459,PMC2893119,22654,"Carvedilol has additional adrenergic receptor blocking properties, beta-1, beta-2 and alfa-1, along with antioxidative properties [30] compared to metoprolol, a beta-blocker with beta-1 adrenergic receptor blocking properties.",Discussion,[133645],[20846],[21072],[False],[0],[0],[False],['0']
2460,PMC2893119,22655,The effect of carvedilol on the endothelium may be explained by either increased endothelial NO-production or decreased NO-breakdown.,Discussion,[133647],[21073],[21206],[False],[0],[0],[False],['0']
2461,PMC2893119,22656,Carvedilol stimulates endothelial nitric oxide production [31] and its hemodynamic effects are blunted during complete inhibition of NO-production [32].,Discussion,[133649],[21207],[21359],[False],[0],[0],[False],['0']
2462,PMC2893119,22657,"In type 2 diabetes, an increased production of free radicals leads to an increased oxidative stress to the vascular wall [33].",Discussion,[133651],[21360],[21486],[False],[0],[0],[False],['0']
2463,PMC2893119,22658,Therefore carvedilol may have beneficial effects on endothelial dysfunction caused by oxidative stress in patients with type 2 diabetes.,Discussion,[133653],[21487],[21623],[False],[0],[0],[False],['0']
2464,PMC2893119,22659,"Vascular studies of long-term treatment with carvedilol have shown to improve endothelial function in patients with coronary artery disease which was attributed to the antioxidative properties of carvedilol [34], but in a recent study improvement of endothelial function after treatment with carvedilol in patients with diabetes, no changes in markers of oxidative stress could be found [35].",Discussion,[133655],[21624],[22016],[False],[0],[0],[False],['0']
2465,PMC2893119,22660,"As described, studies show inconclusive effects of the anti-oxidant property of carvedilol on endothelial function.",Discussion,[133657],[22017],[22132],[False],[0],[0],[False],['0']
2466,PMC2893119,22661,"We have not been able to demonstrate a benefit on endothelial function from treatment with carvedilol in patients with type 2 diabetes, despite the increased oxidative stress in this group of patients [36].",Discussion,[133659],[22133],[22339],[False],[0],[0],[False],['0']
2467,PMC2893119,22662,"But our study indicates that carvedilol has supplemental effects and this might be of importance when treating diabetic vascular diseases; to our knowledge, this is the first study to demonstrate a direct effect on insulin-stimulated endothelial function in patients with type 2 diabetes, when treated with different generations of beta-blockers.",Discussion,[133661],[22340],[22686],[False],[0],[0],[False],['0']
2468,PMC2893119,22663,Limitations to the study,Discussion|Limitations to the study,[133663],[22687],[22711],[False],[0],[0],[False],['0']
2469,PMC2893119,22664,The lack of changes in serotonin stimulated endothelial function after treatment with carvedilol or metoprolol might be caused by the small number of patients included in the study.,Discussion|Limitations to the study,[133665],[22712],[22893],[True],['SampleSize'],['the small number of patients included in the study'],[True],['UnderpoweredStudy']
2470,PMC2893119,22665,Nevertheless we were able to demonstrate a difference between the insulin stimulated endothelial function in the group of patients treated with carvedilol and not even a trend of change in serotonin stimulated endothelial function.,Discussion|Limitations to the study,[133669],[22894],[23125],[False],[0],[0],[False],['0']
2471,PMC2893119,22666,The number of patients included in the study might not be the only explanation to the lack of change after beta blocker treatment.,Discussion|Limitations to the study,[133671],[23126],[23256],[False],[0],[0],[False],['0']
2472,PMC2893119,22667,This a small interventional study with the purpose of finding changes in endothelial function between groups.,Discussion|Limitations to the study,[133674],[23257],[23366],[True],['SampleSize'],['This a small interventional study'],[True],['UnderpoweredStudy']
2473,PMC2893119,22668,Therefore changes in baseline characteristics could not be expected to be found with a statistical significance in this study.,Discussion|Limitations to the study,[133677],[23367],[23493],[False],[0],[0],[False],['0']
2474,PMC2893119,22669,A large interventional study is needed to find the actual differences in endothelial function after treatment with either carvedilol or metoprolol with correction for the baseline characteristics and changes found in this study.,Discussion|Limitations to the study,[133679],[23494],[23722],[False],[0],[0],[False],['0']
2475,PMC2893119,22670,Competing interests,Competing interests,[133681],[23723],[23743],[False],[0],[0],[False],['0']
2476,PMC2893119,22671,The authors declare that they have no competing interests.,Competing interests,[133683],[23744],[23802],[False],[0],[0],[False],['0']
2477,PMC2893119,22672,Authors' contributions,Authors' contributions,[133685],[23803],[23826],[False],[0],[0],[False],['0']
2478,PMC2893119,22673,"BK carried out study design, examinations of the patients, data analysis and statistics and drafted the manuscript.",Authors' contributions,[133687],[23827],[23942],[False],[0],[0],[False],['0']
2479,PMC2893119,22674,"TSH, CRM, LK, CTP and HD participated in designing the study, data analysis and statistics and critically revising the manuscript.",Authors' contributions,[133689],[23943],[24073],[False],[0],[0],[False],['0']
2480,PMC2893119,22675,"AMP, BC, JRM and CRM participated in the design of the study and revising the manuscript.",Authors' contributions,[133691],[24074],[24163],[False],[0],[0],[False],['0']
2481,PMC2893119,22676,Acknowledgements,Acknowledgements,[133693],[24164],[24181],[False],[0],[0],[False],['0']
2482,PMC2893119,22677,Grant has been provided for Britt Kveiborg from The Danish Heart Foundation and Bispebjerg Hospital Research Foundation.,Acknowledgements,[133695],[24182],[24302],[False],[0],[0],[False],['0']
3537,PMC3018567,9348,"Effect of single-dose anthelmintic treatment during pregnancy on an infant's response to immunisation and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial",Title,[56228],[33764],[211],[False],[0],[0],[False],['0']
3538,PMC3018567,9349,Summary,Abstract,[56233],[212],[220],[False],[0],[0],[False],['0']
3539,PMC3018567,9350,Background,Abstract,[56238],[221],[231],[False],[0],[0],[False],['0']
3540,PMC3018567,9351,Helminth infections affect the human immune response.,Abstract,[56243],[232],[285],[False],[0],[0],[False],['0']
3541,PMC3018567,9352,We investigated whether prenatal exposure to and treatment of maternal helminth infections affects development of an infant's immune response to immunisations and unrelated infections.,Abstract,[56248],[286],[470],[False],[0],[0],[False],['0']
3542,PMC3018567,9353,Methods,Abstract,[56253],[471],[478],[False],[0],[0],[False],['0']
3543,PMC3018567,9354,"In this randomised, double-blind, placebo-controlled trial, we enrolled 2507 women in the second or third trimester of pregnancy who were planning to deliver in Entebbe General Hospital, Entebbe, Uganda.",Abstract,[56258],[479],[682],[False],[0],[0],[False],['0']
3544,PMC3018567,9355,"With a computer-generated random number sequence in blocks of 100, we assigned patients to 440 mg albendazole and 40 mg/kg praziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching placebo (n=628).",Abstract,[56263],[683],[1036],[False],[0],[0],[False],['0']
3545,PMC3018567,9356,All participants and hospital staff were masked to allocation.,Abstract,[56268],[1037],[1099],[False],[0],[0],[False],['0']
3546,PMC3018567,9357,"Primary outcomes were immune response at age 1 year to BCG, tetanus, and measles immunisation; incidence of infectious diseases during infancy; and vertical HIV transmission.",Abstract,[56273],[1100],[1274],[False],[0],[0],[False],['0']
3547,PMC3018567,9358,Analysis was by intention-to-treat.,Abstract,[56278],[1275],[1310],[False],[0],[0],[False],['0']
3548,PMC3018567,9359,"This trial is registered, number ISRCTN32849447.",Abstract,[56283],[1311],[1359],[False],[0],[0],[False],['0']
3549,PMC3018567,9360,Findings,Abstract,[56288],[1360],[1368],[False],[0],[0],[False],['0']
3550,PMC3018567,9361,"Data were available at delivery for 2356 women, with 2345 livebirths; 2115 (90%) of liveborn infants remained in follow-up at 1 year of age.",Abstract,[56293],[1369],[1509],[False],[0],[0],[False],['0']
3551,PMC3018567,9362,"Neither albendazole nor praziquantel treatments affected infant response to BCG, tetanus, or measles immunisation.",Abstract,[56298],[1510],[1624],[False],[0],[0],[False],['0']
3552,PMC3018567,9363,"However, in infants of mothers with hookworm infection, albendazole treatment reduced interleukin-5 (geometric mean ratio 0·50, 95% CI 0·30–0·81, interaction p=0·02) and interleukin-13 (0·52, 0·34–0·82, 0·0005) response to tetanus toxoid.",Abstract,[56303],[1625],[1863],[False],[0],[0],[False],['0']
3553,PMC3018567,9364,"The rate per 100 person-years of malaria was 40·9 (95% CI 38·3–43·7), of diarrhoea was 134·1 (129·2–139·2), and of pneumonia was 22·3 (20·4–24·4).",Abstract,[56308],[1864],[2010],[False],[0],[0],[False],['0']
3554,PMC3018567,9365,"We noted no effect on infectious disease incidence for albendazole treatment (malaria [hazard ratio 0·95, 95% CI 0·79–1.14], diarrhoea [1·06, 0·96–1·16], pneumonia [1·11, 0·90–1·38]) or praziquantel treatment (malaria [1·00, 0·84–1·20], diarrhoea [1·07, 0·98–1·18], pneumonia [1·00, 0·80–1·24]).",Abstract,[56313],[2011],[2306],[False],[0],[0],[False],['0']
3555,PMC3018567,9366,"In HIV-exposed infants, 39 (18%) were infected at 6 weeks; vertical transmission was not associated with albendazole (odds ratio 0·70, 95% CI 0·35–1·42) or praziquantel (0·60, 0·29–1·23) treatment.",Abstract,[56318],[2307],[2504],[False],[0],[0],[False],['0']
3556,PMC3018567,9367,Interpretation,Abstract,[56323],[2505],[2519],[False],[0],[0],[False],['0']
3557,PMC3018567,9368,"These results do not accord with the recently advocated policy of routine antenatal anthelmintic treatment, and the value of such a policy may need to be reviewed.",Abstract,[56328],[2520],[2683],[False],[0],[0],[False],['0']
3558,PMC3018567,9369,Funding,Abstract,[56333],[2684],[2691],[False],[0],[0],[False],['0']
3559,PMC3018567,9370,Wellcome Trust.,Abstract,[56338],[2692],[2707],[False],[0],[0],[False],['0']
3560,PMC3018567,9371,Introduction,Introduction|Introduction,[56343],[2708],[2721],[False],[0],[0],[False],['0']
3561,PMC3018567,9372,"Worldwide, infectious diseases account for more than 50% of deaths of children younger than 5 years; pneumonia, diarrhoeal disease, and malaria are the three most common causes.",Introduction|Introduction,[56348],[2722],[2899],[False],[0],[0],[False],['0']
3562,PMC3018567,9373,"More than half of these deaths occur in sub-Saharan Africa, where roughly 2·5 million children younger than 5 years are estimated to die every year from one of these three diseases.",Introduction|Introduction,[56353],[2900],[3081],[False],[0],[0],[False],['0']
3563,PMC3018567,9374,"Immunisation is a key strategy to combat infectious diseases, but immunisation programmes in developing countries vary in effectiveness.",Introduction|Introduction,[56358],[3082],[3218],[False],[0],[0],[False],['0']
3564,PMC3018567,9375,"For example, increases in measles immunisation coverage have led to substantial falls in the incidence of measles; by contrast, despite high immunisation coverage, the prevalence of tuberculosis is high in sub-Saharan Africa, and is one of the leading causes of deaths in adults.",Introduction|Introduction,[56363],[3219],[3498],[False],[0],[0],[False],['0']
3565,PMC3018567,9376,BCG is the only available vaccine against tuberculosis and its effectiveness is lowest in countries closest to the equator.,Introduction|Introduction,[56368],[3499],[3622],[False],[0],[0],[False],['0']
3566,PMC3018567,9377,"Soil-transmitted helminth infections and schistosomiasis are also prevalent in developing countries, and their geographical distribution has extensive overlap with areas in which rates of infectious diseases are highest and the effectiveness of BCG immunisation is lowest.",Introduction|Introduction,[56373],[3623],[3895],[False],[0],[0],[False],['0']
3567,PMC3018567,9378,"Such overlap in disease distributions has led to the suggestion that chronic helminth infections could affect the epidemiological patterns of other diseases, through impairment of immune responses to immunisations and unrelated infections.",Introduction|Introduction,[56378],[3896],[4135],[False],[0],[0],[False],['0']
3568,PMC3018567,9379,"This hypothesis was supported by the finding that T-helper-1 (Th1) cell responses (characterised by interferon-γ production, induced by viral and bacterial antigens, and required for protection against mycobacteria and other intracellular pathogens) and T-helper-2 (Th2) cell responses (characterised by production of interleukins 4, 5, and 13 and induced by allergens such as helminth antigens) are mutually inhibitory.",Introduction|Introduction,[56383],[4136],[4556],[False],[0],[0],[False],['0']
3569,PMC3018567,9380,"However, helminth infections induce immunoregulation by various other mechanisms, such as interleukin-10 production, and affect responses to non-helminth antigens.",Introduction|Introduction,[56388],[4557],[4720],[False],[0],[0],[False],['0']
3570,PMC3018567,9381,"Thus helminth infections could inhibit protective Th1 responses to unrelated organisms, such as viruses, bacteria, and vaccines, by inducing a Th1 to Th2 switch and through immunoregulatory mechanisms.",Introduction|Introduction,[56393],[4721],[4922],[False],[0],[0],[False],['0']
3571,PMC3018567,9382,Several studies of animals and human beings lend support to this hypothesis.,Introduction|Introduction,[56398],[4923],[4999],[False],[0],[0],[False],['0']
3572,PMC3018567,9383,"Although helminth infections are generally thought to have detrimental effects on host responses to infectious pathogens, a beneficial effect against other diseases is also possible through suppression of pathological inflammatory responses; some researchers have suggested an inverse association between helminth infections and incidence of severe malaria.",Introduction|Introduction,[56403],[5000],[5357],[False],[0],[0],[False],['0']
3573,PMC3018567,9384,"Helminth infections are rare in infancy, when immunisations are given and many infectious disease-related deaths occur.",Introduction|Introduction,[56408],[5358],[5477],[False],[0],[0],[False],['0']
3574,PMC3018567,9385,"However, evidence exists that prenatal exposure to maternal helminth infection could have important effects on an infant's immune response.",Introduction|Introduction,[56413],[5478],[5617],[False],[0],[0],[False],['0']
3575,PMC3018567,9386,"Prenatal sensitisation to Wuchereria bancrofti, a filarial worm, is associated with increased susceptibility to W bancrofti infection in childhood, and prenatal sensitisation to filarial or schistosome antigens with reduced Th1 and increased Th2 cytokine responses to mycobacterial antigens after BCG immunisation at birth.",Introduction|Introduction,[56418],[5618],[5941],[False],[0],[0],[False],['0']
3576,PMC3018567,9387,"Such findings suggest that prenatal exposure to maternal helminth infection modulates an infant's immune response to vaccination and infectious pathogens, and that anthelmintic treatment during pregnancy can prevent these effects.",Introduction|Introduction,[56423],[5942],[6172],[False],[0],[0],[False],['0']
3577,PMC3018567,9388,We designed this trial of anthelmintic treatment during pregnancy to address this hypothesis.,Introduction|Introduction,[56428],[6173],[6266],[False],[0],[0],[False],['0']
3578,PMC3018567,9389,"We also examined effects of anthelmintic treatment during pregnancy on infant mortality, and on anaemia and growth at age 1 year, to assess the overall risks and benefits of anthelmintic treatment during pregnancy.",Introduction|Introduction,[56433],[6267],[6481],[False],[0],[0],[False],['0']
3579,PMC3018567,9390,Methods,Methods,[56438],[6482],[6490],[False],[0],[0],[False],['0']
3580,PMC3018567,9391,Study design and patients,Methods|Study design and patients,[56443],[6491],[6516],[False],[0],[0],[False],['0']
3581,PMC3018567,9392,The study is described in detail elsewhere.,Methods|Study design and patients,[56448],[6517],[6560],[False],[0],[0],[False],['0']
3582,PMC3018567,9393,"Briefly, the study area was Entebbe Municipality and Katabi subcounty, beside Lake Victoria, Uganda.",Methods|Study design and patients,[56453],[6561],[6661],[False],[0],[0],[False],['0']
3583,PMC3018567,9394,"The area is occupied by urban, rural, and fishing communities.",Methods|Study design and patients,[56458],[6662],[6724],[False],[0],[0],[False],['0']
3584,PMC3018567,9395,"Helminth infection is highly prevalent in the area, and malaria, diarrhoea, and pneumonia are common in young children.",Methods|Study design and patients,[56463],[6725],[6844],[False],[0],[0],[False],['0']
3585,PMC3018567,9396,"The study population consisted of pregnant women who presented at the government-funded antenatal clinic at Entebbe General Hospital between April 9, 2003, and Nov 24, 2005, where roughly 70% of pregnant women from the study area received antenatal care.",Methods|Study design and patients,[56468],[6845],[7099],[False],[0],[0],[False],['0']
3586,PMC3018567,9397,"Women were included if resident in the study area, planning to deliver in the hospital, willing to know their HIV status, and in the second or third trimester of pregnancy.",Methods|Study design and patients,[56473],[7100],[7272],[False],[0],[0],[False],['0']
3587,PMC3018567,9398,"They were excluded if they had possible helminth-induced pathological changes (haemoglobin <80 g/L, clinically apparent severe liver disease, or diarrhoea with blood in stool), a history of an adverse reaction to anthelmintics, already been enrolled in the trial during an earlier pregnancy, or if the pregnancy was deemed abnormal by a midwife.",Methods|Study design and patients,[56478],[7273],[7618],[False],[0],[0],[False],['0']
3588,PMC3018567,9399,"All participants gave written, informed consent.",Methods|Study design and patients,[56483],[7619],[7667],[False],[0],[0],[False],['0']
3589,PMC3018567,9400,"Ethics approval was given by the Uganda Virus Research Institute, Uganda National Council for Science and Technology, and London School of Hygiene and Tropical Medicine.",Methods|Study design and patients,[56488],[7668],[7837],[False],[0],[0],[False],['0']
3590,PMC3018567,9401,Randomisation and masking,Methods|Randomisation and masking,[56493],[7838],[7863],[False],[0],[0],[False],['0']
3591,PMC3018567,9402,"We used a two-by-two factorial design to randomly assign patients in a 1:1:1:1 ratio to receive simultaneously either single-dose albendazole (440 mg) and single-dose praziquantel (40 mg/kg), albendazole and a praziquantel-matching placebo, an albendazole-matching placebo and praziquantel, or an albendazole-matching placebo and a praziquantel-matching placebo (albendazole and matching placebo, Glaxosmithkline, Brentford, UK; praziquantel and matching placebo, Medochemie Ltd, Limassal, Cyprus).",Methods|Randomisation and masking,[56498],[7864],[8362],[False],[0],[0],[False],['0']
3592,PMC3018567,9403,"The randomisation code was generated by the trial statistician with a computer-generated random number sequence, with block size 100.",Methods|Randomisation and masking,[56503],[8363],[8496],[False],[0],[0],[False],['0']
3593,PMC3018567,9404,Treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the Medical Research Council Unit in Entebbe who did not otherwise contribute to the trial.,Methods|Randomisation and masking,[56508],[8497],[8687],[False],[0],[0],[False],['0']
3594,PMC3018567,9405,Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study.,Methods|Randomisation and masking,[56513],[8688],[8851],[False],[0],[0],[False],['0']
3595,PMC3018567,9406,Treatment allocation was masked from all participants and staff during the study.,Methods|Randomisation and masking,[56518],[8852],[8933],[False],[0],[0],[False],['0']
3596,PMC3018567,9407,Procedures,Methods|Procedures,[56523],[8934],[8944],[False],[0],[0],[False],['0']
3597,PMC3018567,9408,"Demographic and clinical details, and blood samples were obtained at screening; stool samples were obtained before enrolment.",Methods|Procedures,[56528],[8945],[9070],[False],[0],[0],[False],['0']
3598,PMC3018567,9409,"After enrolment, women continued to receive standard antenatal care, including haematinics, tetanus immunisation, and intermittent presumptive treatment for malaria twice after their first trimester of pregnancy; women with HIV were offered intrapartum and neonatal single-dose nevirapine for prevention of mother-to-child (vertical) HIV transmission.",Methods|Procedures,[56533],[9071],[9422],[False],[0],[0],[False],['0']
3599,PMC3018567,9410,"Stool samples were obtained after delivery to assess effectiveness of anthelmintic treatment; thereafter, all mothers received praziquantel and albendazole.",Methods|Procedures,[56538],[9423],[9579],[False],[0],[0],[False],['0']
3600,PMC3018567,9411,"Infants received BCG and polio immunisation at birth; diphtheria, pertussis, tetanus, Haemophilus influenzae, hepatitis B, and polio immunisation at 6, 10, and 14 weeks; and measles immunisation at 9 months.",Methods|Procedures,[56543],[9580],[9787],[False],[0],[0],[False],['0']
3601,PMC3018567,9412,"Children also attended the study clinic when unwell; doctors diagnosed, treated, and recorded their illnesses.",Methods|Procedures,[56548],[9788],[9898],[False],[0],[0],[False],['0']
3602,PMC3018567,9413,"Community fieldworkers visited each participant's home twice a month, measured the child's temperature, and recorded symptoms reported by the child's carer.",Methods|Procedures,[56553],[9899],[10055],[False],[0],[0],[False],['0']
3603,PMC3018567,9414,"At age 12 months, blood and stool samples were obtained from the children and growth outcomes were measured.",Methods|Procedures,[56558],[10056],[10164],[False],[0],[0],[False],['0']
3604,PMC3018567,9415,Children who were unwell at their 12-month visit were given appropriate treatment and asked to return to complete the visit procedures when well.,Methods|Procedures,[56563],[10165],[10310],[False],[0],[0],[False],['0']
3605,PMC3018567,9416,"The primary outcomes were immune response at age 1 year to BCG, tetanus, and measles immunisation; incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis during infancy as diagnosed by doctors at the study clinic; and vertical HIV transmission.",Methods|Procedures,[56568],[10311],[10570],[False],[0],[0],[False],['0']
3606,PMC3018567,9417,Planned secondary outcomes were growth and anaemia at age 1 year.,Methods|Procedures,[56573],[10571],[10636],[False],[0],[0],[False],['0']
3607,PMC3018567,9418,Community-reported data for illness events were included as a secondary outcome for comparison with doctor-diagnosed illness events from clinic visits.,Methods|Procedures,[56578],[10637],[10788],[False],[0],[0],[False],['0']
3608,PMC3018567,9419,We also considered two additional unplanned secondary outcomes: infant mortality and asymptomatic malaria (presence of malaria parasitaemia) at 1 year of age.,Methods|Procedures,[56583],[10789],[10947],[False],[0],[0],[False],['0']
3609,PMC3018567,9420,Cytokine responses at 1 year of age to crude culture filtrate proteins of Mycobacterium tuberculosis (cCFP) were measured as an indicator of response to BCG immunisation.,Methods|Procedures,[56588],[10948],[11118],[False],[0],[0],[False],['0']
3610,PMC3018567,9421,Cytokine responses at age 1 year to tetanus toxoid were measured as an indicator of response to tetanus immunisation.,Methods|Procedures,[56593],[11119],[11236],[False],[0],[0],[False],['0']
3611,PMC3018567,9422,"We examined stimulated interferon-γ (type 1), interleukin-5 (type 2), interleukin-13 (type 2), and interleukin-10 (regulatory) responses in a whole-blood assay, as previously described.",Methods|Procedures,[56598],[11237],[11422],[False],[0],[0],[False],['0']
3612,PMC3018567,9423,"Total serum IgG, IgG4, and IgE responses to tetanus toxoid were measured by ELISA (webappendix p 1).",Methods|Procedures,[56603],[11423],[11523],[False],[0],[0],[False],['0']
3613,PMC3018567,9424,"Total serum measles-specific IgG was measured by ELISA (Dade Behring/Siemens, Eschborn, Germany) according to the manufacturer's protocol.",Methods|Procedures,[56608],[11524],[11662],[False],[0],[0],[False],['0']
3614,PMC3018567,9425,"Immunological assays were done after all samples had been obtained, in a randomised sequence (by use of a computer-generated random number sequence), to avoid confounding of secular trends with variations in assay performance.",Methods|Procedures,[56613],[11663],[11889],[False],[0],[0],[False],['0']
3615,PMC3018567,9426,"For the primary outcome, doctor-diagnosed illness events, clinical malaria was fever (temperature ≥37·5°C) with parasitaemia; diarrhoea was an infant's carer's definition, with stool frequency recorded; pneumonia was cough with difficulty in breathing, and age-specific fast breathing; measles was defined by standard clinical criteria and confirmed by measurement of specific antibody; and children with suspected tuberculosis were investigated as clinically indicated.",Methods|Procedures,[56618],[11890],[12360],[False],[0],[0],[False],['0']
3616,PMC3018567,9427,"For the secondary outcome, community-reported illnesses, febrile illness was defined as measured by fieldworkers (temperature ≥37·5°C) or as reported by the child's carer; diarrhoea as reported by the carer, with stool frequency recorded; presumptive pneumonia was cough with difficulty in breathing, or age-specific fast breathing as measured by fieldworkers.",Methods|Procedures,[56623],[12361],[12721],[False],[0],[0],[False],['0']
3617,PMC3018567,9428,"Stool samples were examined for helminth ova with the Kato-Katz method and by charcoal culture for Strongyloides sterocoralis infection; two Kato-Katz slides were prepared from each sample and examined for hookworm ova within 30 mins of preparation, or examined the next day for other species.",Methods|Procedures,[56628],[12722],[13015],[False],[0],[0],[False],['0']
3618,PMC3018567,9429,"Hookworm and Schistosoma mansoni infections were classified into low, medium, and high intensities according to WHO guidelines.",Methods|Procedures,[56633],[13016],[13143],[False],[0],[0],[False],['0']
3619,PMC3018567,9430,Blood samples were examined by a modified Knott's method for Mansonella perstans and by thick film for malaria parasites.,Methods|Procedures,[56638],[13144],[13265],[False],[0],[0],[False],['0']
3620,PMC3018567,9431,"Haemoglobin was estimated by Coulter analyser (Beckman Coulter, Nyon, Switzerland).",Methods|Procedures,[56643],[13266],[13349],[False],[0],[0],[False],['0']
3621,PMC3018567,9432,"Quality control for Kato-Katz analyses was provided by the Vector Control Programme of the Ministry of Health, Uganda, and for haematology and malaria parasitology through the UK National External Quality Assessment Schemes.",Methods|Procedures,[56648],[13350],[13574],[False],[0],[0],[False],['0']
3622,PMC3018567,9433,Mothers' HIV serology was done by rapid test algorithm.,Methods|Procedures,[56653],[13575],[13630],[False],[0],[0],[False],['0']
3623,PMC3018567,9434,Blood was obtained from cord and at 6 weeks of age from infants of mothers with HIV for assessment of vertical HIV transmission.,Methods|Procedures,[56658],[13631],[13759],[False],[0],[0],[False],['0']
3624,PMC3018567,9435,Plasma and whole blood cell pellet were separated by centrifugation and stored at −80°C until assays were done.,Methods|Procedures,[56663],[13760],[13871],[False],[0],[0],[False],['0']
3625,PMC3018567,9436,"For detection of HIV-1 proviral DNA in infants at 6 weeks, DNA was extracted from stored whole blood cell pellets and amplified by nested PCR of three conserved viral regions, tat, gp41, and nef (webappendix p 1).",Methods|Procedures,[56668],[13872],[14085],[False],[0],[0],[False],['0']
3626,PMC3018567,9437,"For both cord and 6-week samples, plasma HIV load was measured with Bayer Versant branched DNA assay version 3.0 (Bayer, Leverkusen, Germany) or Roche Amplicor HIV-1 RNA Monitor test version 1.5 (Roche, NJ, USA).",Methods|Procedures,[56673],[14086],[14298],[False],[0],[0],[False],['0']
3627,PMC3018567,9438,"Infants were regarded as being HIV positive if the 6-week sample had a positive DNA PCR for any of the viral regions and a viral load of 1000 copies per mL or more; for four infants, only viral load data were available, so they were used to establish HIV status.",Methods|Procedures,[56678],[14299],[14561],[False],[0],[0],[False],['0']
3628,PMC3018567,9439,"Viral load and DNA-PCR results were concordant apart from one infant (viral load 6699 copies per mL, PCR negative) who was seronegative by rapid test algorithm at age 18 months and was classified as HIV negative.",Methods|Procedures,[56683],[14562],[14774],[False],[0],[0],[False],['0']
3629,PMC3018567,9440,"In infants with HIV infection, transmission was regarded as likely to have been intrauterine if the viral load in cord blood was 1000 copies per mL or more.",Methods|Procedures,[56688],[14775],[14931],[False],[0],[0],[False],['0']
3630,PMC3018567,9441,Statistical analysis,Methods|Statistical analysis,[56693],[14932],[14952],[False],[0],[0],[False],['0']
3631,PMC3018567,9442,Analysis was done after all children were older than 15 months.,Methods|Statistical analysis,[56698],[14953],[15016],[False],[0],[0],[False],['0']
3632,PMC3018567,9443,"Data for samples and measurements obtained at routine, 1-year visits were included if the child attended within 2 months after their first birthday.",Methods|Statistical analysis,[56703],[15017],[15165],[False],[0],[0],[False],['0']
3633,PMC3018567,9444,Data for illness events and mortality were censored strictly at 1 year.,Methods|Statistical analysis,[56708],[15166],[15237],[False],[0],[0],[False],['0']
3634,PMC3018567,9445,Results for younger twins were excluded from all analyses.,Methods|Statistical analysis,[56713],[15238],[15296],[False],[0],[0],[False],['0']
3635,PMC3018567,9446,"On the basis of our preliminary study, the planned cohort size of 2500 was expected to accrue 1860 person-years of follow-up in infancy and 1594 infants were expected to be seen at age 1 year.",Methods|Statistical analysis,[56718],[15297],[15489],[False],[0],[0],[False],['0']
3636,PMC3018567,9447,"For either maternal treatment, assuming no interaction between treatments, this number would give 80% power to detect rate ratios of 0·82 for malaria, 0·91 for diarrhoea, and 0·76 for pneumonia, with p values of less than 0·05, assuming frequency of disease in the placebo groups to be 50 per 100 person-years for malaria, 190 per 100 person-years for diarrhoea, and 25 per 100 person-years for pneumonia.",Methods|Statistical analysis,[56723],[15490],[15895],[False],[0],[0],[False],['0']
3637,PMC3018567,9448,"Incidence of both tuberculosis and measles was expected to be low, therefore only very large differences in incidence would be detected.",Methods|Statistical analysis,[56728],[15896],[16032],[False],[0],[0],[False],['0']
3638,PMC3018567,9449,Samples from 1594 infants assessed at 1 year would detect differences in infant cytokine responses of 0·11 log10 between intervention groups.,Methods|Statistical analysis,[56733],[16033],[16174],[False],[0],[0],[False],['0']
3639,PMC3018567,9450,The patients that were included in analysis for each of the primary outcomes differed because data for each outcome was obtained at different times.,Methods|Statistical analysis,[56738],[16175],[16323],[False],[0],[0],[False],['0']
3640,PMC3018567,9451,"For immune response at age 1 year, analysis included all children who provided a blood sample at 1 year and who had received full BCG (for cCFP analysis) or tetanus (for tetanus toxoid analysis) immunisation at Entebbe Hospital; second-born twins were excluded.",Methods|Statistical analysis,[56743],[16324],[16585],[False],[0],[0],[False],['0']
3641,PMC3018567,9452,"For incidence of infectious diseases during infancy, analysis included all liveborn children, excluding second-born twins.",Methods|Statistical analysis,[56748],[16586],[16708],[False],[0],[0],[False],['0']
3642,PMC3018567,9453,"For vertical HIV transmission, analysis included all children whose mothers were not receiving highly-active antiretroviral therapy, and from whom blood samples at age 6 weeks were available; second-born twins were excluded.",Methods|Statistical analysis,[56753],[16709],[16933],[False],[0],[0],[False],['0']
3643,PMC3018567,9454,"Cytokine and antibody responses showed skewed distributions, with disproportionate numbers of zero values.",Methods|Statistical analysis,[56758],[16934],[17040],[False],[0],[0],[False],['0']
3644,PMC3018567,9455,Results were transformed to log10(concentration+1) and analysed by linear regression with bootstrapping to estimate bias-corrected accelerated confidence intervals.,Methods|Statistical analysis,[56763],[17041],[17205],[False],[0],[0],[False],['0']
3645,PMC3018567,9456,Regression coefficients were back-transformed to give geometric mean ratios.,Methods|Statistical analysis,[56768],[17206],[17282],[False],[0],[0],[False],['0']
3646,PMC3018567,9457,Interactions were examined with Wald tests.,Methods|Statistical analysis,[56773],[17283],[17326],[False],[0],[0],[False],['0']
3647,PMC3018567,9458,"For doctor-diagnosed disease incidence, time at risk began at birth and was censored at loss to follow-up, death, or age 1 year.",Methods|Statistical analysis,[56778],[17327],[17455],[False],[0],[0],[False],['0']
3648,PMC3018567,9459,"All children with known date of birth were included in the analysis until censoring, irrespective of whether they had made a clinic visit for illness.",Methods|Statistical analysis,[56783],[17456],[17606],[False],[0],[0],[False],['0']
3649,PMC3018567,9460,"For each disease, we calculated incidence rates for all events.",Methods|Statistical analysis,[56788],[17607],[17670],[False],[0],[0],[False],['0']
3650,PMC3018567,9461,"Disease episodes within 14 days of an initial presentation with the same disease were regarded as part of the same episode and excluded from the analysis; time at risk was adjusted accordingly, excluding these 14-day periods from the total person-time denominator.",Methods|Statistical analysis,[56793],[17671],[17935],[False],[0],[0],[False],['0']
3651,PMC3018567,9462,"Hazard ratios (HRs) for effects of treatment were calculated with Cox regression, with robust SEs to allow for within-child clustering.",Methods|Statistical analysis,[56798],[17936],[18071],[False],[0],[0],[False],['0']
3652,PMC3018567,9463,"For community-reported illness data, a generalised-estimating-equation approach with exchangeable correlation structure was used to model effects of treatment on repeated binary outcomes.",Methods|Statistical analysis,[56803],[18072],[18259],[False],[0],[0],[False],['0']
3653,PMC3018567,9464,Odds ratios (ORs) for the effects of treatment on vertical HIV transmission were calculated with logistic regression.,Methods|Statistical analysis,[56808],[18260],[18377],[False],[0],[0],[False],['0']
3654,PMC3018567,9465,The prevalence of asymptomatic malaria at 1 year was compared between treatment groups with logistic regression.,Methods|Statistical analysis,[56813],[18378],[18490],[False],[0],[0],[False],['0']
3655,PMC3018567,9466,"Infant mortality per 1000 livebirths was estimated from Kaplan-Meier survival probabilities to age 1 year, and effects of maternal anthelmintic treatment were assessed by Cox regression.",Methods|Statistical analysis,[56818],[18491],[18677],[False],[0],[0],[False],['0']
3656,PMC3018567,9467,"Weight-for-age, height-for-age, and weight-for-height Z scores at 1 year were derived from WHO growth standard reference scales, with igrowup macros.",Methods|Statistical analysis,[56823],[18678],[18827],[False],[0],[0],[False],['0']
3657,PMC3018567,9468,We examined effects of maternal treatment on Z scores and on haemoglobin at 1 year by linear regression.,Methods|Statistical analysis,[56828],[18828],[18932],[False],[0],[0],[False],['0']
3658,PMC3018567,9469,"We did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.",Methods|Statistical analysis,[56833],[18933],[19151],[False],[0],[0],[False],['0']
3659,PMC3018567,9470,Differences between subgroups were examined by fitting interaction terms in regression models.,Methods|Statistical analysis,[56838],[19152],[19246],[False],[0],[0],[False],['0']
3660,PMC3018567,9471,All p values were two-sided with no adjustment made for multiple comparisons.,Methods|Statistical analysis,[56843],[19247],[19324],[False],[0],[0],[False],['0']
3661,PMC3018567,9472,Analyses were done with Stata 10.1.,Methods|Statistical analysis,[56848],[19325],[19360],[False],[0],[0],[False],['0']
3662,PMC3018567,9473,Role of the funding source,Methods|Role of the funding source,[56853],[19361],[19387],[False],[0],[0],[False],['0']
3663,PMC3018567,9474,"The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.",Methods|Role of the funding source,[56858],[19388],[19520],[False],[0],[0],[False],['0']
3664,PMC3018567,9475,AME had full access to all the data in the study and had final responsibility for the decision to submit for publication.,Methods|Role of the funding source,[56863],[19521],[19642],[False],[0],[0],[False],['0']
3665,PMC3018567,9476,Results,Results,[56868],[19643],[19651],[False],[0],[0],[False],['0']
3666,PMC3018567,9477,The figure shows the trial profile.,Results,[56873],[19652],[19687],[False],[0],[0],[False],['0']
3667,PMC3018567,9478,"2507 women were randomly assigned to treatment groups, 1309 (52%) of whom were in the second trimester of pregnancy and 1195 (48%) of whom were in the third trimester of pregnancy.",Results,[56878],[19688],[19868],[False],[0],[0],[False],['0']
3668,PMC3018567,9479,The median length of time between receiving the study intervention and delivery was 87 days (IQR 54–118).,Results,[56883],[19869],[19974],[False],[0],[0],[False],['0']
3669,PMC3018567,9480,"Data were available for 2356 women (94%) at delivery and there were 2345 livebirths; results for 30 liveborn younger twins or triplets were excluded, which left data for follow-up of 2315 liveborn infants.",Results,[56888],[19975],[20180],[False],[0],[0],[False],['0']
3670,PMC3018567,9481,"Of these infants, 2092 (90%) remained in follow-up at 1 year of age, of whom 1701 (81%) attended the 1-year visit.",Results,[56893],[20181],[20295],[False],[0],[0],[False],['0']
3671,PMC3018567,9482,Baseline characteristics of mothers were similar between the four groups (table 1).,Results,[56898],[20296],[20379],[False],[0],[0],[False],['0']
3672,PMC3018567,9483,"Mothers of children who did not contribute to follow-up were, on average, younger, more likely to be pregnant for the first time, have malaria or HIV infection, and have enrolled earlier during pregnancy than mothers of children who contributed to follow up (data not shown).",Results,[56903],[20380],[20655],[False],[0],[0],[False],['0']
3673,PMC3018567,9484,Mothers of children who provided samples at 1 year of age were of higher socioeconomic status and less likely to reside in remote parts of the study area than were mothers of children who did not provide samples at age 1 year (data not shown).,Results,[56908],[20656],[20899],[False],[0],[0],[False],['0']
3674,PMC3018567,9485,"At enrolment, 1693 (68%) of women were infected with at least one helminth species.",Results,[56913],[20900],[20983],[False],[0],[0],[False],['0']
3675,PMC3018567,9486,"Individual prevalences of each species were: hookworm 45%, M perstans 21%, S mansoni 18%, S stercoralis 12%, Trichuris trichiura 9%, and Ascaris lumbricoides 2%.",Results,[56918],[20984],[21145],[False],[0],[0],[False],['0']
3676,PMC3018567,9487,"Infections were generally mild, with 942 (85%) of hookworm infections and 297 (65%) of S mansoni infections classified as light.",Results,[56923],[21146],[21274],[False],[0],[0],[False],['0']
3677,PMC3018567,9488,"Subgroups of 648 mothers who received albendazole-matching placebo and 658 mothers who received praziquantel-matching placebo had three stool samples examined before being treated 6 weeks after delivery; in these women, the sensitivity of one stool sample compared with three stool samples was 89% for hookworm infection and 66% for schistosomiasis.",Results,[56928],[21275],[21624],[False],[0],[0],[False],['0']
3678,PMC3018567,9489,1957 mothers (78%) received at least one documented dose of tetanus immunisation during pregnancy; 1447 (74%) received all documented tetanus immunisations before the anthelmintic treatment intervention (median 4 days [IQR 3–7] before intervention).,Results,[56933],[21625],[21874],[False],[0],[0],[False],['0']
3679,PMC3018567,9490,We noted no evidence of interaction between maternal albendazole and praziquantel treatments for any outcome (all interaction p values>0·1; webappendix pp 3–4); therefore the effects of each treatment were assessed independently.,Results,[56938],[21875],[22104],[False],[0],[0],[False],['0']
3680,PMC3018567,9491,"Results for cytokine responses at age 1 year were available for 1542 infants, of whom 1506 had received BCG immunisation at birth at Entebbe Hospital and 1015 had received all three doses of tetanus immunisation at Entebbe Hospital.",Results,[56943],[22105],[22337],[False],[0],[0],[False],['0']
3681,PMC3018567,9492,"The proportion of infants for whom positive responses to cCFP and tetanus toxoid were detected varied by cytokine; for cCFP, 1356 (90%) infants had positive responses to interferon-γ, 449 (30%) had positive responses to interleukin 5, 1005 (67%) had positive responses to interleukin 13, and 1316 (87%) had positive responses to interleukin-10.",Results,[56948],[22338],[22682],[False],[0],[0],[False],['0']
3682,PMC3018567,9493,"For tetanus toxoid, 655 (65%) infants had positive responses to interferon-γ, 499 (49%) had positive responses to interleukin 5, 766 (75%) had positive responses to interleukin 13, and 498 (49%) had positive responses to interleukin 10.",Results,[56953],[22683],[22919],[False],[0],[0],[False],['0']
3683,PMC3018567,9494,"Albendazole treatment of mothers was associated with a small reduction in unstimulated interleukin-10 production by their children (geometric mean ratio 0·83, 95% CI 0·70–0·98).",Results,[56958],[22920],[23097],[False],[0],[0],[False],['0']
3684,PMC3018567,9495,We recorded no other overall effects of maternal treatment on unstimulated cytokine production.,Results,[56963],[23098],[23193],[False],[0],[0],[False],['0']
3685,PMC3018567,9496,"Results for effects on responses to stimulation were similar, irrespective of whether background cytokine production was subtracted (data not shown).",Results,[56968],[23194],[23343],[False],[0],[0],[False],['0']
3686,PMC3018567,9497,We detected no effects of either albendazole or praziquantel treatments on the overall antigen-specific response after immunisation (table 2).,Results,[56973],[23344],[23486],[False],[0],[0],[False],['0']
3687,PMC3018567,9498,"However, in infants of mothers with a hookworm infection, maternal albendazole treatment was associated with a small non-significant reduction in the interferon-γ response to cCFP and with reductions in their response to tetanus toxoid for the type 2 cytokines interleukin 5 and interleukin 13 (table 3).",Results,[56978],[23487],[23791],[False],[0],[0],[False],['0']
3688,PMC3018567,9499,We recorded no significant effect of praziquantel treatment in infants of mothers with schistosomiasis (table 3).,Results,[56983],[23792],[23905],[False],[0],[0],[False],['0']
3689,PMC3018567,9500,"We recorded no overall effects for either albendazole or praziquantel treatments on antibody concentrations for tetanus or measles (table 2), nor did we detect differential effects for either albendazole or praziquantel treatment according to susceptible worm species (table 3).",Results,[56988],[23906],[24184],[False],[0],[0],[False],['0']
3690,PMC3018567,9501,"Of the 2315 liveborn children, 2083 (90%) made at least one illness-related clinic visit during infancy.",Results,[56993],[24185],[24289],[False],[0],[0],[False],['0']
3691,PMC3018567,9502,The number of illness visits by children in all four treatment groups were similar (webappendix p 4).,Results,[56998],[24290],[24391],[False],[0],[0],[False],['0']
3692,PMC3018567,9503,"During the study period, the rate of malaria was 41 episodes per 100 person-years (95% CI 38–44), of diarrhoea 134 episodes per 100 person-years (129–139), and of pneumonia 22 episodes per 100 person-years (20–24).",Results,[57003],[24392],[24606],[False],[0],[0],[False],['0']
3693,PMC3018567,9504,"Measles and tuberculosis were rare, with two episodes of each, so we could not assess the effect of maternal anthelmintic treatment on their frequency.",Results,[57008],[24607],[24758],[False],[0],[0],[False],['0']
3694,PMC3018567,9505,"We noted no evidence for effects of either albendazole or praziquantel treatments on doctor-diagnosed malaria, diarrhoea, or pneumonia incidence (table 4).",Results,[57013],[24759],[24914],[False],[0],[0],[False],['0']
3695,PMC3018567,9506,Subgroup analyses by maternal hookworm and schistosomiasis infection status showed no evidence of a differential effect of either treatment according to susceptible worm species (table 5).,Results,[57018],[24915],[25103],[False],[0],[0],[False],['0']
3696,PMC3018567,9507,"299 women tested positive for HIV at enrolment; of these, 16 were lost to follow-up before delivery, five had miscarriages, and nine had stillbirths.",Results,[57023],[25104],[25253],[False],[0],[0],[False],['0']
3697,PMC3018567,9508,"Five women were on highly-active antiretroviral therapy; their children, and seven second-born twins were excluded from the analysis, leaving 264 infants suitable for inclusion.",Results,[57028],[25254],[25431],[False],[0],[0],[False],['0']
3698,PMC3018567,9509,"6-week blood samples were available from 211 infants (80%), of whom 39 (18%) were diagnosed with HIV infection.",Results,[57033],[25432],[25543],[False],[0],[0],[False],['0']
3699,PMC3018567,9510,"Of infants with HIV infection, 31 had cord samples available, of which 20 (65%) showed an HIV viral load of 1000 copies per mL or more, which is consistent with intrauterine HIV transmission.",Results,[57038],[25544],[25735],[False],[0],[0],[False],['0']
3700,PMC3018567,9511,"We recorded no evidence for any effect of either albendazole (OR 0·70, 95% CI 0·35–1·42; p=0·33) or praziquantel (0·60, 0·29–1·23; p=0·17) treatment on vertical HIV transmission, although statistical power was restricted because the study was only powered to detect a large effect for this outcome.",Results,[57043],[25736],[26034],[False],[0],[0],[False],['0']
3701,PMC3018567,9512,No evidence was noted for any differential effect of treatment according to susceptible worm species; ORs for the effect of albendazole treatment on HIV transmission were 0·77 (0·25–2·40) in mothers with hookworm infection and 0·66 (0·27–1·60) in those without hookworm infection (interaction p=0·83).,Results,[57048],[26035],[26336],[False],[0],[0],[False],['0']
3702,PMC3018567,9513,"We recorded similar results for praziquantel (OR 0·75, 0·18–3·14, for mothers with schistosomiasis; 0·56, 0·24–1·29 for those without schistosomiasis; interaction p=0·73).",Results,[57053],[26337],[26508],[False],[0],[0],[False],['0']
3703,PMC3018567,9514,"For the secondary outcome of community-reported illness data, the overall recorded prevalences of each illness collated every 14 days throughout infancy was 13% for febrile illness, 12% for diarrhoea, and 1% for presumptive pneumonia.",Results,[57058],[26509],[26743],[False],[0],[0],[False],['0']
3704,PMC3018567,9515,"These data were consistent with doctor-diagnosed outcomes and showed no effects of treatment with albendazole or praziquantel on febrile illnesses (OR 1·07, 95% CI 0·97–1·18, p=0·18; and 1·03, 0·93–1·13, 0·58), diarrhoea (1·08, 0·98–1·20, 0·13; and 0·93, 0·84–1·03, 0·18), or presumptive pneumonia (0·92, 0·65–1·31, 0·66; and 0·91, 0·64–1·30, 0·62).",Results,[57063],[26744],[27093],[False],[0],[0],[False],['0']
3705,PMC3018567,9516,The prevalence of asymptomatic malaria parasitaemia at 1 year was similar between treatment groups (webappendix p 5).,Results,[57068],[27094],[27211],[False],[0],[0],[False],['0']
3706,PMC3018567,9517,"81 infants in the cohort died, 44 of whom were neonates, giving a neonatal mortality rate of 19·0 per 1000 livebirths (95% CI 14·2–25·5) and an infant mortality rate of 35·7 per 1000 livebirths (28·8–44·2).",Results,[57073],[27212],[27418],[False],[0],[0],[False],['0']
3707,PMC3018567,9518,Maternal anthelmintic treatment had no pronounced effect on mortality (webappendix p 5).,Results,[57078],[27419],[27507],[False],[0],[0],[False],['0']
3708,PMC3018567,9519,"Height-for-age and weight-for-age Z scores were low compared with the WHO standards; however, the weight-for-height distribution was similar.",Results,[57083],[27508],[27649],[False],[0],[0],[False],['0']
3709,PMC3018567,9520,Mean haemoglobin score at age 1 year was 102 g/L (SD 14 g/L).,Results,[57088],[27650],[27711],[False],[0],[0],[False],['0']
3710,PMC3018567,9521,"We noted no evidence for any difference in mean growth indices or mean haemoglobin between children of albendazole-treated and placebo-treated mothers, or between children of praziquantel-treated and placebo-treated mothers (webappendix p 5).",Results,[57093],[27712],[27954],[False],[0],[0],[False],['0']
3711,PMC3018567,9522,Numbers of serious adverse events are reported elsewhere and were distributed evenly between treatment groups.,Results,[57098],[27955],[28065],[False],[0],[0],[False],['0']
3712,PMC3018567,9523,Discussion,Discussion,[57103],[28066],[28077],[False],[0],[0],[False],['0']
3713,PMC3018567,9524,"In this randomised, placebo-controlled trial, we have shown that maternal anthelmintic treatment during pregnancy can have a small effect on an infant's response to tetanus immunisation, but has no effects, either beneficial or detrimental, on the occurrence of infectious diseases during infancy, infant mortality, or growth and anaemia outcomes at 1 year of age.",Discussion,[57108],[28078],[28442],[False],[0],[0],[False],['0']
3714,PMC3018567,9525,"One dose of albendazole was effective for the treatment of hookworm and A lumbricoides infections, and praziquantel was effective for the treatment of schistosomiasis.",Discussion,[57113],[28443],[28610],[False],[0],[0],[False],['0']
3715,PMC3018567,9526,"At delivery, the prevalence of hookworm infections had decreased to 5% in the albendazole group, and remained at 45% in the placebo group; the prevalence of S mansoni infection had decreased to 5% in the praziquantel group, and remained at 21% in the placebo group.",Discussion,[57118],[28611],[28876],[False],[0],[0],[False],['0']
3716,PMC3018567,9527,Thus we would have expected to see any noticeable effects of the removal of these maternal helminth infections.,Discussion,[57123],[28877],[28988],[False],[0],[0],[False],['0']
3717,PMC3018567,9528,A possible source of imprecision is that the Kato-Katz method has suboptimum sensitivity for diagnosis of intestinal helminth infections when one stool sample is used.,Discussion,[57128],[28989],[29156],[True],['ResponsivenessOfMeasurement'],['the Kato-Katz method has suboptimum sensitivity for diagnosis of intestinal helminth infections when one stool sample is used'],[True],['OutcomeMeasures']
3718,PMC3018567,9529,"In this study, the sensitivity for detecting both hookworm infection and schistosomiasis was greater when three stool samples were taken than when only one was taken.",Discussion,[57138],[29157],[29323],[False],[0],[0],[False],['0']
3719,PMC3018567,9530,"As expected, one dose of albendazole was not effective for treatment of S stercoralis, T trichiura, or M perstans.",Discussion,[57143],[29324],[29438],[False],[0],[0],[False],['0']
3720,PMC3018567,9531,Albendazole treatment in pregnancy was associated with reduced interleukin-5 and interleukin-13 responses to tetanus toxoid in infants of mothers with hookworm infection.,Discussion,[57148],[29439],[29609],[False],[0],[0],[False],['0']
3721,PMC3018567,9532,"These results should be interpreted with caution because of the large number of statistical tests done, but they accord with earlier findings on effects of helminths on type-2 responses to tetanus immunisation in adults; by contrast with these previous studies, we recorded no reciprocal effect on interferon-γ response.",Discussion,[57153],[29610],[29930],[False],[0],[0],[False],['0']
3722,PMC3018567,9533,"Such responses will probably not change the effectiveness of tetanus immunisation, because this immunisation depends on the production of toxin-neutralising IgG antibodies, which was not affected by maternal treatment.",Discussion,[57158],[29931],[30149],[False],[0],[0],[False],['0']
3723,PMC3018567,9534,"However, the patterns recorded lend support to the hypothesis that maternal helminths promote a type-2 bias in an infant's response to unrelated antigens and that anthelmintic treatment modifies this effect.",Discussion,[57163],[30150],[30357],[False],[0],[0],[False],['0']
3724,PMC3018567,9535,These findings suggest that the effect of anthelmintic treatment can be transmitted in utero.,Discussion,[57168],[30358],[30451],[False],[0],[0],[False],['0']
3725,PMC3018567,9536,Neither intervention showed any overall effect on response to BCG immunisation in infants.,Discussion,[57173],[30452],[30542],[False],[0],[0],[False],['0']
3726,PMC3018567,9537,Our preliminary study had suggested an unexpected positive association between maternal hookworm infection and interferon-γ responses to cCFP in infants.,Discussion,[57178],[30543],[30696],[False],[0],[0],[False],['0']
3727,PMC3018567,9538,"In the present, larger study, interferon-γ responses were higher in infants of mothers with hookworm infection, and albendazole treatment was associated with a weak reduction in interferon-γ responses in infants of women with hookworm infection.",Discussion,[57183],[30697],[30942],[False],[0],[0],[False],['0']
3728,PMC3018567,9539,These findings contrast with our initial hypothesis that maternal hookworm infection would inhibit the Th1 response and that albendazole treatment would reverse this effect.,Discussion,[57188],[30943],[31116],[False],[0],[0],[False],['0']
3729,PMC3018567,9540,"The absence of effect of praziquantel treatment was also unexpected, in view of Malhotra and colleagues' finding that infants who are sensitised to schistosome or filarial antigens in utero had reduced interferon-γ and increased interleukin-5 responses to neonatal BCG immunisation.",Discussion,[57193],[31117],[31399],[False],[0],[0],[False],['0']
3730,PMC3018567,9541,"However, all infants in Malhotra and colleagues' study were exposed to maternal helminth infections, and comparisons were made between those not sensitised or sensitised to helminth antigens.",Discussion,[57198],[31400],[31591],[False],[0],[0],[False],['0']
3731,PMC3018567,9542,"The idea that single-dose praziquantel treatment completely removes the likelihood of fetal sensitisation to schistosome antigens might be too simplistic, because worm and egg antigens can take some time to be cleared from maternal tissues.",Discussion,[57203],[31592],[31832],[False],[0],[0],[False],['0']
3732,PMC3018567,9543,"Moreover, the killing of adult schistosomes results in release of worm antigen into the circulation and might have complex effects on the fetus, dependent on placental transfer of antigens or antibodies and the stage of development of the fetal immune system.",Discussion,[57208],[31833],[32092],[False],[0],[0],[False],['0']
3733,PMC3018567,9544,The recorded effects on an infant's response to tetanus immunisation contrasted with the absence of effects seen for measles and BCG.,Discussion,[57213],[32093],[32226],[False],[0],[0],[False],['0']
3734,PMC3018567,9545,"A possible explanation is that tetanus immunisation given to women during pregnancy could have led to the priming of an infant's antitetanus response in utero, and the profile of the primed response could have been affected by concomitant exposure to a maternal helminth infection, which depended on whether or not an infant's mother received treatment with albendazole.",Discussion,[57218],[32227],[32597],[False],[0],[0],[False],['0']
3735,PMC3018567,9546,"In keeping with the broad absence of effect of maternal anthelmintic treatment on an infant's response to vaccination, we recorded no effect of either treatment for the co-primary outcome of infectious disease incidence during infancy.",Discussion,[57223],[32598],[32833],[False],[0],[0],[False],['0']
3736,PMC3018567,9547,"A possible source of imprecision is that data for doctor-diagnosed disease incidence were obtained passively, and therefore rates are likely to have been underestimated.",Discussion,[57229],[32834],[33003],[True],['PrecisionOfMeasurement'],['data for doctor-diagnosed disease incidence were obtained passively'],[True],['OutcomeMeasures']
3737,PMC3018567,9548,"However, 90% of infants attended the clinic for illness at least once, and underestimation would be non-differential between treatment groups; therefore this imprecision is unlikely to have affected our findings.",Discussion,[57238],[33004],[33216],[False],[0],[0],[False],['0']
3738,PMC3018567,9549,"Moreover, results from community-reported illness events (which are less likely to be under-reported), and malaria parasitaemia at 1 year of age (which is independent of reporting biases) were both consistent with the recorded absence of treatment effect.",Discussion,[57243],[33217],[33472],[False],[0],[0],[False],['0']
3739,PMC3018567,9550,"We also detected no evidence that anthelmintic treatment affected vertical transmission of HIV, although power to detect an effect was restricted.",Discussion,[57250],[33473],[33619],[True],['UnderpoweredStudy'],['power to detect an effect was restricted'],[True],['UnderpoweredStudy']
3740,PMC3018567,9551,"The only other study to investigate the relation between anthelmintic treatment during pregnancy and post-neonatal outcomes, undertaken in Nepal, showed that treatment with albendazole during pregnancy was associated with a pronounced reduction in infant mortality at 6 months.",Discussion,[57258],[33620],[33897],[False],[0],[0],[False],['0']
3741,PMC3018567,9552,"We recorded no such effect, although the number of deaths in the cohort was small so the possibility of a reduction cannot be ruled out.",Discussion,[57263],[33898],[34034],[False],[0],[0],[False],['0']
3742,PMC3018567,9553,The Nepal study was not randomised and recorded a 41% reduction in 6-month mortality associated with two doses of albendazole but no effect on infant mortality for one dose.,Discussion,[57268],[34035],[34208],[False],[0],[0],[False],['0']
3743,PMC3018567,9554,"The researchers speculated that the greater benefit of two doses might result from prevention of reinfection between treatment and delivery, but this theory would not explain the contrast with our findings, because only 5% of women who received albendazole in our study had hookworm infection at delivery.",Discussion,[57273],[34209],[34514],[False],[0],[0],[False],['0']
3744,PMC3018567,9555,"Our analyses needed many statistical tests, especially for the measurement of cytokine responses to immunisation, because we aimed to assess overall response profiles rather than concentrations of only one cytokine.",Discussion,[57278],[34515],[34730],[False],[0],[0],[False],['0']
3745,PMC3018567,9556,"Consistency between all cytokine responses was expected, and can be interpreted as compelling evidence of an effect, compared with isolated change in an individual response.",Discussion,[57283],[34731],[34904],[False],[0],[0],[False],['0']
3746,PMC3018567,9557,Therefore we did not increase confidence limits or use methods that assume independence of tests to formally adjust p values.,Discussion,[57288],[34905],[35030],[False],[0],[0],[False],['0']
3747,PMC3018567,9558,"In the event, very few outcomes showed any evidence of association at a p value less than 0·05 so absence of adjustment for multiplicity is unlikely to have affected the interpretation of our results.",Discussion,[57296],[35031],[35231],[True],['StatisticalAnalysis'],['absence of adjustment for multiplicity'],[True],['StatisticalAnalysis']
3748,PMC3018567,9559,A strength of this study was the randomised intervention design; effects of helminth infections reported in observational studies could have been affected by confounding factors.,Discussion,[57303],[35232],[35410],[False],[0],[0],[False],['0']
3749,PMC3018567,9560,Our findings do not show that exposure to maternal helminth infections in utero has no important effect on the development of the fetal immune system.,Discussion,[57308],[35411],[35561],[False],[0],[0],[False],['0']
3750,PMC3018567,9561,Some observational studies do suggest such an effect.,Discussion,[57313],[35562],[35615],[False],[0],[0],[False],['0']
3751,PMC3018567,9562,"Rather, our findings suggest that one effective anthelmintic intervention given in the second or third trimester of pregnancy is insufficient to alter any effect of maternal worms on vaccine and infectious disease outcomes in infancy.",Discussion,[57318],[35616],[35850],[False],[0],[0],[False],['0']
3752,PMC3018567,9563,This study examined only effects of maternal anthelmintic treatment on vaccine responses and disease incidence in newborn children.,Discussion,[57327],[35851],[35982],[True],['RelevantOutcomeExcluded'],['examined only effects of maternal anthelmintic treatment on vaccine responses and disease incidence in newborn children'],[True],['OutcomeMeasures']
3753,PMC3018567,9564,Further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment.,Discussion,[57333],[35983],[36121],[False],[0],[0],[False],['0']
3754,PMC3018567,9565,"Our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults, which is a common pattern in areas that are endemic for helminth infection.",Discussion,[57338],[36122],[36314],[False],[0],[0],[False],['0']
3755,PMC3018567,9566,Findings might differ in populations with higher infection intensities.,Discussion,[57343],[36315],[36386],[False],[0],[0],[False],['0']
3756,PMC3018567,9567,"These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic treatment during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",Discussion,[57348],[36387],[36623],[False],[0],[0],[False],['0']
3757,PMC3018567,9568,We have previously reported a similar absence of effect on maternal and perinatal outcomes.,Discussion,[57353],[36624],[36715],[False],[0],[0],[False],['0']
3758,PMC3018567,9569,"These results contrast with the expected benefits of routine antenatal anthelmintic treatment recently advocated, and the value of such a policy may need to be reviewed.",Discussion,[57358],[36716],[36885],[False],[0],[0],[False],['0']
3759,PMC3018567,9570,"The study cohort is being followed up to establish whether these conclusions are still valid up to when children are aged 5 years, and to relate effects on the cytokine response to BCG immunisation to incidence of M tuberculosis infection and disease.",Discussion,[57363],[36886],[37137],[False],[0],[0],[False],['0']
3760,PMC3018567,9571,Web Extra Material,Web Extra Material,[57368],[37138],[37157],[False],[0],[0],[False],['0']
3761,PMC3018567,9572,Trial profile,Web Extra Material|Trial profile,[57373],[37158],[37171],[False],[0],[0],[False],['0']
3762,PMC3018567,9573,Baseline characteristics,Web Extra Material|Baseline characteristics,[57378],[37172],[37196],[False],[0],[0],[False],['0']
3763,PMC3018567,9574,	Albendazole+ praziquantel (n=628)	Praziquantel only (n=626)	Albendazole only (n=625)	Placebo (n=628)	 	Age (years)	 	<20	145 (23%)	165 (26%)	162 (26%)	158 (25%)	 	20–24	223 (36%)	230 (37%)	238 (38%)	255 (41%)	 	25–29	159 (25%)	143 (23%)	139 (22%)	122 (19%)	 	30–34	66 (11%)	62 (10%)	55 (9%)	70 (11%)	 	≥35	35 (6%)	26 (4%)	31 (5%)	23 (4%)	 	Education (4 missing values)	 	None	25 (4%)	23 (4%)	17 (3%)	32 (5%)	 	Primary	311 (50%)	318 (51%)	318 (51%)	316 (50%)	 	Secondary	235 (37%)	229 (37%)	244 (39%)	226 (36%)	 	Tertiary	56 (9%)	55 (9%)	45 (7%)	53 (8%)	 	Tribe (1 missing value)	 	Baganda	303 (48%)	314 (50%)	313 (50%)	301 (48%)	 	Banyankole	64 (10%)	47 (8%)	56 (9%)	67 (11%)	 	Batoro	19 (3%)	27 (4%)	24 (4%)	32 (5%)	 	Basoga	36 (6%)	23 (4%)	27 (4%)	20 (3%)	 	Luo	32 (5%)	41 (7%)	30 (5%)	37 (6%)	 	Banyarwanda	38 (6%)	36 (6%)	31 (5%)	37 (6%)	 	Others	136 (22%)	138 (22%)	144 (23%)	133 (21%)	 	Household socioeconomic status (49 missing values)*	 	1 (low)	33 (5%)	40 (7%)	35 (6%)	39 (6%)	 	2	54 (9%)	57 (9%)	54 (9%)	52 (8%)	 	3	190 (31%)	199 (33%)	182 (30%)	194 (32%)	 	4	174 (28%)	174 (28%)	179 (29%)	183 (30%)	 	5	130 (21%)	109 (18%)	131 (21%)	115 (19%)	 	6 (high)	37 (6%)	32 (5%)	33 (5%)	32 (5%)	 	Gravidity	 	1	178 (28%)	172 (27%)	181 (29%)	164 (26%)	 	2–4	339 (54%)	354 (57%)	350 (56%)	369 (59%)	 	≥5	111 (18%)	100 (16%)	94 (15%)	95 (15%)	 	Helminth infections	 	Hookworm (11 missing values)	270 (43%)	301 (48%)	262 (42%)	277 (44%)	 	Schistosoma mansoni (11 missing values)	117 (19%)	104 (17%)	123 (20%)	114 (18%)	 	Mansonella perstans (8 missing values)	135 (22%)	136 (22%)	117 (19%)	143 (23%)	 	HIV status	 	Positive	79 (13%)	61 (10%)	71 (11%)	88 (14%)	 	Malaria parasitaemia (48 missing values)	 	Positive	61 (10%)	59 (10%)	63 (10%)	85 (14%),Web Extra Material|Baseline characteristics,[57383],[37197],[38946],[False],[0],[0],[False],['0']
3764,PMC3018567,9575,Data have been previously reported by Ndibazza and colleagues.,Web Extra Material|Baseline characteristics,[57388],[38947],[39012],[False],[0],[0],[False],['0']
3765,PMC3018567,9576,"Household socioeconomic status was scored on the basis of building materials of the home, number of rooms, and items owned.",Web Extra Material|Baseline characteristics,[57393],[39013],[39136],[False],[0],[0],[False],['0']
3766,PMC3018567,9577,"Effects of maternal anthelmintic treatment in pregnancy on infant response to BCG, tetanus, and measles immunisation",Web Extra Material|Baseline characteristics,[57398],[39137],[39253],[False],[0],[0],[False],['0']
3767,PMC3018567,9578,		Geometric mean*	Geometric mean ratio (95% CI)†	Geometric mean*	Geometric mean ratio (95% CI)†	 			Albendazole	Placebo		Praziquantel	Placebo		 	Cytokine responses	 	cCFP‡	 		Interferon-γ (pg/mL)	322	313	1·03 (0·83–1·27)	320	314	1·02 (0·82–1·26)	 		Interleukin 5 (pg/mL)	3·5	3·8	0·91 (0·74–1·11)	3·6	3·7	0·95 (0·78–1·17)	 		Interleukin 13 (pg/mL)	17	18	0·95 (0·77–1·18)	18	17	1·05 (0·84–1·30)	 		Interleukin 10 (pg/mL)	90	102	0·88 (0·73–1·06)	98	95	1·03 (0·85–1·24)	 	Tetanus toxoid§	 		Interferon-γ (pg/mL)	31	36	0·85 (0·61–1·20)	34	33	1·03 (0·75–1·44)	 		Interleukin 5 (pg/mL)	10	13	0·76 (0·56–1·04)	11	11	0·93 (0·68–1·27)	 		Interleukin 13 (pg/mL)	40	41	0·97 (0·73–1·27)	37	44	0·84 (0·63–1·12)	 		Interleukin 10 (pg/mL)	4·7	5·9	0·79 (0·61–1·02)	5·0	5·6	0·89 (0·69–1·16)	 	Antibody concentrations	 	Tetanus toxoid¶	 		Total IgG (mIU/mL)	160	251	0·64 (0·39–1·05)	227	176	1·32 (0·78–2·12)	 		IgG4 (ng/mL)	50	69	0·72 (0·37–1·37)	48	71	0·68 (0·36–1·29)	 		IgE (ng/mL)	1389	1507	0·92 (0·76–1·11)	1460	1430	1·02 (0·85–1·24)	 	Measles‖	 		Total IgG (mIU/mL)	336	348	0·96 (0·85–1·10)	332	353	0·94 (0·83–1·07),Web Extra Material|Baseline characteristics,[57403],[39254],[40356],[False],[0],[0],[False],['0']
3768,PMC3018567,9579,cCFP=crude culture filtrate proteins of Mycobacterium tuberculosis.,Web Extra Material|Baseline characteristics,[57408],[40357],[40427],[False],[0],[0],[False],['0']
3769,PMC3018567,9580,Geometric mean of response concentration + 1.,Web Extra Material|Baseline characteristics,[57413],[40428],[40473],[False],[0],[0],[False],['0']
3770,PMC3018567,9581,Bias-corrected accelerated CIs computed by bootstrapping.,Web Extra Material|Baseline characteristics,[57418],[40474],[40531],[False],[0],[0],[False],['0']
3771,PMC3018567,9582,cCFP cytokine responses were available for 1506 infants given BCG at Entebbe hospital.,Web Extra Material|Baseline characteristics,[57423],[40532],[40618],[False],[0],[0],[False],['0']
3772,PMC3018567,9583,Tetanus toxoid cytokine results were available for 1015 infants who received all three doses of tetanus toxoid; one missing value for interferon-γ response.,Web Extra Material|Baseline characteristics,[57428],[40619],[40775],[False],[0],[0],[False],['0']
3773,PMC3018567,9584,"Tetanus toxoid antibody results were available for 1058 (IgG), 1057 (IgG4), and 979 (IgE) infants who received all three doses of tetanus toxoid.",Web Extra Material|Baseline characteristics,[57433],[40776],[40921],[False],[0],[0],[False],['0']
3774,PMC3018567,9585,Measles antibody results were available for 1233 infants who received measles immunisation.,Web Extra Material|Baseline characteristics,[57438],[40922],[41013],[False],[0],[0],[False],['0']
3775,PMC3018567,9586,"Effect of maternal anthelmintic treatment on response to BCG, tetanus, and measles immunisation, by maternal helminth infection status",Web Extra Material|Baseline characteristics,[57443],[41014],[41148],[False],[0],[0],[False],['0']
3776,PMC3018567,9587,"	Albendazole	Praziquantel	 		Effect of treatment in women with hookworm infection (GMR, 95% CI)	Effect of treatment in women without hookworm infection (GMR, 95% CI)	p value for interaction	Effect of treatment in women with schistosomiasis (GMR, 95% CI)	Effect of treatment in women without schistosomiasis (GMR, 95% CI)	p value for interaction	 	cCFP*	 	Interferon-γ	0·73 (0·52–1·02)	1·31 (1·00–1·74)	0·009	0·88 (0·50–1·56)	1·05 (0·83–1·33)	0·56	 	Interleukin 5	1·06 (0·78–1·44)	0·82 (0·62–1·08)	0·22	1·20 (0·75–1·87)	0·91 (0·73–1·15)	0·30	 	Interleukin 13	0·96 (0·69–1·32)	0·95 (0·70–1·26)	0·97	1·07 (0·64–1·80)	1·04 (0·82–1·32)	0·92	 	Interleukin 10	0·93 (0·70–1·26)	0·85 (0·66–1·08)	0·62	1·14 (0·68–1·92)	1·00 (0·82–1·22)	0·65	 	Tetanus toxoid†	 	Interferon–γ	0·61 (0·36–1·05)	1·08 (0·71–1·66)	0·10	0·71 (0·32–1·60)	1·11 (0·78–1·60)	0·32	 	Interleukin 5	0·50 (0·30–0·81)	1·02 (0·68–1·52)	0·02	0·60 (0·30–1·28)	1·02 (0·72–1·43)	0·19	 	Interleukin 13	0·52 (0·34–0·82)	1·45 (1·02–2·10)	0·0005	0·56 (0·28–1·09)	0·92 (0·68–1·25)	0·18	 	Interleukin 10	0·74 (0·48–1·13)	0·83 (0·59–1·16)	0·68	0·94 (0·52–1·71)	0·89 (0·66–1·18)	0·86	 	Tetanus toxoid‡	 	Total IgG	0·52 (0·24–1·16)	0·74 (0·39–1·42)	0·51	0·72 (0·22–2·40)	1·43 (0·83–2·49)	0·30	 	IgG4	0·71 (0·25–1·96)	0·74 (0·31–1·71)	0·95	0·51 (0·10–2·56)	0·71 (0·36–1·45)	0·72	 	IgE	0·93 (0·69–1·25)	0·92 (0·71–1·16)	0·95	0·70 (0·45–1·17)	1·10 (0·90–1·36)	0·09	 	Measles§	 	Total IgG	1·02 (0·83–1·26)	0·93 (0·79–1·09)	0·51	0·92 (0·69–1·24)	0·94 (0·82–1·08)	0·88",Web Extra Material|Baseline characteristics,[57448],[41149],[42654],[False],[0],[0],[False],['0']
3777,PMC3018567,9588,cCFP=crude culture filtrate proteins of Mycobacterium tuberculosis.,Web Extra Material|Baseline characteristics,[57453],[42655],[42725],[False],[0],[0],[False],['0']
3778,PMC3018567,9589,GMR=geometric mean ratio.,Web Extra Material|Baseline characteristics,[57458],[42726],[42751],[False],[0],[0],[False],['0']
3779,PMC3018567,9590,cCFP cytokine responses were available for 1506 infants given BCG at Entebbe Hospital; four missing values in this analysis for infants of women with no stool result for Kato-Katz analysis.,Web Extra Material|Baseline characteristics,[57463],[42752],[42941],[False],[0],[0],[False],['0']
3780,PMC3018567,9591,Tetanus toxoid cytokine results were available for 1015 infants who received all three doses of tetanus toxoid; two missing values in this analysis for infants of women with no stool result for Kato-Katz analysis; one missing value for interferon-γ response to tetanus toxoid.,Web Extra Material|Baseline characteristics,[57468],[42942],[43218],[False],[0],[0],[False],['0']
3781,PMC3018567,9592,"Tetanus toxoid antibody results were available for 1058 (IgG), 1057 (IgG4), and 979 (IgE) infants who received all three doses of tetanus toxoid; one missing value in this analysis for an infant of a woman with no stool result for Kato-Katz analysis.",Web Extra Material|Baseline characteristics,[57473],[43219],[43469],[False],[0],[0],[False],['0']
3782,PMC3018567,9593,Measles antibody results were available for 1233 infants who received measles immunisation; three missing values in this analysis for infants of women with no stool result for Kato-Katz analysis.,Web Extra Material|Baseline characteristics,[57478],[43470],[43665],[False],[0],[0],[False],['0']
3783,PMC3018567,9594,"Effects of maternal anthelmintic treatment in pregnancy on incidence of malaria, diarrhoea, and pneumonia in infancy",Web Extra Material|Baseline characteristics,[57483],[43666],[43782],[False],[0],[0],[False],['0']
3784,PMC3018567,9595,	Albendazole	Albendazole-matching placebo	HR (95% CI)*	p value*	Praziquantel	Praziquantel-matching placebo	HR (95% CI)†	p value†	 		Events (person-years)	Rate per 100 person-years (95% CI)	Events (person-years)	Rate per 100 person-years (95% CI)			Events (person–years)	Rate per 100 person–years (95% CI)	Events (person–years)	Rate per 100 person–years (95% CI)			 	Malaria	431 (1081)	39·9 (36·3–43·8)	446 (1062)	42·0 (38·3–46·1)	0·95 (0·79–1·14)	0·56	440 (1073)	41·0 (37·3–45·0)	437 (1070)	40·9 (37·2–44·9)	1·00 (0·84–1·20)	0·97	 	Diarrhoea	1438 (1043)	137·9 (131·0–145·3)	1339 (1029)	130·2 (123·4–137·3)	1·06 (0·96–1·16)	0·24	1437 (1036)	138·7 (131·7–146·1)	1340 (1035)	129·4 (122·7–136·6)	1·07 (0·98–1·18)	0·15	 	Pneumonia	256 (1087)	23·5 (20·8–26·6)	226 (1070)	21·1 (18·5–24·1)	1·11 (0·90–1·38)	0·33	241 (1081)	22·3 (19·7–25·3)	241 (1077)	22·4 (19·7–25·4)	1·00 (0·80–1·24)	0·97,Web Extra Material|Baseline characteristics,[57488],[43783],[44664],[False],[0],[0],[False],['0']
3785,PMC3018567,9596,HR=hazard ratio.,Web Extra Material|Baseline characteristics,[57493],[44665],[44684],[False],[0],[0],[False],['0']
3786,PMC3018567,9597,Between albendazole and albendazole-matching placebo.,Web Extra Material|Baseline characteristics,[57498],[44685],[44738],[False],[0],[0],[False],['0']
3787,PMC3018567,9598,Between praziquantel and praziquantel-matching placebo.,Web Extra Material|Baseline characteristics,[57503],[44739],[44794],[False],[0],[0],[False],['0']
3788,PMC3018567,9599,"Effect of maternal anthelmintic treatment in pregnancy on disease incidence, by maternal helminth status",Web Extra Material|Baseline characteristics,[57508],[44795],[44899],[False],[0],[0],[False],['0']
3789,PMC3018567,9600,	Albendazole	Praziquantel	 		Effect of treatment in women with hookworm infection HR (95% CI)	Effect of treatment in women without hookworm infection HR (95% CI)	p value for interaction	Effect of treatment in women with schistosomiasis HR (95% CI)	Effect of treatment in women without schistosomiasis HR (95% CI)	p value for interaction	 	Malaria*	1·01 (0·78–1·31)	0·89 (0·69–1·15)	0·48	0·94 (0·62–1·41)	1·03 (0·84–1·26)	0·70	 	Diarrhoea*	1·10 (0·95–1·27)	1·02 (0·90–1·16)	0·44	1·23 (0·99–1·54)	1·05 (0·94–1·16)	0·18	 	Pneumonia*	1·08 (0·77–1·53)	1·12 (0·85–1·48)	0·88	0·94 (0·61–1·45)	1·01 (0·79–1·30)	0·79,Web Extra Material|Baseline characteristics,[57513],[44900],[45507],[False],[0],[0],[False],['0']
3790,PMC3018567,9601,HR=hazard ratio.,Web Extra Material|Baseline characteristics,[57518],[45508],[45527],[False],[0],[0],[False],['0']
3791,PMC3018567,9602,Excludes nine women with no stool result for Kato-Katz analysis.,Web Extra Material|Baseline characteristics,[57523],[45528],[45592],[False],[0],[0],[False],['0']
4011,PMC3036630,2694,Airway inflammation and mannitol challenge test in COPD,Title,[15535],[34410],[55],[False],[0],[0],[False],['0']
4012,PMC3036630,2695,Background,Abstract,[15541],[56],[67],[False],[0],[0],[False],['0']
4013,PMC3036630,2696,Eosinophilic airway inflammation has successfully been used to tailor anti-inflammatory therapy in chronic obstructive pulmonary disease (COPD).,Abstract,[15547],[68],[212],[False],[0],[0],[False],['0']
4014,PMC3036630,2697,Airway hyperresponsiveness (AHR) by indirect challenges is associated with airway inflammation.,Abstract,[15553],[213],[308],[False],[0],[0],[False],['0']
4015,PMC3036630,2698,We hypothesized that AHR to inhaled mannitol captures eosinophilia in induced sputum in COPD.,Abstract,[15559],[309],[402],[False],[0],[0],[False],['0']
4016,PMC3036630,2699,Methods,Abstract,[15565],[403],[410],[False],[0],[0],[False],['0']
4017,PMC3036630,2700,"Twenty-eight patients (age 58 ± 7.8 yr, packyears 40 ± 15.5, post-bronchodilator FEV1 77 ± 14.0%predicted, no inhaled steroids ≥4 wks) with mild-moderate COPD (GOLD I-II) completed two randomized visits with hypertonic saline-induced sputum and mannitol challenge (including sputum collection).",Abstract,[15571],[411],[705],[False],[0],[0],[False],['0']
4018,PMC3036630,2701,"AHR to mannitol was expressed as response-dose-ratio (RDR) and related to cell counts, ECP, MPO and IL-8 levels in sputum.",Abstract,[15577],[706],[828],[False],[0],[0],[False],['0']
4019,PMC3036630,2702,Results,Abstract,[15583],[829],[836],[False],[0],[0],[False],['0']
4020,PMC3036630,2703,"There was a positive correlation between RDR to mannitol and eosinophil numbers (r = 0.47, p = 0.03) and level of IL-8 (r = 0.46, p = 0.04) in hypertonic saline-induced sputum.",Abstract,[15589],[837],[1013],[False],[0],[0],[False],['0']
4021,PMC3036630,2704,"Furthermore, significant correlations were found between RDR and eosinophil numbers (r = 0.71, p = 0.001), level of ECP (r = 0.72, p = 0.001), IL-8 (r = 0.57, p = 0.015) and MPO (r = 0.64, p = 0.007) in sputum collected after mannitol challenge.",Abstract,[15595],[1014],[1259],[False],[0],[0],[False],['0']
4022,PMC3036630,2705,ROC-curves showed 60% sensitivity and 100% specificity of RDR for >2.5% eosinophils in mannitol-induced sputum.,Abstract,[15601],[1260],[1371],[False],[0],[0],[False],['0']
4023,PMC3036630,2706,Conclusions,Abstract,[15607],[1372],[1383],[False],[0],[0],[False],['0']
4024,PMC3036630,2707,In mild-moderate COPD mannitol hyperresponsiveness is associated with biomarkers of airway inflammation.,Abstract,[15613],[1384],[1488],[False],[0],[0],[False],['0']
4025,PMC3036630,2708,"The high specificity of mannitol challenge suggests that the test is particularly suitable to exclude eosinophilic airways inflammation, which may facilitate individualized treatment in COPD.",Abstract,[15619],[1489],[1680],[False],[0],[0],[False],['0']
4026,PMC3036630,2709,Trial registration,Abstract,[15625],[1681],[1699],[False],[0],[0],[False],['0']
4027,PMC3036630,2710,Netherlands Trial Register (NTR): NTR1283,Abstract,[15631],[1700],[1741],[False],[0],[0],[False],['0']
4028,PMC3036630,2711,Introduction,Introduction,[15637],[1742],[1755],[False],[0],[0],[False],['0']
4029,PMC3036630,2712,Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disease characterized by non-reversible airflow limitation.,Introduction,[15643],[1756],[1886],[False],[0],[0],[False],['0']
4030,PMC3036630,2713,Airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gasses.,Introduction,[15649],[1887],[2027],[False],[0],[0],[False],['0']
4031,PMC3036630,2714,The treatment options in COPD are still limited and current efforts focus on therapy targeted to particular phenotypes of the disease.,Introduction,[15655],[2028],[2162],[False],[0],[0],[False],['0']
4032,PMC3036630,2715,"A non-invasive, standardised way to measure and monitor airway inflammation in COPD is hypertonic saline-induced sputum.",Introduction,[15661],[2163],[2283],[False],[0],[0],[False],['0']
4033,PMC3036630,2716,"Analysis of induced sputum provides information about cell counts (eosinophils, neutrophils, lymphocytes, macrophages) and cell activity by mediator concentrations (e.g.",Introduction,[15667],[2284],[2453],[False],[0],[0],[False],['0']
4034,PMC3036630,2717,"ECP, MPO and IL-8).",Introduction,[15673],[2454],[2473],[False],[0],[0],[False],['0']
4035,PMC3036630,2718,In COPD patients the identification of sputum eosinophilia has shown to be of clinical value as it predicts a response to corticosteroids.,Introduction,[15679],[2474],[2612],[False],[0],[0],[False],['0']
4036,PMC3036630,2719,"Furthermore, guiding inhaled steroid therapy by sputum eosinophil counts leads to a reduction in exacerbations in COPD, without an increase in steroid dose.",Introduction,[15685],[2613],[2769],[False],[0],[0],[False],['0']
4037,PMC3036630,2720,These observations demonstrate the value of identifying inflammatory subphenotypes in the treatment of COPD.,Introduction,[15691],[2770],[2878],[False],[0],[0],[False],['0']
4038,PMC3036630,2721,"However, the application of sputum analysis is somewhat limited by the requirement of lab facilities and the not-directly available results.",Introduction,[15697],[2879],[3019],[False],[0],[0],[False],['0']
4039,PMC3036630,2722,"Therefore, there is a need for adequate surrogate markers of airway inflammation in COPD.",Introduction,[15703],[3020],[3109],[False],[0],[0],[False],['0']
4040,PMC3036630,2723,"Airway hyperresponsiveness (AHR) may serve as a surrogate measure of airway inflammation, since it is associated with the presence of inflammatory cells and release of mediators in the airways.",Introduction,[15709],[3110],[3303],[False],[0],[0],[False],['0']
4041,PMC3036630,2724,"In particular, this holds for indirect challenges, amongst which dry powder mannitol challenge is relatively easy to apply.",Introduction,[15715],[3304],[3427],[False],[0],[0],[False],['0']
4042,PMC3036630,2725,"Local mannitol deposition results in an osmotic change, likely to induce the release of mediators from inflammatory cells in the airways.",Introduction,[15721],[3428],[3565],[False],[0],[0],[False],['0']
4043,PMC3036630,2726,Studies in asthma showed that AHR to mannitol is indeed related to the degree of eosinophilic airway inflammation and is sensitive to treatment with inhaled corticosteroids.,Introduction,[15727],[3566],[3739],[False],[0],[0],[False],['0']
4044,PMC3036630,2727,"Interestingly, a proof of concept study demonstrated that mannitol challenge might also be useful in identifying COPD patients who will most likely benefit from inhaled corticosteroids.",Introduction,[15733],[3740],[3925],[False],[0],[0],[False],['0']
4045,PMC3036630,2728,This may suggest that AHR to mannitol identifies the degree of eosinophilic inflammation in COPD.,Introduction,[15739],[3926],[4023],[False],[0],[0],[False],['0']
4046,PMC3036630,2729,We postulated that AHR to mannitol captures eosinophilic airway inflammation in adults with mild to moderate COPD.,Introduction,[15745],[4024],[4138],[False],[0],[0],[False],['0']
4047,PMC3036630,2730,"Our aim was to test this hypothesis by examining the relationship between AHR to mannitol and markers of inflammation in hypertonic saline-induced sputum, blood and exhaled air.",Introduction,[15751],[4139],[4316],[False],[0],[0],[False],['0']
4048,PMC3036630,2731,"As secondary aim, we investigated whether similar relations can be observed when using spontaneously produced sputum during or directly after the mannitol challenge itself.",Introduction,[15757],[4317],[4489],[False],[0],[0],[False],['0']
4049,PMC3036630,2732,"Finally, we constructed receiver operating characteristic (ROC) curves using AHR against sputum eosinophilia in COPD.",Introduction,[15763],[4490],[4607],[False],[0],[0],[False],['0']
4050,PMC3036630,2733,Methods,Methods,[15769],[4608],[4616],[False],[0],[0],[False],['0']
4051,PMC3036630,2734,Patients,Methods|Patients,[15775],[4617],[4625],[False],[0],[0],[False],['0']
4052,PMC3036630,2735,"Thirty-two patients with mild to moderately severe COPD were included from two respiratory clinics in Amsterdam, The Netherlands.",Methods|Patients,[15781],[4626],[4755],[False],[0],[0],[False],['0']
4053,PMC3036630,2736,The definition of COPD was based on GOLD.,Methods|Patients,[15787],[4756],[4797],[False],[0],[0],[False],['0']
4054,PMC3036630,2737,"Inclusion criteria were symptoms of dyspnea, chronic cough or sputum production, current or ex-smoker with at least 20 packyears of smoking history, postbronchodilator FEV1 >1.5 liter and >50% of predicted value, FEV1/FVC <0.70 and clinically stable for ≥ 4 weeks prior to recruitment.",Methods|Patients,[15793],[4798],[5083],[False],[0],[0],[False],['0']
4055,PMC3036630,2738,"Exclusion criteria were (inhaled) steroid therapy or antibiotic treatment or exacerbation or chest infection ≤ 4 weeks prior to recruitment, treatment with β-blockers, respiratory disease other than COPD including known asthma or allergic rhinitis and contra-indications for challenge testing according to international guidelines.",Methods|Patients,[15799],[5084],[5415],[False],[0],[0],[False],['0']
4056,PMC3036630,2739,Patients were asked to withhold strenuous exercise and smoking for 6 hrs and eating for 2 hrs; caffeine and short-acting bronchodilators for 8 hrs; long-acting bronchodilators for 48 hrs; short-acting anti-cholinergics for 24 hrs; long-acting anti-cholinergics and anti-histamines for 72 hrs; and leukotriene antagonists for 4 days prior to the mannitol challenge.,Methods|Patients,[15805],[5416],[5780],[False],[0],[0],[False],['0']
4057,PMC3036630,2740,The study was approved by the Hospital Medical Ethics Committee and all patients gave their written informed consent.,Methods|Patients,[15811],[5781],[5898],[False],[0],[0],[False],['0']
4058,PMC3036630,2741,"The study was registered in the Netherlands trial register under NTR 1283, was designed, performed and analysed by the authors, and was not sponsored by others than the Academic Medical Centre, Amsterdam, The Netherlands itself.",Methods|Patients,[15817],[5899],[6127],[False],[0],[0],[False],['0']
4059,PMC3036630,2742,Study design,Methods|Study design,[15823],[6128],[6140],[False],[0],[0],[False],['0']
4060,PMC3036630,2743,The study had a cross-sectional design with two studies days comprising randomized challenges with hypertonic saline and mannitol (figure 1).,Methods|Study design,[15829],[6141],[6282],[False],[0],[0],[False],['0']
4061,PMC3036630,2744,"At a separate screening visit, inclusion and exclusion criteria were examined, postbronchodilator (400 μg salbutamol) spirometry was performed and diffusion capacity was measured.",Methods|Study design,[15835],[6283],[6462],[False],[0],[0],[False],['0']
4062,PMC3036630,2745,Study design.,Methods|Study design.,[15841],[6463],[6476],[False],[0],[0],[False],['0']
4063,PMC3036630,2746,The sequence of the two study visits was randomized [interval (median (range)):7(7-15) days].,Methods|Study design.,[15847],[6477],[6570],[False],[0],[0],[False],['0']
4064,PMC3036630,2747,On one day sputum was induced by hypertonic saline and a venous blood sample was obtained.,Methods|Study design.,[15853],[6571],[6661],[False],[0],[0],[False],['0']
4065,PMC3036630,2748,"On the other day exhaled nitric oxide was measured first, followed by assessment of atopy and mannitol challenge testing.",Methods|Study design.,[15859],[6662],[6783],[False],[0],[0],[False],['0']
4066,PMC3036630,2749,Measurements,Methods|Measurements,[15865],[6784],[6796],[False],[0],[0],[False],['0']
4067,PMC3036630,2750,Lung function,Methods|Lung function,[15871],[6797],[6810],[False],[0],[0],[False],['0']
4068,PMC3036630,2751,"Spirometry (MasterscreenPneumo; Jaeger; Würzburg, Germany) was performed by a trained respiratory technician according to the latest recommendations.",Methods|Lung function,[15877],[6811],[6960],[False],[0],[0],[False],['0']
4069,PMC3036630,2752,"Diffusion capacity of the lung for carbon monoxide (DL, CO) was measured according to the recommendations using the single breath method and was corrected for haemoglobin.",Methods|Lung function,[15883],[6961],[7132],[False],[0],[0],[False],['0']
4070,PMC3036630,2753,Mannitol challenge,Methods|Mannitol challenge,[15889],[7133],[7151],[False],[0],[0],[False],['0']
4071,PMC3036630,2754,"Mannitol challenge was performed using a commercially available kit (Pharmaxis Ltd; Sydney, Australia) as described by Anderson et al.",Methods|Mannitol challenge,[15895],[7152],[7286],[False],[0],[0],[False],['0']
4072,PMC3036630,2755,"Patients inhaled sequential doses of 5, 10, 20, 40, 80, 160, 160 and 160 mg of mannitol via the inhaler.",Methods|Mannitol challenge,[15901],[7287],[7391],[False],[0],[0],[False],['0']
4073,PMC3036630,2756,The test stopped when 15% fall in FEV1 was achieved or the cumulative dose of 635 mg had been administered.,Methods|Mannitol challenge,[15907],[7392],[7499],[False],[0],[0],[False],['0']
4074,PMC3036630,2757,"Response-dose-ratio (RDR) was calculated as the%fall in FEV1 at the last dose, divided by the total cumulative dose mannitol (%fall.mg) in milligrams administered.",Methods|Mannitol challenge,[15913],[7500],[7663],[False],[0],[0],[False],['0']
4075,PMC3036630,2758,"If a patient had to cough spontaneously during the mannitol challenge, he or she was asked to expectorate.",Methods|Mannitol challenge,[15919],[7664],[7770],[False],[0],[0],[False],['0']
4076,PMC3036630,2759,This sputum was labeled as mannitol-induced sputum.,Methods|Mannitol challenge,[15925],[7771],[7822],[False],[0],[0],[False],['0']
4077,PMC3036630,2760,Sputum induction and processing,Methods|Sputum induction and processing,[15931],[7823],[7854],[False],[0],[0],[False],['0']
4078,PMC3036630,2761,"Prior to sputum induction, patients inhaled 200 μg salbutamol.",Methods|Sputum induction and processing,[15937],[7855],[7917],[False],[0],[0],[False],['0']
4079,PMC3036630,2762,Sputum was induced by inhalation of NaCl 4.5% during 3 × 5 min intervals.,Methods|Sputum induction and processing,[15943],[7918],[7991],[False],[0],[0],[False],['0']
4080,PMC3036630,2763,This sputum was labeled as induced sputum.,Methods|Sputum induction and processing,[15949],[7992],[8034],[False],[0],[0],[False],['0']
4081,PMC3036630,2764,Whole sputum samples were processed according to a protocol that has been validated in our laboratory.,Methods|Sputum induction and processing,[15955],[8035],[8137],[False],[0],[0],[False],['0']
4082,PMC3036630,2765,Differential cell counts were expressed as the percentage of non-squamous cells.,Methods|Sputum induction and processing,[15961],[8138],[8218],[False],[0],[0],[False],['0']
4083,PMC3036630,2766,Absolute cell numbers were calculated as (% cell × total cell count)/sputum weight.,Methods|Sputum induction and processing,[15967],[8219],[8302],[False],[0],[0],[False],['0']
4084,PMC3036630,2767,Sputum samples containing >80% non-squamous cells were excluded from analysis.,Methods|Sputum induction and processing,[15973],[8303],[8381],[False],[0],[0],[False],['0']
4085,PMC3036630,2768,All sputum cell counts were performed by one experienced and qualified technician blinded to the clinical details.,Methods|Sputum induction and processing,[15979],[8382],[8496],[False],[0],[0],[False],['0']
4086,PMC3036630,2769,As an extra control 10% of the samples were analyzed by a second technician.,Methods|Sputum induction and processing,[15985],[8497],[8573],[False],[0],[0],[False],['0']
4087,PMC3036630,2770,Analysis of soluble markers in sputum supernatant,Methods|Analysis of soluble markers in sputum supernatant,[15991],[8574],[8623],[False],[0],[0],[False],['0']
4088,PMC3036630,2771,"Levels of eosinophil cationic protein (ECP; detection limit >60 pg/ml), myeloperoxidase (MPO; detection limit >1.5 ng/ml), interleukin-8 (IL-8; detection limit >19.1 pg/ml) and alpha-2-macroglobulin (α2M; detection limit >2.1 mg/ml) were measured by enzyme-linked immunosorbent assays (ELISA).",Methods|Analysis of soluble markers in sputum supernatant,[15997],[8624],[8917],[False],[0],[0],[False],['0']
4089,PMC3036630,2772,Exhaled Nitric Oxide (FeNO),Methods|Exhaled Nitric Oxide (FeNO),[16003],[8918],[8945],[False],[0],[0],[False],['0']
4090,PMC3036630,2773,"FeNO was measured with a portable rapid-response chemoluminescent analyser (flow rate 50 mL/s; NIOX System, Aerocrine, Sweden) according to recent guidelines.",Methods|Exhaled Nitric Oxide (FeNO),[16009],[8946],[9104],[False],[0],[0],[False],['0']
4091,PMC3036630,2774,Statistical analysis,Methods|Statistical analysis,[16015],[9105],[9125],[False],[0],[0],[False],['0']
4092,PMC3036630,2775,The relationship between AHR to mannitol (RDR) and the markers of airway inflammation were analyzed using Pearson's correlation coefficient (rp).,Methods|Statistical analysis,[16021],[9126],[9271],[False],[0],[0],[False],['0']
4093,PMC3036630,2776,Non-normally distributed data were log-transformed for further analysis.,Methods|Statistical analysis,[16027],[9272],[9344],[False],[0],[0],[False],['0']
4094,PMC3036630,2777,"If no cells were counted, a value of 0.1 was taken before log-transformation.",Methods|Statistical analysis,[16033],[9345],[9422],[False],[0],[0],[False],['0']
4095,PMC3036630,2778,"Receiver operating characteristic (ROC) curves were constructed, using RDR against eosinophilic vs non eosinophilic COPD (threshold 2.5% sputum eosinophils).",Methods|Statistical analysis,[16039],[9423],[9580],[False],[0],[0],[False],['0']
4096,PMC3036630,2779,Wilcoxon signed rank test and Bland-Altman analysis was used to compare cell counts of the two sputum samples.,Methods|Statistical analysis,[16045],[9581],[9691],[False],[0],[0],[False],['0']
4097,PMC3036630,2780,A sample size estimation showed that the detectable value of the correlation (r) under the alternative hypothesis with a sample of 23 patients (n) is between 1-0.55 (power = 0.808; alpha = 0.05).,Methods|Statistical analysis,[16051],[9692],[9887],[False],[0],[0],[False],['0']
4098,PMC3036630,2781,"Therefore, thirty-two patients were recruited taking into account an expected 10% drop-out rate and a 20% probability of missing or non-valid data.",Methods|Statistical analysis,[16057],[9888],[10035],[False],[0],[0],[False],['0']
4099,PMC3036630,2782,Results,Results,[16063],[10036],[10044],[False],[0],[0],[False],['0']
4100,PMC3036630,2783,Twenty-eight of the 32 patients completed the study (table 1).,Results,[16069],[10045],[10107],[False],[0],[0],[False],['0']
4101,PMC3036630,2784,"Four patients dropped out for reasons of: non-compliance with medication restrictions (n = 1), lost to follow up (n = 1), FEV1 <1.2 litre prior to challenge (n = 1) and inability to perform all techniques necessary to measure lung function (n = 1).",Results,[16075],[10108],[10356],[False],[0],[0],[False],['0']
4102,PMC3036630,2785,"Two out of 28 mannitol challenges were not completed for reasons of coughing (n = 1) and tiredness (n = 1), but these patients were included since this was not an exclusion criterion.",Results,[16081],[10357],[10540],[False],[0],[0],[False],['0']
4103,PMC3036630,2786,Hypertonic saline-induced sputum was collected in 28 patients and mannitol-induced sputum in 21 patients.,Results,[16087],[10541],[10646],[False],[0],[0],[False],['0']
4104,PMC3036630,2787,Patient characteristics I,Results|Patient characteristics I,[16093],[10647],[10672],[False],[0],[0],[False],['0']
4105,PMC3036630,2788,"	n = 28	 	Male/Female (n)	23/5	 	Gold I/II (n)	12/16	 	Age (years)	58 ± 7.8	 	Current/ex-smoker (n)	12/16	 	Smoking history (pack years)	40 ± 15.5	 	Inhaled corticosteroids before study (n)	14	 	Postbronchodilator FEV1 (L)	2.57 ± 0.6	 	Postbronchodilator FEV1 (%predicted)	77 ± 14.0	 	FEV1/FVC	0.55 ± 0.08	 	Atopy (n)	3	 	DL,CO (% predicted)	65 ± 14.7",Results|Patient characteristics I,[16099],[10673],[11024],[False],[0],[0],[False],['0']
4106,PMC3036630,2789,Values are expressed as mean ± SD,Results|Values are expressed as mean ± SD,[16105],[11025],[11061],[False],[0],[0],[False],['0']
4107,PMC3036630,2790,"Gold, Global Initiative for Chronic Obstructive Lung Disease.",Results|Values are expressed as mean ± SD,[16111],[11062],[11123],[False],[0],[0],[False],['0']
4108,PMC3036630,2791,"; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.",Results|Values are expressed as mean ± SD,[16117],[11124],[11192],[False],[0],[0],[False],['0']
4109,PMC3036630,2792,"; DLCO, Diffusion capacity lung for carbon monoxide",Results|Values are expressed as mean ± SD,[16123],[11193],[11244],[False],[0],[0],[False],['0']
4110,PMC3036630,2793,Correlation of inflammatory markers in hypertonic saline-induced sputum and blood with AHR to mannitol,Results|Values are expressed as mean ± SD,[16129],[11245],[11345],[False],[0],[0],[False],['0']
4111,PMC3036630,2794,The baseline values for airway hyperresponsiveness and inflammatory markers are presented in table 2.,Results|Values are expressed as mean ± SD,[16135],[11346],[11447],[False],[0],[0],[False],['0']
4112,PMC3036630,2795,Five hypertonic saline-induced sputum samples were excluded from analyses as a result of >80% non-squamous cells on differential cell counts.,Results|Values are expressed as mean ± SD,[16141],[11448],[11589],[False],[0],[0],[False],['0']
4113,PMC3036630,2796,"There was a significant positive correlation between the degree of AHR to mannitol (RDR mannitol) and eosinophil counts (r = 0.47, p = 0.03, figure 2) per gram hypertonic saline-induced sputum and with IL-8 levels (r = 0.46, p = 0.04).",Results|Values are expressed as mean ± SD,[16147],[11590],[11825],[False],[0],[0],[False],['0']
4114,PMC3036630,2797,"The correlation between RDR mannitol and blood eosinophils was borderline significant (r = 0.38, p = 0.06, figure 2).",Results|Values are expressed as mean ± SD,[16153],[11826],[11943],[False],[0],[0],[False],['0']
4115,PMC3036630,2798,No other correlations between RDR mannitol and hypertonic saline-induced sputum parameters were found (Table 3).,Results|Values are expressed as mean ± SD,[16159],[11944],[12056],[False],[0],[0],[False],['0']
4116,PMC3036630,2799,"In addition, a significant, positive association between RDR mannitol and the level of FeNO (r = 0.67, p = 0.0002, figure 2) was observed.",Results|Values are expressed as mean ± SD,[16165],[12057],[12195],[False],[0],[0],[False],['0']
4117,PMC3036630,2800,"When using PD15 to mannitol, the correlation coefficients with sputum and blood eosinophils counts were -0.38 (p = 0.09) and -0.43 (p = 0.03), respectively.",Results|Values are expressed as mean ± SD,[16171],[12196],[12352],[False],[0],[0],[False],['0']
4118,PMC3036630,2801,Patient characteristics II- Airway hyperresponsiveness (AHR) and airway inflammation,Results|Values are expressed as mean ± SD,[16177],[12353],[12437],[False],[0],[0],[False],['0']
4119,PMC3036630,2802,Subjects	n = 28	 	Airway responsiveness (n= 26)		 	 - AHR to mannitol*(n)	18	 	 - RDR mannitol (%/mg)	0.044 (0.0204-0.0605)	 	 - Max dose of mannitol (mg)	395 (315-635)	 	 - PD15 mannitol**	331 (196-635)	 	Fraction Exhaled Nitric Oxide		 	 - FeNO (ppb)	14 (9-22.5)	 	Sputum (n= 23)		 	 - Eosinophils (%)	0.8 (0.4-3.1)	 	 - Lymphocytes (%)	1.4 (1.0-2.4)	 	 - Macrophages (%)	18.8 (12.8-22.2)	 	 - Neutrophils (%)	77.2 (70.8-86.0)	 	 - Total cell count (x106/g)	1.6 (0.5-2.8)	 	Blood (n= 28)		 	 - Eosinophils (%)	2.7 (1.8-4.3)	 	 - Neutrophils (%)	55.9 (49.8-61.8),Results|Values are expressed as mean ± SD,[16183],[12438],[13001],[False],[0],[0],[False],['0']
4120,PMC3036630,2803,Values are expressed as median and interquartile range,Results|Values are expressed as median and interquartile range,[16189],[13002],[13059],[False],[0],[0],[False],['0']
4121,PMC3036630,2804,"RDR, Response Dose Ratio (fall FEV1 divided by cumulative dose given); PD15, Provocation Dose of mannitol to cause a 15% fall in FEV1; pbb, parts per billion.",Results|Values are expressed as median and interquartile range,[16195],[13060],[13218],[False],[0],[0],[False],['0']
4122,PMC3036630,2805,"*: positive reaction to mannitol: PD15 <635 mg; **: including 8 patients who did not reach a PD15, we used an assigned value of 635 mg",Results|Values are expressed as median and interquartile range,[16201],[13219],[13353],[False],[0],[0],[False],['0']
4123,PMC3036630,2806,Correlation between AHR to mannitol expressed by the response-dose ratio (RDR) and markers of airway inflammation,Results|Values are expressed as median and interquartile range,[16207],[13354],[13467],[False],[0],[0],[False],['0']
4124,PMC3036630,2807,	r	p- value	 	FEV1 (% predicted)	-0.09	0.67	 	Log FeNO	0.67	0.0002*	 	Hypertonic saline-induced sputum			 	Log (104/g) eosinophils	0.47	0.03*	 	Log (104/g) lymphocytes	0.18	0.45	 	Log (104/g) macrophages	0.27	0.24	 	Log (104/g) neutrophils	0.25	0.28	 	Log (104/g) epithelial cells	0.38	0.10	 	Log (ng/ml) ECP	0.39	0.09	 	Log (pg/ml) IL-8	0.46	0.04*	 	Log (ng/ml) MPO	0.33	0.14	 	Mannitol- induced sputum			 	Log (104/g) eosinophils	0.71	0.001*	 	Log (ng/ml) ECP	0.72	0.001*	 	Log (pg/ml) IL-8	0.57	0.015*	 	Log (ng/ml) MPO	0.64	0.007*	 	Venous blood			 	Log (%) eosinophils	0.38	0.06	 	Log (%) neutrophils	-0.23	0.26,Results|Values are expressed as median and interquartile range,[16213],[13468],[14084],[False],[0],[0],[False],['0']
4125,PMC3036630,2808,RDR is taken as the maximal% fall in FEV1 per cumulative dose; correlation: Pearsons correlation coefficient; FeNO: fraction exhaled nitric oxide in parts per billion.,Results|Values are expressed as median and interquartile range,[16219],[14085],[14255],[False],[0],[0],[False],['0']
4126,PMC3036630,2809,* p < 0.05,Results|Values are expressed as median and interquartile range,[16225],[14256],[14266],[False],[0],[0],[False],['0']
4127,PMC3036630,2810,"Correlation AHR to mannitol and eosinophils in hypertonic saline-induced sputum (left), blood eosinophils (middle) and fraction exhaled nitric oxide (right).",Results|Values are expressed as median and interquartile range,[16231],[14267],[14424],[False],[0],[0],[False],['0']
4128,PMC3036630,2811,Mannitol- induced sputum markers,Results|Mannitol- induced sputum markers,[16237],[14425],[14457],[False],[0],[0],[False],['0']
4129,PMC3036630,2812,Two out of 21 sputum samples were excluded from analyses as a result of >80% non-squamous cells on differential cell counts.,Results|Mannitol- induced sputum markers,[16243],[14458],[14582],[False],[0],[0],[False],['0']
4130,PMC3036630,2813,"There were strongly significant positive correlations between RDR mannitol and the absolute and relative numbers of eosinophils and the level of ECP in mannitol-induced sputum (r = 0.71, p = 0.001; r = 0.60, p = 0.008; r = 0.72, p = 0.001, respectively) (Figure 3).",Results|Mannitol- induced sputum markers,[16249],[14583],[14848],[False],[0],[0],[False],['0']
4131,PMC3036630,2814,"In addition, RDR mannitol was related to the levels IL-8 (r = 0.57, p = 0.015) and MPO (r = 0.64, p = 0.007) (Table 3).",Results|Mannitol- induced sputum markers,[16255],[14849],[14968],[False],[0],[0],[False],['0']
4132,PMC3036630,2815,Correlation AHR to mannitol and the absolute (left) and relative (middle) amount of eosinophils and ECP (right) in mannitol- induced sputum.,Results|Mannitol- induced sputum markers,[16261],[14969],[15109],[False],[0],[0],[False],['0']
4133,PMC3036630,2816,Inflammatory markers as obtained by hypertonic- and mannitol challenge were generally well correlated (Table 4).,Results|Mannitol- induced sputum markers,[16267],[15110],[15222],[False],[0],[0],[False],['0']
4134,PMC3036630,2817,"The limits of agreement by Bland and Altman analyses for eosinophil counts and log ECP were -5.7-8.6% and -0.73-0.72, respectively.",Results|Mannitol- induced sputum markers,[16273],[15223],[15354],[False],[0],[0],[False],['0']
4135,PMC3036630,2818,Induced sputum total and differential cell count and mediators when collected with hypertonic saline or mannitol (18 paired samples),Results|Mannitol- induced sputum markers,[16279],[15355],[15487],[False],[0],[0],[False],['0']
4136,PMC3036630,2819,	Hypertonic saline	Mannitol induced	r	 	Eosinophils (104/g)	1.1 (0.5-6.5)	0.9 (0.3-7.5)	0.81 (p = < 0.001*)	 	Lymphocytes (104/g)	1.8 (1.0-7.0)	1.9 (1.0-3.9)	0.37 (p= 0.132)	 	Macrophages (104/g)	31.7 (13.2-48.7)	20.5 (12.6-34.4)**	0.71 (p = 0.001*)	 	Neutrophils (104/g)	111.1 (59.4-231.5)	108.1 (58.4-160.1)	0.75 (p = < 0.001*)	 	Epithelial cells (104/g )	21.3 (14.5-71.2)	25.5 (12.8-42.3)	0.61 (p = 0.009*)	 	Total cell count (×106/g)	1.6 (0.8-2.6)	1.4 (0.8-2.0)	0.73 (p = 0.001*)	 	Gram sputum	6.9 (5.2-10.9)	4.0 (2.0-9.0)**	0.60 (p = 0.006*)	 	ECP (ng/ml)	147.5 (89.5-492.3)	125.8 (64.1-277.2)	0.85 (p = < 0.001*)	 	IL-8 (pg/ml)	1925.5 (534.8-7076.0)	1595 (862.8-3357.2)	0.72 (p = 0.001*)	 	MPO (ng/ml)	4529.7(1779.4-7414.8)	5174.3(1203.0-11933)	0.84 (p = < 0.001*),Results|Mannitol- induced sputum markers,[16285],[15488],[16258],[False],[0],[0],[False],['0']
4137,PMC3036630,2820,Data expressed as median and interquartile range; r= Pearsons correlation coefficient:,Results|Mannitol- induced sputum markers,[16291],[16259],[16348],[False],[0],[0],[False],['0']
4138,PMC3036630,2821,* = significant; **= significantly different (Wilcoxon rank test).,Results|Mannitol- induced sputum markers,[16297],[16349],[16415],[False],[0],[0],[False],['0']
4139,PMC3036630,2822,ROC curves,Results|ROC curves,[16303],[16416],[16426],[False],[0],[0],[False],['0']
4140,PMC3036630,2823,"The overall accuracy of RDR to mannitol for the assessment of eosinophilic or non eosinophilic COPD, described as the area under the ROC curve (Figure 4), was 67% (95% CI, 33.6 to 97.5%) for hypertonic saline- and 80% (95% CI, 47.7 to 112.3%) for mannitol-induced sputum.",Results|ROC curves,[16309],[16427],[16698],[False],[0],[0],[False],['0']
4141,PMC3036630,2824,"At RDR of 0.08%fall.mg the sensitivity and specificity for >2.5% eosinophils in hypertonic saline-induced sputum was 50% (95% CI, 11.8 to 88.2%) and 93% (95% CI, 68 to 99.8%), respectively.",Results|ROC curves,[16315],[16699],[16888],[False],[0],[0],[False],['0']
4142,PMC3036630,2825,"For mannitol-induced sputum the sensitivity and specificity was 60% (95% CI, 14.7 to 94.7%) and 100% (95% CI, 75.3 to 100%) respectively (Figure 4).",Results|ROC curves,[16321],[16889],[17037],[False],[0],[0],[False],['0']
4143,PMC3036630,2826,"When using a cut-point of 2.0% eosinophils we observed sensitivities of 44% (95% CI, 13.7 to 78.8%) and 43% (95% CI, 9.0 to 81.6%) with specificities of 100% (95% CI, 73.5 to 100.0%) and 100% (95% CI, 71.5 to 100%) for hypertonic saline- and mannitol- induced sputum, respectively.",Results|ROC curves,[16327],[17038],[17319],[False],[0],[0],[False],['0']
4144,PMC3036630,2827,ROC curve.,Results|ROC curves,[16333],[17320],[17330],[False],[0],[0],[False],['0']
4145,PMC3036630,2828,"The curve of sensitivity against 100-specificity is based on using reactivity to mannitol, given as RDR values (%fall.mg), to predict eosinophilic COPD (>2.5%) in hypertonic saline (left) and mannitol-induced (right) sputum.",Results|ROC curves,[16339],[17331],[17555],[False],[0],[0],[False],['0']
4146,PMC3036630,2829,Dotted line: line of identity.,Results|ROC curves,[16345],[17556],[17586],[False],[0],[0],[False],['0']
4147,PMC3036630,2830,Discussion,Discussion,[16351],[17587],[17598],[False],[0],[0],[False],['0']
4148,PMC3036630,2831,"In this group of mild to moderate COPD patients, AHR to inhaled mannitol was consistently associated with eosinophil counts in hypertonic saline- as well as mannitol-induced sputum.",Discussion,[16357],[17599],[17780],[False],[0],[0],[False],['0']
4149,PMC3036630,2832,"In addition, we observed associations between AHR to mannitol and soluble markers of inflammation in sputum.",Discussion,[16363],[17781],[17889],[False],[0],[0],[False],['0']
4150,PMC3036630,2833,"Our results suggest that mannitol challenge identifies inflammatory subphenotypes in COPD, in particular those patients without eosinophilic inflammation due to the high specificity of the test.",Discussion,[16369],[17890],[18084],[False],[0],[0],[False],['0']
4151,PMC3036630,2834,This may facilitate individualized treatment in COPD.,Discussion,[16375],[18085],[18138],[False],[0],[0],[False],['0']
4152,PMC3036630,2835,"To our knowledge, this is the first study assessing the relationship between airway hyperresponsiveness to inhaled mannitol and markers of airway inflammation in sputum and exhaled air in patients with COPD.",Discussion,[16381],[18139],[18346],[False],[0],[0],[False],['0']
4153,PMC3036630,2836,"These observations extend previous findings in COPD using adenosine 5'-monophosphate (AMP), in which a correlation between AHR to AMP and eosinophils in sputum was observed.",Discussion,[16387],[18347],[18520],[False],[0],[0],[False],['0']
4154,PMC3036630,2837,"Interestingly, a similar correlation between RDR to mannitol and sputum eosinophils was recently reported in patients with asthma, also showing absence of eosinophilia in patients without mannitol hyperresponsiveness.",Discussion,[16393],[18521],[18738],[False],[0],[0],[False],['0']
4155,PMC3036630,2838,"Hence, mannitol challenge appears to provide valuable information on the inflammatory profile in both patients with COPD and asthma.",Discussion,[16399],[18739],[18871],[False],[0],[0],[False],['0']
4156,PMC3036630,2839,"In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",Discussion,[16405],[18872],[18997],[False],[0],[0],[False],['0']
4157,PMC3036630,2840,"The patients were derived from a clinical population rather than an epidemiological one, in order to strengthen the applicability of our findings.",Discussion,[16411],[18998],[19144],[False],[0],[0],[False],['0']
4158,PMC3036630,2841,All patients were well characterised by using subjective and objective criteria.,Discussion,[16417],[19145],[19225],[False],[0],[0],[False],['0']
4159,PMC3036630,2842,"This included the presence of symptoms, fixed airway obstruction and smoking history.",Discussion,[16423],[19226],[19311],[False],[0],[0],[False],['0']
4160,PMC3036630,2843,"The full range in sputum eosinophils counts was 0.1 to 7.4%, which is similar to previous studies in COPD.",Discussion,[16429],[19312],[19418],[False],[0],[0],[False],['0']
4161,PMC3036630,2844,"To exclude any confounding effects of inhaled corticosteroids on mannitol challenge, the patients who used inhaled corticosteroids stopped this medication for 4 weeks.",Discussion,[16435],[19419],[19586],[False],[0],[0],[False],['0']
4162,PMC3036630,2845,"In order to answer the research question accurately, we performed mannitol challenge and sputum induction on separate days.",Discussion,[16441],[19587],[19710],[False],[0],[0],[False],['0']
4163,PMC3036630,2846,"In addition, we examined sputum expectorated after the mannitol itself, which confirmed our results.",Discussion,[16447],[19711],[19811],[False],[0],[0],[False],['0']
4164,PMC3036630,2847,"Furthermore, as inflammatory markers we used both, the presence of inflammatory cells and markers of cell activation.",Discussion,[16453],[19812],[19929],[False],[0],[0],[False],['0']
4165,PMC3036630,2848,This provided consistent associations.,Discussion,[16459],[19930],[19968],[False],[0],[0],[False],['0']
4166,PMC3036630,2849,"Nevertheless, our study has limitations.",Discussion,[16465],[19969],[20009],[False],[0],[0],[False],['0']
4167,PMC3036630,2850,"First, we could not obtain adequate sputum samples in all patients at all time points.",Discussion,[16471],[20010],[20096],[True],['MissingData'],['we could not obtain adequate sputum samples in all patients at all time points'],[True],['MissingData']
4168,PMC3036630,2851,"Even though the power of the study was adequate to address the primary objectives, it may not have been adequate to examine our secondary objective.",Discussion,[16484],[20097],[20245],[True],['UnderpoweredStudy'],"['Even though the power of the study was adequate to address the primary objectives, it may not have been adequate to examine our secondary objective']",[True],['UnderpoweredStudy']
4169,PMC3036630,2852,"Second, we can not exclude that our COPD group included patients who also had asthma.",Discussion,[16497],[20246],[20331],[True],['Population'],['we can not exclude that our COPD group included patients who also had asthma'],[True],['Population']
4170,PMC3036630,2853,"We excluded those with a previous history of asthma, but this may not have sufficed.",Discussion,[16510],[20332],[20416],[True],['Population'],"['We excluded those with a previous history of asthma, but this may not have sufficed']",[True],['Population']
4171,PMC3036630,2854,"However, all patients had a smoking history, fixed airflow limitation, met the COPD GOLD criteria, and were diagnosed and treated as COPD patients.",Discussion,[16519],[20417],[20564],[False],[0],[0],[False],['0']
4172,PMC3036630,2856,"Therefore, the test performance cannot be generalized to COPD patients on inhaled steroids.",Discussion,[16541],[20674],[20765],[True],['Generalization'],['the test performance cannot be generalized to COPD patients on inhaled steroids'],[True],['Generalization']
4173,PMC3036630,2857,This will require a separate study.,Discussion,[16549],[20766],[20801],[False],[0],[0],[False],['0']
4174,PMC3036630,2858,"Finally, we did not include a second mannitol challenge for examining reproducibility of our results, which is a limitation of our design.",Discussion,[16560],[20802],[20940],[True],['PrecisionOfMeasurement'],['we did not include a second mannitol challenge for examining reproducibility of our results'],[True],['OutcomeMeasures']
4175,PMC3036630,2859,How can we interpret these results?,Discussion,[16567],[20941],[20976],[False],[0],[0],[False],['0']
4176,PMC3036630,2860,"Mannitol is an osmotic stimulus that causes airway narrowing by release of bronchoconstrictor mediators such as leukotrienes, prostaglandins and histamine.",Discussion,[16573],[20977],[21132],[False],[0],[0],[False],['0']
4177,PMC3036630,2861,The source of these mediators is likely to be mast cells and eosinophils in the airways as both these cell types release mediators in vitro in response to mannitol.,Discussion,[16579],[21133],[21297],[False],[0],[0],[False],['0']
4178,PMC3036630,2862,Mast cells and eosinophils are not unimportant in COPD and may contribute to the fluctuations of airways obstruction as observed e.g.,Discussion,[16585],[21298],[21431],[False],[0],[0],[False],['0']
4179,PMC3036630,2863,during exacerbations.,Discussion,[16591],[21432],[21453],[False],[0],[0],[False],['0']
4180,PMC3036630,2864,"We did not observe associations of mannitol responsiveness with neutrophil counts in sputum or blood, but did found significant correlations with sputum IL-8 and MPO.",Discussion,[16597],[21454],[21620],[False],[0],[0],[False],['0']
4181,PMC3036630,2865,This may suggest that epithelial cell and neutrophil activity are also involved in determining the airway narrowing to inhaled mannitol in COPD.,Discussion,[16603],[21621],[21765],[False],[0],[0],[False],['0']
4182,PMC3036630,2866,"Interestingly, mannitol responsiveness was more strongly associated with FeNO than with sputum eosinophils.",Discussion,[16609],[21766],[21873],[False],[0],[0],[False],['0']
4183,PMC3036630,2867,"However, we did not find a significant association between the latter two parameters.",Discussion,[16615],[21874],[21959],[False],[0],[0],[False],['0']
4184,PMC3036630,2868,This is in keeping with the data by Siva et al.. Our results suggest that mannitol responsiveness is a better marker of eosinophilic inflammation than FeNO in COPD.,Discussion,[16621],[21960],[22124],[False],[0],[0],[False],['0']
4185,PMC3036630,2869,"Notably, we observed that most COPD patients produced adequate sputum samples during the mannitol challenge.",Discussion,[16627],[22125],[22233],[False],[0],[0],[False],['0']
4186,PMC3036630,2870,This occurred even in absence of encouraging the patients to expectorate.,Discussion,[16633],[22234],[22307],[False],[0],[0],[False],['0']
4187,PMC3036630,2871,"Therefore, the success rate of obtaining mannitol-induced sputum may well be improved by adjusting the standard operating procedure of the test.",Discussion,[16639],[22308],[22452],[False],[0],[0],[False],['0']
4188,PMC3036630,2872,"Our findings extend a recent study in asthma, showing adequate sputum samples after mannitol challenge.",Discussion,[16645],[22453],[22556],[False],[0],[0],[False],['0']
4189,PMC3036630,2873,"Inhaled mannitol changes osmolarity and reduces viscoelasticity, surface tension, contact angle and the solids content of sputum.",Discussion,[16651],[22557],[22686],[False],[0],[0],[False],['0']
4190,PMC3036630,2874,This may explain why 75% of the patients gave up sputum during mannitol challenge.,Discussion,[16657],[22687],[22769],[False],[0],[0],[False],['0']
4191,PMC3036630,2875,"Our results suggest that mannitol activated eosinophils, neutrophils and epithelial cells.",Discussion,[16663],[22770],[22860],[False],[0],[0],[False],['0']
4192,PMC3036630,2876,"Hence, even though AHR to mannitol was associated with eosinophilic airway inflammation, it is likely to be a more pleiotropic stimulus within the airways.",Discussion,[16669],[22861],[23016],[False],[0],[0],[False],['0']
4193,PMC3036630,2877,What are the clinical implications of our study?,Discussion,[16675],[23017],[23065],[False],[0],[0],[False],['0']
4194,PMC3036630,2878,Eosinophilic airway inflammation predicts the response of COPD patients to systemic and inhaled corticosteroids.,Discussion,[16681],[23066],[23178],[False],[0],[0],[False],['0']
4195,PMC3036630,2879,"In addition, inhaled steroid therapy guided by sputum eosinophils reduces exacerbation rate in patients with COPD.",Discussion,[16687],[23179],[23293],[False],[0],[0],[False],['0']
4196,PMC3036630,2880,"Our results suggest that mannitol challenge can identify COPD patients without eosinophilic airway inflammation, who not likely to benefit from inhaled steroid therapy.",Discussion,[16693],[23294],[23462],[False],[0],[0],[False],['0']
4197,PMC3036630,2881,This subphenotype of patients cannot be distinguished from other patients with COPD on clinical grounds or lung function criteria.,Discussion,[16699],[23463],[23593],[False],[0],[0],[False],['0']
4198,PMC3036630,2882,"Therefore, mannitol challenge may qualify as a feasible alternative in the monitoring of anti-inflammatory therapy in COPD.",Discussion,[16705],[23594],[23717],[False],[0],[0],[False],['0']
4199,PMC3036630,2883,The high specificity (100%) in combination with limited sensitivity indicates that mannitol responsiveness is particularly suitable to exclude sputum eosinophilia in COPD.,Discussion,[16711],[23718],[23889],[False],[0],[0],[False],['0']
4200,PMC3036630,2884,"Indeed, inhaled steroids appear to be ineffective in COPD patients with the lowest responsiveness to mannitol.",Discussion,[16717],[23890],[24000],[False],[0],[0],[False],['0']
4201,PMC3036630,2885,"Therefore, mannitol responsiveness may support decisions to refrain from inhaled steroid treatment, thereby potentially preventing overtreatment of COPD.",Discussion,[16723],[24001],[24154],[False],[0],[0],[False],['0']
4202,PMC3036630,2886,This requires a randomized controlled study in COPD comparing a treatment strategy based on AHR to mannitol with the currently recommended treatment strategy based on clinical markers only.,Discussion,[16729],[24155],[24344],[False],[0],[0],[False],['0']
4203,PMC3036630,2887,"It remains to be established whether mannitol challenge can also be an outcome measure of the efficacy of steroids in COPD, as has been shown in asthma.",Discussion,[16735],[24345],[24497],[False],[0],[0],[False],['0']
4204,PMC3036630,2888,"Finally, our data suggest that the assessment of AHR and airway inflammation in COPD can be combined in a single test.",Discussion,[16741],[24498],[24616],[False],[0],[0],[False],['0']
4205,PMC3036630,2889,"This would have large practical advantages, not only in clinical research, but also regarding the guidance and monitoring of anti-inflammatory therapy in clinical practice.",Discussion,[16747],[24617],[24789],[False],[0],[0],[False],['0']
4206,PMC3036630,2890,Conclusions,Conclusions,[16753],[24790],[24802],[False],[0],[0],[False],['0']
4207,PMC3036630,2891,We conclude that airway responsiveness to mannitol can be used to rule out eosinophilic airway inflammation in patients with mild to moderate COPD who are not treated with inhaled corticosteroids.,Conclusions,[16759],[24803],[24999],[False],[0],[0],[False],['0']
4208,PMC3036630,2892,"These finding suggests that mannitol challenge is a candidate for the guidance and monitoring of individualized, anti-inflammatory therapy in COPD, as an alternative to sputum eosinophils.",Conclusions,[16765],[25000],[25188],[False],[0],[0],[False],['0']
4209,PMC3036630,2893,List of abbreviations,List of abbreviations,[16771],[25189],[25211],[False],[0],[0],[False],['0']
4210,PMC3036630,2894,AHR: airway hyperresponsiveness; ECP: eosinophil cationic protein; FeNO: fraction exhaled nitric oxide; FEV1: forced expiratory volume in one second; FEV1/FVC: forced vital capacity divided by the forced expiratory volume in one second; FVC: forced vital capacity; ICS: inhaled corticosteroids; IL-8: interleukin-8; MPO: myeloperoxidase; PD15: provocation dose to cause a fall in FEV1 >15%; RDR: response dose ratio; ROC: receiver operating characteristic.,List of abbreviations,[16777],[25212],[25668],[False],[0],[0],[False],['0']
4211,PMC3036630,2895,Competing interests,Competing interests,[16783],[25669],[25689],[False],[0],[0],[False],['0']
4212,PMC3036630,2896,The authors declare that they have no competing interests.,Competing interests,[16789],[25690],[25748],[False],[0],[0],[False],['0']
4213,PMC3036630,2897,Authors' contributions,Authors' contributions,[16795],[25749],[25772],[False],[0],[0],[False],['0']
4214,PMC3036630,2898,"SdN was the main author of the paper and developed the study design and subject recruitment, collected study data and performed statistical analysis.",Authors' contributions,[16801],[25773],[25922],[False],[0],[0],[False],['0']
4215,PMC3036630,2899,"All other authors contributed significantly to the design of the study, the collection and assessment of clinical data and development of this paper.",Authors' contributions,[16807],[25923],[26072],[False],[0],[0],[False],['0']
4216,PMC3036630,2900,All authors contributed significantly to the development of the manuscript and all have seen and approved the final version and take responsibility for the content.,Authors' contributions,[16813],[26073],[26237],[False],[0],[0],[False],['0']
4217,PMC3036630,2901,Acknowledgements,Acknowledgements,[16819],[26238],[26255],[False],[0],[0],[False],['0']
4218,PMC3036630,2902,We would like to thank the participants in the study and Tamara Dekker for determining the inflammatory parameters.,Acknowledgements,[16825],[26256],[26371],[False],[0],[0],[False],['0']
4219,PMC3036630,2903,"This study was financially supported by the Academic Medical Centre, Amsterdam, without external sponsor.",Acknowledgements,[16831],[26372],[26477],[False],[0],[0],[False],['0']
6270,PMC3217848,23798,Effects of a physical education intervention on cognitive function in young children: randomized controlled pilot study,Title,[139406],[36200],[119],[False],[0],[0],[False],['0']
6271,PMC3217848,23799,Background,Abstract,[139410],[120],[131],[False],[0],[0],[False],['0']
6272,PMC3217848,23800,"Randomized controlled trials (RCT) are required to test relationships between physical activity and cognition in children, but these must be informed by exploratory studies.",Abstract,[139414],[132],[305],[False],[0],[0],[False],['0']
6273,PMC3217848,23801,This study aimed to inform future RCT by: conducting practical utility and reliability studies to identify appropriate cognitive outcome measures; piloting an RCT of a 10 week physical education (PE) intervention which involved 2 hours per week of aerobically intense PE compared to 2 hours of standard PE (control).,Abstract,[139418],[306],[622],[False],[0],[0],[False],['0']
6274,PMC3217848,23802,Methods,Abstract,[139422],[623],[630],[False],[0],[0],[False],['0']
6275,PMC3217848,23803,64 healthy children (mean age 6.2 yrs SD 0.3; 33 boys) recruited from 6 primary schools.,Abstract,[139426],[631],[719],[False],[0],[0],[False],['0']
6276,PMC3217848,23804,"Outcome measures were the Cambridge Neuropsychological Test Battery (CANTAB), the Attention Network Test (ANT), the Cognitive Assessment System (CAS) and the short form of the Connor's Parent Rating Scale (CPRS:S).",Abstract,[139430],[720],[934],[False],[0],[0],[False],['0']
6277,PMC3217848,23805,Physical activity was measured habitually and during PE sessions using the Actigraph accelerometer.,Abstract,[139434],[935],[1034],[False],[0],[0],[False],['0']
6278,PMC3217848,23806,Results,Abstract,[139438],[1035],[1042],[False],[0],[0],[False],['0']
6279,PMC3217848,23807,"Test- retest intraclass correlations from CANTAB Spatial Span (r 0.51) and Spatial Working Memory Errors (0.59) and ANT Reaction Time (0.37) and ANT Accuracy (0.60) were significant, but low.",Abstract,[139442],[1043],[1234],[False],[0],[0],[False],['0']
6280,PMC3217848,23808,Physical activity was significantly higher during intervention vs. control PE sessions (p < 0.0001).,Abstract,[139446],[1235],[1335],[False],[0],[0],[False],['0']
6281,PMC3217848,23809,There were no significant differences between intervention and control group changes in CAS scores.,Abstract,[139450],[1336],[1435],[False],[0],[0],[False],['0']
6282,PMC3217848,23810,"Differences between intervention and control groups favoring the intervention were observed for CANTAB Spatial Span, CANTAB Spatial Working Memory Errors, and ANT Accuracy.",Abstract,[139454],[1436],[1608],[False],[0],[0],[False],['0']
6283,PMC3217848,23811,Conclusions,Abstract,[139458],[1609],[1620],[False],[0],[0],[False],['0']
6284,PMC3217848,23812,"The present study has identified practical and age-appropriate cognitive and behavioral outcome measures for future RCT, and identified that schools are willing to increase PE time.",Abstract,[139462],[1621],[1802],[False],[0],[0],[False],['0']
6285,PMC3217848,23813,Trial registration number,Abstract,[139466],[1803],[1828],[False],[0],[0],[False],['0']
6286,PMC3217848,23814,ISRCTN70853932 (http://www.controlled-trials.com),Abstract,[139470],[1829],[1878],[False],[0],[0],[False],['0']
6287,PMC3217848,23815,Background,Background,[139474],[1879],[1890],[False],[0],[0],[False],['0']
6288,PMC3217848,23816,There has been a resurgence of interest in the relationship between physical activity and human cognitive function in recent years [1-5].,Background,[139478],[1891],[2028],[False],[0],[0],[False],['0']
6289,PMC3217848,23817,Animal evidence suggests that increased physical activity can enhance brain function [6].,Background,[139482],[2029],[2118],[False],[0],[0],[False],['0']
6290,PMC3217848,23818,"Research, largely in older adults, supports the notion that aerobic exercise can enhance human brain structure, prevent age-related brain tissue loss, and improve cognitive performance [7-9].",Background,[139486],[2119],[2310],[False],[0],[0],[False],['0']
6291,PMC3217848,23819,"Aerobic activity may influence executive function specifically [2,7-9].",Background,[139490],[2311],[2382],[False],[0],[0],[False],['0']
6292,PMC3217848,23820,The literature is consistent in reporting that increased time spent on physical education in schools has no detrimental effect on more 'academic' subjects and may even enhance academic attainment [10-13].,Background,[139494],[2383],[2587],[False],[0],[0],[False],['0']
6293,PMC3217848,23821,"Higher levels of physical fitness in children may be associated with improved neurocognitive processing [12], and increased physical activity may enhance school 'on-task' behavior [13].",Background,[139498],[2588],[2773],[False],[0],[0],[False],['0']
6294,PMC3217848,23822,Increased physical activity may therefore provide cognitive and educational benefits across childhood and adolescence.,Background,[139502],[2774],[2892],[False],[0],[0],[False],['0']
6295,PMC3217848,23823,"Experimental evidence in children is very limited [3,5]: < 1% of published exercise and cognition studies have involved child participants, and experimental evidence from pre-school children is absent.",Background,[139506],[2893],[3094],[False],[0],[0],[False],['0']
6296,PMC3217848,23824,There is therefore a need for randomized trials in children to establish definitively the presence of any cognitive effects of physical activity and to identify their nature (e.g.,Background,[139510],[3095],[3274],[False],[0],[0],[False],['0']
6297,PMC3217848,23825,dose-response effects; specificity to particular cognitive processes).,Background,[139514],[3275],[3345],[False],[0],[0],[False],['0']
6298,PMC3217848,23826,The UK Medical Research Council framework for complex interventions suggests that prior to carrying out full RCT it is important to carry out exploratory trials to examine: acceptability of study measurements; feasibility of the proposed trial; likely retention of participants and missing data [14].,Background,[139518],[3346],[3646],[False],[0],[0],[False],['0']
6299,PMC3217848,23827,The measurement of executive function is especially problematic in younger children [15].,Background,[139522],[3647],[3736],[False],[0],[0],[False],['0']
6300,PMC3217848,23828,Testing for effects of exercise on executive function in children is also problematic because of the difficulty of establishing exercise programs that effectively increase the levels of physical activity [16-18].,Background,[139526],[3737],[3949],[False],[0],[0],[False],['0']
6301,PMC3217848,23829,Carrying out well designed and adequately powered RCT to test for relationships between physical activity and executive function in young children therefore presents researchers with a number of major challenges.,Background,[139530],[3950],[4162],[False],[0],[0],[False],['0']
6302,PMC3217848,23830,Future RCT in this area will have to be informed by exploratory studies.,Background,[139534],[4163],[4235],[False],[0],[0],[False],['0']
6303,PMC3217848,23831,These studies need to establish which interventions are practical and what is the optimal 'dose' of physical activity.,Background,[139538],[4236],[4354],[False],[0],[0],[False],['0']
6304,PMC3217848,23832,They will also need to establish the practical utility and reliability of potential measures of executive function (outcome measures) in young children.,Background,[139542],[4355],[4507],[False],[0],[0],[False],['0']
6305,PMC3217848,23833,"Finally, they will need to provide information on effect sizes to calculate sample size and ensure adequate power of future large scale RCT.",Background,[139546],[4508],[4648],[False],[0],[0],[False],['0']
6306,PMC3217848,23834,The present study therefore aimed to collect the data necessary to design and power a future school-based RCT on the influence of aerobic activity on executive function in 5-6 year olds.,Background,[139550],[4649],[4835],[False],[0],[0],[False],['0']
6307,PMC3217848,23835,All cognitive measures were specified a priori as candidate measures potentially sensitive to changes in physical activity.,Background,[139554],[4836],[4959],[False],[0],[0],[False],['0']
6308,PMC3217848,23836,Methods,Methods,[139558],[4960],[4968],[False],[0],[0],[False],['0']
6309,PMC3217848,23837,Participants and Methods,Methods|Participants and Methods,[139562],[4969],[4993],[False],[0],[0],[False],['0']
6310,PMC3217848,23838,"Healthy children, attending the second year of 6 mainstream primary schools were invited to take part in the reliability study, the practical utility study, and the exploratory RCT.",Methods|Participants and Methods,[139566],[4994],[5175],[False],[0],[0],[False],['0']
6311,PMC3217848,23839,Parents gave informed written consent to participation in the study and children provided verbal assent and an initialled consent form.,Methods|Participants and Methods,[139570],[5176],[5311],[False],[0],[0],[False],['0']
6312,PMC3217848,23840,The study was approved by the UK Central Office for Research Ethics (COREC).,Methods|Participants and Methods,[139574],[5312],[5388],[False],[0],[0],[False],['0']
6313,PMC3217848,23841,"Participants were recruited from entire year 2 classes of the 6 volunteering schools in the City of Glasgow, Scotland.",Methods|Participants and Methods,[139578],[5389],[5507],[False],[0],[0],[False],['0']
6314,PMC3217848,23842,"Children were eligible for inclusion in the study (n 185 eligible) if they had no known diagnosed disorder of cognition, and had no physical condition affecting their ability to participate in a school PE program (assessed by parent questionnaire).",Methods|Participants and Methods,[139582],[5508],[5756],[False],[0],[0],[False],['0']
6315,PMC3217848,23843,Study Design,Methods|Study Design,[139586],[5757],[5769],[False],[0],[0],[False],['0']
6316,PMC3217848,23844,"The present study was in two phases: an initial study of practical utility and reliability of the cognitive outcome measures over three weeks, followed by a 10 week exploratory RCT.",Methods|Study Design,[139590],[5770],[5951],[False],[0],[0],[False],['0']
6317,PMC3217848,23845,Psychological Measures,Methods|Psychological Measures,[139594],[5952],[5974],[False],[0],[0],[False],['0']
6318,PMC3217848,23846,A literature search and contact with experts in the field prior to the present study suggested three measures of cognition which might be suitable as candidate outcome measures for an RCT in young children: the Cognitive Assessment System (CAS;[19]); the Cambridge Neuropsychological Test Battery (CANTAB http://www.cantab.com); the Attention Network Test (ANT) [20].,Methods|Psychological Measures,[139598],[5975],[6342],[False],[0],[0],[False],['0']
6319,PMC3217848,23847,"High reliability of measurements in children under age 7 has been reported in one study for the CAS [19], but such data are not available for the ANT or the CANTAB and so reliability data for the ANT and CANTAB were collected in the present study prior to the exploratory RCT.",Methods|Psychological Measures,[139602],[6343],[6619],[False],[0],[0],[False],['0']
6320,PMC3217848,23848,All cognitive tests were administered to children individually in a quiet room in school using a laptop and touch-screen.,Methods|Psychological Measures,[139606],[6620],[6741],[False],[0],[0],[False],['0']
6321,PMC3217848,23849,E-Prime Software (http://www.psnet.com) was used with the ANT.,Methods|Psychological Measures,[139610],[6742],[6804],[False],[0],[0],[False],['0']
6322,PMC3217848,23850,"All children were tested by the same trained researcher (AF), seated comfortably approximately 53 cm from the laptop screen, and with the dominant hand resting on the computer mouse.",Methods|Psychological Measures,[139614],[6805],[6987],[False],[0],[0],[False],['0']
6323,PMC3217848,23851,"For a detailed description of the ANT see http://www.sacklerinstitute.org/users/jin.fan and Rueda et al [20], but in brief, the ANT was administered in four blocks of tests, each lasting approximately 5 minutes: a practice block of tests was used first to train the children in what was expected, and to identify any problems they had in performing the test (e.g.",Methods|Psychological Measures,[139618],[6988],[7351],[False],[0],[0],[False],['0']
6324,PMC3217848,23852,"understanding of what to do/how to do it); in three subsequent blocks which formed the basis of the ANT outcomes in the present study children were asked to perform 48 short tests, each of which involved a 'flanker' (a fish) presented in 12 potential states (congruent, incongruent, neutral; with no cue, a central cue, a double cue, or a down/up cue).",Methods|Psychological Measures,[139622],[7352],[7704],[False],[0],[0],[False],['0']
6325,PMC3217848,23853,After appearance of the fish on the laptop screen children were asked to press the right or left mouse button corresponding to the direction the fish was pointing.,Methods|Psychological Measures,[139626],[7705],[7868],[False],[0],[0],[False],['0']
6326,PMC3217848,23854,The outcomes for the ANT were reaction time to the stimulus of the fish on screen (ms) and accuracy (number of times the correct mouse button was selected).,Methods|Psychological Measures,[139630],[7869],[8025],[False],[0],[0],[False],['0']
6327,PMC3217848,23855,For a detailed description of the CANTAB see http://www.cantab.com.,Methods|Psychological Measures,[139634],[8026],[8093],[False],[0],[0],[False],['0']
6328,PMC3217848,23856,"For the present study the CANTAB working memory battery was administered as recommended by the manufacturer (http://www.cantab.com), incorporating a test of Spatial Memory Span (SSP) and a test of Spatial Working Memory (SWM).",Methods|Psychological Measures,[139638],[8094],[8320],[False],[0],[0],[False],['0']
6329,PMC3217848,23857,"A motor screening test was carried out prior to CANTAB administration to ensure no visual or comprehension problems, and to familiarise participants with the study procedures.",Methods|Psychological Measures,[139642],[8321],[8496],[False],[0],[0],[False],['0']
6330,PMC3217848,23858,The motor screening test involved the appearance of a pink cross on a black laptop screen and children were asked to touch the center of the cross with the dominant hand.,Methods|Psychological Measures,[139646],[8497],[8667],[False],[0],[0],[False],['0']
6331,PMC3217848,23859,"The SWM tests the number of items which can be held in working memory by asking participants to observe the laptop screen as a pattern of boxes appears, then to remember and replicate the pattern by touching boxes which are displayed on the screen.",Methods|Psychological Measures,[139650],[8668],[8916],[False],[0],[0],[False],['0']
6332,PMC3217848,23860,"The SWM starts with two boxes (items) and progresses to a maximum of 9 boxes, but after two failed attempts the SWM ends.",Methods|Psychological Measures,[139654],[8917],[9038],[False],[0],[0],[False],['0']
6333,PMC3217848,23861,"The SSP involves presentation of colored squares on the laptop screen and tests the ability of participants to remember the longest sequences of squares which appear ('span length' test), the ' total errors' (the number of times an incorrect box is chosen) and 'total usage errors' (the number of times boxes are chosen out of the sequence in which they were presented).",Methods|Psychological Measures,[139658],[9039],[9409],[False],[0],[0],[False],['0']
6334,PMC3217848,23862,The CAS is better established for use in children and adults than the other two cognitive tests [19].,Methods|Psychological Measures,[139662],[9410],[9511],[False],[0],[0],[False],['0']
6335,PMC3217848,23863,In the present study it was administered precisely as recommended by the test authors [19].,Methods|Psychological Measures,[139666],[9512],[9603],[False],[0],[0],[False],['0']
6336,PMC3217848,23864,"It has to be administered by Psychologists and involves four sub-scales, each tested using three assessments on the laptop: planning; attention; perceptual processing; memory.",Methods|Psychological Measures,[139670],[9604],[9779],[False],[0],[0],[False],['0']
6337,PMC3217848,23865,"In order to collect test-retest reliability data and to test for changes associated with the intervention in the exploratory RCT, the ANT and CANTAB data were collected on three occasions: 3 weeks before to the intervention; just before the intervention (week 0, just before the intervention began) and following the 10 week intervention or control conditions (end of week 10).",Methods|Psychological Measures,[139674],[9780],[10157],[False],[0],[0],[False],['0']
6338,PMC3217848,23866,"Since encouraging reliability data were available for children of this age with the CAS [19], and resources were limited, it was decided not to collect reliability data for the CAS and administer it only at weeks 0 and 10 for the exploratory RCT.",Methods|Psychological Measures,[139678],[10158],[10404],[False],[0],[0],[False],['0']
6339,PMC3217848,23867,"Research psychologists responsible for administering the CAS, and research assistants entering the pre and post ANT and CANTAB data, were blinded to group allocation, and to the nature of the study.",Methods|Psychological Measures,[139682],[10405],[10603],[False],[0],[0],[False],['0']
6340,PMC3217848,23868,Intervention Study: Intervention and Control Group Allocation and Treatment,Methods|Psychological Measures,[139686],[10604],[10679],[False],[0],[0],[False],['0']
6341,PMC3217848,23869,"Immediately after collection of retest data at week 0, a statistician independent of the present study randomised the six schools by computer to receive either the Intervention or Control PE for ten weeks.",Methods|Psychological Measures,[139690],[10680],[10885],[False],[0],[0],[False],['0']
6342,PMC3217848,23870,"Prior to randomisation the schools had been matched pair-wise to provide three pairs of schools with similar socio-economic profile, assessed using an area based measure; [21], size, geographical location, and availability of space for PE.",Methods|Psychological Measures,[139694],[10886],[11125],[False],[0],[0],[False],['0']
6343,PMC3217848,23871,The local council PE specialists responsible for all public primary schools in Glasgow were asked to devise a 10 week experimental PE curriculum for the intervention which consisted solely of the most aerobically active components of the existing curriculum.,Methods|Psychological Measures,[139698],[11126],[11384],[False],[0],[0],[False],['0']
6344,PMC3217848,23872,The same PE specialists delivered 1 session per week and the usual classroom teacher delivered the other session in the experimental group.,Methods|Psychological Measures,[139702],[11385],[11524],[False],[0],[0],[False],['0']
6345,PMC3217848,23873,"Teachers received training in the experimental Intervention PE programme and were encouraged to make the sessions 'as physically active as possible' 'minimise instruction time', and 'minimise/avoid any time children were waiting to use equipment, or standing around; minimise object control tasks'.",Methods|Psychological Measures,[139706],[11525],[11823],[False],[0],[0],[False],['0']
6346,PMC3217848,23874,"There is evidence that numerous psychological variables can change as a result of any intervention, perhaps related to increased attention being paid to study participants.",Methods|Psychological Measures,[139710],[11824],[11996],[False],[0],[0],[False],['0']
6347,PMC3217848,23875,"To control for any improvement in psychological variables by simply intervening [22] and to try to ensure that any differences between groups might be attributable to the difference in aerobically intense PE between the two groups, control and intervention groups were matched for intervention time.",Methods|Psychological Measures,[139714],[11997],[12296],[False],[0],[0],[False],['0']
6348,PMC3217848,23876,"To match conditions in the intervention group over the same 10 week period the three schools randomly allocated to the control condition received the standard Scottish elementary school PE curriculum, but PE was increased from 1 to two hours per week for the 10 week study, and 1 of the 2 hours of PE per week was delivered by a specialist and one by the class teacher in both groups.",Methods|Psychological Measures,[139718],[12297],[12681],[False],[0],[0],[False],['0']
6349,PMC3217848,23877,"To reduce risk of bias of parent ratings of behavior and participant expectations children and parents were not informed which group was hypothesised to change, and outcome measures were made blind to group allocation.",Methods|Psychological Measures,[139722],[12682],[12900],[False],[0],[0],[False],['0']
6350,PMC3217848,23878,During the 10 week winter school term in which the present study took place standard PE consisted largely of skill development (e.g.,Methods|Psychological Measures,[139726],[12901],[13033],[False],[0],[0],[False],['0']
6351,PMC3217848,23879,"object control - throwing and catching a ball, balance).",Methods|Psychological Measures,[139730],[13034],[13090],[False],[0],[0],[False],['0']
6352,PMC3217848,23880,The lack of emphasis on aerobic activities increased the contrast between intervention and control groups.,Methods|Psychological Measures,[139734],[13091],[13197],[False],[0],[0],[False],['0']
6353,PMC3217848,23881,Physical activity was measured by accelerometry during the sessions.,Methods|Psychological Measures,[139738],[13198],[13266],[False],[0],[0],[False],['0']
6354,PMC3217848,23882,The PE sessions were observed directly by researchers in two randomly selected teacher-directed and two specialist-directed intervention classes in the first two weeks of the intervention.,Methods|Psychological Measures,[139742],[13267],[13455],[False],[0],[0],[False],['0']
6355,PMC3217848,23883,"The direct observations were made to identify problems in the implementation of the intervention, to answer questions about the intervention, and to encourage delivery of the PE intervention as 'prescribed'.",Methods|Psychological Measures,[139746],[13456],[13663],[False],[0],[0],[False],['0']
6356,PMC3217848,23884,Objectively measured physical activity and sedentary behavior,Methods|Objectively measured physical activity and sedentary behavior,[139750],[13664],[13725],[False],[0],[0],[False],['0']
6357,PMC3217848,23885,Habitual physical activity data were collected at week 0 (baseline) by asking participating children to wear the Actigraph GT1M accelerometer (http://www.theactigraph.com) for 7 days.,Methods|Objectively measured physical activity and sedentary behavior,[139754],[13726],[13909],[False],[0],[0],[False],['0']
6358,PMC3217848,23886,Actigraphs were worn over the right hip on a waist belt and used as described previously [23-25] with 1 minute epochs.,Methods|Objectively measured physical activity and sedentary behavior,[139758],[13910],[14028],[False],[0],[0],[False],['0']
6359,PMC3217848,23887,"Evidence based cut points [23-25] were applied to accelerometry output to define sedentary behavior (accelerometer counts per minute < 1100; [23], light intensity physical activity (accelerometer count per minute 1100-3200) and moderate-vigorous intensity physical activity (MVPA, > 3200 counts per minute) [25].",Methods|Objectively measured physical activity and sedentary behavior,[139762],[14029],[14341],[False],[0],[0],[False],['0']
6360,PMC3217848,23888,"Use of cut-points and epochs varies widely between studies, but the options selected for the present study were age-appropriate and choice of cut-point and epoch has only a small impact on the measurement of time spent sedentary and time spent in MVPA [24].",Methods|Objectively measured physical activity and sedentary behavior,[139766],[14342],[14599],[False],[0],[0],[False],['0']
6361,PMC3217848,23889,"Validity of the Actigraph in children has been demonstrated repeatedly against criterion methods of energy expenditure and direct observation [24,26].",Methods|Objectively measured physical activity and sedentary behavior,[139770],[14600],[14750],[False],[0],[0],[False],['0']
6362,PMC3217848,23890,Reliability of Actigraph-measured habitual physical activity in Scottish 5-6 year olds is high so long as at least three days of data are collected [27] and in the present study accelerometry data were excluded if < 3 days and 9 hours each day were obtained.,Methods|Objectively measured physical activity and sedentary behavior,[139774],[14751],[15009],[False],[0],[0],[False],['0']
6363,PMC3217848,23891,Only data collected between the hours of 7 am and 11 pm were included in analyses.,Methods|Objectively measured physical activity and sedentary behavior,[139778],[15010],[15092],[False],[0],[0],[False],['0']
6364,PMC3217848,23892,Statistical analysis and power,Methods|Statistical analysis and power,[139782],[15093],[15123],[False],[0],[0],[False],['0']
6365,PMC3217848,23893,Reliability of the ANT and CANTAB,Methods|Reliability of the ANT and CANTAB,[139786],[15124],[15157],[False],[0],[0],[False],['0']
6366,PMC3217848,23894,"Intraclass correlations (ICC), and standard error of measurement (SEM) - measures of within subject variation from biological difference or equipment 'noise' or error [28] were calculated.",Methods|Reliability of the ANT and CANTAB,[139790],[15158],[15346],[False],[0],[0],[False],['0']
6367,PMC3217848,23895,"The coefficient of variation (CV) - the standard deviation expressed as a percentage of the mean, and limits of agreement (LOA) were calculated using SPSS software and the reliability spreadsheet http://www.sportsci.org/resource/stats.",Methods|Reliability of the ANT and CANTAB,[139794],[15347],[15582],[False],[0],[0],[False],['0']
6368,PMC3217848,23896,"While the required level of reliability of a test will depend on the application, there is general agreement in the psychological literature that ICC's should exceed 0.75 [29].",Methods|Reliability of the ANT and CANTAB,[139798],[15583],[15759],[False],[0],[0],[False],['0']
6369,PMC3217848,23897,Exploratory RCT,Methods|Exploratory RCT,[139802],[15760],[15775],[False],[0],[0],[False],['0']
6370,PMC3217848,23898,"The exploratory RCT examined changes in the cognitive outcomes measured by the ANT, CANTAB, and CAS.",Methods|Exploratory RCT,[139806],[15776],[15876],[False],[0],[0],[False],['0']
6371,PMC3217848,23899,"We also measured parent ratings of child behavior using the short form of the Conner's Parent Rating Scale [30], on the grounds that increases in physical activity could have favorable effects [31].",Methods|Exploratory RCT,[139810],[15877],[16075],[False],[0],[0],[False],['0']
6372,PMC3217848,23900,"All data were checked for normal distribution using graphical summary of data, assessment of skewness, descriptive statistics, and tests of normality.",Methods|Exploratory RCT,[139814],[16076],[16226],[False],[0],[0],[False],['0']
6373,PMC3217848,23901,"For initial between-group comparisons of cognitive data, t tests were carried out on the change in variables over time.",Methods|Exploratory RCT,[139818],[16227],[16346],[False],[0],[0],[False],['0']
6374,PMC3217848,23902,"A general linear model was applied to all psychological and behavioral outcome measures with the follow up score as the response variable, 'group' (Intervention or Control), socio-economic status (SES), gender, school (nested within group) as factors and age and baseline (week 0) score as covariates.",Methods|Exploratory RCT,[139822],[16347],[16648],[False],[0],[0],[False],['0']
6375,PMC3217848,23903,"The study was a pilot, intended to produce data necessary to adequately power a full scale RCT, so was not powered formally.",Methods|Exploratory RCT,[139826],[16649],[16773],[False],[0],[0],[False],['0']
6376,PMC3217848,23904,"However, a sample of around 60 children (30 per group) was considered both practical and adequate for an exploratory study.",Methods|Exploratory RCT,[139830],[16774],[16897],[False],[0],[0],[False],['0']
6377,PMC3217848,23905,Results,Results,[139834],[16898],[16907],[False],[0],[0],[False],['0']
6378,PMC3217848,23906,Characteristics of study participants and flow through the trial,Results,[139838],[16908],[16972],[False],[0],[0],[False],['0']
6379,PMC3217848,23907,Reliability and practical utility studies,Results|Reliability and practical utility studies,[139842],[16973],[17014],[False],[0],[0],[False],['0']
6380,PMC3217848,23908,A total of 71 children and their parents consented to participation and were eligible.,Results|Reliability and practical utility studies,[139846],[17015],[17101],[False],[0],[0],[False],['0']
6381,PMC3217848,23909,"Of these, three were absent from school on the days scheduled for testing with the ANT and CANTAB, providing initial data on 68 children for the reliability and practical utility studies.",Results|Reliability and practical utility studies,[139850],[17102],[17289],[False],[0],[0],[False],['0']
6382,PMC3217848,23910,"Of these 68, a further 4 children were absent from school on days scheduled for the retest, giving a final sample of 64 children for test-retest data for the CANTAB (29 girls, 35 boys; mean age 6.2 years, SD 0.3).",Results|Reliability and practical utility studies,[139854],[17290],[17503],[False],[0],[0],[False],['0']
6383,PMC3217848,23911,"A further 2 children were excluded from the ANT analysis as their reaction times were < 200 ms indicating anticipatory responding (pressing the mouse button before the onset of stimulus), giving a sample of 62 participants for the reliability study for the ANT.",Results|Reliability and practical utility studies,[139858],[17504],[17765],[False],[0],[0],[False],['0']
6384,PMC3217848,23912,Characteristics of participants are given in Table 1.,Results|Reliability and practical utility studies,[139862],[17766],[17819],[False],[0],[0],[False],['0']
6385,PMC3217848,23913,Exploratory RCT,Results|Exploratory RCT,[139866],[17820],[17835],[False],[0],[0],[False],['0']
6386,PMC3217848,23914,Flow of participants through the trial is described in Figure 1.,Results|Exploratory RCT,[139870],[17836],[17900],[False],[0],[0],[False],['0']
6387,PMC3217848,23915,Baseline (week 0) differences in characteristics between intervention and control groups were not significant.,Results|Exploratory RCT,[139874],[17901],[18011],[False],[0],[0],[False],['0']
6388,PMC3217848,23916,Habitual and PE class physical activity data are shown in Table 2.,Results|Exploratory RCT,[139878],[18012],[18078],[False],[0],[0],[False],['0']
6389,PMC3217848,23917,Reliability and practical utility study results,Results|Reliability and practical utility study results,[139882],[18079],[18126],[False],[0],[0],[False],['0']
6390,PMC3217848,23918,Test-retest reliability data for the CANTAB and ANT are provided in Table 3.,Results|Reliability and practical utility study results,[139886],[18127],[18203],[False],[0],[0],[False],['0']
6391,PMC3217848,23919,For the CANTAB and ANT none of the proposed outcomes reached the a priori criterion of acceptability [29].,Results|Reliability and practical utility study results,[139890],[18204],[18310],[False],[0],[0],[False],['0']
6392,PMC3217848,23920,Children's compliance to the CANTAB and ANT was generally very good.,Results|Reliability and practical utility study results,[139894],[18311],[18379],[False],[0],[0],[False],['0']
6393,PMC3217848,23921,"The time taken to complete the testing ranged from 30-39 minutes for the entire ANT, and for the CANTAB varied by scale (2-3 minutes for Motor Screening Test; 3-6 minutes for Spatial Span; 10-15 minutes for Spatial Working Memory).",Results|Reliability and practical utility study results,[139898],[18380],[18611],[False],[0],[0],[False],['0']
6394,PMC3217848,23922,Exploratory RCT results,Results|Exploratory RCT results,[139902],[18612],[18635],[False],[0],[0],[False],['0']
6395,PMC3217848,23923,Compliance of schools with the intervention and control PE was good - in all six schools all 20 of the 'prescribed' sessions were implemented (based on a diary kept by class teachers) during the 10 week study.,Results|Exploratory RCT results,[139906],[18636],[18845],[False],[0],[0],[False],['0']
6396,PMC3217848,23924,Total physical activity was significantly greater during the intervention than control sessions (median difference 649 counts per minute; P < 0.001; Table 2).,Results|Exploratory RCT results,[139910],[18846],[19004],[False],[0],[0],[False],['0']
6397,PMC3217848,23925,"Time spent in MVPA was significantly higher in intervention than in control sessions (P < 0.001), however this equated to approximately only 12 minutes MVPA per 1 hour PE lesson in the intervention group (at 20% of time spent in MVPA) versus 5 minutes MVPA per 1 hour PE lesson in the control sessions (at 9% of time spent in MVPA; Table 2).",Results|Exploratory RCT results,[139914],[19005],[19346],[False],[0],[0],[False],['0']
6398,PMC3217848,23926,The percentage of time spent sedentary during PE was significantly lower in intervention than control PE sessions (P < 0.001).,Results|Exploratory RCT results,[139918],[19347],[19473],[False],[0],[0],[False],['0']
6399,PMC3217848,23927,"However, overall percentage time spent sedentary was high in both the intervention and control sessions (44% and 61% respectively).",Results|Exploratory RCT results,[139922],[19474],[19605],[False],[0],[0],[False],['0']
6400,PMC3217848,23928,Scores and unadjusted and adjusted cognitive and behavioral outcome analyses from week 0 to 10 week are summarised in Table 4.,Results|Exploratory RCT results,[139926],[19606],[19732],[False],[0],[0],[False],['0']
6401,PMC3217848,23929,There were no significant between group differences in any of the CAS scales (all p > 0.05).,Results|Exploratory RCT results,[139930],[19733],[19825],[False],[0],[0],[False],['0']
6402,PMC3217848,23930,The CANTAB Spatial Working Memory Error rate was significantly reduced in the Intervention group in both unadjusted analysis and adjusted analysis.,Results|Exploratory RCT results,[139934],[19826],[19973],[False],[0],[0],[False],['0']
6403,PMC3217848,23931,"In the unadjusted analysis, scores on subscales of the CPRS: the Cognitive Problems/Inattention, Hyperactivity and ADHD index were significantly lower post Intervention than Control.",Results|Exploratory RCT results,[139938],[19974],[20156],[False],[0],[0],[False],['0']
6404,PMC3217848,23932,In the adjusted model only the between-group differences for the Cognitive Problems and Inattention scale remained significant.,Results|Exploratory RCT results,[139942],[20157],[20284],[False],[0],[0],[False],['0']
6405,PMC3217848,23933,Discussion,Discussion,[139946],[20285],[20297],[False],[0],[0],[False],['0']
6406,PMC3217848,23934,Main findings and study implications,Discussion|Main findings and study implications,[139950],[20298],[20334],[False],[0],[0],[False],['0']
6407,PMC3217848,23935,"If causal links between physical activity, including PE, and cognition are established in children and adolescents then educators and policy makers may be more receptive to the promotion of physical activity.",Discussion|Main findings and study implications,[139954],[20335],[20543],[False],[0],[0],[False],['0']
6408,PMC3217848,23936,"Establishing such links will require evidence from experimental studies, and obtaining more definitive evidence of this kind will require exploratory trials upon which more definitive trials are based [14].",Discussion|Main findings and study implications,[139958],[20544],[20750],[False],[0],[0],[False],['0']
6409,PMC3217848,23937,The present study suggests that the cognitive and behavioral measures used were practical in this sample and setting.,Discussion|Main findings and study implications,[139962],[20751],[20868],[False],[0],[0],[False],['0']
6410,PMC3217848,23938,Each cognitive test battery was completed in less than 40 minutes and compliance with study procedures was generally high.,Discussion|Main findings and study implications,[139966],[20869],[20991],[False],[0],[0],[False],['0']
6411,PMC3217848,23939,"Reduced compliance with the Conner's Parents Rating Scale may have resulted from resource limitations of the present study (inability to send out second mailings to parents), or may indicate that this scale has low practical utility and may be unsuitable for future studies.",Discussion|Main findings and study implications,[139970],[20992],[21266],[False],[0],[0],[False],['0']
6412,PMC3217848,23940,Reliability of the cognitive measures was more of a concern.,Discussion|Main findings and study implications,[139974],[21267],[21327],[False],[0],[0],[False],['0']
6413,PMC3217848,23941,"Reliability of the CANTAB and ANT scales, with intraclass correlations between 0.37 and 0.60, were lower than would generally be considered acceptable (29), and this may limit their usefulness as outcome measures in future RCT.",Discussion|Main findings and study implications,[139978],[21328],[21555],[False],[0],[0],[False],['0']
6414,PMC3217848,23942,"While empirical data from young children are scarce, effect sizes may be too small to be detectable with measures of the reliability observed in the present study [3,5,7].",Discussion|Main findings and study implications,[139982],[21556],[21727],[False],[0],[0],[False],['0']
6415,PMC3217848,23943,The present study provides information sufficient to power future trials for a range of cognitive outcomes.,Discussion|Main findings and study implications,[139986],[21728],[21835],[False],[0],[0],[False],['0']
6416,PMC3217848,23944,"For example, the mean difference between groups in the CAS 'Planning' subscale was 7 with an SD of 15.",Discussion|Main findings and study implications,[139990],[21836],[21938],[False],[0],[0],[False],['0']
6417,PMC3217848,23945,"At 80% power and p = 0.05, a sample of 74 per group would be adequate to detect effects of a magnitude which could not be explained by test-retest differences in the CAS measure.",Discussion|Main findings and study implications,[139994],[21939],[22117],[False],[0],[0],[False],['0']
6418,PMC3217848,23946,"The intention in the present study was to develop a PE intervention that delivered around 40 minutes of MVPA within every hour-long PE session, and in this respect the pilot study was not successful.",Discussion|Main findings and study implications,[139998],[22118],[22317],[False],[0],[0],[False],['0']
6419,PMC3217848,23947,"Future RCT should reduce the amount of time children spend not moving during PE, and increase the amount of MVPA.",Discussion|Main findings and study implications,[140002],[22318],[22431],[False],[0],[0],[False],['0']
6420,PMC3217848,23948,"In the study by Davis et al [2] a high intensity of physical activity was achieved by a well chosen activity program, the use of real time heart-rate data to provide feedback on the intensity of physical activity, and the presence of a number of research assistants to instruct each class.",Discussion|Main findings and study implications,[140006],[22432],[22721],[False],[0],[0],[False],['0']
6421,PMC3217848,23949,"These characteristics of the study by Davis et al [2] ensured high fidelity to the prescribed dose of physical activity, but would present challenges to translation of the intervention to the school or after-school setting.",Discussion|Main findings and study implications,[140010],[22722],[22945],[False],[0],[0],[False],['0']
6422,PMC3217848,23950,The ability to develop and implement an enhanced PE intervention is likely to be critical to any future RCT in this area.,Discussion|Main findings and study implications,[140014],[22946],[23067],[False],[0],[0],[False],['0']
6423,PMC3217848,23951,"Previous studies have noted repeatedly that levels of physical activity during PE are often very low, and have also noted the difficulty in producing sustained increases in intensity of physical activity during PE in children [11,16-18,32].",Discussion|Main findings and study implications,[140018],[23068],[23308],[False],[0],[0],[False],['0']
6424,PMC3217848,23952,An essential part of process evaluation of future RCT will be to examine whether or not the 'prescribed' levels of physical activity are actually being reached by children: accelerometry was adequate for this purpose but did not provide teachers or children with real time feedback on the intensity of PE.,Discussion|Main findings and study implications,[140022],[23309],[23614],[False],[0],[0],[False],['0']
6425,PMC3217848,23953,Comparisons with other evidence,Discussion|Comparisons with other evidence,[140026],[23615],[23646],[False],[0],[0],[False],['0']
6426,PMC3217848,23954,"The present studies are not directly comparable with other literature, though the RCT of an after-school based physical activity intervention in sedentary overweight and obese older children and adolescents by Davis et al [2] is the most readily comparable study.",Discussion|Comparisons with other evidence,[140030],[23647],[23910],[False],[0],[0],[False],['0']
6427,PMC3217848,23955,"When designing the present study, outcome data from Davis et al.",Discussion|Comparisons with other evidence,[140034],[23911],[23975],[False],[0],[0],[False],['0']
6428,PMC3217848,23956,"were not available, and even if they had been available their generalisability to children who were on average more than three years younger was unclear.",Discussion|Comparisons with other evidence,[140038],[23976],[24129],[False],[0],[0],[False],['0']
6429,PMC3217848,23957,"There was no guidance on how intense, and how frequent an intervention for a younger age group should be in terms of enhancing cognitive function, or what would be acceptable to primary schools in a different population.",Discussion|Comparisons with other evidence,[140042],[24130],[24350],[False],[0],[0],[False],['0']
6430,PMC3217848,23958,Study Limitations,Discussion|Study Limitations,[140046],[24351],[24368],[False],[0],[0],[False],['0']
6431,PMC3217848,23959,"While sample sizes in the studies described here were relatively small, they were adequate to examine reliability and practical utility of the outcome measures chosen, were adequate for an exploratory RCT, and sufficient to power more definitive RCT in future.",Discussion|Study Limitations,[140050],[24369],[24629],[True],['SampleSize'],['sample sizes in the studies described here were relatively small'],[True],['UnderpoweredStudy']
6432,PMC3217848,23960,The number of tests carried out will have increased the probability of significant differences being observed by chance.,Discussion|Study Limitations,[140059],[24630],[24750],[True],['MultipleTesting'],['The number of tests carried out'],[True],['StatisticalAnalysis']
6433,PMC3217848,23961,It should also be noted that some of the significant differences which favored the intervention group in the present study were observed with small sample sizes and with outcome measures which had low reliability (e.g.,Discussion|Study Limitations,"[140068, 140069]","[24751, 24751]","[24969, 24969]","[True, True]","['SampleSize', 'PrecisionOfMeasurement']","['small sample sizes', 'outcome measures which had low reliability']","[True, True]","['OutcomeMeasures', 'UnderpoweredStudy']"
6434,PMC3217848,23962,ANT accuracy) -the results of the current study should therefore be viewed with caution.,Discussion|Study Limitations,[140074],[24970],[25058],[False],[0],[0],[False],['0']
6435,PMC3217848,23963,"In the present study we lacked the resources to assess the reliability of the CAS, which required administration by psychologists, and at the time of the study we depended on a single study to support the view that reliability of the CAS was high.",Discussion|Study Limitations,[140078],[25059],[25306],[False],[0],[0],[False],['0']
6436,PMC3217848,23964,"Naglieri and Das [19] measured reliability of the CAS in a nationally representative sample of 872 US children and adolescents, age 5-17 years, and reliabilities of all CAS subscales in all age groups ranged from 0.83-0.93 [19].",Discussion|Study Limitations,[140082],[25307],[25535],[False],[0],[0],[False],['0']
6437,PMC3217848,23965,"An assessment of the reliability of the CAS in our sample and setting would have been helpful, and reasons why the reliability of CANTAB and ANT were lower in the present study than reliability previously reported for the CAS are unclear.",Discussion|Study Limitations,[140086],[25536],[25774],[False],[0],[0],[False],['0']
6438,PMC3217848,23966,"While time spent in MVPA was significantly higher in the intervention than in the control group PE classes, both spent a large proportion of time sedentary.",Discussion|Study Limitations,[140090],[25775],[25931],[False],[0],[0],[False],['0']
6439,PMC3217848,23967,"Several biologically plausible mechanisms link physical activity and cognition [4,6,33] but identifying these in future larger-scale and longer-term RCT may require a greater contrast in the 'dose' of physical activity between experimental and control groups.",Discussion|Study Limitations,[140094],[25932],[26191],[False],[0],[0],[False],['0']
6440,PMC3217848,23968,Additional research on the nature of existing PE-before the present study intervention-would have been helpful in designing a PE program which was more physically active.,Discussion|Study Limitations,[140098],[26192],[26362],[False],[0],[0],[False],['0']
6441,PMC3217848,23969,A further difficulty arises from lack of certainty in the optimal accelerometry cut-points.,Discussion|Study Limitations,[140102],[26363],[26454],[False],[0],[0],[False],['0']
6442,PMC3217848,23970,"With lower cut-points than those used in the present study levels of apparent MVPA would have been higher, and levels of apparent sedentary behavior lower, in both the intervention and control groups [24].",Discussion|Study Limitations,[140106],[26455],[26660],[False],[0],[0],[False],['0']
6443,PMC3217848,23971,The present study was designed with longer-term translation to school systems in mind (the rationale for choosing PE as the means of delivering the physical activity intervention).,Discussion|Study Limitations,[140110],[26661],[26841],[False],[0],[0],[False],['0']
6444,PMC3217848,23972,"However, any longer-term translation of this sort of intervention to schools would need to be informed by evidence which the present study did not address, such as needs assessments and qualitative studies with teachers and school pupils.",Discussion|Study Limitations,[140114],[26842],[27080],[False],[0],[0],[False],['0']
6445,PMC3217848,23973,Conclusions,Conclusions,[140118],[27081],[27093],[False],[0],[0],[False],['0']
6446,PMC3217848,23974,The cognitive and behavioral effects of increases in physical activity in children merit greater emphasis in research because of the enormous potential for short and long term academic and health benefits [33].,Conclusions,[140122],[27094],[27304],[False],[0],[0],[False],['0']
6447,PMC3217848,23975,"The greater degree of neural plasticity of young children means that they may have most to gain from increased physical activity, but studying physical activity-cognition relationships in young children is especially challenging.",Conclusions,[140126],[27305],[27534],[False],[0],[0],[False],['0']
6448,PMC3217848,23976,The present studies have provided evidence that should inform the future RCT which will be necessary in order to better understand relationships between physical activity and cognition in young children in future.,Conclusions,[140130],[27535],[27748],[False],[0],[0],[False],['0']
6449,PMC3217848,23977,Conflict of interests,Conflict of interests,[140134],[27749],[27771],[False],[0],[0],[False],['0']
6450,PMC3217848,23978,The authors declare that they have no competing interests.,Conflict of interests,[140138],[27772],[27830],[False],[0],[0],[False],['0']
6451,PMC3217848,23979,Authors' contributions,Authors' contributions,[140142],[27831],[27854],[False],[0],[0],[False],['0']
6452,PMC3217848,23980,"All authors were responsible for study concept & design, and all were involved in study data analysis & interpretation.",Authors' contributions,[140146],[27855],[27974],[False],[0],[0],[False],['0']
6453,PMC3217848,23981,AF and CW collected data.,Authors' contributions,[140150],[27975],[28000],[False],[0],[0],[False],['0']
6454,PMC3217848,23982,All authors were involved in drafting & revision of the manuscript for important intellectual content.,Authors' contributions,[140154],[28001],[28103],[False],[0],[0],[False],['0']
6455,PMC3217848,23983,All authors were responsible for final approval of manuscript submission.,Authors' contributions,[140158],[28104],[28177],[False],[0],[0],[False],['0']
6456,PMC3217848,23984,Pre-publication history,Pre-publication history,[140162],[28178],[28202],[False],[0],[0],[False],['0']
6457,PMC3217848,23985,The pre-publication history for this paper can be accessed here:,Pre-publication history,[140166],[28203],[28267],[False],[0],[0],[False],['0']
6458,PMC3217848,23986,http://www.biomedcentral.com/1471-2431/11/97/prepub,Pre-publication history,[140170],[28268],[28319],[False],[0],[0],[False],['0']
6459,PMC3217848,23987,Acknowledgements,Acknowledgements,[140174],[28320],[28337],[False],[0],[0],[False],['0']
6460,PMC3217848,23988,"We would like to thank the Chief Scientist's Office (CSO) and Yorkhill Children's Foundation for funding this research, and the schools, children and parents involved in the study.",Acknowledgements,[140178],[28338],[28518],[False],[0],[0],[False],['0']
6461,PMC3217848,23989,"We would like to thank the Glasgow City Council primary PE specialists for their invaluable involvement in this project, Catriona Pearson, Paul Cornelius for assistance with data collection, and research psychologists Katie Brady and Elaine Beck.",Acknowledgements,[140182],[28519],[28765],[False],[0],[0],[False],['0']
10311,PMC3590447,10284,Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial,Title,[63358],[43493],[90],[False],[0],[0],[False],['0']
10312,PMC3590447,10285,Summary,Abstract,[63367],[91],[99],[False],[0],[0],[False],['0']
10313,PMC3590447,10286,Background,Abstract,[63376],[100],[110],[False],[0],[0],[False],['0']
10314,PMC3590447,10287,Membranous nephropathy leads to end-stage renal disease in more than 20% of patients.,Abstract,[63385],[111],[196],[False],[0],[0],[False],['0']
10315,PMC3590447,10288,"Although immunosuppressive therapy benefits some patients, trial evidence for the subset of patients with declining renal function is not available.",Abstract,[63394],[197],[345],[False],[0],[0],[False],['0']
10316,PMC3590447,10289,We aimed to assess whether immunosuppression preserves renal function in patients with idiopathic membranous nephropathy with declining renal function.,Abstract,[63403],[346],[497],[False],[0],[0],[False],['0']
10317,PMC3590447,10290,Methods,Abstract,[63412],[498],[505],[False],[0],[0],[False],['0']
10318,PMC3590447,10291,This randomised controlled trial was undertaken in 37 renal units across the UK.,Abstract,[63421],[506],[586],[False],[0],[0],[False],['0']
10319,PMC3590447,10292,"We recruited patients (18–75 years) with biopsy-proven idiopathic membranous nephropathy, a plasma creatinine concentration of less than 300 μmol/L, and at least a 20% decline in excretory renal function measured in the 2 years before study entry, based on at least three measurements over a period of 3 months or longer.",Abstract,[63430],[587],[908],[False],[0],[0],[False],['0']
10320,PMC3590447,10293,"Patients were randomly assigned (1:1:1) by a random number table to receive supportive treatment only, supportive treatment plus 6 months of alternating cycles of prednisolone and chlorambucil, or supportive treatment plus 12 months of ciclosporin.",Abstract,[63439],[909],[1157],[False],[0],[0],[False],['0']
10321,PMC3590447,10294,"The primary outcome was a further 20% decline in renal function from baseline, analysed by intention to treat.",Abstract,[63448],[1158],[1268],[False],[0],[0],[False],['0']
10322,PMC3590447,10295,"The trial is registered as an International Standard Randomised Controlled Trial, number 99959692.",Abstract,[63457],[1269],[1367],[False],[0],[0],[False],['0']
10323,PMC3590447,10296,Findings,Abstract,[63466],[1368],[1376],[False],[0],[0],[False],['0']
10324,PMC3590447,10297,"We randomly assigned 108 patients, 33 of whom received prednisolone and chlorambucil, 37 ciclosporin, and 38 supportive therapy alone.",Abstract,[63475],[1377],[1511],[False],[0],[0],[False],['0']
10325,PMC3590447,10298,"Two patients (one who received ciclosporin and one who received supportive therapy) were ineligible, so were not included in the intention-to-treat analysis, and 45 patients deviated from protocol before study end, mostly as a result of minor dose adjustments.",Abstract,[63484],[1512],[1772],[False],[0],[0],[False],['0']
10326,PMC3590447,10299,Follow up was until primary endpoint or for minimum of 3 years if primary endpoint was not reached.,Abstract,[63493],[1773],[1872],[False],[0],[0],[False],['0']
10327,PMC3590447,10300,"Risk of further 20% decline in renal function was significantly lower in the prednisolone and chlorambucil group than in the supportive care group (19 [58%] of 33 patients reached endpoint vs 31 [84%] of 37, hazard ratio [HR] 0·44 [95% CI 0·24–0·78]; p=0·0042); risk did not differ between the ciclosporin (29 [81%] of 36) and supportive treatment only groups (HR 1·17 [0·70–1·95]; p=0·54), but did differ significantly across all three groups (p=0·003).",Abstract,[63502],[1873],[2327],[False],[0],[0],[False],['0']
10328,PMC3590447,10301,Serious adverse events were frequent in all three groups but were higher in the prednisolone and chlorambucil group than in the supportive care only group (56 events vs 24 events; p=0·048).,Abstract,[63511],[2328],[2517],[False],[0],[0],[False],['0']
10329,PMC3590447,10302,Interpretation,Abstract,[63520],[2518],[2532],[False],[0],[0],[False],['0']
10330,PMC3590447,10303,"For the subset of patients with idiopathic membranous nephropathy and deteriorating excretory renal function, 6 months' therapy with prednisolone and chlorambucil is the treatment approach best supported by our evidence.",Abstract,[63529],[2533],[2753],[False],[0],[0],[False],['0']
10331,PMC3590447,10304,Ciclosporin should be avoided in this subset.,Abstract,[63538],[2754],[2799],[False],[0],[0],[False],['0']
10332,PMC3590447,10305,Funding,Abstract,[63547],[2800],[2807],[False],[0],[0],[False],['0']
10333,PMC3590447,10306,"Medical Research Council, Novartis, Renal Association, Kidney Research UK.",Abstract,[63556],[2808],[2882],[False],[0],[0],[False],['0']
10334,PMC3590447,10307,Introduction,Introduction,[63565],[2883],[2896],[False],[0],[0],[False],['0']
10335,PMC3590447,10308,"Membranous nephropathy is the most common cause of primary nephrotic syndrome in adults, and according to figures from the Netherlands, 30–50 people per million population develop the disorder every 5 years (6–10 per million population per year).",Introduction,[63574],[2897],[3143],[False],[0],[0],[False],['0']
10336,PMC3590447,10309,"Membranous nephropathy results in substantial morbidity and is an important cause of end-stage renal disease, which accounted for expenditure of US$40 billion in the USA in 2008.",Introduction,[63583],[3144],[3322],[False],[0],[0],[False],['0']
10337,PMC3590447,10310,"Optimum treatment for membranous nephropathy is controversial despite several controlled trials having assessed available treatments, not least because the disorder has a variable natural history and many severely affected individuals can undergo spontaneous remission.",Introduction,[63592],[3323],[3592],[False],[0],[0],[False],['0']
10338,PMC3590447,10311,"Only a subset of patients (25–30% in most series) develops progressive loss of kidney function, and since available therapies have substantial adverse effects, some believe that aggressive therapy should be reserved for this subgroup.",Introduction,[63601],[3593],[3827],[False],[0],[0],[False],['0']
10339,PMC3590447,10312,"However, no large prospective randomised controlled trials (RCTs) in this worst-affected subset exist.",Introduction,[63610],[3828],[3930],[False],[0],[0],[False],['0']
10340,PMC3590447,10313,"Studies of the natural history of membranous nephropathy show that once excretory renal function starts to decline, continued deterioration can be expected, which suggests that the really important clinical question in membranous nephropathy is whether treatments that are effective in less severely affected patients are also beneficial in patients showing definite signs of decline in renal function.",Introduction,[63619],[3931],[4333],[False],[0],[0],[False],['0']
10341,PMC3590447,10314,"Thus, findings from prospective RCTs are essential to inform decisions about treatment of this disorder.",Introduction,[63628],[4334],[4438],[False],[0],[0],[False],['0']
10342,PMC3590447,10315,Idiopathic membranous nephropathy is often managed with immunosuppressive drugs.,Introduction,[63637],[4439],[4519],[False],[0],[0],[False],['0']
10343,PMC3590447,10316,"Until recently, evidence that this nephropathy is autoimmune in origin was circumstantial.",Introduction,[63646],[4520],[4610],[False],[0],[0],[False],['0']
10344,PMC3590447,10317,"However, autoantibodies to the phospholipase A2 receptor (PLA2R1) have now been noted in most affected individuals, and a predisposition to the disorder has been very strongly linked to two genetic regions (one in the MHC and the other in the PLA2R1 gene itself)—findings that support an immunological pathogenesis and provide a rationale for immunosuppressive therapy, especially treatment targeted at B lymphocytes.",Introduction,[63655],[4611],[5028],[False],[0],[0],[False],['0']
10345,PMC3590447,10318,"When our study was designed, combined treatment with prednisolone and chlorambucil and single-agent therapy with ciclosporin were supported by RCT evidence.",Introduction,[63664],[5029],[5185],[False],[0],[0],[False],['0']
10346,PMC3590447,10319,We did a questionnaire survey as part of our preliminary research and noted that nephrologists were uncertain about the relative risks of intervention with immunosuppressive therapy compared with supportive therapy alone.,Introduction,[63673],[5186],[5407],[False],[0],[0],[False],['0']
10347,PMC3590447,10320,"Therefore, we aimed to test the hypothesis that immunosuppressive therapy, either with prednisolone and chlorambucil or with ciclosporin, preserves renal function in patients with idiopathic membranous nephropathy with declining renal function compared with supportive therapy alone.",Introduction,[63682],[5408],[5691],[False],[0],[0],[False],['0']
10348,PMC3590447,10321,Methods,Methods,[63691],[5692],[5700],[False],[0],[0],[False],['0']
10349,PMC3590447,10322,Trial design and participants,Methods|Trial design and participants,[63700],[5701],[5730],[False],[0],[0],[False],['0']
10350,PMC3590447,10323,"In this randomised controlled trial, patients were recruited from 37 of 45 renal units in acute hospitals throughout the UK that obtained local ethical approval.",Methods|Trial design and participants,[63709],[5731],[5892],[False],[0],[0],[False],['0']
10351,PMC3590447,10324,"Inclusion criteria were: age 18–75 years; biopsy-proven diagnosis of membranous nephropathy (we did not impose a limit on the time since biopsy), regarded as idiopathic with no evidence of an underlying cause (such as drugs, infections, or tumours); and serum or plasma creatinine concentration of less than 300 μmol/L together with a 20% or greater decline in excretory renal function (measured by creatinine clearance or estimated with the Cockcroft-Gault calculation, and later by the Modification of Diet in Renal Disease [MDRD] formula) that was based on at least three measurements over a period of 3 months or longer within the 2 years before study entry.",Methods|Trial design and participants,[63718],[5893],[6555],[False],[0],[0],[False],['0']
10352,PMC3590447,10325,We excluded patients whose membranous nephropathy was a result of secondary causes (defined according to usual clinical practice).,Methods|Trial design and participants,[63727],[6556],[6686],[False],[0],[0],[False],['0']
10353,PMC3590447,10326,"Other exclusion criteria were: known infection with hepatitis B or C virus or HIV; known malignant disease; positive antibodies to double-stranded DNA; current treatment with gold, penicillamine, non-steroidal anti-inflammatory drugs, cytotoxic drugs, or ciclosporin; more than 3 months' treatment with corticosteroids in the preceding 2 years; pregnancy or unreliable contraception; or a previous adverse reaction to prednisolone, methylprednisolone, chlorambucil or ciclosporin.",Methods|Trial design and participants,[63736],[6687],[7167],[False],[0],[0],[False],['0']
10354,PMC3590447,10327,Ethics approval was obtained from the South West Multicentre Research Ethics Committee (reference MREC/97/6/12).,Methods|Trial design and participants,[63745],[7168],[7280],[False],[0],[0],[False],['0']
10355,PMC3590447,10328,Each participating centre also obtained local ethical approval.,Methods|Trial design and participants,[63754],[7281],[7344],[False],[0],[0],[False],['0']
10356,PMC3590447,10329,All patients gave written informed consent.,Methods|Trial design and participants,[63763],[7345],[7388],[False],[0],[0],[False],['0']
10357,PMC3590447,10330,Randomisation,Methods|Randomisation,[63772],[7389],[7402],[False],[0],[0],[False],['0']
10358,PMC3590447,10331,"Eligible patients were randomly assigned by a member of staff in the clinical trials office at the Glasgow Royal Infirmary, Glasgow, UK, who was not otherwise involved in the trial.",Methods|Randomisation,[63781],[7403],[7584],[False],[0],[0],[False],['0']
10359,PMC3590447,10332,"A random numbers table had been prepared to allocate patients to one of three groups: supportive therapy alone, supportive therapy plus 6 months of prednisolone and chlorambucil, or supportive therapy plus 12 months of ciclosporin.",Methods|Randomisation,[63790],[7585],[7816],[False],[0],[0],[False],['0']
10360,PMC3590447,10333,Treatment allocation was communicated by fax to the clinician entering the patient into the trial.,Methods|Randomisation,[63799],[7817],[7915],[False],[0],[0],[False],['0']
10361,PMC3590447,10334,We did not attempt to mask patients or investigators.,Methods|Randomisation,[63808],[7916],[7969],[False],[0],[0],[False],['0']
10362,PMC3590447,10335,Procedures,Methods|Procedures,[63817],[7970],[7980],[False],[0],[0],[False],['0']
10363,PMC3590447,10336,"We recorded baseline data for the supportive treatment alone group at randomisation, because these patients were effectively continuing their existing management.",Methods|Procedures,[63826],[7981],[8143],[False],[0],[0],[False],['0']
10364,PMC3590447,10337,"In the two groups receiving immunosuppressive treatment in addition to supportive therapy, baseline data were recorded when the new treatment began.",Methods|Procedures,[63835],[8144],[8292],[False],[0],[0],[False],['0']
10365,PMC3590447,10338,We could not always start immunosuppressive treatment immediately after randomisation because the new treatments had to be prescribed and delivered.,Methods|Procedures,[63844],[8293],[8441],[False],[0],[0],[False],['0']
10366,PMC3590447,10339,The treatment schedules were based on best available evidence at the time.,Methods|Procedures,[63853],[8442],[8516],[False],[0],[0],[False],['0']
10367,PMC3590447,10340,"All patients received supportive therapy, including renin-angiotensin blockade, statins, and anticoagulants as indicated.",Methods|Procedures,[63862],[8517],[8638],[False],[0],[0],[False],['0']
10368,PMC3590447,10341,"Those assigned to supportive therapy plus 6 months' prednisolone and chorambucil received intravenous methyl prednisolone 1 g per day for 3 consecutive days then oral prednisolone 0·5 mg/kg per day for 28 days during months 1, 3, and 5.",Methods|Procedures,[63871],[8639],[8875],[False],[0],[0],[False],['0']
10369,PMC3590447,10342,Intravenous prednisolone was administered in hospital.,Methods|Procedures,[63880],[8876],[8930],[False],[0],[0],[False],['0']
10370,PMC3590447,10343,"During months 2, 4, and 6, patients received oral chlorambucil at a starting dose of 0·15 mg/kg per day.",Methods|Procedures,[63889],[8931],[9035],[False],[0],[0],[False],['0']
10371,PMC3590447,10344,We gave this reduced dose because the parent drug and its metabolites are renally excreted and our preliminary work had shown that a dose of 0·2 mg/kg per day was poorly tolerated in patients with impaired excretory renal function.,Methods|Procedures,[63898],[9036],[9267],[False],[0],[0],[False],['0']
10372,PMC3590447,10345,We reduced the dose further if the patient developed leucopenia (weekly full blood counts were advised) and interrupted it if leucopenia was severe.,Methods|Procedures,[63907],[9268],[9416],[False],[0],[0],[False],['0']
10373,PMC3590447,10346,"Those assigned to supportive therapy plus 12 months' of ciclosporin received a starting dose of 5 mg/kg per day, adjusted according to trough blood concentrations of the drug to achieve a concentration of 100–200 μg/L.",Methods|Procedures,[63916],[9417],[9635],[False],[0],[0],[False],['0']
10374,PMC3590447,10347,We reduced the dose if toxicity was evident.,Methods|Procedures,[63925],[9636],[9680],[False],[0],[0],[False],['0']
10375,PMC3590447,10348,"We followed up patients until they met the primary endpoint, or for a minimum of 3 years if they did not do so.",Methods|Procedures,[63934],[9681],[9792],[False],[0],[0],[False],['0']
10376,PMC3590447,10349,The trial was not formally analysed until 3 years after all patients had begun treatment.,Methods|Procedures,[63943],[9793],[9882],[False],[0],[0],[False],['0']
10377,PMC3590447,10350,All surviving trial patients remain under routine follow-up at their renal units.,Methods|Procedures,[63952],[9883],[9964],[False],[0],[0],[False],['0']
10378,PMC3590447,10351,"The primary endpoint was a further 20% decline in excretory renal function from baseline readings, calculated in all patients with the Cockcroft-Gault equation (standard methodology at the start of the trial).",Methods|Procedures,[63961],[9965],[10174],[False],[0],[0],[False],['0']
10379,PMC3590447,10352,Secondary endpoints were proteinuria (measured with 24-h urinary collections or estimated from protein–creatinine ratios by multiplying the ratio [in mg/mmol] by 10) and severe adverse events.,Methods|Procedures,[63970],[10175],[10367],[False],[0],[0],[False],['0']
10380,PMC3590447,10353,The primary investigator (PWM) identified which adverse events were serious and categorised them according to the most affected body system.,Methods|Procedures,[63979],[10368],[10508],[False],[0],[0],[False],['0']
10381,PMC3590447,10354,"We report all serious adverse events as defined by the Medicines and Healthcare products Regulatory Agency (MHRA) guidance—(ie, any adverse event, adverse reaction, or unexpected adverse reaction that results in death, is life-threatening, results in admission to hospital or extends the length of an existing hospital stay, results in persistent or serious disability or incapacity, or consists of a congenital anomaly or birth defect).",Methods|Procedures,[63988],[10509],[10946],[False],[0],[0],[False],['0']
10382,PMC3590447,10355,We also regarded as serious other important medical events that might have jeopardised the patient or needed intervention to prevent one of these outcomes.,Methods|Procedures,[63997],[10947],[11102],[False],[0],[0],[False],['0']
10383,PMC3590447,10356,We recorded information about deaths and development of end-stage renal disease.,Methods|Procedures,[64006],[11103],[11183],[False],[0],[0],[False],['0']
10384,PMC3590447,10357,"In accordance with the Medical Research Council's guidelines for good clinical practice, a trial steering committee and a data monitoring committee were established to receive yearly reports for primary endpoints, adverse events, and deaths.",Methods|Procedures,[64015],[11184],[11425],[False],[0],[0],[False],['0']
10385,PMC3590447,10358,Statistical analysis,Methods|Statistical analysis,[64024],[11426],[11446],[False],[0],[0],[False],['0']
10386,PMC3590447,10359,"To have 90% power to detect a reduction in frequency of the primary endpoint from 80% in the supportive treatment group to 40% in the immunosuppression groups with p<0·05, we calculated that 35 patients would be needed in each group (105 in total).",Methods|Statistical analysis,[64033],[11447],[11695],[False],[0],[0],[False],['0']
10387,PMC3590447,10360,"After allowing for an estimated dropout rate of 10%, we concluded that we needed to recruit 116 patients.",Methods|Statistical analysis,[64042],[11696],[11801],[False],[0],[0],[False],['0']
10388,PMC3590447,10361,"Primary analysis followed the principles of intention to treat, and secondary analysis assessed all patients who received at least one dose of treatment.",Methods|Statistical analysis,[64051],[11802],[11955],[False],[0],[0],[False],['0']
10389,PMC3590447,10362,"Unless otherwise stated, p values and estimates of treatment effects are based on two-way comparisons.",Methods|Statistical analysis,[64060],[11956],[12058],[False],[0],[0],[False],['0']
10390,PMC3590447,10363,We did not make adjustments for multiple comparisons.,Methods|Statistical analysis,[64069],[12059],[12112],[False],[0],[0],[False],['0']
10391,PMC3590447,10364,We analysed time to further 20% decline in renal function by the log-rank test and calculated hazard ratios [HRs] with Cox proportional hazards regression.,Methods|Statistical analysis,[64078],[12113],[12268],[False],[0],[0],[False],['0']
10392,PMC3590447,10365,"We used the log-rank test for other survival endpoints, and repeated measures analysis of variance fowr continuous longitudinal data (eg, proteinuria).",Methods|Statistical analysis,[64087],[12269],[12420],[False],[0],[0],[False],['0']
10393,PMC3590447,10366,We analysed serious adverse event data with the log-rank test on the basis of time to first serious adverse event.,Methods|Statistical analysis,[64096],[12421],[12535],[False],[0],[0],[False],['0']
10394,PMC3590447,10367,We did statistical analyses using SAS software (version 9.2).,Methods|Statistical analysis,[64105],[12536],[12597],[False],[0],[0],[False],['0']
10395,PMC3590447,10368,"In 2003, the trial was shown to comply with the requirements of the EU clinical trials directive, and in 2004, a clinical trial authorisation (CTA) was obtained from the Medicines and Healthcare products Regulatory Authority (CTA number 18524/0001/001).",Methods|Statistical analysis,[64114],[12598],[12851],[False],[0],[0],[False],['0']
10396,PMC3590447,10369,"In 2008, the trial was adopted onto the National Institute for Health Research portfolio and assigned the UK Clinical Research Network identification number 2579.",Methods|Statistical analysis,[64123],[12852],[13014],[False],[0],[0],[False],['0']
10397,PMC3590447,10370,"The trial is registered as an International Standard Randomised Controlled Trial, number 99959692.",Methods|Statistical analysis,[64132],[13015],[13113],[False],[0],[0],[False],['0']
10398,PMC3590447,10371,Role of the funding source,Methods|Role of the funding source,[64141],[13114],[13140],[False],[0],[0],[False],['0']
10399,PMC3590447,10372,"The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.",Methods|Role of the funding source,[64150],[13141],[13274],[False],[0],[0],[False],['0']
10400,PMC3590447,10373,The corresponding author had full access to all the data in the study and had final responsibility to submit for publication.,Methods|Role of the funding source,[64159],[13275],[13400],[False],[0],[0],[False],['0']
10401,PMC3590447,10374,Results,Results,[64168],[13401],[13409],[False],[0],[0],[False],['0']
10402,PMC3590447,10375,"We randomly assigned 108 patients between April 1, 1998, and March 31, 2008, at a steady rate of about one patient per month (figure 1).",Results,[64177],[13410],[13546],[False],[0],[0],[False],['0']
10403,PMC3590447,10376,"We discovered that two patients were ineligible after randomisation, so no follow-up data are available for them, and they weren't included in the primary analysis.",Results,[64186],[13547],[13711],[False],[0],[0],[False],['0']
10404,PMC3590447,10377,"Of the 106 patients included in the intention-to-treat analysis, 37 were assigned to receive supportive therapy alone, 33 to prednisolone and chlorambucil, and 36 to ciclosporin.",Results,[64195],[13712],[13890],[False],[0],[0],[False],['0']
10405,PMC3590447,10378,37 of the 45 centres that obtained ethics approval entered patients into the trial.,Results,[64204],[13891],[13974],[False],[0],[0],[False],['0']
10406,PMC3590447,10379,The groups had similar baseline measurements (table 1).,Results,[64213],[13975],[14030],[False],[0],[0],[False],['0']
10407,PMC3590447,10380,"Times between randomisation and baseline readings are longer in both immunosuppressive groups than in the supportive therapy alone group because of delays relating to prescription, delivery, and administration of treatment.",Results,[64222],[14031],[14254],[False],[0],[0],[False],['0']
10408,PMC3590447,10381,"We classed deviations from the defined protocol, including starting dose of intervention drugs, as either minor (eg, dose reductions because of toxicity) or major (eg, cessation of treatment, including temporary interruptions, or administration of the wrong treatment).",Results,[64231],[14255],[14524],[False],[0],[0],[False],['0']
10409,PMC3590447,10382,We did not classify a delay between randomisation and start of treatment as a default protocol deviation.,Results,[64240],[14525],[14630],[False],[0],[0],[False],['0']
10410,PMC3590447,10383,"However, two patients had excessive delays (2 and 3 months, respectively), and we classified both as major deviations.",Results,[64249],[14631],[14749],[False],[0],[0],[False],['0']
10411,PMC3590447,10384,"Angiotensin-converting enzyme inhibitor was given to 27 (82%) of 33 in the prednisolone and chlorambucil group, 36 (100%) of 36 patients in the ciclosporin group, and 34 (92%) of 37 of those who received supportive treatment only.",Results,[64258],[14750],[14980],[False],[0],[0],[False],['0']
10412,PMC3590447,10385,We did not obtain information about angiotensin-receptor antagonist use.,Results,[64267],[14981],[15053],[False],[0],[0],[False],['0']
10413,PMC3590447,10386,The rate of occurrence of a further 20% decline in excretory renal function from baseline was fastest in the ciclosporin group and slowest in the prednisolone and chlorambucil group (figure 2).,Results,[64276],[15054],[15247],[False],[0],[0],[False],['0']
10414,PMC3590447,10387,"Risk of a further 20% decline in renal function was significantly lower in the prednisolone and chlorambucil group than in the supportive therapy group (19 [58%] of 33 patients vs 31 [84%] of 37 patients, HR 0·44 [95% CI 0·24–0·78]; p=0·0042), with no significant difference noted between the ciclosporin group (29 [81%] of 36 patients) and supportive care group (HR 1·17 [0·70–1·95]; p=0·54).",Results,[64285],[15248],[15641],[False],[0],[0],[False],['0']
10415,PMC3590447,10388,The difference in the proportion of patients who reached the primary endpoint across all three groups was significant (p=0·003 for the three-way comparison; figure 2).,Results,[64294],[15642],[15809],[False],[0],[0],[False],['0']
10416,PMC3590447,10389,Survival analysis showed no significant differences between groups: two (6·1%) of 33 patients in the prednisolone plus chlorambucil group died during the trial follow-up compared with two (5·6%) of 36 patients in the ciclosporin group and one (2·7%) of 37 in the supportive therapy group.,Results,[64303],[15810],[16098],[False],[0],[0],[False],['0']
10417,PMC3590447,10390,We did not classify any deaths as likely to be related to trial treatments.,Results,[64312],[16099],[16174],[False],[0],[0],[False],['0']
10418,PMC3590447,10391,"Of the five deaths, two were due to myocardial infarction (one each in the prednisolone plus chlorambucil and ciclosporin groups), one to septicaemia (in the supportive treatment only group), and two to unknown causes.",Results,[64321],[16175],[16393],[False],[0],[0],[False],['0']
10419,PMC3590447,10392,Malignant disease was reported in two (6·1%) of 33 patients in the prednisolone plus chlorambucil group during follow-up: one had squamous-cell carcinoma of the skin and one had adenocarcinoma of the sigmoid colon.,Results,[64330],[16394],[16608],[False],[0],[0],[False],['0']
10420,PMC3590447,10393,11 patients reached end-stage renal disease: one (3·0%) of 33 in the prednisolone plus chlorambucil group compared with six (16·7%) of 36 in the ciclosporin group and four (10·8%) of 37 in the supportive therapy group.,Results,[64339],[16609],[16827],[False],[0],[0],[False],['0']
10421,PMC3590447,10394,The fall in proteinuria with time was greatest in the prednisolone plus chlorambucil group (figure 3).,Results,[64348],[16828],[16930],[False],[0],[0],[False],['0']
10422,PMC3590447,10395,The difference in the mean reduction of protein in the urine for prednisolone and chlorambucil versus supportive therapy alone was −2·2 g in 24 h (p=0·014).,Results,[64357],[16931],[17087],[False],[0],[0],[False],['0']
10423,PMC3590447,10396,The difference in the mean reduction for ciclosporin versus supportive care alone was −0·7 g in 24 h (p=0·46).,Results,[64366],[17088],[17198],[False],[0],[0],[False],['0']
10424,PMC3590447,10397,"We recorded 390 adverse events, of which 117 were deemed serious by PWM.",Results,[64375],[17199],[17271],[False],[0],[0],[False],['0']
10425,PMC3590447,10398,These 117 events occurred in 54 patients (table 2).,Results,[64384],[17272],[17323],[False],[0],[0],[False],['0']
10426,PMC3590447,10399,"The number of patients with a serious adverse event by 1 year did not differ significantly between the ciclosporin and supportive care groups (17 [46%] of 37 patients in the ciclosporin group vs 11 [29%] of 38 in the supportive therapy only group; p=0·20), but the number of patients in the prednisolone and chlorambucil group with a serious adverse event by 1 year (17 [52%] of 33 patients) was significantly higher than in the supportive care group (p=0·048).",Results,[64393],[17324],[17785],[False],[0],[0],[False],['0']
10427,PMC3590447,10400,"Haematological events were leucopenia, anaemia, and thrombocytopenia, although we did not note any lymphomas or leukaemias.",Results,[64402],[17786],[17909],[False],[0],[0],[False],['0']
10428,PMC3590447,10401,Dermatological effects included rash and shingles.,Results,[64411],[17910],[17960],[False],[0],[0],[False],['0']
10429,PMC3590447,10402,Renal effects were mainly deterioration of excretory renal function or hyperkalaemia.,Results,[64420],[17961],[18046],[False],[0],[0],[False],['0']
10430,PMC3590447,10403,Neurological effects were tremor and headache.,Results,[64429],[18047],[18093],[False],[0],[0],[False],['0']
10431,PMC3590447,10404,"Cardiovascular effects were hypertension, myocardial infarction, chest pain, and pulmonary embolus.",Results,[64438],[18094],[18193],[False],[0],[0],[False],['0']
10432,PMC3590447,10405,Metabolic effects included impairment of glucose tolerance.,Results,[64447],[18194],[18253],[False],[0],[0],[False],['0']
10433,PMC3590447,10406,"Gastroenterological effects included nausea, vomiting, diarrhoea, bleeding, and pancreatitis.",Results,[64456],[18254],[18347],[False],[0],[0],[False],['0']
10434,PMC3590447,10407,"Infection included septicaemia, pneumonia, and cellulitis.",Results,[64465],[18348],[18406],[False],[0],[0],[False],['0']
10435,PMC3590447,10408,"Other effects included cataract, fractured humerus, hernia repairs, and pulmonary sarcoid.",Results,[64474],[18407],[18497],[False],[0],[0],[False],['0']
10436,PMC3590447,10409,"We acknowledge that some potential adverse effects of prednisolone plus chlorambucil and ciclosporin are more longlasting than the effects reported with supportive care alone, especially the risk of lymphoma or other malignant diseases.",Results,[64483],[18498],[18734],[False],[0],[0],[False],['0']
10437,PMC3590447,10410,Discussion,Discussion,[64492],[18735],[18746],[False],[0],[0],[False],['0']
10438,PMC3590447,10411,These results suggest that supportive therapy plus prednisolone and chlorambucil is better at prevention of decline in excretory renal function than is supportive therapy plus ciclosporin or supportive therapy alone in patients with deteriorating function due to idiopathic membranous nephropathy.,Discussion,[64501],[18747],[19044],[False],[0],[0],[False],['0']
10439,PMC3590447,10412,"Ideally the results should be confirmed in a larger study, but because this trial took 10 years to recruit due to the difficulty of running a multicentre trial in slowly progressive glomerular disease, a similar larger study is unlikely to be done.",Discussion,[64515],[19045],[19293],[True],['SampleSize'],['the results should be confirmed in a larger study'],[True],['UnderpoweredStudy']
10440,PMC3590447,10413,"92% of all patients in this trial received angiotensin-converting enzyme inhibitors, showing that this aspect of supportive therapy was virtually universal in all three groups.",Discussion,[64528],[19294],[19470],[False],[0],[0],[False],['0']
10441,PMC3590447,10414,The benefit to renal function was matched by a reduction in proteinuria with prednisolone and chlorambucil.,Discussion,[64537],[19471],[19578],[False],[0],[0],[False],['0']
10442,PMC3590447,10415,"In this severely affected subset of patients, we thought it would be unlikely that even responders would achieve complete remission of proteinuria, hence our decision to make excretory renal function our primary endpoint.",Discussion,[64546],[19579],[19800],[False],[0],[0],[False],['0']
10443,PMC3590447,10416,"Adverse events were frequent, including in the supportive therapy group, suggesting that this group of patients is susceptible to major medical problems.",Discussion,[64555],[19801],[19954],[False],[0],[0],[False],['0']
10444,PMC3590447,10417,"Masking was impossible because of the nature of the treatments involved, but we accept that the fact that the study was unblinded might have affected the reporting of adverse effects.",Discussion,"[64564, 64572]","[19955, 19955]","[20138, 20138]","[True, True]","['Blinding', 'Blinding']","['Masking was impossible because of the nature of the treatments involved', 'the study was unblinded']","[True, True]",['Blinding']
10445,PMC3590447,10418,"In the active intervention groups, the serious adverse effects were predictable from the side-effect profiles of the drugs—particularly headache, tremor, hypertension, deterioration in renal function, or infection in the ciclosporin group and predominantly haematological (especially leucopenia and anaemia) or metabolic (especially glucose intolerance) effects in the prednisolone and chlorambucil group.",Discussion,[64582],[20139],[20544],[False],[0],[0],[False],['0']
10446,PMC3590447,10419,"Dose adjustment of chlorambucil arose frequently and treatment interruptions were common, both accounting for most of the protocol departures in the prednisolone and chlorambucil group.",Discussion,[64591],[20545],[20730],[False],[0],[0],[False],['0']
10447,PMC3590447,10420,"Similarly, in the ciclosporin group, nephrotoxicity was a substantial problem despite the fact that we used target blood concentrations advocated in a previous RCT; dose reductions, treatment interruptions, and reaching of primary endpoint were frequent in this group.",Discussion,[64600],[20731],[20999],[False],[0],[0],[False],['0']
10448,PMC3590447,10421,"Slow trial recruitment was undoubtedly determined by the eligibility criteria: deteriorating renal function in idiopathic membranous nephropathy has become less common with angiotensin-cascade blockade and other aspects of supportive management, and our detailed communications with renal units throughout the UK during the trial showed that the rarity of eligible patients was the main barrier to recruitment.",Discussion,"[64610, 64615]","[21000, 21000]","[21410, 21410]","[True, True]","['VerySpecificPopulation', 'VerySpecificPopulation']","['Slow trial recruitment was undoubtedly determined by the eligibility criteria', 'the rarity of eligible patients was the main barrier to recruitment']","[True, True]",['Population']
10449,PMC3590447,10422,"Of the 37 units that entered patients, 31 recruited four patients or fewer.",Discussion,[64627],[21411],[21486],[False],[0],[0],[False],['0']
10450,PMC3590447,10423,"Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive care only group or the potential toxicity of active therapy—clear evidence that considerable uncertainty surrounds appropriate management of this disorder, and that a definitive RCT is needed.",Discussion,[64636],[21487],[21852],[False],[0],[0],[False],['0']
10451,PMC3590447,10424,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorating excretory renal function.",Discussion,[64645],[21853],[22202],[False],[0],[0],[False],['0']
10452,PMC3590447,10425,Our findings do not support the use of ciclosporin in this group—the adverse effects on renal function make it unsuitable once renal function has started to decline.,Discussion,[64654],[22203],[22368],[False],[0],[0],[False],['0']
10453,PMC3590447,10426,The ciclosporin starting dose in our study was based on an RCT reported by Cattran and colleagues.,Discussion,[64663],[22369],[22467],[False],[0],[0],[False],['0']
10454,PMC3590447,10427,A later trial led by this group used a lower starting dose (3·5 mg/kg per day) but aimed for similar plasma concentrations and reported beneficial effects on proteinuria.,Discussion,[64672],[22468],[22638],[False],[0],[0],[False],['0']
10455,PMC3590447,10428,Other investigators have used a lower dose of ciclosporin in small uncontrolled studies and also reported beneficial effects for proteinuria.,Discussion,[64681],[22639],[22780],[False],[0],[0],[False],['0']
10456,PMC3590447,10429,"Shortly after our study started, Ponticelli and colleagues reported that the choice of alkylating agent (between chlorambucil and the more familiar cyclophosphamide) for idiopathic membranous nephropathy might be immaterial, although cyclophosphamide might be less toxic.",Discussion,[64690],[22781],[23052],[False],[0],[0],[False],['0']
10457,PMC3590447,10430,"We decided not to change our study design, but we agree that cyclophosphamide could probably be substituted for chlorambucil.",Discussion,[64699],[23053],[23178],[False],[0],[0],[False],['0']
10458,PMC3590447,10431,"Uncontrolled studies using a combination of prednisolone and cyclophosphamide in severely affected patients have led to similar conclusions, and one RCT supports this approach in patients with well preserved renal function at entry.",Discussion,[64708],[23179],[23411],[False],[0],[0],[False],['0']
10459,PMC3590447,10432,Our study shows that this form of therapy can still be effective in patients whose renal function has started to deteriorate.,Discussion,[64717],[23412],[23537],[False],[0],[0],[False],['0']
10460,PMC3590447,10433,The use of alkylating agents (with their potent effects on B lymphocytes) for idiopathic membranous nephropathy has a rationale now that autoantibodies to PLA2R1 have been discovered in most patients.,Discussion,[64726],[23538],[23738],[False],[0],[0],[False],['0']
10461,PMC3590447,10434,"Immunosuppressive therapy is also logical in view of our previously published analysis of the genetic basis of idiopathic membranous nephropathy, showing that two genes predispose white people to this disorder, an immune-response gene in the HLA-DQA1 region and the PLA2R1 gene itself.",Discussion,[64735],[23739],[24024],[False],[0],[0],[False],['0']
10462,PMC3590447,10435,"Rituximab for idiopathic membranous nephropathy has shown promise, but so far evidence for its effectiveness is not based on RCT data and the beneficial effects are mostly in reduction of proteinuria rather than preservation of excretory renal function.",Discussion,[64744],[24025],[24278],[False],[0],[0],[False],['0']
10463,PMC3590447,10436,"Furthermore, rituximab is expensive and is associated with important long-term safety concerns such as progressive multifocal leukoencephalopathy.",Discussion,[64753],[24279],[24425],[False],[0],[0],[False],['0']
10464,PMC3590447,10437,"However, progressive multifocal leukoencephalopathy has not been reported in patients with idiopathic membranous nephropathy given rituximab and might be associated with intensity of immunosuppression, since patients who got the disease received rituximab together with other agents.",Discussion,[64762],[24426],[24709],[False],[0],[0],[False],['0']
10465,PMC3590447,10438,"Future RCTs should assess the cost-effectiveness, efficacy, and safety of rituximab for patients with idiopathic membranous nephropathy, perhaps compared with prednisolone plus an alkylating agent (either cyclophosphamide or chlorambucil).",Discussion,[64771],[24710],[24949],[False],[0],[0],[False],['0']
10466,PMC3590447,10439,"Future trials should ideally include patient-reported outcomes and an analysis of the balance between treatment costs (including those associated with adverse effects) and costs of renal replacement therapy in untreated patients, so that the cost–benefit of delaying the need for renal replacement therapy and quality-of-life issues can be assessed.",Discussion,[64780],[24950],[25299],[False],[0],[0],[False],['0']
10467,PMC3590447,10440,"Adverse effects, particularly haematological outcomes, were common in patients given prednisolone and chlorambucil in our study and often necessitated dose reduction or interruption of therapy.",Discussion,[64789],[25300],[25493],[False],[0],[0],[False],['0']
10468,PMC3590447,10441,"Clearly, the preservation of renal function that can be achieved with prednisolone and chlorambucil comes at a price, and careful monitoring of the therapy is needed.",Discussion,[64798],[25494],[25660],[False],[0],[0],[False],['0']
10469,PMC3590447,10442,Benefits of prednisolone and chlorambucil were maintained for at least 3 years of follow-up.,Discussion,[64807],[25661],[25753],[False],[0],[0],[False],['0']
10470,PMC3590447,10443,"Delaying end-stage renal disease, with its associated cardiovascular risk and increased morbidity and mortality, is of undoubted value to patients with idiopathic membranous nephropathy.",Discussion,[64816],[25754],[25940],[False],[0],[0],[False],['0']
10471,PMC3590447,10444,"However, even in patients given prednisolone and chlorambucil, only 40% had not had a further 20% decline in excretory renal function at 3 years.",Discussion,[64825],[25941],[26086],[False],[0],[0],[False],['0']
10472,PMC3590447,10445,"Clearly, more effective and safer forms of therapy are still needed for idiopathic membranous nephropathy.",Discussion,[64834],[26087],[26193],[False],[0],[0],[False],['0']
10473,PMC3590447,10446,"Until new treatments are available and have been properly tested, the evidence favours use of prednisolone and an alkylating agent in the most severely affected patients.",Discussion,[64843],[26194],[26364],[False],[0],[0],[False],['0']
10474,PMC3590447,10447,"This conclusion, and the lack of good RCTs in nephrology to address this and similar questions, are supported by a Cochrane review of the subject and an authoritative review of the international scientific literature on the treatment of glomerulonephritis (panel).",Discussion,[64852],[26365],[26629],[False],[0],[0],[False],['0']
10475,PMC3590447,10448,"The supportive therapy only group effectively continued current treatment whereas the two intervention groups received new treatment, which led to some minor differences in the time between randomisation and baseline readings (ie, initiation of treatment); however, the time differences were small in the context of this slowly progressive disease in comparison with the length of follow-up, and as a result the risk of bias is small.",Discussion,[64861],[26630],[27064],[False],[0],[0],[False],['0']
10476,PMC3590447,10449,Recruitment was very slow and the trial was designed over 14 years ago.,Discussion,[64872],[27065],[27136],[True],['SampleSize'],['Recruitment was very slow'],[True],['UnderpoweredStudy']
10477,PMC3590447,10450,"However, we believe that the trial results are still relevant, not least because few RCTs of drugs for this disease have been done, with none in the subset of patients with deteriorating excretory renal function.",Discussion,[64888],[27137],[27349],[False],[0],[0],[False],['0']
10478,PMC3590447,10451,"One aspect of the slow recruitment was the changes in methods that became established during the trial, both for estimation of excretory kidney function and assessment of proteinuria.",Discussion,"[64900, 64904]","[27350, 27350]","[27533, 27533]","[True, True]","['OutcomeMeasures', 'SampleSize']","['the changes in methods that became established during the trial', 'the slow recruitment']","[True, True]","['OutcomeMeasures', 'UnderpoweredStudy']"
10479,PMC3590447,10452,We used one consistent method for the calculation of primary endpoints.,Discussion,[64915],[27534],[27605],[False],[0],[0],[False],['0']
10480,PMC3590447,10453,We did not use gold-standard methods of measuring kidney function such as isotope clearance studies.,Discussion,[64928],[27606],[27706],[True],['ValidityOfMeasurement'],['We did not use gold-standard methods of measuring kidney function'],[True],['OutcomeMeasures']
10481,PMC3590447,10454,"These methods are expensive and invasive, and although our trial depended on estimations, we believe it is relevant to everyday clinical practice since we used standard estimation techniques that are used in nephrology practice worldwide.",Discussion,[64942],[27707],[27945],[False],[0],[0],[False],['0']
10482,PMC3590447,10455,"In this study we assessed ciclosporin monotherapy and noted that the drug's nephrotoxicity, even at blood concentrations advocated in a previous RCT, was harmful in the severely affected subset that we selected.",Discussion,[64951],[27946],[28157],[False],[0],[0],[False],['0']
10483,PMC3590447,10456,"Some physicians advocate use of ciclosporin together with prednisolone, but we know of no good evidence that this combination reduces renal toxicity.",Discussion,[64960],[28158],[28307],[False],[0],[0],[False],['0']
10484,PMC3590447,10457,"We need to follow up these patients for even longer to absolutely assess the value of the delay to end-stage renal disease that we noted in the prednisolone and chlorambucil group and to gather longer-term data for delayed adverse effects in the two intervention groups, especially lymphomas and other malignancies.",Discussion,[64969],[28308],[28623],[False],[0],[0],[False],['0']
10485,PMC3590447,10458,Trial profile,Discussion|Trial profile,[64978],[28624],[28637],[False],[0],[0],[False],['0']
10486,PMC3590447,10459,Kaplan-Meier analysis of further 20% decline in renal function,Discussion|Trial profile,[64987],[28638],[28700],[False],[0],[0],[False],['0']
10487,PMC3590447,10460,Deaths were censored.,Discussion|Trial profile,[64996],[28701],[28722],[False],[0],[0],[False],['0']
10488,PMC3590447,10461,GFR=glomerular filtration rate.,Discussion|Trial profile,[65005],[28723],[28754],[False],[0],[0],[False],['0']
10489,PMC3590447,10462,Change in measured or calculated 24-h urinary protein,Discussion|Trial profile,[65014],[28755],[28808],[False],[0],[0],[False],['0']
10490,PMC3590447,10463,Datapoints show mean change in 24-h urinary protein from baseline; error bars show 95% CI.,Discussion|Trial profile,[65023],[28809],[28899],[False],[0],[0],[False],['0']
10491,PMC3590447,10464,The numbers of patients from whom readings were taken at each timepoint are presented; variation in numbers was due to dropout and missing readings at those timepoints.,Discussion|Trial profile,[65032],[28900],[29068],[False],[0],[0],[False],['0']
10492,PMC3590447,10465,Baseline values,Discussion|Baseline values,[65041],[29069],[29084],[False],[0],[0],[False],['0']
10493,PMC3590447,10466,		Prednisolone and chlorambucil (n=33)	Ciclosporin (n=36)	Supportive therapy only (n=37)	 	Creatinine clearance (mL/min)	50 (16)	49 (18)	50 (20)	 	Systolic blood pressure (mm Hg)	141 (16)	143 (21)	138 (19)	 	Proteinuria (g per 24 h)	10·1 (5·3)	6·8 (4·7)	9·1 (5·3)	 	Age (years)	58 (12)	58 (11)	56 (16)	 	Time of baseline reading*	 		<2 weeks before randomisation	0	0	3 (8%)	 		>2 weeks after randomisation	11 (33%)	11 (31%)	1 (3%),Discussion|Baseline values,[65050],[29085],[29515],[False],[0],[0],[False],['0']
10494,PMC3590447,10467,Data are mean (SD) or number (%).,Discussion|Baseline values,[65059],[29516],[29552],[False],[0],[0],[False],['0']
10495,PMC3590447,10468,Baseline readings were taken at start of study treatment in the immunosuppressive treatment groups.,Discussion|Baseline values,[65068],[29553],[29652],[False],[0],[0],[False],['0']
10496,PMC3590447,10469,Serious adverse events by treatment and body system affected,Discussion|Baseline values,[65077],[29653],[29713],[False],[0],[0],[False],['0']
10497,PMC3590447,10470,		Prednisolone and chlorambucil	Ciclosporin	Supportive therapy only	 	Patients with at least one SAE*	20/33 (61%)	18/37 (49%)	16/38 (42%)	 	Number of SAEs†	56/117 (48%)	37/117 (32%)	24/117 (21%)	 	Likelihood to be related to treatment‡§	 		None/unlikely	20/56 (36%)	18/37 (49%)	24/24 (100%)	 		Possible	10/56 (18%)	6/37 (16%)	0	 		Likely	26/56 (46%)	13/37 (35%)	0	 	Body system affected	 		Haematological	28	5	3	 		Dermatological	4	2	0	 		Renal	1	5	2	 		Neurological	3	6	4	 		Cardiovascular	4	3	3	 		Metabolic	8	1	5	 		Gastroenterological	3	3	2	 		Infection	3	8	2	 		Other/not specified	2	4	3,Discussion|Baseline values,[65086],[29714],[30306],[False],[0],[0],[False],['0']
10498,PMC3590447,10471,"Data are number, or number (%).",Discussion|Baseline values,[65095],[30307],[30341],[False],[0],[0],[False],['0']
10499,PMC3590447,10472,SAE=serious adverse event.,Discussion|Baseline values,[65104],[30342],[30368],[False],[0],[0],[False],['0']
10500,PMC3590447,10473,Out of number of patients assigned to each treatment group; includes patients removed from the intention-to-treat analysis because they were deemed ineligible after randomisation.,Discussion|Baseline values,[65113],[30369],[30548],[False],[0],[0],[False],['0']
10501,PMC3590447,10474,Out of number of SAEs overall.,Discussion|Out of number of SAEs overall.,[65122],[30549],[30579],[False],[0],[0],[False],['0']
10502,PMC3590447,10475,Out of number of SAEs in each treatment group.,Discussion|Out of number of SAEs overall.,[65131],[30580],[30626],[False],[0],[0],[False],['0']
10503,PMC3590447,10476,Likelihood was assessed by PWM.,Discussion|Likelihood was assessed by PWM.,[65140],[30627],[30658],[False],[0],[0],[False],['0']
10504,PMC3590447,10477,Research in context,Discussion|Research in context,[65149],[30659],[30678],[False],[0],[0],[False],['0']
10505,PMC3590447,10478,Systematic review,Discussion|Systematic review,[65158],[30679],[30696],[False],[0],[0],[False],['0']
10506,PMC3590447,10479,"We searched Medline and PubMed for articles published in any language between Jan 1, 1960, and April 12, 2012, with the keywords “membranous nephropathy” or “membranous glomerulonephritis” and “treatment”, “trial”, and “randomised”.",Discussion|Systematic review,[65167],[30697],[30929],[False],[0],[0],[False],['0']
10507,PMC3590447,10480,The older scientific literature is best summarised in a 2004 Cochrane review and the current literature is well reviewed in a 2012 authoritative guideline on the treatment of glomerulonephritis.,Discussion|Systematic review,[65176],[30930],[31124],[False],[0],[0],[False],['0']
10508,PMC3590447,10481,Interpretation,Discussion|Interpretation,[65185],[31125],[31139],[False],[0],[0],[False],['0']
10509,PMC3590447,10482,This study is the first to focus on the important subset of patients with membranous nephropathy whose excretory renal function is deteriorating.,Discussion|Interpretation,[65194],[31140],[31285],[False],[0],[0],[False],['0']
10510,PMC3590447,10483,The results suggest that therapy with prednisolone and chlorambucil is better than with ciclosporin or supportive therapy alone.,Discussion|Interpretation,[65203],[31286],[31414],[False],[0],[0],[False],['0']
10511,PMC3590447,10484,"This patient population has serious morbidity, and the benefits of treatment need to be weighed against the adverse events.",Discussion|Interpretation,[65212],[31415],[31538],[False],[0],[0],[False],['0']
10512,PMC3590447,10485,"The protection of renal function offered by prednisolone and chlorambucil comes at a price, so this therapy needs to be closely monitored.",Discussion|Interpretation,[65221],[31539],[31677],[False],[0],[0],[False],['0']
11041,PMC3641012,16929,Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial,Title,[100142],[13196],[131],[False],[0],[0],[False],['0']
11042,PMC3641012,16930,Background,Abstract,[100150],[132],[143],[False],[0],[0],[False],['0']
11043,PMC3641012,16931,"Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown.",Abstract,[100158],[144],[330],[False],[0],[0],[False],['0']
11044,PMC3641012,16932,Methods,Methods,[100166],[331],[339],[False],[0],[0],[False],['0']
11045,PMC3641012,16933,We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of high-dose prenatal 3rd trimester vitamin D3 supplementation on maternal and neonatal (cord blood) serum 25-hydroxyvitamin D (25(OH)D) concentration (primary biochemical efficacy outcome) and maternal serum calcium concentration (primary safety measure).,Methods,[100174],[340],[683],[False],[0],[0],[False],['0']
11046,PMC3641012,16934,"Eligibility criteria were pregnant women aged 18 to <35 years, at 26 to 29 weeks gestation, and residing in Dhaka, Bangladesh.",Methods,[100182],[684],[810],[False],[0],[0],[False],['0']
11047,PMC3641012,16935,"160 women were randomized by 1:1 allocation to one of two parallel intervention groups; placebo (n = 80) or 35,000 IU/week of vitamin D3 (n = 80) until delivery.",Methods,[100190],[811],[972],[False],[0],[0],[False],['0']
11048,PMC3641012,16936,"All participants, study personnel and study investigators were blind to treatment allocation.",Methods,[100198],[973],[1066],[False],[0],[0],[False],['0']
11049,PMC3641012,16937,Results,Results,[100206],[1067],[1075],[False],[0],[0],[False],['0']
11050,PMC3641012,16938,"Mean maternal 25(OH)D concentration was similar in the vitamin D and placebo groups at baseline (45 vs. 44 nmol/L; p = 0.66), but was significantly higher in the vitamin D group vs. placebo group among mothers at delivery (134 vs. 38 nmol/L; p < 0.001) and newborns (cord blood: 103 vs. 39; p < 0.001).",Results,[100214],[1076],[1378],[False],[0],[0],[False],['0']
11051,PMC3641012,16939,"In the vitamin D group, 95% of neonates and 100% of mothers attained 25(OH)D >50 nmol/L, versus 21% mothers and 19% of neonates in the placebo group.",Results,[100222],[1379],[1528],[False],[0],[0],[False],['0']
11052,PMC3641012,16940,"No participants met criteria for hypercalcemia, there were no known supplement-related adverse events, and major pregnancy outcomes were similar between groups.",Results,[100230],[1529],[1689],[False],[0],[0],[False],['0']
11053,PMC3641012,16941,Conclusions,Conclusions,[100238],[1690],[1702],[False],[0],[0],[False],['0']
11054,PMC3641012,16942,"Antenatal 3rd-trimester vitamin D3 supplementation (35,000 IU/week) significantly raised maternal and cord serum 25(OH)D concentrations above 50 nmol/L in almost all participants without inducing hypercalcemia or other observed safety concerns.",Conclusions,[100246],[1703],[1947],[False],[0],[0],[False],['0']
11055,PMC3641012,16943,"Doses up to 35,000 IU/week may be cautiously used in further research aimed at establishing the clinical effects and safety of vitamin D3 supplementation in pregnancy.",Conclusions,[100254],[1948],[2115],[False],[0],[0],[False],['0']
11056,PMC3641012,16944,Trial registration,Trial registration,[100262],[2116],[2135],[False],[0],[0],[False],['0']
11057,PMC3641012,16945,This trial was registered at ClinicalTrials.gov (NCT01126528).,Trial registration,[100270],[2136],[2198],[False],[0],[0],[False],['0']
11058,PMC3641012,16946,Introduction,Introduction,[100278],[2199],[2213],[False],[0],[0],[False],['0']
11059,PMC3641012,16947,"Vitamin D status during pregnancy has been proposed to influence the risk of gestational diabetes and hypertensive diseases of pregnancy [1], fetal skeletal growth [2], brain development [3], and neonatal immune function [4].",Introduction,[100286],[2214],[2439],[False],[0],[0],[False],['0']
11060,PMC3641012,16948,"The major circulating vitamin D metabolite, 25-hydroxyvitamin D (25(OH)D), crosses the placenta from the maternal to the fetal circulation, thereby establishing fetal-neonatal vitamin D stores [5].",Introduction,[100294],[2440],[2637],[False],[0],[0],[False],['0']
11061,PMC3641012,16949,"However, the effects of vitamin D on maternal, placental or fetal tissues are uncertain [2], and the extent to which health outcomes are responsive to changes in maternal-fetal vitamin D status remains unknown [2,6,7].",Introduction,[100302],[2638],[2856],[False],[0],[0],[False],['0']
11062,PMC3641012,16950,"Currently, there is insufficient evidence to either support or refute the benefits of any given supplemental vitamin D dose during pregnancy [8,9].",Introduction,[100310],[2857],[3004],[False],[0],[0],[False],['0']
11063,PMC3641012,16951,"Moreover, the safety of high-dose prenatal vitamin D regimens (i.e., doses that substantially exceed the conventional prenatal intake of 400 to 600 IU/day) has yet to be established [6].",Introduction,[100318],[3005],[3191],[False],[0],[0],[False],['0']
11064,PMC3641012,16952,The Institute of Medicine (IOM) Committee to Review Dietary Reference Intakes (DRIs) for Vitamin D and Calcium concluded in 2010 that the recommended dietary allowance (RDA) of 600 IU/day and tolerable upper intake level (UL) of 4000 IU/day for non-pregnant adults were suitable for pregnant women [7].,Introduction,[100326],[3192],[3494],[False],[0],[0],[False],['0']
11065,PMC3641012,16953,"The UL was doubled from 2000 IU/day, as recommended by the IOM in 1997 [10], despite a lack of new pregnancy trial safety data published between 1997 and 2010.",Introduction,[100334],[3495],[3654],[False],[0],[0],[False],['0']
11066,PMC3641012,16954,"Uncertainty surrounding vitamin D requirements in pregnancy has led to divergent dose recommendations; for example, the UNICEF antenatal micronutrient formulation contains 200 IU/day [11], the Canadian Paediatric Society has suggested 2000 IU/day [12], and Hollis et al.",Introduction,[100342],[3655],[3925],[False],[0],[0],[False],['0']
11067,PMC3641012,16955,advised an intake of 4000 IU/day [13].,Introduction,[100350],[3926],[3964],[False],[0],[0],[False],['0']
11068,PMC3641012,16956,"Similarly, the 25(OH)D threshold to define vitamin D sufficiency is debated; the IOM set 50 nmol/L as a lower limit of sufficiency [7], yet other expert bodies such as the American Academy of Pediatrics have suggested that pregnant women attain serum 25(OH)D >80 nmol/L [14].",Introduction,[100358],[3965],[4240],[False],[0],[0],[False],['0']
11069,PMC3641012,16957,"Determination of the vitamin D intake level (and corresponding serum 25(OH)D concentration) that safely optimizes vitamin D-responsive maternal-infant health outcomes would have global implications, but may be particularly relevant to resource-poor communities in South Asia, where a relatively low prenatal vitamin D status overlaps with a high burden of morbidity and mortality associated with adverse birth and early infant health outcomes [15].",Introduction,[100366],[4241],[4689],[False],[0],[0],[False],['0']
11070,PMC3641012,16958,"In open-label pilot studies of high-dose vitamin supplementation in non-pregnant and pregnant women in Dhaka, Bangladesh, we showed that 35,000 IU/week was well tolerated and raised 25(OH)D to >80 nmol/L in pregnant women and newborns [16].",Introduction,[100374],[4690],[4930],[False],[0],[0],[False],['0']
11071,PMC3641012,16959,"To more rigorously establish the biochemical effects of this regimen, and to provide evidence for a UL in pregnancy, we conducted a randomized controlled trial (RCT) of 3rd-trimester vitamin D3 supplementation of 35,000 IU per week in Dhaka.",Introduction,[100382],[4931],[5172],[False],[0],[0],[False],['0']
11072,PMC3641012,16960,"The primary aim of the study was to evaluate the change in maternal and neonatal (cord blood) 25(OH)D concentration and effects on serum calcium concentration, and to generate preliminary data regarding pregnancy outcomes.",Introduction,[100390],[5173],[5395],[False],[0],[0],[False],['0']
11073,PMC3641012,16961,These data may serve to design larger RCTs to measure the effects of antenatal vitamin D supplementation on functional outcomes of clinical and public health importance.,Introduction,[100398],[5396],[5565],[False],[0],[0],[False],['0']
11074,PMC3641012,16962,Subjects and methods,Subjects and methods,[100406],[5566],[5587],[False],[0],[0],[False],['0']
11075,PMC3641012,16963,Study design and participants,Subjects and methods|Study design and participants,[100414],[5588],[5617],[False],[0],[0],[False],['0']
11076,PMC3641012,16964,"The Antenatal Vitamin D in Dhaka (AViDD) trial was a double-blind placebo-controlled RCT conducted in Dhaka, Bangladesh (23°N), through collaboration of the International Center for Diarrheal Disease Research, Bangladesh (icddr,b), The Johns Hopkins Bloomberg School of Public Health (Baltimore), and the Hospital for Sick Children (Toronto).",Subjects and methods|Study design and participants,[100422],[5618],[5960],[False],[0],[0],[False],['0']
11077,PMC3641012,16965,"Enrolment of 160 participants occurred from August 2010 to January 2011, and pregnancies were completed between September 2010 and April 2011.",Subjects and methods|Study design and participants,[100430],[5961],[6103],[False],[0],[0],[False],['0']
11078,PMC3641012,16966,"Participants were enrolled at the Shimantik Urban Primary Health Care Project maternity center, a non-governmental, non-profit facility that provides basic antenatal and obstetric services (including cesarean deliveries) in a low-income area of Dhaka (Khilgaon division).",Subjects and methods|Study design and participants,[100438],[6104],[6375],[False],[0],[0],[False],['0']
11079,PMC3641012,16967,"Participants were screened for eligibility when they presented to the clinic for antenatal care (ANC) visits during regular daytime clinic hours, and were offered enrolment if they met the following inclusion criteria: aged 18 to <35 years; gestational age of 26 to <30 weeks, estimated based on the first day of the last menstrual period (LMP); current residence in Dhaka at a fixed address; planned to deliver at the Shimantik maternity center, and to stay in Dhaka throughout the pregnancy and for at least one month past the date of delivery.",Subjects and methods|Study design and participants,[100446],[6376],[6922],[False],[0],[0],[False],['0']
11080,PMC3641012,16968,"Individuals were not eligible if they had any of the following exclusion criteria: use of any dietary supplement containing more than 400 IU/day (10 mcg/day) of vitamin D within the month prior to enrolment, or refusal to stop taking supplemental vitamin D at any dose after enrollment; current use of anti-convulsant or anti-mycobacterial (tuberculosis) medications; severe anemia (hemoglobin < 70 g/L); systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg; positive urine dipstick for proteinuria or glycosuria; complicated medical or obstetric history; or, reported prior history of delivery of an infant with a major congenital anomaly, birth asphyxia, or perinatal death.",Subjects and methods|Study design and participants,[100454],[6923],[7619],[False],[0],[0],[False],['0']
11081,PMC3641012,16969,Informed consent was obtained from all participants.,Subjects and methods|Study design and participants,[100462],[7620],[7672],[False],[0],[0],[False],['0']
11082,PMC3641012,16970,"The study was approved by ethical review boards at The Johns Hopkins Bloomberg School of Public Health, Hospital for Sick Children, and icddr,b.",Subjects and methods|Study design and participants,[100470],[7673],[7817],[False],[0],[0],[False],['0']
11083,PMC3641012,16971,The trial was registered at ClinicalTrials.gov (NCT01126528).,Subjects and methods|Study design and participants,[100478],[7818],[7879],[False],[0],[0],[False],['0']
11084,PMC3641012,16972,Intervention,Intervention,[100486],[7880],[7893],[False],[0],[0],[False],['0']
11085,PMC3641012,16973,"Participants were randomly assigned to one of two masked parallel intervention groups, with allocation concealment: vitamin D3 (cholecalciferol) 35,000 IU/week or matched placebo.",Intervention,[100494],[7894],[8073],[False],[0],[0],[False],['0']
11086,PMC3641012,16974,"The vitamin D3 was a high-concentration (20,000 IU D3 per mL) liquid formulation (Vigantol Oil, Merck KGaA, Germany), and the placebo was miglyol oil 812 (Sasol, Germany), the vehicle used in Vigantol Oil.",Intervention,[100502],[8074],[8279],[False],[0],[0],[False],['0']
11087,PMC3641012,16975,"Assignment was based on a computer-generated randomization list, with 1:1 allocation, using permuted blocks of size 4 and 8.",Intervention,[100510],[8280],[8404],[False],[0],[0],[False],['0']
11088,PMC3641012,16976,"The allocation sequence was prepared by icddr,b personnel not otherwise involved in the study, and was concealed from investigators.",Intervention,[100518],[8405],[8537],[False],[0],[0],[False],['0']
11089,PMC3641012,16977,Popular Pharmaceuticals Ltd. (Dhaka) prepared the supplements off-site using individual opaque glass vials labeled with unique participant identifiers based on the randomization list.,Intervention,[100526],[8538],[8721],[False],[0],[0],[False],['0']
11090,PMC3641012,16978,Vials were maintained at ambient temperature at the clinic throughout the study.,Intervention,[100534],[8722],[8802],[False],[0],[0],[False],['0']
11091,PMC3641012,16979,The active and placebo supplements were identical in appearance and tasteless.,Intervention,[100542],[8803],[8881],[False],[0],[0],[False],['0']
11092,PMC3641012,16980,Participants and research staff (including lab personnel) were blinded to allocation.,Intervention,[100550],[8882],[8967],[False],[0],[0],[False],['0']
11093,PMC3641012,16981,"Supplement doses were measured in disposable plastic syringes and orally administered by study personnel, beginning at the baseline visit and continuing thereafter at 7-day intervals until delivery.",Intervention,[100558],[8968],[9166],[False],[0],[0],[False],['0']
11094,PMC3641012,16982,"Missed doses could be administered up to 7 days after the scheduled date, but otherwise were skipped.",Intervention,[100566],[9167],[9268],[False],[0],[0],[False],['0']
11095,PMC3641012,16983,"Participants were advised to discontinue all other supplements containing vitamin D, and were offered prenatal iron and folic acid supplements (66 mg elemental iron and 350 mcg/day folic acid per day), routine antenatal monitoring, and obstetric care free of charge.",Intervention,[100574],[9269],[9535],[False],[0],[0],[False],['0']
11096,PMC3641012,16984,Data collection and laboratory analyses,Data collection and laboratory analyses,[100582],[9536],[9576],[False],[0],[0],[False],['0']
11097,PMC3641012,16985,"The baseline visit consisted of a detailed questionnaire, anthropometry, blood pressure measurement, specimen collection, and supplement administration.",Data collection and laboratory analyses,[100590],[9577],[9729],[False],[0],[0],[False],['0']
11098,PMC3641012,16986,"Thereafter, participants were contacted weekly at their homes or in the clinic for supplement administration and a questionnaire that included a checklist of symptoms related to pregnancy complications and hypo-/hypercalcemia.",Data collection and laboratory analyses,[100598],[9730],[9956],[False],[0],[0],[False],['0']
11099,PMC3641012,16987,"Random spot urine specimens were collected at baseline, 2 weeks post-enrolment, and delivery.",Data collection and laboratory analyses,[100606],[9957],[10050],[False],[0],[0],[False],['0']
11100,PMC3641012,16988,"Venous blood specimens were collected at baseline and once between gestational weeks 30 and 37 (the specific week was randomly varied among participants); these specimens were drawn immediately preceding the weekly vitamin D dose administration; a third specimen was collected around the time of delivery, irrespective of when the last vitamin D dose was received.",Data collection and laboratory analyses,[100614],[10051],[10415],[False],[0],[0],[False],['0']
11101,PMC3641012,16989,"Study personnel were on-call to attend deliveries at the maternity center, where they completed a delivery record and collected maternal and cord blood specimens.",Data collection and laboratory analyses,[100622],[10416],[10578],[False],[0],[0],[False],['0']
11102,PMC3641012,16990,A physician examined all infants within 2 days of birth.,Data collection and laboratory analyses,[100630],[10579],[10635],[False],[0],[0],[False],['0']
11103,PMC3641012,16991,"Newborn weight was measured with a digital scale (Seca 354, Seca Corporation, Hanover, USA), length was measured using a locally-manufactured wooden length board.",Data collection and laboratory analyses,[100638],[10636],[10798],[False],[0],[0],[False],['0']
11104,PMC3641012,16992,Anthropometric results were the averages of paired repeated measures.,Data collection and laboratory analyses,[100646],[10799],[10868],[False],[0],[0],[False],['0']
11105,PMC3641012,16993,"Maternal venous blood was collected into serum separator tubes by standard methods, and cord blood specimens were collected from the umbilical vein immediately after delivery of the placenta.",Data collection and laboratory analyses,[100654],[10869],[11060],[False],[0],[0],[False],['0']
11106,PMC3641012,16994,Maternal and cord serum samples were maintained at 4°C prior to same-day transfer to the laboratory.,Data collection and laboratory analyses,[100662],[11061],[11161],[False],[0],[0],[False],['0']
11107,PMC3641012,16995,"Serum aliquots were frozen at −20°C and shipped at ambient temperature from Bangladesh to Toronto for measurement of serum 25(OH)D concentration, a well-established biomarker of systemic vitamin D status [17].",Data collection and laboratory analyses,[100670],[11162],[11371],[False],[0],[0],[False],['0']
11108,PMC3641012,16996,"Serum 25(OH)D concentrations are unaffected by serum storage for several days at refrigerated or room temperatures [18,19], and 25(OH)D is resistant to multiple freeze-thaw cycles [18,20].",Data collection and laboratory analyses,[100678],[11372],[11560],[False],[0],[0],[False],['0']
11109,PMC3641012,16997,Serum 25(OH)D was quantified by high-performance liquid chromatography tandem mass spectroscopy (LC-MS/MS) in the Department of Pathology and Laboratory Medicine at the Hospital for Sick Children.,Data collection and laboratory analyses,[100686],[11561],[11757],[False],[0],[0],[False],['0']
11110,PMC3641012,16998,"Briefly, internal standards (50 μL, 10 μmol/L) were added to 200 μL of serum, calibrator and control samples.",Data collection and laboratory analyses,[100694],[11758],[11867],[False],[0],[0],[False],['0']
11111,PMC3641012,16999,Vitamin D metabolites were extracted from the samples with 4 mL of hexane/methanol (3:1).,Data collection and laboratory analyses,[100702],[11868],[11957],[False],[0],[0],[False],['0']
11112,PMC3641012,17000,"The excess solvent was evaporated to dryness under a stream of N  gas at 37°C, and the residue was re-dissolved in 100 μL of methanol and analyzed by LC-MS/MS.",Data collection and laboratory analyses,[100710],[11958],[12117],[False],[0],[0],[False],['0']
11113,PMC3641012,17001,"Vitamin D metabolites were separated on an Agilent 1100 series HPLC (Agilent Technologies, USA) and a C18 column.",Data collection and laboratory analyses,[100718],[12118],[12231],[False],[0],[0],[False],['0']
11114,PMC3641012,17002,"The isocratic mobile phase composition was A: 2 mmol/L ammonium acetate in H O + 0.1% formic acid, B: 2 mmol/L ammonium acetate in methanol + 0.1% formic acid (10:90).",Data collection and laboratory analyses,[100726],[12232],[12399],[False],[0],[0],[False],['0']
11115,PMC3641012,17003,"The API4000 QTRAP mass spectrometer (Applied Biosystems/Sciex, Concord, ON, Canada) was equipped with a TurboV electrospray ion source operated in the positive mode.",Data collection and laboratory analyses,[100734],[12400],[12565],[False],[0],[0],[False],['0']
11116,PMC3641012,17004,"The ion transition of m/z 401.4→159.2 was monitored for 25-hydroxyvitamin D , m/z 407.3→158.9 for D -25-hydroxyvitamin D  and m/z 413.4→107.2 for 25-hydroxyvitamin D ; however, none of the samples were found to contain detectable 25(OH)D2.",Data collection and laboratory analyses,[100742],[12566],[12805],[False],[0],[0],[False],['0']
11117,PMC3641012,17005,This assay met the performance targets of the international Vitamin D External Quality Assessment Scheme (DEQAS) [21].,Data collection and laboratory analyses,[100750],[12806],[12924],[False],[0],[0],[False],['0']
11118,PMC3641012,17006,"In a quality control subsample, between-run correlation was 0.95 and the mean coefficient of variation (CV%) was 9.9%.",Data collection and laboratory analyses,[100758],[12925],[13043],[False],[0],[0],[False],['0']
11119,PMC3641012,17007,Data were reported using 30 nmol/L and 50 nmol/L cut-offs used in the IOM report [7] and the 80 nmol/L threshold used in the Hollis trial [13].,Data collection and laboratory analyses,[100766],[13044],[13187],[False],[0],[0],[False],['0']
11120,PMC3641012,17008,"Serum/urine aliquots were maintained at 4°C and analyzed within 48 hours of collection for serum calcium, serum albumin, and urine calcium:creatinine ratio (ca:cr) on the AU640 Olympus Autoanalyzer (Olympus Corporation, Japan) in the Clinical Biochemistry Laboratory at icddr,b in Dhaka.",Data collection and laboratory analyses,[100774],[13188],[13475],[False],[0],[0],[False],['0']
11121,PMC3641012,17009,Total serum calcium (Ca) concentration was adjusted for the serum albumin concentration by the following conventional formula: Ca + (0.02*(40-albumin)).,Data collection and laboratory analyses,[100782],[13476],[13628],[False],[0],[0],[False],['0']
11122,PMC3641012,17010,"Intact parathyroid hormone (PTH) was measured at baseline and delivery using a chemiluminescent microparticle immune assay (i1000SR Architect Autoanalyzer, Abbott, USA) at icddr,b.",Data collection and laboratory analyses,[100790],[13629],[13809],[False],[0],[0],[False],['0']
11123,PMC3641012,17011,Safety monitoring,Safety monitoring,[100798],[13810],[13828],[False],[0],[0],[False],['0']
11124,PMC3641012,17012,"Reported severe symptoms, persistence of any mild symptomatic complaints for two consecutive visits, abnormal urinalyses, hypertension, or any other suspected pregnancy complications prompted referral by study personnel to the study physician for further evaluation.",Safety monitoring,[100806],[13829],[14095],[False],[0],[0],[False],['0']
11125,PMC3641012,17013,Biochemical data were reviewed daily by the study physician and at least weekly by the principal investigator.,Safety monitoring,[100814],[14096],[14206],[False],[0],[0],[False],['0']
11126,PMC3641012,17014,"The upper limit of the serum calcium reference range used for safety monitoring was 2.60 mmol/L, which was conservative relative to the threshold for defining hypercalcemia used by the IOM in setting the 1997 DRIs for vitamin D (2.75 mmol/L) [10], and the threshold cited by the IOM committee in its 2010 revision of the vitamin D DRIs (2.63 mmol/L) [7].",Safety monitoring,[100822],[14207],[14561],[False],[0],[0],[False],['0']
11127,PMC3641012,17015,Albumin-adjusted serum calcium concentration (adj-Ca) above 2.60 mmol/L prompted repeat blood sampling within 24 hours of the first sample report to the physician.,Safety monitoring,[100830],[14562],[14725],[False],[0],[0],[False],['0']
11128,PMC3641012,17016,"‘Confirmed hypercalcemia’, the primary supplement-related adverse event which would have prompted cessation of supplementation, was a priori defined as adj-Ca >2.60 mmol/L on two separate consecutive blood specimens.",Safety monitoring,[100838],[14726],[14942],[False],[0],[0],[False],['0']
11129,PMC3641012,17017,This definition was used because isolated values slightly above the upper limit of the reference range were not considered to be consistent with vitamin D toxicity.,Safety monitoring,[100846],[14943],[15107],[False],[0],[0],[False],['0']
11130,PMC3641012,17018,"Urine ca:cr was expressed as mmol Ca/mmol Cr, considering 1.0 as the upper limit of the reference range [22].",Safety monitoring,[100854],[15108],[15217],[False],[0],[0],[False],['0']
11131,PMC3641012,17019,"Urine ca:cr was used as a screening test for possible hypercalcemia, such that unscheduled blood sampling to measure serum calcium concentration was performed if: two consecutive ca:cr > 1.0 mmol/mmol values; or, ca:cr > 1.0 mmol/mmol on two non-consecutive measurements but in the presence of persistent symptoms suggestive of possible hypercalcemia; or, ca:cr > 0.85 mmol/mmol on two consecutive urine specimens that was also ≥2-fold greater than the baseline value in the same participant.",Safety monitoring,[100862],[15218],[15710],[False],[0],[0],[False],['0']
11132,PMC3641012,17020,Participants with screen-positive urine ca:cr as defined by one of the above three criteria were also referred for renal ultrasound to rule-out the presence of nephrocalcinosis or urinary tract calculi.,Safety monitoring,[100870],[15711],[15913],[False],[0],[0],[False],['0']
11133,PMC3641012,17021,"Participants were referred to an antenatal care physician at the maternity clinic for treatment of urinary tract infections, hypertension, or other medical problems diagnosed incidentally during follow-up.",Safety monitoring,[100878],[15914],[16119],[False],[0],[0],[False],['0']
11134,PMC3641012,17022,Participants with obstetric or neonatal complications were transported to a local tertiary-care hospital.,Safety monitoring,[100886],[16120],[16225],[False],[0],[0],[False],['0']
11135,PMC3641012,17023,"Major clinical decisions (e.g., labour induction, cesarean deliveries) were the responsibility of non-study physicians at Shimantik or referral hospitals; however, costs of medical and obstetric care were borne by the study.",Safety monitoring,[100894],[16226],[16450],[False],[0],[0],[False],['0']
11136,PMC3641012,17024,"A data and safety monitoring board (DSMB) met at regular intervals, but there were no a priori early stopping criteria (see Additional file 1 for a note regarding an interim DSMB review).",Safety monitoring,[100902],[16451],[16638],[False],[0],[0],[False],['0']
11137,PMC3641012,17025,Statistical analysis,Statistical analysis,[100910],[16639],[16660],[False],[0],[0],[False],['0']
11138,PMC3641012,17026,The primary pharmacokinetic outcome was the serum 25(OH)D concentration and the primary safety measure was adj-Ca concentration.,Statistical analysis,[100918],[16661],[16789],[False],[0],[0],[False],['0']
11139,PMC3641012,17027,"The primary analysis employed an intention-to-treat approach, including all data irrespective of a participant’s adherence or duration of supplementation.",Statistical analysis,[100926],[16790],[16944],[False],[0],[0],[False],['0']
11140,PMC3641012,17028,"Data were visualized using cross-sectional density plots and longitudinal scatterplots with locally weighted regression (lowess), and described by means, standard deviations (SD) and 95% confidence intervals (95% CI), or median and interquartile range (IQR) for variables with skewed distributions.",Statistical analysis,[100934],[16945],[17243],[False],[0],[0],[False],['0']
11141,PMC3641012,17029,Analyses at 'delivery' were based on specimens collected within +/− 1 day of delivery.,Statistical analysis,[100942],[17244],[17330],[False],[0],[0],[False],['0']
11142,PMC3641012,17030,Urinary ca:cr at two weeks after enrollment was based on specimens collected 14 +/−1 days after the first supplement dose.,Statistical analysis,[100950],[17331],[17453],[False],[0],[0],[False],['0']
11143,PMC3641012,17031,"Between-group differences in the mean maternal and cord serum 25(OH)D, maternal Ca, adj-Ca, and PTH, and maternal urinary ca:cr were analyzed at baseline and delivery using linear regression for cross-sectional comparisons and generalized estimating equations (GEE) for between-group differences in changes from baseline to delivery (to account for within-person correlation of paired measures).",Statistical analysis,[100958],[17454],[17849],[False],[0],[0],[False],['0']
11144,PMC3641012,17032,"PTH and urinary ca:cr were log and square-root transformed, respectively, to approximate normality for parametric tests.",Statistical analysis,[100966],[17850],[17970],[False],[0],[0],[False],['0']
11145,PMC3641012,17033,Bootstrapping was employed to confirm the robustness of inferences.,Statistical analysis,[100974],[17971],[18038],[False],[0],[0],[False],['0']
11146,PMC3641012,17034,"In per-protocol sensitivity analyses, we only included participants who received at least 8 consecutive weekly supplement doses and for whom delivery serum specimens were available.",Statistical analysis,[100982],[18039],[18220],[False],[0],[0],[False],['0']
11147,PMC3641012,17035,Change in mean 25(OH)D over time was modeled as a continuous non-linear parametric function using a negative exponential growth function [16].,Statistical analysis,[100990],[18221],[18363],[False],[0],[0],[False],['0']
11148,PMC3641012,17036,"This approach enabled the estimation of the average difference in 25(OH)D between the two groups at a presumed ‘steady-state’ (i.e., where group-averaged 25(OH)D did not continue to appreciably rise despite ongoing vitamin D supplementation).",Statistical analysis,[100998],[18364],[18606],[False],[0],[0],[False],['0']
11149,PMC3641012,17037,"As a per-protocol sensitivity analysis, change in mean 25(OH)D over time was modeled as a function of cumulative dose (micrograms) of vitamin D actually administered.",Statistical analysis,[101006],[18607],[18773],[False],[0],[0],[False],['0']
11150,PMC3641012,17038,"Changes in serum Ca, adj-Ca, ca:cr, and PTH concentrations were modeled longitudinally using GEE with exchangeable correlation and robust variance estimation.",Statistical analysis,[101014],[18774],[18932],[False],[0],[0],[False],['0']
11151,PMC3641012,17039,"Serum Ca, adj-Ca and urine ca:cr demonstrated non-linear trends over time in visual analysis by lowess plots; therefore, piecewise (spline) linear regressions were employed, with knot placement (the point on the x-axis where the piecewise regression functions join) for ca:cr ratio at day 14 (timing of scheduled urine collection) and at day 60 for serum Ca and adj-Ca.",Statistical analysis,[101022],[18933],[19302],[False],[0],[0],[False],['0']
11152,PMC3641012,17040,Knot placement was based on visual assessment of the trend indicated by the lowess functions.,Statistical analysis,[101030],[19303],[19396],[False],[0],[0],[False],['0']
11153,PMC3641012,17041,"In sensitivity analyses, variation in knot placement did not change the inferences of the model coefficients (data not shown).",Statistical analysis,[101038],[19397],[19523],[False],[0],[0],[False],['0']
11154,PMC3641012,17042,Clinical outcomes were compared between groups using Student’s t-test or Chi-square and Fischer’s exact test.,Statistical analysis,[101046],[19524],[19633],[False],[0],[0],[False],['0']
11155,PMC3641012,17043,"Frequencies of reported symptoms or minor clinical adverse events, based on weekly clinical monitoring, were analyzed using GEE where appropriate to estimate between-group differences.",Statistical analysis,[101054],[19634],[19818],[False],[0],[0],[False],['0']
11156,PMC3641012,17044,"Given the large number of individual symptoms, the Holm procedure was used to correct for multiplicity of pair-wise comparisons [23].",Statistical analysis,[101062],[19819],[19952],[False],[0],[0],[False],['0']
11157,PMC3641012,17045,Data were entered in an electronic database (SQL Server 2005) using a custom-designed interface (Visual Basic 6).,Statistical analysis,[101070],[19953],[20066],[False],[0],[0],[False],['0']
11158,PMC3641012,17046,Built-in range and consistency checks were employed in the data capture system to prevent errors in data entry.,Statistical analysis,[101078],[20067],[20178],[False],[0],[0],[False],['0']
11159,PMC3641012,17047,"Analyses were conducted using Stata version 11 (Stata Corporation, College Station, Texas) and R version 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria).",Statistical analysis,[101086],[20179],[20349],[False],[0],[0],[False],['0']
11160,PMC3641012,17048,"The target sample size was 160 pregnant women, to enable detection of a 0.5 SD difference in the primary outcome (serum 25(OH)D concentration at delivery), with a risk of a type I error rate (alpha) of 0.05, 80% power, and accounting for up to 20% attrition prior to delivery.",Statistical analysis,[101094],[20350],[20626],[False],[0],[0],[False],['0']
11161,PMC3641012,17049,Results,Results,[101102],[20627],[20635],[False],[0],[0],[False],['0']
11162,PMC3641012,17050,"Of the 160 participants recruited and randomly assigned to either vitamin D (35,000 IU/week) or placebo, 13 were lost to follow-up prior to delivery (6 in the placebo group and 7 in the Vitamin D group), all because of having left the Dhaka area (Figure 1).",Results,[101110],[20636],[20893],[False],[0],[0],[False],['0']
11163,PMC3641012,17051,"Serum specimens were available for all participants at baseline and for 130 (81.3%) participants (63 placebo, 67 vitamin D) at delivery.",Results,[101118],[20894],[21030],[False],[0],[0],[False],['0']
11164,PMC3641012,17052,"Cord blood specimens were collected from 67 and 65 mother-infant pairs in the placebo and vitamin D groups, respectively.",Results,[101126],[21031],[21152],[False],[0],[0],[False],['0']
11165,PMC3641012,17053,Maternal characteristics and 25(OH)D at baseline were similar in the placebo and vitamin D groups (Tables 1 and 2).,Results,[101134],[21153],[21268],[False],[0],[0],[False],['0']
11166,PMC3641012,17054,"Weekly supplementation occurred over a median period of approximately 10 weeks in both groups, and adherence was excellent among participants who contributed biochemical outcome data (Table 3).",Results,[101142],[21269],[21462],[False],[0],[0],[False],['0']
11167,PMC3641012,17055,Most participants in both groups were vitamin D insufficient by the IOM threshold (25(OH)D <50 nmol/L) at baseline (Table 2).,Results,[101150],[21463],[21588],[False],[0],[0],[False],['0']
11168,PMC3641012,17056,"Vitamin D status at baseline did not differ between the supplementation groups (Table 4) nor between participants with and without delivery specimens (44.5 vs. 44.8 nmol/L, p = 0.94).",Results,[101158],[21589],[21772],[False],[0],[0],[False],['0']
11169,PMC3641012,17057,"Vitamin D supplementation had a substantial, statistically significant effect on maternal and neonatal vitamin D status at the time of delivery, as reflected in the overall 25(OH)D distributions (Figure 2; Table 4) as well as the proportion of participants considered to have low 25(OH)D using cut-offs (Table 2).",Results,[101166],[21773],[22086],[False],[0],[0],[False],['0']
11170,PMC3641012,17058,"Notably, 100% of mothers (at delivery) and 95% of neonates attained 25(OH)D >50 nmol/L compared to only 21% and 19% of mother and neonates, respectively, in the placebo group (Table 2).",Results,[101174],[22087],[22272],[False],[0],[0],[False],['0']
11171,PMC3641012,17059,"The highest 25(OH)D value in any participant was 200 nmol/L, observed in a vitamin D group participant at delivery; concurrently, her other biochemistry were normal (adj-Ca, 2.47 mmol/L; urine ca:cr, 0.23 mmol/mmol).",Results,[101182],[22273],[22489],[False],[0],[0],[False],['0']
11172,PMC3641012,17060,"Longitudinal analysis of the change in mean 25(OH)D over time revealed an early and rapid rise in 25(OH)D, with a steady-state approached after about 2 months of supplementation (Figure 3; Table 5).",Results,[101190],[22490],[22688],[False],[0],[0],[False],['0']
11173,PMC3641012,17061,"As evidence that this plateau was not an artifact of diminishing supplement adherence over time, a sensitivity analysis in which 25(OH)D was modeled as a function of cumulative vitamin D dose revealed the same pattern (Figure 3), and fit the data well (Table 5).",Results,[101198],[22689],[22951],[False],[0],[0],[False],['0']
11174,PMC3641012,17062,"Vitamin D status declined in the placebo group over time (Figure 3), but was not significantly lower at delivery compared to baseline (38.3 vs. 44.0, p = 0.09).",Results,[101206],[22952],[23112],[False],[0],[0],[False],['0']
11175,PMC3641012,17063,"Given the substantial inter-individual variability in the response to vitamin D supplementation (Figure 3), we explored the role of the following potential modifiers of the magnitude of the change in 25(OH)D (Δ25(OH)D) from baseline to delivery (selected a priori): maternal weight at baseline, maternal age, gestational age, maternal body mass index at baseline (BMI), gravidity, parity, baseline PTH status, season and baseline vitamin D status.",Results,[101214],[23113],[23560],[False],[0],[0],[False],['0']
11176,PMC3641012,17064,None of these factors explained significant inter-individual variability in the change in 25(OH)D status (data not shown).,Results,[101222],[23561],[23683],[False],[0],[0],[False],['0']
11177,PMC3641012,17065,"Although Δ25(OH)D was inversely associated with baseline vitamin D status, and about 24% of the variance in Δ25(OH)D in the vitamin D group was explained by baseline 25(OH)D, this association appeared to be due to regression to the mean, since similar trends were observed in both the vitamin D and placebo groups.",Results,[101230],[23684],[23998],[False],[0],[0],[False],['0']
11178,PMC3641012,17066,"As expected, we found a strong correlation between maternal delivery and cord 25(OH)D (Pearson correlation = 0.87, p < 0.001), yet there was substantial variability among mother-infant pairs with respect to the cord-to-maternal ratio (ranged from 0.24 to 3.93).",Results,[101238],[23999],[24260],[False],[0],[0],[False],['0']
11179,PMC3641012,17067,"Notably, variation in cord 25(OH)D within the vitamin D group was not associated with duration of supplementation (p = 0.86) or cumulative vitamin D supplement dose administered (p = 0.93), indicating that the maternal-fetal vitamin D equilibrium was achieved rapidly.",Results,[101246],[24261],[24529],[False],[0],[0],[False],['0']
11180,PMC3641012,17068,"Mean maternal adj-Ca concentration rose over time within the reference range; the initial rate of rise appeared to be greater in the vitamin D group, but the difference was attenuated after ~2 months of supplementation (Figure 4).",Results,[101254],[24530],[24760],[False],[0],[0],[False],['0']
11181,PMC3641012,17069,The mean adj-Ca at delivery and the change in this parameter from baseline to delivery were slightly but significantly greater in the vitamin D group versus placebo (Table 4; Figure 5).,Results,[101262],[24761],[24946],[False],[0],[0],[False],['0']
11182,PMC3641012,17070,"Conversely, the between-group differences in the mean total unadjusted serum Ca concentration at delivery and the change from baseline to delivery were of lower magnitude and not significant (Table 4).",Results,[101270],[24947],[25148],[False],[0],[0],[False],['0']
11183,PMC3641012,17071,"There were no cases of hypercalcemia in either group, defined a priori as adj-Ca >2.60 nmol/L on two separate consecutive blood specimens.",Results,[101278],[25149],[25287],[False],[0],[0],[False],['0']
11184,PMC3641012,17072,"One participant in the vitamin D group exhibited an isolated adj-Ca value of 2.62 mmol/L at the time of delivery, in the context of an acute diarrheal illness.",Results,[101286],[25288],[25447],[False],[0],[0],[False],['0']
11185,PMC3641012,17073,"Repeat measurements were 2.45 mmol/L on both days 3 and 12 postpartum (see Additional file 2: Table S3 for biochemical adverse events at any time during follow-up); therefore, trial criteria for hypercalcemia were not met.",Results,[101294],[25448],[25670],[False],[0],[0],[False],['0']
11186,PMC3641012,17074,"This participant’s unadjusted total serum Ca measurements were 2.48 mmol/L at delivery, 2.19 mmo/L at 3 days postpartum, and 2.41 mmol/L at 12 days postpartum.",Results,[101302],[25671],[25830],[False],[0],[0],[False],['0']
11187,PMC3641012,17075,Her calcium:creatinine ratio ranged from 0.02 to 0.22 mmol/mmol and 25(OH)D ranged from 22 to 118 nmol/L.,Results,[101310],[25831],[25936],[False],[0],[0],[False],['0']
11188,PMC3641012,17076,"In secondary post-hoc analyses using all maternal serum specimens in which 25(OH)D and calcium were measured simultaneously, adj-Ca was significantly associated with 25(OH)D at 25(OH)D < 100 nmol/L (0.02 mmol/L [95% CI: 0.01, 0.03] increase in adj-Ca per 25 nmol/L increase in 25(OH)D below 100 nmol/L; n = 331), but this association was nullified and non-significant at 25(OH)D > =100 nmol/L (−0.01 mmol/L [95% CI: -0.02, 0.01] per 25 nmol/L increase in 25(OH)D above 100 nmol/L; n = 102).",Results,[101318],[25937],[26427],[False],[0],[0],[False],['0']
11189,PMC3641012,17077,"Urinary ca:cr rose marginally in both groups after the first two weeks of supplementation, but declined thereafter (Figure 4).",Results,[101326],[26428],[26554],[False],[0],[0],[False],['0']
11190,PMC3641012,17078,"Changes over time were similar in both groups (Figure 4), and there were no significant differences in ca:cr between the two groups at delivery (Table 4; Figure 5).",Results,[101334],[26555],[26719],[False],[0],[0],[False],['0']
11191,PMC3641012,17079,"Hypercalciuria, defined a priori as ca:cr >1.0 mmol/mmol on 2 consecutive separate occasions, occurred in one participant in the vitamin D group, at 29 weeks gestation on day 14 of follow-up.",Results,[101342],[26720],[26911],[False],[0],[0],[False],['0']
11192,PMC3641012,17080,"Ca:cr was 1.08 mmol/mmol on day 14 and 1.11 mmol/mmol on day 16, but was normal at delivery (0.23 mmol/mmol) after continuation of vitamin D supplementation for a total of 10 weeks (cumulative dose of 9625 mcg).",Results,[101350],[26912],[27123],[False],[0],[0],[False],['0']
11193,PMC3641012,17081,"Throughout follow-up, this participant’s adj-Ca was within the reference range (2.32 to 2.55 mmol/L) and 25(OH)D concentration ranged from 54 – 147 nmol/L.",Results,[101358],[27124],[27279],[False],[0],[0],[False],['0']
11194,PMC3641012,17082,"A renal ultrasound showed an absence of nephrocalcinosis or renal calculi, and there were no associated clinical consequences.",Results,[101366],[27280],[27406],[False],[0],[0],[False],['0']
11195,PMC3641012,17083,"Transient hypercalciuria, defined as one ca:cr measurement above 1.0 mmol/mmol, was observed in 3 (4.1%) participants in the placebo group and 4 (5.5%) in the vitamin D group (p = 0.72 for between-group difference).",Results,[101374],[27407],[27622],[False],[0],[0],[False],['0']
11196,PMC3641012,17084,"Similarly, the proportion of participants with a ca:cr >0.8 mmol/mmol and >2-fold difference from baseline did not differ significantly between the two groups (2.7% vs. 5.5%, p = 0.44).",Results,[101382],[27623],[27808],[False],[0],[0],[False],['0']
11197,PMC3641012,17085,"Vitamin D supplementation had a significant suppressive effect on maternal PTH concentration, such that the rise in PTH observed in the placebo group was completely attenuated in the vitamin D group (Figure 4), and the average PTH concentration was lower in the vitamin D group at delivery (Figure 2; Table 4).",Results,[101390],[27809],[28119],[False],[0],[0],[False],['0']
11198,PMC3641012,17086,Detailed weekly clinical monitoring did not reveal significant differences in reported symptom or minor adverse event frequencies between the two groups (online supplemental material).,Results,[101398],[28120],[28304],[False],[0],[0],[False],['0']
11199,PMC3641012,17087,"In particular, the overall proportion of encounters in which there was at least one symptom possibly suggestive of hypercalcemia was similar for the placebo and vitamin D groups (54% vs. 53%, p = 0.71; analysis accounted for repeated events within the same participants).",Results,[101406],[28305],[28576],[False],[0],[0],[False],['0']
11200,PMC3641012,17088,Major pregnancy/birth outcome and serious clinical adverse event frequencies and distributions were similar across the two groups (Table 6).,Results,[101414],[28577],[28717],[False],[0],[0],[False],['0']
11201,PMC3641012,17089,Discussion,Discussion,[101422],[28718],[28729],[False],[0],[0],[False],['0']
11202,PMC3641012,17090,"Among pregnant women with relatively low average baseline vitamin D status in Dhaka, 3rd-trimester vitamin D3 supplementation (35,000 IU/week) significantly raised maternal and neonatal (cord blood) serum 25(OH)D concentrations above the IOM cut-off for sufficiency (50 nmol/L) in virtually all participants without inducing hypercalcemia or other apparent short-term clinical adverse effects.",Discussion,[101430],[28730],[29123],[False],[0],[0],[False],['0']
11203,PMC3641012,17091,"This study contributes pharmacokinetic data relevant to South Asia, as well as preliminary evidence in support of a vitamin D3 no observed adverse effect level (NOAEL) of 35,000 IU/week in the third trimester of pregnancy.",Discussion,[101438],[29124],[29346],[False],[0],[0],[False],['0']
11204,PMC3641012,17092,The present findings build primarily on those of Hollis et al.,Discussion,[101446],[29347],[29409],[False],[0],[0],[False],['0']
11205,PMC3641012,17093,"in South Carolina, who randomized 502 pregnant women at 12 to 16 weeks gestation to receive vitamin D3 at doses of 400 IU/day, 2000 IU/day, or 4000 IU/day; 350 participants (70%) were followed-up until delivery [13].",Discussion,[101454],[29410],[29626],[False],[0],[0],[False],['0']
11206,PMC3641012,17094,"From a baseline 25(OH)D of 58 nmol/L, 2000 IU/day and 4000 IU/day raised 25(OH)D to means at the time of delivery of 98 nmol/L (rise of 40 nmol/L) and 111 nmol/L (rise of 52 nmol/L), respectively [13].",Discussion,[101462],[29627],[29828],[False],[0],[0],[False],['0']
11207,PMC3641012,17095,"In the 4000 IU/day group, 82% attained 80 nmol/L at delivery, compared to 97% in the present study (5000 IU/day).",Discussion,[101470],[29829],[29942],[False],[0],[0],[False],['0']
11208,PMC3641012,17096,"In 2012, Dawodu et al.",Discussion,[101478],[29943],[29965],[False],[0],[0],[False],['0']
11209,PMC3641012,17097,"presented unpublished findings from a trial in United Arab Emirates in which 2000 IU/day and 4000 IU/day raised mean 25(OH)D from ~20 nmol/L to ~65 nmol/L (rise of 45 nmol/L) and ~90 nmol/L (rise of 70 nmol/L) at delivery, respectively [24].",Discussion,[101486],[29966],[30207],[False],[0],[0],[False],['0']
11210,PMC3641012,17098,"Our modeled mean increment in maternal 25(OH)D of 102 nmol/L corresponded to a rise of 0.82 nmol/L/mcg/day (95% CI, 0.72 to 0.91), which was similar to the value often cited for non-pregnant adults (~0.7 nmol/L/mcg/day [25,26]) but smaller than the effect observed with lower vitamin D3 doses (e.g., 1.6 nmol/L/mcg/day for doses of ~800 IU/day [27]).",Discussion,[101494],[30208],[30558],[False],[0],[0],[False],['0']
11211,PMC3641012,17099,This is consistent with the hypothesized constraint in hepatic vitamin D–to–25(OH)D conversion that occurs at a 25(OH)D concentration of about 80–90 nmol/L [28].,Discussion,[101502],[30559],[30720],[False],[0],[0],[False],['0']
11212,PMC3641012,17100,"In a preceding pilot trial in Dhaka, we found that 3rd-trimester regimens of 14,000 IU/week (≈2000 IU/day) and 35,000 IU/week (≈5000 IU/day) led to mean 25(OH)D concentrations of 76 nmol/L (rise of 36 nmol/L) and 98 nmol/L (rise of 57 nmol/L), respectively, after 10 weeks of supplementation [16].",Discussion,[101510],[30721],[31018],[False],[0],[0],[False],['0']
11213,PMC3641012,17101,"Thus, compared to the present study, the average response to 35,000 IU/week was less pronounced in the pilot study.",Discussion,[101518],[31019],[31134],[False],[0],[0],[False],['0']
11214,PMC3641012,17102,"However, direct between-study comparisons are tempered by differences in study design (e.g., shorter period of follow-up in the pilot study) and 25(OH)D assays.",Discussion,[101526],[31135],[31295],[False],[0],[0],[False],['0']
11215,PMC3641012,17103,"In comparison to the LC-MS/MS method used here, the immunoassay used in the pilot study (Diasorin Liaison Total) may have under-estimated 25(OH)D because of raised DBP concentrations in pregnancy [29] or relative imprecision at the higher 25(OH)D range attained in the vitamin D group [30,31].",Discussion,[101534],[31296],[31589],[False],[0],[0],[False],['0']
11216,PMC3641012,17104,"Similar to previous trials [13,16], we observed substantial inter-individual variability in the maternal Δ25(OH)D, such that the SD on the mean 25(OH)D nearly doubled from 18.4 nmol/L at baseline to 30.7 nmol/L at delivery in the vitamin D group; in contrast, in the placebo group, the SD at baseline was 20.1 nmol/L and at delivery was 18.1 nmol/L.",Discussion,[101542],[31590],[31939],[False],[0],[0],[False],['0']
11217,PMC3641012,17105,"However, we could not identify any participant factor other than intervention group that significantly explained Δ25(OH)D. The range of published mean cord blood 25(OH)D concentrations in South Asia, from 21 [32] to 59 [33] nmol/L, bounds the mean cord 25(OH)D of 39 nmol/L in the control group.",Discussion,[101550],[31940],[32235],[False],[0],[0],[False],['0']
11218,PMC3641012,17106,"A normal cord 25(OH)D range based on functional outcomes has not been defined; however, Zeghoud et al.",Discussion,[101558],[32236],[32338],[False],[0],[0],[False],['0']
11219,PMC3641012,17107,"(1997) reported that newborn 25(OH)D > 30 nmol/L was associated with suppression of PTH concentrations [34], and 25(OH)D > 50 nmol/L (the 25(OH)D threshold for sufficiency set by the IOM) has been associated with a low risk of rickets [35].",Discussion,[101566],[32339],[32579],[False],[0],[0],[False],['0']
11220,PMC3641012,17108,"In our study, 95% of newborns had a cord-maternal 25(OH)D ratio of 0.5 to 1.5, suggesting that universal maternal prenatal 25(OH)D > 100 nmol/L would ensure that nearly all cord concentrations are above 50 nmol/L.",Discussion,[101574],[32580],[32793],[False],[0],[0],[False],['0']
11221,PMC3641012,17109,We remain guarded in our interpretation of these pharmacokinetic data because the clinical implications of the observed changes in maternal-fetal 25(OH)D and resultant maternal PTH suppression in pregnancy remain to be defined.,Discussion,[101582],[32794],[33021],[False],[0],[0],[False],['0']
11222,PMC3641012,17110,Hollis et al.,Discussion,[101590],[33022],[33035],[False],[0],[0],[False],['0']
11223,PMC3641012,17111,concluded from their trial findings “that the current vitamin D EAR and RDA for pregnant women issued in 2010 by the IOM should be raised to 4000 IU of vitamin D per day” [13].,Discussion,[101598],[33036],[33212],[False],[0],[0],[False],['0']
11224,PMC3641012,17112,"However, we do not believe that above-RDA doses should yet be recommended as routine practice.",Discussion,[101606],[33213],[33307],[False],[0],[0],[False],['0']
11225,PMC3641012,17113,Further clinical data are required before conclusive statements can be made regarding the appropriateness of high-dose antenatal vitamin D supplementation.,Discussion,[101614],[33308],[33463],[False],[0],[0],[False],['0']
11226,PMC3641012,17114,"However, like Hollis et al., we did not encounter any evidence of vitamin D toxicity.",Discussion,[101622],[33464],[33549],[False],[0],[0],[False],['0']
11227,PMC3641012,17115,"Vitamin D did not affect average urinary calcium excretion, yet we did see a small but significant increase in the mean adj-Ca in the vitamin D group compared to the placebo group.",Discussion,[101630],[33550],[33730],[False],[0],[0],[False],['0']
11228,PMC3641012,17116,Several factors suggested this was not likely to be evidence of harm.,Discussion,[101638],[33731],[33800],[False],[0],[0],[False],['0']
11229,PMC3641012,17117,"First, this trend was attenuated and non-significant when the analysis involved uncorrected serum calcium, a less conservative endpoint used in previous trials.",Discussion,[101646],[33801],[33961],[False],[0],[0],[False],['0']
11230,PMC3641012,17118,"Second, we did not observe a linear escalation in adj-Ca over the entire duration of supplementation, but rather found an initial increase in the rate of the natural rise in adj-Ca that occurs in late pregnancy [36] followed by an attenuation of the between-group difference after about 2 months of supplementation.",Discussion,[101654],[33962],[34277],[False],[0],[0],[False],['0']
11231,PMC3641012,17119,"This suggested a homeostatic adjustment to the altered vitamin D status, with no further increase in serum calcium after a steady-state 25(OH)D was reached.",Discussion,[101662],[34278],[34434],[False],[0],[0],[False],['0']
11232,PMC3641012,17120,"Third, a positive association between adj-Ca and 25(OH)D was apparent in the range of 25(OH)D below 100 nmol/L but not above 100 nmol/L; evidence of possible harm would be more consistent with the opposite finding of a serum calcium that was tightly controlled (i.e., unassociated with 25(OH)D) within the lower range of 25(OH)D, but deflected upward at higher 25(OH)D. All maternal uncorrected and adj-Ca values were below the threshold for hypercalcemia used by the IOM in the 1997 vitamin D DRIs (2.75 mmol/L) [10] and the 2010 revision (2.63 mmol/L) [7].",Discussion,[101670],[34435],[34993],[False],[0],[0],[False],['0']
11233,PMC3641012,17121,"We set a conservative upper limit of reference range for trial monitoring (2.60 mmol/L), which was crossed by one participant in the vitamin D group; however, this was not logically attributable to vitamin D toxicity based on normal repeat serum calcium, normal ca:cr, and a 25(OH)D that was well within the range considered to be non-hypercalcemic [37].",Discussion,[101678],[34994],[35348],[False],[0],[0],[False],['0']
11234,PMC3641012,17122,"Based on biochemical findings, and the lack of apparent clinical adverse effects, we cautiously conclude that 35,000 IU/week for an average of 10 weeks (up to 18 weeks) was tolerated by study participants, and could be considered an upper dose limit for use in future research.",Discussion,[101686],[35349],[35626],[False],[0],[0],[False],['0']
11235,PMC3641012,17123,This RCT had several limitations.,Discussion,[101694],[35627],[35660],[False],[0],[0],[False],['0']
11236,PMC3641012,17124,"It was not designed to draw precise inferences regarding pregnancy/birth outcomes, which limits its clinical applications.",Discussion,"[101702, 101708]","[35661, 35661]","[35783, 35783]","[True, True]","['RelevantOutcomeExcluded', 'Generalization']","['not designed to draw precise inferences regarding pregnancy/birth outcomes', 'limits its clinical applications']","[True, True]","['OutcomeMeasures', 'Generalization']"
11237,PMC3641012,17125,The biochemical dose–response curve would have been improved by the inclusion of other dose levels.,Discussion,[101719],[35784],[35883],[True],['Intervention'],['The biochemical dose–response curve would have been improved by the inclusion of other dose levels'],[True],['Intervention']
11238,PMC3641012,17126,"Because of the high dose of vitamin D not previously studied in pregnancy, enrolment was limited to healthy women at low risk of pregnancy complications, and who were most likely to adhere to the protocol; as such, generalizability of the findings may be limited.",Discussion,"[101736, 101737]","[35884, 35884]","[36147, 36147]","[True, True]","['Generalization', 'VerySpecificPopulation']","['generalizability of the findings may be limited', 'enrolment was limited to healthy women at low risk of pregnancy complications']","[True, True]","['Generalization', 'Population']"
11239,PMC3641012,17127,"In addition, enrolment was not conducted throughout the entire season, but rather occurred during a period in which vitamin D status was declining from its summer peak.",Discussion,[101754],[36148],[36316],[True],['Population'],['enrolment was not conducted throughout the entire season'],[True],['Population']
11240,PMC3641012,17128,"Mechanistic inferences were limited because we did not measure serum concentrations of 1,25(OH)2D, vitamin D3, or DBP.",Discussion,[101771],[36317],[36435],[True],['RelevantOutcomeExcluded'],"['we did not measure serum concentrations of 1,25(OH)2D, vitamin D3, or DBP']",[True],['OutcomeMeasures']
11241,PMC3641012,17129,"As well, we did not calculate total intake of vitamin D due to the lack of adequate information regarding vitamin D content in the Bangladeshi food supply.",Discussion,[101789],[36436],[36591],[True],['MissingData'],['we did not calculate total intake of vitamin D'],[True],['MissingData']
11242,PMC3641012,17130,Conclusions,Conclusions,[101798],[36592],[36604],[False],[0],[0],[False],['0']
11243,PMC3641012,17131,"In conclusion, this RCT in Dhaka enabled a detailed characterization of the biochemical response to 35,000 IU/week vitamin D3 supplementation in the third-trimester of pregnancy.",Conclusions,[101806],[36605],[36783],[False],[0],[0],[False],['0']
11244,PMC3641012,17132,Future studies involving equal or lesser doses are required to establish maternal-infant benefits and longer-term safety.,Conclusions,[101814],[36784],[36905],[False],[0],[0],[False],['0']
11245,PMC3641012,17133,Abbreviations,Abbreviations,[101822],[36906],[36920],[False],[0],[0],[False],['0']
11246,PMC3641012,17134,"AViDD: Antenatal Vitamin D in Dhaka; 25(OH)D: 25-Hydroxyvitamin D; IU: International Units; IOM: Institute of Medicine; DRI: Dietary Reference Intake; RDA: Recommended Dietary Allowance; UL: Tolerable Upper Intake Level; UNICEF: United Nations International Children’s Emergency Fund; RCT: Randomized Controlled Trial; icddr, b: International Centre for Diarrhoeal Disease Research, Bangladesh; LC-MS/MS: Liquid Chromatography Tandem Mass Spectroscopy; HPLC: High-Performance Liquid Chromatography; DEQAS: Vitamin D External Quality Assessment Scheme; CV: Coefficient of Variation; Ca:Cr: Calcium: Creatinine Ratio (mmol/mmol); Ca: Serum Calcium; PTH: Parathyroid Hormone; adj-Ca: Albumin-Adjusted Serum Calcium; DSMB: Data and Safety Monitoring Board; GEE: Generalized Estimating Equations; NOAEL: No Observed Adverse Effect Level; 1,25(OH)2D: 1,25-dihydroxyvitamin D; DBP: Vitamin D Binding Protein.",Abbreviations,[101830],[36921],[37822],[False],[0],[0],[False],['0']
11247,PMC3641012,17135,Competing interests,Competing interests,[101838],[37823],[37843],[False],[0],[0],[False],['0']
11248,PMC3641012,17136,The authors declare that they have no competing interests.,Competing interests,[101846],[37844],[37902],[False],[0],[0],[False],['0']
11249,PMC3641012,17137,Authors’ contributions,Authors’ contributions,[101854],[37903],[37926],[False],[0],[0],[False],['0']
11250,PMC3641012,17138,"DR, AM, and AB designed the research; DR, AM, RR, and EA conducted the research; DR, NP and BP performed the data analyses.",Authors’ contributions,[101862],[37927],[38050],[False],[0],[0],[False],['0']
11251,PMC3641012,17139,DR wrote the manuscript and had the primary responsibility for the final content.,Authors’ contributions,[101870],[38051],[38132],[False],[0],[0],[False],['0']
11252,PMC3641012,17140,All authors read and approved the final manuscript.,Authors’ contributions,[101878],[38133],[38184],[False],[0],[0],[False],['0']
11253,PMC3641012,17141,Acknowledgements,Acknowledgements,[101886],[38185],[38203],[False],[0],[0],[False],['0']
11254,PMC3641012,17142,"We appreciate the efforts of: the staff at ICDDR,B and Shimantik in Dhaka, including Shams El Arifeen, Taufiq Rahman, Ashish Chowdhury, and Kazi Moksedur Rahman; Khosrow Adeli, Warren Walsh and Mehrdad Yazdanpanah at the Hospital for Sick Children, Toronto, for measurement of 25-hydroxyvitamin D concentrations; Popular Pharmaceuticals Inc. (Dhaka, Bangladesh) for preparing the supplements; and Dr. Robert Black at the Johns Hopkins Bloomberg School of Public Health.Funding",Acknowledgements,[101894],[38204],[38680],[False],[0],[0],[False],['0']
11255,PMC3641012,17143,"Received funding from the Thrasher Research Fund (Salt Lake City, UT).",Acknowledgements,[101902],[38681],[38751],[False],[0],[0],[False],['0']
11256,PMC3641608,2904,Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial,Title,[16837],[26478],[188],[False],[0],[0],[False],['0']
11257,PMC3641608,2905,Summary,Abstract,[16840],[189],[197],[False],[0],[0],[False],['0']
11258,PMC3641608,2906,Background,Abstract,[16843],[198],[208],[False],[0],[0],[False],['0']
11259,PMC3641608,2907,"No trials have investigated routine laboratory monitoring for children with HIV, nor four-drug induction strategies to increase durability of first-line antiretroviral therapy (ART).",Abstract,[16846],[209],[391],[False],[0],[0],[False],['0']
11260,PMC3641608,2908,Methods,Abstract,[16849],[392],[399],[False],[0],[0],[False],['0']
11261,PMC3641608,2909,"In this open-label parallel-group trial, Ugandan and Zimbabwean children or adolescents with HIV, aged 3 months to 17 years and eligible for ART, were randomly assigned in a factorial design.",Abstract,[16852],[400],[591],[False],[0],[0],[False],['0']
11262,PMC3641608,2910,"Randomisation was to either clinically driven monitoring or routine laboratory and clinical monitoring for toxicity (haematology and biochemistry) and efficacy (CD4 cell counts; non-inferiority monitoring randomisation); and simultaneously to standard three-drug or to four-drug induction first-line ART, in three groups: three-drug treatment (non-nucleoside reverse transcriptase inhibitor [NNRTI], lamivudine, abacavir; group A) versus four-drug induction (NNRTI, lamivudine, abacavir, zidovudine; groups B and C), decreasing after week 36 to three-drug NNRTI, lamivudine, plus abacavir (group B) or lamivudine, abacavir, plus zidovudine (group C; superiority ART-strategy randomisation).",Abstract,[16855],[592],[1282],[False],[0],[0],[False],['0']
11263,PMC3641608,2911,"For patients assigned to routine laboratory monitoring, results were returned every 12 weeks to clinicians; for clinically driven monitoring, toxicity results were only returned for requested clinical reasons or if grade 4.",Abstract,[16858],[1283],[1506],[False],[0],[0],[False],['0']
11264,PMC3641608,2912,Children switched to second-line ART for WHO stage 3 or 4 events or (routine laboratory monitoring only) age-dependent WHO CD4 criteria.,Abstract,[16861],[1507],[1643],[False],[0],[0],[False],['0']
11265,PMC3641608,2913,Randomisation used computer-generated sequentially numbered tables incorporated securely within the database.,Abstract,[16864],[1644],[1753],[False],[0],[0],[False],['0']
11266,PMC3641608,2914,Primary efficacy endpoints were new WHO stage 4 events or death for monitoring and change in CD4 percentage at 72 and 144 weeks for ART-strategy randomisations; the co-primary toxicity endpoint was grade 3 or 4 adverse events.,Abstract,[16867],[1754],[1980],[False],[0],[0],[False],['0']
11267,PMC3641608,2915,Analysis was by intention to treat.,Abstract,[16870],[1981],[2016],[False],[0],[0],[False],['0']
11268,PMC3641608,2916,"This trial is registered, ISRCTN24791884.",Abstract,[16873],[2017],[2058],[False],[0],[0],[False],['0']
11269,PMC3641608,2917,Findings,Abstract,[16876],[2059],[2067],[False],[0],[0],[False],['0']
11270,PMC3641608,2918,"1206 children were randomly assigned to clinically driven (n=606) versus routine laboratory monitoring (n=600), and groups A (n=397), B (n=404), and C (n=405).",Abstract,[16879],[2068],[2227],[False],[0],[0],[False],['0']
11271,PMC3641608,2919,"47 (8%) children on clinically driven monitoring versus 39 (7%) on routine laboratory monitoring had a new WHO stage 4 event or died (hazard ratio [HR] 1·13, 95% CI 0·73–1·73, p=0·59; non-inferiority criterion met).",Abstract,[16882],[2228],[2443],[False],[0],[0],[False],['0']
11272,PMC3641608,2920,"However, in years 2–5, rates were higher in children on clinically driven monitoring (1·3 vs 0·4 per 100 child-years, difference 0·99, 0·37–1·60, p=0·002).",Abstract,[16885],[2444],[2599],[False],[0],[0],[False],['0']
11273,PMC3641608,2921,"One or more grade 3 or 4 adverse events occurred in 283 (47%) children on clinically driven versus 282 (47%) on routine laboratory monitoring (HR 0·98, 0·83–1·16, p=0·83).",Abstract,[16888],[2600],[2771],[False],[0],[0],[False],['0']
11274,PMC3641608,2922,"Mean CD4 percentage change did not differ between ART groups at week 72 (16·5% [SD 8·6] vs 17·1% [8·5] vs 17·3% [8·0], p=0·33) or week 144 (p=0·69), but four-drug groups (B, C) were superior to three-drug group A at week 36 (12·4% [7·2] vs 14·1% [7·1] vs 14·6% [7·3], p<0·0001).",Abstract,[16891],[2772],[3050],[False],[0],[0],[False],['0']
11275,PMC3641608,2923,"Excess grade 3 or 4 events in groups B (one or more events reported by 157 [40%] children in A, 190 [47%] in B; HR [B:A] 1·32, 1·07–1·63) and C (218 [54%] children in C; HR [C:A] 1·58, 1·29–1·94; global p=0·0001) were driven by asymptomatic neutropenia in zidovudine-containing groups (B, C; 86 group A, 133 group B, 184 group C), but resulted in drug substitutions in only zero versus two versus four children, respectively.",Abstract,[16894],[3051],[3476],[False],[0],[0],[False],['0']
11276,PMC3641608,2924,Interpretation,Abstract,[16897],[3477],[3491],[False],[0],[0],[False],['0']
11277,PMC3641608,2925,"NNRTI plus NRTI-based three-drug or four-drug ART can be given across childhood without routine toxicity monitoring; CD4 monitoring provided clinical benefit after the first year on ART, but event rates were very low and long-term survival high, suggesting ART rollout should take priority.",Abstract,[16900],[3492],[3782],[False],[0],[0],[False],['0']
11278,PMC3641608,2926,"CD4 benefits from four-drug induction were not durable, but three-NRTI long-term maintenance was immunologically and clinically similar to NNRTI-based ART and could be valuable during tuberculosis co-treatment.",Abstract,[16903],[3783],[3993],[False],[0],[0],[False],['0']
11279,PMC3641608,2927,Funding,Abstract,[16906],[3994],[4001],[False],[0],[0],[False],['0']
11280,PMC3641608,2928,"UK Medical Research Council, the UK Department for International Development; drugs donated and viral load assays funded by ViiV Healthcare and GlaxoSmithKline.",Abstract,[16909],[4002],[4162],[False],[0],[0],[False],['0']
11281,PMC3641608,2929,Introduction,Introduction,[16912],[4163],[4176],[False],[0],[0],[False],['0']
11282,PMC3641608,2930,"In high-income countries, routine laboratory tests are done (typically every 3–4 months) to monitor efficacy (HIV viral load, CD4 counts) and toxicity (haematology or biochemistry panels) in patients with HIV on antiretroviral therapy (ART).",Introduction,[16915],[4177],[4418],[False],[0],[0],[False],['0']
11283,PMC3641608,2931,"Although not mandated when public health ART rollout started, the extent to which HIV treatment programmes in resource-limited settings should provide routine laboratory monitoring versus focus resources on expanding ART access for the many in need, remains an ongoing debate, particularly relevant with slowing growth in health assistance for resource-limited countries in the current economic crisis.",Introduction,[16918],[4419],[4821],[False],[0],[0],[False],['0']
11284,PMC3641608,2932,"90% of children with HIV live in sub-Saharan Africa; in 2011, only about 28% of those needing ART were receiving it.",Introduction,[16921],[4822],[4938],[False],[0],[0],[False],['0']
11285,PMC3641608,2933,"Infrastructure, personnel, and supply chain constraints all affect the ability to monitor, and tests for detecting toxicity and measuring efficacy are generally unavailable, particularly at low-level facilities.",Introduction,[16924],[4939],[5150],[False],[0],[0],[False],['0']
11286,PMC3641608,2934,Trials in adults have compared routine laboratory with clinical monitoring on ART.,Introduction,[16927],[5151],[5233],[False],[0],[0],[False],['0']
11287,PMC3641608,2935,"These showed no benefit from routine toxicity monitoring, small but significant benefits from CD4 monitoring, and no significant additional benefit of viral load over CD4 monitoring.",Introduction,[16930],[5234],[5416],[False],[0],[0],[False],['0']
11288,PMC3641608,2936,"No trials have evaluated monitoring strategies in children on ART; results in adults might not be generalisable because of differences in frequency of ART toxicity, predictive value of CD4s, and the clinical spectrum of paediatric HIV and its comorbidities, particularly in Africa.",Introduction,[16933],[5417],[5698],[False],[0],[0],[False],['0']
11289,PMC3641608,2937,Children with HIV start ART early and will need to take treatment for longer than adults.,Introduction,[16936],[5699],[5788],[False],[0],[0],[False],['0']
11290,PMC3641608,2938,"Challenges in treatment of young children, in whom viral loads are higher, pharmacokinetics more variable, and adherence more challenging, might account for the lower virological suppression rates in children compared with adults in similar calendar periods.",Introduction,[16939],[5789],[6047],[False],[0],[0],[False],['0']
11291,PMC3641608,2939,"However, four-drug combinations (generally three nucleoside reverse transcriptase inhibitors [NRTIs] plus one non-nucleoside reverse transcriptase inhibitor [NNRTI]) have been reported to show superior virological and immunological responses compared with three-drug ART (two NRTIs plus one NNRTI or protease inhibitor) in an observational study in infants.",Introduction,[16942],[6048],[6405],[False],[0],[0],[False],['0']
11292,PMC3641608,2940,Whether addition of one drug for a short period in an induction-maintenance approach might have benefits across childhood is unknown.,Introduction,[16945],[6406],[6539],[False],[0],[0],[False],['0']
11293,PMC3641608,2941,"A key advantage might be more rapid reduction of high viral loads in ART-naive children, which could have long-term benefits.",Introduction,[16948],[6540],[6665],[False],[0],[0],[False],['0']
11294,PMC3641608,2942,"A triple NRTI regimen after four-drug NRTI plus NNRTI induction also avoids challenges of managing interactions with antituberculosis drugs, particularly for young children unable to take efavirenz.",Introduction,[16951],[6666],[6864],[False],[0],[0],[False],['0']
11295,PMC3641608,2943,We therefore undertook the first paediatric trial (AntiRetroviral Research fOr Watoto [ARROW]) to evaluate the long-term effect of routine efficacy and toxicity monitoring and different first-line ART strategies in a factorial design in African children.,Introduction,[16954],[6865],[7119],[False],[0],[0],[False],['0']
11296,PMC3641608,2944,Methods,Methods,[16957],[7120],[7128],[False],[0],[0],[False],['0']
11297,PMC3641608,2945,Trial design,Methods|Trial design,[16960],[7129],[7141],[False],[0],[0],[False],['0']
11298,PMC3641608,2946,"ARROW was an open-label randomised parallel-group trial in untreated (except for ART to prevent mother-to-child-transmission) children or adolescents (aged 3 months to 17 years) with HIV who met WHO 2006 criteria for ART initiation from three centres in Uganda (Joint Clinical Research Centre, Kampala; Baylor-Uganda, Mulago; MRC/UVRI Uganda Research Unit on AIDS, Entebbe), and one in Zimbabwe (University of Zimbabwe, Harare).",Methods|Trial design,[16963],[7142],[7570],[False],[0],[0],[False],['0']
11299,PMC3641608,2947,"Children with acute infections, on drugs contraindicated with ART, unlikely to adhere or to attend regularly, with laboratory abnormalities contraindicating ART, pregnant or breastfeeding, or perinatally exposed to ART (if <6 months old) were excluded.",Methods|Trial design,[16966],[7571],[7823],[False],[0],[0],[False],['0']
11300,PMC3641608,2948,Participants were randomly assigned (1:1) to clinically driven monitoring versus routine laboratory plus clinical monitoring for toxicity (haematology and biochemistry) and efficacy (CD4).,Methods|Trial design,[16969],[7824],[8012],[False],[0],[0],[False],['0']
11301,PMC3641608,2949,"Children were also randomly assigned (1:1:1) in a factorial design to three approaches for first-line ART: open-label lamivudine, abacavir, plus NNRTI continuously (group A, control); induction-maintenance with four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then lamivudine, abacavir, plus NNRTI (group B); or induction-maintenance with lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then lamivudine, abacavir, plus zidovudine (group C).",Methods|Trial design,[16972],[8013],[8484],[False],[0],[0],[False],['0']
11302,PMC3641608,2950,HLA testing was not done.,Methods|Trial design,[16975],[8485],[8510],[False],[0],[0],[False],['0']
11303,PMC3641608,2951,HIV viral loads were done retrospectively on stored samples.,Methods|Trial design,[16978],[8511],[8571],[False],[0],[0],[False],['0']
11304,PMC3641608,2952,The hypothesis was that clinically driven monitoring would result in similar outcomes to routine laboratory monitoring (non-inferiority) and that four-drug induction-maintenance would have greater efficacy than would standard three-drug ART.,Methods|Trial design,[16981],[8572],[8813],[False],[0],[0],[False],['0']
11305,PMC3641608,2953,The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.,Methods|Trial design,[16984],[8814],[8915],[False],[0],[0],[False],['0']
11306,PMC3641608,2954,Caregivers gave written informed consent; older children (8–17 years) aware of their HIV status also gave assent or consent following national guidelines.,Methods|Trial design,[16987],[8916],[9070],[False],[0],[0],[False],['0']
11307,PMC3641608,2955,"The trial was approved by research ethics committees in Uganda, Zimbabwe, and the UK.",Methods|Trial design,[16990],[9071],[9156],[False],[0],[0],[False],['0']
11308,PMC3641608,2956,Randomisation and masking,Methods|Randomisation and masking,[16993],[9157],[9182],[False],[0],[0],[False],['0']
11309,PMC3641608,2957,"Both factorial randomisations were stratified by centre and age (<7, 7–12, ≥13 years).",Methods|Randomisation and masking,[16996],[9183],[9269],[False],[0],[0],[False],['0']
11310,PMC3641608,2958,"The computer-generated sequentially numbered randomisation list (with variable block sizes) containing both allocations was pre-prepared by the trial statistician and incorporated within the secure database at each trial centre, connected to but not located within each clinical centre, allowing trial managers to access the next number, but not the whole list.",Methods|Randomisation and masking,[16999],[9270],[9631],[False],[0],[0],[False],['0']
11311,PMC3641608,2959,Randomisation was undertaken by clinicians phoning the local trials centre.,Methods|Randomisation and masking,[17002],[9632],[9707],[False],[0],[0],[False],['0']
11312,PMC3641608,2960,"Once randomised, allocation was open—ie, physicians and carers were aware of group assignment.",Methods|Randomisation and masking,[17005],[9708],[9802],[False],[0],[0],[False],['0']
11313,PMC3641608,2961,Procedures,Methods|Procedures,[17008],[9803],[9813],[False],[0],[0],[False],['0']
11314,PMC3641608,2962,"All participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks.",Methods|Procedures,[17011],[9814],[10142],[False],[0],[0],[False],['0']
11315,PMC3641608,2963,Screening results were used to assess eligibility.,Methods|Procedures,[17014],[10143],[10193],[False],[0],[0],[False],['0']
11316,PMC3641608,2964,"All subsequent results for participants assigned to routine laboratory monitoring were returned to clinicians, whereas results at and after randomisation for participants allocated clinically driven monitoring were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in DART, as were grade 4 laboratory toxicities (protocol safety criteria; grades defined apart from neutrophils).",Methods|Procedures,[17017],[10194],[10701],[False],[0],[0],[False],['0']
11317,PMC3641608,2965,"Total lymphocytes and CD4 tests were never returned for participants on clinically driven monitoring, but for all children other investigations could be requested and concomitant drugs prescribed, as clinically indicated.",Methods|Procedures,[17020],[10702],[10923],[False],[0],[0],[False],['0']
11318,PMC3641608,2966,All children received ART as syrups or tablets dosed according to WHO weight-band tables.,Methods|Procedures,[17023],[10924],[11013],[False],[0],[0],[False],['0']
11319,PMC3641608,2967,Children were reviewed every 4–6 weeks by a nurse using a standard symptom checklist.,Methods|Procedures,[17026],[11014],[11099],[False],[0],[0],[False],['0']
11320,PMC3641608,2968,"Antiretroviral drugs could be substituted, preferably within class, after adverse events.",Methods|Procedures,[17029],[11100],[11189],[False],[0],[0],[False],['0']
11321,PMC3641608,2969,"During four-drug induction, a drug could be dropped because of toxicity or drug interactions with antituberculosis treatment.",Methods|Procedures,[17032],[11190],[11315],[False],[0],[0],[False],['0']
11322,PMC3641608,2970,"Switching to second-line ART (including a ritonavir-boosted protease inhibitor) was based on clinical criteria in all participants (new or recurrent WHO stage 4 event; or WHO stage 3 event or events at clinician discretion, particularly if recurrent or persistent), or on laboratory criteria for routine laboratory monitoring (confirmed on-ART CD4 of <15% at age 1–2 years, <10% at 3–4 years, <100 cells/mL at ≥5 years).",Methods|Procedures,[17035],[11316],[11736],[False],[0],[0],[False],['0']
11323,PMC3641608,2971,See appendix for further details.,Methods|Procedures,[17038],[11737],[11770],[False],[0],[0],[False],['0']
11324,PMC3641608,2972,"Co-primary endpoints for the monitoring randomisation were progression to new WHO stage 4 event or death (efficacy), and grade 3 or 4 adverse events not solely related to HIV (safety).",Methods|Procedures,[17041],[11771],[11955],[False],[0],[0],[False],['0']
11325,PMC3641608,2973,Co-primary endpoints for the ART-strategy randomisation were change in CD4 percentage from randomisation to 72 and 144 weeks (efficacy) and grade 3 or 4 adverse events (safety).,Methods|Procedures,[17044],[11956],[12133],[False],[0],[0],[False],['0']
11326,PMC3641608,2974,"Secondary endpoints for both randomisations (if not co-primary) were: mortality; new (or new or recurrent) WHO stage 4 event or death; new (or new or recurrent) WHO stage 3 or 4 event or death; grade 3 or 4 adverse events definitely, probably, or uncertainly ART-related; serious adverse events not solely HIV-related; ART-modifying adverse events; admissions to hospital; height, weight, and body-mass index for age; CD4; number and class of antiretrovirals received; switch to second-line regimen; adherence; viral load and resistance (done retrospectively; see appendix).",Methods|Procedures,[17047],[12134],[12708],[False],[0],[0],[False],['0']
11327,PMC3641608,2975,"All WHO stage 3 or 4 events, deaths, and serious adverse events were reviewed against prespecified criteria by an endpoint review committee with an independent chair and members, masked to randomised allocations.",Methods|Procedures,[17050],[12709],[12921],[False],[0],[0],[False],['0']
11328,PMC3641608,2976,Statistical analysis,Methods|Statistical analysis,[17053],[12922],[12942],[False],[0],[0],[False],['0']
11329,PMC3641608,2977,"1200 children followed up for 3·5–5·0 years with less than 10% loss to follow-up provided 90% power to establish that clinically driven monitoring was not inferior to routine laboratory monitoring on the primary efficacy outcome, defined as the upper 95% confidence limit for the difference (clinically driven minus routine laboratory monitoring) in rate of first new WHO stage 4 event or deaths per 100 child-years being no greater than 1·6 per 100 child-years (assumed rate for routine laboratory monitoring of 2·5 per 100 child-years).",Methods|Statistical analysis,[17056],[12943],[13481],[False],[0],[0],[False],['0']
11330,PMC3641608,2978,"For the ART-strategy randomisation, 1200 children provided 80% power to detect differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing data (loss to follow-up, missed visit or test) and standard deviation 10%.",Methods|Statistical analysis,[17059],[13482],[13765],[False],[0],[0],[False],['0']
11331,PMC3641608,2979,Interim data were reviewed annually by an independent data monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,Methods|Statistical analysis,[17062],[13766],[13907],[False],[0],[0],[False],['0']
11332,PMC3641608,2980,"Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse event outcomes, censoring at the earlier of trial closure or last follow-up.",Methods|Statistical analysis,[17065],[13908],[14229],[False],[0],[0],[False],['0']
11333,PMC3641608,2981,Categorical variables were compared with χ2 or exact (if indicated) tests.,Methods|Statistical analysis,[17068],[14230],[14304],[False],[0],[0],[False],['0']
11334,PMC3641608,2982,Change in CD4 percentage was compared with normal linear regression adjusted for randomisation stratification factors.,Methods|Statistical analysis,[17071],[14305],[14423],[False],[0],[0],[False],['0']
11335,PMC3641608,2983,Laboratory measurements and adherence were compared across randomised groups over time with generalised estimating equations (independent correlation; closest measurement to each scheduled visit within equally spaced windows).,Methods|Statistical analysis,[17074],[14424],[14650],[False],[0],[0],[False],['0']
11336,PMC3641608,2984,All comparisons were as randomised (intention-to-treat).,Methods|Statistical analysis,[17077],[14651],[14707],[False],[0],[0],[False],['0']
11337,PMC3641608,2985,"Subgroups specified in the analysis plan were the factorial randomisations, time on ART, sex, age, centre, CD4, weight for age, randomisation year, and previous ART for prevention of mother-to-child transmission.",Methods|Statistical analysis,[17080],[14708],[14920],[False],[0],[0],[False],['0']
11338,PMC3641608,2986,Baseline values were those nearest to but before and within 42 days of randomisation.,Methods|Statistical analysis,[17083],[14921],[15006],[False],[0],[0],[False],['0']
11339,PMC3641608,2987,Z scores were determined with the British reference because it covers the full age range of ARROW children.,Methods|Statistical analysis,[17086],[15007],[15114],[False],[0],[0],[False],['0']
11340,PMC3641608,2988,All analyses were done with Stata 12.1.,Methods|Statistical analysis,[17089],[15115],[15154],[False],[0],[0],[False],['0']
11341,PMC3641608,2989,All p values are two-sided.,Methods|Statistical analysis,[17092],[15155],[15182],[False],[0],[0],[False],['0']
11342,PMC3641608,2990,"This trial is registered, ISRCTN24791884.",Methods|Statistical analysis,[17095],[15183],[15224],[False],[0],[0],[False],['0']
11343,PMC3641608,2991,Role of the funding sources,Methods|Role of the funding sources,[17098],[15225],[15252],[False],[0],[0],[False],['0']
11344,PMC3641608,2992,"The sponsor (UK Medical Research Council), other funders (UK Department for International Development), and ViiV Healthcare/GlaxoSmithKline (donated drugs; funded viral load assays) had no direct role in study design, data collection, analysis, interpretation, report writing, or the decision to submit for publication.",Methods|Role of the funding sources,[17101],[15253],[15572],[False],[0],[0],[False],['0']
11345,PMC3641608,2993,The corresponding author had full access to all data and responsibility for submission for publication.,Methods|Role of the funding sources,[17104],[15573],[15676],[False],[0],[0],[False],['0']
11346,PMC3641608,2994,Results,Results,[17107],[15677],[15685],[False],[0],[0],[False],['0']
11347,PMC3641608,2995,"1210 children were enrolled (March 15, 2007–Nov 18, 2008).",Results,[17110],[15686],[15744],[False],[0],[0],[False],['0']
11348,PMC3641608,2996,"One was randomly assigned twice at different centres (second randomisation was excluded), and three had major eligibility violations, leaving 600 children assigned to routine laboratory and 606 to clinically driven monitoring, and 397 to group A, 404 to group B, and 405 to group C (figure 1).",Results,[17113],[15745],[16038],[False],[0],[0],[False],['0']
11349,PMC3641608,2997,Baseline characteristics were similar across randomised groups (table 1).,Results,[17116],[16039],[16112],[False],[0],[0],[False],['0']
11350,PMC3641608,2998,"Median follow-up to planned trial closure (March 16, 2012) was 4·0 (IQR 3·7–4·4) years in each monitoring and ART-strategy group (maximum 5·0 years; total 4685 child-years).",Results,[17119],[16113],[16286],[False],[0],[0],[False],['0']
11351,PMC3641608,2999,Only 33 (3%) children (median follow-up 150 [IQR 46–169] weeks) not known to have died were not seen after trial closure (figure 1).,Results,[17122],[16287],[16419],[False],[0],[0],[False],['0']
11352,PMC3641608,3000,"Completeness of nurse visits every 4–6 weeks and doctor visits every 12 weeks was more than 95% (46 531/48 461 nurse, 19 088/19 765 doctor visits) and was similar in all groups.",Results,[17125],[16420],[16597],[False],[0],[0],[False],['0']
11353,PMC3641608,3001,"For children assigned to clinically driven monitoring, clinicians could request individual laboratory toxicity results from routine haematology or biochemistry panels for clinical reasons.",Results,[17128],[16598],[16786],[False],[0],[0],[False],['0']
11354,PMC3641608,3002,Panel tests could also be requested in both groups at extra patient-initiated visits.,Results,[17131],[16787],[16872],[False],[0],[0],[False],['0']
11355,PMC3641608,3003,"However, most were done at routine visits (10 805 [92%] haematology and 10 778 [94%] biochemistry; appendix).",Results,[17134],[16873],[16982],[False],[0],[0],[False],['0']
11356,PMC3641608,3004,"In clinically driven monitoring, apart from week 8 haemoglobin (returned per protocol), very few results were released (from 486 [4%] panels); most commonly requested results were haemoglobin (2%, n=265) and neutrophils (3%, n=323; appendix).",Results,[17137],[16983],[17225],[False],[0],[0],[False],['0']
11357,PMC3641608,3005,"More additional haematology tests were requested during nurse visits or extra visits in routine laboratory than in clinically driven monitoring (p<0·0001); there were no significant differences in requests for additional biochemistry tests (p=0·17) or other non-routine (eg, electrolytes) tests (p=0·97).",Results,[17140],[17226],[17530],[False],[0],[0],[False],['0']
11358,PMC3641608,3006,"At trial end, 578 (95%) children on clinically driven monitoring versus 565 (94%) on routine laboratory monitoring were still on first-line ART (table 2); 330 (83%) children in group A, 356 (88%) in group B, and 367 (91%) in group C were still on their original randomised regimen.",Results,[17143],[17531],[17812],[False],[0],[0],[False],['0']
11359,PMC3641608,3007,"Among 151 first-line drug changes, equal numbers were due to adverse events and antituberculosis therapy (both 59 changes [39%]; table 2).",Results,[17146],[17813],[17951],[False],[0],[0],[False],['0']
11360,PMC3641608,3008,"Changes to first-line therapy occurred at rates of 3·3 per 100 child-years in routine laboratory monitoring versus 3·2 per 100 child-years in clinically driven monitoring (p=0·94); and 3·5, 3·7, and 2·6 per 100 child-years in groups A, B, and C, respectively (p=0·25).",Results,[17149],[17952],[18220],[False],[0],[0],[False],['0']
11361,PMC3641608,3009,"30 children in group A, 20 in group B, and nine in group C stopped nevirapine because of starting antituberculosis treatment.",Results,[17152],[18221],[18346],[False],[0],[0],[False],['0']
11362,PMC3641608,3010,"Whereas in group A nevirapine was mainly substituted with zidovudine (<3 years) or efavirenz (>3 years), in the four-drug groups, about a third (five children in group B and six in C) simply dropped nevirapine during four-drug induction to continue on three NRTIs.",Results,[17155],[18347],[18611],[False],[0],[0],[False],['0']
11363,PMC3641608,3011,"Adverse events resulted in a drug being substituted or dropped in five children in group A, 28 in group B, and 26 in group C; most changes were zidovudine-related (16 in B, 20 in C; table 2).",Results,[17158],[18612],[18803],[False],[0],[0],[False],['0']
11364,PMC3641608,3012,Adherence by self-reported questionnaire was similar in both monitoring groups: mean 6·7% (1813/26 917) of children on clinically driven monitoring reported missing doses in the past 28 days versus 6·5% (1683/25 935) on routine laboratory monitoring (p=0·26).,Results,[17161],[18804],[19063],[False],[0],[0],[False],['0']
11365,PMC3641608,3013,"There were small but significant differences by ART strategy, with fewer reporting missing doses in the past 28 days in group A through week 36 (induction period; 7·9% [253/2966] in group A, 9·8% [326/3014] in group B, 9·0% [295/2999] in group C; p=0·02) and overall (6·1% [1059/16345], 7·3% [1302/16640], 6·5% [1135/16371], respectively; p<0·0001).",Results,[17164],[19064],[19413],[False],[0],[0],[False],['0']
11366,PMC3641608,3014,No child switched to second-line treatment during their first year on ART.,Results,[17167],[19414],[19488],[False],[0],[0],[False],['0']
11367,PMC3641608,3015,"Overall, 28 (5%) children on clinically driven monitoring versus 35 (6%) on routine laboratory monitoring switched to second-line treatment (hazard ratio [HR] 0·78, 95% CI 0·48–1·29, p=0·22; table 2; figure 2), after median 2·8 (IQR 1·8–3·3) years versus 2·2 (1·5–3·0) years, respectively.",Results,[17170],[19489],[19778],[False],[0],[0],[False],['0']
11368,PMC3641608,3016,All children on routine laboratory monitoring meeting CD4 switch criteria actually switched.,Results,[17173],[19779],[19871],[False],[0],[0],[False],['0']
11369,PMC3641608,3017,"At switch, median CD4 percentage was 8·5% (IQR 1·5–22·5) in the clinically driven monitoring group and 7% (3–13) in the routine laboratory monitoring group; 11 children (39%) versus 14 (40%) had CD4 percentage less than 5% and six children (21%) versus none had CD4 percentage greater than 25%, respectively.",Results,[17176],[19872],[20180],[False],[0],[0],[False],['0']
11370,PMC3641608,3018,2% of follow-up (40/2373 child-years) was spent on second-line treatment in children on clinically driven monitoring versus 3% (67/2311 child-years) in those on routine laboratory monitoring.,Results,[17179],[20181],[20372],[False],[0],[0],[False],['0']
11371,PMC3641608,3019,26 [7%] children in group A switched to second-line treatment versus 17 [4%] in group B and 20 (5%) in group C; these differences were not significant (p=0·25; figure 2).,Results,[17182],[20373],[20543],[False],[0],[0],[False],['0']
11372,PMC3641608,3020,"There was no evidence of interaction between monitoring and induction-maintenance ART strategies in primary or secondary outcomes (heterogeneity p>0·1) except for WHO stage 4 events or death in the first year on ART, for which the relative difference between clinically driven and routine laboratory monitoring varied by first-line ART strategy (appendix).",Results,[17185],[20544],[20900],[False],[0],[0],[False],['0']
11373,PMC3641608,3021,"Since most variation was between groups B and C, who received identical ART for the first 36 weeks, this year 1 interaction appeared attributable to chance in children initiating ART with severe immunodeficiency.",Results,[17188],[20901],[21113],[False],[0],[0],[False],['0']
11374,PMC3641608,3022,"47 (8%) children on clinically driven monitoring versus 39 (7%) on routine laboratory monitoring had a new WHO stage 4 event or died (2·0 vs 1·7 per 100 child-years, respectively).",Results,[17191],[21114],[21294],[False],[0],[0],[False],['0']
11375,PMC3641608,3023,"The absolute difference of 0·32 per 100 child-years (95% CI −0·47 to 1·12) translated into a relative HR of 1·13 (95% CI 0·73–1·73, p=0·59; figure 3).",Results,[17194],[21295],[21445],[False],[0],[0],[False],['0']
11376,PMC3641608,3024,The upper 95% confidence limit for the absolute difference was below the non-inferiority margin of 1·6.,Results,[17197],[21446],[21549],[False],[0],[0],[False],['0']
11377,PMC3641608,3025,"Although overall progression was similar, a prespecified subgroup analysis showed children on routine laboratory monitoring had higher event rates during the first 3 months on ART and lower rates from the second year on ART compared with those on clinically driven monitoring (heterogeneity p=0·045; appendix).",Results,[17200],[21550],[21860],[False],[0],[0],[False],['0']
11378,PMC3641608,3026,"After year 1, 23 (4%) children on clinically driven monitoring versus six (1%) on routine laboratory monitoring had a first WHO stage 4 event or died (difference 0·99 per 100 child-years, 95% CI 0·37–1·60, p=0·002).",Results,[17203],[21861],[22076],[False],[0],[0],[False],['0']
11379,PMC3641608,3027,The most common WHO stage 4 events were oesophageal candidiasis (eight on clinically driven and five on routine laboratory monitoring) and severe unexplained failure-to-thrive (nine on clinically driven and three on routine laboratory monitoring).,Results,[17206],[22077],[22324],[False],[0],[0],[False],['0']
11380,PMC3641608,3028,"25 (4%) children died in the clinically driven monitoring group versus 29 (5%) in the routine laboratory monitoring group (1·1 vs 1·3 per 100 child-years, respectively; difference −0·2 per 100 child-years, 95% CI −0·82 to 0·41; HR 0·84, 95% CI 0·49–1·44; p=0·45; appendix).",Results,[17209],[22325],[22598],[False],[0],[0],[False],['0']
11381,PMC3641608,3029,Most deaths (19 clinically driven and 20 routine laboratory monitoring) were primarily HIV-related; only one was drug-related (chemotherapy plus zidovudine).,Results,[17212],[22599],[22756],[False],[0],[0],[False],['0']
11382,PMC3641608,3030,"Similar variation over time (heterogeneity p=0·03; appendix) was observed for deaths alone as for the combined endpoint of WHO stage 4 or death (13 deaths on clinically driven and 27 on routine laboratory monitoring in first year, 12 vs two subsequently; difference 0·56 per 100 child-years, 95% CI 0·15–0·97, with 12 of the 14 deaths after 1 year in children aged >8 years).",Results,[17215],[22757],[23132],[False],[0],[0],[False],['0']
11383,PMC3641608,3031,"Progression to new WHO stage 3 or 4 events or death gave similar results (HR [clinically driven:routine laboratory monitoring] 1·00, 0·73–1·38; p=0·98; appendix).",Results,[17218],[23133],[23295],[False],[0],[0],[False],['0']
11384,PMC3641608,3032,"Pulmonary tuberculosis was the commonest WHO stage 3 event (25 clinically driven monitoring, 28 routine laboratory monitoring).",Results,[17221],[23296],[23423],[False],[0],[0],[False],['0']
11385,PMC3641608,3033,"Among 45 WHO stage 3 or 4 events reported on clinically driven monitoring and 21 on routine laboratory monitoring from the second year onwards, 14 versus one were failure-to-thrive and 15 versus 15 were extrapulmonary or pulmonary tuberculosis, highlighting the potential of weight monitoring to identify first-line CD4 failure clinically.",Results,[17224],[23424],[23763],[False],[0],[0],[False],['0']
11386,PMC3641608,3034,CD4 percentage increased throughout the first 3 years on ART before plateauing in both groups (figure 3; p=0·23).,Results,[17227],[23764],[23877],[False],[0],[0],[False],['0']
11387,PMC3641608,3035,Only 11 (2%) children on clinically driven monitoring versus two (<1%) on routine laboratory monitoring had CD4 less than 5% at their last visit (exact p=0·01; appendix).,Results,[17230],[23878],[24048],[False],[0],[0],[False],['0']
11388,PMC3641608,3036,Viral load suppression was similar in both monitoring groups (figure 3; global p>0·7).,Results,[17233],[24049],[24135],[False],[0],[0],[False],['0']
11389,PMC3641608,3037,"At the latest test, median 3·7 (IQR 3·0–4·1) years after ART initiation, 351 (77%) of 458 children on clinically driven monitoring versus 345 (78%) of 443 on routine laboratory monitoring had viral load less than 400 copies per mL (p=0·66), similar across ages (heterogeneity p=0·25); 329 (72%) on clinically driven monitoring versus 313 (71%) on routine laboratory monitoring had viral load less than 80 copies per mL (p=0·70).",Results,[17236],[24136],[24564],[False],[0],[0],[False],['0']
11390,PMC3641608,3038,"Weight for age and height for age did not differ significantly between groups (p=0·71, p=0·07; appendix).",Results,[17239],[24565],[24670],[False],[0],[0],[False],['0']
11391,PMC3641608,3039,49 (9%) children on clinically driven monitoring versus 29 (5%) on routine laboratory monitoring had weight-for-age Z score less than −3 (approximate one thousandth percentile of normal UK weight) at last visit (global p=0·12).,Results,[17242],[24671],[24898],[False],[0],[0],[False],['0']
11392,PMC3641608,3040,"One or more grade 3 or 4 adverse events (co-primary endpoint) occurred in 283 (47%) children on clinically driven monitoring versus 282 (47%) on routine laboratory monitoring (HR 0·98, 95% CI 0·83–1·16, p=0·83; figure 3).",Results,[17245],[24899],[25120],[False],[0],[0],[False],['0']
11393,PMC3641608,3041,"Of 1170 adverse events (621 clinically driven monitoring, 549 routine laboratory monitoring), 810 (69%) were asymptomatic laboratory results, most commonly grade 3 neutropenia (171 clinically driven monitoring, 167 routine laboratory monitoring; appendix); only 87 (7%) were definitely, probably, or uncertainly ART-related (41 clinically driven monitoring, 46 routine laboratory monitoring).",Results,[17248],[25121],[25513],[False],[0],[0],[False],['0']
11394,PMC3641608,3042,"111 (18%) children on clinically driven monitoring versus 109 (18%) on routine laboratory monitoring had one or more grade 4 adverse events (HR 0·99, 0·76–1·29, p=0·94).",Results,[17251],[25514],[25683],[False],[0],[0],[False],['0']
11395,PMC3641608,3043,"Although there was no difference in grade 4 adverse events, 147 (24%) children on clinically driven monitoring versus 117 (20%) on routine laboratory monitoring had one or more serious adverse events (any grade; HR 1·30, 1·02–1·66, p=0·04).",Results,[17254],[25684],[25924],[False],[0],[0],[False],['0']
11396,PMC3641608,3044,"Most of the 362 serious adverse events (217 clinically driven, 145 routine laboratory monitoring) were malaria (113 clinically driven, 65 routine laboratory monitoring), and most (179 clinically driven, 117 routine laboratory monitoring) were admissions to hospital.",Results,[17257],[25925],[26191],[False],[0],[0],[False],['0']
11397,PMC3641608,3045,"The excess malaria serious adverse events in the clinically driven monitoring group were mostly in children with parasite counts less than 500 per 200 white blood cells, or were not diagnostically confirmed (figure 3).",Results,[17260],[26192],[26410],[False],[0],[0],[False],['0']
11398,PMC3641608,3046,"Differences in time to first hospital admission were smaller (HR 1·18, 0·99–1·41, p=0·07), with no difference in duration of admission (median 5 [IQR 3–6] days in clinically driven and routine laboratory monitoring; rank-sum p=0·54).",Results,[17263],[26411],[26644],[False],[0],[0],[False],['0']
11399,PMC3641608,3047,"ART-modifying adverse events occurred in 31 (5%) children on clinically driven monitoring versus 32 (5%) on routine laboratory monitoring (HR 0·95, 0·58–1·56, p=0·84).",Results,[17266],[26645],[26812],[False],[0],[0],[False],['0']
11400,PMC3641608,3048,"The most common modification (14 clinically driven, 13 routine laboratory monitoring) was to stop (on four-drug regimen) or substitute zidovudine.",Results,[17269],[26813],[26959],[False],[0],[0],[False],['0']
11401,PMC3641608,3049,There was no significant difference between the three ART strategy randomisation groups in mean CD4 percentage change at week 72 (p=0·33) or 144 (p=0·69; figure 4).,Results,[17272],[26960],[27124],[False],[0],[0],[False],['0']
11402,PMC3641608,3050,"However, at week 36 (when all children moved to three drugs), CD4 percentage responses were significantly greater in the four-drug induction groups (p<0·0001; figure 4; appendix).",Results,[17275],[27125],[27304],[False],[0],[0],[False],['0']
11403,PMC3641608,3051,"Viral load suppression less than 400 copies per mL was similar in the three ART strategy groups at weeks 4, 36, and 48 (p>0·4), but differed significantly at weeks 24 (p=0·009) and 144 (p=0·009; figure 4).",Results,[17278],[27305],[27510],[False],[0],[0],[False],['0']
11404,PMC3641608,3052,"At week 24, suppression was significantly greater in induction groups receiving four drugs (285 [88%] of 324 children in groups B and C vs 114 [77%] of 148 in group A).",Results,[17281],[27511],[27679],[False],[0],[0],[False],['0']
11405,PMC3641608,3053,"By contrast, similarly to week 144, at the latest test suppression was significantly greater in children receiving two NRTIs plus an NNRTI (496 [84%] of 591 in groups A and B vs 200 [65%] of 310 in group C).",Results,[17284],[27680],[27887],[False],[0],[0],[False],['0']
11406,PMC3641608,3054,"No significant difference was seen in suppression less than 80 copies per mL at week 24 (p=0·41); however, suppression less than 80 copies per mL was significantly greater in groups A and B at week 144 and latest test (466 [79%] in groups A and B vs 176 [57%] in group C; p<0·0001).",Results,[17287],[27888],[28170],[False],[0],[0],[False],['0']
11407,PMC3641608,3055,Results were similar when restricted to children younger than 5 years (not shown) or 3 years (appendix).,Results,[17290],[28171],[28275],[False],[0],[0],[False],['0']
11408,PMC3641608,3056,"There was no evidence of differences between ART-strategy groups in progression to new WHO stage 4 event or death (HR [B:A] 0·89, 95% CI 0·53–1·48; HR [C:A] 0·91, 0·54–1·52; global p=0·89), WHO stage 3 or 4 event or death (HR [B:A] 0·82, 0·55–1·20; HR [C:A] 0·80, 0·54–1·17; global p=0·44), or mortality overall (HR [B:A] 0·66, 0·33–1·31; HR [C:A] 0·97, 0·52–1·81; global p=0·43; figure 4; appendix).",Results,[17293],[28276],[28676],[False],[0],[0],[False],['0']
11409,PMC3641608,3057,"In particular, there was no evidence that greater initial CD4 increases in groups B or C significantly reduced disease progression risks in the first year (13 deaths in group A vs nine in group B vs 18 in group C; 22 vs 19 vs 24 WHO stage 4 events or deaths; 36 vs 35 vs 37 WHO stage 3 or 4 events or deaths).",Results,[17296],[28677],[28986],[False],[0],[0],[False],['0']
11410,PMC3641608,3058,"However, there was also no suggestion of higher event rates in group C receiving long-term three-NRTI maintenance, despite lower long-term viral load suppression; if anything, fewer events occurred after 1 year (seven deaths in group A vs five in group B vs two in group C; 18 vs 13 vs eight WHO stage 4 events or deaths; 37 vs 26 vs 17 WHO stage 3 or 4 events or deaths).",Results,[17299],[28987],[29359],[False],[0],[0],[False],['0']
11411,PMC3641608,3059,There was no evidence of differences in weight for age (p=0·58) or height for age (p=0·90) across ART strategies (appendix).,Results,[17302],[29360],[29484],[False],[0],[0],[False],['0']
11412,PMC3641608,3060,"157 (40%) children in group A, 190 (47%) in group B, and 218 (54%) in group C had one or more grade 3 or 4 adverse events (co-primary endpoint; HR [B:A] 1·32, 95% CI 1·07–1·63; HR [C:A] 1·58, 1·29–1·94; global p=0·0001; figure 4).",Results,[17305],[29485],[29715],[False],[0],[0],[False],['0']
11413,PMC3641608,3061,The difference was almost exclusively driven by excess asymptomatic neutropenia (86 vs 133 vs 184 events; appendix).,Results,[17308],[29716],[29832],[False],[0],[0],[False],['0']
11414,PMC3641608,3062,"There were 15 versus 41 versus 31 definitely, probably, or uncertainly ART-related grade 3 or 4 adverse events, respectively.",Results,[17311],[29833],[29958],[False],[0],[0],[False],['0']
11415,PMC3641608,3063,"There were no significant differences in grade 3 or 4 anaemia or grade 4 only anaemia (with or without clinical symptoms; grade 3 or 4: 38 vs 44 vs 44, respectively; grade 4: 21 vs 24 vs 25, respectively).",Results,[17314],[29959],[30164],[False],[0],[0],[False],['0']
11416,PMC3641608,3064,"There were also no significant differences in the numbers of children with one or more grade 4 adverse events (63 [16%] vs 81 [20%] vs 76 [19%]; HR [B:A] 1·27, 0·91–1·76; HR [C:A] 1·20, 0·86–1·68; global p=0·34) or serious adverse events (87 [22%] vs 82 [20%] vs 95 [23%]; HR [B:A] 0·92, 0·68–1·25; HR [C:A] 1·09, 0·81–1·46; global p=0·53).",Results,[17317],[30165],[30505],[False],[0],[0],[False],['0']
11417,PMC3641608,3065,"ART-modifying adverse events occurred in eight (2%) children in group A versus 30 (7%) in group B and 25 (6%) in group C (HR [B:A] 3·80, 95% CI 1·74–8·29; HR (C:A) 3·09, 1·39–6·85; global p=0·002; figure 4).",Results,[17320],[30506],[30713],[False],[0],[0],[False],['0']
11418,PMC3641608,3066,"The most common modification (13 children in group B, 14 in C) was to stop (on four-drug regimen) or substitute zidovudine because of anaemia, even though grade 3 and 4 anaemias occurred similarly across all three groups.",Results,[17323],[30714],[30935],[False],[0],[0],[False],['0']
11419,PMC3641608,3067,"Despite substantial numbers of grade 3 neutropenias, only six children (two in group B, four in group C) modified ART (zidovudine) for this reason.",Results,[17326],[30936],[31083],[False],[0],[0],[False],['0']
11420,PMC3641608,3068,Three children substituted zidovudine because of lipoatrophy in group C; two children in group A and three in group B substituted efavirenz because of lipodystrophy or gynaecomastia.,Results,[17329],[31084],[31266],[False],[0],[0],[False],['0']
11421,PMC3641608,3069,Discussion,Discussion,[17332],[31267],[31278],[False],[0],[0],[False],['0']
11422,PMC3641608,3070,The DART trial in African adults with HIV showed that routine laboratory monitoring for ART side-effects had no effect on toxicity outcomes.,Discussion,[17335],[31279],[31419],[False],[0],[0],[False],['0']
11423,PMC3641608,3071,"Although routine CD4 monitoring had significant benefits on disease progression and mortality, absolute differences were small.",Discussion,[17338],[31420],[31547],[False],[0],[0],[False],['0']
11424,PMC3641608,3072,Health-economic analyses suggested point-of-care CD4 tests would need to cost less than US$3·80 for monitoring every 12 weeks after the first year on ART to be cost-effective.,Discussion,[17341],[31548],[31723],[False],[0],[0],[False],['0']
11425,PMC3641608,3073,"Smaller adult trials of routine CD4 or viral load monitoring, or both, have shown similar results, although no other trial has investigated toxicity monitoring.",Discussion,[17344],[31724],[31884],[False],[0],[0],[False],['0']
11426,PMC3641608,3074,"These results provide strong reassurance that increasing coverage by rollout of ART to adults at lower-level health facilities is the most rational and cost-effective policy at a population level, irrespective of provision of laboratory monitoring.",Discussion,[17347],[31885],[32133],[False],[0],[0],[False],['0']
11427,PMC3641608,3075,Most health centres in resource-limited settings treat adults and children with HIV in the same clinics.,Discussion,[17350],[32134],[32238],[False],[0],[0],[False],['0']
11428,PMC3641608,3076,"However, results from studies in adults might not generalise to children who have different comorbidities (eg, more anaemia associated with malnutrition, malaria, and sepsis, which could affect haematological monitoring).",Discussion,[17353],[32239],[32460],[False],[0],[0],[False],['0']
11429,PMC3641608,3077,"Differences in predictive value and interpretation of CD4 tests, faster disease progression in young children, and greater sensitivity of ART-related weight gain (which has reflected virological response) could also affect the relative benefits of laboratory versus clinical monitoring.",Discussion,[17356],[32461],[32747],[False],[0],[0],[False],['0']
11430,PMC3641608,3078,We therefore undertook the first paediatric trial investigating ART monitoring in children with fairly advanced HIV disease (panel).,Discussion,[17359],[32748],[32880],[False],[0],[0],[False],['0']
11431,PMC3641608,3079,"We found that NNRTI-based regimens, including WHO-recommended NRTIs, can be delivered safely across childhood without routine toxicity monitoring.",Discussion,[17362],[32881],[33027],[False],[0],[0],[False],['0']
11432,PMC3641608,3080,"Toxicity substitutions were infrequent, as previously reported; most were because of asymptomatic haematology results in children on zidovudine.",Discussion,[17365],[33028],[33172],[False],[0],[0],[False],['0']
11433,PMC3641608,3081,"Interestingly, grade 3 and 4 and grade 4 anaemias occurred similarly across groups receiving and not receiving zidovudine, both short and long term, suggesting that anaemia in children on ART is most likely caused by chronic HIV infection rather than antiretroviral drugs.",Discussion,[17368],[33173],[33445],[False],[0],[0],[False],['0']
11434,PMC3641608,3082,"Therefore, routine haemoglobin monitoring is likely unnecessary, even in children on zidovudine, and continuation of zidovudine without substitution (as occurred in clinically driven monitoring group C children) is unlikely to result in harm.",Discussion,[17371],[33446],[33688],[False],[0],[0],[False],['0']
11435,PMC3641608,3083,"Further, lack of haemoglobin testing before initiation of ART should not prevent zidovudine use, since haemoglobin values increased after ART initiation.",Discussion,[17374],[33689],[33842],[False],[0],[0],[False],['0']
11436,PMC3641608,3084,"Crucially, we observed no evidence of interaction between monitoring and ART strategies on any toxicity outcome.",Discussion,[17377],[33843],[33955],[False],[0],[0],[False],['0']
11437,PMC3641608,3085,We previously reported very few possible hypersensitivity reactions to abacavir (four [<1%] in 1206 patients) or difficulties managing abacavir plus nevirapine together in African children.,Discussion,[17380],[33956],[34145],[False],[0],[0],[False],['0']
11438,PMC3641608,3086,"Importantly for programme planners, first-line drug substitutions occurred as often for tuberculosis as for adverse events.",Discussion,[17383],[34146],[34269],[False],[0],[0],[False],['0']
11439,PMC3641608,3087,Tuberculosis was also by far the most common WHO stage 3 or 4 event.,Discussion,[17386],[34270],[34338],[False],[0],[0],[False],['0']
11440,PMC3641608,3088,One advantage of the four-drug induction regimen was the ability to simply drop nevirapine in children starting rifampicin.,Discussion,[17389],[34339],[34462],[False],[0],[0],[False],['0']
11441,PMC3641608,3089,"The ongoing tuberculosis incidence illustrates the potential usefulness of three-NRTI regimens in children, with 91% randomly assigned to group C still receiving maintenance with lamivudine, abacavir, and zidovudine after median 4 years.",Discussion,[17392],[34463],[34700],[False],[0],[0],[False],['0']
11442,PMC3641608,3090,"Tuberculosis remains particularly difficult to manage in children younger than 3 years who cannot take efavirenz, because rifampicin coadministration significantly reduces nevirapine and lopinavir concentrations.",Discussion,[17395],[34701],[34913],[False],[0],[0],[False],['0']
11443,PMC3641608,3091,"Super-boosting with additional ritonavir has been recommended with lopinavir, but ritonavir is unpalatable and difficult to dose.",Discussion,[17398],[34914],[35043],[False],[0],[0],[False],['0']
11444,PMC3641608,3092,"Substitution to three NRTIs is frequently used for children on NNRTI plus two NRTIs developing tuberculosis, but there have been concerns about reduced efficacy.",Discussion,[17401],[35044],[35205],[False],[0],[0],[False],['0']
11445,PMC3641608,3093,Viral load suppression was similar to standard NNRTI-based ART at 48 weeks for children moving to maintenance three-NRTI at 36 weeks.,Discussion,[17404],[35206],[35339],[False],[0],[0],[False],['0']
11446,PMC3641608,3094,"However, viral load suppression was significantly lower at 144 weeks, suggesting that long-term three-NRTI treatment would not be advisable (even after four-drug induction).",Discussion,[17407],[35340],[35513],[False],[0],[0],[False],['0']
11447,PMC3641608,3095,"Importantly, there was no evidence of immunological or clinical harm from roughly 15% lower viral load suppression long-term with three NRTIs; if anything this group had fewer clinical events, similar to previous randomised adult data.",Discussion,[17410],[35514],[35749],[False],[0],[0],[False],['0']
11448,PMC3641608,3096,These findings provide reassurance that a three-NRTI regimen is safe for children on ART when they need antituberculosis co-treatment.,Discussion,[17413],[35750],[35884],[False],[0],[0],[False],['0']
11449,PMC3641608,3097,"Overall, there was no evidence that clinically driven monitoring was inferior to routine laboratory monitoring in terms of disease progression or mortality.",Discussion,[17416],[35885],[36041],[False],[0],[0],[False],['0']
11450,PMC3641608,3098,"However, we found interactions with time on ART, disease progression or death being somewhat lower in the clinically driven monitoring group in the first year.",Discussion,[17419],[36042],[36201],[False],[0],[0],[False],['0']
11451,PMC3641608,3099,"Chance seems the most likely explanation, because management was similar with no child switching to second-line during the first year in both groups.",Discussion,[17422],[36202],[36351],[False],[0],[0],[False],['0']
11452,PMC3641608,3100,"The only other possible explanation is that receiving CD4, biochemistry, and haematology results was actually harmful for children (eg, resulting in clinicians failing to undertake proper clinical evaluations), which seems implausible.",Discussion,[17425],[36352],[36587],[False],[0],[0],[False],['0']
11453,PMC3641608,3101,"From the second year, our results are qualitatively similar to those of the DART trial, with small but significant clinical event excesses in clinically driven monitoring.",Discussion,[17428],[36588],[36759],[False],[0],[0],[False],['0']
11454,PMC3641608,3102,"However, event rates were substantially lower than in DART, so the excess remained within the non-inferiority margin; also fewer children switched to second-line ART with similar proportions in both groups.",Discussion,[17431],[36760],[36966],[False],[0],[0],[False],['0']
11455,PMC3641608,3103,"Unlike DART, there was no evidence of excess switching with very low CD4 in clinically driven monitoring.",Discussion,[17434],[36967],[37072],[False],[0],[0],[False],['0']
11456,PMC3641608,3104,"Whereas switches in routine laboratory monitoring were predominantly triggered by falling CD4, in clinically driven monitoring most switches were for failure to thrive, which might be a more sensitive indicator of first-line CD4 failure than in adults and could be used where CD4 monitoring is unavailable.",Discussion,[17437],[37073],[37379],[False],[0],[0],[False],['0']
11457,PMC3641608,3105,"Unnecessary switching at high CD4 did occur, as in DART, but in very few children (six on clinically driven monitoring and none on routine monitoring switched with CD4 greater than 25%).",Discussion,[17440],[37380],[37566],[False],[0],[0],[False],['0']
11458,PMC3641608,3106,"Other paediatric studies in which routine CD4 and viral load monitoring were used have also reported fairly low rates of switching from first-line NNRTI-based ART over 5–6 years (eg, 8% of 2570 Ugandan children; 22% in the PENPACT-1 trial).",Discussion,[17443],[37567],[37807],[False],[0],[0],[False],['0']
11459,PMC3641608,3107,"As expected and previously reported, most deaths were soon after starting ART in children with lowest pre-ART CD4 or weight for age.",Discussion,[17446],[37808],[37940],[False],[0],[0],[False],['0']
11460,PMC3641608,3108,"Irrespective of monitoring strategy, 5-year survival was remarkably high (96%, compared with 88% in DART), emphasising the importance of good clinical care, and availability of continuous ART and concomitant treatments.",Discussion,[17449],[37941],[38160],[False],[0],[0],[False],['0']
11461,PMC3641608,3109,"Loss to follow-up was only 2·7%, providing confidence that results are robust.",Discussion,[17452],[38161],[38239],[False],[0],[0],[False],['0']
11462,PMC3641608,3110,We also observed no differences between clinically driven and routine laboratory monitoring in CD4 or viral load responses.,Discussion,[17455],[38240],[38363],[False],[0],[0],[False],['0']
11463,PMC3641608,3111,"The only difference between monitoring strategies was in serious adverse events, due to an excess of clinical malaria admissions to hospital in clinically driven monitoring.",Discussion,[17458],[38364],[38537],[False],[0],[0],[False],['0']
11464,PMC3641608,3112,"One limitation is that the trial allocation was of necessity open; lack of knowledge of CD4 in a child on clinically driven monitoring presenting with fever could have influenced decisions about hospital admission, given the plausible differential diagnosis of bacteraemia.",Discussion,[17461],[38538],[38811],[True],['Blinding'],['the trial allocation was of necessity open'],[True],['Blinding']
11465,PMC3641608,3113,"Data for viral load from the 78% of children with results suggest that initiation of ART with four drugs might significantly improve early viral load suppression, consistent with greater early CD4 responses, particularly in those with very low pre-ART CD4.",Discussion,[17467],[38812],[39068],[False],[0],[0],[False],['0']
11466,PMC3641608,3114,"By design all children moved to three drugs at 36 weeks, in view of the possible toxicity and costs of four-drug regimens in the long term.",Discussion,[17470],[39069],[39208],[False],[0],[0],[False],['0']
11467,PMC3641608,3115,"Since toxicity differences were restricted to asymptomatic laboratory results with no effect on ART management, results hint that a longer-term four-drug, three NRTIs plus one NNRTI regimen might have continued to provide viral load and CD4 benefits, although this might not have translated into clinical benefit.",Discussion,[17473],[39209],[39522],[False],[0],[0],[False],['0']
11468,PMC3641608,3116,"However, viral load suppression with two NRTIs plus an NNRTI was fairly high, with 83% of children receiving an NNRTI with abacavir plus lamivudine throughout achieving less than 400 copies per mL long term, irrespective of monitoring strategy, so further gains from a fourth drug might be less plausible.",Discussion,[17476],[39523],[39828],[False],[0],[0],[False],['0']
11469,PMC3641608,3117,"Viral load suppression was similar to other trials in which viral load monitoring was done routinely (eg, 82% <400 copies per mL after median 5 years on two NRTIs plus an NNRTI or a protease inhibitor; 85% of infants <400 copies per mL after median 5 years on two NRTI plsu lopinavir or ritonavir (A Violari, personal communication); 85% and 75% of children <3 years <400 copies per mL after 48 weeks on two NRTI plus lopinavir or ritonavir, or nevirapine, respectively).",Discussion,[17479],[39829],[40300],[False],[0],[0],[False],['0']
11470,PMC3641608,3118,"This finding might be partly because of superiority of abacavir (in the ARROW two-NRTI backbone) over zidovudine, as previously reported.",Discussion,[17482],[40301],[40438],[False],[0],[0],[False],['0']
11471,PMC3641608,3119,"Coupled with the low clinical event rates after 1 year in ARROW, our data suggest any additional benefits from routine viral load monitoring are likely to be small.",Discussion,[17485],[40439],[40603],[False],[0],[0],[False],['0']
11472,PMC3641608,3120,"Although CD4 and viral load failure do not correlate well, the implications of late detection of viral load failure are likely to depend largely on how resistance evolves with persisting viral replication.",Discussion,[17488],[40604],[40809],[False],[0],[0],[False],['0']
11473,PMC3641608,3121,"In PENPACT-1, lamivudine and NNRTI resistance occurred with low-level viral load failure, so the consequences of delaying switch on these regimens until CD4 failure might be small; the 3-year PHPT trial in adults, which randomly assigned patients to routine CD4 with or without viral load monitoring, found no additional benefit from viral load, although patients in both groups of this trial had high viral load suppression.",Discussion,[17491],[40810],[41235],[False],[0],[0],[False],['0']
11474,PMC3641608,3122,"Although open allocation was an unavoidable limitation of the monitoring randomisation and was not undertaken for the ART-strategy randomisation, the endpoint review committee adjudicated endpoints masked to randomisation.",Discussion,[17495],[41236],[41458],[True],['PoorRandomizationMethods'],['open allocation'],[True],['Randomization']
11475,PMC3641608,3123,"In a survey at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring reported having CD4 testing done privately; clinicians remained masked.",Discussion,[17500],[41459],[41624],[False],[0],[0],[False],['0']
11476,PMC3641608,3124,"One possible criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.",Discussion,[17503],[41625],[41934],[False],[0],[0],[False],['0']
11477,PMC3641608,3125,This scenario seems unlikely since substantial CD4 variability and complexity around toxicity test interpretation mean that simple rules for acting on routine test results are unlikely ever to be optimum.,Discussion,[17508],[41935],[42139],[True],['PrecisionOfMeasurement'],['simple rules for acting on routine test results are unlikely ever to be optimum'],[True],['OutcomeMeasures']
11478,PMC3641608,3126,"Rather, clinicians providing the best clinical care are plausibly also best able to interpret and act on routine laboratory results.",Discussion,[17512],[42140],[42272],[False],[0],[0],[False],['0']
11479,PMC3641608,3127,"Thus although the overall risks of WHO events or death might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.",Discussion,[17515],[42273],[42528],[False],[0],[0],[False],['0']
11480,PMC3641608,3128,"Of note, we found no evidence that small benefits from CD4 monitoring varied by pre-ART CD4 or percentage, suggesting our results are robust to changes in ART initiation thresholds.",Discussion,[17518],[42529],[42710],[False],[0],[0],[False],['0']
11481,PMC3641608,3129,Toxicity monitoring has no benefit and costs money; it cannot therefore be cost-effective.,Discussion,[17521],[42711],[42801],[False],[0],[0],[False],['0']
11482,PMC3641608,3130,"This fact should reinforce WHO guidelines that routine toxicity tests are not required for paediatric ART provision, as for adults.",Discussion,[17524],[42802],[42933],[False],[0],[0],[False],['0']
11483,PMC3641608,3131,"Formal cost-effectiveness analysis is ongoing: given reduced efficacy of CD4 monitoring compared with DART, CD4 monitoring every 12 weeks is unlikely to be cost-effective in children overall (P Revill, personal communication), although it might have some potential to pick up earlier failure in older children or adolescents concealing adherence challenges.",Discussion,[17527],[42934],[43291],[False],[0],[0],[False],['0']
11484,PMC3641608,3132,"Cost-effectiveness analysis and systematic review is also planned to compare the induction-maintenance ART strategy with NNRTI and protease inhibitor-based first-line ART, including sensitivity analyses to account for increased efficacy but greater cost of abacavir versus zidovudine.",Discussion,[17530],[43292],[43576],[False],[0],[0],[False],['0']
11485,PMC3641608,3133,"In conclusion, ARROW results should send a strong message to African ART programmes to accelerate ART rollout to children since this process currently lags woefully behind adults.",Discussion,[17533],[43577],[43756],[False],[0],[0],[False],['0']
11486,PMC3641608,3134,The key finding is that ART provides enormous benefits to children and can be delivered safely with good-quality clinical care and without routine toxicity monitoring.,Discussion,[17536],[43757],[43924],[False],[0],[0],[False],['0']
11487,PMC3641608,3135,"For children initiating ART with severe immune suppression, addition of a fourth drug improves short-term immunological and virological responses; whether continuing a four-drug regimen longer-term would be advantageous remains unclear.",Discussion,[17539],[43925],[44161],[False],[0],[0],[False],['0']
11488,PMC3641608,3136,"However, ARROW results support short-term use of three-drug NRTI regimens during antituberculosis treatment in children already on ART.",Discussion,[17542],[44162],[44297],[False],[0],[0],[False],['0']
11489,PMC3641608,3137,"Simple point-of-care CD4 tests might have a future role, at least to confirm clinical need to switch to second-line ART, as in DART.",Discussion,[17545],[44298],[44430],[False],[0],[0],[False],['0']
11490,PMC3641608,3138,"In children, monitoring of weight gain should be emphasised as an important additional clinical aid for identification of first-line failure.",Discussion,[17548],[44431],[44572],[False],[0],[0],[False],['0']
11491,PMC3641608,3139,Laboratory tests remain important for assessment of ART eligibility and for diagnosis and management of intercurrent infections.,Discussion,[17551],[44573],[44701],[False],[0],[0],[False],['0']
11492,PMC3641608,3140,Mentoring of health-care workers to foster quality clinical care and reassurance that children do very well without laboratory monitoring of ART should energise faster and further scale-up of ART rollout for children with HIV in Africa.,Discussion,[17554],[44702],[44938],[False],[0],[0],[False],['0']
11493,PMC3641608,3141,"Correspondence to: Prof Diana M Gibb, MRC Clinical Trials Unit, London WC2B 6NH, UK, dmg@ctu.mrc.ac.uk",Discussion,[17557],[44939],[45041],[False],[0],[0],[False],['0']
11494,PMC3641608,3142,Supplementary Material,Supplementary Material,[17560],[45042],[45065],[False],[0],[0],[False],['0']
11495,PMC3641608,3143,Supplementary Material,Supplementary Material|Supplementary Material,[17563],[45066],[45089],[False],[0],[0],[False],['0']
11496,PMC3641608,3144,Trial profile,Supplementary Material|Trial profile,[17566],[45090],[45103],[False],[0],[0],[False],['0']
11497,PMC3641608,3145,"Study ended on March 16, 2012.",Supplementary Material|Trial profile,[17569],[45104],[45134],[False],[0],[0],[False],['0']
11498,PMC3641608,3146,ART=antiretroviral therapy.,Supplementary Material|Trial profile,[17572],[45135],[45162],[False],[0],[0],[False],['0']
11499,PMC3641608,3147,*Predominant reason for ineligibility given according to frequency.,Supplementary Material|Trial profile,[17575],[45163],[45230],[False],[0],[0],[False],['0']
11500,PMC3641608,3148,"† First randomisation included, second excluded.",Supplementary Material|Trial profile,[17578],[45231],[45279],[False],[0],[0],[False],['0']
11501,PMC3641608,3149,‡Communication error at enrolment.,Supplementary Material|Trial profile,[17581],[45280],[45314],[False],[0],[0],[False],['0']
11502,PMC3641608,3150,§Both on intensive phase of tuberculosis treatment.,Supplementary Material|Trial profile,[17584],[45315],[45366],[False],[0],[0],[False],['0']
11503,PMC3641608,3151,Substitution in first-line ART (any reason) and switch to second-line ART (A) By monitoring strategy.,Supplementary Material|Trial profile,[17587],[45367],[45468],[False],[0],[0],[False],['0']
11504,PMC3641608,3152,(B) By ART strategy.,Supplementary Material|Trial profile,[17590],[45469],[45489],[False],[0],[0],[False],['0']
11505,PMC3641608,3153,"Lines show cumulative incidence of switch to second-line treatment before death on first-line, and of substitution in first-line before death on first-line estimated treating death on first-line as a competing risk.",Supplementary Material|Trial profile,[17593],[45490],[45705],[False],[0],[0],[False],['0']
11506,PMC3641608,3154,ART=antiretroviral therapy.,Supplementary Material|Trial profile,[17596],[45706],[45733],[False],[0],[0],[False],['0']
11507,PMC3641608,3155,CHR=cause-specific hazard ratio.,Supplementary Material|Trial profile,[17599],[45734],[45766],[False],[0],[0],[False],['0']
11508,PMC3641608,3156,CDM=clinically driven monitoring.,Supplementary Material|Trial profile,[17602],[45767],[45800],[False],[0],[0],[False],['0']
11509,PMC3641608,3157,LCM=laboratory and clinical monitoring.,Supplementary Material|Trial profile,[17605],[45801],[45840],[False],[0],[0],[False],['0']
11510,PMC3641608,3158,"New WHO 4 stage event or death (A), CD4 (B), viral load (C), and adverse events (D), by monitoring strategy",Supplementary Material|Trial profile,[17608],[45841],[45948],[False],[0],[0],[False],['0']
11511,PMC3641608,3159,CDM=clinically driven monitoring.,Supplementary Material|Trial profile,[17611],[45949],[45982],[False],[0],[0],[False],['0']
11512,PMC3641608,3160,LCM=laboratory and clinical monitoring.,Supplementary Material|Trial profile,[17614],[45983],[46022],[False],[0],[0],[False],['0']
11513,PMC3641608,3161,ART=antiretroviral therapy.,Supplementary Material|Trial profile,[17617],[46023],[46050],[False],[0],[0],[False],['0']
11514,PMC3641608,3162,AE=adverse event.,Supplementary Material|Trial profile,[17620],[46051],[46068],[False],[0],[0],[False],['0']
11515,PMC3641608,3163,SAE=serious adverse event.,Supplementary Material|Trial profile,[17623],[46069],[46095],[False],[0],[0],[False],['0']
11516,PMC3641608,3164,*CD4 cell count in children aged 5 years or older at ART initiation.,Supplementary Material|Trial profile,[17626],[46096],[46164],[False],[0],[0],[False],['0']
11517,PMC3641608,3165,† Upper lines show suppression less than 400 copies per mL and lower lines suppression less than 80 copies per mL (2:1 dilution used for most samples because of low stored volumes).,Supplementary Material|Trial profile,[17629],[46165],[46346],[False],[0],[0],[False],['0']
11518,PMC3641608,3166,"New WHO 4 stage event or death (A), CD4 (B), viral load (C), and adverse events (D), by ART strategy",Supplementary Material|Trial profile,[17632],[46347],[46447],[False],[0],[0],[False],['0']
11519,PMC3641608,3167,ART=antiretroviral therapy.,Supplementary Material|Trial profile,[17635],[46448],[46475],[False],[0],[0],[False],['0']
11520,PMC3641608,3168,AE=adverse event.,Supplementary Material|Trial profile,[17638],[46476],[46493],[False],[0],[0],[False],['0']
11521,PMC3641608,3169,SAE=serious adverse event.,Supplementary Material|Trial profile,[17641],[46494],[46520],[False],[0],[0],[False],['0']
11522,PMC3641608,3170,*CD4 cell count in children aged 5 years or older at ART initiation.,Supplementary Material|Trial profile,[17644],[46521],[46589],[False],[0],[0],[False],['0']
11523,PMC3641608,3171,† Upper lines show suppression less than 400 copies per mL and lower lines suppression less than 80 copies per mL (2:1 dilution used for most samples because of low stored volumes).,Supplementary Material|Trial profile,[17647],[46590],[46771],[False],[0],[0],[False],['0']
11524,PMC3641608,3172,Characteristics at randomisation,Supplementary Material|Characteristics at randomisation,[17650],[46772],[46804],[False],[0],[0],[False],['0']
11525,PMC3641608,3173,"		Monitoring strategy	First-line ART strategy	 			Clinically driven monitoring (n=606)	Routine laboratory and clinical monitoring (n=600)	Group A (n=397)	Group B (n=404)	Group C (n=405)	 	Centre	 		Entebbe, Uganda	92 (15%)	96 (16%)	61 (15%)	61 (15%)	66 (16%)	 		Joint Clinical Research Centre, Kampala, Uganda	161 (27%)	157 (26%)	104 (26%)	108 (27%)	106 (26%)	 		Paediatric Infectious Disease Centre, Mulago, Uganda	152 (25%)	148 (25%)	101 (25%)	99 (25%)	100 (25%)	 		University of Zimbabwe, Harare, Zimbabwe	201 (33%)	199 (33%)	131 (33%)	136 (34%)	133 (33%)	 	Male	298 (49%)	298 (50%)	193 (49%)	207 (51%)	196 (48%)	 	Age (years)	5·9 (2·2 to 9·2)	6·0 (2·6 to 9·4)	6·1 (2·4 to 9·3)	6·2 (2·5 to 9·4)	5·7 (2·3 to 9·3)	 	Children younger than 3 years	197 (33%)	173 (29%)	121 (30%)	117 (29%)	132 (33%)	 	Vertical exposure*	605 (>99%)	594 (99%)	395 (99%)	401 (99%)	403 (>99%)	 	CD4	 		Median CD4 percentage (%)	12·5% (7·5 to 17·3)	12·0% (7·0 to 17·0)	11·7% (6·9 to 17·5)	12·0% (7·1 to 17·0)	12·5% (8·0 to 17·0)	 		Children with CD4 percentage <5%	92 (15%)	110 (18%)	75 (19%)	67 (17%)	60 (15%)	 		Median CD4 cell count†	244 (114 to 369)	237 (94 to 366)	221 (87 to 341)	242 (108 to 369)	262 (114 to 373)	 	WHO stage	 		1	13 (2%)	7 (1%)	4 (1%)	7 (2%)	9 (2%)	 		2	160 (26%)	174 (29%)	119 (30%)	116 (29%)	99 (24%)	 		3	346 (57%)	337 (56%)	217 (55%)	228 (56%)	238 (59%)	 		4	87 (14%)	82 (14%)	57 (14%)	53 (13%)	59 (15%)	 	Eligibility for ART	 		Clinical only	95 (16%)	96 (16%)	67 (17%)	59 (15%)	65 (16%)	 		Immunological only	160 (26%)	167 (28%)	114 (29%)	114 (28%)	99 (24%)	 		Clinical and immunological	351 (58%)	337 (56%)	216 (54%)	231 (57%)	241 (60%)	 	Median weight-for-age Z score‡	−2·3 (−3·4 to −1·3)	−2·2 (−3·3 to −1·3)	−2·3 (−3·5 to −1·3)	−2·2 (−3·2 to −1·4)	−2·2 (−3·4 to −1·3)	 	Weight-for-age Z score <–3	191 (32%)	184 (31%)	130 (33%)	119 (29%)	126 (31%)	 	Median height-for-age Z score‡	−2·5 (−3·4 to −1·5)	−2·4 (−3·4 to −1·5)	−2·4 (−3·4 to −1·5)	−2·5 (−3·4 to −1·5)	−2·4 (−3·3 to −1·5)	 	Height-for-age Z score <–3	211 (35%)	191 (32%)	139 (35%)	127 (31%)	136 (34%)	 	Haemoglobin (g/L)	105 (95 to 115)	106 (96 to 116)	105 (94 to 115)	107 (96 to 116)	106 (94 to 115)	 	Neutrophils (×1000 cells per mL)	2·0 (1·4 to 2·9)	2·1 (1·5 to 2·9)	2·0 (1·4 to 2·8)	2·2 (1·5 to 3·0)	2·0 (1·4 to 2·8)	 	First-line ART, abacavir plus lamivudine plus	 		Nevirapine	129 (21%)	125 (21%)	253 (64%)	1 (<1%)	0	 		Efavirenz§	71 (12%)	72 (12%)	143 (36%)	0	0	 		Zidovudine plus nevirapine¶	256 (42%)	248 (41%)	1 (<1%)	249 (62%)	254 (63%)	 		Zidovudine plus efavirenz¶	150 (25%)	155 (26%)	0	154 (38%)	151 (37%)	 	Prophylaxis use from enrolment	 		Co-trimoxazole	603 (>99%)	598 (>99%)	396 (>99%)	402 (>99%)	403 (>99%)	 		Dapsone	3 (<1%)	0	1 (<1%)	1 (<1%)	1 (<1%)	 		None	0	2‖ (<1%)	0	1‖ (<1%)	1‖ (<1%)",Supplementary Material|Characteristics at randomisation,[17653],[46805],[49580],[False],[0],[0],[False],['0']
11526,PMC3641608,3174,Data are n (%) or median (IQR).,Supplementary Material|Characteristics at randomisation,[17656],[49581],[49615],[False],[0],[0],[False],['0']
11527,PMC3641608,3175,ART=antiretroviral therapy.,Supplementary Material|Characteristics at randomisation,[17659],[49616],[49643],[False],[0],[0],[False],['0']
11528,PMC3641608,3176,Seven children with missing route of HIV transmission had no evidence of HIV infection in the biological mother who was already deceased at the time of trial enrolment with no other evidence suggesting infection.,Supplementary Material|Characteristics at randomisation,[17662],[49644],[49856],[False],[0],[0],[False],['0']
11529,PMC3641608,3177,Age older than 5 years at enrolment.,Supplementary Material|Characteristics at randomisation,[17665],[49857],[49893],[False],[0],[0],[False],['0']
11530,PMC3641608,3178,Z score using UK 1990 reference to include full age range.,Supplementary Material|Characteristics at randomisation,[17668],[49894],[49952],[False],[0],[0],[False],['0']
11531,PMC3641608,3179,Efavirenz not licensed for children younger than 3 years.,Supplementary Material|Characteristics at randomisation,[17671],[49953],[50010],[False],[0],[0],[False],['0']
11532,PMC3641608,3180,"Children initiating ART with four drugs dropped either nevirapine, efavirenz, or zidovudine at week 36 in factorial randomisation.",Supplementary Material|Characteristics at randomisation,[17674],[50011],[50141],[False],[0],[0],[False],['0']
11533,PMC3641608,3181,Grade 2 neutropenia at enrolment: initiated co-trimoxazole 1 and 4 months later.,Supplementary Material|Characteristics at randomisation,[17677],[50142],[50222],[False],[0],[0],[False],['0']
11534,PMC3641608,3182,ART received,Supplementary Material|ART received,[17680],[50223],[50235],[False],[0],[0],[False],['0']
11535,PMC3641608,3183,"			Monitoring strategy	First-line ART strategy	 				Clinically driven monitoring (n=606)	Routine laboratory and clinical monitoring (n=600)	Group A (n=397)	Group B (n=404)	Group C (n=405)	 	At end of trial or when last seen alive	 	Remained on first-line ART	578 (95%)	565 (94%)	371 (93%)	387 (96%)	385 (95%)	 		On randomised first-line ART	534 (88%)	519 (87%)	330 (83%)	356 (88%)	367 (91%)	 	Had switched to second-line ART	28 (5%)	35 (6%)	26 (7%)	17 (4%)	20 (5%)	 		For CD4 criteria, per protocol	0	17	10	3	4	 		For other CD4 concerns*	0	11	3	4	4	 		For new or recurrent WHO stage 4 event per protocol†	26	6	11	10	11	 			Severe failure to-thrive	15	3	5	7	6	 		For persistent WHO stage 3 event per protocol	2	1	2	0	1	 			Moderately severe failure-to-thrive	1	0	0	0	1	 	Ever changed a drug in first-line ART	 	All	69 (11%)	68 (11%)	46 (12%)	53 (13%)	38 (9%)	 	Ever changed a drug for toxicity‡	40 (7%)	44 (7%)	19 (5%)	35 (9%)	30 (7%)	 	Ever substituted a drug for toxicity	27 (4%)	26 (4%)	19 (5%)	17 (4%)	17 (4%)	 	Ever changed a drug for tuberculosis‡	31 (5%)	28 (5%)	30 (8%)	20 (5%)	9 (2%)	 	Ever substituted a drug for tuberculosis	24 (4%)	24 (4%)	30 (8%)	15 (4%)	3 (1%)	 	Total changes to first-line ART	 	All	75 (100%)	76 (100%)	53 (100%)	58 (100%)	40 (100%)	 	Total changes for toxicity	29 (39%)	30 (39%)	5 (9%)	28 (48%)	26 (65%)	 		Dropped zidovudine for haematological AE	11	13	0	15	9	 		Substituted zidovudine for haematological AE	5	5	0	1	9	 		Changed for rash or hypersensitivity	6	7	3	6	4	 		Changed for raised liver function tests	3	2	1	3	1	 		Changed for lipodystrophy or lipoatrophy	4	3	1	3	3	 	Total changes for tuberculosis	31 (41%)	28 (37%)	30 (57%)	20 (34%)	9 (23%)	 		Dropped nevirapine	7	4	0	5	6	 		Substituted nevirapine with another drug	24	24	30	15	3	 	Total changes for other reasons§	15 (20%)	18 (24%)	18 (34%)	10 (17%)	5 (13%)",Supplementary Material|ART received,[17683],[50236],[52089],[False],[0],[0],[False],['0']
11536,PMC3641608,3184,Data are n (% of children).,Supplementary Material|ART received,[17686],[52090],[52120],[False],[0],[0],[False],['0']
11537,PMC3641608,3185,ART=antiretroviral therapy.,Supplementary Material|ART received,[17689],[52121],[52148],[False],[0],[0],[False],['0']
11538,PMC3641608,3186,AE=adverse event.,Supplementary Material|ART received,[17692],[52149],[52166],[False],[0],[0],[False],['0']
11539,PMC3641608,3187,"Typically CD4 slightly higher than the WHO thresholds (confirmed on-ART CD4 <15% if age 1–2 years, <10% if 3–4 years, <100 cells per mL if ≥5 years).",Supplementary Material|ART received,[17695],[52167],[52316],[False],[0],[0],[False],['0']
11540,PMC3641608,3188,Some events that led to switching were not adjudicated to meet prespecified protocol criteria by the endpoint review committee and so were not included as primary or secondary endpoints.,Supplementary Material|ART received,[17698],[52317],[52503],[False],[0],[0],[False],['0']
11541,PMC3641608,3189,"Children randomly assigned to four-drug induction could drop one of the four original drugs for toxicity or other reasons, without having to substitute.",Supplementary Material|ART received,[17701],[52504],[52656],[False],[0],[0],[False],['0']
11542,PMC3641608,3190,"11 dispensing errors, six changes due to pregnancy, 16 other carer preference or domestic reasons.",Supplementary Material|ART received,[17704],[52657],[52755],[False],[0],[0],[False],['0']
11543,PMC3641608,3191,Research in context,Supplementary Material|Research in context,[17707],[52756],[52775],[False],[0],[0],[False],['0']
11544,PMC3641608,3192,Systematic review,Supplementary Material|Systematic review,[17710],[52776],[52793],[False],[0],[0],[False],['0']
11545,PMC3641608,3193,"We searched PubMed up to Jan 5, 2013, with search terms “HIV” AND “monitoring” AND (“antiretroviral therapy” OR “ART”) AND “trial”*.",Supplementary Material|Systematic review,[17713],[52794],[52926],[False],[0],[0],[False],['0']
11546,PMC3641608,3194,We identified three trials in adults; one further trial had been presented but not published.,Supplementary Material|Systematic review,[17716],[52927],[53020],[False],[0],[0],[False],['0']
11547,PMC3641608,3195,There were no trials in children.,Supplementary Material|Systematic review,[17719],[53021],[53054],[False],[0],[0],[False],['0']
11548,PMC3641608,3196,"Trials in adults showed that clinical monitoring was safe and feasible, but CD4 monitoring to detect first-line failure provided small additional benefits; addition of viral load to routine CD4 monitoring provided no further benefits.",Supplementary Material|Systematic review,[17722],[53055],[53289],[False],[0],[0],[False],['0']
11549,PMC3641608,3197,"Replacement of “monitoring” with child* identified previous short-term (24 or 48 week) trials that showed three-drug protease inhibitor-based (lopinavir or ritonavir) ART to be superior to nevirapine-based ART in children younger than 3 years; however, studies in older children found similar responses, and lopinavir and ritonavir are costly and logistically challenging to administer.",Supplementary Material|Systematic review,[17725],[53290],[53676],[False],[0],[0],[False],['0']
11550,PMC3641608,3198,Interpretation,Supplementary Material|Interpretation,[17728],[53677],[53691],[False],[0],[0],[False],['0']
11551,PMC3641608,3199,"Routine laboratory monitoring for toxicity on non-nucleoside reverse transcriptase inhibitors (NNRTIs) plus nucleoside reverse transcriptase inhibitors (NRTIs; abacavir or zidovudine plus lamivudine) is not needed in children, as in adults; requiring such monitoring might be a barrier to life-saving treatment.",Supplementary Material|Interpretation,[17731],[53692],[54003],[False],[0],[0],[False],['0']
11552,PMC3641608,3200,"CD4 monitoring provided a small but significant reduction in disease progression or death after the second year on ART in children, as in adults.",Supplementary Material|Interpretation,[17734],[54004],[54149],[False],[0],[0],[False],['0']
11553,PMC3641608,3201,"However, unlike adults, CD4 and viral load responses were very similar irrespective of CD4 versus clinical monitoring.",Supplementary Material|Interpretation,[17737],[54150],[54268],[False],[0],[0],[False],['0']
11554,PMC3641608,3202,"Monitoring weight-gain appeared a sensitive indicator of first-line CD4 failure, and drug changes occurred as often for concurrent tuberculosis as for adverse events.",Supplementary Material|Interpretation,[17740],[54269],[54435],[False],[0],[0],[False],['0']
11555,PMC3641608,3203,"Four-drug ART with an NNRTI plus three NRTIs provided superior short-term virological suppression and CD4 responses, but these benefits were not sustained during maintenance three-drug ART.",Supplementary Material|Interpretation,[17743],[54436],[54625],[False],[0],[0],[False],['0']
11556,PMC3641608,3204,"However, 83% of children in ARROW had viral load less than 400 copies per mL with abacavir, lamivudine, and a NNRTI for 3·7 years, irrespective of age, supporting previously reported superiority of abacavir over zidovudine.",Supplementary Material|Interpretation,[17746],[54626],[54849],[False],[0],[0],[False],['0']
11557,PMC3641608,3205,"Three-NRTI long-term maintenance was clinically and immunologically similar to NNRTI-based ART, and would be useful during tuberculosis cotreatment.",Supplementary Material|Interpretation,[17749],[54850],[54998],[False],[0],[0],[False],['0']
11558,PMC3641608,3206,Results support an integrated approach to treatment of adults and children in treatment rollout.,Supplementary Material|Interpretation,[17752],[54999],[55095],[False],[0],[0],[False],['0']
11559,PMC3641608,3207,"Cost and feasibility (eg, through point-of-care tests) of provision of CD4 monitoring are future challenges.",Supplementary Material|Interpretation,[17755],[55096],[55204],[False],[0],[0],[False],['0']
12225,PMC3679996,17144,Associations between oral health-related impacts and rate of weight gain after extraction of pulpally involved teeth in underweight preschool Filipino children,Title,[101910],[38752],[159],[False],[0],[0],[False],['0']
12226,PMC3679996,17145,Background,Abstract,[101923],[160],[171],[False],[0],[0],[False],['0']
12227,PMC3679996,17146,Severe dental caries in young children is associated with underweight and failure to thrive.,Abstract,[101936],[172],[264],[False],[0],[0],[False],['0']
12228,PMC3679996,17147,"One possible mechanism for severe caries affecting growth is that the resulting pain and discomfort influences sleeping and eating, and that affects growth and weight.",Abstract,[101949],[265],[432],[False],[0],[0],[False],['0']
12229,PMC3679996,17148,The objective of this study was to assess whether rate of weight gain after extraction of severely decayed teeth in underweight preschool Filipino children was related to reductions in oral health-related impacts and dental pain from severe dental caries affecting eating and sleeping.,Abstract,[101962],[433],[718],[False],[0],[0],[False],['0']
12230,PMC3679996,17149,Methods,Methods,[101975],[719],[727],[False],[0],[0],[False],['0']
12231,PMC3679996,17150,"Data are from the Weight Gain Study, a stepped wedge cluster randomized clinical trial where underweight Filipino children with severe dental decay had their pulpally involved teeth extracted.",Methods,[101988],[728],[920],[False],[0],[0],[False],['0']
12232,PMC3679996,17151,Day care centers were randomly divided into two groups; A and B.,Methods,[102001],[921],[985],[False],[0],[0],[False],['0']
12233,PMC3679996,17152,Group A children received treatment first and Group B children were treated four months after Group A.,Methods,[102014],[986],[1088],[False],[0],[0],[False],['0']
12234,PMC3679996,17153,Clinical oral examinations used WHO criteria and the pufa-index.,Methods,[102027],[1089],[1153],[False],[0],[0],[False],['0']
12235,PMC3679996,17154,"Self-reported oral health-related impacts and anthropometric measurements were collected for both groups at baseline, four months after treatment of Group A children and four months after treatment of Group B children.",Methods,[102040],[1154],[1372],[False],[0],[0],[False],['0']
12236,PMC3679996,17155,Weight-for-age z-scores were calculated using 2006 and 2007 WHO standards.,Methods,[102053],[1373],[1447],[False],[0],[0],[False],['0']
12237,PMC3679996,17156,"Data were converted to a one-group pre-test post-test study design, where all children received treatment.",Methods,[102066],[1448],[1554],[False],[0],[0],[False],['0']
12238,PMC3679996,17157,Associations between changes in oral health-related impacts and weight-for-age z-scores after dental treatment were assessed.,Methods,[102079],[1555],[1680],[False],[0],[0],[False],['0']
12239,PMC3679996,17158,Results,Results,[102092],[1681],[1689],[False],[0],[0],[False],['0']
12240,PMC3679996,17159,Data on 145 children (mean age 61.4 months) were analyzed.,Results,[102105],[1690],[1748],[False],[0],[0],[False],['0']
12241,PMC3679996,17160,There was a significant association between oral health-related impacts and rate of weight gain after extraction of pulpally involved teeth (p=0.02).,Results,[102118],[1749],[1898],[False],[0],[0],[False],['0']
12242,PMC3679996,17161,Children free of impacts on sleeping related to having severely decayed teeth extracted gained significantly more weight compared to children who reported sleeping problems after dental treatment (p<0.01).,Results,[102131],[1899],[2104],[False],[0],[0],[False],['0']
12243,PMC3679996,17162,Conclusions,Conclusions,[102144],[2105],[2117],[False],[0],[0],[False],['0']
12244,PMC3679996,17163,"After extraction of severely decayed teeth in underweight Filipino children, levels of oral health-related impacts were associated with rate of weight gain.",Conclusions,[102157],[2118],[2274],[False],[0],[0],[False],['0']
12245,PMC3679996,17164,Decreases in oral health impacts on sleeping appeared to be most strongly associated with weight gain.,Conclusions,[102170],[2275],[2377],[False],[0],[0],[False],['0']
12246,PMC3679996,17165,Trial registration,Trial registration,[102183],[2378],[2397],[False],[0],[0],[False],['0']
12247,PMC3679996,17166,ISRCTN: ISRCTN90779069,Trial registration,[102196],[2398],[2420],[False],[0],[0],[False],['0']
12248,PMC3679996,17167,Background,Background,[102209],[2421],[2433],[False],[0],[0],[False],['0']
12249,PMC3679996,17168,Untreated severe dental caries in preschool children is very common in many low- and middle-income countries [1].,Background,[102222],[2434],[2547],[False],[0],[0],[False],['0']
12250,PMC3679996,17169,"In the Philippines, caries levels are among the highest in South-East Asia.",Background,[102235],[2548],[2623],[False],[0],[0],[False],['0']
12251,PMC3679996,17170,The 2006 Philippine National Oral Health Survey revealed that the mean number of decayed or missing teeth in 6-years-olds was 8.4 [2].,Background,[102248],[2624],[2758],[False],[0],[0],[False],['0']
12252,PMC3679996,17171,Children had on average 3.4 teeth where caries had progressed into the pulp.,Background,[102261],[2759],[2835],[False],[0],[0],[False],['0']
12253,PMC3679996,17172,Severe dental caries affects young children’s quality of life and well-being.,Background,[102274],[2836],[2913],[False],[0],[0],[False],['0']
12254,PMC3679996,17173,Children with untreated early childhood caries (ECC) had significantly poorer oral health-related quality of life (OHRQoL) than those without ECC [3].,Background,[102287],[2914],[3064],[False],[0],[0],[False],['0']
12255,PMC3679996,17174,"Dental rehabilitation resulted in significant improvements in children’s OHRQoL with significant reductions in dental pain, sleeping and eating problems, and their eating and appetite improved [4-7].",Background,[102300],[3065],[3264],[False],[0],[0],[False],['0']
12256,PMC3679996,17175,Poor oral health in children is associated with underweight and failure to thrive [8].,Background,[102313],[3265],[3351],[False],[0],[0],[False],['0']
12257,PMC3679996,17176,Children requiring multiple extractions of severely decayed teeth had significantly lower body weights than caries free children [9-11].,Background,[102326],[3352],[3488],[False],[0],[0],[False],['0']
12258,PMC3679996,17177,Similar results were observed in the Philippine National Oral Health Survey [12].,Background,[102339],[3489],[3570],[False],[0],[0],[False],['0']
12259,PMC3679996,17178,"Alkarimi demonstrated that there is a graded inverse relationship between severe dental caries and weight, height and BMI in Saudi children [13].",Background,[102352],[3571],[3716],[False],[0],[0],[False],['0']
12260,PMC3679996,17179,"Dental rehabilitation of underweight children with severe dental caries was associated with an increased rate of weight gain [14,15].",Background,[102365],[3717],[3850],[False],[0],[0],[False],['0']
12261,PMC3679996,17180,"Extraction of pulpally involved primary teeth resulted in significant weight gain in underweight children participating in the Weight Gain Study (WGS), a cluster randomized clinical trial conducted in the Philippines [16].",Background,[102378],[3851],[4073],[False],[0],[0],[False],['0']
12262,PMC3679996,17181,There are several plausible mechanisms explaining why dental rehabilitation leads to an increased rate of weight gain.,Background,[102391],[4074],[4192],[False],[0],[0],[False],['0']
12263,PMC3679996,17182,"Severe dental decay can cause dental pain and that can negatively affect children’s ability to eat and sleep [4,5].",Background,[102404],[4193],[4308],[False],[0],[0],[False],['0']
12264,PMC3679996,17183,"Impacts on eating may affect the quality and quantity of nutritious food consumed, resulting in inadequate caloric intake, while disturbed sleep due to dental pain can affect the secretion of growth hormones [17] or may cause excessive energy expenditure.",Background,[102417],[4309],[4564],[False],[0],[0],[False],['0']
12265,PMC3679996,17184,Another theory is that dental inflammation from pulpally involved teeth suppresses growth through a metabolic pathway by reducing hemoglobin levels as a result of depressed erythrocyte production in the bone marrow [18].,Background,[102430],[4565],[4785],[False],[0],[0],[False],['0']
12266,PMC3679996,17185,"However, none of these theories have been thoroughly tested.",Background,[102443],[4786],[4846],[False],[0],[0],[False],['0']
12267,PMC3679996,17186,The objective of this study was to assess whether rate of weight gain after extraction of severely decayed teeth in underweight preschool Filipino children was related to reductions in oral health-related impacts and dental pain from severe dental caries affecting eating and sleeping.,Background,[102456],[4847],[5132],[False],[0],[0],[False],['0']
12268,PMC3679996,17187,Methods,Methods,[102469],[5133],[5141],[False],[0],[0],[False],['0']
12269,PMC3679996,17188,Study design,Methods|Study design,[102482],[5142],[5154],[False],[0],[0],[False],['0']
12270,PMC3679996,17189,"The present study used data from the Weight Gain Study, which was a stepped wedge cluster randomized clinical trial [19,20].",Methods|Study design,[102495],[5155],[5279],[False],[0],[0],[False],['0']
12271,PMC3679996,17190,"In the WGS, thirteen day care centers in ten municipalities in the province of Misamis Oriental were randomly divided into two groups; intervention Group A (six day care centers) and waiting list control Group B (seven day care centers).",Methods|Study design,[102508],[5280],[5517],[False],[0],[0],[False],['0']
12272,PMC3679996,17191,Children from Group A (n=100) had all pulpally involved primary teeth extracted under local anesthesia [17].,Methods|Study design,[102521],[5518],[5626],[False],[0],[0],[False],['0']
12273,PMC3679996,17192,Their other carious teeth were treated with silver-diamine-fluoride Arrest of Caries Technique (ACT) [21].,Methods|Study design,[102534],[5627],[5733],[False],[0],[0],[False],['0']
12274,PMC3679996,17193,Children in Group B (n=102) were treated four months later in the same way as Group A children.,Methods|Study design,[102547],[5734],[5829],[False],[0],[0],[False],['0']
12275,PMC3679996,17194,"Anthropometric measurements, data on oral health-related impacts and blood samples were collected at the same time for both groups at the beginning of the study, four months after treatment of Group A children and four months after treatment of Group B children (Figure 1, Design I).",Methods|Study design,[102560],[5830],[6113],[False],[0],[0],[False],['0']
12276,PMC3679996,17195,For this study data from the WGS were converted into a one-group pretest-posttest study design where all children received treatment.,Methods|Study design,[102573],[6114],[6247],[False],[0],[0],[False],['0']
12277,PMC3679996,17196,"Baseline data existed of the measurements of all children from Groups A and B, collected immediately before they received dental treatment.",Methods|Study design,[102586],[6248],[6387],[False],[0],[0],[False],['0']
12278,PMC3679996,17197,"The follow-up data were measurements collected four months after the children were treated (Figure 1, Design II).",Methods|Study design,[102599],[6388],[6501],[False],[0],[0],[False],['0']
12279,PMC3679996,17198,Study population,Study population,[102612],[6502],[6519],[False],[0],[0],[False],['0']
12280,PMC3679996,17199,"Children in the WGS, aged between 48 and 68 months, were recruited from day care centers in municipalities in the province of Misamis Oriental, Northern Mindanao, Philippines.",Study population,[102625],[6520],[6695],[False],[0],[0],[False],['0']
12281,PMC3679996,17200,"All children were underweight and had severe dental caries, with one or more pulpally involved primary teeth.",Study population,[102638],[6696],[6805],[False],[0],[0],[False],['0']
12282,PMC3679996,17201,Children were defined as underweight if their BMI was below the 5th percentile according to CDC Growth Charts.,Study population,[102651],[6806],[6916],[False],[0],[0],[False],['0']
12283,PMC3679996,17202,"Children who tested positive for active tuberculosis infection at the screening stage were excluded, and referred for treatment.",Study population,[102664],[6917],[7045],[False],[0],[0],[False],['0']
12284,PMC3679996,17203,Mentally handicapped children were also excluded for ethical reasons.,Study population,[102677],[7046],[7115],[False],[0],[0],[False],['0']
12285,PMC3679996,17204,"None of the included children had systemic medical conditions and/or infectious diseases, according to parental reports.",Study population,[102690],[7116],[7236],[False],[0],[0],[False],['0']
12286,PMC3679996,17205,All parents or caregivers signed an informed consent.,Study population,[102703],[7237],[7290],[False],[0],[0],[False],['0']
12287,PMC3679996,17206,"Written ethical approval was obtained from the Ethics Commission of Xavier University, Cagayan do Oro City.",Study population,[102716],[7291],[7398],[False],[0],[0],[False],['0']
12288,PMC3679996,17207,Data collection,Data collection,[102729],[7399],[7415],[False],[0],[0],[False],['0']
12289,PMC3679996,17208,"XPrior to group assignment, all children were orally screened.",Data collection,[102742],[7416],[7478],[False],[0],[0],[False],['0']
12290,PMC3679996,17209,Socio-demographic data were collected through a parental questionnaire and a face-to-face interview with parents at baseline.,Data collection,[102755],[7479],[7604],[False],[0],[0],[False],['0']
12291,PMC3679996,17210,"At each stage of the trial, data collection involved the collection of anthropometric measurements, completion of an interview-administered OHRQoL-questionnaire and collection of blood samples.",Data collection,[102768],[7605],[7798],[False],[0],[0],[False],['0']
12292,PMC3679996,17211,"Blood samples were taken to assess the effect of extraction of severely decayed teeth on hemoglobin levels to explore a metabolic pathway between severe dental caries and body growth, which will be reported in a separate paper.",Data collection,[102781],[7799],[8026],[False],[0],[0],[False],['0']
12293,PMC3679996,17212,This paper reports only on the data relating to weight gain and oral health-related impacts.,Data collection,[102794],[8027],[8119],[False],[0],[0],[False],['0']
12294,PMC3679996,17213,Oral screening,Oral screening,[102807],[8120],[8135],[False],[0],[0],[False],['0']
12295,PMC3679996,17214,Clinical dental data were collected using standard WHO basic methods [22].,Oral screening,[102820],[8136],[8210],[False],[0],[0],[False],['0']
12296,PMC3679996,17215,One trained and calibrated general dentist carried out all examinations.,Oral screening,[102833],[8211],[8283],[False],[0],[0],[False],['0']
12297,PMC3679996,17216,"Children were examined outside the day care centers, using the daylight as direct light source.",Oral screening,[102846],[8284],[8379],[False],[0],[0],[False],['0']
12298,PMC3679996,17217,They were examined lying in supine position on the carers’ and examiner’s laps (‘knee to knee’ position).,Oral screening,[102859],[8380],[8485],[False],[0],[0],[False],['0']
12299,PMC3679996,17218,Caries was scored when the ball end CPI probe could penetrate the dental caries cavity.,Oral screening,[102872],[8486],[8573],[False],[0],[0],[False],['0']
12300,PMC3679996,17219,Caries experience was recorded using the dmft-index.,Oral screening,[102885],[8574],[8626],[False],[0],[0],[False],['0']
12301,PMC3679996,17220,"In addition, the severity of oral conditions resulting from untreated severe dental decay was scored using the pufa-index [23].",Oral screening,[102898],[8627],[8754],[False],[0],[0],[False],['0']
12302,PMC3679996,17221,"The pufa-index records presence of severely decayed teeth with visible pulpal involvement (p), ulceration caused by dislocated tooth fragments (u), fistula (f) and abscess (a).",Oral screening,[102911],[8755],[8931],[False],[0],[0],[False],['0']
12303,PMC3679996,17222,The pufa-score per person is calculated in the same cumulative way as for the dmft-score and represents number of teeth meeting pufa diagnostic criteria.,Oral screening,[102924],[8932],[9085],[False],[0],[0],[False],['0']
12304,PMC3679996,17223,Children with a minimum of one pulpally involved tooth (pufa-score of at least 1) were included in the study.,Oral screening,[102937],[9086],[9195],[False],[0],[0],[False],['0']
12305,PMC3679996,17224,Data on oral health-related impacts,Data on oral health-related impacts,[102950],[9196],[9232],[False],[0],[0],[False],['0']
12306,PMC3679996,17225,Data on children’s oral health-related impacts were collected using the Scale of Oral Health Outcomes (SOHO-5); an interviewer-administered OHRQoL questionnaire developed for five-year old children [24].,Data on oral health-related impacts,[102963],[9233],[9436],[False],[0],[0],[False],['0']
12307,PMC3679996,17226,Tsakos et al.,Data on oral health-related impacts,[102976],[9437],[9450],[False],[0],[0],[False],['0']
12308,PMC3679996,17227,"demonstrated that the SOHO-5 is an internally consistent and valid questionnaire: SOHO-5 scores were significantly associated with different subjective oral health outcomes of 5-year old schoolchildren and scores discriminated between different clinical groups in relation to active caries lesions, pulp involvement and dental sepsis [24].",Data on oral health-related impacts,[102989],[9451],[9790],[False],[0],[0],[False],['0']
12309,PMC3679996,17228,"The SOHO-5 was translated into Visayan, the local language, and back translated into English.",Data on oral health-related impacts,[103002],[9791],[9884],[False],[0],[0],[False],['0']
12310,PMC3679996,17229,A pilot study showed that the questionnaire could be used in the Philippine setting.,Data on oral health-related impacts,[103015],[9885],[9969],[False],[0],[0],[False],['0']
12311,PMC3679996,17230,"The SOHO-5 questionnaire contained ten questions; seven of these assessed oral health-related impacts, including eating difficulty, drinking difficulty, speaking difficulty, difficulty playing, avoiding smiling (due to appearance), avoiding smiling (due to pain), and difficulty sleeping, two questions measured current and past toothache and one question assessed children’s satisfaction with oral health.",Data on oral health-related impacts,[103028],[9970],[10376],[False],[0],[0],[False],['0']
12312,PMC3679996,17231,"All questions were assessed using a 3-point scale with the answering options ‘no’ (coded 0), ‘a little’ (coded 1) and ‘a lot’ (coded 2).",Data on oral health-related impacts,[103041],[10377],[10513],[False],[0],[0],[False],['0']
12313,PMC3679996,17232,"A cumulative SOHO-5-score was calculated for the seven items on oral health-related impacts, which reflects the overall presence of oral health-related impacts, ranging from 0 (free from impacts) to 14 (most severe possible score).",Data on oral health-related impacts,[103054],[10514],[10745],[False],[0],[0],[False],['0']
12314,PMC3679996,17233,Only the question assessing current toothache was used in the present study.,Data on oral health-related impacts,[103067],[10746],[10822],[False],[0],[0],[False],['0']
12315,PMC3679996,17234,Anthropometric data,Anthropometric data,[103080],[10823],[10843],[False],[0],[0],[False],['0']
12316,PMC3679996,17235,Weight and height was measured in duplicate by a trained nurse who was blinded as to which children had dental extractions first.,Anthropometric data,[103093],[10844],[10973],[False],[0],[0],[False],['0']
12317,PMC3679996,17236,She used the ‘WHO Anthropometric Indicators Measurements Guide’ [25].,Anthropometric data,[103106],[10974],[11043],[False],[0],[0],[False],['0']
12318,PMC3679996,17237,The average of two readings was recorded.,Anthropometric data,[103119],[11044],[11085],[False],[0],[0],[False],['0']
12319,PMC3679996,17238,"Weight was measured to the nearest 0.1 kg using portable hanging scales (Salter scale, UNICEF procurement), and calibrated after every five measurements.",Anthropometric data,[103132],[11086],[11239],[False],[0],[0],[False],['0']
12320,PMC3679996,17239,"Standing height was measured to the nearest 0.1 cm using a stadiometer (‘Leicester’ Model, Children’s Growth Foundation, UK).",Anthropometric data,[103145],[11240],[11365],[False],[0],[0],[False],['0']
12321,PMC3679996,17240,"Weight and height measurements were converted to z-scores, namely weight-for-age (WAZ), height-for-age (HAZ) and BMI-for-age (BAZ) with the lmsGrowth Excel add-in (Medical Research Council, 2008), using the 2006 [26] and 2007 [27] WHO Growth Standards.",Anthropometric data,[103158],[11366],[11618],[False],[0],[0],[False],['0']
12322,PMC3679996,17241,"Z-scores allow comparison of an individual’s weight, height or BMI, adjusting for age and sex relative to a reference population, expressed in standard deviations (SD) from the reference mean.",Anthropometric data,[103171],[11619],[11811],[False],[0],[0],[False],['0']
12323,PMC3679996,17242,Statistical analysis,Statistical analysis,[103184],[11812],[11833],[False],[0],[0],[False],['0']
12324,PMC3679996,17243,"Statistical analysis was carried out using STATA 10 (Stata Corp, College Station, Texas, USA).",Statistical analysis,[103197],[11834],[11928],[False],[0],[0],[False],['0']
12325,PMC3679996,17244,A p-value of <0.05 was regarded as significant.,Statistical analysis,[103210],[11929],[11976],[False],[0],[0],[False],['0']
12326,PMC3679996,17245,All children with missing data due to loss to follow-up or unrecorded data were excluded from the analysis.,Statistical analysis,[103223],[11977],[12084],[False],[0],[0],[False],['0']
12327,PMC3679996,17246,Oral health-related impacts and anthropometric measurements recorded before and after treatment were assessed using the paired T-test and the McNemar test.,Statistical analysis,[103236],[12085],[12240],[False],[0],[0],[False],['0']
12328,PMC3679996,17247,"A series of simple linear regression analyses were performed to assess baseline associations between presence of oral health-related impacts and WAZ at baseline, and to assess the association between oral health-related impacts and weight gain after treatment.",Statistical analysis,[103249],[12241],[12501],[False],[0],[0],[False],['0']
12329,PMC3679996,17248,"Weight gain was the outcome variable in the regression models, which was expressed as the difference in WAZ between before and after dental treatment.",Statistical analysis,[103262],[12502],[12652],[False],[0],[0],[False],['0']
12330,PMC3679996,17249,"The explanatory variables referred to oral health-related impacts, which were analyzed one by one in simple linear regression models as the overall SOHO-5-score, eating impacts, sleeping impacts and dental pain.",Statistical analysis,[103275],[12653],[12864],[False],[0],[0],[False],['0']
12331,PMC3679996,17250,"Oral health-related impacts were expressed in two ways; as changes in oral health-related impacts between before and after treatment, categorized as ‘improvement’, ‘no difference’ or ‘deterioration’, and as the prevalence of oral health-related impacts after treatment (dichotomized as ‘present’ or ‘absent’).",Statistical analysis,[103288],[12865],[13174],[False],[0],[0],[False],['0']
12332,PMC3679996,17251,The categories ‘deterioration’ and ‘present’ were used as reference values.,Statistical analysis,[103301],[13175],[13250],[False],[0],[0],[False],['0']
12333,PMC3679996,17252,"Then the number of teeth with dentally-related infections (pufa-score), WAZ at baseline and the time interval between treatment and follow-up were entered in the regression analyses to test whether these covariates moderated the association between oral health-related impacts and weight gain.",Statistical analysis,[103314],[13251],[13544],[False],[0],[0],[False],['0']
12334,PMC3679996,17253,Results,Results,[103327],[13545],[13553],[False],[0],[0],[False],['0']
12335,PMC3679996,17254,Two hundred and two children participated in the WGS (100 children in Group A and 102 in Group B).,Results,[103340],[13554],[13652],[False],[0],[0],[False],['0']
12336,PMC3679996,17255,Eighty one percent of them (164 children; 85 in Group A and 79 in Group B) were reassessed at the first follow-up stage four months later and 71.3% (144 children; 74 in Group A and 70 in Group B) completed all stages of the study.,Results,[103353],[13653],[13883],[False],[0],[0],[False],['0']
12337,PMC3679996,17256,The frequent migration of families was the main reason for loss to follow-up.,Results,[103366],[13884],[13961],[False],[0],[0],[False],['0']
12338,PMC3679996,17257,"For this study, data on 145 children (83 from Group A and 62 from Group B) were analyzed (71.8%), after excluding all children with missing data due to drop-out or unrecorded data (Figure 1, Design II).",Results,[103379],[13962],[14164],[False],[0],[0],[False],['0']
12339,PMC3679996,17258,Characteristics at baseline and follow-up,Characteristics at baseline and follow-up,[103392],[14165],[14207],[False],[0],[0],[False],['0']
12340,PMC3679996,17259,The mean age of the children at baseline was 61.4±5.1 months (Table 1).,Characteristics at baseline and follow-up,[103405],[14208],[14279],[False],[0],[0],[False],['0']
12341,PMC3679996,17260,There were significantly more girls (62.1%) than boys (37.9%) (p=0.02).,Characteristics at baseline and follow-up,[103418],[14280],[14351],[False],[0],[0],[False],['0']
12342,PMC3679996,17261,The mean dmft of the children was 10.9±4.4.,Characteristics at baseline and follow-up,[103431],[14352],[14395],[False],[0],[0],[False],['0']
12343,PMC3679996,17262,"All children had at least one pulpally infected tooth at baseline, with an average pufa-score of 2.3±1.6.",Characteristics at baseline and follow-up,[103444],[14396],[14501],[False],[0],[0],[False],['0']
12344,PMC3679996,17263,"They had a mean of 2.0±1.7 teeth with pulp involvement (88.7%), 0.2±0.5 teeth with a fistula (9.1%) and 0.05±0.02 teeth with an abscess (2.1%).",Characteristics at baseline and follow-up,[103457],[14502],[14645],[False],[0],[0],[False],['0']
12345,PMC3679996,17264,"In this study on average 2.2±1.1 teeth were extracted per child, ranging from one to nine extractions.",Characteristics at baseline and follow-up,[103470],[14646],[14748],[False],[0],[0],[False],['0']
12346,PMC3679996,17265,The mean time interval between the extraction of pulpally involved teeth and the follow-up was 4.5±0.8 months.,Characteristics at baseline and follow-up,[103483],[14749],[14859],[False],[0],[0],[False],['0']
12347,PMC3679996,17266,All children were underweight at baseline.,Characteristics at baseline and follow-up,[103496],[14860],[14902],[False],[0],[0],[False],['0']
12348,PMC3679996,17267,"The average WAZ, HAZ and BAZ z-scores were 2.14±0.6, 1.58±0.8 and 1.67±0.5 SD, respectively, below the mean of the reference population (Table 2).",Characteristics at baseline and follow-up,[103509],[14903],[15049],[False],[0],[0],[False],['0']
12349,PMC3679996,17268,All children gained a significant amount of weight and height between baseline and follow-up four months after surgical tooth extraction.,Characteristics at baseline and follow-up,[103522],[15050],[15187],[False],[0],[0],[False],['0']
12350,PMC3679996,17269,"The average WAZ and BAZ significantly increased after dental treatment, while HAZ significantly decreased.",Characteristics at baseline and follow-up,[103535],[15188],[15294],[False],[0],[0],[False],['0']
12351,PMC3679996,17270,"The increase in WAZ and BAZ from a negative value to a less negative value implies that children were closer to the weight-for-age and BMI-for-age of the reference population of the same age and sex after treatment, which means that children had an increased rate of weight gain.",Characteristics at baseline and follow-up,[103548],[15295],[15574],[False],[0],[0],[False],['0']
12352,PMC3679996,17271,The decrease in HAZ implies that children gained less height than would be expected in four months based on their age and sex relative to the reference population.,Characteristics at baseline and follow-up,[103561],[15575],[15738],[False],[0],[0],[False],['0']
12353,PMC3679996,17272,"Seventy-eight percent of the children increased their WAZ after treatment, while the WAZ of 28% of the children decreased (results not shown in a table).",Characteristics at baseline and follow-up,[103574],[15739],[15892],[False],[0],[0],[False],['0']
12354,PMC3679996,17273,Before treatment the average SOHO-5-score was 4.1±3.4 (Table 3); 120 children (82.8%) reported at least one impact.,Characteristics at baseline and follow-up,[103587],[15893],[16008],[False],[0],[0],[False],['0']
12355,PMC3679996,17274,"Four months after treatment the average SOHO-5-score significantly decreased to 1.4±2.9, with only 40 children (27.6%) still reporting an impact.",Characteristics at baseline and follow-up,[103600],[16009],[16154],[False],[0],[0],[False],['0']
12356,PMC3679996,17275,"There was a significant reduction after surgical tooth extraction in the percentage of children having eating impacts, sleeping impacts and dental pain.",Characteristics at baseline and follow-up,[103613],[16155],[16307],[False],[0],[0],[False],['0']
12357,PMC3679996,17276,The majority of children experienced less oral health-related impacts after dental treatment.,Characteristics at baseline and follow-up,[103626],[16308],[16401],[False],[0],[0],[False],['0']
12358,PMC3679996,17277,"However, 15.9%, 9.7%, 11.0% and 5.5% children reported a deterioration in SOHO-5-scores relating to eating impacts, sleeping impacts and dental pain, respectively.",Characteristics at baseline and follow-up,[103639],[16402],[16565],[False],[0],[0],[False],['0']
12359,PMC3679996,17278,Baseline associations between oral health-related impacts and weight,Characteristics at baseline and follow-up,[103652],[16566],[16635],[False],[0],[0],[False],['0']
12360,PMC3679996,17279,"An increase of one in SOHO-5-score was significantly associated with a 0.03SD (0.00, 0.06) lower WAZ at baseline (Table 4).",Characteristics at baseline and follow-up,[103665],[16636],[16759],[False],[0],[0],[False],['0']
12361,PMC3679996,17280,"Children reporting eating impacts at baseline had significantly lower body weights than children who were free of eating impacts, yet no significant associations were found for sleeping impacts and for presence of oral pain with WAZ at baseline (Table 4).",Characteristics at baseline and follow-up,[103678],[16760],[17015],[False],[0],[0],[False],['0']
12362,PMC3679996,17281,Associations between oral health-related impacts and weight gain after treatment,Baseline associations between oral health-related impacts and weight,[103691],[17016],[17097],[False],[0],[0],[False],['0']
12363,PMC3679996,17282,Children with improved SOHO-5 scores after tooth extraction gained significantly more weight compared to children who deteriorated in SOHO-5 scores after treatment (Table 5).,Baseline associations between oral health-related impacts and weight,[103704],[17098],[17272],[False],[0],[0],[False],['0']
12364,PMC3679996,17283,"Having a lower SOHO-5 score after treatment was also associated with an increased rate of weight gain, compared to children with higher SOHO-5 scores after treatment (Table 6).",Baseline associations between oral health-related impacts and weight,[103717],[17273],[17449],[False],[0],[0],[False],['0']
12365,PMC3679996,17284,"Simple linear regression analyses of the influence of individual impacts on weight gain showed that children who improved or reported no difference in their ability to sleep, gained significantly more weight than children whose sleeping ability deteriorated (Table 5).",Baseline associations between oral health-related impacts and weight,[103730],[17450],[17718],[False],[0],[0],[False],['0']
12366,PMC3679996,17285,A similar association was found between the presence or absence of sleeping impacts after treatment and weight gain; children free from sleeping impacts after tooth extraction had a significant increased rate of weight gain compared to children who reported sleeping impacts after extractions (Table 6).,Baseline associations between oral health-related impacts and weight,[103743],[17719],[18022],[False],[0],[0],[False],['0']
12367,PMC3679996,17286,No significant associations were found between weight gain and changes in eating impacts and changes in dental pain experience after treatment.,Baseline associations between oral health-related impacts and weight,[103756],[18023],[18166],[False],[0],[0],[False],['0']
12368,PMC3679996,17287,"The number of teeth with dental infections, WAZ at baseline and the time interval between the extraction of severely decayed teeth and follow-up was not significantly related to rate of weight gain (Table 7).",Baseline associations between oral health-related impacts and weight,[103769],[18167],[18375],[False],[0],[0],[False],['0']
12369,PMC3679996,17288,Therefore it was not necessary to adjust the association between oral health-related impacts and weight gain for these covariates in multiple regression models.,Baseline associations between oral health-related impacts and weight,[103782],[18376],[18536],[False],[0],[0],[False],['0']
12370,PMC3679996,17289,Discussion,Discussion,[103795],[18537],[18548],[False],[0],[0],[False],['0']
12371,PMC3679996,17290,Findings of this intervention study indicate that there was a statistically significant association between self-reported oral health-related impacts and the rate of weight gain after extraction of severely decayed teeth in preschool Filipino children.,Discussion,[103808],[18549],[18801],[False],[0],[0],[False],['0']
12372,PMC3679996,17291,"At baseline, eating impacts were related to reduced body weight.",Discussion,[103821],[18802],[18866],[False],[0],[0],[False],['0']
12373,PMC3679996,17292,"However, improvement in eating ability, or being free from eating impacts after surgical tooth extraction, was not associated with weight gain.",Discussion,[103834],[18867],[19010],[False],[0],[0],[False],['0']
12374,PMC3679996,17293,"On the other hand, reductions in the impacts on sleeping had a consistent significant association with increased rate of weight gain, suggesting that the impact on sleeping might be an important factor in the relationship between extraction of severely decayed teeth and weight gain.",Discussion,[103847],[19011],[19294],[False],[0],[0],[False],['0']
12375,PMC3679996,17294,Impacts on sleeping can play an important role in growth retardation due to disturbance in production of growth hormones resulting from lack of sleep [17].,Discussion,[103860],[19295],[19450],[False],[0],[0],[False],['0']
12376,PMC3679996,17295,"Based on theories of such a mechanism, it is expected that sleeping would have a stronger impact on height than on weight.",Discussion,[103873],[19451],[19573],[False],[0],[0],[False],['0']
12377,PMC3679996,17296,"However, in this study the height-for-age significantly decreased after dental treatment, suggesting that children grew less in height in four months than would be expected based on their age and sex, relative to a reference population.",Discussion,[103886],[19574],[19810],[False],[0],[0],[False],['0']
12378,PMC3679996,17297,"Height, however, takes longer to change than weight.",Discussion,[103899],[19811],[19863],[False],[0],[0],[False],['0']
12379,PMC3679996,17298,"The process of growth is described as saltation and stasis, whereby infant growth follows a series of rapid growth spurts (saltation), separated by periods of stasis [28,29].",Discussion,[103912],[19864],[20038],[False],[0],[0],[False],['0']
12380,PMC3679996,17299,This indicates that children first put on weight before growing in height.,Discussion,[103925],[20039],[20113],[False],[0],[0],[False],['0']
12381,PMC3679996,17300,This complex process of catch-up growth and the short timespan between dental extractions and follow-up in this study may explain why height did not increase.,Discussion,[103938],[20114],[20272],[False],[0],[0],[False],['0']
12382,PMC3679996,17301,Height measurements were not regularly monitored.,Discussion,[103951],[20273],[20322],[True],['MissingData'],['Height measurements were not regularly monitored'],[True],['MissingData']
12383,PMC3679996,17302,"That, and the short time interval between baseline and follow-up that was necessary for ethical reasons, are reasons why it was not possible to rigorously assess the association between sleeping impacts and height gain after dental treatment.",Discussion,[103978],[20323],[20565],[True],['StudyDuration'],['the short time interval between baseline and follow-up'],[True],['StudyDuration']
12384,PMC3679996,17303,Dental pain was hypothesized to be the intermediate factor for the associations between impacts on eating and sleeping and weight gain.,Discussion,[104003],[20566],[20701],[False],[0],[0],[False],['0']
12385,PMC3679996,17304,"However, there was no association between oral pain and body weight.",Discussion,[104016],[20702],[20770],[False],[0],[0],[False],['0']
12386,PMC3679996,17305,That may be related to how dental pain was measured.,Discussion,[104031],[20771],[20823],[True],['PrecisionOfMeasurement'],['how dental pain was measured'],[True],['OutcomeMeasures']
12387,PMC3679996,17306,Dental pain was assessed as ‘do your teeth hurt now?’.,Discussion,[104055],[20824],[20878],[False],[0],[0],[False],['0']
12388,PMC3679996,17307,"Since dental decay leads mainly to dental pain that is not permanently present, not all children with severe dental decay reported having dental pain at baseline.",Discussion,[104068],[20879],[21041],[False],[0],[0],[False],['0']
12389,PMC3679996,17308,"The number of children with dental pain at baseline and after dental treatment (n=36 and n=12, respectively) may have been too small to demonstrate a statistically significant association between dental pain and weight gain.",Discussion,[104084],[21042],[21266],[True],['SampleSize'],"['The number of children with dental pain at baseline and after dental treatment (n=36 and n=12, respectively) may have been too small']",[True],['UnderpoweredStudy']
12390,PMC3679996,17309,"Oral health-related impacts were assessed in two ways: as changes in impacts between before and after treatment (‘improvement’, ‘no difference’ or ‘deterioration’) and as the prevalence of impacts after treatment (‘present’ or ‘absent’).",Discussion,[104107],[21267],[21504],[False],[0],[0],[False],['0']
12391,PMC3679996,17310,"The findings of this study suggest that the absence of oral health-related impacts after dental treatment is a stronger, and probably more accurate predictor of weight gain, compared to assessing a decrease in reported impacts between before and after treatment.",Discussion,[104120],[21505],[21767],[False],[0],[0],[False],['0']
12392,PMC3679996,17311,"Children who improved from having ‘a lot’ of impacts at baseline to ‘a little’ after treatment were still experiencing problems, while children who did not report a difference in impacts could have been free of impacts at both stages of the study.",Discussion,[104133],[21768],[22015],[False],[0],[0],[False],['0']
12393,PMC3679996,17312,A notable finding was that in some children weight-for-age decreased after dental treatment.,Discussion,[104146],[22016],[22108],[False],[0],[0],[False],['0']
12394,PMC3679996,17313,"This may be related to other factors, such as dietary factors, poor environments and other social and medical factors that confounded the association between severe dental decay and weight gain.",Discussion,[104159],[22109],[22303],[False],[0],[0],[False],['0']
12395,PMC3679996,17314,These factors are more likely to have a stronger influence on weight gain than dental treatment.,Discussion,[104172],[22304],[22400],[False],[0],[0],[False],['0']
12396,PMC3679996,17315,"For example, the prevalence of soil-transmitted helminths in under-5-year-old children in the Philippines ranged from 49% to 93% [30].",Discussion,[104185],[22401],[22535],[False],[0],[0],[False],['0']
12397,PMC3679996,17316,Worm infestation has a negative impact on nutrition.,Discussion,[104198],[22536],[22588],[False],[0],[0],[False],['0']
12398,PMC3679996,17317,"Other medical factors, such as anemia and infectious diseases including malaria and diarrhea, can negatively influence weight gain [31].",Discussion,[104211],[22589],[22725],[False],[0],[0],[False],['0']
12399,PMC3679996,17318,"Most children in this study were from very deprived municipalities, where access to food was the highest priority.",Discussion,[104224],[22726],[22840],[False],[0],[0],[False],['0']
12400,PMC3679996,17319,"This could contribute to parental stress, which is related to a child’s failure to thrive [31].",Discussion,[104237],[22841],[22936],[False],[0],[0],[False],['0']
12401,PMC3679996,17320,"The aforementioned factors were not assessed in this study, and may have influenced the rate of weight gain and its association with oral health-related impacts.",Discussion,[104254],[22937],[23098],[True],['ConfoundingFactors'],['The aforementioned factors were not assessed in this study'],[True],['StatisticalAnalysis']
12402,PMC3679996,17321,"Other factors that were hypothesized to moderate the association were number of pulpally infected teeth, weight-for-age at baseline and the time interval between treatment and follow-up.",Discussion,[104276],[23099],[23285],[False],[0],[0],[False],['0']
12403,PMC3679996,17322,"It was presumed that children with several infected teeth would benefit more from treatment, compared to children with only one tooth affected.",Discussion,[104289],[23286],[23429],[False],[0],[0],[False],['0']
12404,PMC3679996,17323,"Weight at baseline was hypothesized to be an important moderator, as there is a tendency for children who are taller, to grow slightly less than smaller children, a ‘regression to the mean’ [32].",Discussion,[104302],[23430],[23625],[False],[0],[0],[False],['0']
12405,PMC3679996,17325,None of the abovementioned assumptions were supported by results of this study.,Discussion,[104341],[23772],[23851],[False],[0],[0],[False],['0']
12406,PMC3679996,17326,"Whether the relationship between the abovementioned covariates and weight gain are truly non-existent or if the non-significant findings resulted from the small sample size and effects of other medical, social and environmental factors, should be further investigated.",Discussion,"[104359, 104360]","[23852, 23852]","[24120, 24120]","[True, True]","['SampleSize', 'ConfoundingFactors']","['the small sample size', 'effects of other medical, social and environmental factors']","[True, True]","['StatisticalAnalysis', 'UnderpoweredStudy']"
12407,PMC3679996,17327,"One of the main strengths of this study was that the data were derived from a stepped wedge cluster randomized clinical trial, which demonstrated the benefit on weight gain of dental extractions.",Discussion,[104380],[24121],[24316],[False],[0],[0],[False],['0']
12408,PMC3679996,17328,"For this study, data were converted to a prospective cohort design, allowing assessment of the relationship between oral health-related impacts and rate of weight gain over time.",Discussion,[104393],[24317],[24495],[False],[0],[0],[False],['0']
12409,PMC3679996,17329,Some potential limitations of the study should however be taken into account.,Discussion,[104406],[24496],[24573],[False],[0],[0],[False],['0']
12410,PMC3679996,17330,"A fair number of children were lost to follow-up, which may have affected the results as children who dropped out may have responded differently to dental treatment than those children who completed all stages of the study.",Discussion,[104426],[24574],[24797],[True],['HighLossToFollowUp'],['A fair number of children were lost to follow-up'],[True],['MissingData']
12411,PMC3679996,17331,The unequal distribution of gender in the study sample may also have influenced the results.,Discussion,[104453],[24798],[24890],[True],['Population'],['The unequal distribution of gender in the study sample'],[True],['Population']
12412,PMC3679996,17332,"Although a validated questionnaire was used to collect information on oral health-related impacts, there may have been bias in children’s self-reports.",Discussion,[104480],[24891],[25042],[True],['PrecisionOfMeasurement'],['there may have been bias in children’s self-reports'],[True],['OutcomeMeasures']
12413,PMC3679996,17333,The relatively small number of children in the study may have resulted in some weak associations between oral health-related impacts and weight gain and the time interval between surgical tooth extraction and follow-up may have been too short for children to gain much weight and height following treatment.,Discussion,"[104507, 104508]","[25043, 25043]","[25350, 25350]","[True, True]","['SampleSize', 'FollowUpDuration']","['The relatively small number of children in the study', 'follow-up may have been too short']","[True, True]","['UnderpoweredStudy', 'StudyDuration']"
12414,PMC3679996,17334,A cause-effect relationship cannot be deduced from the one-group pretest-posttest design.,Discussion,[104535],[25351],[25440],[True],['StudyDesign'],['one-group pretest-posttest design'],[True],['StudyDesign']
12415,PMC3679996,17335,More research is needed to further explore the causal mechanisms between severe dental decay and body growth in young children.,Discussion,[104549],[25441],[25568],[False],[0],[0],[False],['0']
12416,PMC3679996,17336,"Studies should also investigate the metabolic pathways and incorporate parameters related to general health, psychosocial relationships and environmental factors, as body growth is influenced by numerous factors.",Discussion,[104562],[25569],[25781],[False],[0],[0],[False],['0']
12417,PMC3679996,17337,The time interval between dental treatment and follow-up should be longer and anthropometric measurements should be regularly monitored to investigate the relationships between severe dental decay and height.,Discussion,[104575],[25782],[25990],[False],[0],[0],[False],['0']
12418,PMC3679996,17338,Conclusions,Conclusions,[104588],[25991],[26003],[False],[0],[0],[False],['0']
12419,PMC3679996,17339,"This study shows that after extraction of severely decayed teeth in underweight Filipino children, levels of oral health-related impacts were associated with rate of weight gain.",Conclusions,[104601],[26004],[26182],[False],[0],[0],[False],['0']
12420,PMC3679996,17340,Decreases in oral health impacts on sleeping after tooth extraction appeared to be most strongly associated with weight gain.,Conclusions,[104614],[26183],[26308],[False],[0],[0],[False],['0']
12421,PMC3679996,17341,"Despite the growing recognition that a common condition, such as untreated severe dental decay affects children’s growth and well-being, investment in improving oral health is still neglected in many low- and middle-income countries.",Conclusions,[104627],[26309],[26542],[False],[0],[0],[False],['0']
12422,PMC3679996,17342,"If the evidence of an impact of oral health on body constitution can be further established by understanding its underlying causal mechanisms, then emphasis on prevention of dental decay and the provision of access to basic oral care needs to be one of the priorities of integrated health promotion programs to enhance growth and well-being of millions of underweight children.",Conclusions,[104640],[26543],[26920],[False],[0],[0],[False],['0']
12423,PMC3679996,17343,Abbreviations,Abbreviations,[104653],[26921],[26935],[False],[0],[0],[False],['0']
12424,PMC3679996,17344,"ACT: Arrest of caries technique; BAZ: BMI-for-age z-score; BMI: Body mass index; CPI: Community periodontal index; dmft: decayed, missing and filled teeth; ECC: Early childhood caries; HAZ: Height-for-age z-score; OHRQoL: Oral health related quality of life; pufa: Presence of severely decayed teeth with visible pulpal involvement, ulceration caused by dislocated tooth fragments, fistula, abscess; SD: Standard deviation; SOHO-5: Scale of Oral Health Outcomes for 5-year-old children; WAZ: Weight-for-age z-score; WGS: Weight gain study; WHO: World Health Organization.",Abbreviations,[104666],[26936],[27507],[False],[0],[0],[False],['0']
12425,PMC3679996,17345,Competing interests,Competing interests,[104679],[27508],[27528],[False],[0],[0],[False],['0']
12426,PMC3679996,17346,The authors declare that they have no competing interests.,Competing interests,[104692],[27529],[27587],[False],[0],[0],[False],['0']
12427,PMC3679996,17347,Authors’ contributions,Authors’ contributions,[104705],[27588],[27611],[False],[0],[0],[False],['0']
12428,PMC3679996,17348,"Conception and study protocol (BM, AS, MHH), adaption of the questionnaires to the local context (GI), study implementation and data collection (BM), data analysis (DD), interpretation of findings (DD, AS, MHH, GI, BM), drafting of the initial manuscript (DD), revision of the manuscript (DD, AS, MHH, GI, BM), agreed to the final version of the manuscript (DD, AS, MHH, GI, BM).",Authors’ contributions,[104718],[27612],[27991],[False],[0],[0],[False],['0']
12429,PMC3679996,17349,Pre-publication history,Pre-publication history,[104731],[27992],[28016],[False],[0],[0],[False],['0']
12430,PMC3679996,17350,The pre-publication history for this paper can be accessed here:,Pre-publication history,[104744],[28017],[28081],[False],[0],[0],[False],['0']
12431,PMC3679996,17351,http://www.biomedcentral.com/1471-2458/13/533/prepub,Pre-publication history,[104757],[28082],[28134],[False],[0],[0],[False],['0']
12432,PMC3679996,17352,Acknowledgements,Acknowledgements,[104770],[28135],[28152],[False],[0],[0],[False],['0']
12433,PMC3679996,17353,"The authors express their sincere gratitude and appreciation to Dietmar Schug, Dr C. Molo, G. Salipongo and R. Amante of the Community Health Care Center of Xavier University in Cagayan de Oro, Philippines, who carried out all the fieldwork of this study.",Acknowledgements,[104783],[28153],[28408],[False],[0],[0],[False],['0']
12434,PMC3679996,17354,"We thank Vilma Schug Padilla, the coordinator of the ‘Mother’s House’ in Cagayan de Oro for involving her network and facilitating contacts in the participating barangays.",Acknowledgements,[104796],[28409],[28580],[False],[0],[0],[False],['0']
12435,PMC3679996,17355,"We also thank all barangay leaders, barangay health workers and nutrition scholars who supported the study in their villages.",Acknowledgements,[104809],[28581],[28706],[False],[0],[0],[False],['0']
12436,PMC3679996,17356,"Without the substantial logistic support provided by Moresco Uno, the electric power cooperative of the province of Misamis Oriental the study would have not been possible.",Acknowledgements,[104822],[28707],[28879],[False],[0],[0],[False],['0']
12437,PMC3679996,17357,Financial support was provided by a grant from the FDI World Dental Federation.,Acknowledgements,[104835],[28880],[28959],[False],[0],[0],[False],['0']
12438,PMC3682293,15234,Late pharmacologic conditioning with volatile anesthetics after cardiac surgery,Title,[90878],[21227],[79],[False],[0],[0],[False],['0']
12439,PMC3682293,15235,Introduction,Abstract,[90887],[80],[93],[False],[0],[0],[False],['0']
12440,PMC3682293,15236,The aim of this randomized controlled trial was to investigate whether volatile anesthetics used for postoperative sedation have any beneficial effects on myocardial injury in cardiac surgery patients after on-pump valve replacement.,Abstract,[90896],[94],[327],[False],[0],[0],[False],['0']
12441,PMC3682293,15237,Methods,Methods,[90905],[328],[336],[False],[0],[0],[False],['0']
12442,PMC3682293,15238,Anesthesia was performed with propofol.,Methods,[90914],[337],[376],[False],[0],[0],[False],['0']
12443,PMC3682293,15239,"After arrival in the intensive care unit (ICU), 117 patients were randomized to be sedated for at least 4 hours with either propofol or sevoflurane.",Methods,[90923],[377],[525],[False],[0],[0],[False],['0']
12444,PMC3682293,15240,Sevoflurane was administered by using the anesthetic-conserving device.,Methods,[90932],[526],[597],[False],[0],[0],[False],['0']
12445,PMC3682293,15241,"Troponin T, creatine kinase, creatine kinase from heart muscle tissue, myoglobin, and oxygenation index were determined on arrival at the ICU, 4 hours after sedation, and in the morning of the first postoperative day (POD1).",Methods,[90941],[598],[822],[False],[0],[0],[False],['0']
12446,PMC3682293,15242,Primary end points were cardiac injury markers on POD1.,Methods,[90950],[823],[878],[False],[0],[0],[False],['0']
12447,PMC3682293,15243,"As secondary end points oxygenation, postoperative pulmonary complications, and ICU and hospital stay were documented.",Methods,[90959],[879],[997],[False],[0],[0],[False],['0']
12448,PMC3682293,15244,Results,Results,[90968],[998],[1006],[False],[0],[0],[False],['0']
12449,PMC3682293,15245,"Fifty-six patients were analyzed in the propofol arm, and 46 patients in the sevoflurane arm.",Results,[90977],[1007],[1100],[False],[0],[0],[False],['0']
12450,PMC3682293,15246,Treatment groups were comparable with regard to patient demographics and intraoperative characteristics.,Results,[90986],[1101],[1205],[False],[0],[0],[False],['0']
12451,PMC3682293,15247,"Concentration of troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).",Results,[90995],[1206],[1511],[False],[0],[0],[False],['0']
12452,PMC3682293,15248,Conclusions,Conclusions,[91004],[1512],[1524],[False],[0],[0],[False],['0']
12453,PMC3682293,15249,"The data presented in this investigation indicate that late postconditioning with the volatile anesthetic sevoflurane might mediate cardiac protection, even with a late, brief, and low-dose application.",Conclusions,[91013],[1525],[1727],[False],[0],[0],[False],['0']
12454,PMC3682293,15250,Trial registration,Trial registration,[91022],[1728],[1747],[False],[0],[0],[False],['0']
12455,PMC3682293,15251,ClinicalTrials.gov: NCT00924222.,Trial registration,[91031],[1748],[1780],[False],[0],[0],[False],['0']
12456,PMC3682293,15252,Introduction,Introduction,[91040],[1781],[1795],[False],[0],[0],[False],['0']
12457,PMC3682293,15253,"Cardiac surgery requiring extracorporeal circulation (ECC) is a common procedure, which is used for valve repair, valve replacement, as well as for coronary artery bypass grafting.",Introduction,[91049],[1796],[1976],[False],[0],[0],[False],['0']
12458,PMC3682293,15254,"During ECC, the myocardium is exposed to transient ischemia, followed by reperfusion, sometimes leading to myocardial infarction.",Introduction,[91058],[1977],[2106],[False],[0],[0],[False],['0']
12459,PMC3682293,15255,This is linked to an increased long-term incidence of adverse cardiovascular events [1].,Introduction,[91067],[2107],[2195],[False],[0],[0],[False],['0']
12460,PMC3682293,15256,"Additionally, a systemic inflammatory response of various degrees is observed with cardiopulmonary bypass, possibly leading to systemic inflammatory response syndrome and/or single or multiple organ dysfunctions [2-5].",Introduction,[91076],[2196],[2414],[False],[0],[0],[False],['0']
12461,PMC3682293,15257,Both ischemia-reperfusion injury and the inflammatory response syndrome negatively affect patient outcome.,Introduction,[91085],[2415],[2521],[False],[0],[0],[False],['0']
12462,PMC3682293,15258,"For several years, inhalational agents have been successfully used for sedation of ventilator-dependent patients in the intensive care unit (ICU) and have become a valuable alternative to commonly used intravenous drugs [6].",Introduction,[91094],[2522],[2746],[False],[0],[0],[False],['0']
12463,PMC3682293,15259,"Studies have shown that the method of sedation with volatile anesthetics [7] results in shorter time to extubation and faster mental recovery compared with intravenously administered sedatives [8,9].",Introduction,[91103],[2747],[2946],[False],[0],[0],[False],['0']
12464,PMC3682293,15260,"Recently, a new tool for postoperative volatile sedation of ventilated patients in the ICU has been established: the Anaesthetic Conserving Device (AnaConDa; Sedana Medical, Uppsala, Sweden).",Introduction,[91112],[2947],[3138],[False],[0],[0],[False],['0']
12465,PMC3682293,15261,The protective effects of volatile anesthetics on organ preservation have been studied extensively.,Introduction,[91121],[3139],[3238],[False],[0],[0],[False],['0']
12466,PMC3682293,15262,Several clinical trials have demonstrated that volatile anesthetics decrease cardiac injury after procedures involving the use of ECC [10-13].,Introduction,[91130],[3239],[3381],[False],[0],[0],[False],['0']
12467,PMC3682293,15263,"Most often, volatile anesthetics have been used in a preconditioning manner or during the entire surgical procedure.",Introduction,[91139],[3382],[3498],[False],[0],[0],[False],['0']
12468,PMC3682293,15264,"This randomized controlled trial, in contrast, examined the effect of sevoflurane in a clinical setting of late postconditioning in patients undergoing cardiac surgery with ECC.",Introduction,[91148],[3499],[3676],[False],[0],[0],[False],['0']
12469,PMC3682293,15265,"Sevoflurane was therefore administered only postoperatively by using the AnaConDa system [14,15].",Introduction,[91157],[3677],[3774],[False],[0],[0],[False],['0']
12470,PMC3682293,15266,We hypothesized that late and short-time application of sevoflurane in low anesthetic gas concentration would attenuate myocardial ischemia-reperfusion injury after cardiopulmonary bypass procedures and possibly have a positive impact on pulmonary function.,Introduction,[91166],[3775],[4032],[False],[0],[0],[False],['0']
12471,PMC3682293,15267,Materials and methods,Materials and methods,[91175],[4033],[4055],[False],[0],[0],[False],['0']
12472,PMC3682293,15268,Study design,Materials and methods|Study design,[91184],[4056],[4068],[False],[0],[0],[False],['0']
12473,PMC3682293,15269,This is a prospective randomized parallel group trial comparing postoperative propofol with sevoflurane sedation in the ICU after on-pump cardiac surgery.,Materials and methods|Study design,[91193],[4069],[4223],[False],[0],[0],[False],['0']
12474,PMC3682293,15270,"All patients between 18 and 90 years of age, scheduled for elective cardiac surgery requiring the use of ECC at the University Hospital Zurich, Switzerland, were eligible.",Materials and methods|Study design,[91202],[4224],[4395],[False],[0],[0],[False],['0']
12475,PMC3682293,15271,"Exclusion criteria were poor cardiac baseline function, defined as an ejection fraction of < 30%, significant coronary impairment (CCS ≥ 3 or myocardial infarction within 7 days before the surgery date), emergency procedures, previous cardiac surgery, chronic pulmonary disease (FEV < 80% or FEV /FVC < 70% of predicted value), renal dysfunction (creatinine clearance, < 60 ml/min), insulin-dependent diabetes mellitus, pregnancy, and current steroid treatment.",Materials and methods|Study design,[91211],[4396],[4857],[False],[0],[0],[False],['0']
12476,PMC3682293,15272,"Randomization was computer generated with prestratification for the following surgery groups: (a) aortic valve surgery, (b) mitral valve surgery, and (c) combined procedures with coronary artery bypass grafting (CABG) or replacement of the ascending aorta.",Materials and methods|Study design,[91220],[4858],[5114],[False],[0],[0],[False],['0']
12477,PMC3682293,15273,The envelope was opened by an investigator at the end of the case.,Materials and methods|Study design,[91229],[5115],[5181],[False],[0],[0],[False],['0']
12478,PMC3682293,15274,Anesthesiologists and surgeons were blinded to the intervention.,Materials and methods|Study design,[91238],[5182],[5246],[False],[0],[0],[False],['0']
12479,PMC3682293,15275,"The local ethics committee (Ethic committee, Kantonale Ethikkommission, University Hospital Zurich, Switzerland) approved the trial (StV 5-2007).",Materials and methods|Study design,[91247],[5247],[5392],[False],[0],[0],[False],['0']
12480,PMC3682293,15276,The study was registered in ClinicalTrials.gov as NCT00924222.,Materials and methods|Study design,[91256],[5393],[5455],[False],[0],[0],[False],['0']
12481,PMC3682293,15277,Written informed consent was obtained from all study subjects.,Materials and methods|Study design,[91265],[5456],[5518],[False],[0],[0],[False],['0']
12482,PMC3682293,15278,Anesthetic management,Anesthetic management,[91274],[5519],[5541],[False],[0],[0],[False],['0']
12483,PMC3682293,15279,Preoperatively patients underwent routine clinical and laboratory examinations.,Anesthetic management,[91283],[5542],[5621],[False],[0],[0],[False],['0']
12484,PMC3682293,15280,"Before surgery, they received oral midazolam at the clinical discretion of the anesthesiologist.",Anesthetic management,[91292],[5622],[5718],[False],[0],[0],[False],['0']
12485,PMC3682293,15281,"For the surgical procedure, patients were monitored in a standard fashion with a five-lead electrocardiogram, pulse oximetry, invasive blood pressure measurement, central venous pressure measurement, bispectral index (BIS), and transesophageal echocardiography.",Anesthetic management,[91301],[5719],[5980],[False],[0],[0],[False],['0']
12486,PMC3682293,15282,Direct measurement of pulmonary artery pressure was used in more complex cases.,Anesthetic management,[91310],[5981],[6060],[False],[0],[0],[False],['0']
12487,PMC3682293,15283,"The cardiopulmonary bypass (CPB) technique was nonpulsatile, using a roller pump.",Anesthetic management,[91319],[6061],[6142],[False],[0],[0],[False],['0']
12488,PMC3682293,15284,"Active cooling was performed, aiming at temperatures of 32°C to 34°C.",Anesthetic management,[91328],[6143],[6212],[False],[0],[0],[False],['0']
12489,PMC3682293,15285,Crystalloid cardioplegia was used without hot shot.,Anesthetic management,[91337],[6213],[6264],[False],[0],[0],[False],['0']
12490,PMC3682293,15286,"All patients received general anesthesia with a target-controlled infusion of propofol, fentanyl boluses, plus remifentanil as a continuous infusion.",Anesthetic management,[91346],[6265],[6414],[False],[0],[0],[False],['0']
12491,PMC3682293,15287,Muscular relaxation was achieved with pancuronium at the induction of anesthesia.,Anesthetic management,[91355],[6415],[6496],[False],[0],[0],[False],['0']
12492,PMC3682293,15288,Volatile anesthetics were not applied to the patient in the operating room at all.,Anesthetic management,[91364],[6497],[6579],[False],[0],[0],[False],['0']
12493,PMC3682293,15289,"After surgery, patients were transferred to the ICU under continuous analgosedation with propofol and remifentanil.",Anesthetic management,[91373],[6580],[6695],[False],[0],[0],[False],['0']
12494,PMC3682293,15290,ICU management,ICU management,[91382],[6696],[6711],[False],[0],[0],[False],['0']
12495,PMC3682293,15291,"Patients in the control group received propofol titrated by the critical care team within a range of 0.5 to 4.0 mg/kg BW per hour to achieve continuous sedation (total intravenous application, no target-controlled infusion).",ICU management,[91391],[6712],[6936],[False],[0],[0],[False],['0']
12496,PMC3682293,15292,Propofol was started at a rate of 2 mg/kg/h and adjusted according to the sedation score and hemodynamics.,ICU management,[91400],[6937],[7043],[False],[0],[0],[False],['0']
12497,PMC3682293,15293,Remifentanil at a dose of 0.05 to 0.2 μg/kg BW per minute was added as needed to achieve analgesia.,ICU management,[91409],[7044],[7143],[False],[0],[0],[False],['0']
12498,PMC3682293,15294,"In the treatment group, patients were switched to an inhalational sedation regimen with sevoflurane immediately after arrival at the ICU.",ICU management,[91418],[7144],[7281],[False],[0],[0],[False],['0']
12499,PMC3682293,15295,"For this purpose, sevoflurane (Sevorane; Abbot, Abbot Park, IL, USA) was applied via the AnaConDa system at a starting dose of an age-adjusted minimum alveolar concentration (MAC) of 0.5 [16], and was titrated to balance sedation.",ICU management,[91427],[7282],[7512],[False],[0],[0],[False],['0']
12500,PMC3682293,15296,"The end-tidal concentration of sevoflurane was measured by using a Dräger Scio gas module (Dräger Medical, Lübeck, Germany).",ICU management,[91436],[7513],[7637],[False],[0],[0],[False],['0']
12501,PMC3682293,15297,Remifentanil was applied to patients in the sevoflurane arm at the same does as in the propofol group (0.05 to 0.2 μg/kg/BW).,ICU management,[91445],[7638],[7763],[False],[0],[0],[False],['0']
12502,PMC3682293,15298,The minimal duration of sedation was 4 hours.,ICU management,[91454],[7764],[7809],[False],[0],[0],[False],['0']
12503,PMC3682293,15299,"During sedation, the patients were monitored with five-lead electrocardiogram, pulse oximetry, invasive blood pressure measurement, and central venous pressure measurement.",ICU management,[91463],[7810],[7982],[False],[0],[0],[False],['0']
12504,PMC3682293,15300,The AnaConDa module was incorporated in the respiratory circuit of all patients in both groups to control for any unknown effects of the system itself.,ICU management,[91472],[7983],[8134],[False],[0],[0],[False],['0']
12505,PMC3682293,15301,"A CONTRAfluran active charcoal filter (ZeoSys GmbH, Berlin, Germany) was used on the expiratory valve of the ventilator to minimize environmental contamination with sevoflurane.",ICU management,[91481],[8135],[8312],[False],[0],[0],[False],['0']
12506,PMC3682293,15302,"For mechanical ventilation, the ventilator Evita XL (Dräger, Lübeck, Germany) was used in biphasic positive airway pressure (BiPAP) mode with a first positive endexpiratory pressure (PEEP) of 6 cm H O and tidal volumes of 6 to 9 ml/kg.",ICU management,[91490],[8313],[8548],[False],[0],[0],[False],['0']
12507,PMC3682293,15303,The settings were adjusted to maintain a p CO of 5.0 to 6.0 kPa.,ICU management,[91499],[8549],[8613],[False],[0],[0],[False],['0']
12508,PMC3682293,15304,The F O was set to reach an age-adapted p O between 8.5 and 10 kPa.,ICU management,[91508],[8614],[8681],[False],[0],[0],[False],['0']
12509,PMC3682293,15305,"Once the patient fulfilled extubation criteria (adequate cardiac function, hemodynamic stability, no coagulopathy, no bleeding, adequate pulmonary function and respiratory effort, including normal postoperative chest radiograph and sufficient blood gas analysis, as judged by the intensivist), the application of propofol or sevoflurane was stopped.",ICU management,[91517],[8682],[9031],[False],[0],[0],[False],['0']
12510,PMC3682293,15306,"Any postoperative nausea and vomiting (PONV) was treated according to the following scheme: (a) topisetron, 2 mg, plus droperidol, 0.5 mg, intravenously (iv) applied; (b) repeated droperidol, 0.5 mg, iv; (c) meclozin/pyridoxin/caffeine (50/50/20 mg) suppository; and (d) metoclopramide, 10 mg iv.",ICU management,[91526],[9032],[9328],[False],[0],[0],[False],['0']
12511,PMC3682293,15307,Steroids and propofol were not used for this purpose.,ICU management,[91535],[9329],[9382],[False],[0],[0],[False],['0']
12512,PMC3682293,15308,Primary and secondary outcomes,Primary and secondary outcomes,[91544],[9383],[9414],[False],[0],[0],[False],['0']
12513,PMC3682293,15309,The primary outcome was defined as cardiac injury on the first postoperative day (POD1) measured by troponin T 12 to 18 hours after surgery.,Primary and secondary outcomes,[91553],[9415],[9555],[False],[0],[0],[False],['0']
12514,PMC3682293,15310,"Additional biochemical outcomes were creatine kinase (CK), myocardium-specific creatine kinase (CK-MB), and myoglobin.",Primary and secondary outcomes,[91562],[9556],[9674],[False],[0],[0],[False],['0']
12515,PMC3682293,15311,"All laboratory values were determined on arrival in the ICU (considered baseline values), 4 hours after initiating postoperative sedation in the ICU, and in the morning of POD1.",Primary and secondary outcomes,[91571],[9675],[9852],[False],[0],[0],[False],['0']
12516,PMC3682293,15312,"The following normal ranges are accepted for the different parameters: troponin, < 0.014 μg/L; CK, < 190 U/L; CK-MB, 28 to 72 U/L; and myoglobin, < 24 μg/L.",Primary and secondary outcomes,[91580],[9853],[10009],[False],[0],[0],[False],['0']
12517,PMC3682293,15313,"Secondary end points included oxygenation index (p O /F O ) after 4 hours of sedation before extubation and at POD1, incidence of postoperative pulmonary complications (any of the following: temperature > 38.5°C plus productive cough, radiologic signs of pneumonia or pathologic organisms in Gram stain or culture; initiation of antimicrobial therapy; need for reintubation) during hospitalization, duration of ICU and hospital stay, and the need for antiemetics.",Primary and secondary outcomes,[91589],[10010],[10473],[False],[0],[0],[False],['0']
12518,PMC3682293,15314,"To control for possible remaining confounders, the following parameters were additionally recorded: ECC time, aortic cross-clamp (ACC) time, and administration of blood products.",Primary and secondary outcomes,[91598],[10474],[10652],[False],[0],[0],[False],['0']
12519,PMC3682293,15315,Statistics,Statistics,[91607],[10653],[10664],[False],[0],[0],[False],['0']
12520,PMC3682293,15316,"The study was powered to detect a difference of 0.3 U/L in troponin on POD1 between the two groups with a standard deviation of 0.5 U/L, a β of 0.8, and an α of 0.05.",Statistics,[91616],[10665],[10831],[False],[0],[0],[False],['0']
12521,PMC3682293,15317,The expected number in each group was 44.,Statistics,[91625],[10832],[10873],[False],[0],[0],[False],['0']
12522,PMC3682293,15318,"The data analyst was masked for group assignment when performing the statistical analyses, and the randomization code was broken only after the analyses were completed.",Statistics,[91634],[10874],[11042],[False],[0],[0],[False],['0']
12523,PMC3682293,15319,A per-protocol analysis was performed: we analyzed all patients according to the randomization and whether they received the randomly assigned intervention.,Statistics,[91643],[11043],[11199],[False],[0],[0],[False],['0']
12524,PMC3682293,15320,"We did not include patients in the analyses who were extubated early and who could not be sedated appropriately, because we did not collect outcome data for these patients.",Statistics,[91652],[11200],[11372],[False],[0],[0],[False],['0']
12525,PMC3682293,15321,"For all continuous outcomes, unadjusted and adjusted linear regression models were performed.",Statistics,[91661],[11373],[11466],[False],[0],[0],[False],['0']
12526,PMC3682293,15322,"For all dichotomous outcomes, unadjusted and adjusted logistic regression models were calculated.",Statistics,[91670],[11467],[11564],[False],[0],[0],[False],['0']
12527,PMC3682293,15323,The analyses were adjusted for potential confounders.,Statistics,[91679],[11565],[11618],[False],[0],[0],[False],['0']
12528,PMC3682293,15324,"The adjusted models included patient age, need for blood products during the case, as well as the duration of ECC and ACC.",Statistics,[91688],[11619],[11741],[False],[0],[0],[False],['0']
12529,PMC3682293,15325,"For the cardiac injury markers, the models also included baseline values of the corresponding cardiac injury marker on admission to the ICU.",Statistics,[91697],[11742],[11882],[False],[0],[0],[False],['0']
12530,PMC3682293,15326,"For the linear regression models, the distributions of the residuals were evaluated (normal distribution).",Statistics,[91706],[11883],[11989],[False],[0],[0],[False],['0']
12531,PMC3682293,15327,Statistical significance was defined as P < 0.05.,Statistics,[91715],[11990],[12039],[False],[0],[0],[False],['0']
12532,PMC3682293,15328,"STATA was used for all analyses (STATA for Mac, version 12.0; Stata Corp, College Station, TX, USA).",Statistics,[91724],[12040],[12140],[False],[0],[0],[False],['0']
12533,PMC3682293,15329,Results,Results,[91733],[12141],[12149],[False],[0],[0],[False],['0']
12534,PMC3682293,15330,"Between October 2007 and September 2009, 884 patients were assessed for eligibility (Figure 1).",Results,[91742],[12150],[12245],[False],[0],[0],[False],['0']
12535,PMC3682293,15331,"Seven hundred sixty-seven patients did not qualify for the study, 16 refused consent, 33 were included in other RCTs, 713 met exclusion criteria, and five patients had received a volatile anesthetic during surgery.",Results,[91751],[12246],[12460],[False],[0],[0],[False],['0']
12536,PMC3682293,15332,"One hundred seventeen consented and were randomized, 57 patients for sevoflurane and 60 for propofol sedation.",Results,[91760],[12461],[12571],[False],[0],[0],[False],['0']
12537,PMC3682293,15333,"Eleven and 4 dropouts were found in the sevoflurane and propofol groups, respectively: in the sevoflurane group, 7 patients were extubated earlier than the foreseen 4 hours, and in 4 patients, the AnaConDa device had to be removed because of sedation problems, and sedation was continued with propofol.",Results,[91769],[12572],[12874],[False],[0],[0],[False],['0']
12538,PMC3682293,15334,"In the propofol group, 4 early extubations were observed.",Results,[91778],[12875],[12932],[False],[0],[0],[False],['0']
12539,PMC3682293,15335,"The primary analysis was performed with 46 patients randomized to sevoflurane, 56 patients to propofol.",Results,[91787],[12933],[13036],[False],[0],[0],[False],['0']
12540,PMC3682293,15336,The baseline characteristics and intraoperative parameters are presented in Table 1.,Results,[91796],[13037],[13121],[False],[0],[0],[False],['0']
12541,PMC3682293,15337,"As expected with stratified randomization, the distribution of the types of surgery was even between both groups: 28 patients in the propofol group and 27 patients in the sevoflurane group received aortic valve surgery.",Results,[91805],[13122],[13341],[False],[0],[0],[False],['0']
12542,PMC3682293,15338,Nine patients in the propofol group and 4 patients in the sevoflurane group had a mitral valve procedure.,Results,[91814],[13342],[13447],[False],[0],[0],[False],['0']
12543,PMC3682293,15339,"Nineteen patients in the propofol group and 15 in the sevoflurane group had combined cardiac surgery on either the aortic or the mitral valve, together with CABG surgery or replacement of the ascending aorta.",Results,[91823],[13448],[13656],[False],[0],[0],[False],['0']
12544,PMC3682293,15340,"Primary outcome, troponin T on POD1, reached statistical significance in the unadjusted as well as the linear regression model, adjusted for age of the patient, ECC, blood products, as well as the baseline troponin level.",Results,[91832],[13657],[13878],[False],[0],[0],[False],['0']
12545,PMC3682293,15341,"On POD1, the mean of troponin in the sevoflurane group was 0.4 μg/L lower than that in the propofol group (95% CI, -0.7 to -0.1; P < 0.01).",Results,[91841],[13879],[14018],[False],[0],[0],[False],['0']
12546,PMC3682293,15342,"In the adjusted model, this difference reached a value of 0.2 U/L (CI, -0.4 to -0.02; P = 0.03) (Table 2).",Results,[91850],[14019],[14125],[False],[0],[0],[False],['0']
12547,PMC3682293,15343,Aortic cross-clamp time was dropped from the multiple regression model because of its nonsignificant impact on the results as well as because of concerns for collinearity with the ECC time.,Results,[91859],[14126],[14315],[False],[0],[0],[False],['0']
12548,PMC3682293,15344,"In the linear regression model, values for CK reached significance on POD1 in the unadjusted (difference, -258; CI, -434 to -83; P < 0.01), as well as in the adjusted model (without adjustment for ACC) (difference, 169; CI, -331 to -8; P = 0.04) (Table 2).",Results,[91868],[14316],[14572],[False],[0],[0],[False],['0']
12549,PMC3682293,15345,"In the subgroup of patients with aortic valve surgery (28 in the propofol and 27 in the sevoflurane group), the following results were assessed: The unadjusted difference in means between the propofol group and the sevoflurane group was 0.5 μg/L for troponin T on POD1 (CI, -0.8 to -0.1; P = 0.006) (Table 3).",Results,[91877],[14573],[14882],[False],[0],[0],[False],['0']
12550,PMC3682293,15346,"The adjusted difference in means between the groups was 0.3 μg/L (CI, -0.6 to -0.1; P = 0.02).",Results,[91886],[14883],[14977],[False],[0],[0],[False],['0']
12551,PMC3682293,15347,The same model of multiple linear regression was used as described earlier.,Results,[91895],[14978],[15053],[False],[0],[0],[False],['0']
12552,PMC3682293,15348,"For CK values, the difference in mean value was 250 U/L at POD1 in the unadjusted model (CI, -497 to -2; P = 0.048); after adjustment, no significant result was obtained.",Results,[91904],[15054],[15224],[False],[0],[0],[False],['0']
12553,PMC3682293,15349,The mean oxygenation index in the sevoflurane group was 42 points higher on POD1 compared with the propofol group in the unadjusted model (P = 0.04) (Table 4).,Results,[91913],[15225],[15384],[False],[0],[0],[False],['0']
12554,PMC3682293,15350,"After adjusting for age, blood products, and ECC time, the difference decreased to 27 points and was no longer significant.",Results,[91922],[15385],[15508],[False],[0],[0],[False],['0']
12555,PMC3682293,15351,"Postoperative pulmonary complications were lower in the sevoflurane group, with an OR of 0.4, but not statistically significant in comparison with the propofol group I in either the unadjusted logistic regression model or after adjusting for age, blood products, and ECC time (Table 5).",Results,[91931],[15509],[15795],[False],[0],[0],[False],['0']
12556,PMC3682293,15352,The length in ICU stay and hospitalization time did not differ between the two groups in the adjusted and in the unadjusted model (Table 4).,Results,[91940],[15796],[15936],[False],[0],[0],[False],['0']
12557,PMC3682293,15353,"Plasma creatinine levels on POD1 as well as the incidence of PONV and postoperative pulmonary complications were comparable between both groups, and no statistical significant differences were found in the adjusted and in the unadjusted models (Tables 4 and 5).",Results,[91949],[15937],[16198],[False],[0],[0],[False],['0']
12558,PMC3682293,15354,Discussion,Discussion,[91958],[16199],[16210],[False],[0],[0],[False],['0']
12559,PMC3682293,15355,The main result of this randomized controlled trial is that patients after aortic and mitral valve replacement in combination with CABG or ascending aorta surgery receiving a 4-hour sedation with the volatile anesthetic had lower troponin T values as the most-specific cardiac injury marker at POD1 compared with propofol sedation.,Discussion,[91967],[16211],[16542],[False],[0],[0],[False],['0']
12560,PMC3682293,15356,"It is well known from experimental observations that halogenated anesthetics exert many non-anesthetic properties, causing an endogenous adaptive response of cells to injury, such as that of myocardiocytes to an ischemic insult [17,18].",Discussion,[91976],[16543],[16779],[False],[0],[0],[False],['0']
12561,PMC3682293,15357,"In open-heart surgery, myocardial ischemia and reperfusion is an inherent and inevitable part of the surgical procedure itself.",Discussion,[91985],[16780],[16907],[False],[0],[0],[False],['0']
12562,PMC3682293,15358,"Presence and duration of ACC and ECC time are thereby major factors determining the extent of the inflammatory response, injury, and finally, impairing postoperative organ function.",Discussion,[91994],[16908],[17089],[False],[0],[0],[False],['0']
12563,PMC3682293,15359,Relevant protection of postoperative cardiac function was first described in 1999 in a small clinical study that used a preconditioning protocol with isoflurane before cross-clamping [10].,Discussion,[92003],[17090],[17278],[False],[0],[0],[False],['0']
12564,PMC3682293,15360,"The study revealed less release of CK-MB and troponin, indicating attenuated cardiac injury in the isoflurane group.",Discussion,[92012],[17279],[17395],[False],[0],[0],[False],['0']
12565,PMC3682293,15361,"The cardioprotective potential of various volatile anesthetics, applied during surgery, measured by a reduction in biomarkers of cardiac injury, has been confirmed by many authors [11-13,19,20].",Discussion,[92021],[17396],[17590],[False],[0],[0],[False],['0']
12566,PMC3682293,15362,A meta-analysis performed in 2007 clearly suggested that sevoflurane or desflurane is able to reduce the incidence of myocardial infarction and postoperative mortality after cardiac surgery [21].,Discussion,[92030],[17591],[17786],[False],[0],[0],[False],['0']
12567,PMC3682293,15363,"Some of these studies even showed benefits with regard to mechanical ventilation and/or length of hospital stay [12,13].",Discussion,[92039],[17787],[17907],[False],[0],[0],[False],['0']
12568,PMC3682293,15364,"Different windows of pharmacologic protection with early and late pharmacologic preconditioning by the use of volatile anesthetics have been described in the literature, both probably involving different signaling pathways, which are still not understood in detail.",Discussion,[92048],[17908],[18173],[False],[0],[0],[False],['0']
12569,PMC3682293,15365,"Reactive oxygen species, apoptotic signaling pathways, potassium channels, intracellular calcium concentration, nitric oxide, heat-shock proteins, as well as neutrophil and platelets adhesion to the endovascular cells appear to be involved in ischemia and reperfusion injury [22,23].",Discussion,[92057],[18174],[18457],[False],[0],[0],[False],['0']
12570,PMC3682293,15366,"Although the current trial focuses on a sevoflurane intervention after on-pump cardiac surgery (postconditioning), several studies have elucidated the effect of the application of volatile anesthetics during the whole surgical procedure, called conditioning, or preconditioning, when applied before initiation of the ischemic phase.",Discussion,[92066],[18458],[18790],[False],[0],[0],[False],['0']
12571,PMC3682293,15367,Data from Cromheecke et al.,Discussion,[92075],[18791],[18818],[False],[0],[0],[False],['0']
12572,PMC3682293,15368,"[24] reveal that patients randomized to a sevoflurane anesthesia for aortic valve replacement have, in comparison with the propofol group, have a better postoperative cardiac function in the presence of lower troponin I values.",Discussion,[92084],[18819],[19046],[False],[0],[0],[False],['0']
12573,PMC3682293,15369,Landoni et al.,Discussion,[92093],[19047],[19061],[False],[0],[0],[False],['0']
12574,PMC3682293,15370,"[25], however, could not show similar results in patients undergoing mitral valve replacement with a desflurane preconditioning.",Discussion,[92102],[19062],[19190],[False],[0],[0],[False],['0']
12575,PMC3682293,15371,Bignami and co-workers [26] did not assess a difference in postoperative troponin release in patients with coronary artery disease undergoing mitral valve surgery with a propofol anesthesia throughout the surgical procedure versus a sevoflurane anesthesia before and after CPB (pre- and postconditioning).,Discussion,[92111],[19191],[19496],[False],[0],[0],[False],['0']
12576,PMC3682293,15372,The first studies focusing on cardiac postconditioning were performed in vitro as well as in vivo.,Discussion,[92120],[19497],[19595],[False],[0],[0],[False],['0']
12577,PMC3682293,15373,Pravdid and his group [27] showed in an ischemia-reperfusion model of cardiomyocytes that isoflurane was protective when applied in reoxygenation.,Discussion,[92129],[19596],[19742],[False],[0],[0],[False],['0']
12578,PMC3682293,15374,"Similarly, in an isolated rat heart model, postconditioning with sevoflurane attenuated infarct size and improved cardiac function [28].",Discussion,[92138],[19743],[19879],[False],[0],[0],[False],['0']
12579,PMC3682293,15375,De Hert et al.,Discussion,[92147],[19880],[19894],[False],[0],[0],[False],['0']
12580,PMC3682293,15376,[11] were able to show cardioprotection with sevoflurane postconditioning in patients undergoing CABG surgery.,Discussion,[92156],[19895],[20005],[False],[0],[0],[False],['0']
12581,PMC3682293,15377,Hellström et al.,Discussion,[92165],[20006],[20022],[False],[0],[0],[False],['0']
12582,PMC3682293,15378,"[29] performed a postconditioning trial similar to the current one, sedating patients after CABG surgery with either propofol or sevoflurane for 2 hours only.",Discussion,[92174],[20023],[20181],[False],[0],[0],[False],['0']
12583,PMC3682293,15379,"Results of that trial including patients undergoing CABG surgery with sevoflurane anesthesia and a postoperative randomization to propofol or sevoflurane sedation are comparable to those of the current study with patients after valve replacement: although troponin T values, measured at 12 hours after surgery, were the same in both groups, an attenuated statistically significant increase of troponin T, measured from baseline to peak values, was observed in the sevoflurane arm.",Discussion,[92183],[20182],[20662],[False],[0],[0],[False],['0']
12584,PMC3682293,15380,Whether volatile anesthetics are capable of providing organ protection in events of clear ischemia-reperfusion only remains questionable.,Discussion,[92192],[20663],[20800],[False],[0],[0],[False],['0']
12585,PMC3682293,15381,"This may imply myocardial injury after cardiopulmonary bypass, but also with a myocardial ischemia in the perioperative phase of patients with cardiac surgery.",Discussion,[92201],[20801],[20960],[False],[0],[0],[False],['0']
12586,PMC3682293,15382,This topic was extensively discussed and elegantly summarized in an editorial from De Hert [30].,Discussion,[92210],[20961],[21057],[False],[0],[0],[False],['0']
12587,PMC3682293,15383,"Another important aspect is the time point of application of volatile anesthetics in relation to the event of ischemia-reperfusion, which should not be underestimated.",Discussion,[92219],[21058],[21225],[False],[0],[0],[False],['0']
12588,PMC3682293,15384,Volatile anesthetics might induce a protective signaling in the myocardial cells in defined windows only.,Discussion,[92228],[21226],[21331],[False],[0],[0],[False],['0']
12589,PMC3682293,15385,Such considerations would also explain the results of the randomized controlled study performed by Zangrillo et al.,Discussion,[92237],[21332],[21447],[False],[0],[0],[False],['0']
12590,PMC3682293,15386,"[31], in which conditioning with volatile anesthetics in patients undergoing noncardiac surgery was not superior to an anesthesia regimen with propofol.",Discussion,[92246],[21448],[21600],[False],[0],[0],[False],['0']
12591,PMC3682293,15387,Therefore evidence of the guidelines from the American College of Cardiology/American Heart Association [32] recommending volatile anesthetics for maintenance of general anesthesia in patients at risk for myocardial events is questionable [33].,Discussion,[92255],[21601],[21845],[False],[0],[0],[False],['0']
12592,PMC3682293,15388,"Whereas the myocardium-specific marker troponin T was significantly lower in the sevoflurane arm on the first postoperative day, no difference could be detected for CK-MB.",Discussion,[92264],[21846],[22017],[False],[0],[0],[False],['0']
12593,PMC3682293,15389,This could be due to a different kinetic of these markers with a faster peak value for the CK-MB compared with troponin T on injury.,Discussion,[92273],[22018],[22150],[False],[0],[0],[False],['0']
12594,PMC3682293,15390,"Moreover, CK-MB was not recommended for monitoring patients to detect perioperative myocardial infarction after cardiac surgery.",Discussion,[92282],[22151],[22279],[False],[0],[0],[False],['0']
12595,PMC3682293,15391,Sensitivity and specificity of troponin T seem to be superior [34].,Discussion,[92291],[22280],[22347],[False],[0],[0],[False],['0']
12596,PMC3682293,15392,This might explain the observed differences in our trial.,Discussion,[92300],[22348],[22405],[False],[0],[0],[False],['0']
12597,PMC3682293,15393,Myoglobin values peak within hours after a myocardial lesion and therefore were not detected at the time points of 4 hours and POD1.,Discussion,[92309],[22406],[22538],[True],['RelevantOutcomeExcluded'],['Myoglobin values peak within hours after a myocardial lesion and therefore were not detected at the time points of 4 hours and POD1.'],[True],['OutcomeMeasures']
12598,PMC3682293,15394,"Additionally, myoglobin is not a reliable parameter for myocardial infarction in general.",Discussion,[92327],[22539],[22628],[False],[0],[0],[False],['0']
12599,PMC3682293,15395,This study confirms the already well-known cardioprotective properties of sevoflurane as compared with propofol.,Discussion,[92336],[22629],[22741],[False],[0],[0],[False],['0']
12600,PMC3682293,15396,"Remarkably, and in contrast to all other clinical studies on pharmacologic conditioning with volatile anesthetics, we have used for the first time a late postconditioning protocol exposing patients to low concentrations of sevoflurane only in the postoperative phase and for a relatively short period of 4 hours, whereas patients in the study of Hellström et al.",Discussion,[92345],[22742],[23104],[False],[0],[0],[False],['0']
12601,PMC3682293,15397,[29] were also exposed to sevoflurane during surgery.,Discussion,[92354],[23105],[23158],[False],[0],[0],[False],['0']
12602,PMC3682293,15398,Application of volatile anesthetics during surgery might reflect a certain bias for the study result.,Discussion,[92364],[23159],[23260],[True],['Intervention'],['Application of volatile anesthetics during surgery'],[True],['Intervention']
12603,PMC3682293,15399,"In our trial, patients were exclusively exposed to sevoflurane during the sedation phase in the ICU for a minimum of 4 hours.",Discussion,[92381],[23261],[23386],[False],[0],[0],[False],['0']
12604,PMC3682293,15400,An important aspect of our study that must be considered is the fact that only biomarkers were analyzed.,Discussion,[92392],[23387],[23491],[True],['RelevantOutcomeExcluded'],['only biomarkers were analyzed'],[True],['OutcomeMeasures']
12605,PMC3682293,15401,"If such positive results would claim the potential of being translated into clinical routine, similar findings from additional studies would be necessary.",Discussion,[92408],[23492],[23646],[False],[0],[0],[False],['0']
12606,PMC3682293,15402,Such trials would require large numbers of patients.,Discussion,[92420],[23647],[23699],[True],['UnderpoweredStudy'],['Such trials would require large numbers of patients'],[True],['UnderpoweredStudy']
12607,PMC3682293,15403,"Nevertheless, using biomarkers is certainly a reliable approach for a first clinical trial, which allows linking the finding with current preclinical work including in vitro and animal models as a first proof of principle.",Discussion,[92435],[23700],[23922],[False],[0],[0],[False],['0']
12608,PMC3682293,15404,"Propofol is among the most commonly used substances for sedation in the ICU because it is easily administered and does not accumulate as do other substances (for example, benzodiazepines) if used for long-term sedation.",Discussion,[92444],[23923],[24142],[False],[0],[0],[False],['0']
12609,PMC3682293,15405,"However, because the delivery of volatile anesthetics in the ICU has become available with the AnaConDa system, isoflurane and sevoflurane are new options for sedation of postoperative and critically ill patients.",Discussion,[92453],[24143],[24356],[False],[0],[0],[False],['0']
12610,PMC3682293,15406,"It not only allows an alternative method of postoperative sedation, but also might offer new options in selective and delayed use of organ-protective strategies with ischemia-reperfusion injury.",Discussion,[92462],[24357],[24551],[False],[0],[0],[False],['0']
12611,PMC3682293,15407,"Moreover, postconditioning could be adopted as a ""therapeutic"" option to prevent further cell and organ damage after any kind of injury, such as inflammation or trauma.",Discussion,[92471],[24552],[24720],[False],[0],[0],[False],['0']
12612,PMC3682293,15408,Several potential limitations of the study are acknowledged.,Discussion,[92480],[24721],[24781],[False],[0],[0],[False],['0']
12613,PMC3682293,15409,"First, it is known that the controlled substance propofol also has protective characteristics.",Discussion,[92493],[24782],[24876],[True],['ActivePlacebo'],['the controlled substance propofol also has protective characteristics.'],[True],['Control']
12614,PMC3682293,15410,"The antiinflammatory effect of propofol attenuating cytokine response has been demonstrated extensively [35,36].",Discussion,[92507],[24877],[24989],[False],[0],[0],[False],['0']
12615,PMC3682293,15411,"At least some part of this antiinflammatory effect is also attributed to its containing ethylenediaminetetraacetic acid (EDTA), which is an additive in some of the commercially available propofol formulations [37].",Discussion,[92516],[24990],[25204],[False],[0],[0],[False],['0']
12616,PMC3682293,15412,"However, these properties would rather have diminished the observed group differences in cardiac injury markers and in postoperative pulmonary complications between sevoflurane and propofol in our trial.",Discussion,[92525],[25205],[25408],[False],[0],[0],[False],['0']
12617,PMC3682293,15413,"From this point of view, the findings may be even more impressive if another substance not having possible antiinflammatory properties had been used for comparison instead of propofol.",Discussion,[92534],[25409],[25593],[False],[0],[0],[False],['0']
12618,PMC3682293,15414,"Second, the postconditioning phase was relatively short (4 hours) and did not exceed this time interval.",Discussion,[92548],[25594],[25698],[True],['Intervention'],['the postconditioning phase was relatively short'],[True],['Intervention']
12619,PMC3682293,15415,"In addition, the applied dose of sevoflurane reflecting an age-adjusted 0.5 MAC was relatively low when compared with anesthetic doses during the operation and some supraanesthetic concentrations used in preconditioning settings [38].",Discussion,[92567],[25699],[25933],[True],['Intervention'],['the applied dose of sevoflurane reflecting an age-adjusted 0.5 MAC was relatively low'],[True],['Intervention']
12620,PMC3682293,15416,"In this context, the observed results appear very robust, because higher concentrations of volatile anesthetics could possibly exert even more pronounced organ-protective effects.",Discussion,[92579],[25934],[26113],[False],[0],[0],[False],['0']
12621,PMC3682293,15417,"Third, as we were interested only in the per-protocol data, we did not perform an intention-to-treat analysis, which would imply a calculation of the data from all randomized patients, but a per-protocol analysis.",Discussion,[92595],[26114],[26327],[True],['StatisticalAnalysis'],['we did not perform an intention-to-treat analysis'],[True],['StatisticalAnalysis']
12622,PMC3682293,15418,"Fourth, although chlorofluorocarbons (CFCs) are firmly linked with stratospheric ozone depletion and global atmospheric warming, halogenated anesthetics only contribute for a very small amount of man-made air pollution with these substances [39].",Discussion,[92614],[26328],[26574],[True],['Intervention'],['chlorofluorocarbons (CFCs) are firmly linked with stratospheric ozone depletion and global atmospheric warming'],[True],['Intervention']
12623,PMC3682293,15419,A widespread use of low-dose volatile anesthetics for sedation with low flow rates should reduce the negative impact on the environment and thereby not influence global warming [40].,Discussion,[92624],[26575],[26757],[False],[0],[0],[False],['0']
12624,PMC3682293,15420,Conclusions,Conclusions,[92633],[26758],[26770],[False],[0],[0],[False],['0']
12625,PMC3682293,15421,"The data presented in this investigation suggest that anesthetic postconditioning with sevoflurane might mediate cardiac protection, even with the postoperative application of low-dose sevoflurane.",Conclusions,[92642],[26771],[26968],[False],[0],[0],[False],['0']
12626,PMC3682293,15422,The clinical implementation of these agents can offer an additional tool in the treatment or prevention of ischemic organ dysfunction in the postoperative period.,Conclusions,[92651],[26969],[27131],[False],[0],[0],[False],['0']
12627,PMC3682293,15423,Further studies are warranted with clinical end points focusing on morbidity and mortality.,Conclusions,[92660],[27132],[27223],[False],[0],[0],[False],['0']
12628,PMC3682293,15424,Key messages,Key messages,[92669],[27224],[27237],[False],[0],[0],[False],['0']
12629,PMC3682293,15425,• Short application of sevoflurane in the early postoperative phase decreases troponin T.,Key messages,[92678],[27238],[27327],[False],[0],[0],[False],['0']
12630,PMC3682293,15426,• Sedation with a volatile anesthetic in intensive care units is a possible option to attenuate organ injury.,Key messages,[92687],[27328],[27437],[False],[0],[0],[False],['0']
12631,PMC3682293,15427,Abbreviations,Abbreviations,[92696],[27438],[27452],[False],[0],[0],[False],['0']
12632,PMC3682293,15428,ACC: aortic cross-clamp; ANACONDA: anesthetic-conserving device; BIPAP: biphasic positive airway pressure; BIS: bispectral index; CCS: Canadian Cardiovascular Society; CABG: coronary artery bypass graft; CFC: chlorofluorocarbon; CK: creatine kinase; CK-MB: myocardium-specific creatine kinase; ECC: extracorporeal circulation; EDTA: ethylenediaminetetraacetic acid; FEV : forced expiratory volume in 1 second; FRC: functional residual capacity; ICU: intensive care unit; MAC: minimum alveolar concentration; OLV: one-lung ventilation: PEEP: positive end-expiratory pressure; POD: postoperative day; PONV: postoperative nausea and vomiting.,Abbreviations,[92705],[27453],[28092],[False],[0],[0],[False],['0']
12633,PMC3682293,15429,Competing interests,Competing interests,[92714],[28093],[28113],[False],[0],[0],[False],['0']
12634,PMC3682293,15430,The authors have no competing interests.,Competing interests,[92723],[28114],[28154],[False],[0],[0],[False],['0']
12635,PMC3682293,15431,"BBS has received a research grant from Abbott AG, Baar, Switzerland, for basic and translational research (Abbott was not involved in the study design, analyzing the data, or in the process of writing the manuscript).",Competing interests,[92732],[28155],[28372],[False],[0],[0],[False],['0']
12636,PMC3682293,15432,Authors' contributions,Authors' contributions,[92741],[28373],[28396],[False],[0],[0],[False],['0']
12637,PMC3682293,15433,"MPS, MS, ERS, TAN, and BBS designed the trial.",Authors' contributions,[92750],[28397],[28443],[False],[0],[0],[False],['0']
12638,PMC3682293,15434,"MPS, WB, MS, DRS, VF, OMT, ERS, and BBS performed the trial.",Authors' contributions,[92759],[28444],[28504],[False],[0],[0],[False],['0']
12639,PMC3682293,15435,"MPS, MS, and TP analyzed the data.",Authors' contributions,[92768],[28505],[28539],[False],[0],[0],[False],['0']
12640,PMC3682293,15436,"MPS, MS, WB, TP, MS, PD, ERS, DS, TAN, and BBS wrote the manuscript.",Authors' contributions,[92777],[28540],[28608],[False],[0],[0],[False],['0']
12641,PMC3682293,15437,All authors read and approved the final manuscript.,Authors' contributions,[92786],[28609],[28660],[False],[0],[0],[False],['0']
12642,PMC3682293,15438,Acknowledgements,Acknowledgements,[92795],[28661],[28678],[False],[0],[0],[False],['0']
12643,PMC3682293,15439,"We thank Milo A. Puhan, MD, PhD, Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA, for his support in analyzing data.",Acknowledgements,[92804],[28679],[28820],[False],[0],[0],[False],['0']
12644,PMC3682293,15440,"This study was supported with a research grant from Abbott AG, Baar, Switzerland.",Acknowledgements,[92813],[28821],[28902],[False],[0],[0],[False],['0']
13424,PMC3848019,13131,Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study,Title,[79867],[18546],[139],[False],[0],[0],[False],['0']
13425,PMC3848019,13132,Background,Abstract,[79870],[140],[151],[False],[0],[0],[False],['0']
13426,PMC3848019,13133,There is a significant resumption of smoking following smoking cessation using varenicline.,Abstract,[79873],[152],[243],[False],[0],[0],[False],['0']
13427,PMC3848019,13134,Both smoking cessation medications and counseling have been shown to increase smoking quit rates at one year.,Abstract,[79876],[244],[353],[False],[0],[0],[False],['0']
13428,PMC3848019,13135,"Thus, the combination of varenicline and interactive voice response (IVR) telephony followed by extended IVR may further improve smoking cessation rates at one and two years.",Abstract,[79879],[354],[528],[False],[0],[0],[False],['0']
13429,PMC3848019,13136,Methods,Methods,[79882],[529],[537],[False],[0],[0],[False],['0']
13430,PMC3848019,13137,101 participants were recruited from the community via newspaper advertisement.,Methods,[79885],[538],[617],[False],[0],[0],[False],['0']
13431,PMC3848019,13138,They attended a group counseling session and were given smoking information booklets from the Canadian Cancer Society.,Methods,[79888],[618],[736],[False],[0],[0],[False],['0']
13432,PMC3848019,13139,"After 12 weeks of varenicline and 9 IVR calls, all participants who had quit smoking were randomized into 2 groups matched by levels of motivation and addiction as per baseline questionnaire score.",Methods,[79891],[737],[934],[False],[0],[0],[False],['0']
13433,PMC3848019,13140,The intervention group continued to receive bi-weekly IVR support for weeks 13 – 52.,Methods,[79894],[935],[1019],[False],[0],[0],[False],['0']
13434,PMC3848019,13141,The control group no longer received IVR.,Methods,[79897],[1020],[1061],[False],[0],[0],[False],['0']
13435,PMC3848019,13142,"The primary end-point was self-reported abstinence and exhaled carbon monoxide levels of less than 10 ppm for weeks 12, 52 and 2 years.",Methods,[79900],[1062],[1197],[False],[0],[0],[False],['0']
13436,PMC3848019,13143,Data were analyzed by Fisher’s exact test or Wilcoxon rank-sum test.,Methods,[79903],[1198],[1266],[False],[0],[0],[False],['0']
13437,PMC3848019,13144,Results,Results,[79906],[1267],[1275],[False],[0],[0],[False],['0']
13438,PMC3848019,13145,"Of the 101 participants, 44 (43%) had stopped smoking after 12 weeks of varenicline and 9 IVR calls.",Results,[79909],[1276],[1376],[False],[0],[0],[False],['0']
13439,PMC3848019,13146,"Of these, 23 (52%) were randomized to receive IVR calls from weeks 13 to 52.",Results,[79912],[1377],[1453],[False],[0],[0],[False],['0']
13440,PMC3848019,13147,"At 52 weeks, 26 (59%) participants remained smoke-free.",Results,[79915],[1454],[1509],[False],[0],[0],[False],['0']
13441,PMC3848019,13148,"Of the 23 with IVR, 12 (52.2%) stopped smoking compared to 14 of 21 (66.7%) without IVR.",Results,[79918],[1510],[1598],[False],[0],[0],[False],['0']
13442,PMC3848019,13149,"At 2 years, 40 of the 44 (90.9%) randomized participants were contacted and 24 of the 44 (54.5%) came in for testing.",Results,[79921],[1599],[1716],[False],[0],[0],[False],['0']
13443,PMC3848019,13150,"Fourteen (13% of the original cohort, 30% who were abstinent at 12 weeks and 53% who were abstinent at 52 weeks) remained smoke-free.",Results,[79924],[1717],[1850],[False],[0],[0],[False],['0']
13444,PMC3848019,13151,Five of the 23 (21.7%) randomized to IVR and 9 of the 21 (42.9%) randomized to no IVR remained smoke-free at 2 years.,Results,[79927],[1851],[1968],[False],[0],[0],[False],['0']
13445,PMC3848019,13152,Conclusions,Conclusions,[79930],[1969],[1981],[False],[0],[0],[False],['0']
13446,PMC3848019,13153,"In this pilot study of an apparently healthy population, extended IVR did not affect abstinence rates.",Conclusions,[79933],[1982],[2084],[False],[0],[0],[False],['0']
13447,PMC3848019,13154,There was no relapse prevention benefit in offering 9 months of continued IVR to subjects who had stopped smoking after receiving 3 months of varenicline and IVR treatment.,Conclusions,[79936],[2085],[2257],[False],[0],[0],[False],['0']
13448,PMC3848019,13155,Trial registration,Trial registration,[79939],[2258],[2277],[False],[0],[0],[False],['0']
13449,PMC3848019,13156,ClinicalTrial.gov: NCT00832806,Trial registration,[79942],[2278],[2308],[False],[0],[0],[False],['0']
13450,PMC3848019,13157,Background,Background,[79945],[2309],[2321],[False],[0],[0],[False],['0']
13451,PMC3848019,13158,"When administered for 12 weeks, the smoking cessation drug varenicline has been shown to lead to continuous abstinence rates of about 44% during the last 4 weeks of treatment and 22 – 23% at a one-year follow-up [1,2].",Background,[79948],[2322],[2540],[False],[0],[0],[False],['0']
13452,PMC3848019,13159,"Although varenicline’s effect exceeded that of other drugs such as sustained-release bupropion, the cessation rates are still low.",Background,[79951],[2541],[2671],[False],[0],[0],[False],['0']
13453,PMC3848019,13160,"While medications can be effective in reducing withdrawal symptoms and improving treatment outcomes, a combination of pharmacotherapy and behavioral counseling is more likely to increase abstinence rates [3].",Background,[79954],[2672],[2880],[False],[0],[0],[False],['0']
13454,PMC3848019,13161,IVR systems have been applied in a variety of medical settings and have been used successfully to assess patients at home after hospital discharge for adverse outcomes [4].,Background,[79957],[2881],[3053],[False],[0],[0],[False],['0']
13455,PMC3848019,13162,"Three Canadian studies have explored the potential of IVR to follow smokers after discharge as part of a comprehensive hospital-based smoking intervention (the “Ottawa Model”), demonstrating that it is feasible to use IVR in this setting and suggesting an intervention that includes optional automated post-discharge follow-up may increase smoking cessation.",Background,[79960],[3054],[3412],[False],[0],[0],[False],['0']
13456,PMC3848019,13163,"However, the specific contribution of IVR to cessation rates was assessed only in a small pilot study limited to smokers admitted with myocardial infarction.",Background,[79963],[3413],[3570],[False],[0],[0],[False],['0']
13457,PMC3848019,13164,The study showed a benefit of IVR that did not reach statistical significance.,Background,[79966],[3571],[3649],[False],[0],[0],[False],['0']
13458,PMC3848019,13165,"Also, cardiac patients have higher rates of smoking cessation after hospital discharge than a general population [4].",Background,[79969],[3650],[3767],[False],[0],[0],[False],['0']
13459,PMC3848019,13166,The automated IVR uses algorithms and computerized speech recognition to engage smokers on the telephone: it gathers information; provides reinforcing messages and triages them to a study nurse for call-back within 2 working days if either the smoker or the nurse identify that help is required.,Background,[79972],[3768],[4063],[False],[0],[0],[False],['0']
13460,PMC3848019,13167,"IVR is a low cost, high-yield way of contacting smokers when they would not ordinarily be contacted.",Background,[79975],[4064],[4164],[False],[0],[0],[False],['0']
13461,PMC3848019,13168,"In our study everyone received a combination of medication and smoking cessation counseling (through the IVR and call-back), from a study nurse if needed.",Background,[79978],[4165],[4319],[False],[0],[0],[False],['0']
13462,PMC3848019,13169,This combination approach gave all participants proven treatment and an equal opportunity to stop smoking.,Background,[79981],[4320],[4426],[False],[0],[0],[False],['0']
13463,PMC3848019,13170,We hypothesized that IVR telephony may decrease the relapse rate after smoking cessation.,Background,[79984],[4427],[4516],[False],[0],[0],[False],['0']
13464,PMC3848019,13171,Methods,Methods,[79987],[4517],[4525],[False],[0],[0],[False],['0']
13465,PMC3848019,13172,Ethics and study design,Methods|Ethics and study design,[79990],[4526],[4549],[False],[0],[0],[False],['0']
13466,PMC3848019,13173,"This investigator initiated study was sponsored by Pfizer Canada, producers of varenicline.",Methods|Ethics and study design,[79993],[4550],[4641],[False],[0],[0],[False],['0']
13467,PMC3848019,13174,The study was scrutinized internally at the Healthy Heart Program and also by scientists at Pfizer Canada and Pfizer United States of America.,Methods|Ethics and study design,[79996],[4642],[4784],[False],[0],[0],[False],['0']
13468,PMC3848019,13175,It was approved by the Providence Health Care Ethics Committee.,Methods|Ethics and study design,[79999],[4785],[4848],[False],[0],[0],[False],['0']
13469,PMC3848019,13176,"The study is a two-arm, randomized pilot study of 2 years duration to determine the effect of 9 months of extended IVR on the effectiveness of smoking cessation after an initial 3 months of varenicline and IVR treatment.",Methods|Ethics and study design,[80002],[4849],[5069],[False],[0],[0],[False],['0']
13470,PMC3848019,13177,The randomized component of the study included only those who successfully quit smoking at 12 weeks.,Methods|Ethics and study design,[80005],[5070],[5170],[False],[0],[0],[False],['0']
13471,PMC3848019,13178,Varenicline has been approved by Health Canada and marketed since 2007.,Methods|Ethics and study design,[80008],[5171],[5242],[False],[0],[0],[False],['0']
13472,PMC3848019,13179,The IVR system includes the option of direct nurse-to-subject over the telephone counseling.,Methods|Ethics and study design,[80011],[5243],[5335],[False],[0],[0],[False],['0']
13473,PMC3848019,13180,Both the automated IVR system and the direct nurse-to-subject over the telephone contact are classified as counseling.,Methods|Ethics and study design,[80014],[5336],[5454],[False],[0],[0],[False],['0']
13474,PMC3848019,13181,The IVR uses algorithms and speech recognition to collect information from participants and monitor symptoms.,Methods|Ethics and study design,[80017],[5455],[5564],[False],[0],[0],[False],['0']
13475,PMC3848019,13182,It provides encouragement and reinforcing smoking cessation messages.,Methods|Ethics and study design,[80020],[5565],[5634],[False],[0],[0],[False],['0']
13476,PMC3848019,13183,These regular messages may serve to further strengthen participants’ sense of self-efficacy in remaining smoke-free [5].,Methods|Ethics and study design,[80023],[5635],[5755],[False],[0],[0],[False],['0']
13477,PMC3848019,13184,If the participant requests a call-back then a study nurse would call them and help them get back on track with smoking cessation.,Methods|Ethics and study design,[80026],[5756],[5886],[False],[0],[0],[False],['0']
13478,PMC3848019,13185,Short counseling interventions have been found to be very effective.,Methods|Ethics and study design,[80029],[5887],[5955],[False],[0],[0],[False],['0']
13479,PMC3848019,13186,"Callback counseling provides a flexible, cost-effective intervention for smoking cessation that can be provided by a centralized service for a large population.",Methods|Ethics and study design,[80032],[5956],[6116],[False],[0],[0],[False],['0']
13480,PMC3848019,13187,It appears to encourage a greater proportion of quit attempts and to reduce the rate of relapse among those quitting [6].,Methods|Ethics and study design,[80035],[6117],[6238],[False],[0],[0],[False],['0']
13481,PMC3848019,13188,Study population,Study population,[80038],[6239],[6256],[False],[0],[0],[False],['0']
13482,PMC3848019,13189,101 participants were recruited from the community in response to an advertisement in a local newspaper.,Study population,[80041],[6257],[6361],[False],[0],[0],[False],['0']
13483,PMC3848019,13190,None had a history of cardiac or other chronic disease.,Study population,[80044],[6362],[6417],[False],[0],[0],[False],['0']
13484,PMC3848019,13191,Inclusion criteria: smoking 35 or more cigarettes per week or 5 or more cigarettes per day for at least 2 years with no period of abstinence longer than 3 months.,Study population,[80047],[6418],[6580],[False],[0],[0],[False],['0']
13485,PMC3848019,13192,"Exclusion criteria: use of any smoking cessation drugs or nicotine replacement drugs in the last 3 months, use of medications to treat depression or any psychiatric illness, history of depression or an unstable medical condition.",Study population,[80050],[6581],[6810],[False],[0],[0],[False],['0']
13486,PMC3848019,13193,Exclusion criteria were identified by self-report.,Study population,[80053],[6811],[6861],[False],[0],[0],[False],['0']
13487,PMC3848019,13194,The study investigators met with each participant to complete a checklist of inclusion and exclusion criteria as approved by the hospital ethics committee.,Study population,[80056],[6862],[7017],[False],[0],[0],[False],['0']
13488,PMC3848019,13195,None of the participants who attended the initial study information session had a chronic disease.,Study population,[80059],[7018],[7116],[False],[0],[0],[False],['0']
13489,PMC3848019,13196,"Those who had experienced depression or had a mental health condition in the past year were excluded because of the varenicline warning label for agitation, hostility, depression or changes in behaviour or thinking.",Study population,[80062],[7117],[7332],[False],[0],[0],[False],['0']
13490,PMC3848019,13197,We excluded people who had experienced these symptoms in the past year.,Study population,[80065],[7333],[7404],[False],[0],[0],[False],['0']
13491,PMC3848019,13198,"All potential participants attended an information session about smoking, smoking cessation, varenicline, eligibility for the study, and the relevance of the questionnaire about demographics, motivation, stress, and smoking.",Study population,[80068],[7405],[7629],[False],[0],[0],[False],['0']
13492,PMC3848019,13199,They were given an information package including the Canadian Cancer Society booklets For Smokers Who Don’t Want to Quit and For Smokers Who Want to Quit.,Study population,[80071],[7630],[7784],[False],[0],[0],[False],['0']
13493,PMC3848019,13200,All participants gave written informed consent.,Study population|All participants gave written informed consent.,[80074],[7785],[7832],[False],[0],[0],[False],['0']
13494,PMC3848019,13201,"The study was performed in the Healthy Heart Program, an outpatient clinic.",Study population|All participants gave written informed consent.,[80077],[7833],[7908],[False],[0],[0],[False],['0']
13495,PMC3848019,13202,The focus of the program is helping people minimize their risk factors for coronary artery disease.,Study population|All participants gave written informed consent.,[80080],[7909],[8008],[False],[0],[0],[False],['0']
13496,PMC3848019,13203,Initial varenicline and IVR treatment,Initial varenicline and IVR treatment,[80083],[8009],[8047],[False],[0],[0],[False],['0']
13497,PMC3848019,13204,"Participants received a 12-week supply of varenicline: 0.5 mg to be taken on days 1–3, 0.5 mg twice a day on days 4–7, and 1 mg twice a day until the end of week 12.",Initial varenicline and IVR treatment,[80086],[8048],[8213],[False],[0],[0],[False],['0']
13498,PMC3848019,13205,At the initial visit participants chose a target quit date between 8 and 14 days after starting varenicline and gave their preferred calling time for the IVR technology.,Initial varenicline and IVR treatment,[80089],[8214],[8383],[False],[0],[0],[False],['0']
13499,PMC3848019,13206,The IVR intervention consisted of 2 parts: establishing it is speaking to the study participant and the main data collection section.,Initial varenicline and IVR treatment,[80092],[8384],[8517],[False],[0],[0],[False],['0']
13500,PMC3848019,13207,"As instructed at the beginning of the call, the participant answers “yes” or “no” to all questions except when asked about their level of confidence and their side effects.",Initial varenicline and IVR treatment,[80095],[8518],[8690],[False],[0],[0],[False],['0']
13501,PMC3848019,13208,"The IVR asks if they have had a cigarette since their quit date, if they have smoked a cigarette, even a puff, if they have used varenicline in the last 14 days, have they experienced any side effects, how confident they are that they will remain a non-smoker, and would they like to have a study nurse call them to help prevent relapse or provide advice about varenicline.",Initial varenicline and IVR treatment,[80098],[8691],[9064],[False],[0],[0],[False],['0']
13502,PMC3848019,13209,"Finally, there is a positive reinforcing message thanking and congratulating them followed by “remaining smoke-free is the single most important thing you can do for your health”.",Initial varenicline and IVR treatment,[80101],[9065],[9244],[False],[0],[0],[False],['0']
13503,PMC3848019,13210,"The calls are 3–5 minutes long, depending on their answers and which part of the algorithm they are directed to.",Initial varenicline and IVR treatment,[80104],[9245],[9357],[False],[0],[0],[False],['0']
13504,PMC3848019,13211,"The IVR made a call on their quit day, then on day 3, 8, and 11, and every 2 weeks thereafter.",Initial varenicline and IVR treatment,[80107],[9358],[9452],[False],[0],[0],[False],['0']
13505,PMC3848019,13212,"After the 12th week of treatment, those who had stopped smoking were asked to come in for an exhaled carbon monoxide level measurement to confirm their non-smoking status.",Initial varenicline and IVR treatment,[80110],[9453],[9624],[False],[0],[0],[False],['0']
13506,PMC3848019,13213,The primary end-point was self-reported abstinence and exhaled carbon monoxide levels of less than 10 parts per million (ppm) at 12 and 52 weeks and 2 years.,Initial varenicline and IVR treatment,[80113],[9625],[9782],[False],[0],[0],[False],['0']
13507,PMC3848019,13214,Intervention and control cohorts,Intervention and control cohorts,[80116],[9783],[9816],[False],[0],[0],[False],['0']
13508,PMC3848019,13215,Participants who had quit smoking at 12 weeks were randomized into 2 groups matched by their level of motivation and level of addiction as per psychometric questionnaire at baseline.,Intervention and control cohorts,[80119],[9817],[9999],[False],[0],[0],[False],['0']
13509,PMC3848019,13216,This was a stratified randomization whereby participants were categorized by motivation and addiction.,Intervention and control cohorts,[80122],[10000],[10102],[False],[0],[0],[False],['0']
13510,PMC3848019,13217,The intervention group continued to receive IVR calls every 2 weeks from weeks 13 – 52.,Intervention and control cohorts,[80125],[10103],[10190],[False],[0],[0],[False],['0']
13511,PMC3848019,13218,The control group did not receive further IVR.,Intervention and control cohorts,[80128],[10191],[10237],[False],[0],[0],[False],['0']
13512,PMC3848019,13219,"At 52 weeks, all participants were asked to come in for a follow-up appointment and complete the same questionnaire administered at the initial baseline visit.",Intervention and control cohorts,[80131],[10238],[10397],[False],[0],[0],[False],['0']
13513,PMC3848019,13220,Weight and waist circumference were measured and in those who had stopped smoking an exhaled carbon monoxide level was measured.,Intervention and control cohorts,[80134],[10398],[10526],[False],[0],[0],[False],['0']
13514,PMC3848019,13221,At 2 years all participants were asked to come in for a final visit to measure weight and waist circumference and determine smoking status.,Intervention and control cohorts,[80137],[10527],[10666],[False],[0],[0],[False],['0']
13515,PMC3848019,13222,For those who were not smoking an exhaled carbon monoxide level was measured.,Intervention and control cohorts,[80140],[10667],[10744],[False],[0],[0],[False],['0']
13516,PMC3848019,13223,Analysis,Analysis,[80143],[10745],[10754],[False],[0],[0],[False],['0']
13517,PMC3848019,13224,"To date, a single all-encompassing questionnaire to assess level of motivation to stop smoking has not been developed.",Analysis,[80146],[10755],[10873],[False],[0],[0],[False],['0']
13518,PMC3848019,13225,"Rather, it is agreed that assessment of nicotine dependence, stage of change, balance of pros and cons, level of temptation, confidence to stop smoking, and level of stress and mood is best used in combination to assess motivation [7-9].",Analysis,[80149],[10874],[11111],[False],[0],[0],[False],['0']
13519,PMC3848019,13226,Questionnaire data were collected at the initial and 52 week visit.,Analysis,[80152],[11112],[11179],[False],[0],[0],[False],['0']
13520,PMC3848019,13227,The Stage of Change algorithm was used to determine the stage of readiness for change [10].,Analysis,[80155],[11180],[11271],[False],[0],[0],[False],['0']
13521,PMC3848019,13228,Pros and cons of change were assessed using the Decisional Balance Scale [11].,Analysis,[80158],[11272],[11350],[False],[0],[0],[False],['0']
13522,PMC3848019,13229,This measured participants’ perceived benefits and drawbacks of stopping smoking.,Analysis,[80161],[11351],[11432],[False],[0],[0],[False],['0']
13523,PMC3848019,13230,Their self-efficacy was measured on the Self-Efficacy and Temptation Scale [12].,Analysis,[80164],[11433],[11513],[False],[0],[0],[False],['0']
13524,PMC3848019,13231,These questionnaires have been used in the Canadian Heart and Stroke Foundation funded trial – The Multicentre Biofeedback Reactivity Trial: Modifying Cardiovascular Reactivity to Stress During the Acute Phase of Smoking Cessation[13].,Analysis,[80167],[11514],[11749],[False],[0],[0],[False],['0']
13525,PMC3848019,13232,"The Fagerstrom Tolerance Test of Nicotine Dependence was used to determine level of dependence on nicotine and The Stop D Scale (Stress and Mood) to provide severity scores for each of the following areas: depression, anxiety, stress, anger, and poor social support [14,15].",Analysis,[80170],[11750],[12024],[False],[0],[0],[False],['0']
13526,PMC3848019,13233,The answers to the questionnaire provide information about the phenotype – who responds to varenicline and IVR treatment and who does not.,Analysis,[80173],[12025],[12163],[False],[0],[0],[False],['0']
13527,PMC3848019,13234,"Motivation is a complex subject that involves motives, intents, values, and probability of success [16].",Analysis,[80176],[12164],[12268],[False],[0],[0],[False],['0']
13528,PMC3848019,13235,Motivation is considered critical to changing problem behaviours and to engaging in health-protection behaviours such as stopping smoking.,Analysis,[80179],[12269],[12407],[False],[0],[0],[False],['0']
13529,PMC3848019,13236,Motivation for change typically refers to both reasons for change and the strength of the desire or commitment to make the change [17].,Analysis,[80182],[12408],[12543],[False],[0],[0],[False],['0']
13530,PMC3848019,13237,"Age, gender, income, social support and number of cigarettes smoked per day are among the factors that have been shown to influence ability to stop smoking [18,19].",Analysis,[80185],[12544],[12708],[False],[0],[0],[False],['0']
13531,PMC3848019,13238,Table 1 summarizes selected variable frequencies that were included in the questionnaires.,Analysis,[80188],[12709],[12799],[False],[0],[0],[False],['0']
13532,PMC3848019,13239,These are the variables with the strongest trend toward significance.,Analysis,[80191],[12800],[12869],[False],[0],[0],[False],['0']
13533,PMC3848019,13240,Statistical analysis,Statistical analysis,[80194],[12870],[12891],[False],[0],[0],[False],['0']
13534,PMC3848019,13241,Summary statistics were used to describe the demographic characteristics of the study participants.,Statistical analysis,[80197],[12892],[12991],[False],[0],[0],[False],['0']
13535,PMC3848019,13242,The univariate relationship between the outcome and the potential predictors were analyzed by Fisher’s exact test or Wilcoxon rank-sum test as appropriate.,Statistical analysis,[80200],[12992],[13147],[False],[0],[0],[False],['0']
13536,PMC3848019,13243,Results,Results,[80203],[13148],[13156],[False],[0],[0],[False],['0']
13537,PMC3848019,13244,Figure 1 Flow chart..,Results,[80206],[13157],[13178],[False],[0],[0],[False],['0']
13538,PMC3848019,13245,"Of the 101 participants, 44 (43%) had stopped smoking after 12 weeks of varenicline and 9 IVR calls.",Results,[80209],[13179],[13280],[False],[0],[0],[False],['0']
13539,PMC3848019,13246,"Of these 44 subjects, 23 (52%) were randomized to receive extended IVR calls from weeks 13 to 52 and 21 (48%) were in the control group.",Results,[80212],[13281],[13417],[False],[0],[0],[False],['0']
13540,PMC3848019,13247,Table 2 provides the selected variable frequencies in subjects eligible for randomization at week 12 (n = 44).,Results,[80215],[13418],[13528],[False],[0],[0],[False],['0']
13541,PMC3848019,13248,"Of the 44 participants who had quit smoking at 12 weeks, 26 (59%) remained smoke-free at 52 weeks, 12 of these had received extended IVR and 14 were in the control group (12/23 (52%) vs. 14/21 (66.7%); p = 0.33).",Results,[80218],[13529],[13741],[False],[0],[0],[False],['0']
13542,PMC3848019,13249,Table 3 provides the status at 52 weeks for those eligible for randomization at week 12 (n = 44).,Results,[80221],[13742],[13839],[False],[0],[0],[False],['0']
13543,PMC3848019,13250,One participant who was not randomized stopped smoking after surgery for lung cancer.,Results,[80224],[13840],[13925],[False],[0],[0],[False],['0']
13544,PMC3848019,13251,"As a result, there were 27 confirmed non-smokers at 52 weeks but only 26 had been randomized at 12 weeks.",Results,[80227],[13926],[14031],[False],[0],[0],[False],['0']
13545,PMC3848019,13252,"One participant was diagnosed with lymphoma, randomized to receive extended IVR and remained a non-smoker at 52 weeks, and one participant who failed to quit at 12 weeks, died from an AIDS related illness.",Results,[80230],[14032],[14237],[False],[0],[0],[False],['0']
13546,PMC3848019,13253,"At 2 years, 40 (39%) of the original 101 participants were contacted and 24 (23%) had their carbon monoxide measured.",Results,[80233],[14238],[14355],[False],[0],[0],[False],['0']
13547,PMC3848019,13254,"There were 14 (13% of the study population, 30% of those abstinent at 12 weeks, 53% of those abstinent at 52 weeks) who were confirmed non-smokers.",Results,[80236],[14356],[14503],[False],[0],[0],[False],['0']
13548,PMC3848019,13255,"Of these, 5 (21% of those abstinent at 12 weeks) had received extended IVR.",Results,[80239],[14504],[14579],[False],[0],[0],[False],['0']
13549,PMC3848019,13256,"Thus, 5 of 23 (21.7%) on IVR versus 9 of 21 (42.9%) on no IVR (chi-square = 2.26, p = 0.13) remained smoke-free at two years.",Results,[80242],[14580],[14705],[False],[0],[0],[False],['0']
13550,PMC3848019,13257,"Figure 1 displays a summary flowchart of the study results at 12 weeks, 1 and 2 years.",Results,[80245],[14706],[14792],[False],[0],[0],[False],['0']
13551,PMC3848019,13258,The IVR responses did identify those who were struggling to stop smoking and these were the participants that were called back.,Results,[80248],[14793],[14920],[False],[0],[0],[False],['0']
13552,PMC3848019,13259,"There were no common psychosocial or demographic characteristics, as identified in the questionnaire, that indicated who would respond to the IVR calls and who would not.",Results,[80251],[14921],[15091],[False],[0],[0],[False],['0']
13553,PMC3848019,13260,"For participants in the extended IVR group, week 12 – 52, there was a low percentage of IVR calls completed (mean 37%, median 34%) and a lower percentage of assessments completed (mean 16%, median 16%).",Results,[80254],[15092],[15294],[False],[0],[0],[False],['0']
13554,PMC3848019,13261,These were the participants who had stopped smoking at 12 weeks and were the subject of investigation.,Results,[80257],[15295],[15397],[False],[0],[0],[False],['0']
13555,PMC3848019,13262,Variables predicting smoking cessation,Variables predicting smoking cessation,[80260],[15398],[15437],[False],[0],[0],[False],['0']
13556,PMC3848019,13263,"Our study participants were recruited from the community, while many studies included recently hospitalized subjects who may have a greater degree of motivation to stop smoking.",Variables predicting smoking cessation,[80263],[15438],[15615],[False],[0],[0],[False],['0']
13557,PMC3848019,13264,"Income over $54,000.",Variables predicting smoking cessation,[80266],[15616],[15636],[False],[0],[0],[False],['0']
13558,PMC3848019,13265,showed a trend toward improved smoking cessation rates but was not statistically significant.,Variables predicting smoking cessation,[80269],[15637],[15730],[False],[0],[0],[False],['0']
13559,PMC3848019,13266,Table 4 displays a summary of the association between potential predictors and smoking status at week 12.,Variables predicting smoking cessation,[80272],[15731],[15836],[False],[0],[0],[False],['0']
13560,PMC3848019,13267,Table 5 displays a summary of these potential predictors at week 52.,Variables predicting smoking cessation,[80275],[15837],[15905],[False],[0],[0],[False],['0']
13561,PMC3848019,13268,Discussion,Discussion,[80278],[15906],[15917],[False],[0],[0],[False],['0']
13562,PMC3848019,13269,The study had a unique design and a long (2 year) follow-up.,Discussion,[80281],[15918],[15978],[False],[0],[0],[False],['0']
13563,PMC3848019,13270,"The major appeals of using IVR are its high level of accessibility, and cost-effectiveness.",Discussion,[80284],[15979],[16070],[False],[0],[0],[False],['0']
13564,PMC3848019,13271,"Telephones are simple to use and familiar to people of most demographics, an advantage of IVR over some of the similar internet-based approaches that are currently being employed [5].",Discussion,[80287],[16071],[16254],[False],[0],[0],[False],['0']
13565,PMC3848019,13272,Research has shown that levels of IVR compliance tends to be relatively high when used for symptom monitoring and as an adjunct to the treatment of chronic pain [5].,Discussion,[80290],[16255],[16420],[False],[0],[0],[False],['0']
13566,PMC3848019,13273,This may indicate that IVR technology works well for people when they feel that it is beneficial and they are motivated to reach an outcome such as pain management.,Discussion,[80293],[16421],[16585],[False],[0],[0],[False],['0']
13567,PMC3848019,13274,Cardiac patients also have higher rates of smoking cessation after hospital discharge than a general population [4].,Discussion,[80296],[16586],[16702],[False],[0],[0],[False],['0']
13568,PMC3848019,13275,A study from The Ottawa Heart Institute identified almost 1300 patients at admission and 91% received intervention to help them quit smoking.,Discussion,[80299],[16703],[16844],[False],[0],[0],[False],['0']
13569,PMC3848019,13276,Six months after discharge 44% of cardiac patients were not smoking after 10 weeks of nicotine patch therapy and 3 IVR calls [20].,Discussion,[80302],[16845],[16975],[False],[0],[0],[False],['0']
13570,PMC3848019,13277,"A study with a general population showed after 12 weeks of varenicline or 10 weeks of transdermal nicotine patch, the last 4 weeks of treatment showed a significantly greater abstinence rate with varenicline (55.9%) than transdermal nicotine patch (43.2%; OR 1.70, 95% CI 1.26 to 2.28, p < 0.001).",Discussion,[80305],[16976],[17273],[False],[0],[0],[False],['0']
13571,PMC3848019,13278,"At 52 weeks these numbers decreased to 26.1% for varenicline and 20.3% for transdermal nicotine patch (OR 1.40, 95% CI 0.99 to 1.99, p = 0.056) [21].",Discussion,[80308],[17274],[17423],[False],[0],[0],[False],['0']
13572,PMC3848019,13279,At 3 months this 55.9% quit rate with varenicline compares with our 43% quit rate after 3 months of vareniclince and IVR.,Discussion,[80311],[17424],[17545],[False],[0],[0],[False],['0']
13573,PMC3848019,13280,At 52 weeks the 26.1% quit rate compares with 25% of our original group (n = 26 out of 101).,Discussion,[80314],[17546],[17638],[False],[0],[0],[False],['0']
13574,PMC3848019,13281,The quit rates for dual therapy varenicline and IVR were lower at 3 months in our study than for monotherapy varenicline.,Discussion,[80317],[17639],[17760],[False],[0],[0],[False],['0']
13575,PMC3848019,13282,"While our study had a small sample size, it was interesting that those who were not smoking at 12 weeks and received extended IVR from weeks 13 – 52 had a 52.5% quit rate at 52 weeks.",Discussion,[80320],[17761],[17944],[True],['SampleSize'],['our study had a small sample size'],[True],['UnderpoweredStudy']
13576,PMC3848019,13283,Those who were not smoking at 12 weeks and did not receive extended IVR had a 66.7% quit rate.,Discussion,[80326],[17945],[18039],[False],[0],[0],[False],['0']
13577,PMC3848019,13284,It would appear that if you are able to quit by 12 weeks with varenicline and IVR you have a higher likelihood of not smoking at 52 weeks than if you had stopped with use of varenicline alone.,Discussion,[80329],[18040],[18232],[False],[0],[0],[False],['0']
13578,PMC3848019,13285,Relapse prevention,Relapse prevention,[80332],[18233],[18252],[False],[0],[0],[False],['0']
13579,PMC3848019,13286,"The Cochrane Review for “relapse prevention interventions for smoking cessation” found that there is insufficient evidence, at the moment, to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid relapse.",Relapse prevention,[80335],[18253],[18533],[False],[0],[0],[False],['0']
13580,PMC3848019,13287,"The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these.",Relapse prevention,[80338],[18534],[18678],[False],[0],[0],[False],['0']
13581,PMC3848019,13288,There is little research available regarding other behavioural approaches.,Relapse prevention,[80341],[18679],[18753],[False],[0],[0],[False],['0']
13582,PMC3848019,13289,"However, extended treatment with varenicline (past 12 weeks) may prevent relapse [22].",Relapse prevention,[80344],[18754],[18840],[False],[0],[0],[False],['0']
13583,PMC3848019,13290,All participants in the study consented to receiving IVR calls.,Relapse prevention,[80347],[18841],[18904],[False],[0],[0],[False],['0']
13584,PMC3848019,13291,As IVR and varenicline were the basis of the study protocol it is difficult to determine how many were motivated to participate in IVR contact.,Relapse prevention,[80350],[18905],[19048],[False],[0],[0],[False],['0']
13585,PMC3848019,13292,"There were no predictors (age, gender, number of cigarettes smoked per day) at 12 and 52 weeks as to who would respond to the IVR calls.",Relapse prevention,[80353],[19049],[19185],[False],[0],[0],[False],['0']
13586,PMC3848019,13293,"Also, for those who had quit smoking at 12 weeks and were randomized to receive 19 additional calls between week 12 and 52, there were no predictors.",Relapse prevention,[80356],[19186],[19335],[False],[0],[0],[False],['0']
13587,PMC3848019,13294,The IVR initiates contact as opposed to Quit Lines that people call.,Relapse prevention,[80359],[19336],[19404],[False],[0],[0],[False],['0']
13588,PMC3848019,13295,"If participants request a call back or if their IVR responses indicate they are struggling with remaining smoke-free, are smoking, or experiencing side effects, a study nurse calls them.",Relapse prevention,[80362],[19405],[19591],[False],[0],[0],[False],['0']
13589,PMC3848019,13296,"Proactive telephone counseling not initiated by calls to helplines helps smokers interested in quitting (44 studies, >24,000 participants, RR 1.29, 95% CI 1.20 to 1.38) [4].",Relapse prevention,[80365],[19592],[19765],[False],[0],[0],[False],['0']
13590,PMC3848019,13297,There is some evidence of a dose response; one or two brief calls are less likely to provide a measurable benefit.,Relapse prevention,[80368],[19766],[19880],[False],[0],[0],[False],['0']
13591,PMC3848019,13298,"Three or more calls increase the chances of quitting compared to a minimal intervention such as providing standard self-help materials, brief advice, or compared to pharmacotherapy alone.",Relapse prevention,[80371],[19881],[20068],[False],[0],[0],[False],['0']
13592,PMC3848019,13299,"Telephone quitlines provide an important route of access to support for smokers, and call-back counseling enhances their usefulness [23].",Relapse prevention,[80374],[20069],[20206],[False],[0],[0],[False],['0']
13593,PMC3848019,13300,"In our study, participants received 9 IVR calls in the first 12 weeks and those who were randomized to receive extended IVR from weeks 13 – 52 received an additional 19 calls.",Relapse prevention,[80377],[20207],[20382],[False],[0],[0],[False],['0']
13594,PMC3848019,13301,We are not aware of any studies with this many IVR calls for this long of a period.,Relapse prevention,[80380],[20383],[20466],[False],[0],[0],[False],['0']
13595,PMC3848019,13302,"While relapse was progressive from week 13 through 52, those who had quit with IVR and varenicline at 12 weeks had relatively low relapse rates for smoking cessation by 52 weeks.",Relapse prevention,[80383],[20467],[20645],[False],[0],[0],[False],['0']
13596,PMC3848019,13303,"Interestingly, those who had quit at 12 weeks (43%) and went on to receive extended IVR had a 52.5% quit rate at 52 weeks (n = 12/23).",Relapse prevention,[80386],[20646],[20780],[False],[0],[0],[False],['0']
13597,PMC3848019,13304,Those who had quit at 12 weeks and did not receive further care had a 66.7% quit rate (n = 14/21).,Relapse prevention,[80389],[20781],[20879],[False],[0],[0],[False],['0']
13598,PMC3848019,13305,"Future studies will hopefully address the possibility of an inverse benefit ratio of, for example, receiving more than 9 IVR calls.",Relapse prevention,[80392],[20880],[21011],[False],[0],[0],[False],['0']
13599,PMC3848019,13306,"To our knowledge, there have been no published trials providing IVR and telephone call-back counseling as an adjunct to varenicline for smoking cessation.",Relapse prevention,[80395],[21012],[21166],[False],[0],[0],[False],['0']
13600,PMC3848019,13307,We were not able to follow-up with study subjects to find out why they lost interest with the IVR.,Relapse prevention,[80399],[21167],[21265],[True],['HighLossToFollowUp'],['We were not able to follow-up with study subjects'],[True],['MissingData']
13601,PMC3848019,13308,The time of year chosen for follow-up may not have been conducive to attending follow-up appointments and responding to IVR calls.,Relapse prevention,[80404],[21266],[21396],[False],[0],[0],[False],['0']
13602,PMC3848019,13309,"Follow-up appointments were scheduled at 12 weeks, 52 weeks and 2 years.",Relapse prevention,[80407],[21397],[21469],[False],[0],[0],[False],['0']
13603,PMC3848019,13310,All of these times coincided with summer season which may have been a barrier to attending.,Relapse prevention,[80410],[21470],[21561],[False],[0],[0],[False],['0']
13604,PMC3848019,13311,"Also, the opportunity to receive the varenicline at no charge may have attracted a select population.",Relapse prevention,[80415],[21562],[21663],[True],['VerySpecificPopulation'],['the opportunity to receive the varenicline at no charge may have attracted a select population'],[True],['Population']
13605,PMC3848019,13312,"The study participants were a lower income group ($42,000.",Relapse prevention,[80419],[21664],[21722],[False],[0],[0],[False],['0']
13606,PMC3848019,13313,"average annual income) than the provincial average ($67,000).",Relapse prevention,[80422],[21723],[21784],[False],[0],[0],[False],['0']
13607,PMC3848019,13314,"Other studies have shown a link between lower average income and ability to stop smoking [24,25].",Relapse prevention,[80425],[21785],[21882],[False],[0],[0],[False],['0']
13608,PMC3848019,13315,Conclusions,Conclusions,[80428],[21883],[21895],[False],[0],[0],[False],['0']
13609,PMC3848019,13316,Our data show a lack of significant reduction in relapse rates at 52 weeks in apparently healthy participants who had received extended IVR (weeks 12 – 52) after stopping smoking with an initial 12 week treatment of varenicline and IVR.,Conclusions,[80431],[21896],[22132],[False],[0],[0],[False],['0']
13610,PMC3848019,13317,"Although age, treatment, baseline weight and income showed trends as predictors of smoking cessation, they were not statistically significant.",Conclusions,[80434],[22133],[22275],[False],[0],[0],[False],['0']
13611,PMC3848019,13318,These findings suggest a larger study is needed before allocating health care funds for IVR in a healthy population without chronic disease.,Conclusions,[80437],[22276],[22416],[False],[0],[0],[False],['0']
13612,PMC3848019,13319,Competing interests,Competing interests,[80440],[22417],[22437],[False],[0],[0],[False],['0']
13613,PMC3848019,13320,Jiri Frohlich was a member of Pfizer (Canada) Medical Advisory Board and received speaking honoraria.,Competing interests,[80443],[22438],[22539],[False],[0],[0],[False],['0']
13614,PMC3848019,13321,He also participated in several clinical trials and received grants for investigator initiated studies.,Competing interests,[80446],[22540],[22643],[False],[0],[0],[False],['0']
13615,PMC3848019,13322,Authors’ contributions,Authors’ contributions,[80449],[22644],[22667],[False],[0],[0],[False],['0']
13616,PMC3848019,13323,JF obtained research funding and supervised all intervention development.,Authors’ contributions,[80452],[22668],[22741],[False],[0],[0],[False],['0']
13617,PMC3848019,13324,JF and BM participated in the conception of the study and developed its design.,Authors’ contributions,[80455],[22742],[22821],[False],[0],[0],[False],['0']
13618,PMC3848019,13325,AG and BM developed interactive voice response telephony interview scripts and analyzed and interpreted its data.,Authors’ contributions,[80458],[22822],[22935],[False],[0],[0],[False],['0']
13619,PMC3848019,13326,QY provided questionnaire development and analysis methods.,Authors’ contributions,[80461],[22936],[22995],[False],[0],[0],[False],['0']
13620,PMC3848019,13327,"BM prepared data for analysis, including quality assurance and data consolidation.",Authors’ contributions,[80464],[22996],[23078],[False],[0],[0],[False],['0']
13621,PMC3848019,13328,BM wrote the manuscript draft and JF revised it critically for intellectual content.,Authors’ contributions,[80467],[23079],[23163],[False],[0],[0],[False],['0']
13622,PMC3848019,13329,All authors read and approved the final manuscript.,Authors’ contributions,[80470],[23164],[23215],[False],[0],[0],[False],['0']
13623,PMC3848019,13330,Pre-publication history,Pre-publication history,[80473],[23216],[23240],[False],[0],[0],[False],['0']
13624,PMC3848019,13331,The pre-publication history for this paper can be accessed here:,Pre-publication history,[80476],[23241],[23305],[False],[0],[0],[False],['0']
13625,PMC3848019,13332,http://www.biomedcentral.com/1471-2458/13/824/prepub,Pre-publication history,[80479],[23306],[23358],[False],[0],[0],[False],['0']
13626,PMC3848019,13333,Acknowledgements,Acknowledgements,[80482],[23359],[23376],[False],[0],[0],[False],['0']
13627,PMC3848019,13334,This study was funded by Pfizer Canada.,Acknowledgements,[80485],[23377],[23416],[False],[0],[0],[False],['0']
13628,PMC3848019,13335,"The authors acknowledge Andrew Ignaszewski for helping with patient recruitment, Fred Bass and Greg Bondy for the presentation of smoking related education sessions for participants, Sarah Cockell for questionnaire interpretation, Min Li for data input, Joel Singer and Terry Lee for statistical analysis, Andrew Juren for follow-up assessment and Monica Juren for literature search.",Acknowledgements,[80488],[23417],[23800],[False],[0],[0],[False],['0']
14366,PMC3856515,18564,Postoperative pain and perioperative outcomes after laparoscopic radical hysterectomy and abdominal radical hysterectomy in patients with early cervical cancer: a randomised controlled trial,Title,[111728],[31260],[190],[False],[0],[0],[False],['0']
14367,PMC3856515,18565,Background,Abstract,[111730],[191],[202],[False],[0],[0],[False],['0']
14368,PMC3856515,18566,"Non-randomised studies have suggested that the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",Abstract,[111732],[203],[416],[False],[0],[0],[False],['0']
14369,PMC3856515,18567,"However, no study evaluating postoperative pain comparing both techniques has been published thus far.",Abstract,[111734],[417],[519],[False],[0],[0],[False],['0']
14370,PMC3856515,18568,Our objective was to compare pain intensity and other perioperative outcomes between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in early cervical cancer.,Abstract,[111736],[520],[711],[False],[0],[0],[False],['0']
14371,PMC3856515,18569,Methods,Methods,[111738],[712],[720],[False],[0],[0],[False],['0']
14372,PMC3856515,18570,"This single centre, randomised, controlled trial enrolled 30 cervical cancer patients who were clinically staged IA2 with lymph vascular invasion and IB according to the FIGO (International Federation of Gynaecology and Obstetrics) classification, and underwent LRH or ARH between late 1999 and early 2004.",Methods,[111740],[721],[1027],[False],[0],[0],[False],['0']
14373,PMC3856515,18571,"Postoperative pain, as measured by a 10-point numerical rate scale, was considered the primary endpoint.",Methods,[111742],[1028],[1132],[False],[0],[0],[False],['0']
14374,PMC3856515,18572,Postoperative pain was assessed every six hours during a patient’s usual postoperative care.,Methods,[111744],[1133],[1225],[False],[0],[0],[False],['0']
14375,PMC3856515,18573,Perioperative outcomes were also registered.,Methods,[111746],[1226],[1270],[False],[0],[0],[False],['0']
14376,PMC3856515,18574,Both surgical techniques were executed by the same surgical team.,Methods,[111748],[1271],[1336],[False],[0],[0],[False],['0']
14377,PMC3856515,18575,Secondary outcomes included intraoperative and other postoperative surgicopathological factors and 5-year survival rates.,Methods,[111750],[1337],[1458],[False],[0],[0],[False],['0']
14378,PMC3856515,18576,Results,Results,[111752],[1459],[1467],[False],[0],[0],[False],['0']
14379,PMC3856515,18577,IA2 patients with lymphatic vascular space invasion and IB cervical cancer patients were randomised to either the LRH group (16 patients) or the ARH group (14 patients).,Results,[111754],[1468],[1637],[False],[0],[0],[False],['0']
14380,PMC3856515,18578,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,Results,[111756],[1638],[1782],[False],[0],[0],[False],['0']
14381,PMC3856515,18579,All of the transoperative complications occurred in the LRH group.,Results,[111758],[1783],[1849],[False],[0],[0],[False],['0']
14382,PMC3856515,18580,The relative risk of presenting with complications was 0.70; CI 95% (0.23–2.11); P = 0.694.,Results,[111760],[1850],[1941],[False],[0],[0],[False],['0']
14383,PMC3856515,18581,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04–2.80).,Results,[111762],[1942],[2087],[False],[0],[0],[False],['0']
14384,PMC3856515,18582,The survival results will be published elsewhere.,Results,[111764],[2088],[2137],[False],[0],[0],[False],['0']
14385,PMC3856515,18583,Conclusions,Conclusions,[111766],[2138],[2150],[False],[0],[0],[False],['0']
14386,PMC3856515,18584,LRH provided lower pain scores after 36 h of observation in this series.,Conclusions,[111768],[2151],[2223],[False],[0],[0],[False],['0']
14387,PMC3856515,18585,The perioperative and serious postoperative complications ratios were comparable between the groups.,Conclusions,[111770],[2224],[2324],[False],[0],[0],[False],['0']
14388,PMC3856515,18586,Trial Registration,Trial Registration,[111772],[2325],[2344],[False],[0],[0],[False],['0']
14389,PMC3856515,18587,NCT01258413,Trial Registration,[111774],[2345],[2356],[False],[0],[0],[False],['0']
14390,PMC3856515,18588,Background,Background,[111776],[2357],[2369],[False],[0],[0],[False],['0']
14391,PMC3856515,18589,"Cervical cancer is the second most common cancer among women worldwide, and 83% of cases occur in developing countries [1].",Background,[111778],[2370],[2493],[False],[0],[0],[False],['0']
14392,PMC3856515,18590,"In Brazil, the estimated annual incidence is approximately 19 cases per 100,000 women [2].",Background,[111780],[2494],[2584],[False],[0],[0],[False],['0']
14393,PMC3856515,18591,"Radical hysterectomy with pelvic lymphadenectomy is a (FIGO) International Federation of Gynaecology and Obstetrics recommended treatment for early cervical cancer [3], traditionally performed using the abdominal approach [4].",Background,[111782],[2585],[2811],[False],[0],[0],[False],['0']
14394,PMC3856515,18592,"The advantages of laparoscopic versus the open approach for benign gynaecological diseases reported in the literature include decreased postoperative pain and a shorter hospital stay [5,6].",Background,[111784],[2812],[3001],[False],[0],[0],[False],['0']
14395,PMC3856515,18593,"Some randomised studies have reported an increased operative time [6,7].",Background,[111786],[3002],[3074],[False],[0],[0],[False],['0']
14396,PMC3856515,18594,"Previous studies have shown the feasibility and safety of laparoscopic radical hysterectomy (LRH) [8-10], and non-randomised controlled studies have suggested that LRH has an increased operative time [11-13], a shorter hospital stay [11,12], and fewer postoperative infections [12] compared with the open approach.",Background,[111788],[3075],[3389],[False],[0],[0],[False],['0']
14397,PMC3856515,18595,A histopathological comparison of LRH and abdominal radical hysterectomy (ARH) suggested that they have the same radicality [14].,Background,[111790],[3390],[3519],[False],[0],[0],[False],['0']
14398,PMC3856515,18596,"Preliminary data suggested an equivalent survival rate for the two techniques [13,15].",Background,[111792],[3520],[3606],[False],[0],[0],[False],['0']
14399,PMC3856515,18597,No randomised trials are available that compare laparoscopic radical hysterectomy with abdominal laparoscopic hysterectomy for treating early cervical cancer.,Background,[111794],[3607],[3765],[False],[0],[0],[False],['0']
14400,PMC3856515,18598,"A randomised, prospective international protocol was performed with 740 patients enrolled to evaluate the feasibility, complications, quality of life, and survival in early cervical cancer patients assigned to either abdominal (ARH) or laparoscopic/robotic radical hysterectomies (LRH).",Background,[111796],[3766],[4052],[False],[0],[0],[False],['0']
14401,PMC3856515,18599,Equivalence will be declared if the disease-free survival difference does not exceed 7% at four years [16].,Background,[111798],[4053],[4160],[False],[0],[0],[False],['0']
14402,PMC3856515,18600,Methods,Methods,[111800],[4161],[4169],[False],[0],[0],[False],['0']
14403,PMC3856515,18601,"The detailed eligibility criteria, recruitment details, endpoints, standardisation of surgical procedures, surgical techniques, sample size calculation and randomisation methods have been published elsewhere [17].",Methods,[111802],[4170],[4383],[False],[0],[0],[False],['0']
14404,PMC3856515,18602,"The surgeons that performed the procedures assessed patients in postoperative care during hospital stay and its complications; during the follow-up, the same surgeons evaluated and managed the recurrences.",Methods,[111804],[4384],[4589],[False],[0],[0],[False],['0']
14405,PMC3856515,18603,The nurses who took care of the patients and who measured pain as the 5th vital sign during hospital stay were also not blind.,Methods,[111806],[4590],[4716],[False],[0],[0],[False],['0']
14406,PMC3856515,18604,"Parametrial extension, vaginal cuff, and uterosacral ligament sizes were measured by the leading surgeon in the operative room.",Methods,[111808],[4717],[4844],[False],[0],[0],[False],['0']
14407,PMC3856515,18605,Operative time was measured by the study team surgeons.,Methods,[111810],[4845],[4900],[False],[0],[0],[False],['0']
14408,PMC3856515,18606,Other surgicopathological factors were assessed by the attending pathologist after tissue processing.,Methods,[111812],[4901],[5002],[False],[0],[0],[False],['0']
14409,PMC3856515,18607,"Briefly, this is a single centre, randomised, controlled trial comparing the hysterectomy LRH and ARH procedures.",Methods,[111814],[5003],[5116],[False],[0],[0],[False],['0']
14410,PMC3856515,18608,Eligible patients were randomised in either the LRH or ARH groups.,Methods,[111816],[5117],[5183],[False],[0],[0],[False],['0']
14411,PMC3856515,18609,"The primary endpoint was postoperative pain, as measured by a 10-point numerical rating scale (NRS) during the postoperative period.",Methods,[111818],[5184],[5316],[False],[0],[0],[False],['0']
14412,PMC3856515,18610,Pain was assessed every 6 h by the nursing staff during a patient’s usual postoperative care; the nursing staff had been trained at the beginning of the study.,Methods,[111820],[5317],[5476],[False],[0],[0],[False],['0']
14413,PMC3856515,18611,"One day pre-surgery, they were reminded to ask each patient to score her pain level from 0–10; the nursing staff was unaware of the study objective.",Methods,[111822],[5477],[5625],[False],[0],[0],[False],['0']
14414,PMC3856515,18612,"The secondary outcomes were intraoperative and postoperative complications, histopathological characteristics, overall survival and disease-free survival; these outcomes were registered prospectively.",Methods,[111824],[5626],[5826],[False],[0],[0],[False],['0']
14415,PMC3856515,18613,Inclusion criteria,Inclusion criteria,[111826],[5827],[5846],[False],[0],[0],[False],['0']
14416,PMC3856515,18614,"The following inclusion criteria were applied: women ≥18 years who sought treatment for histologically confirmed primary squamous, adenocarcinoma, or adenosquamous cervical cancer that was diagnosed by biopsy or cervical conization and clinically staged according to the FIGO classification of IA2 with IB or II A lymph vascular invasion [3].",Inclusion criteria,[111828],[5847],[6189],[False],[0],[0],[False],['0']
14417,PMC3856515,18615,Exclusion criteria,Exclusion criteria,[111830],[6190],[6209],[False],[0],[0],[False],['0']
14418,PMC3856515,18616,"The following exclusion criteria were applied: patients with clinically advanced disease (IIB-IV), previous pelvic or abdominal radiotherapy, pregnancy or clinical diseases that would preclude one or both surgical approaches (pulmonary obstructive disease poorly controlled or contraindicating prolonged Trendelenburg position, severe hip disease precluding the use of the dorsolithotomy position; inadequate bone marrow, renal, or hepatic function); obesity; previous abdominal or pelvic surgery and demographic factors were not considered exclusion criteria.",Exclusion criteria,[111832],[6210],[6770],[False],[0],[0],[False],['0']
14419,PMC3856515,18617,Each surgery was performed by the same team.,Exclusion criteria,[111834],[6771],[6815],[False],[0],[0],[False],['0']
14420,PMC3856515,18618,"The leading surgeon (LFC) performed all of the surgeries, and the other team members were first or second assistants (RK and LSC).",Exclusion criteria,[111836],[6816],[6946],[False],[0],[0],[False],['0']
14421,PMC3856515,18619,The leading surgeon had performed more than one hundred abdominal radical hysterectomies before performing laparoscopic radical hysterectomies.,Exclusion criteria,[111838],[6947],[7090],[False],[0],[0],[False],['0']
14422,PMC3856515,18620,"Before the beginning of the study, a surgeon with expertise in abdominal radical hysterectomies standardised the surgical technique by evaluating the digital records of the laparoscopic radical hysterectomies that were performed by the first surgeon.",Exclusion criteria,[111840],[7091],[7341],[False],[0],[0],[False],['0']
14423,PMC3856515,18621,"To evaluate oncologic adequacy, the leading surgeon measured the parametrial and vaginal tissue in the operative room before processing the tissue [18].",Exclusion criteria,[111842],[7342],[7494],[False],[0],[0],[False],['0']
14424,PMC3856515,18622,Surgical techniques,Surgical techniques,[111844],[7495],[7515],[False],[0],[0],[False],['0']
14425,PMC3856515,18623,Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111846],[7516],[7589],[False],[0],[0],[False],['0']
14426,PMC3856515,18624,"Both procedures were performed as previously described [8,9,19]; LRH involves placing a uterine manipulator with chrome place tubing.",Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111848],[7590],[7723],[False],[0],[0],[False],['0']
14427,PMC3856515,18625,Access to the abdominal cavity was obtained though insertion of Verres needle and insufflation before placement of a 10-mm trocar.,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111850],[7724],[7854],[False],[0],[0],[False],['0']
14428,PMC3856515,18626,Laparoscopic radical hysterectomy was performed according to Piver III classification for a radical hysterectomy [20].,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111852],[7855],[7973],[False],[0],[0],[False],['0']
14429,PMC3856515,18627,The vaginal cuff was sutured laparoscopically.,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111854],[7974],[8020],[False],[0],[0],[False],['0']
14430,PMC3856515,18628,Close-suction drainage was placed until the daily drainage fell below 100 mL.,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111856],[8021],[8098],[False],[0],[0],[False],['0']
14431,PMC3856515,18629,ARH was performed according to the Piver type III classification for a radical hysterectomy [20].,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111858],[8099],[8196],[False],[0],[0],[False],['0']
14432,PMC3856515,18630,Access to the abdominal cavity was obtained through a vertical midline skin incision.,Surgical techniques|Laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy,[111860],[8197],[8282],[False],[0],[0],[False],['0']
14433,PMC3856515,18631,Anaesthesia and postoperative analgesia,Anaesthesia and postoperative analgesia,[111862],[8283],[8323],[False],[0],[0],[False],['0']
14434,PMC3856515,18632,"The same team of anaesthesiologists performed anaesthesia following a defined protocol: midazolam 15 mg orally one hour before surgery, IV access and standard monitoring.",Anaesthesia and postoperative analgesia,[111864],[8324],[8494],[False],[0],[0],[False],['0']
14435,PMC3856515,18633,General anaesthesia was induced with fentanyl 3 μg/kg and propofol 2 mg/kg.,Anaesthesia and postoperative analgesia,[111866],[8495],[8570],[False],[0],[0],[False],['0']
14436,PMC3856515,18634,Orotracheal intubation was facilitated by atracurium 0.5 mg/kg.,Anaesthesia and postoperative analgesia,[111868],[8571],[8634],[False],[0],[0],[False],['0']
14437,PMC3856515,18635,"After intubation, the lungs were ventilated with 50% O , 50% N O, and 2% sevoflurane.",Anaesthesia and postoperative analgesia,[111870],[8635],[8720],[False],[0],[0],[False],['0']
14438,PMC3856515,18636,"At the beginning of the lymphadenectomy, ketoprofen 100 mg and metoclopramide 10 mg were administrated via IV.",Anaesthesia and postoperative analgesia,[111872],[8721],[8831],[False],[0],[0],[False],['0']
14439,PMC3856515,18637,"Before the extubation, dipyrone 15 mg/kg IV, and morphine 0.05 mg/kg SC were administered.",Anaesthesia and postoperative analgesia,[111874],[8832],[8922],[False],[0],[0],[False],['0']
14440,PMC3856515,18638,Residual neuromuscular blockade was antagonised with neostigmine and atropine when necessary.,Anaesthesia and postoperative analgesia,[111876],[8923],[9016],[False],[0],[0],[False],['0']
14441,PMC3856515,18639,"Postoperative analgesia: Day 1, diclofenac 75 mg IM BID, dipyrone (15 mg/kg) IV QID and morphine 0.05 mg/kg mg SC every four hours; Day 2, diclofenac 50 mg PO tid and morphine 3 mg SC every four hours (on demand); Day 3, diclofenac 50 mg PO on demand and morphine 3 mg SC every four hours (on demand).",Anaesthesia and postoperative analgesia,[111878],[9017],[9318],[False],[0],[0],[False],['0']
14442,PMC3856515,18640,Adjuvant radiotherapy/chemotherapy,Adjuvant radiotherapy/chemotherapy,[111880],[9319],[9354],[False],[0],[0],[False],['0']
14443,PMC3856515,18641,"At the discretion of the responsible physician, the histopathological findings were used to determine the need for adjuvant postoperative treatment.",Adjuvant radiotherapy/chemotherapy,[111882],[9355],[9503],[False],[0],[0],[False],['0']
14444,PMC3856515,18642,Postoperative follow-up,Postoperative follow-up,[111884],[9504],[9528],[False],[0],[0],[False],['0']
14445,PMC3856515,18643,All of the patients were evaluated by the study team in the early postoperative period.,Postoperative follow-up,[111886],[9529],[9616],[False],[0],[0],[False],['0']
14446,PMC3856515,18644,The long-term follow-up was a minimum of five years by the study team or the patients’ assistant physician.,Postoperative follow-up,[111888],[9617],[9724],[False],[0],[0],[False],['0']
14447,PMC3856515,18645,"Periodically, contact was made with the assistant physician by the surgeons of the study team to ascertain the patients’ status.",Postoperative follow-up,[111890],[9725],[9853],[False],[0],[0],[False],['0']
14448,PMC3856515,18646,All serious complications were documented and managed by the study team.,Postoperative follow-up,[111892],[9854],[9926],[False],[0],[0],[False],['0']
14449,PMC3856515,18647,Assessing perioperative complications,Assessing perioperative complications,[111894],[9927],[9965],[False],[0],[0],[False],['0']
14450,PMC3856515,18648,All of the transoperative and serious postoperative complications were noted.,Assessing perioperative complications,[111896],[9966],[10043],[False],[0],[0],[False],['0']
14451,PMC3856515,18649,We analysed the proportion of patients presenting with perioperative complications in both groups.,Assessing perioperative complications,[111898],[10044],[10142],[False],[0],[0],[False],['0']
14452,PMC3856515,18650,Sample size calculation,Sample size calculation,[111900],[10143],[10167],[False],[0],[0],[False],['0']
14453,PMC3856515,18651,The NRS scale was considered the primary postoperative endpoint.,Sample size calculation,[111902],[10168],[10232],[False],[0],[0],[False],['0']
14454,PMC3856515,18652,We expected a 55% difference in pain scale intensity between the groups.,Sample size calculation,[111904],[10233],[10305],[False],[0],[0],[False],['0']
14455,PMC3856515,18653,"The sample size was calculated by Epi Info version 6.04b software in a 1:1 sample, and we obtained 30 patients.",Sample size calculation,[111906],[10306],[10417],[False],[0],[0],[False],['0']
14456,PMC3856515,18654,Randomisation,Randomisation,[111908],[10418],[10432],[False],[0],[0],[False],['0']
14457,PMC3856515,18655,"The patients were randomly assigned to groups using a random number table of 180 five-digit numbers generated by an independent author (ATS) who did not participate in patient selection, surgery or follow-up.",Randomisation,[111910],[10433],[10641],[False],[0],[0],[False],['0']
14458,PMC3856515,18656,"After informed consent signing and prior to surgery, a random allocation number was determined with a telephone call.",Randomisation,[111912],[10642],[10759],[False],[0],[0],[False],['0']
14459,PMC3856515,18657,Statistical analysis,Statistical analysis,[111914],[10760],[10781],[False],[0],[0],[False],['0']
14460,PMC3856515,18658,"Continuous variables with normal distribution were analysed using Student’s t-test for independent samples and described by means and standard deviation, whereas those not consistent with normal distribution were analysed using the Mann-Whitney U test and described as medians and percentiles.",Statistical analysis,[111916],[10782],[11075],[False],[0],[0],[False],['0']
14461,PMC3856515,18659,"The discrete variables were compared using Pearson’s χ2 test, and Fisher’s exact test was used when any cell was <5.",Statistical analysis,[111918],[11076],[11192],[False],[0],[0],[False],['0']
14462,PMC3856515,18660,"The pain scores and intergroups were analysed with an ANOVA for the repeated measures, and the Bonferroni correction was applied as necessary.",Statistical analysis,[111920],[11193],[11335],[False],[0],[0],[False],['0']
14463,PMC3856515,18661,Statistical significance was set at P <0.05.,Statistical analysis,[111922],[11336],[11380],[False],[0],[0],[False],['0']
14464,PMC3856515,18662,The statistical software package SPSS (Statistical Package for the Social Sciences) version 18.0 was used for all data analysis.,Statistical analysis,[111924],[11381],[11509],[False],[0],[0],[False],['0']
14465,PMC3856515,18663,Ethical considerations,Ethical considerations,[111926],[11510],[11533],[False],[0],[0],[False],['0']
14466,PMC3856515,18664,The Ethics Committee of Grupo Hospitalar Conceição approved the study protocol in 1999.,Ethical considerations,[111928],[11534],[11621],[False],[0],[0],[False],['0']
14467,PMC3856515,18665,This protocol was registered at ClinicalTrials.gov.,Ethical considerations,[111930],[11622],[11673],[False],[0],[0],[False],['0']
14468,PMC3856515,18666,Written informed consent was obtained from all patients prior to enrolment.,Ethical considerations,[111932],[11674],[11749],[False],[0],[0],[False],['0']
14469,PMC3856515,18667,Results,Results,[111934],[11750],[11758],[False],[0],[0],[False],['0']
14470,PMC3856515,18668,"From 1999 to 2004, 30 patients were included in this trial and underwent randomisation; 16 were submitted to LRH and 14 to ARH (Figure 1).",Results,[111936],[11759],[11897],[False],[0],[0],[False],['0']
14471,PMC3856515,18669,No conversion to laparotomy occurred in the LRH group.,Results,[111938],[11898],[11952],[False],[0],[0],[False],['0']
14472,PMC3856515,18670,Table 1 shows some patient characteristics; Table 2 shows the surgicopathological factors.,Results,[111940],[11953],[12043],[False],[0],[0],[False],['0']
14473,PMC3856515,18671,There was no difference in the pelvic lymph node count between the LRH and ARH groups.,Results,[111942],[12044],[12130],[False],[0],[0],[False],['0']
14474,PMC3856515,18672,Parametrial extension was significantly longer for patients submitted to LRH compared to ARH (P = 0.07 for the right parametrium and P = 0.002 for the left parametrium) (Table 2).,Results,[111944],[12131],[12310],[False],[0],[0],[False],['0']
14475,PMC3856515,18673,There was no difference in operative time between the groups.,Results,[111946],[12311],[12372],[False],[0],[0],[False],['0']
14476,PMC3856515,18674,Table 3 shows all the transoperative and serious postoperative complications.,Results,[111948],[12373],[12450],[False],[0],[0],[False],['0']
14477,PMC3856515,18675,Some patients presented with more than one complication.,Results,[111950],[12451],[12507],[False],[0],[0],[False],['0']
14478,PMC3856515,18676,"There were four transoperative complications, all in the LRH group.",Results,[111952],[12508],[12575],[False],[0],[0],[False],['0']
14479,PMC3856515,18677,Two patients underwent inadvertent cystotomies during bladder dissections; both were recognised intraoperatively and sutured laparoscopically.,Results,[111954],[12576],[12718],[False],[0],[0],[False],['0']
14480,PMC3856515,18678,One patient presented with left renal exclusion three months after surgery and underwent nephrostomy.,Results,[111956],[12719],[12820],[False],[0],[0],[False],['0']
14481,PMC3856515,18679,"Ten months after the LRH, she presented with a vesicovaginal fistula and underwent a successful surgical correction.",Results,[111958],[12821],[12937],[False],[0],[0],[False],['0']
14482,PMC3856515,18680,"Two years after LRH, the patient underwent a left nephrectomy.",Results,[111960],[12938],[13000],[False],[0],[0],[False],['0']
14483,PMC3856515,18681,The other patient had an otherwise uncomplicated recovery.,Results,[111962],[13001],[13059],[False],[0],[0],[False],['0']
14484,PMC3856515,18682,"One patient underwent a rectal injury that was sutured vaginally, and on the 14th postoperative day, she presented with a ureterovaginal fistula, which was initially unsuccessfully managed with a JJ catheter.",Results,[111964],[13060],[13268],[False],[0],[0],[False],['0']
14485,PMC3856515,18683,She later underwent a successful correction of the fistula 30 days post-surgery.,Results,[111966],[13269],[13349],[False],[0],[0],[False],['0']
14486,PMC3856515,18684,Another patient presented with a bowel injury unrecognised at the time of surgery and required an additional laparotomy the day after the LRH.,Results,[111968],[13350],[13492],[False],[0],[0],[False],['0']
14487,PMC3856515,18685,An emergency descending colectomy and a colostomy were performed with washing of the cavity.,Results,[111970],[13493],[13585],[False],[0],[0],[False],['0']
14488,PMC3856515,18686,"She developed sepsis and deep venous thrombosis, and underwent a vesicovaginal fistula correction during a subsequent hospitalisation.",Results,[111972],[13586],[13720],[False],[0],[0],[False],['0']
14489,PMC3856515,18687,She also presented with a rectovaginal fistula 24 months after LRH.,Results,[111974],[13721],[13788],[False],[0],[0],[False],['0']
14490,PMC3856515,18688,This patient has been disease-free for 9 years and was fitted with a colostomy pouch.,Results,[111976],[13789],[13874],[False],[0],[0],[False],['0']
14491,PMC3856515,18689,"In the ARH group, one patient developed ureterostenosis after undergoing pelvic radiation indicated for positive pelvic lymph nodes; three patients group presented with abdominal sepsis and had favourable outcomes; and one was diagnosed with renal exclusion and underwent a nephrectomy.",Results,[111978],[13875],[14161],[False],[0],[0],[False],['0']
14492,PMC3856515,18690,"Four (25%) patients in the LRH group presented with transoperative complications, but none of the patients in the ARH group presented with transoperative complications (Fisher’s exact test = 0.10).",Results,[111980],[14162],[14359],[False],[0],[0],[False],['0']
14493,PMC3856515,18691,"Three patients (19%) in the LRH group presented with serious postoperative complications, and five patients (36%) presented with postoperative complications in the ARH group (Fisher exact test: 0.417).",Results,[111982],[14360],[14561],[False],[0],[0],[False],['0']
14494,PMC3856515,18692,Table 4 and Additional file 1: Figure S1 shows the proportion of patients who presented with transoperative and serious postoperative complications (analysed together).,Results,[111984],[14562],[14730],[False],[0],[0],[False],['0']
14495,PMC3856515,18693,"In total, 36% (five) of the patients in the ARH group and 25% (four) of the patients in the LRH group presented with serious complications.",Results,[111986],[14731],[14870],[False],[0],[0],[False],['0']
14496,PMC3856515,18694,"The relative risk of presenting complications was 0.70, 95% CI (0.23–2.11), P = 0.694.",Results,[111988],[14871],[14957],[False],[0],[0],[False],['0']
14497,PMC3856515,18695,No difference was found in the proportion of women who presented with transoperative or serious postoperative complications in this series.,Results,[111990],[14958],[15097],[False],[0],[0],[False],['0']
14498,PMC3856515,18696,Figure 2 shows postoperative pain curves.,Results,[111992],[15098],[15139],[False],[0],[0],[False],['0']
14499,PMC3856515,18697,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04–2.80) (Figure 2).,Results,[111994],[15140],[15296],[False],[0],[0],[False],['0']
14500,PMC3856515,18698,"In the LRH group, one patient (6%) requested “on demand” morphine; in the ARH group, two patients (15%) requested “on demand” morphine (Fisher exact test 0.586) (See also Additional file 2: Figure S2).",Results,[111996],[15297],[15498],[False],[0],[0],[False],['0']
14501,PMC3856515,18699,Discussion,Discussion,[111998],[15499],[15510],[False],[0],[0],[False],['0']
14502,PMC3856515,18700,Laparoscopic radical hysterectomy had lower pain scores compared with abdominal radical hysterectomy in this series.,Discussion,[112000],[15511],[15627],[False],[0],[0],[False],['0']
14503,PMC3856515,18701,Some studies comparing laparoscopic procedures in benign gynaecologic diseases with abdominal or vaginal procedures support our findings.,Discussion,[112002],[15628],[15765],[False],[0],[0],[False],['0']
14504,PMC3856515,18702,A recent study randomised 41 patients who underwent laparoscopic hysterectomy (LH) and 41 patients who underwent vaginal hysterectomy (VH) for benign diseases.,Discussion,[112004],[15766],[15925],[False],[0],[0],[False],['0']
14505,PMC3856515,18703,Postoperative pain was the primary endpoint and was measured using a 10-point verbal analogue scale (VAS).,Discussion,[112006],[15926],[16032],[False],[0],[0],[False],['0']
14506,PMC3856515,18704,"The LH group showed lower VAS pain scores than the VH group at 1, 3, 8, and 24 hours post-surgery [21].",Discussion,[112008],[16033],[16136],[False],[0],[0],[False],['0']
14507,PMC3856515,18705,A randomised study compared 19 patients who underwent laparoscopic myomectomy and 21 patients who underwent abdominal myomectomy.,Discussion,[112010],[16137],[16266],[False],[0],[0],[False],['0']
14508,PMC3856515,18706,The pain scores were measured using a 10-point VAS.,Discussion,[112012],[16267],[16318],[False],[0],[0],[False],['0']
14509,PMC3856515,18707,"The laparoscopic myomectomy group had significantly lower pain scores than the abdominal myomectomy group at 48 h (2.1 ± 1.5 – 4.0 ± 2.3, P >0.01) and 72 h (1.1 ± 3.7 P >0.01) post-surgery [7].",Discussion,[112014],[16319],[16512],[False],[0],[0],[False],['0']
14510,PMC3856515,18708,A meta-analysis compared laparoscopy versus laparotomy in benign ovarian tumours.,Discussion,[112016],[16513],[16594],[False],[0],[0],[False],['0']
14511,PMC3856515,18709,The odds of being pain free at 24–48 hours post-surgery were significantly greater for laparoscopy (110 patients) than laparotomy (108 patients) at 24–48 hours post-surgery [5].,Discussion,[112018],[16595],[16772],[False],[0],[0],[False],['0']
14512,PMC3856515,18710,VAS and NRS are considered equally accurate in assessing postoperative pain and superior to a four-point verbal categorical rating scale [22].,Discussion,[112020],[16773],[16915],[False],[0],[0],[False],['0']
14513,PMC3856515,18711,The differences in the evaluated pain scores can be explained as follows.,Discussion,[112022],[16916],[16989],[False],[0],[0],[False],['0']
14514,PMC3856515,18712,"First, laparoscopic surgery uses electrosurgical devices for dissection and coagulation, whereas abdominal procedures require clamps, scissors and tying knots, particularly when used in abdominal radical hysterectomy.",Discussion,[112024],[16990],[17207],[False],[0],[0],[False],['0']
14515,PMC3856515,18713,"Therefore, ARH like other open techniques, could cause a wider inflammatory reaction [23,24].",Discussion,[112026],[17208],[17301],[False],[0],[0],[False],['0']
14516,PMC3856515,18714,"Second, wider incisions are subjected to more tension, which can lead to more pain [25].",Discussion,[112028],[17302],[17390],[False],[0],[0],[False],['0']
14517,PMC3856515,18715,"The use of morphine “on demand” can alter the results, but we believe that this use did not interfere with our results, as there was no significant difference in the morphine request between the LRH and ARH groups.",Discussion,[112030],[17391],[17605],[False],[0],[0],[False],['0']
14518,PMC3856515,18716,"To our knowledge, there is no randomised controlled trial published on laparoscopic radical hysterectomy versus abdominal radical hysterectomy that must be performed entirely by laparoscopic approach [26,27].",Discussion,[112032],[17606],[17814],[False],[0],[0],[False],['0']
14519,PMC3856515,18717,"A randomized controlled trial comparing laparoscopically assisted vaginal radical hysterectomy and ARH was published, where the inferior part of parametrium and paracolpium were transected by vaginal approach [28].",Discussion,[112034],[17815],[18029],[False],[0],[0],[False],['0']
14520,PMC3856515,18718,This study included patients with tumours <2 cm and postoperative pain was measured by the amount of analgesic consumption [28].,Discussion,[112036],[18030],[18158],[False],[0],[0],[False],['0']
14521,PMC3856515,18719,"Postoperative acute pain can be reliably measured by NRS and VAS, which are considered correlated [29].",Discussion,[112038],[18159],[18262],[False],[0],[0],[False],['0']
14522,PMC3856515,18720,They function best for the patient’s subjective feeling of present pain intensity.,Discussion,[112040],[18263],[18345],[False],[0],[0],[False],['0']
14523,PMC3856515,18721,"They may be used for worst, least, or average pain over last 24 h, or during the last week [22].",Discussion,[112042],[18346],[18442],[False],[0],[0],[False],['0']
14524,PMC3856515,18722,One of the strengths of the present study was the fact that assessment of present pain intensity as 5th vital sign was performed every 6 hours.,Discussion,[112044],[18443],[18586],[False],[0],[0],[False],['0']
14525,PMC3856515,18723,The current study shows that LRH and ARH do not differ in terms of postoperative complications.,Discussion,[112046],[18587],[18682],[False],[0],[0],[False],['0']
14526,PMC3856515,18724,"Four patients presented with transoperative complications, and three of those presented with postoperative complications that could be consequences of the first complication presented.",Discussion,[112048],[18683],[18867],[False],[0],[0],[False],['0']
14527,PMC3856515,18725,Studies of laparoscopic surgery for benign gynaecologic conditions show a lower rate of complications than abdominal procedures.,Discussion,[112050],[18868],[18996],[False],[0],[0],[False],['0']
14528,PMC3856515,18726,"A recent meta-analysis comparing abdominal, laparoscopic and vaginal hysterectomy showed that laparoscopic hysterectomy showed fewer wound or abdominal infections [25].",Discussion,[112052],[18997],[19165],[False],[0],[0],[False],['0']
14529,PMC3856515,18727,"A comparative retrospective study comparing LRH (n = 35) with ARH (n = 54) described 18% vs. 53%, respectively, febrile complication rates (P = 0.001) [12].",Discussion,[112054],[19166],[19322],[False],[0],[0],[False],['0']
14530,PMC3856515,18728,A prospective study with retrospective controls compared 50 women submitted to LRH with 48 women submitted to ARH (controls); a comparative rate of urinary complications was observed in both groups [30].,Discussion,[112056],[19323],[19526],[False],[0],[0],[False],['0']
14531,PMC3856515,18729,Different surgical skill levels can decrease the performance of a surgical technique [31].,Discussion,[112058],[19527],[19617],[False],[0],[0],[False],['0']
14532,PMC3856515,18730,One limitation of our study was the fact that patient inclusion occurred during the learning curve of the leading surgeon; performing this trial at the beginning of the main surgeon’s training period most likely contributed to the LRH complication rate.,Discussion,[112060],[19618],[19871],[True],['Intervention'],['patient inclusion occurred during the learning curve of the leading surgeon'],[True],['Intervention']
14533,PMC3856515,18731,A Finnish cohort of all hysterectomies performed in Finland from 1993 to 2005 reported a progressive decrease in serious complications for laparoscopic hysterectomies [32].,Discussion,[112064],[19872],[20044],[False],[0],[0],[False],['0']
14534,PMC3856515,18732,Oncological safety is always a concern in surgical studies.,Discussion,[112066],[20045],[20104],[False],[0],[0],[False],['0']
14535,PMC3856515,18733,"We included the parametrial extension measures to evaluate the surgical radicality, as proposed by Spirtos [8].",Discussion,[112068],[20105],[20216],[False],[0],[0],[False],['0']
14536,PMC3856515,18734,"A retrospective comparative study comparing LRH (n = 34) with ARH (n = 37) found similar parametrial extensions: 3.8 cm (2.3–6.5) vs. 3.4 (1.7–7.0), P = 0.59; left parametrium 3.6 cm (2–6) vs. 3.5 (1.5–6.5), P = 0.82 [14].",Discussion,[112070],[20217],[20439],[False],[0],[0],[False],['0']
14537,PMC3856515,18735,A comparative retrospective study comparing LRH (n = 35) with ARH (n = 54) also found no differences in the parametrial extension [12].,Discussion,[112072],[20440],[20575],[False],[0],[0],[False],['0']
14538,PMC3856515,18736,"Because we were not expecting any difference in the parametrial extension, we did not use any blinding.",Discussion,[112075],[20576],[20679],[True],['Blinding'],['we did not use any blinding'],[True],['Blinding']
14539,PMC3856515,18737,"Longer parametrial extension measures for LRH could be explained by the magnification of tissue with the laparoscope, allowing a safer dissection near the bony pelvis.",Discussion,[112078],[20680],[20847],[False],[0],[0],[False],['0']
14540,PMC3856515,18738,Conclusions,Conclusions,[112080],[20848],[20860],[False],[0],[0],[False],['0']
14541,PMC3856515,18739,LRH presented lower pain scores after 36 h of observation in this series.,Conclusions,[112082],[20861],[20934],[False],[0],[0],[False],['0']
14542,PMC3856515,18740,The complication frequency was similar.,Conclusions,[112084],[20935],[20974],[False],[0],[0],[False],['0']
14543,PMC3856515,18741,Further studies are required to ascertain a comparable long-term survival rate.,Conclusions,[112086],[20975],[21054],[False],[0],[0],[False],['0']
14544,PMC3856515,18742,Abbreviations,Abbreviations,[112088],[21055],[21069],[False],[0],[0],[False],['0']
14545,PMC3856515,18743,AHS: Abdominal radical hysterectomy; LRH: Laparoscopic radical hysterectomy; NRS: Numerical rating scale; VAS: Verbal analogue scale; VH: Vaginal hysterectomy.,Abbreviations,[112090],[21070],[21229],[False],[0],[0],[False],['0']
14546,PMC3856515,18744,Competing interests,Competing interests,[112092],[21230],[21250],[False],[0],[0],[False],['0']
14547,PMC3856515,18745,The authors declare that they have no competing interests.,Competing interests,[112094],[21251],[21309],[False],[0],[0],[False],['0']
14548,PMC3856515,18746,Authors’ contributions,Authors’ contributions,[112096],[21310],[21333],[False],[0],[0],[False],['0']
14549,PMC3856515,18747,"Conception and design: LSC, LFL, ATS, ANK.",Authors’ contributions,[112098],[21334],[21376],[False],[0],[0],[False],['0']
14550,PMC3856515,18748,Study coordination: LSC.,Authors’ contributions,[112100],[21377],[21401],[False],[0],[0],[False],['0']
14551,PMC3856515,18749,"Inclusion and clinical data collection: LSC, LFL.",Authors’ contributions,[112102],[21402],[21451],[False],[0],[0],[False],['0']
14552,PMC3856515,18750,"Interpretation of data: LSC, LFL, ATS.",Authors’ contributions,[112104],[21452],[21490],[False],[0],[0],[False],['0']
14553,PMC3856515,18751,"Drafting and writing the manuscript: LSC, LFL.",Authors’ contributions,[112106],[21491],[21537],[False],[0],[0],[False],['0']
14554,PMC3856515,18752,"Revision of manuscript: LSC, LFL, ATS, ANK.",Authors’ contributions,[112108],[21538],[21581],[False],[0],[0],[False],['0']
14555,PMC3856515,18753,All authors read and approved the final manuscript.,Authors’ contributions,[112110],[21582],[21633],[False],[0],[0],[False],['0']
14556,PMC3856515,18754,Acknowledgements,Acknowledgements,[112112],[21634],[21652],[False],[0],[0],[False],['0']
14557,PMC3856515,18755,The authors thank Roberto Peter Fernandes for handling the electronic figures.,Acknowledgements,[112114],[21653],[21731],[False],[0],[0],[False],['0']
16221,PMC400670,11475,"Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]",Title,[69332],[19414],[133],[False],[0],[0],[False],['0']
16222,PMC400670,11476,Introduction,Abstract,[69339],[134],[147],[False],[0],[0],[False],['0']
16223,PMC400670,11477,"Isoflavones are hypothesized to protect against breast cancer, but it is not clear whether they act as oestrogens or anti-oestrogens in breast tissue.",Abstract,[69346],[148],[298],[False],[0],[0],[False],['0']
16224,PMC400670,11478,Our aim was to determine the effects of taking a red clover-derived isoflavone supplement daily for 1 year on mammographic breast density.,Abstract,[69353],[299],[437],[False],[0],[0],[False],['0']
16225,PMC400670,11479,"Effects on oestradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), lymphocyte tyrosine kinase activity and menopausal symptoms were also assessed.",Abstract,[69360],[438],[602],[False],[0],[0],[False],['0']
16226,PMC400670,11480,Methods,Methods,[69367],[603],[611],[False],[0],[0],[False],['0']
16227,PMC400670,11481,"A total of 205 women (age range 49–65 years) with Wolfe P2 or DY mammographic breast patterns were randomly assigned to receive either a red clover-derived isoflavone tablet (26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein) or placebo.",Methods,[69374],[612],[873],[False],[0],[0],[False],['0']
16228,PMC400670,11482,"Change in mammographic breast density, serum oestradiol, FSH, LH, menopausal symptoms and lymphocyte tyrosine kinase activity from baseline to 12 months were assessed.",Methods,[69381],[874],[1041],[False],[0],[0],[False],['0']
16229,PMC400670,11483,Results,Results,[69388],[1042],[1050],[False],[0],[0],[False],['0']
16230,PMC400670,11484,A total of 177 women completed the trial.,Results,[69395],[1051],[1092],[False],[0],[0],[False],['0']
16231,PMC400670,11485,Mammographic breast density decreased in both groups but the difference between the treatment and placebo was not statistically significant.,Results,[69402],[1093],[1233],[False],[0],[0],[False],['0']
16232,PMC400670,11486,There was a significant interaction between treatment group and oestrogen receptor (ESR1) PvuII polymorphism for the change in estimated percentage breast density (mean ± standard deviation): TT isoflavone 1.4 ± 12.3% and TT placebo -9.6 ± 14.2%; CT isoflavone -5.2 ± 12.0% and CT placebo -2.8 ± 10.3%; and CC isoflavone -3.4 ± 9.7% and CC placebo -1.1 ± 9.5%.,Results,[69409],[1234],[1594],[False],[0],[0],[False],['0']
16233,PMC400670,11487,"There were no statistically significant treatment effects on oestradiol, FSH, or LH (assessed only in postmenopausal women), or on lymphocyte tyrosine kinase activity.",Results,[69416],[1595],[1762],[False],[0],[0],[False],['0']
16234,PMC400670,11488,"Baseline levels of menopausal symptoms were low, and there were no statistically significant treatment effects on frequency of hot flushes or other menopausal symptoms.",Results,[69423],[1763],[1931],[False],[0],[0],[False],['0']
16235,PMC400670,11489,Conclusion,Conclusion,[69430],[1932],[1943],[False],[0],[0],[False],['0']
16236,PMC400670,11490,"In contrast to studies showing that conventional hormone replacement therapies increase mammographic breast density, the isoflavone supplement did not increase mammographic breast density in this population of women.",Conclusion,[69437],[1944],[2160],[False],[0],[0],[False],['0']
16237,PMC400670,11491,"Furthermore, there were no effects on oestradiol, gonadotrophins, lymphocyte tyrosine kinase activity, or menopausal symptoms.",Conclusion,[69444],[2161],[2287],[False],[0],[0],[False],['0']
16238,PMC400670,11492,Introduction,Introduction,[69451],[2288],[2302],[False],[0],[0],[False],['0']
16239,PMC400670,11493,Isoflavones are biologically active compounds that are naturally present in foods of plant origin.,Introduction,[69458],[2303],[2401],[False],[0],[0],[False],['0']
16240,PMC400670,11494,"They have received considerable attention because of their potential cancer preventive, cardioprotective and bone sparing effects, and because of their potential to provide relief from menopausal symptoms [1,2].",Introduction,[69465],[2402],[2613],[False],[0],[0],[False],['0']
16241,PMC400670,11495,"Soybeans are particularly rich sources of isoflavones such as daidzein and genistein [3], and intakes of isoflavones are markedly higher among Asian populations than in Western ones, largely resulting from soy consumption patterns [4,5].",Introduction,[69472],[2614],[2851],[False],[0],[0],[False],['0']
16242,PMC400670,11496,It is widely perceived that exposure to isoflavones is beneficial because rates of breast cancer and other hormone-dependent conditions are lower in Asian than in Western countries [6-8].,Introduction,[69479],[2852],[3039],[False],[0],[0],[False],['0']
16243,PMC400670,11497,"However, isoflavones can act as weak oestrogens, and two intervention studies with soy have provided evidence for stimulatory effects of isoflavones on breast tissue [9,10].",Introduction,[69486],[3040],[3213],[False],[0],[0],[False],['0']
16244,PMC400670,11498,"Mammographic breast density, characterized by the relative proportions of radiolucent fat and radiodense connective and epithelial tissue within the breast, has consistently been associated with risk for breast cancer.",Introduction,[69493],[3214],[3432],[False],[0],[0],[False],['0']
16245,PMC400670,11499,"In a review of case–control studies [11], odds ratios for breast cancer among women with the highest versus the lowest extents of density ranged from 2.1 to 6.0.",Introduction,[69500],[3433],[3594],[False],[0],[0],[False],['0']
16246,PMC400670,11500,"The mechanism underlying this relationship has not been fully explained, but it has been suggested that breast density provides an index of current and past hormonal and reproductive events that modulate risk for breast cancer [12].",Introduction,[69507],[3595],[3827],[False],[0],[0],[False],['0']
16247,PMC400670,11501,"In support of this, studies have shown that breast density increases when a woman begins hormone replacement therapy (HRT) and decreases when she discontinues [13-18], and anti-oestrogens such as tamoxifen reduce breast density [19-21].",Introduction,[69514],[3828],[4064],[False],[0],[0],[False],['0']
16248,PMC400670,11502,"As a result of such findings, we suggested that breast density can act as a biomarker of oestrogenic or anti-oestrogenic effects of a given treatment on breast tissue [22].",Introduction,[69521],[4065],[4237],[False],[0],[0],[False],['0']
16249,PMC400670,11503,"Diet has been shown to influence breast density, potentially through effects on endogenous hormone levels.",Introduction,[69528],[4238],[4344],[False],[0],[0],[False],['0']
16250,PMC400670,11504,"For example, a low-fat, high-carbohydrate intervention significantly reduced breast density [23]; however, an inverse association has also been reported between breast density and saturated fat intake [24].",Introduction,[69535],[4345],[4551],[False],[0],[0],[False],['0']
16251,PMC400670,11505,"In a cross-sectional study of diet and mammographic density, total protein and carbohydrate intake was significantly and positively associated with breast density, and among postmenopausal women there was a significant positive association between total meat intake and breast density [25].",Introduction,[69542],[4552],[4842],[False],[0],[0],[False],['0']
16252,PMC400670,11506,"More recently, data from a cross-sectional study of soy food intakes and mammographic densities [26] indicated the presence of a significant trend toward higher percentage density through increasing quartiles of soy intake, but a small study of a soy isoflavone supplement [27] did not significantly alter breast density after 1 year of treatment.",Introduction,[69549],[4843],[5190],[False],[0],[0],[False],['0']
16253,PMC400670,11507,"Here, we report the results of a randomized, placebo-controlled trial that was conducted to determine the effects of a red clover-derived isoflavone supplement, taken daily for 1 year, on mammographic breast density.",Introduction,[69556],[5191],[5407],[False],[0],[0],[False],['0']
16254,PMC400670,11508,"In addition, effects on circulating levels of oestradiol, gonadotrophins, lymphocyte tyrosine kinase activity, and menopausal symptoms are reported, and interactions between treatment group and polymorphisms in CYP17, CYP19, and oestrogen receptor (ESR1) genes.",Introduction,[69563],[5408],[5669],[False],[0],[0],[False],['0']
16255,PMC400670,11509,Methods,Methods,[69570],[5670],[5678],[False],[0],[0],[False],['0']
16256,PMC400670,11510,Recruitment,Methods|Recruitment,[69577],[5679],[5690],[False],[0],[0],[False],['0']
16257,PMC400670,11511,"Women were recruited from the Breast Screening Unit, Addenbrooke's Hospital, Cambridge, UK.",Methods|Recruitment,[69584],[5691],[5782],[False],[0],[0],[False],['0']
16258,PMC400670,11512,"Between November 1997 and May 1999, mammograms from 1908 healthy women aged 49–65 years were classified according to Wolfe pattern [28] and recruitment letters were sent to women with Wolfe P2 or DY breast patterns (n = 1149; Fig.",Methods|Recruitment,[69591],[5783],[6013],[False],[0],[0],[False],['0']
16259,PMC400670,11513,1).,Methods|Recruitment,[69598],[6014],[6017],[False],[0],[0],[False],['0']
16260,PMC400670,11514,The letter contained a short description of the study and a reply slip.,Methods|Recruitment,[69605],[6018],[6089],[False],[0],[0],[False],['0']
16261,PMC400670,11515,Women with a history of breast cancer and/or major breast surgery were not approached.,Methods|Recruitment,[69612],[6090],[6176],[False],[0],[0],[False],['0']
16262,PMC400670,11516,"Women who expressed an interest in taking part, and who were not taking HRT, were visited in their own home.",Methods|Recruitment,[69619],[6177],[6285],[False],[0],[0],[False],['0']
16263,PMC400670,11517,"During this initial home visit the study was explained in detail, and all women who wished to participate were asked for written informed consent.",Methods|Recruitment,[69626],[6286],[6432],[False],[0],[0],[False],['0']
16264,PMC400670,11518,A total of 205 women were randomized (Fig.,Methods|Recruitment,[69633],[6433],[6475],[False],[0],[0],[False],['0']
16265,PMC400670,11519,1).,Methods|Recruitment,[69640],[6476],[6479],[False],[0],[0],[False],['0']
16266,PMC400670,11520,Additional home visits were made after approximately 5.5 and 11 months on the study.,Methods|Recruitment,[69647],[6480],[6564],[False],[0],[0],[False],['0']
16267,PMC400670,11521,"All study procedures were approved by the Dunn Human Nutrition Unit Ethics Committee, and the Cambridge Local Research Ethics Committee.",Methods|Recruitment,[69654],[6565],[6701],[False],[0],[0],[False],['0']
16268,PMC400670,11522,Intervention and randomization,Intervention and randomization,[69661],[6702],[6733],[False],[0],[0],[False],['0']
16269,PMC400670,11523,"Participants were randomly assigned to receive either an isoflavone tablet providing 26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein derived from red clover (Promensil; Novogen Ltd, Sydney, Australia) or a placebo of identical appearance.",Intervention and randomization,[69668],[6734],[6998],[False],[0],[0],[False],['0']
16270,PMC400670,11524,Participants were asked to take one tablet each day for 1 year.,Intervention and randomization,[69675],[6999],[7062],[False],[0],[0],[False],['0']
16271,PMC400670,11525,An independent study has shown that Promensil tablets contain the quantity and type of isoflavones stated by the manufacturer [29].,Intervention and randomization,[69682],[7063],[7194],[False],[0],[0],[False],['0']
16272,PMC400670,11526,"Randomization was performed by the Outpatient Pharmacy, Addenbrooke's Hospital, Cambridge, UK, using random number generation in Microsoft Excel.",Intervention and randomization,[69689],[7195],[7340],[False],[0],[0],[False],['0']
16273,PMC400670,11527,Researchers and study participants remained blinded to tablet allocation throughout the study.,Intervention and randomization,[69696],[7341],[7435],[False],[0],[0],[False],['0']
16274,PMC400670,11528,Mammographic density,Mammographic density,[69703],[7436],[7457],[False],[0],[0],[False],['0']
16275,PMC400670,11529,"Recruitment mammograms that were taken as part of the National Health Service Breast Screening Programme were used as the baseline measure, and women were scheduled to undergo a follow-up mammogram after approximately 12 months on the study.",Mammographic density,[69710],[7458],[7699],[False],[0],[0],[False],['0']
16276,PMC400670,11530,"Independently of each other, and blinded to intervention or placebo status, two radiologists (RMLW and ES) assigned Wolfe patterns [28] and visually estimated the percentage density on each set (left and right mediolateral oblique views) of mammograms.",Mammographic density,[69717],[7700],[7952],[False],[0],[0],[False],['0']
16277,PMC400670,11531,"Estimated percentage densities were assigned by drawing a cross on a 100 mm line (representing 0–100% density), and the distance from the start of the line and the cross was measured.",Mammographic density,[69724],[7953],[8136],[False],[0],[0],[False],['0']
16278,PMC400670,11532,"Mammograms from the left and right breasts were presented to the radiologists, and an average of both breasts was used for assigning Wolfe pattern and estimated percentage density.",Mammographic density,[69731],[8137],[8317],[False],[0],[0],[False],['0']
16279,PMC400670,11533,"One radiologist (RMLW) read baseline mammograms at the time of recruitment, and follow up mammograms at the end of the study, and another (ES) read all mammograms at the end of the study but was unaware of the sequence in which the mammograms had been taken (i.e.",Mammographic density,[69738],[8318],[8581],[False],[0],[0],[False],['0']
16280,PMC400670,11534,baseline or follow up).,Mammographic density,[69745],[8582],[8605],[False],[0],[0],[False],['0']
16281,PMC400670,11535,"Correlations between estimated percentage densities assigned by both radiologists were highly significant for the baseline and 12-month mammograms (r = 0.79, P < 0.01 and r = 0.85, P < 0.01, respectively).",Mammographic density,[69752],[8606],[8811],[False],[0],[0],[False],['0']
16282,PMC400670,11536,Excellent (99%) observer agreement between the two radiologists has previously been reported for the P2 and DY categories [30].,Mammographic density,[69759],[8812],[8939],[False],[0],[0],[False],['0']
16283,PMC400670,11537,"In all statistical analyses, the average of the two radiologists' independent readings of percentage breast density was used.",Mammographic density,[69766],[8940],[9065],[False],[0],[0],[False],['0']
16284,PMC400670,11538,"Two women in the placebo group had mammograms taken before the end of the study (because of suspicious palpable lumps), and one woman (also in the placebo group) did not attend her follow-up appointment.",Mammographic density,[69773],[9066],[9269],[False],[0],[0],[False],['0']
16285,PMC400670,11539,Menopausal symptoms,Menopausal symptoms,[69780],[9270],[9290],[False],[0],[0],[False],['0']
16286,PMC400670,11540,All women were asked to complete a 28-day menopausal symptom diary at baseline and after approximately 12 months on the study [31].,Menopausal symptoms,[69787],[9291],[9422],[False],[0],[0],[False],['0']
16287,PMC400670,11541,"They were asked to rate the severity of 21 symptoms associated with the menopause, including night sweats, heart beating quickly or strongly, feeling tense or nervous, difficulty in sleeping, irritability, and feeling unhappy or depressed.",Menopausal symptoms,[69794],[9423],[9662],[False],[0],[0],[False],['0']
16288,PMC400670,11542,"Severity ratings were as follows: 0 = absent, 1 = mild, 2 = moderate and 3 = severe.",Menopausal symptoms,[69801],[9663],[9747],[False],[0],[0],[False],['0']
16289,PMC400670,11543,Women were also asked to note the number of hot flushes experienced on each of the 28 days.,Menopausal symptoms,[69808],[9748],[9839],[False],[0],[0],[False],['0']
16290,PMC400670,11544,"For each woman, a menopausal symptom score was calculated for the baseline and 12 month diaries (severity ratings for each symptom were averaged over the 28 days and a sum of the mean severity ratings was taken).",Menopausal symptoms,[69815],[9840],[10052],[False],[0],[0],[False],['0']
16291,PMC400670,11545,24-Hour urine samples,Menopausal symptoms,[69822],[10053],[10075],[False],[0],[0],[False],['0']
16292,PMC400670,11546,Participants were asked to provide 24-hour urine collections at baseline and after 12 months on the study.,Menopausal symptoms,[69829],[10076],[10182],[False],[0],[0],[False],['0']
16293,PMC400670,11547,"As a compliance check, women also were asked to make a 24-hour urine collection after 6 months.",Menopausal symptoms,[69836],[10183],[10278],[False],[0],[0],[False],['0']
16294,PMC400670,11548,Collection bottles (containing 2 g boric acid/l as a preservative) and three para-amino benzoic acid (PABA) tablets (80 mg/tablet) were given to each participant at each of the three home visits [32].,Menopausal symptoms,[69843],[10279],[10479],[False],[0],[0],[False],['0']
16295,PMC400670,11549,"Verbal and written instructions were given, and for each collection participants were asked to discard the first urine specimen of the day and to collect all subsequent samples up to and including the first specimen passed the following morning.",Menopausal symptoms,[69850],[10480],[10725],[False],[0],[0],[False],['0']
16296,PMC400670,11550,"Participants were asked to take one PABA tablet with each main meal on the day the collection began, and this was used to determine the completeness of urine collection (see below).",Menopausal symptoms,[69857],[10726],[10907],[False],[0],[0],[False],['0']
16297,PMC400670,11551,Samples were brought to the laboratory in the morning on which the urine collection had been completed.,Menopausal symptoms,[69864],[10908],[11011],[False],[0],[0],[False],['0']
16298,PMC400670,11552,"Once received at the laboratory, samples were mixed thoroughly and the total volume of urine was measured.",Menopausal symptoms,[69871],[11012],[11118],[False],[0],[0],[False],['0']
16299,PMC400670,11553,Three 25 ml aliquots were taken and stored at -20°C.,Menopausal symptoms,[69878],[11119],[11171],[False],[0],[0],[False],['0']
16300,PMC400670,11554,Urinary para-amino benzoic acid and isoflavone analysis,24-Hour urine samples,[69885],[11172],[11228],[False],[0],[0],[False],['0']
16301,PMC400670,11555,The PABA content of all 24-hour urine samples was measured using previously described methodology [32].,24-Hour urine samples,[69892],[11229],[11332],[False],[0],[0],[False],['0']
16302,PMC400670,11556,Samples containing 85–110% of the ingested PABA were designated satisfactory.,24-Hour urine samples,[69899],[11333],[11410],[False],[0],[0],[False],['0']
16303,PMC400670,11557,"For samples with PABA recoveries of between 70% and 85% (indicating that all tablets had been taken but that the urine collection was incomplete), urinary excretion of isoflavones was adjusted up to 93% PABA recovery [33].",24-Hour urine samples,[69906],[11411],[11633],[False],[0],[0],[False],['0']
16304,PMC400670,11558,Samples with less than 70% recovery were designated incomplete.,24-Hour urine samples,[69913],[11634],[11697],[False],[0],[0],[False],['0']
16305,PMC400670,11559,"Samples with greater than 110% PABA recovery were designated unsatisfactory, because additional sources of PABA may have been consumed (e.g.",24-Hour urine samples,[69920],[11698],[11838],[False],[0],[0],[False],['0']
16306,PMC400670,11560,a multivitamin) and an accurate determination of sample completeness could therefore not be made.,24-Hour urine samples,[69927],[11839],[11936],[False],[0],[0],[False],['0']
16307,PMC400670,11561,"Urinary excretions of genistein, daidzein, formononetin and biochanin A were measured by high-pressure liquid chromatography (HPLC) using a method modified from that of Setchell and coworkers [34] and Franke and coworkers [35].",24-Hour urine samples,[69934],[11937],[12164],[False],[0],[0],[False],['0']
16308,PMC400670,11562,"Briefly, samples were incubated with β-glucuronidase for 20–72 hours at 37°C.",24-Hour urine samples,[69941],[12165],[12242],[False],[0],[0],[False],['0']
16309,PMC400670,11563,Phenolic components were extracted into an ethyl-acetate (6:4) solvent mixture.,24-Hour urine samples,[69948],[12243],[12322],[False],[0],[0],[False],['0']
16310,PMC400670,11564,"Following 0.5-min vortex and subsequent 10-min centrifugation, the organic phase was transferred to a 2-ml vial and evaporated to dryness under vacuum at 43°C.",24-Hour urine samples,[69955],[12323],[12482],[False],[0],[0],[False],['0']
16311,PMC400670,11565,Extraction residues were reconstituted in 100 μl 50% isopropanol solution and centrifuged for 10 min.,24-Hour urine samples,[69962],[12483],[12584],[False],[0],[0],[False],['0']
16312,PMC400670,11566,"A 5 μl aliquot was then injected directly onto the HPLC column; the HPLC column consisted of an Alltima 250 × 2.1 mm, 5 μmol/l, C-18 stationary phase (Alltech Associates, Sydney, New South Wales, Australia), and a mobile phase (acetonitrile/water) containing 0.05% trifluoroacetic acid with a gradient of acetonitrile from 25% to 100% was used for each run.",24-Hour urine samples,[69969],[12585],[12942],[False],[0],[0],[False],['0']
16313,PMC400670,11567,Detection and quantification were via photo diode array detector.,24-Hour urine samples,[69976],[12943],[13008],[False],[0],[0],[False],['0']
16314,PMC400670,11568,"Flavone was used as the internal standard, and the limit of detection was 0.05 μg/ml and the limit of quantitation was 0.1 μg/ml.",24-Hour urine samples,[69983],[13009],[13138],[False],[0],[0],[False],['0']
16315,PMC400670,11569,Baseline or 12-month urine samples were unavailable for two women in the isoflavone group and three women in the placebo group.,24-Hour urine samples,[69990],[13139],[13266],[False],[0],[0],[False],['0']
16316,PMC400670,11570,Blood samples and body mass index,Blood samples and body mass index,[69997],[13267],[13301],[False],[0],[0],[False],['0']
16317,PMC400670,11571,Fasting blood samples were taken at baseline and at 12 months.,Blood samples and body mass index,[70004],[13302],[13364],[False],[0],[0],[False],['0']
16318,PMC400670,11572,Participants were asked to refrain from eating or drinking beverages (except water) from midnight until after the sample had been taken the following morning.,Blood samples and body mass index,[70011],[13365],[13523],[False],[0],[0],[False],['0']
16319,PMC400670,11573,"A total of 35.5 ml blood was drawn at each visit, which included 9.0 ml blood that was drawn into a lithium heparin tube, 9.0 ml into a serum tube, 9 ml into an EDTA tube and 4 ml into an additional EDTA tube.",Blood samples and body mass index,[70018],[13524],[13733],[False],[0],[0],[False],['0']
16320,PMC400670,11574,The serum tube was left at room temperature for at least an hour before centrifugation to allow clotting.,Blood samples and body mass index,[70025],[13734],[13839],[False],[0],[0],[False],['0']
16321,PMC400670,11575,"Following centrifugation, aliquots of plasma and serum were stored at -20°C.",Blood samples and body mass index,[70032],[13840],[13916],[False],[0],[0],[False],['0']
16322,PMC400670,11576,"Lymphocytes were extracted from the EDTA tubes (total 13 ml whole blood) using Lymphoprep tubes (Nycomed Pharma AS, Oslo, Norway) and stored at -20°C.",Blood samples and body mass index,[70039],[13917],[14067],[False],[0],[0],[False],['0']
16323,PMC400670,11577,"Approximately 1 ml whole blood was removed from the lithium heparin tube before centrifugation, and DNA was extracted using a QIAGEN kit (QIAGEN Ltd, Crawley, UK).",Blood samples and body mass index,[70046],[14068],[14231],[False],[0],[0],[False],['0']
16324,PMC400670,11578,"Polymorphisms in the CYP17 gene (5' untranslated MspA1 polymorphism) and the CYP19 gene (G → T substitution on intron 6) were determined as described previously [36,37].",Blood samples and body mass index,[70053],[14232],[14401],[False],[0],[0],[False],['0']
16325,PMC400670,11579,"The PvuII polymorphism (generated by a C → T substitution on intron 1) in the ESR1 gene was determined via an automated method using TaqMan™ (Applied Biosystems, Cheshire, UK) [38].",Blood samples and body mass index,[70060],[14402],[14583],[False],[0],[0],[False],['0']
16326,PMC400670,11580,The primers used were ESR1-F (TGTTGTCCATCAGTTCATCTGAGT) and ESR1-R (AACTCTAGACCACACTCAGGGTCTCT) and the probes were (AATGTCCCAGCCGTTTTATGCTTTGT) labelled with TET and (AAATGTCCCAGCTGTTTTATGCTTTGTCT) labelled with FAM (Applied Biosystems).,Blood samples and body mass index,[70067],[14584],[14822],[False],[0],[0],[False],['0']
16327,PMC400670,11581,Reactions were conducted according to manufacturer's instructions and detected using an ABI Prism 7700 Sequence Detector (Applied Biosystems).,Blood samples and body mass index,[70074],[14823],[14965],[False],[0],[0],[False],['0']
16328,PMC400670,11582,"Participants' height and weight were measured at baseline and 12 months, and body mass index (BMI) was calculated as follows: weight (kg)/height (m2).",Blood samples and body mass index,[70081],[14966],[15116],[False],[0],[0],[False],['0']
16329,PMC400670,11583,"Oestradiol and gonadotrophins, and menopausal status",Blood samples and body mass index,[70088],[15117],[15170],[False],[0],[0],[False],['0']
16330,PMC400670,11584,Serum oestradiol was measured using previously described methodology [39].,Blood samples and body mass index,[70095],[15171],[15245],[False],[0],[0],[False],['0']
16331,PMC400670,11585,"Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were measured using enzyme immunoassay on an Abbott Axsym automated analyzer (Abbott Diagnostics, Maidenhead, UK).",Blood samples and body mass index,[70102],[15246],[15424],[False],[0],[0],[False],['0']
16332,PMC400670,11586,Baseline and 12-month samples for each participant were assayed in the same batch.,Blood samples and body mass index,[70109],[15425],[15507],[False],[0],[0],[False],['0']
16333,PMC400670,11587,The limit of detection for oestradiol was 3.0 pmol/l.,Blood samples and body mass index,[70116],[15508],[15561],[False],[0],[0],[False],['0']
16334,PMC400670,11588,"Menopausal status was determined using baseline levels of oestradiol and FSH as follows: women were classed as premenopausal if FSH < 30 IU/l and oestradiol > 100 pmol/l; postmenopausal if FSH > 30 IU/l and oestradiol < 100 pmol/l; and perimenopausal if FSH > 30 IU/l and oestradiol > 100 pmol/l, or if FSH < 30 IU/l and oestradiol < 100 pmol/l.",Blood samples and body mass index,[70123],[15562],[15907],[False],[0],[0],[False],['0']
16335,PMC400670,11589,"However, if a woman had noted on her questionnaire at the initial home visit that she was currently menstruating, but her baseline hormone profile was that of a postmenopausal woman (i.e.",Blood samples and body mass index,[70130],[15908],[16095],[False],[0],[0],[False],['0']
16336,PMC400670,11590,"FSH > 30 IU/l and oestradiol < 100 pmol/l), then she was classed as perimenopausal.",Blood samples and body mass index,[70137],[16096],[16179],[False],[0],[0],[False],['0']
16337,PMC400670,11591,Tyrosine kinase,Tyrosine kinase,[70144],[16180],[16196],[False],[0],[0],[False],['0']
16338,PMC400670,11592,Lymphocytes were lysed according to methods reported elsewhere [40] and analyzed for tyrosine kinase activity using an enzyme-linked immunosorbent assay based kit and corrected for protein content (Tyrosine Kinase Assay Kit [product no.,Tyrosine kinase,[70151],[16197],[16433],[False],[0],[0],[False],['0']
16339,PMC400670,11593,29904] and BCA Protein Assay kit [product no.,Tyrosine kinase,[70158],[16434],[16479],[False],[0],[0],[False],['0']
16340,PMC400670,11594,"23225]; Pierce, Rockford, IL, USA).",Tyrosine kinase,[70165],[16480],[16515],[False],[0],[0],[False],['0']
16341,PMC400670,11595,Data analysis,Data analysis,[70172],[16516],[16530],[False],[0],[0],[False],['0']
16342,PMC400670,11596,"Based on the findings of our previous study on the effects of tamoxifen on breast density [19], we estimated that 20% of women in the isoflavone group and 5% of the women in the placebo group would change to a more lucent Wolfe pattern.",Data analysis,[70179],[16531],[16767],[False],[0],[0],[False],['0']
16343,PMC400670,11597,"Thus, to yield 80% power to detect a difference between treatment groups at the 5% significance level (two-tailed), a sample size of 76 women per treatment arm would be needed [41].",Data analysis,[70186],[16768],[16949],[False],[0],[0],[False],['0']
16344,PMC400670,11598,"Statistical analyses were performed using the SAS statistical package version 6.12 (SAS Institute, Cary, NC, USA).",Data analysis,[70193],[16950],[17064],[False],[0],[0],[False],['0']
16345,PMC400670,11599,Pearson correlation coefficients and Student's t-tests were used to assess inter-reader agreement in estimated percentage breast density.,Data analysis,[70200],[17065],[17202],[False],[0],[0],[False],['0']
16346,PMC400670,11600,"Changes in estimated percentage breast density, oestradiol, FSH, LH, tyrosine kinase activity, menopausal symptom score, and number of hot flushes from baseline to 12 months were expressed as absolute change (i.e.",Data analysis,[70207],[17203],[17416],[False],[0],[0],[False],['0']
16347,PMC400670,11601,12-month data – baseline data).,Data analysis,[70214],[17417],[17448],[False],[0],[0],[False],['0']
16348,PMC400670,11602,Differences between treatment groups for changes in breast density and tyrosine kinase activity were tested using an unpaired t-test.,Data analysis,[70221],[17449],[17582],[False],[0],[0],[False],['0']
16349,PMC400670,11603,"Data for changes in oestradiol, FSH, LH, hot flushes, and menopausal symptom score were skewed, and therefore the nonparametric Wilcoxon rank sum test was used to test for differences between treatment groups.",Data analysis,[70228],[17583],[17792],[False],[0],[0],[False],['0']
16350,PMC400670,11604,"Changes in oestradiol, FSH, and LH were assessed only in postmenopausal women because of absence of data on phase of menstrual cycle in which blood samples were taken.",Data analysis,[70235],[17793],[17960],[False],[0],[0],[False],['0']
16351,PMC400670,11605,A general linear model (using the SAS command PROC GLM) was used to determine interaction in effects of genotype on baseline measures and on change from baseline to 12 months.,Data analysis,[70242],[17961],[18136],[False],[0],[0],[False],['0']
16352,PMC400670,11606,"Three women who completed the study were excluded from all analyses either because they had taken an oral contraceptive regularly during the study (one in the isoflavone group, and one in the placebo group) or because they were being treated for alcoholism (one in the isoflavone group).",Data analysis,[70249],[18137],[18424],[False],[0],[0],[False],['0']
16353,PMC400670,11607,Results,Results,[70256],[18425],[18433],[False],[0],[0],[False],['0']
16354,PMC400670,11608,Withdrawals and baseline data,Results|Withdrawals and baseline data,[70263],[18434],[18463],[False],[0],[0],[False],['0']
16355,PMC400670,11609,Twenty-eight women withdrew from the study (Fig.,Results|Withdrawals and baseline data,[70270],[18464],[18512],[False],[0],[0],[False],['0']
16356,PMC400670,11610,1); principal reasons for withdrawal were commencement of HRT and work commitments/family problems preventing completion of study activities.,Results|Withdrawals and baseline data,[70277],[18513],[18654],[False],[0],[0],[False],['0']
16357,PMC400670,11611,"Other reasons included feeling no beneficial effects of the intervention or no interest in continuing on the trial, heavy menstrual bleeding, and illnesses preventing completion of study activities (e.g.",Results|Withdrawals and baseline data,[70284],[18655],[18858],[False],[0],[0],[False],['0']
16358,PMC400670,11612,"severe hip pain, skin irritation and sores, sickness and diarrhoea).",Results|Withdrawals and baseline data,[70291],[18859],[18927],[False],[0],[0],[False],['0']
16359,PMC400670,11613,One woman in the isoflavone group was diagnosed with an interval cancer of the breast (i.e.,Results|Withdrawals and baseline data,[70298],[18928],[19019],[False],[0],[0],[False],['0']
16360,PMC400670,11614,a cancer detected in the interval after a negative mammographic result) 2 months after the start of the intervention and was withdrawn from the study.,Results|Withdrawals and baseline data,[70305],[19020],[19170],[False],[0],[0],[False],['0']
16361,PMC400670,11615,"The difference between treatment groups in the number of withdrawals was not statistically significant (χ2 = 1.123, P = 0.29).",Results|Withdrawals and baseline data,[70312],[19171],[19297],[False],[0],[0],[False],['0']
16362,PMC400670,11616,"Age (mean ± standard deviation [SD]) was 55.1 ± 4.7 years for women in the isoflavone group and 55.2 ± 4.9 years for those in the placebo group (P = 0.65), and BMI (mean ± SD) was 25.3 ± 3.9 kg/m2 and 25.3 ± 3.5 kg/m2 for women in the isoflavone and placebo groups, respectively (P = 0.90).",Results|Withdrawals and baseline data,[70319],[19298],[19588],[False],[0],[0],[False],['0']
16363,PMC400670,11617,"Percentages of women who were premenopausal, perimenopausal and postmenopausal were 16%, 14% and 67%, respectively, for women in the isoflavone group, and 17%, 16% and 68%, respectively, for women in the placebo group (χ2 = 0.04, P = 0.98).",Results|Withdrawals and baseline data,[70326],[19589],[19829],[False],[0],[0],[False],['0']
16364,PMC400670,11618,"Time intervals (mean ± SD) between the screening mammogram and the start of the intervention, and between baseline and 12-month mammograms were 92 ± 32 and 452 ± 45 days, respectively, for women in the isoflavone group, and 87 ± 27 and 454 ± 43 days, respectively, for women in the placebo group.",Results|Withdrawals and baseline data,[70333],[19830],[20126],[False],[0],[0],[False],['0']
16365,PMC400670,11619,Differences between treatment groups were nonsignificant (P > 0.05).,Results|Withdrawals and baseline data,[70340],[20127],[20195],[False],[0],[0],[False],['0']
16366,PMC400670,11620,"There were no significant effects of genotype (for genotype frequencies, see Table 1) on baseline breast density, oestradiol, FSH or LH (P > 0.05).",Results|Withdrawals and baseline data,[70347],[20196],[20343],[False],[0],[0],[False],['0']
16367,PMC400670,11621,Compliance,Compliance,[70354],[20344],[20355],[False],[0],[0],[False],['0']
16368,PMC400670,11622,"According to the PABA check method, 58%, 72% and 77% of the women had complete urine collections at baseline, 6 and 12 months, respectively.",Compliance,[70361],[20356],[20496],[False],[0],[0],[False],['0']
16369,PMC400670,11623,"A further 22%, 11% and 13% had PABA recoveries between 70% and 85% at baseline, 6 and 12 months, respectively.",Compliance,[70368],[20497],[20607],[False],[0],[0],[False],['0']
16370,PMC400670,11624,"Differences between treatment groups in summed isoflavone excretion (sum of daidzein, genistein, formononetin and biochanin A) were nonsignificant at baseline, but differences were highly significant at 6 and 12 months (Fig.",Compliance,[70375],[20608],[20832],[False],[0],[0],[False],['0']
16371,PMC400670,11625,2; data shown do not include women with < 70% or > 110% PABA recovery; inclusion of these women did not alter the results).,Compliance,[70382],[20833],[20956],[False],[0],[0],[False],['0']
16372,PMC400670,11626,"Among women in the placebo group, isoflavone excretion did not change significantly from baseline to 6 months (P = 0.80) or from baseline to 12 months (P = 0.15; Fig.",Compliance,[70389],[20957],[21123],[False],[0],[0],[False],['0']
16373,PMC400670,11627,2).,Compliance,[70396],[21124],[21127],[False],[0],[0],[False],['0']
16374,PMC400670,11628,Breast density,Breast density,[70403],[21128],[21143],[False],[0],[0],[False],['0']
16375,PMC400670,11629,There were no differences between readers (RMLW and ES) in estimated percentage density at baseline or follow-up.,Breast density,[70410],[21144],[21257],[False],[0],[0],[False],['0']
16376,PMC400670,11630,"Densities (mean ± SD) at baseline were 61.8 ± 14.4% and 61.5 ± 18.8% for RMLW and ES, respectively (P = 0.86), and at follow-up they were 58.0 ± 16.5% and 57.4 ± 21.6% for RMLW and ES, respectively (P = 0.81).",Breast density,[70417],[21258],[21467],[False],[0],[0],[False],['0']
16377,PMC400670,11631,"According to RMLW, among women in the isoflavone and placebo groups, respectively, 22% and 18% of women changed to a more lucent Wolfe pattern, 78% and 80% did not change, and 0% and 2% changed to a more dense Wolfe pattern.",Breast density,[70424],[21468],[21692],[False],[0],[0],[False],['0']
16378,PMC400670,11632,Differences between treatment groups were not statistically significant (χ2 = 3.57; P = 0.31).,Breast density,[70431],[21693],[21787],[False],[0],[0],[False],['0']
16379,PMC400670,11633,"According to ES, among women in the isoflavone and placebo groups, respectively, 15% and 19% of women changed to a more lucent Wolfe pattern, 84% and 80% did not change, and 1% and 1% changed to a more dense Wolfe pattern.",Breast density,[70438],[21788],[22010],[False],[0],[0],[False],['0']
16380,PMC400670,11634,"Again, differences between treatment groups were not statistically significant (χ2 = 0.43; P = 0.81).",Breast density,[70445],[22011],[22112],[False],[0],[0],[False],['0']
16381,PMC400670,11635,"Interactions between treatment group and menopausal status for changes in estimated percentage breast density were nonsignificant (P > 0.05), and so changes were assessed for the combined group.",Breast density,[70452],[22113],[22307],[False],[0],[0],[False],['0']
16382,PMC400670,11636,"Percentage breast density (mean ± SD) decreased in both treatment groups to a similar extent: -3.2 ± 11.7% and -3.9 ± 11.7% among women in the isoflavone and placebo groups, respectively (P = 0.73; Fig.",Breast density,[70459],[22308],[22510],[False],[0],[0],[False],['0']
16383,PMC400670,11637,3).,Breast density,[70466],[22511],[22514],[False],[0],[0],[False],['0']
16384,PMC400670,11638,When analyses were restricted to women with complete urine collections (i.e.,Breast density,[70473],[22515],[22591],[False],[0],[0],[False],['0']
16385,PMC400670,11639,"samples containing 85–110% of ingested PABA) at all three time points, or when analyses were adjusted for baseline age and change in BMI, differences between treatment groups remained nonsignificant (P = 0.20 and P = 0.88, respectively).",Breast density,[70480],[22592],[22829],[False],[0],[0],[False],['0']
16386,PMC400670,11640,The interaction between treatment group and the ESR1 polymorphism was significant (P = 0.009).,Breast density,[70487],[22830],[22924],[False],[0],[0],[False],['0']
16387,PMC400670,11641,Changes in estimated percentage breast density (mean ± SD) by treatment group and ESR1 genotype were as follows: TT isoflavone 1.4 ± 12.3% and TT placebo -9.6 ± 14.2%; CT isoflavone -5.2 ± 12.0% and CT placebo -2.8 ± 10.3%; and CC isoflavone -3.4 ± 9.7% and CC placebo -1.1 ± 9.5%.,Breast density,[70494],[22925],[23206],[False],[0],[0],[False],['0']
16388,PMC400670,11642,There were no interactions between treatment group and CYP17 or CYP19 genotypes.,Breast density,[70501],[23207],[23287],[False],[0],[0],[False],['0']
16389,PMC400670,11643,"Oestradiol, follicle-stimulating hormone, luteinizing hormone and tyrosine kinase activity",Breast density,[70508],[23288],[23379],[False],[0],[0],[False],['0']
16390,PMC400670,11644,"There were no significant effects of treatment group on change in oestradiol, FSH, or LH (Table 2).",Breast density,[70515],[23380],[23479],[False],[0],[0],[False],['0']
16391,PMC400670,11645,Restricting the analysis to women with complete urine collections at all three time points did not alter these results (data not shown).,Breast density,[70522],[23480],[23616],[False],[0],[0],[False],['0']
16392,PMC400670,11646,The interaction between CYP19 gene polymorphism and treatment group was of borderline statistical significance for the change in FSH (P = 0.05).,Breast density,[70529],[23617],[23761],[False],[0],[0],[False],['0']
16393,PMC400670,11647,Changes in FSH (IU/l) by treatment group and CYP19 genotype were as follows (mean ± SD): GG isoflavone 1.07 ± 12.74 and GG placebo -5.80 ± 18.46; GT isoflavone -2.93 ± 9.35 and GT placebo -2.69 ± 10.98; and TT isoflavone -10.63 ± 11.30 and TT placebo 1.00 ± 9.13.,Breast density,[70536],[23762],[24025],[False],[0],[0],[False],['0']
16394,PMC400670,11648,"For tyrosine kinase activity, data were available for 46 women in the isoflavone group and for 47 women in the placebo group.",Breast density,[70543],[24026],[24151],[False],[0],[0],[False],['0']
16395,PMC400670,11649,"There was no significant difference in the mean change, from baseline to 12 months, in tyrosine kinase activity (activity/μg protein) between isoflavone and placebo groups (mean ± SD): 1.62 ± 2.18 for women in the isoflavone group and 0.90 ± SD 2.72 for women in the placebo group (P = 0.16).",Breast density,[70550],[24152],[24444],[False],[0],[0],[False],['0']
16396,PMC400670,11650,Hot flushes and menopausal symptoms,Hot flushes and menopausal symptoms,[70557],[24445],[24481],[False],[0],[0],[False],['0']
16397,PMC400670,11651,Interactions between treatment group and menopausal status for changes in menopausal symptom score and number of hot flushes were not statistically significant (P > 0.05).,Hot flushes and menopausal symptoms,[70564],[24482],[24653],[False],[0],[0],[False],['0']
16398,PMC400670,11652,"Among women who experienced hot flushes at either assessment period, or among women whose menopausal symptom score was greater than zero at either assessment period, there were no significant effects of treatment group on hot flushes or menopausal symptoms (Table 3).",Hot flushes and menopausal symptoms,[70571],[24654],[24921],[False],[0],[0],[False],['0']
16399,PMC400670,11653,Discussion,Discussion,[70578],[24922],[24933],[False],[0],[0],[False],['0']
16400,PMC400670,11654,"Combined HRT is associated with an increased risk for breast cancer [42,43] and an increase in mammographic breast density [13,16,44].",Discussion,[70585],[24934],[25068],[False],[0],[0],[False],['0']
16401,PMC400670,11655,"Soy and phyto-oestrogens have been proposed as potential natural alternatives to HRT [45,46], but there are only limited data from small studies on the effect of isoflavones on breast density.",Discussion,[70592],[25069],[25261],[False],[0],[0],[False],['0']
16402,PMC400670,11656,"In the largest and longest study conducted thus far, we did not observe a significant effect of the clover-derived isoflavone supplement, taken daily for 1 year, on mammographic breast density.",Discussion,[70599],[25262],[25455],[False],[0],[0],[False],['0']
16403,PMC400670,11657,"This is in agreement with a small, exploratory study conducted in 30 premenopausal women [27], in which there were no significant effects of a soy isoflavone supplement, providing 100 mg/day isoflavones for 12 months, on mammographic breast density.",Discussion,[70606],[25456],[25705],[False],[0],[0],[False],['0']
16404,PMC400670,11658,"In that study, there was a slight increase in percentage density among women taking the isoflavone supplement, but differences between the intervention and placebo groups were not statistically significant.",Discussion,[70613],[25706],[25912],[False],[0],[0],[False],['0']
16405,PMC400670,11659,"In the present study, breast density decreased to a similar extent in both treatment groups.",Discussion,[70620],[25913],[26005],[False],[0],[0],[False],['0']
16406,PMC400670,11660,This was presumably due to natural changes over time because an inverse relationship between breast density and age exists (for review [11]).,Discussion,[70627],[26006],[26147],[False],[0],[0],[False],['0']
16407,PMC400670,11661,"The decrease in percentage density was of a similar magnitude to that seen among control individuals in other studies [20,47] but was not as great as the decreases seen with anti-oestrogens such as tamoxifen [20].",Discussion,[70634],[26148],[26361],[False],[0],[0],[False],['0']
16408,PMC400670,11662,An attractive hypothesis for the potential chemopreventive actions of isoflavones is via modulation of endocrine function.,Discussion,[70641],[26362],[26484],[False],[0],[0],[False],['0']
16409,PMC400670,11663,"However, the literature is conflicting with regard to the effects of soy intakes on circulating levels of oestradiol in both premenopausal and postmenopausal women; some studies have reported decreases, increases, or little effect [9,48-53].",Discussion,[70648],[26485],[26726],[False],[0],[0],[False],['0']
16410,PMC400670,11664,"In a recent study of premenopausal women [54], consumption of soymilk from which the isoflavones had been removed resulted in a decrease in oestradiol, suggesting that soy protein rather than soy isoflavones may be responsible for the reduction in circulating levels of oestradiol seen in some studies.",Discussion,[70655],[26727],[27029],[False],[0],[0],[False],['0']
16411,PMC400670,11665,"Reported effects of soy intakes on gonadotrophins have also been inconsistent, with limited data showing either no effect [49,51,55] or decreases in FSH and LH with soy supplementation [53].",Discussion,[70662],[27030],[27220],[False],[0],[0],[False],['0']
16412,PMC400670,11666,"Despite the fact that this was one of the longest and largest studies to have investigated the effects of an isoflavone supplement on the hormonal status of postmenopausal women, we did not observe a significant effect of the isoflavone supplement on circulating levels of oestradiol, FSH or LH.",Discussion,[70669],[27221],[27516],[False],[0],[0],[False],['0']
16413,PMC400670,11667,"Phyto-oestrogens have been postulated to have several other anticancer effects and, because of the possible role of genistein as an inhibitor of protein tyrosine kinase activity [56], we investigated levels of lymphocyte tyrosine kinase activity.",Discussion,[70676],[27517],[27763],[False],[0],[0],[False],['0']
16414,PMC400670,11668,"However, we were unable to show significant differences between treatment groups for the change in the levels of lymphocyte tyrosine kinase activity.",Discussion,[70683],[27764],[27913],[False],[0],[0],[False],['0']
16415,PMC400670,11669,"Soy and phyto-oestrogens have received considerable attention because of their potential role in relieving menopausal symptoms, but their efficacy in such a role remains to be fully established.",Discussion,[70690],[27914],[28108],[False],[0],[0],[False],['0']
16416,PMC400670,11670,"Short-term intervention studies among women experiencing frequent hot flushes have shown reductions in the frequency and/or severity of hot flushes with soy consumption, but also among control individuals [57-59], whereas others have shown little or no effect [60-63].",Discussion,[70697],[28109],[28377],[False],[0],[0],[False],['0']
16417,PMC400670,11671,"However, in a recent study of women experiencing more than five hot flushes per day, all study participants were given a placebo tablet in a single-blind, 4-week run-in phase, and during the subsequent 12-week double-blind phase the frequency of hot flushes was reduced by 44% in the women taking two Promensil tablets per day; no further reduction occurred in the placebo group [64].",Discussion,[70704],[28378],[28762],[False],[0],[0],[False],['0']
16418,PMC400670,11672,"In our study, the occurrence of hot flushes and the severity of menopausal symptoms decreased to a similar extent in both treatment groups, suggesting natural improvement over time.",Discussion,[70711],[28763],[28944],[False],[0],[0],[False],['0']
16419,PMC400670,11673,"It is possible that the lack of a significant treatment effect may, in part, have been due to our study population; women were not selected for the study on the basis of suffering from severe or frequent hot flushes and/or other menopausal symptoms.",Discussion,[70718],[28945],[29194],[True],['VerySpecificPopulation'],['women were not selected for the study on the basis of suffering from severe or frequent hot flushes and/or other menopausal symptoms'],[True],['Population']
16420,PMC400670,11674,"As a result, baseline levels of menopausal symptoms were relatively low, which presumably limited the room for improvement in the study.",Discussion,[70732],[29195],[29331],[False],[0],[0],[False],['0']
16421,PMC400670,11675,"Polymorphisms in genes involved in sex hormone metabolism and in genes that encode hormone receptors may have an effect on the production of and exposure to sex hormones, and on the subsequent activation of genes that are responsive to sex hormones.",Discussion,[70739],[29332],[29581],[False],[0],[0],[False],['0']
16422,PMC400670,11676,"We investigated interactions between treatment and selected polymorphisms in the CYP17 and CYP19 genes, both of which are involved in the sex hormone biosynthesis pathway, and the oestrogen receptor (ESR1) gene.",Discussion,[70746],[29582],[29793],[False],[0],[0],[False],['0']
16423,PMC400670,11677,"Polymorphisms in these genes have been associated with risk for breast cancer in some but not all studies [65,66].",Discussion,[70753],[29794],[29908],[False],[0],[0],[False],['0']
16424,PMC400670,11678,"We saw interesting potential gene–treatment effects for the changes in breast density and ESR1 polymorphism and FSH and CYP19 polymorphism, but the study was not powered to investigate these interactions and a larger study is needed to confirm these findings.",Discussion,[70761],[29909],[30168],[True],['UnderpoweredStudy'],['the study was not powered to investigate these interactions'],[True],['UnderpoweredStudy']
16425,PMC400670,11679,"Using the PABA check method as an independent marker of compliance, and urinary excretion of isoflavones, compliance with study procedures appeared to be excellent.",Discussion,[70774],[30169],[30333],[False],[0],[0],[False],['0']
16426,PMC400670,11680,"However, a potential limitation of this study is that, although the study size was based on a case–control study of tamoxifen and breast density [19], changes in breast density among control individuals in this study were greater than anticipated.",Discussion,[70783],[30334],[30581],[True],['Population'],['changes in breast density among control individuals in this study were greater than anticipated'],[True],['Population']
16427,PMC400670,11681,"In addition, our findings may not be generalizable to the population as a whole.",Discussion,[70798],[30582],[30662],[True],['Generalization'],['our findings may not be generalizable'],[True],['Generalization']
16428,PMC400670,11682,"We did not include women in this study who were taking HRT at the time of recruitment (approximately one-third of women in the UK between the ages of 50 and 64 years use HRT [67]), and we only selected women with Wolfe P2 or DY breast patterns (which comprised approximately 60% of all mammograms classified for recruitment purposes).",Discussion,"[70814, 70815]","[30663, 30663]","[30997, 30997]","[True, True]","['VerySpecificPopulation', 'VerySpecificPopulation']","['we only selected women with Wolfe P2 or DY breast patterns', 'We did not include women in this study who were taking HRT at the time of recruitment']","[True, True]",['Population']
16429,PMC400670,11683,"A further limitation of the study is that several statistical tests were carried out, and some of the statistically significant findings may have been due to chance.",Discussion,[70827],[30998],[31163],[True],['MultipleTesting'],['several statistical tests were carried out'],[True],['StatisticalAnalysis']
16430,PMC400670,11684,Conclusion,Conclusion,[70837],[31164],[31175],[False],[0],[0],[False],['0']
16431,PMC400670,11685,"We found that a dietary supplement that provided 26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein daily for 1 year did not increase mammographic breast density in women aged 49–65 years, unlike conventional oestrogen replacement therapies.",Conclusion,[70844],[31176],[31440],[False],[0],[0],[False],['0']
16432,PMC400670,11686,"Furthermore, there were no effects of the isoflavone supplement on oestradiol, FSH or LH in postmenopausal women, or on hot flushes or other menopausal symptoms.",Conclusion,[70851],[31441],[31602],[False],[0],[0],[False],['0']
16433,PMC400670,11687,"Taken together, our findings suggest that the isoflavone supplement at the dose given was not acting as an oestrogen or as an anti-oestrogen.",Conclusion,[70858],[31603],[31744],[False],[0],[0],[False],['0']
16434,PMC400670,11688,Competing interests,Competing interests,[70865],[31745],[31765],[False],[0],[0],[False],['0']
16435,PMC400670,11689,"SA Bingham was in receipt of research support from Novogen Ltd (Australia), who also supplied the Promensil and placebo tablets and performed the urinary isoflavone analyses.",Competing interests,[70872],[31766],[31940],[False],[0],[0],[False],['0']
16436,PMC400670,11690,All other authors have no competing interests to declare.,Competing interests,[70879],[31941],[31998],[False],[0],[0],[False],['0']
16437,PMC400670,11691,Abbreviations,Abbreviations,[70886],[31999],[32013],[False],[0],[0],[False],['0']
16438,PMC400670,11692,BMI = body mass index; ESR1 = estrogen receptor; FSH = follicle-stimulating hormone; HPLC = high-pressure liquid chromatography; HRT = hormone replacement therapy; LH = luteinizing hormone; PABA = para-amino benzoic acid; SD = standard deviation.,Abbreviations,[70893],[32014],[32260],[False],[0],[0],[False],['0']
16439,PMC400670,11693,Addendum,Addendum,[70900],[32261],[32270],[False],[0],[0],[False],['0']
16440,PMC400670,11694,All authors participated fully in the manuscript preparation.,Addendum,[70907],[32271],[32332],[False],[0],[0],[False],['0']
16441,PMC400670,11695,"In addition, individual authors were involved in the following aspects of the trial: Charlotte Atkinson, recruitment and day-to-day running of the trial, sample analyses, and statistical analyses; Ruth ML Warren, breast density; Evis Sala, breast density; Mitch Dowsett, hormone assays; Alison M Dunning, genotyping; Catherine S Healey, genotyping, Shirley Runswick, tyrosine kinase assay; Nicholas E Day, data analysis; Sheila A Bingham, experiment design, sample analysis, and significant advice and consultation regarding all aspects of the trial.",Addendum,[70914],[32333],[32883],[False],[0],[0],[False],['0']
16442,PMC400670,11696,Acknowledgements,Acknowledgements,[70921],[32884],[32901],[False],[0],[0],[False],['0']
16443,PMC400670,11697,This study was supported by grants from the Food Standards Agency FS2034 and the Medical Research Council.,Acknowledgements,[70928],[32902],[33008],[False],[0],[0],[False],['0']
16444,PMC400670,11698,"The authors would thank Sue Gardner, Nicola Duffy, Nasima Siddiqui, Jane Bettany and Jayne Girvan for their assistance with the day-to-day running of the trial, Leanne West for mammogram retrieval, and Addenbrooke's Hospital Pharmacy for administering the tablets.",Acknowledgements,[70935],[33009],[33273],[False],[0],[0],[False],['0']
16445,PMC400670,11699,"SA Bingham was in receipt of research support from Novogen Ltd (Australia), who also supplied the Promensil and placebo tablets and performed the urinary isoflavone analyses.Figures and Tables",Acknowledgements,[70942],[33274],[33466],[False],[0],[0],[False],['0']
16446,PMC400670,11700,Flow chart describing progress of participants through trial.,Acknowledgements,[70949],[33467],[33528],[False],[0],[0],[False],['0']
16447,PMC400670,11701,*Includes two women who completed the trial but were excluded from all analyses because they had taken an oral contraceptive (OC) or were being treated for alcoholism.,Acknowledgements,[70956],[33529],[33696],[False],[0],[0],[False],['0']
16448,PMC400670,11702,"**Includes one woman who was excluded from all analyses because she had taken an OC, two women who had mammograms taken before the end of the study, and one woman who did not attend her follow-up mammogram.",Acknowledgements,[70963],[33697],[33903],[False],[0],[0],[False],['0']
16449,PMC400670,11703,"HRT, hormone replacement therapy.",Acknowledgements,[70970],[33904],[33937],[False],[0],[0],[False],['0']
16450,PMC400670,11704,"Urinary isoflavone (sum of daidzein, genistein, formononetin and biochanin A) excretion at baseline, midway, and at the end of the study, excluding samples with < 70% or > 110% para-amino benzoic acid recovery.",Acknowledgements,[70977],[33938],[34148],[False],[0],[0],[False],['0']
16451,PMC400670,11705,Error bars represent ± standard error of the mean.,Acknowledgements,[70984],[34149],[34199],[False],[0],[0],[False],['0']
16452,PMC400670,11706,"Numbers at each evaluation were as follows: baseline, 66 and 72 in the isoflavone and placebo groups, respectively; 6 months, 70 and 73; and 12 months, 76 and 79.",Acknowledgements,[70991],[34200],[34362],[False],[0],[0],[False],['0']
16453,PMC400670,11707,"The difference in isoflavone excretion between treatment groups was not statistically significant at baseline (P = 0.23), but differences between treatment groups at 6 and 12 months were highly significant (P < 0.001 and P < 0.001).",Acknowledgements,[70998],[34363],[34595],[False],[0],[0],[False],['0']
16454,PMC400670,11708,Estimated percentage density (and 95% confidence intervals) at baseline and follow up by treatment group (77 women in the isoflavone group and 85 in the placebo; P = 0.82).,Acknowledgements,[71005],[34596],[34768],[False],[0],[0],[False],['0']
16455,PMC400670,11709,"Genotype frequencies by treatment group aCYP17 data not available for three and five women in the isoflavone and placebo groups, respectively.",Acknowledgements,[71012],[34769],[34911],[False],[0],[0],[False],['0']
16456,PMC400670,11710,"bCYP19 data not available for five and three women in the isoflavone and placebo groups, respectively.",Acknowledgements,[71019],[34912],[35014],[False],[0],[0],[False],['0']
16457,PMC400670,11711,"cESR1 data not available for seven and three women in the isoflavone and placebo groups, respectively.",Acknowledgements,[71026],[35015],[35117],[False],[0],[0],[False],['0']
16458,PMC400670,11712,Percentages do not always add up to 100% because of rounding.,Acknowledgements,[71033],[35118],[35179],[False],[0],[0],[False],['0']
16459,PMC400670,11713,"Circulating levels of oestradiol, follicle-stimulating hormone and luteinizing hormone at baseline and after 12 months, and change from baseline to 12 months by treatment group Values are expressed as means ± standard deviation.",Acknowledgements,[71040],[35180],[35408],[False],[0],[0],[False],['0']
16460,PMC400670,11714,"aFor change in FSH, n = 60. bP value for difference between treatment groups for change.",Acknowledgements,[71047],[35409],[35497],[False],[0],[0],[False],['0']
16461,PMC400670,11715,"FSH, follicle-stimulating hormone; LH, luteinizing hormone.",Acknowledgements,[71054],[35498],[35557],[False],[0],[0],[False],['0']
16462,PMC400670,11716,"Daily number of hot flushes and menopausal symptom score at baseline and after 12 months, and change from baseline to 12 months by treatment group Analyses based on women who reported hot flushes or menopausal symptoms in one or both diaries.",Acknowledgements,[71061],[35558],[35800],[False],[0],[0],[False],['0']
16463,PMC400670,11717,Values are expressed as means ± standard deviation.,Acknowledgements,[71068],[35801],[35852],[False],[0],[0],[False],['0']
16464,PMC400670,11718,"a Shown in parentueses are the number of women with hot flushes and number of women with any menopausal symptoms, respectively.",Acknowledgements,[71075],[35853],[35980],[False],[0],[0],[False],['0']
16465,PMC400670,11719,bP value for difference between treatment groups for change.,Acknowledgements,[71082],[35981],[36041],[False],[0],[0],[False],['0']
17432,PMC4082496,14930,Compliance of mothers following recommendations to breastfeed or withhold breast milk during rotavirus vaccination in North India: a randomized clinical trial,Title,[89596],[36621],[158],[False],[0],[0],[False],['0']
17433,PMC4082496,14931,Background,Abstract,[89601],[159],[170],[False],[0],[0],[False],['0']
17434,PMC4082496,14932,Neutralizing antibodies in breast milk may adversely influence the immune response to live oral vaccines.,Abstract,[89606],[171],[276],[False],[0],[0],[False],['0']
17435,PMC4082496,14933,Withholding breastfeeding around the time of vaccine administration has been suggested for improving vaccine performance.,Abstract,[89611],[277],[398],[False],[0],[0],[False],['0']
17436,PMC4082496,14934,"However, we do not know whether mothers find withholding breastfeeding around the time of vaccination acceptable and how they perceive this recommendation.",Abstract,[89616],[399],[554],[False],[0],[0],[False],['0']
17437,PMC4082496,14935,Methods,Methods,[89621],[555],[563],[False],[0],[0],[False],['0']
17438,PMC4082496,14936,"In a clinical study designed to examine predictors of poor immune response to rotavirus vaccine in infants in India, Rotarix® was administered to infants at 6 and 10 weeks with other childhood vaccines.",Methods,[89626],[564],[766],[False],[0],[0],[False],['0']
17439,PMC4082496,14937,"For the study, 400 mother–infant pairs were randomized into two groups in a 1:1 ratio.",Methods,[89631],[767],[853],[False],[0],[0],[False],['0']
17440,PMC4082496,14938,Mothers were either recommended to withhold breastfeeding or were encouraged to breastfeed half an hour before and after administration of Rotarix®.,Methods,[89636],[854],[1002],[False],[0],[0],[False],['0']
17441,PMC4082496,14939,The mother–infant pairs were observed and the breastfeeding intervals were recorded during this period.,Methods,[89641],[1003],[1106],[False],[0],[0],[False],['0']
17442,PMC4082496,14940,Mothers were administered a questionnaire about their perception of the intervention after the infants received the second dose of Rotarix®.,Methods,[89646],[1107],[1247],[False],[0],[0],[False],['0']
17443,PMC4082496,14941,Results,Results,[89651],[1248],[1256],[False],[0],[0],[False],['0']
17444,PMC4082496,14942,Almost 98% (391/400) of the infants received both doses of Rotarix®.,Results,[89656],[1257],[1325],[False],[0],[0],[False],['0']
17445,PMC4082496,14943,Adherence to the recommendations was high in both groups.,Results,[89661],[1326],[1383],[False],[0],[0],[False],['0']
17446,PMC4082496,14944,"All mothers in the group who were asked to withhold breastfeeding did so, except one who breastfed her infant before the recommended time after the first dose of Rotarix®.",Results,[89666],[1384],[1555],[False],[0],[0],[False],['0']
17447,PMC4082496,14945,"Of the mothers, 4% (7/195) reported that the recommendation to withhold breastfeeding was difficult to follow.",Results,[89671],[1556],[1666],[False],[0],[0],[False],['0']
17448,PMC4082496,14946,All mothers in this group reported that they would withhold breastfeeding at the time of vaccination if they were asked to by a health-care provider.,Results,[89676],[1667],[1816],[False],[0],[0],[False],['0']
17449,PMC4082496,14947,Only one mother responded that withholding breastfeeding would be a reason for not giving rotavirus vaccine to her infant.,Results,[89681],[1817],[1939],[False],[0],[0],[False],['0']
17450,PMC4082496,14948,Conclusions,Conclusions,[89686],[1940],[1952],[False],[0],[0],[False],['0']
17451,PMC4082496,14949,Withholding breastfeeding half an hour before and after vaccination appears to be acceptable to mothers in this setting.,Conclusions,[89691],[1953],[2073],[False],[0],[0],[False],['0']
17452,PMC4082496,14950,"If withholding breastfeeding produces an improvement in the performance of the vaccine, it could be used to increase the public health impact of rotavirus immunization.",Conclusions,[89696],[2074],[2242],[False],[0],[0],[False],['0']
17453,PMC4082496,14951,Trial registration,Trial registration,[89701],[2243],[2262],[False],[0],[0],[False],['0']
17454,PMC4082496,14952,"Clinical Trial Registry, India (CTRI/2012/10/003057), Clinicaltrials.gov (NCT01700127).",Trial registration,[89706],[2263],[2350],[False],[0],[0],[False],['0']
17455,PMC4082496,14953,"Date of Registration: Clinical Trial Registry, India: 28 September 2012, Clinicaltrials.gov: 3 October 2012.",Trial registration,[89711],[2351],[2459],[False],[0],[0],[False],['0']
17456,PMC4082496,14954,Background,Background,[89716],[2460],[2472],[False],[0],[0],[False],['0']
17457,PMC4082496,14955,"Rotavirus is the most common cause of severe dehydrating diarrhea worldwide in infants and young children, killing approximately 453,000 children under the age of 5 each year [1].",Background,[89721],[2473],[2652],[False],[0],[0],[False],['0']
17458,PMC4082496,14956,"Rotavirus is particularly threatening in India, causing around 100,000 deaths in young children every year [2].",Background,[89726],[2653],[2764],[False],[0],[0],[False],['0']
17459,PMC4082496,14957,Vaccination remains a cornerstone in the prevention of rotavirus-associated morbidity and mortality.,Background,[89731],[2765],[2865],[False],[0],[0],[False],['0']
17460,PMC4082496,14958,"The two oral rotavirus vaccines commercially available, Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) and RotaTeq (Merck and Co, PA, USA), have been shown to be safe and effective [3].",Background,[89736],[2866],[3063],[False],[0],[0],[False],['0']
17461,PMC4082496,14959,"Overall, rotavirus vaccines are associated with 74% and 61% reductions in very severe and severe rotavirus infections, respectively, and a 47% reduction in rotavirus-related hospital admissions [4-8].",Background,[89741],[3064],[3264],[False],[0],[0],[False],['0']
17462,PMC4082496,14960,"However, in low-income countries, these vaccines have a lower efficacy compared to other oral vaccines like polio and cholera [9].",Background,[89746],[3265],[3395],[False],[0],[0],[False],['0']
17463,PMC4082496,14961,"In impoverished high-mortality settings, host factors, including maternal antibodies, interfering bacterial and viral agents, and child and maternal malnutrition, may affect immune responses [10].",Background,[89751],[3396],[3592],[False],[0],[0],[False],['0']
17464,PMC4082496,14962,In vitro studies of the neutralizing effect of breast milk have suggested that withholding breastfeeding around the time of rotavirus vaccine administration may impact vaccine performance [11].,Background,[89756],[3593],[3786],[False],[0],[0],[False],['0']
17465,PMC4082496,14963,Efficacy trials have reported no difference between breastfed and non-breastfed infants.,Background,[89761],[3787],[3875],[False],[0],[0],[False],['0']
17466,PMC4082496,14964,"However, in these studies the breastfeeding practices were self-reported and the interval between breastfeeding and vaccine administration was not adequately evaluated [10,12,13].",Background,[89766],[3876],[4055],[False],[0],[0],[False],['0']
17467,PMC4082496,14965,Breast milk from Indian mothers is reported to have much higher concentrations of rotavirus-neutralizing antibodies than breast milk from mothers in industrialized countries [11].,Background,[89771],[4056],[4235],[False],[0],[0],[False],['0']
17468,PMC4082496,14966,"In phase I/II studies of a recently developed rotavirus vaccine (116E) in India, breast milk was withheld for half an hour before and after each vaccine dose, and the seroconversion rate was almost 90% [14].",Background,[89776],[4236],[4443],[False],[0],[0],[False],['0']
17469,PMC4082496,14967,"Other studies are also being conducted to assess the modifying effect of breast milk on vaccine efficacy [15,16].",Background,[89781],[4444],[4557],[False],[0],[0],[False],['0']
17470,PMC4082496,14968,"If these studies demonstrate an improvement in the immune response by withholding breastfeeding around the time of vaccination, this practice could be used to increase the public health impact of rotavirus vaccination.",Background,[89786],[4558],[4776],[False],[0],[0],[False],['0']
17471,PMC4082496,14969,"However, little is known about mothers’ perceptions of withholding breastfeeding and whether such an intervention would be feasible and acceptable to mothers in low-income settings.",Background,[89791],[4777],[4958],[False],[0],[0],[False],['0']
17472,PMC4082496,14970,The primary aim of the study was to assess the impact of withholding breastfeeding compared to encouraging breastfeeding on the immune response to Rotarix® in infants.,Background,[89796],[4959],[5126],[False],[0],[0],[False],['0']
17473,PMC4082496,14971,The results of the primary aim are not presented here.,Background,[89801],[5127],[5181],[False],[0],[0],[False],['0']
17474,PMC4082496,14972,This paper describes the study methodology and the mothers’ ability to adhere to the breastfeeding recommendation as well as their perception of the recommendation.,Background,[89806],[5182],[5346],[False],[0],[0],[False],['0']
17475,PMC4082496,14973,Methods,Methods,[89811],[5347],[5355],[False],[0],[0],[False],['0']
17476,PMC4082496,14974,Study setting,Methods|Study setting,[89816],[5356],[5369],[False],[0],[0],[False],['0']
17477,PMC4082496,14975,"The trial was conducted in the urban resettlement neighborhoods of Govindpuri-Tigri-Dakshipuri, Tuglakabad and Sangam Vihar in South Delhi, India.",Methods|Study setting,[89821],[5370],[5516],[False],[0],[0],[False],['0']
17478,PMC4082496,14976,These areas are typical urban resettlement neighborhoods.,Methods|Study setting,[89826],[5517],[5574],[False],[0],[0],[False],['0']
17479,PMC4082496,14977,Randomization,Randomization,[89831],[5575],[5589],[False],[0],[0],[False],['0']
17480,PMC4082496,14978,The randomization list was generated by a statistician independent of the study team.,Randomization,[89836],[5590],[5675],[False],[0],[0],[False],['0']
17481,PMC4082496,14979,"Subject ID allocation for each participant was through serially numbered, opaque sealed envelopes.",Randomization,[89841],[5676],[5774],[False],[0],[0],[False],['0']
17482,PMC4082496,14980,Sample size,Sample size,[89846],[5775],[5787],[False],[0],[0],[False],['0']
17483,PMC4082496,14981,The sample size was based on the primary aim of the study.,Sample size,[89851],[5788],[5846],[False],[0],[0],[False],['0']
17484,PMC4082496,14982,"Assuming 60% seroconversion in the infants whose mothers were encouraged to breastfed and 80% in the group in whom breastfeeding was withheld, at 90% power and alpha level of 5%, 200 infants were required in each group.",Sample size,[89856],[5847],[6066],[False],[0],[0],[False],['0']
17485,PMC4082496,14983,This sample also accounted for 30% dropouts and 10% who might be excluded from the analysis because of high levels of antibodies at baseline.,Sample size,[89861],[6067],[6208],[False],[0],[0],[False],['0']
17486,PMC4082496,14984,Enrollment and intervention delivery,Enrollment and intervention delivery,[89866],[6209],[6246],[False],[0],[0],[False],['0']
17487,PMC4082496,14985,Participants were enrolled into the study from October 2012.,Enrollment and intervention delivery,[89871],[6247],[6307],[False],[0],[0],[False],['0']
17488,PMC4082496,14986,Infants aged less than 7 weeks were identified through a household survey.,Enrollment and intervention delivery,[89876],[6308],[6382],[False],[0],[0],[False],['0']
17489,PMC4082496,14987,The families of infants aged 6 to 7 weeks were called to the study clinic for screening and enrollment.,Enrollment and intervention delivery,[89881],[6383],[6486],[False],[0],[0],[False],['0']
17490,PMC4082496,14988,"Infants were enrolled if their parents gave consent for participation, were aged 6 to 7 weeks, had a weight-for-age Z score that was not ≤ −3 [17] and were from a family with no plans to move out of the study area in the next 4 months.",Enrollment and intervention delivery,[89886],[6487],[6722],[False],[0],[0],[False],['0']
17491,PMC4082496,14989,"Infants were excluded if they were not breastfed, had already received a rotavirus vaccination, had a chronic enteric disease and illness requiring hospital referral or causing diarrhea on the day of enrollment or had a condition that the investigator judged to warrant exclusion, or if the mother or infant had an immune deficiency disease.",Enrollment and intervention delivery,[89891],[6723],[7064],[False],[0],[0],[False],['0']
17492,PMC4082496,14990,"During consent, families were informed that if they agreed to take part in the study, their baby would be randomly selected for either the withhold breastfeeding or encourage breastfeeding group.",Enrollment and intervention delivery,[89896],[7065],[7260],[False],[0],[0],[False],['0']
17493,PMC4082496,14991,All information was provided in the local dialect.,Enrollment and intervention delivery,[89901],[7261],[7311],[False],[0],[0],[False],['0']
17494,PMC4082496,14992,The verbatim information in the informed consent form regarding allocation to either group was:,Enrollment and intervention delivery,[89906],[7312],[7407],[False],[0],[0],[False],['0']
17495,PMC4082496,14993,You are being asked permission for your baby to be screened for this study.,Enrollment and intervention delivery,[89911],[7408],[7483],[False],[0],[0],[False],['0']
17496,PMC4082496,14994,This is to check if your baby is healthy enough to receive the rotavirus vaccine and the childhood vaccines.,Enrollment and intervention delivery,[89916],[7484],[7592],[False],[0],[0],[False],['0']
17497,PMC4082496,14995,"If your baby is assessed to be well enough to receive the vaccine, your baby can take part in this study.",Enrollment and intervention delivery,[89921],[7593],[7698],[False],[0],[0],[False],['0']
17498,PMC4082496,14996,"In case you agree to allow your baby to participate, your baby will be randomly (like tossing a coin) selected to either receive breastfeed or not be breastfed 30 minutes before and after receiving the Rotarix®.",Enrollment and intervention delivery,[89926],[7699],[7910],[False],[0],[0],[False],['0']
17499,PMC4082496,14997,It was also explained that the purpose of the study was to test: “The effect of not giving and giving breast milk on the antibody response of the two doses of Rotarix®”.,Enrollment and intervention delivery,[89931],[7911],[8080],[False],[0],[0],[False],['0']
17500,PMC4082496,14998,The rationale for asking mothers to withhold or encourage breastfeeding was: “Your baby’s participation in this study may help in generating information about the usefulness of giving or not giving breast milk before and after the Rotarix® vaccine”.,Enrollment and intervention delivery,[89936],[8081],[8330],[False],[0],[0],[False],['0']
17501,PMC4082496,14999,"After obtaining written informed consent, 400 eligible mother–infant pairs were enrolled and randomized into one of the two study groups.",Enrollment and intervention delivery,[89941],[8331],[8468],[False],[0],[0],[False],['0']
17502,PMC4082496,15000,Group 1: Mothers were advised to withhold breastfeeding 30 min before and 30 min after each dose of the vaccine.,Enrollment and intervention delivery,[89946],[8469],[8581],[False],[0],[0],[False],['0']
17503,PMC4082496,15001,Group 2: Mothers were encouraged to breastfeed immediately before and after each dose of the vaccine.,Enrollment and intervention delivery,[89951],[8582],[8683],[False],[0],[0],[False],['0']
17504,PMC4082496,15002,The recommendation was given by a trained study team nutritionist in both groups.,Enrollment and intervention delivery,[89956],[8684],[8765],[False],[0],[0],[False],['0']
17505,PMC4082496,15003,The Group 1 mothers were told: “You have been selected to be in the group where breastfeeding needs to be withheld.,Enrollment and intervention delivery,[89961],[8766],[8881],[False],[0],[0],[False],['0']
17506,PMC4082496,15004,Do not breastfeed your child for half an hour before and after receiving the rotavirus vaccine”.,Enrollment and intervention delivery,[89966],[8882],[8978],[False],[0],[0],[False],['0']
17507,PMC4082496,15005,Group 2 mothers were told: “You have been selected to be in the group where you are encouraged to breastfeed your child in the half an hour duration before and after receiving the rotavirus vaccine”.,Enrollment and intervention delivery,[89971],[8979],[9178],[False],[0],[0],[False],['0']
17508,PMC4082496,15006,At the study clinic there were two separate designated areas for the two groups.,Enrollment and intervention delivery,[89976],[9179],[9259],[False],[0],[0],[False],['0']
17509,PMC4082496,15007,Each area was supervised by clinical coordinators.,Enrollment and intervention delivery,[89981],[9260],[9310],[False],[0],[0],[False],['0']
17510,PMC4082496,15008,Mother–infant pairs were required to wait in the designated area as per their group allocation.,Enrollment and intervention delivery,[89986],[9311],[9406],[False],[0],[0],[False],['0']
17511,PMC4082496,15009,"All activities, including specimen collection and administration of vaccines, were conducted in these areas.",Enrollment and intervention delivery,[89991],[9407],[9515],[False],[0],[0],[False],['0']
17512,PMC4082496,15010,The team members were present in the same area to observe the mother–infant pairs during this time.,Enrollment and intervention delivery,[89996],[9516],[9615],[False],[0],[0],[False],['0']
17513,PMC4082496,15011,"After the 30 min of observation following Rotarix® administration, the infants were administered the other childhood vaccines.",Enrollment and intervention delivery,[90001],[9616],[9742],[False],[0],[0],[False],['0']
17514,PMC4082496,15012,"In line with usual practice, infants remained in the study clinic for another 30 min after administration of the childhood vaccines to allow observation, management and documentation of any immediate adverse events.",Enrollment and intervention delivery,[90006],[9743],[9958],[False],[0],[0],[False],['0']
17515,PMC4082496,15013,"In this observation period, the women were not given any specific breastfeeding instructions, although breastfeeding practices were recorded by the project team members.",Enrollment and intervention delivery,[90011],[9959],[10128],[False],[0],[0],[False],['0']
17516,PMC4082496,15014,"Each enrolled infant was given two doses of the Rotarix® vaccine along with a pentavalent vaccine (diphtheria, pertussis, tetanus, hepatitis B and Haemophilus influenzae) and an oral polio vaccine.",Enrollment and intervention delivery,[90016],[10129],[10326],[False],[0],[0],[False],['0']
17517,PMC4082496,15015,"The vaccines were administered at the ages of 6 to 7 and 10 to 14 weeks, maintaining a minimum interval of 4 weeks between the two doses.",Enrollment and intervention delivery,[90021],[10327],[10464],[False],[0],[0],[False],['0']
17518,PMC4082496,15016,The third dose of the pentavalent vaccine was offered to all infants when they came to the study clinic for the end of study activities 4 weeks after the second dose of Rotarix®.,Enrollment and intervention delivery,[90026],[10465],[10643],[False],[0],[0],[False],['0']
17519,PMC4082496,15017,"After enrollment, participants were contacted weekly after each dose of Rotarix® to ascertain whether there were any signs or symptoms of suspected intussusception or whether they had suffered from an illness requiring hospital referral or had been hospitalized.",Enrollment and intervention delivery,[90031],[10644],[10906],[False],[0],[0],[False],['0']
17520,PMC4082496,15018,"Severe adverse events were reported to the Society for Applied Studies, Ethics Review Committee (SAS-ERC).",Enrollment and intervention delivery,[90036],[10907],[11013],[False],[0],[0],[False],['0']
17521,PMC4082496,15019,The follow-up of the last child was completed in May 2013.,Enrollment and intervention delivery,[90041],[11014],[11072],[False],[0],[0],[False],['0']
17522,PMC4082496,15020,Data collection,Data collection,[90046],[11073],[11089],[False],[0],[0],[False],['0']
17523,PMC4082496,15021,Baseline information on maternal and infant characteristics was collected at the time of enrollment.,Data collection,[90051],[11090],[11190],[False],[0],[0],[False],['0']
17524,PMC4082496,15022,"During the observation period, details, such as the time the observation started and ended and the duration of any breastfeeding, were documented in a form.",Data collection,[90056],[11191],[11347],[False],[0],[0],[False],['0']
17525,PMC4082496,15023,"After an infant received the second dose of Rotarix®, its mother was asked a set of structured questions about how she perceived the intervention (the recommendation to withhold or encourage breastfeeding).",Data collection,[90061],[11348],[11554],[False],[0],[0],[False],['0']
17526,PMC4082496,15024,Mothers were also prompted to comment on their answers.,Data collection,[90066],[11555],[11610],[False],[0],[0],[False],['0']
17527,PMC4082496,15025,Biological specimens from mothers and infants were collected to assess immunogenicity.,Data collection,[90071],[11611],[11697],[False],[0],[0],[False],['0']
17528,PMC4082496,15026,"Baseline maternal blood and breast milk specimens, and infant blood, saliva and stool specimens were obtained.",Data collection,[90076],[11698],[11808],[False],[0],[0],[False],['0']
17529,PMC4082496,15027,"Before the second dose of Rotarix®, maternal breast milk specimens and infant saliva specimens were obtained.",Data collection,[90081],[11809],[11918],[False],[0],[0],[False],['0']
17530,PMC4082496,15028,"Four weeks after the second dose of Rotarix®, blood, saliva and stool specimens were collected from the infants.",Data collection,[90086],[11919],[12031],[False],[0],[0],[False],['0']
17531,PMC4082496,15029,Presentation of data,Presentation of data,[90091],[12032],[12053],[False],[0],[0],[False],['0']
17532,PMC4082496,15030,"Descriptive measures of continuous variables are presented as means and standard deviations (SDs) for symmetrical data, and as medians and interquartile ranges for skewed data.",Presentation of data,[90096],[12054],[12230],[False],[0],[0],[False],['0']
17533,PMC4082496,15031,Descriptive measures of categorical data are presented as frequencies and percentages.,Presentation of data,[90101],[12231],[12317],[False],[0],[0],[False],['0']
17534,PMC4082496,15032,An independent-samples t-test was used to explore the relationship between continuous variables.,Presentation of data,[90106],[12318],[12414],[False],[0],[0],[False],['0']
17535,PMC4082496,15033,Ethical clearance,Ethical clearance,[90111],[12415],[12433],[False],[0],[0],[False],['0']
17536,PMC4082496,15034,Ethical clearance was obtained from SAS-ERC (SAS ERC/43/2012) and the South-East Regional Ethical Committee of Norway (2012/193/REK).,Ethical clearance,[90116],[12434],[12567],[False],[0],[0],[False],['0']
17537,PMC4082496,15035,This study was conducted in compliance with the protocol Good Clinical Practices and other relevant regulatory guidelines.,Ethical clearance,[90121],[12568],[12690],[False],[0],[0],[False],['0']
17538,PMC4082496,15036,Results,Results,[90126],[12691],[12699],[False],[0],[0],[False],['0']
17539,PMC4082496,15037,"Of the 533 infants screened for eligibility, 400 were enrolled and randomized (Figure 1).",Results,[90131],[12700],[12789],[False],[0],[0],[False],['0']
17540,PMC4082496,15038,Baseline infant characteristics and socio-economic factors were comparable between the two groups (Table 1).,Results,[90136],[12790],[12898],[False],[0],[0],[False],['0']
17541,PMC4082496,15039,"Nine subjects did not receive the second dose of Rotarix®; five refused further participation and four moved out of the study area, leaving 391 subjects who received both doses of Rotarix® and whose mothers completed the questionnaire on their perception of the intervention.",Results,[90141],[12899],[13174],[False],[0],[0],[False],['0']
17542,PMC4082496,15040,"The number of years in school varied greatly among both mothers and fathers, from 0 to 17 and 0 to 19, respectively.",Results,[90146],[13175],[13291],[False],[0],[0],[False],['0']
17543,PMC4082496,15041,These distributions were similar in the two study groups.,Results,[90151],[13292],[13349],[False],[0],[0],[False],['0']
17544,PMC4082496,15042,"Mothers in the group withholding breastfeeding had a mean of 7.2 (SD, 4.8) years of education and those in the group encouraged to breastfeed had a mean of 7.0 (SD, 4.9) years.",Results,[90156],[13350],[13526],[False],[0],[0],[False],['0']
17545,PMC4082496,15043,"Similar figures were obtained for men (8.9 (SD, 4.1) and 9.1 (SD, 4.4) years, respectively).",Results,[90161],[13527],[13619],[False],[0],[0],[False],['0']
17546,PMC4082496,15044,"With the exception of one mother, all mothers who were advised to withhold breastfeeding adhered fully to this recommendation (Table 2).",Results,[90166],[13620],[13756],[False],[0],[0],[False],['0']
17547,PMC4082496,15045,"Similarly, all mothers who were encouraged to breastfeed, except one, breastfed at least once (range one to four times) in each of the periods before and after vaccine administration.",Results,[90171],[13757],[13940],[False],[0],[0],[False],['0']
17548,PMC4082496,15046,"One woman did not breastfeed following the second dose of Rotarix®, but breastfed in the period before vaccine administration.",Results,[90176],[13941],[14067],[False],[0],[0],[False],['0']
17549,PMC4082496,15047,"The interval between the last breastfeed and the beginning of the intervention period varied widely among subjects, with maximum times of 491 and 388 min and minimum times of 6 and 9 min for the first and second doses, respectively.",Results,[90181],[14068],[14300],[False],[0],[0],[False],['0']
17550,PMC4082496,15048,"Mean intervals were significantly longer for infants who were given supplementary nutrition compared with those who were breastfed exclusively (mean difference, 40 min; P = 0.002).",Results,[90186],[14301],[14481],[False],[0],[0],[False],['0']
17551,PMC4082496,15049,Almost 78% of the infants were not given any other foods and fluids except breast milk; the mean number of breastfeeds per day was ten times.,Results,[90191],[14482],[14623],[False],[0],[0],[False],['0']
17552,PMC4082496,15050,It was found that 75% of the infants in the group withholding breastfeeding were being exclusively breastfed.,Results,[90196],[14624],[14733],[False],[0],[0],[False],['0']
17553,PMC4082496,15051,"Infants were not breastfed for about an average of 49 and 46 min after receiving the first and second doses of Rotarix®, respectively.",Results,[90201],[14734],[14868],[False],[0],[0],[False],['0']
17554,PMC4082496,15052,Adherence to the breastfeeding recommendations was high in both groups.,Results,[90206],[14869],[14940],[False],[0],[0],[False],['0']
17555,PMC4082496,15053,Half of the mothers in each group made additional comments on how they perceived the intervention.,Results,[90211],[14941],[15039],[False],[0],[0],[False],['0']
17556,PMC4082496,15054,"The main emerging theme in both groups was that the mothers found withholding breastfeeding around the time of vaccination acceptable and feasible, understanding that the vaccines were important and beneficial for their child and by withholding breastfeeding they could potentially improve the vaccine effect (Table 3).",Results,[90216],[15040],[15359],[False],[0],[0],[False],['0']
17557,PMC4082496,15055,"Among mothers who were asked to withhold breastfeeding for 30 min before and after vaccine administration, seven (4%) reported that this practice was difficult; five found withholding breastfeeding stressful when their infants cried, one found the interval to be too long and one made no comment.",Results,[90221],[15360],[15656],[False],[0],[0],[False],['0']
17558,PMC4082496,15056,Three of these seven infants were breastfed exclusively.,Results,[90226],[15657],[15713],[False],[0],[0],[False],['0']
17559,PMC4082496,15057,"Only one mother reported that withholding breastfeeding would be a reason for not giving the rotavirus vaccine to her infant, commenting that the duration of the non-breastfeeding period was too long.",Results,[90231],[15714],[15914],[False],[0],[0],[False],['0']
17560,PMC4082496,15058,All mothers withholding breastfeeding reported that they would adhere to this practice if asked to do so by health-care professionals.,Results,[90236],[15915],[16049],[False],[0],[0],[False],['0']
17561,PMC4082496,15059,Thirteen of them said that they would do so since they understood the importance of vaccination.,Results,[90241],[16050],[16146],[False],[0],[0],[False],['0']
17562,PMC4082496,15060,Two mothers said that they did the same when the health workers in the immunization center asked them to do so during oral polio vaccine administration.,Results,[90246],[16147],[16299],[False],[0],[0],[False],['0']
17563,PMC4082496,15061,"Of the mothers who did not find withholding breastfeeding difficult, nine commented that their baby was calm and slept during the observation period, eight commented that the observation period was not too long and five reiterated that they did not find it difficult to withhold breastfeeding.",Results,[90251],[16300],[16593],[False],[0],[0],[False],['0']
17564,PMC4082496,15062,Discussion,Discussion,[90256],[16594],[16605],[False],[0],[0],[False],['0']
17565,PMC4082496,15063,This study assessed the feasibility of asking mothers to withhold breastfeeding.,Discussion,[90261],[16606],[16686],[False],[0],[0],[False],['0']
17566,PMC4082496,15064,Mothers did not have any difficulty in complying with this request.,Discussion,[90266],[16687],[16754],[False],[0],[0],[False],['0']
17567,PMC4082496,15065,The fact that almost all mothers adhered to the recommendations is encouraging and this practice can potentially be adopted into policy.,Discussion,[90271],[16755],[16891],[False],[0],[0],[False],['0']
17568,PMC4082496,15066,It was also observed that the recommendation appeared to be acceptable to mothers as they perceived it to be beneficial for their children.,Discussion,[90276],[16892],[17031],[False],[0],[0],[False],['0']
17569,PMC4082496,15067,The time of 30 min was chosen since this was assumed to be a reasonable time limit for withholding breastfeeding.,Discussion,[90281],[17032],[17145],[False],[0],[0],[False],['0']
17570,PMC4082496,15068,Studies show that the half gastric emptying time varies between 47 and 61 min [18-20].,Discussion,[90286],[17146],[17232],[False],[0],[0],[False],['0']
17571,PMC4082496,15069,Withholding breastfeeding for an hour before and after may not have been feasible in this setting.,Discussion,[90294],[17233],[17331],[True],['Intervention'],['Withholding breastfeeding for an hour before and after may not have been feasible'],[True],['Intervention']
17572,PMC4082496,15070,Many infants would likely have been offered supplementary food or water and the intervention could inadvertently have interfered with the World Health Organization’s recommendation of exclusive breastfeeding for the first 6 months of life.,Discussion,[90305],[17332],[17571],[True],['Intervention'],['the intervention could inadvertently have interfered with the World Health Organization’s recommendation of exclusive breastfeeding for the first 6 months of life.'],[True],['Intervention']
17573,PMC4082496,15071,"The 30 min time interval was used in the rotavirus vaccine 116E trials in Delhi [14], which demonstrated good immunogenicity for the vaccine.",Discussion,[90311],[17572],[17713],[False],[0],[0],[False],['0']
17574,PMC4082496,15072,"At least two other studies are underway to assess the importance of withholding breast milk to improve the immunogenicity of oral vaccines [15,16].",Discussion,[90316],[17714],[17861],[False],[0],[0],[False],['0']
17575,PMC4082496,15073,Advising mothers to withhold breast milk around the time of vaccination may be contemplated if there is clear benefit.,Discussion,[90321],[17862],[17980],[False],[0],[0],[False],['0']
17576,PMC4082496,15074,It is essential that children get the maximum effect from their life-saving vaccines and at the same time it is essential to ensure that the benefits of breastfeeding are not undermined.,Discussion,[90326],[17981],[18167],[False],[0],[0],[False],['0']
17577,PMC4082496,15075,Clear messages should be developed and tested further before being used in a program setting.,Discussion,[90331],[18168],[18261],[False],[0],[0],[False],['0']
17578,PMC4082496,15076,It is important that the mothers understand that withholding breastfeeding around the time of vaccination may be required not because there are harmful substances in breast milk but because the beneficial substances may work against the effect of the vaccine.,Discussion,[90336],[18262],[18521],[False],[0],[0],[False],['0']
17579,PMC4082496,15077,This study was conducted with a limited population and the investigators did not measure the mothers’ understanding of the breastfeeding recommendations.,Discussion,"[90341, 90342]","[18522, 18522]","[18675, 18675]","[True, True]","['SampleSize', 'Intervention']","['This study was conducted with a limited population', 'the investigators did not measure the mothers’ understanding of the breastfeeding recommendations']","[True, True]","['Intervention', 'UnderpoweredStudy']"
17580,PMC4082496,15078,It is likely that the high compliance seen in this study is an artifact of the study setting for several reasons.,Discussion,[90351],[18676],[18789],[False],[0],[0],[False],['0']
17581,PMC4082496,15079,"Firstly, the recommendations were given by trained study team members with a background in nutrition and skilled in delivering the message.",Discussion,[90356],[18790],[18929],[False],[0],[0],[False],['0']
17582,PMC4082496,15080,"In this setting, it is well known that mothers are more likely to listen to health workers whom they perceive to be of a higher position and qualification: advice given by physicians or nutritionists is more likely to be adhered to.",Discussion,[90361],[18930],[19162],[False],[0],[0],[False],['0']
17583,PMC4082496,15081,"Secondly, the study team members who gave the recommendations also observed the mothers and were present in the same area as the mother–infant pairs.",Discussion,[90366],[19163],[19312],[False],[0],[0],[False],['0']
17584,PMC4082496,15082,"Thirdly, it is possible that the group of mothers who consented to participate in this study were inherent compliers.",Discussion,[90371],[19313],[19430],[False],[0],[0],[False],['0']
17585,PMC4082496,15083,It is also likely that the mothers’ perceptions of the intervention may have been different in other settings.,Discussion,[90376],[19431],[19541],[False],[0],[0],[False],['0']
17586,PMC4082496,15084,The study was conducted in urban resettlement neighborhoods of South Delhi.,Discussion,[90381],[19542],[19617],[False],[0],[0],[False],['0']
17587,PMC4082496,15085,"Though the participants in this study represent an important group, the generalizability of the study is limited since all the participants were from one area of Delhi.",Discussion,[90388],[19618],[19786],[True],['Generalization'],['the generalizability of the study is limited'],[True],['Generalization']
17588,PMC4082496,15086,"Nevertheless, reporting good quality data generated from smaller studies like this is important before considering larger trials in the population.",Discussion,[90396],[19787],[19934],[False],[0],[0],[False],['0']
17589,PMC4082496,15087,Conclusions,Conclusions,[90401],[19935],[19947],[False],[0],[0],[False],['0']
17590,PMC4082496,15088,"In conclusion, mothers in this setting complied with the recommendations given by the study team to withhold breastfeeding or breastfeed half an hour before and after vaccination.",Conclusions,[90406],[19948],[20127],[False],[0],[0],[False],['0']
17591,PMC4082496,15089,"It is likely that the mothers perceived the recommendation to have potential benefits to the health of their infants, therefore resulting in the high compliance.",Conclusions,[90411],[20128],[20289],[False],[0],[0],[False],['0']
17592,PMC4082496,15090,Abbreviations,Abbreviations,[90416],[20290],[20304],[False],[0],[0],[False],['0']
17593,PMC4082496,15091,"IQR: interquartile range; SAS-ERC: Society for Applied Studies, Ethics Review Committee; SD: Standard deviation.",Abbreviations,[90421],[20305],[20417],[False],[0],[0],[False],['0']
17594,PMC4082496,15092,Competing interests,Competing interests,[90426],[20418],[20438],[False],[0],[0],[False],['0']
17595,PMC4082496,15093,The authors declare that they have no competing interests.,Competing interests,[90431],[20439],[20497],[False],[0],[0],[False],['0']
17596,PMC4082496,15094,Authors’ contributions,Authors’ contributions,[90436],[20498],[20521],[False],[0],[0],[False],['0']
17597,PMC4082496,15095,All authors contributed to the commencement and design of the manuscript.,Authors’ contributions,[90441],[20522],[20595],[False],[0],[0],[False],['0']
17598,PMC4082496,15096,"TRC, NB and TAS were involved in the development of the protocol.",Authors’ contributions,[90446],[20596],[20661],[False],[0],[0],[False],['0']
17599,PMC4082496,15097,"TRC, BAW, TAS and NB wrote the manuscript.",Authors’ contributions,[90451],[20662],[20704],[False],[0],[0],[False],['0']
17600,PMC4082496,15098,"NG, SSR, MM, RR, AA and FAR were responsible for day-to-day implementation of the study.",Authors’ contributions,[90456],[20705],[20793],[False],[0],[0],[False],['0']
17601,PMC4082496,15099,All authors read and approved the final manuscript.,Authors’ contributions,[90461],[20794],[20845],[False],[0],[0],[False],['0']
17602,PMC4082496,15100,Acknowledgements,Acknowledgements,[90466],[20846],[20863],[False],[0],[0],[False],['0']
17603,PMC4082496,15101,This study was funded by the Research Council of Norway (project number 201208).,Acknowledgements,[90471],[20864],[20944],[False],[0],[0],[False],['0']
17604,PMC4082496,15102,"We thank the entire study team at the Centre for Health Research and Development, Society for Applied Studies, for their significant contributions to the project’s success.",Acknowledgements,[90476],[20945],[21117],[False],[0],[0],[False],['0']
17605,PMC4082496,15103,"We also want to thank Pankaj Vohra, the safety advisor.",Acknowledgements,[90481],[21118],[21173],[False],[0],[0],[False],['0']
17606,PMC4082496,15104,We gratefully acknowledge all the participants for their willingness to contribute to the research.,Acknowledgements,[90486],[21174],[21273],[False],[0],[0],[False],['0']
17900,PMC4145439,8491,Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study,Title,[49470],[62147],[166],[False],[0],[0],[False],['0']
17901,PMC4145439,8492,Objectives,Abstract,[49480],[167],[178],[False],[0],[0],[False],['0']
17902,PMC4145439,8493,"The aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibitor therapy.",Abstract,[49490],[179],[477],[False],[0],[0],[False],['0']
17903,PMC4145439,8494,The dose-exposure-response relationship for OKZ was also investigated.,Abstract,[49500],[478],[548],[False],[0],[0],[False],['0']
17904,PMC4145439,8495,Methods,Abstract,[49510],[549],[556],[False],[0],[0],[False],['0']
17905,PMC4145439,8496,"Patients were randomised to one of nine treatment arms receiving placebo (PBO) or OKZ (60, 120 or 240 mg) every 4 weeks (Q4W) or every 2 weeks (Q2W), or 8 mg/kg tocilizumab (TCZ) Q4W.",Abstract,[49520],[557],[740],[False],[0],[0],[False],['0']
17906,PMC4145439,8497,"The primary endpoint was change from baseline in DAS28(C-reactive protein, CRP) at Week 12.",Abstract,[49530],[741],[832],[False],[0],[0],[False],['0']
17907,PMC4145439,8498,"Secondary efficacy endpoints were American College of Rheumatology 20 (ACR20), ACR50 and ACR70 response rates at Week 12.",Abstract,[49540],[833],[954],[False],[0],[0],[False],['0']
17908,PMC4145439,8499,Exploratory analyses included comparisons of OKZ efficacy with TCZ.,Abstract,[49550],[955],[1022],[False],[0],[0],[False],['0']
17909,PMC4145439,8500,Results,Abstract,[49560],[1023],[1030],[False],[0],[0],[False],['0']
17910,PMC4145439,8501,"Across 221 randomised patients, OKZ treatment produced significantly greater reductions in DAS28(CRP) from baseline levels at Week 12, compared to PBO (p<0.001), at all the OKZ doses tested (60 mg OKZ p=0.0001, 120 and 240 mg OKZ p<0.0001).",Abstract,[49570],[1031],[1271],[False],[0],[0],[False],['0']
17911,PMC4145439,8502,"Additionally, ACR20 and ACR50 responses were numerically higher for OKZ than PBO (ACR20: PBO=17.1–29.9%, OKZ=32.5–60.7%; ACR50: PBO=1.3–4.9%, OKZ=11.5–33.2%).",Abstract,[49580],[1272],[1430],[False],[0],[0],[False],['0']
17912,PMC4145439,8503,"OKZ treatment, at several doses, demonstrated similar efficacy to TCZ across multiple endpoints.",Abstract,[49590],[1431],[1527],[False],[0],[0],[False],['0']
17913,PMC4145439,8504,Most adverse events were mild or moderate and comparable between OKZ and TCZ treatment groups.,Abstract,[49600],[1528],[1622],[False],[0],[0],[False],['0']
17914,PMC4145439,8505,Pharmacokinetic/pharmacodynamic modelling demonstrated a shallow dose/exposure response relationship in terms of percentage of patients with DAS28(CRP) <2.6.,Abstract,[49610],[1623],[1780],[False],[0],[0],[False],['0']
17915,PMC4145439,8506,Conclusions,Abstract,[49620],[1781],[1792],[False],[0],[0],[False],['0']
17916,PMC4145439,8507,OKZ produced significantly greater reductions in DAS28(CRP) from baseline at Week 12 compared with PBO.,Abstract,[49630],[1793],[1896],[False],[0],[0],[False],['0']
17917,PMC4145439,8508,"Reported AEs were consistent with the safety profile expected of this class of drug, with no new safety signals identified.",Abstract,[49640],[1897],[2020],[False],[0],[0],[False],['0']
17918,PMC4145439,8509,Trial register number:,Abstract,[49650],[2021],[2043],[False],[0],[0],[False],['0']
17919,PMC4145439,8510,NCT01242488.,Abstract,[49660],[2044],[2056],[False],[0],[0],[False],['0']
17920,PMC4145439,8511,Introduction,Introduction|Introduction,[49670],[2057],[2070],[False],[0],[0],[False],['0']
17921,PMC4145439,8512,"Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease which can lead to destruction and physical dysfunction of joints resulting in a significant increase in morbidity and mortality.",Introduction|Introduction,[49680],[2071],[2267],[False],[0],[0],[False],['0']
17922,PMC4145439,8513,"For patients who have an inadequate response to DMARDs, tumour necrosis factor (TNF) inhibitors are frequently added, usually in combination with methotrexate (MTX).",Introduction|Introduction,[49690],[2268],[2433],[False],[0],[0],[False],['0']
17923,PMC4145439,8514,"Approximately 40–50% of patients receiving TNF inhibitors, however, also have an inadequate response to this treatment.",Introduction|Introduction,[49700],[2434],[2553],[False],[0],[0],[False],['0']
17924,PMC4145439,8515,Therapeutic approaches using alternative mechanisms of action are therefore an important unmet need for this patient population.,Introduction|Introduction,[49710],[2554],[2682],[False],[0],[0],[False],['0']
17925,PMC4145439,8516,An alternate therapeutic target is the pro-inflammatory cytokine interleukin-6 (IL-6).,Introduction|Introduction,[49720],[2683],[2769],[False],[0],[0],[False],['0']
17926,PMC4145439,8517,"IL-6 is an important mediator of inflammation and is involved in key immunologic processes underlying the pathology of RA, such as T-cell activation and B-cell proliferation, as well as osteoclast differentiation.",Introduction|Introduction,[49730],[2770],[2983],[False],[0],[0],[False],['0']
17927,PMC4145439,8518,The amount of IL-6 present in the synovial fluid of patients with RA has been shown to correlate with the severity of synovitis and joint destruction.,Introduction|Introduction,[49740],[2984],[3134],[False],[0],[0],[False],['0']
17928,PMC4145439,8519,"An anti-IL-6 receptor (IL-6R) antibody, tocilizumab (TCZ), has been approved for the treatment of RA.",Introduction|Introduction,[49750],[3135],[3236],[False],[0],[0],[False],['0']
17929,PMC4145439,8520,TCZ is a humanised monoclonal antibody that binds to the IL-6 receptor.,Introduction|Introduction,[49760],[3237],[3308],[False],[0],[0],[False],['0']
17930,PMC4145439,8521,"Olokizumab (OKZ, CDP6038), a humanised monoclonal antibody specific for the IL-6 cytokine, is currently in development for the treatment of RA.",Introduction|Introduction,[49770],[3309],[3452],[False],[0],[0],[False],['0']
17931,PMC4145439,8522,"It targets the IL-6 cytokine rather than the receptor, and selectively blocks the final assembly of the signalling complex.",Introduction|Introduction,[49780],[3453],[3576],[False],[0],[0],[False],['0']
17932,PMC4145439,8523,"In Phase I (healthy volunteers) and IIa (patients with RA on MTX) clinical trials, OKZ was well tolerated after intravenous and subcutaneous delivery with a median plasma half-life of approximately 31 days, 76% bioavailability and no apparent antidrug antibody-mediated clearance.",Introduction|Introduction,[49790],[3577],[3857],[False],[0],[0],[False],['0']
17933,PMC4145439,8524,OKZ also markedly reduced free IL-6 levels and suppressed C-reactive protein (CRP) up to 12 weeks after single-dose subcutaneous administration in patients with RA.,Introduction|Introduction,[49800],[3858],[4022],[False],[0],[0],[False],['0']
17934,PMC4145439,8525,"The primary aims of this Phase IIb, dose-ranging study were to evaluate the efficacy and safety of OKZ in an active RA population who had previously failed TNF inhibitor therapy.",Introduction|Introduction,[49810],[4023],[4201],[False],[0],[0],[False],['0']
17935,PMC4145439,8526,Materials and methods,Materials and methods,[49820],[4202],[4224],[False],[0],[0],[False],['0']
17936,PMC4145439,8527,Study design,Materials and methods|Study design,[49830],[4225],[4237],[False],[0],[0],[False],['0']
17937,PMC4145439,8528,"This was a 12-week, Phase IIb, dose-ranging, double-blind, placebo (PBO) and active-controlled, multicenter, randomised study (NCT01242488), conducted between November 2010 and June 2012, to evaluate the efficacy and safety of subcutaneous OKZ in patients with moderately to severely active RA who had previously failed TNF inhibitor therapy.",Materials and methods|Study design,[49840],[4238],[4580],[False],[0],[0],[False],['0']
17938,PMC4145439,8529,The study protocol was approved by the Institutional Review Board/Independent Ethics Committee as defined in local regulations and performed according to the Declaration of Helsinki.,Materials and methods|Study design,[49850],[4581],[4763],[False],[0],[0],[False],['0']
17939,PMC4145439,8530,All patients provided written consent.,Materials and methods|Study design,[49860],[4764],[4802],[False],[0],[0],[False],['0']
17940,PMC4145439,8531,The primary objective of the study was to evaluate the efficacy of OKZ at different doses and administration frequencies compared with PBO.,Materials and methods|Study design,[49870],[4803],[4942],[False],[0],[0],[False],['0']
17941,PMC4145439,8532,"Secondary objectives were to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of repeated doses of OKZ, and to assess the dose-response and exposure-response relationship of OKZ with efficacy.",Materials and methods|Study design,[49880],[4943],[5171],[False],[0],[0],[False],['0']
17942,PMC4145439,8533,An exploratory endpoint was to compare the efficacy and safety of OKZ with TCZ.,Materials and methods|Study design,[49890],[5172],[5251],[False],[0],[0],[False],['0']
17943,PMC4145439,8534,"Of the 398 patients enrolled in the study, 221 were randomised to 1 of 9 treatment arms (figure 1).",Materials and methods|Study design,[49900],[5252],[5351],[False],[0],[0],[False],['0']
17944,PMC4145439,8535,Randomisation was performed centrally using an interactive voice-response system.,Materials and methods|Study design,[49910],[5352],[5433],[False],[0],[0],[False],['0']
17945,PMC4145439,8536,"Patients received either PBO or OKZ (60, 120 or 240 mg) every 4 weeks (Q4W) or every 2 weeks (Q2W), or 8 mg/kg TCZ Q4W.",Materials and methods|Study design,[49920],[5434],[5553],[False],[0],[0],[False],['0']
17946,PMC4145439,8537,"Doses were selected in order to cover 35–75% of the maximal anticipated effect on DAS28(erythrocyte sedimentation rate, ESR) at 12 weeks, or 45–85% of the maximal anticipated effect at 24 weeks, based on PK/PD analysis of previous study data.",Materials and methods|Study design,[49930],[5554],[5796],[False],[0],[0],[False],['0']
17947,PMC4145439,8538,Patient disposition.,Materials and methods|Patient disposition.,[49940],[5797],[5818],[False],[0],[0],[False],['0']
17948,PMC4145439,8539,Randomisation was stratified according to the number of prior failed TNF inhibitors (1 vs 2 or more).,Materials and methods|Patient disposition.,[49950],[5819],[5920],[False],[0],[0],[False],['0']
17949,PMC4145439,8540,Two safety follow-up visits were undertaken 6 and 12 weeks after the last study dose.,Materials and methods|Patient disposition.,[49960],[5921],[6006],[False],[0],[0],[False],['0']
17950,PMC4145439,8541,"To maintain blinding of the treatment, all patients received an intravenous infusion Q4W and two 1.2 mL subcutaneous injections Q2W.",Materials and methods|Patient disposition.,[49970],[6007],[6139],[False],[0],[0],[False],['0']
17951,PMC4145439,8542,"TCZ dose is the approved dose in Europe by the EMA, and the highest dose approved by the US Food and Drug Administration (FDA).",Materials and methods|Patient disposition.,[49980],[6140],[6267],[False],[0],[0],[False],['0']
17952,PMC4145439,8543,Patients who completed the study were eligible to receive OKZ in an open-label extension study (NCT01296711).,Materials and methods|Patient disposition.,[49990],[6268],[6377],[False],[0],[0],[False],['0']
17953,PMC4145439,8544,Patients,Materials and methods|Patients,[50000],[6378],[6386],[False],[0],[0],[False],['0']
17954,PMC4145439,8545,"This study population were individuals with active RA and an inadequate response to MTX, and at least one previous anti-TNF therapy.",Materials and methods|Patients,[50010],[6387],[6519],[False],[0],[0],[False],['0']
17955,PMC4145439,8546,"Patients were ≥18 years old, with adult-onset RA of at least 6 months duration (1987 American College of Rheumatology (ACR) classification criteria) or a score of ≥6 by the ACR/European League Against Rheumatism (EULAR) Classification and Diagnostic Criteria for RA.",Materials and methods|Patients,[50020],[6520],[6786],[False],[0],[0],[False],['0']
17956,PMC4145439,8547,"Eligible patients had tender joint count ≥6 (TJC; assessment of 68 joints) and swollen joint count ≥6 (SJC; assessment of 66 joints) and CRP ≥1.2 times the upper limit of normal (ULN), or ESR >28 mm/h.",Materials and methods|Patients,[50030],[6787],[6988],[False],[0],[0],[False],['0']
17957,PMC4145439,8548,Patients were required to be on a stable dose of MTX and continued current steroids and NSAIDs.,Materials and methods|Patients,[50040],[6989],[7084],[False],[0],[0],[False],['0']
17958,PMC4145439,8549,"Major exclusion criteria included diagnoses of other inflammatory arthritis or a non-inflammatory type of arthritis that interfered with efficacy evaluations, functional capacity Steinbrocker Class IV, and prior exposure to IL-6 inhibitors.",Materials and methods|Patients,[50050],[7085],[7325],[False],[0],[0],[False],['0']
17959,PMC4145439,8550,Patients were not permitted to use DMARDs other than MTX within 12 weeks prior to screening (unless undertaking appropriate washout).,Materials and methods|Patients,[50060],[7326],[7459],[False],[0],[0],[False],['0']
17960,PMC4145439,8551,"Patients with a known risk of severe or major infections, or elevated levels at screening of creatinine, alanine aminotransferase (ALT) or aspartate aminotransferase (AST), or reduced platelets, white blood cell count or neutrophil count were excluded.",Materials and methods|Patients,[50070],[7460],[7712],[False],[0],[0],[False],['0']
17961,PMC4145439,8552,Efficacy analyses,Materials and methods|Efficacy analyses,[50080],[7713],[7730],[False],[0],[0],[False],['0']
17962,PMC4145439,8553,"Efficacy outcomes were assessed in the Full Analysis Set (FAS), consisting of all randomised patients who received at least one dose of study medication and had at least one post-baseline efficacy measurement.",Materials and methods|Efficacy analyses,[50090],[7731],[7940],[False],[0],[0],[False],['0']
17963,PMC4145439,8554,The primary efficacy endpoint was the change from baseline in DAS28(CRP) at Week 12.,Materials and methods|Efficacy analyses,[50100],[7941],[8025],[False],[0],[0],[False],['0']
17964,PMC4145439,8555,"Secondary efficacy endpoints were ACR20, ACR50 and ACR70 at Week 12 for OKZ and PBO.",Materials and methods|Efficacy analyses,[50110],[8026],[8110],[False],[0],[0],[False],['0']
17965,PMC4145439,8556,"Major exploratory analyses included: ACR20/50/70 response rates (at Weeks 1, 2, 4, 6, 8, 10 and 12), % of patients with DAS28(CRP) <2.6 at Weeks 2, 4, 8 and 12), TJC, SJC, Clinical Disease Activity Index (CDAI) and the Health Assessment Questionnaire-Disability Index (HAQ-DI).",Materials and methods|Efficacy analyses,[50120],[8111],[8388],[False],[0],[0],[False],['0']
17966,PMC4145439,8557,Safety,Materials and methods|Safety,[50130],[8389],[8395],[False],[0],[0],[False],['0']
17967,PMC4145439,8558,Safety assessments included measurement of vital signs and laboratory parameters as well as recording of treatment-emergent adverse events (TEAEs) and serious TEAEs.,Materials and methods|Safety,[50140],[8396],[8561],[False],[0],[0],[False],['0']
17968,PMC4145439,8559,"Safety variables were analysed using the Safety Set (SS) (all patients who received at least 1 dose, or partial dose, of study medication).",Materials and methods|Safety,[50150],[8562],[8701],[False],[0],[0],[False],['0']
17969,PMC4145439,8560,Statistical analyses,Materials and methods|Statistical analyses,[50160],[8702],[8722],[False],[0],[0],[False],['0']
17970,PMC4145439,8561,"Unless specifically stated, FAS was used for all analyses.",Materials and methods|Statistical analyses,[50170],[8723],[8781],[False],[0],[0],[False],['0']
17971,PMC4145439,8562,DAS28(CRP) was analysed using a mixed effects model for repeated measures (MMRM).,Materials and methods|Statistical analyses,[50180],[8782],[8863],[False],[0],[0],[False],['0']
17972,PMC4145439,8563,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,Materials and methods|Statistical analyses,[50190],[8864],[8993],[False],[0],[0],[False],['0']
17973,PMC4145439,8564,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,Materials and methods|Statistical analyses,[50200],[8994],[9111],[False],[0],[0],[False],['0']
17974,PMC4145439,8565,Non-responder imputation was used for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,Materials and methods|Statistical analyses,[50210],[9112],[9224],[False],[0],[0],[False],['0']
17975,PMC4145439,8566,The number of prior failed TNF inhibitors was included as a categorical covariate in all statistical analyses.,Materials and methods|Statistical analyses,[50220],[9225],[9335],[False],[0],[0],[False],['0']
17976,PMC4145439,8567,"Unless otherwise stated, all statistical tests were two-sided.",Materials and methods|Statistical analyses,[50230],[9336],[9398],[False],[0],[0],[False],['0']
17977,PMC4145439,8568,"Power and sample size calculations were based upon simulations for change from baseline in DAS28 at all assessed postbaseline visits, using the MMRM method specified for the primary efficacy analysis.",Materials and methods|Statistical analyses,[50240],[9399],[9599],[False],[0],[0],[False],['0']
17978,PMC4145439,8569,Pharmacokinetic/pharmacodynamic analyses,Materials and methods|Pharmacokinetic/pharmacodynamic analyses,[50250],[9600],[9640],[False],[0],[0],[False],['0']
17979,PMC4145439,8570,"Blood samples for determination of plasma OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",Materials and methods|Pharmacokinetic/pharmacodynamic analyses,[50260],[9641],[9772],[False],[0],[0],[False],['0']
17980,PMC4145439,8571,Non-linear mixed modelling was employed for the analysis of the OKZ PK data.,Materials and methods|Pharmacokinetic/pharmacodynamic analyses,[50270],[9773],[9849],[False],[0],[0],[False],['0']
17981,PMC4145439,8572,The final population PK model was used to derive individual concentration or exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Materials and methods|Pharmacokinetic/pharmacodynamic analyses,[50280],[9850],[10111],[False],[0],[0],[False],['0']
17982,PMC4145439,8573,Results,Results,[50290],[10112],[10120],[False],[0],[0],[False],['0']
17983,PMC4145439,8574,Baseline characteristics and patient disposition,Results|Baseline characteristics and patient disposition,[50300],[10121],[10169],[False],[0],[0],[False],['0']
17984,PMC4145439,8575,Figure 1 details the patient disposition; 89.6% of randomised patients completed the 12-week treatment phase.,Results|Baseline characteristics and patient disposition,[50310],[10170],[10279],[False],[0],[0],[False],['0']
17985,PMC4145439,8576,"Patient demographics across the treatment groups were similar and representative of patients with RA with long-standing, active disease (table 1).",Results|Baseline characteristics and patient disposition,[50320],[10280],[10426],[False],[0],[0],[False],['0']
17986,PMC4145439,8577,Most patients were using MTX at baseline (95% of patients).,Results|Baseline characteristics and patient disposition,[50330],[10427],[10486],[False],[0],[0],[False],['0']
17987,PMC4145439,8578,"The most common previous TNF inhibitors were etanercept (50.7%), adalimumab (45.2%) and infliximab (36.5%); certolizumab pegol and golimumab had each been previously used by 13.7% of patients.",Results|Baseline characteristics and patient disposition,[50340],[10487],[10679],[False],[0],[0],[False],['0']
17988,PMC4145439,8579,More than 40% of patients had failed to respond to at least two TNF inhibitors.,Results|Baseline characteristics and patient disposition,[50350],[10680],[10759],[False],[0],[0],[False],['0']
17989,PMC4145439,8580,Previous non-TNF-targeting biologics used included abatacept (16.0%) and rituximab (11.0%).,Results|Baseline characteristics and patient disposition,[50360],[10760],[10851],[False],[0],[0],[False],['0']
17990,PMC4145439,8581,"At recruitment, 107 patients (48.9%) met the inclusion criteria for ESR (>28 mm/h) and CRP (≥1.2 ULN); 89 (40.6%) and 21 (9.6%) patients met only the criteria for ESR or CRP, respectively.",Results|Baseline characteristics and patient disposition,[50370],[10852],[11040],[False],[0],[0],[False],['0']
17991,PMC4145439,8582,Baseline patient demographics and disease characteristics (full analysis set),Results|Baseline characteristics and patient disposition,[50380],[11041],[11118],[False],[0],[0],[False],['0']
17992,PMC4145439,8583,"	PBOQ2W (N=22)	OKZ60 mgQ2W (N=20)	OKZ120 mgQ2W (N=22)	OKZ240 mgQ2W (N=23)	PBOQ4W (N=22)	OKZ60 mgQ4W (N=22)	OKZ120 mg Q4W (N=23)	OKZ240 mg Q4W(N=22)	TCZ8 mg/kgQ4W (N=43)	All patients (N=219)	 	Population demographic	 	 Age, mean years	59.36	55.50	53.09	55.48	58.18	52.64	53.52	54.55	56.58	55.53	 	 Female, %	86.4	80.0	86.4	91.3	77.3	90.9	87.0	77.3	86.0	84.9	 	Prior and concomitant medication	 	 Prior failed TNF-inhibitor, n (%)	 	  1	12 (54.5)	14 (70.0)	12 (54.5)	14 (60.9)	12 (54.5)	12 (54.5)	12 (52.2)	13 (59.1)	25 (58.1)	126 (57.5)	 	  ≥2	10 (45.5)	6 (30.0)	10 (45.5)	9 (39.1)	10 (45.5)	10 (45.5)	11 (47.8)	9 (40.9)	18 (41.9)	93 (42.5)	 	 Concomitant MTX, n (%)	20 (90.9)	19 (95.0)	20 (90.9)	22 (95.7)	21 (95.5)	21 (95.5)	22 (95.7)	21 (95.5)	42 (97.7)	208 (95.0)	 	Baseline disease characteristics	 	 Disease duration, median years	10.56	12.30	8.07	8.22	7.45	10.89	11.58	7.83	10.55	9.99	 	 CRP >15 mg/L, n (%)	5 (22.7)	4 (20.0)	6 (27.3)	8 (34.8)	7 (31.8)	7 (31.8)	7 (30.4)	6 (27.3)	16 (37.2)	66 (30.1)	 	 DAS28(CRP), mean	5.53	5.57	5.96	5.94	5.69	6.14	5.61	5.83	5.72	5.77	 	 DAS28(CRP) >5.1, n (%)	14 (63.6)	14 (70.0)	15 (68.2)	18 (78.3)	16 (72.7)	19 (86.4)	16 (69.6)	14 (63.6)	33 (76.7)	159 (72.6)	 	 TJC, median (min-max)	32.74 (9.3–56.7)	18.50 (9.0–68.0)	26.50 (8.0–62.0)	33.00 (6.0–51.0)	22.00 (8.0–58.0)	36.00 (9.0–68.0)	29.29 (7.0–57.0)	25.86 (11.0–59.8)	25.00 (4.0–66.0)	27.00 (4.0–68.0)	 	 SJC, median (min-max)	12.00 (6.0–30.0)	16.50 (6.0–50.0)	14.50 (6.0–58.0)	18.86 (7.0–41.6)	13.17 (4.0–44.7)	21.50 (6.0–58.0)	13.00 (5.2–36.7)	14.50 (6.0–38.9)	12.38 (6.0–32.0)	14.00 (4.0–58.0)	 	 CDAI, median (min-max)	36.83 (20.7–53.9)	36.28 (22.2–66.3)	42.90 (20.2–71.2)	45.20 (18.1–64.3)	36.25 (19.0–60.0)	46.60 (21.4–69.2)	39.92 (14.3–59.7)	40.50 (24.2–59.2)	35.65 (17.7–62.5)	38.90 (14.3–71.2)	 	 HAQ-DI, median (min-max)	1.56 (0.3–2.6)	1.63 (0.5–2.1)	1.44 (0.6–3.0)	1.75 (0.6–2.6)	1.38 (0.0–2.4)	1.81 (0.1–2.9)	1.50 (0.3–2.9)	1.69 (0.0–2.8)	1.63 (0.0–2.9)	1.63 (0.0–3.0)",Results|Baseline characteristics and patient disposition,[50390],[11119],[13096],[False],[0],[0],[False],['0']
17993,PMC4145439,8584,"CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint count; HAQ-DI, HAQ (Health Assessment Questionnaire) Disability Index; MTX, methotrexate; OKZ, Olokizumab; PBO, placebo; SJC, swollen joint count; TCZ, Tocilizumab; TJC, tender joint count; TNF, tumour necrosis factor.",Results|Baseline characteristics and patient disposition,[50400],[13097],[13421],[False],[0],[0],[False],['0']
17994,PMC4145439,8585,Clinical efficacy,Results|Clinical efficacy,[50410],[13422],[13439],[False],[0],[0],[False],['0']
17995,PMC4145439,8586,Change from baseline in DAS28(CRP),Results|Clinical efficacy,[50420],[13440],[13474],[False],[0],[0],[False],['0']
17996,PMC4145439,8587,"Across all dose groups, treatment with OKZ resulted in a greater improvement in DAS28(CRP) mean change from baseline at Week 12 compared with PBO (table 2), with the greatest improvement observed in the OKZ 240 mg Q2W group.",Results|Clinical efficacy,[50430],[13475],[13699],[False],[0],[0],[False],['0']
17997,PMC4145439,8588,Decreases in DAS28(CRP) from baseline were seen from Week 1 (figure 2A).,Results|Clinical efficacy,[50440],[13700],[13772],[False],[0],[0],[False],['0']
17998,PMC4145439,8589,"For every treatment dose, DAS28(CRP) change from baseline was significantly different to the PBO group (for 60 mg OKZ p=0.0001, for 120 and 240 mg OKZ p<0.0001), as were the overall dose response trends across both dosing frequencies (p<0.0001) (figure 2B).",Results|Clinical efficacy,[50450],[13773],[14030],[False],[0],[0],[False],['0']
17999,PMC4145439,8590,"Comparisons of dosing frequency (Q2W vs Q4W) and dose-by-dose frequency interactions (Q2W trend vs Q4W trend) were not significant (p=0.6927 and p=0.9912, respectively).",Results|Clinical efficacy,[50460],[14031],[14200],[False],[0],[0],[False],['0']
18000,PMC4145439,8591,The improvements from baseline in DAS28(CRP) observed in several OKZ treatment groups were comparable to those seen in the TCZ treatment group (table 2).,Results|Clinical efficacy,[50470],[14201],[14354],[False],[0],[0],[False],['0']
18001,PMC4145439,8592,"No significant response differences were seen between patients who had previously failed treatment with 1, 2 or >2 TNF inhibitors.",Results|Clinical efficacy,[50480],[14355],[14485],[False],[0],[0],[False],['0']
18002,PMC4145439,8593,Efficacy outcomes at week 12 (full analysis set),Results|Clinical efficacy,[50490],[14486],[14534],[False],[0],[0],[False],['0']
18003,PMC4145439,8594,"Efficacy endpoint	Dosingfrequency	PBO	OKZ60 mg	OKZ120 mg	OKZ240 mg	TCZ8 mg/kg	 	ΔDAS28(CRP),* LS mean (SE)	Q2W	−0.78 (0.26)	−1.16 (0.28)	−1.88 (0.26)	−2.01 (0.25)	–	 	Q4W	−0.19 (0.26)	−1.91 (0.28)	−1.84 (0.26)	−1.63 (0.25)	−2.01 (0.19)	 	DAS28(CRP)≤3.2,%†	Q2W	13.6	20.0	22.7	30.4	–	 	Q4W	4.5	18.2	30.4	27.3	30.2	 	DAS28(CRP)<2.6,%†	Q2W	4.5	10.0	13.6	26.1	–	 	Q4W	0.0	13.6	21.7	9.1	20.9	 	ΔDAS28(ESR),* LS mean (SE)	Q2W	−0.65 (0.25)	−1.53 (0.27)	−2.05 (0.25)	−1.80 (0.25)	–	 	Q4W	−0.16 (0.25)	−2.04 (0.26)	−1.57 (0.26)	−1.59 (0.25)	−1.79 (0.18)	 	ACR20, estimated response % (95% CI)‡	Q2W	29.9 (15.3 to 50.2)	49.7 (31.0 to 68.5)	55.5 (36.9 to 72.7)	55.5 (37.1 to 72.4)	–	 	Q4W	17.1 (7.3 to 35.0)	60.7 (41.4 to 77.1)	58.4 (39.5 to 75.1)	32.5 (18.1 to 51.2)	68.3 (53.0 to 80.5)	 	ACR50, estimated response % (95% CI)‡	Q2W	4.9 (0.7 to 28.0)	19.1 (7.6 to 40.4)	24.9 (11.4 to 46.2)	31.9 (16.0 to 53.5)	 –	 	Q4W	1.3 (0.1 to 14.4)	33.2 (16.8 to 55.0)	21.3 (9.0 to 42.8)	11.5 (4.2 to 27.7)	27.7 (15.4 to 44.8)	 	ACR20, observed response n (%)†	Q2W	7 (33.3)	6 (35.3)	10 (50.0)	11 (52.4)	–	 	Q4W	1 (5.0)	12 (75.0)	11 (61.1)	7 (33.3)	27 (65.9)	 	ACR50, observed response n (%)†	Q2W	1 (4.8)	3 (17.6)	5 (25.0)	5 (23.8)	–	 	Q4W	0	6 (37.5)	3 (16.7)	3 (14.3)	10 (24.4)	 	ΔCDAI,*	Q2W	−8.95 (−41.5, 13.8)	−8.00 (−36.4, 19.0)	−14.65 (−57.9, 14.3)	−16.30 (−58.2, 8.9)	–	 	Median (min, max)	Q4W	−3.03 (−44.1, 23.8)	−18.51 (−69.2, 48.0)	−19.09 (−35.2, 8.8)	−12.99 (−42.9, 4.0)	−17.30 (−49.2, 15.1)	 	CDAI≤10.0, estimated response % (95% CI)§,¶	Q2W	13.6 (4.5 to 34.8)	9.9 (2.5 to 32.3)	22.7 (9.8 to 44.3)	30.3 (15.1 to 51.5)	–	 	Q4W	9.1 (2.3 to 29.9)	9.1 (2.3 to 29.9)	30.4 (15.2 to 51.5)	13.6 (4.4 to 34.7)	27.8 (16.5 to 42.9)	 	CDAI≤10.0, observed response n (%)¶	Q2W	3 (13.6)	2 (10.0)	5 (22.7)	7 (30.4)	–	 	Q4W	2 (9.1)	2 (9.1)	7 (30.4)	3 (13.6)	12 (27.9)	 	ΔHAQ-DI,* median (min, max)	Q2W	0.00 (−1.0, 0.6)	−0.25 (−1.0, 0.9)	−0.25 (−0.9, 1.4)	−0.38 (−1.6, 0.1)	–	 	Q4W	0.06 (−1.0, 2.1)	−0.50 (−1.6, −0.1)	−0.25 (−1.5, 0.4)	0.00 (−1.0, 0.5)	−0.25 (−1.5, 0.3)	 	ΔTJC,* median (min, max)	Q2W	−10.00 (−46.0, 33.0)	−8.00 (−34.0, 5.0)	−10.00 (−55.0, 3.2)	−10.30 (−48.0, 13.0)	–	 	Q4W	−3.00 (−49.0, 18.3)	−18.00 (−68.0, 7.7)	−15.00 (−29.0, 12.0)	−8.50 (−18.3, 7.0)	−11.00 (−46.0, 8.0)	 	ΔSJC,* median (min, max)	Q2W	−3.00 (−18.0, 22.3)	−7.00 (−26.0, 4.0)	−7.00 (−55.0, 7.0)	−10.00 (−41.6, 7.0)	–	 	Q4W	−3.00 (−37.0, 22.0)	−11.00 (−51.0, 19.0)	−9.89 (−21.0, 15.0)	−8.25 (−22.3, 22.0)	−7.45 (−29.5, 11.0)",Results|Clinical efficacy,[50500],[14535],[17009],[False],[0],[0],[False],['0']
18004,PMC4145439,8595,"*change (Δ) from baseline, MMRM analysis.",Results|Clinical efficacy,[50510],[17010],[17054],[False],[0],[0],[False],['0']
18005,PMC4145439,8596,†observed rate.,Results|†observed rate.,[50520],[17055],[17070],[False],[0],[0],[False],['0']
18006,PMC4145439,8597,‡estimate from the GEE-MI model.,Results|†observed rate.,[50530],[17071],[17103],[False],[0],[0],[False],['0']
18007,PMC4145439,8598,§estimate from the Logistic Regression (non-response imputation) model.,Results|†observed rate.,[50540],[17104],[17175],[False],[0],[0],[False],['0']
18008,PMC4145439,8599,¶results of posthoc analysis.,Results|¶results of posthoc analysis.,[50550],[17176],[17205],[False],[0],[0],[False],['0']
18009,PMC4145439,8600,"ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint count; ESR, erythrocyte sedimentation rate; GEE, generalised estimating equation; HAQ-DI, HAQ (Health Assessment Questionnaire) Disability Index; LDA, low disease activity; LS, least squares; MI, multiple imputation; MMRM, mixed effects model for repeated measures; OKZ, olokizumab; PBO, placebo; SJC, swollen joint count; TCZ, Tocilizumab; TJC, tender joint count.",Results|¶results of posthoc analysis.,[50560],[17206],[17713],[False],[0],[0],[False],['0']
18010,PMC4145439,8601,Analysis of efficacy endpoints.,Results|¶results of posthoc analysis.,[50570],[17714],[17745],[False],[0],[0],[False],['0']
18011,PMC4145439,8602,(A) DAS28(CRP) scorea; (B) DAS28(CRP) change from baseline at Week 12; (C) ACR20 response ratea and (D) ACR50 response ratea.,Results|¶results of posthoc analysis.,[50580],[17746],[17871],[False],[0],[0],[False],['0']
18012,PMC4145439,8603,"Posthoc analysis revealed that at low OKZ doses, a greater response was seen in patients with CRP ≥1.2 ULN compared to all other patients (for OKZ 60 mg Q4W patients mean changes from baseline at Week 12 were −2.47 and −0.98, respectively).",Results|¶results of posthoc analysis.,[50590],[17872],[18112],[False],[0],[0],[False],['0']
18013,PMC4145439,8604,This was not apparent at higher dose levels (−1.87 and −2.08 for OKZ 240 mg Q2W patients).,Results|¶results of posthoc analysis.,[50600],[18113],[18203],[False],[0],[0],[False],['0']
18014,PMC4145439,8605,"ACR20, ACR50 and ACR70 response rates",Results|¶results of posthoc analysis.,[50610],[18204],[18241],[False],[0],[0],[False],['0']
18015,PMC4145439,8606,The ACR20 and ACR50 response rates were higher in OKZ-treated patients than those receiving PBO at Week 12 (table 2).,Results|¶results of posthoc analysis.,[50620],[18242],[18359],[False],[0],[0],[False],['0']
18016,PMC4145439,8607,This study was not powered to detect significant differences in ACR20/50/70 response rates.,Results|¶results of posthoc analysis.,[50630],[18360],[18451],[False],[0],[0],[False],['0']
18017,PMC4145439,8608,"However, responses were numerically higher for ACR20 (p=0.0636) and ACR50 (p=0.0574) than PBO (table 2).",Results|¶results of posthoc analysis.,[50640],[18452],[18556],[False],[0],[0],[False],['0']
18018,PMC4145439,8609,"Improvements in ACR20 and ACR50 were rapid, with increased responses over PBO observed from as early as Week 1 and Week 4, respectively, and were generally maintained or increased throughout the treatment period (figure 2C,D).",Results|¶results of posthoc analysis.,[50650],[18557],[18783],[False],[0],[0],[False],['0']
18019,PMC4145439,8610,These responses were similar for the TCZ treatment group.,Results|¶results of posthoc analysis.,[50660],[18784],[18841],[False],[0],[0],[False],['0']
18020,PMC4145439,8611,Seven patients in OKZ treatment groups and four patients on TCZ were observed ACR70 responders at Week 12.,Results|¶results of posthoc analysis.,[50670],[18842],[18948],[False],[0],[0],[False],['0']
18021,PMC4145439,8612,Additional efficacy endpoints,Results|Additional efficacy endpoints,[50680],[18949],[18978],[False],[0],[0],[False],['0']
18022,PMC4145439,8613,"Exploratory analysis of additional efficacy endpoints revealed improvements in OKZ-treated patients at Week 12 in physical function (as assessed by HAQ-DI) compared with the PBO groups, as well as greater reductions in TJC, SJC and CDAI (table 2).",Results|Additional efficacy endpoints,[50690],[18979],[19226],[False],[0],[0],[False],['0']
18023,PMC4145439,8614,"Additionally, a higher percentage of patients demonstrated DAS28(CRP) <2.6 or DAS28(CRP) ≤3.2 following treatment with OKZ than PBO.",Results|Additional efficacy endpoints,[50700],[19227],[19359],[False],[0],[0],[False],['0']
18024,PMC4145439,8615,"The percentage of patients demonstrating DAS28(CRP) <2.6 in the OKZ 240 mg Q2W group was more than fivefold higher than that in the PBO Q2W group (26.1% and 4.5%, respectively).",Results|Additional efficacy endpoints,[50710],[19360],[19537],[False],[0],[0],[False],['0']
18025,PMC4145439,8616,"Posthoc analysis showed that at Week 12, low disease activity (CDAI ≤10.0) was achieved by patients from all treatment groups, including PBO, with a higher proportion of patients demonstrating this in the OKZ 120 mg and 240 mg dose groups than the OKZ 60 mg and PBO groups (table 2).",Results|Additional efficacy endpoints,[50720],[19538],[19821],[False],[0],[0],[False],['0']
18026,PMC4145439,8617,"Five of 132 patients in OKZ treatment groups (from 5 different cohorts), and 5 of 43 patients on TCZ achieved CDAI remission (CDAI ≤2.8) at Week 12; compared with none of the 22 patients in PBO groups.",Results|Additional efficacy endpoints,[50730],[19822],[20023],[False],[0],[0],[False],['0']
18027,PMC4145439,8618,Pharmacokinetic/pharmacodynamic analyses,Results|Pharmacokinetic/pharmacodynamic analyses,[50740],[20024],[20064],[False],[0],[0],[False],['0']
18028,PMC4145439,8619,"The OKZ plasma concentration-time data were adequately described by a two-compartment, first-order absorption, linear elimination model.",Results|Pharmacokinetic/pharmacodynamic analyses,[50750],[20065],[20201],[False],[0],[0],[False],['0']
18029,PMC4145439,8620,The OKZ PK characteristics were consistent with those in healthy and mild-to-moderate patients with RA.,Results|Pharmacokinetic/pharmacodynamic analyses,[50760],[20202],[20305],[False],[0],[0],[False],['0']
18030,PMC4145439,8621,"The overall estimate of bioavailability across the Phase I, IIa and IIb studies was 63.3% (% relative standard error=4.9%).",Results|Pharmacokinetic/pharmacodynamic analyses,[50770],[20306],[20429],[False],[0],[0],[False],['0']
18031,PMC4145439,8622,"PK/PD (DAS28(CRP)) data were adequately described by an indirect concentration-effect sigmoid Emax model, with inhibition of DAS28(CRP) production.",Results|Pharmacokinetic/pharmacodynamic analyses,[50780],[20430],[20578],[False],[0],[0],[False],['0']
18032,PMC4145439,8623,"Simulations performed with the resulting model, extrapolated to Week 24, highlighted the existence of a shallow dose/exposure response relationship (in terms of percentage of patients with DAS28(CRP)<2.6, see online supplementary figure S1).",Results|Pharmacokinetic/pharmacodynamic analyses,[50790],[20579],[20820],[False],[0],[0],[False],['0']
18033,PMC4145439,8624,"A successful description of the ACR20 data and its correlation with exposure, taking into account drop-out using a logistic model, was also possible.",Results|Pharmacokinetic/pharmacodynamic analyses,[50800],[20821],[20970],[False],[0],[0],[False],['0']
18034,PMC4145439,8625,"By contrast with DAS28(CRP), simulations exploring the dose-response surface for ACR20 revealed a steep response curve.",Results|Pharmacokinetic/pharmacodynamic analyses,[50810],[20971],[21090],[False],[0],[0],[False],['0']
18035,PMC4145439,8626,Immunogenicity,Results|Immunogenicity,[50820],[21091],[21105],[False],[0],[0],[False],['0']
18036,PMC4145439,8627,Analysis of plasma samples for anti-OKZ antibodies was conducted.,Results|Immunogenicity,[50830],[21106],[21171],[False],[0],[0],[False],['0']
18037,PMC4145439,8628,"Using a study-specific cut-off, based on blinded analysis of drug-naive baseline samples, 13 patients (9.8%) in OKZ-treated groups were anti-OKZ antibody positive.",Results|Immunogenicity,[50840],[21172],[21335],[False],[0],[0],[False],['0']
18038,PMC4145439,8629,"Importantly, four of these patients were pre-dose positive, and only one of them displayed a PK profile characteristic of drug-clearing immunogenicity.",Results|Immunogenicity,[50850],[21336],[21487],[False],[0],[0],[False],['0']
18039,PMC4145439,8630,"Furthermore, five patients in the PBO groups (11.3%) and two patients in the TCZ group (9.8%) were also anti-OKZ antibody positive.",Results|Immunogenicity,[50860],[21488],[21619],[False],[0],[0],[False],['0']
18040,PMC4145439,8631,Non-specific interference by pre-existing immunoglobulins in patients’ plasma has been previously reported  and was shown to be the case for some of these nominally positive samples with a posthoc analysis.,Results|Immunogenicity,[50870],[21620],[21826],[False],[0],[0],[False],['0']
18041,PMC4145439,8632,"Thus, the true incidence of specific anti-OKZ antibodies is likely to be less than nominally determined.",Results|Immunogenicity,[50880],[21827],[21931],[False],[0],[0],[False],['0']
18042,PMC4145439,8633,Details of the immunogenicity investigations and the efficacy response of the 13 patients who were found nominally anti-OKZ antibody positive can be found in online supplementary material (table S1).,Results|Immunogenicity,[50890],[21932],[22131],[False],[0],[0],[False],['0']
18043,PMC4145439,8634,Safety (SS),Results|Safety (SS),[50900],[22132],[22143],[False],[0],[0],[False],['0']
18044,PMC4145439,8635,"There were similar numbers of TEAEs reported in the OKZ and TCZ active dose groups, and the PBO group (range across OKZ treatment groups: 63.6–87.0%; PBO: 77.3–86.4%; TCZ: 86.0%) (table 3).",Results|Safety (SS),[50910],[22144],[22333],[False],[0],[0],[False],['0']
18045,PMC4145439,8636,The majority of TEAEs in all treatment groups were mild in intensity.,Results|Safety (SS),[50920],[22334],[22403],[False],[0],[0],[False],['0']
18046,PMC4145439,8637,"Most frequently reported TEAEs (occurring in ≥10% of patients in any treatment group) consisted of diarrhoea, headache, injection site reactions (PBO: 18.2%; OKZ: 17.4–47.8%; TCZ: 20.9%), and infections including upper respiratory tract infections, urinary tract infections and nasopharyngitis (PBO: 31.8–50.0%; OKZ: 25.0–36.4%).",Results|Safety (SS),[50930],[22404],[22733],[False],[0],[0],[False],['0']
18047,PMC4145439,8638,There were no incidences of diverticulitis and no gastrointestinal (GI) perforations reported.,Results|Safety (SS),[50940],[22734],[22828],[False],[0],[0],[False],['0']
18048,PMC4145439,8639,"All TEAEs are reported to Week 12, and thus represent short-term safety outcomes.",Results|Safety (SS),[50950],[22829],[22910],[False],[0],[0],[False],['0']
18049,PMC4145439,8640,Treatment-emergent adverse events and serious treatment-emergent adverse events (safety set),Results|Safety (SS),[50960],[22911],[23003],[False],[0],[0],[False],['0']
18050,PMC4145439,8641,"MedDRA (V.14.0)system organ classPreferred term	Dosing frequency	PBOn/N (%)	OKZ 60 mgn/N (%)	OKZ 120 mgn/N (%)	OKZ 240 mgn/N (%)	TCZ 8 mg/kgn/N (%)	 	Any TEAEs	Q2W	19/22 (86.4)	14/20 (70.0)	14/22 (63.6)	19/23 (82.6)	–	 	Q4W	17/22 (77.3)	18/22 (81.8)	20/23 (87.0)	19/22 (86.4)	37/43 (86.0)	 	 Gastrointestinal disorders	Q2W	7/22 (31.8)	3/20 (15.0)	3/22 (13.6)	5/23 (21.7)	–	 	Q4W	2/22 (9.1)	3/22 (13.6)	4/23 (17.4)	8/22 (36.4)	9/43 (20.9)	 	 General disorders and administration site reactions	Q2W	4/22 (18.2)	5/20 (25.0)	5/22 (22.7)	11/23 (47.8)	–	 	Q4W	4/22 (18.2)	9/22 (40.9)	4/23 (17.4)	6/22 (27.3)	9/43 (20.9)	 	 Infections and infestations	Q2W	7/22 (31.8)	5/20 (25.0)	6/22 (27.3)	7/23 (30.4)	–	 	Q4W	11/22 (50.0)	6/22 (27.3)	8/23 (34.8)	8/22 (36.4)	16/43 (37.2)	 	Serious TEAEs	Q2W	2 (9.1)	3 (15.0)	0	0	–	 	Q4W	1 (4.5)	1 (4.5)	0	2 (9.1)	4 (9.3)	 	 Anaemia	Q2W	0	0	0	0	–	 	Q4W	1/22 (4.5)	0	0	0	0	 	 Investigations	Q2W	0	0	0	0	–	 	Q4W	0	1/22 (4.5)	0	0	1/43 (2.3)	 	  Liver function test abnormal	Q2W	0	0	0	0	–	 	Q4W	0	1/22 (4.5)	0	0	0	 	  Blood triglycerides increased	Q2W	0	0	0	0	–	 	Q4W	0	0	0	0	1/43 (2.3)	 	 Infections and infestations	Q2W	0	0	0	0	–	 	Q4W	0	0	0	2/22 (9.1)	2/43 (4.7)	 	  Pneumonia	Q2W	0	0	0	0	–	 	Q4W	0	0	0	1/22 (4.5)	1/43 (2.3)	 	 Neoplasms, benign malignant and unspecified	Q2W	0	1/20 (5.0)	0	0	–	 	Q4W	0	0	0	0	0	 	  Basal cell carcinoma	Q2W	0	1/20 (5.0)	0	0	–	 	Q4W	0	0	0	0	0	 	Deaths	Q2W	0	0	0	0	–	 	Q4W	0	0	0	0	0",Results|Safety (SS),[50970],[23004],[24444],[False],[0],[0],[False],['0']
18051,PMC4145439,8642,"OKZ, olokizumab; PBO, placebo; TCZ, tocilizumab; TEAE, treatment emergent adverse event.",Results|Safety (SS),[50980],[24445],[24536],[False],[0],[0],[False],['0']
18052,PMC4145439,8643,"The incidence of serious TEAEs was similar between treatment groups, and no serious TEAE was reported by >1 patient (table 3).",Results|Safety (SS),[50990],[24537],[24663],[False],[0],[0],[False],['0']
18053,PMC4145439,8644,"In the OKZ treatment groups, serious TEAEs reported were chest pain, pneumonia, perineal abscess, abnormal liver function test (LFT), back pain, basal cell carcinoma and mania.",Results|Safety (SS),[51000],[24664],[24840],[False],[0],[0],[False],['0']
18054,PMC4145439,8645,"One serious pneumonia case was reported in the TCZ treatment arm (2.3% patients); other serious TEAEs in the TCZ group included increased blood triglycerides and limb abscess (2.3% patients, respectively).",Results|Safety (SS),[51010],[24841],[25046],[False],[0],[0],[False],['0']
18055,PMC4145439,8646,There were no deaths throughout the study.,Results|Safety (SS),[51020],[25047],[25089],[False],[0],[0],[False],['0']
18056,PMC4145439,8647,"Laboratory abnormalities included elevated levels of ALT, AST and gamma glutamyl transferase (GGT), as well as decreased neutrophil counts and increased blood cholesterol (table 4).",Results|Safety (SS),[51030],[25090],[25271],[False],[0],[0],[False],['0']
18057,PMC4145439,8648,"In the OKZ treatment groups, 4.3–18.2% of patients had ALT levels >3× ULN and 4.3–9.1% had AST levels >3× ULN at least at one postbaseline measurement.",Results|Safety (SS),[51040],[25272],[25423],[False],[0],[0],[False],['0']
18058,PMC4145439,8649,No increases in either enzyme >3× ULN were seen in PBO or TCZ treated patients.,Results|Safety (SS),[51050],[25424],[25503],[False],[0],[0],[False],['0']
18059,PMC4145439,8650,Neutrophil and leukocyte counts were reduced from baseline levels in each of the active treatment arms (including TCZ) from as early as Week 1; the incidence of markedly abnormal neutrophil counts (defined as laboratory values graded 3 or 4 according to the National Cancer Institute Common Terminology Critera for Adverse Events (CTCAE)) was similar between OKZ and TCZ treatment groups (range for OKZ: 0–4.5%; TCZ: 4.7%).,Results|Safety (SS),[51060],[25504],[25927],[False],[0],[0],[False],['0']
18060,PMC4145439,8651,There were no incidences of markedly abnormal leukocyte counts or thrombocytopenia.,Results|Safety (SS),[51070],[25928],[26011],[False],[0],[0],[False],['0']
18061,PMC4145439,8652,"For the majority of clinical chemistry parameters there were no significant differences in mean values between PBO, OKZ and TCZ treatment groups, and no clinically significant fluctuations in mean values over time.",Results|Safety (SS),[51080],[26012],[26226],[False],[0],[0],[False],['0']
18062,PMC4145439,8653,"One subject in the OKZ 60 mg Q4W group was found to have elevations in ALT and AST, which was reported as a serious TEAE.",Results|Safety (SS),[51090],[26227],[26348],[False],[0],[0],[False],['0']
18063,PMC4145439,8654,"There were four incidences of Grade 3 or 4 elevations in GGT values, and four reports of abnormally high Grade 3 total cholesterol values, across the OKZ and TCZ treated patients.",Results|Safety (SS),[51100],[26349],[26528],[False],[0],[0],[False],['0']
18064,PMC4145439,8655,"All these cases had values that were elevated at baseline and/or screening, prior to treatment with the study drug.",Results|Safety (SS),[51110],[26529],[26644],[False],[0],[0],[False],['0']
18065,PMC4145439,8656,There was one recorded serious TEAE of increased blood triglycerides which occurred in the TCZ group.,Results|Safety (SS),[51120],[26645],[26746],[False],[0],[0],[False],['0']
18066,PMC4145439,8657,Markedly abnormal laboratory values (laboratory values graded 3 or 4 according to CTCAE* V.4.0) (safety set),Results|Safety (SS),[51130],[26747],[26855],[False],[0],[0],[False],['0']
18067,PMC4145439,8658,MedDRA (V.14.0)System organ classpreferred term	Dosing frequency	PBOn/N (%)	OKZ 60 mgn/N (%)	OKZ 120 mgn/N (%)	OKZ 240 mgn/N (%)	TCZ 8 mg/kgn/N (%)	 	Liver function tests	 	 Alanine aminotransferase increased	Q2W	0	0	0	0	–	 	Q4W	0	1/22 (4.5)	0	0	0	 	 Aspartate aminotransferase increased	Q2W	0	0	0	0	–	 	Q4W	0	1/22 (4.5)	0	0	0	 	 γ glutamyl transferase increased	Q2W	0	0	0	0	–	 	Q4W	0	1/22 (4.5)	0	1/22 (4.5)	1/43 (2.3)	 	Haematology	 	 Neutrophil count decreased	Q2W	0	0	0	0	–	 	Q4W	0	1/22 (4.5)	0	0	2/43 (4.7)	 	 Leukocyte count decreased	Q2W	0	0	0	0	–	 	Q4W	0	0	0	0	0	 	Lipids	 	 Total cholesterol increased	Q2W	1/22 (4.5)	0	0	1/23 (4.3)	–	 	Q4W	0	1/22 (4.5)	0	1/22 (4.5)	0	 	 Low density lipoprotein increased	Q2W	0	0	0	0	–	 	Q4W	0	0	0	0	0	 	 High density lipoprotein increase	Q2W	0	0	0	0	–	 	Q4W	0	0	0	0	0	 	 Triglycerides increased	Q2W	0	0	0	0	–	 	Q4W	0	0	0	0	0,Results|Safety (SS),[51140],[26856],[27723],[False],[0],[0],[False],['0']
18068,PMC4145439,8659,*National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) V.4.,Results|Safety (SS),[51150],[27724],[27813],[False],[0],[0],[False],['0']
18069,PMC4145439,8660,Markedly abnormal values are those graded 3 or 4 and worse than baseline value.,Results|Safety (SS),[51160],[27814],[27893],[False],[0],[0],[False],['0']
18070,PMC4145439,8661,"OKZ, olokizumab; PBO, placebo; TCZ, tocilizumab.",Results|Safety (SS),[51170],[27894],[27942],[False],[0],[0],[False],['0']
18071,PMC4145439,8662,Discussion,Discussion,[51180],[27943],[27954],[False],[0],[0],[False],['0']
18072,PMC4145439,8663,"In this Phase II study of patients with RA who had previously failed TNF inhibitor therapy, treatment with OKZ resulted in significantly greater reductions in DAS28(CRP) from baseline levels at Week 12 compared with treatment with PBO.",Discussion,[51190],[27955],[28190],[False],[0],[0],[False],['0']
18073,PMC4145439,8664,"This improvement was demonstrated at all the OKZ doses tested with generally comparable efficacy and across both dosing frequencies, and was statistically significant for all dose group comparisons (60, 120 or 240 mg vs PBO).",Discussion,[51200],[28191],[28416],[False],[0],[0],[False],['0']
18074,PMC4145439,8665,"At low OKZ doses, a posthoc analysis showed greater responses in patients who met the criterion of high CRP at study entry compared to all other patients.",Discussion,[51210],[28417],[28571],[False],[0],[0],[False],['0']
18075,PMC4145439,8666,The primary efficacy endpoint was further supported by the secondary efficacy variables.,Discussion,[51220],[28572],[28660],[False],[0],[0],[False],['0']
18076,PMC4145439,8667,"Estimated ACR20 and ACR50 response rates at Week 12 were numerically higher in all OKZ treatment arms than PBO groups, although the study was not powered to show a statistical difference in the ACR response rates.",Discussion,[51230],[28661],[28874],[True],['UnderpoweredStudy'],['the study was not powered to show a statistical difference in the ACR response rates'],[True],['UnderpoweredStudy']
18077,PMC4145439,8668,Few patients in any treatment group were ACR70 responders.,Discussion,[51250],[28875],[28933],[False],[0],[0],[False],['0']
18078,PMC4145439,8669,"Comparisons of exploratory efficacy variables, including health outcomes endpoints generally suggested greater improvement in OKZ treatment groups compared with the PBO groups.",Discussion,[51260],[28934],[29110],[False],[0],[0],[False],['0']
18079,PMC4145439,8670,"Overall, exploratory comparison showed similar responses to subcutaneous OKZ treatment and intravenously administered TCZ across multiple efficacy endpoints and for several OKZ treatment groups.",Discussion,[51270],[29111],[29305],[False],[0],[0],[False],['0']
18080,PMC4145439,8671,"Reported TEAEs in this study were consistent with the safety profile expected of this class of drug, with no new safety signals identified.",Discussion,[51280],[29306],[29445],[False],[0],[0],[False],['0']
18081,PMC4145439,8672,"Commonly reported TEAEs in OKZ treated patients included gastrointestinal disorders, infections and infestations (primarily upper and lower respiratory tract infections and urinary tract infections) and nervous system disorders, which is qualitatively similar to the safety profile observed for TCZ in this and other previously published trials, as well as other anti-IL6 s in development.",Discussion,[51290],[29446],[29835],[False],[0],[0],[False],['0']
18082,PMC4145439,8673,"These TEAEs occurred at similar frequencies in the PBO, OKZ and TCZ treated groups.",Discussion,[51300],[29836],[29919],[False],[0],[0],[False],['0']
18083,PMC4145439,8674,There were no incidences of diverticulitis or gastrointestinal perforations reported during the study.,Discussion,[51310],[29920],[30022],[False],[0],[0],[False],['0']
18084,PMC4145439,8675,"In accordance with the role of IL-6 in immune regulation, inflammation and haematopoiesis, reported TEAEs included increases in AST, ALT and lipids, and decreases in neutrophil levels.",Discussion,[51320],[30023],[30207],[False],[0],[0],[False],['0']
18085,PMC4145439,8676,"As expected, small increases from baseline in median total cholesterol, LDL and triglycerides and decreases in neutrophils were observed in each of the active treatment arms, including the TCZ group, throughout the 12-week study.",Discussion,[51330],[30208],[30437],[False],[0],[0],[False],['0']
18086,PMC4145439,8677,No patients fulfilled the Hy's law criteria for drug-induced liver injury.,Discussion,[51340],[30438],[30512],[False],[0],[0],[False],['0']
18087,PMC4145439,8678,"Most TEAEs were mild to moderate in nature, with no deaths.",Discussion,[51350],[30513],[30572],[False],[0],[0],[False],['0']
18088,PMC4145439,8679,"In the OKZ and TCZ treatment groups, there were no opportunistic infections, but two serious infections (one pneumonia and one abscess reported in patients treated with each study drug).",Discussion,[51360],[30573],[30759],[False],[0],[0],[False],['0']
18089,PMC4145439,8680,Injection site reactions were more commonly reported after injection with OKZ compared with PBO or TCZ which was administered intravenously.,Discussion,[51370],[30760],[30901],[False],[0],[0],[False],['0']
18090,PMC4145439,8681,"The highest incidence was reported in the OKZ 240 mg Q2W group, in accordance with these patients receiving the greatest number of active subcutaneous injections.",Discussion,[51380],[30902],[31064],[False],[0],[0],[False],['0']
18091,PMC4145439,8682,No serious injection site reactions were reported.,Discussion,[51390],[31065],[31115],[False],[0],[0],[False],['0']
18092,PMC4145439,8683,The limitations of this study included the small number of patients in each treatment group and the resultant lack of statistical power for comparisons beyond the primary endpoint.,Discussion,"[51401, 51402]","[31116, 31116]","[31296, 31296]","[True, True]","['SampleSize', 'UnderpoweredStudy']","['the small number of patients in each treatment group', 'the resultant lack of statistical power for comparisons beyond the primary endpoint']","[True, True]",['UnderpoweredStudy']
18093,PMC4145439,8684,"This small sample size, along with the heterogeneity of the study population, resulted in high variability, quantified by the PBO groups.",Discussion,"[51423, 51424]","[31297, 31297]","[31434, 31434]","[True, True]","['SampleSize', 'DiagnosticCriteria']","['This small sample size', 'the heterogeneity of the study population']","[True, True]","['Population', 'UnderpoweredStudy']"
18094,PMC4145439,8685,Although PBO patients were randomised to nominal ‘Q4W’ and ‘Q2W’ groups they received identical treatments at all visits and results in these groups (while demonstrating overall consistency with previous published RA clinical trials) were variable.,Discussion,"[51448, 51449]","[31435, 31435]","[31683, 31683]","[True, True]","['PrecisionOfMeasurement', 'Intervention']","['results in these groups (while demonstrating overall consistency with previous published RA clinical trials) were variable', 'they received identical treatments at all visits']","[True, True]","['Intervention', 'OutcomeMeasures']"
18095,PMC4145439,8686,"Despite this, OKZ across all treatment groups demonstrated statistically significant improvements in the predefined primary efficacy variable.",Discussion,[51460],[31684],[31826],[False],[0],[0],[False],['0']
18096,PMC4145439,8687,"Graphical comparisons of different doses and dosing regimens did not reveal significant differences in responses; integration of study data and analysis using PK/PD methodology revealed dose-exposure-response relationships for DAS28(CRP) and ACR20 endpoints, albeit shallow; no significant impact of the number of previous failed treatments with TNF inhibitors could be observed, which may also be due to small sample sizes.",Discussion,[51470],[31827],[32251],[False],[0],[0],[False],['0']
18097,PMC4145439,8688,This study used a primary endpoint of 12 weeks.,Discussion,[51480],[32252],[32299],[False],[0],[0],[False],['0']
18098,PMC4145439,8689,Study duration is another potential study limitation given the long half-life of OKZ (31 days) and the time required to plateau plasma concentration drug levels.,Discussion,[51495],[32300],[32461],[True],['ExperimentalPhaseDuration'],['Study duration'],[True],['StudyDuration']
18099,PMC4145439,8690,"Additionally, in this study, all patients had previously been treated with, and failed to respond to, at least one TNF inhibitor, and thus, results seen here may not be directly applicable to the wider RA population.",Discussion,"[51516, 51517]","[32462, 32462]","[32678, 32678]","[True, True]","['VerySpecificPopulation', 'Generalization']","['all patients had previously been treated with, and failed to respond to, at least one TNF inhibitor', 'results seen here may not be directly applicable to the wider RA population']","[True, True]","['Generalization', 'Population']"
18100,PMC4145439,8691,"In addition to OKZ, several other antibodies targeting the IL-6 pathway are in development.",Discussion,[51530],[32679],[32770],[False],[0],[0],[False],['0']
18101,PMC4145439,8692,"Potential differentiating factors for these antibodies include targeted protein (IL-6 or IL6R), targeted step of the IL-6 signalling complex cascade, route of administration, level of humanisation, immunoglobulin type and/or antibody construct.",Discussion,[51540],[32771],[33015],[False],[0],[0],[False],['0']
18102,PMC4145439,8693,"However, these antibodies are currently in Phase II or III of clinical development.",Discussion,[51550],[33016],[33099],[False],[0],[0],[False],['0']
18103,PMC4145439,8694,"Thus, the impact of these factors on efficacy and/or safety has not yet been fully evaluated.",Discussion,[51560],[33100],[33193],[False],[0],[0],[False],['0']
18104,PMC4145439,8695,"The data presented here show that in this Phase II trial, OKZ demonstrated improvements in multiple efficacy variables compared with PBO in patients with moderate-to-severe RA who had previously failed TNF inhibitor therapy with results comparable to TCZ.",Discussion,[51570],[33194],[33449],[False],[0],[0],[False],['0']
18105,PMC4145439,8696,"Additionally, the safety profile following treatment with OKZ at doses up to 240 mg Q2W was in line with expectations for this class of drug, with a TEAE and laboratory test profile consistent with the use of IL-6 targeted therapy in patients with moderate-to-severe RA.",Discussion,[51580],[33450],[33720],[False],[0],[0],[False],['0']
18106,PMC4145439,8697,"Taken together, the results of this Phase II study are encouraging and support further studies with OKZ in RA.",Discussion,[51590],[33721],[33831],[False],[0],[0],[False],['0']
18107,PMC4145439,8698,Supplementary Material,Supplementary Material,[51600],[33832],[33855],[False],[0],[0],[False],['0']
18108,PMC4145439,8699,"Contributors: All authors met the following criteria for authorship: Substantial contributions to the acquisition, analysis, and interpretation of data for the work; and contributed to drafting the work and revising it critically; and gave final approval of the version submitted; and agreed to be accountable for all aspects of the work.",Supplementary Material,[51610],[33856],[34194],[False],[0],[0],[False],['0']
18109,PMC4145439,8700,Funding: This study was funded by UCB Pharma.,Supplementary Material,[51620],[34195],[34240],[False],[0],[0],[False],['0']
18110,PMC4145439,8701,"Competing interests: MCG reports grants and personal fees from UCB Pharma, outside the submitted work; RF reports grants and personal fees from Roche, grants and personal fees from Abbott, grants and personal fees from Amgen, grants and personal fees from UCB Pharma, grants and personal fees from Pfizer, grants and personal fees from BMS, grants and personal fees from Lilly, grants and personal fees from Sanofi-Aventis, grants and personal fees from Lexicon, grants and personal fees from Novartis, grants and personal fees from Astellas, grants and personal fees from AstraZeneca, grants and personal fees from Janssen, grants and personal fees from HGS, grants from BiogenIdec, grants from MSD, grants from Genentech Inc, outside the submitted work; DF reports grants and personal fees from UCB Pharma, outside the submitted work; NJ reports reports grants, personal fees and non-financial support from UCB Pharma, during the conduct of the study; grants from Roche/Genentech, grants from Novartis, grants from Sanofi, grants from Pfizer, grants from Glaxo Smith Kline, grants from Janssen, outside the submitted work; JC reports grants from Genentech and Takeda Pharmaceuticals NA, Inc, outside the submitted work; BD reports grants from ACR, grants from EULAR, grants from Health Technology Assessment, grants from Research for Patient Benefits (RFPB), grants from British Heart Foundation, grants from Napp, from Fight for Sight, personal fees from Roche, personal fees from Merck, personal fees from Sobi, personal fees from Mundipharma, outside the submitted work; JB is an employee of UCB Pharma and holds stock options for UCB Pharma; BD is an employee of UCB Pharma and holds stock options for UCB Pharma; WZ is an employee of UCB Pharma; CP reports grants and personal fees from Abbott, grants and personal fees from AZ/MedImmune, grants and personal fees from Pfizer, grants and personal fees from Roche/Genentech, grants and personal fees from UCB Pharma, outside the submitted work; PD has nothing to disclose; KK is an employee of UCB Pharma and holds stock options for UCB Pharma.",Supplementary Material,[51630],[34241],[36341],[False],[0],[0],[False],['0']
18111,PMC4145439,8702,Ethics approval: UCB Pharma Institutional Review Board (IRB)/Independent Ethics Committee (IEC) as defined in local regulations.,Supplementary Material,[51640],[36342],[36470],[False],[0],[0],[False],['0']
18112,PMC4145439,8703,Provenance and peer review: Not commissioned; externally peer reviewed.,Supplementary Material,[51650],[36471],[36542],[False],[0],[0],[False],['0']
20757,PMC4461648,13336,Efficiency of a mechanical device in controlling tracheal cuff pressure in intubated critically ill patients: a randomized controlled study,Title,[80491],[23801],[139],[False],[0],[0],[False],['0']
20758,PMC4461648,13337,Background,Abstract,[80498],[140],[151],[False],[0],[0],[False],['0']
20759,PMC4461648,13338,Cuff pressure (P ) control is mandatory to avoid leakage of oral secretions passing the tracheal tube and tracheal ischemia.,Abstract,[80505],[152],[276],[False],[0],[0],[False],['0']
20760,PMC4461648,13339,"The aim of the present trial was to determine the efficacy of a mechanical device (PressureEasy®) in the continuous control of P  in patients intubated with polyvinyl chloride (PVC)-cuffed tracheal tubes, compared with routine care using a manometer.",Abstract,[80512],[277],[527],[False],[0],[0],[False],['0']
20761,PMC4461648,13340,Methods,Methods,[80519],[528],[536],[False],[0],[0],[False],['0']
20762,PMC4461648,13341,"This is a prospective, randomized, controlled, cross-over study.",Methods,[80526],[537],[601],[False],[0],[0],[False],['0']
20763,PMC4461648,13342,All patients requiring intubation with a predicted duration of mechanical ventilation ≥48 h were eligible.,Methods,[80533],[602],[708],[False],[0],[0],[False],['0']
20764,PMC4461648,13343,"Eighteen patients randomly received continuous control of P  with PressureEasy® device for 24 h, followed by discontinuous control (every 4 h) with a manual manometer for 24 h, or vice versa.",Methods,[80540],[709],[900],[False],[0],[0],[False],['0']
20765,PMC4461648,13344,P  and airway pressure were continuously recorded.,Methods,[80547],[901],[951],[False],[0],[0],[False],['0']
20766,PMC4461648,13345,P  target was 25 cmH O during the two periods.,Methods,[80554],[952],[998],[False],[0],[0],[False],['0']
20767,PMC4461648,13346,Results,Results,[80561],[999],[1007],[False],[0],[0],[False],['0']
20768,PMC4461648,13347,"The percentage of time spent with P  20–30 cmH O (median (IQR) 34 % (17–57) versus 50 % (35–64), p = 0.184) and the percentage of time spent with P  <20 cmH O (23 % (5–63) versus 43 % (16–60), p = 0.5) were similar during continuous control of P  and routine care, respectively.",Results,[80568],[1008],[1286],[False],[0],[0],[False],['0']
20769,PMC4461648,13348,"However, the percentage of time spent with P  >30 cmH O was significantly higher during continuous control compared with routine care of tracheal cuff (26 % (14–39) versus 7 % (1–18), p = 0.002).",Results,[80575],[1287],[1482],[False],[0],[0],[False],['0']
20770,PMC4461648,13349,"No significant difference was found in P  (25 (18–28) versus 21 (18–26), p = 0.17), mean airway pressure (14 (10–17) versus 14 (11–16), p = 0.679), or coefficient of variation of P  (19 % (11–26) versus 20 % (11–25), p = 0.679) during continuous control compared with routine care of tracheal cuff, respectively.",Results,[80582],[1483],[1795],[False],[0],[0],[False],['0']
20771,PMC4461648,13350,Conclusions,Conclusions,[80589],[1796],[1808],[False],[0],[0],[False],['0']
20772,PMC4461648,13351,"PressureEasy® did not demonstrate a better control of P  between 20 and 30 cmH O, compared with routine care using a manometer.",Conclusions,[80596],[1809],[1936],[False],[0],[0],[False],['0']
20773,PMC4461648,13352,"Moreover, the device use resulted in significantly higher time spent with overinflation of tracheal cuff, which might increase the risk for tracheal ischemic lesions.",Conclusions,[80603],[1937],[2103],[False],[0],[0],[False],['0']
20774,PMC4461648,13353,Trial registration,Trial registration,[80610],[2104],[2123],[False],[0],[0],[False],['0']
20775,PMC4461648,13354,Clinicaltrial.gov: NCT02109003,Trial registration,[80617],[2124],[2154],[False],[0],[0],[False],['0']
20776,PMC4461648,13355,Background,Background,[80624],[2155],[2167],[False],[0],[0],[False],['0']
20777,PMC4461648,13356,Intubation is an invasive procedure that is still performed in a large proportion of critically ill patients [1].,Background,[80631],[2168],[2281],[False],[0],[0],[False],['0']
20778,PMC4461648,13357,"Some long-term intubation-related complications are caused by inappropriate cuff pressure (P ), and include microaspiration, and tracheal ischemic lesions [2, 3].",Background,[80638],[2282],[2444],[False],[0],[0],[False],['0']
20779,PMC4461648,13358,"Microaspiration of contaminated oropharyngeal secretions is the main route of entry for bacteria into the lower respiratory tract [4, 5].",Background,[80645],[2445],[2582],[False],[0],[0],[False],['0']
20780,PMC4461648,13359,Colonization of the lower respiratory tract could progress into ventilator-associated pneumonia (VAP) when local or general defense mechanisms are altered in intubated critically ill patients [6].,Background,[80652],[2583],[2779],[False],[0],[0],[False],['0']
20781,PMC4461648,13360,"VAP is the most frequent infection acquired in the ICU and is associated with high morbidity and mortality, especially in patients with comorbidities [7].",Background,[80659],[2780],[2934],[False],[0],[0],[False],['0']
20782,PMC4461648,13361,"Tracheal ischemic injury is also associated with high morbidity, especially when routine care for tracheal cuff is not adequately provided [8–11].",Background,[80666],[2935],[3081],[False],[0],[0],[False],['0']
20783,PMC4461648,13362,"Based on international recommendations, P  should be kept between 20 and 30 cmH O using a manometer [12, 13].",Background,[80673],[3082],[3191],[False],[0],[0],[False],['0']
20784,PMC4461648,13363,"However, several recent studies suggested that a noncontinuous control of P  using a manometer is not effective in intubated critically ill patients [14].",Background,[80680],[3192],[3346],[False],[0],[0],[False],['0']
20785,PMC4461648,13364,"Further, previous studies did not identify modifiable risk factors for overinflation or underinflation of tracheal cuff [15–18].",Background,[80687],[3347],[3475],[False],[0],[0],[False],['0']
20786,PMC4461648,13365,"Recently, several devices allowing continuous control of P  were evaluated [19–22].",Background,[80694],[3476],[3559],[False],[0],[0],[False],['0']
20787,PMC4461648,13366,"These devices are classified into pneumatic (i.e., does not require power supply, but a single-use 200-ml cylindrical cuff) and electronic devices (requiring power supply).",Background,[80701],[3560],[3732],[False],[0],[0],[False],['0']
20788,PMC4461648,13367,"Two prospective randomized controlled animal and human studies first validated the use of a pneumatic device [19, 20].",Background,[80708],[3733],[3851],[False],[0],[0],[False],['0']
20789,PMC4461648,13368,A noncommercially available device has also been validated and proved to be efficient in continuously controlling P  in ICU patients [22].,Background,[80715],[3852],[3990],[False],[0],[0],[False],['0']
20790,PMC4461648,13369,"However, other commercially available automated devices were only validated in in vitro studies [23, 24].",Background,[80722],[3991],[4096],[False],[0],[0],[False],['0']
20791,PMC4461648,13370,Recent data suggest that these devices interfere with the self-sealing characteristics of high-volume low-pressure (HVLP) tracheal cuffs [23].,Background,[80729],[4097],[4239],[False],[0],[0],[False],['0']
20792,PMC4461648,13371,"Further, these electronic devices have been shown to be less efficient than the pneumatic device in continuous control of P , because of rapid correction of overinflation episodes [21].",Background,[80736],[4240],[4425],[False],[0],[0],[False],['0']
20793,PMC4461648,13372,"A new mechanical device with an improved design aiming at continuously controlling P  has been commercialized (PressureEasy®, Smiths medical).",Background,[80743],[4426],[4568],[False],[0],[0],[False],['0']
20794,PMC4461648,13373,The advantages of using such device are its small size and lower cost compared with other devices.,Background,[80750],[4569],[4667],[False],[0],[0],[False],['0']
20795,PMC4461648,13374,"However, to our knowledge, no study has evaluated the efficiency of this device in controlling P .",Background,[80757],[4668],[4766],[False],[0],[0],[False],['0']
20796,PMC4461648,13375,"Therefore, we conducted this prospective randomized cross-over study to determine the efficiency of this device in continuously controlling P .",Background,[80764],[4767],[4910],[False],[0],[0],[False],['0']
20797,PMC4461648,13376,"Our hypothesis was that this mechanical device would allow significant reduction of time spent with underinflation or overinflation of P , compared with routine care, using a manual manometer.",Background,[80771],[4911],[5103],[False],[0],[0],[False],['0']
20798,PMC4461648,13377,Methods,Methods,[80778],[5104],[5112],[False],[0],[0],[False],['0']
20799,PMC4461648,13378,Ethical aspects,Methods|Ethical aspects,[80785],[5113],[5128],[False],[0],[0],[False],['0']
20800,PMC4461648,13379,"This prospective randomized controlled study was performed in a 16-bed ICU of the teaching hospital of Sabadell (Spain), from April 2014 to July 2014.",Methods|Ethical aspects,[80792],[5129],[5279],[False],[0],[0],[False],['0']
20801,PMC4461648,13380,The institutional review board of the Parc Tauli University Hospital approved the study.,Methods|Ethical aspects,[80799],[5280],[5368],[False],[0],[0],[False],['0']
20802,PMC4461648,13381,Written consent was obtained from the patients or from their next of kin (ClinicalTrials.gov identifier: NCT02109003 http://clinicaltrials.gov/show/NCT02109003).,Methods|Ethical aspects,[80806],[5369],[5530],[False],[0],[0],[False],['0']
20803,PMC4461648,13382,Inclusion and exclusion criteria,Inclusion and exclusion criteria,[80813],[5531],[5564],[False],[0],[0],[False],['0']
20804,PMC4461648,13383,All patients older than 18 years who were intubated with a predicted duration of mechanical ventilation ≥48 h were eligible for the study.,Inclusion and exclusion criteria,[80820],[5565],[5703],[False],[0],[0],[False],['0']
20805,PMC4461648,13384,"Patients were excluded if they (1) were admitted to the ICU with a previous tracheostomy, (2) were enrolled in another study that might influence this study results, or (3) were intubated and mechanically ventilated >48 h at the time of randomization.",Inclusion and exclusion criteria,[80827],[5704],[5955],[False],[0],[0],[False],['0']
20806,PMC4461648,13385,Randomization,Randomization,[80834],[5956],[5970],[False],[0],[0],[False],['0']
20807,PMC4461648,13386,Fig.,Randomization,[80841],[5971],[5975],[False],[0],[0],[False],['0']
20808,PMC4461648,13387,1 The PressureEasy® device.,Randomization,[80848],[5976],[6003],[False],[0],[0],[False],['0']
20809,PMC4461648,13388,"a Tracheal tube, (b) ventilator circuit, (c) PressureEasy®, and (d) external tracheal cuff.",Randomization,[80855],[6004],[6095],[False],[0],[0],[False],['0']
20810,PMC4461648,13389,Patients were randomly assigned to receive continuous control of P  with the mechanical device (PressureEasy®) (Fig.,Randomization,[80862],[6096],[6212],[False],[0],[0],[False],['0']
20811,PMC4461648,13390,"1) for 24 h, followed by discontinuous control (every 4 h) with a manual manometer (Hi-Lo Hand Pressure Gauge, Covidien, TM, Malinckrodt TM) for 24 h; or discontinuous control of P  followed by continuous control of P .",Randomization,[80869],[6213],[6432],[False],[0],[0],[False],['0']
20812,PMC4461648,13391,The target of P  was 25 cmH O during the two periods.,Randomization,[80876],[6433],[6486],[False],[0],[0],[False],['0']
20813,PMC4461648,13392,Randomization was performed using a computer-generated random assignment list in balanced blocs of four.,Randomization,[80883],[6487],[6591],[False],[0],[0],[False],['0']
20814,PMC4461648,13393,Treatment assignments were contained in sealed opaque envelopes sequentially numbered.,Randomization,[80890],[6592],[6678],[False],[0],[0],[False],['0']
20815,PMC4461648,13394,"PressureEasy® is a single-patient use device, designed to continuously monitor tracheal P .",Randomization,[80897],[6679],[6770],[False],[0],[0],[False],['0']
20816,PMC4461648,13395,Its indicator window signals that P  is maintained between 20 and 30 cmH O.,Randomization,[80904],[6771],[6846],[False],[0],[0],[False],['0']
20817,PMC4461648,13396,"In addition, the airway pressure auto-feedback feature boosts P  to ensure proper sealing when high pressures are used during ventilation.",Randomization,[80911],[6847],[6985],[False],[0],[0],[False],['0']
20818,PMC4461648,13397,A pressure feedback line is designed to eliminate cuff leaks at peak inspiratory pressure.,Randomization,[80918],[6986],[7076],[False],[0],[0],[False],['0']
20819,PMC4461648,13398,Outcome measurement,Outcome measurement,[80925],[7077],[7097],[False],[0],[0],[False],['0']
20820,PMC4461648,13399,Fig.,Outcome measurement,[80932],[7098],[7102],[False],[0],[0],[False],['0']
20821,PMC4461648,13400,"2 Description of connections between pressure transducers, ventilator, and tracheal tube.",Outcome measurement,[80939],[7103],[7192],[False],[0],[0],[False],['0']
20822,PMC4461648,13401,"a Tracheal tube, (b) connection between external cuff and the three-way stopcock, (c) ventilator, (d) three-way stopcock, (e) PressureEasy® device or manometer, (f) pressure transducers connected to the ventilator and to tracheal cuff, and (g) laptop.",Outcome measurement,[80946],[7193],[7444],[False],[0],[0],[False],['0']
20823,PMC4461648,13402,"In order to determine the percentage of patients with underinflation and overinflation of tracheal cuff and the duration of these episodes, the P  and the airway pressure were continuously recorded at a digitizing frequency of 100 Hz for 48 h (Physiotrace®; Estaris, Lille, France) [25], including 24 h of continuous control of P  using the mechanical device and 24 h of manual control of P  using the manometer.",Outcome measurement,[80953],[7445],[7857],[False],[0],[0],[False],['0']
20824,PMC4461648,13403,"The connection between the pressure transducer and the tracheal cuff was identical in the two study periods, with a three-way stopcock of which the third port was either connected to the mechanical device or closed and connected to the manometer every 4 h (Fig.",Outcome measurement,[80960],[7858],[8119],[False],[0],[0],[False],['0']
20825,PMC4461648,13404,2).,Outcome measurement,[80967],[8120],[8123],[False],[0],[0],[False],['0']
20826,PMC4461648,13405,"A second pressure transducer was connected to the heat and moisture exchanger, in order to record respiratory pressure.",Outcome measurement,[80974],[8124],[8243],[False],[0],[0],[False],['0']
20827,PMC4461648,13406,"Pressure transducers were connected to a laptop, in order to continuously transfer pressure-time curves and mean values.",Outcome measurement,[80981],[8244],[8364],[False],[0],[0],[False],['0']
20828,PMC4461648,13407,"Connections were checked every 4 h. The engineer who analyzed the data (JDJ), using the same program, was blinded to the randomization order.",Outcome measurement,[80988],[8365],[8506],[False],[0],[0],[False],['0']
20829,PMC4461648,13408,Study population,Study population,[80995],[8507],[8524],[False],[0],[0],[False],['0']
20830,PMC4461648,13409,"All the patients were intubated with a high-volume low-pressure PVC-cuffed tracheal tube with continuous subglottic secretion drainage (TaperGuard Evac, Covidien, Mallinckrodt) and were included within the first 48 h of intubation.",Study population,[81002],[8525],[8756],[False],[0],[0],[False],['0']
20831,PMC4461648,13410,"Tracheal tube size was 8 and 7.5 in men and women, respectively.",Study population,[81009],[8757],[8821],[False],[0],[0],[False],['0']
20832,PMC4461648,13411,"During the manometer period, nurses adjusted P  every 4 h. Tracheal suctioning was performed six times a day or more frequently if clinically indicated.",Study population,[81016],[8822],[8974],[False],[0],[0],[False],['0']
20833,PMC4461648,13412,Other definitions,Other definitions,[81023],[8975],[8993],[False],[0],[0],[False],['0']
20834,PMC4461648,13413,Underinflation of tracheal cuff was defined as P  <20 cmH 0 for >5 min over the 24-h period of recording.,Other definitions,[81030],[8994],[9099],[False],[0],[0],[False],['0']
20835,PMC4461648,13414,Overinflation of tracheal cuff was defined as P  >30 cmH 0 for >5 min over the 24-h period of recording [14].,Other definitions,[81037],[9100],[9209],[False],[0],[0],[False],['0']
20836,PMC4461648,13415,"The primary objective was to determine the efficiency of the mechanical device in reducing the percentage of time spent with underinflation or overinflation of tracheal cuff, compared with routine care using a manometer.",Other definitions,[81044],[9210],[9430],[False],[0],[0],[False],['0']
20837,PMC4461648,13416,"The secondary objective was to determine the efficiency of the mechanical device in reducing the percentage of patients with underinflation or overinflation of tracheal cuff, compared with routine care.",Other definitions,[81051],[9431],[9633],[False],[0],[0],[False],['0']
20838,PMC4461648,13417,The coefficient of variation of P  was calculated as standard deviation/mean P  × 100.,Other definitions,[81058],[9634],[9720],[False],[0],[0],[False],['0']
20839,PMC4461648,13418,Statistical analyses,Statistical analyses,[81065],[9721],[9742],[False],[0],[0],[False],['0']
20840,PMC4461648,13419,Sample size calculation,Statistical analyses|Sample size calculation,[81072],[9743],[9766],[False],[0],[0],[False],['0']
20841,PMC4461648,13420,"Based on unpublished preliminary results, the mean percentage of time spent with underinflation or overinflation of tracheal cuff was 30 % (SD 20 %) in patients intubated with a PVC-cuffed tracheal tube receiving routine care of P  using a manual manometer.",Statistical analyses|Sample size calculation,[81079],[9767],[10024],[False],[0],[0],[False],['0']
20842,PMC4461648,13421,The expected mean percentage of time with underinflation or overinflation of tracheal cuff using the mechanical device was 10 % (expected difference of 20 %).,Statistical analyses|Sample size calculation,[81086],[10025],[10183],[False],[0],[0],[False],['0']
20843,PMC4461648,13422,"Considering a power of 90 % and an alpha risk of 5 %, the inclusion of 22 patients was required in a parallel-group design.",Statistical analyses|Sample size calculation,[81093],[10184],[10307],[False],[0],[0],[False],['0']
20844,PMC4461648,13423,"However, when we took into account the cross-over design, the number of patients to include was 18.",Statistical analyses|Sample size calculation,[81100],[10308],[10407],[False],[0],[0],[False],['0']
20845,PMC4461648,13424,Result analysis,Result analysis,[81107],[10408],[10424],[False],[0],[0],[False],['0']
20846,PMC4461648,13425,All analyses were performed in an intention-to-treat manner.,Result analysis,[81114],[10425],[10485],[False],[0],[0],[False],['0']
20847,PMC4461648,13426,Distribution of quantitative variables was tested using the Shapiro-Wilk test.,Result analysis,[81121],[10486],[10564],[False],[0],[0],[False],['0']
20848,PMC4461648,13427,"Normally and nonnormally distributed variables were expressed as mean ± SD and median (25th, 75th interquartile), respectively.",Result analysis,[81128],[10565],[10692],[False],[0],[0],[False],['0']
20849,PMC4461648,13428,The difference between the two groups was considered as significant if p < 0.05.,Result analysis,[81135],[10693],[10773],[False],[0],[0],[False],['0']
20850,PMC4461648,13429,"McNemar and Wilcoxon tests were used to compare qualitative and quantitative variables between the two 24-h periods, respectively.",Result analysis,[81142],[10774],[10904],[False],[0],[0],[False],['0']
20851,PMC4461648,13430,"We calculated the median (25th, 75th interquartile) value of mean airway pressure in all patients and considered patients with airway pressure >75th interquartile as patients with high airway pressure.",Result analysis,[81149],[10905],[11106],[False],[0],[0],[False],['0']
20852,PMC4461648,13431,"In order to determine the impact of high airway pressure on the efficiency of the mechanical device, we repeated all statistical analyses after exclusion of patients with high airway pressure.",Result analysis,[81156],[11107],[11299],[False],[0],[0],[False],['0']
20853,PMC4461648,13432,Results,Results,[81163],[11300],[11308],[False],[0],[0],[False],['0']
20854,PMC4461648,13433,Patient characteristics,Results|Patient characteristics,[81170],[11309],[11332],[False],[0],[0],[False],['0']
20855,PMC4461648,13434,Table 1 Patient characteristics during the 48 h following randomization.,Results|Patient characteristics,[81177],[11333],[11405],[False],[0],[0],[False],['0']
20856,PMC4461648,13435,Table 2 Impact of the mechanical device on tracheal cuff pressure.,Results|Patient characteristics,[81184],[11406],[11472],[False],[0],[0],[False],['0']
20857,PMC4461648,13436,Eighteen patients were included in this study.,Results|Patient characteristics,[81191],[11473],[11519],[False],[0],[0],[False],['0']
20858,PMC4461648,13437,Their mean age was 62 ± 12 years.,Results|Patient characteristics,[81198],[11520],[11553],[False],[0],[0],[False],['0']
20859,PMC4461648,13438,"At ICU admission, SAPS II and SOFA scores were 51 ± 14 and 7.7 ± 3.1, respectively.",Results|Patient characteristics,[81205],[11554],[11637],[False],[0],[0],[False],['0']
20860,PMC4461648,13439,"Duration of mechanical ventilation and ICU stay were 25 ± 18 days and 33 ± 21 days, respectively.",Results|Patient characteristics,[81212],[11638],[11735],[False],[0],[0],[False],['0']
20861,PMC4461648,13440,No significant difference was found between the two study periods regarding the percentage of patients receiving sedation or neuromuscular-blocking agents.,Results|Patient characteristics,[81219],[11736],[11891],[False],[0],[0],[False],['0']
20862,PMC4461648,13441,"Glasgow Coma score, SOFA score, and PEEP were also similar during the two periods (Table 1).",Results|Patient characteristics,[81226],[11892],[11984],[False],[0],[0],[False],['0']
20863,PMC4461648,13442,All patients received assist-control ventilation during the recording period.,Results|Patient characteristics,[81233],[11985],[12062],[False],[0],[0],[False],['0']
20864,PMC4461648,13443,No significant difference was found in mean airway pressure between the two study periods (Table 2.),Results|Patient characteristics,[81240],[12063],[12163],[False],[0],[0],[False],['0']
20865,PMC4461648,13444,Impact of the mechanical device on Pcuff,Impact of the mechanical device on Pcuff,[81247],[12164],[12205],[False],[0],[0],[False],['0']
20866,PMC4461648,13445,"No significant difference was found in mean P , percentage of time spent with P  between 20 and 30 cmH O, percentage of time spent with P  <20 cmH O, or coefficient of variation of P .",Impact of the mechanical device on Pcuff,[81254],[12206],[12390],[False],[0],[0],[False],['0']
20867,PMC4461648,13446,The percentage of time spent with P  >30 cmH O was significantly higher during continuous control compared with routine care of tracheal cuff (Table 2).,Impact of the mechanical device on Pcuff,[81261],[12391],[12543],[False],[0],[0],[False],['0']
20868,PMC4461648,13447,"No significant difference was found in the percentage of patients with P  20–30 cmH O, P  <20 cmH O, or P  >30 cmH O during continuous control of P  and routine care (Table 2).",Impact of the mechanical device on Pcuff,[81268],[12544],[12720],[False],[0],[0],[False],['0']
20869,PMC4461648,13448,"No significant difference was found in the number of underinflation episodes between continuous control and routine care periods (median (IQR) 0 (0, 5) versus 2 (0, 7), p = 0.733).",Impact of the mechanical device on Pcuff,[81275],[12721],[12901],[False],[0],[0],[False],['0']
20870,PMC4461648,13449,Subgroup analysis,Subgroup analysis,[81282],[12902],[12920],[False],[0],[0],[False],['0']
20871,PMC4461648,13450,"After exclusion of the four patients with high mean airway pressure (>17 cmH O), no significant difference was found in mean P  (26 (18, 28) versus 22 (19, 27) cmH O, p = 0.177), percentage of time spent with P  between 20 and 30 cmH O (50 (24, 58) versus 53 (24, 71), p = 0.124), percentage of time spent with P  <20 cmH O (16 (2, 51) versus 35 (9, 51), p = 0.3), or coefficient of variation of P  (15 (10, 22) versus 16 (10, 24), p = 0.363).",Subgroup analysis,[81289],[12921],[13364],[False],[0],[0],[False],['0']
20872,PMC4461648,13451,"The percentage of time spent with P  >30 cmH O was still significantly higher during continuous control compared with routine care of tracheal cuff (31 (18, 42) versus 8 (3, 20), p = 0.006).",Subgroup analysis,[81296],[13365],[13555],[False],[0],[0],[False],['0']
20873,PMC4461648,13452,Discussion,Discussion,[81303],[13556],[13567],[False],[0],[0],[False],['0']
20874,PMC4461648,13453,"The results of our study suggest that PressureEasy® was not more efficient in maintaining P  within the recommended range (20–30 cmH O) than routine care of tracheal cuff using a manometer every 4 h. No significant difference was found between continuous control of P  using the mechanical device and routine care regarding P , percentage of time spent with underinflation of tracheal cuff, and coefficient of variation of P .",Discussion,[81310],[13568],[13994],[False],[0],[0],[False],['0']
20875,PMC4461648,13454,"However, the percentage of time spent with overinflation of tracheal cuff was significantly higher during continuous control compared with routine care.",Discussion,[81317],[13995],[14147],[False],[0],[0],[False],['0']
20876,PMC4461648,13455,"One potential explanation for this result is the high frequency of P  control using the manometer, i.e., every 4 h, during routine care.",Discussion,[81324],[14148],[14284],[False],[0],[0],[False],['0']
20877,PMC4461648,13456,A recent prospective study performed in a cohort of 102 patients receiving invasive mechanical ventilation and manual control of P  using a manometer every 8 h found a lower percentage of time (18 %) spent within the target range [14].,Discussion,[81331],[14285],[14520],[False],[0],[0],[False],['0']
20878,PMC4461648,13457,"However, this explanation is unlikely because our results are in agreement with those of another recent trial, in which P  was controlled using a manometer every 8 h [13].",Discussion,[81338],[14521],[14692],[False],[0],[0],[False],['0']
20879,PMC4461648,13458,"Further, previous studies showed that each time a manometer is connected to the tracheal cuff, a sudden drop of P  is observed [22, 26].",Discussion,[81345],[14693],[14829],[False],[0],[0],[False],['0']
20880,PMC4461648,13459,This is probably related to transient underinflation of tracheal cuff and might promote microaspiration of contaminated secretions [27].,Discussion,[81352],[14830],[14966],[False],[0],[0],[False],['0']
20881,PMC4461648,13460,"Therefore, controlling P  more frequently in order to maintain it within the target range could probably not be recommended.",Discussion,[81359],[14967],[15091],[False],[0],[0],[False],['0']
20882,PMC4461648,13461,"In spite of strictly applying instructions for user of the mechanical device, the percentage of time spent within the target range of P  was only 34 %.",Discussion,[81366],[15092],[15243],[False],[0],[0],[False],['0']
20883,PMC4461648,13462,"Previous studies using different devices to continuously control P  reported better performances and a percentage within the targeted range >90 % [19, 20, 22, 28].",Discussion,[81373],[15244],[15407],[False],[0],[0],[False],['0']
20884,PMC4461648,13463,Another potential explanation for the low efficiency of the device is the mechanism of P  control.,Discussion,[81380],[15408],[15506],[False],[0],[0],[False],['0']
20885,PMC4461648,13464,This device uses the respiratory flow to inflate tracheal cuff during inspiration.,Discussion,[81387],[15507],[15589],[False],[0],[0],[False],['0']
20886,PMC4461648,13465,"Therefore, it is dependent on respiratory flow and airway pressure that may widely vary in critically ill patients.",Discussion,[81394],[15590],[15705],[False],[0],[0],[False],['0']
20887,PMC4461648,13466,"In addition, the key principle is probably an equilibrium between airway pressure and P , which means that the time constant of the system might play a role in the higher P  [29, 30].",Discussion,[81401],[15706],[15889],[False],[0],[0],[False],['0']
20888,PMC4461648,13467,"Further, the exact P  target, using the mechanical device, could not be precisely determined or modified.",Discussion,[81408],[15890],[15995],[False],[0],[0],[False],['0']
20889,PMC4461648,13468,"In order to test the hypothesis that our results could be explained by the bad performance of the device in patients with high airway pressures, we repeated all statistical analyses after exclusion of patients with the highest mean airway pressure but found similar results.",Discussion,[81415],[15996],[16270],[False],[0],[0],[False],['0']
20890,PMC4461648,13469,This might be explained by the fact that high airway pressure could have occurred during only a short period of the total recording time and the relatively small number of included patients.,Discussion,[81422],[16271],[16461],[False],[0],[0],[False],['0']
20891,PMC4461648,13470,"To our knowledge, our study is the first to evaluate the PressureEasy® mechanical device, and its results suggest that the device should not be used in critically ill patients.",Discussion,[81429],[16462],[16638],[False],[0],[0],[False],['0']
20892,PMC4461648,13471,Our study also raises the important question of why medical devices such as tracheal tubes or P  controllers could obtain the Communauté Européenne (CE) mark and be used in critically ill patients without any published clinical data proving their efficiency.,Discussion,[81436],[16639],[16897],[False],[0],[0],[False],['0']
20893,PMC4461648,13472,"Nevertheless, clinical evaluation before CE mark could be very complex and might reduce the development of new technologies.",Discussion,[81443],[16898],[17022],[False],[0],[0],[False],['0']
20894,PMC4461648,13473,No significant difference was found in coefficient of variation of P  between the two study periods.,Discussion,[81450],[17023],[17123],[False],[0],[0],[False],['0']
20895,PMC4461648,13474,"However, P  variation in study patients was relatively small and had probably no clinical impact, except in those patients with P  around 20 or 30 cmH O.",Discussion,[81457],[17124],[17277],[False],[0],[0],[False],['0']
20896,PMC4461648,13475,Some limitations of our study should be acknowledged.,Discussion,[81464],[17278],[17331],[False],[0],[0],[False],['0']
20897,PMC4461648,13476,"First, this was a single-center study.",Discussion,[81471],[17332],[17370],[True],['Unicentric'],['this was a single-center study.'],[True],['Setting']
20898,PMC4461648,13477,"All study patients received assist-control ventilation, and a high proportion of them were sedated.",Discussion,[81485],[17371],[17470],[False],[0],[0],[False],['0']
20899,PMC4461648,13478,"Therefore, our results may not be generalized to patients in other ICUs, especially to nonsedated patients receiving pressure support ventilation.",Discussion,[81493],[17471],[17617],[True],['Generalization'],['results may not be generalized to patients in other ICUs'],[True],['Generalization']
20900,PMC4461648,13479,"Second, the number of studied patients was relatively small.",Discussion,[81508],[17618],[17678],[True],['SampleSize'],['the number of studied patients was relatively small.'],[True],['UnderpoweredStudy']
20901,PMC4461648,13480,"However, P  was continuously recorded for 48 h. In addition, the number of included patients was calculated based on our hypothesis before starting the study.",Discussion,[81520],[17679],[17837],[False],[0],[0],[False],['0']
20902,PMC4461648,13481,"Third, because of the study design, namely the fact that every patient was its own control, we could not evaluate complications related to underinflation or overinflation of tracheal cuff.",Discussion,[81530],[17838],[18026],[True],['StudyDesign'],['every patient was its own control'],[True],['StudyDesign']
20903,PMC4461648,13482,"However, we think that this design is probably optimal as a first step in order to validate the device, before performing larger studies evaluating its impact on complications.",Discussion,[81541],[18027],[18203],[False],[0],[0],[False],['0']
20904,PMC4461648,13483,"Our study design allowed adjustment of patient-related confounding factors, such as tracheal anatomy, tracheal tube size, and airway pressure.",Discussion,[81548],[18204],[18346],[False],[0],[0],[False],['0']
20905,PMC4461648,13484,"Fourth, we excluded patients who could not be included during the first 48 h of their invasive mechanical ventilation.",Discussion,[81559],[18347],[18465],[True],['VerySpecificPopulation'],['we excluded patients who could not be included during the first 48\xa0h of their invasive mechanical ventilation'],[True],['Population']
20906,PMC4461648,13485,This exclusion criterion was selected because duration of intubation was identified as a risk factor for underinflation of tracheal cuff [14].,Discussion,[81569],[18466],[18608],[False],[0],[0],[False],['0']
20907,PMC4461648,13486,"Fifth, we did not collect P  values obtained manually during the routine care period and did not evaluate the relationship between manometer connection and any drop in P .",Discussion,[81581],[18609],[18780],[True],['RelevantOutcomeExcluded'],['we did not collect P  values obtained manually during the routine care period'],[True],['OutcomeMeasures']
20908,PMC4461648,13487,"However, several previous well-designed and performed studies have clearly confirmed this relationship [22, 26].",Discussion,[81590],[18781],[18893],[False],[0],[0],[False],['0']
20909,PMC4461648,13488,"Finally, Glascow Coma score was used to evaluate consciousness in study patients.",Discussion,[81597],[18894],[18975],[False],[0],[0],[False],['0']
20910,PMC4461648,13489,"However, a sedation score would have been more appropriate in sedated patients.",Discussion,[81610],[18976],[19055],[True],['ValidityOfMeasurement'],['a sedation score would have been more appropriate in sedated patients'],[True],['OutcomeMeasures']
20911,PMC4461648,13490,Conclusions,Conclusions,[81618],[19056],[19068],[False],[0],[0],[False],['0']
20912,PMC4461648,13491,"The PressureEasy® device did not demonstrate a better control of P  within the target range (20–30 cmH O), compared with routine care using a manometer every 4 h. Moreover, the percentage of time spent with overinflation of tracheal cuff was more frequent using this device compared with routine care, which might increase the risk for tracheal ischemic lesions.",Conclusions,[81625],[19069],[19431],[False],[0],[0],[False],['0']
20913,PMC4461648,13492,"Therefore, the use of this device could not be recommended in critically ill patients.",Conclusions,[81632],[19432],[19518],[False],[0],[0],[False],['0']
20914,PMC4461648,13493,Further large studies are required to confirm our results.,Conclusions,[81639],[19519],[19577],[False],[0],[0],[False],['0']
20915,PMC4461648,13494,Abbreviations,Abbreviations,[81646],[19578],[19592],[False],[0],[0],[False],['0']
20916,PMC4461648,13495,CE Communauté Européene,Abbreviations|CE Communauté Européene,[81653],[19593],[19616],[False],[0],[0],[False],['0']
20917,PMC4461648,13496,HPLV high-volume low-pressure,Abbreviations|HPLV high-volume low-pressure,[81660],[19617],[19646],[False],[0],[0],[False],['0']
20918,PMC4461648,13497,Pcuff cuff pressure,Abbreviations|Pcuff cuff pressure,[81667],[19647],[19666],[False],[0],[0],[False],['0']
20919,PMC4461648,13498,PEP positive expiratory pressure,Abbreviations|PEP positive expiratory pressure,[81674],[19667],[19699],[False],[0],[0],[False],['0']
20920,PMC4461648,13499,SAPS simplified acute physiology score,Abbreviations|SAPS simplified acute physiology score,[81681],[19700],[19738],[False],[0],[0],[False],['0']
20921,PMC4461648,13500,SOFA sequential organ failure assessment,Abbreviations|SOFA sequential organ failure assessment,[81688],[19739],[19779],[False],[0],[0],[False],['0']
20922,PMC4461648,13501,PVC polyvinyl chlorideCompeting interests,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81695],[19780],[19821],[False],[0],[0],[False],['0']
20923,PMC4461648,13502,SN is a member of the advisory board in Covidien.,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81702],[19822],[19871],[False],[0],[0],[False],['0']
20924,PMC4461648,13503,The other authors declare that they have no competing interests.Authors’ contributions,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81709],[19872],[19958],[False],[0],[0],[False],['0']
20925,PMC4461648,13504,"SN, JV, AA, and IML designed the study.",Abbreviations|PVC polyvinyl chlorideCompeting interests,[81716],[19959],[19998],[False],[0],[0],[False],['0']
20926,PMC4461648,13505,"AR and PS included the patients, performed the pressure recording, and collected the data.",Abbreviations|PVC polyvinyl chlorideCompeting interests,[81723],[19999],[20089],[False],[0],[0],[False],['0']
20927,PMC4461648,13506,JDJ performed the data analyses.,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81730],[20090],[20122],[False],[0],[0],[False],['0']
20928,PMC4461648,13507,SN and IML coordinated the study.,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81737],[20123],[20156],[False],[0],[0],[False],['0']
20929,PMC4461648,13508,SN performed the statistical analysis and drafted the manuscript.,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81744],[20157],[20222],[False],[0],[0],[False],['0']
20930,PMC4461648,13509,All authors participated in the data interpretation and read and approved the final manuscript.,Abbreviations|PVC polyvinyl chlorideCompeting interests,[81751],[20223],[20318],[False],[0],[0],[False],['0']
22529,PMC4647309,21291,Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis,Title,[128677],[35751],[203],[False],[0],[0],[False],['0']
22530,PMC4647309,21292,Background,Abstract,[128680],[204],[215],[False],[0],[0],[False],['0']
22531,PMC4647309,21293,The aim of this study was to assess the safety and the efficacy of the novel sirolimus-eluting Prolim® stent with a biodegradable polymer in the all-comers population.,Abstract,[128683],[216],[383],[False],[0],[0],[False],['0']
22532,PMC4647309,21294,Methods,Abstract,[128686],[384],[391],[False],[0],[0],[False],['0']
22533,PMC4647309,21295,We prospectively enrolled all patients with stable coronary artery disease or acute coronary syndrome treated with Prolim® stent between January and December 2013 in two interventional cardiology centers in Poland.,Abstract,[128689],[392],[606],[False],[0],[0],[False],['0']
22534,PMC4647309,21296,"Angiographic control was planned at 12 months, in which 15 % of patients (randomly chosen) underwent optical coherence tomography imaging.",Abstract,[128692],[607],[745],[False],[0],[0],[False],['0']
22535,PMC4647309,21297,"The primary end-point was the cumulative rate of cardiac death, myocardial infarction, and target lesion revascularization at 12 months.",Abstract,[128695],[746],[882],[False],[0],[0],[False],['0']
22536,PMC4647309,21298,Results,Abstract,[128698],[883],[890],[False],[0],[0],[False],['0']
22537,PMC4647309,21299,"There were 204 patients enrolled, in whom 238 Prolim® stents were deployed (1.17 stent per patient).",Abstract,[128701],[891],[991],[False],[0],[0],[False],['0']
22538,PMC4647309,21300,The mean age was 68 ± 10 years and 32.8 % were females.,Abstract,[128704],[992],[1047],[False],[0],[0],[False],['0']
22539,PMC4647309,21301,"The examined stent was implanted in 5.9 % in STEMI patients, in 21.6 % - in NSTE-ACS and in 72.5 % - in patients with stable coronary artery disease.",Abstract,[128707],[1048],[1197],[False],[0],[0],[False],['0']
22540,PMC4647309,21302,The Prolim® stent was most frequently implanted in right coronary artery (38.2 %) followed by left anterior descending artery (34.0 %).,Abstract,[128710],[1198],[1333],[False],[0],[0],[False],['0']
22541,PMC4647309,21303,"The cumulative major adverse cardiovascular events rate at 12 months was 6.9 %, and the clinically-driven target lesion revascularization rate – 5.4 %.",Abstract,[128713],[1334],[1485],[False],[0],[0],[False],['0']
22542,PMC4647309,21304,"At 12 months in quantitative coronary angiography the late lumen loss was 0.21 ± 0.18 mm, and in optical coherence tomography the mean neointima burden was 24.6 ± 8.6 %.",Abstract,[128716],[1486],[1655],[False],[0],[0],[False],['0']
22543,PMC4647309,21305,Conclusions,Abstract,[128719],[1656],[1667],[False],[0],[0],[False],['0']
22544,PMC4647309,21306,Sirolimus-eluting Prolim® stent with a biodegradable polymer is a feasible device with a very good safety profile and long-term clinical effectiveness.,Abstract,[128722],[1668],[1819],[False],[0],[0],[False],['0']
22545,PMC4647309,21307,Trial registration number,Abstract,[128725],[1820],[1846],[False],[0],[0],[False],['0']
22546,PMC4647309,21308,ClinicalTrials.gov NCT02545985.,Abstract,[128728],[1847],[1878],[False],[0],[0],[False],['0']
22547,PMC4647309,21309,Background,Background,[128731],[1879],[1890],[False],[0],[0],[False],['0']
22548,PMC4647309,21310,Drug eluting stents (DES) reduce the incidence of restenosis and thereby also the incidence of repeated revascularizations.,Background,[128734],[1891],[2014],[False],[0],[0],[False],['0']
22549,PMC4647309,21311,"Simultaneously, DES also impair proper healing and endothelialization, what might lead to the increased risk of late and very late stent thrombosis [1].",Background,[128737],[2015],[2167],[False],[0],[0],[False],['0']
22550,PMC4647309,21312,In 2003 Polish physicians and engineers created the concept of covering bare metal stents with a biodegradable polymer [2].,Background,[128740],[2168],[2291],[False],[0],[0],[False],['0']
22551,PMC4647309,21313,"This was associated with the discovery of the negative impact of permanent polymers of the first generation DES on the vessel wall, which resulted in impaired healing and endothelialization [3].",Background,[128743],[2292],[2486],[False],[0],[0],[False],['0']
22552,PMC4647309,21314,"The idea assumed that the biodegradable polymer would be absorbed from the stent surface after drug elution, and the remaining bare metal stent platform covered with neointima would not evoke further irritation to the artery wall [4].",Background,[128746],[2487],[2721],[False],[0],[0],[False],['0']
22553,PMC4647309,21315,Preclinical observations in the porcine model proved favorable vessel healing after Prolim® stent deployment [5].,Background,[128749],[2722],[2835],[False],[0],[0],[False],['0']
22554,PMC4647309,21316,The aim of this study was to assess the safety and the efficacy of Prolim® stent in the all-comers population.,Background,[128752],[2836],[2946],[False],[0],[0],[False],['0']
22555,PMC4647309,21317,Methods,Methods,[128755],[2947],[2955],[False],[0],[0],[False],['0']
22556,PMC4647309,21318,Study population and study design,Methods|Study population and study design,[128758],[2956],[2989],[False],[0],[0],[False],['0']
22557,PMC4647309,21319,"It was a prospective, single-arm, open-label clinical study, in which patients were enrolled in two invasive cardiology centers in Poland (Warsaw and Olsztyn) between January and December 2013.",Methods|Study population and study design,[128761],[2990],[3183],[False],[0],[0],[False],['0']
22558,PMC4647309,21320,The blinded data were entered into the electronic case report form by collaborating physicians in these centers.,Methods|Study population and study design,[128764],[3184],[3296],[False],[0],[0],[False],['0']
22559,PMC4647309,21321,"The inclusion criteria were: age ≥ 18 years old, stable coronary artery disease (SCAD) or acute coronary syndrome (unstable angina – UA, non-ST elevation myocardial infarction – NSTEMI or ST-elevation myocardial infarction – STEMI) and the signed informed consent.",Methods|Study population and study design,[128767],[3297],[3561],[False],[0],[0],[False],['0']
22560,PMC4647309,21322,"Main exclusion criteria were: inability to take dual antiplatelet therapy for 12 months, left ventricular ejection fraction ≤ 30 %, chronic total occlusions, and in-stent restenosis.",Methods|Study population and study design,[128770],[3562],[3744],[False],[0],[0],[False],['0']
22561,PMC4647309,21323,The Ethics Committee of the Central Clinical Hospital of the Ministry of Interior in Warsaw approved the study protocol (ClinicalTrials.gov Identifier: NCT02545985).,Methods|Study population and study design,[128773],[3745],[3910],[False],[0],[0],[False],['0']
22562,PMC4647309,21324,Study device,Methods|Study device,[128776],[3911],[3923],[False],[0],[0],[False],['0']
22563,PMC4647309,21325,Fig.,Methods|Study device,[128779],[3924],[3928],[False],[0],[0],[False],['0']
22564,PMC4647309,21326,1 The Prolim® stent.,Methods|Study device,[128782],[3929],[3949],[False],[0],[0],[False],['0']
22565,PMC4647309,21327,"a Lesion in LAD before stent implantation, b LAD directly after Prolim® 3.5 × 15 mm deployment, c LAD at 12 months after stent implantation, d OCT analysis of Prolim® stent at 12 months.",Methods|Study device,[128785],[3950],[4136],[False],[0],[0],[False],['0']
22566,PMC4647309,21328,The Prolim® stent is a balloon expandable coronary stent with RX delivery system.,Methods|Study device,[128788],[4137],[4218],[False],[0],[0],[False],['0']
22567,PMC4647309,21329,The stent platform is made of a laser-cut 316 L metallic tube with a wall thickness of 115 μm.,Methods|Study device,[128791],[4219],[4313],[False],[0],[0],[False],['0']
22568,PMC4647309,21330,This stent is characterized by a relatively high radial force (8.5 – 9 PSI).,Methods|Study device,[128794],[4314],[4390],[False],[0],[0],[False],['0']
22569,PMC4647309,21331,"The stent diameter ranges from 2.0 mm to 5.0 mm, and length - from 8 mm to 40 mm.",Methods|Study device,[128797],[4391],[4472],[False],[0],[0],[False],['0']
22570,PMC4647309,21332,"The profile of the whole implantation system, including stent, is 0.038"".",Methods|Study device,[128800],[4473],[4546],[False],[0],[0],[False],['0']
22571,PMC4647309,21333,The nominal shortening of the stent during stent expansion is low (<0.5 %).,Methods|Study device,[128803],[4547],[4622],[False],[0],[0],[False],['0']
22572,PMC4647309,21334,The Prolim® stent is covered with a structure containing a co-polymer of lactic and glycolic acids mixed with a solvent and the drug - sirolimus (1.2 μg/mm2).,Methods|Study device,[128806],[4623],[4781],[False],[0],[0],[False],['0']
22573,PMC4647309,21335,The coating degrades almost entirely within 8 weeks [5] [Fig.,Methods|Study device,[128809],[4782],[4843],[False],[0],[0],[False],['0']
22574,PMC4647309,21336,1].,Methods|Study device,[128812],[4844],[4847],[False],[0],[0],[False],['0']
22575,PMC4647309,21337,Procedure,Methods|Procedure,[128815],[4848],[4857],[False],[0],[0],[False],['0']
22576,PMC4647309,21338,Percutaneous coronary interventions (PCI) were performed according to local standards via radial or femoral access using 6 Fr or 7 Fr guiding catheters.,Methods|Procedure,[128818],[4858],[5010],[False],[0],[0],[False],['0']
22577,PMC4647309,21339,Pharmacological treatment was according to the most recent guidelines.,Methods|Procedure,[128821],[5011],[5081],[False],[0],[0],[False],['0']
22578,PMC4647309,21340,"Troponin I (TnI), creatine kinase (CK) and creatine kinase-myocardial band (CK-MB) were measured pre-procedural and after 6 h and 24 h postprocedure in all patients.",Methods|Procedure,[128824],[5082],[5247],[False],[0],[0],[False],['0']
22579,PMC4647309,21341,Periprocedural myocardial infarction (type 4a) was defined according to the third universal definition [6].,Methods|Procedure,[128827],[5248],[5355],[False],[0],[0],[False],['0']
22580,PMC4647309,21342,Follow-up,Methods|Follow-up,[128830],[5356],[5365],[False],[0],[0],[False],['0']
22581,PMC4647309,21343,"The assessment of the anginal status, data collection of adverse events, details of any subsequent coronary interventions, and the use and changes in concomitant medications were collected at 30 ± 7 days and 12 ± 0.5 months.",Methods|Follow-up,[128833],[5366],[5590],[False],[0],[0],[False],['0']
22582,PMC4647309,21344,"The angiographic control was planned at 12 months, in which 15 % of patients (randomly chosen) underwent optical coherence tomography (OCT) examination.",Methods|Follow-up,[128836],[5591],[5743],[False],[0],[0],[False],['0']
22583,PMC4647309,21345,Endpoints,Methods|Endpoints,[128839],[5744],[5753],[False],[0],[0],[False],['0']
22584,PMC4647309,21346,"The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE) consisting of cardiac death, myocardial infarction (MI) and clinically-driven target lesion revascularization (TLR).",Methods|Endpoints,[128842],[5754],[5961],[False],[0],[0],[False],['0']
22585,PMC4647309,21347,"Secondary endpoints included cardiac death, all-cause death, MI, TLR, target vessel revascularization (TVR), stent thrombosis, late lumen loss (LLL) assessed in quantitative coronary angiography (QCA), the percentage of covered struts and neointima volume and morphology characteristics assessed in OCT, as well as the device success rate.",Methods|Endpoints,[128845],[5962],[6301],[False],[0],[0],[False],['0']
22586,PMC4647309,21348,"Cardiac death included death resulting from an acute MI, sudden cardiac death, death due to heart failure and death due to cardiac procedures.",Methods|Endpoints,[128848],[6302],[6444],[False],[0],[0],[False],['0']
22587,PMC4647309,21349,All deaths were deemed cardiac unless proven otherwise.,Methods|Endpoints,[128851],[6445],[6500],[False],[0],[0],[False],['0']
22588,PMC4647309,21350,MI was defined according to third universal definition [6].,Methods|Endpoints,[128854],[6501],[6560],[False],[0],[0],[False],['0']
22589,PMC4647309,21351,Clinically-driven TLR was defined as reintervention of the target lesion due to presence of a symptomatic ≥ 50 % diameter stenosis during follow-up.,Methods|Endpoints,[128857],[6561],[6709],[False],[0],[0],[False],['0']
22590,PMC4647309,21352,TVR was defined as any revascularization of any segment of the index coronary artery.,Methods|Endpoints,[128860],[6710],[6795],[False],[0],[0],[False],['0']
22591,PMC4647309,21353,Device success was defined as successful deployment of the intended stent in the target site without a system failure.,Methods|Endpoints,[128863],[6796],[6914],[False],[0],[0],[False],['0']
22592,PMC4647309,21354,The definite stent thrombosis was defined as state with symptoms suggestive of an acute coronary syndrome and angiographic or pathologic confirmation of stent thrombosis.,Methods|Endpoints,[128866],[6915],[7085],[False],[0],[0],[False],['0']
22593,PMC4647309,21355,"The probable stent thrombsis was defined as the unexplained death within 30 days or target vessel myocardial infarction without angiographic confirmation of stent thrombosis, and the possible stent thrombosis was defined as any unexplained death after 30 days [7].",Methods|Endpoints,[128869],[7086],[7350],[False],[0],[0],[False],['0']
22594,PMC4647309,21356,Quantitative angiography analysis,Methods|Quantitative angiography analysis,[128872],[7351],[7384],[False],[0],[0],[False],['0']
22595,PMC4647309,21357,All coronary angiograms were recorded after an intracoronary administration of 200 μg of nitroglycerin.,Methods|Quantitative angiography analysis,[128875],[7385],[7488],[False],[0],[0],[False],['0']
22596,PMC4647309,21358,Two orthogonal views were chosen to visualize the target lesion.,Methods|Quantitative angiography analysis,[128878],[7489],[7553],[False],[0],[0],[False],['0']
22597,PMC4647309,21359,"A QCA analysis was performed using commercially available software (QCA-CMS version 5.0, Medis, Leiden, the Netherlands).",Methods|Quantitative angiography analysis,[128881],[7554],[7675],[False],[0],[0],[False],['0']
22598,PMC4647309,21360,Catheter calibration was used in all cases.,Methods|Quantitative angiography analysis,[128884],[7676],[7719],[False],[0],[0],[False],['0']
22599,PMC4647309,21361,"The following parameters: lesion length, reference vessel diameter, minimal lumen diameter, % diameter stenosis, acute lumen gain and LLL were calculated as described previously [8].",Methods|Quantitative angiography analysis,[128887],[7720],[7902],[False],[0],[0],[False],['0']
22600,PMC4647309,21362,The analysis was performed independently by two interventional cardiologists: TP and JB.,Methods|Quantitative angiography analysis,[128890],[7903],[7991],[False],[0],[0],[False],['0']
22601,PMC4647309,21363,Optical coherent tomography analysis,Methods|Optical coherent tomography analysis,[128893],[7992],[8028],[False],[0],[0],[False],['0']
22602,PMC4647309,21364,Time-domain OCT examinations were performed using a well validated non-occlusive technique [9].,Methods|Optical coherent tomography analysis,[128896],[8029],[8124],[False],[0],[0],[False],['0']
22603,PMC4647309,21365,"Briefly, after wiring the artery with the guidewire as described previously, the Dragon Fly catheter (LigthLab Co.) was advanced distally to the implanted stent and during continuous contrast media flush (Iodixanol, Visipaque GE Healthcare), the automatic pullback was performed.",Methods|Optical coherent tomography analysis,[128899],[8125],[8404],[False],[0],[0],[False],['0']
22604,PMC4647309,21366,The commercially available console (M2 or M3 by LigthLab Co.) was used.,Methods|Optical coherent tomography analysis,[128902],[8405],[8476],[False],[0],[0],[False],['0']
22605,PMC4647309,21367,"Optical coherence tomography images were obtained along the region of interest, which was the implanted stent plus 5 mm both proximal and distal.",Methods|Optical coherent tomography analysis,[128905],[8477],[8622],[False],[0],[0],[False],['0']
22606,PMC4647309,21368,Off-line analysis was performed after careful recalibration of acquired images along the reconstructed longitudinal segment.,Methods|Optical coherent tomography analysis,[128908],[8623],[8747],[False],[0],[0],[False],['0']
22607,PMC4647309,21369,"Calibration was obtained by adjusting the z-offset, the zero-point setting of the system.",Methods|Optical coherent tomography analysis,[128911],[8748],[8837],[False],[0],[0],[False],['0']
22608,PMC4647309,21370,The analysis was performed applying a dedicated off-line software (St Jude Medical).,Methods|Optical coherent tomography analysis,[128914],[8838],[8922],[False],[0],[0],[False],['0']
22609,PMC4647309,21371,Quantitative measurements of the minimal lumen area and minimal lumen diameter were obtained in all consecutive frames along the region of interest using semi-automated algorithm.,Methods|Optical coherent tomography analysis,[128917],[8923],[9102],[False],[0],[0],[False],['0']
22610,PMC4647309,21372,"Additionally, the mean value of all lumen area cross-sections measured inside the region was calculated.",Methods|Optical coherent tomography analysis,[128920],[9103],[9207],[False],[0],[0],[False],['0']
22611,PMC4647309,21373,"Additionally, lumen volume analysis was performed along region of interest - all measured lumen area cross-sections were summed.",Methods|Optical coherent tomography analysis,[128923],[9208],[9336],[False],[0],[0],[False],['0']
22612,PMC4647309,21374,Mean neointimal burden was calculated as the ratio of the mean neointima area to the mean stent area.,Methods|Optical coherent tomography analysis,[128926],[9337],[9438],[False],[0],[0],[False],['0']
22613,PMC4647309,21375,"Moreover, to assess stent apposition OCT analysis was performed every 0.2 mm of the stent.",Methods|Optical coherent tomography analysis,[128929],[9439],[9529],[False],[0],[0],[False],['0']
22614,PMC4647309,21376,The stent struts apposition was classified as: 1) apposed 2) protruded and 3) malapposed according to a distance length between vessel wall and center of the stent strut.,Methods|Optical coherent tomography analysis,[128932],[9530],[9700],[False],[0],[0],[False],['0']
22615,PMC4647309,21377,"If such distance was: 1) more than 130 μm, malapposition was detected, 2) in range of 20 to 130 μm, protrusion was detected.",Methods|Optical coherent tomography analysis,[128935],[9701],[9825],[False],[0],[0],[False],['0']
22616,PMC4647309,21378,"The morphology of the neointima was analyzed according to the previously validated OCT criteria, and classified as type I (thin cap neoatheroma, lipid-rich), type II (thick-cap, layered), type III (peri-strut, homogenous) and type IV (pre-existing, homogenous) [10, 11].",Methods|Optical coherent tomography analysis,[128938],[9826],[10096],[False],[0],[0],[False],['0']
22617,PMC4647309,21379,The analysis was performed independently by two interventional cardiologists: TP and JB.,Methods|Optical coherent tomography analysis,[128941],[10097],[10185],[False],[0],[0],[False],['0']
22618,PMC4647309,21380,Statistical analysis,Methods|Statistical analysis,[128944],[10186],[10206],[False],[0],[0],[False],['0']
22619,PMC4647309,21381,Continuous variables were presented as mean ± standard deviation.,Methods|Statistical analysis,[128947],[10207],[10272],[False],[0],[0],[False],['0']
22620,PMC4647309,21382,Categorical data were presented as numbers (%).,Methods|Statistical analysis,[128950],[10273],[10320],[False],[0],[0],[False],['0']
22621,PMC4647309,21383,"Continuous variables were compared using an unpaired student two-sided t test, and categorical data using the χ2 test or Fisher exact test, as appropriate.",Methods|Statistical analysis,[128953],[10321],[10476],[False],[0],[0],[False],['0']
22622,PMC4647309,21384,"If distribution was not normal (verified with the Shapiro–Wilk test), Wilcoxon signed-rank tests and Mann–Whitney U-tests were used.",Methods|Statistical analysis,[128956],[10477],[10609],[False],[0],[0],[False],['0']
22623,PMC4647309,21385,P values of < 0.05 were considered statistically significant.,Methods|Statistical analysis,[128959],[10610],[10671],[False],[0],[0],[False],['0']
22624,PMC4647309,21386,"Statistical analyses were performed using R 3.0.2 for OS (R Foundation, Vienna, Austria).",Methods|Statistical analysis,[128962],[10672],[10761],[False],[0],[0],[False],['0']
22625,PMC4647309,21387,Results,Results,[128965],[10762],[10770],[False],[0],[0],[False],['0']
22626,PMC4647309,21388,Baseline clinical and angiographic characteristics,Results|Baseline clinical and angiographic characteristics,[128968],[10771],[10821],[False],[0],[0],[False],['0']
22627,PMC4647309,21389,Table 1 Baseline clinical characteristics.,Results|Baseline clinical and angiographic characteristics,[128971],[10822],[10864],[False],[0],[0],[False],['0']
22628,PMC4647309,21390,A total of 204 patients were enrolled into this study.,Results|Baseline clinical and angiographic characteristics,[128974],[10865],[10919],[False],[0],[0],[False],['0']
22629,PMC4647309,21391,"The mean age was 68 ± 10 years, and 28.8 % of patients were women (n = 67).",Results|Baseline clinical and angiographic characteristics,[128977],[10920],[10995],[False],[0],[0],[False],['0']
22630,PMC4647309,21392,"The reasons for PCI were: symptomatic SCAD (72.5 %, n = 148) followed by NSTEMI (11.8 %, n = 24), unstable angina (9.8 %, n = 20) and STEMI (5.9 %, n = 12).",Results|Baseline clinical and angiographic characteristics,[128980],[10996],[11152],[False],[0],[0],[False],['0']
22631,PMC4647309,21393,The detailed clinical characteristic is presented in Table 1.,Results|Baseline clinical and angiographic characteristics,[128983],[11153],[11214],[False],[0],[0],[False],['0']
22632,PMC4647309,21394,Table 2 Baseline angiographic characteristics.,Results|Baseline clinical and angiographic characteristics,[128986],[11215],[11261],[False],[0],[0],[False],['0']
22633,PMC4647309,21395,"In most cases patients presented with the multivessel disease (62.3 %) and lesions of the moderate complexity (type A – 31.4 %, type B1 – 31.9 %).",Results|Baseline clinical and angiographic characteristics,[128989],[11262],[11408],[False],[0],[0],[False],['0']
22634,PMC4647309,21396,"Lesions were located most frequently in right coronary artery (38.2 %, n = 78) and in the left anterior descending artery (33.8 %, n = 69).",Results|Baseline clinical and angiographic characteristics,[128992],[11409],[11548],[False],[0],[0],[False],['0']
22635,PMC4647309,21397,In 38.8 % (n = 79) of cases lesions within coronary bifurcation were treated.,Results|Baseline clinical and angiographic characteristics,[128995],[11549],[11626],[False],[0],[0],[False],['0']
22636,PMC4647309,21398,More details are presented in Table 2.,Results|Baseline clinical and angiographic characteristics,[128998],[11627],[11665],[False],[0],[0],[False],['0']
22637,PMC4647309,21399,Procedural characteristics,Results|Procedural characteristics,[129001],[11666],[11692],[False],[0],[0],[False],['0']
22638,PMC4647309,21400,Table 3 Procedural characteristics.,Results|Procedural characteristics,[129004],[11693],[11728],[False],[0],[0],[False],['0']
22639,PMC4647309,21401,The main procedural variables are presented in Table 3.,Results|Procedural characteristics,[129007],[11729],[11784],[False],[0],[0],[False],['0']
22640,PMC4647309,21402,The device success rate was 99 %.,Results|Procedural characteristics,[129010],[11785],[11818],[False],[0],[0],[False],['0']
22641,PMC4647309,21403,"There were two delivery failures in which the stent was deformed due to heavy calcification, but did not fall from the balloon.",Results|Procedural characteristics,[129013],[11819],[11946],[False],[0],[0],[False],['0']
22642,PMC4647309,21404,After safe removal of the stent delivery system and further predilatations patients were successfully treated with the new Prolim® stent.,Results|Procedural characteristics,[129016],[11947],[12084],[False],[0],[0],[False],['0']
22643,PMC4647309,21405,"The mean nominal Prolim® stent parameters were: 3.22 ± 0.52 mm and 18.41 ± 5.41 mm, while the mean maximal implantation pressure was 15.2 ± 2.5 atm.",Results|Procedural characteristics,[129019],[12085],[12233],[False],[0],[0],[False],['0']
22644,PMC4647309,21406,On average 1.17 Prolim® stents were implanted per patient.,Results|Procedural characteristics,[129022],[12234],[12292],[False],[0],[0],[False],['0']
22645,PMC4647309,21407,"The predilatation rate was 59.8 %, while the postdilatation rate was 27.5 % (mean pressure 20.1 ± 3.7 atm).",Results|Procedural characteristics,[129025],[12293],[12400],[False],[0],[0],[False],['0']
22646,PMC4647309,21408,"Most postdilatations were performed with non-compliant balloons (49/56, 87.5 %).",Results|Procedural characteristics,[129028],[12401],[12481],[False],[0],[0],[False],['0']
22647,PMC4647309,21409,Almost all procedures were performed via the 6 F guiding catheter (99 %) and in 92.6 % - the radial access was preferred.,Results|Procedural characteristics,[129031],[12482],[12603],[False],[0],[0],[False],['0']
22648,PMC4647309,21410,There were 34 bifurcation cases (16.7 %) with the side branch diameter < 2 mm.,Results|Procedural characteristics,[129034],[12604],[12682],[False],[0],[0],[False],['0']
22649,PMC4647309,21411,"These cases were treated with provisonal T-stenting technique without protection of the side branch in 1,1,0 Medina classification.",Results|Procedural characteristics,[129037],[12683],[12814],[False],[0],[0],[False],['0']
22650,PMC4647309,21412,"Additionally, there were 45 cases (22.1 %) of bifurcation with the side branch > 2 mm.",Results|Procedural characteristics,[129040],[12815],[12901],[False],[0],[0],[False],['0']
22651,PMC4647309,21413,"In those patients provisonal T-stenting technique was used, however in 8 of them the procedure ended up with the second stent delpoyed in side branch using the T and protrude technique (TAP).",Results|Procedural characteristics,[129043],[12902],[13093],[False],[0],[0],[False],['0']
22652,PMC4647309,21414,Clinical outcomes,Results|Clinical outcomes,[129046],[13094],[13111],[False],[0],[0],[False],['0']
22653,PMC4647309,21415,There was seven (3.4 %) periprocedural MI due to distal dissection and debris embolization.,Results|Clinical outcomes,[129049],[13112],[13203],[False],[0],[0],[False],['0']
22654,PMC4647309,21416,"Additionally, there were 9 (4.4 %) patients with in-hospital increased TnI levels (max 1.6 ng/mL).",Results|Clinical outcomes,[129052],[13204],[13302],[False],[0],[0],[False],['0']
22655,PMC4647309,21417,"These were all asymptomatic, without ECG changes and did not require to repeat coronary angiography (i.e.",Results|Clinical outcomes,[129055],[13303],[13408],[False],[0],[0],[False],['0']
22656,PMC4647309,21418,they did not meet the criteria of MI type 4a).,Results|Clinical outcomes,[129058],[13409],[13455],[False],[0],[0],[False],['0']
22657,PMC4647309,21419,Table 4 Clinical results.,Results|Clinical outcomes,[129061],[13456],[13481],[False],[0],[0],[False],['0']
22658,PMC4647309,21420,The clinical follow-up at 12 months was available in all patients (Table 4).,Results|Clinical outcomes,[129064],[13482],[13558],[False],[0],[0],[False],['0']
22659,PMC4647309,21421,The cumulative incidence of MACE was 6.9 % (n = 14).,Results|Clinical outcomes,[129067],[13559],[13611],[False],[0],[0],[False],['0']
22660,PMC4647309,21422,In the observation period there was no death or stent thrombosis.,Results|Clinical outcomes,[129070],[13612],[13677],[False],[0],[0],[False],['0']
22661,PMC4647309,21423,The MI rate was 1.5 % (n = 3).,Results|Clinical outcomes,[129073],[13678],[13708],[False],[0],[0],[False],['0']
22662,PMC4647309,21424,"In detail, there were three MI cases after in-hospital period caused by one case of TLR and two cases were caused by new lesions in other coronary arteries.",Results|Clinical outcomes,[129076],[13709],[13865],[False],[0],[0],[False],['0']
22663,PMC4647309,21425,The clinically-driven TLR rate was 5.4 % (n = 11).,Results|Clinical outcomes,[129079],[13866],[13916],[False],[0],[0],[False],['0']
22664,PMC4647309,21426,"All cases were treated by PCI (plain old balloon angioplasty – 4 cases, DES – 7 cases).",Results|Clinical outcomes,[129082],[13917],[14004],[False],[0],[0],[False],['0']
22665,PMC4647309,21427,Quantitative coronary angiography and optical coherence tomography analysis,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129085],[14005],[14080],[False],[0],[0],[False],['0']
22666,PMC4647309,21428,Table 5 Quantitative coronary angiographic analysis.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129088],[14081],[14133],[False],[0],[0],[False],['0']
22667,PMC4647309,21429,The QCA data are presented in Table 5.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129091],[14134],[14172],[False],[0],[0],[False],['0']
22668,PMC4647309,21430,The immediate angiographic success rate was 100 %.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129094],[14173],[14223],[False],[0],[0],[False],['0']
22669,PMC4647309,21431,Acute lumen gain was 1.87 ± 0.41 mm.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129097],[14224],[14260],[False],[0],[0],[False],['0']
22670,PMC4647309,21432,The 12-month follow-up angiography was available in 89 patients (43.6 %).,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129100],[14261],[14334],[False],[0],[0],[False],['0']
22671,PMC4647309,21433,Late lumen loss was 0.21 ± 0.18 mm.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129103],[14335],[14370],[False],[0],[0],[False],['0']
22672,PMC4647309,21434,Table 6 Optical coherence tomography analysis at 12 months.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129106],[14371],[14430],[False],[0],[0],[False],['0']
22673,PMC4647309,21435,The OCT analysis data are presented in Table 6.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129109],[14431],[14478],[False],[0],[0],[False],['0']
22674,PMC4647309,21436,The OCT at 12 months was performed in 29 patients (14.2 %).,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129112],[14479],[14538],[False],[0],[0],[False],['0']
22675,PMC4647309,21437,After that period only 0.07 % of struts were uncovered and 0.1 % were malapposed.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129115],[14539],[14620],[False],[0],[0],[False],['0']
22676,PMC4647309,21438,"The nominal analyzed stent diameter was 3.25 ± 0.42 mm, and in OCT the stent diameter was 3.23 ± 0.38 mm.",Results|Quantitative coronary angiography and optical coherence tomography analysis,[129118],[14621],[14726],[False],[0],[0],[False],['0']
22677,PMC4647309,21439,The mean neointima burden was 24.6 ± 8.6 % and the neointima volume was 28.16 ± 15.10 mm3.,Results|Quantitative coronary angiography and optical coherence tomography analysis,[129121],[14727],[14817],[False],[0],[0],[False],['0']
22678,PMC4647309,21440,"The morphological analysis revealed that thin-cap atheroma was present only in 1 (3.4 %) case, and in the majority (82.8 %, n = 24) the neointima was homogenous with plaque presence only around the stent struts.",Results|Quantitative coronary angiography and optical coherence tomography analysis,[129124],[14818],[15029],[False],[0],[0],[False],['0']
22679,PMC4647309,21441,Discussion,Discussion,[129127],[15030],[15041],[False],[0],[0],[False],['0']
22680,PMC4647309,21442,This is the first study presenting clinical outcomes of Prolim® stent deployment in all-comers with de novo coronary lesions with the use OCT for the precise assessment of vascular healing.,Discussion,[129130],[15042],[15231],[False],[0],[0],[False],['0']
22681,PMC4647309,21443,"The main findings of this study confirmed that Prolim® stent characterized the very good performance with MACE and clinically driven TLR rates at 12 months of 6.9 % and 5.4 %, respectively.",Discussion,[129133],[15232],[15421],[False],[0],[0],[False],['0']
22682,PMC4647309,21444,"Moreover, the long-term safety was confirmed by the lack of thrombosis cases and the extremely low number of uncovered stent struts as well as by the homogenous structure of neointima in the OCT analysis.",Discussion,[129136],[15422],[15626],[False],[0],[0],[False],['0']
22683,PMC4647309,21445,The deployment of a durable polymer DES (DP-DES) is a standard of care in patients with coronary artery lesions.,Discussion,[129139],[15627],[15739],[False],[0],[0],[False],['0']
22684,PMC4647309,21446,"However, studies assessing biodegradable polymer DES (BP-DES) proved the non-inferiority to DP-DES with the expectation for the decreased inflammatory response after stent implantation and, as a consequence, for faster vessel healing [12].",Discussion,[129142],[15740],[15979],[False],[0],[0],[False],['0']
22685,PMC4647309,21447,"Moreover, sirolimus-eluting BP-DES and DP-DES showed similar results in STEMI patients [13].",Discussion,[129145],[15980],[16072],[False],[0],[0],[False],['0']
22686,PMC4647309,21448,"The Prolim® study group consisted of patients with both stable coronary artery disease as well as acute coronary syndromes, including STEMI and NSTEMI.",Discussion,[129148],[16073],[16224],[False],[0],[0],[False],['0']
22687,PMC4647309,21449,"Moreover, 3.9 % of stented lesions were located in saphenous grafts, 38.8 % - within bifurcation lesions and 36.7 % - in complex lesions (type B2/C).",Discussion,[129151],[16225],[16374],[False],[0],[0],[False],['0']
22688,PMC4647309,21450,"The primary study endpoint occurred in 6.9 % of patients (n = 14), and clinically-driven TLR rate was 5.4 % (n = 11).",Discussion,[129154],[16375],[16492],[False],[0],[0],[False],['0']
22689,PMC4647309,21451,There was no death or in-stent thrombosis.,Discussion,[129157],[16493],[16535],[False],[0],[0],[False],['0']
22690,PMC4647309,21452,These results are in line with previous studies with BP-SES implantation.,Discussion,[129160],[16536],[16609],[False],[0],[0],[False],['0']
22691,PMC4647309,21453,"In the study assessing Supralimus® stent (Sahajanand Medical Technologies, Gujarat, India) MACE rate was 0 % after one month, 6 % at 9-month follow-up and 7 % after 30 months follow-up [14].",Discussion,[129163],[16610],[16800],[False],[0],[0],[False],['0']
22692,PMC4647309,21454,Initial results of the prospective trial assessing Excel® stent (BP-SES) showed that at 12 months MACE and TLR rates were both 4 % [15].,Discussion,[129166],[16801],[16937],[False],[0],[0],[False],['0']
22693,PMC4647309,21455,"Whereas in the BIOFLOW III Registry with Orsiro® (Biotronik, Berlin, Germany) stent the TLR rate was 5.1 % [16].",Discussion,[129169],[16938],[17050],[False],[0],[0],[False],['0']
22694,PMC4647309,21456,"Worth mentioning is the BIOFLOW II trial, in which Orsiro® stent was compared with everolimus-eluting Xience® stent (MACE at 1 year SES 6.5 % versus EES 8.0 %) [17].",Discussion,[129172],[17051],[17216],[False],[0],[0],[False],['0']
22695,PMC4647309,21457,"Moreover, in the ISAR-TEST-4 study patients presenting with stable coronary disease or acute coronary syndromes undergoing DES implantation in de novo coronary lesions were randomly assigned to treatment with BP-DES (sirolimus-eluting; n = 1299) or DP-DES (n = 1304: sirolimus-eluting, Cypher® or everolimus-eluting, Xience®).",Discussion,[129175],[17217],[17543],[False],[0],[0],[False],['0']
22696,PMC4647309,21458,"BP-DES was non-inferior to DP-DES concerning the primary endpoint (13.8 % vs. 14.4 %, p = 0.66) and showed similar rates of cardiac death or MI related to the target vessel (6.3 % vs. 6.2 %, p = 0.94), TLR (8.8 % vs. 9.4 %, p = 0.58), and stent thrombosis (definite/probable: 1.0 % vs. 1.5 %, p = 0.29) [18].",Discussion,[129178],[17544],[17852],[False],[0],[0],[False],['0']
22697,PMC4647309,21459,At 12 months the late lumen loss of the Prolim® stent was 0.21 ± 0.18 mm.,Discussion,[129181],[17853],[17926],[False],[0],[0],[False],['0']
22698,PMC4647309,21460,"Worth mentioning is ISAR-TEST3 study, in which patients with de novo coronary lesions were randomly assigned to receive a BP-DES, a polymer-free DES stent or DP-DES (Cypher®).",Discussion,[129184],[17927],[18102],[False],[0],[0],[False],['0']
22699,PMC4647309,21461,"The mean late lumen loss at 6–8-month follow-up was 0.17 ± 0.45 mm in the BP stent group, 0.23 ± 0.46 mm in the Cypher® cohort, and 0.47 ± 0.56 mm in the polymer-free stent group [19].",Discussion,[129187],[18103],[18287],[False],[0],[0],[False],['0']
22700,PMC4647309,21462,"In previously mentioned studies the late lumen loss values were as followed: for Excel® stent - 0.12 ± 0.34 mm, for Orsiro® stent – 0.10 ± 0.32 mm, for Xience® stent – 0.11 ± 0.29 mm, and for Supralimus® stent – 0.09 ± 0.37 mm [14, 15, 17].",Discussion,[129190],[18288],[18528],[False],[0],[0],[False],['0']
22701,PMC4647309,21463,"Simultaneously one must underline that the Prolim® stent is a relatively thick-strut DES, which platform is made of stainless steel 316 L (115 μm).",Discussion,[129193],[18529],[18676],[False],[0],[0],[False],['0']
22702,PMC4647309,21464,And as earlier studies showed this might be associated with worse clinical and angiographic outcomes both in BMS as well as in DES [20–22].,Discussion,[129196],[18677],[18816],[False],[0],[0],[False],['0']
22703,PMC4647309,21465,"However, in our study higher LLL value did not translate into worse clinical outcomes.",Discussion,[129199],[18817],[18903],[False],[0],[0],[False],['0']
22704,PMC4647309,21466,The safety profile of the stent is confirmed by a high rate of the device success (99 %) and a low rate of periprocedural complications.,Discussion,[129202],[18904],[19040],[False],[0],[0],[False],['0']
22705,PMC4647309,21467,The rate of MI type 4a of 3.4 % might have been associated with the fact that certain implantations were performed in lesions located within bifurcations or venous grafts.,Discussion,[129205],[19041],[19212],[False],[0],[0],[False],['0']
22706,PMC4647309,21468,"Worth mentioning is the fact that despite the relative small stent cells size (for Prolim® stent of 3 mm in diameter, the maximal diameter of the expanded stent cell is 1.8 mm), the side branch occlusion was not nearly (0.98 %) observed.",Discussion,[129208],[19213],[19450],[False],[0],[0],[False],['0']
22707,PMC4647309,21469,The second issue associated with safety is the rate of thrombosis.,Discussion,[129211],[19451],[19517],[False],[0],[0],[False],['0']
22708,PMC4647309,21470,In case of Prolim® stent there was no early or late in-stent thrombosis.,Discussion,[129214],[19518],[19590],[False],[0],[0],[False],['0']
22709,PMC4647309,21471,"Presently, stent thrombosis in second or third generation stents is a rare clinical scenario [23].",Discussion,[129217],[19591],[19689],[False],[0],[0],[False],['0']
22710,PMC4647309,21472,"Also, as confirmed in several meta-analyses BP-DES compared with DP-DES are associated with a lower rate of very late stent thrombosis and an equivalent risk of MACE [24, 25].",Discussion,[129220],[19690],[19865],[False],[0],[0],[False],['0']
22711,PMC4647309,21473,"This probably might be associated with the fact that over time, the drug-coated polymers of BP-DES can gradually degrade into completely harmless CO  and H O molecules that are excreted from a patient’s body.",Discussion,[129223],[19866],[20074],[False],[0],[0],[False],['0']
22712,PMC4647309,21474,"In this manner, a BP- DES can completely transform into a BMS following a slow, controlled drug release.",Discussion,[129226],[20075],[20179],[False],[0],[0],[False],['0']
22713,PMC4647309,21475,"Thus, comparing to DP-DES, BP-DES can reduce drug-induced delays in vascular endothelialization and inflammatory responses of local vessel walls caused by the presence of a permanent polymer, thereby achieving the dual purpose of preventing both in-stent restenosis and late stent thrombosis [26].",Discussion,[129229],[20180],[20477],[False],[0],[0],[False],['0']
22714,PMC4647309,21476,Safety is always the major concern in a novel DES.,Discussion,[129232],[20478],[20528],[False],[0],[0],[False],['0']
22715,PMC4647309,21477,Initial OCT studies reported that BP-SES characterized faster neointima coverage comparing with durable polymer SES [27].,Discussion,[129235],[20529],[20650],[False],[0],[0],[False],['0']
22716,PMC4647309,21478,"Therefore, we performed an OCT subgroup analysis to better understand the endothelialization process over time.",Discussion,[129238],[20651],[20762],[False],[0],[0],[False],['0']
22717,PMC4647309,21479,We found almost complete vessel healing with 99.3 % stent strut coverage 12 months after the index procedure.,Discussion,[129241],[20763],[20872],[False],[0],[0],[False],['0']
22718,PMC4647309,21480,"This was superior to the 96.5 % coverage rate of everolimus-eluting stent Xience V® (Abbott Vascular, Santa Clara, CA) and the 93.5 % coverage rate of the zotarolimus-eluting stent Resolute Integrity® (Medtronic Inc., Santa Rosa, CA) in the 13-month OCT substudy of the RESOLUTE All Comers trial [28].",Discussion,[129244],[20873],[21174],[False],[0],[0],[False],['0']
22719,PMC4647309,21481,"Also, this was in line with an OCT substudy of LEADERS trial, in which BP-DES characterized a more complete stent coverage (99.4 %) as compared with DP-DES (97.9 %) at 9 months follow-up [29].",Discussion,[129247],[21175],[21367],[False],[0],[0],[False],['0']
22720,PMC4647309,21482,"Also, the RUTTS score (Ratio of Uncovered to Total Stent Struts Per Cross Section) indicated very good healing (RUTTS ≤ 30 % = 100 %).",Discussion,[129250],[21368],[21502],[False],[0],[0],[False],['0']
22721,PMC4647309,21483,This is crucial since RUTTS score is a useful predictor for late stent thrombosis [30].,Discussion,[129253],[21503],[21590],[False],[0],[0],[False],['0']
22722,PMC4647309,21484,"Moreover, no thrombi were detected under OCT inspection.",Discussion,[129256],[21591],[21647],[False],[0],[0],[False],['0']
22723,PMC4647309,21485,"However, this excellent strut tissue coverage might have been achieved at the price of excessive neointimal growth.",Discussion,[129259],[21648],[21763],[False],[0],[0],[False],['0']
22724,PMC4647309,21486,In OCT analysis mean neointima volume was 28.16 ± 15.10 mm3 and mean neointima burden was 24.6 ± 8.6 %.,Discussion,[129262],[21764],[21867],[False],[0],[0],[False],['0']
22725,PMC4647309,21487,"These findings correlated with mean neointimal area per section of 2.17 ± 1.37 mm2 that was thicker as compared with that observed in BP-DES in paper by Davlouros (0.4 mm2) or in NOBORI stent (biodegradable polymer, biolimus-eluting stent, 0.5 mm2) [31, 32].",Discussion,[129265],[21868],[22126],[False],[0],[0],[False],['0']
22726,PMC4647309,21488,"However, recently published STACCATO trail showed in OCT a significantly higher percentage of uncovered struts in the BioMatrix BES stent compared with the XIENCE EES at nine-month follow-up.",Discussion,[129268],[22127],[22318],[False],[0],[0],[False],['0']
22727,PMC4647309,21489,This study presented the opposite findings and did not support a preferential use of stents with biodegradable polymer-based biolimus elution to reduce the risk for stent thrombosis [33].,Discussion,[129271],[22319],[22506],[False],[0],[0],[False],['0']
22728,PMC4647309,21490,"Ultimately, OCT results provided the additional insight in the characteristics of neointima formation in BP-DES at 12 months after its implantation.",Discussion,[129274],[22507],[22655],[False],[0],[0],[False],['0']
22729,PMC4647309,21491,"In most cases homogenous peristrut or preexisting atheroma (82.8 %, n = 24) was observed, and only in 4 (13.8 %) cases there was layered neoatheroslerosis, and in 1 (3.4 %) case there was a heterogenous, thin-cap neoatheroma.",Discussion,[129277],[22656],[22881],[False],[0],[0],[False],['0']
22730,PMC4647309,21492,"These data are crucial since the homogeneous neointima pattern correlated in earlier reports with a high proportion of connective tissue and smooth muscle cells in histopathology indicating favorable vessel healing, whereas, heterogenous neointima was found to correlate with higher presence of fibrin as compared to homogenous one and was associated with poorer clinical outcomes.",Discussion,[129280],[22882],[23263],[False],[0],[0],[False],['0']
22731,PMC4647309,21493,"Also the layered neointima corresponded with peristrut inflammation, and a small proportion of layered neointima suggested a lower inflammatory response to BP-DES as compared with DP-DES [34, 35].",Discussion,[129283],[23264],[23460],[False],[0],[0],[False],['0']
22732,PMC4647309,21494,"However, one must remember that OCT imaging is not as good as fractional flow reserve measurements in predicting the significance of the coronary lesion [36].",Discussion,[129286],[23461],[23619],[False],[0],[0],[False],['0']
22733,PMC4647309,21495,"Clinical results of our study have proved the safe profile of healing process after Prolim® stent implantation and indirectly have confirmed that similarly to other trials with BP-DES this particular stent does not require a prolonged dual antiplatelet therapy since it increases the risk of bleeding, and might be associated with adverse cardiac events at 1-year follow-up [37].",Discussion,[129289],[23620],[23999],[False],[0],[0],[False],['0']
22734,PMC4647309,21496,Study limitations,Study limitations,[129292],[24000],[24018],[False],[0],[0],[False],['0']
22735,PMC4647309,21497,This registry has several limitations that should be acknowledged.,Study limitations,[129295],[24019],[24085],[False],[0],[0],[False],['0']
22736,PMC4647309,21498,First of all the sample size was relatively small and no sample size calculation was performed.,Study limitations,"[129299, 129300]","[24086, 24086]","[24181, 24181]","[True, True]","['SampleSize', 'StatisticalAnalysis']","['the sample size was relatively small', 'no sample size calculation was performed']","[True, True]","['StatisticalAnalysis', 'UnderpoweredStudy']"
22737,PMC4647309,21499,Other limitations of this study are its non-randomized manner and all known drawbacks of registry studies.,Study limitations,[129301],[24182],[24288],[True],['Randomization'],['its non-randomized manner'],[True],['Randomization']
22738,PMC4647309,21500,The study was based mainly on clinical follow-up and control coronary angiography was performed in half of patients therefore some Prolim® stent failures might have been missed.,Study limitations,[129304],[24289],[24466],[False],[0],[0],[False],['0']
22739,PMC4647309,21501,"However, despite this it was not restricted only to symptomatic patients and in addition a representative part was supplemented with OCT analysis.",Study limitations,[129307],[24467],[24613],[False],[0],[0],[False],['0']
22740,PMC4647309,21502,Conclusions,Conclusions,[129310],[24614],[24626],[False],[0],[0],[False],['0']
22741,PMC4647309,21503,Sirolimus-eluting Prolim® stent with a biodegradable polymer is a feasible device with a very good safety profile and long-term clinical effectiveness.,Conclusions,[129313],[24627],[24778],[False],[0],[0],[False],['0']
22742,PMC4647309,21504,The OCT analysis showed excellent vessel healing with homogenous neointima proliferation.,Conclusions,[129316],[24779],[24868],[False],[0],[0],[False],['0']
22743,PMC4647309,21505,(ClinicalTrials.gov identifier: NCT02545985),Conclusions,[129319],[24869],[24913],[False],[0],[0],[False],['0']
22744,PMC4647309,21506,Abbreviations,Abbreviations,[129322],[24914],[24928],[False],[0],[0],[False],['0']
22745,PMC4647309,21507,ACS Acute coronary syndrome,Abbreviations|ACS Acute coronary syndrome,[129325],[24929],[24956],[False],[0],[0],[False],['0']
22746,PMC4647309,21508,CK Creatine kinase,Abbreviations|CK Creatine kinase,[129328],[24957],[24975],[False],[0],[0],[False],['0']
22747,PMC4647309,21509,CK-MB Ceatine kinase myocardial band,Abbreviations|CK-MB Ceatine kinase myocardial band,[129331],[24976],[25012],[False],[0],[0],[False],['0']
22748,PMC4647309,21510,BP-DES Biodegradable polymer drug eluting stent,Abbreviations|BP-DES Biodegradable polymer drug eluting stent,[129334],[25013],[25060],[False],[0],[0],[False],['0']
22749,PMC4647309,21511,DES Drug eluting stent,Abbreviations|DES Drug eluting stent,[129337],[25061],[25083],[False],[0],[0],[False],['0']
22750,PMC4647309,21512,DP-DES Durable polimer drug eluting stent,Abbreviations|DES Drug eluting stent,[129340],[25084],[25125],[False],[0],[0],[False],['0']
22751,PMC4647309,21513,LLL Late lumen loss,Abbreviations|LLL Late lumen loss,[129343],[25126],[25145],[False],[0],[0],[False],['0']
22752,PMC4647309,21514,MACE Major cardiovascular adverse events,Abbreviations|MACE Major cardiovascular adverse events,[129346],[25146],[25186],[False],[0],[0],[False],['0']
22753,PMC4647309,21515,MI Myocardial infarction,Abbreviations|MI Myocardial infarction,[129349],[25187],[25211],[False],[0],[0],[False],['0']
22754,PMC4647309,21516,NSTEMI non-ST elevation myocardial infarction,Abbreviations|MI Myocardial infarction,[129352],[25212],[25257],[False],[0],[0],[False],['0']
22755,PMC4647309,21517,OCT Optical coherence tomography,Abbreviations|OCT Optical coherence tomography,[129355],[25258],[25290],[False],[0],[0],[False],['0']
22756,PMC4647309,21518,QCA Quantitative coronary angiography,Abbreviations|QCA Quantitative coronary angiography,[129358],[25291],[25328],[False],[0],[0],[False],['0']
22757,PMC4647309,21519,PCI Percutaneous coronary intervention,Abbreviations|PCI Percutaneous coronary intervention,[129361],[25329],[25367],[False],[0],[0],[False],['0']
22758,PMC4647309,21520,SCAD Stable coronary artery disease,Abbreviations|SCAD Stable coronary artery disease,[129364],[25368],[25403],[False],[0],[0],[False],['0']
22759,PMC4647309,21521,STEMI Myocardial infarction,Abbreviations|STEMI Myocardial infarction,[129367],[25404],[25431],[False],[0],[0],[False],['0']
22760,PMC4647309,21522,TLR Target lesion revascularization,Abbreviations|TLR Target lesion revascularization,[129370],[25432],[25467],[False],[0],[0],[False],['0']
22761,PMC4647309,21523,TVR Target vessel revascularization,Abbreviations|TVR Target vessel revascularization,[129373],[25468],[25503],[False],[0],[0],[False],['0']
22762,PMC4647309,21524,TnI Troponin I,Abbreviations|TnI Troponin I,[129376],[25504],[25518],[False],[0],[0],[False],['0']
22763,PMC4647309,21525,UA Unstable anginaCompeting interests,Abbreviations|UA Unstable anginaCompeting interests,[129379],[25519],[25556],[False],[0],[0],[False],['0']
22764,PMC4647309,21526,"RJG was the consultant of Balton company (lectures and proctoring associated with dedicated bifurcation coronary stent BiOSS), JB, AK, TP, PS, ZS – nothing to declare.Authors’ contributions",Abbreviations|UA Unstable anginaCompeting interests,[129382],[25557],[25746],[False],[0],[0],[False],['0']
22765,PMC4647309,21527,"JB performed PCI, gathered and analyzed the data, prepared the manuscript, RJG participated in the study design and coordination, and helped to write the manuscript, AK – performed PCI, gathered data, and helped to draft the manuscript, TP, PS and ZS - performed PCI, and helped to draft the manuscript carried.",Abbreviations|UA Unstable anginaCompeting interests,[129385],[25747],[26058],[False],[0],[0],[False],['0']
22766,PMC4647309,21528,All authors read and approved the final manuscript.,Abbreviations|UA Unstable anginaCompeting interests,[129388],[26059],[26110],[False],[0],[0],[False],['0']
22973,PMC4745832,35904,Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis,Title,[210970],[31604],[126],[False],[0],[0],[False],['0']
22974,PMC4745832,35905,Background,Abstract,[210972],[127],[138],[False],[0],[0],[False],['0']
22975,PMC4745832,35906,Limited data are available on mesalamine (5-aminosalicylic acid; 5-ASA) use in pediatric ulcerative colitis (UC).,Abstract,[210974],[139],[252],[False],[0],[0],[False],['0']
22976,PMC4745832,35907,Aim,Aim,[210976],[253],[257],[False],[0],[0],[False],['0']
22977,PMC4745832,35908,"To evaluate pharmacokinetic and safety profiles of 5-ASA and metabolite acetyl-5-ASA (Ac-5-ASA) after once-daily, oral administration of multimatrix mesalamine to children and adolescents with UC.",Aim,[210978],[258],[454],[False],[0],[0],[False],['0']
22978,PMC4745832,35909,Methods,Methods,[210980],[455],[463],[False],[0],[0],[False],['0']
22979,PMC4745832,35910,"Participants (5–17 years of age; 18–82 kg, stratified by weight) with UC received multi-matrix mesalamine 30, 60, or 100 mg/kg/day once daily (to 4,800 mg/day) for 7 days.",Methods,[210982],[464],[635],[False],[0],[0],[False],['0']
22980,PMC4745832,35911,Blood samples were collected pre-dose on days 5 and 6.,Methods,[210984],[636],[690],[False],[0],[0],[False],['0']
22981,PMC4745832,35912,"On days 7 and 8, blood and urine samples were collected and safety was evaluated.",Methods,[210986],[691],[772],[False],[0],[0],[False],['0']
22982,PMC4745832,35913,5-ASA and Ac-5-ASA plasma and urine concentrations were analyzed by non-compartmental methods and used to develop a population pharmacokinetic model.,Methods,[210988],[773],[922],[False],[0],[0],[False],['0']
22983,PMC4745832,35914,Results,Results,[210990],[923],[931],[False],[0],[0],[False],['0']
22984,PMC4745832,35915,Fifty-two subjects (21 [30 mg/kg]; 22 [60 mg/kg]; 9 [100 mg/kg]) were randomized.,Results,[210992],[932],[1013],[False],[0],[0],[False],['0']
22985,PMC4745832,35916,"On day 7, systemic exposures of 5-ASA and Ac-5-ASA exhibited a dose-proportional increase between 30 and 60 mg/kg/day cohorts.",Results,[210994],[1014],[1140],[False],[0],[0],[False],['0']
22986,PMC4745832,35917,"For 30, 60, and 100 mg/kg/day doses, mean percentages of 5-ASA absorbed were 29.4%, 27.0%, and 22.1%, respectively.",Results,[210996],[1141],[1256],[False],[0],[0],[False],['0']
22987,PMC4745832,35918,"Simulated steady-state exposures and variabilities for 5-ASA and Ac-5-ASA (coefficient of variation approximately 50% and 40%–45%, respectively) were similar to those observed previously in adults at comparable doses.",Results,[210998],[1257],[1474],[False],[0],[0],[False],['0']
22988,PMC4745832,35919,Treatment-emergent adverse events were reported by ten subjects.,Results,[211000],[1475],[1539],[False],[0],[0],[False],['0']
22989,PMC4745832,35920,Events were similar among different doses and age groups with no new safety signals identified.,Results,[211002],[1540],[1635],[False],[0],[0],[False],['0']
22990,PMC4745832,35921,Conclusion,Conclusion,[211004],[1636],[1647],[False],[0],[0],[False],['0']
22991,PMC4745832,35922,Children and adolescents with UC receiving multimatrix mesalamine demonstrated 5-ASA and Ac-5-ASA pharmacokinetic profiles similar to historical adult data.,Conclusion,[211006],[1648],[1804],[False],[0],[0],[False],['0']
22992,PMC4745832,35923,Multimatrix mesalamine was well tolerated across all dose and age groups.,Conclusion,[211008],[1805],[1878],[False],[0],[0],[False],['0']
22993,PMC4745832,35924,ClinicalTrials.gov Identifier: NCT01130844.,Conclusion,[211010],[1879],[1922],[False],[0],[0],[False],['0']
22994,PMC4745832,35925,Introduction,Introduction,[211012],[1923],[1937],[False],[0],[0],[False],['0']
22995,PMC4745832,35926,"Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum distinguished by cycles of remission and relapse over the life of the subject.1,2 While the incidence of UC peaks around early adulthood, onset of the disorder can occur from early childhood through adulthood.3 UC is one of the more prevalent chronic diseases in children, with an incidence rate of 2.1 per 100,000 children within the United States.4",Introduction,[211014],[1938],[2370],[False],[0],[0],[False],['0']
22996,PMC4745832,35927,"The primary goals in UC management are induction and maintenance of remission to improve subjects’ health and quality of life.5 Oral 5-aminosalicylic acid (5-ASA) formulations, such as multimatrix mesalamine (Shire US Inc., Wayne, PA, USA), have proven effective in the induction and maintenance of UC remission,6–10 and are recommended first-line therapy for adults with active mild-to-moderate UC.5,6 5-ASAs are also commonly used as the standard of care first-line therapy in pediatric UC.",Introduction,[211016],[2371],[2863],[False],[0],[0],[False],['0']
22997,PMC4745832,35928,"However, while studies that support 5-ASA use in adult subjects with UC are abundant,11 evidence on the efficacy and safety of 5-ASA in pediatric UC subjects is less substantial, with only a few randomized, controlled clinical studies for the induction or maintenance of remission by 5-ASA in pediatric subjects having been conducted.12,13 To date, no 5-ASA product has been licensed for maintenance of remission of UC in children.",Introduction,[211018],[2864],[3295],[False],[0],[0],[False],['0']
22998,PMC4745832,35929,"As the first step in a program evaluating multimatrix mesalamine in pediatric UC, the primary objective of this randomized Phase I study (ClinicalTrials.gov Identifier: NCT01130844) was to assess the pharmacokinetics of 5-ASA and its major metabolite acetyl-5-ASA (Ac-5-ASA) after administration of once-daily multimatrix mesalamine at three different doses (30, 60, or 100 mg/kg/day) for 7 days in children and adolescents diagnosed with UC.",Introduction,[211020],[3296],[3738],[False],[0],[0],[False],['0']
22999,PMC4745832,35930,"Secondary objectives included examining the safety and tolerability of multimatrix mesalamine at these doses in children and adolescents with UC, and evaluating the extent of absorption of 5-ASA from multimatrix mesalamine at steady state.",Introduction,[211022],[3739],[3978],[False],[0],[0],[False],['0']
23000,PMC4745832,35931,Methods,Methods,[211024],[3979],[3987],[False],[0],[0],[False],['0']
23001,PMC4745832,35932,Study design,Methods|Study design,[211026],[3988],[4000],[False],[0],[0],[False],['0']
23002,PMC4745832,35933,"This Phase I, multicenter, randomized, open-label, three-arm study was conducted in 12 sites across three countries (United States, Poland, and Slovakia).",Methods|Study design,[211028],[4001],[4155],[False],[0],[0],[False],['0']
23003,PMC4745832,35934,"Children and adolescents (aged 5–17 years) with a diagnosis of UC were randomly assigned to receive multimatrix mesalamine 30, 60, or 100 mg/kg once daily (up to a maximum of 4,800 mg/day) each morning for 7 days.",Methods|Study design,[211030],[4156],[4369],[False],[0],[0],[False],['0']
23004,PMC4745832,35935,"To achieve these doses in children, smaller-sized 300 and 600 mg tablets were developed for this study to augment the existing approved 1,200 mg multimatrix mesalamine tablet.",Methods|Study design,[211032],[4370],[4545],[False],[0],[0],[False],['0']
23005,PMC4745832,35936,"Total daily doses for the study ranged from 900 to 4,800 mg/day.",Methods|Study design,[211034],[4546],[4610],[False],[0],[0],[False],['0']
23006,PMC4745832,35937,"Randomization was stratified by body weight (18–24, 25–49, and 50–82 kg); subjects weighing 18–24 kg were only randomized to 60 and 100 mg/kg/day groups to avoid receiving doses less than 900 mg, and subjects weighing 50–82 kg were only randomized to 30 and 60 mg/kg/day groups to avoid receiving doses greater than 4,800 mg, the maximum approved dose in adult subjects.",Methods|Study design,[211036],[4611],[4981],[False],[0],[0],[False],['0']
23007,PMC4745832,35938,"Randomization was achieved via use of a randomization number allocated prior to dosing, once eligibility had been determined, and a randomization schedule was produced by an interactive voice response system vendor.",Methods|Study design,[211038],[4982],[5197],[False],[0],[0],[False],['0']
23008,PMC4745832,35939,"Subjects were dosed with multimatrix mesalamine every morning for 7 days, at home on days 1–4, and on-site on days 5–7.",Methods|Study design,[211040],[5198],[5317],[False],[0],[0],[False],['0']
23009,PMC4745832,35940,"On day 7, blood and urine pharmacokinetic samples were collected and safety assessments were performed until 24 hours post-dose.",Methods|Study design,[211042],[5318],[5446],[False],[0],[0],[False],['0']
23010,PMC4745832,35941,"The study protocol, protocol amendments, informed consent documents, relevant supporting information, and subject recruitment information were submitted to and approved by the respective independent ethics committees, institutional review boards, and regulatory agencies prior to study initiation.",Methods|Study design,[211044],[5447],[5744],[False],[0],[0],[False],['0']
23011,PMC4745832,35942,"The independent ethics committees, institutional review boards, and regulatory agencies are from the following: United States: Arkansas Children’s Hospital, Advanced Clinical Research Institute, University of California, San Francisco, Connecticut Children’s Medical Center, University of Maryland Medical Center for Children, and Mayo Clinic; Australia: Royal Children’s Hospital Melbourne; Poland: Klinika Pediatrii Gastroenterologii i Zywienia, Uniwersytecki Szpital Dzieciecy w Krakowie, Klinika Pediatrii Dzieciecy Szpital Kliniczny im prof Antoniego Gebali, Kliniczny Oddzial Pediatrii z Pododdzialem Neurologii Dzieciecej Szpital Wojewodzki, Klinika Gastroenterolofii Pediatrii, Instytut Centrum Zdrowia Matki Polki, Oddzial Gastroenterologii i Hepatologii, and Instytut Pomnik-Centrum Zdrowia Dziecka; Slovakia: Gastroenterologicka ambulancia, Univerzitna nemocnica Martin, and DFNsP Banska Bystrica; and the United Kingdom: Alder Hey Children’s NHS Foundation Trust, Barts Health NHS Trust/Royal London Hospital, Somers Clinical Research Facility/Great Ormond Street Hospital, Southampton General Hospital.",Methods|Study design,[211046],[5745],[6860],[False],[0],[0],[False],['0']
23012,PMC4745832,35943,Further details are available at https://clinicaltrials.gov/ct2/show/NCT01130844.,Methods|Study design,[211048],[6861],[6942],[False],[0],[0],[False],['0']
23013,PMC4745832,35944,"All authors had access to the study data, and reviewed and approved the final manuscript.",Methods|Study design,[211050],[6943],[7032],[False],[0],[0],[False],['0']
23014,PMC4745832,35945,Study population,Study population,[211052],[7033],[7050],[False],[0],[0],[False],['0']
23015,PMC4745832,35946,"Children (aged 5–12 years) and adolescents (aged 13–17 years), weighing 18–82 kg, with a diagnosis of UC ≥3 months prior to the first dose of study drug were enrolled.",Study population,[211054],[7051],[7218],[False],[0],[0],[False],['0']
23016,PMC4745832,35947,Subjects already on a 5-ASA product had to have been on a stable regimen for ≥4 weeks prior to the first dose of study drug.,Study population,[211056],[7219],[7343],[False],[0],[0],[False],['0']
23017,PMC4745832,35948,"In addition to each subject documenting assent, the subject’s parent or legal representative had to provide informed consent.",Study population,[211058],[7344],[7469],[False],[0],[0],[False],['0']
23018,PMC4745832,35949,"Subjects with current or recurrent disease (other than UC) that could affect the colon or the action, absorption, or disposition of the study drug were excluded.",Study population,[211060],[7470],[7631],[False],[0],[0],[False],['0']
23019,PMC4745832,35950,"Additional exclusion criteria included: UC confined to the rectum; allergy, hypersensitivity, or poor tolerability to salicylates or aminosalicylates; history of hepatic or renal impairment, pancreatitis, or Reyes syndrome; use of another investigational product ≤30 days prior to the first dose of study drug; serious, severe, or unstable psychiatric or physical illness; positive urine screen for drugs or abuse of alcohol; and pregnancy or lactation in female subjects.",Study population,[211062],[7632],[8104],[False],[0],[0],[False],['0']
23020,PMC4745832,35951,Pharmacokinetic evaluations,Pharmacokinetic evaluations,[211064],[8105],[8133],[False],[0],[0],[False],['0']
23021,PMC4745832,35952,"Blood samples (2 mL) for the measurement of 5-ASA and Ac-5-ASA plasma concentrations were taken pre-dose on days 5 and 6 and at the following time points on day 7: pre-dose, and 2, 4, 6, 9, 12, 16, and 24 hours after dosing.",Pharmacokinetic evaluations,[211066],[8134],[8358],[False],[0],[0],[False],['0']
23022,PMC4745832,35953,"In addition, a complete 0- to 24-hour urine collection was made for the determination of urinary excretion of 5-ASA and Ac-5-ASA, starting within 30 minutes before the morning meal on day 7 until the final void scheduled for 30 minutes before the morning meal on day 8.",Pharmacokinetic evaluations,[211068],[8359],[8628],[False],[0],[0],[False],['0']
23023,PMC4745832,35954,Plasma and urine concentrations of 5-ASA and Ac-5-ASA were determined by validated methods based on liquid chromatography with tandem mass spectrometry (LC-MS/MS).,Pharmacokinetic evaluations,[211070],[8629],[8792],[False],[0],[0],[False],['0']
23024,PMC4745832,35955,"The bioanalytical methods used for the quantitation of the plasma and the urine samples were validated, and quality control and calibration standard data were accepted in accordance with the U.S. Food and Drug Administration (FDA) guidance for bioanalytical method validation.14 Pharmacokinetic parameters were determined from the plasma concentration–time data by non-compartmental analysis.",Pharmacokinetic evaluations,[211072],[8793],[9185],[False],[0],[0],[False],['0']
23025,PMC4745832,35956,"The plasma assay ranged from 5 to 5,000 ng/mL for both 5-ASA and Ac-5-ASA.",Pharmacokinetic evaluations,[211074],[9186],[9260],[False],[0],[0],[False],['0']
23026,PMC4745832,35957,"In each analytical batch, two low, two mid, and two high quality control (QC) samples were analyzed along with the study samples.",Pharmacokinetic evaluations,[211076],[9261],[9390],[False],[0],[0],[False],['0']
23027,PMC4745832,35958,"The QC sample concentrations of both analytes in plasma were 12.5, 2,500, and 4,000 ng/mL.",Pharmacokinetic evaluations,[211078],[9391],[9481],[False],[0],[0],[False],['0']
23028,PMC4745832,35959,The inter-day coefficient of variation (CV) values ranged from 5.0% to 7.6% for 5-ASA and from 4.8% to 10.1% for Ac-5-ASA.,Pharmacokinetic evaluations,[211080],[9482],[9604],[False],[0],[0],[False],['0']
23029,PMC4745832,35960,Accuracy (expressed as percentage of the difference of the mean value for each pool from the theoretical concentration) values ranged from −0.8% to 1.6% for 5-ASA and from 2.4% to 5.2% for Ac-5-ASA.,Pharmacokinetic evaluations,[211082],[9605],[9803],[False],[0],[0],[False],['0']
23030,PMC4745832,35961,"In 12 out of 14 analytical batches, three dilution QC samples were analyzed along with the study samples.",Pharmacokinetic evaluations,[211084],[9804],[9909],[False],[0],[0],[False],['0']
23031,PMC4745832,35962,"The dilution QC sample concentrations for both analytes in plasma were each 10,000 ng/mL, and the dilution QC samples were analyzed after a 1:5 dilution with control plasma.",Pharmacokinetic evaluations,[211086],[9910],[10083],[False],[0],[0],[False],['0']
23032,PMC4745832,35963,"The inter-day CV value was 5.5% for 5-ASA and 6.1% for Ac-5-ASA, and the accuracy values were 4.0% and 4.0%, respectively.",Pharmacokinetic evaluations,[211088],[10084],[10206],[False],[0],[0],[False],['0']
23033,PMC4745832,35964,Recoveries of 5-ASA and Ac-5-ASA from plasma were shown during assay validation to be >95%.,Pharmacokinetic evaluations,[211090],[10207],[10298],[False],[0],[0],[False],['0']
23034,PMC4745832,35965,"The urine assay ranged from 5 to 1,000 µg/mL for both 5-ASA and Ac-5-ASA.",Pharmacokinetic evaluations,[211092],[10299],[10372],[False],[0],[0],[False],['0']
23035,PMC4745832,35966,"In each analytical batch, two low, two mid, and two high QC samples were analyzed along with the study samples.",Pharmacokinetic evaluations,[211094],[10373],[10484],[False],[0],[0],[False],['0']
23036,PMC4745832,35967,"The QC sample concentrations of both analytes were 15, 400, and 800 µg/mL.",Pharmacokinetic evaluations,[211096],[10485],[10559],[False],[0],[0],[False],['0']
23037,PMC4745832,35968,The inter-day CV values ranged from 6.7% to 11.7% for 5-ASA and from 7.6% to 10.2% for Ac-5-ASA.,Pharmacokinetic evaluations,[211098],[10560],[10656],[False],[0],[0],[False],['0']
23038,PMC4745832,35969,Accuracy values ranged from −5.5% to −1.3% for 5-ASA and from 1.4% to 4.0% for Ac-5-ASA.,Pharmacokinetic evaluations,[211100],[10657],[10745],[False],[0],[0],[False],['0']
23039,PMC4745832,35970,"In three out of nine analytical batches, three dilution QC samples were analyzed along with the study samples.",Pharmacokinetic evaluations,[211102],[10746],[10856],[False],[0],[0],[False],['0']
23040,PMC4745832,35971,"The dilution QC sample concentrations for both analytes in urine were each 2,000 µg/mL, and the dilution QC samples were analyzed after a 1:5 dilution with control urine.",Pharmacokinetic evaluations,[211104],[10857],[11027],[False],[0],[0],[False],['0']
23041,PMC4745832,35972,"The inter-day CV value was 7.8% for 5-ASA and 7.2% for Ac-5-ASA, and the accuracy values were −2.5% and 2.0%, respectively.",Pharmacokinetic evaluations,[211106],[11028],[11151],[False],[0],[0],[False],['0']
23042,PMC4745832,35973,Recoveries of 5-ASA and Ac-5-ASA from urine were shown during assay validation to be >90%.,Pharmacokinetic evaluations,[211108],[11152],[11242],[False],[0],[0],[False],['0']
23043,PMC4745832,35974,A total of 52 plasma samples and six urine samples were re-analyzed to assess incurred sample reproducibility.,Pharmacokinetic evaluations,[211110],[11243],[11353],[False],[0],[0],[False],['0']
23044,PMC4745832,35975,"Results for 100% of these samples were found to be within ±20% of the mean of the original and re-assay results, meeting the predefined acceptance criteria.",Pharmacokinetic evaluations,[211112],[11354],[11510],[False],[0],[0],[False],['0']
23045,PMC4745832,35976,Safety,Safety,[211114],[11511],[11518],[False],[0],[0],[False],['0']
23046,PMC4745832,35977,"Safety was evaluated by reported adverse events (AEs) at each study visit and while the subject was on-site, and included assessment of clinical laboratory parameters, physical examination findings, vital signs, and 12-lead electrocardiogram.",Safety,[211116],[11519],[11761],[False],[0],[0],[False],['0']
23047,PMC4745832,35978,Safety analyses were performed on all randomized subjects who took ≥1 dose of study drug and had ≥1 post-dose safety assessment (safety analysis set).,Safety,[211118],[11762],[11912],[False],[0],[0],[False],['0']
23048,PMC4745832,35979,Safety data were summarized by treatment group and by treatment group stratified by age (5–12 years and 13–17 years).,Safety,[211120],[11913],[12030],[False],[0],[0],[False],['0']
23049,PMC4745832,35980,Sample size,Sample size,[211122],[12031],[12043],[False],[0],[0],[False],['0']
23050,PMC4745832,35981,It was anticipated that up to 60 subjects would be needed for screening to enroll 45 subjects.,Sample size,[211124],[12044],[12138],[False],[0],[0],[False],['0']
23051,PMC4745832,35982,"Thirty subjects were required to complete the study and, per agreement with the FDA, a minimum of six subjects were to be assigned to each age group (5–12 years and 13–17 years), as well as a minimum of six subjects per dose level (30, 60, and 100 mg/kg/day).",Sample size,[211126],[12139],[12398],[False],[0],[0],[False],['0']
23052,PMC4745832,35983,Non-compartmental pharmacokinetic analysis,Non-compartmental pharmacokinetic analysis,[211128],[12399],[12442],[False],[0],[0],[False],['0']
23053,PMC4745832,35984,"Pharmacokinetic parameters were determined (WinNonlin 5.2; Pharsight Corporation, Mountain View, CA, USA) for 5-ASA and Ac-5-ASA for all subjects in the safety analysis set who generated sufficient plasma samples to allow reliable determination of maximum concentration (C ) and area under the curve for the defined interval between doses (AUC ; tau=24 h) at steady state (ie, the pharmacokinetic set).",Non-compartmental pharmacokinetic analysis,[211130],[12443],[12845],[False],[0],[0],[False],['0']
23054,PMC4745832,35985,All calculations were based on actual sampling times.,Non-compartmental pharmacokinetic analysis,[211132],[12846],[12899],[False],[0],[0],[False],['0']
23055,PMC4745832,35986,"Pharmacokinetic parameters that were derived based on 5-ASA and/or Ac-5-ASA concentrations, as appropriate, included AUC , C , time of maximum observed concentration sampled during a dosing interval (t ), cumulative amount recovered in urine in time interval 0–24 hours (Xu ), clearance from the blood by the kidneys (CL ), metabolic ratio (Ac-5-ASA:5-ASA) calculated using C  (MR ), metabolic ratio (Ac-5-ASA:5-ASA) calculated using AUC  (MR ), and percentage of the dose absorbed, calculated as:  where 0.7847 is the ratio of the molecular weight of 5-ASA (153.14) to the molecular weight of Ac-5-ASA (195.15).",Non-compartmental pharmacokinetic analysis,[211134],[12900],[13512],[False],[0],[0],[False],['0']
23056,PMC4745832,35987,"AUC values were calculated using the linear trapezoidal method when concentrations were increasing, and the logarithmic trapezoidal method when concentrations were decreasing.",Non-compartmental pharmacokinetic analysis,[211136],[13513],[13688],[False],[0],[0],[False],['0']
23057,PMC4745832,35988,No inferential statistical analyses were conducted on the pharmacokinetic data.,Non-compartmental pharmacokinetic analysis,[211138],[13689],[13768],[False],[0],[0],[False],['0']
23058,PMC4745832,35989,"Summary statistics were presented by treatment group and by treatment group stratified by age (5–12 years, 13–17 years) for all pharmacokinetic parameters.",Non-compartmental pharmacokinetic analysis,[211140],[13769],[13924],[False],[0],[0],[False],['0']
23059,PMC4745832,35990,"Achievement of steady state was assessed by visual inspection of pre-dose plasma concentrations on days 5, 6, and 7.",Non-compartmental pharmacokinetic analysis,[211142],[13925],[14041],[False],[0],[0],[False],['0']
23060,PMC4745832,35991,"Systemic exposure (C  and AUC ) was assessed by comparison with historical data in healthy adult subjects administered multimatrix mesalamine 2,400 or 4,800 mg/day.15,16",Non-compartmental pharmacokinetic analysis,[211144],[14042],[14211],[False],[0],[0],[False],['0']
23061,PMC4745832,35992,Population pharmacokinetic analysis,Population pharmacokinetic analysis,[211146],[14212],[14248],[False],[0],[0],[False],['0']
23062,PMC4745832,35993,"A population pharmacokinetic model was developed using non-linear mixed effects modeling (NONMEM® program, Version 7.2.0; ICON, Ellicott City, MD, USA) to describe the population variability in 5-ASA/Ac-5-ASA pharmacokinetics and the relationship between pharmacokinetic parameters and potential explanatory covariates (eg, age, weight, and sex).",Population pharmacokinetic analysis,[211148],[14249],[14595],[False],[0],[0],[False],['0']
23063,PMC4745832,35994,"Pharmacokinetic parameters were estimated using Monte-Carlo Importance Sampling Expectation Maximization method with “Mu Referencing”.17 Development of the population pharmacokinetic model consisted of building a base model, followed by development of a covariate model using an interim data cut (40 subjects); the final model was updated with data from an additional 12 subjects from the study.",Population pharmacokinetic analysis,[211150],[14596],[14991],[False],[0],[0],[False],['0']
23064,PMC4745832,35995,"Structural model selection was data driven, based on goodness-of-fit plots (observed vs predicted concentration, conditional weighted residual vs predicted concentration or time, histograms of individual random effects, etc), successful convergence, plausibility and precision of parameter estimates, and the minimum objective function value.",Population pharmacokinetic analysis,[211152],[14992],[15334],[False],[0],[0],[False],['0']
23065,PMC4745832,35996,Missing drug concentrations and concentrations reported as “not quantifiable” were excluded in the analysis.,Population pharmacokinetic analysis,[211154],[15335],[15443],[False],[0],[0],[False],['0']
23066,PMC4745832,35997,"The final pharmacokinetic model was evaluated using visual predictive check (VPC), and this model was used to simulate the expected 5-ASA and Ac-5-ASA plasma concentration profiles in a broader population of children and adolescents using Trial Simulator (Version 2.2.1, Pharsight Corporation).",Population pharmacokinetic analysis,[211156],[15444],[15738],[False],[0],[0],[False],['0']
23067,PMC4745832,35998,"Data presentation and construction of plots were performed using S-PLUS (Version 8.1; Tibco Software Inc., Palo Alto, CA, USA).",Population pharmacokinetic analysis,[211158],[15739],[15866],[False],[0],[0],[False],['0']
23068,PMC4745832,35999,"The simulated exposures were compared to historical adult exposures.15,16",Population pharmacokinetic analysis,[211160],[15867],[15940],[False],[0],[0],[False],['0']
23069,PMC4745832,36000,Results,Results,[211162],[15941],[15949],[False],[0],[0],[False],['0']
23070,PMC4745832,36001,Subjects,Results|Subjects,[211164],[15950],[15958],[False],[0],[0],[False],['0']
23071,PMC4745832,36002,"Between October 2010 and June 2013, a total of 52 subjects were screened, randomized, and treated; all completed the study (21 subjects [5 children, 16 adolescents] in the 30 mg/kg/day dose group, 22 [4 children, 18 adolescents] in the 60 mg/kg/day dose group, and 9 [7 children, 2 adolescents] in the 100 mg/kg/day dose group; Figure 1).",Results|Subjects,[211166],[15959],[16297],[False],[0],[0],[False],['0']
23072,PMC4745832,36003,"While the study met the FDA enrollment requirement of a minimum of six subjects per dose level, more patients were enrolled into the 30 and 60 mg/kg/day dose groups than into the 100 mg/kg/day dose group due to difficulties enrolling children who weighed <49 kg.",Results|Subjects,[211168],[16298],[16560],[False],[0],[0],[False],['0']
23073,PMC4745832,36004,"Overall, demographic data and baseline disease characteristics were well balanced between dose groups, although fewer subjects were studied in the 100 mg/kg/day dose group due to enrollment difficulties (Table 1).",Results|Subjects,[211170],[16561],[16774],[False],[0],[0],[False],['0']
23074,PMC4745832,36005,Non-compartmental pharmacokinetics,Non-compartmental pharmacokinetics,[211172],[16775],[16810],[False],[0],[0],[False],['0']
23075,PMC4745832,36006,Inter-assay accuracy and precision data for 5-ASA and Ac-5-ASA in the QC samples at three concentrations each in human plasma and urine across all analytical batches are shown in Table S1.,Non-compartmental pharmacokinetics,[211174],[16811],[16999],[False],[0],[0],[False],['0']
23076,PMC4745832,36007,"For 5-ASA, mean plasma concentration–time profiles attained maxima at ~6 or 9 hours post-dose, with a secondary peak at 24 hours post-dose (Figure 2A; Table 2).",Non-compartmental pharmacokinetics,[211176],[17000],[17160],[False],[0],[0],[False],['0']
23077,PMC4745832,36008,"Median t  was 6 and 9 hours (range 0–24 hours for all dose levels) post-dose for 30 and 60 mg/kg/day doses, respectively.",Non-compartmental pharmacokinetics,[211178],[17161],[17282],[False],[0],[0],[False],['0']
23078,PMC4745832,36009,"For 100 mg/kg/day, median t  was approximately 2 hours post-dose; however, there were only nine subjects at 100 mg/kg/day.",Non-compartmental pharmacokinetics,[211180],[17283],[17405],[False],[0],[0],[False],['0']
23079,PMC4745832,36010,Steady-state plasma concentrations for 5-ASA were attained by day 5 for all doses.,Non-compartmental pharmacokinetics,[211182],[17406],[17488],[False],[0],[0],[False],['0']
23080,PMC4745832,36011,"On day 7, systemic exposure to 5-ASA (mean AUC  and C ) increased in a dose-proportional manner between 30 and 60 mg/kg/day doses, but in a subproportional manner between 60 and 100 mg/kg/day doses.",Non-compartmental pharmacokinetics,[211184],[17489],[17687],[False],[0],[0],[False],['0']
23081,PMC4745832,36012,"Based on urinary recovery, the mean percentages of 5-ASA absorbed from multimatrix mesalamine were 29.4%, 27.0%, and 22.1% for 30, 60, and 100 mg/kg/day doses, respectively.",Non-compartmental pharmacokinetics,[211186],[17688],[17861],[False],[0],[0],[False],['0']
23082,PMC4745832,36013,"High between-subject variability was noted for 5-ASA AUC  and C , with arithmetic CV values ranging from 36% to 52% and 52% to 60%, respectively.",Non-compartmental pharmacokinetics,[211188],[17862],[18007],[False],[0],[0],[False],['0']
23083,PMC4745832,36014,"Mean CL  ranged from 5.0 to 6.5 L/h, with a trend toward decreasing with increasing dose.",Non-compartmental pharmacokinetics,[211190],[18008],[18097],[False],[0],[0],[False],['0']
23084,PMC4745832,36015,"Mean plasma concentration–time profiles of plasma Ac-5-ASA were similar to those of the parent drug 5-ASA (Figure 2B; Table 2), with median t  of 9, 7.5, and 2 hours post-dose for 30, 60, and 100 mg/kg/day doses, respectively.",Non-compartmental pharmacokinetics,[211192],[18098],[18324],[False],[0],[0],[False],['0']
23085,PMC4745832,36016,Steady-state plasma concentrations for Ac-5-ASA were attained by day 5 for all doses.,Non-compartmental pharmacokinetics,[211194],[18325],[18410],[False],[0],[0],[False],['0']
23086,PMC4745832,36017,"On day 7, as for 5-ASA, systemic exposure to Ac-5-ASA increased in a dose-proportional manner between 30 and 60 mg/kg/day doses, but in a subproportional manner between 60 and 100 mg/kg/day doses.",Non-compartmental pharmacokinetics,[211196],[18411],[18607],[False],[0],[0],[False],['0']
23087,PMC4745832,36018,"The metabolite Ac-5-ASA was more abundant than the parent drug (Table 2; MR  of Ac-5-ASA:5-ASA), with no apparent trend across dose.",Non-compartmental pharmacokinetics,[211198],[18608],[18740],[False],[0],[0],[False],['0']
23088,PMC4745832,36019,"Mean CL  ranged from 10.0 to 16.2 L/h, with a trend toward decreasing with increasing dose.",Non-compartmental pharmacokinetics,[211200],[18741],[18832],[False],[0],[0],[False],['0']
23089,PMC4745832,36020,"Moderate to high between-subject variability was noted for AUC  and C , with arithmetic CV values ranging from 35% to 44% and 40% to 59%, respectively.",Non-compartmental pharmacokinetics,[211202],[18833],[18984],[False],[0],[0],[False],['0']
23090,PMC4745832,36021,"There was no apparent difference in 5-ASA or Ac-5-ASA systemic exposure, as measured by mean AUC  and C , between children (aged 5–12 years) and adolescents (aged 13–17 years) for this weight-based dosing paradigm (data not shown).",Non-compartmental pharmacokinetics,[211204],[18985],[19216],[False],[0],[0],[False],['0']
23091,PMC4745832,36022,Population pharmacokinetics,Population pharmacokinetics,[211206],[19217],[19245],[False],[0],[0],[False],['0']
23092,PMC4745832,36023,"The pharmacokinetics of 5-ASA and Ac-5-ASA were adequately described by the population pharmacokinetic structural model (Figure S1) that included: first-order absorption from two depot compartments, absorption lag times, and separate central compartments for 5-ASA and Ac-5-ASA with respective urine compartments for renal clearance.",Population pharmacokinetics,[211208],[19246],[19579],[False],[0],[0],[False],['0']
23093,PMC4745832,36024,"Non-renal clearance of 5-ASA was assumed to involve only metabolism to Ac-5-ASA, and all elimination processes were based on the first-order kinetics.",Population pharmacokinetics,[211210],[19580],[19730],[False],[0],[0],[False],['0']
23094,PMC4745832,36025,"Allometric scaling by body weight was applied to all clearance and volume parameters, with the exponents fixed to the theoretical value of 0.75 for clearance and 1 for volume parameters.18 Parameter estimates for the final model are shown in Table S2; following evaluation by VPC, less than 9% of the observed concentrations fell outside the 90% prediction intervals for both analytes, suggesting that the final model adequately described the observed data.",Population pharmacokinetics,[211212],[19731],[20188],[False],[0],[0],[False],['0']
23095,PMC4745832,36026,"For a 70 kg individual, the typical value of 5-ASA apparent renal clearance was estimated to be 1.15 L/h (95% confidence interval [CI]: 1.01–1.32 L/h), and apparent metabolic clearance was estimated to be 85.6 L/h (95% CI: 75.9–96.5 L/h).",Population pharmacokinetics,[211214],[20189],[20427],[False],[0],[0],[False],['0']
23096,PMC4745832,36027,"The typical value of Ac-5-ASA apparent renal clearance was estimated to be 2.54 L/h (95% CI: 2.27–2.86 L/h), and apparent non-renal clearance was estimated to be 74.4 L/h (95% CI: 66.7–83.1 L/h).",Population pharmacokinetics,[211216],[20428],[20623],[False],[0],[0],[False],['0']
23097,PMC4745832,36028,Typical estimates of the central volume of distribution were 109 L (95% CI: 70.1–169 L) for 5-ASA and 7.10 L (95% CI: 5.31–9.49 L) for Ac-5-ASA.,Population pharmacokinetics,[211218],[20624],[20768],[False],[0],[0],[False],['0']
23098,PMC4745832,36029,Estimated absorption rates from depot 1 and depot 3 were 0.0334 h−1 (95% CI: 0.0207–0.0539 h−1) and 0.273 h−1 (95% CI: 0.165–0.448 h−1).,Population pharmacokinetics,[211220],[20769],[20905],[False],[0],[0],[False],['0']
23099,PMC4745832,36030,Corresponding estimated absorption lag times from each depot were 5.10 hours (95% CI: 4.31–6.05 hours) and 15.0 hours (95% CI: 14.0–16.1 hours); the lag time from depot 3 represented the additional lag following delay in absorption from depot 1.,Population pharmacokinetics,[211222],[20906],[21151],[False],[0],[0],[False],['0']
23100,PMC4745832,36031,"The fraction of dose absorbed from depot 1 was estimated to be 0.734 (95% CI: 0.413–1.06), and remaining dose fractions were assumed to be absorbed from depot 3.",Population pharmacokinetics,[211224],[21152],[21313],[False],[0],[0],[False],['0']
23101,PMC4745832,36032,Goodness-of-fit plots for 5-ASA and Ac-5-ASA plasma concentrations are shown in Figures S2 and S3.,Population pharmacokinetics,[211226],[21314],[21412],[False],[0],[0],[False],['0']
23102,PMC4745832,36033,"The population pharmacokinetic model was used to simulate steady-state profiles for both 5-ASA and Ac-5-ASA for four weight groups (18–23, 24–35, 36–50, and 51–90 kg) at planned high doses (1,800, 2,400, 3,600, and 4,800 mg) and low doses (900, 1,200, 1,800, and 2,400 mg) in 80 subjects with 1,000 replications (Figure 3A–D; Tables S3 and S4).",Population pharmacokinetics,[211228],[21413],[21757],[False],[0],[0],[False],['0']
23103,PMC4745832,36034,The variability in the predicted steady-state exposures for children and adolescents was approximately 50% (CV%) for 5-ASA AUC (Table S3) and 40%–45% for Ac-5-ASA AUC (Table S4).,Population pharmacokinetics,[211230],[21758],[21936],[False],[0],[0],[False],['0']
23104,PMC4745832,36035,"The proposed low dose of multimatrix mesalamine for each weight category is predicted to provide comparable steady-state exposure for both 5-ASA and Ac-5 -ASA to those observed following administration of a fixed 2,400 mg dose in the adult population (Figure 3A–D).",Population pharmacokinetics,[211232],[21937],[22202],[False],[0],[0],[False],['0']
23105,PMC4745832,36036,"The proposed high dose for each weight category is predicted to provide comparable steady-state AUC for both 5-ASA and Ac-5-ASA to those observed following administration of a fixed 4,800 mg dose in the adult population.",Population pharmacokinetics,[211234],[22203],[22423],[False],[0],[0],[False],['0']
23106,PMC4745832,36037,Safety,Safety,[211236],[22424],[22431],[False],[0],[0],[False],['0']
23107,PMC4745832,36038,The incidence of treatment-emergent adverse events (TEAEs) was 19.2% (ten subjects overall); all TEAEs were mild to moderate (Table 3).,Safety,[211238],[22432],[22567],[False],[0],[0],[False],['0']
23108,PMC4745832,36039,"Incidence rates were similar among different dose groups, and the most commonly reported TEAEs were abdominal pain, musculoskeletal pain, and headache, each reported in 3.8% of subjects (n=2 each).",Safety,[211240],[22568],[22765],[False],[0],[0],[False],['0']
23109,PMC4745832,36040,There were no TEAEs leading to premature discontinuation.,Safety,[211242],[22766],[22823],[False],[0],[0],[False],['0']
23110,PMC4745832,36041,"Two subjects (3.8%) experienced a TEAE considered by the investigator to be related to the study drug: one subject in the 30 mg/kg/day dose group experienced abdominal pain, dehydration, and vomiting, and one subject in the 60 mg/kg/day dose group experienced moderate upper abdominal pain.",Safety,[211244],[22824],[23114],[False],[0],[0],[False],['0']
23111,PMC4745832,36042,"No relevant differences between the age groups were observed with regard to the occurrence, severity, or relatedness of TEAEs, and no clinically relevant abnormalities in biochemistry, hematology, urinalysis, or vital sign values were observed.",Safety,[211246],[23115],[23359],[False],[0],[0],[False],['0']
23112,PMC4745832,36043,No new safety signals were reported.,Safety,[211248],[23360],[23396],[False],[0],[0],[False],['0']
23113,PMC4745832,36044,Discussion,Discussion,[211250],[23397],[23408],[False],[0],[0],[False],['0']
23114,PMC4745832,36045,This is the first study to evaluate the safety and pharmacokinetics of multimatrix mesalamine in children and adolescents diagnosed with UC.,Discussion,[211252],[23409],[23549],[False],[0],[0],[False],['0']
23115,PMC4745832,36046,Multimatrix mesalamine was generally safe and well tolerated.,Discussion,[211254],[23550],[23611],[False],[0],[0],[False],['0']
23116,PMC4745832,36047,"No fatal TEAEs, other serious TEAEs, or TEAEs leading to discontinuation of treatment occurred during the study, and the incidence of TEAEs was comparable between dose and age groups.",Discussion,[211256],[23612],[23795],[False],[0],[0],[False],['0']
23117,PMC4745832,36048,"Furthermore, the types and frequencies of clinical laboratory abnormalities and other safety parameters were low, and comparable between dose and age groups.",Discussion,[211258],[23796],[23953],[False],[0],[0],[False],['0']
23118,PMC4745832,36049,"The pharmacokinetic profiles of 5-ASA and Ac-5-ASA at 30 or 60 mg/kg once daily were similar to those observed historically in adults after a 2,400 mg daily dose.15,16 Likewise, the pharmacokinetic profiles of 5-ASA and Ac-5-ASA at 100 mg/kg once daily were also similar to those in adults after a 4,800 mg daily dose.15,16 These conclusions were based on the variable absorption profiles with initial and secondary peaks, the percentage of the 5-ASA absorbed, renal clearance of 5-ASA and Ac-5-ASA, plasma exposure (AUC  and C ), and the inter-subject variability in pharmacokinetic parameters (Table 2).15,16 For example, in adults, the total absorption of 5-ASA from multimatrix mesalamine 2.4 or 4.8 g administered once daily for 14 days to healthy volunteers was approximately 21%–22% of the administered dose.15 In the current study, 5-ASA absorption ranged from 22% to 29% across doses.",Discussion,[211260],[23954],[24847],[False],[0],[0],[False],['0']
23119,PMC4745832,36050,"The overall similarity in 5-ASA and Ac-5-ASA exposures between children/adolescents and adults suggests that the novel, smaller 300 and 600 mg multimatrix mesalamine tablets developed for this study performed as intended, delivering 5-ASA to the colon in a similar fashion to the commercial 1,200 mg multimatrix mesalamine tablets.",Discussion,[211262],[24848],[25179],[False],[0],[0],[False],['0']
23120,PMC4745832,36051,"Hence, these new 300 and 600 mg tablets may be suitable for use in future studies.",Discussion,[211264],[25180],[25262],[False],[0],[0],[False],['0']
23121,PMC4745832,36052,"For both 5-ASA and Ac-5-ASA, pharmacokinetic steady state was attained by day 5 for all doses, and systemic exposure of 5-ASA and Ac-5-ASA (measured by mean AUC  and C ) on day 7 increased in a dose-proportional manner between 30 and 60 mg/kg/day doses (Table 2).",Discussion,[211266],[25263],[25526],[False],[0],[0],[False],['0']
23122,PMC4745832,36053,"Mean AUC  and C  increased subproportionally between 60 and 100 mg/kg/day doses, possibly due to the maximum dose restriction of 4,800 mg/day, with the highest dose of 100 mg/kg only being administered to subjects weighing less than 50 kg.",Discussion,[211268],[25527],[25766],[False],[0],[0],[False],['0']
23123,PMC4745832,36054,"In the 100 mg/kg/day dose group, a mean of 22.1% of the dose was absorbed (similar to the 21%–22% observed in adults),15 whereas the corresponding values for the 30 and 60 mg/kg/day dose groups were higher (29.4% and 27.0%, respectively), suggesting that there also may be differences in the extent of absorption.",Discussion,[211270],[25767],[26080],[False],[0],[0],[False],['0']
23124,PMC4745832,36055,"Nevertheless, these assessments of dose-proportionality should be interpreted with caution due to the large inter-subject pharmacokinetic variability and the small sample size (n=9) receiving 100 mg/kg/day.",Discussion,"[211272, 211273]","[26081, 26081]","[26287, 26287]","[True, True]","['NonstandardTreatmentCharacteristics', 'SampleSize']","['the large inter-subject pharmacokinetic variability', 'the small sample size (n=9) receiving 100 mg/kg/day']","[True, True]","['Intervention', 'UnderpoweredStudy']"
23125,PMC4745832,36056,"In addition to the typical non-compartmental pharmacokinetic analysis, a population pharmacokinetic model was developed to describe the pharmacokinetics of 5-ASA and Ac-5-ASA (Figure S1), and was subsequently used to simulate exposures in a broader population of children and adolescents with UC, following repeat oral administration of multimatrix mesalamine (Figures 3A–D; Tables S3 and S4).",Discussion,[211274],[26288],[26681],[False],[0],[0],[False],['0']
23126,PMC4745832,36057,"The variability in the predicted steady-state exposures for children and adolescents was similar to the observed variability in adults for both 5-ASA AUC (CV ≈50% in children and adolescents and 60% in adults) and Ac-5-ASA AUC (CV ≈40%–45% in both populations).15,16 Additionally, absorption from two depots, as described in the final model, is consistent with the multimatrix mesalamine tablet, delivering an initial burst of 5-ASA that occurs from disintegration of the enteric coating, followed by leaching of 5-ASA out of the core as the tablet travels through the terminal ileum and colon.",Discussion,[211276],[26682],[27276],[False],[0],[0],[False],['0']
23127,PMC4745832,36058,"Therefore, the absorption data provide support for the drug being delivered in accordance with the design concept.",Discussion,[211278],[27277],[27391],[False],[0],[0],[False],['0']
23128,PMC4745832,36059,"Finally, results from the modeling and simulation in the current analysis suggest that the proposed dosing regimen for examining the safety and efficacy of multimatrix mesalamine in children and adolescents is likely to produce exposures to 5-ASA and Ac-5-ASA within the range of exposures at which safety and efficacy have been established in adults.",Discussion,[211280],[27392],[27743],[False],[0],[0],[False],['0']
23129,PMC4745832,36060,"As a result, these data supported the proposed doses for the Phase III safety and efficacy trial of multimatrix mesalamine in pediatric patients with UC (PACE; NCT02093663).",Discussion,[211282],[27744],[27917],[False],[0],[0],[False],['0']
23130,PMC4745832,36061,Acknowledgments,Acknowledgments,[211284],[27918],[27935],[False],[0],[0],[False],['0']
23131,PMC4745832,36062,"The authors would like to thank Richard Abbott and York Bioanalytical Solutions for excellent bioanalytical support, and Susi Inglis for statistical support.",Acknowledgments,[211286],[27936],[28093],[False],[0],[0],[False],['0']
23132,PMC4745832,36063,"Research was funded by the sponsor, Shire Development LLC.",Acknowledgments,[211288],[28094],[28152],[False],[0],[0],[False],['0']
23133,PMC4745832,36064,"Under the direction of the authors, Jason Jung, PhD, an employee of MedErgy, provided writing assistance for this manuscript.",Acknowledgments,[211290],[28153],[28278],[False],[0],[0],[False],['0']
23134,PMC4745832,36065,"Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by MedErgy.",Acknowledgments,[211292],[28279],[28390],[False],[0],[0],[False],['0']
23135,PMC4745832,36066,Representatives from Shire also reviewed and edited this manuscript for scientific accuracy.,Acknowledgments,[211294],[28391],[28483],[False],[0],[0],[False],['0']
23136,PMC4745832,36067,Shire Development LLC provided funding to MedErgy for support in writing and editing this manuscript.Disclosure,Acknowledgments,[211296],[28484],[28595],[False],[0],[0],[False],['0']
23137,PMC4745832,36068,"Carmen Cuffari served as a consultant for Shire, Prometheus, and Abbott Nutritionals.",Acknowledgments,[211298],[28596],[28681],[False],[0],[0],[False],['0']
23138,PMC4745832,36069,"David Pierce is a former employee of Shire, and holds stock in Shire and in GlaxoSmithKline.",Acknowledgments,[211300],[28682],[28774],[False],[0],[0],[False],['0']
23139,PMC4745832,36070,Bartosz Korczowski and Krzysztof Fyderek received grants from Shire for the study research conducted.,Acknowledgments,[211302],[28775],[28876],[False],[0],[0],[False],['0']
23140,PMC4745832,36071,"Heather Van Heusen, Hong Wan, and Patrick Martin are employees of Shire, and hold stock and/or stock options at Shire.",Acknowledgments,[211304],[28877],[28995],[False],[0],[0],[False],['0']
23141,PMC4745832,36072,"Stuart Hossack is an employee of Covance Clinical Research Unit Limited, which received funding from Shire for assistance with data analysis.",Acknowledgments,[211306],[28996],[29137],[False],[0],[0],[False],['0']
23142,PMC4745832,36073,"Alena YZ Edwards is an employee of ICON Early Phase Services, which received funding from Shire for assistance with data analysis.Author contributions",Acknowledgments,[211308],[29138],[29288],[False],[0],[0],[False],['0']
23143,PMC4745832,36074,Carmen Cuffari was involved with the study design as well as data analysis and interpretation.,Acknowledgments,[211310],[29289],[29383],[False],[0],[0],[False],['0']
23144,PMC4745832,36075,"David Pierce was involved with study concept and design, oversight of the analysis, and interpretation of data (including oversight of pharmacokinetic details included in the manuscript).",Acknowledgments,[211312],[29384],[29571],[False],[0],[0],[False],['0']
23145,PMC4745832,36076,Bartosz Korczowski and Krzysztof Fyderek supervised the study conduct and were involved with data acquisition.,Acknowledgments,[211314],[29572],[29682],[False],[0],[0],[False],['0']
23146,PMC4745832,36077,"Heather Van Heusen was involved with study concept and design; oversight of study conduct, execution, and data analyses; development of the clinical study report; and development of the protocol.",Acknowledgments,[211316],[29683],[29878],[False],[0],[0],[False],['0']
23147,PMC4745832,36078,Stuart Hossack was involved with non-compartmental pharmacokinetic data analysis and interpretation of data for the clinical study report.,Acknowledgments,[211318],[29879],[30017],[False],[0],[0],[False],['0']
23148,PMC4745832,36079,"Hong Wan was involved with acquisition of data, analysis and interpretation of data, and statistical analysis.",Acknowledgments,[211320],[30018],[30128],[False],[0],[0],[False],['0']
23149,PMC4745832,36080,Alena YZ Edwards was involved with analysis and interpretation of data.,Acknowledgments,[211322],[30129],[30200],[False],[0],[0],[False],['0']
23150,PMC4745832,36081,"Patrick Martin was involved with the overarching study concept, design, conduct, and reporting, and as the article guarantor, he takes responsibility for the integrity of the work as a whole, from inception to published article.",Acknowledgments,[211324],[30201],[30429],[False],[0],[0],[False],['0']
23151,PMC4745832,36082,"All authors contributed to drafting of the manuscript or critical revision of the manuscript for important intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.",Acknowledgments,[211326],[30430],[30667],[False],[0],[0],[False],['0']
23361,PMC4772661,33009,The effect of balance training on postural control in people with multiple sclerosis using the CAREN virtual reality system: a pilot randomized controlled trial,Title,[194993],[31012],[160],[False],[0],[0],[False],['0']
23362,PMC4772661,33010,Background,Abstract,[194996],[161],[172],[False],[0],[0],[False],['0']
23363,PMC4772661,33011,Multiple sclerosis (MS) is a multi-focal progressive disorder of the central nervous system often resulting in diverse clinical manifestations.,Abstract,[194999],[173],[316],[False],[0],[0],[False],['0']
23364,PMC4772661,33012,Imbalance appears in most people with multiple sclerosis (PwMS).,Abstract,[195002],[317],[381],[False],[0],[0],[False],['0']
23365,PMC4772661,33013,A popular balance training tool is virtual reality (VR) with several advantages including increased compliance and user satisfaction.,Abstract,[195005],[382],[515],[False],[0],[0],[False],['0']
23366,PMC4772661,33014,"Therefore, the aim of this pilot RCT (Trial registration number, date: ISRCTN14425615, 21/01/2016) was to examine the efficacy of a 6-week VR balance training program using the computer assisted rehabilitation environment (CAREN) system (Motek Medical BV, Amsterdam, Netherlands) on balance measures in PwMS.",Abstract,[195008],[516],[824],[False],[0],[0],[False],['0']
23367,PMC4772661,33015,Results were compared with those of a conventional balance exercise group.,Abstract,[195011],[825],[899],[False],[0],[0],[False],['0']
23368,PMC4772661,33016,Secondary aims included the impact of this program on the fear of falling.,Abstract,[195014],[900],[974],[False],[0],[0],[False],['0']
23369,PMC4772661,33017,Methods,Methods,[195017],[975],[983],[False],[0],[0],[False],['0']
23370,PMC4772661,33018,Thirty-two PwMS were equally randomized into the VR intervention group or the control group.,Methods,[195020],[984],[1076],[False],[0],[0],[False],['0']
23371,PMC4772661,33019,"Each group received balance training sessions for 6 consecutive weeks, two sessions per week, 30 min sessions.",Methods,[195023],[1077],[1187],[False],[0],[0],[False],['0']
23372,PMC4772661,33020,Clinical balance tests and instrumented posturography outcome measures were collected upon initiation of the intervention programs and at termination.,Methods,[195026],[1188],[1338],[False],[0],[0],[False],['0']
23373,PMC4772661,33021,Results,Results,[195029],[1339],[1347],[False],[0],[0],[False],['0']
23374,PMC4772661,33022,"Final analysis included 30 patients (19 females, 11 males; mean age, (S.D.)",Results,[195032],[1348],[1423],[False],[0],[0],[False],['0']
23375,PMC4772661,33023,= 45.2 (11.6) years; mean EDSS (S.D.),Results,[195035],[1424],[1461],[False],[0],[0],[False],['0']
23376,PMC4772661,33024,"= 4.1 (1.3), mean disease duration (S.D.)",Results,[195038],[1462],[1503],[False],[0],[0],[False],['0']
23377,PMC4772661,33025,= 11.0 (8.9) years).,Results,[195041],[1504],[1524],[False],[0],[0],[False],['0']
23378,PMC4772661,33026,"Both groups showed a main effect of time on the center of pressure (CoP) path length with eyes open (F = 5.278, P = .024), sway rate with eyes open (F = 5.852, P = .035), Functional Reach Test (F = 20.841, P = .001), Four Square Step Test (F = 9.011, P = .031) and the Fear of Falls self-reported questionnaire (F = 17.815, P = .023).",Results,[195044],[1525],[1859],[False],[0],[0],[False],['0']
23379,PMC4772661,33027,"In addition, significant differences in favor of the VR program were observed for the group x time interactions of the Functional Reach Test (F = 10.173, P = .009) and fear of falling (F = 6.710, P = .021).",Results,[195047],[1860],[2066],[False],[0],[0],[False],['0']
23380,PMC4772661,33028,Conclusions,Conclusions,[195050],[2067],[2079],[False],[0],[0],[False],['0']
23381,PMC4772661,33029,We demonstrated that balance training based on the CAREN device is an effective method of balance training for PwMS.,Conclusions,[195053],[2080],[2196],[False],[0],[0],[False],['0']
23382,PMC4772661,33030,Background,Background,[195056],[2197],[2209],[False],[0],[0],[False],['0']
23383,PMC4772661,33031,"Imbalance is present and evident in most people with multiple sclerosis (PwMS) and can appear as the initial symptom of MS [1], even in those with minimal changes on clinical examination [2, 3].",Background,[195059],[2210],[2404],[False],[0],[0],[False],['0']
23384,PMC4772661,33032,"In most cases, as the disease progresses, balance difficulties persist and become more pronounced [4, 5].",Background,[195062],[2405],[2510],[False],[0],[0],[False],['0']
23385,PMC4772661,33033,"Moreover, poor balance control is known as one of the main risk factors for falls and an elevated fear of falling [6, 7].",Background,[195065],[2511],[2632],[False],[0],[0],[False],['0']
23386,PMC4772661,33034,"Intervention programs directed at improving balance control have employed various approaches, e.g.",Background,[195068],[2633],[2731],[False],[0],[0],[False],['0']
23387,PMC4772661,33035,"motor and sensory strategies [8], Feldenkrais exercises [9] and neuromuscular facilitation [10].",Background,[195071],[2732],[2828],[False],[0],[0],[False],['0']
23388,PMC4772661,33036,"According to a recent systematic review, balance may improve in PwMS through exercise interventions [11].",Background,[195074],[2829],[2934],[False],[0],[0],[False],['0']
23389,PMC4772661,33037,"However, the authors note that disparities in interventions, outcomes and methodologies imply that the results must be viewed with caution.",Background,[195077],[2935],[3074],[False],[0],[0],[False],['0']
23390,PMC4772661,33038,"Thus, given the adverse consequences of impaired balance, additional intervention strategies to reduce this phenomenon are still warranted.",Background,[195080],[3075],[3214],[False],[0],[0],[False],['0']
23391,PMC4772661,33039,"In this situation, balance training together with a virtual reality (VR) system can provide training in a stimulating and enriching environment [12].",Background,[195083],[3215],[3364],[False],[0],[0],[False],['0']
23392,PMC4772661,33040,"VR can supply immediate feedback as to performance, thus assisting with the learning of new motor strategies of movement and is an acceptable approximation of the real world (e.g.",Background,[195086],[3365],[3544],[False],[0],[0],[False],['0']
23393,PMC4772661,33041,"walking on an uneven or slippery surface, walking in a crowded area, etc.)",Background,[195089],[3545],[3619],[False],[0],[0],[False],['0']
23394,PMC4772661,33042,[13].,Background,[195092],[3620],[3625],[False],[0],[0],[False],['0']
23395,PMC4772661,33043,"Additionally, due to the diverse settings and game situations placed in many VR systems, compliance, retention and user satisfaction are increased and are therefore, potentially beneficial for long-term effectiveness of rehabilitation programs [14].",Background,[195095],[3626],[3875],[False],[0],[0],[False],['0']
23396,PMC4772661,33044,"VR balance training has been shown to improve balance capabilities in the elderly, in patients following stroke and people with Parkinson’s disease [15–17].",Background,[195098],[3876],[4032],[False],[0],[0],[False],['0']
23397,PMC4772661,33045,"According to a recent systematic review investigating the efficacy of VR training in stroke survivors, dynamic balance improved significantly following VR-based interventions as compared to other interventions [18].",Background,[195101],[4033],[4248],[False],[0],[0],[False],['0']
23398,PMC4772661,33046,"Furthermore, VR-based interventions favorably affected participants in terms of dealing with environmental challenges, which may also facilitate independent community ambulation [18].",Background,[195104],[4249],[4432],[False],[0],[0],[False],['0']
23399,PMC4772661,33047,"Justifiably, VR balance training could be useful for PwMS.",Background,[195107],[4433],[4491],[False],[0],[0],[False],['0']
23400,PMC4772661,33048,"Yet, only a few reports have investigated this intervention tool in the MS population [19–23].",Background,[195110],[4492],[4586],[False],[0],[0],[False],['0']
23401,PMC4772661,33049,"Although results of these reports are promising, all favoring the efficacy of VR balance training; most studies were relatively small and without a comparison group.",Background,[195113],[4587],[4752],[False],[0],[0],[False],['0']
23402,PMC4772661,33050,"In the present randomized controlled trial (RCT), we examined the effects of balance training utilizing the computer assisted rehabilitation environment (CAREN) system (Motek Medical BV, Amsterdam, Netherlands).",Background,[195116],[4753],[4964],[False],[0],[0],[False],['0']
23403,PMC4772661,33051,"Recently, balance training, using the CAREN system, showed an improvement in balance performance in persons with traumatic brain injury [24] and individuals with transtibial amputation [25].",Background,[195119],[4965],[5155],[False],[0],[0],[False],['0']
23404,PMC4772661,33052,"To date, no RCT publication examining this system in the MS community was found in the Pubmed database.",Background,[195122],[5156],[5259],[False],[0],[0],[False],['0']
23405,PMC4772661,33053,"Therefore, the aim of this RCT was to examine the efficacy on balance measures in PwMS for a 6-week VR balance training program using the CAREN system.",Background,[195125],[5260],[5411],[False],[0],[0],[False],['0']
23406,PMC4772661,33054,Results were compared with those of a conventional balance exercise group.,Background,[195128],[5412],[5486],[False],[0],[0],[False],['0']
23407,PMC4772661,33055,Secondary aims included the impact of this program on the fear of falling.,Background,[195131],[5487],[5561],[False],[0],[0],[False],['0']
23408,PMC4772661,33056,"We hypothesized that following the intervention period, both groups would demonstrate improved balance capabilities; nonetheless, we expected greater improvements in the VR training group.",Background,[195134],[5562],[5750],[False],[0],[0],[False],['0']
23409,PMC4772661,33057,Methods,Methods,[195137],[5751],[5759],[False],[0],[0],[False],['0']
23410,PMC4772661,33058,Participants,Methods|Participants,[195140],[5760],[5772],[False],[0],[0],[False],['0']
23411,PMC4772661,33059,The implemented study design was executed according to the rigor of the CONSORT guidelines [26].,Methods|Participants,[195143],[5773],[5869],[False],[0],[0],[False],['0']
23412,PMC4772661,33060,"The RCT was a pilot, prospective, assessor blinded, parallel group, performed at the Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel, between June 2014 and May 2015.",Methods|Participants,[195146],[5870],[6057],[False],[0],[0],[False],['0']
23413,PMC4772661,33061,"Eligible PwMS were enrolled according to the following criteria: (1) diagnosis of definite relapsing-remitting MS according to the revised McDonald criteria 2010 [27], (2) 25–55 years of age, (3) moderate neurological disability as scored by the expanded disability status scale (EDSS), ranging from 3.0 to 6.0 inclusive with a pyramidal functional score of at least 3.",Methods|Participants,[195149],[6058],[6427],[False],[0],[0],[False],['0']
23414,PMC4772661,33062,"Exclusion criteria were: (1) MS clinical relapse or treatment with corticosteroid therapy within 6-months prior to examination, (2) patients experiencing major depression or cognitive decline, (3) orthopedic disorders that could negatively affect balance, (4) pregnancy, (5) blurred vision, or (6) cardiovascular disorders.",Methods|Participants,[195152],[6428],[6751],[False],[0],[0],[False],['0']
23415,PMC4772661,33063,All participants gave informed consent prior to participation.,Methods|Participants,[195155],[6752],[6814],[False],[0],[0],[False],['0']
23416,PMC4772661,33064,"Additionally, written informed consent for publication of clinical images was obtained from the participants.",Methods|Participants,[195158],[6815],[6924],[False],[0],[0],[False],['0']
23417,PMC4772661,33065,Approval was obtained from the Sheba Medical Center Independent Ethics Committee prior to commencement of the study.,Methods|Participants,[195161],[6925],[7041],[False],[0],[0],[False],['0']
23418,PMC4772661,33066,Sample size,Sample size,[195164],[7042],[7054],[False],[0],[0],[False],['0']
23419,PMC4772661,33067,The sample size estimate was based on extrapolations from our preliminary data and other related studies examining the effects of VR on balance capabilities in PwMS.,Sample size,[195167],[7055],[7220],[False],[0],[0],[False],['0']
23420,PMC4772661,33068,"Accordingly, we used the effect size (0.9) of the functional reach test (FRT) for calculations.",Sample size,[195170],[7221],[7316],[False],[0],[0],[False],['0']
23421,PMC4772661,33069,"Power was set at 80 %, alpha was set at 5 % and we accounted for dropout rate of 10 %.",Sample size,[195173],[7317],[7403],[False],[0],[0],[False],['0']
23422,PMC4772661,33070,"Using a relatively conservative estimate, a total of 32 subjects (16 in each group) would be required to detect differences between the two treatment groups assuming non-inferiority with moderate correlations among covariates (R-squared = 0.50).",Sample size,[195176],[7404],[7649],[False],[0],[0],[False],['0']
23423,PMC4772661,33071,Study design,Study design,[195179],[7650],[7663],[False],[0],[0],[False],['0']
23424,PMC4772661,33072,"After consenting to participate and fulfilling the inclusion criteria, thirty-two people with relapsing-remitting MS were equally randomized into the VR intervention group or the conventional exercise program control group with a 1:1 allocation ratio.",Study design,[195182],[7664],[7915],[False],[0],[0],[False],['0']
23425,PMC4772661,33073,"For randomization, sealed envelopes were prepared in advance and marked on the inside with an O or X. Randomization was performed one hour prior to the start of the pretest by a physical therapist who was not involved in the assessment or treatment of the subjects.",Study design,[195185],[7916],[8181],[False],[0],[0],[False],['0']
23426,PMC4772661,33074,"The intervention period of both groups was identical, 6 consecutive weeks, two sessions per week, 30 min sessions.",Study design,[195188],[8182],[8296],[False],[0],[0],[False],['0']
23427,PMC4772661,33075,"Outcome measures were collected twice, upon initiation of the intervention programs and at termination of the 6-week intervention period.",Study design,[195191],[8297],[8434],[False],[0],[0],[False],['0']
23428,PMC4772661,33076,"All measurements were completed by an experienced physical therapist specialized in neurological rehabilitation, blinded to participant grouping.",Study design,[195194],[8435],[8580],[False],[0],[0],[False],['0']
23429,PMC4772661,33077,A research coordinator documented all training and examination sessions.,Study design,[195197],[8581],[8653],[False],[0],[0],[False],['0']
23430,PMC4772661,33078,"Within the first three weeks of the study period, one subject from each group withdrew from the training program due to difficulties in reaching the MS Center.",Study design,[195200],[8654],[8813],[False],[0],[0],[False],['0']
23431,PMC4772661,33079,"Thus, data from 30 patients (19 females, 11 males; mean age, (S.D.)",Study design,[195203],[8814],[8881],[False],[0],[0],[False],['0']
23432,PMC4772661,33080,= 45.2 (11.6) years; mean EDSS (S.D.),Study design,[195206],[8882],[8919],[False],[0],[0],[False],['0']
23433,PMC4772661,33081,"= 4.1 (1.3), mean disease duration (S.D.)",Study design,[195209],[8920],[8961],[False],[0],[0],[False],['0']
23434,PMC4772661,33082,"= 11.0 (8.9) years), were analyzed.",Study design,[195212],[8962],[8997],[False],[0],[0],[False],['0']
23435,PMC4772661,33083,The VR intervention program,The VR intervention program,[195215],[8998],[9026],[False],[0],[0],[False],['0']
23436,PMC4772661,33084,Fig.,The VR intervention program,[195218],[9027],[9031],[False],[0],[0],[False],['0']
23437,PMC4772661,33085,1 The CAREN Integrated Virtual Reality System.,The VR intervention program,[195221],[9032],[9078],[False],[0],[0],[False],['0']
23438,PMC4772661,33086,Fig.,The VR intervention program,[195224],[9079],[9083],[False],[0],[0],[False],['0']
23439,PMC4772661,33087,2 The virtual road scene projected on the system’s screen.,The VR intervention program,[195227],[9084],[9142],[False],[0],[0],[False],['0']
23440,PMC4772661,33088,The VR system used was the CAREN Integrated Reality System with D-flow software.,The VR intervention program,[195230],[9143],[9223],[False],[0],[0],[False],['0']
23441,PMC4772661,33089,"This system, designed by Motek Medical BV, works in real-time, enabling the creation of a variety of controlled and repeated simulated environments via dedicated software which includes 3D visual, sound, and proprioceptive stimuli.",The VR intervention program,[195233],[9224],[9455],[False],[0],[0],[False],['0']
23442,PMC4772661,33090,"The following components are incorporated in the system:Motion Platform - CAREN consists of an electro-hydraulic 2 m diameter motion platform (Rexroth Hydraudyne, MOTEK, Micro motion) that can be manipulated by 6° of freedom (x-y-z translation and pitch-roll-yaw rotation).",The VR intervention program,[195236],[9456],[9729],[False],[0],[0],[False],['0']
23443,PMC4772661,33091,The movement of the platform is either driven by the subject’s movements or preprogrammed in synchrony with function curves that define a specific pathway in the virtual environment (Fig.,The VR intervention program,[195239],[9730],[9917],[False],[0],[0],[False],['0']
23444,PMC4772661,33092,1)..,The VR intervention program,[195242],[9918],[9922],[False],[0],[0],[False],['0']
23445,PMC4772661,33093,Projection: The virtual scene is projected on a large screen (3 m × 2.5 m).,The VR intervention program,[195245],[9923],[9998],[False],[0],[0],[False],['0']
23446,PMC4772661,33094,"In the present study, a VR setting entitled ‘road scene’ was used which requires subjects to stand on a motion platform while maintaining their balance and advancing along a pre-defined road.",The VR intervention program,[195248],[9999],[10190],[False],[0],[0],[False],['0']
23447,PMC4772661,33095,"The scene, consisting of a virtual road, bounded on both sides by walls is projected onto the screen, in front of the subject.",The VR intervention program,[195251],[10191],[10317],[False],[0],[0],[False],['0']
23448,PMC4772661,33096,"The road itself has flat, straight and vertical bumpy sections (movement along the y-axis), right and left tilts (rotation of ‘z axis’ - “roll”) and right and left translations (movement along the ‘x axis’ - “sway”).",The VR intervention program,[195254],[10318],[10534],[False],[0],[0],[False],['0']
23449,PMC4772661,33097,"The platform’s movement is correlated with the visual stimulus (i.e., when the subject arrives at a bump on the screen, the platform elevates.",The VR intervention program,[195257],[10535],[10677],[False],[0],[0],[False],['0']
23450,PMC4772661,33098,"When the road tilts, the platform tilts accordingly in the same direction).",The VR intervention program,[195260],[10678],[10753],[False],[0],[0],[False],['0']
23451,PMC4772661,33099,The length of the road is 1230 m. The road’s default velocity was set at 30 m/min which is equal to 1.8 km/h (Fig.,The VR intervention program,[195263],[10754],[10868],[False],[0],[0],[False],['0']
23452,PMC4772661,33100,2).,The VR intervention program,[195266],[10869],[10872],[False],[0],[0],[False],['0']
23453,PMC4772661,33101,The instructions during VR training were as follows: “In front of you will appear a road that advances toward you.,The VR intervention program,[195269],[10873],[10988],[False],[0],[0],[False],['0']
23454,PMC4772661,33102,Your goal is to keep your balance in response to changes in the slope or direction of the road”.,The VR intervention program,[195272],[10989],[11085],[False],[0],[0],[False],['0']
23455,PMC4772661,33103,Fig.,The VR intervention program,[195275],[11086],[11090],[False],[0],[0],[False],['0']
23456,PMC4772661,33104,3 The virtual road scene while intercepting moving targets.,The VR intervention program,[195278],[11091],[11150],[False],[0],[0],[False],['0']
23457,PMC4772661,33105,The VR training session included a secondary task: intercepting 18 moving targets (a colored ball of 12.5 cm diameter) appearing above the road.,The VR intervention program,[195281],[11151],[11295],[False],[0],[0],[False],['0']
23458,PMC4772661,33106,Each target can be intercepted when appearing no further than 20 cm from the subject’s hands (which are reflected on the screen as a 4.5 cm in diameter ball).,The VR intervention program,[195284],[11296],[11454],[False],[0],[0],[False],['0']
23459,PMC4772661,33107,"The targets appear one at a time, at pre-set points along the road, alternately on the right and left sides of the subject’s body.",The VR intervention program,[195287],[11455],[11585],[False],[0],[0],[False],['0']
23460,PMC4772661,33108,Each ball is displayed for 5 s and then disappears (unless intercepted).,The VR intervention program,[195290],[11586],[11658],[False],[0],[0],[False],['0']
23461,PMC4772661,33109,"In the event of this occurring, the participant is instructed to maintain his balance (as before) but also to try and reach out with his arms to touch the virtual balls (Fig.",The VR intervention program,[195293],[11659],[11833],[False],[0],[0],[False],['0']
23462,PMC4772661,33110,3).,The VR intervention program,[195296],[11834],[11837],[False],[0],[0],[False],['0']
23463,PMC4772661,33111,"After intercepting a ball, the subject is instructed to return to the ‘home position’ (hands at the sides of the body).",The VR intervention program,[195299],[11838],[11957],[False],[0],[0],[False],['0']
23464,PMC4772661,33112,"In either scene, participants and/or the physical therapist were allowed to increase the system’s setting (platform’s tilt, amplitude and velocity (range 3.0-1.0 km/h)) once they felt that the balance challenge was too low, thus the VR training settings for each participant varied slightly in order to maximize the effectiveness of balance training.",The VR intervention program,[195302],[11958],[12308],[False],[0],[0],[False],['0']
23465,PMC4772661,33113,"During all training sessions, participants wore a safety harness that did not support any body weight.",The VR intervention program,[195305],[12309],[12411],[False],[0],[0],[False],['0']
23466,PMC4772661,33114,"Additionally, a physical therapist stood behind the patient protecting him from falling.",The VR intervention program,[195308],[12412],[12500],[False],[0],[0],[False],['0']
23467,PMC4772661,33115,"Patients participated in 12 sessions of CAREN VR over six weeks, with a total of 30 min of balance training during each session.",The VR intervention program,[195311],[12501],[12629],[False],[0],[0],[False],['0']
23468,PMC4772661,33116,"Rest breaks were allowed if requested, but were not included in the overall practice time.",The VR intervention program,[195314],[12630],[12720],[False],[0],[0],[False],['0']
23469,PMC4772661,33117,"Typically, the participants took three rest breaks during each practice session, each lasting approximately 3–4 min.",The VR intervention program,[195317],[12721],[12837],[False],[0],[0],[False],['0']
23470,PMC4772661,33118,The training session lasted 45–50 min.,The VR intervention program,[195320],[12838],[12876],[False],[0],[0],[False],['0']
23471,PMC4772661,33119,Participants were instructed to continue their regular physical activities between intervention sessions.,The VR intervention program,[195323],[12877],[12982],[False],[0],[0],[False],['0']
23472,PMC4772661,33120,"To date, there is no consensus as to the optimal duration, frequency and intensity of balance training intervention programs in MS.",The VR intervention program,[195326],[12983],[13114],[False],[0],[0],[False],['0']
23473,PMC4772661,33121,"According to Gunn et al’s, systematic review, the duration of balance programs in PwMS vary between 3 and 12 weeks, while intense practice sessions per week vary between 30 and 210 min [11].",The VR intervention program,[195329],[13115],[13305],[False],[0],[0],[False],['0']
23474,PMC4772661,33122,"Therefore, the intervention timeframe was based on our desire to remain effective in terms of balance training frequency, nonetheless, minimize the difficulties involved in transporting the patients to the MS Center, as this could have probably increased the study’s dropout rate.",The VR intervention program,[195332],[13306],[13586],[False],[0],[0],[False],['0']
23475,PMC4772661,33123,The conventional exercise program,The conventional exercise program,[195335],[13587],[13621],[False],[0],[0],[False],['0']
23476,PMC4772661,33124,"In each of the 12 sessions, the participants underwent 10 min of stretching exercises and 20 min of intervention.",The conventional exercise program,[195338],[13622],[13735],[False],[0],[0],[False],['0']
23477,PMC4772661,33125,"The training protocol included a combination of static postural control, weight shifting and perturbations exercises.",The conventional exercise program,[195341],[13736],[13853],[False],[0],[0],[False],['0']
23478,PMC4772661,33126,"During the static postural control exercises, the patients were encouraged to stand motionless on pieces of unstable foam with eyes open or closed for approximately one minute (depending upon the patient’s ability).",The conventional exercise program,[195344],[13854],[14069],[False],[0],[0],[False],['0']
23479,PMC4772661,33127,The difficulty was increased by adding more unstable pieces and reducing the base of support.,The conventional exercise program,[195347],[14070],[14163],[False],[0],[0],[False],['0']
23480,PMC4772661,33128,Weight shifting was achieved by a physical therapist who threw a ball in numerous directions.,The conventional exercise program,[195350],[14164],[14257],[False],[0],[0],[False],['0']
23481,PMC4772661,33129,The patients had to catch the ball approximately 30 times by reaching and stepping.,The conventional exercise program,[195353],[14258],[14341],[False],[0],[0],[False],['0']
23482,PMC4772661,33130,"The difficulty was increased by changing the ball size, throwing further distances and at faster speeds.",The conventional exercise program,[195356],[14342],[14446],[False],[0],[0],[False],['0']
23483,PMC4772661,33131,"As to the perturbations exercises, patients were encouraged to stand on an unstable base (i.e.",The conventional exercise program,[195359],[14447],[14541],[False],[0],[0],[False],['0']
23484,PMC4772661,33132,"a wobble board) while the physical therapist deliberately pushed the top of the board in a downward direction, on different places and at various speeds.",The conventional exercise program,[195362],[14542],[14695],[False],[0],[0],[False],['0']
23485,PMC4772661,33133,"During all sessions, the patient was supervised by the physical therapist in order to prevent falls.",The conventional exercise program,[195365],[14696],[14796],[False],[0],[0],[False],['0']
23486,PMC4772661,33134,The conventional balance training protocol was similar to the protocol used by Yen et al.,The conventional exercise program,[195368],[14797],[14886],[False],[0],[0],[False],['0']
23487,PMC4772661,33135,in their study of people with Parkinson’s disease [28].,The conventional exercise program,[195371],[14887],[14942],[False],[0],[0],[False],['0']
23488,PMC4772661,33136,Instrumented posturography,Instrumented posturography,[195374],[14943],[14970],[False],[0],[0],[False],['0']
23489,PMC4772661,33137,"Posturography parameters were obtained from the Zebris FDM-T Treadmill data (Zebris® Medical GmbH, Germany) taken at the Center of Advanced Technologies in Rehabilitation, Sheba Medical Center, Israel.",Instrumented posturography,[195377],[14971],[15172],[False],[0],[0],[False],['0']
23490,PMC4772661,33138,"A description of the Zebris treadmill is detailed in our previous report on postural control, falls and fear of falling in PwMS [7].",Instrumented posturography,[195380],[15173],[15305],[False],[0],[0],[False],['0']
23491,PMC4772661,33139,"A set of outcome measures taken from the center of pressure (CoP) trajectories during the static stance were:Ellipse sway area (mm2): defined as the 95 % confidence ellipse for the mean of the CoP anterior, posterior, medial and lateral coordinates.. CoP path length (mm): defined as the absolute length of the CoP path movements throughout the testing period..",Instrumented posturography,[195383],[15306],[15667],[False],[0],[0],[False],['0']
23492,PMC4772661,33140,Sway rate (mm/s): defined as the mean speed of movement of the CoP during the testing period..,Instrumented posturography,[195386],[15668],[15762],[False],[0],[0],[False],['0']
23493,PMC4772661,33141,The average pressure distribution of the left and right feet expressed in bodyweight (%).,Instrumented posturography,[195389],[15763],[15852],[False],[0],[0],[False],['0']
23494,PMC4772661,33142,"Additionally, the bilateral pressure distribution asymmetry score was calculated as the absolute difference in pressure distribution between the legs.",Instrumented posturography,[195392],[15853],[16003],[False],[0],[0],[False],['0']
23495,PMC4772661,33143,"In a perfect symmetrical stance, this variable is zero.",Instrumented posturography,[195395],[16004],[16059],[False],[0],[0],[False],['0']
23496,PMC4772661,33144,Each subject completed a sequence of three consecutive tests under two different task conditions (eyes open and eyes closed) with a 1-min break between tasks.,Instrumented posturography,[195398],[16060],[16219],[False],[0],[0],[False],['0']
23497,PMC4772661,33145,"Each task was repeated three times, for 30 s, followed by a 30 s rest period.",Instrumented posturography,[195401],[16220],[16297],[False],[0],[0],[False],['0']
23498,PMC4772661,33146,Posturography results are presented as the mean value of the three tests.,Instrumented posturography,[195404],[16298],[16371],[False],[0],[0],[False],['0']
23499,PMC4772661,33147,The CoP path length was selected as the primary outcome in view of the fact that previous investigations have confirmed a significant association between CoP path length to falls and white matter tract damage in PwMS [29].,Instrumented posturography,[195407],[16372],[16594],[False],[0],[0],[False],['0']
23500,PMC4772661,33148,Clinical balance tests,Clinical balance tests,[195410],[16595],[16618],[False],[0],[0],[False],['0']
23501,PMC4772661,33149,The FRT assesses the subject’s stability by measuring the maximum distance an individual can reach forward while standing in a fixed position.,Clinical balance tests,[195413],[16619],[16761],[False],[0],[0],[False],['0']
23502,PMC4772661,33150,A longer reaching distance indicates improved postural control [30].,Clinical balance tests,[195416],[16762],[16830],[False],[0],[0],[False],['0']
23503,PMC4772661,33151,"The Berg Balance Test (BBS) consists of a set of 14 simple balance related tasks, ranging from rising from a sitting position to standing on one foot.",Clinical balance tests,[195419],[16831],[16981],[False],[0],[0],[False],['0']
23504,PMC4772661,33152,The score ranges from 0 to 56.,Clinical balance tests,[195422],[16982],[17012],[False],[0],[0],[False],['0']
23505,PMC4772661,33153,"A score of 41–56 indicates a low fall risk, 21–40 = medium fall risk and 0 –20 = high fall risk [31].",Clinical balance tests,[195425],[17013],[17114],[False],[0],[0],[False],['0']
23506,PMC4772661,33154,"The Four Square Step Test (FSST) is a timed test, intended to challenge the rapid change in direction while stepping forward, backward and sideways over a low obstacle.",Clinical balance tests,[195428],[17115],[17283],[False],[0],[0],[False],['0']
23507,PMC4772661,33155,"The faster the time measured to perform the task, signifies a superior level of dynamic balance abilities [32].",Clinical balance tests,[195431],[17284],[17395],[False],[0],[0],[False],['0']
23508,PMC4772661,33156,The minimal detectable change estimate for the FSST in MS is 4.6 s [33].,Clinical balance tests,[195434],[17396],[17468],[False],[0],[0],[False],['0']
23509,PMC4772661,33157,"The Falls Efficacy Scale International (FES-I) is a patient self-reported questionnaire used to assess the level of concern relating to falls during 16 activities of daily living, ranging from basic to more demanding activities, including social activities that may contribute to quality of life.",Clinical balance tests,[195437],[17469],[17765],[False],[0],[0],[False],['0']
23510,PMC4772661,33158,"The scores can range from 16 to 64; the higher the score, the more the fear of falling [34].",Clinical balance tests,[195440],[17766],[17858],[False],[0],[0],[False],['0']
23511,PMC4772661,33159,Statistical analysis,Statistical analysis,[195443],[17859],[17880],[False],[0],[0],[False],['0']
23512,PMC4772661,33160,"Data analysis was performed using IBM SPSS statistics software (Version 22.0 for Windows, SPSS Inc. NY, USA).",Statistical analysis,[195446],[17881],[17990],[False],[0],[0],[False],['0']
23513,PMC4772661,33161,"Data was initially examined for normality violations, outliers, errors and missing values.",Statistical analysis,[195449],[17991],[18081],[False],[0],[0],[False],['0']
23514,PMC4772661,33162,Groups were compared at baseline using the t-test for independent samples for continuous variables and the chi-square test for categorical data.,Statistical analysis,[195452],[18082],[18226],[False],[0],[0],[False],['0']
23515,PMC4772661,33163,All outcome variables showed normal distribution.,Statistical analysis,[195455],[18227],[18276],[False],[0],[0],[False],['0']
23516,PMC4772661,33164,The repeated measure analysis of variance (ANOVAs) was selected to examine the effects of each group and determine whether a specific intervention had any advantage in terms of primary and secondary outcome balance measures.,Statistical analysis,[195458],[18277],[18501],[False],[0],[0],[False],['0']
23517,PMC4772661,33165,A P-value in each case < .05 was considered significant.,Statistical analysis,[195461],[18502],[18558],[False],[0],[0],[False],['0']
23518,PMC4772661,33166,Results,Results,[195464],[18559],[18567],[False],[0],[0],[False],['0']
23519,PMC4772661,33167,Fig.,Results,[195467],[18568],[18572],[False],[0],[0],[False],['0']
23520,PMC4772661,33168,4 A flow chart of the study.,Results,[195470],[18573],[18601],[False],[0],[0],[False],['0']
23521,PMC4772661,33169,Table 1 Demographics and clinical characteristics of the study group.,Results,[195473],[18602],[18671],[False],[0],[0],[False],['0']
23522,PMC4772661,33170,Table 2 Comparison of the study outcome measures.,Results,[195476],[18672],[18721],[False],[0],[0],[False],['0']
23523,PMC4772661,33171,A flow chart of the study is shown in Fig.,Results,[195479],[18722],[18764],[False],[0],[0],[False],['0']
23524,PMC4772661,33172,4.,Results,[195482],[18765],[18767],[False],[0],[0],[False],['0']
23525,PMC4772661,33173,Demographic and clinical data of the 30 subjects who fulfilled the study is presented in Table 1.,Results,[195485],[18768],[18865],[False],[0],[0],[False],['0']
23526,PMC4772661,33174,All participants participated in at least 10 (out of the planned 12) training sessions.,Results,[195488],[18866],[18953],[False],[0],[0],[False],['0']
23527,PMC4772661,33175,No significant differences in terms of baseline values were observed between the VR and control group.,Results,[195491],[18954],[19056],[False],[0],[0],[False],['0']
23528,PMC4772661,33176,No adverse or harmful events were reported in both groups.,Results,[195494],[19057],[19115],[False],[0],[0],[False],['0']
23529,PMC4772661,33177,Table 2 shows the values of all outcome measures.,Results,[195497],[19116],[19165],[False],[0],[0],[False],['0']
23530,PMC4772661,33178,"Both groups showed a main effect of time on the CoP path length with eyes open (F = 5.278, P = .024), sway rate with eyes open (F = 5.852, P = .035), FRT (F = 20.841, P = .001), FSST (F = 9.011, P = .031) and the FES-I self-reported questionnaire (F = 17.815, P = .023).",Results,[195500],[19166],[19436],[False],[0],[0],[False],['0']
23531,PMC4772661,33179,"In addition, significant differences supporting VR intervention were observed for the group x time interactions of the FRT (F = 10.173, P = .009) and FES-I (F = 6.710, P = .021).",Results,[195503],[19437],[19615],[False],[0],[0],[False],['0']
23532,PMC4772661,33180,There was no main effect of time in both groups in terms of posturography parameters performed in the closed eyes condition.,Results,[195506],[19616],[19740],[False],[0],[0],[False],['0']
23533,PMC4772661,33181,Discussion,Discussion,[195509],[19741],[19752],[False],[0],[0],[False],['0']
23534,PMC4772661,33182,"The primary objective of the current study was to investigate the effect of VR training on balance in PwMS, utilizing the CAREN system.",Discussion,[195512],[19753],[19888],[False],[0],[0],[False],['0']
23535,PMC4772661,33183,"To our knowledge, our study is the first RCT conducted with the CAREN system in the neurological population.",Discussion,[195515],[19889],[19997],[False],[0],[0],[False],['0']
23536,PMC4772661,33184,"Following six weeks of VR training, both MS groups demonstrated a significant effect on clinical balance tests and 2 (out of 8) posturography measures.",Discussion,[195518],[19998],[20149],[False],[0],[0],[False],['0']
23537,PMC4772661,33185,"Additionally significant differences for the group x time interactions, in favor of the VR group were demonstrated in the functional reach test and the fear of falling questionnaire.",Discussion,[195521],[20150],[20332],[False],[0],[0],[False],['0']
23538,PMC4772661,33186,"Generally, our results resemble several trials performed on other neurological populations such as stroke survivors, people with Parkinson’s disease, and elderly fallers [15–17].",Discussion,[195524],[20333],[20511],[False],[0],[0],[False],['0']
23539,PMC4772661,33187,"In a recent Cochrane systematic review (37 trials, n = 1019) examining the efficacy of VR training on stroke rehabilitation, the authors reported that VR was beneficial in improving the activities of daily living (ADL) function [35].",Discussion,[195527],[20512],[20745],[False],[0],[0],[False],['0']
23540,PMC4772661,33188,"However, the same group noted that there was insufficient evidence as to the effect of VR on gait speed or global motor function.",Discussion,[195530],[20746],[20875],[False],[0],[0],[False],['0']
23541,PMC4772661,33189,At present it is still undetermined as to which VR characteristics are most important for gait and balance training and whether these effects are sustained over an extended period of time.,Discussion,[195533],[20876],[21064],[False],[0],[0],[False],['0']
23542,PMC4772661,33190,"Worth noting, due to the wide variety of VR rehabilitation systems, comparisons between studies are confusing and could be misleading.",Discussion,[195536],[21065],[21199],[False],[0],[0],[False],['0']
23543,PMC4772661,33191,"This refers mainly to systematic reviews that inadvertently defined low-cost commercial exergaming devices (e.g Nintendo Wii, Sony eye-toy, Microsoft Kinect) as VR training tools.",Discussion,[195539],[21200],[21379],[False],[0],[0],[False],['0']
23544,PMC4772661,33192,We note several significant differences between these two training tools.,Discussion,[195542],[21380],[21453],[False],[0],[0],[False],['0']
23545,PMC4772661,33193,"Originally, exergaming devices were developed for playing needs of healthy children.",Discussion,[195545],[21454],[21538],[False],[0],[0],[False],['0']
23546,PMC4772661,33194,"Therefore, it is questionable whether the playing scenarios offered by these devices are relevant for the rehabilitation needs of patients with mobility difficulties.",Discussion,[195548],[21539],[21705],[False],[0],[0],[False],['0']
23547,PMC4772661,33195,"According to a recent systematic review, the addition of Wii gaming to conventional rehabilitation in patients with chronic stroke, significantly improved in performance in the Timed up and go test but not in the other physical measures (e.g functional independence measure score, BBS and anterior-posterior sway).",Discussion,[195551],[21706],[22020],[False],[0],[0],[False],['0']
23548,PMC4772661,33196,"Furthermore, the pooled effect statistic was small and not beyond the minimal detectable change [36].",Discussion,[195554],[22021],[22122],[False],[0],[0],[False],['0']
23549,PMC4772661,33197,"Moreover, commercial exergaming devices do not allow scenario adjustments that in many cases are necessary to meet the physical abilities and treatment goals of the patient.",Discussion,[195557],[22123],[22296],[False],[0],[0],[False],['0']
23550,PMC4772661,33198,"In contrast, VR system training scenarios can be set up according to the patient’s abilities and progress during the intervention program.",Discussion,[195560],[22297],[22435],[False],[0],[0],[False],['0']
23551,PMC4772661,33199,"Additionally, VR training can be conducted in a controlled environment in order to regulate mechanical and visual cues.",Discussion,[195563],[22436],[22555],[False],[0],[0],[False],['0']
23552,PMC4772661,33200,"As such, rehabilitation outcomes may be specifically investigated without the risk of confounding variables.",Discussion,[195566],[22556],[22664],[False],[0],[0],[False],['0']
23553,PMC4772661,33201,"In line with the distinction between commercial exergaming and VR training, our study explored a medically-oriented VR system, the CAREN system.",Discussion,[195569],[22665],[22809],[False],[0],[0],[False],['0']
23554,PMC4772661,33202,"Previous studies examining the efficacy of this device on balance performance primarily studied patients with orthopedic and vestibular pathologies, with promising results [24, 25, 37].",Discussion,[195572],[22810],[22995],[False],[0],[0],[False],['0']
23555,PMC4772661,33203,"The CAREN system challenges subjects both physically and cognitively in realistic, interactive and controlled environments.",Discussion,[195575],[22996],[23119],[False],[0],[0],[False],['0']
23556,PMC4772661,33204,Patients can interact with the system due to the integrated force plates measuring weight shifting and body motion.,Discussion,[195578],[23120],[23235],[False],[0],[0],[False],['0']
23557,PMC4772661,33205,Detailed visual displays are projected onto a large screen and move in synchronization with the platform and the subjects’ movements.,Discussion,[195581],[23236],[23369],[False],[0],[0],[False],['0']
23558,PMC4772661,33206,Engagement is further enhanced with realistic sounds and scents.,Discussion,[195584],[23370],[23434],[False],[0],[0],[False],['0']
23559,PMC4772661,33207,"Additionally, treatment on the CAREN can allow the subject to identify problematic balance situations that occasionally occur in the community but cannot be replicated in traditional physical therapy.",Discussion,[195587],[23435],[23635],[False],[0],[0],[False],['0']
23560,PMC4772661,33208,"To date, this is the first RCT study examining the CAREN system in the MS population.",Discussion,[195590],[23636],[23721],[False],[0],[0],[False],['0']
23561,PMC4772661,33209,"In accordance with our findings, we are confident that this system is safe and feasible for use in balance rehabilitation programs for PwMS.",Discussion,[195593],[23722],[23862],[False],[0],[0],[False],['0']
23562,PMC4772661,33210,"Notably, none of the patients reported any motion sickness during the practice sessions.",Discussion,[195596],[23863],[23951],[False],[0],[0],[False],['0']
23563,PMC4772661,33211,"In addition, although information regarding engagement and motivation while practicing with the CAREN system wasn’t systematically collected, we report that participants in the VR group barely missed a practice session.",Discussion,[195599],[23952],[24171],[False],[0],[0],[False],['0']
23564,PMC4772661,33212,"Moreover, although a similar appearance rate was recorded in the conventional exercise program, at termination, most VR patients indicated an interest in continuing with the VR system.",Discussion,[195602],[24172],[24356],[False],[0],[0],[False],['0']
23565,PMC4772661,33213,We hypothesize that this unofficial outcome is correlated with the fear of falling self-report questionnaire findings.,Discussion,[195605],[24357],[24475],[False],[0],[0],[False],['0']
23566,PMC4772661,33214,Participants in the VR group significantly reported less fear of falling compared to the control group.,Discussion,[195608],[24476],[24579],[False],[0],[0],[False],['0']
23567,PMC4772661,33215,"We speculate that the CAREN’s unique environment is related to this outcome, as has been raised in Collins et al’s recent systematic review [37].",Discussion,[195611],[24580],[24725],[False],[0],[0],[False],['0']
23568,PMC4772661,33216,"While most MS patients are familiar and have a basic knowledge regarding physical therapy sessions, this is not the case with interventions based on high technology VR systems.",Discussion,[195614],[24726],[24902],[False],[0],[0],[False],['0']
23569,PMC4772661,33217,"As noted previously, the CAREN system includes a huge screen, surround audio speakers and a large platform tilting and rolling in all directions.",Discussion,[195617],[24903],[25048],[False],[0],[0],[False],['0']
23570,PMC4772661,33218,"Moreover, this sophisticated system is placed in a dedicated darkened room and activated by a technician.",Discussion,[195620],[25049],[25154],[False],[0],[0],[False],['0']
23571,PMC4772661,33219,"There is a possibility that all these factors, combined with the new experience, had a positive effect on the patient’s level of confidence.",Discussion,[195623],[25155],[25295],[False],[0],[0],[False],['0']
23572,PMC4772661,33220,"Nevertheless, future studies are needed to confirm this assumption.",Discussion,[195626],[25296],[25363],[False],[0],[0],[False],['0']
23573,PMC4772661,33221,"In line with this finding, Duque et al.",Discussion,[195629],[25364],[25403],[False],[0],[0],[False],['0']
23574,PMC4772661,33222,[15] examined the effectiveness of a 6-week balance training program in 60 community older subjects using a VR system.,Discussion,[195632],[25404],[25522],[False],[0],[0],[False],['0']
23575,PMC4772661,33223,The authors reported a significant reduction in the incidence of falls and fear of falling at termination of the intervention period in the VR group compared with the control group [15].,Discussion,[195635],[25523],[25709],[False],[0],[0],[False],['0']
23576,PMC4772661,33224,Our study has some strengths and limitations.,Discussion,[195638],[25710],[25755],[False],[0],[0],[False],['0']
23577,PMC4772661,33225,"The major strength of this study is that this is the first demonstration of the beneficial effect of balance training on balance parameters and fear of falling in PwMS by using a novel, accurate, safe and effective VR method.",Discussion,[195641],[25756],[25981],[False],[0],[0],[False],['0']
23578,PMC4772661,33226,Another contribution of the study was the use of computerized posturography to document changes in balance parameters.,Discussion,[195644],[25982],[26100],[False],[0],[0],[False],['0']
23579,PMC4772661,33227,"One of the advantages of this method is a more precise determination of changes in balance parameters, compared to the usual clinical balance tests [38].",Discussion,[195647],[26101],[26254],[False],[0],[0],[False],['0']
23580,PMC4772661,33228,This data could be valuable for comparison in future studies examining postural control in PwMS.,Discussion,[195650],[26255],[26351],[False],[0],[0],[False],['0']
23581,PMC4772661,33229,Limitations,Limitations,[195653],[26352],[26364],[False],[0],[0],[False],['0']
23582,PMC4772661,33230,"Performing a double-blind, controlled trial to test this system is clearly unfeasible; therefore we decided to use an open approach in which both the participants and medical team were aware of the interventions.",Limitations,[195656],[26365],[26577],[True],['Blinding'],"['Performing a double-blind, controlled trial to test this system is clearly unfeasible']",[True],['Blinding']
23583,PMC4772661,33231,"However, to prevent any assessment bias, different physiotherapists with no access to the subjects’ data were specifically assigned to perform either assessment or training.",Limitations,[195662],[26578],[26751],[False],[0],[0],[False],['0']
23584,PMC4772661,33232,"Another limitation of the study was the absence of a follow up examination; consequently, we were unable to report whether the improvements demonstrated by the VR participants were maintained over time.",Limitations,[195666],[26752],[26954],[True],['RelevantOutcomeExcluded'],['the absence of a follow up examination'],[True],['OutcomeMeasures']
23585,PMC4772661,33233,This important information deserves further exploration in future longitudinal clinical trials.,Limitations,[195671],[26955],[27050],[False],[0],[0],[False],['0']
23586,PMC4772661,33234,"Finally, in light of the fact that this is a pilot study, the sample size was relatively small.",Limitations,[195676],[27051],[27146],[True],['SampleSize'],['the sample size was relatively small'],[True],['UnderpoweredStudy']
23587,PMC4772661,33235,"Nevertheless, our results may serve future studies to generate effect sizes, which can be used to power a larger clinical trial aimed at improving postural control, reducing falls in PwMS and other neurological populations based on VR technology.",Limitations,[195680],[27147],[27393],[False],[0],[0],[False],['0']
23588,PMC4772661,33236,Conclusions,Conclusions,[195683],[27394],[27406],[False],[0],[0],[False],['0']
23589,PMC4772661,33237,We have successfully demonstrated that balance training based on the CAREN device is an effective method in balance training for PwMS.,Conclusions,[195686],[27407],[27541],[False],[0],[0],[False],['0']
23590,PMC4772661,33238,"Although it is not intended to replace, but rather complement other balance intervention programs, VR training offers a safe and well-accepted intervention with appropriate levels of effectiveness and adherence.",Conclusions,[195689],[27542],[27753],[False],[0],[0],[False],['0']
23591,PMC4772661,33239,"While traditional therapy methods will continue to be employed in the clinic, VR based balance training programs have demonstrated the ability to directly influence balance performance.",Conclusions,[195692],[27754],[27939],[False],[0],[0],[False],['0']
23592,PMC4772661,33240,"Nevertheless, it is worth noting that while the CAREN system has numerous clinical advantages, the financial and spatial requirements for the system may preclude this device from being a rehabilitation aid in several medical centers and in cases of MS patients treated in the community and/or restricted to their homes.",Conclusions,[195695],[27940],[28259],[False],[0],[0],[False],['0']
23593,PMC4772661,33241,Abbreviations,Abbreviations,[195698],[28260],[28274],[False],[0],[0],[False],['0']
23594,PMC4772661,33242,ANOVA Analysis of variance,Abbreviations|ANOVA Analysis of variance,[195701],[28275],[28301],[False],[0],[0],[False],['0']
23595,PMC4772661,33243,BBS Berg balance scale,Abbreviations|BBS Berg balance scale,[195704],[28302],[28324],[False],[0],[0],[False],['0']
23596,PMC4772661,33244,CAREN Computer assisted rehabilitation environment,Abbreviations|CAREN Computer assisted rehabilitation environment,[195707],[28325],[28375],[False],[0],[0],[False],['0']
23597,PMC4772661,33245,CoP Center of pressure,Abbreviations|CoP Center of pressure,[195710],[28376],[28398],[False],[0],[0],[False],['0']
23598,PMC4772661,33246,EDSS Expanded Disability Status Scale,Abbreviations|EDSS Expanded Disability Status Scale,[195713],[28399],[28436],[False],[0],[0],[False],['0']
23599,PMC4772661,33247,FES-I Falls Efficacy Scale International,Abbreviations|FES-I Falls Efficacy Scale International,[195716],[28437],[28477],[False],[0],[0],[False],['0']
23600,PMC4772661,33248,FRT Functional reach test,Abbreviations|FRT Functional reach test,[195719],[28478],[28503],[False],[0],[0],[False],['0']
23601,PMC4772661,33249,FSST Four square step test,Abbreviations|FSST Four square step test,[195722],[28504],[28530],[False],[0],[0],[False],['0']
23602,PMC4772661,33250,MS Multiple sclerosis,Abbreviations|MS Multiple sclerosis,[195725],[28531],[28552],[False],[0],[0],[False],['0']
23603,PMC4772661,33251,PwMS Persons with MS,Abbreviations|PwMS Persons with MS,[195728],[28553],[28573],[False],[0],[0],[False],['0']
23604,PMC4772661,33252,VR Virtual realityCompeting interests,Abbreviations|VR Virtual realityCompeting interests,[195731],[28574],[28611],[False],[0],[0],[False],['0']
23605,PMC4772661,33253,The authors declare that they have no competing interests.Authors’ contributions,Abbreviations|VR Virtual realityCompeting interests,[195734],[28612],[28692],[False],[0],[0],[False],['0']
23606,PMC4772661,33254,"AK made a substantial contribution to conception and design, acquisition of data and analysis and interpretation of data; drafted the manuscript; gave final approval of the version to be published; agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.",Abbreviations|VR Virtual realityCompeting interests,[195737],[28693],[29076],[False],[0],[0],[False],['0']
23607,PMC4772661,33255,"IL, FL had an active role in implementation of the intervention groups.",Abbreviations|VR Virtual realityCompeting interests,[195740],[29077],[29148],[False],[0],[0],[False],['0']
23608,PMC4772661,33256,HB had a major role in assessment of participants prior and at termination of the intervention period.,Abbreviations|VR Virtual realityCompeting interests,[195743],[29149],[29251],[False],[0],[0],[False],['0']
23609,PMC4772661,33257,AA was responsible to secure that all patients recruited for the study were eligible according to the study’s criteria; had an active role in drafting the final manuscript.,Abbreviations|VR Virtual realityCompeting interests,[195746],[29252],[29424],[False],[0],[0],[False],['0']
23610,PMC4772661,33258,All authors takes public responsibility for appropriate portions of the content.,Abbreviations|VR Virtual realityCompeting interests,[195749],[29425],[29505],[False],[0],[0],[False],['0']
23611,PMC4772661,33259,All authors read and approved the final manuscript.,Abbreviations|VR Virtual realityCompeting interests,[195752],[29506],[29557],[False],[0],[0],[False],['0']
23612,PMC4772661,33260,Acknowledgements,Abbreviations|Acknowledgements,[195755],[29558],[29574],[False],[0],[0],[False],['0']
23613,PMC4772661,33261,This investigation was supported by a Pilot Research Award from the National Multiple Sclerosis Society (PP2208).,Abbreviations|Acknowledgements,[195758],[29575],[29688],[False],[0],[0],[False],['0']
26129,PMC5070122,34333,Motivational counselling and SMS-reminders for reduction of daily sitting time in patients with rheumatoid arthritis: a descriptive randomised controlled feasibility study,Title,[201465],[28053],[171],[False],[0],[0],[False],['0']
26130,PMC5070122,34334,Background,Abstract,[201469],[172],[183],[False],[0],[0],[False],['0']
26131,PMC5070122,34335,Patients with rheumatoid arthritis (RA) spend a high proportion of their waking time in sedentary behaviour (SB) and have an increased risk of cardiovascular disease.,Abstract,[201473],[184],[350],[False],[0],[0],[False],['0']
26132,PMC5070122,34336,Reduction of SB and increase in light intensity physical activity has been suggested as a means of improvement of health in patients with mobility problems.,Abstract,[201477],[351],[507],[False],[0],[0],[False],['0']
26133,PMC5070122,34337,Short-term intervention studies have demonstrated that SB can be reduced by behavioural interventions in sedentary populations.,Abstract,[201481],[508],[635],[False],[0],[0],[False],['0']
26134,PMC5070122,34338,"To evaluate descriptively the feasibility of recruitment, randomisation, outcome assessments, retention and the acceptability of an individually tailored, theory-based behavioural intervention targeting reduction in daily sitting time in patients with RA.",Abstract,[201485],[636],[891],[False],[0],[0],[False],['0']
26135,PMC5070122,34339,Methods,Methods,[201489],[892],[900],[False],[0],[0],[False],['0']
26136,PMC5070122,34340,"A randomised, controlled trial with two parallel groups.",Methods,[201493],[901],[957],[False],[0],[0],[False],['0']
26137,PMC5070122,34341,RA patients >18 years of age and Health Assessment Questionnaire (HAQ) score < 2.5 were consecutively invited and screened for daily leisure time sitting > 4 h. The 16-week intervention included 1) three individual motivational counselling sessions and 2) individual text message reminders aimed at reducing daily sitting time.,Methods,[201497],[958],[1285],[False],[0],[0],[False],['0']
26138,PMC5070122,34342,The control group was encouraged to maintain their usual lifestyles.,Methods,[201501],[1286],[1354],[False],[0],[0],[False],['0']
26139,PMC5070122,34343,Outcomes were assessed at baseline and after the 16 week intervention.,Methods,[201505],[1355],[1425],[False],[0],[0],[False],['0']
26140,PMC5070122,34344,Daily sitting time was measured using an ActivPAL3TM activity monitor.,Methods,[201509],[1426],[1496],[False],[0],[0],[False],['0']
26141,PMC5070122,34345,The study was not powered to show superiority; rather the objective was to focus on acceptability among patients and clinical health professionals.,Methods,[201513],[1497],[1644],[False],[0],[0],[False],['0']
26142,PMC5070122,34346,Results,Results,[201517],[1645],[1653],[False],[0],[0],[False],['0']
26143,PMC5070122,34347,"In total, 107 patients were invited and screened before 20 met eligibility criteria and consented; reasons for declining study participation were mostly flares, lack of time and co-morbidities.",Results,[201521],[1654],[1847],[False],[0],[0],[False],['0']
26144,PMC5070122,34348,One patient from the control group dropped out before end of intervention (due to a RA flare).,Results,[201525],[1848],[1942],[False],[0],[0],[False],['0']
26145,PMC5070122,34349,Intervention participants completed all counselling sessions.,Results,[201529],[1943],[2004],[False],[0],[0],[False],['0']
26146,PMC5070122,34350,All procedures regarding implementation of the trial protocol were feasible.,Results,[201533],[2005],[2081],[False],[0],[0],[False],['0']
26147,PMC5070122,34351,The daily sitting time was reduced on average by 0.30 h in the intervention group unlike the control group that tended to increase it by 0.15 h after 16 weeks.,Results,[201537],[2082],[2241],[False],[0],[0],[False],['0']
26148,PMC5070122,34352,Conclusions,Conclusions,[201541],[2242],[2254],[False],[0],[0],[False],['0']
26149,PMC5070122,34353,This study shows that an individually tailored behavioural intervention targeting reduction of SB was feasible and acceptable to patients with RA.,Conclusions,[201545],[2255],[2401],[False],[0],[0],[False],['0']
26150,PMC5070122,34354,Trial registration,Trial registration,[201549],[2402],[2421],[False],[0],[0],[False],['0']
26151,PMC5070122,34355,The Danish Data Protection Agency (ref.nb.,Trial registration,[201553],[2422],[2464],[False],[0],[0],[False],['0']
26152,PMC5070122,34356,"711-1-08 - 20 March 2011), the Ethics Committee of the Capital Region of Denmark (ref.nb.",Trial registration,[201557],[2465],[2554],[False],[0],[0],[False],['0']
26153,PMC5070122,34357,"H-2-2012-112- 17 October 2012), clinicaltrials.gov (NCT01969604 - October 17 2013, retrospectively registered).",Trial registration,[201561],[2555],[2666],[False],[0],[0],[False],['0']
26154,PMC5070122,34358,Background,Background,[201565],[2667],[2679],[False],[0],[0],[False],['0']
26155,PMC5070122,34359,Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting 0.5–1.0 % of the population in developed countries [1].,Background,[201569],[2680],[2805],[False],[0],[0],[False],['0']
26156,PMC5070122,34360,"It is associated with pain and fatigue, decreased health-related quality of life and co-morbidity such as cardiovascular diseases and osteoporosis [1–4].",Background,[201573],[2806],[2959],[False],[0],[0],[False],['0']
26157,PMC5070122,34361,"Short-term health benefits from exercise have been documented in patients with RA [5, 6].",Background,[201577],[2960],[3049],[False],[0],[0],[False],['0']
26158,PMC5070122,34362,"However, the majority of patients with RA do not meet recommendations of moderate to vigorous physical activity (MVPA) [7] and spend a higher proportion of their waking hours sitting than the general population (71 % and 62 % respectively of waking hours, objectively measured by accelerometer) [8].",Background,[201581],[3050],[3349],[False],[0],[0],[False],['0']
26159,PMC5070122,34363,Sedentary behaviour (SB) is defined as any waking behaviour characterized by energy expenditure <1.,Background,[201585],[3350],[3449],[False],[0],[0],[False],['0']
26160,PMC5070122,34364,5 metabolic equivalents (METs) while in a sitting or reclined position [9].,Background,[201589],[3450],[3525],[False],[0],[0],[False],['0']
26161,PMC5070122,34365,"Recent population-based observational studies measuring SB as self-reported TV-viewing [10–14], leisure time sitting [15, 16] and total daily sitting time [13, 15, 17] have suggested that SB may be a behaviourally independent risk factor for cardiovascular disease [10, 16, 17], premature death [10, 11, 13], cardio-metabolic biomarkers [12, 15] and certain types of cancer [14].",Background,[201593],[3526],[3905],[False],[0],[0],[False],['0']
26162,PMC5070122,34366,"Accordingly, a meta-analysis of interventions aiming to reduce SB in adults has proposed beneficial effects of interventions targeting reduction of SB specifically [18].",Background,[201597],[3906],[4075],[False],[0],[0],[False],['0']
26163,PMC5070122,34367,"Moreover, a review from 2012 has suggested that aiming to increase PA levels among patients with mobility disability should not focus solely on increasing MVPA, but should also target reduction of sitting time and increase of light intensity activity, the “non-exercise” part of the activity continuum [19].",Background,[201601],[4076],[4383],[False],[0],[0],[False],['0']
26164,PMC5070122,34368,This approach may prove feasible for improving and maintaining health in patients with chronic disease and mobility limitations.,Background,[201605],[4384],[4512],[False],[0],[0],[False],['0']
26165,PMC5070122,34369,"Nonetheless, there are no previous intervention studies specifically targeting reduction of SB in patients with RA.",Background,[201609],[4513],[4628],[False],[0],[0],[False],['0']
26166,PMC5070122,34370,"Intervention studies using objective measures of sitting time as outcome measures in older [20], overweight and obese adults [21, 22], and in desk-based office employees [23, 24] have demonstrated that sitting time can be reduced through behavioural interventions [20, 21], use of sit-stand workstations [23] and height-adjustable workstations, combined with face-to-face coaching and telephone support [24].",Background,[201613],[4629],[5037],[False],[0],[0],[False],['0']
26167,PMC5070122,34371,"Moreover, energy expenditure can be increased by reducing TV-viewing time [22], possibly as a result of replacing sedentary TV-viewing time with activities that require higher energy expenditure e.g.",Background,[201617],[5038],[5237],[False],[0],[0],[False],['0']
26168,PMC5070122,34372,standing or moving about.,Background,[201621],[5238],[5263],[False],[0],[0],[False],['0']
26169,PMC5070122,34373,Means to reduce SB have included motivational counselling for encouraging people to make behavioural changes to improve their health.,Background,[201625],[5264],[5397],[False],[0],[0],[False],['0']
26170,PMC5070122,34374,"This has shown positive effects on health behaviours, such as alcohol- and tobacco use or sedentary behaviour in a range of medical care settings [25] and on waist circumference and insulin in healthy adults [26].",Background,[201629],[5398],[5611],[False],[0],[0],[False],['0']
26171,PMC5070122,34375,"In addition, studies that have included text messages addressing changes in daily physical activity as part of the behavioural intervention have shown positive effects on physical activity levels and weight in clinical settings [27].",Background,[201633],[5612],[5845],[False],[0],[0],[False],['0']
26172,PMC5070122,34376,Whether reduction of SB is a beneficial health promotion strategy in patients with RA is yet to be determined.,Background,[201637],[5846],[5956],[False],[0],[0],[False],['0']
26173,PMC5070122,34377,We wanted to investigate this by means of an individually tailored behavioural intervention in a randomized controlled trial.,Background,[201641],[5957],[6082],[False],[0],[0],[False],['0']
26174,PMC5070122,34378,"However, considering the novelty of this approach and the fluctuating severity of RA, we found it essential to determine first whether the methods, practicalities and demands of such a study were acceptable for patients with RA and for those involved in implementing the intervention.",Background,[201645],[6083],[6367],[False],[0],[0],[False],['0']
26175,PMC5070122,34379,"We wanted to evaluate individual reactions to the intervention and time and resources spent on recruitment, intervention and assessments.",Background,[201649],[6368],[6505],[False],[0],[0],[False],['0']
26176,PMC5070122,34380,"Therefore, the aim of the present study was to evaluate descriptively the feasibility of recruitment, randomisation, retention, and outcome assessments at baseline and immediately after the intervention.",Background,[201653],[6506],[6709],[False],[0],[0],[False],['0']
26177,PMC5070122,34381,"Furthermore, to evaluate the acceptability of an individually tailored, theory-based behavioural intervention targeting reduction in daily sedentary behaviour in patients with RA.",Background,[201657],[6710],[6889],[False],[0],[0],[False],['0']
26178,PMC5070122,34382,Methods,Methods,[201661],[6890],[6898],[False],[0],[0],[False],['0']
26179,PMC5070122,34383,Design,Methods|Design,[201665],[6899],[6905],[False],[0],[0],[False],['0']
26180,PMC5070122,34384,"A 16 week randomised controlled trial with focus on feasibility and acceptability, and with blinded outcome assessors.",Methods|Design,[201669],[6906],[7024],[False],[0],[0],[False],['0']
26181,PMC5070122,34385,Setting and participants,Setting and participants,[201673],[7025],[7050],[False],[0],[0],[False],['0']
26182,PMC5070122,34386,"Participants were recruited from the rheumatology outpatient clinic at Rigshospitalet, Glostrup.",Setting and participants,[201677],[7051],[7147],[False],[0],[0],[False],['0']
26183,PMC5070122,34387,Inclusion criteria were: RA (defined by the 1987 American College of Rheumatology/European League Against Rheumatism classification criteria for RA) [28]; > 18 years of age; disease duration > 1 year; a Health Assessment Questionnaire (HAQ)-score < 2.5; understanding/speaking Danish; daily leisure-time sitting > 4 h and access to a mobile phone.,Setting and participants,[201681],[7148],[7495],[False],[0],[0],[False],['0']
26184,PMC5070122,34388,Exclusion criteria were: vigorous intensity physical activity > 8 h per week; HAQ-score > 2.5 and pregnancy.,Setting and participants,[201685],[7496],[7604],[False],[0],[0],[False],['0']
26185,PMC5070122,34389,The project coordinator (TT) screened medical records systematically for potentially eligible patients who were consecutively invited by letter.,Setting and participants,[201689],[7605],[7749],[False],[0],[0],[False],['0']
26186,PMC5070122,34390,A few days later TT conducted a telephone-based screening to ensure that the patients met the eligibility criteria regarding SB and vigorous physical activity using the Physical Activity Scale (PAS 2.1) [29].,Setting and participants,[201693],[7750],[7958],[False],[0],[0],[False],['0']
26187,PMC5070122,34391,Eligible patients were invited to an individual information session with TT.,Setting and participants,[201697],[7959],[8035],[False],[0],[0],[False],['0']
26188,PMC5070122,34392,Informed consent was obtained from each patient immediately following the session or during the following two days.,Setting and participants,[201701],[8036],[8151],[False],[0],[0],[False],['0']
26189,PMC5070122,34393,Randomisation and assessor blinding,Randomisation and assessor blinding,[201705],[8152],[8188],[False],[0],[0],[False],['0']
26190,PMC5070122,34394,"Randomisation was conducted by an external collaborator, ZiteLab Aps (http://www.zitelab.dk/), which was not involved in the assessments or intervention.",Randomisation and assessor blinding,[201709],[8189],[8342],[False],[0],[0],[False],['0']
26191,PMC5070122,34395,It was performed immediately after baseline measurements via computer-generated “random numbers” with randomisation to either an intervention group (n = 10) or a control group (n = 10).,Randomisation and assessor blinding,[201713],[8343],[8528],[False],[0],[0],[False],['0']
26192,PMC5070122,34396,The outcome assessors were blinded to participants’ allocation status throughout the study.,Randomisation and assessor blinding,[201717],[8529],[8620],[False],[0],[0],[False],['0']
26193,PMC5070122,34397,Behaviour change intervention,Behaviour change intervention,[201721],[8621],[8651],[False],[0],[0],[False],['0']
26194,PMC5070122,34398,"The 16 week intervention was conducted at Rigshospitalet, Glostrup, and consisted of 1) three individual motivational counselling sessions and 2) individual text message reminders targeting reduction of SB.",Behaviour change intervention,[201725],[8652],[8858],[False],[0],[0],[False],['0']
26195,PMC5070122,34399,"TT monitored overall programme adherence, programme logistics and the dispatch of the text messages.",Behaviour change intervention,[201729],[8859],[8959],[False],[0],[0],[False],['0']
26196,PMC5070122,34400,Training of project staff prior to the intervention,Training of project staff prior to the intervention,[201733],[8960],[9012],[False],[0],[0],[False],['0']
26197,PMC5070122,34401,"Five of the project staff (three project nurses, BAE and TT) conducted the motivational counselling sessions and attended a one-day tailored motivational interviewing (MI) training course supervised by a clinical psychologist with broad experience in MI and health behaviour change.",Training of project staff prior to the intervention,[201737],[9013],[9295],[False],[0],[0],[False],['0']
26198,PMC5070122,34402,"The course featured MI theory, principles and interview techniques.",Training of project staff prior to the intervention,[201741],[9296],[9363],[False],[0],[0],[False],['0']
26199,PMC5070122,34403,"During the study, the project staff received continuous supervision by the psychologist including discussion of conducted counselling sessions.",Training of project staff prior to the intervention,[201745],[9364],[9507],[False],[0],[0],[False],['0']
26200,PMC5070122,34404,Two occupational therapists with broad clinical experience in rheumatology conducted the outcome assessments.,Training of project staff prior to the intervention,[201749],[9508],[9617],[False],[0],[0],[False],['0']
26201,PMC5070122,34405,Prior to study start the therapists received supervision from BAE and TT on how to perform the assessments.,Training of project staff prior to the intervention,[201753],[9618],[9725],[False],[0],[0],[False],['0']
26202,PMC5070122,34406,"In addition, they were trained to save all recorded data through an online interface via a tablet.",Training of project staff prior to the intervention,[201757],[9726],[9824],[False],[0],[0],[False],['0']
26203,PMC5070122,34407,During the study the assessors were continuously supervised by TT in order to secure a uniform data collection methodology.,Training of project staff prior to the intervention,[201761],[9825],[9948],[False],[0],[0],[False],['0']
26204,PMC5070122,34408,Structure and content of the intervention,Structure and content of the intervention,[201765],[9949],[9991],[False],[0],[0],[False],['0']
26205,PMC5070122,34409,Participants received three individual motivational counselling sessions.,Structure and content of the intervention,[201769],[9992],[10065],[False],[0],[0],[False],['0']
26206,PMC5070122,34410,The first session took place on the day the participants were randomised and informed about allocation status; the second and third sessions took place two and ten weeks after the first session.,Structure and content of the intervention,[201773],[10066],[10260],[False],[0],[0],[False],['0']
26207,PMC5070122,34411,"The sessions were conducted either in a room at the rheumatology outpatient clinic or in the research unit, where the same interviewer (BAE, TT or a project nurse) conducted all three sessions.",Structure and content of the intervention,[201777],[10261],[10454],[False],[0],[0],[False],['0']
26208,PMC5070122,34412,Fig.,Structure and content of the intervention,[201781],[10455],[10459],[False],[0],[0],[False],['0']
26209,PMC5070122,34413,1 Time schedule of the 16 week intervention period including the applied behaviour change techniques according to the intervention taxonomy by Michie et al.,Structure and content of the intervention,[201785],[10460],[10616],[False],[0],[0],[False],['0']
26210,PMC5070122,34414,[33].,Structure and content of the intervention,[201789],[10617],[10622],[False],[0],[0],[False],['0']
26211,PMC5070122,34415,The intervention was based on behavioural choice theory [30] which addresses how people replace the choice of an unhealthy reinforcing behaviour with less reinforcing and more healthy alternatives.,Structure and content of the intervention,[201793],[10623],[10820],[False],[0],[0],[False],['0']
26212,PMC5070122,34416,Self-efficacy [31] was chosen because it in particular addresses an individual’s own belief in what one can do under different conditions with the skills the individual holds.,Structure and content of the intervention,[201797],[10821],[10996],[False],[0],[0],[False],['0']
26213,PMC5070122,34417,"Furthermore, motivational interviewing techniques were included in the intervention [32].",Structure and content of the intervention,[201801],[10997],[11086],[False],[0],[0],[False],['0']
26214,PMC5070122,34418,The first motivational counselling session commenced by identifying the participant’s physical activity and SB patterns during a typical weekday and the interviewer reporting the health benefits of reducing SB.,Structure and content of the intervention,[201805],[11087],[11297],[False],[0],[0],[False],['0']
26215,PMC5070122,34419,The session also incorporated individual behavioural goal-setting and action-planning for change in SB with the participants identifying daily behavioural choices and describing possible behaviour alternatives (e.g.,Structure and content of the intervention,[201809],[11298],[11513],[False],[0],[0],[False],['0']
26216,PMC5070122,34420,‘Every day at work I will hold my telephone conversations standing up’ or ‘I will leave the remote at the TV tonight so I’ll have to get up whenever I want to change the channel’).,Structure and content of the intervention,[201813],[11514],[11694],[False],[0],[0],[False],['0']
26217,PMC5070122,34421,"In session two and three, behavioural goals were reviewed, including discussion of pros and cons of the outcomes of the behaviour, identity associated with the changed behaviour, and feed-back on the behaviour from the interviewer.",Structure and content of the intervention,[201817],[11695],[11926],[False],[0],[0],[False],['0']
26218,PMC5070122,34422,"Potentially, behavioural goals were modified or new ones were set.",Structure and content of the intervention,[201821],[11927],[11993],[False],[0],[0],[False],['0']
26219,PMC5070122,34423,"During the three sessions the interviewer was supported by a number of MI sheets, including prompt sheets with relevant questions for the participants, a “decisional balance” work sheet and sheets to assess importance and self-belief in reducing daily SB.",Structure and content of the intervention,[201825],[11994],[12249],[False],[0],[0],[False],['0']
26220,PMC5070122,34424,A time schedule of the intervention and the applied behaviour change techniques according to the intervention taxonomy by Michie et al.,Structure and content of the intervention,[201829],[12250],[12385],[False],[0],[0],[False],['0']
26221,PMC5070122,34425,[33] is provided in Fig.,Structure and content of the intervention,[201833],[12386],[12410],[False],[0],[0],[False],['0']
26222,PMC5070122,34426,1.,Structure and content of the intervention,[201837],[12411],[12413],[False],[0],[0],[False],['0']
26223,PMC5070122,34427,Key messages,Key messages,[201841],[12414],[12428],[False],[0],[0],[False],['0']
26224,PMC5070122,34428,"The intervention focused on four key messages regarding reduction of SB; 1) reduce TV-viewing, 2) substitute sitting with standing when possible – at work and/or at home, 3) break up prolonged sitting by standing up frequently and 4) maximum 30 min of sitting per episode.",Key messages,[201845],[12429],[12701],[False],[0],[0],[False],['0']
26225,PMC5070122,34429,During the intervention the participants were provided with four booklets containing each of the key messages with specific suggestions and ideas for reduction of daily sitting time.,Key messages,[201849],[12702],[12884],[False],[0],[0],[False],['0']
26226,PMC5070122,34430,Individual text message reminders,Individual text message reminders,[201853],[12885],[12919],[False],[0],[0],[False],['0']
26227,PMC5070122,34431,"After each motivational counselling session, based on the participants’ individual behavioural goal(s) and their gender, age, partner status, housing, work status and hobbies, an external communications consultant drafted individually tailored text messages to each one reminding them of their behavioural goal(s).",Individual text message reminders,[201857],[12920],[13234],[False],[0],[0],[False],['0']
26228,PMC5070122,34432,In the motivational counselling session the participants had decided frequency and timing of the text messages.,Individual text message reminders,[201861],[13235],[13346],[False],[0],[0],[False],['0']
26229,PMC5070122,34433,"Participants could receive a maximum of one reminder per weekday, i.e.",Individual text message reminders,[201865],[13347],[13417],[False],[0],[0],[False],['0']
26230,PMC5070122,34434,a maximum of five reminders per week.,Individual text message reminders,[201869],[13418],[13455],[False],[0],[0],[False],['0']
26231,PMC5070122,34435,"SMS-Track Aps, (https://www.sms-track.com/) developed and monitored the technical system supporting the sending of the text messages.",Individual text message reminders,[201873],[13456],[13589],[False],[0],[0],[False],['0']
26232,PMC5070122,34436,Control group,Control group,[201877],[13590],[13604],[False],[0],[0],[False],['0']
26233,PMC5070122,34437,Participants in the control group were encouraged to maintain their usual lifestyle during the 16-week intervention period.,Control group,[201881],[13605],[13728],[False],[0],[0],[False],['0']
26234,PMC5070122,34438,They were not in contact with the project staff until the post intervention assessment.,Control group,[201885],[13729],[13816],[False],[0],[0],[False],['0']
26235,PMC5070122,34439,Feasibility and acceptability of the intervention,Feasibility and acceptability of the intervention,[201889],[13817],[13867],[False],[0],[0],[False],['0']
26236,PMC5070122,34440,TT documented all components of the recruitment and screening procedure.,Feasibility and acceptability of the intervention,[201893],[13868],[13940],[False],[0],[0],[False],['0']
26237,PMC5070122,34441,This included documentation of the number of invited and screened patients and reasons for exclusion or declining study participation.,Feasibility and acceptability of the intervention,[201897],[13941],[14075],[False],[0],[0],[False],['0']
26238,PMC5070122,34442,"Adherence to the intervention was monitored using an interviewer-administered log sheet in which information on participant, behavioural goals, text message reminders and acceptability and progress of the sessions were recorded.",Feasibility and acceptability of the intervention,[201901],[14076],[14304],[False],[0],[0],[False],['0']
26239,PMC5070122,34443,That also included acceptability of frequency and content of text message reminders.,Feasibility and acceptability of the intervention,[201905],[14305],[14389],[False],[0],[0],[False],['0']
26240,PMC5070122,34444,"Furthermore, by the end of the intervention period, the participants evaluated the intervention by filling in a short questionnaire about the structure and content of the intervention, potential changes in everyday habits and the impact of the intervention on physical activity patterns of friends and families.",Feasibility and acceptability of the intervention,[201909],[14390],[14701],[False],[0],[0],[False],['0']
26241,PMC5070122,34445,Outcome measures,Outcome measures,[201913],[14702],[14719],[False],[0],[0],[False],['0']
26242,PMC5070122,34446,Assessments took place at baseline prior to randomisation and at end of the 16-week intervention period.,Outcome measures,[201917],[14720],[14824],[False],[0],[0],[False],['0']
26243,PMC5070122,34447,Detailed description of the measurements is reported elsewhere [34].,Outcome measures,[201921],[14825],[14893],[False],[0],[0],[False],['0']
26244,PMC5070122,34448,Outcome measures are briefly described below.,Outcome measures,[201925],[14894],[14939],[False],[0],[0],[False],['0']
26245,PMC5070122,34449," Change in daily sitting time was objectively measured using an ActivPAL®3TM Activity Monitor (PAL Technologies, Glasgow, UK), which has demonstrated reliability and validity for measuring posture and motion during everyday physical activities [35] and is currently considered the best choice for measurements of sitting/lying.",Outcome measures,[201929],[14940],[15267],[False],[0],[0],[False],['0']
26246,PMC5070122,34450,"The monitor was worn anteriorly on the upper right thigh, enfolded in waterproof dressing and kept in place by adhesive tape.",Outcome measures,[201933],[15268],[15393],[False],[0],[0],[False],['0']
26247,PMC5070122,34451,The participants wore the ActivPAL for a seven-day period for each assessment.,Outcome measures,[201937],[15394],[15472],[False],[0],[0],[False],['0']
26248,PMC5070122,34452,"The ActivPAL does not distinguish between sitting and lying posture, which is why the participants, during the assessments, kept a diary of their sleeping time in order to separate this from their sitting/lying time while awake.",Outcome measures,[201941],[15473],[15701],[False],[0],[0],[False],['0']
26249,PMC5070122,34453,Changes in daily sitting time were also measured by self-report using the Physical Activity Scale 2.1 (PAS 2.1) [29] and by specific questions about the total time spent sitting and the longest uninterrupted time spent sitting during both work and leisure [36].,Outcome measures,[201945],[15702],[15963],[False],[0],[0],[False],['0']
26250,PMC5070122,34454,Change in number of breaks in daily sitting time was also measured using the ActivPAL monitor.,Outcome measures,[201949],[15964],[16058],[False],[0],[0],[False],['0']
26251,PMC5070122,34455,"Change in pain was measured using the Visual Analogue Scale (VAS) which transforms the subjective experience of pain by putting a mark on a 100 mm line, ranging from “no pain” to “worst imaginable pain” [37].",Outcome measures,[201953],[16059],[16267],[False],[0],[0],[False],['0']
26252,PMC5070122,34456,Change in fatigue was measured using the 20-item Multidimensional Fatigue Inventory (MFI) [38].,Outcome measures,[201957],[16268],[16363],[False],[0],[0],[False],['0']
26253,PMC5070122,34457,"It classifies fatigue in five dimensions; 1) general fatigue, 2) physical fatigue, 3) mental fatigue, 4) reduced activity and 5) reduced motivation.",Outcome measures,[201961],[16364],[16512],[False],[0],[0],[False],['0']
26254,PMC5070122,34458,"The scores range from 4 to 20, with higher scores indicating higher levels of fatigue.",Outcome measures,[201965],[16513],[16599],[False],[0],[0],[False],['0']
26255,PMC5070122,34459,Fatigue was also measured by VAS [37].,Outcome measures,[201969],[16600],[16638],[False],[0],[0],[False],['0']
26256,PMC5070122,34460,"Change in functional function was measured by the Health Assessment Questionnaire (HAQ), which contains 20 items with four possible answers in eight categories of function within daily activities.",Outcome measures,[201973],[16639],[16835],[False],[0],[0],[False],['0']
26257,PMC5070122,34461,"The highest scores of each dimension are summarized and divided by 8, resulting in a possible range of total scores (HAQ score) from 0 (no difficulty) to 3 (unable to do) [39].",Outcome measures,[201977],[16836],[17012],[False],[0],[0],[False],['0']
26258,PMC5070122,34462,"Change in Health-Related Quality of Life (HR-QoL) was measured using the generic Short Form Health Survey (SF-36) [40], which was divided into two SF-36 summary scales; 1) the physical component summary scale (PCS) and 2) the mental component summary scale (MCS) and each domain is scored from 0 (low) - 100 (high).",Outcome measures,[201981],[17013],[17328],[False],[0],[0],[False],['0']
26259,PMC5070122,34463,"Change in self-efficacy was measured using the 10-item General Self-Efficacy Scale (GSES) and possible response categories are “not at all true”, “hardly true”, “moderately true” and “exactly true”, yielding a total score between 10 (low) – 40 (high) [41].",Outcome measures,[201985],[17329],[17585],[False],[0],[0],[False],['0']
26260,PMC5070122,34464,GSES measures the general sense of perceived self-efficacy in coping with a variety of demands in life.,Outcome measures,[201989],[17586],[17689],[False],[0],[0],[False],['0']
26261,PMC5070122,34465,Changes in biomarkers and blood pressure; non-fasting venous blood samples were drawn.,Outcome measures,[201993],[17690],[17776],[False],[0],[0],[False],['0']
26262,PMC5070122,34466,"Total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and triglycerides were measured by an enzymatic method on the Vitros 5.1 FS from Ortho Clinical Diagnostics.",Outcome measures,[201997],[17777],[17990],[False],[0],[0],[False],['0']
26263,PMC5070122,34467,C-reactive protein (CRP) and HbA1c were measured on the Vitros 5.1 FS and G8 HPLC Analyzer from TOSOH.,Outcome measures,[202001],[17991],[18093],[False],[0],[0],[False],['0']
26264,PMC5070122,34468,"In addition, after 5–10 min of resting (sitting), blood pressure was measured digitally three times at the right upper arm and the average of the three measurements was recorded.",Outcome measures,[202005],[18094],[18272],[False],[0],[0],[False],['0']
26265,PMC5070122,34469,"Changes in weight, waist circumference, BMI and waist-hip-ratio; Weight was measured to the nearest 0.1 kg in light clothing and without shoes; Waist circumference was measured to the nearest 0.5 cm midway between the lower rib margin and the iliac crest and hip circumference was measured to the nearest 0.5 cm at the point yielding the maximum circumference over the buttocks.",Outcome measures,[202009],[18273],[18651],[False],[0],[0],[False],['0']
26266,PMC5070122,34470,"Subsequently, body mass index (BMI, kg/m2) and waist-hip ratio were calculated.",Outcome measures,[202013],[18652],[18731],[False],[0],[0],[False],['0']
26267,PMC5070122,34471,At baseline each participant’s height was also measured to the nearest centimetre without shoes.,Outcome measures,[202017],[18732],[18828],[False],[0],[0],[False],['0']
26268,PMC5070122,34472,Descriptive variables,Descriptive variables,[202021],[18829],[18851],[False],[0],[0],[False],['0']
26269,PMC5070122,34473,"Additional descriptive data included self-reported data about demography, lifestyle (smoking and alcohol) and medical history (consumption of painkillers and co-morbidities).",Descriptive variables,[202025],[18852],[19026],[False],[0],[0],[False],['0']
26270,PMC5070122,34474,"Additionally, clinical data (medical treatment, RA duration, DAS28-score, IgM Rheumatoid Factor and anti-CCP) were obtained from the DANBIO database at Rigshospitalet, Glostrup [42].",Descriptive variables,[202029],[19027],[19209],[False],[0],[0],[False],['0']
26271,PMC5070122,34475,Data management and statistical analyses,Data management and statistical analyses,[202033],[19210],[19251],[False],[0],[0],[False],['0']
26272,PMC5070122,34476,All data (except for ActivPAL-data and blood test results) were entered directly by the participants and the two assessors through an online interface via a tablet.,Data management and statistical analyses,[202037],[19252],[19416],[False],[0],[0],[False],['0']
26273,PMC5070122,34477,All data were stored in unidentifiable form (using participant-numbers) in the DANBIO database [42].,Data management and statistical analyses,[202041],[19417],[19517],[False],[0],[0],[False],['0']
26274,PMC5070122,34478,The scoring of the standardised questionnaires was carried out according to the guidelines from the instrument developers.,Data management and statistical analyses,[202045],[19518],[19640],[False],[0],[0],[False],['0']
26275,PMC5070122,34479,"ActivPAL-data were processed using the ActivPAL software, version 7.2.32.",Data management and statistical analyses,[202049],[19641],[19714],[False],[0],[0],[False],['0']
26276,PMC5070122,34480,"All calculations were performed using SAS software (v. 9.3; SAS Institute Inc., Cary, NC, USA); descriptive statistics were computed for presentation of participants’ characteristics, including medians, means (M) and standard deviations (SD) for continuous data and frequencies (%) for categorical data.",Data management and statistical analyses,[202053],[19715],[20018],[False],[0],[0],[False],['0']
26277,PMC5070122,34481,"Changes in outcome measures from baseline to follow-up were reported as within-group differences in the intervention and the control group separately, by medians, means (M) and standard deviations (SD), and between-group differences were summarised as mean changes and standard deviations between intervention and control groups.",Data management and statistical analyses,[202057],[20019],[20348],[False],[0],[0],[False],['0']
26278,PMC5070122,34482,Results,Results,[202061],[20349],[20357],[False],[0],[0],[False],['0']
26279,PMC5070122,34483,Recruitment and sample characteristics,Results|Recruitment and sample characteristics,[202065],[20358],[20396],[False],[0],[0],[False],['0']
26280,PMC5070122,34484,Fig.,Results|Recruitment and sample characteristics,[202069],[20397],[20401],[False],[0],[0],[False],['0']
26281,PMC5070122,34485,2 The participants’ flow through the study.,Results|Recruitment and sample characteristics,[202073],[20402],[20445],[False],[0],[0],[False],['0']
26282,PMC5070122,34486,The recruitment process commenced on 1st of November 2012 and continued until 28th of January 2013.,Results|Recruitment and sample characteristics,[202077],[20446],[20545],[False],[0],[0],[False],['0']
26283,PMC5070122,34487,TT screened 181 medical journals; 107 patients were potentially eligible and invited by letter before 20 were identified as meeting all eligibility criteria and had consented to participate.,Results|Recruitment and sample characteristics,[202081],[20546],[20736],[False],[0],[0],[False],['0']
26284,PMC5070122,34488,"Reasons for declining study participation were mostly flares, i.e.",Results|Recruitment and sample characteristics,[202085],[20737],[20803],[False],[0],[0],[False],['0']
26285,PMC5070122,34489,a worsening in disease activity e.g.,Results|Recruitment and sample characteristics,[202089],[20804],[20840],[False],[0],[0],[False],['0']
26286,PMC5070122,34490,"painful and tender joints, and lack of time and co-morbidities.",Results|Recruitment and sample characteristics,[202093],[20841],[20904],[False],[0],[0],[False],['0']
26287,PMC5070122,34491,The flow of participants through the trial is presented in Fig.,Results|Recruitment and sample characteristics,[202097],[20905],[20968],[False],[0],[0],[False],['0']
26288,PMC5070122,34492,2.,Results|Recruitment and sample characteristics,[202101],[20969],[20971],[False],[0],[0],[False],['0']
26289,PMC5070122,34493,Table 1 Baseline characteristics of the participants by allocated group and total.,Results|Recruitment and sample characteristics,[202105],[20972],[21055],[False],[0],[0],[False],['0']
26290,PMC5070122,34494,Data are presented as numbers (N) unless otherwise stated.,Results|Recruitment and sample characteristics,[202109],[21056],[21114],[False],[0],[0],[False],['0']
26291,PMC5070122,34495,There were no major differences at baseline between the intervention and the control group in terms of demographic and clinical characteristics (Table 1).,Results|Recruitment and sample characteristics,[202113],[21115],[21269],[False],[0],[0],[False],['0']
26292,PMC5070122,34496,All participants completed baseline assessments.,Results|Recruitment and sample characteristics,[202117],[21270],[21318],[False],[0],[0],[False],['0']
26293,PMC5070122,34497,One participant in the control group dropped out before end of intervention period due to disease flare.,Results|Recruitment and sample characteristics,[202121],[21319],[21423],[False],[0],[0],[False],['0']
26294,PMC5070122,34498,The remaining 19 participants completed post intervention assessment including all self-reported and objective assessments.,Results|Recruitment and sample characteristics,[202125],[21424],[21547],[False],[0],[0],[False],['0']
26295,PMC5070122,34499,Intervention adherence,Intervention adherence,[202129],[21548],[21572],[False],[0],[0],[False],['0']
26296,PMC5070122,34500,All intervention participants completed the three individual motivational counselling sessions which ranged from 29 to 102 min (average 68 min).,Intervention adherence,[202133],[21573],[21717],[False],[0],[0],[False],['0']
26297,PMC5070122,34501,"Furthermore, all participants set behavioural goals and planned actions to reduce their daily sitting time.",Intervention adherence,[202137],[21718],[21825],[False],[0],[0],[False],['0']
26298,PMC5070122,34502,The number of behavioural goals for each participant ranged from 1 to 5.,Intervention adherence,[202141],[21826],[21898],[False],[0],[0],[False],['0']
26299,PMC5070122,34503,"The behavioural goals were reduction of TV-viewing, to go for an evening stroll rather than turning on the TV immediately after dinner, inviting the partner or other family members to join on these strolls, going for an extra walk with the dog, and to work standing up for an hour or two after lunch and to get up more frequently to go to the printer.",Intervention adherence,[202145],[21899],[22250],[False],[0],[0],[False],['0']
26300,PMC5070122,34504,All ten participants chose to receive text message reminders each week reminding them of their behavioural goals and action plans.,Intervention adherence,[202149],[22251],[22381],[False],[0],[0],[False],['0']
26301,PMC5070122,34505,Frequency of reminders ranged from 1 to 4 per week for each participant.,Intervention adherence,[202153],[22382],[22454],[False],[0],[0],[False],['0']
26302,PMC5070122,34506,Examples of behavioural goals and subsequent text message reminders according to the four key messages are provided in the Appendix.,Intervention adherence,[202157],[22455],[22587],[False],[0],[0],[False],['0']
26303,PMC5070122,34507,Participants’ response to and evaluation of the intervention,Intervention adherence,[202161],[22588],[22649],[False],[0],[0],[False],['0']
26304,PMC5070122,34508,Response to and evaluation of the intervention were obtained through both a) the interviewer-administered log sheets that were collected during the individual motivational counselling session and b) the evaluation questionnaires that were distributed after the intervention (n = 9).,Intervention adherence,[202165],[22650],[22932],[False],[0],[0],[False],['0']
26305,PMC5070122,34509,From the individual motivational counselling session we learned that the intervention in general was well accepted by the participants because of its individual approach and limited number (three) of scheduled visits to the hospital.,Intervention adherence,[202169],[22933],[23166],[False],[0],[0],[False],['0']
26306,PMC5070122,34510,"Likewise, meeting the same interviewer throughout all three motivational counselling sessions was welcomed by the participants.",Intervention adherence,[202173],[23167],[23294],[False],[0],[0],[False],['0']
26307,PMC5070122,34511,The participants understood rather quickly that the main health promoting focus of the intervention was not to increase daily MVPA but a low-intensity approach of increasing light-intensity physical activity by reducing daily sedentary behaviour.,Intervention adherence,[202177],[23295],[23541],[False],[0],[0],[False],['0']
26308,PMC5070122,34512,All interviewers made efforts to explain this focus during the motivational counselling sessions.,Intervention adherence,[202181],[23542],[23639],[False],[0],[0],[False],['0']
26309,PMC5070122,34513,"However, two participants still had trouble understanding this approach and thus trouble in articulating how they would reduce their sitting time, and they chose a single and more general behavioural goal to reduce sitting time.",Intervention adherence,[202185],[23640],[23868],[False],[0],[0],[False],['0']
26310,PMC5070122,34514,"In addition, all participants reported some changes in daily habits, activities or bodily experiences during or after the intervention.",Intervention adherence,[202189],[23869],[24004],[False],[0],[0],[False],['0']
26311,PMC5070122,34515,This included e.g.,Intervention adherence,[202193],[24005],[24023],[False],[0],[0],[False],['0']
26312,PMC5070122,34516,"reduced TV-viewing, more walking and more frequent interruptions of sitting time.",Intervention adherence,[202197],[24024],[24105],[False],[0],[0],[False],['0']
26313,PMC5070122,34517,"They considered that these changes had become part of their daily life, but not necessarily easily maintained ones.",Intervention adherence,[202201],[24106],[24221],[False],[0],[0],[False],['0']
26314,PMC5070122,34518,"Regarding text message reminders, the participants’ perception of the messages varied regarding applicability, frequency and quality The participants were satisfied with the wording and content of the messages, and most of the participants felt motivated to pursue their behavioral goals and action plans when receiving the message and they re-read them several times.",Intervention adherence,[202205],[24222],[24590],[False],[0],[0],[False],['0']
26315,PMC5070122,34519,"However, two participants did not use the messages at all after the second counselling session.",Intervention adherence,[202209],[24591],[24686],[False],[0],[0],[False],['0']
26316,PMC5070122,34520,From the evaluation questionnaire we found that participants reported physical changes in terms of e.g.,Intervention adherence,[202213],[24687],[24790],[False],[0],[0],[False],['0']
26317,PMC5070122,34521,"reduced pain from back, hips or knees and weight reduction.",Intervention adherence,[202217],[24791],[24850],[False],[0],[0],[False],['0']
26318,PMC5070122,34522,Two participants reported increased pain from their hips and one experienced increased pain from the knees.,Intervention adherence,[202221],[24851],[24958],[False],[0],[0],[False],['0']
26319,PMC5070122,34523,They attributed this pain to the increased amount of walking.,Intervention adherence,[202225],[24959],[25020],[False],[0],[0],[False],['0']
26320,PMC5070122,34524,Eight participants found the frequency and duration of sessions suitable while two expressed a need for more sessions with the interviewer.,Intervention adherence,[202229],[25021],[25160],[False],[0],[0],[False],['0']
26321,PMC5070122,34525,Adverse events and completeness of data,Adverse events and completeness of data,[202233],[25161],[25201],[False],[0],[0],[False],['0']
26322,PMC5070122,34526,Two participants reported redness and itching on the thigh after a couple of days wearing the ActivPAL monitor.,Adverse events and completeness of data,[202237],[25202],[25313],[False],[0],[0],[False],['0']
26323,PMC5070122,34527,Advice about changing the adhesive tape more frequently was given accordingly.,Adverse events and completeness of data,[202241],[25314],[25392],[False],[0],[0],[False],['0']
26324,PMC5070122,34528,Complaints about wearing the ActivPAL monitors did not affect the completeness of ActivPAL-data.,Adverse events and completeness of data,[202245],[25393],[25489],[False],[0],[0],[False],['0']
26325,PMC5070122,34529,All assessor – and participants entered data were complete.,Adverse events and completeness of data,[202249],[25490],[25549],[False],[0],[0],[False],['0']
26326,PMC5070122,34530,Four participants were not familiar with the use of a tablet and chose to report data via a questionnaire in paper format.,Adverse events and completeness of data,[202253],[25550],[25672],[False],[0],[0],[False],['0']
26327,PMC5070122,34531,These data were later entered into the DANBIO database by a project staff.,Adverse events and completeness of data,[202257],[25673],[25747],[False],[0],[0],[False],['0']
26328,PMC5070122,34532,Outcome measures,Outcome measures,[202261],[25748],[25765],[False],[0],[0],[False],['0']
26329,PMC5070122,34533,Table 2 Change from baseline in assessed outcomes at end of the 16-week intervention.,Outcome measures,[202265],[25766],[25851],[False],[0],[0],[False],['0']
26330,PMC5070122,34534,"The main behavioural and clinical outcomes are presented in Table 2, which shows within-group and between-group changes from baseline to follow-up after the intervention period.",Outcome measures,[202269],[25852],[26029],[False],[0],[0],[False],['0']
26331,PMC5070122,34535,The mean change in daily sitting time was −0.30 (SD 1.90) hours per day in the intervention group versus 0.15 (SD 1.43) hours per day in the control group (Table 2).,Outcome measures,[202273],[26030],[26195],[False],[0],[0],[False],['0']
26332,PMC5070122,34536,The sample size was too small to draw any valid conclusions on within- and between-group changes in outcome measures.,Outcome measures,[202277],[26196],[26313],[False],[0],[0],[False],['0']
26333,PMC5070122,34537,"However, the aim of the present study was not to detect effects of the intervention but to study the feasibility of study procedures, and procedures in relation to collection of outcome measures proved feasible and acceptable to participants and staff.",Outcome measures,[202281],[26314],[26566],[False],[0],[0],[False],['0']
26334,PMC5070122,34538,Discussion,Discussion,[202285],[26567],[26579],[False],[0],[0],[False],['0']
26335,PMC5070122,34539,"The primary aim of this study was to evaluate descriptively the feasibility of recruitment, randomisation, outcome assessments, retention and the acceptability of an individually tailored, theory-based behavioural intervention targeting reduction in daily sedentary behaviour in patients with RA.",Discussion,[202289],[26580],[26876],[False],[0],[0],[False],['0']
26336,PMC5070122,34540,"The study showed that the procedures of recruitment, randomization, outcome assessments, retention and analysis were feasible and that the intervention was well accepted by the participants.",Discussion,[202293],[26877],[27067],[False],[0],[0],[False],['0']
26337,PMC5070122,34541,"The study sample was relatively homogenous in terms of disease activity, medical treatment, duration of RA and physical function.",Discussion,[202297],[27068],[27197],[False],[0],[0],[False],['0']
26338,PMC5070122,34542,"The tailored approach, accommodating all levels of physical function, cognitive ability and disease activity, was a main feature of the intervention enabling all participants to take part fully.",Discussion,[202301],[27198],[27392],[False],[0],[0],[False],['0']
26339,PMC5070122,34543,Adherence to the motivational counselling sessions was good and consistent with findings from a recent pilot study testing the effect of motivational counselling on medication adherence in patients with RA [43].,Discussion,[202305],[27393],[27604],[False],[0],[0],[False],['0']
26340,PMC5070122,34544,"The participants in our study responded positively to the counselling style, especially regarding the individual approach and meeting the same interviewer throughout all sessions.",Discussion,[202309],[27605],[27784],[False],[0],[0],[False],['0']
26341,PMC5070122,34545,"In accordance with this, previous research has shown that patients with RA prefer education about the disease and its treatment and management to be delivered on a one-to-one basis by health professionals [44].",Discussion,[202313],[27785],[27995],[False],[0],[0],[False],['0']
26342,PMC5070122,34546,"The individual approach enabled our participants to make specific and individual behavioural goals and action plans to reduce their sitting time, comprising simple initiatives such as standing up every half an hour while watching a movie or going for a stroll every evening.",Discussion,[202317],[27996],[28270],[False],[0],[0],[False],['0']
26343,PMC5070122,34547,"However, we cannot be certain whether a group-based intervention and experience sharing between the participants would have facilitated other perspectives on SB, and thus inspired different behavioural goals or approaches in reducing sitting time.",Discussion,[202321],[28271],[28518],[False],[0],[0],[False],['0']
26344,PMC5070122,34548,Being in a group might have been beneficial for those participants who had difficulty understanding the concept of reduction of SB as an non-exercise health promotion strategy [45] and thus trouble articulating how they would reduce their daily sitting time.,Discussion,[202325],[28519],[28777],[False],[0],[0],[False],['0']
26345,PMC5070122,34549,During the motivational counselling sessions the interviewers experienced the need to give repeated examples of how to reduce daily sitting that did not necessarily included exercise or MVPA.,Discussion,[202329],[28778],[28969],[False],[0],[0],[False],['0']
26346,PMC5070122,34550,A consideration for future studies might be to ensure that all motivational interviewers understand how to deliver this information in the best way to the participants.,Discussion,[202333],[28970],[29138],[False],[0],[0],[False],['0']
26347,PMC5070122,34551,"In general, the content, duration and frequency of the motivational sessions appeared to be acceptable, feasible and of benefit.",Discussion,[202337],[29139],[29267],[False],[0],[0],[False],['0']
26348,PMC5070122,34552,"To the best of our knowledge, this is the first study documenting the use of text message reminders in an intervention targeting reduction of daily SB.",Discussion,[202341],[29268],[29419],[False],[0],[0],[False],['0']
26349,PMC5070122,34553,A previous pilot study targeting increase in daily physical activity in adults suggested that interventions applying text message reminders on behavioural goals and action plans are not more effective than those without such reminders [46].,Discussion,[202345],[29420],[29660],[False],[0],[0],[False],['0']
26350,PMC5070122,34554,"However, the text message reminders in that study were generic, and not, as they were in our study, tailored to the individual.",Discussion,[202349],[29661],[29788],[False],[0],[0],[False],['0']
26351,PMC5070122,34555,"In our study, the receipt of the tailored text message reminders was diverse among the participants.",Discussion,[202353],[29789],[29889],[False],[0],[0],[False],['0']
26352,PMC5070122,34556,"We were attentive to let the wording in the messages be as positive as possible, reflecting an assumption that the participants were already carrying out their behavioural goals and action plans.",Discussion,[202357],[29890],[30085],[False],[0],[0],[False],['0']
26353,PMC5070122,34557,In keeping the intervention as individualized as possible there was no minimum in the frequency of text messages.,Discussion,[202361],[30086],[30199],[False],[0],[0],[False],['0']
26354,PMC5070122,34558,This could possibly lead to diversity in the intensity of the intervention among the participants.,Discussion,[202365],[30200],[30298],[False],[0],[0],[False],['0']
26355,PMC5070122,34559,"However, a recent systematic review found that message tailoring and personalization and varying message frequency were significantly associated with greater intervention efficacy in physical activity interventions [47].",Discussion,[202369],[30299],[30519],[False],[0],[0],[False],['0']
26356,PMC5070122,34560,"Finally, Hall et al.",Discussion,[202373],[30520],[30540],[False],[0],[0],[False],['0']
26357,PMC5070122,34561,(2015) argue in their systematic review that to date no strong recommendations can be drawn on what characteristics work better than others in text message-based interventions [27].,Discussion,[202377],[30541],[30722],[False],[0],[0],[False],['0']
26358,PMC5070122,34562,The strengths of this study included using objective measurement of daily sitting time and the two assessors’ considerable experience and expertise in working with patients with RA.,Discussion,[202381],[30723],[30904],[False],[0],[0],[False],['0']
26359,PMC5070122,34563,"In addition, the assessors were blinded to group allocation.",Discussion,[202385],[30905],[30965],[False],[0],[0],[False],['0']
26360,PMC5070122,34564,We believe that the simple structure of the intervention with only three required visits to the hospital and the flexibility the two assessors displayed in changing assessment schedules in cases of flare was reflected in the good retention rates.,Discussion,[202389],[30966],[31212],[False],[0],[0],[False],['0']
26361,PMC5070122,34565,"Only one participant dropped out due to flare, which was expected due to the fluctuating character of the disease.",Discussion,[202393],[31213],[31327],[False],[0],[0],[False],['0']
26362,PMC5070122,34566,"Even though the participants found the duration of the sessions suitable, the longest lasting motivational counselling session lasted 102 min which must be considered very time-consuming for both research purposes and for a potential implementation of the intervention in clinical practice.",Discussion,[202397],[31328],[31618],[False],[0],[0],[False],['0']
26363,PMC5070122,34567,"When the results from the final clinical study and the cost effectiveness study are available, we will be able to assess the benefits of the intervention comparing to both time spent and patients’ and health professionals’ efforts.",Discussion,[202401],[31619],[31850],[False],[0],[0],[False],['0']
26364,PMC5070122,34568,A few recruitment challenges need to be addressed.,Discussion,[202405],[31851],[31901],[False],[0],[0],[False],['0']
26365,PMC5070122,34569,A total of 50 % (n = 53) of the invited patients declined to participate and 45 % (n = 24) of these reported RA-related disease activity as the main reason for doing so.,Discussion,[202409],[31902],[32071],[False],[0],[0],[False],['0']
26366,PMC5070122,34570,Several of these patients additionally reported that the disease activity was always high during winter.,Discussion,[202413],[32072],[32176],[False],[0],[0],[False],['0']
26367,PMC5070122,34571,"We carried out the recruitment during the winter (November –January), which may have influenced the number of patients willing to participate.",Discussion,[202417],[32177],[32319],[True],['Population'],['We carried out the recruitment during the winter'],[True],['Population']
26368,PMC5070122,34572,Another recruitment challenge was the inclusion criterion of at least four hours of daily leisure-time sitting.,Discussion,[202426],[32320],[32431],[True],['DiagnosticCriteria'],['the inclusion criterion of at least four hours of daily leisure-time sitting'],[True],['Population']
26369,PMC5070122,34573,This was based on the results from a Danish cross-sectional study showing a median score of four hours of self-reported leisure-time sitting in patients with RA [48].,Discussion,[202433],[32432],[32598],[False],[0],[0],[False],['0']
26370,PMC5070122,34574,"Of the 28 patients not meeting eligibility criteria after the telephone-based screening, 24 (86 %) were excluded because they reported less than four hours of daily leisure-time sitting.",Discussion,[202439],[32599],[32785],[True],['VerySpecificPopulation'],['28 patients not meeting eligibility criteria'],[True],['Population']
26371,PMC5070122,34575,Most of these patients were working full- or part time.,Discussion,[202445],[32786],[32841],[False],[0],[0],[False],['0']
26372,PMC5070122,34576,"Hence, they would have less leisure time per day to spend sitting.",Discussion,[202449],[32842],[32908],[False],[0],[0],[False],['0']
26373,PMC5070122,34577,"However, they could have spent most of their work day sitting and thus, potentially, still achieve health benefits by reducing daily sitting time.",Discussion,[202453],[32909],[33055],[False],[0],[0],[False],['0']
26374,PMC5070122,34578,"Accordingly, only four of the participants in our study were working.",Discussion,[202460],[33056],[33125],[True],['VerySpecificPopulation'],['only four of the participants in our study were working'],[True],['Population']
26375,PMC5070122,34579,Future studies may consider changing this inclusion criterion to cover total daily sitting time and not leisure-time sitting only and to increase the minimum criterion of hours spent sitting during a day.,Discussion,[202465],[33126],[33330],[False],[0],[0],[False],['0']
26376,PMC5070122,34580,This feasibility study was not intended to or powered to show a statistically significant reduction in daily sitting time in the intervention group compared to the control group.,Discussion,[202469],[33331],[33509],[False],[0],[0],[False],['0']
26377,PMC5070122,34581,"However, the selection of outcome measures appears to be appropriate and acceptable and potential health benefits of this intervention among people with RA could be safely explored at larger scale.",Discussion,[202473],[33510],[33707],[False],[0],[0],[False],['0']
26378,PMC5070122,34582,We find it appropriate to conduct a full-scale and sufficiently powered randomised controlled trial to achieve more solid conclusions for behavioural and clinical outcomes.,Discussion,[202477],[33708],[33880],[False],[0],[0],[False],['0']
26379,PMC5070122,34583,Conclusion,Conclusion,[202481],[33881],[33892],[False],[0],[0],[False],['0']
26380,PMC5070122,34584,This randomised controlled feasibility study showed that an individually tailored behavioural intervention targeting reduction of SB was feasible and acceptable to patients with RA.,Conclusion,[202485],[33893],[34074],[False],[0],[0],[False],['0']
26381,PMC5070122,34585,We recommend the testing of a similar intervention in a randomised controlled trial powered to detect an effect on daily sitting time as the primary outcome measure.,Conclusion,[202489],[34075],[34240],[False],[0],[0],[False],['0']
26382,PMC5070122,34586,Abbreviations,Abbreviations,[202493],[34241],[34255],[False],[0],[0],[False],['0']
26383,PMC5070122,34587,GSES General self-efficacy scale,Abbreviations|GSES General self-efficacy scale,[202497],[34256],[34288],[False],[0],[0],[False],['0']
26384,PMC5070122,34588,HAQ Health assessment questionnaire,Abbreviations|HAQ Health assessment questionnaire,[202501],[34289],[34324],[False],[0],[0],[False],['0']
26385,PMC5070122,34589,HDL High density lipoprotein cholesterol,Abbreviations|HDL High density lipoprotein cholesterol,[202505],[34325],[34365],[False],[0],[0],[False],['0']
26386,PMC5070122,34590,HR-QOL Health-related quality of life,Abbreviations|HDL High density lipoprotein cholesterol,[202509],[34366],[34403],[False],[0],[0],[False],['0']
26387,PMC5070122,34591,LDL Low density lipoprotein cholesterol,Abbreviations|LDL Low density lipoprotein cholesterol,[202513],[34404],[34443],[False],[0],[0],[False],['0']
26388,PMC5070122,34592,MI Motivational interviewing,Abbreviations|MI Motivational interviewing,[202517],[34444],[34472],[False],[0],[0],[False],['0']
26389,PMC5070122,34593,MVPA Moderate to vigorous physical activity,Abbreviations|MVPA Moderate to vigorous physical activity,[202521],[34473],[34516],[False],[0],[0],[False],['0']
26390,PMC5070122,34594,PAS 2 Physical activity scale 2,Abbreviations|MVPA Moderate to vigorous physical activity,[202525],[34517],[34548],[False],[0],[0],[False],['0']
26391,PMC5070122,34595,RA Rheumatoid arthritis,Abbreviations|RA Rheumatoid arthritis,[202529],[34549],[34572],[False],[0],[0],[False],['0']
26392,PMC5070122,34596,SB Sedentary behaviour,Abbreviations|SB Sedentary behaviour,[202533],[34573],[34595],[False],[0],[0],[False],['0']
26393,PMC5070122,34597,SF36-MCS SF36- mental component scale,Abbreviations|SB Sedentary behaviour,[202537],[34596],[34633],[False],[0],[0],[False],['0']
26394,PMC5070122,34598,SF36-PCS SF36-physical component scale,Abbreviations|SB Sedentary behaviour,[202541],[34634],[34672],[False],[0],[0],[False],['0']
26395,PMC5070122,34599,VAS Visual analogue scaleAcknowledgements,Abbreviations|SB Sedentary behaviour,[202545],[34673],[34714],[False],[0],[0],[False],['0']
26396,PMC5070122,34600,We thank the study participants for their support of this research.,Abbreviations|SB Sedentary behaviour,[202549],[34715],[34782],[False],[0],[0],[False],['0']
26397,PMC5070122,34601,"We thank the following for their contributions to the running of the study: Outcome assessors Berit Bjerg (occupational therapist), Maj-Britt Jensen (occupational therapist) and Interviewers: Mette Madsen (project nurse), Charlotte Frengler (project nurse), Gydda Espersen (project nurse).",Abbreviations|SB Sedentary behaviour,[202553],[34783],[35072],[False],[0],[0],[False],['0']
26398,PMC5070122,34602,"Also, Morten Christoffersen (communication consultant), Rasmus Kyhn og Thomas Jørgensen (SMS-tracking) and Mikkel Abildtoft (IT-supporter).",Abbreviations|SB Sedentary behaviour,[202557],[35073],[35212],[False],[0],[0],[False],['0']
26399,PMC5070122,34603,"Furthermore, we thank MSc in Clinical Psychology Torsten Sonne for his expertise and help during the preparation of the motivational counselling sessions and we thank Carsten Agger (Research Centre for Prevention and Health, Rigshospitalet, Glostrup Hospital, Capital Region of Denmark) for processing the ActivPAL-data.",Abbreviations|SB Sedentary behaviour,[202561],[35213],[35533],[False],[0],[0],[False],['0']
26400,PMC5070122,34604,Funding,Abbreviations|Funding,[202565],[35534],[35541],[False],[0],[0],[False],['0']
26401,PMC5070122,34605,"The study was supported by grants from the Danish Rheumatism Association, the Novo Nordic Foundation, the Lundbeck Foundation, the Research Foundation of the Capital Region of Denmark, the Bevica Foundation, Maersk McKinney Møller Foundation and Glostrup Hospital, Denmark.",Abbreviations|Funding,[202569],[35542],[35815],[False],[0],[0],[False],['0']
26402,PMC5070122,34606,Musculoskeletal Statistics Unit at the Parker Institute (RC) is supported by grants from the Oak Foundation.,Abbreviations|Funding,[202573],[35816],[35924],[False],[0],[0],[False],['0']
26403,PMC5070122,34607,"The funders had no role in the design of the study or the collection, analysis, and interpretation of data in writing the manuscript.",Abbreviations|Funding,[202577],[35925],[36058],[False],[0],[0],[False],['0']
26404,PMC5070122,34608,Availability of data and material,Abbreviations|Availability of data and material,[202581],[36059],[36092],[False],[0],[0],[False],['0']
26405,PMC5070122,34609,The datasets generated during and/or analyzed during the current study are not publicly available but are available upon request to the last author (BAE).,Abbreviations|Availability of data and material,[202585],[36093],[36247],[False],[0],[0],[False],['0']
26406,PMC5070122,34610,Authors’ contributions,Abbreviations|Authors’ contributions,[202589],[36248],[36270],[False],[0],[0],[False],['0']
26407,PMC5070122,34611,All authors made contributions in the conception and design of the study.,Abbreviations|Authors’ contributions,[202593],[36271],[36344],[False],[0],[0],[False],['0']
26408,PMC5070122,34612,"TT was responsible for study logistics and data collection, assisted in analysing the data and drafted the manuscript.",Abbreviations|Authors’ contributions,[202597],[36345],[36463],[False],[0],[0],[False],['0']
26409,PMC5070122,34613,"MAA provided guidance on the collection, analysis and interpretation of ActivPAL-data.",Abbreviations|Authors’ contributions,[202601],[36464],[36550],[False],[0],[0],[False],['0']
26410,PMC5070122,34614,RC provided guidance in the analysis of data and how to interpret and report a feasibility study.,Abbreviations|Authors’ contributions,[202605],[36551],[36648],[False],[0],[0],[False],['0']
26411,PMC5070122,34615,"All authors read, revised and approved the final manuscript.",Abbreviations|Authors’ contributions,[202609],[36649],[36709],[False],[0],[0],[False],['0']
26412,PMC5070122,34616,Authors information,Abbreviations|Authors information,[202613],[36710],[36729],[False],[0],[0],[False],['0']
26413,PMC5070122,34617,"Ph.D. Tanja Thomsen (TT), Rigshospitalet, Ndr.",Abbreviations|Authors information,[202617],[36730],[36776],[False],[0],[0],[False],['0']
26414,PMC5070122,34618,"Ringvej 57, Building 5, 2600 Glostrup, DK.",Abbreviations|Authors information,[202621],[36777],[36819],[False],[0],[0],[False],['0']
26415,PMC5070122,34619,"Email: tanja.thomsen01@regionh.dk Associate Professor, Mette Aadahl (MA), Glostrup Hospital, Ndr.",Abbreviations|Authors information,[202625],[36820],[36917],[False],[0],[0],[False],['0']
26416,PMC5070122,34620,"Ringvej 57, building 84/85, 2600, Glostrup, DK.",Abbreviations|Authors information,[202629],[36918],[36965],[False],[0],[0],[False],['0']
26417,PMC5070122,34621,"Email: mette.aadahl@regionh.dk Associate Professor, Nina Beyer (NB), Bispebjerg & Frederiksberg Hospitals, Bispebjerg Bakke 23, 2400 Copenhagen NV, DK.",Abbreviations|Authors information,[202633],[36966],[37117],[False],[0],[0],[False],['0']
26418,PMC5070122,34622,"Email: ninabeyer@oncable.dk Professor, Merete Lund Hetland (MLH), Rigshospitalet, Ndr.",Abbreviations|Authors information,[202637],[37118],[37204],[False],[0],[0],[False],['0']
26419,PMC5070122,34623,"Ringvej 57, Building 5, 2600 Glostrup, DK.",Abbreviations|Authors information,[202641],[37205],[37247],[False],[0],[0],[False],['0']
26420,PMC5070122,34624,"Email: merete.hetland@dadlnet.dk Ph.D., Katrine Bjerre Løppenthin (KL), Rigshospitalet, Ndr.",Abbreviations|Authors information,[202645],[37248],[37340],[False],[0],[0],[False],['0']
26421,PMC5070122,34625,"Ringvej 57, Building 5, 2600 Glostrup, DK.",Abbreviations|Authors information,[202649],[37341],[37383],[False],[0],[0],[False],['0']
26422,PMC5070122,34626,"Email: katrine.bjerre.loeppenthin@regionh.dk Associate Professor, Julie Midtgaard (JM), Department 9701 (UCSF), Blegdamsvej 9, 2100 Copenhagen Ø, DK.",Abbreviations|Authors information,[202653],[37384],[37533],[False],[0],[0],[False],['0']
26423,PMC5070122,34627,"Email: julie@ucsf.dk Professor, Robin Christensen (RC), The, Parker Institute, Bispebjerg og Frederiksberg Hospital, Nordre Fasanvej 57, Building 19, 1st Floor, 2000 Copenhagen F, DK.",Abbreviations|Authors information,[202657],[37534],[37717],[False],[0],[0],[False],['0']
26424,PMC5070122,34628,"Email: robin.christensen@regionh.dk Research Manager, Bente Appel Esbensen (BAE), Rigshospitalet, Ndr.",Abbreviations|Authors information,[202661],[37718],[37820],[False],[0],[0],[False],['0']
26425,PMC5070122,34629,"Ringvej 57, building 5, 2600 Glostrup, DK.",Abbreviations|Authors information,[202665],[37821],[37863],[False],[0],[0],[False],['0']
26426,PMC5070122,34630,Email: bente.appel.esbensen@regionh.dk,Abbreviations|Authors information,[202669],[37864],[37902],[False],[0],[0],[False],['0']
26427,PMC5070122,34631,Competing interests,Abbreviations|Competing interests,[202673],[37903],[37922],[False],[0],[0],[False],['0']
26428,PMC5070122,34632,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[202677],[37923],[37981],[False],[0],[0],[False],['0']
26429,PMC5070122,34633,Consent for publication,Abbreviations|Consent for publication,[202681],[37982],[38005],[False],[0],[0],[False],['0']
26430,PMC5070122,34634,Not applicable.,Abbreviations|Not applicable.,[202685],[38006],[38021],[False],[0],[0],[False],['0']
26431,PMC5070122,34635,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[202689],[38022],[38064],[False],[0],[0],[False],['0']
26432,PMC5070122,34636,All study participants provided written informed consent to participate.,Abbreviations|Ethics approval and consent to participate,[202693],[38065],[38137],[False],[0],[0],[False],['0']
26433,PMC5070122,34637,The study was reported to the Danish Data Protection Agency (ref.nb.,Abbreviations|Ethics approval and consent to participate,[202697],[38138],[38206],[False],[0],[0],[False],['0']
26434,PMC5070122,34638,711-1-08) and was approved by the Danish Health Research Ethics Committee System (ref.nb.,Abbreviations|Ethics approval and consent to participate,[202701],[38207],[38296],[False],[0],[0],[False],['0']
26435,PMC5070122,34639,H-2-2012-112) and was performed in compliance with the Helsinki Declaration.,Abbreviations|Ethics approval and consent to participate,[202705],[38297],[38373],[False],[0],[0],[False],['0']
26436,PMC5083764,30938,"Methoxyflurane Analgesia in Adult Patients in the Emergency Department: A Subgroup Analysis of a Randomized, Double-blind, Placebo-controlled Study (STOP!)",Title,[186594],[19684],[155],[False],[0],[0],[False],['0']
26437,PMC5083764,30939,Introduction,Abstract,[186597],[156],[169],[False],[0],[0],[False],['0']
26438,PMC5083764,30940,Acute pain remains highly prevalent in the Emergency Department (ED) setting.,Abstract,[186600],[170],[247],[False],[0],[0],[False],['0']
26439,PMC5083764,30941,"This double-blind, randomized, placebo-controlled UK study investigated the efficacy and safety of low-dose methoxyflurane analgesia for the treatment of acute pain in the ED in the adult population of the STOP!",Abstract,[186603],[248],[459],[False],[0],[0],[False],['0']
26440,PMC5083764,30942,trial.,Abstract,[186606],[460],[466],[False],[0],[0],[False],['0']
26441,PMC5083764,30943,Methods,Methods,[186609],[467],[475],[False],[0],[0],[False],['0']
26442,PMC5083764,30944,"Patients presenting to the ED requiring analgesia for acute pain (pain score of 4–7 on the Numerical Rating Scale) due to minor trauma were randomized in a 1:1 ratio to receive methoxyflurane (up to 6 mL) or placebo (normal saline), both via a Penthrox® (Medical Developments International Limited, Scoresby, Australia) inhaler.",Methods,[186612],[476],[804],[False],[0],[0],[False],['0']
26443,PMC5083764,30945,Rescue medication (paracetamol/opioids) was available immediately upon request.,Methods,[186615],[805],[884],[False],[0],[0],[False],['0']
26444,PMC5083764,30946,Change from baseline in visual analog scale (VAS) pain intensity was the primary endpoint.,Methods,[186618],[885],[975],[False],[0],[0],[False],['0']
26445,PMC5083764,30947,Results,Results,[186621],[976],[984],[False],[0],[0],[False],['0']
26446,PMC5083764,30948,300 adult and adolescent patients were randomized; data are presented for the adult subgroup (N = 204).,Results,[186624],[985],[1088],[False],[0],[0],[False],['0']
26447,PMC5083764,30949,Mean baseline VAS pain score was ~66 mm in both groups.,Results,[186627],[1089],[1144],[False],[0],[0],[False],['0']
26448,PMC5083764,30950,"The mean change from baseline to 5, 10, 15 and 20 min was greater for methoxyflurane (−20.7, −27.4, −33.3 and −34.8 mm, respectively) than placebo (−8.0, −11.1, −12.3 and −15.2 mm, respectively).",Results,[186630],[1145],[1340],[False],[0],[0],[False],['0']
26449,PMC5083764,30951,The primary analysis showed a highly significant treatment effect overall across all four time points (−17.4 mm; 95% confidence interval: −22.3 to −12.5 mm; p < 0.0001).,Results,[186633],[1341],[1510],[False],[0],[0],[False],['0']
26450,PMC5083764,30952,"Median time to first pain relief was 5 min with methoxyflurane [versus 20 min with placebo; (hazard ratio: 2.32; 95% CI: 1.63, 3.30; p < 0.0001)]; 79.4% of methoxyflurane-treated patients experienced pain relief within 1–10 inhalations.",Results,[186636],[1511],[1747],[False],[0],[0],[False],['0']
26451,PMC5083764,30953,22.8% of placebo-treated patients requested rescue medication within 20 min compared with 2.0% of methoxyflurane-treated patients (p = 0.0003).,Results,[186639],[1748],[1891],[False],[0],[0],[False],['0']
26452,PMC5083764,30954,"Methoxyflurane treatment was rated ‘Excellent’, ‘Very Good’ or ‘Good’ by 77.6% of patients, 74.5% of physicians and 72.5% of nurses.",Results,[186642],[1892],[2024],[False],[0],[0],[False],['0']
26453,PMC5083764,30955,Treatment-related adverse events (mostly dizziness/headache) were reported by 42.2% of patients receiving methoxyflurane and 14.9% of patients receiving placebo; none caused withdrawal and the majority were mild and transient.,Results,[186645],[2025],[2251],[False],[0],[0],[False],['0']
26454,PMC5083764,30956,Conclusion,Conclusion,[186648],[2252],[2263],[False],[0],[0],[False],['0']
26455,PMC5083764,30957,"The results of this study support the evidence from previous trials that low-dose methoxyflurane administered via the Penthrox inhaler is a well-tolerated, efficacious and rapid-acting analgesic.",Conclusion,[186651],[2264],[2459],[False],[0],[0],[False],['0']
26456,PMC5083764,30958,Funding,Funding,[186654],[2460],[2468],[False],[0],[0],[False],['0']
26457,PMC5083764,30959,Medical Developments International (MDI) Limited and Mundipharma Research GmbH & Co.KG.,Funding,[186657],[2469],[2556],[False],[0],[0],[False],['0']
26458,PMC5083764,30960,Trial registration,Trial registration,[186660],[2557],[2576],[False],[0],[0],[False],['0']
26459,PMC5083764,30961,"Clinicaltrials.gov identifier: NCT01420159, EudraCT number: 2011-000338-12.",Trial registration,[186663],[2577],[2652],[False],[0],[0],[False],['0']
26460,PMC5083764,30962,Introduction,Introduction,[186666],[2653],[2667],[False],[0],[0],[False],['0']
26461,PMC5083764,30963,"Despite advances in pain medication and widely accepted guidelines for the treatment of pain such as the World Health Organization’s analgesic ladder [1], inadequate assessment and management of acute pain remains common in both the pre-hospital and Emergency Department (ED) setting, with pain prevalence figures of up to 90% in the ED [2, 3] and many patients undertreated [4–6].",Introduction,[186669],[2668],[3049],[False],[0],[0],[False],['0']
26462,PMC5083764,30964,Pain relief regimes work optimally when effective analgesics are supported by formal protocols/guidelines underpinned by staff and patient education [7].,Introduction,[186672],[3050],[3203],[False],[0],[0],[False],['0']
26463,PMC5083764,30965,"The ‘ideal analgesic’ for acute pain should have rapid onset of action, act over an extended period of time, be well-tolerated and effective across a wide range of pain types in different populations.",Introduction,[186675],[3204],[3404],[False],[0],[0],[False],['0']
26464,PMC5083764,30966,Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetics.,Introduction,[186678],[3405],[3489],[False],[0],[0],[False],['0']
26465,PMC5083764,30967,"It was first introduced as an inhalation anesthetic in the 1960s [8], but its use was generally discontinued by the late 1970s due to availability of newer anesthetic agents and reports of dose-related renal tubular damage at anesthetic doses [9–11].",Introduction,[186681],[3490],[3740],[False],[0],[0],[False],['0']
26466,PMC5083764,30968,"Among inhalational fluorinated anesthetics, methoxyflurane is unique in having well-documented analgesic properties at low doses [12].",Introduction,[186684],[3741],[3875],[False],[0],[0],[False],['0']
26467,PMC5083764,30969,"It has been used extensively for over 30 years in Australia and New Zealand (administered via a handheld inhaler; Penthrox®, Medical Developments International Limited, Scoresby, Australia) as a self-administered, rapid-acting analgesic agent for short-term pain relief in emergency medicine, minor surgical and dental procedures.",Introduction,[186687],[3876],[4206],[False],[0],[0],[False],['0']
26468,PMC5083764,30970,"The Penthrox inhaler is a green whistle-shaped single-use device that delivers methoxyflurane in analgesic doses, with a maximum recommended dose in 24 h of two 3 mL vials [13].",Introduction,[186690],[4207],[4384],[False],[0],[0],[False],['0']
26469,PMC5083764,30971,"The historical concern regarding methoxyflurane has been nephrotoxicity, which was reported following significantly higher doses with deep methoxyflurane anesthesia [9].",Introduction,[186693],[4385],[4554],[False],[0],[0],[False],['0']
26470,PMC5083764,30972,"Renal damage is most likely due to the metabolism of methoxyflurane in the liver and kidney and release of fluoride ions [14, 15].",Introduction,[186696],[4555],[4685],[False],[0],[0],[False],['0']
26471,PMC5083764,30973,Clinical experience suggests that a low but effective analgesic dose is not associated with the risk of renal adverse events [16].,Introduction,[186699],[4686],[4816],[False],[0],[0],[False],['0']
26472,PMC5083764,30974,"Laboratory evidence also shows a large safety margin for analgesic use of methoxyflurane in the Penthrox inhaler [a dose of 6 mL/day and 15 mL/week results in exposure of 0.59 methoxyflurane minimum alveolar concentration (MAC)-hours, which is well below the reported level of risk of nephrotoxicity of 2.0 MAC-hours [14]].",Introduction,[186702],[4817],[5140],[False],[0],[0],[False],['0']
26473,PMC5083764,30975,"Therefore, it has been concluded that the use of methoxyflurane in analgesic doses does not carry a risk of nephrotoxicity [17].",Introduction,[186705],[5141],[5269],[False],[0],[0],[False],['0']
26474,PMC5083764,30976,Studies of low-dose methoxyflurane as an analgesic agent show decreases in pain scores and indicate that methoxyflurane is an efficacious analgesic in the ED and pre-hospital settings [18–20] and for procedural analgesia [21].,Introduction,[186708],[5270],[5496],[False],[0],[0],[False],['0']
26475,PMC5083764,30977,"Due to the physiochemical characteristics of methoxyflurane, absorption is rapid, providing fast onset of analgesic action (usually within 6–10 inhalations) to treat acute pain rapidly [13, 17].",Introduction,[186711],[5497],[5691],[False],[0],[0],[False],['0']
26476,PMC5083764,30978,The portability of the Penthrox inhaler and self-administration by the patient mean that it has practical advantages over alternatives such as nitrous oxide.,Introduction,[186714],[5692],[5849],[False],[0],[0],[False],['0']
26477,PMC5083764,30979,"Penthrox is a noncontrolled drug making it easier to prescribe and requiring less patient monitoring than opioid analgesics; it does not interfere with other analgesic agents or anesthetic drugs, and therefore does not limit subsequent treatment choices, and its effects are quickly reversible.",Introduction,[186717],[5850],[6144],[False],[0],[0],[False],['0']
26478,PMC5083764,30980,"Its characteristics make it suitable as a bridging analgesic, should more powerful intravenous (IV) analgesia be required, or for patients in whom IV access is difficult or impractical, or patients with contraindications or intolerance to other pain medications including opioids.",Introduction,[186720],[6145],[6425],[False],[0],[0],[False],['0']
26479,PMC5083764,30981,"Penthrox may eliminate the need for opioid analgesia for dislocations or fractures, for example, since the pain relief from Penthrox with or without the addition of simple non-opioid analgesia, may be sufficient for reduction or splinting.",Introduction,[186723],[6426],[6665],[False],[0],[0],[False],['0']
26480,PMC5083764,30982,"Despite a large volume of published literature supporting the efficacy and safety of methoxyflurane at analgesic concentrations [18], previous studies have been mostly observational and uncontrolled.",Introduction,[186726],[6666],[6865],[False],[0],[0],[False],['0']
26481,PMC5083764,30983,"Furthermore, little data have been generated within an ED setting, or outside Australia and New Zealand.",Introduction,[186729],[6866],[6970],[False],[0],[0],[False],['0']
26482,PMC5083764,30984,"This double-blind, randomized, placebo-controlled, UK-based study evaluated the short-term efficacy and safety of methoxyflurane at low analgesic doses for the treatment of acute pain in patients presenting to the ED with minor trauma.",Introduction,[186732],[6971],[7206],[False],[0],[0],[False],['0']
26483,PMC5083764,30985,The study included both adult and adolescent patients aged ≥12 years and the results for the full study population have been reported previously [22].,Introduction,[186735],[7207],[7357],[False],[0],[0],[False],['0']
26484,PMC5083764,30986,"Since Penthrox has recently been approved in Europe for the treatment of adult patients, a subgroup analysis was performed to evaluate the data in patients aged ≥18 years, and the data for this adult subgroup are the focus of this secondary paper.",Introduction,[186738],[7358],[7605],[False],[0],[0],[False],['0']
26485,PMC5083764,30987,Methods,Methods,[186741],[7606],[7614],[False],[0],[0],[False],['0']
26486,PMC5083764,30988,Study Design,Methods|Study Design,[186744],[7615],[7627],[False],[0],[0],[False],['0']
26487,PMC5083764,30989,"This was a randomized, double-blind, multicenter, placebo-controlled study (The STOP!",Methods|Study Design,[186747],[7628],[7713],[False],[0],[0],[False],['0']
26488,PMC5083764,30990,"Trial, Clinicaltrials.gov identifier: NCT01420159; EudraCT number: 2011-000338-12), undertaken between August 5, 2011 and July 26, 2012, at six EDs in the UK.",Methods|Study Design,[186750],[7714],[7872],[False],[0],[0],[False],['0']
26489,PMC5083764,30991,Patient eligibility for the study was established at time of presentation to the ED.,Methods|Study Design,[186753],[7873],[7957],[False],[0],[0],[False],['0']
26490,PMC5083764,30992,A total of 300 patients presenting with acute pain requiring analgesia were randomized in a 1:1 ratio to receive treatment with either methoxyflurane or placebo via a Penthrox inhaler while in the ED.,Methods|Study Design,[186756],[7958],[8158],[False],[0],[0],[False],['0']
26491,PMC5083764,30993,"Study assessments were performed by a blinded research nurse, who remained with the patient in the ED while they were receiving care.",Methods|Study Design,[186759],[8159],[8292],[False],[0],[0],[False],['0']
26492,PMC5083764,30994,Patients attended a post-treatment safety follow-up 14 ± 2 days after discharge from the ED.,Methods|Study Design,[186762],[8293],[8385],[False],[0],[0],[False],['0']
26493,PMC5083764,30995,"The randomized study population included 96 adolescent patients (aged 12–17 years) whose data are not presented here, and 204 adult patients whose data have been analyzed separately for this report.",Methods|Study Design,[186765],[8386],[8584],[False],[0],[0],[False],['0']
26494,PMC5083764,30996,The full methodology for this study has been previously described in the primary publication [22].,Methods|Study Design,[186768],[8585],[8683],[False],[0],[0],[False],['0']
26495,PMC5083764,30997,Study Participants,Study Participants,[186771],[8684],[8703],[False],[0],[0],[False],['0']
26496,PMC5083764,30998,"Eligible patients were those presenting to the ED with minor trauma (where trauma referred to ‘a physical wound or injury’, such as fractures, lacerations, burns, dislocations, contusions or injury due to foreign bodies) and requiring analgesia for acute pain [defined as a pain score ≥4 to ≤7 as measured using the 11-point Numerical Rating Scale (NRS) at the time of admission] who were able to give written informed consent.",Study Participants,[186774],[8704],[9131],[False],[0],[0],[False],['0']
26497,PMC5083764,30999,"For this adult subgroup analysis, all patients were aged ≥18 years.",Study Participants,[186777],[9132],[9199],[False],[0],[0],[False],['0']
26498,PMC5083764,31000,The NRS was used for the assessment of patient eligibility only and was not used to evaluate efficacy in this study.,Study Participants,[186780],[9200],[9316],[False],[0],[0],[False],['0']
26499,PMC5083764,31001,"Patients with a life-threatening condition requiring immediate admission to the operating room or intensive care unit, acute intoxication with drugs or alcohol, treatment with any analgesic agent within 5 h before presentation to the ED (except diclofenac sodium, which was prohibited within 8 h before presentation to ED), ongoing use of analgesic agents for chronic pain, use of methoxyflurane within the previous 4 weeks, known personal or familial hypersensitivity to fluorinated anesthetics, or clinically significant respiratory depression, cardiovascular instability, renal or hepatic impairment, were excluded from the participation.",Study Participants,[186783],[9317],[9958],[False],[0],[0],[False],['0']
26500,PMC5083764,31002,Treatments,Treatments,[186786],[9959],[9970],[False],[0],[0],[False],['0']
26501,PMC5083764,31003,Patients were randomized in a 1:1 ratio to receive either methoxyflurane or placebo (sterile normal saline) via a Penthrox inhaler.,Treatments,[186789],[9971],[10102],[False],[0],[0],[False],['0']
26502,PMC5083764,31004,"The handheld Penthrox inhaler is a small, lightweight, disposable, cylindrical polyethylene device, approximately 15 cm long in a distinctive green color comprising a whistle-like mouthpiece on one end and a cap insert at the other end.",Treatments,[186792],[10103],[10339],[False],[0],[0],[False],['0']
26503,PMC5083764,31005,"Internally, the device contains an S-shaped polypropylene wick which absorbs the liquid methoxyflurane/normal saline, and a one-way valve that allows fresh air and methoxyflurane/normal saline vapor to be inhaled through the wick; and prevent expired air and moisture passing back through the wick.",Treatments,[186795],[10340],[10638],[False],[0],[0],[False],['0']
26504,PMC5083764,31006,An activated carbon unit attached to the outlet of the inhaler minimizes the release of methoxyflurane in the vicinity of the patient.,Treatments,[186798],[10639],[10773],[False],[0],[0],[False],['0']
26505,PMC5083764,31007,"Treatment randomization (using permuted block randomization), stratified by center and age group (adolescent/adult) was prepared by an independent statistician.",Treatments,[186801],[10774],[10934],[False],[0],[0],[False],['0']
26506,PMC5083764,31008,"At enrollment, each individual patient was allocated the next randomization number in the appropriate stratum.",Treatments,[186804],[10935],[11045],[False],[0],[0],[False],['0']
26507,PMC5083764,31009,"To prevent selection bias and maintain the blind, the assembling and dispensing of study medication was performed by an unblinded research team member, who loaded the inhalers and then placed each inhaler into a plastic bag, which was sealed, labeled with the patient randomization number and weighed.",Treatments,[186807],[11046],[11347],[False],[0],[0],[False],['0']
26508,PMC5083764,31010,"The patient and all other personnel involved with the conduct and interpretation of the study, including the investigators, site personnel and the study team, were blinded to the treatment allocation.",Treatments,[186810],[11348],[11548],[False],[0],[0],[False],['0']
26509,PMC5083764,31011,"The inhalers looked the same, but as methoxyflurane has a characteristic odor, one drop of methoxyflurane was placed on the outside of the primed inhaler before sealing the plastic bag so that the smell between active and placebo treatments was indistinguishable to the patient and treating physician upon opening.",Treatments,[186813],[11549],[11863],[False],[0],[0],[False],['0']
26510,PMC5083764,31012,"The relative density of methoxyflurane (1.42) is greater than that of normal saline (1), therefore to maintain the blind in respect of inhaler weight, a larger volume of saline solution was contained in the placebo inhalers (5 mL) compared with the volume of methoxyflurane in the active inhalers (3 mL).",Treatments,[186816],[11864],[12168],[False],[0],[0],[False],['0']
26511,PMC5083764,31013,"Patients were supplied with one Penthrox inhaler containing 3 mL of methoxyflurane or 5 mL placebo as soon as possible following enrollment and initial assessments, which was utilized as required.",Treatments,[186819],[12169],[12365],[False],[0],[0],[False],['0']
26512,PMC5083764,31014,"Study medication was self-administered by the patient by inhaling from the device, assisted where required by the research nurse.",Treatments,[186822],[12366],[12495],[False],[0],[0],[False],['0']
26513,PMC5083764,31015,"Each inhaler had a diluter hole at the mouthpiece end, which when covered with the patient’s index finger, allowed the patient to inhale a higher concentration of study medication.",Treatments,[186825],[12496],[12676],[False],[0],[0],[False],['0']
26514,PMC5083764,31016,A second inhaler containing 3 mL of methoxyflurane or 5 mL placebo was supplied if requested by the patient; no patient received a dose greater than 6 mL methoxyflurane (2 × 3 mL) or 10 mL placebo (2 × 5 mL).,Treatments,[186828],[12677],[12885],[False],[0],[0],[False],['0']
26515,PMC5083764,31017,It was estimated that each inhaler could provide up to 1 h pain relief when used intermittently.,Treatments,[186831],[12886],[12982],[False],[0],[0],[False],['0']
26516,PMC5083764,31018,"Following use, the inhaler(s) were weighed by the unblinded member of the research team to determine the dose of methoxyflurane or placebo inhaled by the patient.",Treatments,[186834],[12983],[13145],[False],[0],[0],[False],['0']
26517,PMC5083764,31019,"To ensure that the placebo control study design was ethical and acceptable to patients and investigators, rescue medication was made available immediately upon request for all patients at any time during or after treatment with study medication, as recommended in the Committee for Medicinal Products for Human Use guideline CPMP/EWP/612/00 [23] and guidance from the Declaration of Helsinki on the use of placebo control.",Treatments,[186837],[13146],[13568],[False],[0],[0],[False],['0']
26518,PMC5083764,31020,"Rescue medications permitted while the patient was in the ED included IV, intranasal or oral opioids or paracetamol.",Treatments,[186840],[13569],[13685],[False],[0],[0],[False],['0']
26519,PMC5083764,31021,At the time of discharge patients received 16 × 500 mg paracetamol tablets as rescue medication for the treatment of pain during the 14 ± 2 day follow-up period.,Treatments,[186843],[13686],[13847],[False],[0],[0],[False],['0']
26520,PMC5083764,31022,Efficacy Assessments,Efficacy Assessments,[186846],[13848],[13869],[False],[0],[0],[False],['0']
26521,PMC5083764,31023,"Pain intensity was measured using the Painlog™ (Schlenker Enterprises, Ltd., Lombard, IL, USA) 100 mm visual analog scale (VAS) before the first inhalation of study medication, at 5, 10, 15, 20 and 30 min after the start of study medication inhalation and every 30 min thereafter until rescue medication was administered or discharged from the ED, whichever was sooner.",Efficacy Assessments,[186849],[13870],[14239],[False],[0],[0],[False],['0']
26522,PMC5083764,31024,"The pain VAS is frequently used in pain studies because it is easy to use, requires no verbal or reading skills, and is sufficiently versatile to be employed in a variety of settings [24, 25].",Efficacy Assessments,[186852],[14240],[14432],[False],[0],[0],[False],['0']
26523,PMC5083764,31025,"The time point at which the patient first reported pain relief, the number of inhalations administered until pain relief was achieved, and whether the patient covered the hole in the inhaler during inhalation were recorded.",Efficacy Assessments,[186855],[14433],[14656],[False],[0],[0],[False],['0']
26524,PMC5083764,31026,"It was noted whether or not the patient requested rescue medication, and if applicable, the time of request for rescue medication.",Efficacy Assessments,[186858],[14657],[14787],[False],[0],[0],[False],['0']
26525,PMC5083764,31027,"Prior to ED discharge, the patient, the treating physician and the research nurse completed an assessment of GMP measured using a 5-point Likert scale (‘Poor’, ‘Fair’, ‘Good’, ‘Very Good’, or ‘Excellent’).",Efficacy Assessments,[186861],[14788],[14993],[False],[0],[0],[False],['0']
26526,PMC5083764,31028,Safety Assessments,Safety Assessments,[186864],[14994],[15013],[False],[0],[0],[False],['0']
26527,PMC5083764,31029,"Patients were monitored by a research nurse for the duration of the ED visit and any adverse events, not related to the trauma presentation, were recorded from the time of consent until the time of ED discharge.",Safety Assessments,[186867],[15014],[15225],[False],[0],[0],[False],['0']
26528,PMC5083764,31030,Information on any adverse events occurring during the follow-up period was collected at the 14 ± 2 day follow-up visit.,Safety Assessments,[186870],[15226],[15346],[False],[0],[0],[False],['0']
26529,PMC5083764,31031,"For each adverse event, the investigator provided a ‘Yes/No’ assessment as to whether there was a reasonable possibility that the event may have been caused by methoxyflurane and evaluated its severity according to the National Cancer Institute Common Toxicity Criteria where applicable.",Safety Assessments,[186873],[15347],[15634],[False],[0],[0],[False],['0']
26530,PMC5083764,31032,"Vital signs (blood pressure, heart rate and rhythm, and respiratory rate) were assessed at enrollment and at 5, 10, 15, 20 and 30 min after the start of study medication inhalation and every 30 min thereafter until rescue medication was administered or discharged from the ED, whichever was sooner.",Safety Assessments,[186876],[15635],[15933],[False],[0],[0],[False],['0']
26531,PMC5083764,31033,"Level of consciousness was measured using the 15-point Glasgow coma score at 10, 20 and 30 min after the start of study medication inhalation and prior to ED discharge.",Safety Assessments,[186879],[15934],[16102],[False],[0],[0],[False],['0']
26532,PMC5083764,31034,"Blood samples were drawn for clinical laboratory tests (complete blood count and clinical chemistry including blood glucose, sodium, potassium, calcium, chloride, serum creatinine, alanine transaminase, aspartate transaminase, gamma-glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, total bilirubin, blood urea nitrogen, albumin and total protein) within −10 to +5 min of the start of study medication inhalation and at the 14 ± 2 day follow-up visit.",Safety Assessments,[186882],[16103],[16571],[False],[0],[0],[False],['0']
26533,PMC5083764,31035,Statistical Analyses,Statistical Analyses,[186885],[16572],[16593],[False],[0],[0],[False],['0']
26534,PMC5083764,31036,"The primary efficacy endpoint was the change in pain intensity as measured using the VAS scale from baseline to 5, 10, 15 and 20 min after the start of study medication inhalation, which was analyzed using repeated measures analysis of covariance adjusted for baseline VAS score, and the interaction between time point and treatment.",Statistical Analyses,[186888],[16594],[16927],[False],[0],[0],[False],['0']
26535,PMC5083764,31037,The primary analysis was the overall test for treatment effect considering all four time points.,Statistical Analyses,[186891],[16928],[17024],[False],[0],[0],[False],['0']
26536,PMC5083764,31038,Treatment effects were estimated as least squares mean differences between the methoxyflurane group and the placebo group.,Statistical Analyses,[186894],[17025],[17147],[False],[0],[0],[False],['0']
26537,PMC5083764,31039,"Secondary efficacy endpoints included use of rescue medication within 20 min of the start of treatment (yes/no), time to request for rescue medication, time to first pain relief, number of inhalations taken before first pain relief, and global medication performance (GMP).",Statistical Analyses,[186897],[17148],[17421],[False],[0],[0],[False],['0']
26538,PMC5083764,31040,The time from the start of treatment to first pain relief and first request for rescue medication were each compared between the treatment groups using the Cox proportional hazards model.,Statistical Analyses,[186900],[17422],[17609],[False],[0],[0],[False],['0']
26539,PMC5083764,31041,"Time was censored at the soonest of: 2 h from the start of treatment, physician-initiated rescue medication, start of treatment for the injury, or early withdrawal.",Statistical Analyses,[186903],[17610],[17774],[False],[0],[0],[False],['0']
26540,PMC5083764,31042,Use of rescue medication within 20 min of the start of treatment (yes/no) was compared using logistic regression.,Statistical Analyses,[186906],[17775],[17888],[False],[0],[0],[False],['0']
26541,PMC5083764,31043,"The assessment of the GMP by the patient, research nurse and treating physician were each compared between the treatment groups using ordinal logistic regression with proportional odds assumption.",Statistical Analyses,[186909],[17889],[18085],[False],[0],[0],[False],['0']
26542,PMC5083764,31044,All analyses were adjusted for baseline VAS scores (patients with no baseline VAS pain score were excluded from the analysis).,Statistical Analyses,[186912],[18086],[18212],[False],[0],[0],[False],['0']
26543,PMC5083764,31045,Other efficacy endpoints were summarized descriptively.,Statistical Analyses,[186915],[18213],[18268],[False],[0],[0],[False],['0']
26544,PMC5083764,31046,"All statistical analyses were performed using SAS® version 9.2 or higher (SAS Institute Inc., Cary, NC, USA).",Statistical Analyses,[186918],[18269],[18378],[False],[0],[0],[False],['0']
26545,PMC5083764,31047,All hypothesis testing was carried out at the 5% (two-sided) significance level unless stated otherwise.,Statistical Analyses,[186921],[18379],[18483],[False],[0],[0],[False],['0']
26546,PMC5083764,31048,"There was no imputation of missing data; if a baseline value was missing, no change from baseline was calculated.",Statistical Analyses,[186924],[18484],[18597],[False],[0],[0],[False],['0']
26547,PMC5083764,31049,Baseline was defined as the last recorded value before the first dose.,Statistical Analyses,[186927],[18598],[18668],[False],[0],[0],[False],['0']
26548,PMC5083764,31050,"Efficacy analyses were performed using the intention-to-treat population, defined as all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment.",Statistical Analyses,[186930],[18669],[18884],[False],[0],[0],[False],['0']
26549,PMC5083764,31051,"Safety presentations were descriptive and based on the safety population, which included all randomized patients who received at least one dose of study medication.",Statistical Analyses,[186933],[18885],[19049],[False],[0],[0],[False],['0']
26550,PMC5083764,31052,"Adverse events from enrollment to 14 ± 2 days after ED discharge were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 14.0, McLean, VA, USA) coding system.",Statistical Analyses,[186936],[19050],[19234],[False],[0],[0],[False],['0']
26551,PMC5083764,31053,Events were classified as treatment-emergent if they started or increased in severity on or after the first date and time of study medication dosing.,Statistical Analyses,[186939],[19235],[19384],[False],[0],[0],[False],['0']
26552,PMC5083764,31054,Sample Size,Sample Size,[186942],[19385],[19397],[False],[0],[0],[False],['0']
26553,PMC5083764,31055,"The sample size calculation for the whole study including both adult and adolescent patients, estimated that 150 patients per arm would provide at least 94.5% power to detect a treatment difference of 13 mm [26] in change from baseline of VAS pain score after 20 min using repeated measures analysis of variance of assessments at 5, 10, 15 and 20 min.",Sample Size,[186945],[19398],[19749],[False],[0],[0],[False],['0']
26554,PMC5083764,31056,"Given the setting of the study, the dropout rate was expected to be minimal, and a sample size of 150 patients per arm was considered adequate.",Sample Size,[186948],[19750],[19893],[False],[0],[0],[False],['0']
26555,PMC5083764,31057,"The planned sample size was achieved in the full study population (300 patients were randomized); however, the study was not intended to be sufficiently powered to demonstrate a statistically significant treatment difference in the adult-only subgroup that we report here (102 patients in the methoxyflurane treatment group and 101 patients in the placebo group).",Sample Size,[186951],[19894],[20257],[False],[0],[0],[False],['0']
26556,PMC5083764,31058,Compliance with Ethics Guidelines,Compliance with Ethics Guidelines,[186954],[20258],[20292],[False],[0],[0],[False],['0']
26557,PMC5083764,31059,"The study was conducted in accordance with International Council on Harmonization Good Clinical Practice adhering to the ethical principles of the Helsinki Declaration of 1964, as revised in 2013, as well as local guidelines.",Compliance with Ethics Guidelines,[186957],[20293],[20518],[False],[0],[0],[False],['0']
26558,PMC5083764,31060,The protocol was reviewed by and received favorable opinion from a central National Health Service ethics committee.,Compliance with Ethics Guidelines,[186960],[20519],[20635],[False],[0],[0],[False],['0']
26559,PMC5083764,31061,Each participating center’s research and development department reviewed and approved the protocol and all amendments.,Compliance with Ethics Guidelines,[186963],[20636],[20754],[False],[0],[0],[False],['0']
26560,PMC5083764,31062,Written informed consent was obtained from all patients before enrollment.,Compliance with Ethics Guidelines,[186966],[20755],[20829],[False],[0],[0],[False],['0']
26561,PMC5083764,31063,Results,Results,[186969],[20830],[20838],[False],[0],[0],[False],['0']
26562,PMC5083764,31064,Study Patients,Results|Study Patients,[186972],[20839],[20853],[False],[0],[0],[False],['0']
26563,PMC5083764,31065,Fig.,Results|Study Patients,[186975],[20854],[20858],[False],[0],[0],[False],['0']
26564,PMC5083764,31066,1 Participant flow.,Results|Study Patients,[186978],[20859],[20878],[False],[0],[0],[False],['0']
26565,PMC5083764,31067,"NRS numerical rating scale, ITT intention-to-treat population.",Results|Study Patients,[186981],[20879],[20941],[False],[0],[0],[False],['0']
26566,PMC5083764,31068,The ITT population is defined as those patients in the safety population who have at least one post-baseline efficacy assessment.,Results|Study Patients,[186984],[20942],[21071],[False],[0],[0],[False],['0']
26567,PMC5083764,31069,Participant flow is shown in Fig.,Results|Study Patients,[186987],[21072],[21105],[False],[0],[0],[False],['0']
26568,PMC5083764,31070,1.,Results|Study Patients,[186990],[21106],[21108],[False],[0],[0],[False],['0']
26569,PMC5083764,31071,"A total of 205 adult patients were screened; one patient failed screening because her second NRS score of 8 was outside the inclusion range, and the remaining 204 patients were randomized to double-blind treatment (103 patients to methoxyflurane and 101 patients to placebo).",Results|Study Patients,[186993],[21109],[21384],[False],[0],[0],[False],['0']
26570,PMC5083764,31072,"One patient in the methoxyflurane group discontinued due to an adverse event (light headed/hyperventilation) before receiving study treatment, therefore 203 patients were treated and analyzed for efficacy (intention-to-treat population) and safety.",Results|Study Patients,[186996],[21385],[21633],[False],[0],[0],[False],['0']
26571,PMC5083764,31073,"The majority of patients completed the study to Day 14 ± 2; however, 12 patients (11.7%) in the methoxyflurane group and 11 patients (10.9%) in the placebo group were lost to follow-up.",Results|Study Patients,[186999],[21634],[21819],[False],[0],[0],[False],['0']
26572,PMC5083764,31074,Table 1 Demographic and baseline characteristics (intention-to-treat population).,Results|Study Patients,[187002],[21820],[21902],[False],[0],[0],[False],['0']
26573,PMC5083764,31075,Demographic and baseline characteristics are presented in Table 1.,Results|Study Patients,[187005],[21903],[21969],[False],[0],[0],[False],['0']
26574,PMC5083764,31076,"Most patients (96.1%) were White, with an even gender split (51.2% male: 48.8% female) and a mean age of 36 years (range 18–84 years) overall.",Results|Study Patients,[187008],[21970],[22112],[False],[0],[0],[False],['0']
26575,PMC5083764,31077,"First injury type was most commonly classified as ‘other’ (50.2% of patients, largely injuries such as sprains, soft tissue injury and muscular pain); 23.6% of patients had contusions, 17.7% of patients had fractures, while burns, dislocations, lacerations and injuries due to foreign body were each reported for <5% of patients.",Results|Study Patients,[187011],[22113],[22442],[False],[0],[0],[False],['0']
26576,PMC5083764,31078,"Eleven patients had >1 injury, including two who had three injuries (second and third injury types included contusions, lacerations and ‘other’).",Results|Study Patients,[187014],[22443],[22588],[False],[0],[0],[False],['0']
26577,PMC5083764,31079,"Mean baseline VAS pain intensity score was 66.2 mm in the methoxyflurane group and 65.5 mm in the placebo group, indicating that on average, patients were experiencing pain of at least moderate severity at baseline [27].",Results|Study Patients,[187017],[22589],[22809],[False],[0],[0],[False],['0']
26578,PMC5083764,31080,"Overall, the two treatment groups were evenly matched with regard to patient demographic characteristics, injury type and baseline pain severity.",Results|Study Patients,[187020],[22810],[22955],[False],[0],[0],[False],['0']
26579,PMC5083764,31081,Efficacy,Efficacy,[187023],[22956],[22966],[False],[0],[0],[False],['0']
26580,PMC5083764,31082,Table 2 Analysis of VAS Pain Intensity Score (intention-to-treat population).,Efficacy,[187026],[22967],[23044],[False],[0],[0],[False],['0']
26581,PMC5083764,31083,Methoxyflurane significantly reduced pain intensity compared with placebo.,Efficacy,[187029],[23045],[23119],[False],[0],[0],[False],['0']
26582,PMC5083764,31084,"Table 2 shows that for the overall change from baseline in VAS pain (primary analysis), there was a highly significant treatment difference [estimated treatment effect: −17.4 mm; 95% confidence interval (CI): −22.3 to −12.5 mm; p < 0.0001].",Efficacy,[187032],[23120],[23360],[False],[0],[0],[False],['0']
26583,PMC5083764,31085,"The mean change in VAS pain from baseline was also significantly greater for the methoxyflurane group compared with the placebo group at each individual time point (5, 10, 15 and 20 min).",Efficacy,[187035],[23361],[23548],[False],[0],[0],[False],['0']
26584,PMC5083764,31086,The greatest treatment effect was observed at 15 min after the start of dosing (estimated treatment effect: −21.0 mm; 95% CI: −26.8 to −15.3 mm).,Efficacy,[187038],[23549],[23694],[False],[0],[0],[False],['0']
26585,PMC5083764,31087,Table 3 Analysis of secondary pain relief endpoints (intention-to-treat population).,Efficacy,[187041],[23695],[23780],[False],[0],[0],[False],['0']
26586,PMC5083764,31088,The majority of patients in the methoxyflurane group (82.4%) experienced pain relief.,Efficacy,[187044],[23781],[23866],[False],[0],[0],[False],['0']
26587,PMC5083764,31089,"The median time to first pain relief was significantly shorter in the methoxyflurane group (5 min) compared with the placebo group (20 min, Table 3) (hazard ratio for difference between methoxyflurane and placebo: 2.32; 95% CI: 1.63, 3.30; p < 0.0001).",Efficacy,[187047],[23867],[24119],[False],[0],[0],[False],['0']
26588,PMC5083764,31090,"In the methoxyflurane group, 45 patients (44.1%) reported pain relief within the first five inhalations, 36 patients (35.3%) reported pain relief within 6–10 inhalations, five patients (4.9%) took >10 inhalations, while 16 patients (15.7%) reported no pain relief prior to taking rescue medication.",Efficacy,[187050],[24120],[24418],[False],[0],[0],[False],['0']
26589,PMC5083764,31091,"In contrast, in the placebo group, almost half of the patients [47 (46.5%)] reported no pain relief prior to taking rescue medication, while for those who did report pain relief, overall it was reported after a greater number of inhalations compared with the methoxyflurane group (Table 3).",Efficacy,[187053],[24419],[24709],[False],[0],[0],[False],['0']
26590,PMC5083764,31092,"The proportion of patients who used rescue medication in the first 20 min was significantly lower in the methoxyflurane group (2.0%) than the placebo group (22.8%) (odds ratio: 0.07; 95% CI: 0.02, 0.29; p = 0.0003).",Efficacy,[187056],[24710],[24926],[False],[0],[0],[False],['0']
26591,PMC5083764,31093,"When considering requests for rescue medication at any time (prior to censoring), rescue medication use was again significantly lower for the methoxyflurane group (11.8%) compared with the placebo group (38.6%), with a significantly longer time to request for rescue medication (hazard ratio: 0.23; 95% CI: 0.12, 0.44; p < 0.0001).",Efficacy,[187059],[24927],[25258],[False],[0],[0],[False],['0']
26592,PMC5083764,31094,The proportion of patients requesting rescue medication at any time (prior to censoring) did not reach a level where the median time to request could be estimated.,Efficacy,[187062],[25259],[25422],[False],[0],[0],[False],['0']
26593,PMC5083764,31095,Table 4 Global medication performance (intention-to-treat population).,Efficacy,[187065],[25423],[25493],[False],[0],[0],[False],['0']
26594,PMC5083764,31096,"The GMP ratings by the patient, treating physician and research nurse at ED discharge were all significantly better in the methoxyflurane group compared with the placebo group (p < 0.0001, Table 4).",Efficacy,[187068],[25494],[25692],[False],[0],[0],[False],['0']
26595,PMC5083764,31097,"Approximately, three-quarters of patients, physicians and research nurses rated methoxyflurane treatment as ‘Excellent’, ‘Very Good’ or ‘Good’ (77.6% of patients, 74.5% of physicians and 72.5% of research nurses).",Efficacy,[187071],[25693],[25906],[False],[0],[0],[False],['0']
26596,PMC5083764,31098,Inhaler Use,Inhaler Use,[187074],[25907],[25920],[False],[0],[0],[False],['0']
26597,PMC5083764,31099,A total of 25 patients (24.5%) in the methoxyflurane group and 15 patients (14.9%) in the placebo group requested a second inhaler.,Inhaler Use,[187077],[25921],[26052],[False],[0],[0],[False],['0']
26598,PMC5083764,31100,The median time between dispensing the first and second inhalers was 54 min (range 30–120 min) for patients receiving methoxyflurane and 50 min (range 20–72 min) for patients receiving placebo.,Inhaler Use,[187080],[26053],[26246],[False],[0],[0],[False],['0']
26599,PMC5083764,31101,The number of patients covering the diluter hole on inhalation (allowing the patient to inhale a higher concentration of methoxyflurane/placebo) was slightly higher in the placebo group [43 patients (42.6%)] compared with the methoxyflurane group [37 patients (36.3%)].,Inhaler Use,[187083],[26247],[26516],[False],[0],[0],[False],['0']
26600,PMC5083764,31102,Safety,Safety,[187086],[26517],[26524],[False],[0],[0],[False],['0']
26601,PMC5083764,31103,Table 5 Treatment-emergent adverse events (safety population).,Safety,[187089],[26525],[26587],[False],[0],[0],[False],['0']
26602,PMC5083764,31104,Treatment-emergent adverse events were reported by 64 patients (62.7%) in the methoxyflurane group and 41 patients (40.6%) in the placebo group (Table 5); these were considered to be treatment-related (according to the investigator’s causality assessment) for 43 patients (42.2%) receiving methoxyflurane and 15 patients (14.9%) receiving placebo.,Safety,[187092],[26588],[26935],[False],[0],[0],[False],['0']
26603,PMC5083764,31105,"The most common adverse events in the methoxyflurane group were dizziness [37 patients (36.3%)] and headache [20 patients (19.6%)], which were both reported more frequently than in the placebo group [dizziness: 11 patients (10.9%); headache: 13 patients (12.9%)].",Safety,[187095],[26936],[27199],[False],[0],[0],[False],['0']
26604,PMC5083764,31106,All other adverse events were reported by <5% of patients in either treatment group.,Safety,[187098],[27200],[27284],[False],[0],[0],[False],['0']
26605,PMC5083764,31107,"There were no other notable differences between the treatment groups in the incidence of adverse events, except for somnolence, which was reported by five methoxyflurane-treated patients and one placebo-treated patient.",Safety,[187101],[27285],[27504],[False],[0],[0],[False],['0']
26606,PMC5083764,31108,No patients discontinued treatment with methoxyflurane due to adverse events and one placebo-treated patient discontinued due to vomiting.,Safety,[187104],[27505],[27643],[False],[0],[0],[False],['0']
26607,PMC5083764,31109,The majority of adverse events were mild and transient in nature; no patients experienced a severe adverse event (severity was not recorded for six adverse events).,Safety,[187107],[27644],[27808],[False],[0],[0],[False],['0']
26608,PMC5083764,31110,One serious adverse event (lower respiratory tract infection requiring hospitalization) was reported in a methoxyflurane-treated patient 5 days after treatment.,Safety,[187110],[27809],[27969],[False],[0],[0],[False],['0']
26609,PMC5083764,31111,The patient had enrolled into the study with blunt trauma (from falling off a chair) and complained of right-sided rib pain and an injury to the right knee.,Safety,[187113],[27970],[28126],[False],[0],[0],[False],['0']
26610,PMC5083764,31112,The investigator considered that the event was not related to the study treatment and that the most likely cause was blunt trauma.,Safety,[187116],[28127],[28257],[False],[0],[0],[False],['0']
26611,PMC5083764,31113,The administration of low dose methoxyflurane had no observable effects on cardiovascular or respiratory parameters.,Safety,[187119],[28258],[28375],[False],[0],[0],[False],['0']
26612,PMC5083764,31114,"Mean changes from baseline in heart rate were within ±5 beats per minute, while mean changes from baseline in systolic and diastolic blood pressure were within ±6 mmHg, and mean respiratory rate remained constant at 14–15 breaths/min.",Safety,[187122],[28376],[28610],[False],[0],[0],[False],['0']
26613,PMC5083764,31115,"Glasgow coma score was 15 for all patients at all-time points, except two patients who recorded a score of 14 (one at 10, 20 and 30 min and one at 30 min only).",Safety,[187125],[28611],[28771],[False],[0],[0],[False],['0']
26614,PMC5083764,31116,"There were no renal or liver concerns arising from the results of the clinical laboratory evaluations at baseline and at the follow-up visit, and mean values for all parameters were within normal limits.",Safety,[187128],[28772],[28975],[False],[0],[0],[False],['0']
26615,PMC5083764,31117,Discussion,Discussion,[187131],[28976],[28987],[False],[0],[0],[False],['0']
26616,PMC5083764,31118,The results of this study confirm that methoxyflurane is a highly effective analgesic for adult patients in the ED setting.,Discussion,[187134],[28988],[29111],[False],[0],[0],[False],['0']
26617,PMC5083764,31119,"There was a highly significant difference between the methoxyflurane and placebo groups (p < 0.0001) in the analysis of the VAS pain intensity score at all-time points tested, despite a considerable ‘placebo effect’.",Discussion,[187137],[29112],[29328],[False],[0],[0],[False],['0']
26618,PMC5083764,31120,"In a previous hypothesis-generating study, Todd et al.",Discussion,[187140],[29329],[29383],[False],[0],[0],[False],['0']
26619,PMC5083764,31121,"found that a difference of approximately 13 mm on a 100 mm VAS scale represented the minimum change in acute pain that was clinically significant in a cohort of trauma patients [28], which was supported by findings of Gallagher et al.",Discussion,[187143],[29384],[29618],[False],[0],[0],[False],['0']
26620,PMC5083764,31122,[26].,Discussion,[187146],[29619],[29624],[False],[0],[0],[False],['0']
26621,PMC5083764,31123,"This was appreciably exceeded in our adult population results, with a treatment difference of −17.4 mm (95% CI: −22.3, −12.5 mm) overall in favor of methoxyflurane.",Discussion,[187149],[29625],[29789],[False],[0],[0],[False],['0']
26622,PMC5083764,31124,A reduction of approximately two points or 30% in the pain intensity NRS has also been postulated to represent a clinically important difference by Farrar and colleagues [29].,Discussion,[187152],[29790],[29965],[False],[0],[0],[False],['0']
26623,PMC5083764,31125,"While the primary efficacy results of the current study are based on the VAS pain score and acute pain, rather than the 11-point NRS and chronic pain (as evaluated by Farrar), the overall adjusted change from baseline in VAS pain intensity of −29.0 mm in the methoxyflurane group (from a baseline mean of 66.2 mm) represents a reduction in pain of ~44%, also considerably exceeding this definition of clinical significance.",Discussion,[187155],[29966],[30389],[False],[0],[0],[False],['0']
26624,PMC5083764,31126,"This is important, as small differences in mean VAS score can be declared “statistically significant”, even though they may be of little clinical significance to the patient [30].",Discussion,[187158],[30390],[30569],[False],[0],[0],[False],['0']
26625,PMC5083764,31127,"In comparison, the overall adjusted change from baseline in VAS pain intensity in the placebo group was −11.6 mm (from a baseline mean of 65.5 mm), representing an 18% reduction.",Discussion,[187161],[30570],[30748],[False],[0],[0],[False],['0']
26626,PMC5083764,31128,Although the STOP!,Discussion,[187164],[30749],[30767],[False],[0],[0],[False],['0']
26627,PMC5083764,31129,"study was placebo-controlled, our results for methoxyflurane are similar to those observed for IV morphine and intranasal fentanyl in a study by Borland et al.",Discussion,[187167],[30768],[30927],[False],[0],[0],[False],['0']
26628,PMC5083764,31130,with a similar design and endpoint in pediatric patients presenting to the ED with acute long-bone fractures [31].,Discussion,[187170],[30928],[31042],[False],[0],[0],[False],['0']
26629,PMC5083764,31131,"This study showed mean changes from baseline in 100 mm VAS pain scores at 5, 10 and 20 min of −25, −26 and −32 mm for morphine and −13, −22 and −31 mm for fentanyl from a baseline of 67 and 68 mm, respectively, compared with our results for methoxyflurane of −21, −27 and −35 mm from a baseline of 66 mm.",Discussion,[187173],[31043],[31347],[False],[0],[0],[False],['0']
26630,PMC5083764,31132,"The secondary efficacy results supported the findings of the primary efficacy analysis, with significantly fewer methoxyflurane-treated patients requiring rescue medication than placebo-treated patients (11.8% vs. 38.6%), and approximately three-quarters of patients, physicians and research nurses rating methoxyflurane treatment as ‘Excellent’, ‘Very Good’ or ‘Good’.",Discussion,[187176],[31348],[31717],[False],[0],[0],[False],['0']
26631,PMC5083764,31133,The high patient and treating medical professional satisfaction with methoxyflurane analgesia observed in this study is consistent with results reported by Buntine et al.,Discussion,[187179],[31718],[31888],[False],[0],[0],[False],['0']
26632,PMC5083764,31134,"[20], who reported that 81.9% of paramedics and 72.3% of patients felt satisfied with methoxyflurane pre-hospital analgesia.",Discussion,[187182],[31889],[32013],[False],[0],[0],[False],['0']
26633,PMC5083764,31135,"As expected, the onset of pain relief with methoxyflurane was rapid (median 5 min) with 79.4% of patients experiencing pain relief within 1–10 inhalations.",Discussion,[187185],[32014],[32169],[False],[0],[0],[False],['0']
26634,PMC5083764,31136,This is consistent with the rapid onset of pain relief reported by Johnston et al.,Discussion,[187188],[32170],[32252],[False],[0],[0],[False],['0']
26635,PMC5083764,31137,"in their study of pre-hospital analgesia for visceral pain, which found a mean reduction in visual/verbal analog scale pain score (0–10 scale) with methoxyflurane of 2.0 (95% CI: 1.7, 2.2) after 5 min and 2.5 (95% CI: 2.1–2.9) on arrival at hospital, compared with 1.6 (95% CI: 1.4, 1.8) and 3.2 (95% CI: 2.9, 3.5), respectively, for intranasal fentanyl [19].",Discussion,[187191],[32253],[32612],[False],[0],[0],[False],['0']
26636,PMC5083764,31138,The onset of pain relief with methoxyflurane is also similar to that reported by Tveita et al.,Discussion,[187194],[32613],[32707],[False],[0],[0],[False],['0']
26637,PMC5083764,31139,for a 10 mg bolus dose of IV morphine [32].,Discussion,[187197],[32708],[32751],[False],[0],[0],[False],['0']
26638,PMC5083764,31140,"Although methoxyflurane is currently only licensed for emergency relief of pain due to trauma in Europe, several studies in Australia and New Zealand have also demonstrated its effectiveness as a procedural analgesic [21, 33–36].",Discussion,[187200],[32752],[32981],[False],[0],[0],[False],['0']
26639,PMC5083764,31141,"The rate of treatment-related adverse events was higher with methoxyflurane (42.2%) than placebo (14.9%); this was mostly attributable to a higher incidence of dizziness/lightheadedness and headache in the methoxyflurane group, which are both adverse events already captured in the product label [13].",Discussion,[187203],[32982],[33283],[False],[0],[0],[False],['0']
26640,PMC5083764,31142,"However, the majority of adverse events were mild and transient in nature, no patients discontinued use of methoxyflurane due to adverse events and patients rated their satisfaction with methoxyflurane treatment highly, (77.6% assessing treatment as ‘Excellent’, ‘Very Good’ or ‘Good’).",Discussion,[187206],[33284],[33570],[False],[0],[0],[False],['0']
26641,PMC5083764,31143,"It should also be taken into account that study treatment exposure was higher in the methoxyflurane group than the placebo group; patients in the placebo group requested rescue medication significantly earlier than patients in the methoxyflurane group, and 24.5% of patients in the methoxyflurane group compared with 14.9% in the placebo group used a second inhaler.",Discussion,[187209],[33571],[33937],[False],[0],[0],[False],['0']
26642,PMC5083764,31144,"While this is unlikely to have affected the key efficacy endpoints, which mainly considered the early effects of study treatment (in the first 20 min), it may have had an impact on safety results.",Discussion,[187212],[33938],[34134],[False],[0],[0],[False],['0']
26643,PMC5083764,31145,"We also observed no effects of methoxyflurane on vital signs, which are consistent with the findings from two retrospective, observational studies of methoxyflurane analgesia in the pre-hospital setting that looked at records of 1217 patients treated by the Australian Ambulance Service [19, 37].",Discussion,[187215],[34135],[34431],[False],[0],[0],[False],['0']
26644,PMC5083764,31146,"In this study, although clinical laboratory sampling was limited, no evidence of nephro- or hepatotoxicity was observed.",Discussion,[187218],[34432],[34552],[False],[0],[0],[False],['0']
26645,PMC5083764,31147,"Similarly, in patients receiving methoxyflurane as procedural analgesia for bone marrow biopsy, blood analysis of urea and electrolytes was no different between those patients receiving methoxyflurane and those receiving placebo [35].",Discussion,[187221],[34553],[34787],[False],[0],[0],[False],['0']
26646,PMC5083764,31148,"These observations are consistent with the findings of Dayan [17], who reviewed laboratory and clinical data relevant to nephrotoxicity and methoxyflurane and concluded that low-dose use of methoxyflurane for analgesia has a large safety margin (at least 2.7- to 8-fold based on methoxyflurane MAC-hours or serum fluoride level) and does not carry a risk of causing renal dysfunction or damage.",Discussion,[187224],[34788],[35182],[False],[0],[0],[False],['0']
26647,PMC5083764,31149,"Furthermore, over 5 million doses of Penthrox have been sold with no pharmacovigilance-related trends suggesting nephrotoxicity.",Discussion,[187227],[35183],[35311],[False],[0],[0],[False],['0']
26648,PMC5083764,31150,"In a much larger controlled observational study of patients receiving analgesia during ambulance transport, comparing 17,629 patients receiving methoxyflurane with 118,141 patients not receiving methoxyflurane, no link between methoxyflurane use for emergency analgesia and renal disease (or hepatic disease) was observed [16].",Discussion,[187230],[35312],[35639],[False],[0],[0],[False],['0']
26649,PMC5083764,31151,"Whilst the literature and post-marketing surveillance in Australia suggest that nephrotoxicity and/or hepatotoxicity of methoxyflurane at analgesic doses is not a risk [16, 17], a study is underway in the UK to understand hepatotoxicity in the pre-hospital and ED settings.",Discussion,[187233],[35640],[35913],[False],[0],[0],[False],['0']
26650,PMC5083764,31152,"A limitation of the study was the lack of an active comparator, as previously observed by Carley and Body [38].",Discussion,[187236],[35914],[36025],[True],['Control'],['the lack of an active comparator'],[True],['Control']
26651,PMC5083764,31153,"An active comparator was not considered feasible in this study due to the unique mode of delivery and smell of methoxyflurane, as well as the difficulty in blinding possible inhaled comparators such as nitrous oxide.",Discussion,[187243],[36026],[36242],[True],['Control'],['An active comparator was not considered feasible'],[True],['Control']
26652,PMC5083764,31154,"Due to methoxyflurane’s fast onset of action, if an oral comparator was used, it would have been evident which treatment the patient had been randomized to.",Discussion,[187248],[36243],[36399],[False],[0],[0],[False],['0']
26653,PMC5083764,31155,"Placebo use is considered warranted when the placebo effect is known to be very variable (e.g., pain) and when associated with minimization measures, e.g., rescue treatment [39].",Discussion,[187251],[36400],[36578],[False],[0],[0],[False],['0']
26654,PMC5083764,31156,"Patients randomized to placebo had immediate access to rescue medication to mitigate the risk of under treatment, therefore the placebo group was considered to be ethically justified and was approved by the National Research Ethics Committee, and the decision to include placebo as the comparator was ratified by regulatory agencies.",Discussion,[187254],[36579],[36912],[False],[0],[0],[False],['0']
26655,PMC5083764,31157,"A double-blind, double-dummy study design would have been required for an active comparator, which would have had implications in terms of the time taken to dispense and administer study medication (when rapid analgesia is required in the ED), and also in terms of affecting the provision of rescue analgesia.",Discussion,[187259],[36913],[37222],[True],['Blinding'],"['A double-blind, double-dummy study design']",[True],['Blinding']
26656,PMC5083764,31158,"Despite the lack of active control, the study provided meaningful and clinically relevant results indicating a beneficial clinical effect of methoxyflurane.",Discussion,[187263],[37223],[37379],[False],[0],[0],[False],['0']
26657,PMC5083764,31159,Conclusion,Conclusion,[187266],[37380],[37391],[False],[0],[0],[False],['0']
26658,PMC5083764,31160,"In conclusion, consistent with evidence from previous studies, the results of this study show that low-dose methoxyflurane administered via the Penthrox inhaler is an easy to use, well-tolerated, effective and rapid-acting analgesic in the ED setting.",Conclusion,[187269],[37392],[37643],[False],[0],[0],[False],['0']
26659,PMC5083764,31161,"Considering its fast onset of action, ease of use and minimal impact on subsequent treatment choices, methoxyflurane may also lend itself as a bridging agent in the pre-hospital/ED setting until it is possible to administer more powerful analgesia if required, and also as a short-term procedural analgesic.",Conclusion,[187272],[37644],[37951],[False],[0],[0],[False],['0']
26660,PMC5083764,31162,Enhanced content,Enhanced content,[187275],[37952],[37969],[False],[0],[0],[False],['0']
26661,PMC5083764,31163,To view enhanced content for this article go to http://www.medengine.com/Redeem/D395F0600606EF5E.,Enhanced content,[187278],[37970],[38067],[False],[0],[0],[False],['0']
26662,PMC5083764,31164,Disclosures,Enhanced content|Disclosures,[187281],[38068],[38079],[False],[0],[0],[False],['0']
26663,PMC5083764,31165,The study was funded by Medical Developments International (MDI) Limited.,Enhanced content|Disclosures,[187284],[38080],[38153],[False],[0],[0],[False],['0']
26664,PMC5083764,31166,This article processing charges and open access fee were funded by Mundipharma Research GmbH & Co.KG.,Enhanced content|Disclosures,[187287],[38154],[38255],[False],[0],[0],[False],['0']
26665,PMC5083764,31167,All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.,Enhanced content|Disclosures,[187290],[38256],[38414],[False],[0],[0],[False],['0']
26666,PMC5083764,31168,Editorial assistance in the preparation of this manuscript was provided by Karen Mower of Scientific Editorial and funded by Mundipharma Research GmbH & Co.KG.,Enhanced content|Disclosures,[187293],[38415],[38574],[False],[0],[0],[False],['0']
26667,PMC5083764,31169,"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.",Enhanced content|Disclosures,[187296],[38575],[38829],[False],[0],[0],[False],['0']
26668,PMC5083764,31170,Disclosures,Enhanced content|Disclosures,[187299],[38830],[38842],[False],[0],[0],[False],['0']
26669,PMC5083764,31171,Frank Coffey was paid travel and subsistence expenses by MDI for one investigator’s meeting.,Enhanced content|Disclosures,[187302],[38843],[38935],[False],[0],[0],[False],['0']
26670,PMC5083764,31172,Frank Coffey’s institution was paid by MDI to run the study.,Enhanced content|Disclosures,[187305],[38936],[38996],[False],[0],[0],[False],['0']
26671,PMC5083764,31173,Patrick Dissmann’s institution was paid by MDI to run the study.,Enhanced content|Disclosures,[187308],[38997],[39061],[False],[0],[0],[False],['0']
26672,PMC5083764,31174,Kazim Mirza’s institution was paid by MDI to run the study.,Enhanced content|Disclosures,[187311],[39062],[39121],[False],[0],[0],[False],['0']
26673,PMC5083764,31175,Mark Lomax is an employee of Mundipharma Research Limited.,Enhanced content|Disclosures,[187314],[39122],[39180],[False],[0],[0],[False],['0']
26674,PMC5083764,31176,Compliance with Ethics Guidelines,Enhanced content|Compliance with Ethics Guidelines,[187317],[39181],[39214],[False],[0],[0],[False],['0']
26675,PMC5083764,31177,"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.",Enhanced content|Compliance with Ethics Guidelines,[187320],[39215],[39430],[False],[0],[0],[False],['0']
26676,PMC5083764,31178,Favorable opinion for the study was received from the National Research Ethics Service (REC reference 11/YH/0116).,Enhanced content|Compliance with Ethics Guidelines,[187323],[39431],[39545],[False],[0],[0],[False],['0']
26677,PMC5083764,31179,Informed consent was obtained from all patients for being included in the study.,Enhanced content|Compliance with Ethics Guidelines,[187326],[39546],[39626],[False],[0],[0],[False],['0']
26678,PMC5083764,31180,® PENTHROX is a registered trademark of MDI Limited.,Enhanced content|Compliance with Ethics Guidelines,[187329],[39627],[39679],[False],[0],[0],[False],['0']
26679,PMC5083764,31181,Open Access,Enhanced content|Open Access,[187332],[39680],[39691],[False],[0],[0],[False],['0']
26680,PMC5083764,31182,"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Enhanced content|Open Access,[187335],[39692],[40106],[False],[0],[0],[False],['0']
26681,PMC5094537,32683,Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis,Title,[194337],[31359],[131],[False],[0],[0],[False],['0']
26682,PMC5094537,32684,Objective,Abstract,[194339],[132],[142],[False],[0],[0],[False],['0']
26683,PMC5094537,32685,To report 2‐year patient‐reported outcomes (PROs) from the head‐to‐head Abatacept versus Adalimumab Comparison in Biologic‐Naive RA Subjects with Background Methotrexate (MTX) (AMPLE) trial.,Abstract,[194341],[143],[333],[False],[0],[0],[False],['0']
26684,PMC5094537,32686,Methods,Methods,[194343],[334],[342],[False],[0],[0],[False],['0']
26685,PMC5094537,32687,"AMPLE was a phase IIIb, randomized, investigator‐blinded trial.",Methods,[194345],[343],[406],[False],[0],[0],[False],['0']
26686,PMC5094537,32688,Biologic‐naive patients with rheumatoid arthritis (RA) and an inadequate response to MTX were randomized to subcutaneous (SC) abatacept (125 mg/week) or adalimumab (40 mg every 2 weeks) with background MTX.,Methods,[194347],[407],[613],[False],[0],[0],[False],['0']
26687,PMC5094537,32689,"PROs (pain, fatigue, ability to perform work, and ability to perform daily activities) were compared up to year 2 for patients in each treatment group, as well as those who achieved low disease activity at both years 1 and 2 (responders) and those who did not (nonresponders).",Methods,[194349],[614],[890],[False],[0],[0],[False],['0']
26688,PMC5094537,32690,Results,Results,[194351],[891],[899],[False],[0],[0],[False],['0']
26689,PMC5094537,32691,A total of 646 patients were randomized and treated with SC abatacept (n = 318) or adalimumab (n = 328).,Results,[194353],[900],[1004],[False],[0],[0],[False],['0']
26690,PMC5094537,32692,Baseline characteristics were balanced between the 2 treatment arms.,Results,[194355],[1005],[1073],[False],[0],[0],[False],['0']
26691,PMC5094537,32693,"Comparable improvements in PROs were observed in the abatacept and adalimumab groups over 2 years, with both groups achieving clinically meaningful improvements in PROs from baseline.",Results,[194357],[1074],[1257],[False],[0],[0],[False],['0']
26692,PMC5094537,32694,"At year 2, fatigue improved by 23.4 mm and 21.5 mm on a 100‐mm visual analog scale with abatacept and adalimumab, respectively.",Results,[194359],[1258],[1385],[False],[0],[0],[False],['0']
26693,PMC5094537,32695,Clinical responders achieved greater improvements in PROs than nonresponders.,Results,[194361],[1386],[1463],[False],[0],[0],[False],['0']
26694,PMC5094537,32696,Conclusion,Conclusion,[194363],[1464],[1475],[False],[0],[0],[False],['0']
26695,PMC5094537,32697,"In biologic‐naive patients with active RA, despite prior MTX, treatment with SC abatacept or adalimumab with background MTX resulted in comparable improvements in PROs, which were highly correlated with physician‐reported clinical response end points.",Conclusion,[194365],[1476],[1727],[False],[0],[0],[False],['0']
26696,PMC5094537,32698,INTRODUCTION,INTRODUCTION,[194367],[1728],[1742],[False],[0],[0],[False],['0']
26697,PMC5094537,32699,"Rheumatoid arthritis (RA) can have a major impact on patient‐reported outcomes (PROs) that evaluate health, quality of life, and treatment response from the perspective of the patient.",INTRODUCTION,[194369],[1743],[1927],[False],[0],[0],[False],['0']
26698,PMC5094537,32700,"PROs that are considered to have a particularly large impact on the quality of life of patients with RA include pain, fatigue, the ability to perform work, and the ability to perform daily activities 1.",INTRODUCTION,[194371],[1928],[2130],[False],[0],[0],[False],['0']
26699,PMC5094537,32701,"The treat‐to‐target strategies employed in RA aim to achieve significant improvements in clinical outcomes, with the goal of remission, or if remission cannot be achieved, low disease activity.",INTRODUCTION,[194373],[2131],[2324],[False],[0],[0],[False],['0']
26700,PMC5094537,32702,"However, whether achievement of these goals is associated with meaningful improvements in PROs remains unclear.",INTRODUCTION,[194375],[2325],[2436],[False],[0],[0],[False],['0']
26701,PMC5094537,32703,"It is, therefore, important that PROs are evaluated in conjunction with clinical outcomes, particularly when disease activity is assessed using a measure that does not include a patient‐reported component.",INTRODUCTION,[194377],[2437],[2642],[False],[0],[0],[False],['0']
26702,PMC5094537,32704,"As both clinical outcomes and PROs are important, their interrelationship should be investigated.",INTRODUCTION,[194379],[2643],[2740],[False],[0],[0],[False],['0']
26703,PMC5094537,32705,"Both the current American College of Rheumatology (ACR) recommendations and the European League Against Rheumatism guidelines recommend methotrexate (MTX) as first‐line therapy for RA, with the addition of biologic disease‐modifying antirheumatic drugs (DMARDs) in patients who experience an inadequate response to MTX 2, 3.",INTRODUCTION,[194381],[2741],[3065],[False],[0],[0],[False],['0']
26704,PMC5094537,32706,"Abatacept is a T‐cell costimulation modulator that has shown efficacy in patients with RA in a wide range of disease and treatment durations 4, 5, 6, 7, 8, 9, 10, 11.",INTRODUCTION,[194383],[3066],[3232],[False],[0],[0],[False],['0']
26705,PMC5094537,32707,"The AMPLE (Abatacept versus Adalimumab Comparison in Biologic‐Naive RA Subjects with Background MTX) trial, the first head‐to‐head trial comparing biologic DMARDs in patients with RA receiving MTX, demonstrated noninferiority for abatacept versus adalimumab by the ACR 20% improvement response (ACR20) at year 1 (64.8% subcutaneous [SC] abatacept versus 63.4% adalimumab; estimated difference between treatments 1.8% [95% confidence interval (95% CI) −5.6, 9.2] in an intent‐to‐treat analysis) 12.",INTRODUCTION,[194385],[3233],[3730],[False],[0],[0],[False],['0']
26706,PMC5094537,32708,"In AMPLE, there was a similar time of onset of ACR20 response in both treatment groups, with the response maintained up to year 2 13.",INTRODUCTION,[194387],[3731],[3864],[False],[0],[0],[False],['0']
26707,PMC5094537,32709,AMPLE included a diverse range of PRO analyses and is the first biologic DMARD head‐to‐head evaluation of PROs in RA.,INTRODUCTION,[194389],[3865],[3982],[False],[0],[0],[False],['0']
26708,PMC5094537,32710,"Comparable improvements from baseline to year 1 were seen in fatigue with SC abatacept and adalimumab (−23.2% SC abatacept versus −21.4% adalimumab; adjusted treatment difference −1.8% [95% CI −5.8, 2.2]) 12.",INTRODUCTION,[194391],[3983],[4191],[False],[0],[0],[False],['0']
26709,PMC5094537,32711,Results for pain over 1 and 2 years have also been presented previously 14.,INTRODUCTION,[194393],[4192],[4267],[False],[0],[0],[False],['0']
26710,PMC5094537,32712,"Here, 2‐year results from the AMPLE trial are reported, directly comparing the effects of abatacept and adalimumab on the PROs of pain, fatigue, the ability to perform work, and the ability to perform daily activities, as well as the relationship between these 4 PROs and clinical outcomes.",INTRODUCTION,[194395],[4268],[4558],[False],[0],[0],[False],['0']
26711,PMC5094537,32713,PATIENTS AND METHODS,PATIENTS AND METHODS,[194397],[4559],[4580],[False],[0],[0],[False],['0']
26712,PMC5094537,32714,The AMPLE study design and patient inclusion/exclusion criteria have been described previously 13.,PATIENTS AND METHODS,[194399],[4581],[4679],[False],[0],[0],[False],['0']
26713,PMC5094537,32715,"Briefly, patients had active RA for ≤5 years, as defined by the 1987 ACR criteria for RA 15, had reported an inadequate response to MTX, were biologics‐naive, and had a Disease Activity Score in 28 joints using the C‐reactive protein (DAS28‐CRP) level ≥3.2.",PATIENTS AND METHODS,[194401],[4680],[4937],[False],[0],[0],[False],['0']
26714,PMC5094537,32716,"Patients were randomly assigned (1:1) to either SC abatacept (125 mg/week) or adalimumab (40 mg every 2 weeks), in addition to a stable dose of MTX (15–25 mg/week).",PATIENTS AND METHODS,[194403],[4938],[5102],[False],[0],[0],[False],['0']
26715,PMC5094537,32717,"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki; with Good Clinical Practice, as defined by the International Conference on Harmonization; with the ethical principles underlying European Union Directive 2001/20/EC; and with the US Code of Federal Regulations, Title 21, Part 50 (21CFR50).",PATIENTS AND METHODS,[194405],[5103],[5441],[False],[0],[0],[False],['0']
26716,PMC5094537,32718,The laws and regulatory requirements of all countries participating in this study were followed.,PATIENTS AND METHODS,[194407],[5442],[5538],[False],[0],[0],[False],['0']
26717,PMC5094537,32719,PRO assessments,PRO assessments,[194409],[5539],[5555],[False],[0],[0],[False],['0']
26718,PMC5094537,32720,PRO assessments,PRO assessments|PRO assessments,[194411],[5556],[5571],[False],[0],[0],[False],['0']
26719,PMC5094537,32721,"PROs deemed important to patients with RA and assessed in AMPLE were pain, fatigue, ability to perform work, and ability to perform daily activities.",PRO assessments|PRO assessments,[194413],[5572],[5721],[False],[0],[0],[False],['0']
26720,PMC5094537,32722,"All except pain were evaluated on day 1, month 6, year 1, and year 2.",PRO assessments|PRO assessments,[194415],[5722],[5791],[False],[0],[0],[False],['0']
26721,PMC5094537,32723,Pain and fatigue,Pain and fatigue,[194417],[5792],[5809],[False],[0],[0],[False],['0']
26722,PMC5094537,32724,"Pain was measured using a 100‐mm visual analog scale (VAS), with a minimum clinically important difference (MCID) defined as a change of −10 mm from baseline 14, 16.",Pain and fatigue,[194419],[5810],[5975],[False],[0],[0],[False],['0']
26723,PMC5094537,32725,"Pain was evaluated at days 1, 15, and 29, and every 4 weeks thereafter during year 1, and every 3 months during year 2.",Pain and fatigue,[194421],[5976],[6095],[False],[0],[0],[False],['0']
26724,PMC5094537,32726,Patients’ assessment of the severity of fatigue over the past week was measured using a 100‐mm VAS.,Pain and fatigue,[194423],[6096],[6195],[False],[0],[0],[False],['0']
26725,PMC5094537,32727,An MCID was defined as a change of −10 mm from baseline 17.,Pain and fatigue,[194425],[6196],[6255],[False],[0],[0],[False],['0']
26726,PMC5094537,32728,Ability to perform work,Ability to perform work,[194427],[6256],[6280],[False],[0],[0],[False],['0']
26727,PMC5094537,32729,"Four components of the Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis (WPAI:RA) were analyzed, including absenteeism (work time missed), presenteeism (impairment at work/reduced on‐the‐job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment.",Ability to perform work,[194429],[6281],[6621],[False],[0],[0],[False],['0']
26728,PMC5094537,32730,"For baseline values these components are reported as work time missed, impairment at work, overall work impairment, and activity impairment.",Ability to perform work,[194431],[6622],[6762],[False],[0],[0],[False],['0']
26729,PMC5094537,32731,"For posttreatment values they are reported as work time gained, reduced impairment while working, overall reduced work impairment, and activity gained.",Ability to perform work,[194433],[6763],[6914],[False],[0],[0],[False],['0']
26730,PMC5094537,32732,An MCID for WPAI:RA was defined as a 7% absolute change in WPAI:RA score 18.,Ability to perform work,[194435],[6915],[6991],[False],[0],[0],[False],['0']
26731,PMC5094537,32733,Ability to perform daily activities,Ability to perform daily activities,[194437],[6992],[7028],[False],[0],[0],[False],['0']
26732,PMC5094537,32734,The Activity Limitation Questionnaire was used to assess the number of days in the past 30 days that a patient was unable (baseline values) or able (posttreatment values) to perform usual activities owing to RA.,Ability to perform daily activities,[194439],[7029],[7240],[False],[0],[0],[False],['0']
26733,PMC5094537,32735,"An MCID was defined as a change of 4 days from baseline (i.e., patients able to perform daily activities on 4 additional days) 17.",Ability to perform daily activities,[194441],[7241],[7371],[False],[0],[0],[False],['0']
26734,PMC5094537,32736,Post hoc analyses: PROs in clinical responders versus nonresponders,Ability to perform daily activities,[194443],[7372],[7440],[False],[0],[0],[False],['0']
26735,PMC5094537,32737,"Post hoc analyses were performed to determine the proportions of patients who achieved clinical response scores according to the following criteria: ACR20 response, Clinical Disease Activity Index (CDAI) low disease activity (<10) and remission (<2.8), Simplified Disease Activity Index (SDAI) low disease activity (<11) and remission (<3.3), and Boolean remission (<1).",Ability to perform daily activities,[194445],[7441],[7811],[False],[0],[0],[False],['0']
26736,PMC5094537,32738,"The 4 PROs (pain, fatigue, ability to perform work, and ability to perform daily activities) were compared for patients with clinical responses (responders, as defined above) and those without (nonresponders) at month 6, year 1, and year 2.",Ability to perform daily activities,[194447],[7812],[8052],[False],[0],[0],[False],['0']
26737,PMC5094537,32739,Statistical analysis,Statistical analysis,[194449],[8053],[8074],[False],[0],[0],[False],['0']
26738,PMC5094537,32740,"All efficacy analyses were performed on the intent‐to‐treat population, which included all patients who were randomized and received ≥1 dose of study drug.",Statistical analysis,[194451],[8075],[8230],[False],[0],[0],[False],['0']
26739,PMC5094537,32741,Baseline demographics and clinical characteristics were analyzed descriptively.,Statistical analysis,[194453],[8231],[8310],[False],[0],[0],[False],['0']
26740,PMC5094537,32742,"For fatigue and ability to perform daily activities, changes from baseline were summarized by treatment and visit, and 95% CIs for the treatment differences were constructed.",Statistical analysis,[194455],[8311],[8485],[False],[0],[0],[False],['0']
26741,PMC5094537,32743,"For ability to perform work, percentage reduction from baseline in each of the 4 components of impairment was reported by treatment and visit.",Statistical analysis,[194457],[8486],[8628],[False],[0],[0],[False],['0']
26742,PMC5094537,32744,Between–treatment group differences in impairment reduction were also assessed using the point estimation and 95% CI.,Statistical analysis,[194459],[8629],[8746],[False],[0],[0],[False],['0']
26743,PMC5094537,32745,Definitions of MCIDs for individual outcomes are given above.,Statistical analysis,[194461],[8747],[8808],[False],[0],[0],[False],['0']
26744,PMC5094537,32746,"For all patients who completed day 729 (year 2), individual responses/nonresponses for ACR20 response and remission/low disease activity (CDAI, SDAI, and Boolean) were calculated using post hoc analyses of as‐observed data (i.e., all data available).",Statistical analysis,[194463],[8809],[9059],[False],[0],[0],[False],['0']
26745,PMC5094537,32747,"All patients who prematurely discontinued the study after receiving study drug, regardless of reason, were considered nonresponders at all subsequent visits for the clinical response measures.",Statistical analysis,[194465],[9060],[9252],[False],[0],[0],[False],['0']
26746,PMC5094537,32748,"For all PROs, adjusted mean changes from baseline were summarized by treatment group and were based on an analysis of covariance model, with treatment as the main factor and baseline values with DAS28‐CRP stratification as covariates.",Statistical analysis,[194467],[9253],[9487],[False],[0],[0],[False],['0']
26747,PMC5094537,32749,RESULTS,RESULTS,[194469],[9488],[9496],[False],[0],[0],[False],['0']
26748,PMC5094537,32750,"A total of 646 patients were randomized and treated, 318 patients in the SC abatacept group and 328 patients in the adalimumab group.",RESULTS,[194471],[9497],[9630],[False],[0],[0],[False],['0']
26749,PMC5094537,32751,"Demographic and baseline clinical characteristics, including PRO measures, were well balanced between the 2 treatment groups (Table 1).",RESULTS,[194473],[9631],[9766],[False],[0],[0],[False],['0']
26750,PMC5094537,32752,"Overall, 79.2% of patients treated with SC abatacept and 74.7% of patients treated with adalimumab completed the 2‐year study.",RESULTS,[194475],[9767],[9893],[False],[0],[0],[False],['0']
26751,PMC5094537,32753,Change in PROs during the study period,Change in PROs during the study period,[194477],[9894],[9933],[False],[0],[0],[False],['0']
26752,PMC5094537,32754,Change in PROs during the study period,Change in PROs during the study period|Change in PROs during the study period,[194479],[9934],[9972],[False],[0],[0],[False],['0']
26753,PMC5094537,32755,Pain,Change in PROs during the study period|Pain,[194481],[9973],[9977],[False],[0],[0],[False],['0']
26754,PMC5094537,32756,"Over the 2‐year study period, comparable improvements were seen in the SC abatacept and adalimumab treatment groups for most of the 4 PROs assessed.",Change in PROs during the study period|Pain,[194483],[9978],[10126],[False],[0],[0],[False],['0']
26755,PMC5094537,32757,Numerically greater improvements in pain were observed for patients who received abatacept versus adalimumab over 2 years 14.,Change in PROs during the study period|Pain,[194485],[10127],[10252],[False],[0],[0],[False],['0']
26756,PMC5094537,32758,"Mean ± SEM improvements in pain at year 2 for abatacept versus adalimumab were 53.7% ± 6.2% versus 38.5% ±6.1%, respectively, with an adjusted mean treatment difference of 15.2% (95% CI −1.2, 31.6) (published previously) 14.",Change in PROs during the study period|Pain,[194487],[10253],[10477],[False],[0],[0],[False],['0']
26757,PMC5094537,32759,An MCID in pain was reached from day 15 for both treatment groups.,Change in PROs during the study period|Pain,[194489],[10478],[10544],[False],[0],[0],[False],['0']
26758,PMC5094537,32760,Fatigue,Fatigue,[194491],[10545],[10553],[False],[0],[0],[False],['0']
26759,PMC5094537,32761,Comparable improvements in fatigue were observed in the abatacept and adalimumab treatment groups over 2 years (Figure 1).,Fatigue,[194493],[10554],[10676],[False],[0],[0],[False],['0']
26760,PMC5094537,32762,"Adjusted mean change in fatigue reached an MCID (−10 mm) as early as day 15 in both treatment groups, with improvements being maintained up to year 2.",Fatigue,[194495],[10677],[10827],[False],[0],[0],[False],['0']
26761,PMC5094537,32763,Ability to perform work,Ability to perform work,[194497],[10828],[10852],[False],[0],[0],[False],['0']
26762,PMC5094537,32764,The 4 components of the WPAI:RA were found to be similarly improved in patients receiving abatacept and those receiving adalimumab over the 2‐year study (Figure 2).,Ability to perform work,[194499],[10853],[11017],[False],[0],[0],[False],['0']
26763,PMC5094537,32765,"In both the abatacept and the adalimumab treatment groups, improvements in the components of reduced impairment while working, overall reduced work impairment, and activity gained reached an MCID (7%) at all postbaseline assessments (month 6, year 1, and year 2).",Ability to perform work,[194501],[11018],[11281],[False],[0],[0],[False],['0']
26764,PMC5094537,32766,Ability to perform daily activities,Ability to perform daily activities,[194503],[11282],[11318],[False],[0],[0],[False],['0']
26765,PMC5094537,32767,"As seen for the ability to perform work assessments, improvements in patients’ ability to perform daily activities over 2 years were similar in both the abatacept and the adalimumab treatment groups (Figure 3).",Ability to perform daily activities,[194505],[11319],[11529],[False],[0],[0],[False],['0']
26766,PMC5094537,32768,"Again, the MCID for ability to perform daily activities of 4 additional days was seen in both treatment groups at all postbaseline assessments (month 6, year 1, and year 2).",Ability to perform daily activities,[194507],[11530],[11703],[False],[0],[0],[False],['0']
26767,PMC5094537,32769,PROs in clinical responders versus nonresponders,PROs in clinical responders versus nonresponders,[194509],[11704],[11753],[False],[0],[0],[False],['0']
26768,PMC5094537,32770,"The results of the post hoc analyses showed that, for each of the 4 PROs evaluated, there was clear separation between patients who achieved clinical response (responders) and those who did not (nonresponders), regardless of whether they received abatacept or adalimumab.",PROs in clinical responders versus nonresponders,[194511],[11754],[12025],[False],[0],[0],[False],['0']
26769,PMC5094537,32771,"This separation was true for each of the 6 clinical outcomes assessed, except when using Boolean remission to assess the ability to perform daily activities in clinical responders versus nonresponders.",PROs in clinical responders versus nonresponders,[194513],[12026],[12227],[False],[0],[0],[False],['0']
26770,PMC5094537,32772,"As pain was assessed more frequently than the other PROs, which were assessed at month 6, year 1, and year 2, the association of pain improvement with clinical response is shown in Figure 4 and Supplementary Figure 1 (available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22763/abstract) as a representative example.",PROs in clinical responders versus nonresponders,[194515],[12228],[12592],[False],[0],[0],[False],['0']
26771,PMC5094537,32773,Adjusted mean improvements in pain reached an MCID as early as day 15 in both responder and nonresponder groups for all low disease activity and remission criteria; these improvements were maintained up to year 2 (see Figure 4 and Supplementary Figure 1).,PROs in clinical responders versus nonresponders,[194517],[12593],[12848],[False],[0],[0],[False],['0']
26772,PMC5094537,32774,"For each PRO and each clinical measure, the number of patients was similar in the 2 treatment groups, for both responder and nonresponder subgroups.",PROs in clinical responders versus nonresponders,[194519],[12849],[12997],[False],[0],[0],[False],['0']
26773,PMC5094537,32775,Abatacept and adalimumab responders had similar improvements in each PRO over time.,PROs in clinical responders versus nonresponders,[194521],[12998],[13081],[False],[0],[0],[False],['0']
26774,PMC5094537,32776,DISCUSSION,DISCUSSION,[194523],[13082],[13093],[False],[0],[0],[False],['0']
26775,PMC5094537,32777,"Over 2 years of the AMPLE trial, patients treated with SC abatacept or adalimumab while receiving background MTX achieved comparable, clinically meaningful improvements with a similar onset of response in 4 PROs: pain 14, fatigue, ability to perform work, and ability to perform daily activities.",DISCUSSION,[194525],[13094],[13390],[False],[0],[0],[False],['0']
26776,PMC5094537,32778,"Furthermore, post hoc analysis of the 4 PROs showed a clear association between clinical response according to several clinical criteria (ACR20 response, CDAI low disease activity, CDAI remission, SDAI low disease activity, SDAI remission, and Boolean remission) and improvement in PROs, with the exception of an association between Boolean remission and the ability to perform daily activities.",DISCUSSION,[194527],[13391],[13786],[False],[0],[0],[False],['0']
26777,PMC5094537,32779,PROs capture the effects of treatment from a patient's perspective and are critical to ensuring that a clinical response corresponds to benefits that are perceptible and important to the patient 19.,DISCUSSION,[194529],[13787],[13985],[False],[0],[0],[False],['0']
26778,PMC5094537,32780,"Patients and clinicians want RA treatments that rapidly improve health‐related quality of life and reduce or halt functional impairment, with improvements maintained over time 20.",DISCUSSION,[194531],[13986],[14165],[False],[0],[0],[False],['0']
26779,PMC5094537,32781,"Pain and loss of physical function are meaningful outcomes that need to be considered by clinicians as important consequences of RA 21; patients also identify fatigue as having a considerable influence on quality of life 22, 23.",DISCUSSION,[194533],[14166],[14394],[False],[0],[0],[False],['0']
26780,PMC5094537,32782,"The results reported here are consistent with data from other published studies of the effect of abatacept on PROs, including ATTEST (Abatacept or Infliximab Versus Placebo: A Trial for Tolerability, Efficacy, and Safety in Treating RA), AIM (Abatacept in Inadequate Responders to MTX), and ACQUIRE (Abatacept Comparison of SC Versus Intravenous in Inadequate Responders to MTX).",DISCUSSION,[194535],[14395],[14774],[False],[0],[0],[False],['0']
26781,PMC5094537,32783,"As in AMPLE, these 3 abatacept studies included patients with an inadequate response to MTX who were biologics‐naive 5, 24, 25, 26.",DISCUSSION,[194537],[14775],[14906],[False],[0],[0],[False],['0']
26782,PMC5094537,32784,"The results presented here are also consistent with published PRO data for adalimumab 27, 28, 29.",DISCUSSION,[194539],[14907],[15004],[False],[0],[0],[False],['0']
26783,PMC5094537,32785,"In the Anti‐TNF Research Study Program of the Monoclonal Antibody Adalimumab trial, patients who had an inadequate response to MTX and were treated with adalimumab plus MTX demonstrated significant improvements in physical function from baseline to year 4 (mean Health Assessment Questionnaire disability index [HAQ DI] 0.7 and 1.5, respectively [P < 0.001]) 27.",DISCUSSION,[194541],[15005],[15367],[False],[0],[0],[False],['0']
26784,PMC5094537,32786,"Similarly, in the DE019 adalimumab study, patients who had an inadequate response to MTX who received up to 10 years of adalimumab plus MTX therapy demonstrated a reduction in mean HAQ DI from 1.4 at baseline to 0.7 at year 10, while 42% of patients achieved HAQ DI <0.5 (normal functionality) at year 10 28.",DISCUSSION,[194543],[15368],[15676],[False],[0],[0],[False],['0']
26785,PMC5094537,32787,"In the PREMIER study, significant improvements from baseline to year 2 in HAQ DI (P < 0.0001), Short Form 36 health survey physical component summary score (P < 0.0001), patient global assessment score (P < 0.0001), and pain score (P < 0.0001) were reported by patients with early RA treated with adalimumab plus MTX versus patients treated with MTX monotherapy 29.",DISCUSSION,[194545],[15677],[16042],[False],[0],[0],[False],['0']
26786,PMC5094537,32788,"The goal of current treat‐to‐target strategies in patients with RA is the achievement of remission, but with the recognition that low disease activity may be an acceptable alternative if remission is not achievable, particularly for those with advanced established disease 30.",DISCUSSION,[194547],[16043],[16319],[False],[0],[0],[False],['0']
26787,PMC5094537,32789,"By correlating clinical response with PROs that are important to both physicians and patients, such as pain, fatigue, work productivity, and activity impairment, the achievement of how a good clinical response translates into meaningful benefits for the patient in their daily life can be better understood.",DISCUSSION,[194549],[16320],[16627],[False],[0],[0],[False],['0']
26788,PMC5094537,32790,"Greater reductions in the signs and symptoms of RA (ACR20 response) and disease activity (low disease activity or remission, as assessed by SDAI, CDAI, or Boolean criteria) were associated with greater improvements over 2 years in the 4 PROs assessed (except for ability to perform daily activities when assessed by Boolean remission), with comparable benefits observed with SC abatacept and adalimumab.",DISCUSSION,[194551],[16628],[17031],[False],[0],[0],[False],['0']
26789,PMC5094537,32791,"Concerning the effect of RA on the ability to maintain employment, previous studies have found greater disease activity to be significantly correlated with higher numbers of missed work hours (absenteeism), greater work impairment (presenteeism), and greater activity impairment 31, 32.",DISCUSSION,[194553],[17032],[17318],[False],[0],[0],[False],['0']
26790,PMC5094537,32792,"How relatively small changes in disease activity, such as from low disease activity to remission, can impact PROs is unclear.",DISCUSSION,[194555],[17319],[17444],[False],[0],[0],[False],['0']
26791,PMC5094537,32793,"Nonetheless, reaching an MCID in pain, fatigue, or physical function can result in significantly greater improvements in work productivity compared with patients who did not achieve MCID in these outcomes 33.",DISCUSSION,[194557],[17445],[17653],[False],[0],[0],[False],['0']
26792,PMC5094537,32794,"Furthermore, a recent study reported worse work productivity in patients achieving low disease activity than in those achieving disease remission 34.",DISCUSSION,[194559],[17654],[17803],[False],[0],[0],[False],['0']
26793,PMC5094537,32795,Limitations to this analysis should be considered.,DISCUSSION,[194561],[17804],[17854],[False],[0],[0],[False],['0']
26794,PMC5094537,32796,"Although the AMPLE trial was powered to compare abatacept and adalimumab directly, it was a single‐blind design, rather than double‐blind, which may have introduced bias 14.",DISCUSSION,[194563],[17855],[18028],[True],['StudyTeam'],['single‐blind design'],[True],['Blinding']
26795,PMC5094537,32797,An additional limitation was the post hoc nature of the analyses that compared PROs in patient subgroups based on clinical response.,DISCUSSION,[194568],[18029],[18161],[True],['MultipleTesting'],['the post hoc nature of the analyses that compared PROs in patient subgroups'],[True],['StatisticalAnalysis']
26796,PMC5094537,32798,"In summary, this study demonstrated that in patients with RA who were biologics‐naive, treatment with SC abatacept or adalimumab is associated with comparable improvements in PROs that are considered particularly important in RA (pain, fatigue, work productivity, and activity limitation).",DISCUSSION,[194571],[18162],[18451],[False],[0],[0],[False],['0']
26797,PMC5094537,32799,"Furthermore, improved PROs were associated with physician‐reported clinical responses.",DISCUSSION,[194573],[18452],[18538],[False],[0],[0],[False],['0']
26798,PMC5094537,32800,AUTHOR CONTRIBUTIONS,AUTHOR CONTRIBUTIONS,[194575],[18539],[18560],[False],[0],[0],[False],['0']
26799,PMC5094537,32801,"All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication.",AUTHOR CONTRIBUTIONS,[194577],[18561],[18748],[False],[0],[0],[False],['0']
26800,PMC5094537,32802,Dr. Fleischmann had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.,AUTHOR CONTRIBUTIONS,[194579],[18749],[18906],[False],[0],[0],[False],['0']
26801,PMC5094537,32803,Study conception and design,Study conception and design,[194581],[18907],[18935],[False],[0],[0],[False],['0']
26802,PMC5094537,32804,"Fleischmann, Weinblatt, Schiff, Khanna, Maldonado, Nadkarni, Furst.",Study conception and design,[194583],[18936],[19003],[False],[0],[0],[False],['0']
26803,PMC5094537,32805,Acquisition of data,Acquisition of data,[194585],[19004],[19024],[False],[0],[0],[False],['0']
26804,PMC5094537,32806,"Fleischmann, Furst.","Acquisition of data|Fleischmann, Furst.",[194587],[19025],[19044],[False],[0],[0],[False],['0']
26805,PMC5094537,32807,Analysis and interpretation of data,Analysis and interpretation of data|Analysis and interpretation of data,[194589],[19045],[19081],[False],[0],[0],[False],['0']
26806,PMC5094537,32808,"Fleischmann, Weinblatt, Schiff, Khanna, Nadkarni, Furst.",Analysis and interpretation of data|Analysis and interpretation of data,[194591],[19082],[19138],[False],[0],[0],[False],['0']
26807,PMC5094537,32809,ROLE OF THE STUDY SPONSOR,ROLE OF THE STUDY SPONSOR,[194593],[19139],[19165],[False],[0],[0],[False],['0']
26808,PMC5094537,32810,Bristol‐Myers Squibb facilitated the study design and reviewed and approved the manuscript prior to submission.,ROLE OF THE STUDY SPONSOR,[194595],[19166],[19277],[False],[0],[0],[False],['0']
26809,PMC5094537,32811,"The authors had full access to the study data, contributed to the interpretation of the results, and had ultimate control over the decision to publish and the final version of the manuscript submitted for publication.",ROLE OF THE STUDY SPONSOR,[194597],[19278],[19495],[False],[0],[0],[False],['0']
26810,PMC5094537,32812,ACKNOWLEDGMENT,ACKNOWLEDGMENT,[194599],[19496],[19512],[False],[0],[0],[False],['0']
26811,PMC5094537,32813,"Professional medical writing and editorial assistance were provided by Carolyn Tubby, PhD (Caudex), and funded by Bristol‐Myers Squibb.",ACKNOWLEDGMENT,[194601],[19513],[19648],[False],[0],[0],[False],['0']
29259,PMC5222895,32155,A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus,Title,[192441],[35351],[168],[False],[0],[0],[False],['0']
29260,PMC5222895,32156,Background,Abstract,[192443],[169],[180],[False],[0],[0],[False],['0']
29261,PMC5222895,32157,"Due to population aging, an increasing number of elderly patients with diabetes use insulin.",Abstract,[192445],[181],[273],[False],[0],[0],[False],['0']
29262,PMC5222895,32158,It is therefore important to investigate the characteristics of new insulins in this population.,Abstract,[192447],[274],[370],[False],[0],[0],[False],['0']
29263,PMC5222895,32159,Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with faster absorption.,Abstract,[192449],[371],[485],[False],[0],[0],[False],['0']
29264,PMC5222895,32160,This study investigated the pharmacological properties of faster aspart in elderly subjects with type 1 diabetes mellitus (T1DM).,Abstract,[192451],[486],[615],[False],[0],[0],[False],['0']
29265,PMC5222895,32161,Methods,Methods,[192453],[616],[624],[False],[0],[0],[False],['0']
29266,PMC5222895,32162,"In a randomised, double-blind, two-period crossover trial, 30 elderly (≥65 years) and 37 younger adults (18–35 years) with T1DM received single subcutaneous faster aspart or IAsp dosing (0.2 U/kg) and underwent an euglycaemic clamp (target 5.5 mmol/L) for up to 12 h.",Methods,[192455],[625],[892],[False],[0],[0],[False],['0']
29267,PMC5222895,32163,Results,Results,[192457],[893],[901],[False],[0],[0],[False],['0']
29268,PMC5222895,32164,The pharmacokinetic and pharmacodynamic time profiles were left-shifted for faster aspart versus IAsp.,Results,[192459],[902],[1004],[False],[0],[0],[False],['0']
29269,PMC5222895,32165,"In each age group, onset of appearance occurred approximately twice as fast (~3 min earlier) and early exposure (area under the concentration–time curve [AUC] for serum IAsp from time zero to 30 min [AUC ]) was greater (by 86% in elderly and 67% in younger adults) for faster aspart than for IAsp.",Results,[192461],[1005],[1302],[False],[0],[0],[False],['0']
29270,PMC5222895,32166,"Likewise, onset of action occurred 10 min faster in the elderly and 9 min faster in younger adults, and early glucose-lowering effect (AUC for the glucose infusion rate [GIR] from time zero to 30 min [AUC ]) was greater (by 109%) for faster aspart than for IAsp in both age groups.",Results,[192463],[1303],[1584],[False],[0],[0],[False],['0']
29271,PMC5222895,32167,"Total exposure (AUC ) and the maximum concentration (C  ) for faster aspart were greater (by 30 and 28%, respectively) in elderly than in younger adults.",Results,[192465],[1585],[1738],[False],[0],[0],[False],['0']
29272,PMC5222895,32168,No age group differences were seen for the total (AUC ) or maximum (GIR ) glucose-lowering effect.,Results,[192467],[1739],[1837],[False],[0],[0],[False],['0']
29273,PMC5222895,32169,Conclusion,Conclusion,[192469],[1838],[1849],[False],[0],[0],[False],['0']
29274,PMC5222895,32170,This study demonstrated that the ultra-fast pharmacological properties of faster aspart are similar in elderly subjects and younger adults with T1DM.,Conclusion,[192471],[1850],[1999],[False],[0],[0],[False],['0']
29275,PMC5222895,32171, ClinicalTrials.gov Identifier: NCT02003677.,Conclusion,[192473],[2000],[2044],[False],[0],[0],[False],['0']
29276,PMC5222895,32172,Electronic supplementary material,Electronic supplementary material,[192475],[2045],[2079],[False],[0],[0],[False],['0']
29277,PMC5222895,32173,"The online version of this article (doi:10.1007/s40266-016-0418-6) contains supplementary material, which is available to authorized users.",Electronic supplementary material,[192477],[2080],[2219],[False],[0],[0],[False],['0']
29278,PMC5222895,32174,Key Points,Key Points,[192479],[2220],[2232],[False],[0],[0],[False],['0']
29279,PMC5222895,32175, .,Key Points| .   ,[192481],[2233],[2235],[False],[0],[0],[False],['0']
29280,PMC5222895,32176,Introduction,Introduction|Introduction,[192483],[2236],[2252],[False],[0],[0],[False],['0']
29281,PMC5222895,32177,"Due to a continuously growing elderly population, the number of elderly patients with diabetes who are being treated with insulin is also increasing [1].",Introduction|Introduction,[192485],[2253],[2406],[False],[0],[0],[False],['0']
29282,PMC5222895,32178,One implication of this is that it has become even more important to characterise the pharmacokinetic and pharmacodynamic properties of any new insulin product specifically in the elderly population.,Introduction|Introduction,[192487],[2407],[2606],[False],[0],[0],[False],['0']
29283,PMC5222895,32179,"Faster-acting insulin aspart (faster aspart) is insulin aspart in a new formulation with two added excipients ( -arginine and niacinamide), which are both listed in the US Food and Drug Administration (FDA) inactive ingredient database as products approved for injection [2].",Introduction|Introduction,[192489],[2607],[2882],[False],[0],[0],[False],['0']
29284,PMC5222895,32180,"L-arginine acts as a stabilising agent, while niacinamide results in faster initial absorption after subcutaneous administration.",Introduction|Introduction,[192491],[2883],[3012],[False],[0],[0],[False],['0']
29285,PMC5222895,32181,The aim of this formulation is to improve postprandial glucose control over current rapid-acting insulins.,Introduction|Introduction,[192493],[3013],[3119],[False],[0],[0],[False],['0']
29286,PMC5222895,32182,"Clinical pharmacology studies have shown that faster aspart has an onset of appearance that is twice as fast and a twofold higher early insulin exposure than insulin aspart, which leads to more than 50% greater early glucose-lowering effect [3–5].",Introduction|Introduction,[192495],[3120],[3367],[False],[0],[0],[False],['0']
29287,PMC5222895,32183,"In phase III trials conducted in subjects with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, postprandial glucose increments in standardised meal-tests were reduced with faster aspart versus insulin aspart [6, 7].",Introduction|Introduction,[192497],[3368],[3586],[False],[0],[0],[False],['0']
29288,PMC5222895,32184,"As the majority of subjects in these previous studies with faster aspart were below 65 years of age, there is a need for specific knowledge about the pharmacological properties of faster aspart in the elderly population.",Introduction|Introduction,[192499],[3587],[3807],[False],[0],[0],[False],['0']
29289,PMC5222895,32185,"The objectives of the current study were to investigate the overall pharmacokinetic and pharmacodynamic characteristics of faster aspart in elderly subjects compared with those in younger adults, and to compare the early pharmacokinetic and pharmacodynamic properties between faster aspart and insulin aspart in elderly subjects using the same comparison in younger adults as a reference.",Introduction|Introduction,[192501],[3808],[4196],[False],[0],[0],[False],['0']
29290,PMC5222895,32186,"The study was conducted in subjects with T1DM in order to be able to assess the glucose-lowering effect of the investigational insulins in a glucose clamp setting, without interference from endogenous insulin secretion.",Introduction|Introduction,[192503],[4197],[4416],[False],[0],[0],[False],['0']
29291,PMC5222895,32187,Methods,Methods,[192505],[4417],[4425],[False],[0],[0],[False],['0']
29292,PMC5222895,32188,Trial Design,Methods|Trial Design,[192507],[4426],[4438],[False],[0],[0],[False],['0']
29293,PMC5222895,32189,"This was a randomised, single-centre (Profil, Neuss, Germany), double-blind, two-period, crossover trial in elderly and younger adults with T1DM.",Methods|Trial Design,[192509],[4439],[4584],[False],[0],[0],[False],['0']
29294,PMC5222895,32190,The trial protocol was reviewed and approved by the local health authority (Bundesinstitut für Arzneimittel und Medizinprodukte) and by an independent ethics committee (Ärztekammer Nordrhein).,Methods|Trial Design,[192511],[4585],[4777],[False],[0],[0],[False],['0']
29295,PMC5222895,32191,"The trial was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice and relevant regulatory guidance on clinical trials in the elderly [8–10].",Methods|Trial Design,[192513],[4778],[4993],[False],[0],[0],[False],['0']
29296,PMC5222895,32192,Written informed consent was obtained before initiation of any trial-related activities.,Methods|Trial Design,[192515],[4994],[5082],[False],[0],[0],[False],['0']
29297,PMC5222895,32193,The trial was registered at ClinicalTrials.gov (trial identifier: NCT02003677).,Methods|Trial Design,[192517],[5083],[5162],[False],[0],[0],[False],['0']
29298,PMC5222895,32194,Participants,Participants,[192519],[5163],[5176],[False],[0],[0],[False],['0']
29299,PMC5222895,32195,"Eligible subjects were elderly (≥65 years) or younger adult (18–35 years) men and women diagnosed with T1DM ≥12 months before being included in the trial who were treated with multiple daily insulin injections or continuous subcutaneous insulin infusion for ≥12 months (total daily insulin dose <1.2 (I)U/kg/day and total daily bolus insulin dose <0.7 (I)U/kg/day), with glycosylated haemoglobin (HbA ) ≤9.5% (80 mmol/mol), body mass index (BMI) 18.5–28.0 kg/m2 and fasting C-peptide ≤0.3 nmol/L.",Participants,[192521],[5177],[5673],[False],[0],[0],[False],['0']
29300,PMC5222895,32196,"Subjects were excluded if they had clinically significant concomitant diseases or clinically significant abnormal values in clinical laboratory screening tests, were smokers or were treated with any drugs that might interfere with glucose metabolism.",Participants,[192523],[5674],[5924],[False],[0],[0],[False],['0']
29301,PMC5222895,32197,Procedures,Procedures,[192525],[5925],[5936],[False],[0],[0],[False],['0']
29302,PMC5222895,32198,"The trial consisted of a screening visit (3–21 days before the first dosing visit), two dosing visits separated by 3–12 days of washout and a follow-up visit (7–21 days after the second dosing visit).",Procedures,[192527],[5937],[6137],[False],[0],[0],[False],['0']
29303,PMC5222895,32199,"At the dosing visits, subjects received single 0.2 U/kg dosing of faster aspart (100 U/mL; Novo Nordisk, Bagsværd, Denmark) or insulin aspart (NovoRapid®; 100 U/mL; Novo Nordisk) in a randomised sequence.",Procedures,[192529],[6138],[6342],[False],[0],[0],[False],['0']
29304,PMC5222895,32200,Both trial products were provided in a blinded PDS290 pen-injector prefilled pen (Novo Nordisk) and were administered by subcutaneous injection into a lifted skin fold of the lower abdominal wall above the inguinal area.,Procedures,[192531],[6343],[6563],[False],[0],[0],[False],['0']
29305,PMC5222895,32201,"At each dosing visit, subjects attended the clinic in the morning after an overnight fast.",Procedures,[192533],[6564],[6654],[False],[0],[0],[False],['0']
29306,PMC5222895,32202,"They were advised to avoid any physical exercise during the last 2 days before each dosing visit and to come to the clinic by car, taxi or public transport.",Procedures,[192535],[6655],[6811],[False],[0],[0],[False],['0']
29307,PMC5222895,32203,"Subjects received a single dose of trial product in a euglycaemic glucose clamp setting (ClampArt®; Profil, Neuss, Germany) as previously described [4].",Procedures,[192537],[6812],[6964],[False],[0],[0],[False],['0']
29308,PMC5222895,32204,The blood glucose (BG) clamp target level was 5.5 mmol/L (100 mg/dL) and the clamp lasted up to 12 h after dosing.,Procedures,[192539],[6965],[7079],[False],[0],[0],[False],['0']
29309,PMC5222895,32205,The quality of the conducted clamps [11] for each treatment and age group is presented in the Electronic Supplementary Material (Online Resource Table S1).,Procedures,[192541],[7080],[7235],[False],[0],[0],[False],['0']
29310,PMC5222895,32206,"Blood samples for pharmacokinetic assessment were drawn within 2 min before dosing, then every 2 min from dosing until 20 min after dosing, every 5 min from 20 to 80 min, every 10 min from 80 min to 2 h, every 15 min from 2 to 3 h, and then at 3.5, 4, 5, 6, 7, 8, 10 and 12 h after dosing.",Procedures,[192543],[7236],[7525],[False],[0],[0],[False],['0']
29311,PMC5222895,32207,Assessments,Assessments,[192545],[7526],[7538],[False],[0],[0],[False],['0']
29312,PMC5222895,32208,Free serum insulin aspart concentrations (polyethylene glycol-precipitated) were measured by a validated insulin aspart-specific enzyme-linked immunosorbent assay.,Assessments,[192547],[7539],[7702],[False],[0],[0],[False],['0']
29313,PMC5222895,32209,The glucose infusion rate (GIR) needed to keep the BG concentration at the clamp target level was recorded automatically every minute during the glucose clamp.,Assessments,[192549],[7703],[7862],[False],[0],[0],[False],['0']
29314,PMC5222895,32210,"Safety assessments included adverse events, local tolerability at the injection site, hypoglycaemic episodes, laboratory safety parameters, physical examination, vital signs and electrocardiogram.",Assessments,[192551],[7863],[8059],[False],[0],[0],[False],['0']
29315,PMC5222895,32211,"Hypoglycaemic episodes were defined as ‘confirmed’ when they were either ‘severe’ according to American Diabetes Association criteria, i.e.",Assessments,[192553],[8060],[8199],[False],[0],[0],[False],['0']
29316,PMC5222895,32212,"requiring third-party assistance [12], or verified by a plasma glucose level of <3.1 mmol/L (56 mg/dL).",Assessments,[192555],[8200],[8303],[False],[0],[0],[False],['0']
29317,PMC5222895,32213,Endpoints,Endpoints,[192557],[8304],[8314],[False],[0],[0],[False],['0']
29318,PMC5222895,32214,"Endpoints evaluating onset of exposure and onset of glucose-lowering effect included the pharmacokinetic endpoints, onset of appearance (time from trial product administration until the first time serum insulin aspart concentration was greater than or equal to the lower limit of quantification [LLOQ; 10 pmol/L]), time to early 50% of maximum insulin aspart concentration (t  ) and time to maximum insulin aspart concentration (t  ), and the pharmacodynamic endpoints, onset of action (time from trial product administration until the BG concentration had decreased by at least 0.3 mmol/L [5 mg/dL] from baseline, where baseline was defined as the mean BG concentration from −5 to −1 min), time to early 50% of maximum GIR (t  ) and time to maximum GIR (tGIR ).",Endpoints,[192559],[8315],[9077],[False],[0],[0],[False],['0']
29319,PMC5222895,32215,"Early exposure and early glucose-lowering effect were evaluated by deriving the early partial area under the concentration–time curve (AUC) values for serum insulin aspart (AUC for insulin aspart from time zero to 15 min [AUC ], 30 min [AUC ], 1 h [AUC ], 1.5 h [AUC ], and 2 h [AUC ]) to assess pharmacokinetics and the AUCs for GIR (AUC for GIR from time zero to 30 min [AUC ], 1 h [AUC ], 1.5 h [AUC ], and 2 h [AUC ]) to assess pharmacodynamics.",Endpoints,[192561],[9078],[9527],[False],[0],[0],[False],['0']
29320,PMC5222895,32216,"Overall exposure and glucose-lowering effect were evaluated by deriving the pharmacokinetic endpoints, total insulin aspart exposure (AUC ) and maximum insulin aspart concentration (C  ), and the pharmacodynamic endpoints, total glucose-lowering effect (AUC ; primary endpoint) and maximum GIR (GIR ).",Endpoints,[192563],[9528],[9829],[False],[0],[0],[False],['0']
29321,PMC5222895,32217,"In order to calculate onset of appearance and AUC , the insulin aspart concentration was imputed during the period from dosing of trial product until the time of the first insulin aspart concentration above LLOQ using compartmental modelling.",Endpoints,[192565],[9830],[10072],[False],[0],[0],[False],['0']
29322,PMC5222895,32218,This approach was also used for the initial part of the AUC in calculating all other AUC  endpoints for consistency.,Endpoints,[192567],[10073],[10189],[False],[0],[0],[False],['0']
29323,PMC5222895,32219,AUC  was derived by calculating the AUC until the time of last quantifiable insulin aspart concentration and then extrapolating until 12 h (the last pharmacokinetic sampling timepoint) based on the terminal slope.,Endpoints,[192569],[10190],[10403],[False],[0],[0],[False],['0']
29324,PMC5222895,32220,AUC  was calculated until time of last GIR observation >0.,Endpoints,[192571],[10404],[10462],[False],[0],[0],[False],['0']
29325,PMC5222895,32221,"In order to ensure robust calculation of t  , GIR  and tGIR , these endpoints were derived from LOESS smoothed GIR profiles (using a smoothing factor of 0.1).",Endpoints,[192573],[10463],[10621],[False],[0],[0],[False],['0']
29326,PMC5222895,32222,All other endpoints were derived from the raw profiles.,Endpoints,[192575],[10622],[10677],[False],[0],[0],[False],['0']
29327,PMC5222895,32223,Statistical Analyses,Statistical Analyses,[192577],[10678],[10699],[False],[0],[0],[False],['0']
29328,PMC5222895,32224,No formal sample size calculation was performed.,Statistical Analyses,[192579],[10700],[10748],[False],[0],[0],[False],['0']
29329,PMC5222895,32225,"Before initiation of the trial, the number of subjects required to complete the trial was set to 40 (20 in each age group).",Statistical Analyses,[192581],[10749],[10872],[False],[0],[0],[False],['0']
29330,PMC5222895,32226,"With this sample size, assuming a total variance of log(AUC ) of 0.17 [3], the 95% confidence interval (CI) for the ratio of elderly/younger adults with respect to AUC  would be expected to range from 0.77 to 1.30 times the estimated age group ratio.",Statistical Analyses,[192583],[10873],[11123],[False],[0],[0],[False],['0']
29331,PMC5222895,32227,This was considered a sufficient precision for the current study.,Statistical Analyses,[192585],[11124],[11189],[False],[0],[0],[False],['0']
29332,PMC5222895,32228,"To account for potential dropouts, it was pre-planned to randomise 44 subjects (22 subjects per age group).",Statistical Analyses,[192587],[11190],[11297],[False],[0],[0],[False],['0']
29333,PMC5222895,32229,All statistical analyses were performed at a 5% significance level using all randomised subjects who received at least one dose of trial product.,Statistical Analyses,[192589],[11298],[11443],[False],[0],[0],[False],['0']
29334,PMC5222895,32230,"SAS® version 9.3 (SAS Institute, Cary, NC, USA) was used for all analyses.",Statistical Analyses,[192591],[11444],[11518],[False],[0],[0],[False],['0']
29335,PMC5222895,32231,"Pharmacokinetic and pharmacodynamic endpoints were log-transformed (except for onset of appearance, t  , t  , onset of action, t  , tGIR  and AUC ) and analysed in a linear mixed model with age group, treatment, interaction between age group and treatment, and period as fixed effects and subject as a random effect.",Statistical Analyses,[192593],[11519],[11835],[False],[0],[0],[False],['0']
29336,PMC5222895,32232,The variance of the random subject effect and the residual variance depended on the age group.,Statistical Analyses,[192595],[11836],[11930],[False],[0],[0],[False],['0']
29337,PMC5222895,32233,The pharmacokinetic and pharmacodynamic properties were compared between faster aspart and insulin aspart for elderly and younger adults using treatment ratios and 95% CIs derived by back-transforming the model-based treatment differences and corresponding CIs.,Statistical Analyses,[192597],[11931],[12192],[False],[0],[0],[False],['0']
29338,PMC5222895,32234,Treatment ratios and 95% CIs for endpoints analysed without log-transformation were calculated by Fieller’s method [13].,Statistical Analyses,[192599],[12193],[12313],[False],[0],[0],[False],['0']
29339,PMC5222895,32235,"To compare overall insulin exposure and overall glucose-lowering effect between elderly and younger adults for both faster aspart and insulin aspart, age group ratios and 95% CIs were calculated for AUC , C  , AUC  (statistical analysis of primary endpoint) and GIR  from the same model as described above.",Statistical Analyses,[192601],[12314],[12620],[False],[0],[0],[False],['0']
29340,PMC5222895,32236,"For all analyses, a p value for test of no interaction between age group and treatment was derived.",Statistical Analyses,[192603],[12621],[12720],[False],[0],[0],[False],['0']
29341,PMC5222895,32237,Safety endpoints were summarised by descriptive statistics for subjects receiving at least one dose of trial product.,Statistical Analyses,[192605],[12721],[12838],[False],[0],[0],[False],['0']
29342,PMC5222895,32238,Results,Results,[192607],[12839],[12847],[False],[0],[0],[False],['0']
29343,PMC5222895,32239,Subject Disposition and Baseline Characteristics,Results|Subject Disposition and Baseline Characteristics,[192609],[12848],[12896],[False],[0],[0],[False],['0']
29344,PMC5222895,32240,A total of 85 subjects were screened and 67 subjects (30 elderly and 37 younger adults) were randomised and treated with trial product (Online Resource Fig.,Results|Subject Disposition and Baseline Characteristics,[192611],[12897],[13053],[False],[0],[0],[False],['0']
29345,PMC5222895,32241,S1).,Results|Subject Disposition and Baseline Characteristics,[192613],[13054],[13058],[False],[0],[0],[False],['0']
29346,PMC5222895,32242,"Two subjects (one elderly and one younger adult) withdrew consent after the first dosing visit (insulin aspart and faster aspart, respectively).",Results|Subject Disposition and Baseline Characteristics,[192615],[13059],[13203],[False],[0],[0],[False],['0']
29347,PMC5222895,32243,"Thus, 29 elderly subjects and 36 younger adults completed the trial.",Results|Subject Disposition and Baseline Characteristics,[192617],[13204],[13272],[False],[0],[0],[False],['0']
29348,PMC5222895,32244,All 67 randomised subjects were included in the pharmacokinetic and safety analyses.,Results|Subject Disposition and Baseline Characteristics,[192619],[13273],[13357],[False],[0],[0],[False],['0']
29349,PMC5222895,32245,A total of 23 randomised subjects (8 elderly and 15 younger adults) were excluded from the pharmacodynamic analysis based on a blinded review conducted after completion of the first 44 subjects.,Results|Subject Disposition and Baseline Characteristics,[192621],[13358],[13552],[False],[0],[0],[False],['0']
29350,PMC5222895,32246,"During this blinded review, it was discovered that the Biostator algorithm [14], used at that time by ClampArt®, to determine the GIR based on BG concentrations did not consistently react fast enough to the rapid changes in metabolic activity induced by the study insulins.",Results|Subject Disposition and Baseline Characteristics,[192623],[13553],[13826],[False],[0],[0],[False],['0']
29351,PMC5222895,32247,"This led to high oscillations in BG and GIR, particularly shortly after dosing, in some clamp experiments depending on the exact glucodynamics.",Results|Subject Disposition and Baseline Characteristics,[192625],[13827],[13970],[False],[0],[0],[False],['0']
29352,PMC5222895,32248,"The technical issue affected at least one of the two glucose clamps in each of the 23 subjects, implying that clamp quality was insufficient for the valid calculation and interpretation of pharmacodynamic endpoints, especially in the early post-dosing period.",Results|Subject Disposition and Baseline Characteristics,[192627],[13971],[14230],[False],[0],[0],[False],['0']
29353,PMC5222895,32249,The algorithm was therefore optimised to react faster to changes in BG and to reduce the high oscillations in BG and GIR observed with the Biostator algorithm.,Results|Subject Disposition and Baseline Characteristics,[192629],[14231],[14390],[False],[0],[0],[False],['0']
29354,PMC5222895,32250,"Both the Biostator algorithm and the optimised algorithm are proportional–integral–derivative (PID) controllers with comparable design, but with different aggressiveness.",Results|Subject Disposition and Baseline Characteristics,[192631],[14391],[14561],[False],[0],[0],[False],['0']
29355,PMC5222895,32251,"In order to achieve the planned number of completers for pharmacodynamic evaluation, 23 additional subjects were subsequently enrolled and assigned to the same treatment sequence as the subject being replaced.",Results|Subject Disposition and Baseline Characteristics,[192633],[14562],[14771],[False],[0],[0],[False],['0']
29356,PMC5222895,32252,"Thus, 44 subjects (22 in each age group) were included in the pharmacodynamic analysis.",Results|Subject Disposition and Baseline Characteristics,[192635],[14772],[14859],[False],[0],[0],[False],['0']
29357,PMC5222895,32253,"As the pharmacokinetic data were not affected by the technical clamp issues, the pharmacokinetic data obtained in the replaced subjects were included in the analysis (Online Resource Fig.",Results|Subject Disposition and Baseline Characteristics,[192637],[14860],[15047],[False],[0],[0],[False],['0']
29358,PMC5222895,32254,S1).,Results|Subject Disposition and Baseline Characteristics,[192639],[15048],[15052],[False],[0],[0],[False],['0']
29359,PMC5222895,32255,Table 1 Subject characteristics.,Results|Subject Disposition and Baseline Characteristics,[192641],[15053],[15085],[False],[0],[0],[False],['0']
29360,PMC5222895,32256,"Subject characteristics were comparable between age groups, except for the pre-defined difference in age between the two groups and the consequently longer duration of diabetes in the elderly group (Table 1).",Results|Subject Disposition and Baseline Characteristics,[192643],[15086],[15294],[False],[0],[0],[False],['0']
29361,PMC5222895,32257,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,Results,[192645],[15295],[15367],[False],[0],[0],[False],['0']
29362,PMC5222895,32258,Fig.,Results,[192647],[15368],[15372],[False],[0],[0],[False],['0']
29363,PMC5222895,32259,1 Mean serum insulin aspart concentration–time profiles for 5 h (a) and 2 h (b) after administration of faster aspart and insulin aspart (0.2 U/kg) in elderly subjects with type 1 diabetes mellitus.,Results,[192649],[15373],[15571],[False],[0],[0],[False],['0']
29364,PMC5222895,32260,Fig.,Results,[192651],[15572],[15576],[False],[0],[0],[False],['0']
29365,PMC5222895,32261,2 Mean glucose-lowering effect–time profiles for 5 h (a) and 2 h (b) after administration of faster aspart and insulin aspart (0.2 U/kg) in elderly subjects with type 1 diabetes mellitus.,Results,[192653],[15577],[15764],[False],[0],[0],[False],['0']
29366,PMC5222895,32262,"In elderly subjects, both the mean serum insulin aspart concentration–time profile (Fig.",Results,[192655],[15765],[15853],[False],[0],[0],[False],['0']
29367,PMC5222895,32263,1) and the glucose-lowering effect–time profile (Fig.,Results,[192657],[15854],[15907],[False],[0],[0],[False],['0']
29368,PMC5222895,32264,2) were left-shifted for faster aspart compared with insulin aspart.,Results,[192659],[15908],[15976],[False],[0],[0],[False],['0']
29369,PMC5222895,32265,Similar left-shifts of the pharmacokinetic and pharmacodynamic profiles were observed in younger adults (Online Resource Figs.,Results,[192661],[15977],[16103],[False],[0],[0],[False],['0']
29370,PMC5222895,32266,S2 and S3).,Results,[192663],[16104],[16115],[False],[0],[0],[False],['0']
29371,PMC5222895,32267,Table 2 Onset of exposure and glucose-lowering effect after administration of faster aspart versus insulin aspart (0.2 U/kg) in elderly subjects with type 1 diabetes mellitus.,Results,[192665],[16116],[16293],[False],[0],[0],[False],['0']
29372,PMC5222895,32268,"Onset of appearance of faster aspart in the elderly subjects occurred twice as fast (~3 min earlier; p < 0.001), and t   was shorter by ~10 min (p < 0.001), as compared with insulin aspart (Table 2).",Results,[192667],[16294],[16493],[False],[0],[0],[False],['0']
29373,PMC5222895,32269,"In the elderly subjects, t   occurred 7 min earlier for faster aspart than for insulin aspart; however, the difference was not statistically significant (Table 2).",Results,[192669],[16494],[16657],[False],[0],[0],[False],['0']
29374,PMC5222895,32270,Similar results were obtained with respect to onset of exposure in younger adults (Online Resource Table S2).,Results,[192671],[16658],[16767],[False],[0],[0],[False],['0']
29375,PMC5222895,32271,"Accordingly, the effect of treatment on onset of exposure did not differ statistically significantly between elderly and younger adults.",Results,[192673],[16768],[16904],[False],[0],[0],[False],['0']
29376,PMC5222895,32272,"p values for treatment by age group interaction were 0.904, 0.304 and 0.760 for onset of appearance, t   and t  , respectively.",Results,[192675],[16905],[17032],[False],[0],[0],[False],['0']
29377,PMC5222895,32273,"Onset of action and t   occurred ~10 min faster (p < 0.001) and ~6 min earlier (p = 0.003), respectively, with faster aspart compared with insulin aspart in the elderly subjects, while tGIR  did not differ statistically significantly between treatments (Table 2).",Results,[192677],[17033],[17297],[False],[0],[0],[False],['0']
29378,PMC5222895,32274,A similarly accelerated onset of glucose-lowering effect was obtained in the group of younger adults (Online Resource Table S2).,Results,[192679],[17298],[17426],[False],[0],[0],[False],['0']
29379,PMC5222895,32275,No statistically significant differences between elderly and younger adults were observed with respect to treatment effect for onset of glucose-lowering effect.,Results,[192681],[17427],[17587],[False],[0],[0],[False],['0']
29380,PMC5222895,32276,"p values for the treatment by age group interaction were 0.707, 0.121 and 0.948 for onset of action, t   and tGIR , respectively.",Results,[192683],[17588],[17717],[False],[0],[0],[False],['0']
29381,PMC5222895,32277,Treatment Differences in Early Exposure and Glucose-Lowering Effect,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192685],[17718],[17786],[False],[0],[0],[False],['0']
29382,PMC5222895,32278,Fig.,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192687],[17787],[17791],[False],[0],[0],[False],['0']
29383,PMC5222895,32279,3 Early exposure (a) and glucose-lowering effect (b) after administration of faster aspart versus insulin aspart (0.2 U/kg) in elderly subjects with type 1 diabetes mellitus.,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192689],[17792],[17966],[False],[0],[0],[False],['0']
29384,PMC5222895,32280,"AUC area under the curve, CI confidence interval, GIR glucose infusion rate, IAsp insulin aspart, LS Mean least square mean, P-value treatment comparison of faster aspart versus insulin aspart.",Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192691],[17967],[18160],[False],[0],[0],[False],['0']
29385,PMC5222895,32281,"In the elderly subjects, early insulin exposure up to 2 h after dosing was statistically significantly greater for faster aspart than for insulin aspart (Fig.",Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192693],[18161],[18319],[False],[0],[0],[False],['0']
29386,PMC5222895,32282,3a).,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192695],[18320],[18324],[False],[0],[0],[False],['0']
29387,PMC5222895,32283,Insulin exposure was ~3-fold greater during the first 15 min after dosing (AUC ; p < 0.001) and ~2-fold greater within the first 30 min after dosing (AUC ; p < 0.001) for faster aspart than for insulin aspart.,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192697],[18325],[18534],[False],[0],[0],[False],['0']
29388,PMC5222895,32284,"Similar results were obtained in younger adults, although the treatment difference for AUC  and AUC  did not reach statistical significance in this age group (Online Resource Fig.",Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192699],[18535],[18714],[False],[0],[0],[False],['0']
29389,PMC5222895,32285,S4).,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192701],[18715],[18719],[False],[0],[0],[False],['0']
29390,PMC5222895,32286,The treatment effect on early exposure was not statistically significantly different between age groups.,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192703],[18720],[18824],[False],[0],[0],[False],['0']
29391,PMC5222895,32287,"p values for treatment by age group interaction were 0.283, 0.449, 0.583, 0.622 and 0.663 for AUC , AUC , AUC , AUC  and AUC , respectively.",Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192705],[18825],[18965],[False],[0],[0],[False],['0']
29392,PMC5222895,32288,Early glucose-lowering effect was statistically significantly greater for faster aspart than for insulin aspart in the elderly subjects up to 2 h after dosing (Fig.,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192707],[18966],[19131],[False],[0],[0],[False],['0']
29393,PMC5222895,32289,3b).,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192709],[19132],[19136],[False],[0],[0],[False],['0']
29394,PMC5222895,32290,An ~2-fold greater glucose-lowering effect was observed with faster aspart than with insulin aspart within the first 30 min after dosing (AUC ; p = 0.001).,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192711],[19137],[19292],[False],[0],[0],[False],['0']
29395,PMC5222895,32291,"Similar treatment differences were observed in the group of younger adults, although the treatment difference for AUC  did not reach statistical significance in this age group (Online Resource Fig.",Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192713],[19293],[19490],[False],[0],[0],[False],['0']
29396,PMC5222895,32292,S4).,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192715],[19491],[19495],[False],[0],[0],[False],['0']
29397,PMC5222895,32293,There was no statistically significant impact of age group on the treatment differences in early glucose-lowering effect.,Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192717],[19496],[19617],[False],[0],[0],[False],['0']
29398,PMC5222895,32294,"p values for treatment by age group interaction were 0.914, 0.605, 0.869 and 0.959 for AUC , AUC , AUC  and AUC , respectively.",Treatment Differences in Onset of Exposure and Glucose-Lowering Effect,[192719],[19618],[19745],[False],[0],[0],[False],['0']
29399,PMC5222895,32295,Treatment Differences in Overall Exposure and Glucose-Lowering Effect,Treatment Differences in Early Exposure and Glucose-Lowering Effect,[192721],[19746],[19816],[False],[0],[0],[False],['0']
29400,PMC5222895,32296,Table 3 Overall exposure and glucose-lowering effect after administration of faster aspart versus insulin aspart (0.2 U/kg) in elderly subjects with type 1 diabetes mellitus.,Treatment Differences in Early Exposure and Glucose-Lowering Effect,[192723],[19817],[19991],[False],[0],[0],[False],['0']
29401,PMC5222895,32297,"AUC , C  , AUC  and GIR  were all comparable for faster aspart and insulin aspart, irrespective of age group (Table 3 and Online Resource Table S3).",Treatment Differences in Early Exposure and Glucose-Lowering Effect,[192725],[19992],[20140],[False],[0],[0],[False],['0']
29402,PMC5222895,32298,Age Group Differences in Overall Exposure and Glucose-Lowering Effect,Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192727],[20141],[20212],[False],[0],[0],[False],['0']
29403,PMC5222895,32299,Table 4 Overall exposure and glucose-lowering effect after administration of faster aspart and insulin aspart (0.2 U/kg) in elderly versus younger adults with type 1 diabetes mellitus.,Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192729],[20213],[20397],[False],[0],[0],[False],['0']
29404,PMC5222895,32300,"AUC  and C   for faster aspart were greater in elderly than in younger adults (estimated ratio of elderly/younger adults [95% CI] 1.30 [1.07–1.57], p = 0.008, and 1.28 [1.02–1.61], p = 0.031) (Table 4).",Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192731],[20398],[20600],[False],[0],[0],[False],['0']
29405,PMC5222895,32301,"For insulin aspart, the point estimates for the age group ratios were comparable with those for faster aspart, although no statistically significant difference was seen for C  .",Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192733],[20601],[20778],[False],[0],[0],[False],['0']
29406,PMC5222895,32302,The effect of age on overall exposure did not differ statistically significantly between faster aspart and insulin aspart.,Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192735],[20779],[20901],[False],[0],[0],[False],['0']
29407,PMC5222895,32303,"p values for treatment by age group interaction were 0.867 and 0.431 for AUC  and C  , respectively.",Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192737],[20902],[21002],[False],[0],[0],[False],['0']
29408,PMC5222895,32304,"There were no statistically significant differences in AUC  and GIR  between elderly and younger adults for faster aspart or for insulin aspart (estimated ratio of elderly/younger adults [95% CI] 0.93 [0.73–1.17], p = 0.517, and 0.85 [0.66–1.10], p = 0.209) (Table 4).",Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192739],[21003],[21272],[False],[0],[0],[False],['0']
29409,PMC5222895,32305,"p values for treatment by age group interaction were 0.403 and 0.430 for AUC  and GIR , respectively.",Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192741],[21273],[21374],[False],[0],[0],[False],['0']
29410,PMC5222895,32306,"Least square means for AUC , C  , AUC  and GIR  for both faster aspart and insulin aspart are presented for elderly subjects in Table 3 and for younger adults in Online Resource Table S3.",Treatment Differences in Overall Exposure and Glucose-Lowering Effect,[192743],[21375],[21562],[False],[0],[0],[False],['0']
29411,PMC5222895,32307,Safety,Safety,[192745],[21563],[21570],[False],[0],[0],[False],['0']
29412,PMC5222895,32308,"Faster aspart and insulin aspart were well-tolerated in both elderly and younger adults, and no safety issues were identified during the trial.",Safety,[192747],[21571],[21714],[False],[0],[0],[False],['0']
29413,PMC5222895,32309,There were no serious adverse events and all adverse events were either moderate (six events for faster aspart and eight events for insulin aspart) or mild (nine for faster aspart and two for insulin aspart) in intensity.,Safety,[192749],[21715],[21936],[False],[0],[0],[False],['0']
29414,PMC5222895,32310,No confirmed hypoglycaemic episodes and no injection-site reactions occurred during the trial.,Safety,[192751],[21937],[22031],[False],[0],[0],[False],['0']
29415,PMC5222895,32311,Discussion,Discussion,[192753],[22032],[22043],[False],[0],[0],[False],['0']
29416,PMC5222895,32312,The main findings of the present study were the faster onset and greater early exposure and glucose-lowering effect observed with faster aspart versus insulin aspart in elderly subjects.,Discussion,[192755],[22044],[22230],[False],[0],[0],[False],['0']
29417,PMC5222895,32313,"The left shift of the pharmacokinetic and pharmacodynamic profiles of faster aspart versus insulin aspart in the elderly mirrors that seen in younger adults in the current study as well as in previous studies [3–5], indicating that the ultra-fast pharmacological properties of faster aspart are preserved in elderly patients with diabetes.",Discussion,[192757],[22231],[22570],[False],[0],[0],[False],['0']
29418,PMC5222895,32314,The faster onset and greater early glucose-lowering effect of faster aspart than with insulin aspart indicate that faster aspart better mimics the insulin action seen in the healthy state in response to a meal.,Discussion,[192759],[22571],[22781],[False],[0],[0],[False],['0']
29419,PMC5222895,32315,"Thus, faster aspart may provide better mealtime coverage than current rapid-acting insulins.",Discussion,[192761],[22782],[22874],[False],[0],[0],[False],['0']
29420,PMC5222895,32316,"Indeed, in subjects with T1DM, superiority of faster aspart over insulin aspart in 2-h postprandial glucose excursion and a statistically significant difference in favour of faster aspart in 1-h postprandial glucose excursion were demonstrated in a meal-test [6].",Discussion,[192763],[22875],[23138],[False],[0],[0],[False],['0']
29421,PMC5222895,32317,"Likewise, in subjects with T2DM, the 1-h postprandial glucose excursion was statistically significantly reduced for faster aspart versus insulin aspart, while the treatment difference in 2-h postprandial glucose excursion in favour of faster aspart did not reach statistical significance [7].",Discussion,[192765],[23139],[23431],[False],[0],[0],[False],['0']
29422,PMC5222895,32318,"These two latter trials were conducted mainly in younger adults [6, 7].",Discussion,[192767],[23432],[23503],[False],[0],[0],[False],['0']
29423,PMC5222895,32319,On the basis of the results of the current study we would hypothesise that similar improvements in postprandial glucose excursions would be achieved in elderly patients with diabetes.,Discussion,[192769],[23504],[23687],[False],[0],[0],[False],['0']
29424,PMC5222895,32320,"However, the potential for faster aspart to improve postprandial glucose control in elderly patients with diabetes still remains to be confirmed in further investigations.",Discussion,[192771],[23688],[23859],[False],[0],[0],[False],['0']
29425,PMC5222895,32321,"The faster pharmacokinetic and pharmacodynamic properties of faster aspart may provide the option of post-meal administration, when necessary, thereby allowing the insulin dose to be more accurately adjusted to the actual food intake.",Discussion,[192773],[23860],[24094],[False],[0],[0],[False],['0']
29426,PMC5222895,32322,This could be particularly useful in those elderly patients with cognitive impairment and/or irregular eating patterns.,Discussion,[192775],[24095],[24214],[False],[0],[0],[False],['0']
29427,PMC5222895,32323,"Potential benefits include improved control of postprandial glucose and, not least, a reduced risk of hypoglycaemia, which is considered a particularly serious problem and a barrier to optimal glycaemic control in elderly patients with diabetes [15, 16].",Discussion,[192777],[24215],[24469],[False],[0],[0],[False],['0']
29428,PMC5222895,32324,"In a standardised meal-test in elderly subjects with T2DM, insulin aspart administered at meal ingestion and regular human insulin administered 30 min before meal ingestion resulted in similar insulin and postprandial glucose profiles [17].",Discussion,[192779],[24470],[24710],[False],[0],[0],[False],['0']
29429,PMC5222895,32325,Post-meal insulin lispro provided greater control of mean daily BG and a reduced incidence of hypoglycaemia and hyperglycaemia compared with regular human insulin administered 30 min before each meal in elderly subjects with T2DM living in nursing homes [18].,Discussion,[192781],[24711],[24970],[False],[0],[0],[False],['0']
29430,PMC5222895,32326,"Thus, it appears that current rapid-acting insulins allow for post-meal dosing, while still providing at least as good postprandial glucose control as regular human insulin administered pre-meal.",Discussion,[192783],[24971],[25166],[False],[0],[0],[False],['0']
29431,PMC5222895,32327,"In a similar manner, faster aspart administered 20 min post-meal has been compared with insulin aspart administered at mealtime in adult subjects with T1DM [6].",Discussion,[192785],[25167],[25327],[False],[0],[0],[False],['0']
29432,PMC5222895,32328,"The 2-h postprandial glucose increment was not statistically significantly different between post-meal faster aspart and mealtime insulin aspart, while the 1-h postprandial glucose increment was statistically significantly in favour of mealtime insulin aspart.",Discussion,[192787],[25328],[25588],[False],[0],[0],[False],['0']
29433,PMC5222895,32329,"The HbA  reduction seen during the 26-week treatment period was non-inferior, and overall rates of severe and confirmed hypoglycaemia were comparable, for post-meal faster aspart versus mealtime insulin aspart [6].",Discussion,[192789],[25589],[25803],[False],[0],[0],[False],['0']
29434,PMC5222895,32330,Clinical evidence is needed to confirm the option of post-meal dosing of faster aspart in elderly patients with diabetes and the optimal time window for such administration.,Discussion,[192791],[25804],[25977],[False],[0],[0],[False],['0']
29435,PMC5222895,32331,We found a higher total exposure and C   of faster aspart in elderly than in younger adults.,Discussion,[192793],[25978],[26070],[False],[0],[0],[False],['0']
29436,PMC5222895,32332,"The same was seen for insulin aspart, although it was only statistically significant for total exposure.",Discussion,[192795],[26071],[26175],[False],[0],[0],[False],['0']
29437,PMC5222895,32333,"A similar trend has been observed in previous studies for the insulin degludec/insulin aspart combination, insulin degludec alone and for insulin detemir [19–21], and would be in accordance with a reduced insulin clearance with increasing age [22].",Discussion,[192797],[26176],[26424],[False],[0],[0],[False],['0']
29438,PMC5222895,32334,"Importantly, we found comparable AUC  and GIR  in elderly and younger adults, as previously shown [19].",Discussion,[192799],[26425],[26528],[False],[0],[0],[False],['0']
29439,PMC5222895,32335,"The similar glucose-lowering effect in elderly and younger adults despite higher exposure in the elderly is in line with the well-known decrease in insulin sensitivity with aging [23, 24].",Discussion,[192801],[26529],[26717],[False],[0],[0],[False],['0']
29440,PMC5222895,32336,"In this context, it is also important to emphasise that the insulin dose should always be adjusted on an individual basis, depending on each patient’s needs.",Discussion,[192803],[26718],[26875],[False],[0],[0],[False],['0']
29441,PMC5222895,32337,"It follows that faster aspart should be considered safe also in elderly diabetes patients in terms of possible hypoglycaemia, although clinical data are needed to confirm this.",Discussion,[192805],[26876],[27052],[False],[0],[0],[False],['0']
29442,PMC5222895,32338,The clamp quality in the current study was high both in terms of precision and control deviation (Online Resource Table S1).,Discussion,[192807],[27053],[27177],[False],[0],[0],[False],['0']
29443,PMC5222895,32339,"Thus, the technical clamp issues experienced during the initial part of the study seem to have had no adverse impact on the quality of the results, as would also be expected since the affected data were excluded during a blinded review (see Sect.",Discussion,[192809],[27178],[27424],[False],[0],[0],[False],['0']
29444,PMC5222895,32340,3.1).,Discussion,[192811],[27425],[27430],[False],[0],[0],[False],['0']
29445,PMC5222895,32341,"In fact, the control deviation (i.e.",Discussion,[192813],[27431],[27467],[False],[0],[0],[False],['0']
29446,PMC5222895,32342,the mean difference between the measured and the target BG concentration) was lower than in a previous series of experiments using the Biostator algorithm [11].,Discussion,[192815],[27468],[27628],[False],[0],[0],[False],['0']
29447,PMC5222895,32343,"Thus, optimising the algorithm as done during the present study may have contributed to reducing the control deviation.",Discussion,[192817],[27629],[27748],[False],[0],[0],[False],['0']
29448,PMC5222895,32344,Several review articles have emphasised the generally limited number of clinical trials investigating diabetes interventions in the elderly [25–27].,Discussion,[192819],[27749],[27897],[False],[0],[0],[False],['0']
29449,PMC5222895,32345,"Accordingly, to our knowledge, glucose clamp studies comparing the pharmacokinetic and pharmacodynamic properties of an insulin between elderly and younger adults and/or between two insulins in elderly subjects have only been conducted for a few insulin products [19, 20, 28].",Discussion,[192821],[27898],[28174],[False],[0],[0],[False],['0']
29450,PMC5222895,32346,"Therefore, a strength of the current study was the use of the euglycaemic glucose clamp technique to assess the pharmacodynamic properties.",Discussion,[192823],[28175],[28314],[False],[0],[0],[False],['0']
29451,PMC5222895,32347,"It is, however, also important to emphasise that an inherent limitation of the glucose clamp method is the experimental and standardised setting, which imposes some challenges in directly translating to clinical practice.",Discussion,[192825],[28315],[28536],[True],['ValidityOfMeasurement'],['an inherent limitation of the glucose clamp method is the experimental and standardised setting'],[True],['OutcomeMeasures']
29452,PMC5222895,32348,Another limitation of the present study was the relatively few subjects per age group.,Discussion,[192830],[28537],[28623],[True],['SampleSize'],['the relatively few subjects per age group'],[True],['UnderpoweredStudy']
29453,PMC5222895,32349,"Still, the number of subjects was higher than in similar previous studies in elderly subjects [19, 20], and was sufficient to demonstrate statistically significant differences in pharmacokinetic and pharmacodynamic properties between faster aspart and insulin aspart in both age groups.",Discussion,[192833],[28624],[28910],[False],[0],[0],[False],['0']
29454,PMC5222895,32350,Conclusion,Conclusion,[192835],[28911],[28922],[False],[0],[0],[False],['0']
29455,PMC5222895,32351,The present study demonstrated that faster aspart has a faster onset and a greater early exposure and glucose-lowering effect than insulin aspart in elderly subjects with T1DM.,Conclusion,[192837],[28923],[29099],[False],[0],[0],[False],['0']
29456,PMC5222895,32352,"The results observed in the elderly subjects are in line with those seen in the younger adults, suggesting that faster aspart also has the potential to improve postprandial glucose control compared with current rapid-acting insulins in elderly patients with diabetes.",Conclusion,[192839],[29100],[29367],[False],[0],[0],[False],['0']
29457,PMC5222895,32353,Electronic supplementary material,Electronic supplementary material,[192841],[29368],[29402],[False],[0],[0],[False],['0']
29458,PMC5222895,32354,Below is the link to the electronic supplementary material.,Electronic supplementary material,[192843],[29403],[29462],[False],[0],[0],[False],['0']
29459,PMC5222895,32355,Supplementary material 1 (PDF 385 kb),Electronic supplementary material,[192845],[29463],[29500],[False],[0],[0],[False],['0']
29460,PMC5222895,32356,Acknowledgements,Acknowledgements,[192847],[29501],[29520],[False],[0],[0],[False],['0']
29461,PMC5222895,32357,"The authors would like to thank Theis Gondolf, MD, Novo Nordisk, for his review of and input into the manuscript and Carsten Roepstorff, PhD, CR Pharma Consult, Copenhagen, Denmark for providing medical writing support, which was funded by Novo Nordisk.",Acknowledgements,[192849],[29521],[29774],[False],[0],[0],[False],['0']
29462,PMC5222895,32358,Funding,Acknowledgements|Funding,[192851],[29775],[29782],[False],[0],[0],[False],['0']
29463,PMC5222895,32359,This study was funded by Novo Nordisk.,Acknowledgements|Funding,[192853],[29783],[29821],[False],[0],[0],[False],['0']
29464,PMC5222895,32360,Conflict of interest,Acknowledgements|Conflict of interest,[192855],[29822],[29842],[False],[0],[0],[False],['0']
29465,PMC5222895,32361,"Tim Heise is a shareholder of Profil, which has received research funds from Adocia, AstraZeneca, Becton Dickinson, Biocon, Boehringer Ingelheim, Dance Biopharm, Eli Lilly, Grünenthal, Gulf Pharmaceutical Industries, Johnson & Johnson, Marvel, MedImmune, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Senseonics and Zealand Pharma.",Acknowledgements|Conflict of interest,[192857],[29843],[30190],[False],[0],[0],[False],['0']
29466,PMC5222895,32362,"In addition, Tim Heise is a member of advisory panels for Novo Nordisk and received speaker honoraria and travel grants from Eli Lilly, Mylan and Novo Nordisk.",Acknowledgements|Conflict of interest,[192859],[30191],[30350],[False],[0],[0],[False],['0']
29467,PMC5222895,32363,"Kirstine Stender-Petersen, Jacob Bonde Jacobsen and Hanne Haahr are employees and shareholders of Novo Nordisk.",Acknowledgements|Conflict of interest,[192861],[30351],[30462],[False],[0],[0],[False],['0']
29468,PMC5222895,32364,Eric Zijlstra received travel grants from Dance Biopharm and Novo Nordisk and speaker honoraria from Novo Nordisk and Roche Diabetes Care.,Acknowledgements|Conflict of interest,[192863],[30463],[30601],[False],[0],[0],[False],['0']
29469,PMC5222895,32365,Ulrike Hövelmann declares no conflicts of interest.,Acknowledgements|Conflict of interest,[192865],[30602],[30653],[False],[0],[0],[False],['0']
30682,PMC5410698,31897,Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial,Title,[191393],[25433],[146],[False],[0],[0],[False],['0']
30683,PMC5410698,31898,Background,Abstract,[191397],[147],[158],[False],[0],[0],[False],['0']
30684,PMC5410698,31899,The efficacy of disease management programs in improving the outcome of heart failure patients remains uncertain and may vary across health systems.,Abstract,[191401],[159],[307],[False],[0],[0],[False],['0']
30685,PMC5410698,31900,This study explores whether a countrywide disease management program is superior to usual care in reducing adverse health outcomes and improving well-being among community-dwelling adult patients with moderate-to-severe chronic heart failure who have universal access to advanced health-care services and technologies.,Abstract,[191405],[308],[626],[False],[0],[0],[False],['0']
30686,PMC5410698,31901,Methods,Methods,[191409],[627],[635],[False],[0],[0],[False],['0']
30687,PMC5410698,31902,"In this multicenter open-label trial, 1,360 patients recruited after hospitalization for heart failure exacerbation (38%) or from the community (62%) were randomly assigned to either disease management or usual care.",Methods,[191413],[636],[852],[False],[0],[0],[False],['0']
30688,PMC5410698,31903,"Disease management, delivered by multi-disciplinary teams, included coordination of care, patient education, monitoring disease symptoms and patient adherence to medication regimen, titration of drug therapy, and home tele-monitoring of body weight, blood pressure and heart rate.",Methods,[191417],[853],[1133],[False],[0],[0],[False],['0']
30689,PMC5410698,31904,Patients assigned to usual care were treated by primary care practitioners and consultant cardiologists.,Methods,[191421],[1134],[1238],[False],[0],[0],[False],['0']
30690,PMC5410698,31905,The primary composite endpoint was the time elapsed till first hospital admission for heart failure exacerbation or death from any cause.,Methods,[191425],[1239],[1376],[False],[0],[0],[False],['0']
30691,PMC5410698,31906,"Secondary endpoints included the number of all hospital admissions, health-related quality of life and depression during follow-up.",Methods,[191429],[1377],[1508],[False],[0],[0],[False],['0']
30692,PMC5410698,31907,Intention-to-treat comparisons between treatments were adjusted for baseline patient data and study center.,Methods,[191433],[1509],[1616],[False],[0],[0],[False],['0']
30693,PMC5410698,31908,Results,Results,[191437],[1617],[1625],[False],[0],[0],[False],['0']
30694,PMC5410698,31909,"During the follow-up, 388 (56.9%) patients assigned to disease management and 387 (57.1%) assigned to usual care had a primary endpoint event.",Results,[191441],[1626],[1768],[False],[0],[0],[False],['0']
30695,PMC5410698,31910,"The median (range) time elapsed until the primary endpoint event or end of study was 2.0 (0–5.0) years among patients assigned to disease management, and 1.8 (0–5.0) years among patients assigned to usual care (adjusted hazard ratio, 0.908; 95% confidence interval, 0.788 to 1.047).",Results,[191445],[1769],[2051],[False],[0],[0],[False],['0']
30696,PMC5410698,31911,Hospital admissions were mostly (70%) unrelated to heart failure.,Results,[191449],[2052],[2117],[False],[0],[0],[False],['0']
30697,PMC5410698,31912,Patients assigned to disease management had a better health-related quality of life and a lower depression score during follow-up.,Results,[191453],[2118],[2248],[False],[0],[0],[False],['0']
30698,PMC5410698,31913,Conclusions,Conclusions,[191457],[2249],[2261],[False],[0],[0],[False],['0']
30699,PMC5410698,31914,"This comprehensive disease management intervention was not superior to usual care with respect to the primary composite endpoint, but it improved health-related quality of life and depression.",Conclusions,[191461],[2262],[2454],[False],[0],[0],[False],['0']
30700,PMC5410698,31915,A disease-centered approach may not suffice to make a significant impact on hospital admissions and mortality in patients with chronic heart failure who have universal access to health care.,Conclusions,[191465],[2455],[2645],[False],[0],[0],[False],['0']
30701,PMC5410698,31916,Clinical trial registration,Clinical trial registration,[191469],[2646],[2674],[False],[0],[0],[False],['0']
30702,PMC5410698,31917,Clinicaltrials.gov identifier: NCT00533013.,Clinical trial registration,[191473],[2675],[2718],[False],[0],[0],[False],['0']
30703,PMC5410698,31918,Trial registration date: 9 August 2007.,Clinical trial registration,[191477],[2719],[2758],[False],[0],[0],[False],['0']
30704,PMC5410698,31919,Initial protocol release date: 20 September 2007.,Clinical trial registration,[191481],[2759],[2808],[False],[0],[0],[False],['0']
30705,PMC5410698,31920,Electronic supplementary material,Electronic supplementary material,[191485],[2809],[2843],[False],[0],[0],[False],['0']
30706,PMC5410698,31921,"The online version of this article (doi:10.1186/s12916-017-0855-z) contains supplementary material, which is available to authorized users.",Electronic supplementary material,[191489],[2844],[2983],[False],[0],[0],[False],['0']
30707,PMC5410698,31922,Background,Background,[191493],[2984],[2996],[False],[0],[0],[False],['0']
30708,PMC5410698,31923,Disease management programs for patients with chronic heart failure were introduced in the mid-1990s to improve patient outcomes and reduce health-care costs [1].,Background,[191497],[2997],[3159],[False],[0],[0],[False],['0']
30709,PMC5410698,31924,"Typically, these programs include some or all of the following components: delivery of care by multi-disciplinary teams, patient empowerment and self-care education, coordination of care, reorganization of care delivery systems, use of information systems and reliance on evidence-based practices [2].",Background,[191501],[3160],[3461],[False],[0],[0],[False],['0']
30710,PMC5410698,31925,"Meta-analyses of randomized controlled trials have shown that, compared to usual care, disease management programs reduced hospital admissions and mortality related to heart failure and to all causes among patients with chronic heart failure [3–5].",Background,[191505],[3462],[3710],[False],[0],[0],[False],['0']
30711,PMC5410698,31926,"Nevertheless, some recent large-scale studies in patients with chronic heart failure failed to show any clinical [6–8] or economic [9] benefit of disease management programs over usual care.",Background,[191509],[3711],[3901],[False],[0],[0],[False],['0']
30712,PMC5410698,31927,"Some of the conflicting results may be attributed to variations in the types of interventions included in these programs, in patient characteristics and in the quality of care given to patients assigned to the control group [10].",Background,[191513],[3902],[4131],[False],[0],[0],[False],['0']
30713,PMC5410698,31928,Usual care may be more effective in achieving a good outcome among heart failure patients in health systems that provide universal access to health care.,Background,[191517],[4132],[4285],[False],[0],[0],[False],['0']
30714,PMC5410698,31929,"In Israel, the National Health Insurance Law enables universal access to primary, secondary and tertiary care and advanced health technologies, which are delivered by four health maintenance organizations.",Background,[191521],[4286],[4491],[False],[0],[0],[False],['0']
30715,PMC5410698,31930,"We aimed to evaluate the long-term effect of a countrywide comprehensive disease management program among patients with chronic heart failure, insured by Maccabi Health Services, the second largest health maintenance organization in Israel.",Background,[191525],[4492],[4732],[False],[0],[0],[False],['0']
30716,PMC5410698,31931,Methods,Methods,[191529],[4733],[4741],[False],[0],[0],[False],['0']
30717,PMC5410698,31932,Study design,Methods|Study design,[191533],[4742],[4754],[False],[0],[0],[False],['0']
30718,PMC5410698,31933,"In this multicenter open-label randomized trial, we compared the efficacy of a disease management program versus usual care among ambulatory adult patients (age ≥18 years) with moderate-to-severe chronic heart failure [New York Heart Association (NYHA) functional classes II to IV [11]].",Methods|Study design,[191537],[4755],[5042],[False],[0],[0],[False],['0']
30719,PMC5410698,31934,"Patients were referred within 2 months after hospital admission for heart failure exacerbation or from the community, by nurse supervisors at the public hospitals or by primary care practitioners and consultant cardiologists in the community, respectively.",Methods|Study design,[191541],[5043],[5299],[False],[0],[0],[False],['0']
30720,PMC5410698,31935,Screening for study eligibility was carried out in ten designated community heart failure centers.,Methods|Study design,[191545],[5300],[5398],[False],[0],[0],[False],['0']
30721,PMC5410698,31936,Diagnosis of heart failure was based on typical signs and symptoms and objective echocardiographic evidence of functional or structural abnormality of the heart at rest [12].,Methods|Study design,[191549],[5399],[5573],[False],[0],[0],[False],['0']
30722,PMC5410698,31937,"Patients with severe comorbidity, functional or cognitive impairment, or substance abuse were excluded (detailed information on eligibility criteria is available in the study protocol, see Additional file 1).",Methods|Study design,[191553],[5574],[5782],[False],[0],[0],[False],['0']
30723,PMC5410698,31938,"After completing eligibility and baseline assessments and providing signed informed consent, patients were randomly assigned to either disease management or usual care, using a computerized randomization program with a permuted-block design linked to the patients’ electronic medical record.",Methods|Study design,[191557],[5783],[6074],[False],[0],[0],[False],['0']
30724,PMC5410698,31939,Randomization was in a 1:1 ratio and stratified by heart failure center.,Methods|Study design,[191561],[6075],[6147],[False],[0],[0],[False],['0']
30725,PMC5410698,31940,The study safety committee reviewed the randomization process and found no evidence of violation or tampering with the randomization protocol.,Methods|Study design,[191565],[6148],[6290],[False],[0],[0],[False],['0']
30726,PMC5410698,31941,The study was approved by the Maccabi Health Services and the Sheba Medical Center research ethics committees.,Methods|Study design,[191569],[6291],[6401],[False],[0],[0],[False],['0']
30727,PMC5410698,31942,Interventions,Interventions,[191573],[6402],[6416],[False],[0],[0],[False],['0']
30728,PMC5410698,31943,"Patients enrolled in disease management were assigned to nurses who maintained regular remote contact with them between their scheduled visits to the heart failure centers, either through telephone calls or computer video sessions.",Interventions,[191577],[6417],[6648],[False],[0],[0],[False],['0']
30729,PMC5410698,31944,"During these sessions, the nurses provided comprehensive care and support to the patients and their caregivers, including self-care education, monitoring disease signs and symptoms, titration of heart failure medications following designated protocols, monitoring adherence to the medical therapy and its side effects, coordination of care vis-à-vis other caregivers and counselling in the event of an acute change in health status.",Interventions,[191581],[6649],[7081],[False],[0],[0],[False],['0']
30730,PMC5410698,31945,All disease management activities were recorded in the patients’ electronic medical records and supervised by the program director.,Interventions,[191585],[7082],[7213],[False],[0],[0],[False],['0']
30731,PMC5410698,31946,The initial frequency of remote contacts with patients assigned to disease management was once a week and was further modified according to needs.,Interventions,[191589],[7214],[7360],[False],[0],[0],[False],['0']
30732,PMC5410698,31947,"Patients monitored their body weight, blood pressure and pulse rate daily, after a night's sleep and voiding, using home tele-monitoring equipment (Medic4All®).",Interventions,[191593],[7361],[7521],[False],[0],[0],[False],['0']
30733,PMC5410698,31948,The tele-monitoring records were transmitted to the patients’ electronic medical records.,Interventions,[191597],[7522],[7611],[False],[0],[0],[False],['0']
30734,PMC5410698,31949,Automatic alerts were generated and presented to the nurses if the signals were out of the patient-specific preset range.,Interventions,[191601],[7612],[7733],[False],[0],[0],[False],['0']
30735,PMC5410698,31950,"The frequency of follow-up visits at the heart failure centers was determined according to the patients’ needs, but was not less than once every 6 months.",Interventions,[191605],[7734],[7888],[False],[0],[0],[False],['0']
30736,PMC5410698,31951,"During these visits, the patients were evaluated by cardiologists and nurses, and their treatment plan was modified accordingly.",Interventions,[191609],[7889],[8017],[False],[0],[0],[False],['0']
30737,PMC5410698,31952,Counselling by dietitians and social workers at the heart failure center was provided when needed.,Interventions,[191613],[8018],[8116],[False],[0],[0],[False],['0']
30738,PMC5410698,31953,"Patients assigned to usual care were referred to their primary care practitioners, after clinical assessment and provision of a treatment plan by cardiologists at the heart failure center.",Interventions,[191617],[8117],[8305],[False],[0],[0],[False],['0']
30739,PMC5410698,31954,"In general, ambulatory heart failure patients insured with Maccabi Health Services are cared for by primary care practitioners and consultant cardiologists.",Interventions,[191621],[8306],[8462],[False],[0],[0],[False],['0']
30740,PMC5410698,31955,The frequency of visits to the cardiologists was determined according to the patients’ needs.,Interventions,[191625],[8463],[8556],[False],[0],[0],[False],['0']
30741,PMC5410698,31956,"In addition, patients assigned to usual care were evaluated every 6 months by cardiologists at the heart failure center.",Interventions,[191629],[8557],[8677],[False],[0],[0],[False],['0']
30742,PMC5410698,31957,"These patients did not receive any intervention from the nurses at the call center, or from dietitians and social workers at the heart failure centers (detailed information is also available in the study protocol, see Additional file 1).",Interventions,[191633],[8678],[8915],[False],[0],[0],[False],['0']
30743,PMC5410698,31958,Study assessment and endpoints,Study assessment and endpoints,[191637],[8916],[8947],[False],[0],[0],[False],['0']
30744,PMC5410698,31959,All patients were evaluated at the heart failure centers at baseline and at 6-month intervals thereafter.,Study assessment and endpoints,[191641],[8948],[9053],[False],[0],[0],[False],['0']
30745,PMC5410698,31960,"These assessments included obtaining patient history and patient-completed questionnaires, a 6-minute walk test and NYHA classification.",Study assessment and endpoints,[191645],[9054],[9190],[False],[0],[0],[False],['0']
30746,PMC5410698,31961,"From 2009 onwards, assessments included also point-of-care brain natriuretic peptide (BNP) testing (using Triage® BNP Test and Triage® MeterPro, Alere, Switzerland).",Study assessment and endpoints,[191649],[9191],[9356],[False],[0],[0],[False],['0']
30747,PMC5410698,31962,"Except for the baseline evaluation, assessors were not blinded to the patients’ assigned intervention.",Study assessment and endpoints,[191653],[9357],[9459],[False],[0],[0],[False],['0']
30748,PMC5410698,31963,The primary composite endpoint was the time to first hospital admission for heart failure or to death from any cause.,Study assessment and endpoints,[191657],[9460],[9577],[False],[0],[0],[False],['0']
30749,PMC5410698,31964,"Secondary endpoints included the individual components of the primary composite endpoint; the total number of hospital admissions and in-hospital days for heart failure and for all causes; follow-up assessments of a 6-minute walk test, NYHA classification, health-related quality of life assessed with the 36-item short-form questionnaire (SF-36) [13], depression symptoms assessed with the nine-item patient health depression scale (PHQ-9) [14], BNP levels (in a subset of patients), and purchases of recommended medications for patients with chronic heart failure [i.e.",Study assessment and endpoints,[191661],[9578],[10149],[False],[0],[0],[False],['0']
30750,PMC5410698,31965,"angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) and beta adrenergic receptor blocking agents [12]].",Study assessment and endpoints,[191665],[10150],[10289],[False],[0],[0],[False],['0']
30751,PMC5410698,31966,Information on hospital admissions and deaths during follow-up was obtained.,Study assessment and endpoints,[191669],[10290],[10366],[False],[0],[0],[False],['0']
30752,PMC5410698,31967,"Discharge summaries, available for 5,748 (99.7%) of 5,766 hospital admissions, were adjudicated by two independent investigators blinded to the patients’ assigned treatment, and were classified as either related to heart failure (i.e.",Study assessment and endpoints,[191673],[10367],[10601],[False],[0],[0],[False],['0']
30753,PMC5410698,31968,"decompensated heart failure, complications of heart failure or heart failure treatment) or other causes.",Study assessment and endpoints,[191677],[10602],[10706],[False],[0],[0],[False],['0']
30754,PMC5410698,31969,"Disagreement between the assessors occurred for 581 (10.1%) of the hospital discharge summaries, and a third assessment was provided by a third blinded investigator, with the final classification following the majority opinion.",Study assessment and endpoints,[191681],[10707],[10934],[False],[0],[0],[False],['0']
30755,PMC5410698,31970,Safety committee,Safety committee,[191685],[10935],[10952],[False],[0],[0],[False],['0']
30756,PMC5410698,31971,"A safety committee, comprising a statistician, cardiologist and epidemiologist, monitored the cumulative event rates of hospital admissions and deaths from all causes among the study participants every 6 months.",Safety committee,[191689],[10953],[11164],[False],[0],[0],[False],['0']
30757,PMC5410698,31972,The committee members were not blinded to the participants’ assigned intervention.,Safety committee,[191693],[11165],[11247],[False],[0],[0],[False],['0']
30758,PMC5410698,31973,The committee discussions were not disclosed to the investigators during the trial.,Safety committee,[191697],[11248],[11331],[False],[0],[0],[False],['0']
30759,PMC5410698,31974,"Guided by a predefined level of statistical significance [15], the mandate of the committee was to provide warning in the event of an excess number of deaths or hospital admissions from all causes in the disease management arm.",Safety committee,[191701],[11332],[11559],[False],[0],[0],[False],['0']
30760,PMC5410698,31975,"In practice, no such excess was found and the study continued to its planned conclusion.",Safety committee,[191705],[11560],[11648],[False],[0],[0],[False],['0']
30761,PMC5410698,31976,Sample size consideration,Sample size consideration,[191709],[11649],[11675],[False],[0],[0],[False],['0']
30762,PMC5410698,31977,"The planned sample size of 1,200 patients, 600 in each treatment arm, was based on the assumption that 50% of the participants assigned to the usual care arm would be admitted to hospital for heart failure or die during the first 12 months and that the odds ratio (OR) for this primary endpoint was 0.67 for disease management versus usual care.",Sample size consideration,[191713],[11676],[12021],[False],[0],[0],[False],['0']
30763,PMC5410698,31978,The assumptions were based on a published meta-analysis of previous disease management trials among heart failure patients [3].,Sample size consideration,[191717],[12022],[12149],[False],[0],[0],[False],['0']
30764,PMC5410698,31979,"This sample size provided 90% statistical power, using a two-sided 0.05 significance level.",Sample size consideration,[191721],[12150],[12241],[False],[0],[0],[False],['0']
30765,PMC5410698,31980,"The final study sample included 1,360 patients, to account for drop-outs and the time needed for organizational learning and adaptation.",Sample size consideration,[191725],[12242],[12378],[False],[0],[0],[False],['0']
30766,PMC5410698,31981,Statistical analysis,Statistical analysis,[191729],[12379],[12400],[False],[0],[0],[False],['0']
30767,PMC5410698,31982,The statistical analysis was performed according to a pre-specified plan.,Statistical analysis,[191733],[12401],[12474],[False],[0],[0],[False],['0']
30768,PMC5410698,31983,Unadjusted comparisons between the two treatment groups with respect to the primary composite endpoint (time to first hospital admission due to heart failure or death from any cause) and its two individual components were made using the log-rank statistic.,Statistical analysis,[191737],[12475],[12731],[False],[0],[0],[False],['0']
30769,PMC5410698,31984,"The Cox proportional hazards model was used to compare the two treatment groups with respect to the primary composite endpoint and its components, adjusted for baseline characteristics (sex, age, heart failure center, 6-minute walk test and NYHA classification).",Statistical analysis,[191741],[12732],[12994],[False],[0],[0],[False],['0']
30770,PMC5410698,31985,"In supportive analyses, adjustment was also made for other baseline variables that were significantly associated with hospital readmission due to heart failure or death from any cause (including source of recruitment, the main underlying cause of heart failure, body mass index, renal failure and hemoglobin level).",Statistical analysis,[191745],[12995],[13310],[False],[0],[0],[False],['0']
30771,PMC5410698,31986,"The median time to first hospital admission for heart failure and its 95% confidence interval were estimated in the two treatment groups, standardized to the most common patient baseline profile using an inverse transformation of the predicted survival curve at 50%.",Statistical analysis,[191749],[13311],[13577],[False],[0],[0],[False],['0']
30772,PMC5410698,31987,Predefined interactions between the treatment group and baseline variables were also tested.,Statistical analysis,[191753],[13578],[13670],[False],[0],[0],[False],['0']
30773,PMC5410698,31988,The proportional hazards assumption for the treatment group was tested in all of these models.,Statistical analysis,[191757],[13671],[13765],[False],[0],[0],[False],['0']
30774,PMC5410698,31989,"To compare hospital admission data recorded every 6 months in the two treatment groups, non-linear mixed models were used with a random intercept for each subject, allowing for correlation between repeated measurements of the same subject.",Statistical analysis,[191761],[13766],[14005],[False],[0],[0],[False],['0']
30775,PMC5410698,31990,"Due to the over-dispersion commonly seen in hospital admission data [16], a negative binomial model was used.",Statistical analysis,[191765],[14006],[14115],[False],[0],[0],[False],['0']
30776,PMC5410698,31991,"Using the NLMIXED procedure (SAS version 9.4), this method was implemented for the following four secondary outcomes: number of hospital admissions and days of hospitalization, for heart failure and all causes.",Statistical analysis,[191769],[14116],[14326],[False],[0],[0],[False],['0']
30777,PMC5410698,31992,"These models were adjusted for baseline characteristics and time since randomization in intervals of 6 months, and effectively dealt with the varying length of follow-up among individuals due to censoring.",Statistical analysis,[191773],[14327],[14532],[False],[0],[0],[False],['0']
30778,PMC5410698,31993,The coefficient of the treatment group variable represented the log incidence rate ratio for 6 months.,Statistical analysis,[191777],[14533],[14635],[False],[0],[0],[False],['0']
30779,PMC5410698,31994,Absolute differences between treatment groups in the number of hospital admissions and in-hospital days over the first 2 years were calculated from the estimated incidence rate ratio and the mean outcome in the usual care group.,Statistical analysis,[191781],[14636],[14864],[False],[0],[0],[False],['0']
30780,PMC5410698,31995,"Other secondary endpoints were dichotomously categorized to represent successful attainment (or not) of a minimal clinically important difference from baseline, as follows: physical component summary and mental component summary scores of SF-36 (≥2.5 points increase [17]); NYHA classification (≥1 class decrease [18]); 6-minute walk test (≥50 m increase [19]), and moderate-to-severe depression symptoms at follow-up (PHQ-9 score ≥10 [14]).",Statistical analysis,[191785],[14865],[15306],[False],[0],[0],[False],['0']
30781,PMC5410698,31996,The treatment OR of success was estimated using a logistic model within the same mixed-model framework described above.,Statistical analysis,[191789],[15307],[15426],[False],[0],[0],[False],['0']
30782,PMC5410698,31997,Interactions between the treatment group and baseline value of the endpoint were tested.,Statistical analysis,[191793],[15427],[15515],[False],[0],[0],[False],['0']
30783,PMC5410698,31998,"Using the Maccabi Health Services database on drug purchases, adherence to medical therapy was defined as the number of days in a 6-month period covered by therapy with ACE-I/ARBs and beta adrenergic receptor blocking agents according to the defined daily dose [20], classified into five categories (the first category representing no treatment and the second to the fifth categories representing defined daily dose quartiles for patients taking the medication).",Statistical analysis,[191797],[15516],[15978],[False],[0],[0],[False],['0']
30784,PMC5410698,31999,The treatment OR of attaining a higher level of coverage by drug therapy was estimated using an ordered logistic regression model within the mixed-model framework.,Statistical analysis,[191801],[15979],[16142],[False],[0],[0],[False],['0']
30785,PMC5410698,32000,The assumption of proportional odds for each cut-point of the adherence variables was tested.,Statistical analysis,[191805],[16143],[16236],[False],[0],[0],[False],['0']
30786,PMC5410698,32001,"All analyses were carried out according to the intention-to-treat principle, at a critical two-sided significance level of 0.05.",Statistical analysis,[191809],[16237],[16365],[False],[0],[0],[False],['0']
30787,PMC5410698,32002,Results,Results,[191813],[16366],[16374],[False],[0],[0],[False],['0']
30788,PMC5410698,32003,"Participants were recruited between August 2007 and June 2011, and followed until death or end of study (July 2012).",Results,[191817],[16375],[16491],[False],[0],[0],[False],['0']
30789,PMC5410698,32004,The median time of follow-up was 2.7 years (range 0–5).,Results,[191821],[16492],[16547],[False],[0],[0],[False],['0']
30790,PMC5410698,32005,Fig.,Results,[191825],[16548],[16552],[False],[0],[0],[False],['0']
30791,PMC5410698,32006,"1 Screening, randomization and completion of follow-up.",Results,[191829],[16553],[16608],[False],[0],[0],[False],['0']
30792,PMC5410698,32007,"CHF congestive heart failure, NYHA New York Heart Association.",Results,[191833],[16609],[16671],[False],[0],[0],[False],['0']
30793,PMC5410698,32008,"A total of 5,295 patients were screened for eligibility, of whom 3,673 were found non-eligible, 262 declined participation, and 1,360 were randomly assigned either to usual care (678) or to disease management (682).",Results,[191837],[16672],[16887],[False],[0],[0],[False],['0']
30794,PMC5410698,32009,"Altogether, 22 participants did not receive the allocated intervention; 12 because of withdrawn consent and because ten participants died within 1 month after randomization.",Results,[191841],[16888],[17061],[False],[0],[0],[False],['0']
30795,PMC5410698,32010,Three participants were lost to follow-up and 96 discontinued the intervention (Fig.,Results,[191845],[17062],[17146],[False],[0],[0],[False],['0']
30796,PMC5410698,32011,1).,Results,[191849],[17147],[17150],[False],[0],[0],[False],['0']
30797,PMC5410698,32012,All randomized patients were included in the analyses.,Results,[191853],[17151],[17205],[False],[0],[0],[False],['0']
30798,PMC5410698,32013,Table 1 Baseline characteristics of the study participants.,Results,[191857],[17206],[17266],[False],[0],[0],[False],['0']
30799,PMC5410698,32014,"The mean age (standard deviation) of participants was 70.7 (11.3) years, and 987 (72.5%) were men.",Results,[191861],[17267],[17365],[False],[0],[0],[False],['0']
30800,PMC5410698,32015,Most were NYHA functional class III (79%) and 82% had reduced left ventricular ejection fraction (<50%).,Results,[191865],[17366],[17470],[False],[0],[0],[False],['0']
30801,PMC5410698,32016,Nine NYHA class I patients were recruited by mistake (five assigned to disease management and four to usual care).,Results,[191869],[17471],[17585],[False],[0],[0],[False],['0']
30802,PMC5410698,32017,"At enrolment, a large proportion of participants were taking medication recommended for treating chronic heart failure.",Results,[191873],[17586],[17705],[False],[0],[0],[False],['0']
30803,PMC5410698,32018,"Compared to patients assigned to usual care, those assigned to disease management were less likely to be male, were more likely to be NYHA functional class IV and performed slightly worse on a 6-minute walk test.",Results,[191877],[17706],[17918],[False],[0],[0],[False],['0']
30804,PMC5410698,32019,"Although statistically significant, the absolute differences between the two study groups for these variables were small.",Results,[191881],[17919],[18040],[False],[0],[0],[False],['0']
30805,PMC5410698,32020,"Otherwise, the baseline characteristics of the patients were similar across the two groups (Table 1).",Results,[191885],[18041],[18142],[False],[0],[0],[False],['0']
30806,PMC5410698,32021,Endpoints,Endpoints,[191889],[18143],[18154],[False],[0],[0],[False],['0']
30807,PMC5410698,32022,"Table 2 Total and per study group visits to a cardiologist, hospital admissions and deaths during follow-up.",Endpoints,[191893],[18155],[18263],[False],[0],[0],[False],['0']
30808,PMC5410698,32023,"During 3,421 patient-years, there were 5,766 hospital admissions for 1,184 participants; 1,707 hospital admissions for 628 participants were for heart failure, and 450 participants died (Table 2).",Endpoints,[191897],[18264],[18460],[False],[0],[0],[False],['0']
30809,PMC5410698,32024,Primary endpoint and its components,Primary endpoint and its components,[191901],[18461],[18498],[False],[0],[0],[False],['0']
30810,PMC5410698,32025,Fig.,Primary endpoint and its components,[191905],[18499],[18503],[False],[0],[0],[False],['0']
30811,PMC5410698,32026,2  a First hospital admission for heart failure or death from all causes by study group.,Primary endpoint and its components,[191909],[18504],[18592],[False],[0],[0],[False],['0']
30812,PMC5410698,32027,b First hospital admission for heart failure by study group.,Primary endpoint and its components,[191913],[18593],[18653],[False],[0],[0],[False],['0']
30813,PMC5410698,32028,c Death from all causes by study group.,Primary endpoint and its components,[191917],[18654],[18693],[False],[0],[0],[False],['0']
30814,PMC5410698,32029,The p value refers to a comparison between the two study groups using a log-rank test.,Primary endpoint and its components,[191921],[18694],[18780],[False],[0],[0],[False],['0']
30815,PMC5410698,32030,"DM Disease management, UC Usual care.",Primary endpoint and its components,[191925],[18781],[18818],[False],[0],[0],[False],['0']
30816,PMC5410698,32031,"The primary composite endpoint, first hospital admission for heart failure or death from any cause, occurred in 388 (56.9%) patients assigned to disease management, and in 387 (57.1%) patients assigned to usual care.",Primary endpoint and its components,[191929],[18819],[19035],[False],[0],[0],[False],['0']
30817,PMC5410698,32032,"The median (range) time to a primary endpoint event or end of follow-up was 2.0 (0–5.0) years among patients assigned to disease management, and 1.8 (0–5.0) years among patients assigned to usual care [hazard ratio (HR), 0.981; 95% confidence interval (CI), 0.852 to 1.129] (Fig.",Primary endpoint and its components,[191933],[19036],[19315],[False],[0],[0],[False],['0']
30818,PMC5410698,32033,2a).,Primary endpoint and its components,[191937],[19316],[19320],[False],[0],[0],[False],['0']
30819,PMC5410698,32034,"Further adjustment for age, sex, heart failure center, and baseline NYHA classification and 6-minute walk test did not show a statistically significant advantage of disease management over usual care (adjusted HR, 0.908; 95% CI, 0.788 to 1.047) (Table 1).",Primary endpoint and its components,[191941],[19321],[19576],[False],[0],[0],[False],['0']
30820,PMC5410698,32035,"Disease management delayed the time to first hospital admission for heart failure (adjusted HR, 0.832; 95% CI, 0.708 to 0.977).",Primary endpoint and its components,[191945],[19577],[19705],[False],[0],[0],[False],['0']
30821,PMC5410698,32036,"The median (95% CI) time to first hospital admission for heart failure, estimated for a participant with a typical profile (72.5-year-old male, NYHA functional class III, recruited from the community with ischemic heart failure, renal failure and median values of hemoglobin and 6-minute walking distance) was 3.0 years (2.3 to 3.8) if assigned to disease management versus 2.2 years (1.8 to 2.8) if assigned to usual care.",Primary endpoint and its components,[191949],[19706],[20129],[False],[0],[0],[False],['0']
30822,PMC5410698,32037,Table 3 The effect of the intervention (disease management versus usual care) on the primary endpoint and its components.,Primary endpoint and its components,[191953],[20130],[20251],[False],[0],[0],[False],['0']
30823,PMC5410698,32038,"There two treatment groups did not differ by mortality from all causes (adjusted HR, 0.997; 95% CI, 0.820 to 1.213) (Table 3 and Fig.",Primary endpoint and its components,[191957],[20252],[20385],[False],[0],[0],[False],['0']
30824,PMC5410698,32039,2c).,Primary endpoint and its components,[191961],[20386],[20390],[False],[0],[0],[False],['0']
30825,PMC5410698,32040,Fig.,Primary endpoint and its components,[191965],[20391],[20396],[False],[0],[0],[False],['0']
30826,PMC5410698,32041,3  a Effect of disease management on the composite outcome (first hospital admission for heart failure or death) by subgroups of patients.,Primary endpoint and its components,[191969],[20397],[20535],[False],[0],[0],[False],['0']
30827,PMC5410698,32042,b Effect of disease management on all-cause mortality by subgroups of patients.,Primary endpoint and its components,[191973],[20536],[20615],[False],[0],[0],[False],['0']
30828,PMC5410698,32043,c Effect of disease management on first hospital admission for heart failure by subgroups of patients.,Primary endpoint and its components,[191977],[20616],[20718],[False],[0],[0],[False],['0']
30829,PMC5410698,32044,"Information on the effect of disease management in subgroups of patients was derived from Cox proportional hazard models, adjusted for age, sex, heart failure center and baseline values of NYHA functional class and 6-minute walk test.",Primary endpoint and its components,[191981],[20719],[20953],[False],[0],[0],[False],['0']
30830,PMC5410698,32045,NYHA New York Heart Association.,Primary endpoint and its components,[191985],[20954],[20986],[False],[0],[0],[False],['0']
30831,PMC5410698,32046,"None of the pre-specified interactions tested were found statistically significant, with respect to the intervention effect on the primary endpoint or its components.",Primary endpoint and its components,[191989],[20987],[21153],[False],[0],[0],[False],['0']
30832,PMC5410698,32047,"Nevertheless, among patients recruited after recent hospital admission for heart failure or with ischemic heart failure, the disease management intervention was associated with a lower hazard for first hospital admission for heart failure compared to usual care [corresponding adjusted HRs (95% CIs): 0.74 (0.58 to 0.94) and 0.79 (0.66 to 0.95); see more detailed information for pre-specified patient subgroups in Fig.",Primary endpoint and its components,[191993],[21154],[21573],[False],[0],[0],[False],['0']
30833,PMC5410698,32048,3].,Primary endpoint and its components,[191997],[21574],[21577],[False],[0],[0],[False],['0']
30834,PMC5410698,32049,Other secondary endpoints,Other secondary endpoints,[192001],[21578],[21605],[False],[0],[0],[False],['0']
30835,PMC5410698,32050,Table 4 The effect of the intervention (disease management versus usual care) on hospital admission endpoints.,Other secondary endpoints,[192005],[21606],[21716],[False],[0],[0],[False],['0']
30836,PMC5410698,32051,The total number of hospital admissions and in-hospital days for heart failure and for all causes during follow-up did not significantly differ between the two study groups.,Other secondary endpoints,[192009],[21717],[21890],[False],[0],[0],[False],['0']
30837,PMC5410698,32052,"On average, the number of in-hospital days for heart failure among patients assigned to disease management was 28% lower than among patients assigned to usual care [adjusted rate ratio (RR): 0.720; 95% CI, 0.508 to 1.021] (Table 4).",Other secondary endpoints,[192013],[21891],[22123],[False],[0],[0],[False],['0']
30838,PMC5410698,32053,"Compared to a patient assigned to usual care, on average, a patient assigned to disease management stayed about 1.6 fewer days in the hospital for heart failure during the first 2 years of follow-up (95% CI, −2.9 to +0.1 days).",Other secondary endpoints,[192017],[22124],[22351],[False],[0],[0],[False],['0']
30839,PMC5410698,32054,"Similarly, the average number of heart failure hospital admissions was 18% lower among patients assigned to disease management than among patients assigned to usual care (adjusted RR: 0.816; 95% CI, 0.665 to 1.001) (Table 4).",Other secondary endpoints,[192021],[22352],[22577],[False],[0],[0],[False],['0']
30840,PMC5410698,32055,"Compared to a patient assigned to usual care, on average, a patient assigned to disease management had about 0.2 fewer heart failure hospital admissions during the first 2 years of follow-up (95% CI, −0.3 to 0.0; p = 0.051).",Other secondary endpoints,[192025],[22578],[22802],[False],[0],[0],[False],['0']
30841,PMC5410698,32056,"There were no statistically significant differences between the two treatment groups with respect to the total number of in-hospital days (adjusted RR: 0.886; 95% CI, 0.749 to 1.048), and the total number of hospital admissions for all causes (adjusted RR: 0.935; 95% CI, 0.840 to 1.040).",Other secondary endpoints,[192029],[22803],[23092],[False],[0],[0],[False],['0']
30842,PMC5410698,32057,"Table 5 The effect of the intervention (disease management versus usual care) on other secondary outcome and process endpoints, adjusted for baseline characteristics.",Other secondary endpoints,[192033],[23093],[23259],[False],[0],[0],[False],['0']
30843,PMC5410698,32058,Patients assigned to disease management were less likely to experience moderate-to-severe depression symptoms and more likely to experience clinically important improvements in health-related quality of life than those assigned to usual care.,Other secondary endpoints,[192037],[23260],[23502],[False],[0],[0],[False],['0']
30844,PMC5410698,32059,They were also more likely to improve their NYHA functional class.,Other secondary endpoints,[192041],[23503],[23569],[False],[0],[0],[False],['0']
30845,PMC5410698,32060,There were no significant differences between the treatment groups with respect to a clinically important change in the 6-minute walk test (Table 5).,Other secondary endpoints,[192045],[23570],[23719],[False],[0],[0],[False],['0']
30846,PMC5410698,32061,There were also no significant differences between the treatment groups with respect to the level of coverage for therapy by ACE-Is/ARBs or beta adrenergic receptor blocking agents during follow-up (Table 5).,Other secondary endpoints,[192049],[23720],[23929],[False],[0],[0],[False],['0']
30847,PMC5410698,32062,Process variables,Process variables,[192053],[23930],[23948],[False],[0],[0],[False],['0']
30848,PMC5410698,32063,The mean (standard deviation) number of remote contacts with a nurse for patients assigned to disease management was 27.3 (17.8) during the first year after enrolment and 18.8 (13.7) per year during the total stay in the program.,Process variables,[192057],[23949],[24178],[False],[0],[0],[False],['0']
30849,PMC5410698,32064,The mean (standard deviation) number of annual visits to a cardiologist during the total follow-up period was 7.9 (6.3) for patients assigned to disease management and 5.6 (4.5) for patients assigned to usual care (p < 0.001).,Process variables,[192061],[24179],[24405],[False],[0],[0],[False],['0']
30850,PMC5410698,32065,"There was no significant difference in the mean number of visits to a primary practitioner between patients assigned to disease management and those assigned to usual care [mean (standard deviation) number of visits per year; 22.2 (14.4) and 20.9 (12.9), respectively; p = 0.141] (Table 2).",Process variables,[192065],[24406],[24696],[False],[0],[0],[False],['0']
30851,PMC5410698,32066,Discussion,Discussion,[192069],[24697],[24708],[False],[0],[0],[False],['0']
30852,PMC5410698,32067,"In this trial, treatment with disease management was not superior to usual care with respect to the primary outcome, i.e.",Discussion,[192073],[24709],[24830],[False],[0],[0],[False],['0']
30853,PMC5410698,32068,time to first hospital admission for heart failure or death from any cause.,Discussion,[192077],[24831],[24906],[False],[0],[0],[False],['0']
30854,PMC5410698,32069,"The study intervention prolonged the time to first hospital admission for heart failure, especially among patients enrolled after recent hospitalization for heart failure or with ischemic heart failure.",Discussion,[192081],[24907],[25109],[False],[0],[0],[False],['0']
30855,PMC5410698,32070,"There was also a trend, although not statistically significant, towards a reduction in the number of hospital admissions and in-hospital days for heart failure.",Discussion,[192085],[25110],[25270],[False],[0],[0],[False],['0']
30856,PMC5410698,32071,The intervention was also effective in achieving clinically important improvements in health-related quality of life and it reduced the likelihood of depression.,Discussion,[192089],[25271],[25432],[False],[0],[0],[False],['0']
30857,PMC5410698,32072,"The disease management intervention tested in this study was comprehensive and included delivery of care by multi-disciplinary teams within designated heart failure centers and a central call center, home tele-monitoring, employment of information technology to promote sharing of patient information among all caregivers and utilization of standardized care processes.",Discussion,[192093],[25433],[25802],[False],[0],[0],[False],['0']
30858,PMC5410698,32073,"Nevertheless, the intervention did not conclusively reduce the number of hospitalizations due to all causes, nor did it reduce mortality.",Discussion,[192097],[25803],[25940],[False],[0],[0],[False],['0']
30859,PMC5410698,32074,"In this respect, our study confirms the results of recent studies showing little or no effect of disease management in reducing recurrent hospital admissions or mortality in ambulatory patients with chronic heart failure [6–8].",Discussion,[192101],[25941],[26168],[False],[0],[0],[False],['0']
30860,PMC5410698,32075,Much of the marginal effect of disease management interventions tested in controlled trials depends upon the type of care delivered to patients assigned to the control group.,Discussion,[192105],[26169],[26343],[False],[0],[0],[False],['0']
30861,PMC5410698,32076,"In Israel, there is universal access to primary, secondary and tertiary health-care services and advanced health-care technologies.",Discussion,[192109],[26344],[26475],[False],[0],[0],[False],['0']
30862,PMC5410698,32077,This was reflected by the high proportion of patients receiving evidence-based drug therapy upon recruitment and the small difference between the treatment groups with respect to the number of contacts with cardiologists during follow-up.,Discussion,[192113],[26476],[26714],[False],[0],[0],[False],['0']
30863,PMC5410698,32078,The intervention tested in this study included remote contact with the patients between their scheduled visits to the heart failure centers.,Discussion,[192117],[26715],[26855],[False],[0],[0],[False],['0']
30864,PMC5410698,32079,Some studies reported that disease management programs that included home visits by nurses were effective in reducing recurrent hospital admissions or deaths among patients recruited after recent hospitalization for heart failure [21–24].,Discussion,[192121],[26856],[27094],[False],[0],[0],[False],['0']
30865,PMC5410698,32080,"However, other studies failed to show the efficacy of such interventions [6, 25–27].",Discussion,[192125],[27095],[27179],[False],[0],[0],[False],['0']
30866,PMC5410698,32081,"Although most patients in our study had at least one hospital admission during follow-up, fewer than half were hospitalized because of heart failure, and heart failure accounted for only 30% of the total hospital admissions.",Discussion,[192129],[27180],[27404],[False],[0],[0],[False],['0']
30867,PMC5410698,32082,Mejhert et al.,Discussion,[192133],[27405],[27419],[False],[0],[0],[False],['0']
30868,PMC5410698,32083,"reported that among Swedish patients with heart failure, non-cardiac and cardiac hospital admissions accounted for 40% and 30% of the total long-term health-care expenditure, respectively [28].",Discussion,[192137],[27420],[27613],[False],[0],[0],[False],['0']
30869,PMC5410698,32084,"Patients with heart failure often have other comorbidities, of which the most common are hypertension, coronary artery disease and diabetes [29].",Discussion,[192141],[27614],[27759],[False],[0],[0],[False],['0']
30870,PMC5410698,32085,This was also the case in our study.,Discussion,[192145],[27760],[27796],[False],[0],[0],[False],['0']
30871,PMC5410698,32086,"Thus, a disease-centerd approach may not suffice to make a significant impact on all-cause hospital admissions and mortality in patients with chronic heart failure.",Discussion,[192149],[27797],[27961],[False],[0],[0],[False],['0']
30872,PMC5410698,32087,A recent systematic review showed that case-management interventions addressing the complex needs of patients with chronic heart failure who had been previously hospitalized for heart failure exacerbation were associated with a 12-month reduction in all-cause mortality and all-cause hospital admissions [4].,Discussion,[192153],[27962],[28270],[False],[0],[0],[False],['0']
30873,PMC5410698,32088,"In our study, disease management had no significant effect on the long-term adherence to drug therapy recommended for patients with chronic heart failure.",Discussion,[192157],[28271],[28425],[False],[0],[0],[False],['0']
30874,PMC5410698,32089,A possible explanation may be the high proportion of patients who were already treated with these medications upon recruitment.,Discussion,[192161],[28426],[28553],[False],[0],[0],[False],['0']
30875,PMC5410698,32090,"We found that the study intervention was highly effective in improving patients’ health-related quality of life and depression symptoms, but these improvements were not associated with objective evidence of improved physical functioning, as tested with the 6-minute walk test.",Discussion,[192165],[28554],[28830],[False],[0],[0],[False],['0']
30876,PMC5410698,32091,It may be that the psycho-social support delivered during the frequent contacts with the disease management nurses is the main factor in these changes.,Discussion,[192169],[28831],[28982],[False],[0],[0],[False],['0']
30877,PMC5410698,32092,"Interestingly, the diagnosis of heart failure, taken from administrative health-care data, was not confirmed in 1,452 (27.4%) patients screened for eligibility in this study.",Discussion,[192173],[28983],[29157],[False],[0],[0],[False],['0']
30878,PMC5410698,32093,"This highlights the importance of reliance on explicit diagnostic criteria, including echocardiographic examination, for the diagnosis of heart failure.",Discussion,[192177],[29158],[29310],[False],[0],[0],[False],['0']
30879,PMC5410698,32094,"A recent systematic review showed a high variability of the positive predictive value of heart failure diagnosis based on administrative data, ranging between 12% and 100% [30].",Discussion,[192181],[29311],[29488],[False],[0],[0],[False],['0']
30880,PMC5410698,32095,Study limitations and strengths,Study limitations and strengths,[192185],[29489],[29521],[False],[0],[0],[False],['0']
30881,PMC5410698,32096,This study was powered to detect a 33% reduction in the hazard for hospital admission for heart failure caused by the disease management intervention.,Study limitations and strengths,[192189],[29522],[29672],[False],[0],[0],[False],['0']
30882,PMC5410698,32097,"Thus, it may be that the study sample did not provide enough statistical power to detect a smaller effect.",Study limitations and strengths,[192193],[29673],[29779],[True],['UnderpoweredStudy'],['did not provide enough statistical power'],[True],['UnderpoweredStudy']
30883,PMC5410698,32098,"In fact, the point estimates for the intervention effect on the total number of in-hospital days and hospital admissions due to heart failure show less than a 33% reduction, and point in this direction.",Study limitations and strengths,[192201],[29780],[29982],[False],[0],[0],[False],['0']
30884,PMC5410698,32099,"The patients assigned to usual care were evaluated by the cardiologists at the heart failure centers every 6 months during follow-up, thus some contamination of the control intervention may be possible.",Study limitations and strengths,[192206],[29983],[30185],[True],['Control'],['some contamination of the control intervention may be possible'],[True],['Control']
30885,PMC5410698,32100,"In addition, the follow-up assessments of the patients' NYHA classification and 6-minute walk test were performed by assessors who were not blinded to the patients' assigned intervention.",Study limitations and strengths,[192215],[30186],[30373],[True],['StudyTeam'],['assessors who were not blinded'],[True],['Blinding']
30886,PMC5410698,32101,"Nevertheless, there was no significant difference between the two study interventions in patients’ likelihood of experiencing a clinically important improvement in the 6-minute walk test during follow-up.",Study limitations and strengths,[192221],[30374],[30578],[False],[0],[0],[False],['0']
30887,PMC5410698,32102,"Thus, this measure may be less prone to biased assessments due to lack of blinding.",Study limitations and strengths,[192225],[30579],[30662],[False],[0],[0],[False],['0']
30888,PMC5410698,32103,Our study was carried-out in an environment with universal access to high-quality health care.,Study limitations and strengths,[192229],[30663],[30757],[False],[0],[0],[False],['0']
30889,PMC5410698,32104,"In other health-care systems with barriers to universal access, the study intervention might have proven more effective in reducing hospital re-admissions and deaths.",Study limitations and strengths,[192236],[30758],[30924],[True],['Generalization'],['In other health-care systems with barriers to universal access'],[True],['Generalization']
30890,PMC5410698,32105,"Nevertheless, this study included a large sample size with a long follow-up, had a relatively small attrition rate and complete ascertainment of the major study endpoints.",Study limitations and strengths,[192241],[30925],[31096],[False],[0],[0],[False],['0']
30891,PMC5410698,32106,The information derived from this study may apply to other countries with similar health-care systems.,Study limitations and strengths,[192245],[31097],[31199],[False],[0],[0],[False],['0']
30892,PMC5410698,32107,Conclusions,Conclusions,[192249],[31200],[31212],[False],[0],[0],[False],['0']
30893,PMC5410698,32108,"This comprehensive disease management program among ambulatory patients with chronic heart failure was not proven to be superior to usual care with respect to the primary study endpoint, but delayed the time until first hospital admission for heart failure and significantly improved patient-centered outcomes, i.e.",Conclusions,[192253],[31213],[31528],[False],[0],[0],[False],['0']
30894,PMC5410698,32109,health-related quality of life and depression.,Conclusions,[192257],[31529],[31575],[False],[0],[0],[False],['0']
30895,PMC5410698,32110,Further research is needed to assess the efficacy of alternative clinical service organization methods in improving the outcomes of ambulatory patients with chronic heart failure.,Conclusions,[192261],[31576],[31755],[False],[0],[0],[False],['0']
30896,PMC5410698,32111,Abbreviations,Abbreviations,[192265],[31756],[31770],[False],[0],[0],[False],['0']
30897,PMC5410698,32112,ACE-I angiotensin-converting enzyme inhibitor,Abbreviations|ACE-I angiotensin-converting enzyme inhibitor,[192269],[31771],[31816],[False],[0],[0],[False],['0']
30898,PMC5410698,32113,ARB Angiotensin receptor blocker,Abbreviations|ARB Angiotensin receptor blocker,[192273],[31817],[31849],[False],[0],[0],[False],['0']
30899,PMC5410698,32114,BNP Brain natriuretic peptide,Abbreviations|BNP Brain natriuretic peptide,[192277],[31850],[31879],[False],[0],[0],[False],['0']
30900,PMC5410698,32115,CHF Congestive heart failure,Abbreviations|CHF Congestive heart failure,[192281],[31880],[31908],[False],[0],[0],[False],['0']
30901,PMC5410698,32116,CI Confidence interval,Abbreviations|CI Confidence interval,[192285],[31909],[31931],[False],[0],[0],[False],['0']
30902,PMC5410698,32117,HR Hazard ratio,Abbreviations|HR Hazard ratio,[192289],[31932],[31947],[False],[0],[0],[False],['0']
30903,PMC5410698,32118,IQR Interquartile range,Abbreviations|IQR Interquartile range,[192293],[31948],[31971],[False],[0],[0],[False],['0']
30904,PMC5410698,32119,NYHA New York Heart Association,Abbreviations|NYHA New York Heart Association,[192297],[31972],[32003],[False],[0],[0],[False],['0']
30905,PMC5410698,32120,OR Odds ratio,Abbreviations|OR Odds ratio,[192301],[32004],[32017],[False],[0],[0],[False],['0']
30906,PMC5410698,32121,PHQ-9 Nine-item patient health depression scale,Abbreviations|OR Odds ratio,[192305],[32018],[32065],[False],[0],[0],[False],['0']
30907,PMC5410698,32122,RR Rate ratio,Abbreviations|RR Rate ratio,[192309],[32066],[32079],[False],[0],[0],[False],['0']
30908,PMC5410698,32123,s.d.,Abbreviations|s.d. Standard deviation,[192313],[32080],[32084],[False],[0],[0],[False],['0']
30909,PMC5410698,32124,Standard deviation,Abbreviations|s.d. Standard deviation,[192317],[32085],[32103],[False],[0],[0],[False],['0']
30910,PMC5410698,32125,SF-36 36-item short form questionnaireAcknowledgements,Abbreviations|s.d. Standard deviation,[192321],[32104],[32158],[False],[0],[0],[False],['0']
30911,PMC5410698,32126,"List of the Israeli Heart Failure Disease Management Study (IHF-DMS) investigators: Dan Admon, Miriam Amitai, Michael Arad, Elad Asher, Michal Benderly, Tali Cukierman-Yaffe, Yaakov Dvorkin, Laurence S Freedman, Dov Freimark, Nurit Friedman, Vered Gercenshtein, Dorit Goldman, Avishay Grupper, Ofra Kalter-Leibovici, Galit Kaufman, Robert Klempner, Lev Lerner, Doron M Menachemi, Havi Murad, Diab Mutlak, Yael Peled-Potashnik, Shmuel Rispler, Simcha Rosenblatt, Yaron Satanovsky, Mordechai Shani, Ronit Shohat-Zabarski, Haim Silber, Barbara G Silverman, Edgar Socher, Zvi Vered, Arnona Ziv, Donna R Zwas.",Abbreviations|s.d. Standard deviation,[192325],[32159],[32763],[False],[0],[0],[False],['0']
30912,PMC5410698,32127,Study committees: I.,Abbreviations|s.d. Standard deviation,[192329],[32764],[32784],[False],[0],[0],[False],['0']
30913,PMC5410698,32128,"Members of the Study Steering Committee: Miriam Amitai, Dorit Goldman, Dov Freimark, Nurit Friedman, Ofra Kalter-Leibovici, Galit Kaufman, Mordechai Shani, Naftali Shani, Haim Silber II.",Abbreviations|s.d. Standard deviation,[192333],[32785],[32971],[False],[0],[0],[False],['0']
30914,PMC5410698,32129,"Members of the Study Safety Committee: Laurence S Freedman, Jeremy D Kark, Shlomi Matetzky III.",Abbreviations|s.d. Standard deviation,[192337],[32972],[33067],[False],[0],[0],[False],['0']
30915,PMC5410698,32130,"Members of the Data Management Committee: Nurit Friedman, Barbara G Silverman, Arnona Ziv IV.",Abbreviations|s.d. Standard deviation,[192341],[33068],[33161],[False],[0],[0],[False],['0']
30916,PMC5410698,32131,"Members of the Endpoint Adjudication Committee: Elad Asher, Tali Cukierman-Yaffe, Dov Freimark, Avishay Grupper V. Members of the Data Analysis Committee: Michal Benderly, Laurence S Freedman, Ofra Kalter-Leibovici, Havi Murad, Liraz Olmer, Liat Wulffhart The authors wish to extend their profound gratitude to the study nurses in Maccabi Health Services, and to Mrs Naomi Mevorach and Mr Igor Frenzel for their invaluable contribution to the study conduction, data collection and management.",Abbreviations|s.d. Standard deviation,[192345],[33162],[33654],[False],[0],[0],[False],['0']
30917,PMC5410698,32132,Funding,Abbreviations|Funding,[192349],[33655],[33662],[False],[0],[0],[False],['0']
30918,PMC5410698,32133,"This study was funded by Maccabi Institute for Health Services Research, Tel-Aviv, Israel, and the Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA), Tel-Hashomer, Israel.",Abbreviations|Funding,[192353],[33663],[33886],[False],[0],[0],[False],['0']
30919,PMC5410698,32134,"The funders approved the study protocol but had no role in the study design, data analysis or manuscript preparation.",Abbreviations|Funding,[192357],[33887],[34004],[False],[0],[0],[False],['0']
30920,PMC5410698,32135,Availability of data and materials,Abbreviations|Availability of data and materials,[192361],[34005],[34039],[False],[0],[0],[False],['0']
30921,PMC5410698,32136,"Data are available from the Maccabi Healthcare Services, the Gertner Institute for Epidemiology & Health Policy Research, for researchers who meet the criteria for access to patients’ confidential data.",Abbreviations|Availability of data and materials,[192365],[34040],[34242],[False],[0],[0],[False],['0']
30922,PMC5410698,32137,Authors’ contributions,Abbreviations|Authors’ contributions,[192369],[34243],[34265],[False],[0],[0],[False],['0']
30923,PMC5410698,32138,"OKL, HS, DF and LSF conceived and designed the study.",Abbreviations|Authors’ contributions,[192373],[34266],[34319],[False],[0],[0],[False],['0']
30924,PMC5410698,32139,"GK, BGS, NF and AZ acquired the data.",Abbreviations|Authors’ contributions,[192377],[34320],[34357],[False],[0],[0],[False],['0']
30925,PMC5410698,32140,"LSF, HM, OKL, MB, DF, EA, AG and TCY interpreted and analysed the data.",Abbreviations|Authors’ contributions,[192381],[34358],[34429],[False],[0],[0],[False],['0']
30926,PMC5410698,32141,"OKL, GK, DF, HS, DG and MS handled the funding and supervision.",Abbreviations|Authors’ contributions,[192385],[34430],[34493],[False],[0],[0],[False],['0']
30927,PMC5410698,32142,OKL drafted the manuscript.,Abbreviations|Authors’ contributions,[192389],[34494],[34521],[False],[0],[0],[False],['0']
30928,PMC5410698,32143,"LSF, HM, MB, DF and HS critically reviewed the manuscript for important intellectual content.",Abbreviations|Authors’ contributions,[192393],[34522],[34615],[False],[0],[0],[False],['0']
30929,PMC5410698,32144,All authors approved the version submitted.,Abbreviations|Authors’ contributions,[192397],[34616],[34659],[False],[0],[0],[False],['0']
30930,PMC5410698,32145,Competing interests,Abbreviations|Competing interests,[192401],[34660],[34679],[False],[0],[0],[False],['0']
30931,PMC5410698,32146,"OKL, HS and LSF received research grants from the Maccabi Institute for Health Services Research for this study.",Abbreviations|Competing interests,[192405],[34680],[34792],[False],[0],[0],[False],['0']
30932,PMC5410698,32147,"MS is the director of the Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA), Tel-Hashomer, Israel.",Abbreviations|Competing interests,[192409],[34793],[34943],[False],[0],[0],[False],['0']
30933,PMC5410698,32148,Consent for publication,Abbreviations|Consent for publication ,[192413],[34944],[34967],[False],[0],[0],[False],['0']
30934,PMC5410698,32149,Not applicable.,Abbreviations|Not applicable.,[192417],[34968],[34984],[False],[0],[0],[False],['0']
30935,PMC5410698,32150,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[192421],[34985],[35027],[False],[0],[0],[False],['0']
30936,PMC5410698,32151,The study was approved by the Maccabi Health Services and the Sheba Medical Center research ethics committees.,Abbreviations|Ethics approval and consent to participate,[192425],[35028],[35138],[False],[0],[0],[False],['0']
30937,PMC5410698,32152,All patients signed a written informed consent form prior to randomization.,Abbreviations|Ethics approval and consent to participate,[192429],[35139],[35214],[False],[0],[0],[False],['0']
30938,PMC5410698,32153,Publisher’s Note,Abbreviations|Publisher’s Note,[192433],[35215],[35231],[False],[0],[0],[False],['0']
30939,PMC5410698,32154,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[192437],[35232],[35350],[False],[0],[0],[False],['0']
31957,PMC5472276,36083,Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial,Title,[211328],[30668],[155],[False],[0],[0],[False],['0']
31958,PMC5472276,36084,Background,Abstract,[211332],[156],[167],[False],[0],[0],[False],['0']
31959,PMC5472276,36085,"Systemic corticosteroids have anti-inflammatory effects, whereas macrolides also have immunomodulatory activity in addition to their primary antimicrobial actions.",Abstract,[211336],[168],[331],[False],[0],[0],[False],['0']
31960,PMC5472276,36086,"We aimed to evaluate the potential interaction effect between corticosteroids and macrolides on the systemic inflammatory response in patients with severe community-acquired pneumonia to determine if combining these two immunomodulating agents was harmful, or possibly beneficial.",Abstract,[211340],[332],[612],[False],[0],[0],[False],['0']
31961,PMC5472276,36087,Methods,Methods,[211344],[613],[621],[False],[0],[0],[False],['0']
31962,PMC5472276,36088,We performed a post-hoc exploratory analysis of a randomized clinical trial conducted in three tertiary hospitals in Spain.,Methods,[211348],[622],[745],[False],[0],[0],[False],['0']
31963,PMC5472276,36089,This trial included patients with severe community-acquired pneumonia with high inflammatory response (C-reactive protein [CRP] >15 mg/dL) who were randomized to receive methylprednisolone 0.5 mg/kg/tpd or placebo.,Methods,[211352],[746],[960],[False],[0],[0],[False],['0']
31964,PMC5472276,36090,The choice of antibiotic treatment was at the physician's discretion.,Methods,[211356],[961],[1030],[False],[0],[0],[False],['0']
31965,PMC5472276,36091,One hundred and six patients were classified into four groups according to antimicrobial therapy combination (β-lactam plus macrolide or β-lactam plus fluoroquinolone) and corticosteroid arm (placebo or corticosteroids).,Methods,[211360],[1031],[1251],[False],[0],[0],[False],['0']
31966,PMC5472276,36092,"The primary outcome was treatment failure (composite outcome of early treatment failure, or of late treatment failure, or of both early and late treatment failure).",Methods,[211364],[1252],[1416],[False],[0],[0],[False],['0']
31967,PMC5472276,36093,Results,Results,[211368],[1417],[1425],[False],[0],[0],[False],['0']
31968,PMC5472276,36094,"The methylprednisolone with β-lactam plus macrolide group had more elderly patients, with comorbidities, and higher pneumonia severity index (PSI) risk class V, but a lower proportion of intensive care unit admission, compared to the other groups.",Results,[211372],[1426],[1673],[False],[0],[0],[False],['0']
31969,PMC5472276,36095,"We found non differences in treatment failure between groups (overall p = 0.374); however, a significant difference in late treatment failure was observed (4 patients in the placebo with β-lactam plus macrolide group (31%) vs. 9 patients in the placebo with β-lactam plus fluoroquinolone group (24%) vs. 0 patients in the methylprednisolone with β-lactam plus macrolide group (0%) vs. 2 patients [5%] in the methylprednisolone with β-lactam plus fluoroquinolone group overall p = 0.009).",Results,[211376],[1674],[2161],[False],[0],[0],[False],['0']
31970,PMC5472276,36096,We found a significant difference for In-hospital mortality in the per protocol population (overall p = 0.01).,Results,[211380],[2162],[2272],[False],[0],[0],[False],['0']
31971,PMC5472276,36097,"We did not find significant differences in treatment failure, early or late; or In-hospital mortality after adjusting for severity (PSI), year and centre of enrolment.",Results,[211384],[2273],[2440],[False],[0],[0],[False],['0']
31972,PMC5472276,36098,Conclusions,Conclusions,[211388],[2441],[2453],[False],[0],[0],[False],['0']
31973,PMC5472276,36099,"In this exploratory analysis, we observed that the glucocorticosteroids and macrolides combination had no statistically significant association with main clinical outcomes compared with other combinations in patients with severe community acquired pneumonia and a high inflammatory response after taking account potential confounders.",Conclusions,[211392],[2454],[2788],[False],[0],[0],[False],['0']
31974,PMC5472276,36100,Trial registration,Trial registration,[211396],[2789],[2808],[False],[0],[0],[False],['0']
31975,PMC5472276,36101,Clinicaltrials.gov NCT00908713.,Trial registration,[211400],[2809],[2840],[False],[0],[0],[False],['0']
31976,PMC5472276,36102,Background,Background,[211404],[2841],[2853],[False],[0],[0],[False],['0']
31977,PMC5472276,36103,"Despite advances in antibiotic treatment, the mortality of hospitalized community-acquired pneumonia (CAP) patients is still high, especially in those with severe illness[1,2].",Background,[211408],[2854],[3030],[False],[0],[0],[False],['0']
31978,PMC5472276,36104,"In severe CAP, high levels of inflammatory cytokines can be harmful and cause pulmonary dysfunction associated with adverse outcomes[3,4].",Background,[211412],[3031],[3169],[False],[0],[0],[False],['0']
31979,PMC5472276,36105,"On the other hand, a reduced inflammatory reaction, as seen in immunosuppressed patients or elderly can be dangerous and lead to worse outcomes[5–7].",Background,[211416],[3170],[3319],[False],[0],[0],[False],['0']
31980,PMC5472276,36106,"Several treatments have been tested to control the dysregulated inflammatory response in CAP [8,9], however it is still not clear which therapies could best achieve these goals, leading to improved outcomes or which could worsen the condition.",Background,[211420],[3320],[3563],[False],[0],[0],[False],['0']
31981,PMC5472276,36107,The mortality of patients with severe CAP can be high regardless of whether they receive adequate and prompt antibiotic treatment.,Background,[211424],[3564],[3694],[False],[0],[0],[False],['0']
31982,PMC5472276,36108,"Macrolide combination therapy was associated with reduced mortality in retrospective analyses and in non-interventional studies, mainly in patients with severe pneumonia[10,11].",Background,[211428],[3695],[3872],[False],[0],[0],[False],['0']
31983,PMC5472276,36109,"The use of systemic corticosteroids in addition to the antibiotic treatment in CAP seems to have beneficial effects, mainly for severe CAP[12–16].",Background,[211432],[3873],[4019],[False],[0],[0],[False],['0']
31984,PMC5472276,36110,Systemic corticosteroids have anti-inflammatory effects and macrolides also have immunomodulatory activity in addition to their primary antimicrobial actions.,Background,[211436],[4020],[4178],[False],[0],[0],[False],['0']
31985,PMC5472276,36111,Macrolides are concentrated in phagocytic cells and dampen the inflammatory response by inhibiting the generation of proinflammatory cytokines[17].,Background,[211440],[4179],[4326],[False],[0],[0],[False],['0']
31986,PMC5472276,36112,"They have been used in low doses for long-term therapy in asthma[18], chronic obstructive pulmonary disease[19], cystic fibrosis[20] and bronchiectasis[21] because of these anti-inflammatory actions.",Background,[211444],[4327],[4526],[False],[0],[0],[False],['0']
31987,PMC5472276,36113,There is a gap in knowledge about whether the potential anti-inflammatory effect of corticosteroids could be potentiated by the administration of a macrolide.,Background,[211448],[4527],[4685],[False],[0],[0],[False],['0']
31988,PMC5472276,36114,"The combination of macrolide plus corticosteroids is currently used without a scientific evaluation, although we do not know whether this combination could decrease the inflammatory response to a very low level, increasing the risk of side effects.",Background,[211452],[4686],[4934],[False],[0],[0],[False],['0']
31989,PMC5472276,36115,"We hypothesized that when macrolides are used with adjunctive glucocorticosteroid treatment, there would be a better modulation of the inflammatory response without greater risk of side effects, than with either agent alone, which could, in turn, lead to a lower rate of treatment failure.",Background,[211456],[4935],[5224],[False],[0],[0],[False],['0']
31990,PMC5472276,36116,Methods,Methods,[211460],[5225],[5233],[False],[0],[0],[False],['0']
31991,PMC5472276,36117,"We conducted an exploratory post-hoc analysis of data from a multicentre, randomized, double-blind, placebo-controlled trial (Clinicaltrials.gov Identifier: NCT00908713) involving patients with both severe CAP and a high inflammatory response, defined by a level of C-reactive protein (CRP) >15 mg/dL on admission, as described in detail elsewhere[12].",Methods,[211464],[5234],[5586],[False],[0],[0],[False],['0']
31992,PMC5472276,36118,"We included 106 patients with severe CAP and a high inflammatory response, who received placebo or glucocorticosteroids and antibiotic therapy with a β-lactam plus macrolide or β-lactam plus fluoroquinolone.",Methods,[211468],[5587],[5794],[False],[0],[0],[False],['0']
31993,PMC5472276,36119,Fourteen patients who received antibiotic monotherapy were excluded from the analysis since this is not the recommended empiric antibiotic treatment for severe pneumonia.,Methods,[211472],[5795],[5965],[False],[0],[0],[False],['0']
31994,PMC5472276,36120,Patients with influenza infection were also excluded from the original trial.,Methods,[211476],[5966],[6043],[False],[0],[0],[False],['0']
31995,PMC5472276,36121,Patients were recruited from the Departments of Pneumology of three tertiary Spanish hospitals.,Methods,[211480],[6044],[6139],[False],[0],[0],[False],['0']
31996,PMC5472276,36122,The local ethic committee ¨Comité Ético de Investigación Clínica del Hospital Clinic de Barcelona¨ approved the study protocol and written informed consent was obtained from all participants or from their authorized representatives.,Methods,[211484],[6140],[6372],[False],[0],[0],[False],['0']
31997,PMC5472276,36123,Antimicrobial treatment,Antimicrobial treatment,[211488],[6373],[6397],[False],[0],[0],[False],['0']
31998,PMC5472276,36124,All patients were treated with antibiotics according to current international guidelines[22].,Antimicrobial treatment,[211492],[6398],[6491],[False],[0],[0],[False],['0']
31999,PMC5472276,36125,All patients in this analysis received a β-lactam plus a macrolide or a fluoroquinolone.,Antimicrobial treatment,[211496],[6492],[6580],[False],[0],[0],[False],['0']
32000,PMC5472276,36126,"Switch from intravenous to oral therapy and duration of the antibiotic treatment was entirely left to the discretion of the medical team, as was the decision to transfer patients to the intensive care unit or for hospital discharge.",Antimicrobial treatment,[211500],[6581],[6813],[False],[0],[0],[False],['0']
32001,PMC5472276,36127,Data collection,Data collection,[211504],[6814],[6830],[False],[0],[0],[False],['0']
32002,PMC5472276,36128,"The following data were collected on admission: age, gender, smoking history, clinical symptoms, physical examination and comorbidities.",Data collection,[211508],[6831],[6967],[False],[0],[0],[False],['0']
32003,PMC5472276,36129,The initial risk class was calculated using a pneumonia severity index (PSI) score[23] and severity criteria were assessed according to the ATS criteria modified by Ewig et al[24].,Data collection,[211512],[6968],[7148],[False],[0],[0],[False],['0']
32004,PMC5472276,36130,Patients were evaluated daily for treatment failure and time to clinical stability until discharge day [25].,Data collection,[211516],[7149],[7257],[False],[0],[0],[False],['0']
32005,PMC5472276,36131,Adverse events and mortality were recorded during the hospital stay.,Data collection,[211520],[7258],[7326],[False],[0],[0],[False],['0']
32006,PMC5472276,36132,Microbiologic examination methods are described elsewhere [12].,Data collection,[211524],[7327],[7390],[False],[0],[0],[False],['0']
32007,PMC5472276,36133,Biormarker measurements,Biormarker measurements,[211528],[7391],[7415],[False],[0],[0],[False],['0']
32008,PMC5472276,36134,"Samples for cytokine, procalcitonin and C-reactive protein (CRP) determinations were obtained on the first day and after 72h and 7 days of treatment, centrifuged and frozen at -80°C until analysis.",Biormarker measurements,[211532],[7416],[7613],[False],[0],[0],[False],['0']
32009,PMC5472276,36135,"Determination of interleukin (IL)- 6, IL-8 and IL-10 levels was performed using a commercial enzyme immunoassay technique (Biosource, Nivelles, Belgium).",Biormarker measurements,[211536],[7614],[7767],[False],[0],[0],[False],['0']
32010,PMC5472276,36136,"An immunoluminometric technique was used to measure procalcitonin (Liaison Brahms PCT; DiaSorin, Saluggia, Italy) with a detection limit of 0.3 ng/ml.",Biormarker measurements,[211540],[7768],[7918],[False],[0],[0],[False],['0']
32011,PMC5472276,36137,"CRP was measured with an immunoturbidimetric method using a commercially available test (Bayer Diagnostics, Leverkusen, Germany) with an Advia 2400.",Biormarker measurements,[211544],[7919],[8067],[False],[0],[0],[False],['0']
32012,PMC5472276,36138,Outcomes,Outcomes,[211548],[8068],[8077],[False],[0],[0],[False],['0']
32013,PMC5472276,36139,"The primary outcome was the rate of treatment failure, which includes treatment failure that occurred early, late, or at both times.",Outcomes,[211552],[8078],[8210],[False],[0],[0],[False],['0']
32014,PMC5472276,36140,"Secondary outcomes were the levels in inflammatory markers (IL-6, IL-8, IL-10, procalcitonin, and CRP) after 3 days of treatment, time to clinical stability, length of intensive care unit (ICU) and hospital stay, and in-hospital mortality.",Outcomes,[211556],[8211],[8450],[False],[0],[0],[False],['0']
32015,PMC5472276,36141,"Early treatment failure was defined as clinical deterioration within 72 hours of treatment (including development of shock, need for invasive mechanical ventilation not present at baseline, or death).",Outcomes,[211560],[8451],[8651],[False],[0],[0],[False],['0']
32016,PMC5472276,36142,"Late treatment failure was defined as radiographic progression, persistence of severe respiratory failure, development of shock, need for invasive mechanical ventilation not present at baseline, or death between 72 hours and 120 hours after treatment initiation.",Outcomes,[211564],[8652],[8914],[False],[0],[0],[False],['0']
32017,PMC5472276,36143,Statistical analysis,Statistical analysis,[211568],[8915],[8936],[False],[0],[0],[False],['0']
32018,PMC5472276,36144,Efficacy data were analyzed for both the intention-to-treat and the per-protocol populations.,Statistical analysis,[211572],[8937],[9030],[False],[0],[0],[False],['0']
32019,PMC5472276,36145,The intention-to-treat population included all randomized patients who received at least one dose of the study drug.,Statistical analysis,[211576],[9031],[9147],[False],[0],[0],[False],['0']
32020,PMC5472276,36146,"The per-protocol population included all randomized patients who met all inclusion criteria, received at least six doses of the study drug, and did not deviate substantially from the protocol.",Statistical analysis,[211580],[9148],[9340],[False],[0],[0],[False],['0']
32021,PMC5472276,36147,"We report the number and percentage of patients for categorical variables, the mean (standard deviation) and median (interquartile range) for continuous variables.",Statistical analysis,[211584],[9341],[9504],[False],[0],[0],[False],['0']
32022,PMC5472276,36148,Categorical variables were compared using the χ2 test or the Fisher exact test.,Statistical analysis,[211588],[9505],[9584],[False],[0],[0],[False],['0']
32023,PMC5472276,36149,Continuous variables were compared using nonparametric Kruskal-Wallis test.,Statistical analysis,[211592],[9585],[9660],[False],[0],[0],[False],['0']
32024,PMC5472276,36150,Pairwise comparisons were carried out via the Bonferroni method in order to control for the experiment-wise error rate.,Statistical analysis,[211596],[9661],[9780],[False],[0],[0],[False],['0']
32025,PMC5472276,36151,"We also performed logistic regression models to examine differences in the rate of treatment failure, early and late treatment failure and in-hospital mortality between groups, adjusting for the PSI risk class, year of recruitment, and centre.",Statistical analysis,[211600],[9781],[10024],[False],[0],[0],[False],['0']
32026,PMC5472276,36152,"Time to clinical stability and length of ICU and hospital stay in the groups were analyzed by means of Cox proportional hazards models, adjusting for the PSI risk class, year of recruitment, and centre.",Statistical analysis,[211604],[10025],[10227],[False],[0],[0],[False],['0']
32027,PMC5472276,36153,The odds ratio (OR) or hazard ratio (HR) and their 95% confidence intervals (CI) were estimated.,Statistical analysis,[211608],[10228],[10324],[False],[0],[0],[False],['0']
32028,PMC5472276,36154,"We fitted analysis of covariance (ANCOVA) models to analyze the inflammatory response at day 3, adjusting for the baseline inflammatory marker value, PSI risk class, year of recruitment, and centre.",Statistical analysis,[211612],[10325],[10523],[False],[0],[0],[False],['0']
32029,PMC5472276,36155,Inflammatory markers were log-transformed to fit the ANCOVA model.,Statistical analysis,[211616],[10524],[10590],[False],[0],[0],[False],['0']
32030,PMC5472276,36156,Each treatment effect was estimated by the least squares mean and its 95% CI.,Statistical analysis,[211620],[10591],[10668],[False],[0],[0],[False],['0']
32031,PMC5472276,36157,"We conducted a sensitivity analysis adjusting the previous multivariate models for age, ICU admission, year and centre of enrolment.",Statistical analysis,[211624],[10669],[10801],[False],[0],[0],[False],['0']
32032,PMC5472276,36158,"The quality of the logistic regression models and ANCOVA models were tested using the Hosmer-Lemeshow test and Akaike information criterion, respectively.",Statistical analysis,[211628],[10802],[10956],[False],[0],[0],[False],['0']
32033,PMC5472276,36159,All tests were 2-tailed and significance was set at 0.05.,Statistical analysis,[211632],[10957],[11014],[False],[0],[0],[False],['0']
32034,PMC5472276,36160,"All analyses were performed with IBM SPSS Statistics version 22.0 (Armonk, New York, USA).",Statistical analysis,[211636],[11015],[11105],[False],[0],[0],[False],['0']
32035,PMC5472276,36161,Results,Results,[211640],[11106],[11114],[False],[0],[0],[False],['0']
32036,PMC5472276,36162,"Of the 106 patients, 28 received combination therapy consisting of a β-lactam plus macrolide (13 [12%] in the placebo group and 15 [14%] in the methylprednisolone group) and 78 received the combination of a β-lactam plus fluoroquinolone (37 [35%] in the placebo group and 41 [39%] in the methylprednisolone group) ¨Fig 1¨.",Results,[211644],[11115],[11437],[False],[0],[0],[False],['0']
32037,PMC5472276,36163,The baseline characteristics are presented in Table 1.,Results,[211648],[11438],[11492],[False],[0],[0],[False],['0']
32038,PMC5472276,36164,"The methylprednisolone with β-lactam plus macrolide group had more elderly patients, with comorbidities, and higher PSI risk class V, but a lower proportion of ICU admission, compared to the other groups.",Results,[211652],[11493],[11697],[False],[0],[0],[False],['0']
32039,PMC5472276,36165,The rate of etiologic diagnosis was higher in the methylprednisolone with β-lactam plus fluoroquinolone group.,Results,[211656],[11698],[11808],[False],[0],[0],[False],['0']
32040,PMC5472276,36166,Streptococcus pneumoniae was the most common etiologic agent in the four groups (Table 2).,Results,[211660],[11809],[11899],[False],[0],[0],[False],['0']
32041,PMC5472276,36167,"Distribution of the pathogens did not differ among groups, except for polymicrobial infection (24% in the methylprednisolone with β-lactam plus fluoroquinolone group vs. 0% in the methylprednisone with β-lactam plus macrolide group [p = 0.018]).",Results,[211664],[11900],[12145],[False],[0],[0],[False],['0']
32042,PMC5472276,36168,"The most common antimicrobial treatment used was ceftriaxone plus levofloxacin in 33 [31%] patients in the group of placebo and 37 [34%] in the methylprednisolone group), ceftriaxone plus azithromycin was used in 11 (10%) patients of placebo group and 13 (12%) patients in the methylprednisolone group.",Results,[211668],[12146],[12448],[False],[0],[0],[False],['0']
32043,PMC5472276,36169,"More data about antimicrobial treatment, duration and time to the first dose are described elsewhere[12].",Results,[211672],[12449],[12554],[False],[0],[0],[False],['0']
32044,PMC5472276,36170,"Treatment failure did not differ among the four groups (Table 3), nor did early treatment failure.",Results,[211676],[12555],[12653],[False],[0],[0],[False],['0']
32045,PMC5472276,36171,"However, late treatment failure did differ among the four groups (4 patients in the placebo with β-lactam plus macrolide group (31%) vs. 9 patients in the placebo with β-lactam plus fluoroquinolone group (24%) vs. 0 patients in the methylprednisolone with β-lactam plus macrolide group (0%) vs. 2 patients [5%] in the methylprednisolone with β-lactam plus fluoroquinolone group, overall crude comparison: p = 0.009).",Results,[211680],[12654],[13070],[False],[0],[0],[False],['0']
32046,PMC5472276,36172,Similar results were obtained in the per-protocol population.,Results,[211684],[13071],[13132],[False],[0],[0],[False],['0']
32047,PMC5472276,36173,"Despite no statistically significant differences between groups were observed for in-hospital mortality in the intention-to-treat population, these differences were statistically significant in the per-protocol population (3 patients in the placebo with β-lactam plus macrolide group [23%] vs. 1 patients in the placebo with β-lactam plus fluoroquinolone group [3%] vs. 2 patients in the methylprednisolone with β-lactam plus macrolide group [14%] vs. 0 patients in the methylprednisolone with β-lactam plus fluoroquinolone group [0%], overall crude comparison p = 0.010).",Results,[211688],[13133],[13705],[False],[0],[0],[False],['0']
32048,PMC5472276,36174,"We did not find significant differences in treatment failure, early or late; or In-hospital mortality after adjusting for severity (PSI), year and centre of enrolmentin either the intention-to-treat population (Table 4) or the per-protocol population.",Results,[211692],[13706],[13957],[False],[0],[0],[False],['0']
32049,PMC5472276,36175,"Results of statistical analyses of the inflammatory response at day 3, adjusting for the baseline inflammatory marker value, PSI risk class, year of recruitment, and centre of enrolment based on the ANCOVA models showed a significant effect of corticosteroids for IL-6, procalcitonin, and IL-8 (p<0.001, p = 0.016 and p = 0.028, respectively) (Table 5).",Results,[211696],[13958],[14311],[False],[0],[0],[False],['0']
32050,PMC5472276,36176,"For the interaction between glucocorticosteroids and antibiotics for procalcitonin a trend towards statistical significance was observed, mainly driven by lower values in the methylprednisolone with β-lactam plus macrolide group after adjustments for potential confounders.",Results,[211700],[14312],[14585],[False],[0],[0],[False],['0']
32051,PMC5472276,36177,"For IL-8, we observed lower values in the methylprednisolone with β-lactam plus macrolide group, although the interaction was not significant.",Results,[211704],[14586],[14728],[False],[0],[0],[False],['0']
32052,PMC5472276,36178,Similar results were obtained in the per-protocol population.,Results,[211708],[14729],[14790],[False],[0],[0],[False],['0']
32053,PMC5472276,36179,"Analyses of primary and secondary outcomes, adjusting for age and ICU admission, showed no significance differences between groups (Tables B and C in S1 Supplementary file).",Results,[211712],[14791],[14964],[False],[0],[0],[False],['0']
32054,PMC5472276,36180,The results of the methods for assessing the quality of the models are shown in Table D in S1 Supplementary file.,Results,[211716],[14965],[15078],[False],[0],[0],[False],['0']
32055,PMC5472276,36181,"Comparing only patients who received methylprednisolone with a β-lactam plus macrolide with the overall population, we did not observe significant differences (Tables E and F in S1 Supplementary file).",Results,[211720],[15079],[15280],[False],[0],[0],[False],['0']
32056,PMC5472276,36182,Discussion,Discussion,[211724],[15281],[15292],[False],[0],[0],[False],['0']
32057,PMC5472276,36183,"In this post-hoc exploratory analysis, we observed that patients who received glucocorticosteroids combined with macrolides did not have worse outcomes than those patients who received other combinations.",Discussion,[211728],[15293],[15497],[False],[0],[0],[False],['0']
32058,PMC5472276,36184,"Thus it does not appear to be unsafe to combine a macrolide with glucocorticosteroids when treating CAP, even though both have immune modulating effects.",Discussion,[211732],[15498],[15651],[False],[0],[0],[False],['0']
32059,PMC5472276,36185,"Furthermore, we observed a lower rate of late treatment failure and a trend of interaction for improved trend in biomarker findings, when using both glucocorticosteroids and macrolides, as reflected by procalcitonin at day 3.",Discussion,[211736],[15652],[15877],[False],[0],[0],[False],['0']
32060,PMC5472276,36186,"Severe pneumonia patients have shown increased serum levels of IL-6, IL-8 and IL-10, and the excess of IL-6 and IL-10 are associated with an increase in mortality from 4.8% to 11.4%[26].",Discussion,[211740],[15878],[16064],[False],[0],[0],[False],['0']
32061,PMC5472276,36187,Corticosteroids and macrolides share some anti-inflammatory effects regulating cytokine release[27].,Discussion,[211744],[16065],[16165],[False],[0],[0],[False],['0']
32062,PMC5472276,36188,"As regards macrolides, this effect has been observed in in vitro and in vivo studies.",Discussion,[211748],[16166],[16251],[False],[0],[0],[False],['0']
32063,PMC5472276,36189,"In addition, macrolides have effects on structural cells of the respiratory tract such as endothelial and epithelial cells.",Discussion,[211752],[16252],[16375],[False],[0],[0],[False],['0']
32064,PMC5472276,36190,In animal studies macrolides show a reduction of histological inflammatory signs[28].,Discussion,[211756],[16376],[16461],[False],[0],[0],[False],['0']
32065,PMC5472276,36191,These studies have been performed predominantly with Streptococcus pneumoniae or Mycoplasma pneumoniae models of pneumonia.,Discussion,[211760],[16462],[16585],[False],[0],[0],[False],['0']
32066,PMC5472276,36192,"In an in-vitro study, the macrolides showed an improvement in sensitive corticosteroids and higher inhibition in IL-8 levels[29].",Discussion,[211764],[16586],[16715],[False],[0],[0],[False],['0']
32067,PMC5472276,36193,"In a recent human study, treatment with corticosteroids and macrolides reduced the level of inflammatory biomarkers such as IL-6 and IL-8 in bronchoalveolar lavage of patients with non-responding pneumonia[30], also in a recent post-hoc analysis of STEP study the patients who receiving corticosteroids plus macrolides presented lower re-hospitalisation than those received β-lactam monotherapy[31].",Discussion,[211768],[16716],[17115],[False],[0],[0],[False],['0']
32068,PMC5472276,36194,"Macrolides and corticosteroids act on different targets[32], and their combination could potentiate their immunomodulatory effects.",Discussion,[211772],[17116],[17247],[False],[0],[0],[False],['0']
32069,PMC5472276,36195,"Interestingly, quinolones have also been associated with immunomodulatory effects during in vitro experiments, ex-vivo investigations, in vivo pre-clinical models and in the clinical setting[33,34].",Discussion,[211776],[17248],[17446],[False],[0],[0],[False],['0']
32070,PMC5472276,36196,"Treatment failure is common in patients with severe pneumonia, reaching rates of 35% in high-risk patients (PSI class V)[35,36].",Discussion,[211780],[17447],[17575],[False],[0],[0],[False],['0']
32071,PMC5472276,36197,"This rate was reduced with corticosteroid treatment to 13% in the original trial[12] and, in this post-hoc analysis, we found an even lower rate in patients receiving antibiotic treatment with a macrolide and a ß-lactam, along with the glucocorticosteroids, where late treatment failure was reduced to 0%.",Discussion,[211784],[17576],[17881],[False],[0],[0],[False],['0']
32072,PMC5472276,36198,"However, because we had few events, we were unpowered to observe a potential statistically significant interaction between glucocorticosteroid and antibiotic groups.",Discussion,[211788],[17882],[18047],[True],['UnderpoweredStudy'],['we were unpowered to observe a potential statistically significant interaction between glucocorticosteroid and antibiotic groups'],[True],['UnderpoweredStudy']
32073,PMC5472276,36199,"Our study included a specific population of patients with community-acquired pneumonia with high inflammatory response measured by high CRP levels at randomization, and all patients received β-lactam antibiotic treatment.",Discussion,[211796],[18048],[18269],[False],[0],[0],[False],['0']
32074,PMC5472276,36200,"These criteria allowed us to analyse the target effect of macrolides and glucocorticosteroids, taking account that different cytokine profiles were described accordingly to pneumonia aetiology, severity and due to the bactericidal properties of antimicrobial treatments[26].",Discussion,[211800],[18270],[18544],[False],[0],[0],[False],['0']
32075,PMC5472276,36201,"There are more than one definition for treatment failure for community-acquired pneumonia, and we choose the definition developed in the Neumofail study, which has shown relationship with mortality[36].",Discussion,[211804],[18545],[18747],[False],[0],[0],[False],['0']
32076,PMC5472276,36202,Our study has limitations that must be acknowledged.,Discussion,[211808],[18748],[18800],[False],[0],[0],[False],['0']
32077,PMC5472276,36203,"First, the antibiotic choice was not randomized, resulting in heterogeneous groups with differences in baseline characteristics including severity and admission to ICU.",Discussion,[211813],[18801],[18969],[True],['PoorRandomizationMethods'],['the antibiotic choice was not randomized'],[True],['Randomization']
32078,PMC5472276,36204,It would appear that attending physicians treat elderly patients with comorbidities with macrolides and patients admitted to ICU with fluoroquinolones.,Discussion,[211820],[18970],[19121],[False],[0],[0],[False],['0']
32079,PMC5472276,36205,"We tried to overcome this limitation by adjusting for PSI score, which accounts for age, comorbidities and severity.",Discussion,[211824],[19122],[19238],[False],[0],[0],[False],['0']
32080,PMC5472276,36206,"Second, the number of patients who received macrolides was small, hindering the possibility of a fully-adjusted analysis for proper comparison with patients who received fluoroquinolones and their interaction with glucocorticosteroids.",Discussion,[211830],[19239],[19474],[True],['SampleSize'],['the number of patients who received macrolides was small'],[True],['UnderpoweredStudy']
32081,PMC5472276,36207,"Third, we did not measure baseline cortisol, which may be an important marker for measuring the effects of glucocorticosteroids.",Discussion,[211839],[19475],[19603],[True],['RelevantOutcomeExcluded'],['we did not measure baseline cortisol'],[True],['OutcomeMeasures']
32082,PMC5472276,36208,In conclusion the glucocorticosteroids and macrolides combination had no statistically significant association with main clinical outcomes compared with other combinations in patients with severe community acquired pneumonia and a high inflammatory response after taking account potential confounders.,Discussion,[211844],[19604],[19905],[False],[0],[0],[False],['0']
32083,PMC5472276,36209,We believe this report could be a hypothesis generator to further RCTs combining glucocorticosteroids with macrolides or fluoroquinolones.,Discussion,[211848],[19906],[20044],[False],[0],[0],[False],['0']
32263,PMC5483256,22678,Effect of exercising at minimum recommendations of the multiple sclerosis exercise guideline combined with structured education or attention control education – secondary results of the step it up randomised controlled trial,Title,[133697],[24303],[224],[False],[0],[0],[False],['0']
32264,PMC5483256,22679,Background,Abstract,[133702],[225],[236],[False],[0],[0],[False],['0']
32265,PMC5483256,22680,Recent exercise guidelines for people with multiple sclerosis (MS) recommend a minimum of 30 min moderate intensity aerobic exercise and resistance exercise twice per week.,Abstract,[133707],[237],[409],[False],[0],[0],[False],['0']
32266,PMC5483256,22681,This trial compared the secondary outcomes of a combined 10-week guideline based intervention and a Social Cognitive Theory (SCT) education programme with the same exercise intervention involving an attention control education.,Abstract,[133712],[410],[637],[False],[0],[0],[False],['0']
32267,PMC5483256,22682,Methods,Abstract,[133717],[638],[645],[False],[0],[0],[False],['0']
32268,PMC5483256,22683,"Physically inactive people with MS, scoring 0–3 on Patient Determined Disease Steps Scale, with no MS relapse or change in MS medication, were randomised to 10-week exercise plus SCT education or exercise plus attention control education conditions.",Abstract,[133722],[646],[895],[False],[0],[0],[False],['0']
32269,PMC5483256,22684,"Outcomes included fatigue, depression, anxiety, strength, physical activity, SCT constructs and impact of MS and were measured by a blinded assessor pre and post-intervention and 3 and 6 month follow up.",Abstract,[133727],[896],[1099],[False],[0],[0],[False],['0']
32270,PMC5483256,22685,Results,Abstract,[133732],[1100],[1107],[False],[0],[0],[False],['0']
32271,PMC5483256,22686,"One hundred and seventy-four expressed interest, 92 were eligible and 65 enrolled.",Abstract,[133737],[1108],[1190],[False],[0],[0],[False],['0']
32272,PMC5483256,22687,"Using linear mixed effects models, the differences between groups on all secondary measures post-intervention and at follow-up were not significant.",Abstract,[133742],[1191],[1339],[False],[0],[0],[False],['0']
32273,PMC5483256,22688,"Post-hoc, exploratory, within group analysis identified improvements in both groups post intervention in fatigue (mean ∆(95% CI) SCT -4.99(−9.87, −0.21), p = 0.04, Control −7.68(−12.13, −3.23), p = 0.00), strength (SCT -1.51(−2.41, −0.60), p < 0.01, Control −1.55(−2.30, −0.79), p < 0.01), physical activity (SCT 9.85(5.45, 14.23), p < 0.01, Control 12.92(4.69, 20.89), goal setting (SCT 7.30(4.19, 10.4), p < 0.01, Control 5.96(2.92, 9.01), p < 0.01) and exercise planning (SCT 5.88(3.37, 8.39), p < 0.01, Control 3.76(1.27, 6.25), p < 0.01) that were maintained above baseline at 3 and 6 month follow up (all p < 0.05).",Abstract,[133747],[1340],[1961],[False],[0],[0],[False],['0']
32274,PMC5483256,22689,"Only the SCT group improved at 3 and 6 month follow up in physical impact of MS(−4.45(−8.68, −0.22), −4.12(−8.25, 0.01), anxiety(−1.76(−3.20, −0.31), −1.99(−3.28, −0.71), depression(−1.51(−2.89, −0.13), −1.02(−2.05, 0.01)) and cognition(5.04(2.51, 7.57), 3.05(0.81, 5.28), with a medium effect for cognition and fitness (Hedges’ g 0.75(0.24, 1.25), 0.51(0.01, 1.00) at 3 month follow up.",Abstract,[133752],[1962],[2349],[False],[0],[0],[False],['0']
32275,PMC5483256,22690,Conclusions,Abstract,[133757],[2350],[2361],[False],[0],[0],[False],['0']
32276,PMC5483256,22691,"There were no statistically significant differences between groups for the secondary outcomes once age, gender, time since diagnosis and type of MS were accounted for.",Abstract,[133762],[2362],[2529],[False],[0],[0],[False],['0']
32277,PMC5483256,22692,"However, within the SCT group only there were improvements in anxiety, depression, cognition and physical impact of MS.",Abstract,[133767],[2530],[2649],[False],[0],[0],[False],['0']
32278,PMC5483256,22693,"Exercising at the minimum guideline amount has a positive effect on fatigue, strength and PA that is sustained at 3 and 6 months following the cessation of the program.",Abstract,[133772],[2650],[2818],[False],[0],[0],[False],['0']
32279,PMC5483256,22694,Trial registration,Abstract,[133777],[2819],[2837],[False],[0],[0],[False],['0']
32280,PMC5483256,22695,"ClinicalTrials.gov, NCT02301442, retrospectively registered on November 13th 2014.",Abstract,[133782],[2838],[2920],[False],[0],[0],[False],['0']
32281,PMC5483256,22696,Background,Background,[133787],[2921],[2932],[False],[0],[0],[False],['0']
32282,PMC5483256,22697,Multiple sclerosis (MS) is a chronic and often progressive condition affecting the central nervous system.,Background,[133792],[2933],[3039],[False],[0],[0],[False],['0']
32283,PMC5483256,22698,"MS has many consequences, including impaired strength, fitness, mood, fatigue and cognition, along with limitations of activities such as walking that impact on quality of life.",Background,[133797],[3040],[3217],[False],[0],[0],[False],['0']
32284,PMC5483256,22699,"Available evidence supports the beneficial effects of exercise on fatigue [1, 2], depression [3] fitness [4], walking mobility [5, 6], in addition to quality of life [7].",Background,[133802],[3218],[3388],[False],[0],[0],[False],['0']
32285,PMC5483256,22700,"Indeed, this evidence has led to the development of the MS Exercise guideline [8, 9] which recommends moderate intensity aerobic exercise for 30 min and resistance training involving major muscle groups twice weekly.",Background,[133807],[3389],[3605],[False],[0],[0],[False],['0']
32286,PMC5483256,22701,"We are not aware of a single trial that has actually documented the benefits of the exercise guidelines in MS. Of further concern, there are few studies in the MS exercise literature that have evaluated the long-term benefits of exercise interventions, and the results are mixed.",Background,[133812],[3606],[3885],[False],[0],[0],[False],['0']
32287,PMC5483256,22702,"For example, we reported positive improvements from a combined aerobic and resistance exercise programme in the community [10]; however, the improvements generally were not maintained 12 weeks post-intervention [11], suggesting that additional measures are required to enable sustained increases in physical activity behaviour among PwMS.",Background,[133817],[3886],[4224],[False],[0],[0],[False],['0']
32288,PMC5483256,22703,This need to foster long-term exercise participation is not unique to PwMS and authors have highlighted the need to include theory-based behaviour change interventions [12].,Background,[133822],[4225],[4398],[False],[0],[0],[False],['0']
32289,PMC5483256,22704,"Social cognitive theory has been extensively investigated among PwMS, and exercise self-efficacy and goal setting are consistently associated with [13] and predictive of [14] physical activity behaviour.",Background,[133827],[4399],[4602],[False],[0],[0],[False],['0']
32290,PMC5483256,22705,Indeed a recent meta-analysis demonstrated significant associations of these constructs and outcome expectancies with physical activity [15].,Background,[133832],[4603],[4744],[False],[0],[0],[False],['0']
32291,PMC5483256,22706,"We have conducted a series of clinical trials (i.e., Phase I and II) with relatively small samples for examining the efficacy of an Internet-delivered behavioural intervention based on social cognitive theory (SCT) for increasing physical activity among ambulatory persons with MS [16–19].",Background,[133837],[4745],[5034],[False],[0],[0],[False],['0']
32292,PMC5483256,22707,"Our most recent trial included the website and one-one-one video coaching and demonstrated moderate to large improvements in minutes/day of moderate/vigorous physical activity, endurance walking performance, information processing speed, symptoms of fatigue, depression, anxiety, and pain, and quality of life (QOL) over a six-month period [20].",Background,[133842],[5035],[5380],[False],[0],[0],[False],['0']
32293,PMC5483256,22708,"Collectively, such data support the efficacy of the behavioural intervention for increasing and sustaining physical activity in PwMS and possibly improving walking, cognition  symptoms, and QOL outcomes.",Background,[133847],[5381],[5584],[False],[0],[0],[False],['0']
32294,PMC5483256,22709,The Step it Up study [21] combined the collective knowledge and expertise gained from the Irish community exercise programme with the U.S. online intervention.,Background,[133852],[5585],[5744],[False],[0],[0],[False],['0']
32295,PMC5483256,22710,The 10-week programme firstly aimed to enable inactive PwMS to reach the recently published aerobic and resistance exercise guidelines.,Background,[133857],[5745],[5880],[False],[0],[0],[False],['0']
32296,PMC5483256,22711,We further investigated how embedding this exercise programme in a structured SCT-based education intervention compared to an attention-control education intervention.,Background,[133862],[5881],[6048],[False],[0],[0],[False],['0']
32297,PMC5483256,22712,"The current paper reports the results for the secondary outcomes of MS symptoms, physical activity, and SCT constructs.",Background,[133867],[6049],[6168],[False],[0],[0],[False],['0']
32298,PMC5483256,22713,"The primary outcome and feasibility metrics, presented elsewhere (Hayes et al.",Background,[133872],[6169],[6247],[False],[0],[0],[False],['0']
32299,PMC5483256,22714,"in press) demonstrated that both groups improved significantly in the primary outcome, the six minute walk test (6MWT), and this improvement was maintained at 6 month follow-up.",Background,[133877],[6248],[6425],[False],[0],[0],[False],['0']
32300,PMC5483256,22715,An exploratory analysis of those with three of four assessments demonstrated that the SCT group had a ~ 40 m greater improvement in 6MWT than the control group post-intervention and at 6-month follow up (p = 0.04 for both).,Background,[133882],[6426],[6649],[False],[0],[0],[False],['0']
32301,PMC5483256,22716,Methods,Methods,[133887],[6650],[6658],[False],[0],[0],[False],['0']
32302,PMC5483256,22717,Design,Methods|Design,[133892],[6659],[6665],[False],[0],[0],[False],['0']
32303,PMC5483256,22718,"This was a multicentre, double blind, randomised controlled trial (RCT).",Methods|Design,[133897],[6666],[6738],[False],[0],[0],[False],['0']
32304,PMC5483256,22719,Setting and participants,Methods|Setting and participants,[133902],[6739],[6763],[False],[0],[0],[False],['0']
32305,PMC5483256,22720,"Participants were recruited through the MS Society of Ireland, and via neurology clinics in three urban locations in the Republic of Ireland.",Methods|Setting and participants,[133907],[6764],[6905],[False],[0],[0],[False],['0']
32306,PMC5483256,22721,Details of the recruitment process are further detailed in the protocol paper [21].,Methods|Setting and participants,[133912],[6906],[6989],[False],[0],[0],[False],['0']
32307,PMC5483256,22722,"Inclusion criteria were: (1) physician-confirmed formal diagnosis of MS, (2) aged 18 years or more, (3) Patient Determined Disease Steps (PDDS) scale score of 0–3, (4) a sedentary lifestyle (<30 min of moderate to strenuous exercise one day or more per week over the last six months) and (5) willing to give written informed consent.",Methods|Setting and participants,[133917],[6990],[7323],[False],[0],[0],[False],['0']
32308,PMC5483256,22723,"Exclusion criteria were: (1) pregnancy, (2) MS relapse in the previous 12 weeks and (3) changes to MS medication or steroid treatment in the previous 12 weeks.",Methods|Setting and participants,[133922],[7324],[7483],[False],[0],[0],[False],['0']
32309,PMC5483256,22724,"Participants were sent the consent form in advance of the baseline assessment, and written consent was obtained in person by a blinded assessor.",Methods|Setting and participants,[133927],[7484],[7628],[False],[0],[0],[False],['0']
32310,PMC5483256,22725,Randomisation and blinding,Methods|Randomisation and blinding,[133932],[7629],[7655],[False],[0],[0],[False],['0']
32311,PMC5483256,22726,Participants were randomly allocated into the exercise plus SCT-based intervention or the exercise plus attention control education intervention.,Methods|Randomisation and blinding,[133937],[7656],[7801],[False],[0],[0],[False],['0']
32312,PMC5483256,22727,Random allocation procedures have been previously outlined [21] and were adhered to.,Methods|Randomisation and blinding,[133942],[7802],[7886],[False],[0],[0],[False],['0']
32313,PMC5483256,22728,"JN generated the random allocation sequence, SH enrolled participants, and SC assigned participants to interventions.",Methods|Randomisation and blinding,[133947],[7887],[8004],[False],[0],[0],[False],['0']
32314,PMC5483256,22729,"The outcome assessor (SH) was blind to allocation throughout the study as were the statisticians (CS, JN).",Methods|Randomisation and blinding,[133952],[8005],[8111],[False],[0],[0],[False],['0']
32315,PMC5483256,22730,"All participants were informed that the study aimed to examine the effect of combining exercise and education, and therefore were blinded regarding group allocation.",Methods|Randomisation and blinding,[133957],[8112],[8277],[False],[0],[0],[False],['0']
32316,PMC5483256,22731,Screening questionnaire,Methods|Screening questionnaire,[133962],[8278],[8301],[False],[0],[0],[False],['0']
32317,PMC5483256,22732,"Potential participants were screened for eligibility for this study using a questionnaire that included the Patient Determined Disease Steps (PDDS) scale [22], confirmation from participant of MS diagnosis and questions regarding PA levels that have been detailed elsewhere [21].",Methods|Screening questionnaire,[133967],[8302],[8581],[False],[0],[0],[False],['0']
32318,PMC5483256,22733,Outcomes,Methods|Outcomes,[133972],[8582],[8590],[False],[0],[0],[False],['0']
32319,PMC5483256,22734,Outcome measures were conducted pre-intervention post-intervention and at 3 and 6 month follow-up.,Methods|Outcomes,[133977],[8591],[8689],[False],[0],[0],[False],['0']
32320,PMC5483256,22735,"At baseline, participants provided demographic details and a researcher formally trained in the use of the Expanded Disability Status Scale (EDSS [23]) (SH) administered the EDSS to all participants at baseline.",Methods|Outcomes,[133982],[8690],[8901],[False],[0],[0],[False],['0']
32321,PMC5483256,22736,MS diagnosis according to the McDonald or Poser criteria was confirmed in writing from the participant’s consultant neurologist.,Methods|Outcomes,[133987],[8902],[9030],[False],[0],[0],[False],['0']
32322,PMC5483256,22737,The SenseWear Arm band (SWA) provided an objective estimate of PA [24] using both mean daily step count and mean daily energy expenditure estimates over a 7-day period.,Methods|Outcomes,[133992],[9031],[9199],[False],[0],[0],[False],['0']
32323,PMC5483256,22738,"The 5 times sit to stand test (5xSTS) [25], the Modified Canadian Aerobic Fitness Test (mCAFT) [26] and the Godin Health Index of the Godin Leisure-Time Exercise Questionnaire (GLTEQ) [27] measured lower extremity muscle strength, aerobic capacity and PA behaviour, respectively.",Methods|Outcomes,[133997],[9200],[9479],[False],[0],[0],[False],['0']
32324,PMC5483256,22739,"The Hospital Anxiety and Depression Scale (HADS) [28], Symbol Digit Modalities Test (SDMT) [29], Multiple Sclerosis Impact Scale 29 (MSIS-29) [30], and Modified Fatigue Impact Scale (MFIS) [31] measured depression, anxiety, cognitive processing speed, impact of MS and fatigue, respectively.",Methods|Outcomes,[134002],[9480],[9771],[False],[0],[0],[False],['0']
32325,PMC5483256,22740,Five questionnaires were implemented to measure SCT domains.,Methods|Outcomes,[134007],[9772],[9832],[False],[0],[0],[False],['0']
32326,PMC5483256,22741,"These included the Exercise Self-Efficacy Scale (EXSE) [32], Exercise Goal Setting (EGS) scale [33], Multidimensional Outcomes Expectations for Exercise Scale (MOEES) [34], Social Provisions Scale (SPS) [35], and Exercise Benefits and Barriers questionnaire [36].",Methods|Outcomes,[134012],[9833],[10096],[False],[0],[0],[False],['0']
32327,PMC5483256,22742,These measures and associated psychometric properties have been described in the trial protocol [21].,Methods|Outcomes,[134017],[10097],[10198],[False],[0],[0],[False],['0']
32328,PMC5483256,22743,Interventions,Methods|Interventions,[134022],[10199],[10212],[False],[0],[0],[False],['0']
32329,PMC5483256,22744,The exercise intervention was common to both groups and was delivered by physiotherapists.,Methods|Interventions,[134027],[10213],[10303],[False],[0],[0],[False],['0']
32330,PMC5483256,22745,"The aim of the exercise component was to progressively increase the intensity of both aerobic and strengthening exercise to enable the participants to reach the published exercise guidelines for people with mild-to-moderate MS [37], and has been previously described in detail [21].",Methods|Interventions,[134032],[10304],[10586],[False],[0],[0],[False],['0']
32331,PMC5483256,22746,"Over the 10-week programme participants attended the group exercise class on six occasions, supplemented with a telephone coaching call in the weeks without classes (intervention weeks 4, 6, 7 and 9).",Methods|Interventions,[134037],[10587],[10787],[False],[0],[0],[False],['0']
32332,PMC5483256,22747,"After each of the group exercise classes the attention control group received an education session about topics unrelated to PA behaviour, e.g.",Methods|Interventions,[134042],[10788],[10931],[False],[0],[0],[False],['0']
32333,PMC5483256,22748,"diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.",Methods|Interventions,[134047],[10932],[11018],[False],[0],[0],[False],['0']
32334,PMC5483256,22749,"The exercise plus SCT-based intervention group received a similar duration of education based on the principles of SCT for health behaviour change, namely: self-efficacy, outcome expectations, goal-setting, barriers and benefits and has been previously described [21].",Methods|Interventions,[134052],[11019],[11287],[False],[0],[0],[False],['0']
32335,PMC5483256,22750,Analysis,Methods|Analysis,[134057],[11288],[11296],[False],[0],[0],[False],['0']
32336,PMC5483256,22751,"The study was powered for the primary outcome, 6MWT and consistent with data from a large international study [38], it was assumed that the effect of the intervention would yield an average improvement in 6MWT distance of 36 m with an estimated standard deviation of 48.2 m. In order to have 80% power (at the 5% significance level) to detect such a difference in mean improvement in 6MWT over the study period between groups, a sample of size 62 randomised equally to two arms (i.e.",Methods|Analysis,[134062],[11297],[11780],[False],[0],[0],[False],['0']
32337,PMC5483256,22752,31 per arm) was needed.,Methods|Analysis,[134067],[11781],[11804],[False],[0],[0],[False],['0']
32338,PMC5483256,22753,Suitable numerical statistics and graphical summaries were used to describe characteristics of the sample at baseline and to assess the validity of any distributional assumptions needed for the formal analysis.,Methods|Analysis,[134072],[11805],[12015],[False],[0],[0],[False],['0']
32339,PMC5483256,22754,All tests of significance were two-sided and conducted at an alpha = 0.05 level of statistical significance.,Methods|Analysis,[134077],[12016],[12124],[False],[0],[0],[False],['0']
32340,PMC5483256,22755,The statistical modelling compared differences in the longitudinal response variables between the two intervention arms at each of the three post-intervention follow-ups while correcting for the baseline measurements for each participant.,Methods|Analysis,[134082],[12125],[12363],[False],[0],[0],[False],['0']
32341,PMC5483256,22756,"A linear mixed model for a continuous response over time due to the two interventions, whilst adjusting for participant-specific covariates and factors; namely the response of interest at baseline, age, gender, time since diagnosis and MS type (i.e.",Methods|Analysis,[134087],[12364],[12613],[False],[0],[0],[False],['0']
32342,PMC5483256,22757,"benign, primary progressive and relapsing-remitting) was developed.",Methods|Analysis,[134092],[12614],[12681],[False],[0],[0],[False],['0']
32343,PMC5483256,22758,"Treatment and time (and their interaction) were specified as fixed effects, centre (three levels) and participant (nested in centre) as random effects in order to account for homogeneity within centre and within participant correlation over time.",Methods|Analysis,[134097],[12682],[12928],[False],[0],[0],[False],['0']
32344,PMC5483256,22759,"Initially a model containing the main effects of the treatment, time and a treatment-by-time interaction was specified in order to test whether there is evidence that the treatment effects varies over time.",Methods|Analysis,[134102],[12929],[13135],[False],[0],[0],[False],['0']
32345,PMC5483256,22760,"If the interaction was deemed unnecessary (using a likelihood ratio test) the model was refitted excluding the interaction term, so the treatment effect was then constant over time.",Methods|Analysis,[134107],[13136],[13317],[False],[0],[0],[False],['0']
32346,PMC5483256,22761,All analyses were carried out using all available measurements.,Methods|Analysis,[134112],[13318],[13381],[False],[0],[0],[False],['0']
32347,PMC5483256,22762,All models were fitted in R 3.2.0 using the lme4 and lmerTest packages.,Methods|Analysis,[134117],[13382],[13453],[False],[0],[0],[False],['0']
32348,PMC5483256,22763,Model diagnostics involved suitable plots of the residuals.,Methods|Analysis,[134122],[13454],[13513],[False],[0],[0],[False],['0']
32349,PMC5483256,22764,"Given increased calls across the literature to move beyond null-hypothesis significance testing in favour of effect sizes and confidence intervals [39] we also quantified and compared the magnitude of change in secondary outcomes using Hedges’ g effect sizes and associated 95% confidence intervals (95%CI) using Cohen’s conventions for effect sizes (0.2 small, 0.5 moderate, 0.8 large).",Methods|Analysis,[134127],[13514],[13901],[False],[0],[0],[False],['0']
32350,PMC5483256,22765,"For each outcome measure, the mean baseline to post intervention and 3 and 6 month change for the control condition was subtracted from the mean baseline to post intervention and 3 and 6 month change for the intervention condition and divided by the pooled baseline standard deviation [40].",Methods|Analysis,[134132],[13902],[14192],[False],[0],[0],[False],['0']
32351,PMC5483256,22766,Effect sizes were calculated such that greater improvements in outcomes in the intervention group compared to the control group resulted in positive effect sizes.,Methods|Analysis,[134137],[14193],[14355],[False],[0],[0],[False],['0']
32352,PMC5483256,22767,An exploratory paired t-test between baseline post intervention and 3- and 6- month follow-ups was also conducted.,Methods|Analysis,[134142],[14356],[14470],[False],[0],[0],[False],['0']
32353,PMC5483256,22768,This provides a summary of the effects of the estimated treatment and control from the raw data.,Methods|Analysis,[134147],[14471],[14567],[False],[0],[0],[False],['0']
32354,PMC5483256,22769,These “unadjusted” results do not account for the patient covariates and repeated measurements.,Methods|Analysis,[134152],[14568],[14663],[False],[0],[0],[False],['0']
32355,PMC5483256,22770,Results,Results,[134157],[14664],[14672],[False],[0],[0],[False],['0']
32356,PMC5483256,22771,Fig.,Results,[134162],[14673],[14677],[False],[0],[0],[False],['0']
32357,PMC5483256,22772,"1 CONSORT Flow Diagram, DNA: did not attend.",Results,[134167],[14678],[14722],[False],[0],[0],[False],['0']
32358,PMC5483256,22773,Table 1 Clinical baseline characteristics of those receiving exercise plus SCT (SCT) and exercise plus control education (CON).,Results,[134172],[14723],[14850],[False],[0],[0],[False],['0']
32359,PMC5483256,22774,One hundred and seventy-four PwMS contacted the trial centre and were screened for inclusion over the phone between September 2013 and May 2014.,Results,[134177],[14851],[14995],[False],[0],[0],[False],['0']
32360,PMC5483256,22775,"Figure 1 illustrates the flow through the trial, including reasons for loss to follow-up and discontinuation of intervention.",Results,[134182],[14996],[15121],[False],[0],[0],[False],['0']
32361,PMC5483256,22776,We randomised 92 individual participants and waited for 6 participants in a region to run a group before baseline assessment.,Results,[134187],[15122],[15247],[False],[0],[0],[False],['0']
32362,PMC5483256,22777,"While waiting for others to be randomised, 27 people became ineligible or declined to participate.",Results,[134192],[15248],[15346],[False],[0],[0],[False],['0']
32363,PMC5483256,22778,One participant was not treated as randomised (two acquaintances had been randomised to the other group and the participant wanted to exercise with them).,Results,[134197],[15347],[15501],[False],[0],[0],[False],['0']
32364,PMC5483256,22779,"Sixty-five participants were assessed at baseline and commenced the intervention (intervention group n = 33, control group n = 32).",Results,[134202],[15502],[15633],[False],[0],[0],[False],['0']
32365,PMC5483256,22780,Baseline demographics are presented in Table 1; the groups were similar at baseline.,Results,[134207],[15634],[15718],[False],[0],[0],[False],['0']
32366,PMC5483256,22781,"Feasibility, fidelity and adherence metrics are published elsewhere (Hayes et al.",Results,[134212],[15719],[15800],[False],[0],[0],[False],['0']
32367,PMC5483256,22782,in press).,Results,[134217],[15801],[15811],[False],[0],[0],[False],['0']
32368,PMC5483256,22783,Table 2 Mean (SD) for secondary outcome measures at each time point.,Results,[134222],[15812],[15882],[False],[0],[0],[False],['0']
32369,PMC5483256,22784,Table 3 Estimated treatment effects for secondary outcomes at each time point from linear mixed effects model and effect sizes.,Results,[134227],[15883],[16010],[False],[0],[0],[False],['0']
32370,PMC5483256,22785,The raw data at each time point is presented in Table 2.,Results,[134232],[16011],[16067],[False],[0],[0],[False],['0']
32371,PMC5483256,22786,Linear mixed effects models showed no statistically significant differences between the SCT and control groups for any secondary outcome at post intervention and at 3 and 6 month follow up assessment points (Table 2).,Results,[134237],[16068],[16285],[False],[0],[0],[False],['0']
32372,PMC5483256,22787,Hedges’ g effect sizes and associated 95% CIs are also presented for each group in Table 3.,Results,[134242],[16286],[16377],[False],[0],[0],[False],['0']
32373,PMC5483256,22788,"At three month follow up, compared to the control group, the exercise and SCT education resulted in statistically significant moderate-to-large improvements in cognitive processing speed (SDMT: g = 0.75, 95% CI: 0.24, 1.25) and aerobic capacity (mCAFT: g = 0.51, 95% CI: 0.01, 1.00).",Results,[134247],[16378],[16661],[False],[0],[0],[False],['0']
32374,PMC5483256,22789,"Though not statistically significant, compared to control post intervention, the SCT group had small-to-moderate improvements in the perceived psychological impact of MS (g = 0.25), anxiety symptoms (g = 0.34), estimated energy expenditure (g = 0.39), exercise planning (g = 0.34), and social support (g = 0.40).",Results,[134252],[16662],[16974],[False],[0],[0],[False],['0']
32375,PMC5483256,22790,"Compared to control at three month follow-up, the SCT group had nonsignificant, small-to-moderate improvements in the perceived psychological impact of MS (g = 0.34), anxiety (g = 0.37) and depressive (g = 0.20) symptoms, lower extremity muscle strength (g = 0.41), estimated energy expenditure (g = 0.40), exercise planning (g = 0.31), exercise self-efficacy (g = 0.33), and social support (g = 0.49).",Results,[134257],[16975],[17377],[False],[0],[0],[False],['0']
32376,PMC5483256,22791,"At six month follow-up, compared to control the intervention showed nonsignificant small-to-moderate improvements in anxiety (g = 0.17) and depressive (g = 0.23) symptoms, cognitive processing speed (g = 0.15), lower extremity muscle strength (g = 0.49), aerobic capacity (g = 0.34), exercise planning (g = 0.17), exercise self-efficacy (g = 0.28), and social support (g = 0.45).",Results,[134262],[17378],[17757],[False],[0],[0],[False],['0']
32377,PMC5483256,22792,Table 4 Unadjusted comparisons of change in secondary outcome measures in each group at each time point.,Results,[134267],[17758],[17864],[False],[0],[0],[False],['0']
32378,PMC5483256,22793,"Within-group outcome changes, including the unadjusted, unstandardized mean changes from baseline, associated 95%CIs, and paired t-test results for both groups, are presented in Table 4.",Results,[134272],[17865],[18051],[False],[0],[0],[False],['0']
32379,PMC5483256,22794,"Both groups demonstrated significant improvements from baseline following the 10-week intervention in the perceived impact of fatigue (MFIS), lower extremity muscle strength (5xSTS), self-reported PA (Godin Health Index), exercise goal setting, and exercise planning that are maintained above baseline at three and six month follow-up.",Results,[134277],[18052],[18387],[False],[0],[0],[False],['0']
32380,PMC5483256,22795,"Only the SCT group had significant improvements in perceived physical impact of MS (MSIS-29 physical), anxiety (HADS-A) and depressive (HADS-D) symptoms, and cognitive processing speed (SDMT) at three and six month follow-up.",Results,[134282],[18388],[18613],[False],[0],[0],[False],['0']
32381,PMC5483256,22796,"There was no significant change in objectively-measured PA using the outputs of steps and energy expenditure, and no significant change in exercise self-efficacy in either group across time points.",Results,[134287],[18614],[18811],[False],[0],[0],[False],['0']
32382,PMC5483256,22797,Discussion,Discussion,[134292],[18812],[18824],[False],[0],[0],[False],['0']
32383,PMC5483256,22798,This paper presents the secondary outcome results from an intervention designed to enable inactive people with MS to reach the minimum recommendation of the MS Exercise Guidelines and further compared the effect of a structured SCT-based education to an attention-control education intervention.,Discussion,[134297],[18825],[19120],[False],[0],[0],[False],['0']
32384,PMC5483256,22799,Null hypothesis testing demonstrated no statistically significant between-group differences for any secondary outcome over time.,Discussion,[134302],[19121],[19249],[False],[0],[0],[False],['0']
32385,PMC5483256,22800,"However, examination of the magnitude of change quantified by Hedges’ g effect sizes illustrated potentially important differences between exercise plus SCT compared to the attention control condition, including significant moderate-to-large improvements in cognitive processing speed and aerobic capacity at three month follow-up.",Discussion,[134307],[19250],[19581],[False],[0],[0],[False],['0']
32386,PMC5483256,22801,"Additionally, though not statistically significant, compared to the attention-control condition, exercise plus SCT resulted in small-to-moderate improvements of ¼ to ½ standard deviation in anxiety and depressive symptoms, the perceived psychological impact of MS, cognitive processing speed, aerobic capacity, estimated energy expenditure, exercise planning, and social support, and the magnitude of many of these improvements persisted at 24- and 36-week follow-up.",Discussion,[134312],[19582],[20049],[False],[0],[0],[False],['0']
32387,PMC5483256,22802,"The magnitude of improvements in these outcomes is consistent with previous reports of the positive effects of exercise training on symptoms among PwMS, including fatigue [1], anxiety [41], depression [42, 43], quality of life [7, 44], and mobility [5], and highlights the potential additive benefit of combined SCT-based education and exercise training.",Discussion,[134317],[20050],[20404],[False],[0],[0],[False],['0']
32388,PMC5483256,22803,The finding that both groups improved in strength and physical activity is not surprising given the content of the intervention.,Discussion,[134322],[20405],[20533],[False],[0],[0],[False],['0']
32389,PMC5483256,22804,Participants completed twice weekly resistance exercise and moderate intensity walking exercise.,Discussion,[134327],[20534],[20630],[False],[0],[0],[False],['0']
32390,PMC5483256,22805,"The changes in lower extremity muscle strength 6 months post intervention, measured with the 5xSTS test, are in line broadly with previously reported changes using that measure [45], providing support for the fidelity of the current intervention to enhance strength.",Discussion,[134332],[20631],[20897],[False],[0],[0],[False],['0']
32391,PMC5483256,22806,"The Health Index score of the GLTEQ also increased in both groups, confirming the exercise log data which indicated that SCT and the CON group groups completed an average of 33.2 of 44 available sessions (75.5%) and 32.0 sessions (72.6%), respectively (Hayes et al.",Discussion,[134337],[20898],[21163],[False],[0],[0],[False],['0']
32392,PMC5483256,22807,in press).,Discussion,[134342],[21164],[21174],[False],[0],[0],[False],['0']
32393,PMC5483256,22808,"Of note, the objective measure of PA, mean steps/day and mean energy expenditure/day did not change in line with the positive effects on walking mobility and the increase in PA reported in the exercise logs and the GLTEQ Health Index.",Discussion,[134347],[21175],[21409],[False],[0],[0],[False],['0']
32394,PMC5483256,22809,"This may be due to reduced non-exercise physical activity, such that participants reduced leisure, transport and occupational PA in order to engage in exercise training, thereby maintaining, or even decreasing, their overall PA levels.",Discussion,[134352],[21410],[21645],[False],[0],[0],[False],['0']
32395,PMC5483256,22810,"There has been some support in the literature for initial decreases in non-exercise physical activity when beginning an exercise training intervention, though the available evidence suggests that decreased activity dissipates with continued training [46].",Discussion,[134357],[21646],[21901],[False],[0],[0],[False],['0']
32396,PMC5483256,22811,"It is also possible that the arm worn accelerometer did not capture the changes in PA or that an alternative output, such as increased mild/moderate PA specifically or a reduction in sedentary behaviour, may capture the changes due to the intervention.",Discussion,[134366],[21902],[22154],[True],['PrecisionOfMeasurement'],['It is also possible that the arm worn accelerometer did not capture the changes in PA'],[True],['OutcomeMeasures']
32397,PMC5483256,22812,"Importantly, the results of within-group changes confirmed the positive effect of exercise on fatigue for people with MS [1, 2].",Discussion,[134372],[22155],[22283],[False],[0],[0],[False],['0']
32398,PMC5483256,22813,"The included sample of PwMS started with scores on the MFIS greater than 38 [47], indicative of clinically meaningful fatigue, and both groups improved, reporting scores below 38 at three and 6 month follow up.",Discussion,[134377],[22284],[22494],[False],[0],[0],[False],['0']
32399,PMC5483256,22814,"To the authors’ knowledge, this is the first study to confirm that exercising at the minimum recommendations of the Canadian MS Exercise guideline [9] has a positive effect on fatigue for inactive people with MS with mild-moderate disability.",Discussion,[134382],[22495],[22737],[False],[0],[0],[False],['0']
32400,PMC5483256,22815,Both groups also improved in exercise goal setting and planning and these improvements were maintained at both follow-up assessments.,Discussion,[134387],[22738],[22871],[False],[0],[0],[False],['0']
32401,PMC5483256,22816,This was expected in the SCT group because the structured education intervention specifically addressed these and other SCT domains.,Discussion,[134392],[22872],[23004],[False],[0],[0],[False],['0']
32402,PMC5483256,22817,The improvement in the control group was unexpected as they engaged in didactic education on topics unrelated to exercise.,Discussion,[134397],[23005],[23127],[False],[0],[0],[False],['0']
32403,PMC5483256,22818,"On reflection, in our efforts to document adherence and fidelity to the intervention, we inadvertently provided the control group with several physical activity behaviour change techniques (BCT’s) [12].",Discussion,[134402],[23128],[23330],[False],[0],[0],[False],['0']
32404,PMC5483256,22819,"This involved exercising in a group setting, advice on the guideline amount and its benefits, recording exercise in a log, seeing personal improvements and monitoring step count on a pedometer.",Discussion,[134407],[23331],[23524],[False],[0],[0],[False],['0']
32405,PMC5483256,22820,Participants further reported in our qualitative data that knowing they were going to be assessed at 3- and 6-months further served as a motivator to keep exercising.,Discussion,[134412],[23525],[23691],[False],[0],[0],[False],['0']
32406,PMC5483256,22821,"These, somewhat “simple”, BCT’s warrant consideration for inclusion in interventions that aim to enable long term exercise behaviour and its benefits though we note that there was a greater improvement in the SCT group for the primary outcome of walking endurance seen in a per protocol analysis (Hayes et al.",Discussion,[134417],[23692],[24001],[False],[0],[0],[False],['0']
32407,PMC5483256,22822,in press).,Discussion,[134422],[24002],[24012],[False],[0],[0],[False],['0']
32408,PMC5483256,22823,Adding a booster session with both assessment and intervention in the follow up periods may further maintain exercise behaviour and its associated outcomes and is in line with a recent systematic review [48] and reports from participants in this study.,Discussion,[134427],[24013],[24265],[False],[0],[0],[False],['0']
32409,PMC5483256,22824,Interestingly exercise self efficacy did not change neither did outcome expectancies or exercise benefits.,Discussion,[134432],[24266],[24372],[False],[0],[0],[False],['0']
32410,PMC5483256,22825,"Notably, compared to the control condition, exercise plus SCT resulted in small, nonsignificant improvements in self-efficacy and exercise plus SCT also resulted in near half-standard deviation improvements in social support, measured with the Social Provisions Scale, at all time points.",Discussion,[134437],[24373],[24661],[False],[0],[0],[False],['0']
32411,PMC5483256,22826,"Though the objective of the current study was not to examine plausible mediators of the effects of exercise plus SCT on outcomes, given previous evidence of the potential intermediary role of social support in the effects of physical activity and exercise among PwMS [49], the ability of exercise to concurrently improve social support and symptoms may be particularly important.",Discussion,[134442],[24662],[25041],[False],[0],[0],[False],['0']
32412,PMC5483256,22827,"Interestingly only the SCT group demonstrated improvements in physical impact of MS, anxiety, depression and cognition.",Discussion,[134447],[25042],[25161],[False],[0],[0],[False],['0']
32413,PMC5483256,22828,"Compared to the attention-control condition, the exercise plus SCT group showed small-to-moderate improvements in anxiety and depressive symptoms, the perceived psychological impact of MS, and cognitive processing speed.",Discussion,[134452],[25162],[25382],[False],[0],[0],[False],['0']
32414,PMC5483256,22829,These findings warrant further focused examination but may be due in part to the greater change in walking mobility seen in the exercise plus SCT group (Hayes et al.,Discussion,[134457],[25383],[25548],[False],[0],[0],[False],['0']
32415,PMC5483256,22830,in press).,Discussion,[134462],[25549],[25559],[False],[0],[0],[False],['0']
32416,PMC5483256,22831,"Both groups improved significantly in six minute walk test (6MWT) distance after treatment and at 3- and 6-month follow-up, and using intention-to-treat analysis the SCT group demonstrated 22.70 m, 11.80 m and 27.42 m greater improvements in this measure.",Discussion,[134467],[25560],[25815],[False],[0],[0],[False],['0']
32417,PMC5483256,22832,"Data suggest that a 21 m change is clinically meaningful to participants, supporting the hypothesis that the SCT group had more meaningful changes in 6MWT distance at 3- and 6-month follow-up that may have resulted in reduced physical impact of MS. More of the SCT group reached the guideline and they reported completing more sessions.",Discussion,[134472],[25816],[26152],[False],[0],[0],[False],['0']
32418,PMC5483256,22833,"This increased “total exercise dose” and the resulting change in depression is supported by our recent systematic review and meta-regression analysis [42], which found increased frequency of exercise was associated with greater reductions of depression.",Discussion,[134477],[26153],[26406],[False],[0],[0],[False],['0']
32419,PMC5483256,22834,There is limited specific information on the dose/response relationship of exercise for MS and this warrants consideration in trials designed specifically to address this question.,Discussion,[134482],[26407],[26587],[False],[0],[0],[False],['0']
32420,PMC5483256,22835,Strengths and limitations,Discussion|Strengths and limitations,[134487],[26588],[26613],[False],[0],[0],[False],['0']
32421,PMC5483256,22836,The main strength of this study is that we purposely recruited inactive people with MS and engaged them in a 10-week exercise and education programme with the aim of enabling long-term physical activity engagement and its associated benefits.,Discussion|Strengths and limitations,[134492],[26614],[26856],[False],[0],[0],[False],['0']
32422,PMC5483256,22837,"A weakness is that we did not power the study for these secondary outcomes; nonetheless, the preliminary findings presented in the current paper, particularly the magnitude of improvements in fatigue, anxiety and depressive symptoms, the perceived impact of MS, strength and aerobic capacity, and cognitive processing speed, will inform future trials and targeted analyses of these important factors.",Discussion|Strengths and limitations,[134497],[26857],[27257],[True],['UnderpoweredStudy'],['we did not power the study for these secondary outcomes'],[True],['UnderpoweredStudy']
32423,PMC5483256,22838,"A further strength is that we measured a broad range of MS symptoms, and reported the effect of the resistance and aerobic exercise programme on strength, fitness, and subjectively and objectively measured PA. A limitation is that the measures of objective PA and fitness did not change and a more direct measure of fitness, such as cycle ergometry to determine VO2 max, is recommended [50].",Discussion|Strengths and limitations,[134508],[27258],[27649],[True],['ValidityOfMeasurement'],"['a more direct measure of fitness, such as cycle ergometry to determine VO2 max, is recommended']",[True],['OutcomeMeasures']
32424,PMC5483256,22839,"Participants reported some dissatisfaction with the SWA arm band; therefore, alternative tools for objectively measuring PA among PwMS are warranted.",Discussion|Strengths and limitations,[134519],[27650],[27799],[True],['OutcomeMeasures'],['alternative tools for objectively measuring PA among PwMS are warranted'],[True],['OutcomeMeasures']
32425,PMC5483256,22840,"A further strength is that we used exercise logs to capture intensity of aerobic exercise using steps from a pedometer, but a limitation is that we did not record heart rate and this is recommended in future trials.",Discussion|Strengths and limitations,[134530],[27800],[28015],[True],['MissingData'],['we did not record heart rate'],[True],['MissingData']
32426,PMC5483256,22841,Conclusion,Conclusion,[134537],[28016],[28027],[False],[0],[0],[False],['0']
32427,PMC5483256,22842,This paper presents data to suggest that enabling inactive people with mild-moderate disability due to MS to exercise at the minimum suggested by the exercise guideline results in a range of benefits.,Conclusion,[134542],[28028],[28228],[False],[0],[0],[False],['0']
32428,PMC5483256,22843,"Improvements in fatigue, strength, goal setting and planning were seen in both the structured SCT and attention control groups and were maintained at 3 and 6 month follow up.",Conclusion,[134547],[28229],[28403],[False],[0],[0],[False],['0']
32429,PMC5483256,22844,The similar responses in both groups for these secondary outcomes can be explained as they both had the same exercise intervention and by the inadvertent inclusion of several behaviour change techniques for the control group through our adherence logging and trial structure.,Conclusion,[134552],[28404],[28679],[False],[0],[0],[False],['0']
32430,PMC5483256,22845,The results of this pilot trial for the secondary outcome measures suggest that the SCT group had greater improvements in cognitive processing and aerobic capacity at 3 month follow up.,Conclusion,[134557],[28680],[28865],[False],[0],[0],[False],['0']
32431,PMC5483256,22846,"This paper further presents preliminary evidence for improvements in physical impact of MS, anxiety, depression and cognition in the exercise plus SCT group alone.",Conclusion,[134562],[28866],[29029],[False],[0],[0],[False],['0']
32432,PMC5483256,22847,This may in part be due to the greater improvements in walking mobility reported elsewhere or due to the content of the education element and therefore further testing of the intervention model is warranted.,Conclusion,[134567],[29030],[29237],[False],[0],[0],[False],['0']
32433,PMC5483256,22848,"These findings, in combination with the effects for the primary outcome measure, warrant progression to a definitive RCT and suggest the importance of studies directly investigating the dose-response relationship with focal outcomes.",Conclusion,[134572],[29238],[29471],[False],[0],[0],[False],['0']
32434,PMC5483256,22849,Abbreviations,Abbreviations,[134577],[29472],[29486],[False],[0],[0],[False],['0']
32435,PMC5483256,22850,5xSTS 5 times sit to stand test,Abbreviations,[134582],[29487],[29518],[False],[0],[0],[False],['0']
32436,PMC5483256,22851,6MWT Six minute walk test,Abbreviations,[134587],[29519],[29544],[False],[0],[0],[False],['0']
32437,PMC5483256,22852,BCT Behaviour change technique,Abbreviations|BCT Behaviour change technique,[134592],[29545],[29575],[False],[0],[0],[False],['0']
32438,PMC5483256,22853,EDSS Expanded disability status scale,Abbreviations|EDSS Expanded disability status scale,[134597],[29576],[29613],[False],[0],[0],[False],['0']
32439,PMC5483256,22854,EXSE Exercise self-efficacy scale,Abbreviations|EXSE Exercise self-efficacy scale,[134602],[29614],[29647],[False],[0],[0],[False],['0']
32440,PMC5483256,22855,GLTEQ Godin leisure-time exercise questionnaire,Abbreviations|EXSE Exercise self-efficacy scale,[134607],[29648],[29695],[False],[0],[0],[False],['0']
32441,PMC5483256,22856,HADS Hospital anxiety and depression scale,Abbreviations|HADS Hospital anxiety and depression scale,[134612],[29696],[29738],[False],[0],[0],[False],['0']
32442,PMC5483256,22857,mCAFT Modified Canadian aerobic fitness test,Abbreviations|mCAFT Modified Canadian aerobic fitness test,[134617],[29739],[29783],[False],[0],[0],[False],['0']
32443,PMC5483256,22858,MFIS Modified fatigue impact scale,Abbreviations|MFIS Modified fatigue impact scale,[134622],[29784],[29818],[False],[0],[0],[False],['0']
32444,PMC5483256,22859,MOEES Multidimensional outcomes expectations for exercise scale,Abbreviations|MOEES Multidimensional outcomes expectations for exercise scale,[134627],[29819],[29882],[False],[0],[0],[False],['0']
32445,PMC5483256,22860,MS Multiple sclerosis,Abbreviations|MS Multiple sclerosis,[134632],[29883],[29904],[False],[0],[0],[False],['0']
32446,PMC5483256,22861,MSIS-29 Multiple sclerosis impact scale 29,Abbreviations|MS Multiple sclerosis,[134637],[29905],[29947],[False],[0],[0],[False],['0']
32447,PMC5483256,22862,PDDS Patient determined disease steps,Abbreviations|PDDS Patient determined disease steps,[134642],[29948],[29985],[False],[0],[0],[False],['0']
32448,PMC5483256,22863,PwMS People with multiple sclerosis,Abbreviations|PwMS People with multiple sclerosis,[134647],[29986],[30021],[False],[0],[0],[False],['0']
32449,PMC5483256,22864,QOL Quality of life,Abbreviations|QOL Quality of life,[134652],[30022],[30041],[False],[0],[0],[False],['0']
32450,PMC5483256,22865,RCT Randomised controlled trial,Abbreviations|RCT Randomised controlled trial,[134657],[30042],[30073],[False],[0],[0],[False],['0']
32451,PMC5483256,22866,SCT Social cognitive theory,Abbreviations|SCT Social cognitive theory,[134662],[30074],[30101],[False],[0],[0],[False],['0']
32452,PMC5483256,22867,SDMT Symbol digit modalities test,Abbreviations|SDMT Symbol digit modalities test,[134667],[30102],[30135],[False],[0],[0],[False],['0']
32453,PMC5483256,22868,SPS Social provisions scale,Abbreviations|SPS Social provisions scale,[134672],[30136],[30163],[False],[0],[0],[False],['0']
32454,PMC5483256,22869,SWA SenseWear ArmbandAcknowledgements,Abbreviations|SPS Social provisions scale,[134677],[30164],[30201],[False],[0],[0],[False],['0']
32455,PMC5483256,22870,"We would like to thank MS Ireland Southern, Mid-Western and Western regional offices for their assistance in recruiting participants for this trial.",Abbreviations|SPS Social provisions scale,[134682],[30202],[30350],[False],[0],[0],[False],['0']
32456,PMC5483256,22871,Funding,Abbreviations|Funding,[134687],[30351],[30358],[False],[0],[0],[False],['0']
32457,PMC5483256,22872,"This work is supported by the Irish Health Research Board Health Research Award, grant number: HRA_PHR/2013–264.",Abbreviations|Funding,[134692],[30359],[30471],[False],[0],[0],[False],['0']
32458,PMC5483256,22873,"The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.",Abbreviations|Funding,[134697],[30472],[30611],[False],[0],[0],[False],['0']
32459,PMC5483256,22874,Availability of data and materials,Abbreviations|Availability of data and materials,[134702],[30612],[30646],[False],[0],[0],[False],['0']
32460,PMC5483256,22875,The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.,Abbreviations|Availability of data and materials,[134707],[30647],[30772],[False],[0],[0],[False],['0']
32461,PMC5483256,22876,Authors’ contributions,Abbreviations|Authors’ contributions,[134712],[30773],[30795],[False],[0],[0],[False],['0']
32462,PMC5483256,22877,"SC was the principal investigator for the study, co-initiated the project, contributed to the design of the trial, drafted the paper and approved the final version.",Abbreviations|Authors’ contributions,[134717],[30796],[30960],[False],[0],[0],[False],['0']
32463,PMC5483256,22878,"MU was a post-doctoral researcher on the trial, commented on drafts of the paper and approved the final version.",Abbreviations|Authors’ contributions,[134722],[30961],[31073],[False],[0],[0],[False],['0']
32464,PMC5483256,22879,"MH contributed to the conceptualization of the paper, analysis of data, including Hedge’s g effect size calculation, provided critical revisions to the paper, and approved the final version.",Abbreviations|Authors’ contributions,[134727],[31074],[31264],[False],[0],[0],[False],['0']
32465,PMC5483256,22880,"SH was a post-doctoral researcher on the trial, contributed to the design of the study, collected data, commented on drafts of the paper, and approved the final version.",Abbreviations|Authors’ contributions,[134732],[31265],[31434],[False],[0],[0],[False],['0']
32466,PMC5483256,22881,"SG contributed to the design and evaluation of the trial, commented on drafts of the paper, and approved the final version.",Abbreviations|Authors’ contributions,[134737],[31435],[31558],[False],[0],[0],[False],['0']
32467,PMC5483256,22882,"AL contributed to the recruitment strategy employed, commented on drafts of the paper, and approved the final version.",Abbreviations|Authors’ contributions,[134742],[31559],[31677],[False],[0],[0],[False],['0']
32468,PMC5483256,22883,"JN and CS were the statisticians on the trial, cleaned and analysed the data, provided most of the statistics presented, commented on drafts of the paper, and approved the final version.",Abbreviations|Authors’ contributions,[134747],[31678],[31864],[False],[0],[0],[False],['0']
32469,PMC5483256,22884,"RM co-initiated the project and contributed to the design of the trial, drafted the paper, and approved the final version.",Abbreviations|Authors’ contributions,[134752],[31865],[31987],[False],[0],[0],[False],['0']
32470,PMC5483256,22885,Competing interests,Abbreviations|Competing interests,[134757],[31988],[32007],[False],[0],[0],[False],['0']
32471,PMC5483256,22886,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[134762],[32008],[32066],[False],[0],[0],[False],['0']
32472,PMC5483256,22887,Consent for publication,Abbreviations|Consent for publication,[134767],[32067],[32090],[False],[0],[0],[False],['0']
32473,PMC5483256,22888,Not applicable.,Abbreviations|Not applicable.,[134772],[32091],[32106],[False],[0],[0],[False],['0']
32474,PMC5483256,22889,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[134777],[32107],[32149],[False],[0],[0],[False],['0']
32475,PMC5483256,22890,"Ethics approval was given by the Faculty of Education and Health Science Research Ethics Committee, University of Limerick (2014_02_20_EHS), in addition to the Research Ethics Committees at the University College Hospital Galway, University Hospital Limerick and Cork University Hospital.",Abbreviations|Ethics approval and consent to participate,[134782],[32150],[32438],[False],[0],[0],[False],['0']
32476,PMC5483256,22891,All participants gave written informed consent.,Abbreviations|Ethics approval and consent to participate,[134787],[32439],[32486],[False],[0],[0],[False],['0']
32477,PMC5483256,22892,Publisher’s Note,Abbreviations|Publisher’s Note,[134792],[32487],[32503],[False],[0],[0],[False],['0']
32478,PMC5483256,22893,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[134797],[32504],[32622],[False],[0],[0],[False],['0']
32858,PMC5499060,39221,"Hepatic, adipocyte, enteric and pancreatic hormones: response to dietary macronutrient composition and relationship with metabolism",Title,[228773],[17770],[131],[False],[0],[0],[False],['0']
32859,PMC5499060,39222,Background,Abstract,[228775],[132],[143],[False],[0],[0],[False],['0']
32860,PMC5499060,39223,We sought to characterize the effects of dietary macronutrient composition on various hormones implicated in the regulation of insulin sensitivity (IS) and energy expenditure (EE).,Abstract,[228777],[144],[324],[False],[0],[0],[False],['0']
32861,PMC5499060,39224,Methods,Methods,[228779],[325],[333],[False],[0],[0],[False],['0']
32862,PMC5499060,39225,"Following 10–15% weight loss, 21 overweight subjects consumed 3 weight-loss maintenance diets [low fat (LF), low glycemic index (LGI) and very low carbohydrate (VLC)] in random order, each for 4 weeks.",Methods,[228781],[334],[535],[False],[0],[0],[False],['0']
32863,PMC5499060,39226,"At baseline and at the end of each treatment period, fasting samples for fibroblast growth factor (FGF)-21, heme-oxygenase-1 (HO-1), chemerin, irisin, secreted frizzle-related protein (SFRP-4), total bile acids, ghrelin, gastrin inhibitory peptide (GIP), peptide-Y, and amylin; hepatic and peripheral IS; and EE were obtained.",Methods,[228783],[536],[862],[False],[0],[0],[False],['0']
32864,PMC5499060,39227,"Analyses were controlled for age, gender, baseline body mass index, and diet sequence.",Methods,[228785],[863],[949],[False],[0],[0],[False],['0']
32865,PMC5499060,39228,Results,Results,[228787],[950],[958],[False],[0],[0],[False],['0']
32866,PMC5499060,39229,"FGF-21 decreased (P < 0.0001), with differential effect by macronutrient composition (mean change from baseline ± SEM: LF −49.4 ± 16.6, LGI -58.6 ± 16.3, VLC -76.7 ± 18.2 pg/mL, P = 0.0002).",Results,[228789],[959],[1149],[False],[0],[0],[False],['0']
32867,PMC5499060,39230,"Change in FGF-21 was inversely associated with change in hepatic IS [Beta = −0.565 units/log(ng/mL), P = 0.02], but not with peripheral IS or EE.",Results,[228791],[1150],[1295],[False],[0],[0],[False],['0']
32868,PMC5499060,39231,"Heme-oxygenase-1 (HO-1) increased (P = 0.003), without differential effect by macronutrient composition (LF 0.40 ± 0.26, LGI 0.98 ± 0.63, VLC 0.49 ± 0.29 ng/mL, P = 0.07).",Results,[228793],[1296],[1467],[False],[0],[0],[False],['0']
32869,PMC5499060,39232,"Ghrelin increased (P = 0.0003), while chemerin decreased (P = 0.001) without macronutrient effect.",Results,[228795],[1468],[1566],[False],[0],[0],[False],['0']
32870,PMC5499060,39233,"Total bile acid, irisin, SFRP-4, GIP, peptide-Y and amylin levels did not change.",Results,[228797],[1567],[1648],[False],[0],[0],[False],['0']
32871,PMC5499060,39234,Conclusions,Conclusions,[228799],[1649],[1661],[False],[0],[0],[False],['0']
32872,PMC5499060,39235,"FGF-21 levels decreased with dietary intervention in proportion to carbohydrate content, and correlated with hepatic insulin sensitivity, suggesting a pattern of improving FGF-21 resistance.",Conclusions,[228801],[1662],[1852],[False],[0],[0],[False],['0']
32873,PMC5499060,39236,"HO-1 increased in response to dietary intervention, a tendency to greater increase in response to the LGI diet.",Conclusions,[228803],[1853],[1964],[False],[0],[0],[False],['0']
32874,PMC5499060,39237,"Dietary intervention affected ghrelin and chemerin, independent of macronutrient composition.",Conclusions,[228805],[1965],[2058],[False],[0],[0],[False],['0']
32875,PMC5499060,39238,"These findings may elucidate relationships between dietary composition, insulin sensitivity and metabolism.",Conclusions,[228807],[2059],[2166],[False],[0],[0],[False],['0']
32876,PMC5499060,39239,Trial registration,Trial registration,[228809],[2167],[2186],[False],[0],[0],[False],['0']
32877,PMC5499060,39240, NCT00315354.,Trial registration,[228811],[2187],[2200],[False],[0],[0],[False],['0']
32878,PMC5499060,39241,Background,Background,[228813],[2201],[2213],[False],[0],[0],[False],['0']
32879,PMC5499060,39242,"Previous data suggest that dietary composition modulates weight-loss induced changes in energy expenditure, insulin sensitivity and satiety.",Background,[228815],[2214],[2354],[False],[0],[0],[False],['0']
32880,PMC5499060,39243,"For instance, among subjects following a feeding protocol, energy expenditure decreased by approximately 325 kcal/day more following a low fat vs. low carb diet controlled for energy intake [1].",Background,[228817],[2355],[2549],[False],[0],[0],[False],['0']
32881,PMC5499060,39244,"Other studies have reported metabolic benefits and improved satiety with reduction of glycemic load [2, 3], but the mechanisms mediating these effects remain incompletely described.",Background,[228819],[2550],[2731],[False],[0],[0],[False],['0']
32882,PMC5499060,39245,Hormones secreted from the gastrointestinal tract and related organs have been implicated in these relationships.,Background,[228821],[2732],[2845],[False],[0],[0],[False],['0']
32883,PMC5499060,39246,"Fibroblast growth factor (FGF)-21, secreted by the liver, enhances glucose uptake into adipocytes [4].",Background,[228823],[2846],[2948],[False],[0],[0],[False],['0']
32884,PMC5499060,39247,"Administration of FGF-21 to humans modestly decreases body weight [5], and in animal models improves insulin sensitivity, energy expenditure and hepatic steatosis [6], with maximal effect at low doses.",Background,[228825],[2949],[3150],[False],[0],[0],[False],['0']
32885,PMC5499060,39248,"However, FGF-21 levels are elevated in humans with obesity and type 2 diabetes mellitus [7], in association with markers of metabolic syndrome, which suggests a pattern of FGF-21 resistance [8] that may comprise a fourth component of the obesity-related resistance triad of insulin, leptin and sympathetic tone.",Background,[228827],[3151],[3462],[False],[0],[0],[False],['0']
32886,PMC5499060,39249,"Indeed, FGF-21 levels decrease with bariatric surgery [9], although the effect of diet induced weight loss has not been well-characterized.",Background,[228829],[3463],[3602],[False],[0],[0],[False],['0']
32887,PMC5499060,39250,"Chemerin, a novel hepatocyte and adipocyte-derived hormone, is a chemoattractant for tissue injury that regulates adipocyte differentiation and thermogenesis.",Background,[228831],[3603],[3761],[False],[0],[0],[False],['0']
32888,PMC5499060,39251,Chemerin levels are increased in obesity [10] and correlate with degree of fatty liver [11].,Background,[228833],[3762],[3854],[False],[0],[0],[False],['0']
32889,PMC5499060,39252,Chemerin levels decrease with weight loss from diet [12] and bariatric surgery [11] but effects of dietary macronutrient composition are unknown.,Background,[228835],[3855],[4000],[False],[0],[0],[False],['0']
32890,PMC5499060,39253,"Bile acids, also produced by hepatocytes, modulate body weight, insulin sensitivity and energy expenditure in rodent models [13], though little is known about the effects of weight loss or dietary composition in humans.",Background,[228837],[4001],[4220],[False],[0],[0],[False],['0']
32891,PMC5499060,39254,Heme oxygenase (HO)-1 is secreted by adipose tissue and reduces oxidative stress.,Background,[228839],[4221],[4302],[False],[0],[0],[False],['0']
32892,PMC5499060,39255,"Induction in animals decreases body weight, inflammatory cytokine profiles, and insulin resistance [14].",Background,[228841],[4303],[4407],[False],[0],[0],[False],['0']
32893,PMC5499060,39256,"Levels are elevated in patients with type 2 diabetes [15], but the effects of weight loss and dietary composition on HO-1 are unknown.",Background,[228843],[4408],[4542],[False],[0],[0],[False],['0']
32894,PMC5499060,39257,Several novel proteins have recently emerged as potential mediators of insulin dynamics and energy expenditure.,Background,[228845],[4543],[4654],[False],[0],[0],[False],['0']
32895,PMC5499060,39258,Secreted frizzle-related protein-4 (SFRP-4) is a newly discovered pancreatic protein that decreases insulin secretion [16].,Background,[228847],[4655],[4778],[False],[0],[0],[False],['0']
32896,PMC5499060,39259,"Levels are elevated in subjects with type 2 diabetes, and appear to precede the development of type 2 diabetes [16].",Background,[228849],[4779],[4895],[False],[0],[0],[False],['0']
32897,PMC5499060,39260,The myokine irisin stimulates uncoupling protein-1 expression in adipocytes and prevents diet-induced obesity and diabetes in mouse models [17].,Background,[228851],[4896],[5040],[False],[0],[0],[False],['0']
32898,PMC5499060,39261,"Serum irisin levels are lower in patients with obesity and hepatic steatosis [18], and increase with exercise [17].",Background,[228853],[5041],[5156],[False],[0],[0],[False],['0']
32899,PMC5499060,39262,The effects of diet-induced weight loss in adults and dietary composition on SFRP-4 and irisin levels are not well-characterized.,Background,[228855],[5157],[5286],[False],[0],[0],[False],['0']
32900,PMC5499060,39263,Multiple enteric and pancreatic hormones have emerged as important mediators of food intake.,Background,[228857],[5287],[5379],[False],[0],[0],[False],['0']
32901,PMC5499060,39264,"Ghrelin, secreted from the stomach, rises acutely with fasting to stimulate hunger, and increases with weight loss [19].",Background,[228859],[5380],[5500],[False],[0],[0],[False],['0']
32902,PMC5499060,39265,"Peptide-YY (PYY), secreted by the distal ileum, increases with nutritional intake to convey a satiety signal.",Background,[228861],[5501],[5610],[False],[0],[0],[False],['0']
32903,PMC5499060,39266,PYY levels decrease with diet-induced weight loss [19].,Background,[228863],[5611],[5666],[False],[0],[0],[False],['0']
32904,PMC5499060,39267,"Amylin, which is co-secreted by the pancreas with insulin, decreases food intake and body weight [20], and levels decrease in response to weight-loss maintenance [19].",Background,[228865],[5667],[5834],[False],[0],[0],[False],['0']
32905,PMC5499060,39268,"Taken together, this pattern of hormonal alterations can contribute to weight regain [19].",Background,[228867],[5835],[5925],[False],[0],[0],[False],['0']
32906,PMC5499060,39269,Gastric inhibitory polypeptide (GIP) is secreted by K cells in the duodenum in response to intraluminal glucose and fat.,Background,[228869],[5926],[6046],[False],[0],[0],[False],['0']
32907,PMC5499060,39270,"Mice lacking GIP receptor are protected against diet-induced obesity, due to higher energy expenditure, and insulin resistance [21].",Background,[228871],[6047],[6179],[False],[0],[0],[False],['0']
32908,PMC5499060,39271,"In the setting of weight maintenance, GIP levels tend to be lower in response to low glycemic index diets [22].",Background,[228873],[6180],[6291],[False],[0],[0],[False],['0']
32909,PMC5499060,39272,The effects of weight loss on GIP levels are less clear.,Background,[228875],[6292],[6348],[False],[0],[0],[False],['0']
32910,PMC5499060,39273,"In this study, we aimed to characterize the changes in these metabolic hormones in response to weight loss and diets varying in composition, and analyze the potential contribution of these hormones to changes in physiology and metabolism.",Background,[228877],[6349],[6587],[False],[0],[0],[False],['0']
32911,PMC5499060,39274,Methods,Methods,[228879],[6588],[6596],[False],[0],[0],[False],['0']
32912,PMC5499060,39275,Study design,Methods|Study design,[228881],[6597],[6609],[False],[0],[0],[False],['0']
32913,PMC5499060,39276,Fig.,Methods|Study design,[228883],[6610],[6614],[False],[0],[0],[False],['0']
32914,PMC5499060,39277,1 Study schema.,Methods|Study design,[228885],[6615],[6630],[False],[0],[0],[False],['0']
32915,PMC5499060,39278,The overall study design was previously reported [1].,Methods|Study design,[228887],[6631],[6684],[False],[0],[0],[False],['0']
32916,PMC5499060,39279,"In brief, participants who were overweight or obese, and otherwise healthy, achieved 10–15% weight-loss over 12 weeks by consuming a standardized reduced-calorie diet providing 60% of estimated needs and consisting of 45% carbohydrate, 30% fat and 25% protein.",Methods|Study design,[228889],[6685],[6945],[False],[0],[0],[False],['0']
32917,PMC5499060,39280,Participants then received each of 3 weight loss maintenance test diets for 4 weeks in random order (Figure 1).,Methods|Study design,[228891],[6946],[7057],[False],[0],[0],[False],['0']
32918,PMC5499060,39281,"The diets were isocaloric, designed to achieve 100% of estimated caloric needs, but varied in macronutrient composition as follows: low fat (60% carbohydrate, 20% fat and 20% protein), low glycemic index (40% carbohydrate, 40% fat and 20% protein), and very low carbohydrate (10% carbohydrate, 60% fat, 30% protein).",Methods|Study design,[228893],[7058],[7374],[False],[0],[0],[False],['0']
32919,PMC5499060,39282,All study meals were designed and prepared in the metabolic kitchen at the Brigham and Women’s Hospital (BWH).,Methods|Study design,[228895],[7375],[7485],[False],[0],[0],[False],['0']
32920,PMC5499060,39283,"Participants consumed one meal each weekday on site, with remainder of meals and snacks packaged for consumption at home, and completed a daily compliance diary.",Methods|Study design,[228897],[7486],[7647],[False],[0],[0],[False],['0']
32921,PMC5499060,39284,Participants were admitted to BWH or Boston Children’s Hospital for a four-day hospitalization at baseline (prior to weight loss) and after each of the three test diets (during period of weight maintenance).,Methods|Study design,[228899],[7648],[7855],[False],[0],[0],[False],['0']
32922,PMC5499060,39285,"At each study visit, a full assessment was performed, including resting energy expenditure, insulin sensitivity and measurement of metabolic hormones.",Methods|Study design,[228901],[7856],[8006],[False],[0],[0],[False],['0']
32923,PMC5499060,39286,"As previously reported [1], resting energy expenditure was measured by indirect calorimetry and total energy expenditure was measured under free living conditions by doubly-labeled water technique.",Methods|Study design,[228903],[8007],[8204],[False],[0],[0],[False],['0']
32924,PMC5499060,39287,Hepatic and peripheral insulin sensitivity were calculated from glucose and insulin responses to oral glucose tolerance test (OGTT) as per Abdul-Ghani et al.,Methods|Study design,[228905],[8205],[8362],[False],[0],[0],[False],['0']
32925,PMC5499060,39288,[23].,Methods|Study design,[228907],[8363],[8368],[False],[0],[0],[False],['0']
32926,PMC5499060,39289,"For hepatic insulin sensitivity, we calculated the product of the glucose and insulin areas under the curve during the first 30 min of the OGTT and then obtained the inverse.",Methods|Study design,[228909],[8369],[8543],[False],[0],[0],[False],['0']
32927,PMC5499060,39290,"For peripheral insulin sensitivity, we calculated the rate of decline of glucose levels from peak to nadir during the OGTT and then divided by mean insulin levels.",Methods|Study design,[228911],[8544],[8707],[False],[0],[0],[False],['0']
32928,PMC5499060,39291,Participants maintained their habitual levels of physical activity throughout the course of the study.,Methods|Study design,[228913],[8708],[8810],[False],[0],[0],[False],['0']
32929,PMC5499060,39292,"[1] The study was approved by the Boston Children’s Hospital and Partner’s Institutional Review Boards, and registered on clinicaltrials.gov (NCT00315354).",Methods|Study design,[228915],[8811],[8966],[False],[0],[0],[False],['0']
32930,PMC5499060,39293,Serologic hormone assays,Serologic hormone assays,[228917],[8967],[8993],[False],[0],[0],[False],['0']
32931,PMC5499060,39294,Fasting samples were obtained at baseline (prior to weight loss) and at the end of each dietary treatment period (during weight loss maintenance) after a 12-h overnight fast.,Serologic hormone assays,[228919],[8994],[9168],[False],[0],[0],[False],['0']
32932,PMC5499060,39295,Serum was frozen at −80 °C until analysis.,Serologic hormone assays,[228921],[9169],[9211],[False],[0],[0],[False],['0']
32933,PMC5499060,39296,"Samples from all time-points were available from 21 patients, except for HO-1 (N = 16) and irisin (N = 18).",Serologic hormone assays,[228923],[9212],[9319],[False],[0],[0],[False],['0']
32934,PMC5499060,39297,"FGF-21 [intra-assay coefficient of variation (CV) 1.9–5%, inter-assay CV 1.2–9%, limit of detection 15.6 pg/mL; Millipore, St. Charles, MO], chemerin (intra-assay CV 5%, inter-assay CV 4–6%, limit of detection 1.56 ng/mL; Millipore), heme oxygenase-1 (intra-assay CV < 10%, inter-assay CV < 12%, limit of detection 0.25 ng/mL; USCN Life Science Inc., Wuhan, Hubei, China), total serum bile acids (intra-assay CV <10%, inter-assay CV <10%, limit of detection 7.48 μmol/L; Crystal Chem, Inc., Downers Grove, IL), SFRP-4 (intra-assay CV <10%, inter-assay CV <12%, limit of detection 42.026 pg/ml; USCN Life Science Inc.) and irisin (intra-assay CV < 10%, inter-assay CV < 10%, limit of detection 4.15 ng/mL; Phoenix Pharmaceuticals, Burlingame, CA) levels were was measured by ELISA.",Serologic hormone assays,[228925],[9320],[10100],[False],[0],[0],[False],['0']
32935,PMC5499060,39298,"Ghrelin (intra-assay CV 3%, inter-assay CV 7%, limit of detection 14 pg/mL), GIP (intra-assay CV 4%, inter-assay CV 10%, limit of detection3 pg/mL), active amylin (intra-assay CV 3%, inter-assay CV 21%, limit of detection 46.07 pg/mL) were analyzed by Luminex xMAP (Milliplex, Millipore, MA).",Serologic hormone assays,[228927],[10101],[10393],[False],[0],[0],[False],['0']
32936,PMC5499060,39299,"Analyses were performed at the Joslin Diabetes Center Specialized Assay Core (Boston, MA).",Serologic hormone assays,[228929],[10394],[10484],[False],[0],[0],[False],['0']
32937,PMC5499060,39300,"In a subset of 8 patients, as previously reported [24], fasting non-esterified free fatty acid (FFA) concentration was measured at Boston Children’s Hospital Clinical Lab by an in vitro enzymatic colorimetric assay, using Roche P Modular system (Roche Diagnostics, Indianapolis, IN) and reagents from Wako Chemicals USA (Richmond, VA).",Serologic hormone assays,[228931],[10485],[10820],[False],[0],[0],[False],['0']
32938,PMC5499060,39301,Statistical analyses,Statistical analyses,[228933],[10821],[10842],[False],[0],[0],[False],['0']
32939,PMC5499060,39302,"Effect of dietary composition on change in fasting hormone levels were evaluated by linear mixed effects repeated measures model with age, gender, change in BMI and diet sequence as covariates.",Statistical analyses,[228935],[10843],[11036],[False],[0],[0],[False],['0']
32940,PMC5499060,39303,"Effect of weight loss was analyzed within a similar model by comparing the observed change to the null hypothesis of no change, using adjusted average change over each of the three test diet periods, and adjusting for age, gender, baseline BMI and diet and diet sequence as covariates.",Statistical analyses,[228937],[11037],[11322],[False],[0],[0],[False],['0']
32941,PMC5499060,39304,"For those hormones which changed in response to dietary composition, the relationships with changes in insulin sensitivity and energy expenditure were analyzed using a similar mixed effects model.",Statistical analyses,[228939],[11323],[11519],[False],[0],[0],[False],['0']
32942,PMC5499060,39305,Results are presented as mean ± standard error of the mean unless otherwise indicated.,Statistical analyses,[228941],[11520],[11606],[False],[0],[0],[False],['0']
32943,PMC5499060,39306,"Hormones with skewed distribution were log -transformed for analysis, and are presented as raw data mean (interquartile range) for generalizability.",Statistical analyses,[228943],[11607],[11755],[False],[0],[0],[False],['0']
32944,PMC5499060,39307,Statistical significance was set as a two-sided alpha value of P < 0.05.,Statistical analyses,[228945],[11756],[11828],[False],[0],[0],[False],['0']
32945,PMC5499060,39308,"Using a strict Bonferroni correction for the 22 analyses performed, the inferences regarding the primary hormone of interest (FGF-21) are unchanged.",Statistical analyses,[228947],[11829],[11977],[False],[0],[0],[False],['0']
32946,PMC5499060,39309,Results,Results,[228949],[11978],[11986],[False],[0],[0],[False],['0']
32947,PMC5499060,39310,Study population,Results|Study population,[228951],[11987],[12003],[False],[0],[0],[False],['0']
32948,PMC5499060,39311,Table 1 Patient demographics and baseline characteristics.,Results|Study population,[228953],[12004],[12062],[False],[0],[0],[False],['0']
32949,PMC5499060,39312,"Participant demographics, as previously reported [1, 25], and baseline characteristics are presented in Table 1   Participants were 30.3 ± 5.7 (SD) years old, 62% male, with BMI 34.4 ± 4.9 (SD) kg/m2.",Results|Study population,[228955],[12063],[12263],[False],[0],[0],[False],['0']
32950,PMC5499060,39313,Samples were available for all 21 participants who completed the study.,Results|Study population,[228957],[12264],[12335],[False],[0],[0],[False],['0']
32951,PMC5499060,39314,"FFA concentration was measured in a subset of 8 participants who were largely representative of the primary cohort [mean age 30.8 ± 6.4 (SD) years old, 50% male, with BMI 33.4 ± 4.8 (SD) kg/m2] [24].",Results|Study population,[228959],[12336],[12535],[False],[0],[0],[False],['0']
32952,PMC5499060,39315,"All participants lost 10–15% of body weight during the initial weight loss period, and no subject regained more than 2% of this initial weight loss, or lost more than an additional 4%, during the weight maintenance period.",Results|Study population,[228961],[12536],[12758],[False],[0],[0],[False],['0']
32953,PMC5499060,39316,"Mean BMI decreased to 30.2 ± 0.9 kg/m2 following weight loss period, and stabilized during the weight maintenance period (low fat 29.8 ± 0.9, low glycemic index 29.7 ± 0.9 and very low carbohydrate 29.8 ± 0.9 kg/m2, P = 0.29).",Results|Study population,[228963],[12759],[12985],[False],[0],[0],[False],['0']
32954,PMC5499060,39317,Effects of dietary macronutrient composition on hormone levels,Results,[228965],[12986],[13050],[False],[0],[0],[False],['0']
32955,PMC5499060,39318,Table 2 Effects of weight loss and dietary composition during weight loss maintenance on fasting hormone levels*.,Results,[228967],[13051],[13164],[False],[0],[0],[False],['0']
32956,PMC5499060,39319,"FGF-21 decreased in response to dietary intervention (P < 0.0001), with differential effect by macronutrient composition (change from baseline: low fat −49.4 ± 16.6, low glycemic index −58.6 ± 16.3, very low carbohydrate −76.7 ± 18.2 pg/mL, P = 0.0002) as shown in Table 2.",Results,[228969],[13165],[13438],[False],[0],[0],[False],['0']
32957,PMC5499060,39320,"Insulin decreased with the intervention (P < 0.0001), also with differential effect by diet [low fat −5.3 ± 1.1, low glycemic index −6.0 ± 1.1, very low carbohydrate −6.1 ± 1.0mIU/L, P = 0.004, Table 2).",Results,[228971],[13439],[13642],[False],[0],[0],[False],['0']
32958,PMC5499060,39321,"HO-1 increased (P = 0.02), with a trend for a differential effect by diet (low fat 0.40 ± 0.26, low glycemic load 0.98 ± 0.63, and very low carbohydrate 0.49 ± 0.29 ng/mL, P = 0.07, N = 16, Table 2).",Results,[228973],[13643],[13842],[False],[0],[0],[False],['0']
32959,PMC5499060,39322,Chemerin decreased (P = 0.001) and ghrelin increased (P = 0.0003) without differential diet effect.,Results,[228975],[13843],[13942],[False],[0],[0],[False],['0']
32960,PMC5499060,39323,"Total bile acid levels, irisin, SFRP-4, GIP, PYY and amylin did not change in response to the test diets (Table 2).",Results,[228977],[13943],[14058],[False],[0],[0],[False],['0']
32961,PMC5499060,39324,"Relationships between changes in metabolic hormones, insulin sensitivity and energy expenditure",Effects of dietary macronutrient composition on hormone levels,[228979],[14059],[14156],[False],[0],[0],[False],['0']
32962,PMC5499060,39325,Fig.,Effects of dietary macronutrient composition on hormone levels,[228981],[14157],[14161],[False],[0],[0],[False],['0']
32963,PMC5499060,39326,"2 Relationship between change in FGF-21 and change in hepatic insulin sensitivity during weight loss maintenance, adjusted for age, baseline BMI, gender, diet composition and diet sequence.",Effects of dietary macronutrient composition on hormone levels,[228983],[14162],[14351],[False],[0],[0],[False],['0']
32964,PMC5499060,39327,Hepatic IS units calculated per Abdul-Ghani et al.,Effects of dietary macronutrient composition on hormone levels,[228985],[14352],[14402],[False],[0],[0],[False],['0']
32965,PMC5499060,39328,[23].,Effects of dietary macronutrient composition on hormone levels,[228987],[14403],[14408],[False],[0],[0],[False],['0']
32966,PMC5499060,39329,"Effects of test diets on absolute changes in insulin sensitivity and energy expenditure were previously reported [1, 25].",Effects of dietary macronutrient composition on hormone levels,[228989],[14409],[14530],[False],[0],[0],[False],['0']
32967,PMC5499060,39330,"A greater decrease in FGF-21 levels [β = −0.565 unit/log(ng/mL), P = 0.02, Fig.",Effects of dietary macronutrient composition on hormone levels,[228991],[14531],[14610],[False],[0],[0],[False],['0']
32968,PMC5499060,39331,"2] was associated with greater improvements in hepatic, but not peripheral, insulin sensitivity.",Effects of dietary macronutrient composition on hormone levels,[228993],[14611],[14707],[False],[0],[0],[False],['0']
32969,PMC5499060,39332,"In the subset of patients in whom free fatty acid levels were measured, the relationship between changes in FGF-21 and hepatic insulin sensitivity was independent of FFA [β = −1.23unit/log(ng/mL), P = 0.04].",Effects of dietary macronutrient composition on hormone levels,[228995],[14708],[14915],[False],[0],[0],[False],['0']
32970,PMC5499060,39333,Changes in insulin and HO-1 did not predict changes in insulin sensitivity indices or changes in total or resting energy expenditure.,Effects of dietary macronutrient composition on hormone levels,[228997],[14916],[15049],[False],[0],[0],[False],['0']
32971,PMC5499060,39334,Discussion,Discussion,[228999],[15050],[15062],[False],[0],[0],[False],['0']
32972,PMC5499060,39335,The main finding from this study is that FGF-21 levels decreased in response to dietary intervention with marked effect by macronutrient composition.,Discussion,[229001],[15063],[15212],[False],[0],[0],[False],['0']
32973,PMC5499060,39336,"Owing to differences in assay type, the absolute values of FGF-21 in our study are lower than some published reports [26], yet consistent with more recent publications [27, 28].",Discussion,[229003],[15213],[15390],[False],[0],[0],[False],['0']
32974,PMC5499060,39337,The greatest reduction in FGF-21 occurred on the very low carbohydrate diet.,Discussion,[229005],[15391],[15467],[False],[0],[0],[False],['0']
32975,PMC5499060,39338,"This finding extends recent observations that consumption of carbohydrate, specifically sugar, increases FGF-21 levels [29–32] and affects preference for sweets [30, 32], and that changes in sweet preference occur with sugar restriction.",Discussion,[229007],[15468],[15705],[False],[0],[0],[False],['0']
32976,PMC5499060,39339,"While the exact mechanism by which FGF-21 responds to nutrient intake is unclear, FGF-21 is stimulated by FFA [33], insulin [33] and ketones [34], and is necessary for changes in lipid and glucose metabolism induced by very low carbohydrate diets [35].",Discussion,[229009],[15706],[15958],[False],[0],[0],[False],['0']
32977,PMC5499060,39340,"In our study, the effect of diet on FGF-21 was independent of FFA concentration, suggesting an alternate mechanism.",Discussion,[229011],[15959],[16074],[False],[0],[0],[False],['0']
32978,PMC5499060,39341,"We speculate (but cannot prove) that the decrease in FGF-21 increased FGF-21 sensitivity, as evidenced by the close relationship with other physiologically relevant variables.",Discussion,[229013],[16075],[16250],[False],[0],[0],[False],['0']
32979,PMC5499060,39342,"Decreases in FGF-21 levels correlated with improvements in hepatic insulin sensitivity, consistent with previous studies showing that FGF-21 administration improves hepatic insulin sensitivity [34].",Discussion,[229015],[16251],[16449],[False],[0],[0],[False],['0']
32980,PMC5499060,39343,"In this context, our findings suggest that obesity comprises a state of FGF-21 resistance.",Discussion,[229017],[16450],[16540],[False],[0],[0],[False],['0']
32981,PMC5499060,39344,This hypothesis is in accordance with recently published data suggesting decreased FGF-21 with weight loss in an adolescent population [36].,Discussion,[229019],[16541],[16681],[False],[0],[0],[False],['0']
32982,PMC5499060,39345,"In addition, the results raise concern for the proposed use of FGF-21 as pharmacologic treatment in obesity until physiological actions are further clarified [35].",Discussion,[229021],[16682],[16845],[False],[0],[0],[False],['0']
32983,PMC5499060,39346,"This scenario may be analogous to leptin treatment in obesity and insulin treatment in type 2 diabetes, in which endogenous hormone resistance may limit efficacy and result in side effects.",Discussion,[229023],[16846],[17035],[False],[0],[0],[False],['0']
32984,PMC5499060,39347,We also measured several other novel obesity-related hormones.,Discussion,[229025],[17036],[17098],[False],[0],[0],[False],['0']
32985,PMC5499060,39348,"Our data are the first to demonstrate that circulating heme oxygenase-1 levels increase with dietary intervention, which may be an endogenous anti-inflammatory response to reduce oxidative stress and inflammation [14], though the clinical significance remains unclear.",Discussion,[229027],[17099],[17367],[False],[0],[0],[False],['0']
32986,PMC5499060,39349,"Though not statistically significant, the largest improvement in HO-1 levels was seen in response to the low glycemic index diet.",Discussion,[229029],[17368],[17497],[False],[0],[0],[False],['0']
32987,PMC5499060,39350,"While there is very little data regarding nutritional regulation of HO-1, this effect may have arisen as a direct result of macronutrient composition on HO-1 or indirectly via weight-loss induced improvement in insulin action [37].",Discussion,[229031],[17498],[17729],[False],[0],[0],[False],['0']
32988,PMC5499060,39351,"We show that chemerin, a chemoattractant for tissue injury, decreased with dietary intervention, similar to previous reports [12].",Discussion,[229033],[17730],[17860],[False],[0],[0],[False],['0']
32989,PMC5499060,39352,"The improved cytokine profile is most likely a response to weight loss, but may also reflect improved dietary quality.",Discussion,[229035],[17861],[17979],[False],[0],[0],[False],['0']
32990,PMC5499060,39353,"We also measured the novel hormones SFRP-4, a biochemical harbinger of type 2 diabetes [16], and irisin, the myokine that may mediate beneficial effects of exercise [17], and bile acids, implicated in regulation of energy expenditure [13].",Discussion,[229037],[17980],[18219],[False],[0],[0],[False],['0']
32991,PMC5499060,39354,These did not change throughout the study.,Discussion,[229039],[18220],[18262],[False],[0],[0],[False],['0']
32992,PMC5499060,39355,"Consistent with previous data [19], fasting ghrelin levels decreased after dietary intervention without specific effect of dietary composition.",Discussion,[229041],[18263],[18406],[False],[0],[0],[False],['0']
32993,PMC5499060,39356,"While very low carbohydrate diets are typically associated with improved satiety and decreased post-prandial intake [3], ghrelin levels did not change across the test diets, likely the result of the complex regulation of hunger.",Discussion,[229043],[18407],[18635],[False],[0],[0],[False],['0']
32994,PMC5499060,39357,"In contrast to previous data [19], we did not observe effects of dietary intervention on the satiety hormones PYY or amylin.",Discussion,[229045],[18636],[18760],[False],[0],[0],[False],['0']
32995,PMC5499060,39358,The primary limitation to these analyses is that hormone concentrations were not measured immediately following the weight loss period.,Discussion,[229047],[18761],[18896],[True],['RelevantOutcomeExcluded'],['hormone concentrations were not measured'],[True],['OutcomeMeasures']
32996,PMC5499060,39359,"In addition, multiple comparisons may increase the false discovery rate.",Discussion,[229052],[18897],[18969],[True],['MultipleTesting'],['multiple comparisons'],[True],['StatisticalAnalysis']
32997,PMC5499060,39360,"Nevertheless, our primary findings regarding FGF-21 would withstand adjustment for multiple comparisons.",Discussion,[229055],[18970],[19074],[False],[0],[0],[False],['0']
32998,PMC5499060,39361,Dietary adherence was measured using a daily diary as completed by the participant.,Discussion,[229057],[19075],[19158],[False],[0],[0],[False],['0']
32999,PMC5499060,39362,"The clear differentiation in several metabolic variables with known dietary effects, such as triglycerides [previously discussed by Ebbeling et al.",Discussion,[229059],[19159],[19306],[False],[0],[0],[False],['0']
33000,PMC5499060,39363,"[1]], suggests excellent compliance.",Discussion,[229061],[19307],[19343],[False],[0],[0],[False],['0']
33001,PMC5499060,39364,"Strengths include a rigorously conducted feeding protocol, outstanding retention rate, and a crossover design allowing for maximal power and control for unmeasured confounding variables.",Discussion,[229063],[19344],[19530],[False],[0],[0],[False],['0']
33002,PMC5499060,39365,Conclusions,Conclusions,[229065],[19531],[19543],[False],[0],[0],[False],['0']
33003,PMC5499060,39366,"In summary, FGF-21 levels decreased in response to dietary interventions varying in macronutrient content, likely secondary to decreasing carbohydrate content, and correlated with hepatic insulin sensitivity.",Conclusions,[229067],[19544],[19752],[False],[0],[0],[False],['0']
33004,PMC5499060,39367,"Overall, this pattern is suggestive of improving FGF-21 resistance, independent of diet-induced effects on free fatty acid concentration.",Conclusions,[229069],[19753],[19890],[False],[0],[0],[False],['0']
33005,PMC5499060,39368,"Dietary intervention affected HO-1 and chemerin concentrations, consistent with an improved inflammatory cytokine profile.",Conclusions,[229071],[19891],[20013],[False],[0],[0],[False],['0']
33006,PMC5499060,39369,Future studies are needed to further define the mechanisms underlying diet and weight loss effects on metabolic hormones.,Conclusions,[229073],[20014],[20135],[False],[0],[0],[False],['0']
33007,PMC5499060,39370,Abbreviations,Abbreviations,[229075],[20136],[20150],[False],[0],[0],[False],['0']
33008,PMC5499060,39371,BMI Body mass index,Abbreviations|BMI Body mass index,[229077],[20151],[20170],[False],[0],[0],[False],['0']
33009,PMC5499060,39372,CV Coefficient of variation,Abbreviations|CV Coefficient of variation,[229079],[20171],[20198],[False],[0],[0],[False],['0']
33010,PMC5499060,39373,FFA Free fatty acid,Abbreviations|FFA Free fatty acid,[229081],[20199],[20218],[False],[0],[0],[False],['0']
33011,PMC5499060,39374,FGF-21 Fibroblast growth factor-21,Abbreviations|FFA Free fatty acid,[229083],[20219],[20253],[False],[0],[0],[False],['0']
33012,PMC5499060,39375,GIP Gastric inhibitory polypeptide,Abbreviations|GIP Gastric inhibitory polypeptide,[229085],[20254],[20288],[False],[0],[0],[False],['0']
33013,PMC5499060,39376,HO Heme oxygenase-1,Abbreviations|GIP Gastric inhibitory polypeptide,[229087],[20289],[20308],[False],[0],[0],[False],['0']
33014,PMC5499060,39377,LF Low fat,Abbreviations|LF Low fat,[229089],[20309],[20319],[False],[0],[0],[False],['0']
33015,PMC5499060,39378,LGI Low glycemic index,Abbreviations|LGI Low glycemic index,[229091],[20320],[20342],[False],[0],[0],[False],['0']
33016,PMC5499060,39379,PYY Peptide-YY,Abbreviations|PYY Peptide-YY,[229093],[20343],[20357],[False],[0],[0],[False],['0']
33017,PMC5499060,39380,SFRP-4 Secreted frizzle-related protein-4,Abbreviations|PYY Peptide-YY,[229095],[20358],[20399],[False],[0],[0],[False],['0']
33018,PMC5499060,39381,VLC Very low carbohydrateAcknowledgements,Abbreviations|PYY Peptide-YY,[229097],[20400],[20441],[False],[0],[0],[False],['0']
33019,PMC5499060,39382,The authors would like to thank the nursing staff at the BCH Clinical and Translational Studies Units and BWH Center for Clinical Investigation and the study participants.,Abbreviations|PYY Peptide-YY,[229099],[20442],[20613],[False],[0],[0],[False],['0']
33020,PMC5499060,39383,Funding,Abbreviations|Funding,[229101],[20614],[20621],[False],[0],[0],[False],['0']
33021,PMC5499060,39384,"National Institutes of Health (R01DK072428, K24DK082730, M01RR02172, M01RR02635, UL1RR02575801, T32 DK007477–31, F32 HL122080) and New Balance Foundation.",Abbreviations|Funding,[229103],[20622],[20776],[False],[0],[0],[False],['0']
33022,PMC5499060,39385,Availability of data and materials,Abbreviations|Availability of data and materials,[229105],[20777],[20811],[False],[0],[0],[False],['0']
33023,PMC5499060,39386,The datasets analyzed during the current study are available from the corresponding author on reasonable request.,Abbreviations|Availability of data and materials,[229107],[20812],[20925],[False],[0],[0],[False],['0']
33024,PMC5499060,39387,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[229109],[20926],[20968],[False],[0],[0],[False],['0']
33025,PMC5499060,39388,This study was approved by the Boston Children’s Hospital (P00009571) and Partners HealthCare Institutional Review Boards (2005-P-001445).,Abbreviations|Ethics approval and consent to participate,[229111],[20969],[21107],[False],[0],[0],[False],['0']
33026,PMC5499060,39389,Consent for publication,Abbreviations|Consent for publication,[229113],[21108],[21131],[False],[0],[0],[False],['0']
33027,PMC5499060,39390,Not applicable.,Abbreviations|Not applicable.,[229115],[21132],[21147],[False],[0],[0],[False],['0']
33028,PMC5499060,39391,Competing interests,Abbreviations|Competing interests,[229117],[21148],[21167],[False],[0],[0],[False],['0']
33029,PMC5499060,39392,DSL has received royalties from books on nutrition.,Abbreviations|Competing interests,[229119],[21168],[21219],[False],[0],[0],[False],['0']
33030,PMC5499060,39393,The other authors have no competing interests to disclose.,Abbreviations|Competing interests,[229121],[21220],[21278],[False],[0],[0],[False],['0']
33031,PMC5499060,39394,Publisher’s Note,Abbreviations|Publisher’s Note,[229123],[21279],[21295],[False],[0],[0],[False],['0']
33032,PMC5499060,39395,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[229125],[21296],[21414],[False],[0],[0],[False],['0']
33471,PMC5529963,703,Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis,Title,[4940],[30698],[94],[False],[0],[0],[False],['0']
33472,PMC5529963,704,Objective,Abstract,[4943],[95],[105],[False],[0],[0],[False],['0']
33473,PMC5529963,705,Patients with rheumatoid arthritis (RA) are at increased cardiovascular risk.,Abstract,[4946],[106],[183],[False],[0],[0],[False],['0']
33474,PMC5529963,706,Recent studies suggest that high-density lipoprotein (HDL) may lose its protective vascular phenotype in inflammatory conditions.,Abstract,[4949],[184],[313],[False],[0],[0],[False],['0']
33475,PMC5529963,707,"However, the effects of common anti-inflammatory treatments on HDL function are not yet known.",Abstract,[4952],[314],[408],[False],[0],[0],[False],['0']
33476,PMC5529963,708,Methods,Abstract,[4955],[409],[416],[False],[0],[0],[False],['0']
33477,PMC5529963,709,We compared the function of HDL in 18 patients with RA and 18 matched healthy controls.,Abstract,[4958],[417],[504],[False],[0],[0],[False],['0']
33478,PMC5529963,710,"Subsequently, patients were randomised to (methotrexate+infliximab (M+I) (5 mg/kg)) or methotrexate+placebo (M+P) infusions for 54 weeks.",Abstract,[4961],[505],[642],[False],[0],[0],[False],['0']
33479,PMC5529963,711,"At week 54 and thereafter, all patients received infliximab therapy until completion of the trial (110 weeks), enabling assessment of the impact of 1 year of infliximab therapy in all patients.",Abstract,[4964],[643],[836],[False],[0],[0],[False],['0']
33480,PMC5529963,712,"HDL functional properties were assessed at baseline, 54 weeks and 110 weeks by measuring the impact on endothelial nitric oxide (NO) bioavailability and superoxide production (SO), paraoxonase activity (PON-1) and cholesterol efflux.",Abstract,[4967],[837],[1070],[False],[0],[0],[False],['0']
33481,PMC5529963,713,Results,Abstract,[4970],[1071],[1078],[False],[0],[0],[False],['0']
33482,PMC5529963,714,All HDL vascular assays were impaired in patients compared with controls.,Abstract,[4973],[1079],[1152],[False],[0],[0],[False],['0']
33483,PMC5529963,715,"After 54 weeks, NO in response to HDL was significantly greater in patients who received M+I compared with those who received M+P.",Abstract,[4976],[1153],[1283],[False],[0],[0],[False],['0']
33484,PMC5529963,716,"Endothelial SO in response to HDL was reduced in both groups, but PON-1 and cholesterol efflux remained unchanged.",Abstract,[4979],[1284],[1398],[False],[0],[0],[False],['0']
33485,PMC5529963,717,All vascular measures improved compared with baseline after ≥1 infliximab therapy in the analysis at 110 weeks.,Abstract,[4982],[1399],[1510],[False],[0],[0],[False],['0']
33486,PMC5529963,718,No significant trend was noted for cholesterol efflux.,Abstract,[4985],[1511],[1565],[False],[0],[0],[False],['0']
33487,PMC5529963,719,Conclusions,Abstract,[4988],[1566],[1577],[False],[0],[0],[False],['0']
33488,PMC5529963,720,HDL function can be improved with anti-inflammatory treatment in patients with RA.,Abstract,[4991],[1578],[1660],[False],[0],[0],[False],['0']
33489,PMC5529963,721,"The M+I combination was superior to the M+P alone, suggesting that the tumour necrosis factor-α pathway may have a role in HDL vascular properties.",Abstract,[4994],[1661],[1808],[False],[0],[0],[False],['0']
33490,PMC5529963,722,Introduction,Introduction,[4997],[1809],[1822],[False],[0],[0],[False],['0']
33491,PMC5529963,723,Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with rheumatoid arthritis (RA).,Introduction,[5000],[1823],[1947],[False],[0],[0],[False],['0']
33492,PMC5529963,724,"Conventional risk factors do not account fully for this, and increased levels of inflammation associated with RA may be an important determinant of CV outcomes.",Introduction,[5003],[1948],[2108],[False],[0],[0],[False],['0']
33493,PMC5529963,725,"In a study of 651 patients, an elevated inflammatory state was associated with an increased CV event rate but a paradoxical reduction in circulating lipid levels.",Introduction,[5006],[2109],[2271],[False],[0],[0],[False],['0']
33494,PMC5529963,726,"This suggests that the relationship between lipid levels and increased CV disease is altered in RA and may be explained, at least in part, by qualitative changes to lipoproteins as a result of the inflammatory milieu.",Introduction,[5009],[2272],[2489],[False],[0],[0],[False],['0']
33495,PMC5529963,727,High-density lipoprotein (HDL) has been suggested to exert anti-atherosclerotic effects via reverse cholesterol transport and activation of protective endothelial pathways.,Introduction,[5012],[2490],[2662],[False],[0],[0],[False],['0']
33496,PMC5529963,728,"In conditions such as RA however, HDL has been shown to acquire pro-inflammatory and pro-thrombotic phenotype that can promote atherogenesis and potentially increase CV risk.",Introduction,[5015],[2663],[2837],[False],[0],[0],[False],['0']
33497,PMC5529963,729,"A previous study from our group demonstrated that the beneficial function of HDL can be restored after resolution of acute inflammatory stimulus, suggesting that the modification of systemic inflammation offers potential for CV risk reduction.",Introduction,[5018],[2838],[3081],[False],[0],[0],[False],['0']
33498,PMC5529963,730,"In our current study, we examined the influence of standard (methotrexate (MTX)) and novel anti-inflammatory treatments (infliximab) on HDL function in patients with RA in a randomised controlled trial over 1 year.",Introduction,[5021],[3082],[3297],[False],[0],[0],[False],['0']
33499,PMC5529963,731,We also assessed the long-term effect of infliximab on HDL function and CV and RA risk factors.,Introduction,[5024],[3298],[3393],[False],[0],[0],[False],['0']
33500,PMC5529963,732,Our findings support the concept that HDL dysfunction can be improved by anti-inflammatory drugs that are widely used for RA therapy and this may confer CV benefit.,Introduction,[5027],[3394],[3558],[False],[0],[0],[False],['0']
33501,PMC5529963,733,Methods,Methods,[5030],[3559],[3567],[False],[0],[0],[False],['0']
33502,PMC5529963,734,Study population and protocol,Methods|Study population and protocol,[5033],[3568],[3597],[False],[0],[0],[False],['0']
33503,PMC5529963,735,RA population,Methods|RA population,[5036],[3598],[3611],[False],[0],[0],[False],['0']
33504,PMC5529963,736,"We studied 18 patients with early erosive RA who were required to have (i) a diagnosis of RA according to the American College of Rheumatology 1987 criteria, (ii) symptoms for 6 months—3 years, (iii) a minimum of two swollen metacarpophalangeal (MCP) joints despite treatment with MTX and (iv) seropositivity for IgM rheumatoid factor.",Methods|RA population,[5039],[3612],[3947],[False],[0],[0],[False],['0']
33505,PMC5529963,737,"In addition, eligible patients were required to have either (i) erosion of ≥1 MCP joint as demonstrated on plain radiography or as a cortical break with irregular margins (or contour) on greyscale ultrasound in both the longitudinal and transverse scanning planes or (ii) erosions of ≥2 MCP joints (cortical breaks with irregular margins/contour on greyscale ultrasound in either the transverse or the longitudinal plane associated with a strong vascular signal in power Doppler mode at the site of the cortical break).",Methods|RA population,[5042],[3948],[4467],[False],[0],[0],[False],['0']
33506,PMC5529963,738,"All patients received oral MTX for greater than or equal to at least 8 weeks, at a minimum stable dosage of 12.5 mg/week but not exceeding 17.5 mg/week.",Methods|RA population,[5045],[4468],[4620],[False],[0],[0],[False],['0']
33507,PMC5529963,739,Patients being treated with oral corticosteroids must have been receiving a stable dosage (10 mg prednisolone per day) for 4 weeks.,Methods|RA population,[5048],[4621],[4752],[False],[0],[0],[False],['0']
33508,PMC5529963,740,Study 1: case–control study,Methods|RA population,[5051],[4753],[4780],[False],[0],[0],[False],['0']
33509,PMC5529963,741,Vascular properties of HDL from 18 patients with RA were compared with 18 healthy control subjects.,Methods|RA population,[5054],[4781],[4880],[False],[0],[0],[False],['0']
33510,PMC5529963,742,"Healthy controls had no CV risk factors by history, clinical examination and laboratory tests, and were matched to patients with RA for age and gender.",Methods|RA population,[5057],[4881],[5032],[False],[0],[0],[False],['0']
33511,PMC5529963,743,Study 2: randomised clinical trial (double-blind phase)—secondary analysis,Methods|RA population,[5060],[5033],[5107],[False],[0],[0],[False],['0']
33512,PMC5529963,744,"All physicians, patients, nurses and other non-clinical members of the study team were blinded for the first year of the study.",Methods|RA population,[5063],[5108],[5235],[False],[0],[0],[False],['0']
33513,PMC5529963,745,Eighteen patients with RA were randomised into one of two treatment groups by a pharmacist who did not participate in the screening visit.,Methods|RA population,[5066],[5236],[5374],[False],[0],[0],[False],['0']
33514,PMC5529963,746,"Eleven patients received infusions of infliximab at 5 mg/kg and seven received placebo (normal saline) infusions at weeks 0, 2 and 6, and then every 8 weeks through week 46.",Methods|RA population,[5069],[5375],[5548],[False],[0],[0],[False],['0']
33515,PMC5529963,747,"At the end of the first year, all patients were maintained a single-blinded study for a further year.",Methods|RA population,[5072],[5549],[5650],[False],[0],[0],[False],['0']
33516,PMC5529963,748,"Patients in the methotrexate+infliximab (M+I ) group received infliximab infusions at weeks 54, 56, 62 and thereafter every 8 weeks.",Methods|RA population,[5075],[5651],[5783],[False],[0],[0],[False],['0']
33517,PMC5529963,749,Those in the M+I group received a placebo infusion at week 56 in order to maintain blinding and received infliximab infusions every 8 weeks until the end of the study (110 weeks) (see online supplementary appendix figure 1).,Methods|RA population,[5078],[5784],[6008],[False],[0],[0],[False],['0']
33518,PMC5529963,750,"As a result, all patients received a minimum of 1 year of infliximab in the two phases of the study.",Methods|RA population,[5081],[6009],[6109],[False],[0],[0],[False],['0']
33519,PMC5529963,751,Baseline dosages of MTX or corticosteroid were maintained during the first 18 weeks of the study.,Methods|RA population,[5084],[6110],[6207],[False],[0],[0],[False],['0']
33520,PMC5529963,752,"After week 18, if any patient failed to achieve a 50% reduction from baseline in the number of swollen hand and wrist joints, the weekly dose of MTX was increased by 2.5 mg once every 4 weeks until a 50% reduction from baseline in the number of swollen hand and wrist joints was achieved, until the dosage of oral MTX reached 25 mg/week or until the dose escalation was limited by toxicity.",Methods|RA population,[5087],[6208],[6598],[False],[0],[0],[False],['0']
33521,PMC5529963,753,"Thereafter, irrespective of their response status, patients continued to receive the maximum tolerated MTX dosage until the end of the study.",Methods|RA population,[5090],[6599],[6740],[False],[0],[0],[False],['0']
33522,PMC5529963,754,"The study was approved by Riverside Research Ethics Committee, and all patients provided informed consent.",Methods|RA population,[5093],[6741],[6847],[False],[0],[0],[False],['0']
33523,PMC5529963,755,"Clinical monitoring of the study was performed independently (Centocor, Malvern, Pennsylvania, USA).",Methods|RA population,[5096],[6848],[6948],[False],[0],[0],[False],['0']
33524,PMC5529963,756,Laboratory assays,Methods|Laboratory assays,[5099],[6949],[6966],[False],[0],[0],[False],['0']
33525,PMC5529963,757,Anthropometric and biochemical measurements,Methods|Anthropometric and biochemical measurements,[5102],[6967],[7010],[False],[0],[0],[False],['0']
33526,PMC5529963,758,Anthropometric measurements were made and body mass index (BMI (kg/m2)) was calculated from weight and height.,Methods|Anthropometric and biochemical measurements,[5105],[7011],[7121],[False],[0],[0],[False],['0']
33527,PMC5529963,759,"Blood pressure was measured in triplicate (HEM-705CP, Omron), and the average of the readings was calculated.",Methods|Anthropometric and biochemical measurements,[5108],[7122],[7231],[False],[0],[0],[False],['0']
33528,PMC5529963,760,"Blood was drawn and processed after an overnight fast, and serum and plasma samples were stored at −70°C for subsequent analysis.",Methods|Anthropometric and biochemical measurements,[5111],[7232],[7361],[False],[0],[0],[False],['0']
33529,PMC5529963,761,"Full blood count, lipid and glucose level measurements were made with standard biochemistry assays and C reactive protein (CRP) was measured with an immunoturbidimetric, high-sensitivity assay (Tina-quant assay performed on a Cobas Integra analyzer, Roche Diagnostics).",Methods|Anthropometric and biochemical measurements,[5114],[7362],[7631],[False],[0],[0],[False],['0']
33530,PMC5529963,762,HDL measurements,Methods|HDL measurements,[5117],[7632],[7648],[False],[0],[0],[False],['0']
33531,PMC5529963,763,"Measurements of HDL function were carried out at baseline, 54 weeks and 110 weeks in patients with RA.",Methods|HDL measurements,[5120],[7649],[7751],[False],[0],[0],[False],['0']
33532,PMC5529963,764,Baseline measurements were compared with those from healthy controls.,Methods|HDL measurements,[5123],[7752],[7821],[False],[0],[0],[False],['0']
33533,PMC5529963,765,HDL isolation,Methods|HDL isolation,[5126],[7822],[7835],[False],[0],[0],[False],['0']
33534,PMC5529963,766,HDL was isolated by sequential ultracentrifugation (d=1.063–1.21 g/mL) using solid potassium bromide for density adjustment.,Methods|HDL isolation,[5129],[7836],[7960],[False],[0],[0],[False],['0']
33535,PMC5529963,767,All functional assays of HDL were carried out within two weeks of isolation by a blinded investigator in duplicate.,Methods|HDL isolation,[5132],[7961],[8076],[False],[0],[0],[False],['0']
33536,PMC5529963,768,Endothelial nitric oxide bioavailability,Methods|Endothelial nitric oxide bioavailability,[5135],[8077],[8117],[False],[0],[0],[False],['0']
33537,PMC5529963,769,"The effect of HDL (50 μg/mL: 60 min, 37°C) on endothelial nitric oxide (NO) bioavailability (bovine aortic endothelial cells (BAECs): passage 4–7; Lonza Bioscience) was measured using a fluorescent indicator.",Methods|Endothelial nitric oxide bioavailability,[5138],[8118],[8326],[False],[0],[0],[False],['0']
33538,PMC5529963,770,"BAECs were incubated with 4,5-diaminofluorescein diacetate (DAF-2; 1Um; Cayman Chemical), and triazolofluorescein fluorescence was measured using an excitation wavelength of 485 nm.",Methods|Endothelial nitric oxide bioavailability,[5141],[8327],[8508],[False],[0],[0],[False],['0']
33539,PMC5529963,771,Endothelial superoxide production,Methods|Endothelial superoxide production,[5144],[8509],[8542],[False],[0],[0],[False],['0']
33540,PMC5529963,772,"The effect of HDL on endothelial cell superoxide production (SO) was measured in unstimulated and tumour necrosis factor-α (TNF-α)-stimulated (5 ng/mL, R&D Systems) human aortic endothelial cells (HAECs) by erythrocyte sedimentation rate (ESR) spectroscopy.",Methods|Endothelial superoxide production,[5147],[8543],[8800],[False],[0],[0],[False],['0']
33541,PMC5529963,773,"HAECs were incubated with HDL from patients and controls (50 μg/mL, 60 min, 37°C), with or without TNF-α and resuspended in Krebs-Hepes buffer (pH 7.4; Noxygen) containing diethyldithiocarbamic acid sodium salt (5 μM, Noxygen) and deferoxamine methanesulfonate salt (25 μM, Noxygen).",Methods|Endothelial superoxide production,[5150],[8801],[9084],[False],[0],[0],[False],['0']
33542,PMC5529963,774,"ESR spectra were recorded after addition of the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH; Noxygen; final concentration 200 μM) using a Bruker e-scan spectrometer (Bruker Biospin).",Methods|Endothelial superoxide production,[5153],[9085],[9298],[False],[0],[0],[False],['0']
33543,PMC5529963,775,The ESR instrumental settings were centre field (B0) 3495 G; field sweep width 10 G; microwave frequency 9.75 GHz; microwave power 19.91 mW; magnetic field modulation frequency 86.00 kHz; modulation amplitude 2.60 G; conversion time 10.24 ms; and number of x-scans 1020.,Methods|Endothelial superoxide production,[5156],[9299],[9569],[False],[0],[0],[False],['0']
33544,PMC5529963,776,Cholesterol efflux capacity,Methods|Cholesterol efflux capacity,[5159],[9570],[9597],[False],[0],[0],[False],['0']
33545,PMC5529963,777,HDL for measurements of efflux capacity was extracted from serum by ApoB depletion.,Methods|Cholesterol efflux capacity,[5162],[9598],[9681],[False],[0],[0],[False],['0']
33546,PMC5529963,778,"Whole serum was incubated for 20 min with a 20% polyethylene glycol (PEG) solution (20% PEG 8000 (sigma P2139) in 200 mM glycine (sigma G8898, pH=10)).",Methods|Cholesterol efflux capacity,[5165],[9682],[9833],[False],[0],[0],[False],['0']
33547,PMC5529963,779,"Samples were centrifuged at 1900 g, and the supernatant was collected and stored at 4°C.",Methods|Cholesterol efflux capacity,[5168],[9834],[9922],[False],[0],[0],[False],['0']
33548,PMC5529963,780,J774 cells were radiolabeled for 24 hours in a medium containing 2 μCi of [3H]-cholesterol per microlitre.,Methods|Cholesterol efflux capacity,[5171],[9923],[10029],[False],[0],[0],[False],['0']
33549,PMC5529963,781,Addition of 0.3 mM 8-(4-chlorophenylthio)-cyclic AMP for 6 hours upregulated expression of ABCA1.,Methods|Cholesterol efflux capacity,[5174],[10030],[10127],[False],[0],[0],[False],['0']
33550,PMC5529963,782,An efflux medium containing 2.8% apolipoprotein B-depleted serum from each individual was added for 4 hours.,Methods|Cholesterol efflux capacity,[5177],[10128],[10236],[False],[0],[0],[False],['0']
33551,PMC5529963,783,"To prevent cholesterol esterification during labelling, equilibration and flux, 2 μg/mL of CP113,818, a acyl-coenzyme A:cholesterol acyltransferase inhibitor was added to all mediums.",Methods|Cholesterol efflux capacity,[5180],[10237],[10420],[False],[0],[0],[False],['0']
33552,PMC5529963,784,Efflux capacity was quantified using liquid scintillation to measure radioactive cholesterol effluxed from the cells (medium+intracellular lipids).,Methods|Cholesterol efflux capacity,[5183],[10421],[10568],[False],[0],[0],[False],['0']
33553,PMC5529963,785,All assays were performed in duplicate and the final average value normalised against a baseline control for statistical analyses between time points.,Methods|Cholesterol efflux capacity,[5186],[10569],[10719],[False],[0],[0],[False],['0']
33554,PMC5529963,786,Paraoxonase-1 activity,Methods|Cholesterol efflux capacity,[5189],[10720],[10742],[False],[0],[0],[False],['0']
33555,PMC5529963,787,"Serum paraoxonase activities were measured by ultraviolet spectrophotometry in a 96-well plate format using paraoxon (Sigma-Aldrich, St Louis, Missouri, USA).",Methods|Cholesterol efflux capacity,[5192],[10743],[10901],[False],[0],[0],[False],['0']
33556,PMC5529963,788,"Briefly, 50 μg/mL HDL was diluted in a reaction mixture containing 10 mM Tris hydrochloride (pH 8.0), 1 M sodium chloride and 2 mM calcium chloride.",Methods|Cholesterol efflux capacity,[5195],[10902],[11050],[False],[0],[0],[False],['0']
33557,PMC5529963,789,"At 24°C, 1.5 mM paraoxon was added to initiate the reaction, and the increase in absorbance at 405 nm was recorded over 30 min.",Methods|Cholesterol efflux capacity,[5198],[11051],[11178],[False],[0],[0],[False],['0']
33558,PMC5529963,790,An extinction coefficient (at 405 nm) of 17 000 M−1 • cm−1 was used to calculate units of paraoxonase-1 (PON-1).,Methods|Cholesterol efflux capacity,[5201],[11179],[11291],[False],[0],[0],[False],['0']
33559,PMC5529963,791,Statistics,Methods|Statistics,[5204],[11292],[11302],[False],[0],[0],[False],['0']
33560,PMC5529963,792,"HDL studies were powered for a 1:1 randomised controlled trial on the basis of NO bioavailability using paired assessments in 35 healthy controls (mean=0.98, SD =0.13, and intraclass correlation 0.91).",Methods|Statistics,[5207],[11303],[11504],[False],[0],[0],[False],['0']
33561,PMC5529963,793,"From this power calculation, a total of seven patients per group was required (power=80% and α=0.05) to detect a 5% difference in the primary outcome (NO bioavailability).",Methods|Statistics,[5210],[11505],[11676],[False],[0],[0],[False],['0']
33562,PMC5529963,794,Normal distribution was assessed using the Shapiro-Wilk test.,Methods|Statistics,[5213],[11677],[11738],[False],[0],[0],[False],['0']
33563,PMC5529963,795,All measures are reported as mean (SD) or median (IQR) for those not normally distributed.,Methods|Statistics,[5216],[11739],[11829],[False],[0],[0],[False],['0']
33564,PMC5529963,796,Baseline comparisons were performed using an independent t-test or Mann-Whitney U test if data was non-normally distributed.,Methods|Statistics,[5219],[11830],[11954],[False],[0],[0],[False],['0']
33565,PMC5529963,797,"Post hoc multivariate analysis of variance (ANOVA) modelling was performed to evaluate the effects of treatment with infliximab (vs placebo) and duration of treatment on HDL function, CV and clinical markers at 54 weeks.",Methods|Statistics,[5222],[11955],[12175],[False],[0],[0],[False],['0']
33566,PMC5529963,798,"A repeated-measures ANOVA, with time point comparisons using Bonferroni-corrected t-tests, was performed to determine differences in HDL function, CV and clinical markers in patients who received 2 years infliximab treatment.",Methods|Statistics,[5225],[12176],[12401],[False],[0],[0],[False],['0']
33567,PMC5529963,799,The Greenhouse-Geisser correction for the F test was used to adjust the degrees of freedom for deviation from sphericity.,Methods|Statistics,[5228],[12402],[12523],[False],[0],[0],[False],['0']
33568,PMC5529963,800,Analysis was performed using GraphPad Prism analysis software.,Methods|Statistics,[5231],[12524],[12586],[False],[0],[0],[False],['0']
33569,PMC5529963,801,A two-sided p value of <0.05 was considered to indicate statistical significance.,Methods|Statistics,[5234],[12587],[12668],[False],[0],[0],[False],['0']
33570,PMC5529963,802,An additional multilevel logistic regression analysis was conducted in R to confirm our results (see online supplementary appendix 2).,Methods|Statistics,[5237],[12669],[12803],[False],[0],[0],[False],['0']
33571,PMC5529963,803,We fit multilevel logistic regression models for measure of HDL function using the lme4 package (http://cran.r-project.org/web/packages/lme4/index.html) in the R statistical language (http://www.r-project.org/).,Methods|Statistics,[5240],[12804],[13015],[False],[0],[0],[False],['0']
33572,PMC5529963,804,All coefficients were taken as random effects.,Methods|Statistics,[5243],[13016],[13062],[False],[0],[0],[False],['0']
33573,PMC5529963,805,Results,Results,[5246],[13063],[13071],[False],[0],[0],[False],['0']
33574,PMC5529963,806,Cross-sectional study: comparison between patients with RA and controls,Results,[5249],[13072],[13143],[False],[0],[0],[False],['0']
33575,PMC5529963,807,"The patients and controls were well matched for age, gender and BMI (table 1).",Results,[5252],[13144],[13222],[False],[0],[0],[False],['0']
33576,PMC5529963,808,"Patients with RA had significantly lower HDL-cholesterol (HDL-c) levels (p=0.01), but increased triglyceride levels (p<0.01).",Results,[5255],[13223],[13348],[False],[0],[0],[False],['0']
33577,PMC5529963,809,Total cholesterol and low-density lipoprotein (LDL)-c were similar between the groups (table 1).,Results,[5258],[13349],[13445],[False],[0],[0],[False],['0']
33578,PMC5529963,810,Patients with RA had significantly higher CRP levels (p<0.01) and lower blood glucose levels compared with controls (p=0.01).,Results,[5261],[13446],[13571],[False],[0],[0],[False],['0']
33579,PMC5529963,811,Baseline characteristics in rheumatoid arthritis and healthy participants,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5264],[13572],[13645],[False],[0],[0],[False],['0']
33580,PMC5529963,812,	Controln=18	Rheumatoid arthritisn=18	p Value	 	Demographics	 	 Age (years)	55.61 (6.37)	58.56 (11.05)	0.20	 	 Gender (proportion female)	10/18	12/18	0.48 (χ2 test)	 	Cardiovascular risk	 	 BMI (kg/m2)	26.27 (2.29)	24.42 (4.71)	0.14	 	 Total cholesterol (mmol/L)	4.93 (0.66)	5.00 (1.43)	0.79	 	 HDL (mmol/L)	1.35 (0.44)	1.02 (0.19)	0.01	 	 LDL (mmol/L)	2.89 (0.88)	3.01 (1.19)	0.74	 	 Triglyceride (mmol/L)	1.13 (0.36)	2.19 (0.96)	<0.01	 	 Glucose (mg/dL)	4.95 [4.70–5.82]	4.49 [3.46–4.94]	0.01	 	Inflammation	 	 CRP (mg/L)	1.00 [1.00–1.00]	22.74 [13.76–40.78]	<0.01,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5267],[13646],[14212],[False],[0],[0],[False],['0']
33581,PMC5529963,813,Values expressed as mean (SD) and median [IQR] for non-normally distributed data.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5270],[14213],[14297],[False],[0],[0],[False],['0']
33582,PMC5529963,814,Comparisons between rheumatoid patients and healthy controls were performed using the independent t-test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5273],[14298],[14403],[False],[0],[0],[False],['0']
33583,PMC5529963,815,Categorical variables were compared using Fisher's exact χ2 test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5276],[14404],[14469],[False],[0],[0],[False],['0']
33584,PMC5529963,816,Comparisons for non-parametric measurements were performed using Mann-Whitney test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5279],[14470],[14553],[False],[0],[0],[False],['0']
33585,PMC5529963,817,"BMI, body mass index; CRP, C reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5282],[14554],[14661],[False],[0],[0],[False],['0']
33586,PMC5529963,818,"HDL, which was isolated from patients with RA, showed reduced NO bioavailability and increased SO production (p<0.01 for both) in cultured endothelial cells compared with controls.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5285],[14662],[14842],[False],[0],[0],[False],['0']
33587,PMC5529963,819,Paraoxonase activity was also impaired in patients with RA (p=0.03) (figure 1).,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5288],[14843],[14922],[False],[0],[0],[False],['0']
33588,PMC5529963,820,Comparison of the functional properties of high-density lipoprotein between patients with rheumatoid arthritis (RA) and healthy controls.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5291],[14923],[15060],[False],[0],[0],[False],['0']
33589,PMC5529963,821,(A) Nitric oxide bioavailability.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5294],[15061],[15094],[False],[0],[0],[False],['0']
33590,PMC5529963,822,(B) Superoxide production.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5297],[15095],[15121],[False],[0],[0],[False],['0']
33591,PMC5529963,823,(C) Paraoxonase-1 (PON-1) activity.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5300],[15122],[15157],[False],[0],[0],[False],['0']
33592,PMC5529963,824,Individual data points for each patients (n=18 in each group).,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5303],[15158],[15220],[False],[0],[0],[False],['0']
33593,PMC5529963,825,Error bars represent mean and SEM.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5306],[15221],[15255],[False],[0],[0],[False],['0']
33594,PMC5529963,826,Double-blind randomised control study: lipid levels and HDL functional properties after 1 year of treatment,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5309],[15256],[15363],[False],[0],[0],[False],['0']
33595,PMC5529963,827,"Both treatment groups were balanced for CV risk factors, RA disease activity and HDL function at baseline (table 2).",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5312],[15364],[15480],[False],[0],[0],[False],['0']
33596,PMC5529963,828,An increase in total cholesterol levels was observed in the infliximab arm at 54 weeks (p=0.04) and was primarily driven by an increase of HDL-c (p=0.02).,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5315],[15481],[15635],[False],[0],[0],[False],['0']
33597,PMC5529963,829,M+P treatment did not alter lipid profile.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5318],[15636],[15678],[False],[0],[0],[False],['0']
33598,PMC5529963,830,"CRP was significantly reduced with infliximab treatment compared with MTX alone (p=0.03), which did not demonstrate a significant change at 54 weeks.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5321],[15679],[15828],[False],[0],[0],[False],['0']
33599,PMC5529963,831,"Clinical and laboratory measures of RA were improved with M+I therapy, but no changes were detected in the M+P arm (table 3).",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5324],[15829],[15954],[False],[0],[0],[False],['0']
33600,PMC5529963,832,Baseline characteristics of patients with RA entering randomised trial,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5327],[15955],[16025],[False],[0],[0],[False],['0']
33601,PMC5529963,833,	Placebon=7	Infliximabn=11	p Value	 	Demographics	 	 Age (years)	55.86 (15.89)	61.30 (11.05)	0.42	 	 Gender (proportion female)	4/7	8/11	0.31 (χ2 test)	 	Cardiovascular risk	 	 BMI (kg/m2)	25.88 (0.55)	24.98 (5.11)	0.73	 	 Total cholesterol (mmol/L)	5.05(1.42)	5.01 (1.5)	0.96	 	 HDL-c (mmol/L)	1.10 (0.22)	0.97 (0.17)	0.20	 	 LDL-c (mmol/L)	3.20 (0.95)	2.90 (1.34)	0.62	 	 Triglyceride (mmol/L)	1.67 (1.00)	2.52 (0.81)	0.63	 	 Glucose (mg/dL)	4.60 (0.70)	4.75 (1.24)	0.59	 	 Systolic BP (mm Hg)	140.70 (7.27)	132.5 (4.67)	0.33	 	 Diastolic BP (mm Hg)	75.71 (3.96)	76.00 (3.70)	0.96	 	HDL function	 	 Nitric oxide bioavailability (% buffer-treated cells)	81.81 (3.97)	84.23 (6.23)	0.37	 	 Superoxide production (nmol/O2-/100 000 cells)	4.37 (1.71)	3.90 (1.66)	0.56	 	 Paraoxonase-1 activity (μmol p-nitrophenol/L/serum/min)	137.52 (1.71)	148.24 (14.49)	0.09	 	 Efflux capacity (%)	12.25 (2.04)	13.52 (1.26)	0.31	 	RA disease activity	 	 CRP (mg/L)	37.65 [19.48–64.31]	26.83 [14.37–37.33]	0.22	 	 ESR (mm/hours)	30.00 [22.00–76.00]	25.00 [14.00–50.50]	0.36	 	 DAS28—CRP score	6.08 (0.71)	5.17 (1.13)	0.09	 	 DAS28—ESR score	5.59 (0.85)	4.68 (1.56)	0.15,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5330],[16026],[17177],[False],[0],[0],[False],['0']
33602,PMC5529963,834,Values expressed as mean (SD) and median [IQR] for non-normally distributed data.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5333],[17178],[17262],[False],[0],[0],[False],['0']
33603,PMC5529963,835,Comparisons between groups were performed using the independent t-test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5336],[17263],[17334],[False],[0],[0],[False],['0']
33604,PMC5529963,836,Categorical variables were compared using Fisher's exact χ2 test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5339],[17335],[17400],[False],[0],[0],[False],['0']
33605,PMC5529963,837,Comparisons for non-parametric measurements were performed using Mann-Whitney test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5342],[17401],[17484],[False],[0],[0],[False],['0']
33606,PMC5529963,838,"APO4, Apolipoprotein A; BMI, body mass index; BP, blood pressure; CRP, C reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; RA, rheumatoid arthritis.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5345],[17485],[17761],[False],[0],[0],[False],['0']
33607,PMC5529963,839,Clinical characteristics and HDL function at 1 year,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5348],[17762],[17813],[False],[0],[0],[False],['0']
33608,PMC5529963,840,	MTX+placebo	MTX+infliximab	 		Baseline	One year	p Value	Baseline	One year	p Value	 	Cardiovascular risk	 	Total cholesterol (mmol/L)	5.05 (1.42)	5.13 (1.55)	0.84	5.01 (1.5)	6.23 (1.63)	0.04	 	HDL-c (mmol/L)	1.10 (0.22)	1.10 (0.42)	0.14	1.02 [0.93–1.09]	1.33 [1.26–1.50]	0.02	 	LDL-c (mmol/L)	3.20 (0.95)	3.18 (1.23)	0.96	2.90 (1.34)	3.65 (1.22)	0.07	 	Triglyceride (mmol/L)	1.35 [1.07–1.62]	1.26 [1.12–1.43]	0.20	2.52 (0.81)	2.48 (0.92)	0.91	 	Glucose (mg/dL)	4.59 [4.28–4.76]	4.40 [4.04–5.12]	0.61	4.75 (1.24)	4.99 (0.95)	0.15	 	HDL function	 	 Nitric oxide bioavailability (% buffer-treated cells)	81.81 (3.97)	82.72 (3.43)	0.67	84.23 (6.23)	89.08 (9.31)	0.02	 	 Superoxide production  (nmol/O2-/100 000 cells)	4.37 (1.71)	3.63 (1.67)	0.03	3.90 (1.66)	2.98 (1.47)	0.01	 	 Paraoxonase-1 activity (μmol p-nitrophenol/L/serum/min)	137.52 (6.41)	153.58 (17.88)	0.07	148.24 (14.49)	155.15 (14.86)	0.07	 	 Efflux capacity (%)	12.25 (2.04)	13.25 (2.52)	0.26	13.52 (1.26)	14.01 (3.23)	0.72	 	RA disease activity	 	 CRP (mg/L)	37.65 [19.48–64.31]	26.00 [13.85–36.83]	0.09	26.83 [14.37–37.33]	2.34 [0.00–6.34]	0.03	 	 ESR (mm/hours)	30.00 [22.00–76.00]	27.50 [16.00–38.00]	0.69	25.00 [14.00–50.50]	20.50 [11.00–30.00]	0.61	 	 DAS28—CRP score	6.08 (0.71)	5.04 (0.85)	0.14	5.17 (1.13)	3.53 (1.06)	<0.01	 	 DAS28—ESR score	5.59 (0.85)	4.43 (1.74)	0.08	4.68 (1.56)	2.25 (0.83)	<0.01,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5351],[17814],[19185],[False],[0],[0],[False],['0']
33609,PMC5529963,841,Values expressed as mean (SD) and median [IQR] for non-normally distributed data.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5354],[19186],[19270],[False],[0],[0],[False],['0']
33610,PMC5529963,842,Comparisons between groups were performed using a paired t-test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5357],[19271],[19335],[False],[0],[0],[False],['0']
33611,PMC5529963,843,Comparisons for non-parametric measurements were performed using Wilcoxon signed-rank test.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5360],[19336],[19427],[False],[0],[0],[False],['0']
33612,PMC5529963,844,"CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; MTX, methotrexate; RA, rheumatoid arthritis.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5363],[19428],[19623],[False],[0],[0],[False],['0']
33613,PMC5529963,845,SO production was reduced from baseline following both M+P and M+I treatments (p=0.03 and 0.01).,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5366],[19624],[19720],[False],[0],[0],[False],['0']
33614,PMC5529963,846,"NO bioavailability was improved (p=0.02) with M+I therapy, but no effect was noted in the M+P patients.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5369],[19721],[19824],[False],[0],[0],[False],['0']
33615,PMC5529963,847,"PON-1 activity increased in a non-significant manner in both groups, but cholesterol efflux capacity remained unchanged (figure 2).",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5372],[19825],[19956],[False],[0],[0],[False],['0']
33616,PMC5529963,848,Between-treatment comparisons at 54 weeks did not demonstrate benefit of M+I treatment over M+P treatment for any measure of HDL function.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5375],[19957],[20095],[False],[0],[0],[False],['0']
33617,PMC5529963,849,These results were confirmed in a multilevel logistic regression model (see online supplementary appendix 2).,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5378],[20096],[20205],[False],[0],[0],[False],['0']
33618,PMC5529963,850,"Comparison of (A) nitric oxide (NO) bioavailability, (B) superoxide production, (C) paraoxonase-1 (PON-1) activity and (D) cholesterol efflux during placebo controlled phase of trial.",Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5381],[20206],[20389],[False],[0],[0],[False],['0']
33619,PMC5529963,851,Box and whisker plot represents mean and 95% CIs.,Results|Baseline characteristics in rheumatoid arthritis and healthy participants,[5384],[20390],[20439],[False],[0],[0],[False],['0']
33620,PMC5529963,852,Single-blinded study,Results|Single-blinded study,[5387],[20440],[20460],[False],[0],[0],[False],['0']
33621,PMC5529963,853,"In grouped analysis of the 18 patients who received 54 weeks of M+I treatment, NO bioavailability increased compared with baseline (p<0.01).",Results|Single-blinded study,[5390],[20461],[20601],[False],[0],[0],[False],['0']
33622,PMC5529963,854,"Furthermore, a reduction in SO (p<0.01) and an increase of PON-1 (both p=0.03) was seen (figure 3).",Results|Single-blinded study,[5393],[20602],[20701],[False],[0],[0],[False],['0']
33623,PMC5529963,855,No change in cholesterol efflux capacity was noted.,Results|Single-blinded study,[5396],[20702],[20753],[False],[0],[0],[False],['0']
33624,PMC5529963,856,Lipid levels were increased and inflammatory and RA disease activity scores were significantly reduced (data not shown).,Results|Single-blinded study,[5399],[20754],[20874],[False],[0],[0],[False],['0']
33625,PMC5529963,857,"Trends in high-density lipoprotein function following 1 year infliximab treatment for (A) nitric oxide (NO) bioavailability, (B) superoxide production and (C) paraoxonase-1 (PON-1) activity.",Results|Single-blinded study,[5402],[20875],[21065],[False],[0],[0],[False],['0']
33626,PMC5529963,858,Individual data points for each patient (n=18).,Results|Single-blinded study,[5405],[21066],[21113],[False],[0],[0],[False],['0']
33627,PMC5529963,859,Error bars represent mean and SEM.,Results|Single-blinded study,[5408],[21114],[21148],[False],[0],[0],[False],['0']
33628,PMC5529963,860,Two years infliximab treatment,Results|Two years infliximab treatment,[5411],[21149],[21179],[False],[0],[0],[False],['0']
33629,PMC5529963,861,Eleven patients received infliximab therapy for 110 weeks.,Results|Two years infliximab treatment,[5414],[21180],[21238],[False],[0],[0],[False],['0']
33630,PMC5529963,862,"Total cholesterol (p=0.08) and LDL-c (p=0.09) showed a non-significant increase at 110 weeks, but there was a significant increase in HDL-c (p=0.01).",Results|Two years infliximab treatment,[5417],[21239],[21388],[False],[0],[0],[False],['0']
33631,PMC5529963,863,CRP and RA disease activity scores were both significantly reduced.,Results|Two years infliximab treatment,[5420],[21389],[21456],[False],[0],[0],[False],['0']
33632,PMC5529963,864,No changes were noted for cholesterol efflux (figure 4).,Results|Two years infliximab treatment,[5423],[21457],[21513],[False],[0],[0],[False],['0']
33633,PMC5529963,865,"Comparison of (A) nitric oxide (NO) bioavailability, (B) superoxide production, (C) paraoxonase-1 (PON-1) activity and (D) cholesterol efflux after 2 years treatment with infliximab.",Results|Two years infliximab treatment,[5426],[21514],[21696],[False],[0],[0],[False],['0']
33634,PMC5529963,866,Individual data points representative for each patient (n=11).,Results|Two years infliximab treatment,[5429],[21697],[21759],[False],[0],[0],[False],['0']
33635,PMC5529963,867,"n.s., not significant.",Results|Two years infliximab treatment,[5432],[21760],[21782],[False],[0],[0],[False],['0']
33636,PMC5529963,868,Repeated-measures ANOVA demonstrated a significant increase in NO bioavailability (p=0.01) and significant reductions in SO production (p=0.02) and PON-1 (p=0.01).,Results|Two years infliximab treatment,[5435],[21783],[21946],[False],[0],[0],[False],['0']
33637,PMC5529963,869,There was no further improvement in HDL function between patients who had received 54 weeks of M+I treatment compared with 110 weeks of M+I treatment.,Results|Two years infliximab treatment,[5438],[21947],[22097],[False],[0],[0],[False],['0']
33638,PMC5529963,870,All measures of HDL function remained impaired compared with the healthy controls (data not shown).,Results|Two years infliximab treatment,[5441],[22098],[22197],[False],[0],[0],[False],['0']
33639,PMC5529963,871,Discussion,Discussion,[5444],[22198],[22209],[False],[0],[0],[False],['0']
33640,PMC5529963,872,This study shows that anti-inflammatory treatments can improve the antioxidant and endothelial protective properties of HDL in patients with erosive RA.,Discussion,[5447],[22210],[22362],[False],[0],[0],[False],['0']
33641,PMC5529963,873,These effects were not accompanied by changes in cholesterol efflux and tracked improvements in RA disease activity.,Discussion,[5450],[22363],[22479],[False],[0],[0],[False],['0']
33642,PMC5529963,874,"Treatment with infliximab in addition to MTX for 2 years showed a benefit for a broad range of HDL functional properties including NO bioavailability, SO production and PON-1 activity.",Discussion,[5453],[22480],[22664],[False],[0],[0],[False],['0']
33643,PMC5529963,875,"These findings suggest that there is a role for anti-inflammatory treatments, particularly those targeting the TNF-α pathway, for improving not only RA disease activity but also potentially CV risk factors in patients with RA.",Discussion,[5456],[22665],[22891],[False],[0],[0],[False],['0']
33644,PMC5529963,876,The threefold increased risk of CV disease in patients with RA is not accounted for by traditional risk factors and is related to increased levels of inflammation.,Discussion,[5459],[22892],[23055],[False],[0],[0],[False],['0']
33645,PMC5529963,877,This influences a range of CV risk factors and causes quantitative and qualitative changes to lipoproteins.,Discussion,[5462],[23056],[23163],[False],[0],[0],[False],['0']
33646,PMC5529963,878,"Substantial evidence has now accumulated, suggesting that inflammation can convert the normally protective HDL into a ‘particle with adverse effects on endothelial function’.",Discussion,[5465],[23164],[23338],[False],[0],[0],[False],['0']
33647,PMC5529963,879,"We showed that HDL has several dysfunctional properties in patients with RA, which may contribute to their increased CV risk.",Discussion,[5468],[23339],[23465],[False],[0],[0],[False],['0']
33648,PMC5529963,880,Our findings are in agreement with previous evidence describing a pro-inflammatory HDL particle with reduced PON-1 activity.,Discussion,[5471],[23466],[23590],[False],[0],[0],[False],['0']
33649,PMC5529963,881,We have now demonstrated an impairment of the beneficial effects of HDL on endothelium with a marked decrease in the stimulation of endothelial NO and increase in SO production compared with healthy controls.,Discussion,[5474],[23591],[23799],[False],[0],[0],[False],['0']
33650,PMC5529963,882,"Diminished production of NO may reflect endothelial dysfunction, an early step in atherogenesis, and represents a novel pathway by which HDL dysfunction can promote arterial disease in patients with RA.",Discussion,[5477],[23800],[24002],[False],[0],[0],[False],['0']
33651,PMC5529963,883,We evaluated the potential for HDL function to be restored following treatment with RA anti-inflammatory therapies.,Discussion,[5480],[24003],[24118],[False],[0],[0],[False],['0']
33652,PMC5529963,884,MTX is commonly used as a first-line treatment in early RA.,Discussion,[5483],[24119],[24178],[False],[0],[0],[False],['0']
33653,PMC5529963,885,Observational studies have demonstrated reduced rates of myocardial infarction and stroke with MTX therapy and the ongoing CIRT trial is evaluating the drug in secondary CV prevention.,Discussion,[5486],[24179],[24363],[False],[0],[0],[False],['0']
33654,PMC5529963,886,"Its exact anti-inflammatory mechanisms remain uncertain, although it has been shown to mediate increased extracellular accumulation of adenosine around connective tissue and reduce levels of CRP and interleukin-6.",Discussion,[5489],[24364],[24577],[False],[0],[0],[False],['0']
33655,PMC5529963,887,Biological inhibition of TNF-α with infliximab in addition to MTX is a more effective approach for reducing RA disease activity.,Discussion,[5492],[24578],[24706],[False],[0],[0],[False],['0']
33656,PMC5529963,888,TNF-α is a proximal cytokine and its blockade has well-established anti-inflammatory actions and effects on lipid metabolism.,Discussion,[5495],[24707],[24832],[False],[0],[0],[False],['0']
33657,PMC5529963,889,"At 54 weeks, NO bioavailability was significantly improved in patients who received infliximab, but not with MTX.",Discussion,[5498],[24833],[24946],[False],[0],[0],[False],['0']
33658,PMC5529963,890,Infliximab has previously been associated with increased AKT/eNOS phosphorylation and improved endothelial function.,Discussion,[5501],[24947],[25063],[False],[0],[0],[False],['0']
33659,PMC5529963,891,Our study provides a novel mechanism by which infliximab can improve endothelial function and contribute to vascular protection by TNF-α inhibition.,Discussion,[5504],[25064],[25212],[False],[0],[0],[False],['0']
33660,PMC5529963,892,"After 1 year of our double-blinded randomised trial, SO production was significantly reduced in both arms.",Discussion,[5507],[25213],[25321],[False],[0],[0],[False],['0']
33661,PMC5529963,893,"MTX is known to inhibit several inflammatory and oxidative stress mediators, associated with increased lipid peroxidation.",Discussion,[5510],[25322],[25444],[False],[0],[0],[False],['0']
33662,PMC5529963,894,Oxidative modification of the HDL particle alters its protective phenotype.,Discussion,[5513],[25445],[25520],[False],[0],[0],[False],['0']
33663,PMC5529963,895,Combination therapy with infliximab caused an additional reduction of SO production compared with MTX alone.,Discussion,[5516],[25521],[25629],[False],[0],[0],[False],['0']
33664,PMC5529963,896,"Previous studies of infliximab in humans suggest that TNF-α inhibition protects against oxidative DNA damage and lipid peroxidation, and this may explain its additional efficacy in reducing SO production.",Discussion,[5519],[25630],[25834],[False],[0],[0],[False],['0']
33665,PMC5529963,897,"Despite a trend towards an increased benefit of infliximab therapy at 1 year, between-treatment comparisons did not reach statistical significance.",Discussion,[5522],[25835],[25982],[False],[0],[0],[False],['0']
33666,PMC5529963,898,Assay of PON-1 provided an additional measure of the antioxidative function of HDL but no significant difference was found in the double-blinded randomised study in either arm at 1 year possibly due to the small sample size.,Discussion,[5526],[25983],[26207],[True],['SampleSize'],['the small sample size'],[True],['UnderpoweredStudy']
33667,PMC5529963,899,"However, PON-1 activity was improved in the single-blinded study at 1 and 2 years treatment of infliximab.",Discussion,[5531],[26208],[26314],[False],[0],[0],[False],['0']
33668,PMC5529963,900,"While the effect of MTX on PON-1 activity has not previously been reported, infliximab is known to improve PON-1 activity through the reduction of lipid peroxidation including myeloperoxidase (MPO) pathways.",Discussion,[5534],[26315],[26522],[False],[0],[0],[False],['0']
33669,PMC5529963,901,Site-specific oxidative modification of PON-1 by MPO impairs the enzymes ability to bind with APOA-1 and reduced MPO could explain the increased PON-1 activity in our patients.,Discussion,[5537],[26523],[26699],[False],[0],[0],[False],['0']
33670,PMC5529963,902,We did not demonstrate any differences in cholesterol efflux with either treatment regimen.,Discussion,[5540],[26700],[26791],[False],[0],[0],[False],['0']
33671,PMC5529963,903,This suggests that anti-inflammatory therapies have a more pronounced impact on the vascular properties of HDL than on its efflux capacity.,Discussion,[5543],[26792],[26931],[False],[0],[0],[False],['0']
33672,PMC5529963,904,These findings support previous reports from our group and indicate that the endothelial function of HDL may be more sensitive to modification than cholesterol efflux.,Discussion,[5546],[26932],[27099],[False],[0],[0],[False],['0']
33673,PMC5529963,905,"However, anti-inflammatory treatments including MTX and infliximab have recently been associated with improved cholesterol efflux in patients with RA, and associated with CV disease in both healthy and at-risk populations.",Discussion,[5549],[27100],[27322],[False],[0],[0],[False],['0']
33674,PMC5529963,906,"These differences may be due to methodological issues in the efflux measurement and their interpretation, and require further investigation.",Discussion,[5552],[27323],[27463],[False],[0],[0],[False],['0']
33675,PMC5529963,907,"Our study was not powered to assess the quantitative relationship between HDL function, inflammation and disease activity.",Discussion,[5555],[27464],[27587],[True],['UnderpoweredStudy'],['Our study was not powered'],[True],['UnderpoweredStudy']
33676,PMC5529963,908,"This also limited our ability to test for between-treatment differences in the randomised study design, although combination therapy demonstrated a clear benefit in the single-blinded study.",Discussion,[5563],[27588],[27778],[True],['UnderpoweredStudy'],['limited our ability to test for between-treatment differences'],[True],['UnderpoweredStudy']
33677,PMC5529963,909,"However, we have demonstrated that a range of vascular properties of HDL can be improved with anti-inflammatory drug therapy.",Discussion,[5567],[27779],[27904],[False],[0],[0],[False],['0']
33678,PMC5529963,910,"HDL function did not return to normal levels following treatment, and this is likely to be as a result of the residual levels of inflammation even after 2 years treatment (data not shown).",Discussion,[5570],[27905],[28093],[False],[0],[0],[False],['0']
33679,PMC5529963,911,The ability of anti-inflammatory treatments to modify CV risk remains an intense area of clinical research.,Discussion,[5573],[28094],[28201],[False],[0],[0],[False],['0']
33680,PMC5529963,912,"Currently, three anti-inflammatory agents are the subject of phase III trials; MTX (CIRT), Darapladib (SOLID-TMI and STABILITY) and canakinumab (CANTOS).",Discussion,[5576],[28202],[28355],[False],[0],[0],[False],['0']
33681,PMC5529963,913,"Recently, both the STABILITY and SOLID-TMI trials reported that darapladib failed to reduce the risk of CV death and myocardial infarction in primary and secondary prevention.",Discussion,[5579],[28356],[28531],[False],[0],[0],[False],['0']
33682,PMC5529963,914,"The CIRT and CANTOS trials are due to report shortly, but our data suggest that monotherapy with MTX alone may not be sufficient.",Discussion,[5582],[28532],[28661],[False],[0],[0],[False],['0']
33683,PMC5529963,915,"Inhibition of TNF-α, a broad immune effector, is more likely to suppress inflammation and may be a better strategy for CV benefit.",Discussion,[5585],[28662],[28792],[False],[0],[0],[False],['0']
33684,PMC5529963,916,This study underlines the need to measure and better understand HDL function.,Discussion,[5588],[28793],[28871],[False],[0],[0],[False],['0']
33685,PMC5529963,917,"It provides evidence for the use of anti-inflammatory treatments, particularly those modulating the TNF-α pathway, to restore the beneficial effects of HDL on the vasculature.",Discussion,[5591],[28872],[29047],[False],[0],[0],[False],['0']
33686,PMC5529963,918,Our findings are of relevance to many recent clinical trials evaluating both HDL elevation and anti-inflammatory therapies with the aim of reducing CV risk.,Discussion,[5594],[29048],[29204],[False],[0],[0],[False],['0']
33687,PMC5529963,919,Key messages,Discussion|Key messages,[5597],[29205],[29217],[False],[0],[0],[False],['0']
33688,PMC5529963,920,What is already known on this subject?,Discussion|What is already known on this subject?,[5600],[29218],[29256],[False],[0],[0],[False],['0']
33689,PMC5529963,921,"Clinical trials aimed at raising high-density lipoprotein (HDL)-cholesterol have thus far failed to improve cardiovascular (CV) outcome, and this may be explained by a dysfunctional HDL phenotype in disease.",Discussion|What is already known on this subject?,[5603],[29257],[29464],[False],[0],[0],[False],['0']
33690,PMC5529963,922,What might this study add?,Discussion|What might this study add?,[5606],[29465],[29491],[False],[0],[0],[False],['0']
33691,PMC5529963,923,This study underlines the need to measure and better understand HDL function.,Discussion|What might this study add?,[5609],[29492],[29569],[False],[0],[0],[False],['0']
33692,PMC5529963,924,"It provides evidence for the use of anti-inflammatory treatments, particularly those modulating the tumour necrosis factor-α pathway, to restore the beneficial effects of HDL on the vasculature.",Discussion|What might this study add?,[5612],[29570],[29764],[False],[0],[0],[False],['0']
33693,PMC5529963,925,How might this impact on clinical practice?,Discussion|How might this impact on clinical practice?,[5615],[29765],[29808],[False],[0],[0],[False],['0']
33694,PMC5529963,926,Our findings are of relevance to many recent clinical trials evaluating both therapies aiming to raise HDL levels and anti-inflammatory agents with the aim of reducing CV risk.,Discussion|How might this impact on clinical practice?,[5618],[29809],[29985],[False],[0],[0],[False],['0']
33695,PMC5529963,927,"Contributors: FON, MC, PC and JD made substantial contributions to the conception and design of the work.",Discussion|How might this impact on clinical practice?,[5621],[29986],[30091],[False],[0],[0],[False],['0']
33696,PMC5529963,928,"FON, EM, NP and ES made substantial contributions to the acquisition, analysis or interpretation of data for the work.",Discussion|How might this impact on clinical practice?,[5624],[30092],[30210],[False],[0],[0],[False],['0']
33697,PMC5529963,929,"FON, MC, CWMK, UL, FD, PCT and JD made substantial contribution to the work or revising it critically for important intellectual content and final approval of the version to be published.",Discussion|How might this impact on clinical practice?,[5627],[30211],[30398],[False],[0],[0],[False],['0']
33698,PMC5529963,930,Funding: F. Hoffmann-La Roche and the Leducq Foundation.,Discussion|How might this impact on clinical practice?,[5630],[30399],[30455],[False],[0],[0],[False],['0']
33699,PMC5529963,931,Competing interests: None declared.,Discussion|How might this impact on clinical practice?,[5633],[30456],[30491],[False],[0],[0],[False],['0']
33700,PMC5529963,932,Patient consent: Obtained.,Discussion|How might this impact on clinical practice?,[5636],[30492],[30518],[False],[0],[0],[False],['0']
33701,PMC5529963,933,Ethics approval: Riverside Research Ethics Committee.,Discussion|How might this impact on clinical practice?,[5639],[30519],[30572],[False],[0],[0],[False],['0']
33702,PMC5529963,934,Provenance and peer review: Not commissioned; externally peer reviewed.,Discussion|How might this impact on clinical practice?,[5642],[30573],[30644],[False],[0],[0],[False],['0']
33962,PMC5544609,30765,Role of Mobile Technology to Improve Diabetes Care in Adults with Type 1 Diabetes: The Remote-T1D Study iBGStar ®  in Type 1 Diabetes Management,Title,[185719],[15281],[144],[False],[0],[0],[False],['0']
33963,PMC5544609,30766,Introduction,Abstract,[185724],[145],[158],[False],[0],[0],[False],['0']
33964,PMC5544609,30767,The role of mobile technology in patient-reported outcomes (PRO) and glycemic control in adults with type 1 diabetes (T1D) needs further evaluation.,Abstract,[185729],[159],[307],[False],[0],[0],[False],['0']
33965,PMC5544609,30768,Methods,Methods,[185734],[308],[316],[False],[0],[0],[False],['0']
33966,PMC5544609,30769,"The single-center, prospective, 6-month, open-label, investigator-initiated study randomized 100 subjects with T1D in a 1:1 fashion to a control group using self-monitoring of blood glucose (SMBG) with Accu-Chek Nano® and an intervention group using SMBG with iPhone plus glucose meter (iBGStar®).",Methods,[185739],[317],[614],[False],[0],[0],[False],['0']
33967,PMC5544609,30770,"The primary endpoint was the change in PRO (hypoglycemia fear score, behavior and worry subscores).",Methods,[185744],[615],[714],[False],[0],[0],[False],['0']
33968,PMC5544609,30771,Secondary outcomes were the improvement in glycemic variability indices and the reduction in A1c values.,Methods,[185749],[715],[819],[False],[0],[0],[False],['0']
33969,PMC5544609,30772,Results,Results,[185754],[820],[828],[False],[0],[0],[False],['0']
33970,PMC5544609,30773,Baseline demographics and glycosylated hemoglobin (A1c) values were similar in the two groups.,Results,[185759],[829],[923],[False],[0],[0],[False],['0']
33971,PMC5544609,30774,"There was a significant decrease in A1c value at 6 months in iBGStar® group compared to the control group (−0.16 vs. −0.51, p = 0.04).",Results,[185764],[924],[1058],[False],[0],[0],[False],['0']
33972,PMC5544609,30775,The total insulin dose increased significantly in the iBGStar® group at 3 months but did not change at 6 months.,Results,[185769],[1059],[1171],[False],[0],[0],[False],['0']
33973,PMC5544609,30776,"The hypoglycemia fear scale (PRO) improved in both groups at 6 months (−1.4 ± 10.0 vs. −3.9 ± 12.5, p = 0.32).",Results,[185774],[1172],[1282],[False],[0],[0],[False],['0']
33974,PMC5544609,30777,Conclusion,Conclusion,[185779],[1283],[1294],[False],[0],[0],[False],['0']
33975,PMC5544609,30778,The use of iBGStar® resulted in better glycemic control and improvement in some PRO (hypoglycemia fear and behavior scores) compared to the control group at 6 months with no increased risk of hypoglycemia.,Conclusion,[185784],[1295],[1500],[False],[0],[0],[False],['0']
33976,PMC5544609,30779,Clinical trial registration,Clinical trial registration,[185789],[1501],[1529],[False],[0],[0],[False],['0']
33977,PMC5544609,30780, ClinicalTrials.gov: NCT01825382.,Clinical trial registration,[185794],[1530],[1563],[False],[0],[0],[False],['0']
33978,PMC5544609,30781,Funding,Funding,[185799],[1564],[1572],[False],[0],[0],[False],['0']
33979,PMC5544609,30782,Sanofi.,Funding|Sanofi.,[185804],[1573],[1580],[False],[0],[0],[False],['0']
33980,PMC5544609,30783,Electronic supplementary material,Electronic supplementary material|Electronic supplementary material,[185809],[1581],[1615],[False],[0],[0],[False],['0']
33981,PMC5544609,30784,"The online version of this article (doi:10.1007/s13300-017-0272-5) contains supplementary material, which is available to authorized users.",Electronic supplementary material|Electronic supplementary material,[185814],[1616],[1755],[False],[0],[0],[False],['0']
33982,PMC5544609,30785,Introduction,Introduction,[185819],[1756],[1770],[False],[0],[0],[False],['0']
33983,PMC5544609,30786,"With increasing incidence of type 1 diabetes (T1D) by 2–5% annually, 5 million people are estimated to have T1D by 2050 in the USA [1, 2].",Introduction,[185824],[1771],[1909],[False],[0],[0],[False],['0']
33984,PMC5544609,30787,"Though intensive insulin therapy (IIT) has been shown to reduce the risk of micro- and macrovascular complications of diabetes, it is associated with a significant increase in the risk for severe hypoglycemia [3].",Introduction,[185829],[1910],[2123],[False],[0],[0],[False],['0']
33985,PMC5544609,30788,"Even fear of hypoglycemia itself poses a significant psychological factor in patients with T1D, preventing them from achieving good glycemic control [4].",Introduction,[185834],[2124],[2277],[False],[0],[0],[False],['0']
33986,PMC5544609,30789,"Despite increases in diabetes care, less than 20% of patients with T1D achieve good glycemic control [as defined by a glycosylated hemoglobin (A1c) of less than 7%] [5].",Introduction,[185839],[2278],[2447],[False],[0],[0],[False],['0']
33987,PMC5544609,30790,Self-monitoring of blood glucose (SMBG) is a valuable tool for decision-making for both patients and clinicians.,Introduction,[185844],[2448],[2560],[False],[0],[0],[False],['0']
33988,PMC5544609,30791,"Frequent SMBG has been shown to improve A1c and reduce hypoglycemia and hypoglycemia fear in patients with type 1 diabetes [6, 7].",Introduction,[185849],[2561],[2691],[False],[0],[0],[False],['0']
33989,PMC5544609,30792,The American Diabetes Association (ADA) recommends that patients whose medication regimen includes multiple daily insulin injections or insulin pumps should test their blood glucose three times or more per day [8].,Introduction,[185854],[2692],[2906],[False],[0],[0],[False],['0']
33990,PMC5544609,30793,"However, not all patients with diabetes test blood glucose three times or more a day [5].",Introduction,[185859],[2907],[2996],[False],[0],[0],[False],['0']
33991,PMC5544609,30794,"Hurdles in poor adherence to SMBG include (a) inaccurate meters, (b) big and bulkier devices, (c) need to poke a finger multiple times, (d) need to carry an additional device all the time, and (e) paper log book entry [6, 7, 9, 10].",Introduction,[185864],[2997],[3229],[False],[0],[0],[False],['0']
33992,PMC5544609,30795,These difficulties result in poor compliance and inadequate glucose control with wide glucose excursions.,Introduction,[185869],[3230],[3335],[False],[0],[0],[False],['0']
33993,PMC5544609,30796,The ubiquity of smartphones and increasing availability of diabetes management mobile applications present a potential method to reduce the daily time and effort required to perform SMBG tasks and share data with a healthcare provider.,Introduction,[185874],[3336],[3571],[False],[0],[0],[False],['0']
33994,PMC5544609,30797,Small studies have shown improvement in glycemic control with the use of electronic log book and Internet-based glucose monitoring systems [11].,Introduction,[185879],[3572],[3716],[False],[0],[0],[False],['0']
33995,PMC5544609,30798,"However, these studies are limited by small sample size and short duration and no reporting of hypoglycemic events [11].",Introduction,[185884],[3717],[3837],[False],[0],[0],[False],['0']
33996,PMC5544609,30799,Using mobile technology to facilitate the review of blood glucose data by both patients and providers could provide an opportunity to reduce glycemic variability and its associated complications [12].,Introduction,[185889],[3838],[4038],[False],[0],[0],[False],['0']
33997,PMC5544609,30800,The iBGStar® system is a blood glucose meter that attaches to an iPhone as a peripheral device.,Introduction,[185894],[4039],[4134],[False],[0],[0],[False],['0']
33998,PMC5544609,30801,"Using the iBGStar® with the Diabetes Manager App, a user’s iPhone can function as a glucometer.",Introduction,[185899],[4135],[4230],[False],[0],[0],[False],['0']
33999,PMC5544609,30802,The Diabetes Manager App takes advantage of the existing user interface and communication capabilities of the iPhone to provide IMBG functionality on a mobile device.,Introduction,[185904],[4231],[4397],[False],[0],[0],[False],['0']
34000,PMC5544609,30803,This study examined the effect of iBGStar® in combination with Diabetes Manager mobile application on patient-reported outcomes (PRO) and glycemic control in adults with T1D.,Introduction,[185909],[4398],[4572],[False],[0],[0],[False],['0']
34001,PMC5544609,30804,Methods,Methods,[185914],[4573],[4581],[False],[0],[0],[False],['0']
34002,PMC5544609,30805,Patient Selection,Methods|Patient Selection,[185919],[4582],[4599],[False],[0],[0],[False],['0']
34003,PMC5544609,30806,"This study was a single-center, prospective, randomized, open-label, and conducted at the Barbara Davis Center for Diabetes.",Methods|Patient Selection,[185924],[4600],[4724],[False],[0],[0],[False],['0']
34004,PMC5544609,30807,The protocol was approved by Colorado Multiple Institutional Review Board at the University of Colorado.,Methods|Patient Selection,[185929],[4725],[4829],[False],[0],[0],[False],['0']
34005,PMC5544609,30808,Adults (≥18 years) with T1D of more than 1-year duration and A1c below 10% were enrolled.,Methods|Patient Selection,[185934],[4830],[4919],[False],[0],[0],[False],['0']
34006,PMC5544609,30809,Pregnant women and those who intended to conceive during the study period were excluded.,Methods|Patient Selection,[185939],[4920],[5008],[False],[0],[0],[False],['0']
34007,PMC5544609,30810,"Participants with T1D on systemic or inhaled steroids, history of severe hypoglycemia in the last 6 months, history of anemia or hemoglobinopathies, history of pancreatitis, history of skin disease, or allergy to adhesives and bandages precluding continuous glucose monitor (CGM) use were also excluded from the study.",Methods|Patient Selection,[185944],[5009],[5327],[False],[0],[0],[False],['0']
34008,PMC5544609,30811,"Study Design, Treatment, and Follow-Up",Methods,[185949],[5328],[5367],[False],[0],[0],[False],['0']
34009,PMC5544609,30812,Subjects were randomized on a 1:1 basis to either the control group or intervention group using stratified block randomization based on a screening A1c <8.5 or ≥8.5 to reduce the possibility of sampling error and ensure that randomization resulted in similar A1c results in each group.,Methods,[185954],[5368],[5653],[False],[0],[0],[False],['0']
34010,PMC5544609,30813,The control group were provided with Accu-Chek Nano® meters and trained on their use at baseline and reinforced at week 1.,Methods,[185959],[5654],[5776],[False],[0],[0],[False],['0']
34011,PMC5544609,30814,"The iBGStar®, an iPhone 4 or 4S, and the Diabetes Manager App were provided to the intervention group.",Methods,[185964],[5777],[5879],[False],[0],[0],[False],['0']
34012,PMC5544609,30815,All subjects were provided with a Dexcom SEVEN Plus® blinded CGM sensor.,Methods,[185969],[5880],[5952],[False],[0],[0],[False],['0']
34013,PMC5544609,30816,"The provider maintained contact with the subjects by electronic communication (email, text, or phone) every 7–14 days during the study.",Methods,[185974],[5953],[6088],[False],[0],[0],[False],['0']
34014,PMC5544609,30817,"Subjects in the control group were encouraged to contact their provider as needed by traditional communication (email, fax, or phone).",Methods,[185979],[6089],[6223],[False],[0],[0],[False],['0']
34015,PMC5544609,30818,"Those in the intervention group were invited to contact the research site if their blood glucose reading was below 60 or above 300 mg/dL using the Diabetes Manager App, which sends a notification text from the iPhone to the provider.",Methods,[185984],[6224],[6457],[False],[0],[0],[False],['0']
34016,PMC5544609,30819,"All diabetes treatment decisions were based on SMBG readings from either the iBGStar® or Accu-Chek Nano® glucometer, depending on group assignment.",Methods,[185989],[6458],[6605],[False],[0],[0],[False],['0']
34017,PMC5544609,30820,Subjects were trained to use glucose log books and instructed to check blood glucose at least three times per day during the study.,Methods,[185994],[6606],[6737],[False],[0],[0],[False],['0']
34018,PMC5544609,30821,"All subjects had similar clinic and phone visits for 3 months, with a 3-month extension.",Methods,[185999],[6738],[6826],[False],[0],[0],[False],['0']
34019,PMC5544609,30822,"A total of eight visits were required—a screening visit, four in-clinic visits, and three phone calls.",Methods,[186004],[6827],[6929],[False],[0],[0],[False],['0']
34020,PMC5544609,30823,"A Dexcom SEVEN Plus® blinded CGM sensor was inserted each clinic visit starting from visit 2 for a total of four visits (for four separate 7-day periods of blinded CGM at visits 2, 4, 6, and 8).",Methods,[186009],[6930],[7124],[False],[0],[0],[False],['0']
34021,PMC5544609,30824,"During the week of blinded CGM use, subjects were not allowed to use their own real-time CGMs.",Methods,[186014],[7125],[7219],[False],[0],[0],[False],['0']
34022,PMC5544609,30825,Subjects were instructed not to take acetaminophen during blinded CGM period as per the label.,Methods,[186019],[7220],[7314],[False],[0],[0],[False],['0']
34023,PMC5544609,30826,Fig.,Methods,[186024],[7315],[7319],[False],[0],[0],[False],['0']
34024,PMC5544609,30827,1 Study design.,Methods,[186029],[7320],[7335],[False],[0],[0],[False],['0']
34025,PMC5544609,30828,"Asterisk CGM blinded insertions 7 days prior to visit, plus sign phone visit.",Methods,[186034],[7336],[7413],[False],[0],[0],[False],['0']
34026,PMC5544609,30829,All the participants were trained on glucose diaries and were asked to check blood glucose at least three times a day during the study period.,Methods,[186039],[7414],[7556],[False],[0],[0],[False],['0']
34027,PMC5544609,30830,All diabetes treatment decisions were based on SMBG readings from iBGStar® in the intervention group and Accu-Chek Nano® glucose meter in the control group.,Methods,[186044],[7557],[7713],[False],[0],[0],[False],['0']
34028,PMC5544609,30831,The study design and visits are shown in Fig.,Methods,[186049],[7714],[7759],[False],[0],[0],[False],['0']
34029,PMC5544609,30832,1.,Methods,[186054],[7760],[7762],[False],[0],[0],[False],['0']
34030,PMC5544609,30833,All participants completed the study and attended to all visits.,Methods,[186059],[7763],[7827],[False],[0],[0],[False],['0']
34031,PMC5544609,30834,"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.",Methods,[186064],[7828],[8044],[False],[0],[0],[False],['0']
34032,PMC5544609,30835,Informed consent was obtained from all participants for being included in the study.,Methods,[186069],[8045],[8129],[False],[0],[0],[False],['0']
34033,PMC5544609,30836,Outcome Measurements,Outcome Measurements,[186074],[8130],[8151],[False],[0],[0],[False],['0']
34034,PMC5544609,30837,"A1C, complete metabolic panel, and complete cell counts were measured at baseline, 1, 3, and 6 months.",Outcome Measurements,[186079],[8152],[8254],[False],[0],[0],[False],['0']
34035,PMC5544609,30838,A1c was measured by DCA 2000.,Outcome Measurements,[186084],[8255],[8284],[False],[0],[0],[False],['0']
34036,PMC5544609,30839,Data on insulin dose was collected from participants by self-report based on logbook entries.,Outcome Measurements,[186089],[8285],[8378],[False],[0],[0],[False],['0']
34037,PMC5544609,30840,The PRO directly describes the patient’s perception of a disease and its treatment without the interpretation of responses by a physician.,Outcome Measurements,[186094],[8379],[8517],[False],[0],[0],[False],['0']
34038,PMC5544609,30841,Hypoglycemia perspective questionnaire and hypoglycemia fear score are the most common tools used for hypoglycemia assessment.,Outcome Measurements,[186099],[8518],[8644],[False],[0],[0],[False],['0']
34039,PMC5544609,30842,Hypoglycemia fear was measured using a 27-question instrument (score range 27–135) with subscales for behavior (10 questions) and worry (17 questions) at the screening and 3- and 6-month visits [13] (Supplement 1).,Outcome Measurements,[186104],[8645],[8859],[False],[0],[0],[False],['0']
34040,PMC5544609,30843,Measurements of average blood glucose and glucose variability were carried out from blinded CGM tracings.,Outcome Measurements,[186109],[8860],[8965],[False],[0],[0],[False],['0']
34041,PMC5544609,30844,Statistical Analysis,Statistical Analysis,[186114],[8966],[8987],[False],[0],[0],[False],['0']
34042,PMC5544609,30845,The analysis was conducted with the intent-to-treat concept.,Statistical Analysis,[186119],[8988],[9048],[False],[0],[0],[False],['0']
34043,PMC5544609,30846,"The primary efficacy endpoint was patient-reported outcomes, including the change in the hypoglycemia fear questionnaire score from baseline to 3 and 6 months.",Statistical Analysis,[186124],[9049],[9208],[False],[0],[0],[False],['0']
34044,PMC5544609,30847,Secondary outcomes were the improvement in glycemic variability indices and the reduction in A1c values.,Statistical Analysis,[186129],[9209],[9313],[False],[0],[0],[False],['0']
34045,PMC5544609,30848,Improvement in glycemic control was measured as the difference in the change in A1c laboratory values of the two arms of the study between baseline and 3 and 6 months.,Statistical Analysis,[186134],[9314],[9481],[False],[0],[0],[False],['0']
34046,PMC5544609,30849,Changes in the primary and secondary efficacy endpoints were assessed using paired t tests examining changes from baseline to 3 months and baseline to 6 months.,Statistical Analysis,[186139],[9482],[9642],[False],[0],[0],[False],['0']
34047,PMC5544609,30850,"Linear regression mixed models were used to assess changes in the primary and secondary endpoints over time, using repeated measures analyses.",Statistical Analysis,[186144],[9643],[9785],[False],[0],[0],[False],['0']
34048,PMC5544609,30851,"As this was a pilot study, formal power calculations were not performed for the primary or secondary endpoints.",Statistical Analysis,[186149],[9786],[9897],[False],[0],[0],[False],['0']
34049,PMC5544609,30852,Statistical significance was defined as p < 0.05.,Statistical Analysis,[186154],[9898],[9947],[False],[0],[0],[False],['0']
34050,PMC5544609,30853,"All analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC, USA).",Statistical Analysis,[186159],[9948],[10030],[False],[0],[0],[False],['0']
34051,PMC5544609,30854,Results,Results,[186164],[10031],[10039],[False],[0],[0],[False],['0']
34052,PMC5544609,30855,Table 1 Baseline characteristics of the study participants (n = 100).,Results,[186169],[10040],[10109],[False],[0],[0],[False],['0']
34053,PMC5544609,30856,"Fifty participants with T1D were randomized to the intervention arm (iBGStar®), and an equal number of participants were randomized to the control group (Accu-Chek Nano®).",Results,[186174],[10110],[10281],[False],[0],[0],[False],['0']
34054,PMC5544609,30857,"The mean age, duration of diabetes, body mass index (BMI), A1c level, the number of self-monitored blood glucose (SMBG) measures, daily insulin basal and bolus dose, and total daily insulin dose per day were similar between control and intervention groups (Table 1).",Results,[186179],[10282],[10548],[False],[0],[0],[False],['0']
34055,PMC5544609,30858,"Similarly, there was no difference in hypoglycemia fear scale, behavior scale, and worry scale between the control and intervention groups at baseline (Table 1).",Results,[186184],[10549],[10710],[False],[0],[0],[False],['0']
34056,PMC5544609,30859,"Table 2 Change in hypoglycemia fear scores, insulin doses, and SMBGs by group over 3 and 6 months.",Results,[186189],[10711],[10810],[False],[0],[0],[False],['0']
34057,PMC5544609,30860,"As shown in Table 2, there were decreases in the overall hypoglycemia fear score in both groups after 3 months, but these decreases were no longer significant at 6 months.",Results,[186194],[10811],[10982],[False],[0],[0],[False],['0']
34058,PMC5544609,30861,There was no difference in the magnitude of the changes in hypoglycemia fear in the study group at either 3 or 6 months.,Results,[186199],[10983],[11103],[False],[0],[0],[False],['0']
34059,PMC5544609,30862,"When examined by subscore, hypoglycemia fear behavior score decreased in only the iBGStar® group at 3 months, but this change did not persist at 6 months.",Results,[186204],[11104],[11258],[False],[0],[0],[False],['0']
34060,PMC5544609,30863,The hypoglycemia fear worry score declined in both groups at 3 months and remained significantly reduced only in the control group at 6 months.,Results,[186209],[11259],[11402],[False],[0],[0],[False],['0']
34061,PMC5544609,30864,"However, the changes in scores for both subscales did not differ by the study group.",Results,[186214],[11403],[11487],[False],[0],[0],[False],['0']
34062,PMC5544609,30865,The total insulin dose increased significantly in the iBGStar® group at 3 months but did not change at 6 months.,Results,[186219],[11488],[11600],[False],[0],[0],[False],['0']
34063,PMC5544609,30866,There was no statistically significant difference between iBGStar® and control groups regarding the number of hypoglycemic events and the average number of SMBG/day.,Results,[186224],[11601],[11766],[False],[0],[0],[False],['0']
34064,PMC5544609,30867,Fig.,Results,[186229],[11767],[11772],[False],[0],[0],[False],['0']
34065,PMC5544609,30868,2 Change in A1c by study group at 3 and 6 months.,Results,[186234],[11773],[11822],[False],[0],[0],[False],['0']
34066,PMC5544609,30869,Fig.,Results,[186239],[11823],[11827],[False],[0],[0],[False],['0']
34067,PMC5544609,30870,3 Percentage of time spent hypoglycemic (<70 mg/dl) by group over 6 months.,Results,[186244],[11828],[11903],[False],[0],[0],[False],['0']
34068,PMC5544609,30871,"There was a decrease in A1c among both the control and iBGStar® groups at 3 months, although the amount of change in A1c was not different between groups (−0.21 vs. −0.4, p = 0.20) (Fig.",Results,[186249],[11904],[12090],[False],[0],[0],[False],['0']
34069,PMC5544609,30872,2).,Results,[186254],[12091],[12094],[False],[0],[0],[False],['0']
34070,PMC5544609,30873,"However, at 6 months, there was a significant decrease in A1c from baseline only in the iBGStar® group, and the amount of change was significantly greater in the iBGStar group than in the control group (−0.16 vs. −0.51, p = 0.04) (Fig.",Results,[186259],[12095],[12330],[False],[0],[0],[False],['0']
34071,PMC5544609,30874,2).,Results,[186264],[12331],[12334],[False],[0],[0],[False],['0']
34072,PMC5544609,30875,The percentage of time spent in hypoglycemia (<70 mg/dl) did not differ by study group (Fig.,Results,[186269],[12335],[12427],[False],[0],[0],[False],['0']
34073,PMC5544609,30876,3).,Results,[186274],[12428],[12431],[False],[0],[0],[False],['0']
34074,PMC5544609,30877,There was no BMI change at 3 and 6 months in groups.,Results,[186279],[12432],[12484],[False],[0],[0],[False],['0']
34075,PMC5544609,30878,Table 3 Hypoglycemia fear predicted by group.,Results,[186284],[12485],[12532],[False],[0],[0],[False],['0']
34076,PMC5544609,30879,"In addition to the univariate analyses, linear mixed modeling was used to examine the change in primary and secondary endpoints over the three study visits using a repeated measures analysis.",Results,[186289],[12533],[12724],[False],[0],[0],[False],['0']
34077,PMC5544609,30880,"Hypoglycemia fear score was examined, adjusting for group, age, diabetes duration, sex, BMI, daily insulin dose per kilogram body weight, and A1c.",Results,[186294],[12725],[12871],[False],[0],[0],[False],['0']
34078,PMC5544609,30881,"There remained no significant differences by group either overall (p = 0.77) or across visits (p = 0.55), but hypoglycemia fear score was significantly lower in men than in women (estimate −5.9, p = 0.046) and was negatively associated with insulin dose (estimate −6.2, p = 0.04).",Results,[186299],[12872],[13152],[False],[0],[0],[False],['0']
34079,PMC5544609,30882,"Hypoglycemia fear score was not associated with age (p = 0.88), diabetes duration (p = 0.50), BMI (p = 0.68), or A1c (p = 0.41) (Table 3).",Results,[186304],[13153],[13291],[False],[0],[0],[False],['0']
34080,PMC5544609,30883,Table 4 A1c prediction by group.,Results,[186309],[13292],[13325],[False],[0],[0],[False],['0']
34081,PMC5544609,30884,"Similarly, linear mixed modeling was used to examine change in A1c across the three visits, adjusted for group, age, diabetes duration, sex, BMI, and daily insulin dose per kilogram body weight.",Results,[186314],[13326],[13520],[False],[0],[0],[False],['0']
34082,PMC5544609,30885,"In this model, there remained no significant difference by study group either overall (p = 0.60) or across visits (p = 0.14), although the change in A1c was significantly associated with insulin dose (estimate 0.5193, p = 0.02).",Results,[186319],[13521],[13749],[False],[0],[0],[False],['0']
34083,PMC5544609,30886,"There was no association between A1c across study visits and age (p = 0.22), diabetes duration (p = 0.76), sex (p = 0.21), or BMI (p = 0.76) (Table 4).",Results,[186324],[13750],[13901],[False],[0],[0],[False],['0']
34084,PMC5544609,30887,"In a post-study survey, 88% of the subjects who used iBGStar® were satisfied with the system.",Results,[186329],[13902],[13996],[False],[0],[0],[False],['0']
34085,PMC5544609,30888,Seventy-five percent of the subjects found the iBGStar® system with the Diabetes Manager App on the iPhone easier than their conventional glucometer for managing their diabetes.,Results,[186334],[13997],[14174],[False],[0],[0],[False],['0']
34086,PMC5544609,30889,Diabetes Manager App was found to be very user-friendly by about 90% of the subjects.,Results,[186339],[14175],[14260],[False],[0],[0],[False],['0']
34087,PMC5544609,30890,Discussion,Discussion,[186344],[14261],[14272],[False],[0],[0],[False],['0']
34088,PMC5544609,30891,"Blood glucose monitoring is an important part of diabetes management, especially in patients on insulin.",Discussion,[186349],[14273],[14377],[False],[0],[0],[False],['0']
34089,PMC5544609,30892,The Diabetes Control and Complications Trial showed that frequent blood glucose monitoring along with intensive therapy is required to maintain tight glycemic control [14].,Discussion,[186354],[14378],[14550],[False],[0],[0],[False],['0']
34090,PMC5544609,30893,"Communication errors between the patients and the providers, absence of documentation of blood glucose results, and failure of downloading glucometers in care centers are common difficulties in diabetes care.",Discussion,[186359],[14551],[14759],[False],[0],[0],[False],['0']
34091,PMC5544609,30894,New technologies require a better understanding by both patients and healthcare workers [15].,Discussion,[186364],[14760],[14853],[False],[0],[0],[False],['0']
34092,PMC5544609,30895,An accurate and convenient way for routine blood glucose monitoring and reporting is essential for following the treatment and making necessary therapeutic changes.,Discussion,[186369],[14854],[15018],[False],[0],[0],[False],['0']
34093,PMC5544609,30896,Integration of smartphones into our life brought new opportunities in healthcare.,Discussion,[186374],[15019],[15100],[False],[0],[0],[False],['0']
34094,PMC5544609,30897,The use of the Diabetes Manager App with the iBGStar® facilitated electronic communication between participants and providers.,Discussion,[186379],[15101],[15227],[False],[0],[0],[False],['0']
34095,PMC5544609,30898,The precision of iBGStar® was shown previously in an in vitro diagnostic device study [16].,Discussion,[186384],[15228],[15319],[False],[0],[0],[False],['0']
34096,PMC5544609,30899,Diabetes Manager App allowed participants to upload and review SMBG data on an iPhone.,Discussion,[186389],[15320],[15406],[False],[0],[0],[False],['0']
34097,PMC5544609,30900,"Even though there was no significant difference between hypoglycemia fear or behavior scales, the subjects indicated that they felt more comfortable using the iBGStar® system.",Discussion,[186394],[15407],[15582],[False],[0],[0],[False],['0']
34098,PMC5544609,30901,Ease of use and convenience probably resulted in greater patient satisfaction at the post-study survey.,Discussion,[186399],[15583],[15686],[False],[0],[0],[False],['0']
34099,PMC5544609,30902,"The app allowed the patient to filter and dynamically interact with log book data, graph trends, and view statistics.",Discussion,[186404],[15687],[15804],[False],[0],[0],[False],['0']
34100,PMC5544609,30903,"Rather than searching through a report, the user can take advantage of features in the app to produce specific queries related to their needs.",Discussion,[186409],[15805],[15947],[False],[0],[0],[False],['0']
34101,PMC5544609,30904,"In our study, using the iBGStar® system improved A1c at 3 months which was maintained at 6 months when compared to the control group.",Discussion,[186414],[15948],[16081],[False],[0],[0],[False],['0']
34102,PMC5544609,30905,Increased insulin requirements may partially explain the decrease of A1C in the iBGStar® group.,Discussion,[186419],[16082],[16177],[False],[0],[0],[False],['0']
34103,PMC5544609,30906,This was a pilot study.,Discussion,[186424],[16178],[16201],[False],[0],[0],[False],['0']
34104,PMC5544609,30907,One of the strengths of this study was that no one had previously evaluated the role of mobile technology in diabetes care.,Discussion,[186429],[16202],[16325],[False],[0],[0],[False],['0']
34105,PMC5544609,30908,Our goal was to learn from this study and plan for a much larger study using social media in the future after implementing changes that would be learned from this pilot study.,Discussion,[186434],[16326],[16501],[False],[0],[0],[False],['0']
34106,PMC5544609,30909,We had objective measures of patient-reported outcomes and treatment satisfaction using validated tools.,Discussion,[186439],[16502],[16606],[False],[0],[0],[False],['0']
34107,PMC5544609,30910,Limitations of this study were that this was a short-term (6 months) study in a single center and we only focused on hypoglycemia risk at CGM and we did not analyze the other blood glucose variabilities.,Discussion,"[186444, 186445, 186446, 186447]","[16607, 16607, 16607, 16607]","[16810, 16810, 16810, 16810]","[True, True, True, True]","['ExperimentalPhaseDuration', 'Unicentric', 'VerySpecificPopulation', 'OutcomeMeasures']","['short-term (6\xa0months)', 'single center', 'only focused on hypoglycemia risk at CGM', 'we did not analyze the other blood glucose variabilities']","[True, True, True, True]","['OutcomeMeasures', 'Population', 'Setting', 'StudyDuration']"
34108,PMC5544609,30911,"Therefore, the results may not be generalized.",Discussion,[186458],[16811],[16857],[True],['Generalization'],['results may not be generalized'],[True],['Generalization']
34109,PMC5544609,30912,Conclusions,Conclusions,[186464],[16858],[16870],[False],[0],[0],[False],['0']
34110,PMC5544609,30913,The use of iBGStar® in combination with Diabetes Manager mobile application improved some PRO (hypoglycemia fear and behavior score) and glycemic control at 6 months without an increased risk of hypoglycemia.,Conclusions,[186469],[16871],[17079],[False],[0],[0],[False],['0']
34111,PMC5544609,30914,Further studies would be required to determine the effects of iBGStar® system and Diabetes Manager App in the long term.,Conclusions,[186474],[17080],[17200],[False],[0],[0],[False],['0']
34112,PMC5544609,30915,Electronic supplementary material,Electronic supplementary material,[186479],[17201],[17235],[False],[0],[0],[False],['0']
34113,PMC5544609,30916,Below is the link to the electronic supplementary material.,Electronic supplementary material,[186484],[17236],[17295],[False],[0],[0],[False],['0']
34114,PMC5544609,30917,Supplementary material 1 (DOCX 15 kb),Electronic supplementary material,[186489],[17296],[17333],[False],[0],[0],[False],['0']
34115,PMC5544609,30918,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.,,[186494],[17334],[17452],[False],[0],[0],[False],['0']
34116,PMC5544609,30919,Acknowledgements,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Acknowledgements,[186499],[17453],[17469],[False],[0],[0],[False],['0']
34117,PMC5544609,30920,Sponsorship for this study was funded by Sanofi as an Investigator Sponsored Study.,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Acknowledgements,[186504],[17470],[17553],[False],[0],[0],[False],['0']
34118,PMC5544609,30921,Article processing charges were funded by the authors.,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Acknowledgements,[186509],[17554],[17608],[False],[0],[0],[False],['0']
34119,PMC5544609,30922,"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval for the version to be published.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Acknowledgements,[186514],[17609],[17853],[False],[0],[0],[False],['0']
34120,PMC5544609,30923,All authors had full access to all the data in this study and took complete responsibility for the integrity of the data and accuracy of the data analysis.,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Acknowledgements,[186519],[17854],[18009],[False],[0],[0],[False],['0']
34121,PMC5544609,30924,Disclosures,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Disclosures,[186524],[18010],[18021],[False],[0],[0],[False],['0']
34122,PMC5544609,30925,"Halis K. Akturk, Christie Beatson, and Janet K Snell-Bergeon have nothing to disclose.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Disclosures,[186529],[18022],[18108],[False],[0],[0],[False],['0']
34123,PMC5544609,30926,"Viral N. Shah’s employer received research Grants from Sanofi, T1D Exchange program.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Disclosures,[186534],[18109],[18193],[False],[0],[0],[False],['0']
34124,PMC5544609,30927,"Viral N. Shah had received speaking fees from the Dexcom Inc. Satish K. Garg had research Grants from Eli Lilly, Novo-Nordisk, Merck, Lexicon, Medtronic, Dario, NCI, T1D Exchange, NIDDK, JDRF, and Sanofi.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Disclosures,[186539],[18194],[18398],[False],[0],[0],[False],['0']
34125,PMC5544609,30928,"Satish K. Garg was on the advisory board and received consulting and travel fees from Medtronic, Roche, Merck, Lexicon, Novo-Nordisk, Sanofi, JNJ, Mannkind, and Eli Lilly.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Disclosures,[186544],[18399],[18570],[False],[0],[0],[False],['0']
34126,PMC5544609,30929,None of the authors have any stocks or equity in any device or pharmaceutical company.,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Disclosures,[186549],[18571],[18657],[False],[0],[0],[False],['0']
34127,PMC5544609,30930,Compliance with Ethics Guidelines,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Compliance with Ethics Guidelines,[186554],[18658],[18691],[False],[0],[0],[False],['0']
34128,PMC5544609,30931,"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Compliance with Ethics Guidelines,[186559],[18692],[18907],[False],[0],[0],[False],['0']
34129,PMC5544609,30932,Informed consent was obtained from all participants for being included in the study.,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Compliance with Ethics Guidelines,[186564],[18908],[18992],[False],[0],[0],[False],['0']
34130,PMC5544609,30933,"The protocol was approved by Colorado Multiple Institutional Review Board at the University of Colorado, Aurora, CO, USA.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Compliance with Ethics Guidelines,[186569],[18993],[19114],[False],[0],[0],[False],['0']
34131,PMC5544609,30934,Data Availability,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Data Availability,[186574],[19115],[19132],[False],[0],[0],[False],['0']
34132,PMC5544609,30935,All data generated or analyzed during this study are included in this published article/as supplementary information files.,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Data Availability,[186579],[19133],[19256],[False],[0],[0],[False],['0']
34133,PMC5544609,30936,Open Access,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Open Access,[186584],[19257],[19268],[False],[0],[0],[False],['0']
34134,PMC5544609,30937,"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4598F0606F7F5B58.|Open Access,[186589],[19269],[19683],[False],[0],[0],[False],['0']
34687,PMC5662095,38711,Male non-insulin users with type 2 diabetes mellitus are predisposed to gastric corpus-predominant inflammation after  H. pylori  infection,Title,[225912],[38682],[139],[False],[0],[0],[False],['0']
34688,PMC5662095,38712,Background,Abstract,[225915],[140],[151],[False],[0],[0],[False],['0']
34689,PMC5662095,38713,Both H. pylori infection and diabetes increase the risk of gastric cancer.,Abstract,[225918],[152],[226],[False],[0],[0],[False],['0']
34690,PMC5662095,38714,This study investigated whether patients with type 2 diabetes mellitus (T2DM) and H. pylori infection had more severe corpus gastric inflammation and higher prevalence of precancerous lesions than non-diabetic controls.,Abstract,[225921],[227],[446],[False],[0],[0],[False],['0']
34691,PMC5662095,38715,Methods,Methods,[225924],[447],[455],[False],[0],[0],[False],['0']
34692,PMC5662095,38716,"A total of 797 patients with type 2 diabetes mellitus were screened for H. pylori, of whom 264 had H. pylori infection.",Methods,[225927],[456],[575],[False],[0],[0],[False],['0']
34693,PMC5662095,38717,"Of these patients, 129 received esophagogastroduodenoscopy to obtain topographic gastric specimens for gastric histology according to the modified Updated Sydney System, corpus-predominant gastritis index (CGI), Operative Link on Gastritis Assessment, and Operative Link on Gastric Intestinal Metaplasia Assessment.",Methods,[225930],[576],[891],[False],[0],[0],[False],['0']
34694,PMC5662095,38718,Non-diabetic dyspeptic patients who had H. pylori infection confirmed by esophagogastroduodenoscopy were enrolled as controls.,Methods,[225933],[892],[1018],[False],[0],[0],[False],['0']
34695,PMC5662095,38719,Results,Results,[225936],[1019],[1027],[False],[0],[0],[False],['0']
34696,PMC5662095,38720,The male as well as total T2DM patients had higher acute/chronic inflammatory and lymphoid follicle scores in the corpus than non-diabetic controls (p < 0.05).,Results,[225939],[1028],[1187],[False],[0],[0],[False],['0']
34697,PMC5662095,38721,"In contrast, the female T2DM patients had higher chronic inflammatory scores in the antrum than the controls (p < 0.05).",Results,[225942],[1188],[1308],[False],[0],[0],[False],['0']
34698,PMC5662095,38722,"In T2DM patients, the males had significantly higher rates of CGI than the females (p < 0.05).",Results,[225945],[1309],[1403],[False],[0],[0],[False],['0']
34699,PMC5662095,38723,"Multivariate logistic regression analysis showed that male patients (odds ratio: 2.28, 95% confidence interval: 1.11–4.69, p = 0.025) and non-insulin users (odds ratio: 0.33, 95% confidence interval: 0.15–0.74, p = 0.007) were independent factors for the presence of CGI in the H. pylori-infected patients with type 2 diabetes mellitus.",Results,[225948],[1404],[1740],[False],[0],[0],[False],['0']
34700,PMC5662095,38724,Conclusions,Conclusions,[225951],[1741],[1753],[False],[0],[0],[False],['0']
34701,PMC5662095,38725,Patients with type 2 diabetes mellitus and H. pylori infection had more severe corpus gastric inflammation than non-diabetic controls.,Conclusions,[225954],[1754],[1888],[False],[0],[0],[False],['0']
34702,PMC5662095,38726,"Moreover, male gender and non-insulin users of T2DM patients were predisposed to have corpus-predominant gastritis after H. pylori infection.",Conclusions,[225957],[1889],[2030],[False],[0],[0],[False],['0']
34703,PMC5662095,38727,Trial registration,Trial registration,[225960],[2031],[2050],[False],[0],[0],[False],['0']
34704,PMC5662095,38728,"ClinicalTrial: NCT02466919, retrospectively registered may 17, 2015.",Trial registration,[225963],[2051],[2119],[False],[0],[0],[False],['0']
34705,PMC5662095,38729,Background,Background,[225966],[2120],[2132],[False],[0],[0],[False],['0']
34706,PMC5662095,38730," H. pylori infection is known to increase the risk of gastric cancers [1, 2], and both chronic atrophic gastritis and intestinal metaplasia have been reported to be precancerous lesions that can potentially develop into gastric adenocarcinoma [3, 4].",Background,[225969],[2133],[2383],[False],[0],[0],[False],['0']
34707,PMC5662095,38731,"The Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) gastritis staging systems are based on the histology of both antrum and corpus tissues and can be applied to assess the risk of gastric cancer in patients with premalignant lesions [5, 6].",Background,[225972],[2384],[2693],[False],[0],[0],[False],['0']
34708,PMC5662095,38732,A more advanced OLGA and OLGIM stage indicates corpus predominance and higher risk of gastric cancer.,Background,[225975],[2694],[2795],[False],[0],[0],[False],['0']
34709,PMC5662095,38733,Our recent previous study further disclosed that the corpus-predominant gastritis index (CGI) can be used to identify H. pylori-infected patients currently without intestinal metaplasia who are at an increased risk of gastric cancer earlier than the OLGA and OLGIM staging systems [7].,Background,[225978],[2796],[3081],[False],[0],[0],[False],['0']
34710,PMC5662095,38734,"Accordingly, if the high-risk group can be identified earlier by gastric histology, H. pylori eradication can be performed to control the risk of gastric cancer [8].",Background,[225981],[3082],[3247],[False],[0],[0],[False],['0']
34711,PMC5662095,38735,Patients with diabetes mellitus (DM) and poor glycemic control are associated with a higher prevalence of gastrointestinal symptoms [9].,Background,[225984],[3248],[3384],[False],[0],[0],[False],['0']
34712,PMC5662095,38736,H. pylori infection has also been associated with insulin resistance and the development of type 2 diabetes mellitus (T2DM) [10–12].,Background,[225987],[3385],[3517],[False],[0],[0],[False],['0']
34713,PMC5662095,38737,"Nevertheless, it remains controversial whether patients with diabetes are predisposed to H. pylori infection [13–16].",Background,[225990],[3518],[3635],[False],[0],[0],[False],['0']
34714,PMC5662095,38738,Several recent studies have shown that patients with DM who live in areas with a higher prevalence of H. pylori and gastric cancer and those with a longer duration of diabetes and poor glycemic control are predisposed to an increased risk of gastric cancer [17–19].,Background,[225993],[3636],[3901],[False],[0],[0],[False],['0']
34715,PMC5662095,38739,"These observations suggest that even though the association between T2DM and a higher rate of H. pylori infection is controversial, the risk of gastric cancer is higher in patients with T2DM once infected with H. pylori.",Background,[225996],[3902],[4122],[False],[0],[0],[False],['0']
34716,PMC5662095,38740,"Therefore, the early detection and prompt treatment of H. pylori infection should be a priority to reduce the risk of gastric cancer in patients with T2DM.",Background,[225999],[4123],[4278],[False],[0],[0],[False],['0']
34717,PMC5662095,38741,Quatrinie et al.,Background,[226002],[4279],[4295],[False],[0],[0],[False],['0']
34718,PMC5662095,38742,"reported 23 diabetic patients with active gastritis, 25% of whom had intestinal metaplasia [14].",Background,[226005],[4296],[4392],[False],[0],[0],[False],['0']
34719,PMC5662095,38743,"In contrast, Małlecki et al.",Background,[226008],[4393],[4421],[False],[0],[0],[False],['0']
34720,PMC5662095,38744,reported a lower prevalence (41% vs. 71%) of chronic active gastritis in 39 patients with DM than in non-diabetic controls [20].,Background,[226011],[4422],[4550],[False],[0],[0],[False],['0']
34721,PMC5662095,38745,"Therefore, we conducted this large-scale comparison between patients with T2DM and non-diabetic dyspeptic controls to investigate whether T2DM predisposes patients to a higher rate of precancerous lesions, more advanced OLGA or OLGIM stage, or a higher rate of CGI to predict the risk of gastric cancer after H. pylori infection.",Background,[226014],[4551],[4880],[False],[0],[0],[False],['0']
34722,PMC5662095,38746,Our results disclosed that male patients and non-insulin users with T2DM were predisposed to have CGI.,Background,[226017],[4881],[4983],[False],[0],[0],[False],['0']
34723,PMC5662095,38747,These findings may offer a promising risk factor stratification tool to identify the high-risk group of patients with T2DM who would benefit from earlier H. pylori eradication to control gastric cancer.,Background,[226020],[4984],[5186],[False],[0],[0],[False],['0']
34724,PMC5662095,38748,Methods,Methods,[226023],[5187],[5195],[False],[0],[0],[False],['0']
34725,PMC5662095,38749,"Patient characteristics, recruitment, and eligibility","Methods|Patient characteristics, recruitment, and eligibility",[226026],[5196],[5249],[False],[0],[0],[False],['0']
34726,PMC5662095,38750,Fig.,"Methods|Patient characteristics, recruitment, and eligibility",[226029],[5250],[5254],[False],[0],[0],[False],['0']
34727,PMC5662095,38751,1 The schematic flow chart of the study protocol and case numbers.,"Methods|Patient characteristics, recruitment, and eligibility",[226032],[5255],[5321],[False],[0],[0],[False],['0']
34728,PMC5662095,38752,We enrolled patients aged ≥ 20 years diagnosed with T2DM who were regularly followed up at the out-patient clinic of National Cheng Kung University Hospital.,"Methods|Patient characteristics, recruitment, and eligibility",[226035],[5322],[5479],[False],[0],[0],[False],['0']
34729,PMC5662095,38753,The diagnostic criteria of T2DM were based on the criteria of American Diabetes Association [21].,"Methods|Patient characteristics, recruitment, and eligibility",[226038],[5480],[5577],[False],[0],[0],[False],['0']
34730,PMC5662095,38754,The schematic flow chart of the study protocol is shown in Fig.,"Methods|Patient characteristics, recruitment, and eligibility",[226041],[5578],[5641],[False],[0],[0],[False],['0']
34731,PMC5662095,38755,1   The Ethical Committee of our institute approved the study design (A-BR-103-021).,"Methods|Patient characteristics, recruitment, and eligibility",[226044],[5642],[5726],[False],[0],[0],[False],['0']
34732,PMC5662095,38756,"The patient’s sera were sent for anti-H. pylori IgG antibody testing (HEL-p TEST™ II; AMRAD Biotech, Perth, Western Australia) using an enzyme-linked immunosorbent assay (ELISA) after obtaining informed consent.","Methods|Patient characteristics, recruitment, and eligibility",[226047],[5727],[5938],[False],[0],[0],[False],['0']
34733,PMC5662095,38757,Patients with seropositive and borderline seropositive results were further confirmed by 13C–UBT.,"Methods|Patient characteristics, recruitment, and eligibility",[226050],[5939],[6036],[False],[0],[0],[False],['0']
34734,PMC5662095,38758,The cutoff value of positive 13C–UBT was defined as an excess 13CO2 ⁄ 12CO2 ratio of more than 4.0‰ [22].,"Methods|Patient characteristics, recruitment, and eligibility",[226053],[6037],[6142],[False],[0],[0],[False],['0']
34735,PMC5662095,38759,"Patients were excluded if they were pregnant, had a critical condition, previously received either successful or unsuccessful H. pylori eradication therapy, bleeding tendency (anti-platelet or anti-coagulant user), or contraindications for esophagogastroduodenoscopy.","Methods|Patient characteristics, recruitment, and eligibility",[226056],[6143],[6410],[False],[0],[0],[False],['0']
34736,PMC5662095,38760,Age- and sex-matched H. pylori-infected non-diabetic patients who had undergone esophagogastroduodenoscopy for upper gastrointestinal diseases in the same period were enrolled as controls.,"Methods|Patient characteristics, recruitment, and eligibility",[226059],[6411],[6599],[False],[0],[0],[False],['0']
34737,PMC5662095,38761,The H. pylori infection of non-diabetic patients was defined by a positive culture or both rapid urea test and histology showing positive.,"Methods|Patient characteristics, recruitment, and eligibility",[226062],[6600],[6738],[False],[0],[0],[False],['0']
34738,PMC5662095,38762,Demographic and laboratory data,Demographic and laboratory data,[226065],[6739],[6772],[False],[0],[0],[False],['0']
34739,PMC5662095,38763,"Among T2DM patients, demographic data including age, sex, body weight and height, duration of diabetes, and the use of oral and intravenous hypoglycemic drugs were recorded.",Demographic and laboratory data,[226068],[6773],[6946],[False],[0],[0],[False],['0']
34740,PMC5662095,38764,The laboratory data included fasting sugar and glycated hemoglobin A1c (HbA1c) at the most recent clinical visit before endoscopy were collected in patietns with T2DM as well.,Demographic and laboratory data,[226071],[6947],[7122],[False],[0],[0],[False],['0']
34741,PMC5662095,38765,Esophagogastroduodenoscopy and gastric histology,Demographic and laboratory data,[226074],[7123],[7172],[False],[0],[0],[False],['0']
34742,PMC5662095,38766,The patients with positive 13C–UBT results were invited to receive an esophagogastroduodenoscopy examination.,Demographic and laboratory data,[226077],[7173],[7282],[False],[0],[0],[False],['0']
34743,PMC5662095,38767,"The gastric biopsy samples were collected for the rapid urea test (one sample) and histology, including from the antrum (two samples), corpus (two samples), and cardia (one sample) sampled topographically as our previous reports [5–7, 23].",Demographic and laboratory data,[226080],[7283],[7522],[False],[0],[0],[False],['0']
34744,PMC5662095,38768,The same pathologist who was blinded to whether or not the patient had diabetes evaluated the histology according to the modified Updated Sydney System [24].,Demographic and laboratory data,[226083],[7523],[7680],[False],[0],[0],[False],['0']
34745,PMC5662095,38769,"Acute inflammation score (AIS, range 0–3), chronic inflammation score (CIS, range 1–3), lymphoid follicle formation (LF, range 0–8), H. pylori density (HPD, range 0–5), atrophic change (AT, range 0–3), and intestinal metaplasia (IM, range 0–3) were scored as in our previous report [24].",Demographic and laboratory data,[226086],[7681],[7968],[False],[0],[0],[False],['0']
34746,PMC5662095,38770,The OLGA and OLGIM grading systems and the presence of CGI were based on our previous reports [5–7].,Demographic and laboratory data,[226089],[7969],[8069],[False],[0],[0],[False],['0']
34747,PMC5662095,38771,H. pylori infection was diagnosed according to a positive 13C–UBT result combined with either positive histology or rapid urea test.,Demographic and laboratory data,[226092],[8070],[8202],[False],[0],[0],[False],['0']
34748,PMC5662095,38772,Statistical analysis,Statistical analysis,[226095],[8203],[8224],[False],[0],[0],[False],['0']
34749,PMC5662095,38773,Categorical data related to baseline characteristics were evaluated using Pearson’s χ2 test or Fisher’s exact test.,Statistical analysis,[226098],[8225],[8340],[False],[0],[0],[False],['0']
34750,PMC5662095,38774,Continuous data were analyzed using the independent t test.,Statistical analysis,[226101],[8341],[8400],[False],[0],[0],[False],['0']
34751,PMC5662095,38775,The histological scores of parameters were compared between the patients with and without T2DM using the Mann-Whitney U test.,Statistical analysis,[226104],[8401],[8526],[False],[0],[0],[False],['0']
34752,PMC5662095,38776,Linear-by-linear regression and multivariate logistic regression analyses were used as appropriate to investigate the independent risk factors for CGI in the patients with T2DM infected with H. pylori.,Statistical analysis,[226107],[8527],[8728],[False],[0],[0],[False],['0']
34753,PMC5662095,38777,"All tests were two-tailed, and a P value less than 0.05 was considered to be statistically significant.",Statistical analysis,[226110],[8729],[8832],[False],[0],[0],[False],['0']
34754,PMC5662095,38778,Results,Results,[226113],[8833],[8841],[False],[0],[0],[False],['0']
34755,PMC5662095,38779,Demographic and endoscopic features of the patients with diabetes and the non-diabetic controls,Results,[226116],[8842],[8937],[False],[0],[0],[False],['0']
34756,PMC5662095,38780,"Of the 797 screened patients with T2DM, the seropositive prevalence of H. pylori infection was 43%.",Results,[226119],[8938],[9037],[False],[0],[0],[False],['0']
34757,PMC5662095,38781,"Of these 797 patients, 264 (249 seropositive and 15 equivocal) had positive 13C–UBT results, of whom 129 received esophagogastroduodenoscopy to obtain gastric biopsies for histological evaluation (Fig.",Results,[226122],[9038],[9239],[False],[0],[0],[False],['0']
34758,PMC5662095,38782,1).,Results,[226125],[9240],[9243],[False],[0],[0],[False],['0']
34759,PMC5662095,38783,Table 1 Comparison of gastric histology assessed according to Updated Sydney System scores among patients with diabetes and non-diabetes controls stratified by gender.,Results,[226128],[9244],[9411],[False],[0],[0],[False],['0']
34760,PMC5662095,38784,"Among these 129 patients (56 females and 73 males), there were no significant differences in mean age between the females and males (61.0 vs. 59.2 years, p > 0.05, Table 1).",Results,[226131],[9412],[9585],[False],[0],[0],[False],['0']
34761,PMC5662095,38785,The mean duration of diabetes in these 129 cases was 11.1 years.,Results,[226134],[9586],[9650],[False],[0],[0],[False],['0']
34762,PMC5662095,38786,"Forty-three (33.3%) of the patients had dyspepsia, nausea, and bloating.",Results,[226137],[9651],[9723],[False],[0],[0],[False],['0']
34763,PMC5662095,38787,The endoscopic diagnoses included 74 (57.4%) cases with non-ulcer gastritis and 55 (23.6%) with peptic ulcers.,Results,[226140],[9724],[9834],[False],[0],[0],[False],['0']
34764,PMC5662095,38788,We also enrolled 129 age- and sex-matched dyspeptic patients who had H. pylori infection confirmed by esophagogastroduodenoscopy (culture or rapid urea test/histology) during the same period as non-diabetic controls.,Results,[226143],[9835],[10051],[False],[0],[0],[False],['0']
34765,PMC5662095,38789,"The rate of non-ulcer gastritis was significantly lower in the controls than in the T2DM patients (45.0% vs. 57.4%, p < 0.05).",Results,[226146],[10052],[10178],[False],[0],[0],[False],['0']
34766,PMC5662095,38790,Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,Results,[226149],[10179],[10275],[False],[0],[0],[False],['0']
34767,PMC5662095,38791,"The patients with T2DM had a significantly higher chronic inflammation score (2.67 vs. 2.48, p = 0.02), acute inflammatory score (1.46 vs. 1.20, p = 0.04), and lymphoid follicle formation score (1.40 vs. 0.67, p = 0.001) in the corpus compared to the controls.",Results,[226152],[10276],[10536],[False],[0],[0],[False],['0']
34768,PMC5662095,38792,"The lymphoid follicle formation score in the antrum was also higher in the patients than in the controls (2.22 vs. 1.73, p = 0.04).",Results,[226155],[10537],[10668],[False],[0],[0],[False],['0']
34769,PMC5662095,38793,"However, there were no significant differences in H. pylori density and the rates of intestinal metaplasia or atrophic change between the patients and controls in any topographic location (antrum, corpus, and cardia) (all p > 0.05).",Results,[226158],[10669],[10901],[False],[0],[0],[False],['0']
34770,PMC5662095,38794,Table 1 shows comparisons of topographic gastric histological features related to H. pylori infection between the patients with T2DM and controls stratified by gender.,Results,[226161],[10902],[11069],[False],[0],[0],[False],['0']
34771,PMC5662095,38795,"Only the male patients with T2DM but not the females gender had statistically significantly higher chronic inflammation score (2.68 vs. 2.32, p = 0.005), acute inflammatory score (1.40 vs. 1.05, p = 0.04), and lymphoid follicle formation score (1.49 vs. 0.66, p = 0.004) in the corpus than the controls.",Results,[226164],[11070],[11373],[False],[0],[0],[False],['0']
34772,PMC5662095,38796,"In contrast, the female patients with T2DM had a significantly higher chronic inflammation score in the antrum than the non-diabetic controls (2.95 vs. 2.77, p = 0.047).",Results,[226167],[11374],[11543],[False],[0],[0],[False],['0']
34773,PMC5662095,38797,"Moreover, there were no significant differences between genders in the rates of intestinal metaplasia and atrophic change between the diabetic patients and controls (all p > 0.05).",Results,[226170],[11544],[11724],[False],[0],[0],[False],['0']
34774,PMC5662095,38798,Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,[226173],[11725],[11821],[False],[0],[0],[False],['0']
34775,PMC5662095,38799,Table 2 The presence of CGI and OLGA and OLGIM grade stratified by gender between the patients with and without diabetes mellitus and non-diabetic controls.,Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,[226176],[11822],[11978],[False],[0],[0],[False],['0']
34776,PMC5662095,38800,"Because the male patients with T2DM had more evident corpus inflammation than the male controls, we further validated whether the male patients with T2DM had a higher rate of CGI or more advanced stages of OLGA or OLGIM than the female patients or controls (Table 2).",Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,[226179],[11979],[12246],[False],[0],[0],[False],['0']
34777,PMC5662095,38801,The male patients with T2DM had a higher rate of CGI than the female patients with T2DM (58.9%.,Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,[226182],[12247],[12342],[False],[0],[0],[False],['0']
34778,PMC5662095,38802,"vs. 39.2%, p = 0.03), but a similar rate of CGI to the non-diabetic male control (58.9% vs. 62.5%, p > 0.05).",Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,[226185],[12343],[12452],[False],[0],[0],[False],['0']
34779,PMC5662095,38803,"In addition, for both genders, there were no significant differences in the rate of either OLGA stage II or higher or OLGIM stage II or higher between the patients and controls (all p > 0.05; Table 2).",Difference in gastric histology between the H. pylori-infected patients with T2DM and controls,[226188],[12453],[12654],[False],[0],[0],[False],['0']
34780,PMC5662095,38804,Non-insulin users and male sex were risk factors for CGI in the H. pylori-infected patients with T2DM,Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226191],[12655],[12758],[False],[0],[0],[False],['0']
34781,PMC5662095,38805,Table 3 The factors related to the presence of corpus-predominant gastritis index in 129 T2DM patients with H. pylori infection.,Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226194],[12759],[12887],[False],[0],[0],[False],['0']
34782,PMC5662095,38806,Fig.,Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226197],[12888],[12892],[False],[0],[0],[False],['0']
34783,PMC5662095,38807,"2 The ratio of precancerous lesions (CGI, OLGIM≥ II, OLGA≥ II) in 73 male and 56 female diabetic patients who did and did not use insulin.",Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226200],[12893],[13031],[False],[0],[0],[False],['0']
34784,PMC5662095,38808,"The trend of the risk of precancerous lesions was analyzed by linear-to-linear regression (CGI, P < 0.001; OLGIM≥ II, P = 0.64; OLGA≥ II, P = 0.51).",Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226203],[13032],[13180],[False],[0],[0],[False],['0']
34785,PMC5662095,38809,We further investigated whether any factors were associated with the presence of CGI in the 129 H. pylori-infected patients with T2DM (Table 3).,Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226206],[13181],[13325],[False],[0],[0],[False],['0']
34786,PMC5662095,38810,"The patients with T2DM with CGI were predominantly male (66.2% vs. 46.9%, p = 0.027) and fewer used insulin for glycemic control (18.5% vs. 42.2%, p = 0.003) than those without CGI.",Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226209],[13326],[13507],[False],[0],[0],[False],['0']
34787,PMC5662095,38811,"However, there were no significant differences in the mean age and duration of DM, rate of non-ulcer gastritis, body mass index, and the levels of fasting sugar and HbA1c between the patients with T2DM with and without CGI (p > 0.05).",Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226212],[13508],[13742],[False],[0],[0],[False],['0']
34788,PMC5662095,38812,"Multivariate logistic regression analysis revealed that male gender (odds ratio: 2.28, 95% confidence interval: 1.11–4.69, p = 0.025) and not using insulin (odds ratio: 0.33, 95% confidence interval: 0.15–0.74, p = 0.007) were independent risk factors for the presence of CGI in the H. pylori-infected patients with T2DM.",Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226215],[13743],[14064],[False],[0],[0],[False],['0']
34789,PMC5662095,38813,"The rates of CGI showed an upward trend for female insulin users, male insulin users, female non-insulin users, and male non-insulin users (p < 0.001 by linear-to-linear regression analysis, Fig.",Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226218],[14065],[14260],[False],[0],[0],[False],['0']
34790,PMC5662095,38814,2).,Male patients with T2DM had a higher rate of CGI than female patients after H. pylori infection,[226221],[14261],[14264],[False],[0],[0],[False],['0']
34791,PMC5662095,38815,Discussions,Discussions,[226224],[14265],[14279],[False],[0],[0],[False],['0']
34792,PMC5662095,38816,"The results of this large-scale, case-control study are highly original to illustrate that male patients with T2DM had higher chronic and acute inflammatory scores in the corpus than non-diabetic dyspeptic controls.",Discussions,[226227],[14280],[14495],[False],[0],[0],[False],['0']
34793,PMC5662095,38817,"Moreover, H. pylori-infected diabetic patients who were male and non-insulin users had a higher risk of CGI.",Discussions,[226230],[14496],[14604],[False],[0],[0],[False],['0']
34794,PMC5662095,38818,This suggests that this high-risk group should receive earlier anti-H. pylori therapy to reduce the risk of gastric cancer.,Discussions,[226233],[14605],[14728],[False],[0],[0],[False],['0']
34795,PMC5662095,38819, H. pylori infection is defined as a type I World Health Organization carcinogen for gastric adenocarcinoma [25].,Discussions,[226236],[14729],[14842],[False],[0],[0],[False],['0']
34796,PMC5662095,38820,A large-scale meta-analysis showed that patients with diabetes had an increased risk of gastric cancer unrelated to their geographical region of residence.,Discussions,[226239],[14843],[14998],[False],[0],[0],[False],['0']
34797,PMC5662095,38821,"Moreover, after adjusting for the prevalence of H. pylori infection, the risk was two-fold higher [26].",Discussions,[226242],[14999],[15102],[False],[0],[0],[False],['0']
34798,PMC5662095,38822,"These results suggest that diabetic patients with H. pylori infection are at a higher risk of gastric cancer, although the underlying mechanism remains unclear.",Discussions,[226245],[15103],[15263],[False],[0],[0],[False],['0']
34799,PMC5662095,38823,"Chronic gastric inflammation has been reported to play a major role in gastric carcinogenesis [27, 28].",Discussions,[226248],[15264],[15367],[False],[0],[0],[False],['0']
34800,PMC5662095,38824,"In addition, more severe chronic gastric inflammation in the corpus has been reported to result in an increased risk of gastric cancer [28].",Discussions,[226251],[15368],[15508],[False],[0],[0],[False],['0']
34801,PMC5662095,38825,We found that the patients with T2DM and H. pylori infection had more severe inflammation in the corpus than those without diabetes.,Discussions,[226254],[15509],[15641],[False],[0],[0],[False],['0']
34802,PMC5662095,38826,"Moreover, the aggregation of lymphoid hyperplasia, which indicates the severity and activity of mucosal inflammation [29], was also severe in both the antrum and corpus of the patients with T2DM.",Discussions,[226257],[15642],[15837],[False],[0],[0],[False],['0']
34803,PMC5662095,38827,A greater severity of chronic gastric inflammation in the corpus in patients with T2DM may therefore lead to an increased risk of gastric cancer.,Discussions,[226260],[15838],[15983],[False],[0],[0],[False],['0']
34804,PMC5662095,38828,"Males are known to have a higher risk of gastric cancer, and is similar in populations with high and low incidence of gastric cancer [30].",Discussions,[226263],[15984],[16122],[False],[0],[0],[False],['0']
34805,PMC5662095,38829,17β-estradiol (E2) has been shown to reduce female gastric neutrophil infiltration and prevent H. pylori-induced gastric cancer in mice [31].,Discussions,[226266],[16123],[16264],[False],[0],[0],[False],['0']
34806,PMC5662095,38830,"Other reproductive factors such as years of fertility and parity are associated to gastric cancer development [32, 33], however, the results are not consistent [34].",Discussions,[226269],[16265],[16430],[False],[0],[0],[False],['0']
34807,PMC5662095,38831,"However, the accurately biological mechanism of gender difference in gastric cancer risk needs more detail study.",Discussions,[226272],[16431],[16544],[False],[0],[0],[False],['0']
34808,PMC5662095,38832,"In the current study, we found that H. pylori-infected male patients with T2DM but not female patients had higher levels of neutrophils and lymphocytes over the corpus (Table 1) compared to the controls.",Discussions,[226275],[16545],[16748],[False],[0],[0],[False],['0']
34809,PMC5662095,38833,"Moreover, the male patients with T2DM had a significantly higher rate of CGI than the female patients with T2DM (Table 2).",Discussions,[226278],[16749],[16871],[False],[0],[0],[False],['0']
34810,PMC5662095,38834,"These findings are consistent with the general concept that males are at a higher risk of gastric cancer, and also that male patients with T2DM are at a higher risk of gastric precancerous lesions than females.",Discussions,[226281],[16872],[17082],[False],[0],[0],[False],['0']
34811,PMC5662095,38835,Insulin is the principle therapy for both patients with type 1 DM and also for those with T2DM with a poor response to oral hypoglycemic agents.,Discussions,[226284],[17083],[17227],[False],[0],[0],[False],['0']
34812,PMC5662095,38836,We found that not using insulin was a significant factor for the development of CGI.,Discussions,[226287],[17228],[17312],[False],[0],[0],[False],['0']
34813,PMC5662095,38837,Kim et al.,Discussions,[226290],[17313],[17323],[False],[0],[0],[False],['0']
34814,PMC5662095,38838,reported that a lower fasting glucose level (<86 mg/dL) was significantly associated with an increased risk of distal gastric cancer compared to a normal level [35].,Discussions,[226293],[17324],[17489],[False],[0],[0],[False],['0']
34815,PMC5662095,38839,"However, there were no significant differences in fasting sugar or HbA1c levels between the patients with and without CGI in this study.",Discussions,[226296],[17490],[17626],[False],[0],[0],[False],['0']
34816,PMC5662095,38840,"Furthermore, the insulin-like growth factor pathway has been reported to play a key role in the malignant progression of esophageal cancer in in vitro and in vivo studies [36].",Discussions,[226299],[17627],[17803],[False],[0],[0],[False],['0']
34817,PMC5662095,38841,"In addition, a large follow-up cohort study showed that the use of insulin and glinides was associated with a higher risk of stomach cancer [37].",Discussions,[226302],[17804],[17949],[False],[0],[0],[False],['0']
34818,PMC5662095,38842,"In contrast to our findings, a large population-based study reported that the use of insulin was not associated with the risk of gastric cancer [38].",Discussions,[226305],[17950],[18099],[False],[0],[0],[False],['0']
34819,PMC5662095,38843,"Therefore, further large-scale longitudinal observational studies are needed to elucidate the association between the use of insulin in patients with diabetes and gastric malignancy.",Discussions,[226308],[18100],[18282],[False],[0],[0],[False],['0']
34820,PMC5662095,38844,"Atrophic gastritis and intestinal metaplasia are known to be precancerous lesions predisposing to gastric carcinogenesis [3, 7].",Discussions,[226311],[18283],[18411],[False],[0],[0],[False],['0']
34821,PMC5662095,38845,Our previous study showed that patients with gastric cancer had a higher prevalence of CGI and OLGIM stage II-IV.,Discussions,[226314],[18412],[18525],[False],[0],[0],[False],['0']
34822,PMC5662095,38846,"In addition, CGI has been reported to be highly correlated to the presence of spasmolytic polypeptide-expressing metaplasia [7].",Discussions,[226317],[18526],[18654],[False],[0],[0],[False],['0']
34823,PMC5662095,38847,"Although we did not find a higher grade of OLGA or OLGIM in the patients with T2DM compared to the controls, the male patients with T2DM had a higher rate of CGI than the female patients with T2DM (Table 3).",Discussions,[226320],[18655],[18862],[False],[0],[0],[False],['0']
34824,PMC5662095,38848,This suggests that the higher prevalence of gastric cancer in H. pylori-infected male patients with T2DM may be caused by chronic corpus inflammation and CGI rather than intestinal metaplasia.,Discussions,[226323],[18863],[19055],[False],[0],[0],[False],['0']
34825,PMC5662095,38849,There are some limitations to this study.,Discussions,[226326],[19056],[19097],[False],[0],[0],[False],['0']
34826,PMC5662095,38850,"First, all of the non-diabetic control patients were dyspeptic, so that we could not investigate the role of dyspeptic symptoms in the development of gastric precancerous lesions.",Discussions,[226329],[19098],[19277],[True],['VerySpecificPopulation'],['all of the non-diabetic control patients were dyspeptic'],[True],['Population']
34827,PMC5662095,38851,"Furthermore, the other risk factors related to gastric cancer such as cigarette smoking, dietary habits, and body mass index were not available in controls.",Discussions,[226336],[19278],[19434],[True],['VerySpecificPopulation'],"['the other risk factors related to gastric cancer such as cigarette smoking, dietary habits, and body mass index were not available in controls']",[True],['Population']
34828,PMC5662095,38852,"Second, the analysis of hypoglycemic drugs for precancerous lesions was limited to insulin.",Discussions,[226343],[19435],[19526],[True],['Intervention'],['the analysis of hypoglycemic drugs for precancerous lesions was limited to insulin'],[True],['Intervention']
34829,PMC5662095,38853,"Third, the exact mechanism by which chronic inflammation rather than chronic atrophic gastritis-intestinal metaplasia induces gastric carcinogenesis in patients with T2DM remains unclear.",Discussions,[226347],[19527],[19714],[False],[0],[0],[False],['0']
34830,PMC5662095,38854,Conclusions,Conclusions,[226350],[19715],[19727],[False],[0],[0],[False],['0']
34831,PMC5662095,38855,"In conclusion, the patients with T2DM had more severe corpus gastric inflammation than the non-diabetic controls after H. pylori infection.",Conclusions,[226353],[19728],[19867],[False],[0],[0],[False],['0']
34832,PMC5662095,38856,Male sex and not using insulin were independent risk factors for CGI after H. pylori infection in the patients with T2DM.,Conclusions,[226356],[19868],[19989],[False],[0],[0],[False],['0']
34833,PMC5662095,38857,Treating male patients with T2DM who do not use insulin for H. pylori treatment may be promising in reducing the risk of gastric cancer.,Conclusions,[226359],[19990],[20126],[False],[0],[0],[False],['0']
34834,PMC5662095,38858,Abbreviations,Abbreviations,[226362],[20127],[20141],[False],[0],[0],[False],['0']
34835,PMC5662095,38859,13C–UBT,Abbreviations,[226365],[20142],[20149],[False],[0],[0],[False],['0']
34836,PMC5662095,38860,13C–Urea breath test,Abbreviations,[226368],[20150],[20171],[False],[0],[0],[False],['0']
34837,PMC5662095,38861,CGI Corpus-predominant gastritis index,Abbreviations|CGI Corpus-predominant gastritis index,[226371],[20172],[20210],[False],[0],[0],[False],['0']
34838,PMC5662095,38862,OLGA Operative link on gastritis assessment,Abbreviations|OLGA Operative link on gastritis assessment,[226374],[20211],[20254],[False],[0],[0],[False],['0']
34839,PMC5662095,38863,OLGIM Operative link on gastric intestinal metaplasia assessment,Abbreviations|OLGA Operative link on gastritis assessment,[226377],[20255],[20319],[False],[0],[0],[False],['0']
34840,PMC5662095,38864,T2DM Type 2 diabetes mellitusAcknowledgements,Abbreviations|OLGA Operative link on gastritis assessment,[226380],[20320],[20365],[False],[0],[0],[False],['0']
34841,PMC5662095,38865,Not applicable.,Abbreviations|Not applicable.,[226383],[20366],[20381],[False],[0],[0],[False],['0']
34842,PMC5662095,38866,Funding,Abbreviations|Funding,[226386],[20382],[20389],[False],[0],[0],[False],['0']
34843,PMC5662095,38867,"This study was supported by a grant from the Excellent Clinical Trial and Research Center in National Cheng Kung University Hospital, Ministry of Health and Welfare, Taiwan (MOHW105-TDU-B- 211-133,016).",Abbreviations|Funding,[226389],[20390],[20592],[False],[0],[0],[False],['0']
34844,PMC5662095,38868,Availability of data and materials,Abbreviations|Availability of data and materials,[226392],[20593],[20627],[False],[0],[0],[False],['0']
34845,PMC5662095,38869,The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.,Abbreviations|Availability of data and materials,[226395],[20628],[20753],[False],[0],[0],[False],['0']
34846,PMC5662095,38870,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[226398],[20754],[20796],[False],[0],[0],[False],['0']
34847,PMC5662095,38871,The study design was reviewed and approved by the Ethical Committee of National Cheng Kung University Hospital (A-BR-103-021).,Abbreviations|Ethics approval and consent to participate,[226401],[20797],[20923],[False],[0],[0],[False],['0']
34848,PMC5662095,38872,All participates have read and signed the consents to participate this study.,Abbreviations|Ethics approval and consent to participate,[226404],[20924],[21001],[False],[0],[0],[False],['0']
34849,PMC5662095,38873,Consent for publication,Abbreviations|Consent for publication,[226407],[21002],[21025],[False],[0],[0],[False],['0']
34850,PMC5662095,38874,All authors have read and approved the content and declared there is no conflict of the decision to submit the paper for publication.,Abbreviations|Consent for publication,[226410],[21026],[21159],[False],[0],[0],[False],['0']
34851,PMC5662095,38875,Competing interests,Abbreviations|Competing interests,[226413],[21160],[21179],[False],[0],[0],[False],['0']
34852,PMC5662095,38876,No conflicts of interest relevant to this article were reported.,Abbreviations|Competing interests,[226416],[21180],[21244],[False],[0],[0],[False],['0']
34853,PMC5662095,38877,Publisher’s Note,Abbreviations|Publisher’s Note,[226419],[21245],[21261],[False],[0],[0],[False],['0']
34854,PMC5662095,38878,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[226422],[21262],[21380],[False],[0],[0],[False],['0']
35207,PMC5702102,25420,"Informed, advance refusals of treatment by people with severe mental illness in a randomised controlled trial of joint crisis plans: demand, content and correlates",Title,[150055],[32218],[163],[False],[0],[0],[False],['0']
35208,PMC5702102,25421,Background,Abstract,[150058],[164],[175],[False],[0],[0],[False],['0']
35209,PMC5702102,25422,"In the UK, crisis planning for mental health care should acknowledge the right to make an informed advance treatment refusal under the Mental Capacity Act 2005.",Abstract,[150061],[176],[336],[False],[0],[0],[False],['0']
35210,PMC5702102,25423,"Our aims were to estimate the demand for such treatment refusals within a sample of service users who had had a recent hospital admission for psychosis or bipolar disorder, and to examine the relationship between refusals, and service user characteristics.",Abstract,[150064],[337],[593],[False],[0],[0],[False],['0']
35211,PMC5702102,25424,Methods,Abstract,[150067],[594],[601],[False],[0],[0],[False],['0']
35212,PMC5702102,25425,"To identify refusals we conducted content analysis of Joint Crisis Plans, which are plans formulated by service users and their clinical team with involvement from an external facilitator, and routine care plans in sub-samples from a multi-centre randomised controlled trial of Joint Crisis Plans (plus routine mental health care) versus routine care alone (CRIMSON) in England.",Abstract,[150070],[602],[980],[False],[0],[0],[False],['0']
35213,PMC5702102,25426,Factors hypothesised to be associated with refusals were identified using the trial data collected through baseline interviews of service users and clinicians and collection of routine clinical data.,Abstract,[150073],[981],[1180],[False],[0],[0],[False],['0']
35214,PMC5702102,25427,Results,Abstract,[150076],[1181],[1188],[False],[0],[0],[False],['0']
35215,PMC5702102,25428,Ninety-nine of 221 (45%) of the Joint Crisis Plans contained a treatment refusal compared to 10 of 424 (2.4%) baseline routine care plans.,Abstract,[150079],[1189],[1327],[False],[0],[0],[False],['0']
35216,PMC5702102,25429,No Joint Crisis Plans recorded disagreement with refusals on the part of clinicians.,Abstract,[150082],[1328],[1412],[False],[0],[0],[False],['0']
35217,PMC5702102,25430,"Among those with completed Joint Crisis Plans, adjusted analyses indicated a significant association between treatment refusals and perceived coercion at baseline (odds ratio = 1.21, 95% CI 1.02–1.43), but not with baseline working alliance or a past history of involuntary admission.",Abstract,[150085],[1413],[1697],[False],[0],[0],[False],['0']
35218,PMC5702102,25431,Conclusions,Abstract,[150088],[1698],[1709],[False],[0],[0],[False],['0']
35219,PMC5702102,25432,"We demonstrated significant demand for written treatment refusals in line with the Mental Capacity Act 2005, which had not previously been elicited by the process of treatment planning.",Abstract,[150091],[1710],[1895],[False],[0],[0],[False],['0']
35220,PMC5702102,25433,Future treatment/crisis plans should incorporate the opportunity for service users to record a treatment refusal during the drafting of such plans.,Abstract,[150094],[1896],[2043],[False],[0],[0],[False],['0']
35221,PMC5702102,25434,Trial registration,Abstract,[150097],[2044],[2062],[False],[0],[0],[False],['0']
35222,PMC5702102,25435,ISRCTN11501328 Registered 13th March 2008.,Abstract,[150100],[2063],[2106],[False],[0],[0],[False],['0']
35223,PMC5702102,25436,Background,Background,[150103],[2107],[2118],[False],[0],[0],[False],['0']
35224,PMC5702102,25437,"Psychiatric crises, such as a relapse of psychosis, may be associated with reduced decision-making capability [1].",Background,[150106],[2119],[2233],[False],[0],[0],[False],['0']
35225,PMC5702102,25438,"In the United Kingdom (UK), health service users have the right under the Mental Capacity Act (MCA) 2005 to make an informed advance treatment refusal [2] when capacitous, regarding times when their decision-making capability is impaired.",Background,[150109],[2234],[2472],[False],[0],[0],[False],['0']
35226,PMC5702102,25439,"Advance refusals are legally binding, but may be overridden if the patient is subject to an involuntary treatment order under the Mental Health Act 1983, amended 2007 (MHA).",Background,[150112],[2473],[2646],[False],[0],[0],[False],['0']
35227,PMC5702102,25440,People subject to the MHA are given reasons for their detention and their rights are explained at the point of detention.,Background,[150115],[2647],[2768],[False],[0],[0],[False],['0']
35228,PMC5702102,25441,"In the case of advance refusals, an appropriate point at which to inform service users of the legal right to make such a refusal and help them to exercise it is during the process of crisis planning for mental health care.",Background,[150118],[2769],[2991],[False],[0],[0],[False],['0']
35229,PMC5702102,25442,"In the national Health Service (NHS) mental health services in England, a written crisis plan is routinely present in the care plan, and is written and updated through the Care Programme Approach (CPA) [3].",Background,[150121],[2992],[3198],[False],[0],[0],[False],['0']
35230,PMC5702102,25443,This provides the current benchmark for written crisis plans.,Background,[150124],[3199],[3260],[False],[0],[0],[False],['0']
35231,PMC5702102,25444,"An audit of CPA forms showed very few documented refusals, at just 2.4% of a sample of 424 crisis plans [4].",Background,[150127],[3261],[3369],[False],[0],[0],[False],['0']
35232,PMC5702102,25445,"In contrast, studies of both facilitated psychiatric advance directives (f-PADs) in the US [5, 6] and Joint Crisis Plans (JCPs) in the UK [7, 8] show much higher rates of refusals, at around three quarters of participants completing a f-PAD [5] or JCP [8].",Background,[150130],[3370],[3626],[False],[0],[0],[False],['0']
35233,PMC5702102,25446,"These are structured research interventions in which an independent mental health professional facilitates a discussion about preferences for future care - including treatment refusals - with the service user and, in the case of the JCP, with professionals involved in his or her care [9].",Background,[150133],[3627],[3916],[False],[0],[0],[False],['0']
35234,PMC5702102,25447,"The discrepancy between these interventions and routine care plans suggests that if service users are given better information about their rights, more would make advance refusals.",Background,[150136],[3917],[4097],[False],[0],[0],[False],['0']
35235,PMC5702102,25448,"However, the previous studies in the UK occurred before the MCA 2005 was introduced, so it is not clear whether the situation concerning refusals has changed.",Background,[150139],[4098],[4256],[False],[0],[0],[False],['0']
35236,PMC5702102,25449,"One trial conducted since the introduction of the MCA 2005 of JCPs for outpatients with borderline personality disorder [10] showed a very high (90.2%) rate of refusals, but no comparison with the rate of refusals in the conventional treatment plan was made.",Background,[150142],[4257],[4515],[False],[0],[0],[False],['0']
35237,PMC5702102,25450,We therefore made use of data from a recent multisite trial of JCPs [11–13] that incorporated and explained the relevant provision in the MCA.,Background,[150145],[4516],[4658],[False],[0],[0],[False],['0']
35238,PMC5702102,25451,Our first aim was to ascertain whether - and to what extent - the JCP process elicited more written advance treatment refusals than the CPA process during the process of a pragmatic randomised controlled trial.,Background,[150148],[4659],[4869],[False],[0],[0],[False],['0']
35239,PMC5702102,25452,Our second aim was to explore the nature of such refusals and the relationships between making a refusal with service user characteristics.,Background,[150151],[4870],[5009],[False],[0],[0],[False],['0']
35240,PMC5702102,25453,To address the first aim we tested the hypothesis that the rate of refusals would be higher in JCPs than in CPA treatment plans.,Background,[150154],[5010],[5138],[False],[0],[0],[False],['0']
35241,PMC5702102,25454,To address the second aim we tested the following hypotheses: (1) the majority of refusals will be accepted by clinicians without concerns that they will reduce the standard of care provided/received [6]; (2) refusals are more likely to be made by participants who either a) have prior experience of coercion i.e.,Background,[150157],[5139],[5452],[False],[0],[0],[False],['0']
35242,PMC5702102,25455,transport or detention under the Mental Health Act; b) report a high level of perceived coercion at baseline; or c) report poor working alliance with professionals at baseline.,Background,[150160],[5453],[5629],[False],[0],[0],[False],['0']
35243,PMC5702102,25456,All of these factors may indicate a lack of acceptance of at least some aspects of treatment and hence a wish to avoid these treatment components in future.,Background,[150163],[5630],[5786],[False],[0],[0],[False],['0']
35244,PMC5702102,25457,Methods,Methods,[150166],[5787],[5795],[False],[0],[0],[False],['0']
35245,PMC5702102,25458,Setting and sample,Methods|Setting and sample,[150169],[5796],[5814],[False],[0],[0],[False],['0']
35246,PMC5702102,25459,The sample for this study is a sub-sample from the CRIMSON trial [11–13].,Methods|Setting and sample,[150172],[5815],[5888],[False],[0],[0],[False],['0']
35247,PMC5702102,25460,The CRIMSON trial was a multi-site randomised controlled trial of JCPs for individuals with psychotic disorders in four mental health Trusts (NHS service provider organisations) in the UK (total n = 569).,Methods|Setting and sample,[150175],[5889],[6093],[False],[0],[0],[False],['0']
35248,PMC5702102,25461,The eligibility criteria for the CRIMSON trial were: diagnosis of a psychotic disorder; admission to a psychiatric ward in the last two years and current contact with a community mental health team.,Methods|Setting and sample,[150178],[6094],[6292],[False],[0],[0],[False],['0']
35249,PMC5702102,25462,Service users who were in hospital or under a section of the Mental Health Act at the time of recruitment were deemed ineligible so as to avoid any potential perceived coercion to participate.,Methods|Setting and sample,[150181],[6293],[6485],[False],[0],[0],[False],['0']
35250,PMC5702102,25463,"No other exclusions were made, thus maximising generalisability.",Methods|Setting and sample,[150184],[6486],[6550],[False],[0],[0],[False],['0']
35251,PMC5702102,25464,This study uses data from three overlapping study samples: (1) intervention group participants who completed the JCP process (n = 221) and whose JCP could therefore be assessed for refusals; and (2) the 424 patients whose CPA care plans were available for assessment for treatment refusals at baseline; and (3) those in the control group whose CPA care plans were available at baseline and follow up (n = 221).,Methods|Setting and sample,[150187],[6551],[6961],[False],[0],[0],[False],['0']
35252,PMC5702102,25465,The intervention,Methods|The intervention,[150190],[6962],[6978],[False],[0],[0],[False],['0']
35253,PMC5702102,25466,"The JCP [7, 14] was developed in the later 1990’s.",Methods|The intervention,[150193],[6979],[7029],[False],[0],[0],[False],['0']
35254,PMC5702102,25467,The starting point was a review of existing models containing information about the service user and requests for treatment during a relapse or crisis [14].,Methods|The intervention,[150196],[7030],[7186],[False],[0],[0],[False],['0']
35255,PMC5702102,25468,Sections were then added to encourage reflection about past crises that would help inform the thinking and planning for future crises.,Methods|The intervention,[150199],[7187],[7321],[False],[0],[0],[False],['0']
35256,PMC5702102,25469,"Headings were included where circumstances or triggers for past relapses could be recorded, as well as details of early signs of relapse and space to record both the good and bad aspects of care received during previous crises.",Methods|The intervention,[150202],[7322],[7549],[False],[0],[0],[False],['0']
35257,PMC5702102,25470,These headings precede the advance planning section so that during the meeting to finalise the plan these aspects are discussed.,Methods|The intervention,[150205],[7550],[7678],[False],[0],[0],[False],['0']
35258,PMC5702102,25471,"Eliciting this information promotes a process of shared decision making at the planning meeting, as the treating clinicians are present and can also share their observations of early warning signs, triggers, and what has been helpful/not helpful in the past [15].",Methods|The intervention,[150208],[7679],[7942],[False],[0],[0],[False],['0']
35259,PMC5702102,25472,The completed JCP contains the service user’s statements about past treatment and preferences for care in the event of a future relapse or crisis.,Methods|The intervention,[150211],[7943],[8089],[False],[0],[0],[False],['0']
35260,PMC5702102,25473,It was produced after two meetings.,Methods|The intervention,[150214],[8090],[8125],[False],[0],[0],[False],['0']
35261,PMC5702102,25474,"At the first meeting, the JCP facilitator - a member of the research team independent of the clinical team - explained the procedure to the service user and the care coordinator.",Methods|The intervention,[150217],[8126],[8304],[False],[0],[0],[False],['0']
35262,PMC5702102,25475,"To finalise each plan, the service user was encouraged to bring a carer, friend, or advocate to a second meeting.",Methods|The intervention,[150220],[8305],[8418],[False],[0],[0],[False],['0']
35263,PMC5702102,25476,"The aim of this meeting was to discuss the views of the service user, his or her informal supports(s) and treating professionals regarding what to do in a future crisis, and to negotiate agreed solutions.",Methods|The intervention,[150223],[8419],[8623],[False],[0],[0],[False],['0']
35264,PMC5702102,25477,The JCP facilitator’s role was to ensure that everyone’s perspective was heard but the final choice of what was included in the plan (including the exact terminology used) lay with the service user.,Methods|The intervention,[150226],[8624],[8822],[False],[0],[0],[False],['0']
35265,PMC5702102,25478,The clinical team was present to discuss options and the implications of the service user’s choice.,Methods|The intervention,[150229],[8823],[8922],[False],[0],[0],[False],['0']
35266,PMC5702102,25479,"When the option of stating which treatment(s) they did not want to receive in future was discussed, the facilitator explained the MCA 2005 provision for making a treatment refusal.",Methods|The intervention,[150232],[8923],[9103],[False],[0],[0],[False],['0']
35267,PMC5702102,25480,All JCPs were written in the first person to reflect the service user’s own description of their mental health issue and wishes for treatment.,Methods|The intervention,[150235],[9104],[9246],[False],[0],[0],[False],['0']
35268,PMC5702102,25481,"At the end of this meeting the JCP facilitator asked clinicians if they were happy to agree to the overall plan, in order to clarify to the service user any content that they thought could not be followed and have this acknowledged on the JCP.",Methods|The intervention,[150238],[9247],[9490],[False],[0],[0],[False],['0']
35269,PMC5702102,25482,"After finalising the JCP, service users were given a copy and an electronic version of the plan was stored on the Trust’s electronic patient record system.",Methods|The intervention,[150241],[9491],[9646],[False],[0],[0],[False],['0']
35270,PMC5702102,25483,"Once completed, the content of the JCP could be updated by service user and the regular clinical team and used in routine care planning.",Methods|The intervention,[150244],[9647],[9783],[False],[0],[0],[False],['0']
35271,PMC5702102,25484,The intervention group received the JCP intervention in addition to treatment as usual (described below).,Methods|The intervention,[150247],[9784],[9889],[False],[0],[0],[False],['0']
35272,PMC5702102,25485,"As the unit of randomisation was the service user, some individual care coordinators and individual doctors may have developed more than one JCP.",Methods|The intervention,[150250],[9890],[10035],[False],[0],[0],[False],['0']
35273,PMC5702102,25486,"Likewise, some individual care coordinators and doctors may have had service users in both the control and intervention groups.",Methods|The intervention,[150253],[10036],[10163],[False],[0],[0],[False],['0']
35274,PMC5702102,25487,Treatment as usual control,Methods|Treatment as usual control,[150256],[10164],[10190],[False],[0],[0],[False],['0']
35275,PMC5702102,25488,The control condition was Treatment As Usual as stipulated under the CPA.,Methods|Treatment as usual control,[150259],[10191],[10264],[False],[0],[0],[False],['0']
35276,PMC5702102,25489,"Treatment As Usual under the CPA includes requirements that all service users are assessed, receive a written care plan that includes a crisis and contingency plan, and that this is reviewed regularly.",Methods|Treatment as usual control,[150262],[10265],[10466],[False],[0],[0],[False],['0']
35277,PMC5702102,25490,"In most situations, service users have a nominated Care Coordinator, whose role is to be the central point for communication regarding the service user and to ensure the service user’s identified health and social care needs are met.",Methods|Treatment as usual control,[150265],[10467],[10700],[False],[0],[0],[False],['0']
35278,PMC5702102,25491,"Treatment As Usual thus in theory allows the making of refusals and their documentation on the CPA form by the Care Coordinator, although the form may not specifically prompt them to do so.",Methods|Treatment as usual control,[150268],[10701],[10890],[False],[0],[0],[False],['0']
35279,PMC5702102,25492,"Thus, the control condition not only lacks the process of facilitation but also depends on existing documentation required by the service.",Methods|Treatment as usual control,[150271],[10891],[11029],[False],[0],[0],[False],['0']
35280,PMC5702102,25493,Assessments,Methods|Assessments,[150274],[11030],[11041],[False],[0],[0],[False],['0']
35281,PMC5702102,25494,Assessment for treatment refusals and whether clinicians would not be able to follow them: Refusals were assessed in both the JCPs and CPA care plans.,Methods|Assessments,[150277],[11042],[11192],[False],[0],[0],[False],['0']
35282,PMC5702102,25495,A content analysis of the JCPs was conducted by SF.,Methods|Assessments,[150280],[11193],[11244],[False],[0],[0],[False],['0']
35283,PMC5702102,25496,"Refusals were coded as present or not present, and content of refusals was thematically coded [16].",Methods|Assessments,[150283],[11245],[11344],[False],[0],[0],[False],['0']
35284,PMC5702102,25497,"For refusals on the CPA care plan, the entire CPA care plan was printed and anonymised by research assistants.",Methods|Assessments,[150286],[11345],[11455],[False],[0],[0],[False],['0']
35285,PMC5702102,25498,SF assessed the content of each plan at baseline and follow-up for the presence of treatment refusals and for the presence of statements by clinicians about any aspect of the JCP that they thought could not be followed/adhered to.,Methods|Assessments,[150289],[11456],[11686],[False],[0],[0],[False],['0']
35286,PMC5702102,25499,"Demographics: Research assistants collected demographic data from service users and Care Coordinators including age, sex, ethnicity, education/qualification and number of years in contact with mental health services.",Methods|Assessments,[150292],[11687],[11903],[False],[0],[0],[False],['0']
35287,PMC5702102,25500,"For Care Coordinators, length of psychiatric practice and length of relationship with the service user were also collected.",Methods|Assessments,[150295],[11904],[12027],[False],[0],[0],[False],['0']
35288,PMC5702102,25501,Hospitalisations: Data regarding psychiatric admissions in the two years prior to baseline and over the follow-up period including duration and admission status (formal/informal) were collected by research assistants from routine Trust data sets and corroborated by service users and clinicians at interview.,Methods|Assessments,[150298],[12028],[12336],[False],[0],[0],[False],['0']
35289,PMC5702102,25502,"Self-harm and harm to others: At baseline interview participants were asked about instances and severity of self-harm, suicide attempts and harm to others in the two years prior to baseline and, at follow-up, they were asked about the period since baseline assessment (usually 18 months).",Methods|Assessments,[150301],[12337],[12625],[False],[0],[0],[False],['0']
35290,PMC5702102,25503, Objective Coercion: use of the Mental Health Act to transport the service user or detain them in a psychiatric unit.,Methods|Assessments,[150304],[12626],[12743],[False],[0],[0],[False],['0']
35291,PMC5702102,25504," Perceived Coercion: was measured by the perceived coercion subscale of the service user self-report measure the MacArthur Perceived Coercion Scale [17], adapted for use in outpatient treatment.",Methods|Assessments,[150307],[12744],[12938],[False],[0],[0],[False],['0']
35292,PMC5702102,25505,Higher scores indicate more perceived coercion.,Methods|Assessments,[150310],[12939],[12986],[False],[0],[0],[False],['0']
35293,PMC5702102,25506," Therapeutic Relationships: The Working Alliance Inventory short form (WAI-S) [18, 19] modified for use in psychiatric samples [20] was rated by service users and clinicians (WAIC and WAIT respectively) at baseline and follow-up.",Methods|Assessments,[150313],[12987],[13216],[False],[0],[0],[False],['0']
35294,PMC5702102,25507, Engagement: was measured by the Service Engagement Scale (SES) [21].,Methods|Assessments,[150316],[13217],[13286],[False],[0],[0],[False],['0']
35295,PMC5702102,25508,"This is a 14-item scale producing four subscales measuring ‘availability’, ‘collaboration’, ‘help seeking’ and ‘treatment adherence’ and a total score.",Methods|Assessments,[150319],[13287],[13438],[False],[0],[0],[False],['0']
35296,PMC5702102,25509,Higher scores on this measure indicate poorer engagement.,Methods|Assessments,[150322],[13439],[13496],[False],[0],[0],[False],['0']
35297,PMC5702102,25510,This measure was rated by the Care Coordinator.,Methods|Assessments,[150325],[13497],[13544],[False],[0],[0],[False],['0']
35298,PMC5702102,25511,Data analysis,Methods|Data analysis,[150328],[13545],[13558],[False],[0],[0],[False],['0']
35299,PMC5702102,25512,"To assess the proportion of refusals not identified through the CPA process we compared the proportion of refusals in the 221 completed JCPs with that in CPA forms available: (1) at baseline for the entire group (n = 424); and (2) at follow-up for the control group only (n = 203), as the presence or absence of a refusal in a JCP could influence whether it was present in the participants’ CPA form at follow-up.",Methods|Data analysis,[150331],[13559],[13972],[False],[0],[0],[False],['0']
35300,PMC5702102,25513,The analyses aimed at identifying factors associated with refusals were restricted to the JCP group as it was only in this group that there was a sufficient number.,Methods|Data analysis,[150334],[13973],[14137],[False],[0],[0],[False],['0']
35301,PMC5702102,25514,Associations between covariates and missing data regarding treatment refusal were investigated using chi-squared and t-tests as appropriate.,Methods|Data analysis,[150337],[14138],[14278],[False],[0],[0],[False],['0']
35302,PMC5702102,25515,Covariates found to be associated with missing data were accounted for in all analyses.,Methods|Data analysis,[150340],[14279],[14366],[False],[0],[0],[False],['0']
35303,PMC5702102,25516,Chi-squared analyses and t-tests were performed to ascertain any relationships between making a refusal and baseline service user clinical or demographic characteristics based on bivariate analysis.,Methods|Data analysis,[150343],[14367],[14565],[False],[0],[0],[False],['0']
35304,PMC5702102,25517,"The hypothesised factors associated with a refusal were: previous compulsory admissions, perceived coercion and service user-rated working alliance at baseline.",Methods|Data analysis,[150346],[14566],[14726],[False],[0],[0],[False],['0']
35305,PMC5702102,25518,These were regressed on an indicator of refusal of treatment using logistic regression.,Methods|Data analysis,[150349],[14727],[14814],[False],[0],[0],[False],['0']
35306,PMC5702102,25519,The logistic regression model was adjusted for covariates associated with missing information or treatment refusal.,Methods|Data analysis,[150352],[14815],[14930],[False],[0],[0],[False],['0']
35307,PMC5702102,25520,Results,Results,[150355],[14931],[14939],[False],[0],[0],[False],['0']
35308,PMC5702102,25521,Rates of refusals in the CPA forms versus JCPs,Results,[150358],[14940],[14986],[False],[0],[0],[False],['0']
35309,PMC5702102,25522,"Of the total sample for the CRIMSON trial (n = 569, 284 control, 285 intervention), 424 (74%) CPA forms were available (221 controls and 203 intervention).",Results,[150361],[14987],[15142],[False],[0],[0],[False],['0']
35310,PMC5702102,25523,We were unable to obtain records from one Trust (n = 48).,Results,[150364],[15143],[15200],[False],[0],[0],[False],['0']
35311,PMC5702102,25524,The remainder were missing due to: not being able to locate a care plan at baseline or follow-up (n = 52); participants being discharged at follow-up (n = 22) or downgraded to care support and thus no care plan (n = 8); deaths (n = 5); and refusing access to records (n = 10).,Results,[150367],[15201],[15477],[False],[0],[0],[False],['0']
35312,PMC5702102,25525,Ten of these 424 CPA forms (2.4%) included refusals at baseline.,Results,[150370],[15478],[15542],[False],[0],[0],[False],['0']
35313,PMC5702102,25526,"For the control group, six of the 221 (2.7%, 95% CI 1.0%–5.8%) included a refusal at follow-up on their CPA forms.",Results,[150373],[15543],[15657],[False],[0],[0],[False],['0']
35314,PMC5702102,25527,In the intervention group 221/285 (77%) completed a JCP.,Results,[150376],[15658],[15714],[False],[0],[0],[False],['0']
35315,PMC5702102,25528,"Of these, 99 (45%, 95% CI 38%–52%) made a refusal as part of the JCP.",Results,[150379],[15715],[15784],[False],[0],[0],[False],['0']
35316,PMC5702102,25529,Agreements with JCPs by clinicians,Results|Agreements with JCPs by clinicians,[150382],[15785],[15819],[False],[0],[0],[False],['0']
35317,PMC5702102,25530,There were no cases where clinicians explicitly disagreed with the final version of the JCP.,Results|Agreements with JCPs by clinicians,[150385],[15820],[15912],[False],[0],[0],[False],['0']
35318,PMC5702102,25531,Types of refusal,Results|Types of refusal,[150388],[15913],[15929],[False],[0],[0],[False],['0']
35319,PMC5702102,25532,"Based on the JCP sample, the most common refusal was regarding aspects of medication: 45/99 (45%) made a refusal of a specific medication (with 53% of this subsample providing a reason for this refusal); 20/99 (20%) refused injections.",Results|Types of refusal,[150391],[15930],[16165],[False],[0],[0],[False],['0']
35320,PMC5702102,25533,"Others made refusals regarding high doses of medication, increases or changes to dose.",Results|Types of refusal,[150394],[16166],[16252],[False],[0],[0],[False],['0']
35321,PMC5702102,25534,Only one participant stated that they would prefer not to take any medication.,Results|Types of refusal,[150397],[16253],[16331],[False],[0],[0],[False],['0']
35322,PMC5702102,25535,"Seventeen refusals regarding specific medications were made: one anti-cholinergic, three different mood stabilisers, two anti-depressants, one anti-anxiolytic and ten anti-psychotics.",Results|Types of refusal,[150400],[16332],[16515],[False],[0],[0],[False],['0']
35323,PMC5702102,25536,"The most frequently refused anti-psychotics were: haloperidol (n = 9), olanzapine (n = 8), risperidone (n = 5), zuclopenthixol (n = 5), quetiapine (n = 4) and chlorpromazine (n = 4).",Results|Types of refusal,[150403],[16516],[16698],[False],[0],[0],[False],['0']
35324,PMC5702102,25537,The next most common category of refusal was electro-convulsive therapy (ECT; 19/99 (19%).,Results|Types of refusal,[150406],[16699],[16789],[False],[0],[0],[False],['0']
35325,PMC5702102,25538,Eighteen participants (18%) made refusals relating to admission to hospital.,Results|Types of refusal,[150409],[16790],[16866],[False],[0],[0],[False],['0']
35326,PMC5702102,25539,"Of these, eight (44%) made refusals about specific aspects of admission, such as which ward they were admitted to.",Results|Types of refusal,[150412],[16867],[16981],[False],[0],[0],[False],['0']
35327,PMC5702102,25540,"The remaining ten (56%) refused hospital admission, though seven added a caveat, for example, “[I refuse] being put in hospital.",Results|Types of refusal,[150415],[16982],[17110],[False],[0],[0],[False],['0']
35328,PMC5702102,25541,I know that this is sometimes necessary however I would like this to be the last resort”.,Results|Types of refusal,[150418],[17111],[17200],[False],[0],[0],[False],['0']
35329,PMC5702102,25542,"While these caveats reflect acknowledgements of the views of clinicians, there was no indication on the other three as to whether clinicians disagreed with these refusals.",Results|Types of refusal,[150421],[17201],[17372],[False],[0],[0],[False],['0']
35330,PMC5702102,25543,Predictors of refusal,Results|Predictors of refusal,[150424],[17373],[17394],[False],[0],[0],[False],['0']
35331,PMC5702102,25544,Sixty-four (22%) of participants in the JCP arm did not complete a JCP.,Results|Predictors of refusal,[150427],[17395],[17466],[False],[0],[0],[False],['0']
35332,PMC5702102,25545,"These participants were similar in most respects to those who did, but tended to have had more psychiatric admissions in the two years prior to the trial, have a higher engagement with care (SES) score and higher clinician-rated working alliance (WAIT).",Results|Predictors of refusal,[150430],[17467],[17720],[False],[0],[0],[False],['0']
35333,PMC5702102,25546,"We therefore adjusted further analyses for the number of admissions, SES and WAIT score to account for bias due to missing data.",Results|Predictors of refusal,[150433],[17721],[17849],[False],[0],[0],[False],['0']
35334,PMC5702102,25547,Table 1 Description of the JCP sample at baseline by refusal status.,Results|Predictors of refusal,[150436],[17850],[17918],[False],[0],[0],[False],['0']
35335,PMC5702102,25548,Table 1 describes the sample with JCP refusal information by refusal status.,Results|Predictors of refusal,[150439],[17919],[17995],[False],[0],[0],[False],['0']
35336,PMC5702102,25549,"Treatment refusal was individually associated with the participant’s location, ethnicity, years in contact with mental health services and the perceived coercion subscale of the McArthur coercion scale before adjustments.",Results|Predictors of refusal,[150442],[17996],[18217],[False],[0],[0],[False],['0']
35337,PMC5702102,25550,There was no bivariate association between having had an involuntary admission in the two years prior to baseline assessment or service user-rated working alliance and treatment refusal.,Results|Predictors of refusal,[150445],[18218],[18404],[False],[0],[0],[False],['0']
35338,PMC5702102,25551,"Table 2 Hypothesised baseline predictors of treatment refusal within the JCP treatment arm, adjusted for covariates listed, n = 168.",Results|Predictors of refusal,[150448],[18405],[18538],[False],[0],[0],[False],['0']
35339,PMC5702102,25552,"Logistic regression of the refusal status on the three hypothesised baseline predictors (involuntary admission, perceived coercion and therapeutic alliance) adjusting for site, ethnicity, contact with services and covariates associated with missingness (SES, number of admissions and carer-rated working alliance) are provided in Table 2.",Results|Predictors of refusal,[150451],[18539],[18877],[False],[0],[0],[False],['0']
35340,PMC5702102,25553,The results indicate that there is no association between working alliance or involuntary admission and advance treatment refusals.,Results|Predictors of refusal,[150454],[18878],[19009],[False],[0],[0],[False],['0']
35341,PMC5702102,25554,"The association between perceived coercion and advance refusals remains significant when other factors are accounted for (odds ratio = 1.34, 95% CI 1.07–1.69, p = 0.013).",Results|Predictors of refusal,[150457],[19010],[19180],[False],[0],[0],[False],['0']
35342,PMC5702102,25555,Table 2 also shows that participant location remains associated with advance refusals after adjustment for other factors.,Results|Predictors of refusal,[150460],[19181],[19302],[False],[0],[0],[False],['0']
35343,PMC5702102,25556,Discussion,Discussion,[150463],[19303],[19315],[False],[0],[0],[False],['0']
35344,PMC5702102,25557,Summary of findings,Discussion|Summary of findings,[150466],[19316],[19335],[False],[0],[0],[False],['0']
35345,PMC5702102,25558,Comparison of the rates of advance refusals made in JCPs with those made in CPA forms among trial participants shows that the potential demand for refusals is barely addressed by the current CPA process used in routine care.,Discussion|Summary of findings,[150469],[19336],[19560],[False],[0],[0],[False],['0']
35346,PMC5702102,25559,Our results also suggest that most refusals made using the JCP were not out of keeping with what the clinicians viewed as safe clinical practice.,Discussion|Summary of findings,[150472],[19561],[19706],[False],[0],[0],[False],['0']
35347,PMC5702102,25560,"In no cases did clinicians attending the JCP meetings disagree with the refusals made, although it should be noted that this does not mean all refusals were then followed in practice.",Discussion|Summary of findings,[150475],[19707],[19890],[False],[0],[0],[False],['0']
35348,PMC5702102,25561,"It is also possible that clinicians did not voice their concerns during the meetings (despite being asked for their views by the facilitator), as suggested by qualitative interviews of some participating clinicians [22].",Discussion|Summary of findings,[150478],[19891],[20111],[False],[0],[0],[False],['0']
35349,PMC5702102,25562,They may instead have wanted to avoid an argument with the service user and/or have judged the process to be non-binding.,Discussion|Summary of findings,[150481],[20112],[20233],[False],[0],[0],[False],['0']
35350,PMC5702102,25563,"Thus, knowing that refusals made under the Mental Capacity Act 2005 can be overridden using the Mental Health Act may reduce the attention paid by clinicians to refusals made by serviced users, despite the possibility of honouring a refusal (such as that of a particular medication) while someone is detained under the Mental Health Act.",Discussion|Summary of findings,[150484],[20234],[20571],[False],[0],[0],[False],['0']
35351,PMC5702102,25564,"Among those who received a JCP, higher perceived coercion at baseline was associated with subsequent treatment refusal, as hypothesised.",Discussion|Summary of findings,[150487],[20572],[20708],[False],[0],[0],[False],['0']
35352,PMC5702102,25565,"However, no association was found with having a previous involuntary admission or working alliance and subsequent treatment refusal.",Discussion|Summary of findings,[150490],[20709],[20841],[False],[0],[0],[False],['0']
35353,PMC5702102,25566,"The association with duration of contact with mental health services, along with the lack of association with involuntary admission or working alliance, suggests that many refusals are made based on experiences of treatments regardless of whether these were experienced while detained under the Mental Health Act.",Discussion|Summary of findings,[150493],[20842],[21155],[False],[0],[0],[False],['0']
35354,PMC5702102,25567,Participant location at the sites outside London was also associated with treatment refusal.,Discussion|Summary of findings,[150496],[21156],[21248],[False],[0],[0],[False],['0']
35355,PMC5702102,25568,"This may indicate differences in implementation of the JCP development process among the sites on the part of the facilitators, despite the provision of supervision of all facilitators by the same member of the research team.",Discussion|Summary of findings,[150499],[21249],[21474],[False],[0],[0],[False],['0']
35356,PMC5702102,25569,"A second possibility is the existence of site level differences in participants’ past experiences of treatment, which were not captured in the assessment and exclude use of the Mental Health Act per se, but which give rise to higher rates of treatment refusal.",Discussion|Summary of findings,[150502],[21475],[21735],[False],[0],[0],[False],['0']
35357,PMC5702102,25570,Limitations of the study,Discussion|Limitations of the study,[150505],[21736],[21760],[False],[0],[0],[False],['0']
35358,PMC5702102,25571,"While the JCP intervention allowed us to assess demand for treatment refusals and their relationship with clinical and demographic factors, the sample was subject to the eligibility criteria for the CRIMSON trial.",Discussion|Limitations of the study,[150509],[21761],[21974],[True],['VerySpecificPopulation'],['the sample was subject to the eligibility criteria for the CRIMSON trial'],[True],['Population']
35359,PMC5702102,25572,This took place in three urban and one rural area within the three sites and included only those with an admission in the last two years; the sample is therefore not fully representative of adults with psychoses using secondary mental health services in England.,Discussion|Limitations of the study,[150514],[21975],[22237],[True],['VerySpecificPopulation'],['the sample is therefore not fully representative of adults with psychoses using secondary mental health services in England'],[True],['Population']
35360,PMC5702102,25573,"Further, we are unable to report the extent to which refusals were honoured due to the CRIMSON trial resource limitations.",Discussion|Limitations of the study,[150522],[22238],[22360],[True],['MissingData'],['we are unable to report the extent to which refusals were honoured'],[True],['MissingData']
35361,PMC5702102,25574,Conclusions,Conclusions,[150526],[22361],[22373],[False],[0],[0],[False],['0']
35362,PMC5702102,25575,"Our findings are consistent with previous research showing there is strong demand for psychiatric advance statements [23–25] and that the content of most advance statements can be followed without compromising care [6, 25, 26].",Conclusions,[150529],[22374],[22601],[False],[0],[0],[False],['0']
35363,PMC5702102,25576,"However, most of those who want to make a statement need support to complete it [5, 27], and despite the existence of UK legislation for advance refusals, services offer no systematic or efficient way of providing this support.",Conclusions,[150532],[22602],[22829],[False],[0],[0],[False],['0']
35364,PMC5702102,25577,We have thus highlighted an aspect of the Mental Capacity Act 2005 which has been under-implemented in mental health services.,Conclusions,[150535],[22830],[22956],[False],[0],[0],[False],['0']
35365,PMC5702102,25578,"The creation of, access to, and honouring of individualised crisis plans which include refusals are important in their own right but are missing from current care pathways [4].",Conclusions,[150538],[22957],[23133],[False],[0],[0],[False],['0']
35366,PMC5702102,25579,"The research evidence is clear that interventions such as Joint Crisis Plans and facilitated psychiatric advance directives are an effective way to inform service users of their legal rights to make advance treatment refusals; they probably also improve working alliance with clinicians [13, 24].",Conclusions,[150541],[23134],[23430],[False],[0],[0],[False],['0']
35367,PMC5702102,25580,"Evidence that these interventions can lead to ‘harder’ outcomes such as reduced use of involuntary treatment [28] and for their cost-effectiveness [12, 29] is more mixed, and may reflect problems in implementation.11 However, a recent systematic review identified advance statements as the only intervention associated with reduction in the use of compulsory treatment [28].",Conclusions,[150544],[23431],[23805],[False],[0],[0],[False],['0']
35368,PMC5702102,25581,"Further work is needed to identify ways to overcome barriers to the creation of advance statements, together with study of the outcomes associated with not just their creation but of their application in routine practice.",Conclusions,[150547],[23806],[24027],[False],[0],[0],[False],['0']
35369,PMC5702102,25582,"Recently arguments have been presented that involuntary detention and treatment under mental health legislation be like that for general health care, that is, based on impaired decision-making capacity and best interests [30].",Conclusions,[150550],[24028],[24254],[False],[0],[0],[False],['0']
35370,PMC5702102,25583,"In such a case, a treatment refusal could not be ‘trumped’ by mental health legislation.",Conclusions,[150553],[24255],[24343],[False],[0],[0],[False],['0']
35371,PMC5702102,25584,"If the law were to be reformed, the patient’s decision-making capacity would need to be assured, especially when a treatment refusal with serious health consequences was desired.",Conclusions,[150556],[24344],[24522],[False],[0],[0],[False],['0']
35372,PMC5702102,25585,"The place of a state’s duty to protect life, as under the European Convention on Human Rights, might need to be considered.",Conclusions,[150559],[24523],[24646],[False],[0],[0],[False],['0']
35373,PMC5702102,25586,"The impact of legal reform on the implementation of support for service users to make advance statements, which may include refusals, is not clear.",Conclusions,[150562],[24647],[24794],[False],[0],[0],[False],['0']
35374,PMC5702102,25587,Abbreviations,Abbreviations,[150565],[24795],[24809],[False],[0],[0],[False],['0']
35375,PMC5702102,25588,CPA Care Programme Approach,Abbreviations|CPA Care Programme Approach,[150568],[24810],[24837],[False],[0],[0],[False],['0']
35376,PMC5702102,25589,f-PAD facilitated Psychiatric Advance Directive,Abbreviations|f-PAD facilitated Psychiatric Advance Directive,[150571],[24838],[24885],[False],[0],[0],[False],['0']
35377,PMC5702102,25590,JCP  Joint Crisis Plan,Abbreviations|JCP  Joint Crisis Plan,[150574],[24886],[24908],[False],[0],[0],[False],['0']
35378,PMC5702102,25591,MCA Mental Capacity Act 2005,Abbreviations|JCP  Joint Crisis Plan,[150577],[24909],[24937],[False],[0],[0],[False],['0']
35379,PMC5702102,25592,"MHA  Mental Health Act 1983, amended 2007",Abbreviations|JCP  Joint Crisis Plan,[150580],[24938],[24979],[False],[0],[0],[False],['0']
35380,PMC5702102,25593,SES Service Engagement Scale,Abbreviations|SES Service Engagement Scale,[150583],[24980],[25008],[False],[0],[0],[False],['0']
35381,PMC5702102,25594,WAIC Working Alliance Inventory short form Client version,Abbreviations|SES Service Engagement Scale,[150586],[25009],[25066],[False],[0],[0],[False],['0']
35382,PMC5702102,25595,WAI-S Working Alliance Inventory short form,Abbreviations|SES Service Engagement Scale,[150589],[25067],[25110],[False],[0],[0],[False],['0']
35383,PMC5702102,25596,WAIT Working Alliance Inventory short form Therapist versionAcknowledgements,Abbreviations|SES Service Engagement Scale,[150592],[25111],[25187],[False],[0],[0],[False],['0']
35384,PMC5702102,25597,This report is of independent research funded by the MRC and managed by the NIHR on behalf of the MRC-NIHR partnership.,Abbreviations|SES Service Engagement Scale,[150595],[25188],[25307],[False],[0],[0],[False],['0']
35385,PMC5702102,25598,"The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.",Abbreviations|SES Service Engagement Scale,[150598],[25308],[25451],[False],[0],[0],[False],['0']
35386,PMC5702102,25599,"Birmingham and Solihull Mental Health Foundation Trust; Lancashire Care NHS Foundation Trust; Manchester Mental Health and Social Care Trust; and South London and Maudsley NHS Foundation Trust, recruiting from generic and specialist community mental health teams.",Abbreviations|SES Service Engagement Scale,[150601],[25452],[25715],[False],[0],[0],[False],['0']
35387,PMC5702102,25600,"GT and CH were funded in relation to a National Institute for Health Research (NIHR) Applied Programme grant awarded to the South London and Maudsley NHS Foundation Trust (GT), and in relation to the NIHR Specialist Mental Health Biomedical Research Centre at the.",Abbreviations|SES Service Engagement Scale,[150604],[25716],[25980],[False],[0],[0],[False],['0']
35388,PMC5702102,25601,"Institute of Psychiatry Psychology and Neuroscience, King’s College London and the South London and Maudsley NHS Foundation Trust.",Abbreviations|SES Service Engagement Scale,[150607],[25981],[26111],[False],[0],[0],[False],['0']
35389,PMC5702102,25602,CH was funded by a grant from Guy’s and St Thomas’s Charitable Trust and a grant from the Big Lottery Fund and Comic Relief.,Abbreviations|SES Service Engagement Scale,[150610],[26112],[26236],[False],[0],[0],[False],['0']
35390,PMC5702102,25603,MB is part-funded by the National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for the West Midlands (CLAHRC-WM).,Abbreviations|SES Service Engagement Scale,[150613],[26237],[26420],[False],[0],[0],[False],['0']
35391,PMC5702102,25604,All opinions expressed here are solely those of the authors.,Abbreviations|SES Service Engagement Scale,[150616],[26421],[26481],[False],[0],[0],[False],['0']
35392,PMC5702102,25605,GT is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College London Foundation Trust.,Abbreviations|SES Service Engagement Scale,[150619],[26482],[26671],[False],[0],[0],[False],['0']
35393,PMC5702102,25606,"The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.",Abbreviations|SES Service Engagement Scale,[150622],[26672],[26794],[False],[0],[0],[False],['0']
35394,PMC5702102,25607,GT acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust.,Abbreviations|SES Service Engagement Scale,[150625],[26795],[27107],[False],[0],[0],[False],['0']
35395,PMC5702102,25608,GT is supported by the European Union Seventh Framework Programme (FP7/2007-2013) Emerald project.,Abbreviations|SES Service Engagement Scale,[150628],[27108],[27206],[False],[0],[0],[False],['0']
35396,PMC5702102,25609,We would also like to acknowledge and thank all the patients and clinical staff who participated in this research.,Abbreviations|SES Service Engagement Scale,[150631],[27207],[27321],[False],[0],[0],[False],['0']
35397,PMC5702102,25610,"In particular we are grateful to: JCP Facilitators: Melanie De Castro; Betina Reid; Rangeni Zinyama; Anita Davies; Research Assistants: Katie Selwood, Liz Doherty, Sam Treacy, Nicola Wright, Sarah Davis, Julia Cook, Gemma Clark, Catherine Finnecy, Gill Brown, Adrine Woodham; Trial Steering Committee: Simon Gilbody; Mary Evans; Paul Farmer; Peter Campbell; Genevra Richardson; Data Monitoring and Ethics Committee: Mike Crawford; Tim Croudace; Ian Harvey; The Mental Health Research Network in each Trust, specifically, Liz Hutt, Amy Mclachan, Mike Kelly; Carly Cooper, Juan Doblado Pavon, Siobhan Keogh, Rachael Clarke; Moira Winters, Maria Kaltsi, Polly Bidwell, Vicky Bell, Deela Monji.",Abbreviations|SES Service Engagement Scale,[150634],[27322],[28012],[False],[0],[0],[False],['0']
35398,PMC5702102,25611,Funding,Abbreviations|Funding,[150637],[28013],[28020],[False],[0],[0],[False],['0']
35399,PMC5702102,25612,The CRIMSON trial was funded by the UK’s Medical Research Council (MRC).,Abbreviations|Funding,[150640],[28021],[28093],[False],[0],[0],[False],['0']
35400,PMC5702102,25613,Availability of data and materials,Abbreviations|Availability of data and materials,[150643],[28094],[28128],[False],[0],[0],[False],['0']
35401,PMC5702102,25614,The datasets generated and/or analysed during the current study are not publicly available due to lack of ethics committee permission but are available given ethics committee approval from the corresponding author on reasonable request.,Abbreviations|Availability of data and materials,[150646],[28129],[28365],[False],[0],[0],[False],['0']
35402,PMC5702102,25615,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[150649],[28366],[28408],[False],[0],[0],[False],['0']
35403,PMC5702102,25616,CRIMSON received approval from the King’s College Hospital Research Ethics Committee (ref# 07_H0808_174) and signed consent from mental health service users and Care Coordinators.,Abbreviations|Ethics approval and consent to participate,[150652],[28409],[28588],[False],[0],[0],[False],['0']
35404,PMC5702102,25617,Competing interests,Abbreviations|Competing interests,[150655],[28589],[28608],[False],[0],[0],[False],['0']
35405,PMC5702102,25618,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[150658],[28609],[28667],[False],[0],[0],[False],['0']
35406,PMC5702102,25619,Publisher’s Note,Abbreviations|Publisher’s Note,[150661],[28668],[28684],[False],[0],[0],[False],['0']
35407,PMC5702102,25620,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[150664],[28685],[28803],[False],[0],[0],[False],['0']
35874,PMC5721594,38879,Socio-demographic determinants and effect of structured personal diabetes care: a 19-year follow-up of the randomized controlled study diabetes Care in General Practice (DCGP),Title,[226425],[21381],[175],[False],[0],[0],[False],['0']
35875,PMC5721594,38880,Background,Abstract,[226433],[176],[187],[False],[0],[0],[False],['0']
35876,PMC5721594,38881,We investigated how four aspects of socio-demography influence the effectiveness of an intervention with structured personal diabetes care on long-term outcomes.,Abstract,[226441],[188],[349],[False],[0],[0],[False],['0']
35877,PMC5721594,38882,Methods,Methods,[226449],[350],[358],[False],[0],[0],[False],['0']
35878,PMC5721594,38883,The Diabetes Care in General Practice (DCGP) study is a cluster-randomized trial involving a population-based sample of 1381 patients with newly diagnosed type 2-diabetes mellitus.,Methods,[226457],[359],[539],[False],[0],[0],[False],['0']
35879,PMC5721594,38884,"We investigated how education, employment, cohabitation status and residence influenced the effectiveness of 6 years of intervention with structured personal diabetes care, resembling present day recommendations.",Methods,[226465],[540],[752],[False],[0],[0],[False],['0']
35880,PMC5721594,38885,"Outcomes were incidence of any diabetes-related endpoint and death during 19 years after diagnosis, and cardiovascular risk factors, behaviour, attitudes and process-of-care variables 6 years after diagnosis.",Methods,[226473],[753],[961],[False],[0],[0],[False],['0']
35881,PMC5721594,38886,Results,Results,[226481],[962],[970],[False],[0],[0],[False],['0']
35882,PMC5721594,38887,"Structured personal care reduced the risk of any diabetes-related endpoint and the effect of the intervention was modified by geographical area (interaction p = 0.034) with HR of 0.71 (95%CI: 0.60–0.85) and of 1.07 (95%CI: 0.77–1.48), for patients in urban and rural areas, respectively.",Results,[226489],[971],[1258],[False],[0],[0],[False],['0']
35883,PMC5721594,38888,"Otherwise, there was no effect modification of education, employment and civil status on the intervention for the final endpoints.",Results,[226497],[1259],[1389],[False],[0],[0],[False],['0']
35884,PMC5721594,38889,"There were no noticeable socio-demographic differences in the effect of the intervention on cardiovascular risk factors, behaviour, attitudes, and process-of-care.",Results,[226505],[1390],[1553],[False],[0],[0],[False],['0']
35885,PMC5721594,38890,Conclusion,Conclusion,[226513],[1554],[1565],[False],[0],[0],[False],['0']
35886,PMC5721594,38891,"Structured personal care reduced the aggregate outcome of any diabetes-related endpoint and independent of socio-demographic factors similar effect on cardiovascular risk factors, behaviour, attitudes and process of care, but the intervention did not change the existing inequity in mortality and morbidity.",Conclusion,[226521],[1566],[1873],[False],[0],[0],[False],['0']
35887,PMC5721594,38892,"Residence modified the uptake of the intervention with patients living in urban areas having more to gain of the intervention than rural patients, further investigations is warranted.",Conclusion,[226529],[1874],[2057],[False],[0],[0],[False],['0']
35888,PMC5721594,38893,Trial registration,Trial registration,[226537],[2058],[2077],[False],[0],[0],[False],['0']
35889,PMC5721594,38894,ClinicalTrials.gov registration no.,Trial registration,[226545],[2078],[2113],[False],[0],[0],[False],['0']
35890,PMC5721594,38895,"NCT01074762 (February 24, 2010).",Trial registration,[226553],[2114],[2146],[False],[0],[0],[False],['0']
35891,PMC5721594,38896,Electronic supplementary material,Electronic supplementary material,[226561],[2147],[2181],[False],[0],[0],[False],['0']
35892,PMC5721594,38897,"The online version of this article (10.1186/s12902-017-0227-x) contains supplementary material, which is available to authorized users.",Electronic supplementary material,[226569],[2182],[2317],[False],[0],[0],[False],['0']
35893,PMC5721594,38898,Background,Background,[226577],[2318],[2330],[False],[0],[0],[False],['0']
35894,PMC5721594,38899,"Epidemiological studies have repeatedly shown increased occurrence of type 2 diabetes mellitus (T2DM) among people with low socioeconomic status [1, 2] and living in rural areas [3].",Background,[226585],[2331],[2513],[False],[0],[0],[False],['0']
35895,PMC5721594,38900,"Primarily due to improved diabetes care, mortality of T2DM patients has decreased substantially in recent decades [4], although this trend has been less favourable among those with low socio-economic status (SES) [5–10].",Background,[226593],[2514],[2734],[False],[0],[0],[False],['0']
35896,PMC5721594,38901,"A recent Scandinavian study showed increased mortality among people of low SES, but could not show any systematic differences in mortality between patients living in rural and urban areas [8].",Background,[226601],[2735],[2927],[False],[0],[0],[False],['0']
35897,PMC5721594,38902,"Social inequality in mortality and morbidity of patients with T2DM can only be partially explained by differences in the increased incidence of other comorbid disease [1, 11].",Background,[226609],[2928],[3103],[False],[0],[0],[False],['0']
35898,PMC5721594,38903,"SES has been reported to influence metabolic control [12], pharmacological treatment [13] and ability to change lifestyle according to the recommendations [14, 15].",Background,[226617],[3104],[3268],[False],[0],[0],[False],['0']
35899,PMC5721594,38904,"Inequality in access to and utilization of health care [16, 17] could influence the course of T2DM [18, 19].",Background,[226625],[3269],[3377],[False],[0],[0],[False],['0']
35900,PMC5721594,38905,"Though SES and place of living influence care and prognosis of T2DM [8, 10, 11, 20], there is only limited evidence as to whether the effectiveness of diabetes interventions differs with regard to SES and residence.",Background,[226633],[3378],[3593],[False],[0],[0],[False],['0']
35901,PMC5721594,38906,"Recent reports suggest that interventions with intensive diabetes care diminish the socio-economic differences in intermediate outcomes [13, 21], but we do not know whether this effect also is seen on long-term outcomes.",Background,[226641],[3594],[3814],[False],[0],[0],[False],['0']
35902,PMC5721594,38907,"One may hypothesize, that an intervention with structured personal care may succeed to reduce the difference between socio-demographic groups [13], as the effectiveness of this intervention in two post hoc analyses have been reported to be especially pronounced in women [22] and in patients with severe mental illness [23].",Background,[226649],[3815],[4139],[False],[0],[0],[False],['0']
35903,PMC5721594,38908,Our aim in the present study is to describe how socio-demographic status and residence influences the effectiveness of an intervention with structured personal care in newly diagnosed patients with T2DM regarding all-cause mortality and any diabetes-related endpoint during 19 years of follow-up.,Background,[226657],[4140],[4436],[False],[0],[0],[False],['0']
35904,PMC5721594,38909,Methods,Methods,[226665],[4437],[4445],[False],[0],[0],[False],['0']
35905,PMC5721594,38910,Patients,Methods|Patients,[226673],[4446],[4454],[False],[0],[0],[False],['0']
35906,PMC5721594,38911,Fig.,Methods|Patients,[226681],[4455],[4459],[False],[0],[0],[False],['0']
35907,PMC5721594,38912,1 Patient flow diagram from inclusion until 19-year register based follow-up.,Methods|Patients,[226689],[4460],[4537],[False],[0],[0],[False],['0']
35908,PMC5721594,38913,"The Diabetes Care in General Practice (DCGP) study was a pragmatic, open, multicentre, cluster-randomized controlled trial (ClinicalTrials.gov registration no.",Methods|Patients,[226697],[4538],[4697],[False],[0],[0],[False],['0']
35909,PMC5721594,38914,NCT01074762) [18].,Methods|Patients,[226705],[4698],[4716],[False],[0],[0],[False],['0']
35910,PMC5721594,38915,"The purpose of the trial was to test whether structured personal care, compared to routine care, for patients newly diagnosed with T2DM, reduced the incidence of seven pre-defined outcomes, including all-cause mortality and any diabetes-related outcome [18, 24].",Methods|Patients,[226713],[4717],[4979],[False],[0],[0],[False],['0']
35911,PMC5721594,38916,"In 1988, a random sample of two thirds of Danish general practices, excluding singlehanded practices with a doctor aged ≥60 years, received an invitation to participate in the study.",Methods|Patients,[226721],[4980],[5162],[False],[0],[0],[False],['0']
35912,PMC5721594,38917,"Of 1902 general practitioners (GPs), 474 (25.4%) volunteered.",Methods|Patients,[226729],[5163],[5224],[False],[0],[0],[False],['0']
35913,PMC5721594,38918,"In 1989–1992, all practices included all patients aged 40 years or over with newly diagnosed diabetes based on strict criteria [18].",Methods|Patients,[226737],[5225],[5357],[False],[0],[0],[False],['0']
35914,PMC5721594,38919,All practices were randomized to either six years of structured personal care or routine care in the period 1989–1995 and all patients had a follow up examination 6 years after diagnosis [24].,Methods|Patients,[226745],[5358],[5550],[False],[0],[0],[False],['0']
35915,PMC5721594,38920,"The inclusion criteria were met by 1590 patients, of which 209 patients were excluded according to predefined criteria, so that the number of study participants was 1381 (Fig.",Methods|Patients,[226753],[5551],[5726],[False],[0],[0],[False],['0']
35916,PMC5721594,38921,1).,Methods|Patients,[226761],[5727],[5730],[False],[0],[0],[False],['0']
35917,PMC5721594,38922,"Among these patients, 1369 (99.1%) were of western European descent and, based on onset of insulin treatment, most were considered to have T2DM (97.5%).",Methods|Patients,[226769],[5731],[5883],[False],[0],[0],[False],['0']
35918,PMC5721594,38923,The Ethics Committee of Copenhagen and Frederiksberg (V.100.869/87) approved the study and all patients gave informed consent.,Methods|Patients,[226777],[5884],[6010],[False],[0],[0],[False],['0']
35919,PMC5721594,38924,Intervention,Intervention,[226785],[6011],[6025],[False],[0],[0],[False],['0']
35920,PMC5721594,38925,"The Danish healthcare system is mainly tax-financed and based on the egalitarian principle of equal healthcare access for all equal healthcare needs, clinic visits are free of charge and expenditures for prescribed drugs are for the most part reimbursed.",Intervention,[226793],[6026],[6280],[False],[0],[0],[False],['0']
35921,PMC5721594,38926,In Denmark the GP usually provides diagnosis and routine care for T2DM and function as gatekeeper for specialist care.,Intervention,[226801],[6281],[6399],[False],[0],[0],[False],['0']
35922,PMC5721594,38927,In the intervention arm follow-up every 3 months and annual screening for diabetes complications were supported by sending out a questionnaire to GPs one month before the next expected consultation.,Intervention,[226809],[6400],[6598],[False],[0],[0],[False],['0']
35923,PMC5721594,38928,"Goal-setting for blood glucose, blood pressure, lipids and weight was individualized [24], and GPs were introduced to possible solutions to therapeutic problems through six annual half-day seminars, descriptive annual reports on individual patients as well as folders and leaflets for doctors and patients, resembling present day recommendations for diabetes care [25, 26].",Intervention,[226817],[6599],[6972],[False],[0],[0],[False],['0']
35924,PMC5721594,38929,None of the intervention procedures were explicitly based on social differentials.,Intervention,[226825],[6973],[7055],[False],[0],[0],[False],['0']
35925,PMC5721594,38930,Patients were never approached by the study centre.,Intervention,[226833],[7056],[7107],[False],[0],[0],[False],['0']
35926,PMC5721594,38931,GPs in the routine care group were free to choose any treatment and change it over time [24] and they were not contacted after patient inclusion had stopped until the intervention was terminated and the 6-year examination was initiated in September 1995.,Intervention,[226841],[7108],[7362],[False],[0],[0],[False],['0']
35927,PMC5721594,38932,Assessments,Assessments,[226849],[7363],[7375],[False],[0],[0],[False],['0']
35928,PMC5721594,38933,"At the time of diagnosis and at the 6-year follow up examination measures of patients’ health and social status were collected in questionnaires to GPs, eye doctors and patients.",Assessments,[226857],[7376],[7554],[False],[0],[0],[False],['0']
35929,PMC5721594,38934,"Upon inclusion, patients gave information about socio-demographic variables in questionnaires: highest attained education level (basic school education only or higher education level); in labour market, out of labour market or retired; and whether patients lived alone or were cohabiting/married.",Assessments,[226865],[7555],[7851],[False],[0],[0],[False],['0']
35930,PMC5721594,38935,Information on smoking habits and leisure-time physical activity was also collected.,Assessments,[226873],[7852],[7936],[False],[0],[0],[False],['0']
35931,PMC5721594,38936,Information on place of living was recorded as rural or urban from area code and population density in accordance with Statistics Denmark [27].,Assessments,[226881],[7937],[8080],[False],[0],[0],[False],['0']
35932,PMC5721594,38937,Clinical and registry based follow-up,Clinical and registry based follow-up,[226889],[8081],[8119],[False],[0],[0],[False],['0']
35933,PMC5721594,38938,"The clinical 6-year follow-up examination included measurement of body weight, blood pressure, urinary albumin, haemoglobin A1c (HbA1c), total cholesterol, fasting triglycerides, and serum creatinine.",Clinical and registry based follow-up,[226897],[8120],[8320],[False],[0],[0],[False],['0']
35934,PMC5721594,38939,"Patients and doctors were asked to fill in questionnaires including questions on health behaviour (smoking, physical activity), attitudes towards disease (altered habits, diet and home monitoring of blood glucose), patient’s motivation for best possible control according to the GP, process-of-care (number of consultations, number of diabetes-related consultations and whether patients had been treated at a diabetes clinic) and if they received pharmacological treatment (cholesterol-lowering, glucose-lowering and antihypertensive drugs).",Clinical and registry based follow-up,[226905],[8321],[8862],[False],[0],[0],[False],['0']
35935,PMC5721594,38940,During 19 years (mean follow-up time) after diabetes diagnosis patients were followed up in the national registers.,Clinical and registry based follow-up,[226913],[8863],[8978],[False],[0],[0],[False],['0']
35936,PMC5721594,38941,Vital and emigration status of all patients were certified through the Danish Civil Registration System [28].,Clinical and registry based follow-up,[226921],[8979],[9088],[False],[0],[0],[False],['0']
35937,PMC5721594,38942,Everyone living in Denmark is registered with a permanent and unique personal identification number allowing linkage between study populations and all national registers.,Clinical and registry based follow-up,[226929],[9089],[9259],[False],[0],[0],[False],['0']
35938,PMC5721594,38943,"Data on mortality, diagnoses and surgical procedures were from The Danish Register of Causes of Death (DCD) [29] and The Danish National Patient Register (DNPR), which includes information on almost all hospital contacts in Denmark [30].",Clinical and registry based follow-up,[226937],[9260],[9497],[False],[0],[0],[False],['0']
35939,PMC5721594,38944,The outcomes used in the registry-based follow up were all-cause mortality and any diabetes-related endpoint.,Clinical and registry based follow-up,[226945],[9498],[9607],[False],[0],[0],[False],['0']
35940,PMC5721594,38945,(e.g.,Clinical and registry based follow-up,[226953],[9608],[9613],[False],[0],[0],[False],['0']
35941,PMC5721594,38946,"stroke, myocardial infarction and renal failure, full list see (Additional file 1)), previously defined [18] and also used in the UK Prospective Diabetes Study [31].",Clinical and registry based follow-up,[226961],[9614],[9779],[False],[0],[0],[False],['0']
35942,PMC5721594,38947,Statistical analysis,Statistical analysis,[226969],[9780],[9801],[False],[0],[0],[False],['0']
35943,PMC5721594,38948,Table 1 Patient characteristics at diabetes diagnosis according to treatment arm.,Statistical analysis,[226977],[9802],[9883],[False],[0],[0],[False],['0']
35944,PMC5721594,38949,Differences in the incidence of death and any diabetes-related endpoint between randomization and socio-demographic groups were analysed univariably with log-rank tests and multivariably in Cox regressions models.,Statistical analysis,[226985],[9884],[10097],[False],[0],[0],[False],['0']
35945,PMC5721594,38950,"In the latter, 95% CIs and p values were determined using a sandwich estimator for the variance to account for clustering of patients within practices [30].",Statistical analysis,[226993],[10098],[10254],[False],[0],[0],[False],['0']
35946,PMC5721594,38951,Absolute risks were calculated as the number of participants experiencing the corresponding outcome divided by person years of risk.,Statistical analysis,[227001],[10255],[10387],[False],[0],[0],[False],['0']
35947,PMC5721594,38952,"Two multivariable models are presented, one adjusted for age at diagnosis, sex and clustering, the other with additional adjustment for the following variables at diagnosis: BMI, hypertension, HbA1c, total cholesterol, urinary albumin, physical activity, smoking, known cardiovascular disease (see Table 1), and prescription of glucose- and/or lipid-lowering and/or antihypertensive drugs.",Statistical analysis,[227009],[10388],[10777],[False],[0],[0],[False],['0']
35948,PMC5721594,38953,"For behavioural, clinical, biochemical and process-of-care variables at the 6-year examination we used multivariable generalized linear regression models (ordinary linear regression for continuous variables, logistic regression for binary variables and negative binomial regression for count variables) and presented the effects of structured care vs. routine care, stratified on sociodemographic groups adjusted for age, sex, and diabetes duration.",Statistical analysis,[227017],[10778],[11228],[False],[0],[0],[False],['0']
35949,PMC5721594,38954,Effect modification was assessed by a test for the interaction between randomization and SES groups in the corresponding model.,Statistical analysis,[227025],[11229],[11356],[False],[0],[0],[False],['0']
35950,PMC5721594,38955,Clustering with GPs was accounted for by the use of generalized estimating equations.,Statistical analysis,[227033],[11357],[11442],[False],[0],[0],[False],['0']
35951,PMC5721594,38956,Due to the multiple comparisons the level of statistical significance at 5% is not interpreted rigorously.,Statistical analysis,[227041],[11443],[11549],[False],[0],[0],[False],['0']
35952,PMC5721594,38957,We performed a log rank test for all-cause mortality and any diabetes-related endpoint comparing the four groups defined by educational background and the intervention.,Statistical analysis,[227049],[11550],[11718],[False],[0],[0],[False],['0']
35953,PMC5721594,38958,"We used the statistical program SAS v9.4 (SAS Institute, Cary, NC, USA).",Statistical analysis,[227057],[11719],[11791],[False],[0],[0],[False],['0']
35954,PMC5721594,38959,Results,Results,[227065],[11792],[11800],[False],[0],[0],[False],['0']
35955,PMC5721594,38960,Fig.,Results,[227073],[11801],[11805],[False],[0],[0],[False],['0']
35956,PMC5721594,38961,"2 Kaplan-Meier plot showing the proportion of surviving patients since diabetes diagnosis in patients according to randomization arm and highest attained education level, only basic schooling vs. higher.",Results,[227081],[11806],[12009],[False],[0],[0],[False],['0']
35957,PMC5721594,38962,Fig.,Results,[227089],[12010],[12014],[False],[0],[0],[False],['0']
35958,PMC5721594,38963,"3 Kaplan-Meier plot showing the proportion of patients without any diabetes related endpoint since diagnosis according to randomization arm and highest attained education level, only basic schooling vs. higher.",Results,[227097],[12015],[12225],[False],[0],[0],[False],['0']
35959,PMC5721594,38964,"Table 2 Any diabetes-related outcome and all-cause mortality during 19 years of follow-up, according to socio-demographic group.",Results,[227105],[12226],[12354],[False],[0],[0],[False],['0']
35960,PMC5721594,38965,The indirect randomization was successful except that relatively more routine care patients were living in rural areas (Table 1).,Results,[227113],[12355],[12484],[False],[0],[0],[False],['0']
35961,PMC5721594,38966,"Overall, a low level of education was associated with higher all-cause mortality (Fig.",Results,[227121],[12485],[12571],[False],[0],[0],[False],['0']
35962,PMC5721594,38967,2) and any diabetes-related endpoint (Fig.,Results,[227129],[12572],[12614],[False],[0],[0],[False],['0']
35963,PMC5721594,38968,"3) showing significant difference between the 4 groups in respectively all cause-mortality and any diabetes related endpoint (log-rank test, p < 0.0001).",Results,[227137],[12615],[12768],[False],[0],[0],[False],['0']
35964,PMC5721594,38969,"During 19 years of registry-based follow up structured personal care lowered the risk of any diabetes-related endpoint by 20% compared with routine care [18], and this effect seems to be most pronounced for patients living in urban areas (HR(95%CI) 0.71; 0.60–0.85), patients with only basic level of education (0.75; 0.63–0.89), patients outside the labour market (0.73; 0.55–0.97) and patients cohabiting (0.78; 0.65–0.93) (Table 2).",Results,[227145],[12769],[13204],[False],[0],[0],[False],['0']
35965,PMC5721594,38970,"The effect of the intervention, however, was only statistically significantly different between patients living in urban and rural areas (interaction p = 0.034).",Results,[227153],[13205],[13366],[False],[0],[0],[False],['0']
35966,PMC5721594,38971,The intervention had no effect on all-cause mortality.,Results,[227161],[13367],[13421],[False],[0],[0],[False],['0']
35967,PMC5721594,38972,"Table 3 The effect of structured personal care on behavioral, clinical, process of care and biochemical variables according to socio-demographic group.",Results,[227169],[13422],[13576],[False],[0],[0],[False],['0']
35968,PMC5721594,38973,"Results describing the role of four different aspects of socio-demography on behavioural, clinical, biochemical and process-of-care variables at the 6-year examination are presented in Additional file 2: Table S1, Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, and summarized with the p-values from the test of the corresponding interaction and a description of the association (Table 3).",Results,[227177],[13577],[14005],[False],[0],[0],[False],['0']
35969,PMC5721594,38974,"Overall, the effect of the intervention on these variables did not differ according to socio-demography.",Results,[227185],[14006],[14110],[False],[0],[0],[False],['0']
35970,PMC5721594,38975,"Only few patients were treated with cholesterol lowering drugs in 1995–96 (1.9% - 5.8%), but relatively fewer patients living in rural areas were treated with cholesterol lowering drugs in response to the intervention compared to urban patients.",Results,[227193],[14111],[14356],[False],[0],[0],[False],['0']
35971,PMC5721594,38976,"The intervention resulted in an increased number of diabetes-related consultations regardless of socio-demographic group, and patients living alone tended to have relatively more consultations compared to patients cohabiting.",Results,[227201],[14357],[14582],[False],[0],[0],[False],['0']
35972,PMC5721594,38977,Discussion,Discussion,[227209],[14583],[14595],[False],[0],[0],[False],['0']
35973,PMC5721594,38978,"The intervention did not influence all-cause mortality [18], but overall patients receiving structured personal care experienced a 20% lower risk of any diabetes-related endpoint compared to patients receiving routine care.",Discussion,[227217],[14596],[14819],[False],[0],[0],[False],['0']
35974,PMC5721594,38979,"This effect was greater among patients living in urban areas compared to rural patients, but otherwise, there was no effect modification of education, employment and civil status on the intervention for the final endpoints.",Discussion,[227225],[14820],[15043],[False],[0],[0],[False],['0']
35975,PMC5721594,38980,"Overall the effect of the intervention on behavioural, biochemical and process-of-care measures was not different between the subgroups of the four aspects of socio-demography.",Discussion,[227233],[15044],[15220],[False],[0],[0],[False],['0']
35976,PMC5721594,38981,Comparison with existing literature,Comparison with existing literature,[227241],[15221],[15257],[False],[0],[0],[False],['0']
35977,PMC5721594,38982,"This study reports social inequity in mortality and diabetes-related morbidity, in line with other studies that have investigated the impact of level of education [9], occupation [8] and socio-economic status [7, 8].",Comparison with existing literature,[227249],[15258],[15474],[False],[0],[0],[False],['0']
35978,PMC5721594,38983,"The present findings suggest that an intervention with structured personal care does not give rise to more social inequity in use of the health care system, as has been described in other studies [13, 21].",Comparison with existing literature,[227257],[15475],[15680],[False],[0],[0],[False],['0']
35979,PMC5721594,38984,"Thus the results do not confirm results from studies of the general population showing that the number of consultations at the GP increases with decreasing socio-economic status [15, 32].",Comparison with existing literature,[227265],[15681],[15868],[False],[0],[0],[False],['0']
35980,PMC5721594,38985,"The fact that socio-economic differences in mortality and morbidity persist, despite formally equal access to the public health care system, could be due to different use of specialist care as suggested by others [17, 20], but this does not seem to be the case for the intervention in our study.",Comparison with existing literature,[227273],[15869],[16164],[False],[0],[0],[False],['0']
35981,PMC5721594,38986,"The presented benefit of structured personal care on long-term endpoints, also for patients with low level of education and patients on welfare benefits, cannot be ascribed to single elements of complex interventions.",Comparison with existing literature,[227281],[16165],[16382],[False],[0],[0],[False],['0']
35982,PMC5721594,38987,"Patients with low level of education and income are frequently reported to be inadequately controlled with hyperglycaemia, hypertension, dyslipidaemia and unhealthy lifestyle [14, 15], and some studies also suggest socio-demographic differences in prescription rates [16, 20].",Comparison with existing literature,[227289],[16383],[16659],[False],[0],[0],[False],['0']
35983,PMC5721594,38988,"Our results are in line with earlier studies, concerning socio-demographic differences of intensive multifactorial interventions, which have been shown not to worsen or introduce social inequity in the control of T2DM [13, 21, 33].",Comparison with existing literature,[227297],[16660],[16891],[False],[0],[0],[False],['0']
35984,PMC5721594,38989,"Prior studies suggest that interventions seem to be effective, also among patient with low SES, in improving cardiovascular risk factors and prescription of medicine, but it is more difficult to assist patients in changing lifestyle and attitudes towards DM [13, 21, 33, 34].",Comparison with existing literature,[227305],[16892],[17167],[False],[0],[0],[False],['0']
35985,PMC5721594,38990,"As a high-risk group patients with low SES have potentially more to win [9, 10], but they are also known to have poor compliance especially regarding lifestyle and attitudes towards DM [5, 14, 15].",Comparison with existing literature,[227313],[17168],[17365],[False],[0],[0],[False],['0']
35986,PMC5721594,38991,"The individualization of diabetes care in the DCGP trial with negotiation of treatment goals, taking patient resources in consideration may explain why this intervention seems to be effective across the spectrum of SES.",Comparison with existing literature,[227321],[17366],[17585],[False],[0],[0],[False],['0']
35987,PMC5721594,38992,Our results indicate that patients living in rural areas may have less benefit of the intervention compared to urban patients.,Comparison with existing literature,[227329],[17586],[17712],[False],[0],[0],[False],['0']
35988,PMC5721594,38993,An explanation for this finding could be because the uptake of the intervention was lower among rural doctors and/or because the compliance with the intervention among rural patients was low.,Comparison with existing literature,[227337],[17713],[17904],[False],[0],[0],[False],['0']
35989,PMC5721594,38994,"We could not see any systematic differences in the 6 year follow up, on cardiovascular risk factors or behaviour between urban and rural patients that could reconcile these finding (Table 3).",Comparison with existing literature,[227345],[17905],[18096],[False],[0],[0],[False],['0']
35990,PMC5721594,38995,"However, our data suggest that rural patients are less often treated with cholesterol-lowering drugs as a result of the intervention, but few patients were actually treated with this medication in the middle of the 1990s.",Comparison with existing literature,[227353],[18097],[18318],[False],[0],[0],[False],['0']
35991,PMC5721594,38996,Other studies have reported that cholesterol-lowering agents are less often prescribed in deprived areas [34].,Comparison with existing literature,[227361],[18319],[18429],[False],[0],[0],[False],['0']
35992,PMC5721594,38997,"A previous Scandinavian study reported no difference in mortality between urban and rural patients [8], like our study, other studies have suggested that people residing in more rural areas more often have undiagnosed diabetes [35, 36].",Comparison with existing literature,[227369],[18430],[18666],[False],[0],[0],[False],['0']
35993,PMC5721594,38998,"This implies that rural patients may be diagnosed at a later stage of the disease, possibly with a higher risk of complications and maybe less susceptible to treatment interventions than patients living in urban areas, this have to be investigated further.",Comparison with existing literature,[227377],[18667],[18923],[False],[0],[0],[False],['0']
35994,PMC5721594,38999,Strengths and weaknesses of the study,Strengths and weaknesses of the study,[227385],[18924],[18962],[False],[0],[0],[False],['0']
35995,PMC5721594,39000,This study contributes to the knowledge on how SES and urbanisation influence the uptake and effect of diabetes interventions and may offer some advantages in comparison to prior studies.,Strengths and weaknesses of the study,[227393],[18963],[19150],[False],[0],[0],[False],['0']
35996,PMC5721594,39001,"It is a strength of the present study that it reports hard endpoints after 19 years of follow up, but on the other hand a limitation that the results are from an early cohort.",Strengths and weaknesses of the study,[227401],[19151],[19326],[False],[0],[0],[False],['0']
35997,PMC5721594,39002,"Furthermore, the results are likely to be generalizable to the wider population of patients with T2DM because the study was population-based, with no upper age limit, but also because the study was conducted in general practice where most T2DM patients are treated.",Strengths and weaknesses of the study,[227409],[19327],[19592],[False],[0],[0],[False],['0']
35998,PMC5721594,39003,"Also, the elements of the intervention, including the negotiation of treatment goals between patient and doctor, resemble standard treatment procedures in current day general practice diabetes care and recommendations [25, 26].",Strengths and weaknesses of the study,[227417],[19593],[19820],[False],[0],[0],[False],['0']
35999,PMC5721594,39004,"Finally, the study had a relative high number of GPs participating and the patient attrition rate was low.",Strengths and weaknesses of the study,[227425],[19821],[19927],[False],[0],[0],[False],['0']
36000,PMC5721594,39005,The most important limitation of this study is that it is a post hoc analysis of a randomized controlled trial.,Strengths and weaknesses of the study,[227433],[19928],[20039],[True],['MultipleTesting'],['a post hoc analysis of a randomized controlled trial'],[True],['StatisticalAnalysis']
36001,PMC5721594,39006,"Since randomization did not take socio-demography into account, this could have created imbalance between the randomization groups in relation to socio-demography, this does not seem to be the case.",Strengths and weaknesses of the study,[227450],[20040],[20238],[True],['PoorRandomizationMethods'],['randomization did not take socio-demography into account'],[True],['Randomization']
36002,PMC5721594,39007,We although found a minor difference in randomization regarding residence that means one should be cautious when interpreting these results.,Strengths and weaknesses of the study,[227467],[20239],[20379],[True],['PoorRandomizationMethods'],['minor difference in randomization regarding residence'],[True],['Randomization']
36003,PMC5721594,39008,The fact that we could not describe any substantial difference between rural and urban patients at the 6 years clinical follow up – means that the described potential difference in effect has to be investigated further.,Strengths and weaknesses of the study,[227481],[20380],[20599],[False],[0],[0],[False],['0']
36004,PMC5721594,39009,It is also a limitation that some elements of the intervention in the structured care arm were later applied to the routine care arm through national diabetes guidelines.,Strengths and weaknesses of the study,[227492],[20600],[20770],[True],['NonstandardTreatmentCharacteristics'],['some elements of the intervention in the structured care arm were later applied to the routine care arm'],[True],['Intervention']
36005,PMC5721594,39010,The intervention could therefore prove to be more efficient than reported.,Strengths and weaknesses of the study,[227505],[20771],[20845],[False],[0],[0],[False],['0']
36006,PMC5721594,39011,"Information on educational level, employment and civil status were self-reported which might cause misclassification, but on the other hand, this information is readily at hand for the physician.",Strengths and weaknesses of the study,[227517],[20846],[21041],[True],['PrecisionOfMeasurement'],"['Information on educational level, employment and civil status were self-reported']",[True],['OutcomeMeasures']
36007,PMC5721594,39012,"Furthermore, some of the reported socio-demographic differences in mortality and morbidity could be due to patients with low level of education, outside the labour market or living alone being diagnosed later in the natural history of diabetes [9, 37] and therefore presenting with a more advanced disease at diagnosis [13].",Strengths and weaknesses of the study,[227536],[21042],[21366],[True],['Population'],['presenting with a more advanced disease at diagnosis'],[True],['Population']
36008,PMC5721594,39013,Also a higher prevalence of comorbidity among patients with low SES in general could influence the result.,Strengths and weaknesses of the study,[227550],[21367],[21473],[True],['VerySpecificPopulation'],['a higher prevalence of comorbidity among patients with low SES'],[True],['Population']
36009,PMC5721594,39014,"We could however only find moderate decline in the association between low socioeconomic status and any diabetes-related endpoint when adjusting for comorbidity and baseline cardiovascular risk factors, which is in accordance with other studies [1, 11].",Strengths and weaknesses of the study,[227561],[21474],[21727],[False],[0],[0],[False],['0']
36010,PMC5721594,39015,Long-term outcomes were registry-based and vital status was confirmed for all study participants.,Strengths and weaknesses of the study,[227569],[21728],[21825],[False],[0],[0],[False],['0']
36011,PMC5721594,39016,"Not all non-fatal outcomes have been tested for validity, but this is generally considered to be acceptable [29, 30], and differential misclassification according to treatment allocation and socio-demography is not expected.",Strengths and weaknesses of the study,[227583],[21826],[22050],[True],['ValidityOfMeasurement'],['Not all non-fatal outcomes have been tested for validity'],[True],['OutcomeMeasures']
36012,PMC5721594,39017,Conclusion,Conclusion,[227593],[22051],[22062],[False],[0],[0],[False],['0']
36013,PMC5721594,39018,"Structured personal diabetes care showed effect on the aggregate outcome any diabetes-related endpoint, even for the high-risk group of patients with low level of education and patients out of the labour market.",Conclusion,[227601],[22063],[22274],[False],[0],[0],[False],['0']
36014,PMC5721594,39019,"Thus, structured personal care did not give rise to more health inequality among patients with diabetes but rather a tendency in the opposite direction.",Conclusion,[227609],[22275],[22427],[False],[0],[0],[False],['0']
36015,PMC5721594,39020,"Patients living in rural areas, however, seemed to have gained less from the intervention compared to patients living in urban areas this finding has to be investigated further.",Conclusion,[227617],[22428],[22605],[False],[0],[0],[False],['0']
36016,PMC5721594,39021,"Still, socio-economic inequity in mortality and morbidity existed despite the intervention.",Conclusion,[227625],[22606],[22697],[False],[0],[0],[False],['0']
36017,PMC5721594,39022,Additional files,Additional files,[227633],[22698],[22715],[False],[0],[0],[False],['0']
36018,PMC5721594,39023," Definition of clinical outcomes in the 19-year registry-based monitoring of the DCGP study, any diabetes related endpoint (list).",Additional files,[227641],[22716],[22846],[False],[0],[0],[False],['0']
36019,PMC5721594,39024,(DOCX 76 kb),Additional files,[227649],[22847],[22859],[False],[0],[0],[False],['0']
36020,PMC5721594,39025,Table S1.,Additional files,[227657],[22860],[22871],[False],[0],[0],[False],['0']
36021,PMC5721594,39026,"The effect of structured personal care on behavioral, clinical, process of care and biochemical variables according to level of education (DOCX 35 kb)",Additional files,[227665],[22872],[23022],[False],[0],[0],[False],['0']
36022,PMC5721594,39027,Table S2.,Additional files,[227673],[23023],[23034],[False],[0],[0],[False],['0']
36023,PMC5721594,39028,"The effect of structured personal care on behavioral, clinical, process of care and biochemical variables according to civil status (DOCX 37 kb)",Additional files,[227681],[23035],[23179],[False],[0],[0],[False],['0']
36024,PMC5721594,39029,Table S3.,Additional files,[227689],[23180],[23191],[False],[0],[0],[False],['0']
36025,PMC5721594,39030,"The effect of structured personal care on behavioral, clinical, process of care and biochemical variables according to employment status (out of labor market vs. in labor market, retired excluded) (DOCX 37 kb)",Additional files,[227697],[23192],[23401],[False],[0],[0],[False],['0']
36026,PMC5721594,39031,Table S4.,Additional files,[227705],[23402],[23413],[False],[0],[0],[False],['0']
36027,PMC5721594,39032,"The effect of structured personal care on behavioral, clinical, process of care and biochemical variables according to residence (Rural vs. Urban) (DOCX 37 kb)",Additional files,[227713],[23414],[23573],[False],[0],[0],[False],['0']
36028,PMC5721594,39033,Abbreviations,Abbreviations,[227721],[23574],[23590],[False],[0],[0],[False],['0']
36029,PMC5721594,39034,BMI Body Mass Index,Abbreviations|BMI Body Mass Index,[227729],[23591],[23610],[False],[0],[0],[False],['0']
36030,PMC5721594,39035,CI Confidence interval,Abbreviations|CI Confidence interval,[227737],[23611],[23633],[False],[0],[0],[False],['0']
36031,PMC5721594,39036,DCD Danish register of Causes of Death,Abbreviations|DCD Danish register of Causes of Death,[227745],[23634],[23672],[False],[0],[0],[False],['0']
36032,PMC5721594,39037,DCGP Diabetes in General Practice,Abbreviations|DCGP Diabetes in General Practice,[227753],[23673],[23706],[False],[0],[0],[False],['0']
36033,PMC5721594,39038,DM Diabetes mellitus,Abbreviations|DM Diabetes mellitus,[227761],[23707],[23727],[False],[0],[0],[False],['0']
36034,PMC5721594,39039,DNPR Danish National Patient Register,Abbreviations|DNPR Danish National Patient Register,[227769],[23728],[23765],[False],[0],[0],[False],['0']
36035,PMC5721594,39040,GP General Practitioner,Abbreviations|GP General Practitioner,[227777],[23766],[23789],[False],[0],[0],[False],['0']
36036,PMC5721594,39041,HbA1c Haemoglobin A1c,Abbreviations|GP General Practitioner,[227785],[23790],[23811],[False],[0],[0],[False],['0']
36037,PMC5721594,39042,HR Hazard Ratio,Abbreviations|HR Hazard Ratio,[227793],[23812],[23827],[False],[0],[0],[False],['0']
36038,PMC5721594,39043,SES Socio-economic status,Abbreviations|SES Socio-economic status,[227801],[23828],[23853],[False],[0],[0],[False],['0']
36039,PMC5721594,39044,T2DM Type 2 Diabetes MellitusElectronic supplementary material,Abbreviations|SES Socio-economic status,[227809],[23854],[23916],[False],[0],[0],[False],['0']
36040,PMC5721594,39045,"The online version of this article (10.1186/s12902-017-0227-x) contains supplementary material, which is available to authorized users.",Abbreviations|SES Socio-economic status,[227817],[23917],[24052],[False],[0],[0],[False],['0']
36041,PMC5721594,39046,Acknowledgements,Abbreviations|Acknowledgements,[227825],[24053],[24069],[False],[0],[0],[False],['0']
36042,PMC5721594,39047,Gratitude to all the participants and GP’s of the DCGP-trial.,Abbreviations|Acknowledgements,[227833],[24070],[24131],[False],[0],[0],[False],['0']
36043,PMC5721594,39048,Funding,Abbreviations|Funding,[227841],[24132],[24139],[False],[0],[0],[False],['0']
36044,PMC5721594,39049,"This project was supported by: Region Zealand Research Fund, Copenhagen University Faculty of health sciences and University of Copenhagen 2016 Excellence program to LIFESTAT.",Abbreviations|Funding,[227849],[24140],[24315],[False],[0],[0],[False],['0']
36045,PMC5721594,39050,Availability of data and materials,Abbreviations|Availability of data and materials,[227857],[24316],[24350],[False],[0],[0],[False],['0']
36046,PMC5721594,39051,The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.,Abbreviations|Availability of data and materials,[227865],[24351],[24476],[False],[0],[0],[False],['0']
36047,PMC5721594,39052,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[227873],[24477],[24519],[False],[0],[0],[False],['0']
36048,PMC5721594,39053,"All patients gave verbal informed consent to participate, following a dialogue with their GP, where the patients could ask questions, to secure an informed consent.",Abbreviations|Ethics approval and consent to participate,[227881],[24520],[24684],[False],[0],[0],[False],['0']
36049,PMC5721594,39054,The Ethics Committee of Copenhagen and Frederiksberg (V.100.869/87) approved the study and this procedure for informed consent.,Abbreviations|Ethics approval and consent to participate,[227889],[24685],[24812],[False],[0],[0],[False],['0']
36050,PMC5721594,39055,When the study started off in 1988 it was coutume to seek informed consent orally.,Abbreviations|Ethics approval and consent to participate,[227897],[24813],[24895],[False],[0],[0],[False],['0']
36051,PMC5721594,39056,Consent for publication,Abbreviations|Consent for publication,[227905],[24896],[24919],[False],[0],[0],[False],['0']
36052,PMC5721594,39057,Not applicable.,Abbreviations|Not applicable.,[227913],[24920],[24935],[False],[0],[0],[False],['0']
36053,PMC5721594,39058,Competing interests,Abbreviations|Competing interests,[227921],[24936],[24955],[False],[0],[0],[False],['0']
36054,PMC5721594,39059,The authors declare that they have no competing interests,Abbreviations|Competing interests,[227929],[24956],[25013],[False],[0],[0],[False],['0']
36055,PMC5721594,39060,Publisher’s Note,Abbreviations|Publisher’s Note,[227937],[25014],[25030],[False],[0],[0],[False],['0']
36056,PMC5721594,39061,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[227945],[25031],[25149],[False],[0],[0],[False],['0']
37191,PMC5845227,39062,The relationship between health literacy and patient activation among frequent users of healthcare services: a cross-sectional study,Title,[227953],[25150],[132],[False],[0],[0],[False],['0']
37192,PMC5845227,39063,Background,Abstract,[227958],[133],[144],[False],[0],[0],[False],['0']
37193,PMC5845227,39064,Frequent users of healthcare services are a vulnerable population that deserves attention due to high costs and negative outcomes such as lower quality of life and higher mortality.,Abstract,[227963],[145],[326],[False],[0],[0],[False],['0']
37194,PMC5845227,39065,"Healthcare systems should offer interventions tailored to their needs and to their level of health literacy, including strategies to promote activation.",Abstract,[227968],[327],[479],[False],[0],[0],[False],['0']
37195,PMC5845227,39066,The relationship between health literacy and patient activation remains to be explored.,Abstract,[227973],[480],[567],[False],[0],[0],[False],['0']
37196,PMC5845227,39067,The aim of this study was to examine the association between health literacy and patient activation in a population of frequent users of healthcare services with chronic diseases.,Abstract,[227978],[568],[747],[False],[0],[0],[False],['0']
37197,PMC5845227,39068,Methods,Methods,[227983],[748],[756],[False],[0],[0],[False],['0']
37198,PMC5845227,39069,Cross-sectional data were collected (before randomization) through a clinical trial evaluating a case management intervention in primary care.,Methods,[227988],[757],[899],[False],[0],[0],[False],['0']
37199,PMC5845227,39070,Participants (n = 247) were recruited from the list of frequent users of 4 Family Medicine Groups (FMG) in the Saguenay-Lac-St-Jean region of Québec (Canada).,Methods,[227993],[900],[1058],[False],[0],[0],[False],['0']
37200,PMC5845227,39071,They completed questionnaires by self-report during an encounter with a research assistant: (1) the Newest Vital Sign (NVS) to evaluate health literacy (independent variable); and (2) the Patient Activation Measure-13 (PAM-13) to evaluate patient activation (dependent variable).,Methods,[227998],[1059],[1338],[False],[0],[0],[False],['0']
37201,PMC5845227,39072,The relationship between health literacy and activation was examined using biserial correlations.,Methods,[228003],[1339],[1436],[False],[0],[0],[False],['0']
37202,PMC5845227,39073,Results,Results,[228008],[1437],[1445],[False],[0],[0],[False],['0']
37203,PMC5845227,39074,"No association was found between health literacy (independent variable) and patient activation (rb = 0.075, ρ = 0.07) for this population of frequent users of healthcare services.",Results,[228013],[1446],[1625],[False],[0],[0],[False],['0']
37204,PMC5845227,39075,Conclusions,Conclusions,[228018],[1626],[1638],[False],[0],[0],[False],['0']
37205,PMC5845227,39076,This study suggests that there is no relationship between health literacy and patient activation among frequent users of healthcare services.,Conclusions,[228023],[1639],[1780],[False],[0],[0],[False],['0']
37206,PMC5845227,39077,Trial registration,Trial registration,[228028],[1781],[1800],[False],[0],[0],[False],['0']
37207,PMC5845227,39078,NCT01719991.,Trial registration,[228033],[1801],[1813],[False],[0],[0],[False],['0']
37208,PMC5845227,39079,"Registered October 25, 2012.",Trial registration,[228038],[1814],[1842],[False],[0],[0],[False],['0']
37209,PMC5845227,39080,Background,Background,[228043],[1843],[1855],[False],[0],[0],[False],['0']
37210,PMC5845227,39081,"It is known that 10% of patients use 80% of healthcare system resources [1, 2].",Background,[228048],[1856],[1935],[False],[0],[0],[False],['0']
37211,PMC5845227,39082,"These frequent users of services present more chronic conditions, a higher level of psychological distress, as well as increased hospital admissions and mortality rates [3–5].",Background,[228053],[1936],[2111],[False],[0],[0],[False],['0']
37212,PMC5845227,39083,"They represent a great challenge for the healthcare system in attempting to optimise care, even more so in a context of chronic disease management.",Background,[228058],[2112],[2259],[False],[0],[0],[False],['0']
37213,PMC5845227,39084,"Healthcare systems should offer interventions tailored to their needs [6, 7], including strategies to promote patient activation.",Background,[228063],[2260],[2389],[False],[0],[0],[False],['0']
37214,PMC5845227,39085,"According to Hibbard et al., patient activation is defined as “someone’s knowledge, skills, confidence and behaviors needed for self-managing one’s condition or health” [8].",Background,[228068],[2390],[2563],[False],[0],[0],[False],['0']
37215,PMC5845227,39086,"They defined four (4) levels of activation: 1) believing the patient role is important, 2) having the confidence and knowledge necessary to take action, 3) actually taking action to maintain and improve one’s health, and 4) staying the course even under stress [9].",Background,[228073],[2564],[2829],[False],[0],[0],[False],['0']
37216,PMC5845227,39087,"Although they are related concepts, patient activation is different from patient empowerment, which relates to the process where patients take control of decisions and actions linked to their health [10].",Background,[228078],[2830],[3034],[False],[0],[0],[False],['0']
37217,PMC5845227,39088,"High patient activation levels was shown to be associated with better self-management and healthy behaviours [11, 12], better use of screening services and eventually decreased costs for the healthcare system [12].",Background,[228083],[3035],[3249],[False],[0],[0],[False],['0']
37218,PMC5845227,39089,"Older age, low level of education or poor income was found to be associated with lower levels of activation [8, 9, 11, 12].",Background,[228088],[3250],[3373],[False],[0],[0],[False],['0']
37219,PMC5845227,39090,"Although the operationalization of health literacy is debated, the World Health Organization (WHO) proposes a definition: “the cognitive and social skills which determine the motivation and ability of individuals to gain access to, understand and use information in ways which promote and maintain good health” [13].",Background,[228093],[3374],[3690],[False],[0],[0],[False],['0']
37220,PMC5845227,39091,The National Adult Literacy Survey (NALS) reported that 75% of patients with chronic diseases had limited literacy skills [14].,Background,[228098],[3691],[3818],[False],[0],[0],[False],['0']
37221,PMC5845227,39092,"A low level of health literacy would be linked to lower treatment compliance [15, 16] and lower preventive care utilization [17, 18].",Background,[228103],[3819],[3952],[False],[0],[0],[False],['0']
37222,PMC5845227,39093,"It was also associated with increased hospital admissions [17, 18], greater risk for poorer health condition [17, 19] and increased mortality [4, 20].",Background,[228108],[3953],[4103],[False],[0],[0],[False],['0']
37223,PMC5845227,39094,"Health literacy was raised as an important variable to consider in the management of chronic disease and as a predictor of health condition [21, 22].",Background,[228113],[4104],[4253],[False],[0],[0],[False],['0']
37224,PMC5845227,39095,A few studies have reported a positive association between health literacy and patient activation [23–27].,Background,[228118],[4254],[4360],[False],[0],[0],[False],['0']
37225,PMC5845227,39096,"However, many included a sample of patients with higher activation or health literacy levels [23–25] compared to the general population [14].",Background,[228123],[4361],[4502],[False],[0],[0],[False],['0']
37226,PMC5845227,39097,"In addition, no study evaluated this association in a population of frequent users of healthcare services with chronic diseases.",Background,[228128],[4503],[4631],[False],[0],[0],[False],['0']
37227,PMC5845227,39098,"This association, if present, could prove to be important for care planning for this vulnerable clientele.",Background,[228133],[4632],[4738],[False],[0],[0],[False],['0']
37228,PMC5845227,39099,It would thus be relevant to integrate interventions targeting low health literacy in order to potentially positively impact patient activation.,Background,[228138],[4739],[4883],[False],[0],[0],[False],['0']
37229,PMC5845227,39100,"Although frequent users of healthcare services represent an additional challenge for the health care system, no study has examined the potential link between health literacy and activation in this population.",Background,[228143],[4884],[5092],[False],[0],[0],[False],['0']
37230,PMC5845227,39101,The aim of this study was to examine the association between health literacy and patient activation among frequent users of healthcare services with chronic disease in primary care settings.,Background,[228148],[5093],[5283],[False],[0],[0],[False],['0']
37231,PMC5845227,39102,Methods,Methods,[228153],[5284],[5292],[False],[0],[0],[False],['0']
37232,PMC5845227,39103,Study design,Methods|Study design,[228158],[5293],[5305],[False],[0],[0],[False],['0']
37233,PMC5845227,39104,"This cross-sectional study presents the secondary analysis of data collected at baseline (T0) from patients recruited for a larger project, V1SAGES, a randomized controlled trial (RCT) aimed to evaluate the effects of a case management intervention for frequent users of healthcare services with chronic disease on patient psychological distress (primary outcome) and patient activation (secondary outcome) [28].",Methods|Study design,[228163],[5306],[5718],[False],[0],[0],[False],['0']
37234,PMC5845227,39105,"The intervention was delivered by primary care nurses in Family Medicine Groups (FMG) in Quebec, Canada.",Methods|Study design,[228168],[5719],[5823],[False],[0],[0],[False],['0']
37235,PMC5845227,39106,A FMG is “a group of family physicians who work in close cooperation with nurses to offer family medicine services to registered individuals” [29].,Methods|Study design,[228173],[5824],[5971],[False],[0],[0],[False],['0']
37236,PMC5845227,39107,"They provide primary care services and offer extended hours of access through scheduled appointments, walk-in clinics, home care, and telephone access and emergency on-call services.",Methods|Study design,[228178],[5972],[6154],[False],[0],[0],[False],['0']
37237,PMC5845227,39108,"A cross-sectional analysis of data collected at baseline (T0) during the V1SAGES project, on the relationship between health literacy and quality of life was also published [30].",Methods|Study design,[228183],[6155],[6333],[False],[0],[0],[False],['0']
37238,PMC5845227,39109,Participants,Participants,[228188],[6334],[6347],[False],[0],[0],[False],['0']
37239,PMC5845227,39110,"We identified frequent users of healthcare services by combining healthcare providers’ judgment with data from a database system, in accordance with current recommendations [31].",Participants,[228193],[6348],[6526],[False],[0],[0],[False],['0']
37240,PMC5845227,39111,"The family physicians received a computerized list generated by the MAGIC Chronique software (Médiamed Technologies), of their most frequent users of hospital services (≥ 3 emergency room (ER) visits and/or hospitalizations in the previous year) having at least one of the targeted chronic diseases.",Participants,[228198],[6527],[6826],[False],[0],[0],[False],['0']
37241,PMC5845227,39112,They then identified the patients with complex care needs they felt could benefit from the case management intervention (n = 323) and suggested additional patients who were frequent users of services in their clinic (n = 81).,Participants,[228203],[6827],[7052],[False],[0],[0],[False],['0']
37242,PMC5845227,39113,"Inclusion criteria were patients between 18 and 80 years of age and having at least one chronic disease (diabetes, cardiovascular disease, respiratory disease, musculoskeletal disease, or chronic pain).",Participants,[228208],[7053],[7255],[False],[0],[0],[False],['0']
37243,PMC5845227,39114,Patients with serious cognitive problems were excluded.,Participants,[228213],[7256],[7311],[False],[0],[0],[False],['0']
37244,PMC5845227,39115,A nurse then contacted the patients to introduce the project and invite them to participate.,Participants,[228218],[7312],[7404],[False],[0],[0],[False],['0']
37245,PMC5845227,39116,"If interested, a research assistant contacted each patient to provide further details about the study, assess their eligibility and obtain their consent.",Participants,[228223],[7405],[7558],[False],[0],[0],[False],['0']
37246,PMC5845227,39117,"Among the patients fitting the inclusion criteria at this stage, 157 were excluded: 113 declined to participate, 36 did not meet the inclusion criteria after further screening, 5 did not respond, 1 passed away and 2 were lost to follow-up.",Participants,[228228],[7559],[7798],[False],[0],[0],[False],['0']
37247,PMC5845227,39118,Two hundred and forty-seven participants accepted to participate in the intervention and completed the baseline questionnaire (T0).,Participants,[228233],[7799],[7930],[False],[0],[0],[False],['0']
37248,PMC5845227,39119,The software used for patient identification served as a system to support decision-making for family physicians that did not have access to this kind of information until the time of the study.,Participants,[228238],[7931],[8125],[False],[0],[0],[False],['0']
37249,PMC5845227,39120,All participants were asked to read and sign a consent form.,Participants,[228243],[8126],[8186],[False],[0],[0],[False],['0']
37250,PMC5845227,39121,The research ethics board of the Centre intégré universitaire de santé et services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean approved this study.,Participants,[228248],[8187],[8334],[False],[0],[0],[False],['0']
37251,PMC5845227,39122,Measures,Measures,[228253],[8335],[8344],[False],[0],[0],[False],['0']
37252,PMC5845227,39123,Baseline characteristics of participants were measured at T0.,Measures,[228258],[8345],[8406],[False],[0],[0],[False],['0']
37253,PMC5845227,39124,Questionnaires were self-administered with the assistance of a research assistant if needed.,Measures,[228263],[8407],[8499],[False],[0],[0],[False],['0']
37254,PMC5845227,39125,"If the patient could not travel, the questionnaires were administered at the participant’s home.",Measures,[228268],[8500],[8596],[False],[0],[0],[False],['0']
37255,PMC5845227,39126,"Health literacy was assessed using the Newest Vital Sign (NVS) [32], a 6-question survey of a nutritional value label, taking approximately 3 min to complete.",Measures,[228273],[8597],[8755],[False],[0],[0],[False],['0']
37256,PMC5845227,39127,"Validated in primary care, the NVS has good internal consistency (Cronbach α > 0.76) and has a moderate correlation with the Test of Functional Health Literacy in Adults (TOFHLA) (r = 0.59, p < 0.001).",Measures,[228278],[8756],[8957],[False],[0],[0],[False],['0']
37257,PMC5845227,39128,"The receiver operating characteristic (ROC) curve for the prediction of the TOFHLA was 0.88 (CI, 0.84–0.93, p < 0,001).",Measures,[228283],[8958],[9077],[False],[0],[0],[False],['0']
37258,PMC5845227,39129,A score greater or equal to 4 indicates adequate health literacy [32].,Measures,[228288],[9078],[9148],[False],[0],[0],[False],['0']
37259,PMC5845227,39130,"Patient activation was measured using the Patient Activation Measure-13 (PAM), based on the definition provided by Hibbard et al.",Measures,[228293],[9149],[9278],[False],[0],[0],[False],['0']
37260,PMC5845227,39131,[9].,Measures,[228298],[9279],[9283],[False],[0],[0],[False],['0']
37261,PMC5845227,39132,"This self-administered questionnaire includes 13 statements allowing evaluating 4 levels of activation, as described previously, and providing a global score.",Measures,[228303],[9284],[9442],[False],[0],[0],[False],['0']
37262,PMC5845227,39133,"It is the short version of the PAM-22 and, in regression analysis, it represented 92% of the variation in the 22-item version estimated activation [9].",Measures,[228308],[9443],[9594],[False],[0],[0],[False],['0']
37263,PMC5845227,39134,Its internal consistency (α = 0.84) and test-retest reliability (Intra class correlation = 0.72) were good allowing for its use in a French- speaking population [33].,Measures,[228313],[9595],[9761],[False],[0],[0],[False],['0']
37264,PMC5845227,39135,The French-language versions of these tools were utilized.,Measures,[228318],[9762],[9820],[False],[0],[0],[False],['0']
37265,PMC5845227,39136,"Sociodemographic data (age, gender, education and family income) were obtained.",Measures,[228323],[9821],[9900],[False],[0],[0],[False],['0']
37266,PMC5845227,39137,"Presence of chronic disease and illness burden were assessed using the validated French-language version of the Disease Burden Morbidity Assessment (DBMA) [34, 35].",Measures,[228328],[9901],[10065],[False],[0],[0],[False],['0']
37267,PMC5845227,39138,Sample size,Sample size,[228333],[10066],[10078],[False],[0],[0],[False],['0']
37268,PMC5845227,39139,Sample size was calculated for the randomized clinical trial.,Sample size,[228338],[10079],[10140],[False],[0],[0],[False],['0']
37269,PMC5845227,39140,"Based on Tabachnick [36], for an α = 0.05 and β = 0.20, the minimum sample size required was approximately 110 participants.",Sample size,[228343],[10141],[10265],[False],[0],[0],[False],['0']
37270,PMC5845227,39141,Our sample size (n = 247) allowed us to obtain adequate statistical power for this cross-sectional study.,Sample size,[228348],[10266],[10371],[False],[0],[0],[False],['0']
37271,PMC5845227,39142,Data analysis,Data analysis,[228353],[10372],[10386],[False],[0],[0],[False],['0']
37272,PMC5845227,39143,Characteristics of participants were described using means and standard deviations (SD) (continuous variables) or percentages (categorical variables).,Data analysis,[228358],[10387],[10537],[False],[0],[0],[False],['0']
37273,PMC5845227,39144,"The association between health literacy (independent dichotomic variable, but with the possibility of being a continuous, variable) and patient activation (continuous dependant variable) was examined using biserial correlation.",Data analysis,[228363],[10538],[10765],[False],[0],[0],[False],['0']
37274,PMC5845227,39145,Literacy was used dichotomously as adequate literacy (NVS score ≥ 4) or low literacy.,Data analysis,[228368],[10766],[10851],[False],[0],[0],[False],['0']
37275,PMC5845227,39146,Patient activation was used as a continuous variable with the global result.,Data analysis,[228373],[10852],[10928],[False],[0],[0],[False],['0']
37276,PMC5845227,39147,PASW Statistics 20 (SPSS Inc.) was used to perform all analyses with a 5% significance level.,Data analysis,[228378],[10929],[11022],[False],[0],[0],[False],['0']
37277,PMC5845227,39148,Results,Results,[228383],[11023],[11031],[False],[0],[0],[False],['0']
37278,PMC5845227,39149,Table 1 Sample characteristics.,Results,[228388],[11032],[11063],[False],[0],[0],[False],['0']
37279,PMC5845227,39150,"Overall, data from 247 participants were included in the analysis (Table 1).",Results,[228393],[11064],[11140],[False],[0],[0],[False],['0']
37280,PMC5845227,39151,"Several of these participants (mean age of 60, SD =13 years, 41.6% male) reported high levels of patient activation (level 3, 34.3%; level 4, 30.8%) but a low health literacy level (NVS < 4, 67.5%).",Results,[228398],[11141],[11339],[False],[0],[0],[False],['0']
37281,PMC5845227,39152,"Most of the participants had considerable illness burden (DBMA mean 13.4, SD = 8.5) and a high number of chronic diseases (mean of 6).",Results,[228403],[11340],[11474],[False],[0],[0],[False],['0']
37282,PMC5845227,39153,"The biserial correlation analysis did not find an association between health literacy and patient activation (rb: 0.075, p = 0.07).",Results,[228408],[11475],[11606],[False],[0],[0],[False],['0']
37283,PMC5845227,39154,Discussion,Discussion,[228413],[11607],[11618],[False],[0],[0],[False],['0']
37284,PMC5845227,39155,This study examined the relationship between health literacy and patient activation among frequent users of healthcare services with chronic diseases in primary care settings.,Discussion,[228418],[11619],[11794],[False],[0],[0],[False],['0']
37285,PMC5845227,39156,No association was found.,Discussion,[228423],[11795],[11820],[False],[0],[0],[False],['0']
37286,PMC5845227,39157,The results of this study are different from others studies evaluating the association between health literacy and patient activation [23–27].,Discussion,[228428],[11821],[11963],[False],[0],[0],[False],['0']
37287,PMC5845227,39158,A cross-sectional study by Sheikh et al.,Discussion,[228433],[11964],[12004],[False],[0],[0],[False],['0']
37288,PMC5845227,39159,"[26] among adult patients seen at the ER demonstrated an association between health literacy and patient activation, but this association was no longer significant when adjusted for age.",Discussion,[228438],[12005],[12191],[False],[0],[0],[False],['0']
37289,PMC5845227,39160,"Similarly, a study by Gwynn et al.",Discussion,[228443],[12192],[12226],[False],[0],[0],[False],['0']
37290,PMC5845227,39161,"[27] reported an association between health literacy and patient activation, but this association was not significant among patients with low comorbidity (0 or 1 comorbidity).",Discussion,[228448],[12227],[12402],[False],[0],[0],[False],['0']
37291,PMC5845227,39162,"In addition, these studies could be influenced by covariables, such as age [23, 26, 27], ethnicity [24] and education [27].",Discussion,[228453],[12403],[12526],[False],[0],[0],[False],['0']
37292,PMC5845227,39163,Our study focussed on frequent users of healthcare services with chronic diseases.,Discussion,[228458],[12527],[12609],[False],[0],[0],[False],['0']
37293,PMC5845227,39164,Their activation and health literacy levels were lower than what was found in previous studies on the subject.,Discussion,[228463],[12610],[12720],[False],[0],[0],[False],['0']
37294,PMC5845227,39165,This could explain the different results.,Discussion,[228468],[12721],[12762],[False],[0],[0],[False],['0']
37295,PMC5845227,39166,"In light of all these studies, the association between health literacy and patient activation could be present only for certain populations such as older individuals, certain cultural groups or among individuals with high level of activation.",Discussion,[228473],[12763],[13005],[False],[0],[0],[False],['0']
37296,PMC5845227,39167,More research could examine these hypotheses.,Discussion,[228478],[13006],[13051],[False],[0],[0],[False],['0']
37297,PMC5845227,39168,"The NVS, the TOFHLA, and the S-TOFHLA are all measurement tools validated for health literacy [32, 37, 38], but this is not an easily assessed concept [39] and there is no consensus on any tool [40].",Discussion,[228483],[13052],[13251],[False],[0],[0],[False],['0']
37298,PMC5845227,39169,The NVS presents the advantage of being available in a French-language version and takes few minutes to complete (3 min).,Discussion,[228488],[13252],[13373],[False],[0],[0],[False],['0']
37299,PMC5845227,39170,The PAM is a well-recognized tool for measuring patient activation [41].,Discussion,[228493],[13374],[13446],[False],[0],[0],[False],['0']
37300,PMC5845227,39171,"It includes aspects such as knowledge, skills, motivation, and confidence.",Discussion,[228498],[13447],[13521],[False],[0],[0],[False],['0']
37301,PMC5845227,39172,This study has strengths and certain limits.,Discussion,[228503],[13522],[13566],[False],[0],[0],[False],['0']
37302,PMC5845227,39173,"It is the first study examining the association between health literacy and patient activation among frequent users of healthcare services, and its statistical power was adequate.",Discussion,[228508],[13567],[13746],[False],[0],[0],[False],['0']
37303,PMC5845227,39174,"However, this study presents the secondary analysis of data collected during the RCT mentioned previously.",Discussion,[228513],[13747],[13853],[False],[0],[0],[False],['0']
37304,PMC5845227,39175,The choice of measurement tools was thus determined before this analysis.,Discussion,[228518],[13854],[13927],[False],[0],[0],[False],['0']
37305,PMC5845227,39176,Health literacy remains a concept that is difficult to assess and there is no tool universally accepted as the measurement standard [39].,Discussion,[228523],[13928],[14065],[True],['OutcomeMeasures'],['Health literacy remains a concept that is difficult to assess'],[True],['OutcomeMeasures']
37306,PMC5845227,39177,"Using a tool with a broader definition of health literacy, that goes beyond the ability to read and comprehend health information could have yielded different results [42, 43].",Discussion,[228536],[14066],[14242],[True],['OutcomeMeasures'],['Using a tool with a broader definition of health literacy'],[True],['OutcomeMeasures']
37307,PMC5845227,39178,"In addition, the questionnaires were self-administered which may have induced a social desirability bias.",Discussion,[228544],[14243],[14348],[True],['PrecisionOfMeasurement'],['the questionnaires were self-administered'],[True],['OutcomeMeasures']
37308,PMC5845227,39179,Participants may have answered questions more positively than the reality of their situation.,Discussion,[228557],[14349],[14442],[True],['OutcomeMeasures'],['Participants may have answered questions more positively than the reality'],[True],['OutcomeMeasures']
37309,PMC5845227,39180,"Even though we followed current recommendations for the identification of patients [31], the intervention of family physicians in the selection process may have introduced a selection bias.",Discussion,[228565],[14443],[14632],[True],['Blinding'],['the intervention of family physicians in the selection process'],[True],['Blinding']
37310,PMC5845227,39181,"However, considering our sample was composed of frequent users, we do not think this had a major impact on our analysis.",Discussion,[228573],[14633],[14753],[False],[0],[0],[False],['0']
37311,PMC5845227,39182,"Although this study did not demonstrate an association, the fact remains that health literacy [17, 18, 40, 44] and patient activation [11, 12] are important concepts for all types of clinicians.",Discussion,[228578],[14754],[14948],[False],[0],[0],[False],['0']
37312,PMC5845227,39183,"Considered separately, health literacy [15, 19] as well as activation [24, 45, 46] have numerous demonstrated impacts on global health.",Discussion,[228583],[14949],[15084],[False],[0],[0],[False],['0']
37313,PMC5845227,39184,The implementation of interventions for the improvement of patient activation as well as health literacy could be more effective than those focussing only on one of these concepts.,Discussion,[228588],[15085],[15265],[False],[0],[0],[False],['0']
37314,PMC5845227,39185,Future studies could assess the association between health literacy and patient activation among frequent users in general and not only those presenting chronic diseases.,Discussion,[228593],[15266],[15436],[False],[0],[0],[False],['0']
37315,PMC5845227,39186,"Further research projects could use more than one measure of health literacy simultaneously, for example: the NVS, a validated French-language version of the TOFHLA and/or another measurement tool for health literacy concurrently.",Discussion,[228598],[15437],[15667],[False],[0],[0],[False],['0']
37316,PMC5845227,39187,A next phase could also detect the effect of time and the intervention on the presence or absence of an association between health literacy and patient activation among frequent users of healthcare services.,Discussion,[228603],[15668],[15875],[False],[0],[0],[False],['0']
37317,PMC5845227,39188,Conclusions,Conclusions,[228608],[15876],[15888],[False],[0],[0],[False],['0']
37318,PMC5845227,39189,This study did not find an association between health literacy and patient activation in a population of frequent users of healthcare services with chronic diseases in primary care settings.,Conclusions,[228613],[15889],[16079],[False],[0],[0],[False],['0']
37319,PMC5845227,39190,An association between health literacy and patient activation could be present but only for certain populations.,Conclusions,[228618],[16080],[16192],[False],[0],[0],[False],['0']
37320,PMC5845227,39191,Abbreviations,Abbreviations,[228623],[16193],[16207],[False],[0],[0],[False],['0']
37321,PMC5845227,39192,CAD Canadian dollars,Abbreviations|CAD Canadian dollars,[228628],[16208],[16228],[False],[0],[0],[False],['0']
37322,PMC5845227,39193,CIUSSS Centre intégré universitaire de santé et services sociaux,Abbreviations|CAD Canadian dollars,[228633],[16229],[16293],[False],[0],[0],[False],['0']
37323,PMC5845227,39194,DBMA Disease burden morbidity assessment,Abbreviations|DBMA Disease burden morbidity assessment,[228638],[16294],[16334],[False],[0],[0],[False],['0']
37324,PMC5845227,39195,ER Emergency room,Abbreviations|ER Emergency room,[228643],[16335],[16352],[False],[0],[0],[False],['0']
37325,PMC5845227,39196,FMG Family medicine group,Abbreviations|FMG Family medicine group,[228648],[16353],[16378],[False],[0],[0],[False],['0']
37326,PMC5845227,39197,NALS National adult literacy survey,Abbreviations|NALS National adult literacy survey,[228653],[16379],[16414],[False],[0],[0],[False],['0']
37327,PMC5845227,39198,NVS Newest vital sign,Abbreviations|NVS Newest vital sign,[228658],[16415],[16436],[False],[0],[0],[False],['0']
37328,PMC5845227,39199,PAM Patient activation measure,Abbreviations|PAM Patient activation measure,[228663],[16437],[16467],[False],[0],[0],[False],['0']
37329,PMC5845227,39200,RCT Randomized controlled trial,Abbreviations|RCT Randomized controlled trial,[228668],[16468],[16499],[False],[0],[0],[False],['0']
37330,PMC5845227,39201,ROC Receiver operating characteristic,Abbreviations|ROC Receiver operating characteristic,[228673],[16500],[16537],[False],[0],[0],[False],['0']
37331,PMC5845227,39202,SD Standard deviation,Abbreviations|SD Standard deviation,[228678],[16538],[16559],[False],[0],[0],[False],['0']
37332,PMC5845227,39203,TOFHLA Test of Functional Health Literacy in Adults,Abbreviations|SD Standard deviation,[228683],[16560],[16611],[False],[0],[0],[False],['0']
37333,PMC5845227,39204,WHO World Health OrganizationFunding,Abbreviations|WHO World Health OrganizationFunding,[228688],[16612],[16648],[False],[0],[0],[False],['0']
37334,PMC5845227,39205,The authors thank Ms. Susie Bernier for her editorial assistance and Ms. Marie-France Dubois for her statistical advice.,Abbreviations|WHO World Health OrganizationFunding,[228693],[16649],[16769],[False],[0],[0],[False],['0']
37335,PMC5845227,39206,Funding,Abbreviations|Funding,[228698],[16770],[16777],[False],[0],[0],[False],['0']
37336,PMC5845227,39207,This research was funded by the Pfizer-FRSQ-MSSS chronic disease fund.,Abbreviations|Funding,[228703],[16778],[16848],[False],[0],[0],[False],['0']
37337,PMC5845227,39208,Availability of data and materials,Abbreviations|Availability of data and materials,[228708],[16849],[16883],[False],[0],[0],[False],['0']
37338,PMC5845227,39209,Data is available on request from the corresponding author.,Abbreviations|Availability of data and materials,[228713],[16884],[16943],[False],[0],[0],[False],['0']
37339,PMC5845227,39210,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[228718],[16944],[16986],[False],[0],[0],[False],['0']
37340,PMC5845227,39211,The study was approved by the research ethics board of the Centre intégré universitaire de santé et services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean.,Abbreviations|Ethics approval and consent to participate,[228723],[16987],[17140],[False],[0],[0],[False],['0']
37341,PMC5845227,39212,All the participants completed and signed an informed consent form.,Abbreviations|Ethics approval and consent to participate,[228728],[17141],[17208],[False],[0],[0],[False],['0']
37342,PMC5845227,39213,Consent for publication,Abbreviations|Consent for publication,[228733],[17209],[17232],[False],[0],[0],[False],['0']
37343,PMC5845227,39214,Not applicable.,Abbreviations|Not applicable.,[228738],[17233],[17248],[False],[0],[0],[False],['0']
37344,PMC5845227,39215,Competing interests,Abbreviations|Competing interests,[228743],[17249],[17268],[False],[0],[0],[False],['0']
37345,PMC5845227,39216,his project is funded by the Pfizer-FRSQ-MSSS chronic disease fund.,Abbreviations|Competing interests,[228748],[17269],[17336],[False],[0],[0],[False],['0']
37346,PMC5845227,39217,"None of the funding agencies - Pfizer, Fonds de recherche du Québec - Santé (FRQ-S) or the ministère de la santé et des services sociaux (MSSS) - had any role in preparing, reviewing or approving the manuscript.",Abbreviations|Competing interests,[228753],[17337],[17548],[False],[0],[0],[False],['0']
37347,PMC5845227,39218,"They will not be involved in the collection, analysis or interpretation of the data.",Abbreviations|Competing interests,[228758],[17549],[17633],[False],[0],[0],[False],['0']
37348,PMC5845227,39219,Publisher’s Note,Abbreviations|Publisher’s Note,[228763],[17634],[17650],[False],[0],[0],[False],['0']
37349,PMC5845227,39220,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[228768],[17651],[17769],[False],[0],[0],[False],['0']
38160,PMC5963181,28327,Effect of the patient education - Learning and Coping strategies - in cardiac rehabilitation on return to work at one year: a randomised controlled trial show (LC-REHAB),Title,[170976],[25753],[169],[False],[0],[0],[False],['0']
38161,PMC5963181,28328,Background,Abstract,[170984],[170],[181],[False],[0],[0],[False],['0']
38162,PMC5963181,28329,Personal resources are identified as important for the ability to return to work (RTW) for patients with ischaemic heart disease (IHD) or heart failure (HF) undergoing cardiac rehabilitation (CR).,Abstract,[170992],[182],[378],[False],[0],[0],[False],['0']
38163,PMC5963181,28330,The patient education ‘Learning and Coping’ (LC) addresses personal resources through a pedagogical approach.,Abstract,[171000],[379],[488],[False],[0],[0],[False],['0']
38164,PMC5963181,28331,This trial aimed to assess effect of adding LC strategies in CR compared to standard CR measured on RTW status at one-year follow-up after CR.,Abstract,[171008],[489],[631],[False],[0],[0],[False],['0']
38165,PMC5963181,28332,Methods,Abstract,[171016],[632],[639],[False],[0],[0],[False],['0']
38166,PMC5963181,28333,"In an open parallel randomised controlled trial, patients with IHD or HF were block-randomised in a 1:1 ratio to the LC arm (LC plus CR) or the control arm (CR alone) across three Danish hospital units.",Abstract,[171024],[640],[842],[False],[0],[0],[False],['0']
38167,PMC5963181,28334,Eligible patients were aged 18 to ≤60 and had not left the labour market.,Abstract,[171032],[843],[916],[False],[0],[0],[False],['0']
38168,PMC5963181,28335,The intervention was developed from an inductive pedagogical approach consisting of individual interviews and group based teaching by health professionals with experienced patients as co-educators.,Abstract,[171040],[917],[1114],[False],[0],[0],[False],['0']
38169,PMC5963181,28336,The control arm consisted of deductive teaching (standard CR).,Abstract,[171048],[1115],[1177],[False],[0],[0],[False],['0']
38170,PMC5963181,28337,RTW status was derived from the Danish Register for Evaluation of Marginalisation (DREAM).,Abstract,[171056],[1178],[1268],[False],[0],[0],[False],['0']
38171,PMC5963181,28338,Blinding was not possible.,Abstract,[171064],[1269],[1295],[False],[0],[0],[False],['0']
38172,PMC5963181,28339,The effect was evaluated by logistic regression analysis and reported as crude and adjusted odds ratios (OR) with 95% confidence interval (CI).,Abstract,[171072],[1296],[1439],[False],[0],[0],[False],['0']
38173,PMC5963181,28340,Results,Abstract,[171080],[1440],[1447],[False],[0],[0],[False],['0']
38174,PMC5963181,28341,The population for the present analysis was N = 244 (LC arm: n = 119 versus control arm: n = 125).,Abstract,[171088],[1448],[1546],[False],[0],[0],[False],['0']
38175,PMC5963181,28342,"No difference in RTW status was found at one year across arms (LC arm: 64.7% versus control arm: 68.8%, adjusted odds ratio OR: 0.76, 95% CI: 0.43-1.31).",Abstract,[171096],[1547],[1700],[False],[0],[0],[False],['0']
38176,PMC5963181,28343,Conclusion,Abstract,[171104],[1701],[1711],[False],[0],[0],[False],['0']
38177,PMC5963181,28344,Addition of LC strategies in CR showed no improvement in RTW at one year follow-up.,Abstract,[171112],[1712],[1795],[False],[0],[0],[False],['0']
38178,PMC5963181,28345,Trial registration,Abstract,[171120],[1796],[1814],[False],[0],[0],[False],['0']
38179,PMC5963181,28346,www.clinicaltrials.gov identifier NCT01668394.,Abstract,[171128],[1815],[1861],[False],[0],[0],[False],['0']
38180,PMC5963181,28347,"First Posted: August 20, 2012.",Abstract,[171136],[1862],[1892],[False],[0],[0],[False],['0']
38181,PMC5963181,28348,Background,Background,[171144],[1893],[1904],[False],[0],[0],[False],['0']
38182,PMC5963181,28349,"During the last decades, mortality from ischaemic heart disease (IHD) and heart failure (HF) has decreased due to improved primary and secondary prevention [1–3].",Background,[171152],[1905],[2067],[False],[0],[0],[False],['0']
38183,PMC5963181,28350,"Thus, along with changed age composition, many people worldwide are living with these conditions which cause disability on several levels [4, 5].",Background,[171160],[2068],[2213],[False],[0],[0],[False],['0']
38184,PMC5963181,28351,Health promotion and risk factor reduction are typically managed in cardiac rehabilitation (CR) and CR is known to improve clinical outcomes [2].,Background,[171168],[2214],[2359],[False],[0],[0],[False],['0']
38185,PMC5963181,28352,"Integrated patient education in CR programmes may also reduce fatal and/or non-fatal cardiovascular events and improve health related quality of life (HRQoL) [3, 6].",Background,[171176],[2360],[2525],[False],[0],[0],[False],['0']
38186,PMC5963181,28353,Patient education is recommended to focus on the individual’s personal resources rather than only increasing knowledge on disease management [7].,Background,[171184],[2526],[2671],[False],[0],[0],[False],['0']
38187,PMC5963181,28354,"However, CR interventions have primarily been evaluated on clinical outcomes and less evaluated on the ability to promote level of function including return to work (RTW).",Background,[171192],[2672],[2843],[False],[0],[0],[False],['0']
38188,PMC5963181,28355,"Work plays an important role for psychological and social wellbeing, and loss of productivity has economic costs for society [4, 8].",Background,[171200],[2844],[2976],[False],[0],[0],[False],['0']
38189,PMC5963181,28356,"Clinical guidelines across nations therefore intend to cover vocational counselling in CR however, RTW internationally still seems to remain suboptimal [9, 10].",Background,[171208],[2977],[3137],[False],[0],[0],[False],['0']
38190,PMC5963181,28357,"In Denmark it has been estimated that 21 and 25% of people with IHD and HF, respectively do not RTW 1 year after engaging in CR [11, 12].",Background,[171216],[3138],[3275],[False],[0],[0],[False],['0']
38191,PMC5963181,28358,"Moreover, some patients struggle to balance workplace demands with the individual resources and health status and therefore experience recurrent sick leave episodes after RTW [13–15].",Background,[171224],[3276],[3459],[False],[0],[0],[False],['0']
38192,PMC5963181,28359,Problems in the work reintegration process has recently been emphasised since a study showed that detachment from employment was three-fold higher among post myocardial infarct patients 1 year after return to work compared with a matched population [16].,Background,[171232],[3460],[3714],[False],[0],[0],[False],['0']
38193,PMC5963181,28360,Personal resources as coping and self-care are important aspects in a successful RTW process [17].,Background,[171240],[3715],[3813],[False],[0],[0],[False],['0']
38194,PMC5963181,28361,"CR-interventions aiming the ability to cope with and engage in everyday life evaluated on RTW have provided inconsistent results [18, 19].",Background,[171248],[3814],[3952],[False],[0],[0],[False],['0']
38195,PMC5963181,28362,"Thus, the evidence of the pedagogical approaches and methods to promote the RTW process is unknown.",Background,[171256],[3953],[4052],[False],[0],[0],[False],['0']
38196,PMC5963181,28363,Learning and coping strategies (LC) is a patient education method that aims to facilitate personal resources through inductive teaching with a high level of patient involvement and includes supplement of individual clarifying interviews.,Background,[171264],[4053],[4290],[False],[0],[0],[False],['0']
38197,PMC5963181,28364,The health professionals and experienced patients jointly perform the group based CR sessions [20].,Background,[171272],[4291],[4390],[False],[0],[0],[False],['0']
38198,PMC5963181,28365,"The LC-REHAB trial was conducted in a hospital setting in Denmark, and aimed to assess the effect of LC strategies on various outcomes and have shown to promote patient adherence to CR [20, 21].",Background,[171280],[4391],[4585],[False],[0],[0],[False],['0']
38199,PMC5963181,28366,In the present trial it was hypothesised that the LC strategies also promoted RTW compared with usual CR by enabling patients to use acquired LC skills in the RTW process.,Background,[171288],[4586],[4757],[False],[0],[0],[False],['0']
38200,PMC5963181,28367,"Furthermore, that those receiving LC strategies would reduce the number of sick leave relapses by the gained insight of health condition and how to cope with that.",Background,[171296],[4758],[4921],[False],[0],[0],[False],['0']
38201,PMC5963181,28368,The primary aim was to assess the effect of adding LC strategies in CR on RTW 1 year after inclusion of patients diagnosed with IHD or HF.,Background,[171304],[4922],[5060],[False],[0],[0],[False],['0']
38202,PMC5963181,28369,Secondary to assess if addition of LC strategies in CR reduced sick leave relapses during one-year follow-up.,Background,[171312],[5061],[5170],[False],[0],[0],[False],['0']
38203,PMC5963181,28370,Methods,Methods,[171320],[5171],[5179],[False],[0],[0],[False],['0']
38204,PMC5963181,28371,Design,Methods|Design,[171328],[5180],[5186],[False],[0],[0],[False],['0']
38205,PMC5963181,28372,"The trial was conducted on a subpopulation from the open randomised parallel group controlled trial, LC-REHAB [20].",Methods|Design,[171336],[5187],[5302],[False],[0],[0],[False],['0']
38206,PMC5963181,28373,"Patients were randomly allocated to the intervention arm (LC strategies in addition to standard CR) or to the control arm (standard CR) in a 1:1 ratio stratified for hospital unit, gender and diagnosis (IHD or HF) in blocks of two to four using a web-based system [20].",Methods|Design,[171344],[5303],[5572],[False],[0],[0],[False],['0']
38207,PMC5963181,28374,The allocation procedure was generated independently by the research team.,Methods|Design,[171352],[5573],[5647],[False],[0],[0],[False],['0']
38208,PMC5963181,28375,Additional eligibility criteria in the present trial were applied after randomisation to exclude patients assessed with permanent work disability at inclusion.,Methods|Design,[171360],[5648],[5807],[False],[0],[0],[False],['0']
38209,PMC5963181,28376,Information on inclusion dates was retrieved from the LC-REHAB trial [20].,Methods|Design,[171368],[5808],[5882],[False],[0],[0],[False],['0']
38210,PMC5963181,28377,Follow-up was defined as the week in which the date equivalent to 12 months after inclusion appeared.,Methods|Design,[171376],[5883],[5984],[False],[0],[0],[False],['0']
38211,PMC5963181,28378,The trial was conducted and reported according to the CONSORT standards – extension for randomised trials of non-pharmacological treatment [22].,Methods|Design,[171384],[5985],[6129],[False],[0],[0],[False],['0']
38212,PMC5963181,28379,Patients and recruitment,Methods|Patients and recruitment,[171392],[6130],[6154],[False],[0],[0],[False],['0']
38213,PMC5963181,28380,Fig.,Methods|Patients and recruitment,[171400],[6155],[6159],[False],[0],[0],[False],['0']
38214,PMC5963181,28381,1 Flow diagram of patient selection for the LC-REHAB trial on RTW status.,Methods|Patients and recruitment,[171408],[6160],[6233],[False],[0],[0],[False],['0']
38215,PMC5963181,28382,"1Patients (all ages, all employment status) assessed to require cardiac rehabilitation estimated from the Disease Management Program for Cardiovascular Diseases, Central Denmark Region [37].",Methods|Patients and recruitment,[171416],[6234],[6424],[False],[0],[0],[False],['0']
38216,PMC5963181,28383,2Attending at least 75% of scheduled sessions corresponding to 18 exercise sessions and 6 educational sessions.,Methods|Patients and recruitment,[171424],[6425],[6536],[False],[0],[0],[False],['0']
38217,PMC5963181,28384,The limit of 75% was set in accordance with recommendations for reducing mortality [38].,Methods|Patients and recruitment,[171432],[6537],[6625],[False],[0],[0],[False],['0']
38218,PMC5963181,28385,Patients were recruited between 30th November 2010 and 20th December 2012.,Methods|Patients and recruitment,[171440],[6626],[6700],[False],[0],[0],[False],['0']
38219,PMC5963181,28386,Trial information was sent by postal mail to eligible patients referred to CR.,Methods|Patients and recruitment,[171448],[6701],[6779],[False],[0],[0],[False],['0']
38220,PMC5963181,28387,Information of the trial was provided by telephone by the last author of this paper.,Methods|Patients and recruitment,[171456],[6780],[6864],[False],[0],[0],[False],['0']
38221,PMC5963181,28388,"Written informed consent, enrolment and randomisation were performed by health professionals at the CR units [20].",Methods|Patients and recruitment,[171464],[6865],[6979],[False],[0],[0],[False],['0']
38222,PMC5963181,28389,A total of 827 patients hospitalised for either IHD or HF were included in the LC-REHAB trial (Fig.,Methods|Patients and recruitment,[171472],[6980],[7079],[False],[0],[0],[False],['0']
38223,PMC5963181,28390,1).,Methods|Patients and recruitment,[171480],[7080],[7083],[False],[0],[0],[False],['0']
38224,PMC5963181,28391,Two patients were excluded due to error in randomisation procedure.,Methods|Patients and recruitment,[171488],[7084],[7151],[False],[0],[0],[False],['0']
38225,PMC5963181,28392,"Of the remaining 825, 413 were randomised to the LC arm and 412 to the control arm.",Methods|Patients and recruitment,[171496],[7152],[7235],[False],[0],[0],[False],['0']
38226,PMC5963181,28393,"Patients were enrolled at the CR unit and were eligible for the LC-REHAB trial if they were aged above 18, referred to, and motivated for CR after hospitalisation for IHD or HF.",Methods|Patients and recruitment,[171504],[7236],[7413],[False],[0],[0],[False],['0']
38227,PMC5963181,28394,"If the patients were diagnosed with both IHD and HF, they were classified as having HF.",Methods|Patients and recruitment,[171512],[7414],[7501],[False],[0],[0],[False],['0']
38228,PMC5963181,28395,"For specific ICD-10 codes included see the initial protocol for the LC-REHAB trial and previous study publication [20, 21].",Methods|Patients and recruitment,[171520],[7502],[7625],[False],[0],[0],[False],['0']
38229,PMC5963181,28396,"The exclusion criteria were acute coronary syndrome within the last 5 days before inclusion; active peri-, myo-, or endocarditis; symptomatic and/or untreated heart valve disease; severe hypertension with blood pressure > 200/110 mmHg; other severe cardiac or extra cardiac disease; planned revascularisation; senile dementia, assessed as having poor compliance for participation in and completion of the trial; or previously participation in the trial.",Methods|Patients and recruitment,[171528],[7626],[8079],[False],[0],[0],[False],['0']
38230,PMC5963181,28397,Eligibility for the subpopulation was assessed after trial completion by pre-defined criteria independent of allocation arms.,Methods|Patients and recruitment,[171536],[8080],[8205],[False],[0],[0],[False],['0']
38231,PMC5963181,28398,"Inclusion criteria applied for the present trial were: aged > 18 to  60 years, being self-supported or received either State Educational grants, labour market-related benefits or health-related benefits that did not indicate a permanent job incapability except for patients in jobs on modified conditions (flexi jobs).",Methods|Patients and recruitment,[171544],[8206],[8524],[False],[0],[0],[False],['0']
38232,PMC5963181,28399,"Exclusion criteria were: aged above 60, receiving disability pension or passive social assistance that indicated pre-existing, long-term work disability.",Methods|Patients and recruitment,[171552],[8525],[8678],[False],[0],[0],[False],['0']
38233,PMC5963181,28400,Patients were assessed eligible based on public transfer payments by the week of inclusion.,Methods|Patients and recruitment,[171560],[8679],[8770],[False],[0],[0],[False],['0']
38234,PMC5963181,28401,Interventions,Methods|Interventions,[171568],[8771],[8784],[False],[0],[0],[False],['0']
38235,PMC5963181,28402,"Patients in both arms received a phase II CR program lasting 8 weeks based on the national Danish guidelines on CR starting the first workday after inclusion [20, 23].",Methods|Interventions,[171576],[8785],[8952],[False],[0],[0],[False],['0']
38236,PMC5963181,28403,The programme was delivered in a hospital setting and consisted of group based sessions all lasting 1.5 h with a weekly education session and three exercise sessions per week.,Methods|Interventions,[171584],[8953],[9128],[False],[0],[0],[False],['0']
38237,PMC5963181,28404,"The content of the education sessions in both arms were split in eight topics, which were chosen in collaboration with experienced health professionals in CR and experienced patients who previously had undergone CR [20].",Methods|Interventions,[171592],[9129],[9349],[False],[0],[0],[False],['0']
38238,PMC5963181,28405,"The topics were: Function and symptoms of the heart, lifestyle effects on the development of IHD and HF, emotional reactions, medication, tiredness, the importance of relatives or other networks, importance and types of exercise, and future life with a chronic disease.",Methods|Interventions,[171600],[9350],[9619],[False],[0],[0],[False],['0']
38239,PMC5963181,28406,The education sessions were primarily managed by a nurse.,Methods|Interventions,[171608],[9620],[9677],[False],[0],[0],[False],['0']
38240,PMC5963181,28407,Exercise sessions consisted of aerobe exercise and muscle strength training managed by a physical therapist.,Methods|Interventions,[171616],[9678],[9786],[False],[0],[0],[False],['0']
38241,PMC5963181,28408,Both arms received CR by the same pair of a nurse and a physiotherapist throughout the CR programme; the pairs were designated to either the intervention or control arm throughout the trial.,Methods|Interventions,[171624],[9787],[9977],[False],[0],[0],[False],['0']
38242,PMC5963181,28409,"Due to the nature of the intervention, blinding of health professionals or patients was not possible.",Methods|Interventions,[171632],[9978],[10079],[False],[0],[0],[False],['0']
38243,PMC5963181,28410,Sessions in the two different arms were performed at different times of the day [20].,Methods|Interventions,[171640],[10080],[10165],[False],[0],[0],[False],['0']
38244,PMC5963181,28411,Intervention arm (LC arm),Methods|Intervention arm (LC arm),[171648],[10166],[10191],[False],[0],[0],[False],['0']
38245,PMC5963181,28412,"In addition to the described CR intervention, LC strategies took a situated, reflexive, and inductive approach to education and exercise.",Methods|Intervention arm (LC arm),[171656],[10192],[10329],[False],[0],[0],[False],['0']
38246,PMC5963181,28413,The rationale behind the pedagogical approach was based on theories behind LC strategies and was described in the initial protocol for the LC-REHAB [20].,Methods|Intervention arm (LC arm),[171664],[10330],[10483],[False],[0],[0],[False],['0']
38247,PMC5963181,28414,"The rationale was applied through practical implications consisting of: Two individual clarifying interviews (before and after CR), experienced patients as co-educators, material developed for each topic including background literature and questions to facilitate discussions.",Methods|Intervention arm (LC arm),[171672],[10484],[10760],[False],[0],[0],[False],['0']
38248,PMC5963181,28415,"The approach was ensured by health professionals completing an 8 days competence-education in LC strategies with experienced patients participating the last 4 days, and 1 h evaluation meetings between the pair of health professionals and experienced patient once a week [20].",Methods|Intervention arm (LC arm),[171680],[10761],[11036],[False],[0],[0],[False],['0']
38249,PMC5963181,28416,Control arm (standard CR),Methods|Control arm (standard CR),[171688],[11037],[11062],[False],[0],[0],[False],['0']
38250,PMC5963181,28417,The CR programme in the control arm was the formerly used in the hospital units (standard CR) [23].,Methods|Control arm (standard CR),[171696],[11063],[11162],[False],[0],[0],[False],['0']
38251,PMC5963181,28418,The rationale was not described and education and exercise consisted of structured deductive teaching.,Methods|Control arm (standard CR),[171704],[11163],[11265],[False],[0],[0],[False],['0']
38252,PMC5963181,28419,"Identical pre-written, educational slide-shows were used as material for the education sessions.",Methods|Control arm (standard CR),[171712],[11266],[11362],[False],[0],[0],[False],['0']
38253,PMC5963181,28420,Outcomes,Methods|Outcomes,[171720],[11363],[11371],[False],[0],[0],[False],['0']
38254,PMC5963181,28421,The primary outcome was RTW status at 1 year follow up.,Methods|Outcomes,[171728],[11372],[11427],[False],[0],[0],[False],['0']
38255,PMC5963181,28422,"After trial completion, information on the RTW outcome was retrieved from DREAM, which is administered by The Danish Ministry of Employment [24].",Methods|Outcomes,[171736],[11428],[11573],[False],[0],[0],[False],['0']
38256,PMC5963181,28423,"The register includes all Danish citizens, who at some point since 1991 have received public benefits.",Methods|Outcomes,[171744],[11574],[11676],[False],[0],[0],[False],['0']
38257,PMC5963181,28424,Patients were identified in DREAM by their social security number.,Methods|Outcomes,[171752],[11677],[11743],[False],[0],[0],[False],['0']
38258,PMC5963181,28425,Each person is registered once a week with a code representing the type of transfer payment received that particular week [25].,Methods|Outcomes,[171760],[11744],[11871],[False],[0],[0],[False],['0']
38259,PMC5963181,28426,"For patients to be categorised as having a RTW status (yes) at 1 year follow up, the four consecutive weeks prior to the week of one-year follow up were either codeless (self-support) or had codes representing State Education Fund grants or flexi jobs.",Methods|Outcomes,[171768],[11872],[12124],[False],[0],[0],[False],['0']
38260,PMC5963181,28427,"For the secondary outcome, each patient was categorised as having an event of RTW during one-year follow up (yes/no).",Methods|Outcomes,[171776],[12125],[12242],[False],[0],[0],[False],['0']
38261,PMC5963181,28428,The first event of four consecutive weeks of either self support or codes representing State Education Fund grants or flexi jobs was categorised as RTW (yes).,Methods|Outcomes,[171784],[12243],[12401],[False],[0],[0],[False],['0']
38262,PMC5963181,28429,The patients who experienced the event of RTW during follow up but were not registered RTW at 1 year follow up were identified.,Methods|Outcomes,[171792],[12402],[12529],[False],[0],[0],[False],['0']
38263,PMC5963181,28430,They were referred to as “relapsed patients”.,Methods|Outcomes,[171800],[12530],[12575],[False],[0],[0],[False],['0']
38264,PMC5963181,28431,Baseline characteristics,Methods|Baseline characteristics,[171808],[12576],[12600],[False],[0],[0],[False],['0']
38265,PMC5963181,28432,"Baseline variables concerning: age, gender, height, weight, diagnosis (IHD or HF), presence of diabetes, smoking, civil status and former participation in CR were reported to dedicated databases in the LC-REHAB trial by the nurses at the CR units [20].",Methods|Baseline characteristics,[171816],[12601],[12853],[False],[0],[0],[False],['0']
38266,PMC5963181,28433,"At the first CR session, the health professionals handed out self-reported questionnaires for assessing: presence of depression, level of education, and the annual household income [20].",Methods|Baseline characteristics,[171824],[12854],[13040],[False],[0],[0],[False],['0']
38267,PMC5963181,28434,Depression (yes/no) was assed by Major Depression Inventory (MDI) [26].,Methods|Baseline characteristics,[171832],[13041],[13112],[False],[0],[0],[False],['0']
38268,PMC5963181,28435,"Level of education was classified by low, medium, or high.",Methods|Baseline characteristics,[171840],[13113],[13171],[False],[0],[0],[False],['0']
38269,PMC5963181,28436,"Household income was classified by low, medium, or high.",Methods|Baseline characteristics,[171848],[13172],[13228],[False],[0],[0],[False],['0']
38270,PMC5963181,28437,"For elaborated classification on level of education and household income, see the initial protocol [20].",Methods|Baseline characteristics,[171856],[13229],[13333],[False],[0],[0],[False],['0']
38271,PMC5963181,28438,"Since work status prior to CR was assumed associated with RTW, additional information on employment was retrieved from DREAM after allocation to the trial arms [14].",Methods|Baseline characteristics,[171864],[13334],[13499],[False],[0],[0],[False],['0']
38272,PMC5963181,28439,No self support prior to CR was dichotomised (yes/no) encompassing whether the patient within 6 months prior to inclusion were self-supported for at least 1 week.,Methods|Baseline characteristics,[171872],[13500],[13662],[False],[0],[0],[False],['0']
38273,PMC5963181,28440,Statistical methods,Methods|Statistical methods,[171880],[13663],[13682],[False],[0],[0],[False],['0']
38274,PMC5963181,28441,"Descriptive statistics were used to compare the baseline characteristics – Chi-squared for the binary and categorical outcomes, and Studen’s t-test for the continuous.",Methods|Statistical methods,[171888],[13683],[13850],[False],[0],[0],[False],['0']
38275,PMC5963181,28442,RTW status at 1 year was compared between the two arms using a logistic regression model.,Methods|Statistical methods,[171896],[13851],[13940],[False],[0],[0],[False],['0']
38276,PMC5963181,28443,The result was presented both as unadjusted and adjusted odds ratios with 95% confidence interval (CI).,Methods|Statistical methods,[171904],[13941],[14044],[False],[0],[0],[False],['0']
38277,PMC5963181,28444,"Adjustments were carried out for the stratification variables: gender, cardiac diagnosis and hospital unit.",Methods|Statistical methods,[171912],[14045],[14152],[False],[0],[0],[False],['0']
38278,PMC5963181,28445,"Additional adjustment for age was performed, as age was expected to be associated with RTW [11].",Methods|Statistical methods,[171920],[14153],[14249],[False],[0],[0],[False],['0']
38279,PMC5963181,28446,"To address the secondary aim of the trial, frequencies and percentages described the number of patients who experienced the event of RTW during follow up across trial arms.",Methods|Statistical methods,[171928],[14250],[14422],[False],[0],[0],[False],['0']
38280,PMC5963181,28447,A comparison of the relapsed patients across arms was performed by chi-square test.,Methods|Statistical methods,[171936],[14423],[14506],[False],[0],[0],[False],['0']
38281,PMC5963181,28448,All analyses were performed based on the intention-to-treat principle.,Methods|Statistical methods,[171944],[14507],[14577],[False],[0],[0],[False],['0']
38282,PMC5963181,28449,Analyses were performed using Stata 14 software [27].,Methods|Statistical methods,[171952],[14578],[14631],[False],[0],[0],[False],['0']
38283,PMC5963181,28450,Data management was performed blinded from allocation.,Methods|Statistical methods,[171960],[14632],[14686],[False],[0],[0],[False],['0']
38284,PMC5963181,28451,Power calculation,Methods|Power calculation,[171968],[14687],[14704],[False],[0],[0],[False],['0']
38285,PMC5963181,28452,Suggesting a 14% difference in RTW proportions between arms estimated from Kruse et al.,Methods|Power calculation,[171976],[14705],[14792],[False],[0],[0],[False],['0']
38286,PMC5963181,28453,"[11], the given sample size on 244 patients left this trial with a power on 89% testing on a 5% level of significance.",Methods|Power calculation,[171984],[14793],[14911],[False],[0],[0],[False],['0']
38287,PMC5963181,28454,Results,Results,[171992],[14912],[14920],[False],[0],[0],[False],['0']
38288,PMC5963181,28455,Baseline data,Results|Baseline data,[172000],[14921],[14934],[False],[0],[0],[False],['0']
38289,PMC5963181,28456,Table 1 Baseline characteristics of patients.,Results|Baseline data,[172008],[14935],[14980],[False],[0],[0],[False],['0']
38290,PMC5963181,28457,"A total of 526 patients were excluded due to age criteria, 55 due to receiving disability pension (n = 47) or passive social assistance (n = 8) on the date of randomisation.",Results|Baseline data,[172016],[14981],[15154],[False],[0],[0],[False],['0']
38291,PMC5963181,28458,"Two-hundred-and-forty-four patients were included for the present trial on RTW; 119 and 125 in the LC arm and control arm, respectively.",Results|Baseline data,[172024],[15155],[15291],[False],[0],[0],[False],['0']
38292,PMC5963181,28459,Mean age was 51.8 years and the majority of the patients were men (77.0%).,Results|Baseline data,[172032],[15292],[15366],[False],[0],[0],[False],['0']
38293,PMC5963181,28460,A small fraction (16.8%) had no self support prior to CR (Table 1).,Results|Baseline data,[172040],[15367],[15434],[False],[0],[0],[False],['0']
38294,PMC5963181,28461,Baseline variables balanced across arms with no statistically significant differences between the two arms on baseline variables except for gender (males accounting for 83.2% in the LC arm vs. 71.2% in the control arm (p = 0.03)) (Table 1).,Results|Baseline data,[172048],[15435],[15675],[False],[0],[0],[False],['0']
38295,PMC5963181,28462,Non-responders balanced across arms in baseline variables containing missing values (results not shown).,Results|Baseline data,[172056],[15676],[15780],[False],[0],[0],[False],['0']
38296,PMC5963181,28463,Outcomes,Results|Outcomes,[172064],[15781],[15789],[False],[0],[0],[False],['0']
38297,PMC5963181,28464,RTW status at one year,Results|RTW status at one year,[172072],[15790],[15812],[False],[0],[0],[False],['0']
38298,PMC5963181,28465,Table 2 RTW status at one-year follow-up with comparison of LC arm and control arm.,Results|RTW status at one year,[172080],[15813],[15896],[False],[0],[0],[False],['0']
38299,PMC5963181,28466,No patients died or emigrated during follow up.,Results|RTW status at one year,[172088],[15897],[15944],[False],[0],[0],[False],['0']
38300,PMC5963181,28467,"Regarding the primary outcome, a successful RTW status was observed for 64.7% (95% CI: 55.4- 73.2) in the LC arm, compared with 68.8% (95% CI: 59.9-76.8) in the control arm at 1 year follow up, corresponding to a crude OR 0.83 (95% CI: 0.49-1.42).",Results|RTW status at one year,[172096],[15945],[16192],[False],[0],[0],[False],['0']
38301,PMC5963181,28468,"Adjusting for gender, hospital unit, diagnosis, and age did not alter the result (OR = 0.76, 95% CI: (0.43-1.31), Table 2).",Results|RTW status at one year,[172104],[16193],[16316],[False],[0],[0],[False],['0']
38302,PMC5963181,28469,Comparison of RTW status at one year and RTW during follow up,Results|RTW status at one year,[172112],[16317],[16378],[False],[0],[0],[False],['0']
38303,PMC5963181,28470,Registering RTW during the 1 year follow-up resulted in a slightly increased proportion of patients that experienced the event of RTW: 80% (95% CI: 72-87) in the LC arm and 83% (95% CI: 76-89) in the control arm.,Results|RTW status at one year,[172120],[16379],[16591],[False],[0],[0],[False],['0']
38304,PMC5963181,28471,"Regarding the secondary outcome, Thirty-six patients were identified as relapsed patients during follow up and they were equally distributed across the LC arm and control arm (p = 0.87, Table 2).",Results|RTW status at one year,[172128],[16592],[16787],[False],[0],[0],[False],['0']
38305,PMC5963181,28472,Discussion,Discussion,[172136],[16788],[16800],[False],[0],[0],[False],['0']
38306,PMC5963181,28473,The present trial showed that addition of LC strategies in hospital based phase II CR did not improve RTW status at one-year follow-up compared to standard CR.,Discussion,[172144],[16801],[16960],[False],[0],[0],[False],['0']
38307,PMC5963181,28474,Nor did addition of LC strategies seem to reduce sick leave relapses during one-year follow-up.,Discussion,[172152],[16961],[17056],[False],[0],[0],[False],['0']
38308,PMC5963181,28475,"Prior to this trial, comparable CR-interventions aiming at facilitating personal resources to improve RTW had consisted of patient-involving educational sessions, making an individual worksheet plan, including the role of the spouse, shared-decision making and a partnership-based approach [18, 19].",Discussion,[172160],[17057],[17356],[False],[0],[0],[False],['0']
38309,PMC5963181,28476,"The evidence for these approaches and methods is inconsistent and rely on a sparse basis [18, 19].",Discussion,[172168],[17357],[17455],[False],[0],[0],[False],['0']
38310,PMC5963181,28477,In cancer rehabilitation no comparable educational interventions established effect regarding RTW neither [28].,Discussion,[172176],[17456],[17567],[False],[0],[0],[False],['0']
38311,PMC5963181,28478,"Comparing the effect of patient educational approaches across studies is however complicated by methodical differences as well as heterogeneity in patients, compared interventions and CR-delivery.",Discussion,[172184],[17568],[17764],[False],[0],[0],[False],['0']
38312,PMC5963181,28479,The trial benefitted from being able to measure the effect of a patient education method developed from a specific pedagogical approach in patient education.,Discussion,[172192],[17765],[17922],[False],[0],[0],[False],['0']
38313,PMC5963181,28480,"Despite the lacking effect of the intervention on RTW, the intervention provides knowledge for further research in CR patient education.",Discussion,[172200],[17923],[18059],[False],[0],[0],[False],['0']
38314,PMC5963181,28481,"According to the first guidance for evaluating complex interventions by the Medical Research Council (MRC), lack of effect may reflect implementation failure rather than genuine ineffectiveness of the intervention and has been identified as problems concerning development, implementation, and evaluation [29].",Discussion,[172208],[18060],[18370],[False],[0],[0],[False],['0']
38315,PMC5963181,28482,The intervention in the LC arm was developed to aim at promoting the individuals’ personal resources rather than targeting multiple factors affecting level of function [30].,Discussion,[172216],[18371],[18544],[False],[0],[0],[False],['0']
38316,PMC5963181,28483,"A more comprehensive approach has however been suggested with beneficial effects on RTW by both a review on CR and a Cochrane review on cancer rehabilitation [10, 28].",Discussion,[172224],[18545],[18712],[False],[0],[0],[False],['0']
38317,PMC5963181,28484,LC strategies in this trial lacked of involvement of contextual factors in general and workplaces in particular.,Discussion,[172232],[18713],[18825],[False],[0],[0],[False],['0']
38318,PMC5963181,28485,"The relapsed patients had jobs in health-care, service jobs and manual labour.",Discussion,[172240],[18826],[18904],[False],[0],[0],[False],['0']
38319,PMC5963181,28486,"Job type and support from the employer is found important for CR patients and recently contextual factors at the workplace and organisational practices have been identified to constrain the margin of manoeuvre in work reintegration [15, 31].",Discussion,[172248],[18905],[19146],[False],[0],[0],[False],['0']
38320,PMC5963181,28487,"This may imply that the physical demanding jobs, that also are low level educational job types among relapsed patients are more difficult to reintegrate into after sick leave due to IHD or HF.",Discussion,[172256],[19147],[19339],[False],[0],[0],[False],['0']
38321,PMC5963181,28488,"Thus, the findings in this trial together with emerging evidence suggest development of interventions that foster accommodation and support from involvement of contextual factors like workplaces in integrated CR programmes [31].",Discussion,[172264],[19340],[19568],[False],[0],[0],[False],['0']
38322,PMC5963181,28489,"The implementation of the theoretical understanding in LC strategies may be questioned, since it was not described to what extent the illness perspective on work resumption was approached by the health professionals in the CR sessions.",Discussion,[172272],[19569],[19804],[False],[0],[0],[False],['0']
38323,PMC5963181,28490,"In the present study low household income, low educational level, no self support prior to CR and higher age at baseline were all statistically significant risk factors for not adhering to the CR exercise sessions (results not shown).",Discussion,[172280],[19805],[20039],[False],[0],[0],[False],['0']
38324,PMC5963181,28491,"These socioeconomic factors are in line with frequently reported predictors for not only poor adherence to CR but also detachment from employment [16, 32].",Discussion,[172288],[20040],[20195],[False],[0],[0],[False],['0']
38325,PMC5963181,28492,It was likely to assume that the poorer adherence in high risk patients contributed to the absent effect of LC strategies.,Discussion,[172296],[20196],[20318],[False],[0],[0],[False],['0']
38326,PMC5963181,28493,"Implementation of future interventions to improve RTW should therefore ensure: adequate RTW-aimed interventions, include practical implications that in particular aim the process of RTW, and optimise adherence to CR for patients in high risk of detachment from employment.",Discussion,[172304],[20319],[20591],[False],[0],[0],[False],['0']
38327,PMC5963181,28494,Evaluation in this trial was done using an outcome that only accommodated a paid job or education and neglected possible enhanced participation in e.g.,Discussion,[172312],[20592],[20743],[False],[0],[0],[False],['0']
38328,PMC5963181,28495,volunteer work or social relations.,Discussion,[172320],[20744],[20779],[False],[0],[0],[False],['0']
38329,PMC5963181,28496,This standardised outcome may have conflicted with the individualised approach in LC strategies.,Discussion,[172334],[20780],[20876],[True],['RelevantOutcomeExcluded'],['This standardised outcome'],[True],['OutcomeMeasures']
38330,PMC5963181,28497,"Alternative evaluation of CR that measures more participation-related outcome might be relevant to reflect the aim of rehabilitation and furthermore to address the important well-known participation restrictions in patients with chronic IHD [5, 33].",Discussion,[172344],[20877],[21126],[False],[0],[0],[False],['0']
38331,PMC5963181,28498,Study limitations and strengths,Discussion|Study limitations and strengths,[172352],[21127],[21158],[False],[0],[0],[False],['0']
38332,PMC5963181,28499,Information bias was considered minimal; DREAM has been validated against workplace-registered job attendance and long-term sick listing and found to have high sensitivity and specificity [34].,Discussion|Study limitations and strengths,[172360],[21159],[21352],[False],[0],[0],[False],['0']
38333,PMC5963181,28500,"Classification of RTW based on transfer payments from DREAM has elsewhere been defined based on various numbers of weeks (ranging from 1 week to 5 weeks) [12, 13, 16].",Discussion|Study limitations and strengths,[172368],[21353],[21520],[False],[0],[0],[False],['0']
38334,PMC5963181,28501,The chosen definition of four consecutive weeks in this trial might have affected the frequencies of RTW but was not expected to be differentiated between arms.,Discussion|Study limitations and strengths,[172376],[21521],[21681],[False],[0],[0],[False],['0']
38335,PMC5963181,28502,"Selection bias was furthermore not considered as there was complete follow up; therefore, threats to the internal validity of the trial were not assumed.",Discussion|Study limitations and strengths,[172384],[21682],[21835],[False],[0],[0],[False],['0']
38336,PMC5963181,28503,The trial was carried out in western Denmark where the population in general is lower educated than the total population of Denmark and the trial enrolled patients with HF [35].,Discussion|Study limitations and strengths,[172392],[21836],[22013],[True],['VerySpecificPopulation'],['in western Denmark where the population in general is lower educated than the total population of Denmark and the trial enrolled patients with HF'],[True],['Population']
38337,PMC5963181,28504,"Both level of education and living with HF are associated with increased risk of not returning to work and may have caused the overall lower RTW proportion (61-73%) in this trial compared to other studies [11, 12, 16].",Discussion|Study limitations and strengths,[172408],[22014],[22232],[False],[0],[0],[False],['0']
38338,PMC5963181,28505,"According to the power calculation, a 14% difference in RTW was expected between the two trial arms; however the trial detected a 4 percentage point difference.",Discussion|Study limitations and strengths,[172416],[22233],[22393],[False],[0],[0],[False],['0']
38339,PMC5963181,28506,It was expected that lacking practical implications in the LC strategies for improving RTW rather than a low sample size was the reason of no difference.,Discussion|Study limitations and strengths,[172424],[22394],[22547],[False],[0],[0],[False],['0']
38340,PMC5963181,28507,The estimate may have been affected towards the null hypothesis as mutual interaction between the arms was plausible due to lack of blinding of the health professionals.,Discussion|Study limitations and strengths,"[172433, 172434]","[22548, 22548]","[22717, 22717]","[True, True]","['StudyTeam', 'Blinding']","['lack of blinding of the health professionals', 'mutual interaction between the arms was plausible']","[True, True]",['Blinding']
38341,PMC5963181,28508,"Moreover, patient education was delivered in both arms and the effect of the patient education in the control arm may have contributed to even out the effect of LC strategies.",Discussion|Study limitations and strengths,[172451],[22718],[22893],[True],['ActivePlacebo'],['patient education in the control arm'],[True],['Control']
38342,PMC5963181,28509,"Approximately, 50% of the population with IHD and HF asked to participate declined to participate in the trial [21].",Discussion|Study limitations and strengths,[172464],[22894],[23010],[False],[0],[0],[False],['0']
38343,PMC5963181,28510,"However, no knowledge of the patients that declined was accessible and it was thus unknown if selection of the patients was present at enrolment.",Discussion|Study limitations and strengths,[172477],[23011],[23156],[True],['Population'],['it was thus unknown if selection of the patients was present at enrolment'],[True],['Population']
38344,PMC5963181,28511,This caused limitation of the generalisability of the results and the trial was not able to provide answers about the effect on the total population of people with IHD or HF.,Discussion|Study limitations and strengths,[172492],[23157],[23331],[True],['Generalization'],['limitation of the generalisability of the results'],[True],['Generalization']
38345,PMC5963181,28512,Temporal and contextual factors affect the ability to RTW and influence the external validity of the outcome measure.,Discussion|Study limitations and strengths,[172511],[23332],[23449],[True],['Generalization'],['the external validity of the outcome measure'],[True],['Generalization']
38346,PMC5963181,28513,"Also, this means that comparing results in an international context should be done carefully due to heterogeneity in RTW definitions and occupational systems.",Discussion|Study limitations and strengths,[172520],[23450],[23608],[False],[0],[0],[False],['0']
38347,PMC5963181,28514,Conclusion,Conclusion,[172528],[23609],[23620],[False],[0],[0],[False],['0']
38348,PMC5963181,28515,Addition of LC strategies in CR showed no improvement of RTW compared to CR alone after 1 year.,Conclusion,[172536],[23621],[23716],[False],[0],[0],[False],['0']
38349,PMC5963181,28516,"Implications for further development and research of patient education methods in CR to improve RTW are: involvement of contextual factors in development of the intervention, and implementation that ensures practical implications targeting RTW like workplace involvement and job type.",Conclusion,[172544],[23717],[24001],[False],[0],[0],[False],['0']
38350,PMC5963181,28517,"Lastly, evaluation should address the interventions’ ability to improve participation among patients living with IHD and HF.",Conclusion,[172552],[24002],[24126],[False],[0],[0],[False],['0']
38351,PMC5963181,28518,Abbreviations,Abbreviations,[172560],[24127],[24141],[False],[0],[0],[False],['0']
38352,PMC5963181,28519,CR Cardiac rehabilitation,Abbreviations|CR Cardiac rehabilitation,[172568],[24142],[24167],[False],[0],[0],[False],['0']
38353,PMC5963181,28520,DREAM Public transfer payments register,Abbreviations|DREAM Public transfer payments register,[172576],[24168],[24207],[False],[0],[0],[False],['0']
38354,PMC5963181,28521,HF Heart failure,Abbreviations|HF Heart failure,[172584],[24208],[24224],[False],[0],[0],[False],['0']
38355,PMC5963181,28522,IHD Ischaemic heart disease,Abbreviations|IHD Ischaemic heart disease,[172592],[24225],[24252],[False],[0],[0],[False],['0']
38356,PMC5963181,28523,LC Learning and coping,Abbreviations|LC Learning and coping,[172600],[24253],[24275],[False],[0],[0],[False],['0']
38357,PMC5963181,28524,RTW Return to workFunding,Abbreviations|RTW Return to workFunding,[172608],[24276],[24301],[False],[0],[0],[False],['0']
38358,PMC5963181,28525,Funding,Funding,[172616],[24302],[24310],[False],[0],[0],[False],['0']
38359,PMC5963181,28526,"The trial was funded by the Danish Ministry of Health, the Health Research Fund of Central Denmark, and the Danish foundation ‘TrygFonden’.",Funding,[172624],[24311],[24450],[False],[0],[0],[False],['0']
38360,PMC5963181,28527,Availability of data and materials,Funding|Availability of data and materials,[172632],[24451],[24485],[False],[0],[0],[False],['0']
38361,PMC5963181,28528,"The data that support the findings of this study are available from Central Denmark Region but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.",Funding|Availability of data and materials,[172640],[24486],[24722],[False],[0],[0],[False],['0']
38362,PMC5963181,28529,Data are however available from the authors upon reasonable request and with permission of Central Denmark Region.,Funding|Availability of data and materials,[172648],[24723],[24837],[False],[0],[0],[False],['0']
38363,PMC5963181,28530,Ethics approval and consent to participate,Funding|Ethics approval and consent to participate,[172656],[24838],[24880],[False],[0],[0],[False],['0']
38364,PMC5963181,28531,All patients gave written consent for participation before enrolment and were informed that they could withdraw the consent at any time [20].,Funding|Ethics approval and consent to participate,[172664],[24881],[25022],[False],[0],[0],[False],['0']
38365,PMC5963181,28532,"The trial was approved by the Regional Ethical Committee of Central Denmark (journal number 20100230) and carried out in agreement with the Declaration of Helsinki, version II [36].",Funding|Ethics approval and consent to participate,[172672],[25023],[25204],[False],[0],[0],[False],['0']
38366,PMC5963181,28533,The LC-REHAB trial and the present analysis have been approved by Danish Data Protection Agency separately.,Funding|Ethics approval and consent to participate,[172680],[25205],[25312],[False],[0],[0],[False],['0']
38367,PMC5963181,28534,Competing interests,Funding|Competing interests,[172688],[25313],[25332],[False],[0],[0],[False],['0']
38368,PMC5963181,28535,The authors declare that they have no competing interests.,Funding|Competing interests,[172696],[25333],[25391],[False],[0],[0],[False],['0']
38369,PMC5963181,28536,Publisher’s Note,Funding|Publisher’s Note,[172704],[25392],[25408],[False],[0],[0],[False],['0']
38370,PMC5963181,28537,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Funding|Publisher’s Note,[172712],[25409],[25527],[False],[0],[0],[False],['0']
38938,PMC5994015,21752,Randomised-controlled trial of a web-based dietary intervention for patients with type 2 diabetes: changes in health cognitions and glycemic control,Title,[130987],[28690],[148],[False],[0],[0],[False],['0']
38939,PMC5994015,21753,Background,Abstract,[130991],[149],[160],[False],[0],[0],[False],['0']
38940,PMC5994015,21754,"Increasing prevalence and disease burden has led to an increasing demand of programs and studies focused on dietary and lifestyle habits, and chronic diseases such as type 2 diabetes mellitus (T2DM).",Abstract,[130995],[161],[360],[False],[0],[0],[False],['0']
38941,PMC5994015,21755,"We evaluated the effects of a 6-month web-based dietary intervention on Dietary Knowledge, Attitude and Behaviour (DKAB), Dietary Stages of Change (DSOC), fasting blood glucose (FBG) and glycosylated haemoglobin (HbA1c) in patients with uncontrolled HbA1c (> 7.0%) in a randomised-controlled trial (myDIDeA) in Malaysia.",Abstract,[130999],[361],[681],[False],[0],[0],[False],['0']
38942,PMC5994015,21756,Methods,Abstract,[131003],[682],[689],[False],[0],[0],[False],['0']
38943,PMC5994015,21757,The e-intervention group (n = 62) received a 6-month web-delivered intensive dietary intervention while the control group (n = 66) continued with their standard hospital care.,Abstract,[131007],[690],[865],[False],[0],[0],[False],['0']
38944,PMC5994015,21758,"Outcomes (DKAB and DSOC scores, FBG and HbA1c) were compared at baseline, post-intervention and follow-up.",Abstract,[131011],[866],[972],[False],[0],[0],[False],['0']
38945,PMC5994015,21759,Results,Abstract,[131015],[973],[980],[False],[0],[0],[False],['0']
38946,PMC5994015,21760,"While both study groups showed improvement in total DKAB score, the margin of improvement in mean DKAB score in e-intervention group was larger than the control group at post-intervention (11.1 ± 0.9 vs. 6.5 ± 9.4,p < 0.001) and follow-up (19.8 ± 1.1 vs. 7.6 ± 0.7,p < 0.001), as compared to the baseline.",Abstract,[131019],[981],[1286],[False],[0],[0],[False],['0']
38947,PMC5994015,21761,"Although there was no significant difference between intervention and control arms with respect to DSOC score and glycaemic control, the e-intervention group showed improved DSOC score (199.7 ± 18.2 vs193.3 ± 14.6,p = 0.046), FBG (7.9 ± 2.5 mmol/L vs. 8.9 ± 3.9 mmol/L,p = 0.015) and HbA1c (8.5 ± 1.8% vs. 9.1 ± 2.0%,p = 0.004) at follow-up compared to the baseline, whereas such improvement was not seen in the control group.",Abstract,[131023],[1287],[1713],[False],[0],[0],[False],['0']
38948,PMC5994015,21762,Conclusions,Abstract,[131027],[1714],[1725],[False],[0],[0],[False],['0']
38949,PMC5994015,21763,Most important impact of myDIDeA was on the overall DKAB score.,Abstract,[131031],[1726],[1789],[False],[0],[0],[False],['0']
38950,PMC5994015,21764,This study is one of the first to demonstrate that an e-intervention can be a feasible method for implementing chronic disease management in developing countries.,Abstract,[131035],[1790],[1952],[False],[0],[0],[False],['0']
38951,PMC5994015,21765,"Concerns such as self-monitoring, length of intervention, intense and individualized intervention, adoption of other domains of Transtheoretical Model and health components, and barriers to change have to be taken into consideration in the development of future intervention programs.",Abstract,[131039],[1953],[2237],[False],[0],[0],[False],['0']
38952,PMC5994015,21766,Trial registration,Abstract,[131043],[2238],[2256],[False],[0],[0],[False],['0']
38953,PMC5994015,21767,ClinicalTrials.gov NCT01246687.,Abstract,[131047],[2257],[2288],[False],[0],[0],[False],['0']
38954,PMC5994015,21768,Background,Background,[131051],[2289],[2300],[False],[0],[0],[False],['0']
38955,PMC5994015,21769,"Type 2 Diabetes Mellitus (T2DM) is an increasingly important medical and public health issue in many countries, including Malaysia.",Background,[131055],[2301],[2432],[False],[0],[0],[False],['0']
38956,PMC5994015,21770,"T2DM is the most common form of diabetes and is characterized by disorders of insulin action and insulin secretion, either of which may be the predominant feature.",Background,[131059],[2433],[2596],[False],[0],[0],[False],['0']
38957,PMC5994015,21771,The latest Malaysian National Health and Morbidity Survey report stated the prevalence of T2DM among adults above 18 years has increased from 11.6% in 2006 to 17.5% in 2015 [1].,Background,[131063],[2597],[2774],[False],[0],[0],[False],['0']
38958,PMC5994015,21772,"The increasing prevalence of diabetes and the resulting disease burden has led to a rising demand for evidence-based programs to improve and evaluate diabetes management, especially in developing countries [2].",Background,[131067],[2775],[2985],[False],[0],[0],[False],['0']
38959,PMC5994015,21773,"Although T2DM could be inherited, modifiable factors such as body composition and nutrition also play important role in the aetiology of T2DM [3].",Background,[131071],[2986],[3132],[False],[0],[0],[False],['0']
38960,PMC5994015,21774,There is accumulating evidence from a range of different behavioural interventions and delivery methods that have shown promising results in prevention and management of chronic diseases such as T2DM [4].,Background,[131075],[3133],[3337],[False],[0],[0],[False],['0']
38961,PMC5994015,21775,"Behavioural interventions have been proven to assist the management of T2DM and websites were found to be a feasible medium for the delivery of such interventions, though the evidence were mostly from Western cultures and did not focus solely on dietary behaviour [5, 6].",Background,[131079],[3338],[3609],[False],[0],[0],[False],['0']
38962,PMC5994015,21776,"Instead, dietary behaviour has been a component of a number of web-based studies that aimed at preventing T2DM [7–10].",Background,[131083],[3610],[3728],[False],[0],[0],[False],['0']
38963,PMC5994015,21777,"Although limited trials were conducted to test the effectiveness of web-based intervention among T2DM patients, the available evidence has shown an improvement in outcomes for individuals using web-based interventions to increase nutritional knowledge and improve glycaemic control [6, 11].",Background,[131087],[3729],[4019],[False],[0],[0],[False],['0']
38964,PMC5994015,21778,"Web-based interventions have demonstrated some favourable outcomes, provided they are further enhanced with appropriate e-research strategies such as use of e-mail or mobile text message reminder to improve log-in rates and use of local languages in content development [5, 12, 13].",Background,[131091],[4020],[4302],[False],[0],[0],[False],['0']
38965,PMC5994015,21779,"Interactive components with tracking and personalised feedback, as well as peer-support components were also shown to be effective strategies in ensuring the success of web-based intervention for patients with T2DM [6].",Background,[131095],[4303],[4522],[False],[0],[0],[False],['0']
38966,PMC5994015,21780,"The use of Internet has been found to significantly contribute towards improvement of some other health behaviour changes in people with T2DM, especially when the intervention is strengthened with a theoretical framework [14, 15].",Background,[131099],[4523],[4753],[False],[0],[0],[False],['0']
38967,PMC5994015,21781,Theory and evidence-based behaviour interventions are long hailed to be the ideal approach towards successful health behaviour changes.,Background,[131103],[4754],[4889],[False],[0],[0],[False],['0']
38968,PMC5994015,21782,"Although no agreement exists as to the best theories for health promotion purposes, the Transtheorical Model (TTM) [16] has become one of the most popular behaviour change models used in health promotion [17].",Background,[131107],[4890],[5099],[False],[0],[0],[False],['0']
38969,PMC5994015,21783,"The most commonly applied component of TTM is the construct of Stages of Change (SOC), where the participants are classified into one of the five distinct stages; pre-contemplation, contemplation, preparation, action, and maintenance [18].",Background,[131111],[5100],[5339],[False],[0],[0],[False],['0']
38970,PMC5994015,21784,The TTM and the SOC construct grew on the understanding how people change their behaviour.,Background,[131115],[5340],[5430],[False],[0],[0],[False],['0']
38971,PMC5994015,21785,"Few studies have assessed the application of TTM in dietary interventions [14, 19, 20], and more than 75% of studies reviewed by Spencer et al.",Background,[131119],[5431],[5574],[False],[0],[0],[False],['0']
38972,PMC5994015,21786,[14] supported the use of SOC model in dietary interventions.,Background,[131123],[5575],[5636],[False],[0],[0],[False],['0']
38973,PMC5994015,21787,"A review of past studies identified various positive impacts of TTM-based dietary interventions, which included reduction of fat consumption, and an increase in the consumption of fruit and vegetables [19].",Background,[131127],[5637],[5843],[False],[0],[0],[False],['0']
38974,PMC5994015,21788,"The evidence is particularly strong in patients with T2DM who received intensive intervention of at least 6 months, and the strong evidence substantiates the effectiveness of self-monitoring among others [20].",Background,[131131],[5844],[6053],[False],[0],[0],[False],['0']
38975,PMC5994015,21789,"Despite the potential, Lee and colleagues (2015) found lack of exploration on the concurrent use of information technology with TTM [21].",Background,[131135],[6054],[6191],[False],[0],[0],[False],['0']
38976,PMC5994015,21790,"To date, there is no published study focused on dietary behaviour change in adults with T2DM via a website-based system.",Background,[131139],[6192],[6312],[False],[0],[0],[False],['0']
38977,PMC5994015,21791,"However, dietary modification has been incorporated as a component of a web-based weight-loss program in prevention of T2DM in adults [8].",Background,[131143],[6313],[6451],[False],[0],[0],[False],['0']
38978,PMC5994015,21792,Calorie count as a part of behaviour e-counselling intervention also significantly reduced the weight of the adults at risk for T2DM [9].,Background,[131147],[6452],[6589],[False],[0],[0],[False],['0']
38979,PMC5994015,21793,"ICAN, a 12-month RCT which tested the efficacy of physical activity and nutrition behaviour changes in improving diabetes control found favourable results as well [10].",Background,[131151],[6590],[6758],[False],[0],[0],[False],['0']
38980,PMC5994015,21794,"Despite the limited evidence, use of Web-based interventions compared to non-web-based interventions showed an improvement in outcomes for individuals using web-based interventions to achieve the specified knowledge and/or behaviour change which include increase in nutritional knowledge and diabetic control [11].",Background,[131155],[6759],[7073],[False],[0],[0],[False],['0']
38981,PMC5994015,21795,A web-based intervention which gives the flexibility for the participants to log in at their own pace and set personalised goals may yield a better and favourable results than generic and non-web-based interventions.,Background,[131159],[7074],[7290],[False],[0],[0],[False],['0']
38982,PMC5994015,21796,"Taking these factors into consideration, we aimed to evaluate the effects of myDIDeA ( ala sian  ietary  ntervention for People with Type 2  iabetes: An  - pproach), a 6-month web-based stage-personalised dietary intervention on Dietary Knowledge, Attitude and Behaviour (DKAB), Dietary Stages of Change (DSOC), fasting blood glucose (FBG) and glycosylated haemoglobin (HbA1c) in patients with uncontrolled HbA1c (> 7.0%).",Background,[131163],[7291],[7713],[False],[0],[0],[False],['0']
38983,PMC5994015,21797,"We hypothesised myDIDeA to result in significant between- and within-group changes in DKAB, DSOC, FBG and HbA1c in our study population.",Background,[131167],[7714],[7850],[False],[0],[0],[False],['0']
38984,PMC5994015,21798,Methods,Methods,[131171],[7851],[7859],[False],[0],[0],[False],['0']
38985,PMC5994015,21799,Study design,Methods|Study design,[131175],[7860],[7872],[False],[0],[0],[False],['0']
38986,PMC5994015,21800,Fig.,Methods|Study design,[131179],[7873],[7877],[False],[0],[0],[False],['0']
38987,PMC5994015,21801,1 Study flow chart.,Methods|Study design,[131183],[7878],[7897],[False],[0],[0],[False],['0']
38988,PMC5994015,21802,This was a two-armed multi-centre RCT.,Methods|Study design,[131187],[7898],[7936],[False],[0],[0],[False],['0']
38989,PMC5994015,21803,"The recruitment of subjects, screening and data collections for this study were conducted in three public hospitals in Klang Valley, Malaysia, namely Hospital Putrajaya, Serdang and Selayang.",Methods|Study design,[131191],[7937],[8128],[False],[0],[0],[False],['0']
38990,PMC5994015,21804,"The study was designed according to the recommendations of the CONSORT statement for randomised-controlled trials of nonpharmacological treatment [22] and commenced after obtaining ethical clearance from the Malaysian Ethics Research Committee (NMRR-09-303-3416) and Monash University’s Human Research Ethics Committee (CF09/1583–2,009,000,877).",Methods|Study design,[131195],[8129],[8474],[False],[0],[0],[False],['0']
38991,PMC5994015,21805,The study flow chart is summarised in Fig.,Methods|Study design,[131199],[8475],[8517],[False],[0],[0],[False],['0']
38992,PMC5994015,21806,1.,Methods|Study design,[131203],[8518],[8520],[False],[0],[0],[False],['0']
38993,PMC5994015,21807,The detailed study protocol has been published previously [23].,Methods|Study design,[131207],[8521],[8584],[False],[0],[0],[False],['0']
38994,PMC5994015,21808,Participant recruitment and randomization process,Methods|Participant recruitment and randomization process,[131211],[8585],[8634],[False],[0],[0],[False],['0']
38995,PMC5994015,21809,Table 1 Eligibility criteria used in the screening of the participants.,Methods|Participant recruitment and randomization process,[131215],[8635],[8706],[False],[0],[0],[False],['0']
38996,PMC5994015,21810,"The eligibility screening (Table 1), recruitment of study participants and data collections were conducted in the outpatient medical and/or diabetes clinics of the three hospitals.",Methods|Participant recruitment and randomization process,[131219],[8707],[8887],[False],[0],[0],[False],['0']
38997,PMC5994015,21811,"Eligible patients, screened by diabetes nurses independent to the study, provided their informed consent.",Methods|Participant recruitment and randomization process,[131223],[8888],[8993],[False],[0],[0],[False],['0']
38998,PMC5994015,21812,"Subsequently, they were randomised to either e-intervention (receiving 6-month web-based dietary intervention in addition to standard care) or control (standard care) groups.",Methods|Participant recruitment and randomization process,[131227],[8994],[9168],[False],[0],[0],[False],['0']
38999,PMC5994015,21813,The allocation sequence was automatically generated based on the order of recruitment.,Methods|Participant recruitment and randomization process,[131231],[9169],[9255],[False],[0],[0],[False],['0']
39000,PMC5994015,21814,The study researcher took the responsibly of the recruitment process.,Methods|Participant recruitment and randomization process,[131235],[9256],[9325],[False],[0],[0],[False],['0']
39001,PMC5994015,21815,"The study researcher was not blinded of participants’ treatment group, while the attending hospital physicians and other hospital staffs were kept blinded.",Methods|Participant recruitment and randomization process,[131239],[9326],[9481],[False],[0],[0],[False],['0']
39002,PMC5994015,21816,The screening and recruitment of study participants was conducted for 3 months.,Methods|Participant recruitment and randomization process,[131243],[9482],[9561],[False],[0],[0],[False],['0']
39003,PMC5994015,21817,"However, commencement of the intervention was done as soon as the patient been randomised into one of the study group.",Methods|Participant recruitment and randomization process,[131247],[9562],[9680],[False],[0],[0],[False],['0']
39004,PMC5994015,21818,"Based on the findings of a previous study [24], a minimum sample of 31 patients was needed in each group to detect a difference in mean behaviour scores between treatment and control groups, with a two-sided alpha of 0.05 and a power of 80%.",Methods|Participant recruitment and randomization process,[131251],[9681],[9922],[False],[0],[0],[False],['0']
39005,PMC5994015,21819,"Based on 30% attrition rate for one year, a minimum of 41 participants were required in each group.",Methods|Participant recruitment and randomization process,[131255],[9923],[10022],[False],[0],[0],[False],['0']
39006,PMC5994015,21820,E-intervention program,Methods|E-intervention program,[131259],[10023],[10045],[False],[0],[0],[False],['0']
39007,PMC5994015,21821,The development of the dietary intervention program can be described in the following systematic six-step planning approach – 1) needs assessment; 2) module development; 3) development of strategies according to behavioural theory; 4) detailed lesson plans development; 5) implementation of web-based program and 6) effect and process evaluation of the program.,Methods|E-intervention program,[131263],[10046],[10407],[False],[0],[0],[False],['0']
39008,PMC5994015,21822,Table 2 Sample of the lesson plans.,Methods|E-intervention program,[131267],[10408],[10443],[False],[0],[0],[False],['0']
39009,PMC5994015,21823,The literature and existing guidelines for patients with T2DM [25–31] were reviewed as part of the needs assessment to identify specific dietary factors of concern.,Methods|E-intervention program,[131271],[10444],[10608],[False],[0],[0],[False],['0']
39010,PMC5994015,21824,A module consisting of twelve dietary lesson plans were then developed based on the evidence (Table 2).,Methods|E-intervention program,[131275],[10609],[10712],[False],[0],[0],[False],['0']
39011,PMC5994015,21825,The content of each of the lesson plans was investigated for its relevance to the local community and tailored to suit local context.,Methods|E-intervention program,[131279],[10713],[10846],[False],[0],[0],[False],['0']
39012,PMC5994015,21826,"TTM and SOC constructs [16, 18] were identified to assist with the intervention program design.",Methods|E-intervention program,[131283],[10847],[10942],[False],[0],[0],[False],['0']
39013,PMC5994015,21827,"Program components were developed based on the recommendations, objectives and DSOC.",Methods|E-intervention program,[131287],[10943],[11027],[False],[0],[0],[False],['0']
39014,PMC5994015,21828,"The lesson plans were translated to Bahasa Malaysia, the national language of Malaysia and back translated to English.",Methods|E-intervention program,[131291],[11028],[11146],[False],[0],[0],[False],['0']
39015,PMC5994015,21829,A working plan of the intervention program that would be delivered via the Internet was then developed and a prototype website was piloted in a small group of patients with T2DM (n = 30) to assess the acceptability and user-friendliness of the intervention structure and web design.,Methods|E-intervention program,[131295],[11147],[11429],[False],[0],[0],[False],['0']
39016,PMC5994015,21830,The staged-tailored recommendations delivered via the study website (myDIDeA) were aimed to address the barriers and motivate the participants according to their DSOC.,Methods|E-intervention program,[131299],[11430],[11597],[False],[0],[0],[False],['0']
39017,PMC5994015,21831,The dietary lesson plans in the intervention package was personalised according to the patients’ DSOC and was expected to improve their DKAB and assist them to progress in their respective DSOC.,Methods|E-intervention program,[131303],[11598],[11792],[False],[0],[0],[False],['0']
39018,PMC5994015,21832,The improvements in DKAB and progress in DSOC were expected to be reflected in the patients’ FBG and HbA1c.,Methods|E-intervention program,[131307],[11793],[11900],[False],[0],[0],[False],['0']
39019,PMC5994015,21833,Only patients recruited into e-intervention group (n = 66) were provided access to myDIDeA and they were required to login with their unique username and password.,Methods|E-intervention program,[131311],[11901],[12064],[False],[0],[0],[False],['0']
39020,PMC5994015,21834,"Twelve lesson plans were made available to the patients one after another over the period of 6 months, with updates every fortnight.",Methods|E-intervention program,[131315],[12065],[12197],[False],[0],[0],[False],['0']
39021,PMC5994015,21835,Log-in reminders were sent via e-mail each time myDIDeA is updated with new lesson plans and participants were followed-up with text messages if they failed to log-in within three days post-update.,Methods|E-intervention program,[131319],[12198],[12395],[False],[0],[0],[False],['0']
39022,PMC5994015,21836,The participants were also encouraged to send their queries to the study nutritionist via the website.,Methods|E-intervention program,[131323],[12396],[12498],[False],[0],[0],[False],['0']
39023,PMC5994015,21837,The effectiveness of the web-delivered intervention program was evaluated via the randomised-controlled trial.,Methods|E-intervention program,[131327],[12499],[12609],[False],[0],[0],[False],['0']
39024,PMC5994015,21838,Process evaluation in form of intervention adherence and program reception were conducted at post intervention.,Methods|E-intervention program,[131331],[12610],[12721],[False],[0],[0],[False],['0']
39025,PMC5994015,21839,"On average, each participant logged in at least once for each lesson plan and spent almost 12 min on the site.",Methods|E-intervention program,[131335],[12722],[12832],[False],[0],[0],[False],['0']
39026,PMC5994015,21840,"The participants’ content satisfaction, acceptability, and usability scores were satisfactory.",Methods|E-intervention program,[131339],[12833],[12927],[False],[0],[0],[False],['0']
39027,PMC5994015,21841,A detailed description of the development and process evaluation of the e-intervention program has been published previously [32].,Methods|E-intervention program,[131343],[12928],[13058],[False],[0],[0],[False],['0']
39028,PMC5994015,21842,Measures,Methods|Measures,[131347],[13059],[13067],[False],[0],[0],[False],['0']
39029,PMC5994015,21843,"Data were collected at baseline, 6-month post-intervention and 12-months follow-up by independent data collectors.",Methods|Measures,[131351],[13068],[13182],[False],[0],[0],[False],['0']
39030,PMC5994015,21844,"A structured bilingual (English and Bahasa Malaysia) questionnaire was used to collect data on socio-demography (age, gender, ethnic group, education, occupation and personal income), family history of diabetes (yes/no), current medication (OHA/insulin/OHA + insulin), duration of diabetes (months/years), self-monitoring of blood glucose (times per week), existing co-morbidities (hypoglycaemia, heart disease, kidney disease, nerve disorder, hypertension and dyslipidaemia), smoking and alcohol drinking habits (yes/no) to describe the study population.",Methods|Measures,[131355],[13183],[13738],[False],[0],[0],[False],['0']
39031,PMC5994015,21845,Physical activity level was measured using International Physical Activity Questionnaire (IPAQ) [33].,Methods|Measures,[131359],[13739],[13840],[False],[0],[0],[False],['0']
39032,PMC5994015,21846,"The primary outcomes were changes in DKAB which were measured using a 36-item Dietary Knowledge, Attitude and Behaviour Questionnaire (DKAB-Q), a validated composite assessment of knowledge, attitude and behaviour related to dietary education for people with diabetes in Malaysia.",Methods|Measures,[131363],[13841],[14121],[False],[0],[0],[False],['0']
39033,PMC5994015,21847,DKAB-Q was developed primarily based on the existing guidelines and recommendations [25–31].,Methods|Measures,[131367],[14122],[14214],[False],[0],[0],[False],['0']
39034,PMC5994015,21848,"The DKAB-Q consists of three domains – Knowledge (12 points), Attitude (60 points) and Behaviour (12 points), with total maximum score of 84 points.",Methods|Measures,[131371],[14215],[14363],[False],[0],[0],[False],['0']
39035,PMC5994015,21849,"The first domain, Knowledge, measured patients’ understanding of important dietary aspects.",Methods|Measures,[131375],[14364],[14455],[False],[0],[0],[False],['0']
39036,PMC5994015,21850,"The 12 items in this domain were measured using responses of “True”, “False” and “Don’t know”.",Methods|Measures,[131379],[14456],[14550],[False],[0],[0],[False],['0']
39037,PMC5994015,21851,"Each correct response was given one point, whilst incorrect responses as well as “Don’t know” responses were given zero point.",Methods|Measures,[131383],[14551],[14677],[False],[0],[0],[False],['0']
39038,PMC5994015,21852,"The second domain, Attitude, measured the attitude of patients towards diet and diabetes.",Methods|Measures,[131387],[14678],[14767],[False],[0],[0],[False],['0']
39039,PMC5994015,21853,"Five items in this domain were scored using Likert scale responses: strongly agree = 5 to strongly disagree = 1, while 7 reversed items were scored from strongly agree = 1 to strongly disagree = 5.",Methods|Measures,[131391],[14768],[14965],[False],[0],[0],[False],['0']
39040,PMC5994015,21854,"The third domain, Behaviour, measured the dietary behaviour of the patients.",Methods|Measures,[131395],[14966],[15042],[False],[0],[0],[False],['0']
39041,PMC5994015,21855,"Responses to twelve items in this domain were scored as “Yes”, “No” and “Not sure”.",Methods|Measures,[131399],[15043],[15126],[False],[0],[0],[False],['0']
39042,PMC5994015,21856,The scoring is similar to that of the Knowledge domain.,Methods|Measures,[131403],[15127],[15182],[False],[0],[0],[False],['0']
39043,PMC5994015,21857,Content and face validity of the instrument have been assessed and DKAB-Q has also shown good internal consistency and test-retest reliability [34].,Methods|Measures,[131407],[15183],[15331],[False],[0],[0],[False],['0']
39044,PMC5994015,21858,"The impact of the intervention on DSOC, FBG and HbA1c was also evaluated.",Methods|Measures,[131411],[15332],[15405],[False],[0],[0],[False],['0']
39045,PMC5994015,21859,A 60-item validated five-point Likert-scaled questionnaire was used to determine the DSOC of the study patients.,Methods|Measures,[131415],[15406],[15518],[False],[0],[0],[False],['0']
39046,PMC5994015,21860,Fasting blood samples for FBG and HbA1c were collected by a trained nurse or phlebotomist from a vein in the arm during patients’ clinic visit.,Methods|Measures,[131419],[15519],[15662],[False],[0],[0],[False],['0']
39047,PMC5994015,21861,"Plasma FBG was measured by UV hexokinase method on automated biochemistry analyser, UNICEL® DXC 800 (Beckman Coulter, Massachusetts, USA), while plasma HbA1c was analysed using the principle of ion-exchange high performance liquid chromatography (HPLC) on the D10 BIORAD system (Biorad Laboratories, Hercules, California, USA).",Methods|Measures,[131423],[15663],[15990],[False],[0],[0],[False],['0']
39048,PMC5994015,21862,The FBG and HbA1c findings were electronically transferred to patients’ medical records.,Methods|Measures,[131427],[15991],[16079],[False],[0],[0],[False],['0']
39049,PMC5994015,21863,All enumerators and hospital personnel involved in data collection were blinded to patients’ study groups.,Methods|Measures,[131431],[16080],[16186],[False],[0],[0],[False],['0']
39050,PMC5994015,21864,Analyses,Methods|Analyses,[131435],[16187],[16195],[False],[0],[0],[False],['0']
39051,PMC5994015,21865,Statistical analysis was undertaken using IBM® SPSS® 20.0 with statistical significance set at p = .05.,Methods|Analyses,[131439],[16196],[16299],[False],[0],[0],[False],['0']
39052,PMC5994015,21866,"Chi square (χ2) or equivalent was used to determine the association between categorical variables, while independent t-test or equivalent was used to determine the mean differences of continuous variables.",Methods|Analyses,[131443],[16300],[16505],[False],[0],[0],[False],['0']
39053,PMC5994015,21867,Significant differences between and within the study groups at various time points were observed using two-way repeated measures ANCOVA.,Methods|Analyses,[131447],[16506],[16642],[False],[0],[0],[False],['0']
39054,PMC5994015,21868,"The evaluation of the intervention was based on an intention-to-treat analysis, applying Last Observation Carried Forward (LOCF) principles [35].",Methods|Analyses,[131451],[16643],[16788],[False],[0],[0],[False],['0']
39055,PMC5994015,21869,Results,Results,[131455],[16789],[16797],[False],[0],[0],[False],['0']
39056,PMC5994015,21870,Characteristics of the study participants,Results|Characteristics of the study participants,[131459],[16798],[16839],[False],[0],[0],[False],['0']
39057,PMC5994015,21871,Table 3 Demography and baseline characteristics of the study participants.,Results|Characteristics of the study participants,[131463],[16840],[16914],[False],[0],[0],[False],['0']
39058,PMC5994015,21872,Participants were 77 male and 51 female patients with T2DM.,Results|Characteristics of the study participants,[131467],[16915],[16974],[False],[0],[0],[False],['0']
39059,PMC5994015,21873,The recruitment rate among patients who met the study eligibility criteria was 86.5%.,Results|Characteristics of the study participants,[131471],[16975],[17060],[False],[0],[0],[False],['0']
39060,PMC5994015,21874,Lack of time to be engaged in a trial was the most common reason of refusal.,Results|Characteristics of the study participants,[131475],[17061],[17137],[False],[0],[0],[False],['0']
39061,PMC5994015,21875,None of the demographic and baseline characteristics of the participants significantly differed between groups (Table 3).,Results|Characteristics of the study participants,[131479],[17138],[17259],[False],[0],[0],[False],['0']
39062,PMC5994015,21876,The mean age of the study participants was 50.5 years old (SD = 10.5).,Results|Characteristics of the study participants,[131483],[17260],[17330],[False],[0],[0],[False],['0']
39063,PMC5994015,21877,Malay was the largest ethnic group participated in this study (72.6%).,Results|Characteristics of the study participants,[131487],[17331],[17401],[False],[0],[0],[False],['0']
39064,PMC5994015,21878,"More than 60% of the study participants had tertiary level education and were employed full-time with a mean personal income of MYR 5166 (SD = 3816) per month (approximately USD1,223 (SD = 903)).",Results|Characteristics of the study participants,[131491],[17402],[17597],[False],[0],[0],[False],['0']
39065,PMC5994015,21879,"On average, study participants had been diagnosed with T2DM 8 years previously.",Results|Characteristics of the study participants,[131495],[17598],[17677],[False],[0],[0],[False],['0']
39066,PMC5994015,21880,A large percentage (83.1%) of them had family history of diabetes.,Results|Characteristics of the study participants,[131499],[17678],[17744],[False],[0],[0],[False],['0']
39067,PMC5994015,21881,"Almost half of the study participants were being treated with oral hypoglycaemic agent, with equal distribution in types of diabetes treatment in both groups.",Results|Characteristics of the study participants,[131503],[17745],[17903],[False],[0],[0],[False],['0']
39068,PMC5994015,21882,"Slightly more than 80% of them were self-monitoring their blood glucose at home, with the majority monitoring it one to three times a week.",Results|Characteristics of the study participants,[131507],[17904],[18043],[False],[0],[0],[False],['0']
39069,PMC5994015,21883,"Based on the self-reported medical history, hypertension (53.1%), dyslipidaemia (46.1%) and previous history of heart diseases (10.2%) were the most common co-morbidities among the participants.",Results|Characteristics of the study participants,[131511],[18044],[18238],[False],[0],[0],[False],['0']
39070,PMC5994015,21884,Physical activity was determined by the total MET per week [36].,Results|Characteristics of the study participants,[131515],[18239],[18303],[False],[0],[0],[False],['0']
39071,PMC5994015,21885,The total MET/week was 733.0 (SD = 213.2).,Results|Characteristics of the study participants,[131519],[18304],[18346],[False],[0],[0],[False],['0']
39072,PMC5994015,21886,"Almost 44% of the participants had low physical activity level, while only 21.0% of them reported to be engaged in high level of physical activity.",Results|Characteristics of the study participants,[131523],[18347],[18494],[False],[0],[0],[False],['0']
39073,PMC5994015,21887,"Only 15.6 and 7.8% of the participants were current smokers and drinkers, respectively.",Results|Characteristics of the study participants,[131527],[18495],[18582],[False],[0],[0],[False],['0']
39074,PMC5994015,21888,"The mean DKAB score was 33.9 (SD = 5.4), which was about 57% of total score of 60 points.",Results|Characteristics of the study participants,[131531],[18583],[18672],[False],[0],[0],[False],['0']
39075,PMC5994015,21889,The mean DSOC score was 192.3 points (SD = 15.4) out of a total possible score of 300 points.,Results|Characteristics of the study participants,[131535],[18673],[18766],[False],[0],[0],[False],['0']
39076,PMC5994015,21890,"The mean FBG and HbA1c were 8.6 mmol/L (SD = 3.5) and 9.0% (SD = 2.0), respectively.",Results|Characteristics of the study participants,[131539],[18767],[18851],[False],[0],[0],[False],['0']
39077,PMC5994015,21891,DKAB score,Results|DKAB score,[131543],[18852],[18862],[False],[0],[0],[False],['0']
39078,PMC5994015,21892,"An overall significant difference in total DKAB score between timelines was found in the e-intervention (F = 244.212, p < 0.001, ƞ2 = 0.790) and in the control (F = 62.453, p < 0.001, ƞ2 = 0.676) groups (Table 4).",Results|DKAB score,[131547],[18863],[19076],[False],[0],[0],[False],['0']
39079,PMC5994015,21893,"Significant difference was found between the study groups (F = 26.818, p < 0.001, ƞ2 = 0.175) and there was also a significant interaction between the study groups and increasing scores across the timeline (F = 53.059, p < 0.001, ƞ2 = 0.296).",Results|DKAB score,[131551],[19077],[19319],[False],[0],[0],[False],['0']
39080,PMC5994015,21894,Figure 2(a) further confirms the rapid increase in the score in the e-intervention group compared to the control group.,Results|DKAB score,[131555],[19320],[19439],[False],[0],[0],[False],['0']
39081,PMC5994015,21895,"Similar to total DKAB score, diabetes-related dietary knowledge, attitude and behaviour domain scores were significantly different across the timeline in both groups.",Results|DKAB score,[131559],[19440],[19606],[False],[0],[0],[False],['0']
39082,PMC5994015,21896,"Significant interactions were found between the knowledge (F = 23.824, p < 0.001, ƞ2 = 0.159, attitude (F = 38.478, p < 0.001, ƞ2 = 0.234), behaviour (F = 27.205, p < 0.001, ƞ2 = 0.178) domain scores and study groups.",Results|DKAB score,[131563],[19607],[19824],[False],[0],[0],[False],['0']
39083,PMC5994015,21897,"The increase in the scores levelled after the 6th month and overall, the participants in e-intervention group had higher score at all data collection points (Fig.",Results|DKAB score,[131567],[19825],[19987],[False],[0],[0],[False],['0']
39084,PMC5994015,21898,"2(b), (c) and (d)).",Results|DKAB score,[131571],[19988],[20007],[False],[0],[0],[False],['0']
39085,PMC5994015,21899,DSOC score,Results|DSOC score,[131575],[20008],[20018],[False],[0],[0],[False],['0']
39086,PMC5994015,21900,"In contrast to DKAB score, there was an overall significant difference in DSOC score between timelines only among the e-intervention participants (F = 3.305, p = 0.046, ƞ2 = 0.049) and there was a significant difference in score between study groups (F = 7.552, p = 0.007, ƞ2 = 0.057).",Results|DSOC score,[131579],[20019],[20304],[False],[0],[0],[False],['0']
39087,PMC5994015,21901,Figure 2(e) presents the patterns of DSOC score change.,Results|DSOC score,[131583],[20305],[20360],[False],[0],[0],[False],['0']
39088,PMC5994015,21902,Glycaemic control,Results|Glycaemic control,[131587],[20361],[20378],[False],[0],[0],[False],['0']
39089,PMC5994015,21903,Although decreasing trends of mean FBG(mmol/L) and HbA1c(%) can be seen in both groups (Fig.,Results|Glycaemic control,[131591],[20379],[20471],[False],[0],[0],[False],['0']
39090,PMC5994015,21904,"2(f) and (g)), the within group analyses showed a significant decrease in FBG among e-intervention group participants at follow-up compared to post-intervention (F = 6.054, p = 0.015, ƞ2 = 0.057).",Results|Glycaemic control,[131595],[20472],[20668],[False],[0],[0],[False],['0']
39091,PMC5994015,21905,"The mean HbA1c of the e-intervention group has significantly decreased by 0.5% at post-intervention (F = 8.334, p = 0.004, ƞ2 = 0.114) and 1.5% at 12th month follow-up (F = 10.934, p = 0.001, ƞ2 = 0.152) as compared to the baseline.",Results|Glycaemic control,[131599],[20669],[20901],[False],[0],[0],[False],['0']
39092,PMC5994015,21906,"However, no significant difference in the group*timeline interactions, changes in FBG and HbA1c between groups and within the control group were found (Table 4).",Results|Glycaemic control,[131603],[20902],[21063],[False],[0],[0],[False],['0']
39093,PMC5994015,21907,Discussion,Discussion,[131607],[21064],[21075],[False],[0],[0],[False],['0']
39094,PMC5994015,21908,Continuous education through the myDIDeA website on various lesson plans has shown a positive impact on the DKAB.,Discussion,[131611],[21076],[21189],[False],[0],[0],[False],['0']
39095,PMC5994015,21909,"The intervention program successfully assisted the participants to achieve a better DKAB score, possibly through matching motivational readiness and accelerating the learning process.",Discussion,[131615],[21190],[21373],[False],[0],[0],[False],['0']
39096,PMC5994015,21910,"Recommendations based on the current DSOC probably gave more valid and feasible suggestions to the patients, leading to improvements of the DKAB scores.",Discussion,[131619],[21374],[21526],[False],[0],[0],[False],['0']
39097,PMC5994015,21911,The e-intervention group scored much higher DKAB score than the control suggesting that receiving additional education through myDIDeA could result in improved dietary health cognitions and behaviours.,Discussion,[131623],[21527],[21728],[False],[0],[0],[False],['0']
39098,PMC5994015,21912,"Similar to the total DKAB score, the knowledge and attitude score of participants in both groups have increased, but those in the e-intervention group have shown a higher margin of increase in score compared to the control group.",Discussion,[131627],[21729],[21958],[False],[0],[0],[False],['0']
39099,PMC5994015,21913,"However, only the e-intervention group has shown significant improvement in the dietary behaviour score at post-intervention and follow-up.",Discussion,[131631],[21959],[22098],[False],[0],[0],[False],['0']
39100,PMC5994015,21914,"The encouraging improvement in knowledge score of the e-intervention participants showed that the intervention was successful in conveying the necessary dietary information, comprehension and skill of the participants.",Discussion,[131635],[22099],[22317],[False],[0],[0],[False],['0']
39101,PMC5994015,21915,"The intervention program also improved the attitude score of the participants, which reflected on positive reaction to the knowledge provided.",Discussion,[131639],[22318],[22460],[False],[0],[0],[False],['0']
39102,PMC5994015,21916,"The improvement of behaviour score in the e-intervention group, further emphasized the success of myDIDeA and it showed that the web-based dietary intervention program can propagate positive change in dietary behaviour.",Discussion,[131643],[22461],[22680],[False],[0],[0],[False],['0']
39103,PMC5994015,21917,"A more comprehensive dietary education program that addressed barriers such as lack of support from family and health services, time management and dietary myths [37–39] could result in an even better dietary behaviour change.",Discussion,[131647],[22681],[22907],[False],[0],[0],[False],['0']
39104,PMC5994015,21918,"A successful program could also take into consideration factors such as meal planning, diet quality, self-monitoring, dietary self-efficacy, social support and time management [40–43], and deliver it through trained professionals such as dieticians or nutritionists functioning as part of multidisciplinary teams [43–45].",Discussion,[131651],[22908],[23229],[False],[0],[0],[False],['0']
39105,PMC5994015,21919,"The DSOC score itself is a continuous measure of the participants’ SOC and it was used to determine participants’ SOC for each dietary lesson plan, and the recommendations given were strictly based on the score obtained.",Discussion,[131655],[23230],[23450],[False],[0],[0],[False],['0']
39106,PMC5994015,21920,The e-intervention group had slightly higher DSOC score compared to control group at the baseline.,Discussion,[131659],[23451],[23549],[False],[0],[0],[False],['0']
39107,PMC5994015,21921,"As the study progressed, the DSOC of e-intervention participants exhibited greater increase than the control group.",Discussion,[131663],[23550],[23665],[False],[0],[0],[False],['0']
39108,PMC5994015,21922,"The increase in DSOC suggests that the intervention was effective in improving the participants’ dietary behaviour, as a higher DSOC score reflects a more advanced readiness to change.",Discussion,[131667],[23666],[23850],[False],[0],[0],[False],['0']
39109,PMC5994015,21923,The participants showed higher SOC probably because the majority of them were educated with access to the Internet.,Discussion,[131671],[23851],[23966],[False],[0],[0],[False],['0']
39110,PMC5994015,21924,It is highly likely that they were aware of the importance of dietary changes in T2DM and trying to change their dietary behaviour.,Discussion,[131675],[23967],[24098],[False],[0],[0],[False],['0']
39111,PMC5994015,21925,"However, without much guidance and intervention it might not be that easy to propagate further from the action stage.",Discussion,[131679],[24099],[24216],[False],[0],[0],[False],['0']
39112,PMC5994015,21926,It has been highlighted that T2DM patients’ SOC varies according to dietary areas and within the dietary habits [46] and the SOC construct will be more useful when used together with other TTM measures such as decisional balance and self-efficacy in developing a more well-rounded intervention program [47].,Discussion,[131683],[24217],[24524],[False],[0],[0],[False],['0']
39113,PMC5994015,21927,There is some level of evidence to suggest that the e-intervention through myDIDeA website was able to help the participants achieve better glycaemic control.,Discussion,[131687],[24525],[24683],[False],[0],[0],[False],['0']
39114,PMC5994015,21928,"Although there is no quality data to support the clinical efficacy of online dietary intervention in improving glycaemic control among people with T2DM, past reviews have suggested improvements in FBG, HbA1c and diabetes knowledge, besides reducing blood pressure, body weight, waist circumference and need for medication following an intervention program [29, 48–50].",Discussion,[131691],[24684],[25052],[False],[0],[0],[False],['0']
39115,PMC5994015,21929,"The reduction in FBG and HbA1c in myDIDeA is comparable to the findings from other web-based lifestyle interventions, which reported a reduction of 0.78 mmol/L of FBG and 0.19 to 0.59% of HbA1c in patients with T2DM [10, 51].",Discussion,[131695],[25053],[25278],[False],[0],[0],[False],['0']
39116,PMC5994015,21930,"Website-based self-monitoring interventions have also suggested improvement in both glycaemic control and lipid markers [52, 53].",Discussion,[131699],[25279],[25408],[False],[0],[0],[False],['0']
39117,PMC5994015,21931,"The decreasing trend in HbA1c and FBG in myDIDeA is encouraging, and it can be anticipated that with longer duration of follow-up and regular reinforcement, better and clinically significant glycaemic control could be achieved.",Discussion,[131703],[25409],[25636],[False],[0],[0],[False],['0']
39118,PMC5994015,21932,Strengths and limitations,Discussion|Strengths and limitations,[131707],[25637],[25662],[False],[0],[0],[False],['0']
39119,PMC5994015,21933,Those with T2DM may be extremely receptive towards improving their diet and physical activity behaviours and this offers the researcher a captive or “teachable moment” to promote behaviour change which may ultimately prevent or delay the onset of diabetes-related complications.,Discussion|Strengths and limitations,[131711],[25663],[25941],[False],[0],[0],[False],['0']
39120,PMC5994015,21934,"Besides, the probability of success in intervention or programs related to dietary behaviour modification increases as the interventional strategies more aptly address the diversity of racial, ethnic, cultural, linguistic, religious and social factors in a community.",Discussion|Strengths and limitations,[131715],[25942],[26209],[False],[0],[0],[False],['0']
39121,PMC5994015,21935,"Thus, dietary interventions that are personalised and modified to suit the local context such as myDIDeA, would have much greater impact than those that only promote the general guidelines.",Discussion|Strengths and limitations,[131719],[26210],[26399],[False],[0],[0],[False],['0']
39122,PMC5994015,21936,"The increasing government’s effort to popularize high-speed broadband and Internet in general, has already resulted in an increasing Internet penetration in Malaysia.",Discussion|Strengths and limitations,[131723],[26400],[26566],[False],[0],[0],[False],['0']
39123,PMC5994015,21937,"While the use of Internet to educate patients is a fairly new area of clinical and research interest in developing countries such as Malaysia, findings from this study have provided support for such education program to be incorporated into the existing healthcare system.",Discussion|Strengths and limitations,[131727],[26567],[26839],[False],[0],[0],[False],['0']
39124,PMC5994015,21938,This study’s findings can be seen as representative of other low- and middle income countries (LMICs) which share similar socio-economic background as Malaysia.,Discussion|Strengths and limitations,[131731],[26840],[27000],[False],[0],[0],[False],['0']
39125,PMC5994015,21939,The myDIDeA is one of the few web-delivered dietary interventions for patients with chronic disease.,Discussion|Strengths and limitations,[131735],[27001],[27101],[False],[0],[0],[False],['0']
39126,PMC5994015,21940,"Being a web-based study, the intervention was flexible to the participants’ availability.",Discussion|Strengths and limitations,[131739],[27102],[27191],[False],[0],[0],[False],['0']
39127,PMC5994015,21941,"Besides, the reinforcement with e-mail and subsequent text message reminders has been helpful to keep the compliance rate high, with average frequency of log-in at 1.26 (SD = 0.16) and duration spent at 11.93 (SD = 2.90) per lesson plan [32].",Discussion|Strengths and limitations,[131743],[27192],[27434],[False],[0],[0],[False],['0']
39128,PMC5994015,21942,This has opened up more avenues for future web-based studies to focus on dietary behaviours.,Discussion|Strengths and limitations,[131747],[27435],[27527],[False],[0],[0],[False],['0']
39129,PMC5994015,21943,"The intervention program has merged four widely accepted guidelines and recommendations for patients with T2DM in Malaysia [25, 26, 28, 31].",Discussion|Strengths and limitations,[131751],[27528],[27668],[False],[0],[0],[False],['0']
39130,PMC5994015,21944,This has enabled the researchers to diversify the content of the intervention by incorporating the international recommendations and local guidelines into one program.,Discussion|Strengths and limitations,[131755],[27669],[27836],[False],[0],[0],[False],['0']
39131,PMC5994015,21945,Most of the dietary factors specified in the guidelines have been explored and included in the intervention program without being too technical.,Discussion|Strengths and limitations,[131759],[27837],[27981],[False],[0],[0],[False],['0']
39132,PMC5994015,21946,The content of the intervention has also been adapted to suit the local culture.,Discussion|Strengths and limitations,[131763],[27982],[28062],[False],[0],[0],[False],['0']
39133,PMC5994015,21947,"For example, we included various types of local dishes with culturally and religiously-sensitive options in the module.",Discussion|Strengths and limitations,[131767],[28063],[28182],[False],[0],[0],[False],['0']
39134,PMC5994015,21948,This culturally adapted intervention can be more widely implemented in other states within the country or in neighbouring regions with a similar culture.,Discussion|Strengths and limitations,[131771],[28183],[28336],[False],[0],[0],[False],['0']
39135,PMC5994015,21949,"Most of the available diabetes Knowledge, Attitude and Behaviour (KAB) or Knowledge, Attitude and Practice (KAP) do not focus solely on diet.",Discussion|Strengths and limitations,[131775],[28337],[28478],[False],[0],[0],[False],['0']
39136,PMC5994015,21950,"While this made the outcome comparison to be more difficult, it also showed the importance of administering a validated questionnaire solely to assess the dietary education for people with diabetes.",Discussion|Strengths and limitations,[131779],[28479],[28677],[False],[0],[0],[False],['0']
39137,PMC5994015,21951,"The DKAB-Q which was developed closely with myDIDeA’s dietary module, measured the impact of the intervention on the primary aspects of dietary KAB.",Discussion|Strengths and limitations,[131783],[28678],[28826],[False],[0],[0],[False],['0']
39138,PMC5994015,21952,The intervention program development had only utilised the SOC in the intervention design.,Discussion|Strengths and limitations,[131787],[28827],[28917],[False],[0],[0],[False],['0']
39139,PMC5994015,21953,"Other constructs of TTM such as process of change could be used, and these constructs have been shown to be more effective than using just SOC alone.",Discussion|Strengths and limitations,[131791],[28918],[29067],[False],[0],[0],[False],['0']
39140,PMC5994015,21954,The web system only managed to track the login frequency and time spent on the website.,Discussion|Strengths and limitations,[131797],[29068],[29155],[True],['Intervention'],['The web system only managed to track the login frequency and time spent on the website'],[True],['Intervention']
39141,PMC5994015,21955,Another feature such as ‘e-Mail the Nutritionist’ was not extensively used.,Discussion|Strengths and limitations,[131806],[29156],[29231],[True],['Intervention'],['Another feature such as ‘e-Mail the Nutritionist’ was not extensively used'],[True],['Intervention']
39142,PMC5994015,21956,"Based on the feedback received from the participants, the two weeks’ gap between modules was considered too long.",Discussion|Strengths and limitations,[131811],[29232],[29345],[False],[0],[0],[False],['0']
39143,PMC5994015,21957,It was initially meant for the patients to adapt to the recommendations and make necessary changes before the next module and not to make them feel rushed.,Discussion|Strengths and limitations,[131815],[29346],[29501],[False],[0],[0],[False],['0']
39144,PMC5994015,21958,"As the study was conducted for a long period (12 months) among patients with uncontrolled diabetes, there is a possibility for changes to be made to the standard treatment or medication given by the attending physician.",Discussion|Strengths and limitations,[131819],[29502],[29721],[False],[0],[0],[False],['0']
39145,PMC5994015,21959,"The trial was also not blinded, with patients and investigators knowing the treatment allocation.",Discussion|Strengths and limitations,[131823],[29722],[29819],[True],['Blinding'],"['not blinded, with patients and investigators knowing the treatment allocation']",[True],['Blinding']
39146,PMC5994015,21960,"While these may potentially be confounding variables, the randomised study design and blinding of attending hospital physicians are expected to eliminate or control these possible confounders.",Discussion|Strengths and limitations,[131831],[29820],[30012],[False],[0],[0],[False],['0']
39147,PMC5994015,21961,Patients were recruited in the clinical setting and all data collections were carried out in the clinics when they attend follow-up treatment.,Discussion|Strengths and limitations,[131835],[30013],[30155],[False],[0],[0],[False],['0']
39148,PMC5994015,21962,"The participants were not required to come to the hospital specifically for data collection purpose, unless they have missed their appointment.",Discussion|Strengths and limitations,[131839],[30156],[30299],[False],[0],[0],[False],['0']
39149,PMC5994015,21963,The aim was to reduce any additional burden to the patients and this might be associated with better compliance to the intervention program.,Discussion|Strengths and limitations,[131843],[30300],[30440],[False],[0],[0],[False],['0']
39150,PMC5994015,21964,The selection of patients with DKAB score of less than 50% and HbA1c of more than 7% meant that only those in dire need of dietary education to improve their glycaemic control were included in this RCT.,Discussion|Strengths and limitations,[131848],[30441],[30643],[True],['VerySpecificPopulation'],['only those in dire need of dietary education to improve their glycaemic control were included in this RCT'],[True],['Population']
39151,PMC5994015,21965,"This offered a teachable moment for the researchers, and detection of significant changes in important outcome measures.",Discussion|Strengths and limitations,[131851],[30644],[30764],[False],[0],[0],[False],['0']
39152,PMC5994015,21966,Future direction,Discussion|Future direction,[131855],[30765],[30781],[False],[0],[0],[False],['0']
39153,PMC5994015,21967,"While the anxiety of the participants in using a new system is understandable, future researchers could prepare the participants to use the system by offering short workshop on web usage at the beginning of the intervention.",Discussion|Future direction,[131859],[30782],[31006],[False],[0],[0],[False],['0']
39154,PMC5994015,21968,"As the two-week gap between the module updates was deemed too long, future studies following the similar style to myDIDeA could opt for a shorter time interval between updates.",Discussion|Future direction,[131863],[31007],[31183],[False],[0],[0],[False],['0']
39155,PMC5994015,21969,myDIDeA has demonstrated that the intake of fruits and vegetables were below the national recommendation level.,Discussion|Future direction,[131867],[31184],[31295],[False],[0],[0],[False],['0']
39156,PMC5994015,21970,"Emphasis can be given on fruits and vegetables in future research, as these are major sources of micronutrients and beneficial phytochemicals, and will add value to a dietary intervention.",Discussion|Future direction,[131871],[31296],[31484],[False],[0],[0],[False],['0']
39157,PMC5994015,21972,"Narrowing the gap between scientific evidence and practice is an emerging priority in health research, particularly in developing countries [54].",Discussion|Future direction,[131883],[31682],[31827],[False],[0],[0],[False],['0']
39158,PMC5994015,21973,The outcomes from this study could be used to strengthen the diabetes management initiatives.,Discussion|Future direction,[131887],[31828],[31921],[False],[0],[0],[False],['0']
39159,PMC5994015,21976,Conclusion,Conclusion,[131907],[32145],[32156],[False],[0],[0],[False],['0']
39160,PMC5994015,21977,"In summary, myDIDeA was a successful intervention program to improve the overall DKAB score, aided by the improvement in the knowledge and attitude sub-domains.",Conclusion,[131911],[32157],[32317],[False],[0],[0],[False],['0']
39161,PMC5994015,21978,"However, other issues such as addressing the barriers, shortening the study duration, making use of other health components, inclusion of self-monitoring and more intense and individualized intervention, would have likely made a difference in the behavioural aspect.",Conclusion,[131915],[32318],[32584],[False],[0],[0],[False],['0']
39162,PMC5994015,21979,The study did find an increasing trend in DSOC score among intervention participants though the increase was not statistically significant.,Conclusion,[131919],[32585],[32724],[False],[0],[0],[False],['0']
39163,PMC5994015,21980,"Excluding patients in the action or maintenance stage, and including only those in the pre-contemplation or contemplation stage could be a good option to focus the intervention on those who absolutely need it.",Conclusion,[131923],[32725],[32934],[False],[0],[0],[False],['0']
39164,PMC5994015,21981,Such measures would allow the researchers to investigate the possible movement in SOC and a better dietary practice and glycaemic control could have achieved.,Conclusion,[131927],[32935],[33093],[False],[0],[0],[False],['0']
39165,PMC5994015,21982,"Besides, other domains of SOC such as process of change and decisional balance should also be taken into consideration in the development of the intervention.",Conclusion,[131931],[33094],[33252],[False],[0],[0],[False],['0']
39166,PMC5994015,21983,Abbreviations,Abbreviations,[131935],[33253],[33267],[False],[0],[0],[False],['0']
39167,PMC5994015,21984,"DKAB Dietary Knowledge, Attitude and Behaviour","Abbreviations|DKAB Dietary Knowledge, Attitude and Behaviour",[131939],[33268],[33314],[False],[0],[0],[False],['0']
39168,PMC5994015,21985,DSOC Dietary Stages of Change,Abbreviations|DSOC Dietary Stages of Change,[131943],[33315],[33344],[False],[0],[0],[False],['0']
39169,PMC5994015,21986,FBG fasting blood glucose,Abbreviations|FBG fasting blood glucose,[131947],[33345],[33370],[False],[0],[0],[False],['0']
39170,PMC5994015,21987,HbA1c glycosylated haemoglobin,Abbreviations|FBG fasting blood glucose,[131951],[33371],[33401],[False],[0],[0],[False],['0']
39171,PMC5994015,21988,myDIDeA Malaysian Dietary Intervention for People with Type 2 Diabetes: An e-Approach,Abbreviations|FBG fasting blood glucose,[131955],[33402],[33487],[False],[0],[0],[False],['0']
39172,PMC5994015,21989,SOC Stages of Change,Abbreviations|SOC Stages of Change,[131959],[33488],[33508],[False],[0],[0],[False],['0']
39173,PMC5994015,21990,T2DM Type 2 Diabetes Mellitus,Abbreviations|SOC Stages of Change,[131963],[33509],[33538],[False],[0],[0],[False],['0']
39174,PMC5994015,21991,TTM Transtheoretical ModelAcknowledgements,Abbreviations|SOC Stages of Change,[131967],[33539],[33581],[False],[0],[0],[False],['0']
39175,PMC5994015,21992,The authors would like to thank the Director General of Health Malaysia for permission to publish this paper.,Abbreviations|SOC Stages of Change,[131971],[33582],[33691],[False],[0],[0],[False],['0']
39176,PMC5994015,21993,Funding,Abbreviations|Funding,[131975],[33692],[33699],[False],[0],[0],[False],['0']
39177,PMC5994015,21994,This study was supported by Seed Grant (MED2009-CM (SG)-004-QKF) funded by the university.,Abbreviations|Funding,[131979],[33700],[33790],[False],[0],[0],[False],['0']
39178,PMC5994015,21995,"The author (AR) of this publication was supported by the ASCEND Program funded by the Fogarty International Centre, National Institutes of Health, under Award Number: D43TW008332.",Abbreviations|Funding,[131983],[33791],[33970],[False],[0],[0],[False],['0']
39179,PMC5994015,21996,The contents of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the ASCEND Program.,Abbreviations|Funding,[131987],[33971],[34161],[False],[0],[0],[False],['0']
39180,PMC5994015,21997,Availability of data and materials,Abbreviations|Availability of data and materials,[131991],[34162],[34196],[False],[0],[0],[False],['0']
39181,PMC5994015,21998,The datasets generated and analysed during the current study are not publicly available due to the ethical concerns related to the identifying personal information.,Abbreviations|Availability of data and materials,[131995],[34197],[34361],[False],[0],[0],[False],['0']
39182,PMC5994015,21999,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[131999],[34362],[34404],[False],[0],[0],[False],['0']
39183,PMC5994015,22000,All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.,Abbreviations|Ethics approval and consent to participate,[132003],[34405],[34668],[False],[0],[0],[False],['0']
39184,PMC5994015,22001,Written informed consent was obtained from all individual participants included in the study.,Abbreviations|Ethics approval and consent to participate,[132007],[34669],[34762],[False],[0],[0],[False],['0']
39185,PMC5994015,22002,"The study has obtained the ethical clearance from the Malaysian Ethics Research Committee (NMRR-09-303-3416) and Monash University’s Human Research Ethics Committee (CF09/1583–2,009,000,877).",Abbreviations|Ethics approval and consent to participate,[132011],[34763],[34954],[False],[0],[0],[False],['0']
39186,PMC5994015,22003,Competing interests,Abbreviations|Competing interests,[132015],[34955],[34974],[False],[0],[0],[False],['0']
39187,PMC5994015,22004,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[132019],[34975],[35033],[False],[0],[0],[False],['0']
39188,PMC5994015,22005,Publisher’s Note,Abbreviations|Publisher’s Note,[132023],[35034],[35050],[False],[0],[0],[False],['0']
39189,PMC5994015,22006,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[132027],[35051],[35169],[False],[0],[0],[False],['0']
41148,PMC7038903,42039,Effectiveness of a locally produced ready‐to‐use supplementary food in preventing growth faltering for children under 2 years in Cambodia: a cluster randomised controlled trial,Title,[249086],[36202],[176],[False],[0],[0],[False],['0']
41149,PMC7038903,42040,Abstract,Abstract,[249092],[177],[185],[False],[0],[0],[False],['0']
41150,PMC7038903,42041,"This cluster randomised controlled trial tested the effectiveness of a locally produced, fish‐based, ready‐to‐use supplementary food (RUSF) to prevent growth faltering (decline in z‐scores).",Abstract,[249098],[186],[376],[False],[0],[0],[False],['0']
41151,PMC7038903,42042,"Cambodian infants (n= 485), aged 6 to 11 months, were randomised by site to receive the RUSF, Corn‐Soy Blend++ (CSB++), micronutrient powders (MNP), or no supplement (control).",Abstract,[249104],[377],[553],[False],[0],[0],[False],['0']
41152,PMC7038903,42043,The intervention was for 6 months.,Abstract,[249110],[554],[588],[False],[0],[0],[False],['0']
41153,PMC7038903,42044,"In unadjusted analysis, the control group had statistically significantly decreased weight‐for‐age z‐scores (WAZ; ‐0.02, 95%CI = ‐0.03 ‐ ‐0.01, P= 0.001) and height‐for‐age z‐scores (HAZ; ‐0.07, 95%CI = ‐0.09 ‐ ‐0.05, P < 0.001), and increased mid‐upper arm‐circumference (MUAC; 0.02cm, 95%CI = 0.01 ‐ 0.04, P = 0.010), but no statistically significant change in weight‐for‐height z‐scores (WHZ).",Abstract,[249116],[589],[985],[False],[0],[0],[False],['0']
41154,PMC7038903,42045,"The RUSF group did not differ significantly from the control for WAZ, HAZ or WHZ (in other words, WAZ and HAZ decreased and WHZ did not change), but had increased MUAC in comparison to the control (0.04cm, 95%CI = 0.01 ‐ 0.06, P = 0.008).",Abstract,[249122],[986],[1224],[False],[0],[0],[False],['0']
41155,PMC7038903,42046,"There were no statistically significant differences between the RUSF group and the CSB++ or MNP groups with respect to WAZ, HAZ, WHZ or MUAC.",Abstract,[249128],[1225],[1366],[False],[0],[0],[False],['0']
41156,PMC7038903,42047,"Interestingly, in adjusted analysis, low consumers of RUSF had increased WAZ, WHZ and MUAC (0.03, 95%CI = 0.01‐0.06, P = 0.006; 0.04, 95%CI = 0.01‐0.08, P = 0.026; and 0.05cm, 95%CI = 0.02‐0.09, P = 0.004, respectively) compared with the control.",Abstract,[249134],[1367],[1613],[False],[0],[0],[False],['0']
41157,PMC7038903,42048,"The novel RUSF, particularly in small quantities, protected against ponderal growth faltering, but the improvements were of limited clinical significance.",Abstract,[249140],[1614],[1768],[False],[0],[0],[False],['0']
41158,PMC7038903,42049,BACKGROUND AND RATIONALE,Abstract,[249146],[1769],[1794],[False],[0],[0],[False],['0']
41159,PMC7038903,42050,"Undernutrition contributes to almost half of all deaths in children under 5 years (Black et al., 2013).",Abstract,[249152],[1795],[1898],[False],[0],[0],[False],['0']
41160,PMC7038903,42051,"In Cambodia, despite impressive economic growth, high rates of undernutrition persist (NIS et al., 2015).",Abstract,[249158],[1899],[2004],[False],[0],[0],[False],['0']
41161,PMC7038903,42052,"In the 2014 Cambodian Demographic and Health Survey (DHS), almost one‐third (32%) of children under 5 years were stunted, 10% were wasted and 24% were underweight (NIS et al., 2015).",Abstract,[249164],[2005],[2187],[False],[0],[0],[False],['0']
41162,PMC7038903,42053,"The majority of growth faltering, indicated by a decline in z‐scores (Victora, de Onis, Hallal, Blössner, & Shrimpton, 2010) in Cambodia occurs from 6 to 20 months (Dewey & Huffman, 2009; NIS et al., 2015).",Abstract,[249170],[2188],[2394],[False],[0],[0],[False],['0']
41163,PMC7038903,42054,"Poor complementary feeding practices are often implicated in the growth faltering observed in low‐ and middle‐income countries (Ferguson et al., 2018).",Abstract,[249176],[2395],[2546],[False],[0],[0],[False],['0']
41164,PMC7038903,42055,"Borbor (white rice porridge, the traditional weaning food in Cambodia) has inadequate energy and micronutrient nutrient density to sustain adequate growth velocity in the first 2 years of life (Black et al., 2008; Ferguson et al., 2018).",Abstract,[249182],[2547],[2784],[False],[0],[0],[False],['0']
41165,PMC7038903,42056,"Nutrition‐specific interventions aimed at improving complementary feeding seem warranted (Black et al., 2013; Pham et al., 2012).",Abstract,[249188],[2785],[2914],[False],[0],[0],[False],['0']
41166,PMC7038903,42057,"High energy, nutrient dense specialised foods can be used to prevent growth faltering and promote improved linear growth and weight gain among children (Bhutta et al., 2013; Pee & Bloem, 2009; Golden, 2009).",Abstract,[249194],[2915],[3122],[False],[0],[0],[False],['0']
41167,PMC7038903,42058,"The development of affordable, acceptable and effective specialised foods, and their comparison with existing products in terms of their potential for preventing growth faltering responds to a need noted by researchers (de Pee & Bloem, 2009; Lazzerini, Rubert, & Pani, 2013).",Abstract,[249200],[3123],[3398],[False],[0],[0],[False],['0']
41168,PMC7038903,42059,"In Cambodia prior to 2013, various supplementary or therapeutic foods had been used or trialled.",Abstract,[249206],[3399],[3495],[False],[0],[0],[False],['0']
41169,PMC7038903,42060,"Corn‐Soy Blend Plus Plus (CSB++, also called SuperCereal Plus, the standard supplementary food that WFP provides to children aged 6 months to 2 years to prevent undernutrition), BP‐100™ and Plumpy'Nut™ had limited acceptability or effectiveness (Boudier, 2009; WFP, 2014; Wieringa, 2014).",Abstract,[249212],[3496],[3784],[False],[0],[0],[False],['0']
41170,PMC7038903,42061,"Micronutrient powders (MNP), while acceptable and effective at improving micronutrient status, did not have any impact on growth (Jack et al., 2012).",Abstract,[249218],[3785],[3934],[False],[0],[0],[False],['0']
41171,PMC7038903,42062,"Therefore, in mid‐2013, UNICEF engaged the French National Research Institute for Sustainable Development (IRD), and the Cambodian Department of Fisheries Post‐harvest Technologies and Quality (DFPTQ), to develop a locally produced ready‐to‐use supplementary food (RUSF).",Abstract,[249224],[3935],[4206],[False],[0],[0],[False],['0']
41172,PMC7038903,42063,"The aim was to develop an RUSF that would be more acceptable, effective and affordable than previously tested or used products (Sigh et al., 2018).",Abstract,[249230],[4207],[4354],[False],[0],[0],[False],['0']
41173,PMC7038903,42064,"Many specialised foods, including CSB++, use milk or whey powder as the animal‐source food (Adu‐Afarwuah, Lartey, Zeilani, & Dewey, 2011; Nga et al., 2013), but in Cambodia, milk is an expensive, imported ingredient.",Abstract,[249236],[4355],[4571],[False],[0],[0],[False],['0']
41174,PMC7038903,42065,"Thus, it was decided to replace milk with fish, which is inexpensive, readily available and highly acceptable in Cambodia (Vilain, Baran, Gallego, & Samadee, 2016).",Abstract,[249242],[4572],[4736],[False],[0],[0],[False],['0']
41175,PMC7038903,42066,"It had previously been demonstrated that fish protein supported linear growth to the same extent as milk protein in a locally produced complementary food in Cambodia (Skau et al., 2015).",Abstract,[249248],[4737],[4923],[False],[0],[0],[False],['0']
41176,PMC7038903,42067,"Since lipid‐based nutrient supplements (LNSs) are particularly promising (de Pee & Bloem, 2009; de Pee, Manary, & Ashorn, 2011), the novel ready‐to‐use supplementary food (RUSF) was formulated as an LNS snack.",Abstract,[249254],[4924],[5133],[False],[0],[0],[False],['0']
41177,PMC7038903,42068,"In June 2015, the RUSF was tested for acceptability in comparison to CSB++ and MNP.",Abstract,[249260],[5134],[5217],[False],[0],[0],[False],['0']
41178,PMC7038903,42069,"The acceptability trial demonstrated that children would eat the RUSF and that caregivers ranked it highly (Borg et al., 2019).",Abstract,[249266],[5218],[5345],[False],[0],[0],[False],['0']
41179,PMC7038903,42070,"Here, we report on the effectiveness of the RUSF in preventing growth faltering for children aged 6 to 17 months, in comparison to CSB++, MNP, and an unsupplemented control group.",Abstract,[249272],[5346],[5525],[False],[0],[0],[False],['0']
41180,PMC7038903,42071,"The main outcomes of interest are weight‐for‐age z‐score (WAZ), height ‐for‐age z‐score (HAZ), weight‐for‐height z‐score (WHZ), and mid‐upper arm circumference (MUAC).",Abstract,[249278],[5526],[5693],[False],[0],[0],[False],['0']
41181,PMC7038903,42072,METHODS,METHODS,[249284],[5694],[5702],[False],[0],[0],[False],['0']
41182,PMC7038903,42073,Study design and setting,METHODS|Study design and setting,[249290],[5703],[5727],[False],[0],[0],[False],['0']
41183,PMC7038903,42074,"The design and methods are detailed in the published protocol (Borg et al., 2017) and briefly described here.",METHODS|Study design and setting,[249296],[5728],[5837],[False],[0],[0],[False],['0']
41184,PMC7038903,42075,The trial took place from February to October 2016.,METHODS|Study design and setting,[249302],[5838],[5889],[False],[0],[0],[False],['0']
41185,PMC7038903,42076,"It was a prospective, non‐blinded, cluster randomised controlled trial among infants that were 6 to 11 months of age at inclusion.",METHODS|Study design and setting,[249308],[5890],[6020],[False],[0],[0],[False],['0']
41186,PMC7038903,42077,"It aimed to establish the superiority of the novel RUSF, using CSB++, and MNP as active comparators and the standard diet as a control.",METHODS|Study design and setting,[249314],[6021],[6156],[False],[0],[0],[False],['0']
41187,PMC7038903,42078,"The trial was conducted in peri‐urban Phnom Penh (Mekong Operational District), which has a large population of urban poor.",METHODS|Study design and setting,[249320],[6157],[6280],[False],[0],[0],[False],['0']
41188,PMC7038903,42079,"Peri‐urban children under 5 years experienced higher rates of underweight (36%) and stunting (29%) than the 25% and 19% reported for Phnom Penh, respectively (UNICEF/ PIN, 2014; NIS et al., 2011).",METHODS|Study design and setting,[249326],[6281],[6477],[False],[0],[0],[False],['0']
41189,PMC7038903,42080,"Twenty‐eight sites were allocated to one of the RUSF, CSB++, MNP, or control groups.",METHODS|Study design and setting,[249332],[6478],[6562],[False],[0],[0],[False],['0']
41190,PMC7038903,42081,RUSF formulation,METHODS|RUSF formulation,[249338],[6563],[6579],[False],[0],[0],[False],['0']
41191,PMC7038903,42082,"The RUSF was based on the recommended nutritional guidelines for ready‐to‐use therapeutic foods (Dewey, 2009; FAO/WHO, 2016).",METHODS|RUSF formulation,[249344],[6580],[6705],[False],[0],[0],[False],['0']
41192,PMC7038903,42083,"It was produced locally, using local ingredients including small freshwater fish, soy, mung beans and coconut.",METHODS|RUSF formulation,[249350],[6706],[6816],[False],[0],[0],[False],['0']
41193,PMC7038903,42084,"The RUSF paste was piped into hollow, cylindrical wafers which are a popular Cambodian snack.",METHODS|RUSF formulation,[249356],[6817],[6910],[False],[0],[0],[False],['0']
41194,PMC7038903,42085,"All processing was conducted in certified facilities, and microbiological safety testing was conducted regularly.",METHODS|RUSF formulation,[249362],[6911],[7024],[False],[0],[0],[False],['0']
41195,PMC7038903,42086,"The ingredients of the RUSF and the comparators are detailed in Tables A1 and A2, and in the acceptability and effectiveness protocols (Borg et al., 2017; Borg et al., 2018).",METHODS|RUSF formulation,[249368],[7025],[7199],[False],[0],[0],[False],['0']
41196,PMC7038903,42087,"The RUSF was provided as a medium quantity supplementary food, that is, providing 50‐100% of the child's daily energy requirements (i.e.",METHODS|RUSF formulation,[249374],[7200],[7336],[False],[0],[0],[False],['0']
41197,PMC7038903,42088,"250 to 500 kcal) excluding breastfeeding (Gera, Pena‐Rosas, Boy‐Mena, & Sachdev, 2017).",METHODS|RUSF formulation,[249380],[7337],[7424],[False],[0],[0],[False],['0']
41198,PMC7038903,42089,"This was 40‐110g of RUSF per day, depending on the child's age.",METHODS|RUSF formulation,[249386],[7425],[7488],[False],[0],[0],[False],['0']
41199,PMC7038903,42090,The nutrient profiles of all the supplements were similar in terms of multiple micronutrients.,METHODS|RUSF formulation,[249392],[7489],[7583],[False],[0],[0],[False],['0']
41200,PMC7038903,42091,"The RUSF and CSB++ were similar in terms of energy, protein, carbohydrate, and lipid content.",METHODS|RUSF formulation,[249398],[7584],[7677],[False],[0],[0],[False],['0']
41201,PMC7038903,42092,Outcomes and their measurement,METHODS|Outcomes and their measurement,[249404],[7678],[7708],[False],[0],[0],[False],['0']
41202,PMC7038903,42093,"The main outcomes of interest were anthropometric measures calculated using World Health Organisation (WHO) 2006 standards (ANTHRO version 3.2.2 January 2011) and expressed as z‐scores, namely WAZ, HAZ, and WHZ, along with MUAC in centimetres (cm).",METHODS|Outcomes and their measurement,[249410],[7709],[7957],[False],[0],[0],[False],['0']
41203,PMC7038903,42094,"Data was collected by a dedicated anthropometrist, supported by a dedicated anthropometric data collector, both of whom received initial and follow up training.",METHODS|Outcomes and their measurement,[249416],[7958],[8118],[False],[0],[0],[False],['0']
41204,PMC7038903,42095,Randomisation and allocation concealment,METHODS|Randomisation and allocation concealment,[249422],[8119],[8159],[False],[0],[0],[False],['0']
41205,PMC7038903,42096,Participants were not individually randomised.,METHODS|Randomisation and allocation concealment,[249428],[8160],[8206],[False],[0],[0],[False],['0']
41206,PMC7038903,42097,"Randomisation of the interventions occurred at site level to ensure better compliance by avoiding potentially confounding social interaction, such as inter‐household sharing of different foods (Van Hoan, Van Phu, Salvignol, Berger, & Trèche, 2009).",METHODS|Randomisation and allocation concealment,[249434],[8207],[8455],[False],[0],[0],[False],['0']
41207,PMC7038903,42098,"Using UNICEF data on health centre coverage, potential sites and their populations were listed.",METHODS|Randomisation and allocation concealment,[249440],[8456],[8551],[False],[0],[0],[False],['0']
41208,PMC7038903,42099,"Sites were then randomly allocated to one of the foods, using an Excel random number table and a randomised incomplete block design.",METHODS|Randomisation and allocation concealment,[249446],[8552],[8684],[False],[0],[0],[False],['0']
41209,PMC7038903,42100,The principal researcher generated the allocation sequence.,METHODS|Randomisation and allocation concealment,[249452],[8685],[8744],[False],[0],[0],[False],['0']
41210,PMC7038903,42101,"Seven sites were allocated to each arm, for a total of 28 sites.",METHODS|Randomisation and allocation concealment,[249458],[8745],[8809],[False],[0],[0],[False],['0']
41211,PMC7038903,42102,"One site yielded only one participant, who dropped out, leaving 27 sites at the end of the study.",METHODS|Randomisation and allocation concealment,[249464],[8810],[8907],[False],[0],[0],[False],['0']
41212,PMC7038903,42103,Sample size,METHODS|Sample size,[249470],[8908],[8919],[False],[0],[0],[False],['0']
41213,PMC7038903,42104,"Based on the assumptions of a difference in mean z‐scores of 0.1 between the groups (95%CI), a standard deviation (SD) of 0.8, and of children providing five measurements (out of a possible total of seven), with a precision of 0.05 and power of 0.8, an overall required sample size of 424 children, or 106 children per group, was calculated.",METHODS|Sample size,[249476],[8920],[9261],[False],[0],[0],[False],['0']
41214,PMC7038903,42105,"We assumed an attrition of 25%, for a total sample of 530 or 133 children per group.",METHODS|Sample size,[249482],[9262],[9346],[False],[0],[0],[False],['0']
41215,PMC7038903,42106,"This sample size was comparable to similar effectiveness studies (Jack et al., 2012; Kuusipalo, Maleta, Briend, Manary, & Ashorn, 2006; Lin, Manary, Maleta, Briend, & Ashorn, 2008; Nga et al., 2013; Pham et al., 2012).",METHODS|Sample size,[249488],[9347],[9565],[False],[0],[0],[False],['0']
41216,PMC7038903,42107,"Eligibility criteria, recruitment, enrolment and consent","METHODS|Eligibility criteria, recruitment, enrolment and consent",[249494],[9566],[9622],[False],[0],[0],[False],['0']
41217,PMC7038903,42108,Healthy singletons aged 6 to 11 months were enrolled.,"METHODS|Eligibility criteria, recruitment, enrolment and consent",[249500],[9623],[9676],[False],[0],[0],[False],['0']
41218,PMC7038903,42109,Village health volunteers invited potential caregivers and children to participate.,"METHODS|Eligibility criteria, recruitment, enrolment and consent",[249506],[9677],[9760],[False],[0],[0],[False],['0']
41219,PMC7038903,42110,The data collection team used a screening form to assess initial eligibility (e.g.,"METHODS|Eligibility criteria, recruitment, enrolment and consent",[249512],[9761],[9843],[False],[0],[0],[False],['0']
41220,PMC7038903,42111,"based on age, singleton status, and willingness to participate).","METHODS|Eligibility criteria, recruitment, enrolment and consent",[249518],[9844],[9908],[False],[0],[0],[False],['0']
41221,PMC7038903,42112,"Most caregivers had a birth certificate or immunisation card with the child's date of birth, or if not, they were asked if they knew the child's birthdate or age.","METHODS|Eligibility criteria, recruitment, enrolment and consent",[249524],[9909],[10071],[False],[0],[0],[False],['0']
41222,PMC7038903,42113,"Children who were ill, severely acutely malnourished (WHZ <‐3 and/or MUAC<11.5cm), obese (WHZ >3), severely anaemic (Hb<70g/l), or had known food intolerances, were excluded and referred for treatment as necessary.","METHODS|Eligibility criteria, recruitment, enrolment and consent",[249530],[10072],[10286],[False],[0],[0],[False],['0']
41223,PMC7038903,42114,Caregivers of eligible participants signed or fingerprinted consent for their children to participate.,"METHODS|Eligibility criteria, recruitment, enrolment and consent",[249536],[10287],[10389],[False],[0],[0],[False],['0']
41224,PMC7038903,42115,Data collection,METHODS|Data collection,[249542],[10390],[10405],[False],[0],[0],[False],['0']
41225,PMC7038903,42116,"Baseline data including demographics; morbidity; anthropometric measures; biochemical samples (blood, stool); dietary data; and developmental milestone achievement was collected.",METHODS|Data collection,[249548],[10406],[10584],[False],[0],[0],[False],['0']
41226,PMC7038903,42117,Baseline and monthly follow up data were collected at community sites (e.g.,METHODS|Data collection,[249554],[10585],[10660],[False],[0],[0],[False],['0']
41227,PMC7038903,42118,"health volunteers' homes, pagodas) or health centres by a team of trained data collectors.",METHODS|Data collection,[249560],[10661],[10751],[False],[0],[0],[False],['0']
41228,PMC7038903,42119,Participants in the intervention groups were provided with a 1‐month supply of the food or supplement to which their site had been allocated.,METHODS|Data collection,[249566],[10752],[10893],[False],[0],[0],[False],['0']
41229,PMC7038903,42120,"Thereafter, data collection and food distribution were conducted monthly for 6 months.",METHODS|Data collection,[249572],[10894],[10980],[False],[0],[0],[False],['0']
41230,PMC7038903,42121,"Anthropometric measurements included weight to the nearest 0.1 kg (SECA scale), recumbent length to the nearest 0.1 cm (wooden UNICEF height board), and mid‐upper arm circumference (MUAC) to the nearest 1mm (flexible UNICEF insertion tape).",METHODS|Data collection,[249578],[10981],[11221],[False],[0],[0],[False],['0']
41231,PMC7038903,42122,"Caregivers were given incentives to participate, including cost of transport, and/or a small gift such as a towel or baby item.",METHODS|Data collection,[249584],[11222],[11349],[False],[0],[0],[False],['0']
41232,PMC7038903,42123,Health promotion messaging was not an explicit part of the project.,METHODS|Data collection,[249590],[11350],[11417],[False],[0],[0],[False],['0']
41233,PMC7038903,42124,"Every month, at the end of data collection, all caregivers were reminded to continue if breastfeeding; to feed their baby normally, three to five times daily; and to maintain adequate hygiene (safe stool disposal, handwashing after defaecation and before eating/feeding).",METHODS|Data collection,[249596],[11418],[11689],[False],[0],[0],[False],['0']
41234,PMC7038903,42125,Caregivers in the intervention arms were reminded to feed their baby the supplement or supplementary food in the recommended dosage.,METHODS|Data collection,[249602],[11690],[11822],[False],[0],[0],[False],['0']
41235,PMC7038903,42126,Caregivers in the RUSF and CSB++ groups were reminded that the supplementary foods were an extra snack in addition to regular feeding.,METHODS|Data collection,[249608],[11823],[11957],[False],[0],[0],[False],['0']
41236,PMC7038903,42127,Statistical analysis,METHODS|Statistical analysis,[249614],[11958],[11978],[False],[0],[0],[False],['0']
41237,PMC7038903,42128,Data was analysed in STATA version 13.1.,METHODS|Statistical analysis,[249620],[11979],[12019],[False],[0],[0],[False],['0']
41238,PMC7038903,42129,"Comparisons between food types for children enrolled at baseline (n = 485) were made using one‐way ANOVA for continuous variables (reported as mean and SD), Kruskal‐Wallis rank test for non‐normally distributed continuous variables (reported as median and interquartile range, IQR), and chi‐squared for categorical variables, (reported as n and %).",METHODS|Statistical analysis,[249626],[12020],[12368],[False],[0],[0],[False],['0']
41239,PMC7038903,42130,These results are reported in Table 1.,METHODS|Statistical analysis,[249632],[12369],[12407],[False],[0],[0],[False],['0']
41240,PMC7038903,42131,"Comparisons between baseline and endline anthropometric measures for the different food types for children with baseline and endline data (n = 292) were made using one‐way ANOVA for continuous variables, and Kruskal‐Wallis rank test for continuous variables for which homogeneity of variance was not observed.",METHODS|Statistical analysis,[249638],[12408],[12717],[False],[0],[0],[False],['0']
41241,PMC7038903,42132,"Changes in proportion from baseline to endline (%) were calculated by subtracting baseline proportion from endline proportion, and P‐values were calculated using Pearson's chi‐squared test.",METHODS|Statistical analysis,[249644],[12718],[12907],[False],[0],[0],[False],['0']
41242,PMC7038903,42133,These results are reported in Table 2.,METHODS|Statistical analysis,[249650],[12908],[12946],[False],[0],[0],[False],['0']
41243,PMC7038903,42134,A mixed effects linear regression model was fit for each anthropometric outcome for children who had baseline and endline data to determine whether there were statistically significant differences in the changes in anthropometric outcomes from baseline to endline for the interventions compared to each of the other groups.,METHODS|Statistical analysis,[249656],[12947],[13270],[False],[0],[0],[False],['0']
41244,PMC7038903,42135,"The model adjusted for clustering by person and site, and used month as an interaction term to account for monthly follow‐up measures.",METHODS|Statistical analysis,[249662],[13271],[13405],[False],[0],[0],[False],['0']
41245,PMC7038903,42136,Baseline values were accounted for in the model within each food group.,METHODS|Statistical analysis,[249668],[13406],[13477],[False],[0],[0],[False],['0']
41246,PMC7038903,42137,"The model included parameters for the slope of the line in the control group with respect to time, and the change in the slope between the intervention versus the control group.",METHODS|Statistical analysis,[249674],[13478],[13655],[False],[0],[0],[False],['0']
41247,PMC7038903,42138,"Children who ate less than 75% of the monthly food supplied were considered to have low consumption, while 75% or more was high consumption.",METHODS|Statistical analysis,[249680],[13656],[13796],[False],[0],[0],[False],['0']
41248,PMC7038903,42139,These results are reported in Table 3.,METHODS|Statistical analysis,[249686],[13797],[13835],[False],[0],[0],[False],['0']
41249,PMC7038903,42140,RESULTS,RESULTS,[249692],[13836],[13844],[False],[0],[0],[False],['0']
41250,PMC7038903,42141,"Of 514 children who were screened as eligible, 485 were recruited.",RESULTS,[249698],[13845],[13911],[False],[0],[0],[False],['0']
41251,PMC7038903,42142,"Among 29 children excluded, one was excluded due to food intolerances, one due to severe anaemia, and 27 due to severe acute malnutrition (MUAC <11.5 and/or WHZ < ‐3) or overnutrition (WHZ > 3).",RESULTS,[249704],[13912],[14106],[False],[0],[0],[False],['0']
41252,PMC7038903,42143,Excluded children were referred for treatment as appropriate.,RESULTS,[249710],[14107],[14168],[False],[0],[0],[False],['0']
41253,PMC7038903,42144,See Figure.,RESULTS,[249716],[14169],[14180],[False],[0],[0],[False],['0']
41254,PMC7038903,42145,"1 for the site selection, recruitment and enrolment of children, and trial completion.",RESULTS,[249722],[14181],[14267],[False],[0],[0],[False],['0']
41255,PMC7038903,42146,A total of 192 children (39.7%) did not attend endline.,RESULTS,[249728],[14268],[14323],[False],[0],[0],[False],['0']
41256,PMC7038903,42147,Loss to follow up ranged from 24.5% in the MNP group to 52.0% in the CSB++ group.,RESULTS,[249734],[14324],[14405],[False],[0],[0],[False],['0']
41257,PMC7038903,42148,There were differences in loss to follow up between the groups.,RESULTS,[249740],[14406],[14469],[False],[0],[0],[False],['0']
41258,PMC7038903,42149,"The MNP group had the lowest loss, while the control, CSB++ and RUSF groups had significantly higher loss to follow up.",RESULTS,[249746],[14470],[14589],[False],[0],[0],[False],['0']
41259,PMC7038903,42150,Older children had slightly higher odds of being lost to follow up.,RESULTS,[249752],[14590],[14657],[False],[0],[0],[False],['0']
41260,PMC7038903,42151,"Children whose caregivers had attended high school or higher had lower odds of being lost to follow up, as did children whose family were poor card holders.",RESULTS,[249758],[14658],[14814],[False],[0],[0],[False],['0']
41261,PMC7038903,42152,Details on loss to follow up can be found in Tables A3a and A3b.,RESULTS,[249764],[14815],[14879],[False],[0],[0],[False],['0']
41262,PMC7038903,42153,Baseline characteristics,RESULTS|Baseline characteristics,[249770],[14880],[14904],[False],[0],[0],[False],['0']
41263,PMC7038903,42154,Table 1 describes the baseline characteristics of children and caregivers.,RESULTS|Baseline characteristics,[249776],[14905],[14979],[False],[0],[0],[False],['0']
41264,PMC7038903,42155,"For most characteristics, there were no significant differences between groups.",RESULTS|Baseline characteristics,[249782],[14980],[15059],[False],[0],[0],[False],['0']
41265,PMC7038903,42156,"However, the control and MNP groups had significantly more females.",RESULTS|Baseline characteristics,[249788],[15060],[15127],[False],[0],[0],[False],['0']
41266,PMC7038903,42157,"The CSB++ and MNP groups had significantly lower HAZ at baseline (however, the histogram showed sufficient overlap for the mixed effect model to account for this baseline difference).",RESULTS|Baseline characteristics,[249794],[15128],[15311],[False],[0],[0],[False],['0']
41267,PMC7038903,42158,Infant feeding indicators were poor.,RESULTS|Baseline characteristics,[249800],[15312],[15348],[False],[0],[0],[False],['0']
41268,PMC7038903,42159,"Prevalence of prelacteal feeding was high, but lower than the Phnom Penh prevalence in the 2014 DHS (NIS et al., 2015).",RESULTS|Baseline characteristics,[249806],[15349],[15468],[False],[0],[0],[False],['0']
41269,PMC7038903,42160,"The prevalence of bottle feeding was very high while prevalence of continued breastfeeding at baseline was very low in comparison to the national prevalence (NIS et al., 2015).",RESULTS|Baseline characteristics,[249812],[15469],[15645],[False],[0],[0],[False],['0']
41270,PMC7038903,42161,"Rates of low birthweight (<2.5kg) were high in comparison to the national prevalence (NIS et al., 2015).",RESULTS|Baseline characteristics,[249818],[15646],[15750],[False],[0],[0],[False],['0']
41271,PMC7038903,42162,"Most children were iron replete, i.e.",RESULTS|Baseline characteristics,[249824],[15751],[15788],[False],[0],[0],[False],['0']
41272,PMC7038903,42163,"ferritin concentrations corrected for inflammation ≥ 15μg/L (Thurnham et al., 2010) at baseline.",RESULTS|Baseline characteristics,[249830],[15789],[15885],[False],[0],[0],[False],['0']
41273,PMC7038903,42164,One‐third of children had experienced diarrhoea in the past 2 weeks.,RESULTS|Baseline characteristics,[249836],[15886],[15954],[False],[0],[0],[False],['0']
41274,PMC7038903,42165,Unsafe disposal of children's faeces (left in the open or thrown in a drain or the garbage) was very high and was significantly different between groups.,RESULTS|Baseline characteristics,[249842],[15955],[16108],[False],[0],[0],[False],['0']
41275,PMC7038903,42166,Anthropometric outcomes,RESULTS|Anthropometric outcomes,[249848],[16109],[16132],[False],[0],[0],[False],['0']
41276,PMC7038903,42167,Table 2 shows the change in anthropometric measures from baseline to endline for children with baseline and endline measurements (n = 292).,RESULTS|Anthropometric outcomes,[249854],[16133],[16272],[False],[0],[0],[False],['0']
41277,PMC7038903,42168,There were no statistically significant differences between the groups for any of the anthropometric changes.,RESULTS|Anthropometric outcomes,[249860],[16273],[16382],[False],[0],[0],[False],['0']
41278,PMC7038903,42169,Mean height increased between 6.4‐6.7cm for all groups.,RESULTS|Anthropometric outcomes,[249866],[16383],[16438],[False],[0],[0],[False],['0']
41279,PMC7038903,42170,Mean weight increased between 1.20 and 1.30kg for all groups.,RESULTS|Anthropometric outcomes,[249872],[16439],[16500],[False],[0],[0],[False],['0']
41280,PMC7038903,42171,"Mean WAZ, HAZ and WHZ decreased overall and for each group.",RESULTS|Anthropometric outcomes,[249878],[16501],[16560],[False],[0],[0],[False],['0']
41281,PMC7038903,42172,Mean MUAC increased overall and for each group.,RESULTS|Anthropometric outcomes,[249884],[16561],[16608],[False],[0],[0],[False],['0']
41282,PMC7038903,42173,"The proportion of children underweight at endline was variable; it was unchanged in the RUSF group, increased in the CSB++ and MNP groups, and decreased in the control group.",RESULTS|Anthropometric outcomes,[249890],[16609],[16783],[False],[0],[0],[False],['0']
41283,PMC7038903,42174,The proportions of children stunted and wasted increased in all groups.,RESULTS|Anthropometric outcomes,[249896],[16784],[16855],[False],[0],[0],[False],['0']
41284,PMC7038903,42175,"The proportion of children with low MUAC at endline compared with baseline decreased for the RUSF group, whereas for the other groups it increased or remained unchanged.",RESULTS|Anthropometric outcomes,[249902],[16856],[17025],[False],[0],[0],[False],['0']
41285,PMC7038903,42176,There were no statistically significant differences between any of the changes in anthropometric measures.,RESULTS|Anthropometric outcomes,[249908],[17026],[17132],[False],[0],[0],[False],['0']
41286,PMC7038903,42177,Figure A1 graphs the change in monthly mean anthropometric measures from baseline to endline.,RESULTS|Anthropometric outcomes,[249914],[17133],[17226],[False],[0],[0],[False],['0']
41287,PMC7038903,42178,A linear mixed effects model that took into account measures at each follow‐up was fitted for each anthropometric measure.,RESULTS|Anthropometric outcomes,[249920],[17227],[17349],[False],[0],[0],[False],['0']
41288,PMC7038903,42179,The results of these models are shown in Table 3.,RESULTS|Anthropometric outcomes,[249926],[17350],[17399],[False],[0],[0],[False],['0']
41289,PMC7038903,42180,"In unadjusted analysis, the control group had statistically significantly decreased WAZ and HAZ, and increased MUAC, but no statistically significant changes in WHZ.",RESULTS|Anthropometric outcomes,[249932],[17400],[17565],[False],[0],[0],[False],['0']
41290,PMC7038903,42181,The RUSF group did not differ significantly from the control for WAZ or HAZ but had increased MUAC in comparison to the control.,RESULTS|Anthropometric outcomes,[249938],[17566],[17694],[False],[0],[0],[False],['0']
41291,PMC7038903,42182,"There were no statistically significant differences between the RUSF group and the CSB++ or MNP groups with respect to WAZ, HAZ, WHZ or MUAC.",RESULTS|Anthropometric outcomes,[249944],[17695],[17836],[False],[0],[0],[False],['0']
41292,PMC7038903,42183,"The CSB++ group did not differ significantly from the control for WAZ, HAZ or WHZ, but had a statistically significantly increased MUAC.",RESULTS|Anthropometric outcomes,[249950],[17837],[17973],[False],[0],[0],[False],['0']
41293,PMC7038903,42184,"The MNP group did not differ significantly from any group for WAZ, HAZ, WHZ or MUAC.",RESULTS|Anthropometric outcomes,[249956],[17974],[18058],[False],[0],[0],[False],['0']
41294,PMC7038903,42185,"In the adjusted model, missing data in the covariates resulted in a smaller n (n = 235).",RESULTS|Anthropometric outcomes,[249962],[18059],[18147],[False],[0],[0],[False],['0']
41295,PMC7038903,42186,"The control group (Month) had statistically significantly decreased WAZ, HAZ, and WHZ, and no statistically significant change in MUAC.",RESULTS|Anthropometric outcomes,[249968],[18148],[18283],[False],[0],[0],[False],['0']
41296,PMC7038903,42187,"High consumers of RUSF did not differ significantly from the control for WAZ, HAZ or WHZ, but had statistically significantly increased MUAC.",RESULTS|Anthropometric outcomes,[249974],[18284],[18425],[False],[0],[0],[False],['0']
41297,PMC7038903,42188,"There were no significant differences between high consumers of RUSF and the CSB++ or MNP groups with respect to WAZ, HAZ, WHZ or MUAC.",RESULTS|Anthropometric outcomes,[249980],[18426],[18561],[False],[0],[0],[False],['0']
41298,PMC7038903,42189,"In comparison to the control, low consumers of RUSF had statistically significantly increased WAZ, WHZ and MUAC, but no statistically significant difference in HAZ.",RESULTS|Anthropometric outcomes,[249986],[18562],[18726],[False],[0],[0],[False],['0']
41299,PMC7038903,42190,"In comparison to the CSB++ group, low consumers of RUSF had statistically significantly increased HAZ, but no differences in other anthropometric measures.",RESULTS|Anthropometric outcomes,[249992],[18727],[18882],[False],[0],[0],[False],['0']
41300,PMC7038903,42191,There were no statistically significant differences between low consumers of RUSF and the MNP group.,RESULTS|Anthropometric outcomes,[249998],[18883],[18983],[False],[0],[0],[False],['0']
41301,PMC7038903,42192,"High consumers of CSB++ had statistically significantly increased WAZ, WHZ and MUAC in comparison to the control group, increased WHZ in comparison to the RUSF group, and increased WAZ and WHZ in comparison to the MNP group.",RESULTS|Anthropometric outcomes,[250004],[18984],[19208],[False],[0],[0],[False],['0']
41302,PMC7038903,42193,"Low consumers of CSB++ had statistically significantly increased WHZ and MUAC in comparison to the control, but decreased HAZ in comparison to all groups.",RESULTS|Anthropometric outcomes,[250010],[19209],[19363],[False],[0],[0],[False],['0']
41303,PMC7038903,42194,High consumers of MNP had statistically significantly increased WAZ and MUAC in comparison to the control.,RESULTS|Anthropometric outcomes,[250016],[19364],[19470],[False],[0],[0],[False],['0']
41304,PMC7038903,42195,Low consumers of MNP had no significant differences to the control for any anthropometric outcome but had decreased WAZ and WHZ in comparison to the RUSF and CSB++ groups.,RESULTS|Anthropometric outcomes,[250022],[19471],[19642],[False],[0],[0],[False],['0']
41305,PMC7038903,42196,"Sex, birthweight, iron status, and diarrhoea significantly affected anthropometric status.",RESULTS|Anthropometric outcomes,[250028],[19643],[19733],[False],[0],[0],[False],['0']
41306,PMC7038903,42197,Bottle feeding and maternal body mass index (BMI) were also significant.,RESULTS|Anthropometric outcomes,[250034],[19734],[19806],[False],[0],[0],[False],['0']
41307,PMC7038903,42198,"Age at baseline, iron repleteness at baseline, prelacteal feeding, cessation of exclusive breastfeeding before 3 months, age of commencing complementary feeding, continued breastfeeding, dietary diversity, caregiver's education, and living in a household that holds a poor card or shares a toilet did not have a significant effect on anthropometric outcomes.",RESULTS|Anthropometric outcomes,[250040],[19807],[20165],[False],[0],[0],[False],['0']
41308,PMC7038903,42199,DISCUSSION,DISCUSSION,[250046],[20166],[20177],[False],[0],[0],[False],['0']
41309,PMC7038903,42200,"In our trial, a locally produced, fish‐based RUSF slowed but did not prevent ponderal growth faltering in Cambodian children aged between 6 and 17 months.",DISCUSSION,[250052],[20178],[20332],[False],[0],[0],[False],['0']
41310,PMC7038903,42201,"However, the impact was of limited clinical significance.",DISCUSSION,[250058],[20333],[20390],[False],[0],[0],[False],['0']
41311,PMC7038903,42202,The RUSF did not prevent linear growth faltering.,DISCUSSION,[250064],[20391],[20440],[False],[0],[0],[False],['0']
41312,PMC7038903,42203,"Nor did CSB++ and MNP prevent growth faltering, or slow it to any clinically significant extent.",DISCUSSION,[250070],[20441],[20537],[False],[0],[0],[False],['0']
41313,PMC7038903,42204,"This is consistent with studies elsewhere and in Cambodia, which have demonstrated the difficulty in preventing undernutrition in a representative population with moderately acutely malnourished (MAM) and non‐MAM children using specialised products.",DISCUSSION,[250076],[20538],[20787],[False],[0],[0],[False],['0']
41314,PMC7038903,42205,"Few trials in a representative, food secure population",DISCUSSION,[250082],[20788],[20842],[False],[0],[0],[False],['0']
41315,PMC7038903,42206,"Despite the consensus that prevention is essential, most specialised foods have been tested with MAM children (WHZ ‐3 to ‐2, and/or MUAC 11.5 to 12.5cm).",DISCUSSION,[250088],[20843],[20996],[False],[0],[0],[False],['0']
41316,PMC7038903,42207,"Few prevention studies exist (Kennedy, Branca, Webb, Bhutta, & Brown, 2015), especially with non‐MAM children receiving a preventative specialised food in comparison to an unsupplemented control group.",DISCUSSION,[250094],[20997],[21198],[False],[0],[0],[False],['0']
41317,PMC7038903,42208,"The children in our study ranged from MAM to overweight, i.e.",DISCUSSION,[250100],[21199],[21260],[False],[0],[0],[False],['0']
41318,PMC7038903,42209,"WHZ 2 to 3 (WHO, 2006).",DISCUSSION,[250106],[21261],[21284],[False],[0],[0],[False],['0']
41319,PMC7038903,42210,"In Cambodia, as in most countries, there is no treatment of children with MAM.",DISCUSSION,[250112],[21285],[21363],[False],[0],[0],[False],['0']
41320,PMC7038903,42211,"Our sample of children had a similar prevalence of MAM as the general population of Cambodian children aged 6 to 17 months (NIS et al., 2015).",DISCUSSION,[250118],[21364],[21506],[False],[0],[0],[False],['0']
41321,PMC7038903,42212,"It can therefore be considered representative of the general population that might be targeted for undernutrition prevention programming, in that this population includes some moderately acutely malnourished children and mostly children that range from WHZ >‐2 to <3 with MUAC > 12.5cm.",DISCUSSION,[250124],[21507],[21793],[False],[0],[0],[False],['0']
41322,PMC7038903,42213,This is not to say that the results can be generalised.,DISCUSSION,[250130],[21794],[21849],[False],[0],[0],[False],['0']
41323,PMC7038903,42214,"One systematic review used the concept of food security and by their definition (Lassi, Das, Zahid, Imdad, & Bhutta, 2013), our population could be considered to be in a food secure, non‐emergency context.",DISCUSSION,[250136],[21850],[22055],[False],[0],[0],[False],['0']
41324,PMC7038903,42215,Do specialised products prevent undernutrition?,DISCUSSION|Do specialised products prevent undernutrition?,[250142],[22056],[22103],[False],[0],[0],[False],['0']
41325,PMC7038903,42216,"In our trial, specialised products had limited effect on reducing growth faltering, as seen in Tables 2 and 3.",DISCUSSION|Do specialised products prevent undernutrition?,[250148],[22104],[22214],[False],[0],[0],[False],['0']
41326,PMC7038903,42217,"To some extent, all the specialised products in our trial, especially the RUSF and CSB++ protected against ponderal growth faltering, but none protected against linear growth faltering.",DISCUSSION|Do specialised products prevent undernutrition?,[250154],[22215],[22400],[False],[0],[0],[False],['0']
41327,PMC7038903,42218,"The RUSF afforded more protection than MNP, but not more than CSB++.",DISCUSSION|Do specialised products prevent undernutrition?,[250160],[22401],[22469],[False],[0],[0],[False],['0']
41328,PMC7038903,42219,"In comparable trials, the impact of supplementary feeding on undernutrition has often been similarly slight, mixed, or nonsignificant.",DISCUSSION|Do specialised products prevent undernutrition?,[250166],[22470],[22604],[False],[0],[0],[False],['0']
41329,PMC7038903,42220,"In those trials, WAZ, WHZ and MUAC usually increased for at least one of the intervention groups, whereas HAZ was less likely to improve and sometimes declined (Dewey & Adu‐Afarwuah, 2008; Iannotti et al., 2014; Lin et al., 2008; Lutter et al., 2008; Ruel et al., 2008; Sguassero, de Onis, Bonotti, & Carroli, 2012; Skau et al., 2015; Thakwalakwa et al., 2012; Tomedi et al., 2012).",DISCUSSION|Do specialised products prevent undernutrition?,[250172],[22605],[22987],[False],[0],[0],[False],['0']
41330,PMC7038903,42221,"One study, like ours, found HAZ decreased more for the CSB++ group than for the control (Mangani et al., 2015).",DISCUSSION|Do specialised products prevent undernutrition?,[250178],[22988],[23099],[False],[0],[0],[False],['0']
41331,PMC7038903,42222,"However, it is worth noting that HAZ was already significantly lower in the CSB++ group at baseline.",DISCUSSION|Do specialised products prevent undernutrition?,[250184],[23100],[23200],[False],[0],[0],[False],['0']
41332,PMC7038903,42223,"Therefore, most interventions providing supplements or specialised foods did not prevent stunting, and some did not even prevent wasting.",DISCUSSION|Do specialised products prevent undernutrition?,[250190],[23201],[23338],[False],[0],[0],[False],['0']
41333,PMC7038903,42224,"Hence, that the interventions in our study did not prevent growth faltering, and only had a small impact on anthropometry in comparison to the control was not unprecedented.",DISCUSSION|Do specialised products prevent undernutrition?,[250196],[23339],[23512],[False],[0],[0],[False],['0']
41334,PMC7038903,42225,"A forthcoming Cochrane Review (see the protocol by Das, Salam, Weise Prinzo, Sadiq Sheikh, & Bhutta, 2017) will assess the effects of preventive lipid‐based nutrient supplements given with complementary foods to infants and young children.",DISCUSSION|Do specialised products prevent undernutrition?,[250202],[23513],[23752],[False],[0],[0],[False],['0']
41335,PMC7038903,42226,This will contribute greatly to the understanding of the effects of specially formulated supplementary foods.,DISCUSSION|Do specialised products prevent undernutrition?,[250208],[23753],[23862],[False],[0],[0],[False],['0']
41336,PMC7038903,42227,Diarrhoea,DISCUSSION|Diarrhoea,[250214],[23863],[23872],[False],[0],[0],[False],['0']
41337,PMC7038903,42228,One possible explanation for the continued growth faltering observed in our study is that the nutrients from both the standard diet and the interventions provided may not have been well absorbed.,DISCUSSION|Diarrhoea,[250220],[23873],[24068],[False],[0],[0],[False],['0']
41338,PMC7038903,42229,"Children who had had diarrhoea in the past 2 weekshad decreased WAZ, WHZ and MUAC.",DISCUSSION|Diarrhoea,[250226],[24069],[24151],[False],[0],[0],[False],['0']
41339,PMC7038903,42230,"The prevalence of diarrhoea in our study population (32% overall) was much higher than the prevalence of diarrhoea in children under 5 years in Phnom Penh (17%) or nationally to children aged 6 to 11 months or twelve to 23 months (20% and 19%, respectively).",DISCUSSION|Diarrhoea,[250232],[24152],[24410],[False],[0],[0],[False],['0']
41340,PMC7038903,42231,"However, it was similar to the prevalence of diarrhoea (40% of children under 5 years) in a comparable survey amongst urban poor in Phnom Penh (UNICEF/PIN , 2014).",DISCUSSION|Diarrhoea,[250238],[24411],[24574],[False],[0],[0],[False],['0']
41341,PMC7038903,42232,"Thus, high rates of diarrhoea may have contributed to continued growth faltering.",DISCUSSION|Diarrhoea,[250244],[24575],[24656],[False],[0],[0],[False],['0']
41342,PMC7038903,42233,"Unsafe stool disposal was common, and may contribute to high rates of diarrhoea.",DISCUSSION|Diarrhoea,[250250],[24657],[24737],[False],[0],[0],[False],['0']
41343,PMC7038903,42234,Sex,DISCUSSION|Sex,[250256],[24738],[24741],[False],[0],[0],[False],['0']
41344,PMC7038903,42235,Another explanation may be related to sex.,DISCUSSION|Sex,[250262],[24742],[24784],[False],[0],[0],[False],['0']
41345,PMC7038903,42236,"In our trial, female children had increased WAZ, HAZ and WHZ compared with male children.",DISCUSSION|Sex,[250268],[24785],[24874],[False],[0],[0],[False],['0']
41346,PMC7038903,42237,The control and MNP groups had significantly more females.,DISCUSSION|Sex,[250274],[24875],[24933],[False],[0],[0],[False],['0']
41347,PMC7038903,42238,"Since gender has been found to have a differential impact on MUAC and WHZ, particularly in the presence of stunting (Fiorentino et al., 2016; Wieringa et al., 2018), this may explain why a greater difference was not seen between the outcomes for the RUSF and CSB++ groups compared with the control and MNP groups.",DISCUSSION|Sex,[250280],[24934],[25247],[False],[0],[0],[False],['0']
41348,PMC7038903,42239,Potential displacement of breastmilk and food,DISCUSSION|Sex,[250286],[25248],[25293],[False],[0],[0],[False],['0']
41349,PMC7038903,42240,"Another possible explanation for the lack of effect on prevention of growth faltering may be that RUSF and CSB++ may have displaced children's normal intake of food and breastmilk rather than actually supplementing the existing diet (Dewey & Adu‐Afarwuah, 2008; Mangani et al., 2015).",DISCUSSION|Sex,[250292],[25294],[25578],[False],[0],[0],[False],['0']
41350,PMC7038903,42241,"The quantities of RUSF and CSB++ given in our study (between 40‐110g/day) were relatively large and could conceivably have displaced breastmilk and other family foods (Dewey & Arimond, 2012).",DISCUSSION|Sex,[250298],[25579],[25770],[False],[0],[0],[False],['0']
41351,PMC7038903,42242,"However, analysis thus far on the displacement of breastmilk and family food does not reveal any difference between dietary intakes across the groups (see Table A4).",DISCUSSION|Sex,[250304],[25771],[25936],[False],[0],[0],[False],['0']
41352,PMC7038903,42243,Other explanations for growth faltering,DISCUSSION|Other explanations for growth faltering,[250310],[25937],[25976],[False],[0],[0],[False],['0']
41353,PMC7038903,42244,"In our trial, children with higher birthweight had significantly greater increase in WAZ, HAZ, WHZ and MUAC from baseline to endline.",DISCUSSION|Other explanations for growth faltering,[250316],[25977],[26110],[False],[0],[0],[False],['0']
41354,PMC7038903,42245,Children of underweight mothers (BMI < 18.5 at baseline) had decreased WHZ.,DISCUSSION|Other explanations for growth faltering,[250322],[26111],[26186],[False],[0],[0],[False],['0']
41355,PMC7038903,42246,This highlights the multifactorial causes of child undernutrition.,DISCUSSION|Other explanations for growth faltering,[250328],[26187],[26253],[False],[0],[0],[False],['0']
41356,PMC7038903,42247,"Additional factors, including birthweight, maternal BMI, iron status, and diarrhoea which contribute to poor anthropometric outcomes, must be taken into consideration, along with interventions to address them, such as maternal supplementation and adequate antenatal care, delayed cord clamping, and diarrhoeal prevention and treatment (Bhutta et al., 2013).",DISCUSSION|Other explanations for growth faltering,[250334],[26254],[26611],[False],[0],[0],[False],['0']
41357,PMC7038903,42248,Non‐milk animal source foods,DISCUSSION|Non‐milk animal source foods,[250340],[26612],[26640],[False],[0],[0],[False],['0']
41358,PMC7038903,42249,"Daily consumption of animal‐source foods is recommended for providing the protein, energy, and micronutrients needed for healthy micronutrient status, linear and ponderal growth (Manary, 2012; Michaelsen, Grummer‐Strawn, & Begin, 2017; Neumann et al., 2013; PAHO/WHO, 2002).",DISCUSSION|Non‐milk animal source foods,[250346],[26641],[26915],[False],[0],[0],[False],['0']
41359,PMC7038903,42250,"Most RUFs use milk or whey; non‐milk supplementary foods using meat, fish or eggs have rarely been compared with milk‐based products (Anderson, Bediako‐Amoa, & Steiner‐Asiedu, 2014; Bogard et al., 2015; Gera et al., 2017; Kuusipalo et al., 2006; Pachón, Domínguez, Creed‐Kanashiro, & Stoltzfus, 2007; Skau et al., 2014).",DISCUSSION|Non‐milk animal source foods,[250352],[26916],[27236],[False],[0],[0],[False],['0']
41360,PMC7038903,42251,"However, the evidence on whether milk or other animal source foods are more effective in preventing undernutrition is mixed.",DISCUSSION|Non‐milk animal source foods,[250358],[27237],[27361],[False],[0],[0],[False],['0']
41361,PMC7038903,42252,Two efficacy studies have involved fish‐based supplementary foods.,DISCUSSION|Non‐milk animal source foods,[250364],[27362],[27428],[False],[0],[0],[False],['0']
41362,PMC7038903,42253,"In Malawi, a study comparing a corn porridge fortified with fish powder to a peanut/soy spread found that children had similar linear and ponderal growth (Lin et al., 2008).",DISCUSSION|Non‐milk animal source foods,[250370],[27429],[27602],[False],[0],[0],[False],['0']
41363,PMC7038903,42254,"In Cambodia, Winfood, based on rice and fish, was compared with CSB++ (containing milk) and CSB+ (containing no milk).",DISCUSSION|Non‐milk animal source foods,[250376],[27603],[27721],[False],[0],[0],[False],['0']
41364,PMC7038903,42255,"Both Winfood and CSB++ promoted linear growth better than CSB+ (Skau et al., 2015).",DISCUSSION|Non‐milk animal source foods,[250382],[27722],[27805],[False],[0],[0],[False],['0']
41365,PMC7038903,42256,"One study that compared milk and meat found meat had a greater impact (Grillenberger et al., 2003).",DISCUSSION|Non‐milk animal source foods,[250388],[27806],[27905],[False],[0],[0],[False],['0']
41366,PMC7038903,42257,"In our trial, both the fish‐based RUSF and the milk‐based CSB++ provided some protection against ponderal growth faltering, demonstrating that fish has the potential to replace milk in specialised foods.",DISCUSSION|Non‐milk animal source foods,[250394],[27906],[28109],[False],[0],[0],[False],['0']
41367,PMC7038903,42258,Micronutrients and macronutrients,DISCUSSION|Micronutrients and macronutrients,[250400],[28110],[28143],[False],[0],[0],[False],['0']
41368,PMC7038903,42259,"Our study is consistent with trials that found that in the absence of adequate macronutrients, micronutrients alone do not contribute to growth (Adu‐Afarwuah et al., 2007; Dewey & Adu‐Afarwuah, 2008; Dewey, Yang, & Boy, 2009; Imdad, Sadiq, & Bhutta, 2011; Jack et al., 2012; Rivera & Habicht, 2002; Zlotkin, 2009).",DISCUSSION|Micronutrients and macronutrients,[250406],[28144],[28458],[False],[0],[0],[False],['0']
41369,PMC7038903,42260,Children in the high consuming MNP group had increased WAZ and MUAC compared with the control in a similar magnitude to the RUSF and CSB++ groups.,DISCUSSION|Micronutrients and macronutrients,[250412],[28459],[28605],[False],[0],[0],[False],['0']
41370,PMC7038903,42261,"Low consumers of MNP had no significant differences to the control for any anthropometric outcome, and had poorer outcomes for WAZ, HAZ and WHZ than children in the RUSF and CSB++ groups.",DISCUSSION|Micronutrients and macronutrients,[250418],[28606],[28793],[False],[0],[0],[False],['0']
41371,PMC7038903,42262,"Since MNP is added to food, these results may be interpreted as children who are high consumers of MNP actually eating more food, thus receiving the necessary macronutrients along with the MNP micronutrients.",DISCUSSION|Micronutrients and macronutrients,[250424],[28794],[29002],[False],[0],[0],[False],['0']
41372,PMC7038903,42263,High and low consumption,DISCUSSION|High and low consumption,[250430],[29003],[29027],[False],[0],[0],[False],['0']
41373,PMC7038903,42264,"In our trial, low rather than high consumers of RUSF experienced a protective effect against faltering of WAZ, WHZ and MUAC.",DISCUSSION|High and low consumption,[250436],[29028],[29152],[False],[0],[0],[False],['0']
41374,PMC7038903,42265,"This suggests that the RUSF, even in small quantities, actually supplements the existing diet as intended.",DISCUSSION|High and low consumption,[250442],[29153],[29259],[False],[0],[0],[False],['0']
41375,PMC7038903,42266,"Other researchers who have worked on small quantity LNSs (20‐50g/day) have found that in small quantities, LNSs may improve growth (Dewey et al., 2017; Hess et al., 2015).",DISCUSSION|High and low consumption,[250448],[29260],[29431],[False],[0],[0],[False],['0']
41376,PMC7038903,42267,"They may also improve appetite (Arimond et al., 2015; Lesorogol, Jean‐Louis, Green, & Iannotti, 2015), something which caregivers in our acceptability trial remarked upon (Borg et al., 2018).",DISCUSSION|High and low consumption,[250454],[29432],[29623],[False],[0],[0],[False],['0']
41377,PMC7038903,42268,This finding warrants a trial of the RUSF in small quantities.,DISCUSSION|High and low consumption,[250460],[29624],[29686],[False],[0],[0],[False],['0']
41378,PMC7038903,42269,"That most plausible interpretation of the increased weight‐related anthropometric measures (WAZ, WHZ and MUAC) among high consumers of CSB++ and MNP in comparison to the control group is that high consumers are eating more food generally.",DISCUSSION|High and low consumption,[250466],[29687],[29925],[False],[0],[0],[False],['0']
41379,PMC7038903,42270,Hence it would be expected that their growth would falter less than the control group.,DISCUSSION|High and low consumption,[250472],[29926],[30012],[False],[0],[0],[False],['0']
41380,PMC7038903,42271,Strengths and limitations,DISCUSSION|Strengths and limitations,[250478],[30013],[30038],[False],[0],[0],[False],['0']
41381,PMC7038903,42272,This study had two main strengths.,DISCUSSION|Strengths and limitations,[250484],[30039],[30073],[False],[0],[0],[False],['0']
41382,PMC7038903,42273,"First, this is one of few undernutrition prevention trials that has compared a novel specially formulated supplementary food to an unsupplemented control group, as well as to CSB++ and MNP which are widely used specialised products.",DISCUSSION|Strengths and limitations,[250490],[30074],[30306],[False],[0],[0],[False],['0']
41383,PMC7038903,42274,Use of an unsupplemented control enables the assessment of the clinical and programmatic significance of the results.,DISCUSSION|Strengths and limitations,[250496],[30307],[30424],[False],[0],[0],[False],['0']
41384,PMC7038903,42275,"It informs programming, by making it possible to compare the provision of specialised products to no intervention (Gera et al., 2017).",DISCUSSION|Strengths and limitations,[250502],[30425],[30559],[False],[0],[0],[False],['0']
41385,PMC7038903,42276,"Second, our study generated much needed evidence in a geographic and social context other than Africa (Gera et al., 2017; Kennedy et al., 2015; Lazzerini et al., 2013).",DISCUSSION|Strengths and limitations,[250508],[30560],[30728],[False],[0],[0],[False],['0']
41386,PMC7038903,42277,There are four main limitations of this trial.,DISCUSSION|Strengths and limitations,[250514],[30729],[30775],[False],[0],[0],[False],['0']
41387,PMC7038903,42278,"First, the high and differential loss to follow up may have introduced bias.",DISCUSSION|Strengths and limitations,"[250520, 250521]","[30776, 30776]","[30852, 30852]","[True, True]","['HighLossToFollowUp', 'UnbalancedDropout']","['high loss to follow up', 'differential loss to follow up']","[True, True]",['MissingData']
41388,PMC7038903,42279,"Second, self‐reporting on compliance favours over‐reporting of consumption, which may lead to underestimation of effectiveness.",DISCUSSION|Strengths and limitations,[250534],[30853],[30980],[True],['PrecisionOfMeasurement'],['self‐reporting on compliance'],[True],['OutcomeMeasures']
41389,PMC7038903,42280,"Third, our findings may not be generalisable to non‐urban Cambodian populations.",DISCUSSION|Strengths and limitations,"[250547, 250548]","[30981, 30981]","[31061, 31061]","[True, True]","['Generalization', 'VerySpecificPopulation']","['our findings may not be generalisable', 'non‐urban Cambodian populations']","[True, True]","['Generalization', 'Population']"
41390,PMC7038903,42281,"Since rural areas of Cambodia experience higher levels of undernutrition and poorer infant and young child feeding practices (NIS et al., 2015), it would be difficult to predict if the interventions would appear more or less effective.",DISCUSSION|Strengths and limitations,[250556],[31062],[31297],[False],[0],[0],[False],['0']
41391,PMC7038903,42282,"Finally, subgroup analysis of the effect of the specialised products specifically on MAM children was not undertaken due to low sample size.",DISCUSSION|Strengths and limitations,[250567],[31298],[31438],[True],['SampleSize'],['low sample size'],[True],['UnderpoweredStudy']
41392,PMC7038903,42283,CONCLUSION,CONCLUSION,[250574],[31439],[31450],[False],[0],[0],[False],['0']
41393,PMC7038903,42284,"Our trial contributes to the limited literature on the supplementation of a population sample of children in a food secure, non‐emergency setting.",CONCLUSION,[250580],[31451],[31597],[False],[0],[0],[False],['0']
41394,PMC7038903,42285,"This makes it useful for programming, which has had to rely on findings from studies that focus specifically on MAM children or food insecure settings.",CONCLUSION,[250586],[31598],[31749],[False],[0],[0],[False],['0']
41395,PMC7038903,42286,"In this trial, the most important finding is that the locally produced, fish‐based RUSF, consumed in small quantities, was superior to a standard diet.",CONCLUSION,[250592],[31750],[31901],[False],[0],[0],[False],['0']
41396,PMC7038903,42287,"In small quantities, the RUSF protected against the wasting and underweight seen in the control group, with improved outcomes for WAZ, WHZ and MUAC.",CONCLUSION,[250598],[31902],[32050],[False],[0],[0],[False],['0']
41397,PMC7038903,42288,"However, the magnitude of improvements was of limited clinical significance",CONCLUSION,[250604],[32051],[32126],[False],[0],[0],[False],['0']
41398,PMC7038903,42289,There were few significant differences between the RUSF and the CSB++ or MNP groups.,CONCLUSION,[250610],[32127],[32211],[False],[0],[0],[False],['0']
41399,PMC7038903,42290,None of the specialised products protected against stunting.,CONCLUSION,[250616],[32212],[32272],[False],[0],[0],[False],['0']
41400,PMC7038903,42291,The RUSF was not superior to CSB++.,CONCLUSION,[250622],[32273],[32308],[False],[0],[0],[False],['0']
41401,PMC7038903,42292,"Both the RUSF and CSB++ groups performed better than low consumers of MNP, which confirms earlier findings that micronutrients in the absence of macronutrients do not improve growth.",CONCLUSION,[250628],[32309],[32491],[False],[0],[0],[False],['0']
41402,PMC7038903,42293,"However, once again, the magnitude of improvements was of limited clinical significance.",CONCLUSION,[250634],[32492],[32580],[False],[0],[0],[False],['0']
41403,PMC7038903,42294,"Further research is warranted to explore the potential role, if any, of supplements and specially formulated supplementary foods in preventing undernutrition in a representative population of Cambodian children.",CONCLUSION,[250640],[32581],[32792],[False],[0],[0],[False],['0']
41404,PMC7038903,42295,"With respect to the RUSF, future trials with MAM children, and with small quantities of the RUSF may be warranted.",CONCLUSION,[250646],[32793],[32907],[False],[0],[0],[False],['0']
41405,PMC7038903,42296,"All future studies should include a control with a standard, unsupplemented diet.",CONCLUSION,[250652],[32908],[32989],[False],[0],[0],[False],['0']
41406,PMC7038903,42297,Programming for the prevention of childhood undernutrition in Cambodia will need to consider other approaches and address additional important factors.,CONCLUSION,[250658],[32990],[33141],[False],[0],[0],[False],['0']
41407,PMC7038903,42298,These findings should assist programmers in selecting nutrition interventions.,CONCLUSION,[250664],[33142],[33220],[False],[0],[0],[False],['0']
41408,PMC7038903,42299,CONFLICTS OF INTEREST,CONFLICTS OF INTEREST,[250670],[33221],[33243],[False],[0],[0],[False],['0']
41409,PMC7038903,42300,The authors declare that they have no conflicts of interest.,CONFLICTS OF INTEREST,[250676],[33244],[33304],[False],[0],[0],[False],['0']
41410,PMC7038903,42301,ETHICAL STATEMENT,ETHICAL STATEMENT,[250682],[33305],[33323],[False],[0],[0],[False],['0']
41411,PMC7038903,42302,Ethics approval was received from the University of Queensland Medical Research Ethics Committee (2014001070) and from Cambodia's National Ethics Committee for Health Research (402 NECHR).,ETHICAL STATEMENT,[250688],[33324],[33512],[False],[0],[0],[False],['0']
41412,PMC7038903,42303,CONTRIBUTIONS,CONTRIBUTIONS,[250694],[33513],[33527],[False],[0],[0],[False],['0']
41413,PMC7038903,42304,"BB developed the research protocol, trial design, and questionnaires, and refined these with FTW, SM, MG, DS, CC, JB, AL and NR.",CONTRIBUTIONS,[250700],[33528],[33656],[False],[0],[0],[False],['0']
41414,PMC7038903,42305,AL and FTW secured funding.,CONTRIBUTIONS,[250706],[33657],[33684],[False],[0],[0],[False],['0']
41415,PMC7038903,42306,BB managed data collection with DS.,CONTRIBUTIONS,[250712],[33685],[33720],[False],[0],[0],[False],['0']
41416,PMC7038903,42307,BB conducted the statistical analysis with support from MG. BB wrote the manuscript and all authors subsequently commented on the manuscript and approved the final version.,CONTRIBUTIONS,[250718],[33721],[33893],[False],[0],[0],[False],['0']
41417,PMC7038903,42308,CLINICAL TRIAL NUMBER,CLINICAL TRIAL NUMBER,[250724],[33894],[33916],[False],[0],[0],[False],['0']
41418,PMC7038903,42309," http://ClinicalTrials.gov, Identifier: LNS‐CAMB‐INFANTS‐EFF; NCT02257762.",CLINICAL TRIAL NUMBER,[250730],[33917],[33991],[False],[0],[0],[False],['0']
41419,PMC7038903,42310,DATA SHARING,DATA SHARING,[250736],[33992],[34005],[False],[0],[0],[False],['0']
41420,PMC7038903,42311,"The datasets generated and/or analysed during the current study will be made available from the corresponding author after the publication of all major outputs, upon reasonable request.",DATA SHARING,[250742],[34006],[34191],[False],[0],[0],[False],['0']
41421,PMC7939944,39884,Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial,Title,[232147],[32782],[130],[False],[0],[0],[False],['0']
41422,PMC7939944,39885,Background,Abstract,[232160],[131],[142],[False],[0],[0],[False],['0']
41423,PMC7939944,39886,The growing epidemic of opioid use disorder (OUD) and associated injection drug use has resulted in a surge of new hepatitis C virus (HCV) infections.,Abstract,[232173],[143],[293],[False],[0],[0],[False],['0']
41424,PMC7939944,39887,Approximately half of the people with HCV infection are unaware of their HCV status.,Abstract,[232186],[294],[378],[False],[0],[0],[False],['0']
41425,PMC7939944,39888,Improving HCV awareness and increasing screening among people with OUD are critical.,Abstract,[232199],[379],[463],[False],[0],[0],[False],['0']
41426,PMC7939944,39889,"Addiction-Comprehensive Health Enhancement Support System (A-CHESS) is an evidence-based, smartphone-delivered relapse prevention system that has been implemented among people with OUD who are receiving medications for addiction treatment (MAT) to improve long-term recovery.",Abstract,[232212],[464],[739],[False],[0],[0],[False],['0']
41427,PMC7939944,39890,Objective,Abstract,[232225],[740],[749],[False],[0],[0],[False],['0']
41428,PMC7939944,39891,We incorporated HCV-related content and functionality into A-CHESS to characterize the HCV care continuum among people in early remission and receiving MAT for OUD and to determine whether incorporating such content and functionality into A-CHESS increases HCV testing.,Abstract,[232238],[750],[1019],[False],[0],[0],[False],['0']
41429,PMC7939944,39892,Methods,Abstract,[232251],[1020],[1027],[False],[0],[0],[False],['0']
41430,PMC7939944,39893,"HCV intervention content, including dissemination of educational information, private messages tailored to individuals’ stage of HCV care, and a public discussion forum, was implemented into the A-CHESS platform.",Abstract,[232264],[1028],[1240],[False],[0],[0],[False],['0']
41431,PMC7939944,39894,"Between April 2016 and April 2020, 416 participants with OUD were enrolled in this study.",Abstract,[232277],[1241],[1330],[False],[0],[0],[False],['0']
41432,PMC7939944,39895,Participants were randomly assigned to receive MAT alone (control arm) or MAT+A-CHESS (experimental arm).,Abstract,[232290],[1331],[1436],[False],[0],[0],[False],['0']
41433,PMC7939944,39896,Quarterly telephone interviews were conducted from baseline to month 24 to assess risk behaviors and HCV testing history.,Abstract,[232303],[1437],[1558],[False],[0],[0],[False],['0']
41434,PMC7939944,39897,Cox proportional hazards regression was used to assess whether participants who used A-CHESS were tested for HCV (either antibody [Ab] or RNA testing) at a higher rate than those in the control arm.,Abstract,[232316],[1559],[1757],[False],[0],[0],[False],['0']
41435,PMC7939944,39898,"To assess the effect of A-CHESS on subsets of participants at the highest risk for HCV, additional analyses were performed to examine the effect of the intervention among participants who injected drugs and shared injection equipment.",Abstract,[232329],[1758],[1992],[False],[0],[0],[False],['0']
41436,PMC7939944,39899,Results,Abstract,[232342],[1993],[2000],[False],[0],[0],[False],['0']
41437,PMC7939944,39900,"Overall, 44.2% (184/416) of the study participants were HCV Ab positive, 30.3% (126/416) were HCV Ab negative, and 25.5% (106/416) were considered untested at baseline.",Abstract,[232355],[2001],[2169],[False],[0],[0],[False],['0']
41438,PMC7939944,39901,"At month 24, there was no overall difference in HCV testing uptake between the intervention and control participants.",Abstract,[232368],[2170],[2287],[False],[0],[0],[False],['0']
41439,PMC7939944,39902,"However, among the subset of 109 participants who engaged in injection drug use, there was a slight trend toward increased HCV testing uptake among those who used A-CHESS (89% vs 85%; hazard ratio: 1.34; 95% CI 0.87-2.05; P=.18), and a stronger trend was observed when focusing on the subset of 32 participants who reported sharing injection equipment (87% vs 56%; hazard ratio: 2.92; 95% CI 0.959-8.86; P=.06).",Abstract,[232381],[2288],[2699],[False],[0],[0],[False],['0']
41440,PMC7939944,39903,Conclusions,Abstract,[232394],[2700],[2711],[False],[0],[0],[False],['0']
41441,PMC7939944,39904,Incorporating HCV prevention and care information into A-CHESS may increase the uptake of HCV testing while preventing opioid relapse when implemented among populations who engage in high-risk behaviors such as sharing contaminated injection equipment.,Abstract,[232407],[2712],[2964],[False],[0],[0],[False],['0']
41442,PMC7939944,39905,"However, more studies that are powered to detect differences in HCV testing among high-risk groups are needed.",Abstract,[232420],[2965],[3075],[False],[0],[0],[False],['0']
41443,PMC7939944,39906,Trial Registration,Abstract,[232433],[3076],[3094],[False],[0],[0],[False],['0']
41444,PMC7939944,39907,ClinicalTrials.gov NCT02712034; https://clinicaltrials.gov/ct2/show/NCT02712034,Abstract,[232446],[3095],[3174],[False],[0],[0],[False],['0']
41445,PMC7939944,39908,International Registered Report Identifier (IRRID),Abstract,[232459],[3175],[3225],[False],[0],[0],[False],['0']
41446,PMC7939944,39909,RR2-10.2196/12620,Abstract,[232472],[3226],[3243],[False],[0],[0],[False],['0']
41447,PMC7939944,39910,Introduction,Introduction,[232485],[3244],[3257],[False],[0],[0],[False],['0']
41448,PMC7939944,39911,Prescription and illicit opioid addiction are a growing public health problem in the United States [1].,Introduction,[232498],[3258],[3361],[False],[0],[0],[False],['0']
41449,PMC7939944,39912,"In 2016, an estimated 2.1 million people had an opioid use disorder (OUD) [2], and more than 47,000 people died from overdosing on opioids [3], killing more Americans each day than motor vehicle car crashes [4].",Introduction,[232511],[3362],[3573],[False],[0],[0],[False],['0']
41450,PMC7939944,39913,The growing opioid epidemic and associated injection drug use have also resulted in a surge of new hepatitis C virus (HCV) infections [5-7].,Introduction,[232524],[3574],[3714],[False],[0],[0],[False],['0']
41451,PMC7939944,39914,"With injection drug use being the primary risk factor for transmission and the leading cause of incidence [8], HCV infection is now the most common chronic blood-borne infection in the United States, surpassing all other nationally notifiable infectious diseases combined [9].",Introduction,[232537],[3715],[3991],[False],[0],[0],[False],['0']
41452,PMC7939944,39915,"From 2004 to 2014, the incidence rate of acute HCV infection increased by 400%, and admission for opioid injection increased by 622% among young Americans [7].",Introduction,[232550],[3992],[4151],[False],[0],[0],[False],['0']
41453,PMC7939944,39916,Effective medications are available for the treatment of both OUD and HCV infection.,Introduction,[232563],[4152],[4236],[False],[0],[0],[False],['0']
41454,PMC7939944,39917,"Medications for Addiction Treatment (MAT) are Food and Drug Administration–approved, evidence-based prescription medications used to assist people in recovery from opioid addiction by relieving withdrawal symptoms and physiological cravings [10].",Introduction,[232576],[4237],[4483],[False],[0],[0],[False],['0']
41455,PMC7939944,39918,"Despite the availability of these effective treatments for OUD, uptake remains low [11].",Introduction,[232589],[4484],[4572],[False],[0],[0],[False],['0']
41456,PMC7939944,39919,"Moreover, highly effective, well-tolerated, direct-acting antiviral agents are now available for the treatment of HCV, which provide a sustained virologic response (SVR, ie, a cure) in more than 90% of treated patients in as little as 8 weeks [12-14].",Introduction,[232602],[4573],[4824],[False],[0],[0],[False],['0']
41457,PMC7939944,39920,"These medications provide hope for eliminating HCV; however, only a small proportion of infected individuals have received treatment [15].",Introduction,[232615],[4825],[4963],[False],[0],[0],[False],['0']
41458,PMC7939944,39921,"One study that examined HCV treatment uptake among patients who received MAT found that among those aware of their infection, only 14% had received HCV treatment [16].",Introduction,[232628],[4964],[5131],[False],[0],[0],[False],['0']
41459,PMC7939944,39922,Exacerbating this problem is the fact that approximately half of the HCV-infected individuals are unaware of their infection [17].,Introduction,[232641],[5132],[5262],[False],[0],[0],[False],['0']
41460,PMC7939944,39923,"Expanding both addiction and HCV screening, treatment, and prevention services are urgently needed in response to the record number of new HCV infections driven by the opioid crisis.",Introduction,[232654],[5263],[5445],[False],[0],[0],[False],['0']
41461,PMC7939944,39924,"Addiction treatment regimens vary considerably depending on the substances used, comorbidities, severity of substance use disorder, and individual preferences.",Introduction,[232667],[5446],[5605],[False],[0],[0],[False],['0']
41462,PMC7939944,39925,"However, the most effective treatments for individuals with OUD uniformly include a combination of MAT, counseling, and access to other behavioral health services and social supports [18-20].",Introduction,[232680],[5606],[5797],[False],[0],[0],[False],['0']
41463,PMC7939944,39926,"The Addiction-Comprehensive Health Enhancement Support System (A-CHESS), developed at the University of Wisconsin, is a smartphone app designed to improve recovery from addiction by offering a bundle of services that address the various challenges often encountered during recovery.",Introduction,[232693],[5798],[6080],[False],[0],[0],[False],['0']
41464,PMC7939944,39927,"A-CHESS provides communication with peers and addiction experts, reminders and alerts to encourage therapeutic goals, educational material, and other support services to patients.",Introduction,[232706],[6081],[6260],[False],[0],[0],[False],['0']
41465,PMC7939944,39928,"In an effort to improve long-term recovery from OUD, our research team conducted a randomized controlled trial (RCT) that paired A-CHESS with MAT [21].",Introduction,[232719],[6261],[6412],[False],[0],[0],[False],['0']
41466,PMC7939944,39929,MAT alone is associated with an estimated 50% reduction in the risk of acquiring HCV [22].,Introduction,[232732],[6413],[6503],[False],[0],[0],[False],['0']
41467,PMC7939944,39930,Combining MAT with harm reduction information and services may further reduce one’s chances of acquiring HCV.,Introduction,[232745],[6504],[6613],[False],[0],[0],[False],['0']
41468,PMC7939944,39931,A systematic review that examined the effect of combining MAT with high-coverage needle and syringe programs found an estimated 74% reduction in HCV infection [22].,Introduction,[232758],[6614],[6778],[False],[0],[0],[False],['0']
41469,PMC7939944,39932,Our research team previously designed and pilot tested a computerized intervention to reduce risky injection practices and improve screening for HCV among people who inject drugs [23].,Introduction,[232771],[6779],[6963],[False],[0],[0],[False],['0']
41470,PMC7939944,39933,The results from this pilot study suggest that the intervention may reduce the harms of sharing of injection equipment and increase HCV screening [24].,Introduction,[232784],[6964],[7115],[False],[0],[0],[False],['0']
41471,PMC7939944,39934,We integrated content and functionality from this computerized intervention into A-CHESS to provide people with OUD who are receiving MAT and addiction counseling access to tailored HCV prevention and care resources.,Introduction,[232797],[7116],[7332],[False],[0],[0],[False],['0']
41472,PMC7939944,39935,Methods,Methods,[232810],[7333],[7341],[False],[0],[0],[False],['0']
41473,PMC7939944,39936,Overall Objectives,Methods|Overall Objectives,[232823],[7342],[7360],[False],[0],[0],[False],['0']
41474,PMC7939944,39937,The primary goal of the RCT was to assess whether A-CHESS can prevent relapse among people with OUD who are in early remission and receiving MAT.,Methods|Overall Objectives,[232836],[7361],[7506],[False],[0],[0],[False],['0']
41475,PMC7939944,39938,Individuals with diagnosed OUD of at least moderate severity who were receiving addiction treatment at 3 centers in Massachusetts and Wisconsin were randomly assigned in a 1:1 ratio to receive either MAT alone (control arm) or MAT+A-CHESS (experimental arm).,Methods|Overall Objectives,[232849],[7507],[7765],[False],[0],[0],[False],['0']
41476,PMC7939944,39939,"A web-based tool was used to generate a sequence of random assignments in blocks of 16 subjects, stratified on recruitment site, gender, and type of MAT.",Methods|Overall Objectives,[232862],[7766],[7919],[False],[0],[0],[False],['0']
41477,PMC7939944,39940,Each assignment was associated with a unique study ID number.,Methods|Overall Objectives,[232875],[7920],[7981],[False],[0],[0],[False],['0']
41478,PMC7939944,39941,The electronic randomization lists were managed by the project director and stored in a secure location in the center’s shared drive.,Methods|Overall Objectives,[232888],[7982],[8115],[False],[0],[0],[False],['0']
41479,PMC7939944,39942,"When subjects completed baseline, they received the next available assignment and study ID on the appropriate randomization list, the group assignment was recorded in Research Electronic Data Capture (REDCap) [25], and the site coordinator was informed by phone or email.",Methods|Overall Objectives,[232901],[8116],[8387],[False],[0],[0],[False],['0']
41480,PMC7939944,39943,We developed and implemented HCV intervention content within the A-CHESS platform to simultaneously evaluate whether A-CHESS improves secondary outcomes related to the HCV care continuum.,Methods|Overall Objectives,[232914],[8388],[8575],[False],[0],[0],[False],['0']
41481,PMC7939944,39944,The objectives of this study were to characterize the HCV care continuum among people in recovery for OUD and to determine whether incorporating HCV-related content and functionality into the A-CHESS system increases HCV testing.,Methods|Overall Objectives,[232927],[8576],[8805],[False],[0],[0],[False],['0']
41482,PMC7939944,39945,Participants were followed for 24 months.,Methods|Overall Objectives,[232940],[8806],[8847],[False],[0],[0],[False],['0']
41483,PMC7939944,39946,Overview of the A-CHESS System,Methods|Overview of the A-CHESS System,[232953],[8848],[8878],[False],[0],[0],[False],['0']
41484,PMC7939944,39947,A-CHESS contains multiple services designed to address several types of challenges facing people with addiction.,Methods|Overview of the A-CHESS System,[232966],[8879],[8991],[False],[0],[0],[False],['0']
41485,PMC7939944,39948,"Key A-CHESS services include a call for help function, cognitive behavioral therapy boosters, a GPS location tracker for avoiding high-risk locations and finding 12-step meeting locations, games, and audio- and video-based relaxation recording, tailored coping support, and coach-monitored discussion groups.",Methods|Overview of the A-CHESS System,[232979],[8992],[9300],[False],[0],[0],[False],['0']
41486,PMC7939944,39949,"A-CHESS provides a platform for people with OUDs to interact with peers and trained counselors, obtain educational information, and provide participant-level data.",Methods|Overview of the A-CHESS System,[232992],[9301],[9464],[False],[0],[0],[False],['0']
41487,PMC7939944,39950,These existing features were used to collect data on participants’ HCV risk behaviors and history of HCV care and deliver behavior change interventions tailored to patients’ self-reported stage of HCV care.,Methods|Overview of the A-CHESS System,[233005],[9465],[9671],[False],[0],[0],[False],['0']
41488,PMC7939944,39951,"The study design, recruitment, eligibility, screening process, and addiction-related services incorporated into A-CHESS have been described in the RCT’s published protocol [21].",Methods|Overview of the A-CHESS System,[233018],[9672],[9849],[False],[0],[0],[False],['0']
41489,PMC7939944,39952,HCV Intervention Content and Functionality,Methods|HCV Intervention Content and Functionality,[233031],[9850],[9892],[False],[0],[0],[False],['0']
41490,PMC7939944,39953,"The HCV intervention content included dissemination of educational information, private messages tailored to individuals’ stage of HCV care, and a public discussion forum.",Methods|HCV Intervention Content and Functionality,[233044],[9893],[10064],[False],[0],[0],[False],['0']
41491,PMC7939944,39954,The educational content is housed within the Information tab of A-CHESS and provides answers to HCV-related frequently asked questions and links to factsheets developed by the Centers for Disease Control and Prevention.,Methods|HCV Intervention Content and Functionality,[233057],[10065],[10284],[False],[0],[0],[False],['0']
41492,PMC7939944,39955,"HCV screening and treatment resources in the individual’s community are provided, along with news articles and videos related to the co-occurring epidemics of opioid injection and infectious diseases.",Methods|HCV Intervention Content and Functionality,[233070],[10285],[10485],[False],[0],[0],[False],['0']
41493,PMC7939944,39956,The private messaging feature of A-CHESS is used by study personnel to send tailored messages related to filling gaps in the HCV care continuum.,Methods|HCV Intervention Content and Functionality,[233083],[10486],[10630],[False],[0],[0],[False],['0']
41494,PMC7939944,39957,Private messaging conversations began by delivering participants in each HCV stage of care a standardized message pertaining to their current stage of care.,Methods|HCV Intervention Content and Functionality,[233096],[10631],[10787],[False],[0],[0],[False],['0']
41495,PMC7939944,39958,Subsequent messages were then guided by each individual’s unique response but toward the same goal of helping each individual advance appropriately along the HCV care continuum.,Methods|HCV Intervention Content and Functionality,[233109],[10788],[10965],[False],[0],[0],[False],['0']
41496,PMC7939944,39959,"A discussion board, named Staying Healthy, was also developed, which provides a forum for participants to ask infectious disease–related questions, share HCV treatment experiences, and discuss barriers to testing and treatment.",Methods|HCV Intervention Content and Functionality,[233122],[10966],[11193],[False],[0],[0],[False],['0']
41497,PMC7939944,39960,"HCV research staff also engage in these conversations to remind A-CHESS users of the importance of being tested for HCV, encourage healthy behaviors, and stimulate discussion related to such topics.",Methods|HCV Intervention Content and Functionality,[233135],[11194],[11392],[False],[0],[0],[False],['0']
41498,PMC7939944,39961,A detailed description of the HCV intervention components and functionality has been previously described [26].,Methods|HCV Intervention Content and Functionality,[233148],[11393],[11504],[False],[0],[0],[False],['0']
41499,PMC7939944,39962,Data Collection,Methods|Data Collection,[233161],[11505],[11520],[False],[0],[0],[False],['0']
41500,PMC7939944,39963,"For 2 years, study participants in both the intervention and control arms completed telephone interviews with 1 of 2 study coordinators at baseline and at quarterly intervals (months 4, 8, 12, 16, 20, and 24).",Methods|Data Collection,[233174],[11521],[11730],[False],[0],[0],[False],['0']
41501,PMC7939944,39964,"At each of these time points, data were collected on illicit opioid use, other nonprescribed substance use, quality of life, retention in treatment, health service use, injection drug use risk behaviors, and HIV and HCV outcomes.",Methods|Data Collection,[233187],[11731],[11960],[False],[0],[0],[False],['0']
41502,PMC7939944,39965,"Participants were asked whether they had been tested for HCV, the type of test they received (antibody [Ab] test or RNA test), and the date and result of their last test, and if positive, linkage to care and HCV treatment initiation or completion were assessed.",Methods|Data Collection,[233200],[11961],[12222],[False],[0],[0],[False],['0']
41503,PMC7939944,39966,"A text field, labeled the comment field, was available on all surveys for interviewers to enter comments pertaining to the individual’s HCV stage of care if they shared additional details.",Methods|Data Collection,[233213],[12223],[12411],[False],[0],[0],[False],['0']
41504,PMC7939944,39967,"For example, interviewers use the comment field to record whether the individual was approximating the date of their last HCV test or whether they expressed uncertainty regarding the type of testing they had received.",Methods|Data Collection,[233226],[12412],[12629],[False],[0],[0],[False],['0']
41505,PMC7939944,39968,Each phone interview lasted approximately 20 to 30 min.,Methods|Data Collection,[233239],[12630],[12685],[False],[0],[0],[False],['0']
41506,PMC7939944,39969,Surveys were identified by a study ID and stored in REDCap [25].,Methods|Data Collection,[233252],[12686],[12750],[False],[0],[0],[False],['0']
41507,PMC7939944,39970,Characterizing the HCV Care Continuum,Methods|Characterizing the HCV Care Continuum,[233265],[12751],[12788],[False],[0],[0],[False],['0']
41508,PMC7939944,39971,"To characterize the HCV care continuum for this study population at baseline, participants were assigned 1 of 7 mutually exclusive stages of HCV care using the criteria specified in Table 1 from the baseline survey.",Methods|Characterizing the HCV Care Continuum,[233278],[12789],[13004],[False],[0],[0],[False],['0']
41509,PMC7939944,39972,"These stages take into consideration the type of test received (Ab or RNA test), test result (positive or negative), and how long ago they were tested.",Methods|Characterizing the HCV Care Continuum,[233291],[13005],[13156],[False],[0],[0],[False],['0']
41510,PMC7939944,39973,"At each quarterly follow-up interview, their stage of HCV care was updated to one of the stages in Table 2 if their survey answers met the specified criteria.",Methods|Characterizing the HCV Care Continuum,[233304],[13157],[13315],[False],[0],[0],[False],['0']
41511,PMC7939944,39974,"If none of the conditions in Table 2 were met at the follow-up interview, the individual’s HCV stage remained the same as it was in the previous interview.",Methods|Characterizing the HCV Care Continuum,[233317],[13316],[13471],[False],[0],[0],[False],['0']
41512,PMC7939944,39975,"If interviewers provided any comments in the comment field indicating the participant should have been in a stage of HCV care different than this logic assigned, the stage was manually altered accordingly.",Methods|Characterizing the HCV Care Continuum,[233330],[13472],[13677],[False],[0],[0],[False],['0']
41513,PMC7939944,39976,We have characterized the HCV care continuum for this population by reporting the number of participants in each stage of HCV care at all 7 time points.,Methods|Characterizing the HCV Care Continuum,[233343],[13678],[13830],[False],[0],[0],[False],['0']
41514,PMC7939944,39977,Measures and Statistical Analysis,Methods|Measures and Statistical Analysis,[233356],[13831],[13864],[False],[0],[0],[False],['0']
41515,PMC7939944,39978,"Baseline descriptive characteristics were assessed to describe the study population in terms of age, age of first opioid use, gender, race or ethnicity, educational attainment, employment status, marital status, HIV comorbidity, mental health conditions, prescribed MAT, and HCV status.",Methods|Measures and Statistical Analysis,[233369],[13865],[14151],[False],[0],[0],[False],['0']
41516,PMC7939944,39979,Differences in baseline sociodemographic characteristics between the intervention and control groups were assessed using Pearson chi-square or Fisher exact tests for categorical variables and the two-sample unpaired t test or Wilcoxon rank-sum test for continuous variables.,Methods|Measures and Statistical Analysis,[233382],[14152],[14426],[False],[0],[0],[False],['0']
41517,PMC7939944,39980,"The primary outcome of interest was days to any HCV test (Ab or RNA test), which was calculated as the number of days between the date of study enrollment and the first reported Ab or RNA HCV test.",Methods|Measures and Statistical Analysis,[233395],[14427],[14624],[False],[0],[0],[False],['0']
41518,PMC7939944,39981,Cox proportional hazards regression was used to compare the time to HCV testing uptake between the intervention and control arms.,Methods|Measures and Statistical Analysis,[233408],[14625],[14754],[False],[0],[0],[False],['0']
41519,PMC7939944,39982,"Participants with no reported HCV test who were lost to follow-up were censored at the time of their last quarterly interview, and those who did not receive an HCV test and completed the 24-month interview were administratively censored.",Methods|Measures and Statistical Analysis,[233421],[14755],[14992],[False],[0],[0],[False],['0']
41520,PMC7939944,39983,"As injection drug use is the primary risk behavior driving HCV transmission, 2 additional Cox proportional hazard models were used to assess the effect of A-CHESS on subsets of participants at the highest risk for HCV, including (1) participants who injected drugs and (2) participants who shared injection equipment with another person.",Methods|Measures and Statistical Analysis,[233434],[14993],[15330],[False],[0],[0],[False],['0']
41521,PMC7939944,39984,"Participants were determined to have injected drugs or shared injection equipment if they reported previously (past 4 months) conducting the behavior on the survey, or any survey before, in which they reported HCV testing or were censored.",Methods|Measures and Statistical Analysis,[233447],[15331],[15570],[False],[0],[0],[False],['0']
41522,PMC7939944,39985,"As individuals’ HCV stage of care likely influenced whether they received follow-up testing and how quickly, all analyses adjusted for baseline stage of HCV care, using the stages defined in Table 1.",Methods|Measures and Statistical Analysis,[233460],[15571],[15770],[False],[0],[0],[False],['0']
41523,PMC7939944,39986,Kaplan-Meier survival curves were created for each risk group to visualize differences in time to HCV testing between intervention and control participants.,Methods|Measures and Statistical Analysis,[233473],[15771],[15927],[False],[0],[0],[False],['0']
41524,PMC7939944,39987,An intention-to-treat approach was used.,Methods|Measures and Statistical Analysis,[233486],[15928],[15968],[False],[0],[0],[False],['0']
41525,PMC7939944,39988,"For each time point, we also describe the mean number of days in the previous 4 months that participants in the intervention group used the A-CHESS app.",Methods|Measures and Statistical Analysis,[233499],[15969],[16121],[False],[0],[0],[False],['0']
41526,PMC7939944,39989,"To determine whether engagement with the A-CHESS app was different for higher-risk participants, we conducted negative binomial regression analyses, with cluster robust standard errors to adjust for the nonindependence of observations within persons over time, to compare app use (ie, the number of days they used the app in the 4 months before each survey) between (1) those who injected drugs and those who did not and (2) those who shared injection equipment and those who did not.",Methods|Measures and Statistical Analysis,[233512],[16122],[16606],[False],[0],[0],[False],['0']
41527,PMC7939944,39990,"All analyses were conducted using Stata version 16 (StataCorp), and statistical significance was determined using α≤.05.",Methods|Measures and Statistical Analysis,[233525],[16607],[16727],[False],[0],[0],[False],['0']
41528,PMC7939944,39991,Results,Results,[233538],[16728],[16736],[False],[0],[0],[False],['0']
41529,PMC7939944,39992,Demographic Characteristics,Results|Demographic Characteristics,[233551],[16737],[16764],[False],[0],[0],[False],['0']
41530,PMC7939944,39993,"Between April 2016 and April 2018, 416 participants enrolled in the A-CHESS study and completed the baseline survey; 207 were randomly assigned to the control arm and 209 were assigned to receive A-CHESS.",Results|Demographic Characteristics,[233564],[16765],[16969],[False],[0],[0],[False],['0']
41531,PMC7939944,39994,"Follow-up was completed for the following number of participants: 382.7% (44/416) at month 4, 79.3% (330/416) at month 8, 72.6%, (302/416) at month 12, 70.4% (293/416) at month 16, 61.8% (257/416) at month 20, and 63.9% (266/416) at month 24.",Results|Demographic Characteristics,[233577],[16970],[17212],[False],[0],[0],[False],['0']
41532,PMC7939944,39995,There were no significant differences between the initial sample of 416 participants and the final sample of 266 participants (Multimedia Appendix 1).,Results|Demographic Characteristics,[233590],[17213],[17363],[False],[0],[0],[False],['0']
41533,PMC7939944,39996,The baseline descriptive characteristics of the sample are displayed in Table 3.,Results|Demographic Characteristics,[233603],[17364],[17444],[False],[0],[0],[False],['0']
41534,PMC7939944,39997,The sample comprised 85.8% (357/416) of non-Hispanic White people and 54.8% (228/416) male participants.,Results|Demographic Characteristics,[233616],[17445],[17549],[False],[0],[0],[False],['0']
41535,PMC7939944,39998,The mean age of the participants was 37 (SD 10) years.,Results|Demographic Characteristics,[233629],[17550],[17604],[False],[0],[0],[False],['0']
41536,PMC7939944,39999,"Of the 416 study participants, 285 (68.5%) had a high school diploma, General Educational Development, or higher degree, and 101 (24.3%) reported being currently employed for wages.",Results|Demographic Characteristics,[233642],[17605],[17786],[False],[0],[0],[False],['0']
41537,PMC7939944,40000,"Mental health illnesses affected 70.4% (293/416) of the participants, with the most common diagnoses being depression (218/416, 52.4%), anxiety (215/416, 51.7%), posttraumatic stress disorder (121/416, 29.1%), and bipolar or manic depression (108/416, 26.0%).",Results|Demographic Characteristics,[233655],[17787],[18046],[False],[0],[0],[False],['0']
41538,PMC7939944,40001,"Overall, 0.01% (4/416) of the participants were HIV positive.",Results|Demographic Characteristics,[233668],[18047],[18108],[False],[0],[0],[False],['0']
41539,PMC7939944,40002,"The majority of the sample (302/416, 72.6%) was receiving methadone at the time of enrollment, and heroin was the most commonly used opioid.",Results|Demographic Characteristics,[233681],[18109],[18249],[False],[0],[0],[False],['0']
41540,PMC7939944,40003,"The average age of participants at first opioid use was 21 (SD 7) years, and 39.4% (164/416) of the participants reported that regular opioid use began through a doctor’s prescription.",Results|Demographic Characteristics,[233694],[18250],[18434],[False],[0],[0],[False],['0']
41541,PMC7939944,40004,"Of the 95 participants who reported using a needle and syringe to inject drugs in the month before study enrollment, 22% (21/95) reported someone else had used their needle after they had used it and 10% (9/95) of the participants reported using a needle after someone else had already used it.",Results|Demographic Characteristics,[233707],[18435],[18729],[False],[0],[0],[False],['0']
41542,PMC7939944,40005,There were no significant differences in baseline characteristics between those assigned to the 2 study arms.,Results|Demographic Characteristics,[233720],[18730],[18839],[False],[0],[0],[False],['0']
41543,PMC7939944,40006,A-CHESS Use,Results|A-CHESS Use,[233733],[18840],[18851],[False],[0],[0],[False],['0']
41544,PMC7939944,40007,The use of A-CHESS decreased over time.,Results|A-CHESS Use,[233746],[18852],[18891],[False],[0],[0],[False],['0']
41545,PMC7939944,40008,"Among participants in the intervention arm who completed the 4-month survey, the mean number of days between baseline and month 4 that A-CHESS was used was 30 days.",Results|A-CHESS Use,[233759],[18892],[19056],[False],[0],[0],[False],['0']
41546,PMC7939944,40009,"The mean number of days A-CHESS was used between further time points were as follows: 19 days between months 4 and 8, 17 days between months 8 and 12, 15 days between months 12 and 16, 7 days between months 16 and 20, and 3 days between months 20 and 24.",Results|A-CHESS Use,[233772],[19057],[19311],[False],[0],[0],[False],['0']
41547,PMC7939944,40010,"There was no significant difference in the mean number of days A-CHESS was used between (1) those who injected drugs and those who did not (odds ratio [OR] 1.06, 95% CI 0.875-1.37; P=.43) and (2) those who shared injection equipment and those who did not (OR 1.08, 95% CI 0.767-1.52; P=.66).",Results|A-CHESS Use,[233785],[19312],[19603],[False],[0],[0],[False],['0']
41548,PMC7939944,40011,Characterizing the HCV Care Continuum,Results|Characterizing the HCV Care Continuum,[233798],[19604],[19641],[False],[0],[0],[False],['0']
41549,PMC7939944,40012,The number of participants in each stage of the HCV care continuum at all time points is presented in Table 4 (Multimedia Appendix 2 visually presents these results for the selected stages).,Results|Characterizing the HCV Care Continuum,[233811],[19642],[19832],[False],[0],[0],[False],['0']
41550,PMC7939944,40013,"Overall, 25.5% (106/416) of the study population was considered HCV untested, 30.3% (126/416) were HCV Ab negative, and 44.2% (184/416) were HCV Ab positive at baseline.",Results|Characterizing the HCV Care Continuum,[233824],[19833],[20002],[False],[0],[0],[False],['0']
41551,PMC7939944,40014,"From baseline to month 24, there was a trend toward a more favorable HCV care continuum overall.",Results|Characterizing the HCV Care Continuum,[233837],[20003],[20099],[False],[0],[0],[False],['0']
41552,PMC7939944,40015,"The proportion of participants untested at each quarterly interview appeared to decrease over time, from 25.5% (106/416) at baseline to 3.4% (9/266) at month 24.",Results|Characterizing the HCV Care Continuum,[233850],[20100],[20261],[False],[0],[0],[False],['0']
41553,PMC7939944,40016,"Similarly, the proportion of HCV Ab-positive participants who had not received an RNA test appeared to decrease over time, from 5.3% (22/416) at baseline to 2.3% (6/266) at month 24, and the proportion of participants achieving SVR appeared to increase over time, from 7.5% (31/416) to 18.4% (49/266).",Results|Characterizing the HCV Care Continuum,[233863],[20262],[20563],[False],[0],[0],[False],['0']
41554,PMC7939944,40017,"In addition, as HCV untested participants underwent HCV testing throughout the duration of the study, the proportion of participants considered HCV Ab-negative increased over time, from 30.3% (126/416) at baseline to 48.9% (130/416) at month 24.",Results|Characterizing the HCV Care Continuum,[233876],[20564],[20809],[False],[0],[0],[False],['0']
41555,PMC7939944,40018,There were no significant differences in the number of participants in each stage of HCV care when comparing those who used A-CHESS with those in the control group over time (Multimedia Appendix 3).,Results|Characterizing the HCV Care Continuum,[233889],[20810],[21008],[False],[0],[0],[False],['0']
41556,PMC7939944,40019,Effect of A-CHESS on HCV Testing,Results|Characterizing the HCV Care Continuum,[233902],[21009],[21041],[False],[0],[0],[False],['0']
41557,PMC7939944,40020,"Among the 364 participants who completed at least one follow-up interview by month 12, 66.2% (241/364) had received any (Ab or RNA) HCV test.",Results|Characterizing the HCV Care Continuum,[233915],[21042],[21183],[False],[0],[0],[False],['0']
41558,PMC7939944,40021,"By month 24, 86.3% (314/364) had been tested for HCV.",Results|Characterizing the HCV Care Continuum,[233928],[21184],[21237],[False],[0],[0],[False],['0']
41559,PMC7939944,40022,"There was no difference in receipt of an HCV test between intervention and control participants overall, where 66.0% (122/185) and 66.5% (119/179) received testing by month 12, and 85.4% (158/185) and 87.2% (156/179) received testing by month 24, respectively.",Results|Characterizing the HCV Care Continuum,[233941],[21238],[21498],[False],[0],[0],[False],['0']
41560,PMC7939944,40023,"Kaplan-Meier curves demonstrating the time to HCV testing among all study participants, by randomization group, are presented in Figure 1.",Results|Characterizing the HCV Care Continuum,[233954],[21499],[21637],[False],[0],[0],[False],['0']
41561,PMC7939944,40024,"Of the 364 study participants who completed at least one follow-up interview, 34.1% (124/364) were considered to have injected drugs in the 4 months before either the baseline or any follow-up survey (70/185, 37.8%, in the intervention arm and 54/179, 30.2%, in the control arm).",Results|Characterizing the HCV Care Continuum,[233967],[21638],[21917],[False],[0],[0],[False],['0']
41562,PMC7939944,40025,"Of the 124 participants, 15 were excluded from the analysis because they did not report the risk of injecting drugs before undergoing HCV testing.",Results|Characterizing the HCV Care Continuum,[233980],[21918],[22064],[False],[0],[0],[False],['0']
41563,PMC7939944,40026,"Among the 109 participants who injected drugs and were included in the analysis (63 in the intervention arm and 46 in the control arm), 89% (56/63) of the participants in the intervention arm received an HCV test after injection reporting compared with 85% (39/46) in the control arm.",Results|Characterizing the HCV Care Continuum,[233993],[22065],[22349],[False],[0],[0],[False],['0']
41564,PMC7939944,40027,"Although not statistically significant, there is a trend toward an increased rate of HCV testing among intervention participants.",Results|Characterizing the HCV Care Continuum,[234006],[22350],[22479],[False],[0],[0],[False],['0']
41565,PMC7939944,40028,"Compared with those in the control group who injected drugs, the rate of HCV testing among those who injected drugs and used A-CHESS was 1.34 times higher (hazard ratio: 1.34; 95% CI 0.87-2.05; P=.18; Figure 2).",Results|Characterizing the HCV Care Continuum,[234019],[22480],[22691],[False],[0],[0],[False],['0']
41566,PMC7939944,40029,"Of the 364 study participants who completed at least one follow-up interview, 11.5% (42/364) were considered to have shared injection equipment with another person in the 4 months before either the baseline or any follow-up survey (28/185, 15.1%, in the intervention arm and 14/179, 7.8%, in the control arm).",Results|Characterizing the HCV Care Continuum,[234032],[22692],[23001],[False],[0],[0],[False],['0']
41567,PMC7939944,40030,"Of the 42 participants, 10 were excluded from the analysis because they did not report the risk of sharing injection equipment before undergoing HCV testing.",Results|Characterizing the HCV Care Continuum,[234045],[23002],[23159],[False],[0],[0],[False],['0']
41568,PMC7939944,40031,"Among the 32 participants who shared injection equipment and were included in the analysis (23 in the intervention arm and 9 in the control arm), 87% (20/23) of the participants in the intervention arm received an HCV test after reporting sharing, compared with 56% (5/9) in the control arm.",Results|Characterizing the HCV Care Continuum,[234058],[23160],[23451],[False],[0],[0],[False],['0']
41569,PMC7939944,40032,"Further approaching statistical significance, the rate of HCV testing among those who shared equipment and used A-CHESS was 2.92 times higher than the rate among those in the control group who shared equipment (hazard ratio: 2.92; 95% CI 0.959-8.86; P=.06; Figure 3).",Results|Characterizing the HCV Care Continuum,[234071],[23452],[23719],[False],[0],[0],[False],['0']
41570,PMC7939944,40033,Discussion,Discussion,[234084],[23720],[23731],[False],[0],[0],[False],['0']
41571,PMC7939944,40034,Principal Findings,Discussion|Principal Findings,[234097],[23732],[23750],[False],[0],[0],[False],['0']
41572,PMC7939944,40035,The goal of this study was to understand the HCV care continuum for people with OUD who are in early remission and receiving MAT and to determine whether implementing HCV-related content and functionality into the evidence-based A-CHESS system may improve HCV outcomes for this population.,Discussion|Principal Findings,[234110],[23751],[24040],[False],[0],[0],[False],['0']
41573,PMC7939944,40036,"We found that 44.2% (184/416) of the participants were HCV Ab positive at baseline, indicating that nearly half of the study population had been exposed to the virus at some point before study enrollment.",Discussion|Principal Findings,[234123],[24041],[24245],[False],[0],[0],[False],['0']
41574,PMC7939944,40037,"An overall improvement in the HCV care continuum between baseline and month 24 was observed, where a smaller proportion of participants were untested and a higher proportion had tested HCV negative and achieved SVR.",Discussion|Principal Findings,[234136],[24246],[24461],[False],[0],[0],[False],['0']
41575,PMC7939944,40038,"These trends appeared among both intervention and control participants, suggesting that there may be external factors influencing changes in the HCV care continuum.",Discussion|Principal Findings,[234149],[24462],[24626],[False],[0],[0],[False],['0']
41576,PMC7939944,40039,"Among the entire study population, we did not observe a difference in HCV testing uptake between those who used A-CHESS and those who did not.",Discussion|Principal Findings,[234162],[24627],[24769],[False],[0],[0],[False],['0']
41577,PMC7939944,40040,"However, when focusing on the subset who engaged in injection drug use, there was a slight trend toward increased HCV testing uptake among those who used A-CHESS (89% vs 85%), and a stronger trend was observed when focusing on those who reported sharing injection equipment with another person (87% vs 56%).",Discussion|Principal Findings,[234175],[24770],[25077],[False],[0],[0],[False],['0']
41578,PMC7939944,40041,These results suggest that A-CHESS may increase HCV testing rates if targeted at those with the highest risk of infection: those who share contaminated injection equipment.,Discussion|Principal Findings,[234188],[25078],[25250],[False],[0],[0],[False],['0']
41579,PMC7939944,40042,The intervention likely had no effect on HCV testing uptake among people who had not injected drugs because those participants are at a significantly lower risk of contracting HCV.,Discussion|Principal Findings,[234201],[25251],[25431],[False],[0],[0],[False],['0']
41580,PMC7939944,40043,Future studies that are powered to detect differences in HCV testing among these highest-risk groups are needed.,Discussion|Principal Findings,[234214],[25432],[25544],[False],[0],[0],[False],['0']
41581,PMC7939944,40044,Limitations,Discussion|Limitations,[234227],[25545],[25556],[False],[0],[0],[False],['0']
41582,PMC7939944,40045,A limitation of this study was that the surveys asked if people injected drugs in the 30 days before the survey and shared injection equipment in the 4 months before the survey.,Discussion|Limitations,[234240],[25557],[25734],[False],[0],[0],[False],['0']
41583,PMC7939944,40046,"The fact that these surveys did not ask whether individuals ever injected drugs or ever shared injection equipment, coupled with the fact that more participants were HCV Ab positive at baseline (n=184) than those who reported injecting drugs (n=124), suggests that we underestimated the number of participants who engaged in these behaviors and who may be at high risk for HCV.",Discussion|Limitations,"[234253, 234254]","[25735, 25735]","[26112, 26112]","[True, True]","['Population', 'Population']","['surveys did not ask whether individuals ever injected drugs or ever shared injection equipment', 'we underestimated the number of participants who engaged in these behaviors and who may be at high risk for HCV']","[True, True]",['Population']
41584,PMC7939944,40047,"In addition, the number of people achieving subsequent steps of the HCV care continuum (eg, linkage to care, and treatment initiation) in this study, particularly among high-risk participants such as those who share injection equipment, limited our ability to test the effect of A-CHESS on these important stages of care.",Discussion|Limitations,[234281],[26113],[26434],[True],['CompositeIntervention'],"['the number of people achieving subsequent steps of the HCV care continuum (eg, linkage to care, and treatment initiation)']",[True],['Intervention']
41585,PMC7939944,40048,"The logic used to assign participants an HCV stage of care at each time point (Tables 1 and 2) allowed us to best characterize the HCV care continuum after each quarterly interview; however, this logic does have limitations because of the complex nature of the disease.",Discussion|Limitations,[234305],[26435],[26704],[False],[0],[0],[False],['0']
41586,PMC7939944,40049,Staging the disease in this manner did not allow us to estimate reinfection or HCV treatment failure experiences.,Discussion|Limitations,[234321],[26705],[26818],[True],['OutcomeMeasures'],['not allow us to estimate reinfection or HCV treatment failure experiences'],[True],['OutcomeMeasures']
41587,PMC7939944,40050,"In addition, this logic allows participants to advance to the latest stage, achieving SVR, during the study period if they had received treatment before the study but had not undergone RNA testing in the year before enrollment and then received an RNA negative test during the study period.",Discussion|Limitations,[234348],[26819],[27109],[True],['NonstandardTreatmentCharacteristics'],"['participants to advance to the latest stage, achieving SVR, during the study period if they had received treatment before the study']",[True],['Intervention']
41588,PMC7939944,40051,Further analysis is required to estimate how many participants were cured during the study versus before the study.,Discussion|Limitations,[234370],[27110],[27225],[False],[0],[0],[False],['0']
41589,PMC7939944,40052,"Our team experiences enrollment challenges at 2 of the 3 addiction treatment centers, primarily because of limited staffing.",Discussion|Limitations,[234388],[27226],[27350],[True],['VerySpecificPopulation'],['enrollment challenges at 2 of the 3 addiction treatment centers'],[True],['Population']
41590,PMC7939944,40053,"Owing to these enrollment challenges, 97% of participants were recruited from 1 center in the state of Massachusetts, limiting the generalizability of this study.",Discussion|Limitations,"[234415, 234416]","[27351, 27351]","[27513, 27513]","[True, True]","['VerySpecificPopulation', 'Generalization']","['97% of participants were recruited from 1 center in the state of Massachusetts', 'limiting the generalizability']","[True, True]","['Generalization', 'Population']"
41591,PMC7939944,40054,"The primary treatment center is located in an urbanized area with a population size of approximately 89,000 residents [27], where HCV testing services may be more accessible than in rural communities.",Discussion|Limitations,[234443],[27514],[27714],[True],['Setting'],['The primary treatment center is located in an urbanized area'],[True],['Setting']
41592,PMC7939944,40055,"As suburban and rural communities have been disproportionately affected by the opioid crisis [28-30] and many HCV outbreaks concentrated in rural communities have been detected [31-33], understanding how A-CHESS serves communities with fewer resources for prevention and treatment is needed.",Discussion|Limitations,[234461],[27715],[28006],[False],[0],[0],[False],['0']
41593,PMC7939944,40056,"Furthermore, only 2 participants were recruited in the state of Wisconsin.",Discussion|Limitations,[234483],[28007],[28081],[True],['Population'],['only 2 participants were recruited in the state of Wisconsin'],[True],['Population']
41594,PMC7939944,40057,"These participants may face unique barriers and facilitators to HCV testing compared with residents of Massachusetts; however, the results described in this paper did not change when the 2 Wisconsin residents were excluded.",Discussion|Limitations,[234500],[28082],[28305],[False],[0],[0],[False],['0']
41595,PMC7939944,40058,Another limitation of this study is the use of self-report.,Discussion|Limitations,[234523],[28306],[28365],[True],['PrecisionOfMeasurement'],['the use of self-report'],[True],['OutcomeMeasures']
41596,PMC7939944,40059,"The ability of HCV to spontaneously clear without antiviral therapy and the varying levels of clinical testing (eg, HCV Ab, HCV RNA, and tests to evaluate liver damage) complicates the disease, making it difficult for laypersons to understand their exact HCV stage of care.",Discussion|Limitations,[234539],[28366],[28639],[False],[0],[0],[False],['0']
41597,PMC7939944,40060,"Prior studies have identified significant gaps in knowledge of HCV among people who inject drugs, particularly with respect to transmission risks, symptoms and clinical markers, and treatment options [34-36].",Discussion|Limitations,[234552],[28640],[28848],[False],[0],[0],[False],['0']
41598,PMC7939944,40061,This study would have been strengthened if serologic confirmation of HCV could have been obtained.,Discussion|Limitations,[234576],[28849],[28947],[True],['RelevantOutcomeExcluded'],['if serologic confirmation of HCV could have been obtained'],[True],['OutcomeMeasures']
41599,PMC7939944,40062,"Likewise, participants often had difficulty remembering the exact date of their last HCV test.",Discussion|Limitations,[234591],[28948],[29042],[False],[0],[0],[False],['0']
41600,PMC7939944,40063,"Consequently, most test dates were estimated.",Discussion|Limitations,[234616],[29043],[29088],[True],['PrecisionOfMeasurement'],['most test dates were estimated'],[True],['OutcomeMeasures']
41601,PMC7939944,40064,Strengths,Discussion|Strengths,[234630],[29089],[29098],[False],[0],[0],[False],['0']
41602,PMC7939944,40065,"As mobile health (mHealth) innovations continue to emerge and evolve, the opportunity to address complex, comorbid health conditions on a larger scale grows.",Discussion|Strengths,[234643],[29099],[29256],[False],[0],[0],[False],['0']
41603,PMC7939944,40066,"To our knowledge, this is the first study to combine an addiction intervention with an HCV intervention to simultaneously address opioid dependence, risky injection behaviors, and HCV infection among people with OUD using a single mHealth app.",Discussion|Strengths,[234656],[29257],[29500],[False],[0],[0],[False],['0']
41604,PMC7939944,40067,"In addition to the novelty of this intervention, many aspects of the design and analysis strengthened this study.",Discussion|Strengths,[234669],[29501],[29614],[False],[0],[0],[False],['0']
41605,PMC7939944,40068,"By randomizing participants to the intervention and control arms, the chances of bias because of confounding factors and selection bias have been reduced.",Discussion|Strengths,[234682],[29615],[29769],[False],[0],[0],[False],['0']
41606,PMC7939944,40069,"In addition, the intention-to-treat analysis maintains the advantages of random assignment and accounts for the fact that some participants assigned to the A-CHESS intervention may have used the app minimally or not at all.",Discussion|Strengths,[234695],[29770],[29993],[False],[0],[0],[False],['0']
41607,PMC7939944,40070,Conclusions,Discussion|Conclusions,[234708],[29994],[30005],[False],[0],[0],[False],['0']
41608,PMC7939944,40071,The prevalence of OUD and associated HCV infections has escalated in the United States.,Discussion|Conclusions,[234721],[30006],[30093],[False],[0],[0],[False],['0']
41609,PMC7939944,40072,Advancements in mHealth technology offer the opportunity to provide information and services for the treatment of both OUD and HCV infection simultaneously.,Discussion|Conclusions,[234734],[30094],[30250],[False],[0],[0],[False],['0']
41610,PMC7939944,40073,"When implemented among populations who engage in high-risk behaviors such as sharing injection equipment, the HCV-enhanced A-CHESS intervention may increase awareness of HCV infection while preventing opioid relapse; however, studies that are powered to detect differences in HCV testing among high-risk groups are needed.",Discussion|Conclusions,[234747],[30251],[30573],[False],[0],[0],[False],['0']
41611,PMC7939944,40074,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members.",Discussion,[234760],[30574],[30748],[False],[0],[0],[False],['0']
41612,PMC7939944,40075,All other authors declare that they have no competing interests.,Discussion,[234773],[30749],[30813],[False],[0],[0],[False],['0']
41613,PMC7939944,40076,Abbreviations,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|Abbreviations",[234786],[30814],[30827],[False],[0],[0],[False],['0']
41614,PMC7939944,40077,Ab antibody,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|Ab antibody",[234799],[30828],[30839],[False],[0],[0],[False],['0']
41615,PMC7939944,40078,A-CHESS Addiction-Comprehensive Health Enhancement Support System,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|Ab antibody",[234812],[30840],[30905],[False],[0],[0],[False],['0']
41616,PMC7939944,40079,HCV hepatitis C virus,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|HCV hepatitis C virus",[234825],[30906],[30927],[False],[0],[0],[False],['0']
41617,PMC7939944,40080,MAT medications for addiction treatment,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|MAT medications for addiction treatment",[234838],[30928],[30967],[False],[0],[0],[False],['0']
41618,PMC7939944,40081,mHealth mobile health,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|mHealth mobile health",[234851],[30968],[30989],[False],[0],[0],[False],['0']
41619,PMC7939944,40082,OR odds ratio,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|OR odds ratio",[234864],[30990],[31003],[False],[0],[0],[False],['0']
41620,PMC7939944,40083,OUD opioid use disorder,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|OUD opioid use disorder",[234877],[31004],[31027],[False],[0],[0],[False],['0']
41621,PMC7939944,40084,RCT randomized controlled trial,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|RCT randomized controlled trial",[234890],[31028],[31059],[False],[0],[0],[False],['0']
41622,PMC7939944,40085,SVR sustained virologic response,"Conflicts of Interest: DG has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. All other authors declare that they have no competing interests.|SVR sustained virologic response",[234903],[31060],[31092],[False],[0],[0],[False],['0']
42182,PMC9007089,40086,"Cogmed Training Does Not Generalize to Real-World Benefits for Adult Hearing Aid Users: Results of a Blinded, Active-Controlled Randomized Trial",Title,[234916],[31093],[144],[False],[0],[0],[False],['0']
42183,PMC9007089,40087,Objectives:,Abstract,[234923],[145],[157],[False],[0],[0],[False],['0']
42184,PMC9007089,40088,"Performance on working memory tasks is positively associated with speech-in-noise perception performance, particularly where auditory inputs are degraded.",Abstract,[234930],[158],[312],[False],[0],[0],[False],['0']
42185,PMC9007089,40089,"It is suggested that interventions designed to improve working memory capacity may improve domain-general working memory performance for people with hearing loss, to benefit their real-world listening.",Abstract,[234937],[313],[514],[False],[0],[0],[False],['0']
42186,PMC9007089,40090,"We examined whether a 5-week training program that primarily targets the storage component of working memory (Cogmed RM, adaptive) could improve cognition, speech-in-noise perception and self-reported hearing in a randomized controlled trial of adult hearing aid users with mild to moderate hearing loss, compared with an active control (Cogmed RM, nonadaptive) group of adults from the same population.",Abstract,[234944],[515],[918],[False],[0],[0],[False],['0']
42187,PMC9007089,40091,Design:,Abstract,[234951],[919],[926],[False],[0],[0],[False],['0']
42188,PMC9007089,40092,"A preregistered randomized controlled trial of 57 adult hearing aid users (n = 27 experimental, n = 30 active control), recruited from a dedicated database of research volunteers, examined on-task learning and generalized improvements in measures of trained and untrained cognition, untrained speech-in-noise perception and self-reported hearing abilities, pre- to post-training.",Abstract,[234958],[927],[1306],[False],[0],[0],[False],['0']
42189,PMC9007089,40093,Participants and the outcome assessor were both blinded to intervention allocation.,Abstract,[234965],[1307],[1390],[False],[0],[0],[False],['0']
42190,PMC9007089,40094,Retention of training-related improvements was examined at a 6-month follow-up assessment.,Abstract,[234972],[1391],[1481],[False],[0],[0],[False],['0']
42191,PMC9007089,40095,Results:,Abstract,[234979],[1482],[1490],[False],[0],[0],[False],['0']
42192,PMC9007089,40096,"Per-protocol analyses showed improvements in trained tasks (Cogmed Index Improvement) that transferred to improvements in a trained working memory task tested outside of the training software (Backward Digit Span) and a small improvement in self-reported hearing ability (Glasgow Hearing Aid Benefit Profile, Initial Disability subscale).",Abstract,[234986],[1491],[1829],[False],[0],[0],[False],['0']
42193,PMC9007089,40097,Both of these improvements were maintained 6-month post-training.,Abstract,[234993],[1830],[1895],[False],[0],[0],[False],['0']
42194,PMC9007089,40098,"There was no transfer of learning shown to untrained measures of cognition (working memory or attention), speech-in-noise perception, or self-reported hearing in everyday life.",Abstract,[235000],[1896],[2072],[False],[0],[0],[False],['0']
42195,PMC9007089,40099,An assessment of individual differences showed that participants with better baseline working memory performance achieved greater learning on the trained tasks.,Abstract,[235007],[2073],[2233],[False],[0],[0],[False],['0']
42196,PMC9007089,40100,Post-training performance for untrained outcomes was largely predicted by individuals’ pretraining performance on those measures.,Abstract,[235014],[2234],[2363],[False],[0],[0],[False],['0']
42197,PMC9007089,40101,Conclusions:,Abstract,[235021],[2364],[2376],[False],[0],[0],[False],['0']
42198,PMC9007089,40102,"Despite significant on-task learning, generalized improvements of working memory training in this trial were limited to (a) improvements for a trained working memory task tested outside of the training software and (b) a small improvement in self-reported hearing ability for those in the experimental group, compared with active controls.",Abstract,[235028],[2377],[2716],[False],[0],[0],[False],['0']
42199,PMC9007089,40103,We found no evidence to suggest that training which primarily targets storage aspects of working memory can result in domain-general improvements that benefit everyday communication for adult hearing aid users.,Abstract,[235035],[2717],[2927],[False],[0],[0],[False],['0']
42200,PMC9007089,40104,These findings are consistent with a significant body of evidence showing that Cogmed training only improves performance for tasks that resemble Cogmed training.,Abstract,[235042],[2928],[3089],[False],[0],[0],[False],['0']
42201,PMC9007089,40105,"Future research should focus on the benefits of interventions that enhance cognition in the context in which it is employed within everyday communication, such as training that targets dynamic aspects of cognitive control important for successful speech-in-noise perception.",Abstract,[235049],[3090],[3364],[False],[0],[0],[False],['0']
42202,PMC9007089,40106,INTRODUCTION,INTRODUCTION,[235056],[3365],[3378],[False],[0],[0],[False],['0']
42203,PMC9007089,40107,The ability to hear is central to individuals’ health and wellbeing.,INTRODUCTION,[235063],[3379],[3447],[False],[0],[0],[False],['0']
42204,PMC9007089,40108,"Hearing loss is a highly prevalent long-term condition, affecting 1.33 billion individuals worldwide (Vos et al.",INTRODUCTION,[235070],[3448],[3560],[False],[0],[0],[False],['0']
42205,PMC9007089,40109,2015).,INTRODUCTION,[235077],[3561],[3567],[False],[0],[0],[False],['0']
42206,PMC9007089,40110,"It is a leading contributor to years lived with disability (YLD), and the second leading global impairment in 2015 (Vos et al.",INTRODUCTION,[235084],[3568],[3694],[False],[0],[0],[False],['0']
42207,PMC9007089,40111,2015).,INTRODUCTION,[235091],[3695],[3701],[False],[0],[0],[False],['0']
42208,PMC9007089,40112,"In the United Kingdom, approximately 12 million people have a significant hearing loss, which equates to more than one in six of the population, estimated to rise to 1 in 5 people by 2035 (RNID 2015, 2021; Office for National Statistics 2019).",INTRODUCTION,[235098],[3702],[3945],[False],[0],[0],[False],['0']
42209,PMC9007089,40113,The vast majority (92%) of those with hearing loss experience mild to moderate loss.,INTRODUCTION,[235105],[3946],[4030],[False],[0],[0],[False],['0']
42210,PMC9007089,40114,"Sensorineural hearing loss is characterized by declines in both peripheral hearing and central auditory processing, which adversely affect both the audibility and clarity of speech, particularly in noise (e.g., Anderson et al.",INTRODUCTION,[235112],[4031],[4257],[False],[0],[0],[False],['0']
42211,PMC9007089,40115,2013a; Mattys et al.,INTRODUCTION,[235119],[4258],[4278],[False],[0],[0],[False],['0']
42212,PMC9007089,40116,2012).,INTRODUCTION,[235126],[4279],[4285],[False],[0],[0],[False],['0']
42213,PMC9007089,40117,"Indeed, listening to speech-in-noise is one of the most common complaints of individuals with hearing loss (Kochkin 2002).",INTRODUCTION,[235133],[4286],[4408],[False],[0],[0],[False],['0']
42214,PMC9007089,40118,"People with mild and moderate hearing loss face substantial difficulties in communication, which can lead to reduced social participation and quality of life (RNID 2015; Barker et al.",INTRODUCTION,[235140],[4409],[4592],[False],[0],[0],[False],['0']
42215,PMC9007089,40119,2017; Heffernan et al.,INTRODUCTION,[235147],[4593],[4615],[False],[0],[0],[False],['0']
42216,PMC9007089,40120,2016).,INTRODUCTION,[235154],[4616],[4622],[False],[0],[0],[False],['0']
42217,PMC9007089,40121,The most common management strategy for hearing loss is the provision and use of hearing aids to amplify sounds (Kiessling et al.,INTRODUCTION,[235161],[4623],[4752],[False],[0],[0],[False],['0']
42218,PMC9007089,40122,2003).,INTRODUCTION,[235168],[4753],[4759],[False],[0],[0],[False],['0']
42219,PMC9007089,40123,A Cochrane systematic review showed that hearing aids significantly improved listening ability and hearing- and health-related quality of life in adults with mild to moderate hearing loss (Ferguson et al.,INTRODUCTION,[235175],[4760],[4964],[False],[0],[0],[False],['0']
42220,PMC9007089,40124,2017).,INTRODUCTION,[235182],[4965],[4971],[False],[0],[0],[False],['0']
42221,PMC9007089,40125,"Nevertheless, hearing aids cannot restore lost hearing and people with hearing loss often report that even for speech sounds that are loud enough to be heard (i.e., supra-threshold), it is not always clear what is being said.",INTRODUCTION,[235189],[4972],[5197],[False],[0],[0],[False],['0']
42222,PMC9007089,40126,"As such, listening can be tiring and effortful (Pichora-Fuller et al.",INTRODUCTION,[235196],[5198],[5267],[False],[0],[0],[False],['0']
42223,PMC9007089,40127,"2016), with listening via hearing aids adding unique cognitive demands (Hafter 2010; Lunner et al.",INTRODUCTION,[235203],[5268],[5366],[False],[0],[0],[False],['0']
42224,PMC9007089,40128,2009; Lunner & Sundewall-Thorén 2007; Ng et al.,INTRODUCTION,[235210],[5367],[5414],[False],[0],[0],[False],['0']
42225,PMC9007089,40129,2014; Rudner and Lunner 2013).,INTRODUCTION,[235217],[5415],[5445],[False],[0],[0],[False],['0']
42226,PMC9007089,40130,Hearing loss has been associated with accelerated rates of cognitive decline and an increased risk of developing dementia (Lin et al.,INTRODUCTION,[235224],[5446],[5579],[False],[0],[0],[False],['0']
42227,PMC9007089,40131,2011b; Lin et al.,INTRODUCTION,[235231],[5580],[5597],[False],[0],[0],[False],['0']
42228,PMC9007089,40132,2013; Livingston et al.,INTRODUCTION,[235238],[5598],[5621],[False],[0],[0],[False],['0']
42229,PMC9007089,40133,2017; 2020 Loughrey et al.,INTRODUCTION,[235245],[5622],[5648],[False],[0],[0],[False],['0']
42230,PMC9007089,40134,2018; Panza et al.,INTRODUCTION,[235252],[5649],[5667],[False],[0],[0],[False],['0']
42231,PMC9007089,40135,"2015; Wayne and Johnsrude 2015), with evidence indicating that hearing loss is the leading modifiable mid-life risk factor for dementia (Livingston et al.",INTRODUCTION,[235259],[5668],[5822],[False],[0],[0],[False],['0']
42232,PMC9007089,40136,2020).,INTRODUCTION,[235266],[5823],[5829],[False],[0],[0],[False],['0']
42233,PMC9007089,40137,"As such, hearing loss is increasingly being recognized as a major public health concern (Livingston et al.",INTRODUCTION,[235273],[5830],[5936],[False],[0],[0],[False],['0']
42234,PMC9007089,40138,2020; Wilson et al.,INTRODUCTION,[235280],[5937],[5956],[False],[0],[0],[False],['0']
42235,PMC9007089,40139,"2019; World Health Organization 2017, 2018) and interventions to address and modify hearing loss are a priority for health research (Henshaw et al.",INTRODUCTION,[235287],[5957],[6104],[False],[0],[0],[False],['0']
42236,PMC9007089,40140,2015; Livingston et al.,INTRODUCTION,[235294],[6105],[6128],[False],[0],[0],[False],['0']
42237,PMC9007089,40141,"2020; NICE 2018; World Health Organization 2017, 2018, 2019).",INTRODUCTION,[235301],[6129],[6190],[False],[0],[0],[False],['0']
42238,PMC9007089,40142,The Role of Working Memory in Listening,INTRODUCTION|The Role of Working Memory in Listening,[235308],[6191],[6230],[False],[0],[0],[False],['0']
42239,PMC9007089,40143,"Over the last three decades, there has been growing consensus that factors including cognitive processes are an essential component to listening (an active process), compared with hearing (a largely passive process) (Dryden et al.",INTRODUCTION|The Role of Working Memory in Listening,[235315],[6231],[6461],[False],[0],[0],[False],['0']
42240,PMC9007089,40144,2017; Gordon-Salant & Fitzgibbons 1997; Anderson Gosselin et al.,INTRODUCTION|The Role of Working Memory in Listening,[235322],[6462],[6526],[False],[0],[0],[False],['0']
42241,PMC9007089,40145,2011; Heinrich et al.,INTRODUCTION|The Role of Working Memory in Listening,[235329],[6527],[6548],[False],[0],[0],[False],['0']
42242,PMC9007089,40146,2016a; Heinrich et al.,INTRODUCTION|The Role of Working Memory in Listening,[235336],[6549],[6571],[False],[0],[0],[False],['0']
42243,PMC9007089,40147,2015; Heinrich et al.,INTRODUCTION|The Role of Working Memory in Listening,[235343],[6572],[6593],[False],[0],[0],[False],['0']
42244,PMC9007089,40148,2016b; Moore et al.,INTRODUCTION|The Role of Working Memory in Listening,[235350],[6594],[6613],[False],[0],[0],[False],['0']
42245,PMC9007089,40149,2014; Pichora-Fuller et al.,INTRODUCTION|The Role of Working Memory in Listening,[235357],[6614],[6641],[False],[0],[0],[False],['0']
42246,PMC9007089,40150,2016).,INTRODUCTION|The Role of Working Memory in Listening,[235364],[6642],[6648],[False],[0],[0],[False],['0']
42247,PMC9007089,40151,One of the most frequently cited frameworks to explain auditory-cognitive interactions for speech-in-noise perception is the Ease of Language Understanding Model (ELU; Rönnberg et al.,INTRODUCTION|The Role of Working Memory in Listening,[235371],[6649],[6832],[False],[0],[0],[False],['0']
42248,PMC9007089,40152,2019; Rönnberg et al.,INTRODUCTION|The Role of Working Memory in Listening,[235378],[6833],[6854],[False],[0],[0],[False],['0']
42249,PMC9007089,40153,2013).,INTRODUCTION|The Role of Working Memory in Listening,[235385],[6855],[6861],[False],[0],[0],[False],['0']
42250,PMC9007089,40154,The basic assumption of the ELU is that individuals possess a battery of stored phonological representations.,INTRODUCTION|The Role of Working Memory in Listening,[235392],[6862],[6971],[False],[0],[0],[False],['0']
42251,PMC9007089,40155,"For cases where the auditory input fails to match stored phonological representation (for example, where auditory input is degraded as a result of hearing loss, or altered by hearing aid signal processing strategies or background noise), increased demands are placed on working memory to help resolve the mismatch (Classon et al.",INTRODUCTION|The Role of Working Memory in Listening,[235399],[6972],[7301],[False],[0],[0],[False],['0']
42252,PMC9007089,40156,2013).,INTRODUCTION|The Role of Working Memory in Listening,[235406],[7302],[7308],[False],[0],[0],[False],['0']
42253,PMC9007089,40157,"Consequently, individuals with greater working memory capacity may be better able to resolve ambiguity, leading to better speech perception in degraded listening conditions (Zekveld et al.",INTRODUCTION|The Role of Working Memory in Listening,[235413],[7309],[7497],[False],[0],[0],[False],['0']
42254,PMC9007089,40158,2012).,INTRODUCTION|The Role of Working Memory in Listening,[235420],[7498],[7504],[False],[0],[0],[False],['0']
42255,PMC9007089,40159,"However, there is a debate in the literature as to whether speech perception relies predominantly on verbal working memory (Rönnberg et al.",INTRODUCTION|The Role of Working Memory in Listening,[235427],[7505],[7644],[False],[0],[0],[False],['0']
42256,PMC9007089,40160,2019; Rönnberg et al.,INTRODUCTION|The Role of Working Memory in Listening,[235434],[7645],[7666],[False],[0],[0],[False],['0']
42257,PMC9007089,40161,"2013), or whether more general working memory, executive, and attentional functions are implicated (see Wayne et al.",INTRODUCTION|The Role of Working Memory in Listening,[235441],[7667],[7783],[False],[0],[0],[False],['0']
42258,PMC9007089,40162,2016).,INTRODUCTION|The Role of Working Memory in Listening,[235448],[7784],[7790],[False],[0],[0],[False],['0']
42259,PMC9007089,40163,"Given the widespread difficulties in speech-in-noise perception, and its association with cognition, interventions such as training programs designed to improve speech-in-noise perception or cognition could play an important role in improving everyday communication, social participation and quality of life for people with hearing loss.",INTRODUCTION|The Role of Working Memory in Listening,[235455],[7791],[8128],[False],[0],[0],[False],['0']
42260,PMC9007089,40164,Auditory and Working Memory Training Interventions,INTRODUCTION|Auditory and Working Memory Training Interventions,[235462],[8129],[8179],[False],[0],[0],[False],['0']
42261,PMC9007089,40165,"Auditory and cognitive training interventions can be delivered via mobile technologies (e.g., smartphones, tablets), computers and the internet, thus offering low-cost forms of self-management support that can be individually tailored and conveniently accessed by people with hearing loss (Ferguson et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235469],[8180],[8485],[False],[0],[0],[False],['0']
42262,PMC9007089,40166,"2015a, 2015b).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235476],[8486],[8500],[False],[0],[0],[False],['0']
42263,PMC9007089,40167,"For any form of training intervention, post-training improvements can be assessed for the trained task(s), termed on-task learning, for untrained tasks, termed off-task learning (or generalization).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235483],[8501],[8699],[False],[0],[0],[False],['0']
42264,PMC9007089,40168,"Generalized improvements can be shown for tasks that are similar to trained tasks (termed near-transfer of learning), or for tasks that are dissimilar to trained tasks (termed far-transfer of learning).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235490],[8700],[8902],[False],[0],[0],[False],['0']
42265,PMC9007089,40169,"In order for a training intervention to be considered effective for people with hearing loss, it should result in sustained generalized improvements that extend beyond trained tasks (i.e.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235497],[8903],[9090],[False],[0],[0],[False],['0']
42266,PMC9007089,40170,"far-transfer of learning), to benefit their everyday listening abilities (Ferguson et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235504],[9091],[9180],[False],[0],[0],[False],['0']
42267,PMC9007089,40171,2015c).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235511],[9181],[9188],[False],[0],[0],[False],['0']
42268,PMC9007089,40172,"Auditory training can be broadly described as a process of training the brain to listen through active engagement with sounds (Schow and Nerbonne 2006), and it has been demonstrated to result in improved speech perception over the course of an adult’s lifespan (Wright and Zhang 2009).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235518],[9189],[9474],[False],[0],[0],[False],['0']
42269,PMC9007089,40173,"As such, auditory training can be offered prior to, or alongside hearing aids to help improve outcomes for people with hearing loss (Ferguson et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235525],[9475],[9623],[False],[0],[0],[False],['0']
42270,PMC9007089,40174,2014; Henshaw & Ferguson 2014).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235532],[9624],[9655],[False],[0],[0],[False],['0']
42271,PMC9007089,40175,"While there is robust evidence to show that auditory training results in improvements for trained tasks, evidence for the transfer of on-task learning to functional improvements for people with hearing loss is mixed (Henshaw et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235539],[9656],[9887],[False],[0],[0],[False],['0']
42272,PMC9007089,40176,2013a).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235546],[9888],[9895],[False],[0],[0],[False],['0']
42273,PMC9007089,40177,We suggest two reasons for this.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235553],[9896],[9928],[False],[0],[0],[False],['0']
42274,PMC9007089,40178,"First, published evidence has historically been of very-low to moderate study quality and so we cannot be certain of the reported estimations of effect.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235560],[9929],[10081],[False],[0],[0],[False],['0']
42275,PMC9007089,40179,"Second, the consideration of auditory-only training stimuli may have overly limited the scope of those prior investigations.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235567],[10082],[10206],[False],[0],[0],[False],['0']
42276,PMC9007089,40180,"Indeed, a number of high-quality studies have since been published (e.g., Anderson et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235574],[10207],[10296],[False],[0],[0],[False],['0']
42277,PMC9007089,40181,2013b; Ferguson et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235581],[10297],[10319],[False],[0],[0],[False],['0']
42278,PMC9007089,40182,2014; Henshaw and Ferguson 2014; Saunders et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235588],[10320],[10368],[False],[0],[0],[False],['0']
42279,PMC9007089,40183,"2016), which show evidence for auditory training-related improvements in untrained measures of cognition, speech perception and self-reported hearing abilities.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235595],[10369],[10529],[False],[0],[0],[False],['0']
42280,PMC9007089,40184,Ferguson et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235602],[10530],[10545],[False],[0],[0],[False],['0']
42281,PMC9007089,40185,"(2014) were the first to suggest that generalized auditory-training-related improvements may be driven by improvements in cognition (attention and working memory), rather than auditory function.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235609],[10546],[10740],[False],[0],[0],[False],['0']
42282,PMC9007089,40186,This prompted us to ask the question “could training cognition directly offer a more effective route to real-world benefit?”,INTRODUCTION|Auditory and Working Memory Training Interventions,[235616],[10741],[10865],[False],[0],[0],[False],['0']
42283,PMC9007089,40187,Cognitive training is defined as a program of mental exercises designed to maintain or improve core cognitive abilities (Simons et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235623],[10866],[11000],[False],[0],[0],[False],['0']
42284,PMC9007089,40188,2016).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235630],[11001],[11007],[False],[0],[0],[False],['0']
42285,PMC9007089,40189,"Although the definition of working memory is often debated, most agree that working memory is a flexible, capacity limited, mental workspace used to store and process information in the service of ongoing cognition (see Morrison & Chein 2011).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235637],[11008],[11251],[False],[0],[0],[False],['0']
42286,PMC9007089,40190,"Cognitive training programs that target working memory abilities train the processing, storage, and manipulation of information in order to challenge and improve this system.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235644],[11252],[11426],[False],[0],[0],[False],['0']
42287,PMC9007089,40191,There are two main approaches to training working memory that differ in terms of their focus on either domain-specific or domain-general components of the working memory system.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235651],[11427],[11604],[False],[0],[0],[False],['0']
42288,PMC9007089,40192,"Domain-specific training targets the development of strategy to enable trainees to recall increasing amounts of information of a particular type (e.g., McNamara & Scott 2001).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235658],[11605],[11780],[False],[0],[0],[False],['0']
42289,PMC9007089,40193,"Domain-general training on the other hand involves core training, such as practice on tasks with increasing working memory demand, to improve domain-general working memory mechanisms (e.g., Klingberg et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235665],[11781],[11987],[False],[0],[0],[False],['0']
42290,PMC9007089,40194,2002).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235672],[11988],[11994],[False],[0],[0],[False],['0']
42291,PMC9007089,40195,"If successful, core training should result in improvements for tasks that are similar to those trained (near-transfer) as well as improvements for cognitive tasks that are untrained (far-transfer).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235679],[11995],[12192],[False],[0],[0],[False],['0']
42292,PMC9007089,40196,"Furthermore, core training may increase performance for other tasks that are reliant on working memory capacity.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235686],[12193],[12305],[False],[0],[0],[False],['0']
42293,PMC9007089,40197,"Given the wealth of published evidence for associations between speech-in-noise perception and working memory performance, and in line with predictions from the ELU model, which state that individuals with greater working memory capacity may be better able to resolve ambiguity, leading to better speech perception in degraded listening conditions (Rönnberg 2013; 2019; Zekveld et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235693],[12306],[12690],[False],[0],[0],[False],['0']
42294,PMC9007089,40198,"2012), we aimed to examine whether improving domain-general working memory processes using core training could improve outcomes for adults with hearing loss who use hearing aids.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235700],[12691],[12869],[False],[0],[0],[False],['0']
42295,PMC9007089,40199,"Based on our prior research, which showed significant generalized improvements in working memory, attention and speech-in-noise performance arising from an auditory training task (phoneme discrimination; Ferguson et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235707],[12870],[13089],[False],[0],[0],[False],['0']
42296,PMC9007089,40200,"2014; Henshaw & Ferguson 2014), we sought to identify whether working memory capacity (core training) directly could result in greater transfer of learning to the same outcome measures, both immediately and for a period of time after the training had concluded.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235714],[13090],[13351],[False],[0],[0],[False],['0']
42297,PMC9007089,40201,"The selected training program for the current trial was Cogmed RM, a commercially available working memory training program suitable for use by adults that has been the subject of significant amount of basic and applied research across a range of healthy and clinical populations (e.g., Gathercole et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235721],[13352],[13656],[False],[0],[0],[False],['0']
42298,PMC9007089,40202,2012; Shipstead et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235728],[13657],[13679],[False],[0],[0],[False],['0']
42299,PMC9007089,40203,"2012, Shinaver et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235735],[13680],[13701],[False],[0],[0],[False],['0']
42300,PMC9007089,40204,2014).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235742],[13702],[13708],[False],[0],[0],[False],['0']
42301,PMC9007089,40205,Cogmed is an 11-task multifaceted training program described as targeting verbal and visuospatial working memory and storage.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235749],[13709],[13834],[False],[0],[0],[False],['0']
42302,PMC9007089,40206,"The majority of training tasks (6/11) target storage aspects of working memory (such as remembering a sequence of numbers, letters, or objects for immediate recall).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235756],[13835],[14000],[False],[0],[0],[False],['0']
42303,PMC9007089,40207,"Some tasks (4/11) required manipulation of information such as recall in reverse or numerical order, and one of the 11 tasks elicits associative memory.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235763],[14001],[14153],[False],[0],[0],[False],['0']
42304,PMC9007089,40208,"Some of the key advantages of Cogmed are that it can be delivered remotely via the internet, making it widely accessible for use at home.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235770],[14154],[14291],[False],[0],[0],[False],['0']
42305,PMC9007089,40209,"Additionally, and importantly for the robust RCT design of the current study, the “research edition” of Cogmed RM offers the ability to effectively blind participants and researchers using adaptive and nonadaptive (placebo) versions of the training.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235777],[14292],[14541],[False],[0],[0],[False],['0']
42306,PMC9007089,40210,"There are however a number of clear limitations to selecting a commercially available training product, including a lack of control over the underlying mechanisms of training, as well as a lack of flexibility in the training protocol itself.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235784],[14542],[14783],[False],[0],[0],[False],['0']
42307,PMC9007089,40211,This is a particular issue for “kitchen-sink” training programs such as Cogmed that use several different types of task and stimuli designed to impact different components of the working memory system as it becomes difficult to determine which components of the training may underlie subsequent cognitive improvements.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235791],[14784],[15102],[False],[0],[0],[False],['0']
42308,PMC9007089,40212,"However, it is also argued that one advantage of such an approach is that the chance of one, or some combination of, the training tasks might result in beneficial improvements in outcomes for trainees (Morrison & Chein 2011).",INTRODUCTION|Auditory and Working Memory Training Interventions,[235798],[15103],[15328],[False],[0],[0],[False],['0']
42309,PMC9007089,40213,The vast literature for the effectiveness of Cogmed training reports mixed findings.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235805],[15329],[15413],[False],[0],[0],[False],['0']
42310,PMC9007089,40214,"Some studies have shown improvements in working memory capacity, individual measures of cognitive control, and fluid intelligence for both adults and children (see Morrison & Chein 2011, Shinaver et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235812],[15414],[15616],[False],[0],[0],[False],['0']
42311,PMC9007089,40215,"2014 for reviews), with improved sustained attention effects reported to persist up to 6 months post-training (Shinaver et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235819],[15617],[15743],[False],[0],[0],[False],['0']
42312,PMC9007089,40216,2014).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235826],[15744],[15750],[False],[0],[0],[False],['0']
42313,PMC9007089,40217,"Specifically, outcomes domains reported to improve as a result of Cogmed training include cognitive control (Stroop) and fluid intelligence (Raven’s Progressive Matrices) in both healthy young adults and children with ADHD (Klingberg et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235833],[15751],[15991],[False],[0],[0],[False],['0']
42314,PMC9007089,40218,2002).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235840],[15992],[15998],[False],[0],[0],[False],['0']
42315,PMC9007089,40219,These findings have been replicated or partially replicated in similar populations (Klingberg et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235847],[15999],[16099],[False],[0],[0],[False],['0']
42316,PMC9007089,40220,2005; Olesen et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235854],[16100],[16119],[False],[0],[0],[False],['0']
42317,PMC9007089,40221,"2004; Westerberg & Klingberg 2007, Holmes et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235861],[16120],[16168],[False],[0],[0],[False],['0']
42318,PMC9007089,40222,2009; Holmes et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235868],[16169],[16188],[False],[0],[0],[False],['0']
42319,PMC9007089,40223,2010) and in studies of healthy children (Thorell et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235875],[16189],[16245],[False],[0],[0],[False],['0']
42320,PMC9007089,40224,2009).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235882],[16246],[16252],[False],[0],[0],[False],['0']
42321,PMC9007089,40225,"However, many other studies have failed to show transfer beyond trained Cogmed tasks, which has been argued to reflect the components of working memory targeted by this training approach (see Shipstead et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235889],[16253],[16461],[False],[0],[0],[False],['0']
42322,PMC9007089,40226,2012 for a comprehensive review).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235896],[16462],[16495],[False],[0],[0],[False],['0']
42323,PMC9007089,40227,Shipstead et al.,INTRODUCTION|Auditory and Working Memory Training Interventions,[235903],[16496],[16512],[False],[0],[0],[False],['0']
42324,PMC9007089,40228,"(2012) argue that greater scientific rigor should be employed across the board, and more attention should be paid to improving component memory processes aligned to the intended target of training (e.g., secondary rather than primary memory for children with ADHD, Gibson et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235910],[16513],[16791],[False],[0],[0],[False],['0']
42325,PMC9007089,40229,2011).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235917],[16792],[16798],[False],[0],[0],[False],['0']
42326,PMC9007089,40230,"For Cogmed training research in older adults, published studies have examined a fairly restricted set of outcomes, which it has been argued may not be ecologically relevant for older populations (Richmond et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235924],[16799],[17010],[False],[0],[0],[False],['0']
42327,PMC9007089,40231,2011).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235931],[17011],[17017],[False],[0],[0],[False],['0']
42328,PMC9007089,40232,"At the time of conception of this research, there was some preliminary evidence to suggest that Cogmed training may result in improved sentence repetition skills in a small pilot study of children with profound hearing loss who used cochlear implants (Kronenberger et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235938],[17018],[17289],[False],[0],[0],[False],['0']
42329,PMC9007089,40233,2011).,INTRODUCTION|Auditory and Working Memory Training Interventions,[235945],[17290],[17296],[False],[0],[0],[False],['0']
42330,PMC9007089,40234,"We sought to expand this field of research to examine applied benefits of Cogmed training to cognition, speech perception, and everyday listening for a population of older adults who used hearing aids, both to generate new knowledge about the associated mechanisms of training and transfer, and to inform future research and intervention development directions.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235952],[17297],[17658],[False],[0],[0],[False],['0']
42331,PMC9007089,40235,"Here, we report the results of a blinded, randomized active-controlled trial designed to assess the benefits of a 5-week program of Cogmed training for adult hearing aid users aged 50 to 74 years old with mild to moderate hearing loss, compared with an active control group from the same population.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235959],[17659],[17958],[False],[0],[0],[False],['0']
42332,PMC9007089,40236,"In line with published recommendations for high-quality research (e.g., Henshaw & Ferguson 2013a; Jaeggi et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235966],[17959],[18070],[False],[0],[0],[False],['0']
42333,PMC9007089,40237,"2013, Melby-Lervåg et al.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235973],[18071],[18096],[False],[0],[0],[False],['0']
42334,PMC9007089,40238,"2016), we employ a robust study design, examine individual differences in training and transfer for participants in the Experimental Group, and extend our assessments to examine long-term (6 months post-training) benefits.",INTRODUCTION|Auditory and Working Memory Training Interventions,[235980],[18097],[18319],[False],[0],[0],[False],['0']
42335,PMC9007089,40239,MATERIALS AND METHODS,MATERIALS AND METHODS,[235987],[18320],[18345],[False],[0],[0],[False],['0']
42336,PMC9007089,40240,This trial is reported in accordance with the CONSORT statement (Schulz et al.,MATERIALS AND METHODS,[235994],[18346],[18424],[False],[0],[0],[False],['0']
42337,PMC9007089,40241,2010).,MATERIALS AND METHODS,[236001],[18425],[18431],[False],[0],[0],[False],['0']
42338,PMC9007089,40242,The working memory training intervention elements are reported in accordance with TIDierR guidance (Hoffmann et al.,MATERIALS AND METHODS,[236008],[18432],[18547],[False],[0],[0],[False],['0']
42339,PMC9007089,40243,2014).,MATERIALS AND METHODS,[236015],[18548],[18554],[False],[0],[0],[False],['0']
42340,PMC9007089,40244,Approvals were received from the Nottingham Research Ethics Committee 2 (08/H0408/172) and Nottingham University Hospitals Trust Research and Development (08ET002).,MATERIALS AND METHODS,[236022],[18555],[18719],[False],[0],[0],[False],['0']
42341,PMC9007089,40245,Research was conducted in accordance with the World Medical Association Declaration of Helsinki.,MATERIALS AND METHODS,[236029],[18720],[18816],[False],[0],[0],[False],['0']
42342,PMC9007089,40246,The trial was preregistered (www.clinicaltrials.gov: NCT01892007) and the study protocol prepublished in a peer-reviewed journal (Henshaw et al.,MATERIALS AND METHODS,[236036],[18817],[18961],[False],[0],[0],[False],['0']
42343,PMC9007089,40247,2013b).,MATERIALS AND METHODS,[236043],[18962],[18969],[False],[0],[0],[False],['0']
42344,PMC9007089,40248,Study Design,MATERIALS AND METHODS|Study Design,[236050],[18970],[18982],[False],[0],[0],[False],['0']
42345,PMC9007089,40249,"A single-center, phase II, active-controlled RCT with participant and outcome assessor blinding, and minimized allocation (Scott et al.",MATERIALS AND METHODS|Study Design,[236057],[18983],[19118],[False],[0],[0],[False],['0']
42346,PMC9007089,40250,"2002) of participants to one of the two groups (adaptive training or nonadaptive training) according to: age (younger = 50 to 62 years/older = 63 to 74 years), sex (m/f), baseline working memory [Backward Digit Span, n trials correct (maximum = 14), low ≤6/high ≥7], and hearing aid use (unilateral/bilateral), with a 1:1 allocation.",MATERIALS AND METHODS|Study Design,[236064],[19119],[19452],[False],[0],[0],[False],['0']
42347,PMC9007089,40251,Group sizes were set with the goal to detect a minimum improvement of 1.5 words (15%) in the primary outcome measure (Visual Letter Monitoring [VLM] Task) based on 80% power and a 1-sided type I error rate of 5%.,MATERIALS AND METHODS|Study Design,[236071],[19453],[19665],[False],[0],[0],[False],['0']
42348,PMC9007089,40252,A pooled SD of 2.118 was used to derive the effect sizes and resulted in a total of 27 participants in each group.,MATERIALS AND METHODS|Study Design,[236078],[19666],[19780],[False],[0],[0],[False],['0']
42349,PMC9007089,40253,"With an anticipated participant attrition rate of 15%, a total of 31 participants were recruited per group.",MATERIALS AND METHODS|Study Design,[236085],[19781],[19888],[False],[0],[0],[False],['0']
42350,PMC9007089,40254,Participants,MATERIALS AND METHODS|Participants,[236092],[19889],[19901],[False],[0],[0],[False],['0']
42351,PMC9007089,40255,Participants were recruited from the NIHR Nottingham Biomedical Research Centre database of hearing research volunteers.,MATERIALS AND METHODS|Participants,[236099],[19902],[20022],[False],[0],[0],[False],['0']
42352,PMC9007089,40256,Adult hearing aid users aged 50 to 74 years were invited to participate in the study.,MATERIALS AND METHODS|Participants,[236106],[20023],[20108],[False],[0],[0],[False],['0']
42353,PMC9007089,40257,The age range was selected to make comparisons with prior auditory training studies (Ferguson et al.,MATERIALS AND METHODS|Participants,[236113],[20109],[20209],[False],[0],[0],[False],['0']
42354,PMC9007089,40258,2014; Henshaw and Ferguson 2014).,MATERIALS AND METHODS|Participants,[236120],[20210],[20243],[False],[0],[0],[False],['0']
42355,PMC9007089,40259,All participants reported that they used their hearing aids daily.,MATERIALS AND METHODS|Participants,[236127],[20244],[20310],[False],[0],[0],[False],['0']
42356,PMC9007089,40260,"We also recorded whether participants had received formal musical training, as this has been repeatedly shown to be associated with enhanced speech-in-noise processing (Strait et al.",MATERIALS AND METHODS|Participants,[236134],[20311],[20493],[False],[0],[0],[False],['0']
42357,PMC9007089,40261,2012; Varnet et al.,MATERIALS AND METHODS|Participants,[236141],[20494],[20513],[False],[0],[0],[False],['0']
42358,PMC9007089,40262,2015).,MATERIALS AND METHODS|Participants,[236148],[20514],[20520],[False],[0],[0],[False],['0']
42359,PMC9007089,40263,Individuals who wished to participate were assessed according to the inclusion and exclusion criteria.,MATERIALS AND METHODS|Participants,[236155],[20521],[20623],[False],[0],[0],[False],['0']
42360,PMC9007089,40264,Eligible individuals took part in an initial screening assessment at the NIHR Nottingham Biomedical Research Centre.,MATERIALS AND METHODS|Participants,[236162],[20624],[20740],[False],[0],[0],[False],['0']
42361,PMC9007089,40265,Procedure,Procedure,[236169],[20741],[20753],[False],[0],[0],[False],['0']
42362,PMC9007089,40266,"Hearing aid users (n = 110) attended an initial screening assessment between September 2012 and March 2014, where informed consent was obtained from those eligible to participate.",Procedure,[236176],[20754],[20933],[False],[0],[0],[False],['0']
42363,PMC9007089,40267,"Following the screening assessment, 62 participants met the inclusion criteria and were recruited into the study.",Procedure,[236183],[20934],[21047],[False],[0],[0],[False],['0']
42364,PMC9007089,40268,"The participants completed two baseline outcome assessments (T1 and T2) at least 2 days apart (mean = 6.9 days, SD = 2.4, range = 2 to 14 days), comprising measures of cognition, speech perception and self-reported hearing (Fig.",Procedure,[236190],[21048],[21276],[False],[0],[0],[False],['0']
42365,PMC9007089,40269,1).,Procedure,[236197],[21277],[21280],[False],[0],[0],[False],['0']
42366,PMC9007089,40270,All outcomes were completed by participants while wearing their hearing aids.,Procedure,[236204],[21281],[21358],[False],[0],[0],[False],['0']
42367,PMC9007089,40271,"Given that performance for the second exposure to a novel measure is assumed to be more reflective of true performance than that of the first exposure, where participants are learning how to complete each task (Ferguson et al.",Procedure,[236211],[21359],[21585],[False],[0],[0],[False],['0']
42368,PMC9007089,40272,"2014; McArthur 2007), T2 was used as the pretraining baseline.",Procedure,[236218],[21586],[21648],[False],[0],[0],[False],['0']
42369,PMC9007089,40273,This minimized the risk of procedural learning effects by providing adequate practice and familiarization before the training phase.,Procedure,[236225],[21649],[21781],[False],[0],[0],[False],['0']
42370,PMC9007089,40274,"On completion of the T2 assessment, participants were randomized into two groups by the lead researcher (H.H.)",Procedure,[236232],[21782],[21892],[False],[0],[0],[False],['0']
42371,PMC9007089,40275,"and allocated log-in details to either the adaptive (experimental group, n = 31) or nonadaptive (active control group, n = 31) web-based working memory training program.",Procedure,[236239],[21893],[22062],[False],[0],[0],[False],['0']
42372,PMC9007089,40276,Both participants and the researchers conducting the outcome assessments were blind to participants’ group allocation.,Procedure,[236246],[22063],[22181],[False],[0],[0],[False],['0']
42373,PMC9007089,40277,At the end of the T2 assessment an initial Cogmed familiarization session was conducted by the lead researcher (H.H.,Procedure,[236253],[22182],[22298],[False],[0],[0],[False],['0']
42374,PMC9007089,40278,"), a psychologist who had received appropriate training from, and held a Research Licence Agreement with, Pearson, Inc (the providers of Cogmed training).",Procedure,[236260],[22299],[22453],[False],[0],[0],[False],['0']
42375,PMC9007089,40279,"Following this, the 5-week training program was completed by participants online, in their own homes using their personal computer or laptop, while wearing their hearing aid(s).",Procedure,[236267],[22454],[22631],[False],[0],[0],[False],['0']
42376,PMC9007089,40280,Training data were automatically uploaded following each session to secure Cogmed servers.,Procedure,[236274],[22632],[22722],[False],[0],[0],[False],['0']
42377,PMC9007089,40281,Participants were encouraged to contact the research unit if they faced any technical issues with the training program.,Procedure,[236281],[22723],[22842],[False],[0],[0],[False],['0']
42378,PMC9007089,40282,"Progress was monitored remotely by the lead researcher, with telephone calls made to participants if sessions were missed in order to help address any issues.",Procedure,[236288],[22843],[23001],[False],[0],[0],[False],['0']
42379,PMC9007089,40283,Participants in both groups attended a post-training outcome measures assessment (T3).,Procedure,[236295],[23002],[23087],[False],[0],[0],[False],['0']
42380,PMC9007089,40284,"Those in the Active Control Group completed the trial at this point and were debriefed as to the nature of the trial and were offered the adaptive training to complete at home, if they wished.",Procedure,[236302],[23088],[23280],[False],[0],[0],[False],['0']
42381,PMC9007089,40285,Those in the Experimental Group only were invited to return to the research unit for a 6-month post-training follow-up appointment (T4).,Procedure,[236309],[23281],[23417],[False],[0],[0],[False],['0']
42382,PMC9007089,40286,"Participants were offered a nominal attendance fee (£5 per hour) and travel expenses for each visit to the research unit, and an inconvenience fee of £20 to, in part, recompense their time for undertaking the at-home training.",Procedure,[236316],[23418],[23644],[False],[0],[0],[False],['0']
42383,PMC9007089,40287,"Five participants (n = 4 Experimental Group, n = 1 Active Control Group) were lost to follow-up at the post-training intervention session T3 (week 7), and five participants in the Experimental Group failed to return for the 6-month follow-up assessment T4 (week 31).",Procedure,[236323],[23645],[23911],[False],[0],[0],[False],['0']
42384,PMC9007089,40288,"Reasons given included illness, the levels of commitment required to complete a longitudinal trial, and the burden of multiple outcome assessments.",Procedure,[236330],[23912],[24059],[False],[0],[0],[False],['0']
42385,PMC9007089,40289,As per the study protocol (Henshaw and Ferguson 2013b) those participants who withdrew from the study were not replaced.,Procedure,[236337],[24060],[24180],[False],[0],[0],[False],['0']
42386,PMC9007089,40290,A total of 57 participants completed the trial and their data were included in all subsequent analyses (Fig.,Procedure,[236344],[24181],[24289],[False],[0],[0],[False],['0']
42387,PMC9007089,40291,2).,Procedure,[236351],[24290],[24293],[False],[0],[0],[False],['0']
42388,PMC9007089,40292,Participants in the two groups did not differ significantly in terms of their demographic information (Table 1).,Procedure,[236358],[24294],[24406],[False],[0],[0],[False],['0']
42389,PMC9007089,40293,"Baseline characteristics for the participants who withdrew from the study were statistically comparable to participants who completed their involvement in the research [5 males, 5 females, x2 (1) = 0.24, p = 0.878; mean age = 65.20, SD = 6.46, t(65) = −0.164, p = 0.870; better-ear pure-tone average audiometric thresholds = 40.80 dB HL, SD = 13.17, t(65) = −0.119, p = 0.906]; T1 Backward digit span = 7.40, SD = 2.76, t(65) = −0.380, p = 0.705.",Procedure,[236365],[24407],[24853],[False],[0],[0],[False],['0']
42390,PMC9007089,40294,Audiometric Testing and Cognitive Screening,Procedure|Audiometric Testing and Cognitive Screening,[236372],[24854],[24897],[False],[0],[0],[False],['0']
42391,PMC9007089,40295,Audiometric testing took place at the initial screening assessment.,Procedure|Audiometric Testing and Cognitive Screening,[236379],[24898],[24965],[False],[0],[0],[False],['0']
42392,PMC9007089,40296,Otoscopy was performed according to the BSA recommended procedure for ear examinations (British Society of Audiology 2010).,Procedure|Audiometric Testing and Cognitive Screening,[236386],[24966],[25089],[False],[0],[0],[False],['0']
42393,PMC9007089,40297,"Unaided pure-tone air conduction thresholds at 0.25, 0.5, 1, 2, 3, 4, and 8 kHz were obtained for each ear and pure-tone bone conduction thresholds at 0.5, 1, and 2 kHz as required, following the BSA recommended procedure for pure-tone audiometry (British Society of Audiology 2011).",Procedure|Audiometric Testing and Cognitive Screening,[236393],[25090],[25373],[False],[0],[0],[False],['0']
42394,PMC9007089,40298,"Thresholds were obtained in a sound-attenuated booth using a Siemens Unity PC audiometer, Sennheiser HDA-200 headphones, and B71 Radioear transducer.",Procedure|Audiometric Testing and Cognitive Screening,[236400],[25374],[25523],[False],[0],[0],[False],['0']
42395,PMC9007089,40299,The Montreal Cognitive Assessment was administered by a researcher in a quiet testing room.,Procedure|Audiometric Testing and Cognitive Screening,[236407],[25524],[25615],[False],[0],[0],[False],['0']
42396,PMC9007089,40300,Scores were adjusted according to education level and a score of 26/30 or greater was considered to indicate normal cognitive function (Nasreddine et al.,Procedure|Audiometric Testing and Cognitive Screening,[236414],[25616],[25769],[False],[0],[0],[False],['0']
42397,PMC9007089,40301,2005).,Procedure|Audiometric Testing and Cognitive Screening,[236421],[25770],[25776],[False],[0],[0],[False],['0']
42398,PMC9007089,40302,Working Memory Training Intervention,Procedure|Working Memory Training Intervention,[236428],[25777],[25813],[False],[0],[0],[False],['0']
42399,PMC9007089,40303,"The research edition of Cogmed RM working memory training (Pearson Education, Inc) is an adaptive, web-based training program comprising 11 working memory training tasks, of which participants were required to work through 8 of the 11 possible tasks at each session (as determined by the training software per session, consistent across participants).",Procedure|Working Memory Training Intervention,[236435],[25814],[26165],[False],[0],[0],[False],['0']
42400,PMC9007089,40304,The training tasks are described as visuospatial and verbal working memory and storage (Henshaw & Ferguson 2013b).,Procedure|Working Memory Training Intervention,[236442],[26166],[26280],[False],[0],[0],[False],['0']
42401,PMC9007089,40305,"Table 2 provides a process-level description of the individual training tasks, which shows that the majority of training tasks target storage aspects of working memory (remembering a sequence of numbers, letters, or objects for immediate recall).",Procedure|Working Memory Training Intervention,[236449],[26281],[26527],[False],[0],[0],[False],['0']
42402,PMC9007089,40306,"Some tasks require manipulation of information such as recall in reverse or numerical order, and one task elicits associative memory.",Procedure|Working Memory Training Intervention,[236456],[26528],[26661],[False],[0],[0],[False],['0']
42403,PMC9007089,40307,"Participants were required to train for approximately 35 to 45 minutes per day, 5 days a week for 5 weeks (total 25 training sessions), completing 8 individual training tasks per day and taking regular breaks where required.",Procedure|Working Memory Training Intervention,[236463],[26662],[26886],[False],[0],[0],[False],['0']
42404,PMC9007089,40308,Auditory and visual feedback was provided for correct and incorrect responses.,Procedure|Working Memory Training Intervention,[236470],[26887],[26965],[False],[0],[0],[False],['0']
42405,PMC9007089,40309,"Participants completed training at home using their own personal computer, laptop or tablet PC.",Procedure|Working Memory Training Intervention,[236477],[26966],[27061],[False],[0],[0],[False],['0']
42406,PMC9007089,40310,Adaptive Training,Procedure|Adaptive Training,[236484],[27062],[27079],[False],[0],[0],[False],['0']
42407,PMC9007089,40311,"Individuals randomized to the Experimental Group received an adaptive version of Cogmed RM working memory training, where training task difficulty (number of to-be-remembered items) was varied based on individual performance, to maintain average daily levels of 60% trials correct.",Procedure|Adaptive Training,[236491],[27080],[27361],[False],[0],[0],[False],['0']
42408,PMC9007089,40312,Nonadaptive Training,Procedure|Nonadaptive Training,[236498],[27362],[27382],[False],[0],[0],[False],['0']
42409,PMC9007089,40313,Individuals randomized to the Active Control Group received identical training software and training protocols.,Procedure|Nonadaptive Training,[236505],[27383],[27494],[False],[0],[0],[False],['0']
42410,PMC9007089,40314,"However, training task difficulty was fixed at 3 to-be-remembered items and did not adapt with individual performance.",Procedure|Nonadaptive Training,[236512],[27495],[27613],[False],[0],[0],[False],['0']
42411,PMC9007089,40315,Training Aides,Procedure|Training Aides,[236519],[27614],[27628],[False],[0],[0],[False],['0']
42412,PMC9007089,40316,"Wherever possible, participants were supported by their most frequent communication partner (typically their spouse), who served as “Training Aide”.",Procedure|Training Aides,[236526],[27629],[27777],[False],[0],[0],[False],['0']
42413,PMC9007089,40317,"This is a requirement of Cogmed training and serves to monitor progress, avoid undesired tactics (such as writing down numbers or saying numbers out loud), offer encouragement, and suggest rest-breaks should participants become tired or frustrated with training tasks.",Procedure|Training Aides,[236533],[27778],[28046],[False],[0],[0],[False],['0']
42414,PMC9007089,40318,"This was particularly important for individuals in the Experimental Group who received a challenging adaptive training program, but was implemented in the same way across both groups to facilitate participant and researcher blinding.",Procedure|Training Aides,[236540],[28047],[28280],[False],[0],[0],[False],['0']
42415,PMC9007089,40319,Training aides supported 28/30 (93.3%) of participants in the Active Control Group and 24/27 (88.9%) of participants in the Experimental Group.,Procedure|Training Aides,[236547],[28281],[28424],[False],[0],[0],[False],['0']
42416,PMC9007089,40320,Training aides attended the unit with participants at the pretraining assessment (T2) where they were briefed on their role.,Procedure|Training Aides,[236554],[28425],[28549],[False],[0],[0],[False],['0']
42417,PMC9007089,40321,Both participants and training aides were introduced to the training software via a short demonstration at the end of the assessment session.,Procedure|Training Aides,[236561],[28550],[28691],[False],[0],[0],[False],['0']
42418,PMC9007089,40322,The demonstration was the same for both participant groups.,Procedure|Training Aides,[236568],[28692],[28751],[False],[0],[0],[False],['0']
42419,PMC9007089,40323,Time-on-Task Weighting,Procedure|Time-on-Task Weighting,[236575],[28752],[28774],[False],[0],[0],[False],['0']
42420,PMC9007089,40324,"Given that the Active Control Group had a task that inherently required less time to complete than the Experimental Group (less to-be-remembered items resulting in shorter trials), the number of trials overall was weighted (increased by 30%, the maximum available weighting allowed by the training software) to help equate the total time spent training between the two groups.",Procedure|Time-on-Task Weighting,[236582],[28775],[29151],[False],[0],[0],[False],['0']
42421,PMC9007089,40325,Cognitive and Speech Testing,Cognitive and Speech Testing,[236589],[29152],[29181],[False],[0],[0],[False],['0']
42422,PMC9007089,40326,Cognitive and speech perception measures were completed in a purpose-designed quiet test room.,Cognitive and Speech Testing,[236596],[29182],[29276],[False],[0],[0],[False],['0']
42423,PMC9007089,40327,"Visual stimuli were presented using a 21″ screen (Genelec, Inc) placed 50 cm in front of the participant.",Cognitive and Speech Testing,[236603],[29277],[29382],[False],[0],[0],[False],['0']
42424,PMC9007089,40328,"Unless otherwise stated, auditory stimuli were delivered via a Logitech LS11 speaker placed directly in front of the participant at a distance of 1 m. Participants wore their hearing aid(s) throughout testing.",Cognitive and Speech Testing,[236610],[29383],[29592],[False],[0],[0],[False],['0']
42425,PMC9007089,40329,Cognitive and speech perception measures were obtained in a fixed order that was the same for all participants and all assessment sessions.,Cognitive and Speech Testing,[236617],[29593],[29732],[False],[0],[0],[False],['0']
42426,PMC9007089,40330,"Volume levels were set to the individual participants most comfortable loudness level (most comfortable loudness [MCL]) (Ventry, Woods, Rubin, & Hill 1971) at the first outcome assessment session (T1) and recorded and maintained for each of their subsequent assessments.",Cognitive and Speech Testing,[236624],[29733],[30003],[False],[0],[0],[False],['0']
42427,PMC9007089,40331,"To determine individuals’ MCL, a list of 5 AB words in quiet (Boothroyd 1968) were played on continuous loop with the speaker volume turned down and participants were asked to indicate to the researcher when the speaker volume was loud enough so that they could clearly hear all of the words but not uncomfortably loud.",Cognitive and Speech Testing,[236631],[30004],[30323],[False],[0],[0],[False],['0']
42428,PMC9007089,40332,"To ensure the MCL level was appropriate, participants were given a second list of AB words in quiet at their chosen MCL and were asked to repeat them back.",Cognitive and Speech Testing,[236638],[30324],[30479],[False],[0],[0],[False],['0']
42429,PMC9007089,40333,"If any of the five words were repeated incorrectly, or if participants’ were unhappy with the MCL they had set, step 1 was repeated.",Cognitive and Speech Testing,[236645],[30480],[30612],[False],[0],[0],[False],['0']
42430,PMC9007089,40334,Outcome Measures,Cognitive and Speech Testing|Outcome Measures,[236652],[30613],[30629],[False],[0],[0],[False],['0']
42431,PMC9007089,40335,"Measures were selected to assess improvements for trained tasks, domain-general improvements in working memory, and any associated improvements in outcome domains important to people with hearing loss and hearing aid users (cognition, speech perception and self-reported hearing, Ferguson et al.",Cognitive and Speech Testing|Outcome Measures,[236659],[30630],[30925],[False],[0],[0],[False],['0']
42432,PMC9007089,40336,2014; Granberg et al.,Cognitive and Speech Testing|Outcome Measures,[236666],[30926],[30947],[False],[0],[0],[False],['0']
42433,PMC9007089,40337,2014).,Cognitive and Speech Testing|Outcome Measures,[236673],[30948],[30954],[False],[0],[0],[False],['0']
42434,PMC9007089,40338,Primary Outcome Measure •,Cognitive and Speech Testing|Primary Outcome Measure •,[236680],[30955],[30980],[False],[0],[0],[False],['0']
42435,PMC9007089,40339,"Visual Letter Monitoring task (VLM), Working Memory Updating (Untrained) •",Cognitive and Speech Testing|Primary Outcome Measure •,[236687],[30981],[31055],[False],[0],[0],[False],['0']
42436,PMC9007089,40340,"The VLM task is a visual task of working memory updating (Gatehouse, Naylor, & Elberling 2006), which is not trained within the Cogmed working memory training program.",Cognitive and Speech Testing|Primary Outcome Measure •,[236694],[31056],[31223],[False],[0],[0],[False],['0']
42437,PMC9007089,40341,Ten consonant-vowel-consonant (CVC) words are embedded in an 80-letter sequence.,Cognitive and Speech Testing|Primary Outcome Measure •,[236701],[31224],[31304],[False],[0],[0],[False],['0']
42438,PMC9007089,40342,"Two sequences are presented to participants at each outcome assessment in a counterbalanced order, at varying difficulty levels.",Cognitive and Speech Testing|Primary Outcome Measure •,[236708],[31305],[31433],[False],[0],[0],[False],['0']
42439,PMC9007089,40343,Individual letters are displayed sequentially on a computer screen at a rate of 2 seconds per letter (least difficult condition: VLM 2 seconds/letter) and 1 second per letter (most difficult condition: VLM 1 second/letter).,Cognitive and Speech Testing|Primary Outcome Measure •,[236715],[31434],[31657],[False],[0],[0],[False],['0']
42440,PMC9007089,40344,"Participants are asked to press the keyboard “space bar” (hit) when three consecutive letters formed a recognized CVC word (for example, M-A-T).",Cognitive and Speech Testing|Primary Outcome Measure •,[236722],[31658],[31802],[False],[0],[0],[False],['0']
42441,PMC9007089,40345,Task performance is scored as the total number of hits (maximum score of ten per list).,Cognitive and Speech Testing|Primary Outcome Measure •,[236729],[31803],[31890],[False],[0],[0],[False],['0']
42442,PMC9007089,40346,"VLM was selected as the primary outcome measure as it provides an opportunity to examine transfer of learning from trained Cogmed tasks to an untrained working memory task, thus assessing domain-general improvements in working memory capacity.",Cognitive and Speech Testing|Primary Outcome Measure •,[236736],[31891],[32134],[False],[0],[0],[False],['0']
42443,PMC9007089,40347,The use of VLM also enables us to draw direct comparisons between results in this trial with our prior studies of auditory training interventions in similar populations (Ferguson et al.,Cognitive and Speech Testing|Primary Outcome Measure •,[236743],[32135],[32320],[False],[0],[0],[False],['0']
42444,PMC9007089,40348,2014; Henshaw and Ferguson 2014).,Cognitive and Speech Testing|Primary Outcome Measure •,[236750],[32321],[32354],[False],[0],[0],[False],['0']
42445,PMC9007089,40349,Secondary Outcome Measures •,Secondary Outcome Measures •,[236757],[32355],[32384],[False],[0],[0],[False],['0']
42446,PMC9007089,40350,Cognition •,Secondary Outcome Measures •|Cognition •,[236764],[32385],[32396],[False],[0],[0],[False],['0']
42447,PMC9007089,40351,"Backward Digit Span, Simple Span Working Memory (Storage and Manipulation, Trained) •",Secondary Outcome Measures •|Cognition •,[236771],[32397],[32482],[False],[0],[0],[False],['0']
42448,PMC9007089,40352,"The backward digit span, which is trained within Cogmed (two training tasks; Input module, Input module with lid) is assessed outside of the training software as a separate task within the outcome measure battery.",Secondary Outcome Measures •|Cognition •,[236778],[32483],[32696],[False],[0],[0],[False],['0']
42449,PMC9007089,40353,"A subtest from the Wechsler Adult Intelligence Scale, Third Edition (WAIS-III) (Wechsler 1997), this task involves listening to a string of numbers of increasing length and repeating them in reverse order.",Secondary Outcome Measures •|Cognition •,[236785],[32697],[32902],[False],[0],[0],[False],['0']
42450,PMC9007089,40354,The test is presented using prerecorded digits delivered using the Medical Research Council (MRC) Institute of Hearing Research System for Testing Auditory Responses (IHR-STAR) platform via a speaker situated directly in front of the participant.,Secondary Outcome Measures •|Cognition •,[236792],[32903],[33149],[False],[0],[0],[False],['0']
42451,PMC9007089,40355,"Trials begin with strings of two numbers, finishing at strings of eight.",Secondary Outcome Measures •|Cognition •,[236799],[33150],[33222],[False],[0],[0],[False],['0']
42452,PMC9007089,40356,Each string length is presented twice.,Secondary Outcome Measures •|Cognition •,[236806],[33223],[33261],[False],[0],[0],[False],['0']
42453,PMC9007089,40357,"Strings increased in length by one digit if participants correctly recall one of the two digit strings at each length, otherwise the test is discontinued.",Secondary Outcome Measures •|Cognition •,[236813],[33262],[33416],[False],[0],[0],[False],['0']
42454,PMC9007089,40358,Task performance is scored as the total number of strings correctly recalled in reverse order (of a maximum 14 trials).,Secondary Outcome Measures •|Cognition •,[236820],[33417],[33536],[False],[0],[0],[False],['0']
42455,PMC9007089,40359,"Size-Comparison Span; Complex Span Interpolated Working Memory (Storage, Manipulation and Inhibition, Untrained) •",Secondary Outcome Measures •|Cognition •,[236827],[33537],[33651],[False],[0],[0],[False],['0']
42456,PMC9007089,40360,"The Size-Comparison Span (SICSPAN) is a measure of complex-span working memory capacity and inhibition of semantic current-list intrusions (Sorqvist, Ljungberg, & Ljung 2010).",Secondary Outcome Measures •|Cognition •,[236834],[33652],[33827],[False],[0],[0],[False],['0']
42457,PMC9007089,40361,"The nature of the task closely resembles the “operation span” (OSPAN) task (Engle 2002), with an important addition of measuring intrusions from items that are part of the task itself, but were never intended for recall.",Secondary Outcome Measures •|Cognition •,[236841],[33828],[34048],[False],[0],[0],[False],['0']
42458,PMC9007089,40362,"Participants view lists of size comparisons (e.g., “tree is larger than acorn”) and respond “yes” or “no” using a button box.",Secondary Outcome Measures •|Cognition •,[236848],[34049],[34174],[False],[0],[0],[False],['0']
42459,PMC9007089,40363,"Participants are then provided with to-be-remembered words from the same semantic category (e.g., “leaf”).",Secondary Outcome Measures •|Cognition •,[236855],[34175],[34281],[False],[0],[0],[False],['0']
42460,PMC9007089,40364,"At the end of the list, participants are required to recall the to-be-remembered words, while inhibiting words included in the size comparison judgments.",Secondary Outcome Measures •|Cognition •,[236862],[34282],[34435],[False],[0],[0],[False],['0']
42461,PMC9007089,40365,"The task begins with lists of two size comparison judgments and to-be-remembered words, increasing to list lengths of three, four, five, and six.",Secondary Outcome Measures •|Cognition •,[236869],[34436],[34581],[False],[0],[0],[False],['0']
42462,PMC9007089,40366,There were two trials at each list length.,Secondary Outcome Measures •|Cognition •,[236876],[34582],[34624],[False],[0],[0],[False],['0']
42463,PMC9007089,40367,"The task continues until all list lengths have been presented, with no discontinuation rule.",Secondary Outcome Measures •|Cognition •,[236883],[34625],[34717],[False],[0],[0],[False],['0']
42464,PMC9007089,40368,The task is scored using the number of list items correctly recalled (maximum 40).,Secondary Outcome Measures •|Cognition •,[236890],[34718],[34800],[False],[0],[0],[False],['0']
42465,PMC9007089,40369,A second measure (intrusions) records the number of incorrect items recalled (errors in inhibition) for each participant.,Secondary Outcome Measures •|Cognition •,[236897],[34801],[34922],[False],[0],[0],[False],['0']
42466,PMC9007089,40370,"The SICspan serves to assess domain-general transfer of learning in terms of increased performance on a complex-span working memory task and improved attentional control, both of which are reliant on working memory capacity (see Tiego et al.",Secondary Outcome Measures •|Cognition •,[236904],[34923],[35164],[False],[0],[0],[False],['0']
42467,PMC9007089,40371,2018 for a discussion).,Secondary Outcome Measures •|Cognition •,[236911],[35165],[35188],[False],[0],[0],[False],['0']
42468,PMC9007089,40372,"Dual Task of Listening and Working Memory; Complex Span Working Memory (Storage and Task Switching, Untrained) •",Secondary Outcome Measures •|Cognition •,[236918],[35189],[35301],[False],[0],[0],[False],['0']
42469,PMC9007089,40373,"The dual task is measure of listening and memory designed to index listening effort (Howard, Munro, & Plack 2010).",Secondary Outcome Measures •|Cognition •,[236925],[35302],[35416],[False],[0],[0],[False],['0']
42470,PMC9007089,40374,Participants are presented with a five-digit memory task that flanks a speech-in-noise comprehension task.,Secondary Outcome Measures •|Cognition •,[236932],[35417],[35523],[False],[0],[0],[False],['0']
42471,PMC9007089,40375,A string of five digits is displayed visually on a computer screen for 5 seconds.,Secondary Outcome Measures •|Cognition •,[236939],[35524],[35605],[False],[0],[0],[False],['0']
42472,PMC9007089,40376,Participants are asked to retain the digits in memory for later recall.,Secondary Outcome Measures •|Cognition •,[236946],[35606],[35677],[False],[0],[0],[False],['0']
42473,PMC9007089,40377,"Participants are then presented with a list of 5 AB isophonemic monosyllabic CVC words (Boothroyd 1968), such as ship, rug and rail, presented in (ICRA) 6-talker babble (Dreschler et al.",Secondary Outcome Measures •|Cognition •,[236953],[35678],[35864],[False],[0],[0],[False],['0']
42474,PMC9007089,40378,2001) at challenging signal-to-noise ratio [0 dB signal-to-noise ratio (SNR); Henshaw & Ferugson 2014] and are asked to repeat each word immediately after presentation.,Secondary Outcome Measures •|Cognition •,[236960],[35865],[36033],[False],[0],[0],[False],['0']
42475,PMC9007089,40379,"After each list of five words, participants are asked to recall the previously presented five digits.",Secondary Outcome Measures •|Cognition •,[236967],[36034],[36135],[False],[0],[0],[False],['0']
42476,PMC9007089,40380,"There are 4 word lists, resulting in a maximum possible score of 20 correctly repeated words and 20 correctly recalled digits.",Secondary Outcome Measures •|Cognition •,[236974],[36136],[36262],[False],[0],[0],[False],['0']
42477,PMC9007089,40381,A dual task score is calculated by adding together the scores for the word and digit tasks (maximum 40).,Secondary Outcome Measures •|Cognition •,[236981],[36263],[36367],[False],[0],[0],[False],['0']
42478,PMC9007089,40382,Prior research has shown improved dual task performance in adult hearing aid users following an average of ~3.25 hours of phoneme discrimination training (Henshaw & Ferguson 2014).,Secondary Outcome Measures •|Cognition •,[236988],[36368],[36548],[False],[0],[0],[False],['0']
42479,PMC9007089,40383,This task serves to assess domain-general improvements in working memory arising from improved working memory capacity.,Secondary Outcome Measures •|Cognition •,[236995],[36549],[36668],[False],[0],[0],[False],['0']
42480,PMC9007089,40384,Test of Attention in Listening; Sustained Selective Attention (Untrained) •,Secondary Outcome Measures •|Cognition •,[237002],[36669],[36744],[False],[0],[0],[False],['0']
42481,PMC9007089,40385,"The Test of Attention in Listening (TAIL) is an auditory attention task that requires participants to make same/different judgements to serially presented tones that vary in both frequency and spatial location (Zhang, Barry, Moore, & Amitay 2012).",Secondary Outcome Measures •|Cognition •,[237009],[36745],[36992],[False],[0],[0],[False],['0']
42482,PMC9007089,40386,Participants are asked to respond as to whether two tones are the “same” or “different” in terms of either frequency or location using a button box response.,Secondary Outcome Measures •|Cognition •,[237016],[36993],[37150],[False],[0],[0],[False],['0']
42483,PMC9007089,40387,Tones are presented in the freefield at participants’ most comfortable loudness (MCL) level (Ventry et al.,Secondary Outcome Measures •|Cognition •,[237023],[37151],[37257],[False],[0],[0],[False],['0']
42484,PMC9007089,40388,1971) via two speakers situated at 90° to the left and 90° to the right of the participant at a distance of 50 cm.,Secondary Outcome Measures •|Cognition •,[237030],[37258],[37372],[False],[0],[0],[False],['0']
42485,PMC9007089,40389,"Tone frequencies are drawn randomly from the range 476 to 2000 Hz, with the constraint that the spectral gap between any two tones is at least 2.1 equivalent rectangular bandwidths (Zhang, Barry, Moore, & Amitay 2012).",Secondary Outcome Measures •|Cognition •,[237037],[37373],[37591],[False],[0],[0],[False],['0']
42486,PMC9007089,40390,An upper frequency limit of 2000 Hz was selected to help ensure that tones were audible by participants with high-frequency hearing loss.,Secondary Outcome Measures •|Cognition •,[237044],[37592],[37729],[False],[0],[0],[False],['0']
42487,PMC9007089,40391,"TAIL measures the ability to focus selectively on a task-relevant dimension (either frequency or location) and ignore information from task-irrelevant dimensions, using reaction time (RT) as the primary performance measure.",Secondary Outcome Measures •|Cognition •,[237051],[37730],[37953],[False],[0],[0],[False],['0']
42488,PMC9007089,40392,"This test produces two measures per condition (frequency and location), calculated from the RT data; Distraction and Conflict Resolution.",Secondary Outcome Measures •|Cognition •,[237058],[37954],[38091],[False],[0],[0],[False],['0']
42489,PMC9007089,40393,"Distraction measures the RT cost of involuntary orientation to the task-irrelevant dimension in terms of processing efficiency, whereas Conflict Resolution measures the RT cost of resolving that conflict (and suggests the involvement of executive control to help resolve) (Zhang, Barry, Moore, & Amitay 2012).",Secondary Outcome Measures •|Cognition •,[237065],[38092],[38401],[False],[0],[0],[False],['0']
42490,PMC9007089,40394,"This task serves to assess improvements in an auditory task of sustained attentional control, which is the ability to maintain goal-relevant information in the face of distraction, resulting from any improvements in working memory capacity (e.g., Kane & Engle 2003.",Secondary Outcome Measures •|Cognition •,[237072],[38402],[38667],[False],[0],[0],[False],['0']
42491,PMC9007089,40395,See also consensus paper (preprint) by von Bastian et al.,Secondary Outcome Measures •|Cognition •,[237079],[38668],[38725],[False],[0],[0],[False],['0']
42492,PMC9007089,40396,2020).,Secondary Outcome Measures •|Cognition •,[237086],[38726],[38732],[False],[0],[0],[False],['0']
42493,PMC9007089,40397,"Test of Everyday Attention, Single and Dual Attention (Untrained) •",Secondary Outcome Measures •|Cognition •,[237093],[38733],[38800],[False],[0],[0],[False],['0']
42494,PMC9007089,40398,"Test of Everyday Attention (TEA) subtests 6 (telephone search) and 7 (telephone search while counting) assess single (visual) attention and dual (auditory and visual) attention (Robertson, Ward, Ridgeway, & Nimmo-Smith 1994).",Secondary Outcome Measures •|Cognition •,[237100],[38801],[39026],[False],[0],[0],[False],['0']
42495,PMC9007089,40399,"For subtest 6, participants are asked to search a telephone directory for matching symbols.",Secondary Outcome Measures •|Cognition •,[237107],[39027],[39118],[False],[0],[0],[False],['0']
42496,PMC9007089,40400,"For subtest 7, participants are asked to search a telephone directory for matching symbols while counting strings of beeps in varying lengths (2 to 12), presented in the freefield at participants’ MCL level, then reporting back the total number of beeps.",Secondary Outcome Measures •|Cognition •,[237114],[39119],[39373],[False],[0],[0],[False],['0']
42497,PMC9007089,40401,"The task is scored using time (seconds) per correctly identified symbol, weighted in subtest 7 by the proportion of correctly counted beep strings.",Secondary Outcome Measures •|Cognition •,[237121],[39374],[39521],[False],[0],[0],[False],['0']
42498,PMC9007089,40402,"A dual task decrement is calculated as the difference in time (in seconds) per correctly identified symbol where two simultaneous tasks are being completed, compared with that for the single task (subtest 7 minus subtest 6).",Secondary Outcome Measures •|Cognition •,[237128],[39522],[39746],[False],[0],[0],[False],['0']
42499,PMC9007089,40403,"Improvements in the dual task decrement (i.e., the ability to divide attention efficiently) would be indicative of improved executive attention, which is closely related to both working memory capacity and executive function (McCabe et al.",Secondary Outcome Measures •|Cognition •,[237135],[39747],[39986],[False],[0],[0],[False],['0']
42500,PMC9007089,40404,2010).,Secondary Outcome Measures •|Cognition •,[237142],[39987],[39993],[False],[0],[0],[False],['0']
42501,PMC9007089,40405,Speech Perception •,Speech Perception •,[237149],[39994],[40014],[False],[0],[0],[False],['0']
42502,PMC9007089,40406,Measures of speech perception performance were selected to assess generalized benefits to speech perception on a continuum of degree of association with working memory (Heinrich et al.,Speech Perception •,[237156],[40015],[40199],[False],[0],[0],[False],['0']
42503,PMC9007089,40407,"2015), ranging from speech constituents in quiet (phonemes, low), target words in high and low predictability sentences in babble (mixed), to competing speech (high).",Speech Perception •,[237163],[40200],[40366],[False],[0],[0],[False],['0']
42504,PMC9007089,40408,Phoneme Discrimination •,Speech Perception •|Phoneme Discrimination •,[237170],[40367],[40391],[False],[0],[0],[False],['0']
42505,PMC9007089,40409,This speech perception task assesses an individual’s ability to distinguish differences between phonemes presented on a continuum.,Speech Perception •|Phoneme Discrimination •,[237177],[40392],[40522],[False],[0],[0],[False],['0']
42506,PMC9007089,40410,The measure is delivered using the Medical Research Council (MRC) Institute of Hearing Research System for Testing Auditory Responses (IHR-STAR) platform.,Speech Perception •|Phoneme Discrimination •,[237184],[40523],[40677],[False],[0],[0],[False],['0']
42507,PMC9007089,40411,"Participants are presented with three discrete phonemes per trial from a continuum of 96 sound files (48 for each phoneme within a pair), which are digitally synthesized from recorded phoneme endpoints.",Speech Perception •|Phoneme Discrimination •,[237191],[40678],[40880],[False],[0],[0],[False],['0']
42508,PMC9007089,40412,"For each trial, two of the phonemes are identical and one is different.",Speech Perception •|Phoneme Discrimination •,[237198],[40881],[40952],[False],[0],[0],[False],['0']
42509,PMC9007089,40413,Participants are asked to identify the odd one out using a button box with three buttons corresponding to the visual display.,Speech Perception •|Phoneme Discrimination •,[237205],[40953],[41078],[False],[0],[0],[False],['0']
42510,PMC9007089,40414,"Two different phoneme pairs: /a/ /e/ (easy) and /d/ /g/ (difficult) are presented for a block of 35 trials in sequential blocks, with a 3-trial demonstration of continuum /a/ /e/ prior to the 2 blocks.",Speech Perception •|Phoneme Discrimination •,[237212],[41079],[41280],[False],[0],[0],[False],['0']
42511,PMC9007089,40415,"The task is presented in a quiet room, and task difficulty is adapted based on individual participant performance using a three-phase adaptive staircase procedure (Moore et al.",Speech Perception •|Phoneme Discrimination •,[237219],[41281],[41457],[False],[0],[0],[False],['0']
42512,PMC9007089,40416,2005).,Speech Perception •|Phoneme Discrimination •,[237226],[41458],[41464],[False],[0],[0],[False],['0']
42513,PMC9007089,40417,Auditory and visual performance feedback is provided to participants after each trial (correct/incorrect response).,Speech Perception •|Phoneme Discrimination •,[237233],[41465],[41580],[False],[0],[0],[False],['0']
42514,PMC9007089,40418,"This task provides a phoneme discrimination threshold, which is calculated as the average distance between the 96 sound files for the last 2 reversals in a block of 35 trials.",Speech Perception •|Phoneme Discrimination •,[237240],[41581],[41756],[False],[0],[0],[False],['0']
42515,PMC9007089,40419,British English Semantic Sentence Test •,Speech Perception •|British English Semantic Sentence Test •,[237247],[41757],[41797],[False],[0],[0],[False],['0']
42516,PMC9007089,40420,"Previously described as the IHR-SPIN (Henshaw and Ferguson 2013b), and based on the Revised Speech Perception in Noise Test (Bilger et al.",Speech Perception •|British English Semantic Sentence Test •,[237254],[41798],[41936],[False],[0],[0],[False],['0']
42517,PMC9007089,40421,1984; Kalikow et al.,Speech Perception •|British English Semantic Sentence Test •,[237261],[41937],[41957],[False],[0],[0],[False],['0']
42518,PMC9007089,40422,"1977), the British English Semantic Sentence Test is a high- and low-predictability speech in noise perception test with sentences produced by a British English native speaker.",Speech Perception •|British English Semantic Sentence Test •,[237268],[41958],[42134],[False],[0],[0],[False],['0']
42519,PMC9007089,40423,Lists of 22 sentences (11 high-predictability and 11 low-predictability) are presented in the freefield in a background of speech-modulated noise with the same long-term average spectrum as the target speech (Knight & Heinrich 2017) at a fixed SNR of −1 dB SNR.,Speech Perception •|British English Semantic Sentence Test •,[237275],[42135],[42396],[False],[0],[0],[False],['0']
42520,PMC9007089,40424,"Two practice sentences (one high- and one low-predictability) are presented to participants at a slightly more favorable fixed SNR (2 dB SNR), prior to commencing the main test.",Speech Perception •|British English Semantic Sentence Test •,[237282],[42397],[42574],[False],[0],[0],[False],['0']
42521,PMC9007089,40425,Participants are asked to listen to each sentence and repeat the last word aloud.,Speech Perception •|British English Semantic Sentence Test •,[237289],[42575],[42656],[False],[0],[0],[False],['0']
42522,PMC9007089,40426,The task is scored as the percentage of last words correctly repeated for both high-predictability and low-predictability lists.,Speech Perception •|British English Semantic Sentence Test •,[237296],[42657],[42785],[False],[0],[0],[False],['0']
42523,PMC9007089,40427,Modified Coordinate Response Measure •,Speech Perception •|Modified Coordinate Response Measure •,[237303],[42786],[42824],[False],[0],[0],[False],['0']
42524,PMC9007089,40428,"The Modified Coordinate Response Measure is measure of target talker speech perception in the presence of another talker, presented at an adaptive signal-to-noise ratio.",Speech Perception •|Modified Coordinate Response Measure •,[237310],[42825],[42994],[False],[0],[0],[False],['0']
42525,PMC9007089,40429,The basic task is described by Hazan et al.,Speech Perception •|Modified Coordinate Response Measure •,[237317],[42995],[43038],[False],[0],[0],[False],['0']
42526,PMC9007089,40430,(2009) and is based on the Coordinate Response Measure (Bolia et al.,Speech Perception •|Modified Coordinate Response Measure •,[237324],[43039],[43107],[False],[0],[0],[False],['0']
42527,PMC9007089,40431,2000).,Speech Perception •|Modified Coordinate Response Measure •,[237331],[43108],[43114],[False],[0],[0],[False],['0']
42528,PMC9007089,40432,Participants are presented with sentences in the form of “show the [animal] where the [color] [number] is”.,Speech Perception •|Modified Coordinate Response Measure •,[237338],[43115],[43222],[False],[0],[0],[False],['0']
42529,PMC9007089,40433,"There are six possible monosyllabic animals (cat, cow, dog, duck, pig, and sheep), six colors (black, blue, green, pink, red, and white), and eight numbers (one to nine, excluding multisyllabic seven).",Speech Perception •|Modified Coordinate Response Measure •,[237345],[43223],[43424],[False],[0],[0],[False],['0']
42530,PMC9007089,40434,"Two sentences are presented to participants concurrently, one produced by a female speaker (target) and one by a male speaker (distracter).",Speech Perception •|Modified Coordinate Response Measure •,[237352],[43425],[43564],[False],[0],[0],[False],['0']
42531,PMC9007089,40435,"Participants are asked to listen for the color and number spoken by the female speaker (“dog” was always the animal target), while ignoring the male speaker, and then respond by pressing the corresponding target color number on a touchscreen computer.",Speech Perception •|Modified Coordinate Response Measure •,[237359],[43565],[43816],[False],[0],[0],[False],['0']
42532,PMC9007089,40436,"The test uses an adaptive 1-up 1-down staircase method with an initial step size of 10 dB until the first reversal, reducing to 7 dB at reversal 2 and 4 dB at reversal 3.",Speech Perception •|Modified Coordinate Response Measure •,[237366],[43817],[43987],[False],[0],[0],[False],['0']
42533,PMC9007089,40437,The test continues until a total of eight reversals are achieved.,Speech Perception •|Modified Coordinate Response Measure •,[237373],[43988],[44053],[False],[0],[0],[False],['0']
42534,PMC9007089,40438,The test is completed twice by each participant and a third time for instances where there is a difference of ≥5 dB SNR between participants’ first two test scores.,Speech Perception •|Modified Coordinate Response Measure •,[237380],[44054],[44218],[False],[0],[0],[False],['0']
42535,PMC9007089,40439,"Speech reception thresholds are calculated using the average of the last two reversals, averaged across the 2 or 3 trials.",Speech Perception •|Modified Coordinate Response Measure •,[237387],[44219],[44341],[False],[0],[0],[False],['0']
42536,PMC9007089,40440,Self-Reported Hearing •,Self-Reported Hearing •,[237394],[44342],[44366],[False],[0],[0],[False],['0']
42537,PMC9007089,40441,Glasgow Hearing Aid Benefit Profile •,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237401],[44367],[44404],[False],[0],[0],[False],['0']
42538,PMC9007089,40442,"The Glasgow Hearing Aid Benefit Profile (GHABP) is a validated questionnaire used to assess self-reported activity limitations (Initial Disability) and participation restrictions (Handicap) arising from difficulties in hearing, as well as hearing aid use, benefit, and satisfaction (Gatehouse 1999).",Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237408],[44405],[44704],[False],[0],[0],[False],['0']
42539,PMC9007089,40443,For the purposes of the present study only the first two measures (Initial Disability and Handicap) were assessed in order to make comparisons with prior auditory training studies (Ferguson et al.,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237415],[44705],[44901],[False],[0],[0],[False],['0']
42540,PMC9007089,40444,2014; Henshaw and Ferguson 2014).,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237422],[44902],[44935],[False],[0],[0],[False],['0']
42541,PMC9007089,40445,The questionnaire is administered via interview with the researcher and completed electronically.,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237429],[44936],[45033],[False],[0],[0],[False],['0']
42542,PMC9007089,40446,"Participants are presented with a series of four listening scenarios (listening to the television, having a conversation with one other person in a quiet room, having a conversation in a busy street or shop, talking to several people in a group) and are asked to rate the amount of difficulty they have in that situation while wearing their hearing aid(s) (1 = no difficulty to 5 = cannot manage at all), together with how much any difficulty either worried, annoyed or upset them (1 = not at all to 5 = very much indeed).",Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237436],[45034],[45556],[False],[0],[0],[False],['0']
42543,PMC9007089,40447,The mean of all four scenarios in each measure are converted to a percentage score for the Initial Disability and Handicap subscales.,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237443],[45557],[45690],[False],[0],[0],[False],['0']
42544,PMC9007089,40448,Hearing Handicap Inventory for the Elderly •,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237450],[45691],[45735],[False],[0],[0],[False],['0']
42545,PMC9007089,40449,The Hearing Handicap Inventory for the Elderly is a 25-item validated questionnaire that quantifies the emotional and social/situational effects of self-perceived hearing impairment to quantify hearing-related quality of life.,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237457],[45736],[45962],[False],[0],[0],[False],['0']
42546,PMC9007089,40450,"Participants were asked to complete the 25-item paper questionnaire answering statements such as “Does a hearing problem cause you to be nervous” with either “yes” (4 points), “no” (0 points), or “sometimes” (2 points).",Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237464],[45963],[46182],[False],[0],[0],[False],['0']
42547,PMC9007089,40451,The questionnaire was scored as total points for all items (maximum 100 points).,Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237471],[46183],[46263],[False],[0],[0],[False],['0']
42548,PMC9007089,40452,"Subtotal scores can also be derived for emotional (12 items, maximum 48 points) and situational item subscales (13 items, maximum 52 points).",Self-Reported Hearing •|Glasgow Hearing Aid Benefit Profile •,[237478],[46264],[46405],[False],[0],[0],[False],['0']
42549,PMC9007089,40453,Statistical Analyses,Statistical Analyses,[237485],[46406],[46429],[False],[0],[0],[False],['0']
42550,PMC9007089,40454,Participant Demographics and Baseline Comparisons,Statistical Analyses|Participant Demographics and Baseline Comparisons,[237492],[46430],[46479],[False],[0],[0],[False],['0']
42551,PMC9007089,40455,"Demographic information was presented for individuals in the Experimental and Active Control Groups as the mean and SD for continuous data, or number and percentage for categorical data.",Statistical Analyses|Participant Demographics and Baseline Comparisons,[237499],[46480],[46666],[False],[0],[0],[False],['0']
42552,PMC9007089,40456,Baseline comparisons assessed whether Experimental and Active Control Groups were comparable in terms of demographics at the outset.,Statistical Analyses|Participant Demographics and Baseline Comparisons,[237506],[46667],[46799],[False],[0],[0],[False],['0']
42553,PMC9007089,40457,Significant differences between groups were assessed using either independent t-tests or Chi square.,Statistical Analyses|Participant Demographics and Baseline Comparisons,[237513],[46800],[46900],[False],[0],[0],[False],['0']
42554,PMC9007089,40458,Primary Analyses,Statistical Analyses|Primary Analyses,[237520],[46901],[46917],[False],[0],[0],[False],['0']
42555,PMC9007089,40459,"Primary analyses assessed on-task learning, transfer to improvements in performance for untrained outcome measures of cognition, speech perception, self-report (Hypothesis 1), and retention of outcome improvements at the 6-month follow-up assessment (Hypothesis 2).",Statistical Analyses|Primary Analyses,[237527],[46918],[47183],[False],[0],[0],[False],['0']
42556,PMC9007089,40460,"Retention of learning was defined as the maintenance of any significant improvement from baseline (T2) at the 6-month follow-up assessment (T4), rather than a nonsignificant decline in performance post-training (T3–T4).",Statistical Analyses|Primary Analyses,[237534],[47184],[47403],[False],[0],[0],[False],['0']
42557,PMC9007089,40461,This was because we were particularly interested (given the applied potential of training as a supplementary intervention) in examining whether any training-related improvement from baseline outcome performance could persist for a period of time after the training had ceased.,Statistical Analyses|Primary Analyses,[237541],[47404],[47680],[False],[0],[0],[False],['0']
42558,PMC9007089,40462,"For all primary analyses, missing data were assumed to be missing at random and were handled as follows.",Statistical Analyses|Primary Analyses,[237548],[47681],[47785],[False],[0],[0],[False],['0']
42559,PMC9007089,40463,"For instances where, for a particular variable, data from less than three individuals were missing, plausible values were imputed on an individual basis and complete case analyses were run to assess the effect of imputation on statistical group results.",Statistical Analyses|Primary Analyses,[237555],[47786],[48039],[False],[0],[0],[False],['0']
42560,PMC9007089,40464,"Imputed values were determined by one of the following methods: when the data point for T2 was missing but T1 present, the T1 data point was substituted as the most realistic value.",Statistical Analyses|Primary Analyses,[237562],[48040],[48221],[False],[0],[0],[False],['0']
42561,PMC9007089,40465,"If the data point was missing from T3 or T4, the mean of the individual’s remaining data points (T2 and T3 for missing T4, or T2 and T4 for missing T3) was calculated and imputed as most plausible value.",Statistical Analyses|Primary Analyses,[237569],[48222],[48425],[False],[0],[0],[False],['0']
42562,PMC9007089,40466,"In these cases, checks were conducted to ensure that the selected imputation method did not change the qualitative nature of the group results (turning a result from nonsignificant to significant or vice versa) by running a complete case analysis (Jakobsen and colleagues 2017), whereby missing values were substituted by the minimum and maximum values for the variable from the group as a whole in order to test the statistical robustness of these boundary conditions.",Statistical Analyses|Primary Analyses,[237576],[48426],[48895],[False],[0],[0],[False],['0']
42563,PMC9007089,40467,"Results of all imputation sensitivity analyses are presented in Table 1 in Supplemental Digital Content 1, http://links.lww.com/EANDH/A855.",Statistical Analyses|Primary Analyses,[237583],[48896],[49035],[False],[0],[0],[False],['0']
42564,PMC9007089,40468,"Given that boundary scores did not change the qualitative nature of the statistical outcome, all reported results are based on the above described imputation of realistic values.",Statistical Analyses|Primary Analyses,[237590],[49036],[49214],[False],[0],[0],[False],['0']
42565,PMC9007089,40469,"Finally, for cases where data from three or more individuals was missing for a particular variable, data were imputed using Multiple Imputation by Chained Equation (van Buuren & Groothuis-Oudshoorn 2011).",Statistical Analyses|Primary Analyses,[237597],[49215],[49419],[False],[0],[0],[False],['0']
42566,PMC9007089,40470,"Five imputation cycles were used, as this has previously been demonstrated to produce acceptable results (van Buuren et al.",Statistical Analyses|Primary Analyses,[237604],[49420],[49543],[False],[0],[0],[False],['0']
42567,PMC9007089,40471,1999).,Statistical Analyses|Primary Analyses,[237611],[49544],[49550],[False],[0],[0],[False],['0']
42568,PMC9007089,40472,Working Memory Training (On-Task Learning) •,Statistical Analyses|Primary Analyses,[237618],[49551],[49595],[False],[0],[0],[False],['0']
42569,PMC9007089,40473,On-task learning was assessed using the Cogmed Index Improvement.,Statistical Analyses|Primary Analyses,[237625],[49596],[49661],[False],[0],[0],[False],['0']
42570,PMC9007089,40474,This cumulative performance measure was calculated using the Start Index (average performance across all training tasks completed during training sessions 2 and 3) subtracted from the Maximum Index (average performance for the two training sessions with the best performance across the full training period).,Statistical Analyses|Primary Analyses,[237632],[49662],[49970],[False],[0],[0],[False],['0']
42571,PMC9007089,40475,On-task learning was assessed within and between groups for the training intervention period (weeks 3 to 7) using paired and independent t-tests.,Statistical Analyses|Primary Analyses,[237639],[49971],[50116],[False],[0],[0],[False],['0']
42572,PMC9007089,40476,Transfer of Learning to Untrained Outcomes •,Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237646],[50117],[50161],[False],[0],[0],[False],['0']
42573,PMC9007089,40477,The primary endpoint for the trial was T3 (week 7).,Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237653],[50162],[50213],[False],[0],[0],[False],['0']
42574,PMC9007089,40478,"Generalized Estimating Equations (GEE) were used to examine performance on untrained measures of cognition, speech perception and self-reported hearing as a function of time (T2–T3) between treatment groups; hence the effect of interest is an interaction between group (control versus treatment) and time (T2 versus T3).",Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237660],[50214],[50534],[False],[0],[0],[False],['0']
42575,PMC9007089,40479,"As only the interaction between group (experimental versus control) and visit (T2 versus T3) was of interest, no post-hoc analyses were required.",Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237667],[50535],[50680],[False],[0],[0],[False],['0']
42576,PMC9007089,40480,Change in performance pretraining to post-training (T2-T3) for both treatment groups are presented with 95% confidence intervals.,Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237674],[50681],[50810],[False],[0],[0],[False],['0']
42577,PMC9007089,40481,We initially planned to use Repeated Measures ANOVA to assess transfer of learning (Henshaw & Ferguson 2013b).,Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237681],[50811],[50921],[False],[0],[0],[False],['0']
42578,PMC9007089,40482,"However, following subsequent advice of a medical statistician who had experience in analyzing repeated measures data, we adopted GEEs as a more rigorous analysis that is better suited to datasets where outcome measures are correlated across time points and within participants (Zeger, Liang, & Albert 1988).",Statistical Analyses|Transfer of Learning to Untrained Outcomes •,[237688],[50922],[51230],[False],[0],[0],[False],['0']
42579,PMC9007089,40483,Retention at Follow-Up •,Statistical Analyses|Retention at Follow-Up •,[237695],[51231],[51255],[False],[0],[0],[False],['0']
42580,PMC9007089,40484,GEEs were used to examine performance across T2 to T4 for the Experimental Group only in order to examine retention of any post-training improvements at a 6-month post-training follow-up assessment.,Statistical Analyses|Retention at Follow-Up •,[237702],[51256],[51454],[False],[0],[0],[False],['0']
42581,PMC9007089,40485,Posthoc comparisons between T2 to T3 and T2 to T4 were performed using unadjusted t-tests.,Statistical Analyses|Retention at Follow-Up •,[237709],[51455],[51545],[False],[0],[0],[False],['0']
42582,PMC9007089,40486,"For on-task learning, effect sizes were calculated using Glass’s delta (Hedges & Olkin 1985), which is suited to between-group comparisons with unequal variance, and uses the SD of the control group to estimate the size of effect (e.g., Glass’s delta of 1.5 indicates that the mean of the training group is 1.5 SDs higher than the mean of the trained group).",Statistical Analyses|Retention at Follow-Up •,[237716],[51546],[51904],[False],[0],[0],[False],['0']
42583,PMC9007089,40487,"For all other analyses, effect sizes were calculated using Cohen’s d (Cohen 1988), with small, medium and large effects interpreted as 0.2, 0.5, and 0.8 respectively.",Statistical Analyses|Retention at Follow-Up •,[237723],[51905],[52071],[False],[0],[0],[False],['0']
42584,PMC9007089,40488,Secondary Analyses,Secondary Analyses,[237730],[52072],[52091],[False],[0],[0],[False],['0']
42585,PMC9007089,40489,Secondary analyses assessed individual differences in the transfer of learning to untrained outcomes.,Secondary Analyses,[237737],[52092],[52193],[False],[0],[0],[False],['0']
42586,PMC9007089,40490,"As such, all secondary analyses were completed using observed data only (without imputation).",Secondary Analyses,[237744],[52194],[52287],[False],[0],[0],[False],['0']
42587,PMC9007089,40491,"For participants in the Experimental Group only, regression models were used to examine whether:",Secondary Analyses,[237751],[52288],[52384],[False],[0],[0],[False],['0']
42588,PMC9007089,40492,"For (a), regression models were used to assess the predictive value of individuals’ baseline working memory performance (Backward Digit Span T2, n trials correct) on their on-task learning (Cogmed Index Improvement) and post training (T3) performance in untrained outcomes of cognition, speech perception, and self-reported hearing.",Secondary Analyses,[237758],[52385],[52717],[False],[0],[0],[False],['0']
42589,PMC9007089,40493,"For (b), stepwise forward regression models (Enter method) were conducted to assess the predictive value of 1. individuals’ baseline outcome measure performance (T2), 2. the degree of on-task learning (Cogmed Index Improvement), and 3. any interaction between the two, on post-training performance (T3) for each outcome measure individually.",Secondary Analyses,[237765],[52718],[53059],[False],[0],[0],[False],['0']
42590,PMC9007089,40494,"For primary and secondary analyses, statistical significance was set to p < 0.05 (two-sided), unless otherwise stated.",Secondary Analyses,[237772],[53060],[53178],[False],[0],[0],[False],['0']
42591,PMC9007089,40495,GEE Analyses were conducted using R version 3.3.3 (R Core Team 2017) and packages “geepack” (Højsgaard et al.,Secondary Analyses,[237779],[53179],[53288],[False],[0],[0],[False],['0']
42592,PMC9007089,40496,"2006), “mice” (van Buuren and Groothuis-Oudshoorn 2011), “dplyr” (Wickham et al.",Secondary Analyses,[237786],[53289],[53369],[False],[0],[0],[False],['0']
42593,PMC9007089,40497,"2017), and “compute.es” (Del Re 2013).",Secondary Analyses,[237793],[53370],[53408],[False],[0],[0],[False],['0']
42594,PMC9007089,40498,IBM SPSS Statistics 24 (IBM Corp. 2016) was used for all other analyses.,Secondary Analyses,[237800],[53409],[53481],[False],[0],[0],[False],['0']
42595,PMC9007089,40499,Quality Assurance,Secondary Analyses|Quality Assurance,[237807],[53482],[53499],[False],[0],[0],[False],['0']
42596,PMC9007089,40500,"Test-retest reliability, standard error of measurement (SEM), and the minimal difference (MD) required to determine true intervention effects was estimated for all outcome measures based on the data from T1 and T2.",Secondary Analyses|Quality Assurance,[237814],[53500],[53714],[False],[0],[0],[False],['0']
42597,PMC9007089,40501,"Test-retest reliability, which indicates the relative consistency of scores, was calculated using intra-class correlation coefficients (ICC) following the procedure of Weir (2005).",Secondary Analyses|Quality Assurance,[237821],[53715],[53895],[False],[0],[0],[False],['0']
42598,PMC9007089,40502,The choice of ICC was determined by whether or not a significant group difference of repeated testing in an outcome variable existed between T1 and T2.,Secondary Analyses|Quality Assurance,[237828],[53896],[54047],[False],[0],[0],[False],['0']
42599,PMC9007089,40503,"When no significant mean difference of repeated testing existed, ICC3,1 was used, otherwise ICC2,1 was selected.",Secondary Analyses|Quality Assurance,[237835],[54048],[54160],[False],[0],[0],[False],['0']
42600,PMC9007089,40504,The SEM indicates the absolute precision of a score (Hopkins 2000; Weir 2005).,Secondary Analyses|Quality Assurance,[237842],[54161],[54239],[False],[0],[0],[False],['0']
42601,PMC9007089,40505,"Finally, the MD was calculated to define the smallest difference/change in outcome measure performance that can be considered to represent a “real” post-training difference.",Secondary Analyses|Quality Assurance,[237849],[54240],[54413],[False],[0],[0],[False],['0']
42602,PMC9007089,40506,"For a more detailed discussion of the choice of ICC, SEM, and MD in relation to hearing-related measures, see also Heinrich et al.",Secondary Analyses|Quality Assurance,[237856],[54414],[54544],[False],[0],[0],[False],['0']
42603,PMC9007089,40507,(2019) and Heinrich & Knight (2020).,Secondary Analyses|Quality Assurance,[237863],[54545],[54581],[False],[0],[0],[False],['0']
42604,PMC9007089,40508,RESULTS,RESULTS,[237870],[54582],[54591],[False],[0],[0],[False],['0']
42605,PMC9007089,40509,Primary Analyses,RESULTS|Primary Analyses,[237877],[54592],[54608],[False],[0],[0],[False],['0']
42606,PMC9007089,40510,Working Memory Training: On-Task Learning (Hypothesis,RESULTS|Primary Analyses,[237884],[54609],[54662],[False],[0],[0],[False],['0']
42607,PMC9007089,40511,All of the 57 participants completed 25/25 training sessions (100% adherence).,RESULTS|Primary Analyses,[237891],[54663],[54741],[False],[0],[0],[False],['0']
42608,PMC9007089,40512,"Mean data for Cogmed measures by group, and statistical comparisons between groups, are presented in Table 3.",RESULTS|Primary Analyses,[237898],[54742],[54851],[False],[0],[0],[False],['0']
42609,PMC9007089,40513,"The average Cogmed Index Improvement for adults aged 50 to 74 years old in the Experimental Group was 24.48 (SD = 6.53, range = 9.74 to 38.84), which is slightly lower than the published mean Cogmed Index Improvement of 30 for adults aged 18 to 65 years old (Cogmed Working Memory Training 2011).",RESULTS|Primary Analyses,[237905],[54852],[55148],[False],[0],[0],[False],['0']
42610,PMC9007089,40514,"Participants in the Active Control Group were unable to improve as their training tasks were presented at a fixed difficulty level of 3 to-be-remembered items, with no adaptation.",RESULTS|Primary Analyses,[237912],[55149],[55328],[False],[0],[0],[False],['0']
42611,PMC9007089,40515,"For participants in the Experimental Group, a comparison of the Cogmed Start Index (mean = 78.95, SD = 6.79) and Maximum Index (mean = 103.43, SD = 10.67) showed a significant on-task learning effect (t[26] = −19.468, p < 0.001).",RESULTS|Primary Analyses,[237919],[55329],[55558],[False],[0],[0],[False],['0']
42612,PMC9007089,40516,"Despite best efforts to weight the Active Control Group for time-on-task using the weighting function inherent within Cogmed (maximum applied), the average time-on-task for the Experimental Group was significantly different between groups.",RESULTS|Primary Analyses,[237926],[55559],[55798],[False],[0],[0],[False],['0']
42613,PMC9007089,40517,"On average, individuals in the Experimental Group trained for approximately 11 minutes longer per session, compared with individuals in the Active Control Group (mean difference = 10.99, Cohen’s d = 2.52).",RESULTS|Primary Analyses,[237933],[55799],[56004],[False],[0],[0],[False],['0']
42614,PMC9007089,40518,"Nevertheless, a linear regression analysis controlling for time-on-task showed that training group remained a highly significant predictor of the Index Improvement score, F(2, 54) = 207.091, p < 0.001.",RESULTS|Primary Analyses,[237940],[56005],[56206],[False],[0],[0],[False],['0']
42615,PMC9007089,40519,Generalization of Learning to Improvements in Untrained Outcomes (Hypothesis 1),RESULTS|Primary Analyses,[237947],[56207],[56286],[False],[0],[0],[False],['0']
42616,PMC9007089,40520,Table 4 shows group means and standard deviation for all untrained outcomes at all measurement time points (T1 to T3 for the Active Control Group; T1 to T4 for the Experimental Group).,RESULTS|Primary Analyses,[237954],[56287],[56471],[False],[0],[0],[False],['0']
42617,PMC9007089,40521,"Missing data were imputed as outlined in the methods, and did not exceed 5.3% for any of the outcome measures across all participants at the pretraining baseline (T2), or the primary endpoint (T3).",RESULTS|Primary Analyses,[237961],[56472],[56669],[False],[0],[0],[False],['0']
42618,PMC9007089,40522,GEE analyses assessed the interaction between performance on untrained tasks as a function of time and treatment group.,RESULTS|Primary Analyses,[237968],[56670],[56789],[False],[0],[0],[False],['0']
42619,PMC9007089,40523,Results from the GEE analyses are presented in Table 5 and summarized below.,RESULTS|Primary Analyses,[237975],[56790],[56866],[False],[0],[0],[False],['0']
42620,PMC9007089,40524,Cognition •,RESULTS|Cognition •,[237982],[56867],[56878],[False],[0],[0],[False],['0']
42621,PMC9007089,40525,"For the primary outcome measure, the Visual Letter Monitoring (VLM) Task, there was no significant group by time interaction shown in either the 2s/letter or 1s/letter conditions.",RESULTS|Cognition •,[237989],[56879],[57058],[False],[0],[0],[False],['0']
42622,PMC9007089,40526,"The results were similar for all other untrained cognitive outcome measures, with the following notable exceptions.",RESULTS|Cognition •,[237996],[57059],[57174],[False],[0],[0],[False],['0']
42623,PMC9007089,40527,"For Backward Digit Span (a version of which is trained within Cogmed RM), there was a significant interaction between group and time with a medium effect size (Cohen’s d = 0.59).",RESULTS|Cognition •,[238003],[57175],[57353],[False],[0],[0],[False],['0']
42624,PMC9007089,40528,The TEA subtest 6 also showed a significant interaction with a medium effect size (Cohen’s d = 0.54).,RESULTS|Cognition •,[238010],[57354],[57455],[False],[0],[0],[False],['0']
42625,PMC9007089,40529,"However, this significant effect was observed as a result of improved TEA subtest 6 for participants in the Active Control Group, with no improvements shown for participants in the Experimental Group, pre- to post-training (T2 to T3).",RESULTS|Cognition •,[238017],[57456],[57690],[False],[0],[0],[False],['0']
42626,PMC9007089,40530,Speech Perception •,RESULTS|Speech Perception •,[238024],[57691],[57710],[False],[0],[0],[False],['0']
42627,PMC9007089,40531,Phoneme discrimination /a/ /e/ was the only speech outcome measure that showed a significant group by time interaction with a medium effect size (Cohen’s d = 0.64).,RESULTS|Speech Perception •,[238031],[57711],[57875],[False],[0],[0],[False],['0']
42628,PMC9007089,40532,"However, closer examination of the group means in Table 4 show that this interaction was driven by the fact that discrimination scores worsened for participants in the Experimental Group T2 to T3 but improved for participants in the Active Control Group.",RESULTS|Speech Perception •,[238038],[57876],[58130],[False],[0],[0],[False],['0']
42629,PMC9007089,40533,Self-Report •,RESULTS|Self-Report •,[238045],[58131],[58144],[False],[0],[0],[False],['0']
42630,PMC9007089,40534,"There was a significant group by time interaction shown for the GHABP Initial Disability scores, with a medium effect size (Cohen’s d = −I.59).",RESULTS|Self-Report •,[238052],[58145],[58288],[False],[0],[0],[False],['0']
42631,PMC9007089,40535,"This interaction occurred because Initial Disability scores decreased (improved) by 5.3% from T2 to T3 in the Experimental Group, with no change shown for Active Controls.",RESULTS|Self-Report •,[238059],[58289],[58460],[False],[0],[0],[False],['0']
42632,PMC9007089,40536,"Figures 3A, B show no significant change in pre- to post-training performance (unimputed data) for the primary outcome measure (VLM) for either the Experimental or Active Control Groups.",RESULTS|Self-Report •,[238066],[58461],[58647],[False],[0],[0],[False],['0']
42633,PMC9007089,40537,"Unimputed pre- to post-training change data by group for all included outcome measures are provided in Table 2 in Supplemental Digital Content 1, http://links.lww.com/EANDH/A855.",RESULTS|Self-Report •,[238073],[58648],[58826],[False],[0],[0],[False],['0']
42634,PMC9007089,40538,Retention of Learning 6 Months Post-Training (Hypothesis,RESULTS,[238080],[58827],[58884],[False],[0],[0],[False],['0']
42635,PMC9007089,40539,"Table 6 shows post-hoc comparisons within the Experimental Group for the main effects of the intervention period (T2 to T3), and the retention of post-training improvements in outcomes from baseline to 6-month follow-up (T2 to T4).",RESULTS,[238087],[58885],[59116],[False],[0],[0],[False],['0']
42636,PMC9007089,40540,Cognition •,Retention of Learning 6 Months Post-Training (Hypothesis|Cognition •,[238094],[59117],[59128],[False],[0],[0],[False],['0']
42637,PMC9007089,40541,"For Backward Digit Span, there was a significant within-group main effect of intervention period, with a medium effect size (Cohen’s d = −o.69) and significant retention of post-training improvements with a large effect size (Cohen’s d = −6.92).",Retention of Learning 6 Months Post-Training (Hypothesis|Cognition •,[238101],[59129],[59374],[False],[0],[0],[False],['0']
42638,PMC9007089,40542,"For the TEA subtest 6, there was no immediate improvement in performance (T2 to T3), but a significant improvement from baseline was detected at the 6-month follow-up assessment (T2 to T4).",Retention of Learning 6 Months Post-Training (Hypothesis|Cognition •,[238108],[59375],[59564],[False],[0],[0],[False],['0']
42639,PMC9007089,40543,"For the Dual Task, despite a significant improvement for participants in the Experimental Group T2 to T3, this improvement was slightly exceeded by participants in the Active Control Group (see Table 4), hence this did not result in a significant group by time interaction.",Retention of Learning 6 Months Post-Training (Hypothesis|Cognition •,[238115],[59565],[59838],[False],[0],[0],[False],['0']
42640,PMC9007089,40544,Speech Perception •,Retention of Learning 6 Months Post-Training (Hypothesis|Speech Perception •,[238122],[59839],[59858],[False],[0],[0],[False],['0']
42641,PMC9007089,40545,No significant post-hoc results were identified within the Experimental Group for any of the speech perception measures.,Retention of Learning 6 Months Post-Training (Hypothesis|Speech Perception •,[238129],[59859],[59979],[False],[0],[0],[False],['0']
42642,PMC9007089,40546,Self-Report •,Retention of Learning 6 Months Post-Training (Hypothesis|Self-Report •,[238136],[59980],[59993],[False],[0],[0],[False],['0']
42643,PMC9007089,40547,"For GHABP Initial Disability scores, there was a statistically significant main effect shown for the intervention period (T2 to T3) with a medium effect size (Cohen’s d = 0.69), and this improvement was shown to be retained at the 6-month follow-up (T2 to T4; Cohen’s d = 0.65).",Retention of Learning 6 Months Post-Training (Hypothesis|Self-Report •,[238143],[59994],[60272],[False],[0],[0],[False],['0']
42644,PMC9007089,40548,Secondary Analyses,Secondary Analyses,[238150],[60273],[60293],[False],[0],[0],[False],['0']
42645,PMC9007089,40549,Predicting Post-Training Performance Using Baseline Working Memory (Hypothesis 3),Secondary Analyses,[238157],[60294],[60375],[False],[0],[0],[False],['0']
42646,PMC9007089,40550,Results from the linear regression models are shown in Table 7.,Secondary Analyses,[238164],[60376],[60439],[False],[0],[0],[False],['0']
42647,PMC9007089,40551,"For on-task learning, individuals’ T2 Backward Digit Span performance account for 27.6% of the variance in Cogmed Index Improvement scores [F(1,24) = 9.143, p = 0.006; R2 of 0.276].",Secondary Analyses,[238171],[60440],[60621],[False],[0],[0],[False],['0']
42648,PMC9007089,40552,Figure 4 shows individuals baseline working memory performance (T2 Backward Digit Span) plotted against their on-task learning (Cogmed Index Improvement) for those in the Experimental Group only.,Secondary Analyses,[238178],[60622],[60817],[False],[0],[0],[False],['0']
42649,PMC9007089,40553,"The results suggest that for each additional correct trial on the Backward Digit Span task at baseline (T2), participants Cogmed Index Improvement increased by an average of 1.894 points.",Secondary Analyses,[238185],[60818],[61005],[False],[0],[0],[False],['0']
42650,PMC9007089,40554,Baseline working memory was not shown to be predictive of pre- to post-training (T2 to T3) change in performance for any of the untrained outcome measures.,Secondary Analyses,[238192],[61006],[61161],[False],[0],[0],[False],['0']
42651,PMC9007089,40555,Predicting Post-Training Performance Using Baseline Outcome Performance and Degree of On-Task Learning (Hypothesis 4),Secondary Analyses,[238199],[61162],[61279],[False],[0],[0],[False],['0']
42652,PMC9007089,40556,"The stepwise regression models are shown in Table 3 in Supplemental Digital Content 1, http://links.lww.com/EANDH/A855.",Secondary Analyses,[238206],[61280],[61399],[False],[0],[0],[False],['0']
42653,PMC9007089,40557,"For 13/20 of the individual measures, the only reliable predictor of post-training (T3) outcome performance was pretraining (T2) performance on the same measure.",Secondary Analyses,[238213],[61400],[61561],[False],[0],[0],[False],['0']
42654,PMC9007089,40558,"This accounted for between 13.7% and 78.7% of variance in post-training performance for cognitive measures [Visual Letter Monitoring 2s/letter Hits 15.5%, 1s/letter Hits 13.7%; Backward Digit Span, 19.2%; Size Comparison Span Total, 63.9%; Dual Task, 63.0%; Test of Everyday Attention Subtest 7 (DTD), 78.7%], between 15.8% and 54.9% for speech perception measures (Phoneme discrimination /e/ /a/, 16.2%, /d/ /g/, 15.8%; British English Semantic Sentence Test High context, 54.9%, Low context, 25.9%; Modified Coordinate Response Measure threshold, 51.3%) and between 68.7% and 88.5% for measures of self-reported hearing, (Glasgow Hearing Aid Benefit Profile Initial Disability, 68.7%, Handicap 75.9%; and Hearing Handicap Inventory for the Elderly total score, 88.5%).",Secondary Analyses,[238220],[61562],[62332],[False],[0],[0],[False],['0']
42655,PMC9007089,40559,"For TAIL attend location IO, and TEA subtest 6, models that predicted post-training (T3) performance using pretraining performance plus degree of on-task learning were statistically superior.",Secondary Analyses,[238227],[62333],[62524],[False],[0],[0],[False],['0']
42656,PMC9007089,40560,"Finally, for three outcomes: Size Comparison Span Intrusions, Test of Attention in Listening Attend frequency IO, and Glasgow Hearing Aid Benefit Profile Handicap, models that incorporated the interaction between baseline outcome performance (T2) and degree of on-task learning (Cogmed Index Improvement) offered a significantly improved fit.",Secondary Analyses,[238234],[62525],[62867],[False],[0],[0],[False],['0']
42657,PMC9007089,40561,"However, these results should be interpreted with some caution given that the incremental difference in variance accounted for by these models over and above baseline performance alone was very small.",Secondary Analyses,[238241],[62868],[63068],[False],[0],[0],[False],['0']
42658,PMC9007089,40562,Quality Assurance of Outcome Measures,Quality Assurance of Outcome Measures,[238248],[63069],[63107],[False],[0],[0],[False],['0']
42659,PMC9007089,40563,"Table 4 in Supplemental Digital Content 1, http://links.lww.com/EANDH/A855 shows the results of the intra-class correlations (ICCs), SEM, and MD for all outcome measures across all participants.",Quality Assurance of Outcome Measures,[238255],[63108],[63302],[False],[0],[0],[False],['0']
42660,PMC9007089,40564,"Following Cicchetti (1994), test-retest reliability scores (reliability coefficients) were interpreted as <0.40 = poor; 0.40 to 0.59 = fair, 0.60 to 0.74 = good, and >0.75 = excellent.",Quality Assurance of Outcome Measures,[238262],[63303],[63487],[False],[0],[0],[False],['0']
42661,PMC9007089,40565,"Only the GHABP (Initial Disability and Handicap, Hearing Handicap Inventory for the Elderly (total score), and SICSPAN (total) fulfill the criterion of excellent reliability.",Quality Assurance of Outcome Measures,[238269],[63488],[63662],[False],[0],[0],[False],['0']
42662,PMC9007089,40566,"Backward Digit Span, SICSPAN (intrusions), Dual Task, British English Semantic Sentence Test (High context) and Modified Coordinate Response Measure all demonstrate good reliability.",Quality Assurance of Outcome Measures,[238276],[63663],[63845],[False],[0],[0],[False],['0']
42663,PMC9007089,40567,Both Visual Letter Monitoring measures (VLM 2 s/letter and 1 s/letter).,Quality Assurance of Outcome Measures,[238283],[63846],[63917],[False],[0],[0],[False],['0']
42664,PMC9007089,40568,"Both Phoneme Discrimination measures (threshold /a/ /e/ and threshold /d/ /g/) demonstrate fair reliability, thus results involving these measures should be interpreted with some caution.",Quality Assurance of Outcome Measures,[238290],[63918],[64105],[False],[0],[0],[False],['0']
42665,PMC9007089,40569,"All four TAIL measures (Attend frequency IO and CR, and Attend location IO and CR) and TEA (subtest 7 DTD) show poor reliability; therefore, results including these measures should be considered unreliable.",Quality Assurance of Outcome Measures,[238297],[64106],[64312],[False],[0],[0],[False],['0']
42666,PMC9007089,40570,"Finally, it is important to note that pre- to post-training change in outcome performance for participants in the Experimental group (see Table 1 in Supplemental Digital Content 1, http://links.lww.com/EANDH/A855) are consistently smaller than the calculated MDs for all outcomes included in this trial.",Quality Assurance of Outcome Measures,[238304],[64313],[64616],[False],[0],[0],[False],['0']
42667,PMC9007089,40571,DISCUSSION,DISCUSSION,[238311],[64617],[64628],[False],[0],[0],[False],['0']
42668,PMC9007089,40572,Listening to speech-in-noise is a complex and frequent real-world challenge for people with hearing loss and hearing aid users.,DISCUSSION,[238318],[64629],[64756],[False],[0],[0],[False],['0']
42669,PMC9007089,40573,"Impaired auditory function is fundamental to this problem; however, cognitive function also has an important role to play.",DISCUSSION,[238325],[64757],[64879],[False],[0],[0],[False],['0']
42670,PMC9007089,40574,"The current trial sought to examine the benefits of Cogmed training, which primarily targets the storage component of working memory, in an active-controlled RCT of 57 adult hearing aid users and compare findings to those of our prior studies of auditory training that used a similar outcome test battery (Ferguson et al.",DISCUSSION,[238332],[64880],[65201],[False],[0],[0],[False],['0']
42671,PMC9007089,40575,"2014, Henshaw & Ferguson 2014).",DISCUSSION,[238339],[65202],[65233],[False],[0],[0],[False],['0']
42672,PMC9007089,40576,"In doing so, we sought to generate new knowledge about the processes underpinning Cogmed training and transfer for this population and use this to inform future research directions and targeted intervention developments.",DISCUSSION,[238346],[65234],[65454],[False],[0],[0],[False],['0']
42673,PMC9007089,40577,"All participants adhered to the full Cogmed training schedule (25/25 sessions, 100% adherence), and analyses showed a highly significant improvement in trained task performance for participants in the Experimental group compared with participants in the Active Control Group who received the same (nonadaptive) training tasks.",DISCUSSION,[238353],[65455],[65781],[False],[0],[0],[False],['0']
42674,PMC9007089,40578,The only difference between the two training protocols (i.e.,DISCUSSION,[238360],[65782],[65842],[False],[0],[0],[False],['0']
42675,PMC9007089,40579,the underlying memory process) was the increase in the number of to-be-remembered items (span) for adaptive training in the Experimental group.,DISCUSSION,[238367],[65843],[65986],[False],[0],[0],[False],['0']
42676,PMC9007089,40580,Results of the GEE analyses showed four statistically significant Time by Group interactions.,DISCUSSION,[238374],[65987],[66080],[False],[0],[0],[False],['0']
42677,PMC9007089,40581,"However, only two of these interactions favoured the Experimental Group over and above the Active Control Group.",DISCUSSION,[238381],[66081],[66193],[False],[0],[0],[False],['0']
42678,PMC9007089,40582,"First, there was a significant interaction shown for a working memory task that was trained within Cogmed, but tested outside of the Cogmed software (Backward Digit Span) in a subtly different way (different talker and presentation software).",DISCUSSION,[238388],[66194],[66436],[False],[0],[0],[False],['0']
42679,PMC9007089,40583,"Second, there was a significant interaction driven by a small improvement in self-reported hearing activity limitations for those in the Experimental Group (as measured by the Initial Disability subscale of the GHABP), for which, despite a statistically significant effect with a medium effect size (Cohen’s d = 0.56), the absolute magnitude of change (<1%) is unlikely to represent anything close to a clinically important effect (Whitmer et al.",DISCUSSION,[238395],[66437],[66883],[False],[0],[0],[False],['0']
42680,PMC9007089,40584,2014).,DISCUSSION,[238402],[66884],[66890],[False],[0],[0],[False],['0']
42681,PMC9007089,40585,"The other two significant interactions were shown for the Test of Everyday Attention subtest 6 (whereby participants in the Active Control Group demonstrated improved performance pre- to post-training, with no improvements shown for those in the Experimental Group) and Phoneme discrimination /a/ /e/ thresholds (where performance deteriorated for those in the Experimental Group but improved for participants in the Active Control group T2 to T3, pre- to post-training).",DISCUSSION,[238409],[66891],[67362],[False],[0],[0],[False],['0']
42682,PMC9007089,40586,"Given that the degree of change for significant effects was small and given that there were no corrections for multiple comparisons included in the analyses, it is plausible that the significant effects observed may have arisen by chance.",DISCUSSION,[238416],[67363],[67601],[False],[0],[0],[False],['0']
42683,PMC9007089,40587,"No post-training improvements were shown for working memory measures that were further removed from the trained tasks, including the primary outcome measure (untrained working memory: Visual Letter Monitoring task), nor measures of speech perception performance, or any of the other self-reported outcomes included in the trial.",DISCUSSION,[238423],[67602],[67930],[False],[0],[0],[False],['0']
42684,PMC9007089,40588,Examination of individual differences revealed that participants with better baseline working memory performance achieved greater on-task learning (as indicated by a higher Cogmed Index Improvement).,DISCUSSION,[238430],[67931],[68130],[False],[0],[0],[False],['0']
42685,PMC9007089,40589,"Termed the “magnification effect”, this finding has been shown for working memory training interventions in both younger and older adults (Guye et al.",DISCUSSION,[238437],[68131],[68281],[False],[0],[0],[False],['0']
42686,PMC9007089,40590,2017; Strobach & Huestegge 2017).,DISCUSSION,[238444],[68282],[68315],[False],[0],[0],[False],['0']
42687,PMC9007089,40591,"However, conflicting evidence suggests the reverse, in that individuals with lower baseline cognition show greater improvements for trained task-switching (Karbach et al.",DISCUSSION,[238451],[68316],[68486],[False],[0],[0],[False],['0']
42688,PMC9007089,40592,2017) and working memory (Blacker et al.,DISCUSSION,[238458],[68487],[68527],[False],[0],[0],[False],['0']
42689,PMC9007089,40593,"2017) tasks (the “compensation’ effect”), as well as greater generalization of learning (Karbach et al.",DISCUSSION,[238465],[68528],[68631],[False],[0],[0],[False],['0']
42690,PMC9007089,40594,2017).,DISCUSSION,[238472],[68632],[68638],[False],[0],[0],[False],['0']
42691,PMC9007089,40595,"In the present trial, baseline working memory performance was not shown to be associated with greater generalization of learning to untrained outcomes.",DISCUSSION,[238479],[68639],[68790],[False],[0],[0],[False],['0']
42692,PMC9007089,40596,"Indeed, in the absence of generalized improvements, the only reliable predictor of individuals’ post-training performance on untrained outcome measures was their pretraining performance on those same outcome measures.",DISCUSSION,[238486],[68791],[69008],[False],[0],[0],[False],['0']
42693,PMC9007089,40597,"Taken together, these results suggest that adaptive Cogmed training is insufficient to elicit domain-general improvements in working memory or far-transfer gains for adult hearing aid users.",DISCUSSION,[238493],[69009],[69199],[False],[0],[0],[False],['0']
42694,PMC9007089,40598,These findings are consistent with a lack of generalized improvements shown for a crossover study assessing the benefits of Cogmed training within a mixed population of older adults with and without hearing loss (Wayne et al.,DISCUSSION,[238500],[69200],[69425],[False],[0],[0],[False],['0']
42695,PMC9007089,40599,2016).,DISCUSSION,[238507],[69426],[69432],[False],[0],[0],[False],['0']
42696,PMC9007089,40600,Mechanisms of Training and Transfer,DISCUSSION|Mechanisms of Training and Transfer,[238514],[69433],[69468],[False],[0],[0],[False],['0']
42697,PMC9007089,40601,Cogmed training is designed to challenge and improve components of the working memory system through tasks that are increasingly challenging in terms of the number of to-be-remembered items.,DISCUSSION|Mechanisms of Training and Transfer,[238521],[69469],[69659],[False],[0],[0],[False],['0']
42698,PMC9007089,40602,"Through an adaptive algorithm that is based on trainee performance, the training requires trainees to work at the “edge” or limit of their ability.",DISCUSSION|Mechanisms of Training and Transfer,[238528],[69660],[69807],[False],[0],[0],[False],['0']
42699,PMC9007089,40603,"It is assumed that this will subsequently result in increased working memory capacity (e.g., Klingberg et al.",DISCUSSION|Mechanisms of Training and Transfer,[238535],[69808],[69917],[False],[0],[0],[False],['0']
42700,PMC9007089,40604,2002).,DISCUSSION|Mechanisms of Training and Transfer,[238542],[69918],[69924],[False],[0],[0],[False],['0']
42701,PMC9007089,40605,"Yet, as argued by Shipstead et al.",DISCUSSION|Mechanisms of Training and Transfer,[238549],[69925],[69959],[False],[0],[0],[False],['0']
42702,PMC9007089,40606,"(2012), the recall of a greater number of to-be-remembered items in itself does not confirm that working memory capacity has increased.",DISCUSSION|Mechanisms of Training and Transfer,[238556],[69960],[70095],[False],[0],[0],[False],['0']
42703,PMC9007089,40607,"Should Cogmed result in true core training, as evidenced by improved working memory capacity, then we would expect to see improvements for both trained working memory tasks (e.g., backward digit span, simple span) and untrained working memory tasks (e.g., SICspan, complex span).",DISCUSSION|Mechanisms of Training and Transfer,[238563],[70096],[70375],[False],[0],[0],[False],['0']
42704,PMC9007089,40608,"Furthermore, there may also be generalized improvements to other outcomes that rely on working memory (Morrison & Chein 2011).",DISCUSSION|Mechanisms of Training and Transfer,[238570],[70376],[70502],[False],[0],[0],[False],['0']
42705,PMC9007089,40609,"Given that we see no evidence for improvements in untrained tasks of working memory nor related aspects of cognition or speech perception performance in this study, our findings are inconsistent with effective core training.",DISCUSSION|Mechanisms of Training and Transfer,[238577],[70503],[70727],[False],[0],[0],[False],['0']
42706,PMC9007089,40610,"One explanation that has been put forward to explain this is that improvements shown for trained Cogmed tasks may have arisen not from an improvement in working memory capacity itself, but as a result of task-specific abilities (i.e.",DISCUSSION|Mechanisms of Training and Transfer,[238584],[70728],[70961],[False],[0],[0],[False],['0']
42707,PMC9007089,40611,"strategies) that enable improved performance (e.g., Chase & Ericsson 1982; Dunning and Holmes 2014, Harrison et al.",DISCUSSION|Mechanisms of Training and Transfer,[238591],[70962],[71077],[False],[0],[0],[False],['0']
42708,PMC9007089,40612,"2013, von Bastian & Oberauer 2014).",DISCUSSION|Mechanisms of Training and Transfer,[238598],[71078],[71113],[False],[0],[0],[False],['0']
42709,PMC9007089,40613,"Indeed, following completion of this trial, participants in the Experimental Group were invited to take part in one of two focus groups to discuss their experiences with the working memory training intervention.",DISCUSSION|Mechanisms of Training and Transfer,[238605],[71114],[71325],[False],[0],[0],[False],['0']
42710,PMC9007089,40614,"When asked to describe their training experiences, individuals in the focus groups described using several different strategies to help them deal with the increasing demands of the adaptive training tasks.",DISCUSSION|Mechanisms of Training and Transfer,[238612],[71326],[71531],[False],[0],[0],[False],['0']
42711,PMC9007089,40615,"Their descriptions were consistent with visualization, grouping, chunking, rehearsal, chaining and inhibition.",DISCUSSION|Mechanisms of Training and Transfer,[238619],[71532],[71642],[False],[0],[0],[False],['0']
42712,PMC9007089,40616,"This explanation is in line with a meta-analytic review of published working memory training interventions looking specifically at far-transfer effects, which suggest that working memory training may not genuinely improve working memory capacity but may simply reflect stimulus-specific overlap between trained and transfer tasks, or the development of task-specific strategies (Melby-Lervåg et al.",DISCUSSION|Mechanisms of Training and Transfer,[238626],[71643],[72041],[False],[0],[0],[False],['0']
42713,PMC9007089,40617,2016).,DISCUSSION|Mechanisms of Training and Transfer,[238633],[72042],[72048],[False],[0],[0],[False],['0']
42714,PMC9007089,40618,"Should working memory capacity itself be unaffected, then it follows suit that there can be no near- or far-transfer of learning (Shipstead et al.",DISCUSSION|Mechanisms of Training and Transfer,[238640],[72049],[72195],[False],[0],[0],[False],['0']
42715,PMC9007089,40619,2012).,DISCUSSION|Mechanisms of Training and Transfer,[238647],[72196],[72202],[False],[0],[0],[False],['0']
42716,PMC9007089,40620,There has been considerable debate in the literature as to whether or not Cogmed training improves working memory capacity [see Shipstead et al.,DISCUSSION|Mechanisms of Training and Transfer,[238654],[72203],[72347],[False],[0],[0],[False],['0']
42717,PMC9007089,40621,(2012) for a review].,DISCUSSION|Mechanisms of Training and Transfer,[238661],[72348],[72369],[False],[0],[0],[False],['0']
42718,PMC9007089,40622,Cogmed comprises 11 training tasks that target different components of the working memory system.,DISCUSSION|Mechanisms of Training and Transfer,[238668],[72370],[72467],[False],[0],[0],[False],['0']
42719,PMC9007089,40623,"However, despite being marketed as a verbal and visuospatial working memory training program, the linguistic complexity of training stimuli is capped at digits and letters, and the majority of memory tasks (6/11) train serial order memory storage.",DISCUSSION|Mechanisms of Training and Transfer,[238675],[72468],[72715],[False],[0],[0],[False],['0']
42720,PMC9007089,40624,"Morrison & Chein (2012) argue that if Cogmed training had been consistently shown to improve performance on measures of working memory that assess more than just short-term storage of materials used during training (for example, complex span working memory, change detection and running memory span), then this would provide comprehensive evidence of improved working memory capacity.",DISCUSSION|Mechanisms of Training and Transfer,[238682],[72716],[73100],[False],[0],[0],[False],['0']
42721,PMC9007089,40625,"As it stands, published literature largely supports the statement made by Shipstead et al.",DISCUSSION|Mechanisms of Training and Transfer,[238689],[73101],[73191],[False],[0],[0],[False],['0']
42722,PMC9007089,40626,"(2012) in that “Cogmed will improve performance on tasks that resemble Cogmed training”, and this is almost certainly a direct consequence of the limited working memory processes targeted within training tasks.",DISCUSSION|Mechanisms of Training and Transfer,[238696],[73192],[73402],[False],[0],[0],[False],['0']
42723,PMC9007089,40627,"Despite some published evidence for Cogmed to result in improved attention, as measured using the Stroop task [see Shipstead et al.",DISCUSSION|Mechanisms of Training and Transfer,[238703],[73403],[73534],[False],[0],[0],[False],['0']
42724,PMC9007089,40628,"(2012) for an overview], as well as improved general attentional stamina (Brehmer et al.",DISCUSSION|Mechanisms of Training and Transfer,[238710],[73535],[73623],[False],[0],[0],[False],['0']
42725,PMC9007089,40629,"2012, Westerberg & Klingberg 2007), we see no evidence of generalized improvements in attention or focus in the current study for either direct measures of attention, nor for general (untrained) task performance.",DISCUSSION|Mechanisms of Training and Transfer,[238717],[73624],[73836],[False],[0],[0],[False],['0']
42726,PMC9007089,40630,There are two key aspects to consider here.,DISCUSSION|Mechanisms of Training and Transfer,[238724],[73837],[73880],[False],[0],[0],[False],['0']
42727,PMC9007089,40631,The first is that the type of task used to assess attention may not be directly aligned with demands on working memory capacity.,DISCUSSION|Mechanisms of Training and Transfer,[238731],[73881],[74009],[True],['ValidityOfMeasurement'],['the type of task used to assess attention may not be directly aligned with demands on working memory capacity'],[True],['OutcomeMeasures']
42728,PMC9007089,40632,"For example, the Test of Everyday Attention and the Test of Attention in Listening require the effective division of attention (TEA) and response inhibition (TAIL), not working memory per se.",DISCUSSION|Mechanisms of Training and Transfer,[238745],[74010],[74201],[False],[0],[0],[False],['0']
42729,PMC9007089,40633,"A second consideration, which is of particular importance for the design of future research, is that the test-retest reliability of both of these outcome measures is poor.",DISCUSSION|Mechanisms of Training and Transfer,[238753],[74202],[74373],[True],['PrecisionOfMeasurement'],['the test-retest reliability of both of these outcome measures is poor'],[True],['OutcomeMeasures']
42730,PMC9007089,40634,"Future training intervention studies should take care to select outcomes based on both the mechanistic alignment of outcomes to trained tasks, as well as outcome reliability, in order to maximise confidence in estimations of effect.",DISCUSSION|Mechanisms of Training and Transfer,[238766],[74374],[74606],[False],[0],[0],[False],['0']
42731,PMC9007089,40635,"In hindsight, it might be reasonable to suggest that the selection of Cogmed as the core training intervention in this trial was a suboptimal choice, particularly given that our results are inconsistent with effective core working memory training.",DISCUSSION|Mechanisms of Training and Transfer,[238775],[74607],[74854],[True],['Intervention'],['the selection of Cogmed as the core training intervention in this trial was a suboptimal choice'],[True],['Intervention']
42732,PMC9007089,40636,"That is not to say that Cogmed cannot be effective at improving working memory capacity, albeit with refinement to better align training tasks to working memory theory (Gibson et al.",DISCUSSION|Mechanisms of Training and Transfer,[238787],[74855],[75037],[False],[0],[0],[False],['0']
42733,PMC9007089,40637,2012; Shipstead et al.,DISCUSSION|Mechanisms of Training and Transfer,[238794],[75038],[75060],[False],[0],[0],[False],['0']
42734,PMC9007089,40638,2012).,DISCUSSION|Mechanisms of Training and Transfer,[238801],[75061],[75067],[False],[0],[0],[False],['0']
42735,PMC9007089,40639,"As the fields of hearing research and cognitive hearing science have developed over the last decade, in order to identify effective training approaches to benefit people with hearing loss, it has become clear that we require theory-driven approaches to understand why and how interventions work (e.g., Coulson et al.",DISCUSSION|Mechanisms of Training and Transfer,[238808],[75068],[75384],[False],[0],[0],[False],['0']
42736,PMC9007089,40640,2016; Ferguson et al.,DISCUSSION|Mechanisms of Training and Transfer,[238815],[75385],[75406],[False],[0],[0],[False],['0']
42737,PMC9007089,40641,2019; Pichora-Fuller et al.,DISCUSSION|Mechanisms of Training and Transfer,[238822],[75407],[75434],[False],[0],[0],[False],['0']
42738,PMC9007089,40642,2016).,DISCUSSION|Mechanisms of Training and Transfer,[238829],[75435],[75441],[False],[0],[0],[False],['0']
42739,PMC9007089,40643,Future directions in training intervention studies for adults with hearing loss should ultimately be directed by the nature of the difficulties people with hearing loss and hearing aid users face.,DISCUSSION|Mechanisms of Training and Transfer,[238836],[75442],[75638],[False],[0],[0],[False],['0']
42740,PMC9007089,40644,"In turn, this will help to clarify the underpinning mechanisms of benefit that should be targeted by the intervention, as well as serve to inform the most appropriate outcomes to assess generalized training-related improvements (Henshaw and Ferguson 2014).",DISCUSSION|Mechanisms of Training and Transfer,[238843],[75639],[75895],[False],[0],[0],[False],['0']
42741,PMC9007089,40645,"For adults with hearing loss, and even more so for those who use hearing aids, listening is a challenging task that is often made more difficult by competing sounds in the environment (e.g., Lunner et al.",DISCUSSION|Mechanisms of Training and Transfer,[238850],[75896],[76100],[False],[0],[0],[False],['0']
42742,PMC9007089,40646,2009).,DISCUSSION|Mechanisms of Training and Transfer,[238857],[76101],[76107],[False],[0],[0],[False],['0']
42743,PMC9007089,40647,Successful speech-in-noise perception is an everyday goal-directed task that requires active listening.,DISCUSSION|Mechanisms of Training and Transfer,[238864],[76108],[76211],[False],[0],[0],[False],['0']
42744,PMC9007089,40648,"Active listening relies on good executive attention or “cognitive control”, which in turn necessitates a good link between working memory and executive functions (Pichora-Fuller & Phillips 2017).",DISCUSSION|Mechanisms of Training and Transfer,[238871],[76212],[76407],[False],[0],[0],[False],['0']
42745,PMC9007089,40649,"In the initial design and development of this trial, we hypothesized that training a core underpinning cognitive process (working memory capacity) may offer a more direct route to the benefits in working memory, attention, and speech perception that had resulted from our earlier studies of auditory training interventions (Ferguson et al.",DISCUSSION|Mechanisms of Training and Transfer,[238878],[76408],[76747],[False],[0],[0],[False],['0']
42746,PMC9007089,40650,"2014, Henshaw & Ferguson 2014).",DISCUSSION|Mechanisms of Training and Transfer,[238885],[76748],[76779],[False],[0],[0],[False],['0']
42747,PMC9007089,40651,"Yet, on closer inspection, the results of those initial studies clearly show that the generalized benefits of training are only evident for cognitive and speech tasks that involve working memory updating, attention switching/shifting, or inhibition.",DISCUSSION|Mechanisms of Training and Transfer,[238892],[76780],[77029],[False],[0],[0],[False],['0']
42748,PMC9007089,40652,There were no improvements shown for tasks that did not tap executive functions (Ferguson & Henshaw 2015).,DISCUSSION|Mechanisms of Training and Transfer,[238899],[77030],[77136],[False],[0],[0],[False],['0']
42749,PMC9007089,40653,"Although these were studies of auditory and not cognitive training, the 3-interval, 3-alternate forced choice paradigm used to deliver the training, required the trainee to simultaneously hold information in memory, while constantly updating that information in order to make same/different comparisons.",DISCUSSION|Mechanisms of Training and Transfer,[238906],[77137],[77440],[False],[0],[0],[False],['0']
42750,PMC9007089,40654,"As such, the transfer of learning shown in these studies may have arisen through the enhancement of cognitive control inherent within an auditory training task that necessitated active listening.",DISCUSSION|Mechanisms of Training and Transfer,[238913],[77441],[77636],[False],[0],[0],[False],['0']
42751,PMC9007089,40655,A systematic review and meta-analysis of the efficacy of auditory and cognitive training interventions to improve cognitive performance for adults with hearing loss (Lawrence et al.,DISCUSSION|Mechanisms of Training and Transfer,[238920],[77637],[77818],[False],[0],[0],[False],['0']
42752,PMC9007089,40656,"2018) showed a small but statistically significant effect of auditory training in terms of generalized improvements in working memory performance, and a large significant effect on overall cognition (combined cognitive tests), with similar results shown for cognitive training.",DISCUSSION|Mechanisms of Training and Transfer,[238927],[77819],[78096],[False],[0],[0],[False],['0']
42753,PMC9007089,40657,"However, a study that used a combined auditory-cognitive approach showed a very large effect (Anderson et al.",DISCUSSION|Mechanisms of Training and Transfer,[238934],[78097],[78206],[False],[0],[0],[False],['0']
42754,PMC9007089,40658,"2013b), demonstrating that a training task that targets cognitive enhancement delivered using auditory tasks resulted in the largest improvements (by far) in cognitive performance for this population.",DISCUSSION|Mechanisms of Training and Transfer,[238941],[78207],[78407],[False],[0],[0],[False],['0']
42755,PMC9007089,40659,"These results, considered in parallel with our own findings (Ferguson & Henshaw 2015), suggest that combined auditory-cognitive training tasks have the potential to offer superior generalized gains in cognition and speech perception, while maintaining trainee motivation to adhere to training through the use of training tasks with high ecological validity (Henshaw et al.",DISCUSSION|Mechanisms of Training and Transfer,[238948],[78408],[78780],[False],[0],[0],[False],['0']
42756,PMC9007089,40660,2015).,DISCUSSION|Mechanisms of Training and Transfer,[238955],[78781],[78787],[False],[0],[0],[False],['0']
42757,PMC9007089,40661,Limitations,DISCUSSION|Limitations,[238962],[78788],[78799],[False],[0],[0],[False],['0']
42758,PMC9007089,40662,"There was a greater number of participant withdrawals from the Experimental Group than from the Active Control Group, which was likely in part due to the high demands of the adaptive working memory training tasks, compared with the low-demand nonadaptive version of the training.",DISCUSSION|Limitations,[238972],[78800],[79079],[True],['UnbalancedDropout'],['a greater number of participant withdrawals from the Experimental Group than from the Active Control Group'],[True],['MissingData']
42759,PMC9007089,40663,This was not a problem in the present research as withdrawals did not exceed the anticipated 15% in either group.,DISCUSSION|Limitations,[238983],[79080],[79193],[False],[0],[0],[False],['0']
42760,PMC9007089,40664,"However, it represents a clear challenge to this type of intervention research and could result in biased group comparisons in future studies if the differences become too pronounced.",DISCUSSION|Limitations,[238990],[79194],[79377],[False],[0],[0],[False],['0']
42761,PMC9007089,40665,"In a similar vein, despite our best efforts, average active training time was significantly greater for participants in the Experimental Group than the Active Control Group over the 5-week training period.",DISCUSSION|Limitations,[239001],[79378],[79583],[True],['Intervention'],['average active training time was significantly greater for participants in the Experimental Group'],[True],['Intervention']
42762,PMC9007089,40666,The maximum time-on-task weighting setting offered within the Cogmed software was unable to fully address the imbalance between groups.,DISCUSSION|Limitations,[239011],[79584],[79719],[False],[0],[0],[False],['0']
42763,PMC9007089,40667,"Additionally, the rigid nature of the training procedure stipulated by Cogmed means that we are unable to identify whether different training durations, or tasks targeting alternative processes, would have resulted in improved training and transfer.",DISCUSSION|Limitations,[239023],[79720],[79969],[True],['Intervention'],['the rigid nature of the training procedure stipulated by Cogmed'],[True],['Intervention']
42764,PMC9007089,40668,A more pervasive argument is whether nonadaptive training should be used at all as an adaptive control task (Morrison & Chein 2012).,DISCUSSION|Limitations,[239032],[79970],[80102],[False],[0],[0],[False],['0']
42765,PMC9007089,40669,"The authors argue that more suitable alternatives to active-control tasks for Cogmed studies may include e.g., trivia training (Jaeggi et al.",DISCUSSION|Limitations,[239039],[80103],[80244],[False],[0],[0],[False],['0']
42766,PMC9007089,40670,"2011), or adaptive visual search (Redick et al.",DISCUSSION|Limitations,[239046],[80245],[80292],[False],[0],[0],[False],['0']
42767,PMC9007089,40671,2012).,DISCUSSION|Limitations,[239053],[80293],[80299],[False],[0],[0],[False],['0']
42768,PMC9007089,40672,"Yet, a critical component of using nonadaptive training as an active control task is that it helps to control for participant expectations of improvement by enabling effective blinding of allocation to experimental and control groups.",DISCUSSION|Limitations,[239060],[80300],[80534],[False],[0],[0],[False],['0']
42769,PMC9007089,40673,"Failure to do so in studies of psychological interventions (e.g., by employing “no-contact” control groups, or tasks that may have differential expectations of improvement) is argued to be “not a minor omission–it is a fundamental design flaw that potentially undermines any causal inference” (Boot et al.",DISCUSSION|Limitations,[239067],[80535],[80840],[False],[0],[0],[False],['0']
42770,PMC9007089,40674,"2013, p.445).",DISCUSSION|Limitations,[239074],[80841],[80854],[False],[0],[0],[False],['0']
42771,PMC9007089,40675,"A nonadaptive version of the same task used in the experimental condition enables the interface, the task and the allocation to be identical for participants in each group.",DISCUSSION|Limitations,[239081],[80855],[81027],[False],[0],[0],[False],['0']
42772,PMC9007089,40676,"Yet, for all of the reasons outlined above, there are several ways beyond allocation in which the tasks are not identical (e.g., the level of challenge, and time-on-task), which could result in differential expectations and demand characteristics between experimental and active-control groups.",DISCUSSION|Limitations,[239088],[81028],[81322],[False],[0],[0],[False],['0']
42773,PMC9007089,40677,Boot et al.,DISCUSSION|Limitations,[239095],[81323],[81334],[False],[0],[0],[False],['0']
42774,PMC9007089,40678,"(2013) argue that as a way forward, it would be important to measure and account for the influence of any differential expectations of improvements between groups, and by carefully selecting outcome measures that are not readily influenced by differential expectations (Boot et al.",DISCUSSION|Limitations,[239102],[81335],[81616],[False],[0],[0],[False],['0']
42775,PMC9007089,40679,2013).,DISCUSSION|Limitations,[239109],[81617],[81623],[False],[0],[0],[False],['0']
42776,PMC9007089,40680,"Although adherence to training was 100% for participants in both groups, it is important to consider the role of the “training aides” (a recommendation of Pearson, the providers of Cogmed training), as well as the active progress monitoring offered by the research team.",DISCUSSION|Limitations,[239116],[81624],[81894],[False],[0],[0],[False],['0']
42777,PMC9007089,40681,It is not known what would have happened to training adherence in the absence of such support.,DISCUSSION|Limitations,[239123],[81895],[81989],[False],[0],[0],[False],['0']
42778,PMC9007089,40682,"Finally, it is important to acknowledge that the method of scoring for cognitive tasks can have important consequences for task performance.",DISCUSSION|Limitations,[239136],[81990],[82130],[True],['PrecisionOfMeasurement'],['the method of scoring for cognitive tasks'],[True],['OutcomeMeasures']
42779,PMC9007089,40683,"Within this study, we employed a discontinuation rule for the Backward Digit Span task whereby the task is terminated if a participant provides an incorrect response for both trials at a given digit list length.",DISCUSSION|Limitations,[239144],[82131],[82342],[False],[0],[0],[False],['0']
42780,PMC9007089,40684,"Future studies might consider scoring approaches that exhaust all available performance information rather than adopting termination rules that could disadvantage participants who happen to fail at both instances of a list length, particularly if this occurs early in the task (see Conway et al.",DISCUSSION|Limitations,[239151],[82343],[82638],[False],[0],[0],[False],['0']
42781,PMC9007089,40685,2005).,DISCUSSION|Limitations,[239158],[82639],[82645],[False],[0],[0],[False],['0']
42782,PMC9007089,40686,CONCLUSIONS,CONCLUSIONS,[239165],[82646],[82658],[False],[0],[0],[False],['0']
42783,PMC9007089,40687,"We found no reliable evidence for the generalization of on-task learning to improvements in untrained objective measures of cognition or speech perception for adult hearing aid users within a blinded, active-controlled RCT of Cogmed RM training.",CONCLUSIONS,[239172],[82659],[82904],[False],[0],[0],[False],['0']
42784,PMC9007089,40688,"For participants in the Experimental Group who received adaptive training, there was a statistically significant improvement shown for a trained working memory task assessed outside of the working memory training program (Backward Digit Span), and a statistically significant improvement in self-reported hearing ability (Glasgow Hearing Aid Benefit Profile).",CONCLUSIONS,[239179],[82905],[83264],[False],[0],[0],[False],['0']
42785,PMC9007089,40689,Both of these effects remained at a 6-months post-training follow-up assessment.,CONCLUSIONS,[239186],[83265],[83345],[False],[0],[0],[False],['0']
42786,PMC9007089,40690,"However, despite moderate effect sizes, the overall magnitude of the effects rendered the clinical importance of the improvements low.",CONCLUSIONS,[239193],[83346],[83480],[False],[0],[0],[False],['0']
42787,PMC9007089,40691,It is hypothesized that improvements for trained tasks may be more representative of task-based strategy development than improvements in working memory capacity.,CONCLUSIONS,[239200],[83481],[83643],[False],[0],[0],[False],['0']
42788,PMC9007089,40692,"Future research should assess the benefits of training interventions that target the enhancement of cognition in the context in which it is employed within everyday communication, such as more dynamic aspects of cognitive control.",CONCLUSIONS,[239207],[83644],[83874],[False],[0],[0],[False],['0']
42789,PMC9007089,40693,"Published evidence suggests that for people with hearing loss, the greatest benefits may be achieved via interventions that combine both auditory and cognitive training elements, particularly those that target the improvement of executive functions using auditory-based training tasks.",CONCLUSIONS,[239214],[83875],[84160],[False],[0],[0],[False],['0']
42790,PMC9007089,40694,"Results from our quality assurance analyses show that for the selection of outcome measures for future training studies, it is important to consider not only the theoretical concepts of mechanisms of benefit and transfer, but also to select the most reliable measures for each outcome domain assessed.",CONCLUSIONS,[239221],[84161],[84462],[False],[0],[0],[False],['0']
42791,PMC9007089,40695,"Finally, training should use stimuli that are relevant to the everyday listening challenges of people with hearing loss (e.g., speech) so that trainees are motivated to engage and adhere.",CONCLUSIONS,[239228],[84463],[84650],[False],[0],[0],[False],['0']
42792,PMC9007089,40696,"We thank Michael LeBeau and Sandra Smith for assistance with participant recruitment, data collection and data management.",CONCLUSIONS,[239235],[84651],[84774],[False],[0],[0],[False],['0']
42793,PMC9007089,40697,Thanks to Mr Rajnikant Mehta for the data analysis plan.,CONCLUSIONS,[239242],[84775],[84831],[False],[0],[0],[False],['0']
42794,PMC9007089,40698,"Thank you to Mr Peter Watson, Dr Duncan Astle and Prof Susan Gathercole, Mr Oliver Zobay and Dr Anne Olson for their expert advice and insight during design, conduct, analysis, and/or write-up of this research.",CONCLUSIONS,[239249],[84832],[85042],[False],[0],[0],[False],['0']
42795,PMC9007089,40699,"published online ahead of print September 14, 2021.Supplemental digital content is available for this article.",,[239256],[85043],[85155],[False],[0],[0],[False],['0']
42796,PMC9007089,40700,"Direct URL citations appear in the printed text and are provided in the HTML and text of this article on the journal’s Web site (www.ear-hearing.com).Cogmed and Cogmed Working Memory Training are trademarks, in the U.S. and/or other countries, of Pearson Education, Inc. or its affiliate(s).The data that support the findings of this study are openly available in ClinicalTrials.gov at https://clinicaltrials.gov/ct2/show/study/NCT01892007, reference number NCT01892007.M.",,[239263],[85156],[85628],[False],[0],[0],[False],['0']
42797,PMC9007089,40701,"A. F. and H. H. designed the study, A. T. collected the outcome data, A. H. analyzed the data, H. H., M. A. F., and A. H. interpreted the results, H. H. and A. H. wrote the paper; all authors reviewed the article and provided critical revision.The authors have no conflicts of interest to disclose.",,[239270],[85629],[85927],[False],[0],[0],[False],['0']
